1.	9th International Forum on Mood and Anxiety Disorders. International journal of psychiatry in clinical practice.
2.	Therapeutic results with fluvoxamine. [German]. Die Therapiewoche. 1985;35:4679 + 4682.
3.	Azamianserin mirtazapine remergon EN=090918. Drugs of the future. 1990;15:1207-1211.
4.	Paroxetine. Aropax, Seroxat. Drugs of the future. 1991;16:184.
5.	Venlafaxine. Drugs of the future. 1991;16:875-876.
6.	Cericlamine hydrochloride. Antidepressant 5-HT uptake inhibitor. Drugs of the future. 1991;16:301-304.
7.	Managing the premenstrual syndrome. Drug and therapeutics bulletin. 1992;30:69-72.
8.	Mirtazapine. Remergon. Drugs of the future. 1992;17:1135.
9.	Venlafaxine. Drugs of the future. 1993;18:878-879.
10.	'Campaign on depression 1994'. Active disease confrontation. [German]. TW Neurologie Psychiatrie. 1994;8:697-698.
11.	Ipsapirone. Phase III Drug Profiles. 1994;4:1-15.
12.	Venlafaxine marketed as antidepressant. American journal of hospital pharmacy. 1994;51:1606.
13.	Venlafaxine - A new antidepressant. Medical letter on drugs and therapeutics. 1994;36:49-50.
14.	FDA panel recommends OCD treatment. Drug therapy. 1994;24:16-17.
15.	Venlafaxine. [Dutch]. Geneesmiddelenbulletin. 1995;29:5.
16.	Tianeptine: Challenging theories of the biochemical basis of depression? Drugs and Therapy Perspectives. 1995;6:5-7.
17.	Fluoxetine. New Zealand medical journal. 1995;108:95.
18.	Highlights of the 1995 Psychiatry Global Medical Conference. Journal of clinical psychiatry. 1995;56:488-499.
19.	Paroxetine cleared for panic disorder. Journal of pharmacy technology. 1996;12:181.
20.	Progress with nefazodone: Introduction. Journal of clinical psychiatry. 1996;57:3-5.
21.	Three new antidepressants. Drug and therapeutics bulletin. 1996;34:65-68.
22.	Paroxetin. [German]. Die Therapiewoche. 1996;46:1252-1255.
23.	Pediatric indication for fluvoxamine. American family physician. 1997;55:2867.
24.	Sertraline. Prescrire international. 1997;6:103-105.
25.	Discussion. European neuropsychopharmacology. 1997;7:S71-S73.
26.	Antidepressant can alleviate severe PMS. International journal of fertility and women's medicine. 1997;42:404.
27.	Citalopram. Prescrire international. 1997;6:36-39.
28.	New administration form for venlafaxine (Efexor XR). [Dutch]. Geneesmiddelenbulletin. 1998;32:97.
29.	Milnacipran. New preparation. Prescrire international. 1998;7:51-53.
30.	Withdrawing patients from antidepressants. Drug and therapeutics bulletin. 1999;37:49-52.
31.	Venlafaxine produces remission rates superior to those of SSRIs. Journal of pharmacy technology. 1999;15:185.
32.	Study shows mirtazapine reduces risk of depression relapse. Journal of pharmacy technology. 2000;16:21.
33.	Better quality of life with sertraline: Successful treatment in young patients. [German]. Psycho. 2000;26:i-iv.
34.	Effexor XR provides increased symptomatic improvement or remission of depression. Journal of the American Osteopathic Association. 2000;100:201.
35.	Withdrawal phenomena following discontinuation of antidepressant therapy - The unknown danger. [German]. MMW Fortschritte der Medizin. 2000;142:50-51.
36.	Hypericum in the treatment of mild and moderate depressions. St. John's efficacy and tolerability. [German]. Nervenheilkunde. 2000;19:92-93.
37.	The drug treatment of depression in primary care. MeReC Bulletin. 2000;11:33-36.
38.	Between anxiety and depression. [German]. Arztliche Praxis Neurologie Psychiatrie. 2000:44.
39.	Venlafaxine XR: Effective in long term management of generalised anxiety disorder. Drugs and Therapy Perspectives. 2001;17:1-4.
40.	Augmentation strategies in resistant depression - Some are effective and well tolerated. Drugs and Therapy Perspectives. 2001;17:6-9.
41.	Severe depression does not respond to st. John's wort, study says. American journal of health-system pharmacy. 2001;58:954+956.
42.	Pharmacogenomics: Can we predict response to antipsychotics? Pharmaceutical journal. 2001;267:658-659.
43.	Nicotine replacement therapy is safer. Prescrire international. 2001;10:163-167.
44.	Approval of citalopram for the treatment of panic disorders. [German]. Deutsche Apotheker-Zeitung. 2001;141:48.
45.	St. John's wort found ineffective for major depression. Economics of Neuroscience. 2001;3:22.
46.	Non-nicotine pharmacotherapy may prove useful in smoking cessation. Drugs and Therapy Perspectives. 2001;17:9-12.
47.	An open, baseline controlled evaluation of sertraline safety and efficacy in the treatment of depression in Thai patients. Chotmaihet thangphaet [Journal of the Medical Association of Thailand]. 2001;84:54-62.
48.	Cancer news of the last 30 days. Oncology Spectrums. 2001;2:310-311.
49.	Antidepressant discontinuation syndromes: Common, under-recognised and not always benign. Drugs and Therapy Perspectives. 2001;17:12-15.
50.	An improving outlook for patients with postherpetic neuralgia. Drugs and Therapy Perspectives. 2001;17:8-11.
51.	Trauma and stress: Diagnosis and treatment. Journal of clinical psychiatry. 2001;62:906-915.
52.	MK 869: Aprepitant, L 754030, MK 0869. Drugs in R and D. 2002;3:200-203.
53.	SSRIs for premenstrual dysphoric disorder. Drug and therapeutics bulletin. 2002;40:70-72.
54.	Fluoxetine approved for paediatric use. WHO Drug Information. 2002;16:290.
55.	Specific issues in depression. MeReC Briefing. 2002:1-5.
56.	SSRIs cut cardiac deaths post-MI. Pharmaceutical journal. 2002;268:755.
57.	S-enantiomer of citalopram effective for depression. Pharmaceutical journal. 2002;268:603.
58.	Escitalopram has faster action and is better tolerated than venlafaxine. Pharmaceutical journal. 2002;269:557.
59.	Pharmacoeconomic data support the use of SSRIs in depression. Drugs and Therapy Perspectives. 2002;18:23-26.
60.	Sertraline safe for depression post-MI. Pharmaceutical journal. 2002;269:239.
61.	CME posttest. Pathophysiology of depression: The emerging role of substance P. Journal of clinical psychiatry. 2002;63:30-31.
62.	Effect of Hypericum performatum (St John's wort) in major depressive disorder: A randomized controlled trial. JAMA: Journal of the American Medical Association. 2002;287:1807-1814.
63.	St John's wort effect not proven for major depression. Pharmaceutical journal. 2002;268:492.
64.	30 Days. Clinical and economic news of the last 30 days. TEN Trends in Evidence-Based Neuropsychiatry. 2002;4:15-17.
65.	Olanzapine is a useful alternative to mood stabilisers for the varied presentations of bipolar I disorder. Drugs and Therapy Perspectives. 2002;18:1-4.
66.	Surgery & watchful waiting for early prostate cancer provide similar outcomes. Expert review of pharmacoeconomics & outcomes research. 2002;2:403-410.
67.	Depression relapse rate decreases with new dual re-uptake inhibitor. Pharmaceutical journal. 2003;271:488.
68.	Paroxetine linked with suicidal behaviour in under 18s. Pharmaceutical journal. 2003;270:813.
69.	Opinion and evidence in neurology and psychiatry. CNS drugs. 2003;17:679-687.
70.	Reducing the risk for suicide in schizophrenia and affective disorders. Journal of clinical psychiatry. 2003;64:1122-1129.
71.	Mild depression in general practice: Time for a rethink? Drug and therapeutics bulletin. 2003;41:60-64.
72.	New analysis for duloxetine. Pharmaceutical journal. 2003;270:821.
73.	Suicide risk warning for children now extended by CSM to cover venlafaxine. Pharmaceutical journal. 2003;271:395.
74.	Opinion and Evidence in Neurology and Psychiatry. CNS drugs. 2003;17:1059-1065.
75.	Study supports SSRI use for depression in children. Pharmaceutical journal. 2003;271:288.
76.	The treatment of alcohol use disorders in adolescents requires greater research. Drugs and Therapy Perspectives. 2003;19:6-9.
77.	Tackling premenstrual syndrome. MeReC Bulletin. 2003;13:1-12.
78.	Age and gender likely to impact upon the treatment of depression. Pharmaceutical journal. 2003;271:556.
79.	Paroxetine: Avoid in children and adolescents. WHO Drug Information. 2003;17:106-107.
80.	Drugs for disruptive features in dementia. Drug and therapeutics bulletin. 2003;41:1-4.
81.	Monitoring psychotropic drugs' utilization and cost in psychiatric services and general practice. [Italian]. Giornale Italiano di Farmacia Clinica. 2003;17:33-47.
82.	Depression also effects the body. [German]. Pharmazie in unserer Zeit. 2003;32:74.
83.	Escitalopram oxalate. Australian Prescriber. 2003;26:147.
84.	Blind faith in double blind studies. [German]. Arztezeitschrift fur Naturheilverfahren und Regulationsmedizin. 2003;44:253.
85.	St John's wort and depression. Prescrire international. 2004;13:187-190+192.
86.	Shortcomings revealed in trials of antidepressants in children. Pharmaceutical journal. 2004;272:465.
87.	MHRA issues new advice on SSRI dose changes, withdrawal and the risk of suicidal behaviour. Pharmaceutical journal. 2004;273:839.
88.	Antidepressants improve poststroke survival. Neuroscientist. 2004;10:277.
89.	Sertraline and venlafaxine: Prevention of recurrent depression: No advance. Pharmacometrics. 2004;66:19-20.
90.	Unpublished studies change risk benefits of SSRIs in children. Pharmaceutical journal. 2004;272:534.
91.	Effective therapy available for adolescents with depression. Pharmaceutical journal. 2004;273:246.
92.	Suicidal ideas with paroxetine or venlafaxine. Prescrire international. 2004;13:21.
93.	Current side-effects of drugs: Severe rhabdomyolosis after use of propofol; didanosine, lamivudine, tenofovir DF; oxycodone (Oxygesic); venlafaxine (Trevilor, trevilor retard). [German]. Tagliche Praxis. 2004;45:198-200.
94.	Helping depressed children. Nature. 2004;431:111.
95.	Tramadol - Biovail Corporation. Drugs in R and D. 2004;5:182-183.
96.	What's wrong with prescribing hypnotics? Drug and therapeutics bulletin. 2004;42:89-93.
97.	The sequential approach to treating recurrent depression shows promise in some patients. Drugs and Therapy Perspectives. 2004;20:11-14.
98.	Depressing research. Lancet. 2004;363:1335.
99.	St John's wort extract versus citalopram. [German]. Pharmazeutische Zeitung. 2004;149:28.
100.	GSK accused of suppressing negative trial data. Nature reviews. Drug discovery. 2004;3:543.
101.	Eszopiclone: Esopiclone, Estorra, S-zopiclone, zopiclone - Sepracor. Drugs in R and D. 2005;6:111-115.
102.	Duloxetine (Cymbalta) for diabetic neuropathic pain. Medical letter on drugs and therapeutics. 2005;47:67-68.
103.	More on St Johns wort. Medicine today. 2005;6:10.
104.	Abnormal drug response: Opportunities for risk reduction through pharmacogenetics. WHO Drug Information. 2005;19:3-12.
105.	St John's wort = SSRI for moderate-severe depression. South African family practice. 2005;47:18.
106.	Drugs minimally effective for neuropsychiatric symptoms of dementia. Journal of family practice. 2005;54:407.
107.	Escitalopram or citalopram for depression in primary care? MeReC Extra. 2005.
108.	More advice on SSRI use. WHO Drug Information. 2005;19:117.
109.	Acute mania treatment. Journal of clinical psychiatry. 2005;66:1598-1601.
110.	Long-term treatment. Journal of clinical psychiatry. 2005;66:1604-1607.
111.	Make use of options for an added therapeutic value. State of the art conference 2005: Innovation and changes in antidepressive therapy in Germany. [German]. Nervenheilkunde. 2005;24:1-8.
112.	Sertraline and venlafaxine. Prevention of recurrent depression: No advance. Prescrire international. 2005;14:19-20.
113.	Drug treatments for bipolar disorder: 1 - Acute manic or depressive episodes. Drug and therapeutics bulletin. 2005;43:28-32.
114.	Physical complaints can overlap mental symptoms. Diffuse pain? It could be depression!. [German]. MMW Fortschritte der Medizin. 2006;148:62-63.
115.	Moderate to severe depression: Long-term treatment. [German]. Schweizerische Zeitschrift fur GanzheitsMedizin. 2006;18:361-362.
116.	Less sexual dysfunction with duloxetine treatment in major depression?. [German]. Psychopharmakotherapie. 2006;13:264-265.
117.	Duloxetine effective for fibromyalgia in some women. Journal of family practice. 2006;55:382.
118.	Chasing quality - Clinical practice guidelines and HEDIS measures of asthma and depression therapy management. Journal of managed care pharmacy. 2006;12:78-80.
119.	Disease management update. Disease Management and Health Outcomes. 2006;14:191-196.
120.	Antidepressant drugs increase suicide risk in children. Journal of family practice. 2006;55:488.
121.	Manifestations and management of chronic insomnia in adults: Key points and implications of the 2005 NIH State-of-the-Science Conference Statement. American journal of managed care. 2006;12:1-12.
122.	Transcranial magnetic stimulation: Do magnetic fields help parkinsonian patients?. [German]. Deutsche Apotheker-Zeitung. 2006;146:30-32.
123.	Duloxetine. Depression and diabetic neuropathy: Too many adverse effects. Prescrire international. 2006;15:168-172.
124.	Transdermal selegiline (Emsam). Medical letter on drugs and therapeutics. 2006;48:41-42.
125.	What did year 2005 bring us? New drugs, developments and side-effects. [Dutch]. Geneesmiddelenbulletin. 2006;40:3-10.
126.	Rasagiline (Azilect) for Parkinson's disease. Medical letter on drugs and therapeutics. 2006;48:97-99.
127.	All SSRIs can cause increased risk of suicide or self-harm in youths with depression. Australian Journal of Pharmacy. 2007;88:86.
128.	Gerontology forum: An update on the literature. Drugs & aging. 2007;24:73-80.
129.	SSRIs show early clinical improvement in depression. Australian Journal of Pharmacy. 2007;88:86.
130.	Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:1503-1526.
131.	Is there a place for  duloxetine? Drug and therapeutics bulletin. 2007;45:29-32.
132.	Aetna launches industry's first bipolar disease management program. Drug Benefit Trends. 2007;19:85-87.
133.	Sleep-promoting medications should be used with caution in elderly nursing home residents. Drugs and Therapy Perspectives. 2007;23:10-13.
134.	Transcranial magnetic stimulation: Potential new treatment for resistant depression. Journal of clinical psychiatry. 2007;68:315-330.
135.	SSRIs show clinical improvement on depression. Australian Journal of Pharmacy. 2007;88:60.
136.	Adding an antidepressant does not improve bipolar depression. Journal of family practice. 2007;56:616.
137.	Cognitive behavioral therapy + alternative selective serotonin reuptake inhibitor better than alternative SSRI alone in adolescent depression. Journal of the National Medical Association. 2008;100:762-763.
138.	Thanks, but no thanks.. Prescrire international. 2008;17:178.
139.	The menopausal transition. Fertility and sterility. 2008;90:S61-S65.
140.	Desvenlafaxine for depression. Medical letter on drugs and therapeutics. 2008;50:37-39.
141.	Desvenlafaxine for depression. Obstetrics and gynecology. 2008;112:694-696.
142.	Depression, antidepressants and heart disease. Drug and therapeutics bulletin. 2008;46:29-32.
143.	Many drugs require more robust evidence to establish their association with suicidal ideation and suicidality. Drugs and Therapy Perspectives. 2008;24:22-24.
144.	Treating depression in alcohol misuse. Drug and therapeutics bulletin. 2008;46:11-14.
145.	Agomelatine: AGO 178, AGO178, S 20098, Drugs in R and D(2008).
146.	Omissions in acknowledgments in: "The treatment for adolescents with depression study (TADS): Long-term effectiveness and safety outcomes". Archives of general psychiatry. 2008;65:101.
147.	Fluoxetine: Depression in children: Too many uncertainties. Prescrire international. 2008;17:186-187.
148.	A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report. American journal of preventive medicine. 2008;35:158-176.
149.	Duloxetine: A guide to its use in major depressive disorder. Drugs and Therapy Perspectives. 2008;24:5-8.
150.	Milnacipran (Savella) for fibromyalgia. Medical letter on drugs and therapeutics. 2009;51:45-46.
151.	Tackling partial response to depression treatment. Primary care companion to the Journal of clinical psychiatry. 2009;11:155-162.
152.	A roadmap to key pharmacologic principles in using antipsychotics in the treatment of older patients. Journal of clinical psychiatry. 2009;70:131-138.
153.	Clinically important differences exist between antidepressants for both efficacy and acceptability. Australian Journal of Pharmacy. 2009;90:77.
154.	Digest. Progress in neurology and psychiatry. 2009;13:40-43.
155.	Antidepressant agents in children and adolescents: Significance of St. John's wort extract. [German]. Schweizerische Zeitschrift fur GanzheitsMedizin. 2009;21:272-273.
156.	Escitalopram, sertraline more effective, better tolerated than other newer antidepressants. Journal of the National Medical Association. 2009;101:741-742.
157.	Escitalopram: Effective in challenging depressive symptoms. [German]. Psychopharmakotherapie. 2009;16:2P.
158.	Agomelatine. Prescrire international. 2009;18:241-243+245.
159.	SSRI escitalopram improves cognitive function recovery in recent stroke survivors. Formulary (Cleveland, Ohio). 2010;45:115.
160.	Digest. Progress in neurology and psychiatry. 2010;14:34-35.
161.	Atypical antipsychotics may be useful as adjuncts to antidepressant therapy in treatment-resistant depression. Drugs and Therapy Perspectives. 2010;26:17-20.
162.	Acupuncture. Focus on Alternative and Complementary Therapies. 2010;15:163-169.
163.	The treatment success in depressive patients in focus: Early and clear pain reduction improves the chance of remission. [German]. MMW Fortschritte der Medizin. 2010;152:78-79.
164.	Two drugs more effective to induce remission of MDD. Journal of the National Medical Association. 2010;102:660-661.
165.	Agomelatine for major depressive episodes. Drug and therapeutics bulletin. 2010;48:93-96.
166.	Effect of paroxetine on personality. Australian Journal of Pharmacy. 2010;91:83.
167.	Herbal medicine. Focus on Alternative and Complementary Therapies. 2010;15:152-157.
168.	Abstracts from Professional Poster Presentations at AMCP's 2010 Educational Conference. Journal of managed care pharmacy. 2010.
169.	Lithium is still a first-line option in the treatment of patients with bipolar disorder. Drugs and Therapy Perspectives. 2010;26:9-14.
170.	Management of seasonal affective disorder. BMJ (Online). 2010;340:1185-1189.
171.	Omega-3 fatty acids not effective for depression in patients with coronary heart disease. Journal of the National Medical Association. 2010;102:151.
172.	Consider the cause of anorexia when treating elderly patients. Drugs and Therapy Perspectives. 2010;26:15-16.
173.	Pregabalin for generalised anxiety disorder. Drug and therapeutics bulletin. 2010;48:19-22.
174.	Sublingual asenapine: A guide to its use in acute mania in adults with bipolar i disorder. Drugs and Therapy Perspectives. 2011;27:1-5.
175.	Treat the symptoms of fibromyalgia with a variety of strategies, as individual therapies provide only moderate benefits. Drugs and Therapy Perspectives. 2011;27:17-20.
176.	Treatment of Parkinson's disease. Psychological disorders: Striking a balance in order to optimise antiparkinsonian treatment. Prescrire international. 2011;20:242-245.
177.	Antidepressants increase risk of adverse effects in Alzheimer's disease. Australian Journal of Pharmacy. 2011;92:76.
178.	A variety of non-hormonal strategies may provide women with relief from vasomotor symptoms. Drugs and Therapy Perspectives. 2011;27:19-22.
179.	Treatment-resistant depression: No panacea, many uncertainties - Adverse effects are a major factor in treatment choice. Prescrire international. 2011;20:128-133.
180.	Consider augmentation or switching strategies when first-line antidepressants are unsuccessful in major depressive disorder. Drugs and Therapy Perspectives. 2011;27:7-12.
181.	A brief summary of the articles appearing in this issue of Biological Psychiatry. Biological psychiatry. 2012;72:521.
182.	Paroxetine and venlafaxine XR are effective in treating depression in patients with Parkinson's disease. Australian Journal of Pharmacy. 2012;93:94.
183.	New drugs for multiple sclerosis. Medical letter on drugs and therapeutics. 2012;54:89-91.
184.	Fluoxetine and venlafaxine decrease suicidal thoughts and behaviour. Australian Journal of Pharmacy. 2012;93:87.
185.	Vortioxetine (Brintellix) for depression. Medical letter on drugs and therapeutics. 2013;55:93.
186.	Pharmacotherapy. Australian Prescriber. 2013;36:157.
187.	Locally advanced prostate cancer: Effective treatments, but many adverse effects. Prescrire international. 2013;22:18-23.
188.	Paroxetine (Brisdelle) for hot flashes. Medical letter on drugs and therapeutics. 2013;55:85.
189.	Tinnitus. Drug and therapeutics bulletin. 2013;51:20-24.
190.	Screening and management of depression for adults with chronic diseases: An evidence-based analysis. Ontario Health Technology Assessment Series. 2013.
191.	Sertraline and mirtazapine ineffective for treating depression in people with dementia. Drug and therapeutics bulletin. 2013;51:50.
192.	Latest reviews from Cochrane. Prescriber. 2013;24:45.
193.	Levomilnacipran (Fetzima): A new SNRI for depression. Medical letter on drugs and therapeutics. 2013;55:101-102.
194.	3rd HPE, TW M, ME K, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. International journal of geriatric psychiatry. 2008;23:625-631.
195.	3rd RCF, Frank E, JM P, et al. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. American journal of psychiatry. 1996;153:1418-1422.
196.	Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management, International journal of geriatric psychiatry(2010).
197.	-F PM, Boyer P. "Venlafaxine and paroxetin in treatment-resistant depression: Double-blind, randomised comparison": Erratum. The British Journal of Psychiatry. 1999;175:394.
198.	-M AJ, -M LP, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2004;30:158-166.
199.	-P OJ, Bayle F, Kasper S. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2003;29:322-328.
200.	-P OJ, Gourion D, Montagne A, Rostin M, -F PM. Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomised, double blind exploratory study. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2009;35:595-604.
201.	[Anonymous]. Duloxetine (Cymbalta). Medical letter on drugs and therapeutics. 2004;46:81-83.
202.	[Anonymous]. Duloxetine (Cymbalta). Medical letter on drugs and therapeutics. 2004;46:81-83.
203.	[Anonymous]. Treatment of Bipolar Depression. Journal of clinical psychiatry. 2005;66:1601-1604.
204.	[Anonymous]. Strategies and Tactics of Treatment for Complicated Depression: an Algorithmic Approach. Journal of clinical psychiatry. 2006;67:315-316.
205.	[Ed] GAJ, [Ed] OJ-O. "Paroxetine versus placebo: A double-blind comparison in depressed patients": Duplicate publication. Journal of clinical psychiatry. 1995;56:81.
206.	A AA, Jonathan S, M TJ. Evidence for short-term psychodynamic psychotherapy for depression. Journal of clinical psychiatry. 2012;73:718.
207.	A AB, SA C, AA N, SH A, Sh R. Petal and stigma of Crocus sativus L. in the treatment of depression: A pilot double - blind randomized trial. Journal of Medicinal Plants. 2008;7:29-36.
208.	A BD, Giovanna P, J EG. Dr. Brent, Ms. Porta, and Dr. Emslie reply. American journal of psychiatry. 2009;166:936-937.
209.	A BD, J EG, N CG, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. American journal of psychiatry. 2009;166:418-426.
210.	A BH, P GA, S MH, MT PT, A LF, L LG. Cytochromes CYP2D6 and CYP2C9 and relapse depression rates in a cohort of adolescents. European neuropsychopharmacology. 2014;Conference:S722-S723.
211.	A BJ, A BD. "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial": Comment. JAMA: Journal of the American Medical Association. 2004;292:2578.
212.	Exercise and pharmacotherapy in the treatment of major depressive disorder, Psychosomatic medicine(2007).
213.	A BJ, Andrew S, A BM, Murali DP, M HB. Exercise, pharmacotherapy, and depression: Response to letters to the editor. Psychosomatic medicine. 2008;70:264-265.
214.	A BJ, Boris B, Satish I, P BR, A BD. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. [Review] [52 refs]. American journal of psychiatry. 2009;166:42-49.
215.	A BJ, Peter M, H MPG, W vdBW. Comparison of 2 treatment strategies for depressed inpatients: Imipramine and lithium addition or mirtazapine and lithium addition. Journal of clinical psychiatry. 1998;59:657-663.
216.	A BJ, Satish I, B SC, et al. Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment - a Meta-Analysis of Randomized Controlled Trials. JAMA: Journal of the American Medical Association. 2007;297:1683-1696.
217.	A BR, M AA, R SD, et al. Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. Nicotine & tobacco research. 2014;16:197-207.
218.	A BW, Mihaly A, Ram S. Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor. American journal of psychiatry. 1986;143:88-90.
219.	A BW, Wilma H. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacology bulletin. 1992;28:253-256.
220.	A BW, Wilma H. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Journal of clinical psychiatry. 1995;56:30-34.
221.	A CA, Sarah L, David N, et al. Adverse effects from antidepressant treatment: Randomised controlled trial of 601 depressed individuals. Psychopharmacology. 2014;231:2921-2931.
222.	A CI, F LA, Elise W, et al. Corrigendum to "Neurophysiologic predictors of treatment response to fluoxetine in major depression.". Psychiatry research. 2000;95:87.
223.	A CI, F LA, Melinda M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120-131.
224.	Association between patient beliefs regarding assigned treatment and clinical response: Reanalysis of data from the Hypericum Depression Trial Study Group, Journal of clinical psychiatry(2011).
225.	A CJ, L TV, I PG. Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. Journal of psychopharmacology (Oxford, England). 2014;28:118-124.
226.	A CL. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Annals of clinical psychiatry. 1997;9:157-164.
227.	A CL, Guy B, S CJ, Guy C, al e. "A comparison of venlafaxine, trazodone, and placebo in major depression": Erratum. Journal of clinical psychopharmacology. 1994;14:292.
228.	A CL, L BR, S CJ, et al. A comparison of venlafaxine, trazodone, and placebo in major depression.[Erratum appears in J Clin Psychopharmacol 1994 Aug;14(4):292]. Journal of clinical psychopharmacology. 1994;14:99-106.
229.	Change in symptoms of erectile dysfunction in depressed men initiating buprenorphine therapy, Journal of substance abuse treatment(2013).
230.	A CS, Doug W, M ST, D BS, Michael C, Gary T. A randomized, double-blind comparison of olanzapine/Fluoxetine combination, olanzapine, fluoxetine, and Venlafaxine in treatment-resistant depression. Depression and anxiety. 2006;23:364-372.
231.	A dB, KK S. Group 1 metabotropic glutamate receptors and schizophrenia. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 2012;1:94-103.
232.	A dBJ, G WH. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline. International clinical psychopharmacology. 1988;3:59-74.
233.	A DE, M BM. "Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease": Comment. JAMA: Journal of the American Medical Association. 2007;297:1879-1880.
234.	A DLI, MA C. Duloxetine in neuropathic pain. [Spanish]. Revista de la Sociedad Espanola del Dolor. 2006;13:21-31.
235.	A DN, P YP, Richard E, L MA. A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxiine Succinate in the Treatment of Major Depressive Disorder. Journal of clinical psychiatry. 2007;68:677-688.
236.	A DR, H MB, J LE, et al. Somatic symptoms of depression in elderly patients with medical comorbidities. International journal of geriatric psychiatry. 2005;20:973-982.
237.	A DR, J GB. Suicidal and homicidal ideations emerging during a placebo period [1]. Journal of clinical psychiatry. 1992;53:171.
238.	A DR, J GB, F JA, M SR. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Journal of clinical psychiatry. 1985;46:84-87.
239.	A DR, M KA, William C. Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine. Journal of clinical psychopharmacology. 1996;16:320-323.
240.	A DS. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol and Alcoholism. 2004;39:528-531.
241.	A DS. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism. 2005;40:545-548.
242.	A DS. A comparative study using Disulfiram and Naltrexone in alcohol-dependent adolescents. Journal of substance use. 2014;19:341-345.
243.	A EK, SH G, Mork A, AA M. Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:535-540.
244.	A F-CJ, F MC, A LD, E MP, G MA, AJr ZC. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study. Journal of affective disorders. 2013;149:319-325.
245.	A FD, J DM, Joachim W, S CA, K KD. The relationship between antidepressant and analgesic responses: Findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. Current medical research and opinion. 2008;24:3105-3115.
246.	A FJ, Douglas SJ, J AS, M BJ, T MR, R JP. Depression outcome in alcohol dependent patients: An evaluation of the role of independent and substance-induced depression and other predictors. Journal of affective disorders. 2015;174:503-510.
247.	A FM, L PM, V BW, et al. Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of affective disorders. 2014;169:S17-S23.
248.	A FT, Tatsuo A, Hideki A, Toru O, Teruhiko H. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of clinical psychopharmacology. 2007;27:531-534.
249.	A G-DA, Guindalini C, Batista-Neves S, IR DO, Miranda-Scippa A, LC Q. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. [Review]. General hospital psychiatry. 2010;32:401-405.
250.	A GB, A UL, Gary E-L, W MI. Premature conclusions about psychotherapy for dysthymia. Journal of clinical psychiatry. 2009;70:1188.
251.	A GH, B KJ, I SS, et al. A genomewide association study of citalopram response in major depressive disorder. Biological psychiatry. 2010;67:133-138.
252.	Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder, American journal of psychiatry(2010).
253.	A GK, R JP, T MR, E LS. Thyroid indices and response to fluoxetine and nortriptyline in major depression. Journal of psychopharmacology (Oxford, England). 2003;17:431-437.
254.	A GS, Walach H. Why Prozak when we have reiki? Focus on Alternative and Complementary Therapies. 2005;10:45-46.
255.	A HJ. Org-3770 (Mirtazapine) Versus Trazodone - a Placebo-Controlled Trial in Depressed Elderly Patients. Human Psychopharmacology: Clinical and Experimental. 1995;10:S125-S133.
256.	A HJ, Spilios A, S RA, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. The British Journal of Psychiatry. 2002;180:528-535.
257.	A HR, B DS, R EA, Til S, F FJ, N GB. Risk of adverse events in treatment-resistant depression: Propensity-score-matched comparison of antidepressant augment and switch strategies. General hospital psychiatry. 2012;34:192-200.
258.	A HRM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. [Review] [58 refs]. Journal of clinical psychiatry. 1999;60:326-335.
259.	A HRM. The use of mirtazapine in difficult-to-treat patient populations. Human Psychopharmacology: Clinical and Experimental. 2002;17:S33-S36.
260.	A HRM. "Does olanzapine have any antidepressant effect?": Dr. Hirschfeld replies. American journal of psychiatry. 2006;163:1839.
261.	A HRM, A VL. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. [Review] [12 refs]. Journal of clinical psychiatry. 2004;65 Suppl 4:46-52.
262.	A HRM, Craig M, C LT, J DM. Time Course of Depression-Symptom Improvement During Treatment with Duloxetine. Depression and anxiety. 2005;21:170-177.
263.	A HRM, J FL, S MJ. To The Editor: Antidepressants for Bipolar Depression. American journal of psychiatry. 2005;162:1546-1547.
264.	A HRM, M RJ, L DP, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Journal of clinical psychiatry. 1998;59:669-675.
265.	A JM, P HJ, L TJ, K BS, Alan F. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. International journal of neuropsychopharmacology. 2000;3:229-235.
266.	A JR. Ketamine for treatment-resistant depression: Ready or not for clinical use? American journal of psychiatry. 2013;170:1079-1081.
267.	A KM, C TA, Diane M, et al. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. [Review] [124 refs]. Journal of clinical psychiatry. 2007;68:1845-1859.
268.	A KR, J CT, J EG, W RJ, W HC, John RA. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: A hypothesis generating study. Journal of affective disorders. 1999;54:269-276.
269.	A KT, Shefali M, Bernardo DO, R CJ, A FM, Leslie C. Balancing benefits and harms of treatments for acute bipolar depression. Journal of affective disorders. 2014;169:S24-S33.
270.	A L-VM, Ioseba I-C, M J-LJ, et al. Depressive symptomatology and response to treatment with antidepressants in patients with a dual diagnosis. Addictive disorders & their treatment. 2014;13:125-132.
271.	A LL, C SS, L RC, F AR, T BK. Does Comorbid Anxiety or Depression Affect Clinical Outcomes in Patients With Post-traumatic Stress Disorder and Alcohol Use Disorders? [References]. Comprehensive psychiatry. 2004;45:304-310.
272.	A LL, Mikkelsen PL, Rasmussen S, P lFH. Paroxetine in the treatment of depression - A randomized comparison with amitriptyline. Acta psychiatrica Scandinavica. 1985;71:249-255.
273.	A MC, Jason B, E SJ-M, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). The American Journal of Geriatric Psychiatry. 2004;12:491-498.
274.	A MG, J TB, J KN, David H, S GM, Ester K. A Comparison of Cognitive-Behavioral Therapy, Sertraline, and Their Combination for Adolescent Depression. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1151-1161.
275.	A MS. New antidepressants and 5-HT uptake inhibitors. Acta neurologica Scandinavica. 1989;80:107-116.
276.	A MS. A review of the safety of paroxetine. European psychiatry. 1993;8:25S-30S.
277.	A MS. Reboxetine: Additional benefits to the depressed patient. Journal of psychopharmacology (Oxford, England). 1997;11:S9-S15.
278.	A MS. Predicting response: Noradrenaline reuptake inhibition. International clinical psychopharmacology. 1999;14:S21-S26.
279.	A MS. Managing the severely ill and long-term depressed. International journal of psychiatry in clinical practice. 1999;3:S13-S17.
280.	A MS. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. International clinical psychopharmacology. 2002;17:S9-S17.
281.	A MS. Major depressive disorders: Clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. European neuropsychopharmacology. 2006;16:S633-S638.
282.	A MS, Dufour H, Brion S, Gailledreau J, al e. The prophylactic efficacy of fluoxetine in unipolar depression. The British Journal of Psychiatry. 1988;153:69-76.
283.	A MS, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International clinical psychopharmacology. 1993;8:189-195.
284.	A MS, F AH. Escitalopram versus venlafaxine XR in the treatment of depression. International clinical psychopharmacology. 2006;21:297-309.
285.	A MS, Hans-Jurgen M. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. [Review] [23 refs]. International clinical psychopharmacology. 2009;24:111-118.
286.	A MS, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. International clinical psychopharmacology. 2004;19:271-280.
287.	A MS, Rasmussen JG. Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. International clinical psychopharmacology. 1992;6 Suppl 5:71-73.
288.	A MS, Rasmussen JG, Lyby K, Connor P, Tanghosj P. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. International clinical psychopharmacology. 1992;6 Suppl 5:65-70.
289.	A MS, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International clinical psychopharmacology. 1993;8:181-188.
290.	A MS, Richard E. Relapse prevention with antidepressants. Nordic journal of psychiatry. 1993;47:83-88.
291.	A MS, S BD, Pierre B, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. [Review] [36 refs][Erratum appears in Int Clin Psychopharmacol. 2008 Jan;23(1):61]. International clinical psychopharmacology. 2007;22:323-329.
292.	A MS, S BD, Pierre B, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence: Erratum. International clinical psychopharmacology. 2008;23:61.
293.	A NA. "Predicting nonresponsiveness to depression treatments": Reply. American journal of psychiatry. 1996;153:1509.
294.	A NA, A AL, Eric P, Gwen Z, Michel R. Trazodone for antidepressant-associated insomnia. American journal of psychiatry. 1994;151:1069-1072.
295.	A NA, A PJ, Kathy C, F RJ, Maurizio F. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Biological psychiatry. 1996;40:691-696.
296.	A NA, M QF, Charlotte K, B KM, E TM. Placebo-controlled continuation treatment with mirtazapine: Acute pattern of response predicts relapse. Neuropsychopharmacology. 2004;29:1012-1018.
297.	A NA, Maurizio F, H TM, et al. Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. American journal of psychiatry. 2006;163:1519-1530.
298.	A NM, Gopalan R, Thomas J, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: Results from a randomized controlled trial. Journal of affective disorders. 2002;69:109-118.
299.	A NP, Rama KKR, Murali DP, M RE, D BE, M CC. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Journal of clinical psychiatry. 2000;61:559-568.
300.	A NT, H BJ, Robert B, Sharon R, M MJ. Impact of early administration of sertraline on depressive symptoms in the first year after traumatic brain injury. Journal of neurotrauma. 2009;26:1921-1928.
301.	A OE. The efficacy of fluvoxamine in patients with severe depression. Progress in neuro-psychopharmacology & biological psychiatry. 1994;18:731-740.
302.	A PA, Ting-Kai L. Treatments for alcohol dependence: Rethinking the role of comorbidity and clinical subtypes. American journal of psychiatry. 2010;167:620-622.
303.	A PL, C MJ, H KJ, C LA, Laura P, L MN. "Sexual functioning in chronically depressed patients with SSRI antidepressants: A pilot study": Reply. American journal of psychiatry. 1999;156:808.
304.	A PM, E RM, C JL, Ernst G, R SJ, P RS. The external validity of MRI-defined vascular depression. International journal of geriatric psychiatry. 2013;28:1189-1196.
305.	A PR, Bengt M, Neven H, et al. Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. Journal of psychiatric research. 2012;46:1333-1338.
306.	A PT, C BP, G TS, et al. Randomized trial of combined treatment versus usual care plus antidepressant in depressed oncologic patients: One-year follow-up. Journal of clinical oncology. 2010.
307.	A RD, Juned S, Lori F, et al. Cost-effectiveness of Evidence-Based Pharmacotherapy or Cognitive Behavior Therapy Compared With Community Referral for Major Depression in Predominantly Low-Income Minority Women. Archives of general psychiatry. 2005;62:868-875.
308.	A RM. Dr. Riddle replies. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:128-130.
309.	A RR, Douglas KF, E GR, Diana C. A comparison between fluoxetine and doxepin in depressed patients. Current therapeutic research, clinical and experimental. 1989;46:842-848.
310.	A RR, Jeffery C, Robin R, et al. Comparison of fluoxetine and desipramine in depressed outpatients. Current therapeutic research, clinical and experimental. 1993;53:457-465.
311.	A RR, Robin R, Margaret O, et al. Comparison of fluvoxamine and amitriptyline in depressed outpatients. Current therapeutic research, clinical and experimental. 1994;55:243-250.
312.	A SA, E LP, Robin HGY, Claudia J. Stay the course-is it justified? [References]. Lancet. 2012;379:220.
313.	A SC, C RT, E AS, B CT. Effects of long-term sertraline treatment and depression on coronary artery atherosclerosis in premenopausal female primates. Psychosomatic medicine. 2015;77:267-278.
314.	A SD, A MJ, L HA, R HD, J ND, Brian H. Comparison of Alterations in c-fos and Egr-l (zif268) Expression Throughout the Rat Brain Following Acute Administration of Different Classes of Antidepressant Compounds. Neuropsychopharmacology. 2005;30:1278-1287.
315.	A SD, David D, Nina E, Steve G. Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos. Depression and anxiety. 2008;25:774-786.
316.	A SF, T YB, Viorel L, Aurora S, Daniel D. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating clinical depression: A randomized clinical trial. Journal of clinical psychology. 2009;65:36-52.
317.	A SJ, Gilaberte I, Boto B, et al. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: Results from a randomized, double-blind clinical trial. International clinical psychopharmacology. 2000;15:107-113.
318.	A SR, L AL, L RN, et al. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Journal of clinical psychiatry. 2000;61:942-946.
319.	A TM, C QL, Filip DF, Marleen DB, Frederic R, Michael BR. Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy. Depression and anxiety. 2015;32:213-220.
320.	A VM. Bupropion for smoking cessation: From the rationale to the quantitative aspects of the results. Acta cardiologica. 2001;56:319-321.
321.	A VR, R CA, S PD. Pharmacotherapy of depressed children and adolescents: current issues and potential directions. [Review] [87 refs]. Biological psychiatry. 2006;59:1021-1028.
322.	A vW, LP H, Westphal A, Harter M, Kriston L. Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis. BMC psychiatry. 2012.
323.	A VW, LP H, Westphal A, Harter M, Kriston L. Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants in the Acute Treatment of Chronic Depression and Dysthymia: a Systematic Review and Meta-Analysis. Journal of affective disorders. 2013;144:7-15.
324.	A WE, D SD. Atypical antidepressants versus imipramine in the treatment of major depression: A meta-analysis. Journal of clinical psychiatry. 1993;54:5-12.
325.	A WE, D SD. "Efficacy of newer antidepressants": Reply. Journal of clinical psychiatry. 1994;55:499-500.
326.	A YK, Christina G, Anita W, Kimberly N, John RA. Paroxetine as a Treatment for Premenstrual Dysphoric Disorder. Journal of clinical psychopharmacology. 1996;16:3-8.
327.	A YK, Haiqun L, B HH, Christopher HA, S CL. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: A randomized controlled trial with paroxetine. Journal of clinical psychiatry. 2008;69:659-665.
328.	A YK, Uriel H, Ellen F, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA: Journal of the American Medical Association. 1997;278:983-988.
329.	A YK, Uriel H, Ellen F, Candace B, Pearlstein T. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacology bulletin. 1996;32:41-46.
330.	A YS, H HP, M BD, S HR. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial. Journal of clinical psychiatry. 1998;59:76-80.
331.	A-K A, Mergl R, Hautzinger M, et al. Treatment of atypical depression: Post-hoc analysis of a RCT testing the efficacy of sertraline and CBT in primary care patients. European psychiatry.
332.	A-L W, Y-F Y. Curative effects on post-stroke depression with Wuling capsule versus Sailuote capsule. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:4-6.
333.	A-M R, M-P A, Parker G. Role of omega-3 fatty acids as a treatment for depression in the perinatal period. Australian and New Zealand journal of psychiatry. 2005;39:274-280.
334.	A-Q S, Dang L. Treatment of accompanied depression in subcortical arteriosclerotic encephalopathy. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:7-9.
335.	A-R E-Z. Hepatitis C comorbidities affecting the course and response to therapy. World journal of gastroenterology. 2009;15:4993-4999.
336.	AA A, SJ N, Bernier D, Tarzwell R, ME B. Review of psychodynamic psychotherapy neuroimaging studies. Psychotherapy and psychosomatics. 2014;83:142-147.
337.	AA A, Trinquart L, Baron G, Desvarieux M, Ravaud P. Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants. BMC medicine. 2012;10:142.
338.	AA A-A, KC W, UK B. Depression in terminally ILL patients: Dilemmas in diagnosis and treatment. Journal of pain and symptom management. 2013;45:926-933.
339.	AA A-E, AM A-F, MA A-A, AA A-N, GM M, Elshazly M. Knowledge and attitude of primary care doctors towards management of postmenopausal symptoms. Alexandria Journal of Medicine. 2012;48:167-173.
340.	AA C. Focus on paroxetine: A potent, selective serotonin uptake inhibitor for use in major depression. Hospital formulary. 1992;27:445-463.
341.	AA C, Lewis G, SJ L, MR M. Systematic Review and Meta-Analysis of Serotonin Transporter Genotype and Discontinuation From Antidepressant Treatment. European neuropsychopharmacology. 2013;23:1143-1150.
342.	AA D, Ravindran A, Allgulander C, SP K, Austin C, Burt T. Sertraline in Generalized Anxiety Disorder: Efficacy in Treating the Psychic and Somatic Anxiety Factors. Acta psychiatrica Scandinavica. 2005;111:429-435.
343.	AA D, Ravindran A, Allgulander C, SP K, Austin C, Burt T. Sertraline in Generalized Anxiety Disorder: Efficacy in Treating the Psychic and Somatic Anxiety Factors. Acta psychiatrica Scandinavica. 2005;111:429-435.
344.	AA DS, J DS, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. Journal of substance abuse treatment. 2008;34:460-463.
345.	AA G, Cosgrove L, Shuv-Ami I, EE W, MJ Y, HJ B. Dynamic informed consent processes vital for treatment with antidepressants. International journal of law and psychiatry. 2012;35:392-397.
346.	AA G, Vishne T, Grunhaus L. Dopamine D2-Like Receptors and the Antidepressant Response. Biological psychiatry. 2007;61:145-153.
347.	AA H, SL K, BC H, R AC, Jordan N, TL-B P. Transcranial magnetic stimulation: Potential treatment for co-occurring alcohol, traumatic brain injury and posttraumatic stress disorders. Neural Regeneration Research. 2014;9:1712-1730.
348.	AA H, YTB L, Markou A. Fluoxetine Combined With a Serotonin-1a Receptor Antagonist Reversed Reward Deficits Observed During Nicotine and Amphetamine Withdrawal in Rats. Neuropsychopharmacology. 2001;25:55-71.
349.	AA L. Pharmacology. Journal of pediatric gastroenterology and nutrition. 2008;47:703-705.
350.	AA M, Hebrani P, Mortezania M, MB H, Javanbakht A. Baclofen Add-on to Citalopram in Treatment of Posttraumatic Stress Disorder. Journal of clinical psychopharmacology. 2014;34:240-243.
351.	AA M, Husum H, AE K, et al. Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role? Physiology & behavior. 2007;92:226-231.
352.	AA M, RK P. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. Journal of supportive oncology. 2006;4:43-52.
353.	AA M-W, DA T, NT M, IG W, JM A, GJ H. Antidepressants and inflammatory bowel disease: A systematic review. Clinical practice and epidemiology in mental health. 2006.
354.	AA M-W, Turnbull D, Holtmann G, JM A. An integrated model of care for inflammatory bowel disease sufferers in Australia: Development and the effects of its implementation. Inflammatory bowel diseases. 2012;18:1573-1581.
355.	AA N. Do Some Antidepressants Work Faster Than Others? Journal of clinical psychiatry. 2001;62:22-25.
356.	AA N. Long-Term Management of Chronic Depression. Journal of clinical psychiatry. 2001;62:17-21.
357.	AA N. An analysis of the efficacy of treatments for bipolar depression. Journal of clinical psychiatry. 2008;69:4-8.
358.	AA N. A critical appraisal of treatments for bipolar disorder. Primary care companion to the Journal of clinical psychiatry. 2010;12:23-29.
359.	AA N. Lessons from the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) effectiveness trial: What have we learned? Where do we go from here? Bipolar disorders. 2010;Conference:62.
360.	AA N. Dr Nierenberg replies. Journal of clinical psychiatry. 2011;72:1015-1016.
361.	AA N, AH F, JE A, et al. Timing of Onset of Antidepressant Response With Fluoxetine Treatment. American journal of psychiatry. 2000;157:1423-1428.
362.	AA N, Akhondzadeh S, Tahmacebi-Pour N, AH J. Hydro-Alcoholic Extract of Crocus Sativus L. Versus Fluoxetine in the Treatment of Mild to Moderate Depression: a Double-Blind, Randomized Pilot Trial. Journal of ethnopharmacology. 2005;97:281-284.
363.	AA N, Akhondzadeh S, Tahmacebi-Pour N, AH J. Hydro-Alcoholic Extract of Crocus Sativus L. Versus Fluoxetine in the Treatment of Mild to Moderate Depression: a Double-Blind, Randomized Pilot Trial. Journal of ethnopharmacology. 2005;97:281-284.
364.	AA N, BR K, VC L, et al. Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine. Journal of clinical psychiatry. 1999;60:221-225.
365.	AA N, EC W. Evolution of Remission as the New Standard in the Treatment of Depression. Journal of clinical psychiatry. 1999;60:7-11.
366.	AA N, Fava M, MH T, et al. A Comparison of Lithium and T-3 Augmentation Following Two Failed Medication Treatments for Depression: a Star*D Report. American journal of psychiatry. 2006;163:1519-1530.
367.	AA N, Fava M, MH T, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. American journal of psychiatry. 2006;163:1519-1530; quiz 1665.
368.	AA N, JE A. Depressive breakthrough. Psychiatric clinics of North America. 2000;23:731-742.
369.	AA N, JE A, BN G, et al. Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. Journal of affective disorders. 2008;108:129-134.
370.	AA N, JE A, Pava J, JF R, Fava M. Course and Treatment of Atypical Depression. Journal of clinical psychiatry. 1998;59:5-9.
371.	AA N, JH G, CH M, et al. Onset of Antidepressant Action and Acute Efficacy and Safety of Duloxetine Versus Escitalopram and Placebo in the Treatment of Major Depressive Disorder. Neuropsychopharmacology. 2005;30:S142.
372.	Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depressive Disorder: Onset of Antidepressant Action, a Non-Inferiority Study, Current medical research and opinion(2007).
373.	AA N, Kansky C, BP B, RC S, Perlis R, DV I. Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. Australian and New Zealand journal of psychiatry. 2013;47:26-42.
374.	AA N, MH T, BN G, et al. Effectiveness Study of Venlafaxine-Xr Combined With Aripiprazole for Chronic or Recurrent Major Depressive Disorder. Australian and New Zealand journal of psychiatry. 2009;43:956-967.
375.	AA N, MJ O, JC H, RM A, Fava M, RH P. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. Journal of Occupational and Environmental Medicine. 2008;50:428-436.
376.	AA N, MJ O, JR C, et al. Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American journal of psychiatry. 2006;163:210-216.
377.	Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report, Psychological medicine(2010).
378.	AA N, NE M, JE A, JJ W, JF R, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. American journal of psychiatry. 1995;152:1500-1503.
379.	AA N, SJ G, Fava M, JF R. Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. Journal of affective disorders. 1995;34:73-77.
380.	AA N, TA K, RH P, Sanacora G, ME T. Easing the burden of bipolar disorder: From urgent situations to remission. Primary care companion to the Journal of clinical psychiatry. 2008;10:391-402.
381.	AA N, TJ P, JE A. Prevention of Relapse and Recurrence in Depression: The Role of Long-Term Pharmacotherapy and Psychotherapy. Journal of clinical psychiatry. 2003;64:13-17.
382.	AA NdB. New antidepressants: Advantages and disadvantages. Adverse effects of mirtazapine. [Portuguese]. Revista Brasileira de Neurologia e Psiquiatria. 1999;3:103-107.
383.	AA P, Bilal L, PS M. Management of fibromyalgia. Current psychiatry reports. 2003;5:218-224.
384.	AA P, GJ T. Drug Treatment of Depression in Hiv-Positive Patients - Safety Considerations. Drug safety. 2005;28:753-762.
385.	AA P, GJ T. Drug Treatment of Depression in Hiv-Positive Patients - Safety Considerations. Drug safety. 2005;28:753-762.
386.	AA P, KB P, C-U P. Selegiline transdermal system in major depressive disorder. Neuropsychiatry. 2012;2:125-134.
387.	AA P, NB P, YV P, KG E. Efficacy of Agomelatine in Depressive Disorders With Anxiety. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2013;113:53-+.
388.	AA P, Peindl K, Mago R, Mannelli P, PS M. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Primary care companion to the Journal of clinical psychiatry. 2006;8:82-87.
389.	AA P, PS M, C-U P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. Journal of clinical psychopharmacology. 2006;26:653-656.
390.	AA P, PS M, Krulewicz S, et al. A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia. American journal of medicine. 2007;120:448-454.
391.	AA R, MT K. Neurologic complications of anesthesia A practical approach. Neurology: Clinical Practice. 2013;3:295-304.
392.	Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with Comorbid depression: A meta-analysis of depression and cognitive outcomes, Drugs & aging(2012).
393.	AA S, Potvin S, Elie R, Stip E. Selective Serotonin Reuptake Inhibitor (Ssri) Add-on Therapy for the Negative Symptoms of Schizophrenia: a Meta-Analysis. Journal of clinical psychiatry. 2007;68:604-610.
394.	AA SS, RL T, RS E-M. Antipsychotic medications in the treatment of bipolar disorder. Current drug targets. 2006;7:1217-1224.
395.	AA W, LA P, EJ S, Ell K. Low-income cancer patients in depression treatment: dropouts and completers. Journal of behavioral health services & research. 2013;40:427-441.
396.	AA W, LA P, XX Q, Ell K. Cancer Patients' Perspectives on Discontinuing Depression Treatment: the "Drop Out" Phenomenon. Patient preference and adherence. 2011;5:465-470.
397.	Lu-Aa21004, a Multimodal Serotonergic Agent, for the Potential Treatment of Depression and Anxiety, IDrugs : the investigational drugs journal(2010).
398.	AABA B. Tdcs as an Add-on Therapy: the Augmentative Role of Tdcs for the Treatment of Depression. Biological psychiatry. 2014;75:3S.
399.	AAGA G. The Extended-Release Formulation of Quetiapine Fumarate (Quetiapine Xr) Adjunctive Treatment in Partially Responsive Generalized Anxiety Disorder (Gad): an Open Label Naturalistic Study. Clinica terapeutica. 2011;162:113-118.
400.	AAGA G. Risperidone, Quetiapine, and Olanzapine Adjunctive Treatments in Major Depression With Psychotic Features: a Comparative Study. Neuropsychiatric disease and treatment. 2013;9:485-492.
401.	AAHAJ H. Pragmatic Consideration of Recent Randomized, Placebo-Controlled Clinical Trials for Treatment of Fibromyalgia. Current pain and headache reports. 2008;12:393-398.
402.	AALAC L. Evolution of Psychopharmacology Trial Design and Analysis: Six Decades in the Making. Journal of clinical psychiatry. 2011;72:331-340.
403.	AALAFG L. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. [Review]. Drugs. 2011;71:273-286.
404.	Aapro M, Cull A. Depression in breast cancer patients: The need for treatment. Annals of oncology. 1999;10:627-636.
405.	Aarsland D. Interview: Unraveling the neuropsychiatric symptoms of Parkinson's and Alzheimer's disease: Current and future progress. Neurodegenerative disease management. 2012;2:455-457.
406.	Aarsland D, Ehrt U, Rektorova I. Cognitive and psychiatric disturbances in Parkinsons disease. Aging health. 2011;7:123-142.
407.	Aarsland D, J-P T, Weintraub D. Psychiatric issues in cognitive impairment. Movement disorders. 2014;29:651-662.
408.	Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Movement disorders. 2009;24:2175-2186.
409.	Aarsland D, Pahlhagen S, CG B, Ehrt U, Svenningsson P. Depression in Parkinson disease - Epidemiology, mechanisms and management. Nature reviews. Neurology. 2012;8:35-47.
410.	AB B, Bhaumik S, Branford D. Treatment-Emergent Behavioural Side Effects With Selective Serotonin Re-Uptake Inhibitors in Adults With Learning Disabilities. Human Psychopharmacology-Clinical and Experimental. 2001;16:133-137.
411.	AB B, Jancke L, Herwig U. Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants. Psychopharmacology. 2011;216:389-399.
412.	AB B, Kaffenberger T, Herwig U. Serotonergic and Noradrenergic Modulation of Emotion Processing by Single Dose Antidepressants. Neuropsychopharmacology. 2010;35:521-533.
413.	AB E. Psychotropic effects of antiepileptic drugs. Neurology. 2006;67:1916-1925.
414.	AB E. Antidepressants in rapid-cycling bipolar disorder. British journal of psychiatry. 2013;203:75.
415.	AB E, CE A. Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain. Neurotherapeutics. 2007;4:75-83.
416.	AB L, Kirst N, CG S. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. American family physician. 2015;91:617-624.
417.	AB OC, SR S, DN H, JD M, RH D. Pain associated with multiple sclerosis: Systematic review and proposed classification. Pain. 2008;137:96-111.
418.	AB S, AV A, IV M, ASh T, EV K. [The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 1994;Korsakova.:60-64.
419.	AB S, CA B, CH N, Byron K, Berk M. Abcb1 Polymorphism Predicts Escitalopram Dose Needed for Remission in Major Depression. Translational psychiatry. 2012;2.
420.	AB S, CA B, CH N, Byron K, Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry Psychiatry. 2012;2:e198.
421.	AB S, CA B, CH N, Byron K, Berk M. Psychomotor depressive symptoms may differentially respond to venlafaxine. International clinical psychopharmacology. 2013;28:121-126.
422.	AB S, CA B, CH N, Byron K, Berk M. Blood brain barrier polymorphism predicts escitalopram dose needed for remission in major depression. Australian and New Zealand journal of psychiatry. 2014;Conference:97-98.
423.	AB S, CA B, CH N, Byron K, Berk M. Effects of Persisting Emotional Impact From Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: a Pilot Study. Clinical Psychopharmacology and Neuroscience. 2015;13:53-61.
424.	AB S, TB P, WA B. Fluoxetine in the treatment of premenstrual syndrome. Psychopharmacology bulletin. 1990;26:331-335.
425.	AB S, TB P, WA B. Fluoxetine in the Treatment of Late Luteal Phase Dysphoric Disorder. Journal of clinical psychiatry. 1991;52:290-293.
426.	AB Z. Special considerations in early-stage breast cancer patients and survivors. Obstetrics and gynecology clinics of North America. 2013;40:573-582.
427.	Abascal K, Yarnell E. New St. John's wort study raises more questions than answers. Alternative and Complementary Therapies. 2001;7:171-173.
428.	Abbas G, RA J, KD L. Fatigue in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology. 2010;7:313-319.
429.	Abbasowa L, LV K, Vinberg M. Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials. Nordic journal of psychiatry. 2013;67:369-382.
430.	Abedini H, Farshi S, Mirabzadeh A, Keshavarz S. Antidepressant Effects of Citalopram on Treatment of Alopecia Areata in Patients With Major Depressive Disorder. Journal of dermatological treatment. 2014;25:153-155.
431.	Abel K. Psychiatric illness and its management in pregnancy and the puerperium. Contemporary Clinical Gynecology and Obstetrics. 2002;2:59-71.
432.	Abel S. Progress ni chromatographic separation. Manufacturing Chemist. 2007;78:34-36.
433.	Abell CA, Farquhar DL, McL GS, Fiona S, Philip AE, Munro JF. Placebo controlled double-blind trial of fluvoxamine maleate in the obese. Journal of psychosomatic research. 1986;30:143-146.
434.	Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, Aperia B, BF K, AA M. Serotonergic 'vulnerability' in Affective Disorder: a Study of the Tryptophan Depletion Test and Relationships Between Peripheral and Central Serotonin Indexes in Citalopram-Responders. Acta psychiatrica Scandinavica. 1998;97:374-380.
435.	Abler B, Seeringer A, Hartmann A, et al. Neural Correlates of Antidepressant-Related Sexual Dysfunction: a Placebo-Controlled Fmri Study on Healthy Males Under Subchronic Paroxetine and Bupropion. Neuropsychopharmacology. 2011;36:1837-1847.
436.	Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the Management of Pain in Older Adults With Knee Osteoarthritis: Randomised Placebo-Controlled Trial. Age and ageing. 2012;41:646-652.
437.	Aboujaoude E, JJ B, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Journal of clinical psychopharmacology. 2009;29:51-55.
438.	Aboukhatwa M, Dosanjh L, Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Molecular neurodegeneration. 2010.
439.	Abrahamian H, Hofmann P, Kinzl J, Toplak H. Diabetes Mellitus and Comorbid Depression: Improvement of Both Diseases With Milnacipran. A Replication Study (Results of the Austrian Major Depression Diabetes Mellitus Study Group). Neuropsychiatric disease and treatment. 2012;8:355-360.
440.	Abramowicz M, Zuccotti G, J-M P, et al. Tetrabenazine (Xenazine) for Huntington's chorea. Medical letter on drugs and therapeutics. 2009;51:7-8.
441.	AC A. New acquisitions on pharmacological treatment. [Italian]. Quaderni Italiani di Psichiatria. 2008;27:43-44.
442.	AC A, Benatti B, Dell'Osso B. Use of atypical antipsychotics as mono/polytherapy with mood stabilizers for the treatment of bipolar disorder. An update. Current Psychopharmacology. 2013;2:47-53.
443.	AC A, Bengtsson F, L VK, Ekselius L. Response, Remission and Relapse in Relation to Adherence in Primary Care Treatment of Depression: a 2-Year Outcome Study. International clinical psychopharmacology. 2006;21:117-124.
444.	AC A, Buoli M, Serati M. Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. Neuropsychiatry. 2011;1:81-90.
445.	AC A, F DN, Guercetti G, Invernizzi G, Percudani M, SA M. Fluoxetine compared with amitriptyline in elderly depression: A controlled clinical trial. International journal of clinical pharmacology research. 1989;9:391-396.
446.	AC A, Lietti L, Dobrea C, Benatti B, Arici C, Dellosso B. Mood stabilizers for patients with bipolar disorder: The state of the art. Expert review of neurotherapeutics. 2011;11:85-99.
447.	AC A, Percudani M. The Use of Antidepressants for Long-Term Treatment of Recurrent Depression - Rationale, Current Methodologies, and Future-Directions. Journal of clinical psychiatry. 1993;54:29-37.
448.	AC A, Pozzoli S, MF B. Long-term treatment of unipolar depression: Focus on the treatment with venlafaxine XR. [Italian]. Italian Journal of Psychopathology. 2006;12:371-381.
449.	AC A, SA M, JF W. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry - Supplementum. 1988:109-112.
450.	AC D, MH P. Establishment of Remission Criteria for Anxiety Disorders. Journal of clinical psychiatry. 2003;64:40-45.
451.	AC DF, ML C. Mood disorders in children and adolescents: Update for pediatricians. Jornal de pediatria. 2011;87:373-381.
452.	AC F, CB N. Selective serotonin reuptake inhibitors in the treatment of depression. Expert opinion on investigational drugs. 1996;5:101-108.
453.	AC H, Rimondini R, Heilig M, AA M, WH S. Dissociation of antidepressant-like activity of escitalopram and nortriptyline on behaviour and hippocampal BDNF expression in female rats. Journal of psychopharmacology (Oxford, England). 2011;25:1378-1387.
454.	AC L. Challenges in designing comparative-effectiveness trials for antidepressants. Clinical pharmacology and therapeutics. 2012;91:165-167.
455.	AC L, Blier P, Culpepper L, et al. An ideal trial to test differential onset of antidepressant effect. Journal of clinical psychiatry. 2001;62 Suppl 4:34-40.
456.	AC L, Blier P, Culpepper L, et al. An Ideal Trial to Test Differential Onset of Antidepressant Effect. Journal of clinical psychiatry. 2001;62:34-36.
457.	AC L, DA S, Li C, et al. Antidepressants and risks of suicide and suicide attempts: A 27-year observational study. Journal of clinical psychiatry. 2011;72:580-586.
458.	AC P. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine) : An evidence-based review. Psychopharmacology. 2007;191:181-193.
459.	AC S, PM D. Focus on citalopram: A selective reuptake inhibitor for the treatment of depression. Formulary (Cleveland, Ohio). 1998;33:725-743.
460.	AC T, DH K, GP H, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. American journal of public health. 2013;103:308-315.
461.	AC V, JHM T, WW VDB, JA B, Passchier J, Pepplinkhuizen L. 24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder. European neuropsychopharmacology. 2002;12:273-278.
462.	AC V, JHM T, WW VDB, JA B, Passchier J, Pepplinkhuizen L. Effects of Imipramine, Fluvoxamine and Depressive Mood on Autonomic Cardiac Functioning in Major Depressive Disorder. Pharmacopsychiatry. 2004;37:18-25.
463.	AC V, JHM T, WW VDB, JA B, Passchier J, Pepplinkhuizen L. Effects of Imipramine, Fluvoxamine and Depressive Mood on Autonomic Cardiac Functioning in Major Depressive Disorder. Pharmacopsychiatry. 2004;37:18-25.
464.	AC V, RJ B, Friedberg J. Discontinuing antidepressant treatment in major depression. Harvard review of psychiatry. 1998;5:293-306.
465.	AC W, Sundstrom-Poromaa I, Allard P, Mjorndal T, Spigset O, Backstrom T. Influence of Postmenopausal Hormone Replacement Therapy on Platelet Serotonin Uptake Site and Seroton(2a) Receptor Binding. Obstetrics and gynecology. 2001;98:450-457.
466.	Acciarresi M, Bogousslavsky J, Paciaroni M. Post-stroke fatigue: Epidemiology, clinical characteristics and treatment. European neurology. 2014;72:255-261.
467.	Achab S, Khazaal Y. Psychopharmacological treatment in pathological gambling: A critical review. Current pharmaceutical design. 2011;17:1389-1395.
468.	Acharya N. Duloxetine: Meta-Analyses of Suicidal Behaviors and Ideation in Clinical Trials for Major Depressive Disorder (Vol 6, Pg 587, 2006). Journal of clinical psychopharmacology. 2007;27:57.
469.	Acharya T, Acharya S, Tringali S, Huang J. Association of Antidepressant and Atypical Antipsychotic Use With Cardiovascular Events and Mortality in a Veteran Population. Pharmacotherapy. 2013;33:1053-1061.
470.	Prospects for improving brain function in individuals with down syndrome, CNS drugs(2013).
471.	Acuna C. Duloxetine for the Treatment of Fibromyalgia. Drugs of today (Barcelona, Spain : 1998). 2008;44:725-734.
472.	AD C, RM K. Sertraline in stuttering [3]. Journal of clinical psychopharmacology. 1995;15:443-444.
473.	AD D, VA M, DA R, AC U. The risks of selective serotonin reuptake inhibitor use in infertile women: A review of the impact on fertility, pregnancy, neonatal health and beyond. Human reproduction (Oxford, England). 2013;28:160-171.
474.	AD F, JF H, RK S, et al. Gepirone extended-release: New evidence for efficacy in the treatment of major depressive disorder. Journal of clinical psychiatry. 2003;64:243-249.
475.	AD F, Rickels K, MA R, DL Z, DS R. Selegiline Transdermal System for the Treatment of Major Depressive Disorder: an 8-Week, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Trial. Journal of clinical psychiatry. 2006;67:1354-1361.
476.	AD F, RJ B, Bremner J, et al. Double-Blind, Placebo-Substitution Study of Nefazodone in the Prevention of Relapse During Continuation Treatment of Outpatients With Major Depression. International clinical psychopharmacology. 1999;14:19-28.
477.	AD K. Depression and insomnia in women. Clinical cornerstone. 2004;6:S19-S28.
478.	AD K. Treating the health, quality of life, and functional impairments in insomnia. Journal of clinical sleep medicine. 2007;3:63-72.
479.	AD K. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep medicine reviews. 2009;13:265-274.
480.	A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression, Journal of clinical psychiatry(2010).
481.	AD M, CA P. Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. Journal of child and adolescent psychopharmacology. 2006;16:33-36.
482.	AD M, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: A meta-analysis. Journal of child and adolescent psychopharmacology. 2006;16:25-32.
483.	AD V. Cancer pain and depression: Management of the dual-diagnosed patient. Current pain and headache reports. 2003;7:262-269.
484.	AD W, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. [Review] [95 refs]. American journal of health-system pharmacy. 2005;62:2481-2490.
485.	Adam G, F KJ, Amanda DM, Patricia H, Carmen A, FIII RC. Anxiety impairs depression remission in partial responders during extended treatment in late-life. Depression and anxiety. 2010;27:451-456.
486.	Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies. Psychological medicine. 2000;30:89-94.
487.	Adegbite-Adeniyi C, Gron B, BM R, CA D, RL F. An update on antidepressant use and suicidality in pediatric depression. Expert opinion on pharmacotherapy. 2012;13:2119-2130.
488.	Adell A. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?. [Review] [133 refs][Erratum appears in Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3)269]. Current drug targets. CNS and neurological disorders. 2004;3:113-121.
489.	Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug discovery today. 2005;10:578-585.
490.	Adetunji B, Basil B, Mathews M, Osinowo T. Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes [1]. Annals of pharmacotherapy. 2007;41:359.
491.	Adetunji B, Mathews J, Basil B, et al. Child psychopharmacology, effect sizes, and the big bang. American journal of psychiatry. 2005;162:818; author reply 818-819.
492.	Adi Y, Juarez-Garcia A, Wang D, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health technology assessment. 2007;11:iii-55.
493.	Adida M, Kaladjian A, Fakra E, Belzeaux R, JM A. Co-Occuring Mood and Substance Use Disorders. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2014;40:S8-S13.
494.	Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European archives of psychiatry and clinical neuroscience. 2005;255:387-400.
495.	Adli M, Wiethoff K, Baethge C, Pfennig A, Stamm T, Bauer M. Olanzapine in the treatment of depression with psychotic features: A prospective open-label study. International journal of psychiatry in clinical practice. 2008;12:202-209.
496.	Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992;32:101-104.
497.	Adriana D, Marc B, Valerie P. Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning. Journal of psychopharmacology (Oxford, England). 1997;11:S17-S23.
498.	Advokat C, Kutlesic V. Pharmacotherapy of the eating disorders: A commentary. Neuroscience and biobehavioral reviews. 1995;19:59-66.
499.	Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease, Pharmacology & therapeutics(2013).
500.	AE B, Tang G, Mazumdar S, et al. Use of OSWALD for analyzing longitudinal data with informative dropout. Computer methods and programs in biomedicine. 2007;85:109-114.
501.	AE C, Monaco F. Placebo treatments: Historical overview and current concepts. [Italian]. Confinia Cephalalgica. 2006;15:3-11.
502.	AE C, Nani A. Antiepileptic drugs and tourette syndrome. International review of neurobiology. 2013;112:373-389.
503.	AE C, Tuulio-Henriksson A, Marttunen M, Suvisaari J, Lonnqvist J. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. Journal of affective disorders. 2008;106:1-27.
504.	AE E, DC G. Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia. CNS drugs. 1996;6:130-147.
505.	AE E, Demopulos C, Yovel I, et al. Inositol Augmentation of Lithium or Valproate for Bipolar Depression. Bipolar disorders. 2006;8:168-174.
506.	AE F. Fluoxetine-induced suicidal ideation: An examination of the medical literature, case law, and the legal liability of drug manufacturers. Food and drug law journal. 2002;57:273-292+iii.
507.	AE G, DJ C, CS G. Medical management of stress urinary incontinence: Is there a future? Current urology reports. 2009;10:401-407.
508.	AE K, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of Citalopram on Climacteric Symptoms. Menopause-the Journal of the North American Menopause Society. 2007;14:223-229.
509.	AE N, Machado S, LF A, et al. Clonazepam for the treatment of panic disorder. Current drug targets. 2013;14:353-364.
510.	AE N, Perna G. Clonazepam in the treatment of psychiatric disorders: An update. International clinical psychopharmacology. 2006;21:131-142.
511.	AE S. Treatment of severe depression with the selective serotonin reuptake inhibitors. Depression and anxiety. 1997;4:182-189.
512.	AE VR, DE A, Kotlyar M. Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality. Journal of cardiovascular pharmacology and therapeutics. 2008;13:32-40.
513.	AEJ M, Mackenzie A, AD W, Smith J, Andrews G. Internet cognitive behavioural treatment for obsessive compulsive disorder: A randomised controlled trial. Behaviour research and therapy. 2014;63:99-106.
514.	AF C. Incidences of New Prescribing by British Child and Adolescent Psychiatrists: a Prospective Study Over 12 Months. Journal of psychopharmacology (Oxford, England). 2004;18:115-120.
515.	AF C. Incidences of New Prescribing by British Child and Adolescent Psychiatrists: a Prospective Study Over 12 Months. Journal of psychopharmacology (Oxford, England). 2004;18:115-120.
516.	AF C, Berk M, TN H, RS M. The integrative management of treatment-resistant depression: A comprehensive review and perspectives. Psychotherapy and psychosomatics. 2014;83:70-88.
517.	AF C, Berk M, TN H, RS M. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. [Review]. Psychotherapy and psychosomatics. 2014;83:70-88.
518.	AF C, DQC R, RS M, et al. Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. Journal of psychiatric research. 2014;59:28-37.
519.	AF C, Hyphantis T, PMG S, et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. [Review]. Cancer treatment reviews. 2014;40:349-355.
520.	AF C, JL C, MS C, MCO L. Augmentation strategies for treatment-resistant depression: A literature review. Journal of clinical pharmacy and therapeutics. 2007;32:415-428.
521.	AF C, JR M, JL C. Augmentation strategies for treatment-resistant depression. Current opinion in psychiatry. 2009;22:7-12.
522.	AF C, KK M, TN H, et al. Cognitive dysfunction in depression - Pathophysiology and novel targets. CNS and Neurological Disorders - Drug Targets. 2014;13:1819-1835.
523.	AF C, RS M, Dimelis D, et al. Predominant polarity as a course specifier for bipolar disorder: A systematic review. Journal of affective disorders. 2014;163:56-64.
524.	AF J, DJ S. Citalopram and anxiety disorders. Reviews in Contemporary Pharmacotherapy. 1999;10:I-131.
525.	AF J, DJ S. Citalopram and Anxiety Disorders. Reviews in Contemporary Pharmacotherapy. 1999;10:79-131.
526.	AF J, Sanchez C, Larsen F. Citalopram. Human Psychopharmacology-Clinical and Experimental. 2000;15:439-451.
527.	Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression, British journal of psychiatry(2014).
528.	AF L, JE P. Treatment of premenstrual dysphoric disorder with selective serotonin reuptake inhibitors. Pharmacotherapy. 2003;23:1131-1140.
529.	AF L, JT M, AM H, IA C, JE A. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. Journal of clinical psychopharmacology. 2009;29:372-377.
530.	AF L, Morgan M, IA C, Dunkin J, Abrams M, Witte E. Pretreatment Neurophysiological and Clinical Characteristics of Placebo Responders in Treatment Trials for Major Depression. Psychopharmacology. 2004;177:15-22.
531.	AF S. Dosing strategies for antidepressant agents. [Review] [30 refs]. Journal of clinical psychiatry. 1991;52 Suppl:14-20.
532.	AF S. Antidepressant Effectiveness in Severe Depression and Melancholia. Journal of clinical psychiatry. 1999;60:14-22.
533.	AF S. Clinical efficacy of reboxetine in major depression. [Review] [38 refs]. Journal of clinical psychiatry. 2000;61 Suppl 1:31-38.
534.	AF S. New Indications for Antidepressants. Journal of clinical psychiatry. 2000;61:9-17.
535.	AF S. Pros and cons of prozac and its relatives. American journal of psychiatry. 2000;157:323-325.
536.	AF S. New approaches to managing psychotic depression. Journal of clinical psychiatry. 2003;64:19-23.
537.	AF S. Safety and Tolerability of Antidepressants: Weighing the Impact on Treatment Decisions. Journal of clinical psychiatry. 2007;68:26-34.
538.	AF S. ABCB-1: Antidepressant response in geriatric depression and chronic depression. Biological psychiatry. 2014;Conference:23S.
539.	AF S, AJ R, BA A, et al. Chronic Depression - Medication (Nefazodone) or Psychotherapy (Cbasp) Is Effective When the Other Is Not. Archives of general psychiatry. 2005;62:513-520.
540.	AF S, AJ R, BA A, et al. Chronic Depression - Medication (Nefazodone) or Psychotherapy (Cbasp) Is Effective When the Other Is Not. Archives of general psychiatry. 2005;62:513-520.
541.	AF S, Dessain E, O'Neil P, DL K, JO C. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. [Review] [56 refs]. Journal of clinical psychopharmacology. 1987;7:44S-49S.
542.	AF S, HC K. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biological psychiatry. 2000;47:736-744.
543.	AF S, Kremer C, HE R, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. The American Journal of Geriatric Psychiatry. 2002;10:541-550.
544.	AF T, Mohan R, Bhugra D. The evidence base of complementary and alternative therapies in depression. Journal of affective disorders. 2007;97:23-35.
545.	Affan M, Shaikh Q, A KK. Should i prevent my patient from developing depression after stroke? What is the best available option? Journal of the Pakistan Medical Association. 2014;64:603.
546.	Affan M, Shaikh Q, AK K. Should I prevent my patient from developing depression after stroke? What is the best available option? Journal of the Pakistan Medical Association. 2014.
547.	AFG L. Depression in Parkinson's disease: Conceptual issues and clinical challenges. Journal of geriatric psychiatry and neurology. 2004;17:120-126.
548.	AG D, OA P, JPA I. Concordance of sleep and pain outcomes of diverse interventions: An umbrella review. PloS one. 2012.
549.	AG H, Li D. Managing sleep disturbance in bipolar disorder. Current psychiatry reviews. 2009;5:194-201.
550.	AG M, DS B. Antidepressants and Their Effect on Sleep. Human Psychopharmacology-Clinical and Experimental. 2005;20:533-559.
551.	AG M, Frank E, ME T, et al. Monoamine oxidase inhibitors are superior to standard antidepressants in bipolar disorder. Bipolar disorders. 2009;Conference:59.
552.	AG P. Escitalopram and Suicidality in Adult Depression and Anxiety. International clinical psychopharmacology. 2005;20:139-143.
553.	AG P. Adaptogens in Mental and Behavioral Disorders. Psychiatric clinics of North America. 2013;36:49-64.
554.	AG R, CG F, VN O. Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder. Clinical Medicine Insights: Therapeutics. 2012;4:57-63.
555.	AG R, PD B, JC R, Grant R. Depression in glioma: A primer for clinicians and researchers. Journal of neurology, neurosurgery, and psychiatry. 2014;85:230-235.
556.	AG S, ICK W. Rational prescribing for children. British medical journal. 2006;332:1464-1465.
557.	AG V. Adverse event management. Brazilian journal of infectious diseases. 2007;11:66-70.
558.	AG W. Antidepressants in Panic Disorder. International clinical psychopharmacology. 1999;14:S13-S17.
559.	AG W. Closing the Antidepressant Efficacy Gap Between Clinical Trials and Real Patient Populations. International journal of psychiatry in clinical practice. 2006;10:25-31.
560.	AG W, CD K, TE S. Baseline severity of depression predicts antidepressant drug response. European neuropsychopharmacology. 2008;Conference:S294.
561.	AG W, Gembert K, Florea I. A Comparative Study of the Efficacy of Acute and Continuation Treatment With Escitalopram Versus Duloxetine in Patients With Major Depressive Disorder. Current medical research and opinion. 2007;23:1605-1614.
562.	AG W, GM C, Young D. A Survey of patient preferences for a placebo orodispersible tablet. International journal of psychiatry in clinical practice. 2011;Conference:40-41.
563.	AG W, GM C, Young D. A Survey of Patient Preferences for a Placebo Orodispersible Tablet. Patient preference and adherence. 2012;6:201-206.
564.	AG W, Saragoussi D, Despiegel N, Francois C, Guelfucci F, Toumi M. Healthcare Expenditure in Severely Depressed Patients Treated With Escitalopram, Generic Ssris or Venlafaxine in the Uk. Current medical research and opinion. 2010;26:1161-1170.
565.	AG W, Toumi I, ME H. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Current medical research and opinion. 2005;21:631-642.
566.	AG W, Toumi I, MEH H. A Probabilistic Cost-Effectiveness Analysis of Escitalopram, Generic Citalopram and Venlafaxine as a First-Line Treatment of Major Depressive Disorder in the Uk. Current medical research and opinion. 2005;21:631-641.
567.	AG W, Toumi I, MEH H. A Probabilistic Cost-Effectiveness Analysis of Escitalopram, Generic Citalopram and Venlafaxine as a First-Line Treatment of Major Depressive Disorder in the Uk. Current medical research and opinion. 2005;21:631-641.
568.	Agarwal V, Tiwari R. Evolution and concept of DSM 5 disruptive mood dysregulation disorder. Journal of Indian Association for Child and Adolescent Mental Health. 2013;9:96-101.
569.	AGI M, Bacciardi S, Rovai L, et al. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: A retrospective study. International journal of environmental research and public health. 2014;11:12983-12996.
570.	Agid O, AY S, Lerer B. Triiodothyronine Augmentation of Selective Serotonin Reuptake Inhibitors in Posttraumatic Stress Disorder. Journal of clinical psychiatry. 2001;62:169-173.
571.	Agius M, Gardner J, Liu K, Zaman R. An audit to compare the discharge rates between different antidepressant monotherapies prescribed for unipolar depression. European psychiatry.
572.	Agius M, Gardner J, Liu K, Zaman R. An audit comparing suicidality rates between antidepressant monotherapies prescribed for unipolar depression. European psychiatry.
573.	Agius M, Oakham H, S MB, Murphy S. The use of card sort exercises in the prevention of relapse in serious mental illness. Psychiatria Danubina. 2006;18:61-73.
574.	Agnes vM, L HKA, J KGP, Inge H, Gert-Jan H. Treatment of trichotillomania with behavioral therapy or fluoxetine: A randomized, waiting-list controlled study. Archives of general psychiatry. 2003;60:517-522.
575.	Agorastos A, Kellner M, Stiedl O, Muhtz C, Wiedemann K, Demiralay C. Blunted Autonomic Reactivity to Pharmacological Panic Challenge Under Long-Term Escitalopram Treatment in Healthy Men. International journal of neuropsychopharmacology. 2015;18.
576.	Agosti V. One year clinical and psychosocial outcomes of early-onset chronic depression. Journal of affective disorders. 1999;54:171-175.
577.	Agosti V, JW S. Six month follow-up of early-onset chronic depression. Depression. 1996;4:63-67.
578.	Agosti V, JW S. Efficacy and Safety of Antidepressant Monotherapy in the Treatment of Bipolar-Ii Depression. International clinical psychopharmacology. 2007;22:309-311.
579.	Agrawal N, Govender S. Epilepsy and neuropsychiatric comorbidities. Advances in Psychiatric Treatment. 2011;17:44-53.
580.	Aguera-Ortiz L, I RG. Efectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder. [Spanish]. Actas espanolas de psiquiatria. 2006;34:153-161.
581.	Aguera-Ortiz L, Ramos GI. [Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder]. [Spanish]. Actas espanolas de psiquiatria. 2006;34:153-161.
582.	Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. International clinical psychopharmacology. 1993;8:197-202.
583.	Aguglia E, Devanna M, MF D. Role of Selective Serotonin Reuptake Inhibitors on the Treatment of Chronic and/or Resistant Major Depression. Giornale Di Neuropsicofarmacologia. 1995;17:73-77.
584.	Aguglia E, M DV, F DGM. The role of selective serotonin reuptake inhibitors (SSRI) in the treatment of chronic and/or resistant major depression. [Italian]. Giornale di Neuropsicofarmacologia. 1995;17:73-77.
585.	AH B, AD V, OB D, et al. Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of clinical oncology. 2011;29:3862-3868.
586.	AH C. Weight issues with depression and antidepressant medications. Primary psychiatry. 2005;12:19-20.
587.	AH C. Extended-release bupropion: An antidepressant with a broad spectrum of therapeutic activity? Expert opinion on pharmacotherapy. 2007;8:457-466.
588.	AH C. Symptoms related to the menstrual cycle: Diagnosis, prevalence, and treatment. Journal of psychiatric practice. 2008;14:13-21.
589.	AH C, AJ L, JP S. Impact of Antidepressant Side Effects on Adolescent Quality of Life. Canadian Journal of Psychiatry. 2003;48:727-733.
590.	AH C, AL M. Major Depressive Disorder, Antidepressants, and Sexual Dysfunction. Journal of clinical psychiatry. 2006;67:33-37.
591.	AH C, Balon R. The impact of mental illness and psychotropic medications on sexual functioning: The evidence and management (CME). Journal of sexual medicine. 2009;6:1200-1211.
592.	AH C, BJ C, Favit A, et al. Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder: a Meta-Analysis Comparing Selegiline Transdermal System and Placebo Using a Patient-Rated Scale. Journal of clinical psychiatry. 2007;68:1860-1866.
593.	AH C, CS D, AJ L. Clinical review of mania, hostility and suicide-related events in children and adolescents treated with antidepressants. Paediatrics & child health. 2005;10:457-463.
594.	AH C, CS D, AJ L, RA Z. Pediatric depressive disorders: Management priorities in primary care. Current opinion in pediatrics. 2008;20:551-559.
595.	AH C, Dennerstein L, Pyke R, Sand M. Flibanserin: A potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Women's Health. 2010;6:639-653.
596.	AH C, DV H. Female Sexual Dysfunction. Psychiatric clinics of North America. 2010;33:323-338.
597.	AH C, Favit A. Concerns in depression treatment: Sexual dysfunction and weight gain. Primary psychiatry. 2007;14:66-75.
598.	AH C, GJ E, TL M. Review of the efficacy and safety of antidepressants in youth depression. Journal of child psychology and psychiatry, and allied disciplines. 2005;46:735-754.
599.	AH C, GJ E, TL M. The Use of Antidepressants to Treat Depression in Children and Adolescents. CMAJ : Canadian Medical Association journal. 2006;174:193-200.
600.	AH C, Gommoll C, Chen D, Nunez R, Mathews M. Effects of vilazodone on sexual dysfunction in major depressive disorder: Randomised, double-blind trial with placebo and active controls. European neuropsychopharmacology. 2014;Conference:S380-S381.
601.	AH C, HA C, Handiwala L. Antidepressants and Sexual Dysfunction: Mechanisms and Clinical Implications. Postgraduate medicine. 2014;126:91-99.
602.	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate, CNS spectrums(2014).
603.	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate, CNS spectrums(2014).
604.	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate, CNS spectrums(2014).
605.	AH C, LF F, LC S. Major depression, SSRIs and sexual dysfunction in women. Journal of sexual medicine. 2010;Conference:199.
606.	AH C, Reddy S, Focht K, Musgnung J, Fayyad R. An Evaluation of Sexual Functioning in Employed Outpatients With Major Depressive Disorder Treated With Desvenlafaxine 50mg or Placebo. Journal of sexual medicine. 2013;10:768-776.
607.	AH C, RS S, Fayyad R, CM C. Sex Differences in Clinical Presentation and Response in Panic Disorder: Pooled Data From Sertraline Treatment Studies. Archives of women's mental health. 2006;9:151-157.
608.	AH C, S EH, J-P I, C PM, AE S. Sexual Dysfunction Associated With Major Depressive Disorder and Antidepressant Treatment. Expert opinion on drug safety. 2014;13:1361-1374.
609.	AH C, SG K, Rosas G, Guico-Pabia C, KA T. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS spectrums. 2009;14:183-195.
610.	AH C, SG W. Combination therapy in fibromyalgia. Current pharmaceutical design. 2006;12:11-16.
611.	AH C, SH K, JB E, Gallipoli S, CR R. The effect of vilazodone on sexual function during the treatment of major depressive disorder. Journal of sexual medicine. 2013;10:2465-2476.
612.	AH F, Flicker L, Mccaul K, et al. The B-Vitage Trial: a Randomized Trial of Homocysteine Lowering Treatment of Depression in Later Life. Trials. 2010;11.
613.	AH F, Flicker L, McCaul K, et al. The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life.[Erratum appears in Trials. 2011;12:193]. Trials [Electronic Resource]. 2010;11:8.
614.	AH F, Flicker L, Thomas J, Norman P, Jamrozik K, OP A. Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men: Results from a 2-year placebo-controlled randomized trial. Journal of clinical psychiatry. 2008;69:1203-1209.
615.	AH G. Does treating post-myocardial infarction depression reduce medical mortality? Archives of general psychiatry. 2005;62:711-712.
616.	AH G. Depression and cardiovascular comorbidity. Dialogues in clinical neuroscience. 2007;9:9-17.
617.	AH G, CM OC, RM C, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina.[Erratum appears in JAMA 2002 Oct 9;288(14):1720]. JAMA: Journal of the American Medical Association. 2002;288:701-709.
618.	AH G, SP R, JT BJ. The Safety of Tricyclic Antidepressants in Cardiac Patients - Risk-Benefit Reconsidered. Jama-Journal of the American Medical Association. 1993;269:2673-2675.
619.	AH K, Gordon E, AJ R, LM W. Improving the prediction of treatment response in depression: Integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS spectrums. 2008;13:1066-1086.
620.	AH K, MA G, RB S, SM A, PJ N. Augmentation of Serotonin Enhances Pleasant and Suppresses Unpleasant Cortical Electrophysiological Responses to Visual Emotional Stimuli in Humans. NeuroImage. 2004;22:1084-1096.
621.	AH K, MA G, RB S, SM A, PJ N. Augmentation of Serotonin Enhances Pleasant and Suppresses Unpleasant Cortical Electrophysiological Responses to Visual Emotional Stimuli in Humans. NeuroImage. 2004;22:1084-1096.
622.	AH K, Moons P. Psychosocial Functioning and Quality of Life in Adults with Congenital Heart Disease and Heart Failure. Heart failure clinics. 2014;10:35-42.
623.	AH M. Antidepressant prophylaxis for cytokine-induced depression. Biomedicine and Pharmacotherapy. 2001;55:414.
624.	AH M. Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain, behavior, and immunity. 2009;23:149-158.
625.	AH M, Capuron L, CL R. Immunologic influences on emotion regulation. Clinical neuroscience research. 2005;4:325-333.
626.	AH M, Gassenferth A, LR S, JJ F, GT R. omega-3 and major depression: A review. Acta neuropsychiatrica. 2014;26:178-185.
627.	AH M, Gassenferth A, LR S, JJ F, GT R. omega-3 And major depression: A review. Acta neuropsychiatrica. 2014;26:178-185.
628.	AH S, JS G, MA S, NZ Z, HM H, NC G. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. International journal of psychiatry in clinical practice. 2013;17:131-138.
629.	Examining antidepressant drug response by smoking status: Why is it important and how often is it done?, Journal of psychopharmacology (Oxford, England)(2011).
630.	A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I), Journal of clinical psychiatry(2010).
631.	A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar i and bipolar II disorder, World journal of biological psychiatry(2014).
632.	Ahmad G, Arvin H. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depression and anxiety. 2013;30:1084-1088.
633.	Ahmadi H, Daneshmand S. Androgen deprivation therapy: Evidence-based management of side effects. BJU international. 2013;111:543-548.
634.	Ahmed A, LJ DI. Use of beta-blockers in older adults with chronic heart failure. American journal of the medical sciences. 2004;328:100-111.
635.	Ahmed A, Simmons Z. Pseudobulbar Affect: Prevalence and Management. Therapeutics and clinical risk management. 2013;9:483-489.
636.	Ahmed F, IM J, JL H, et al. Seizures During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Observations From the Win-R Trial. Journal of clinical gastroenterology. 2011;45:286-292.
637.	Ahmed S, RA B, DA R, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: Implications for clinical practice and health care policy. Medical care. 2012;50:1060-1070.
638.	Ahmer S, II H, Anderson D, Arya P. Do pharmaceutical companies selectively report clinical trial data? Pakistan Journal of Medical Sciences. 2006;22:338-346.
639.	Ahrens T, Frankhauser P, Lederbogen F, Deuschle M. Effect of Single-Dose Sertraline on the Hypothalamus-Pituitary-Adrenal System, Autonomic Nervous System, and Platelet Function. Journal of clinical psychopharmacology. 2007;27:602-606.
640.	AHV S. Future directions in the treatment of Parkinson's disease. Movement disorders. 2007;22:S385-S391.
641.	AI G, JA L, RM H, et al. Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophrenia research. 2006;86:234-243.
642.	AI G, SL M, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: A placebo-controlled monotherapy trial. Human psychopharmacology. 2008;23:1-11.
643.	AI G, TJ B, Mori N, Casuto L, PE K, SL M. Gender differences in binge eating disorder: A pooled analysis of eleven pharmacotherapy trials from one research group. Journal of men's health. 2014;11:183-188.
644.	AI M, Ong S, LM M, EY P, VL S. Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. International journal of clinical practice. 2006;60:993-1002.
645.	AI N, Fatato P, Shenouda M, et al. The Effects of Desvenlafaxine and Paroxetine on the Pharmacokinetics of the Cytochrome P450 2d6 Substrate Desipramine in Healthy Adults. Journal of clinical pharmacology. 2009;49:219-228.
646.	AI N, KA T, SY T, Paul J. Desvenlafaxine for Major Depressive Disorder: Incremental Clinical Benefits From a Second-Generation Serotonin-Norepinephrine Reuptake Inhibitor. Expert opinion on drug metabolism & toxicology. 2010;6:1565-1574.
647.	Ai Q, J-H Z, Tian G, Yang Y, D-Y L, Gao M. Effect of astragalus - Implant on actions of mice with chronic unpredictable mild stress depression. [Chinese]. Journal of Dalian Medical University. 2010;32:405-407.
648.	Ai Q, Zhang H, Miao Y. Modified decoction of six noble herbs for the behavior and regulation of interleukin-1 beta and interleukin-6 levels in model rats with depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:55-57.
649.	AI S, Walter C, MC N, EM S. Pain management in patients with inflammatory bowel disease: Insights for the clinician. Therapeutic advances in gastroenterology. 2012;5:339-357.
650.	AI V, CM C. Guidelines in the management of diabetic nerve pain: Clinical utility of pregabalin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6:57-78.
651.	Aigner M. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2010;11:86-87.
652.	Ailani J. Chronic tension-type headache. Current pain and headache reports. 2009;13:479-483.
653.	Aina Y, JL S. Understanding comorbidity with depression and anxiety disorders. Journal of the American Osteopathic Association. 2006;106:S9-S14.
654.	Ait S, Gilbert T, Cotton F, Bonnefoy M. Cortical blindness and posterior reversible encephalopathy syndrome in an older patient. BMJ case reports. 2012.
655.	AJ B, HV C, MS B, Osullivan G, Shine P. Behavioural Aggression in Panic Disorder After 8 Weeks' Treatment With Alprazolam. Journal of affective disorders. 1995;35:117-123.
656.	AJ B, Zabrecky G, DA M, AB N. Current evidence regarding the management of mood and anxiety disorders using complementary and alternative medicine. Expert review of neurotherapeutics. 2014;14:411-423.
657.	AJ C. Iloperidone: A new option for the treatment of schizophrenia. Expert review of neurotherapeutics. 2009;9:1727-1741.
658.	AJ C, DL D. The Tridimensional Personality Questionnaire in depression: state versus trait issues. Journal of psychiatric research. 1996;30:21-27.
659.	AJ E, KK U, Bergam K, Russo J, Claypoole K, PP R-B. Randomized, Placebo-Controlled Trial of Paroxetine Versus Imipramine in Depressed Hiv-Positive Outpatients. American journal of psychiatry. 1998;155:367-372.
660.	AJ E, PP R-B. Mirtazapine for Depression in Patients With Human Immunodeficiency Virus. Journal of clinical psychopharmacology. 2000;20:265-267.
661.	AJ F. Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents. Drugs & aging. 1998;13:269-280.
662.	AJ F. Anxiety disorders in late life. Canadian Family Physician. 1999;45:2672-2679.
663.	AJ F. Anxiety disorders in late life. Hong Kong Practitioner. 2000;22:293-299.
664.	AJ F. Generalised Anxiety Disorder in Elderly Patients - Epidemiology, Diagnosis and Treatment Options. Drugs & aging. 2005;22:101-114.
665.	AJ F. Generalised Anxiety Disorder in Elderly Patients - Epidemiology, Diagnosis and Treatment Options. Drugs & aging. 2005;22:101-114.
666.	AJ F, Gagnon N. Diagnosis and Management of Panic Disorder in Older Patients. Drugs & aging. 2003;20:881-891.
667.	Sertraline on risk of falling in older adults with psychotic depression on olanzapine: Results of a randomized placebo-controlled trial, American journal of geriatric psychiatry(2014).
668.	Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: Results of a randomized placebo-controlled trial, The American Journal of Geriatric Psychiatry(2014).
669.	Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial, American journal of geriatric psychiatry(2014).
670.	AJ F, KL N. Telaprevir: A new hope in the treatment of chronic hepatitis C? Advances in therapy. 2010;27:512-522.
671.	AJ F, R VR. The Pharmacologic Treatment of Alzheimer's Disease: a Guide for the General Psychiatrist. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1998;43:689-697.
672.	AJ F, SL R. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. Journal of clinical psychopharmacology. 1994;14:353-356.
673.	AJ F, SL R. Anxious depression in elderly patients. Response to antidepressant treatment. American journal of geriatric psychiatry. 1997;5:107-115.
674.	AJ G, J-O O. Editorial statement. Acta psychiatrica Scandinavica. 1995;91:145.
675.	AJ G, J-O O. Duplicate publication [1]. Journal of clinical psychiatry. 1995;56:81.
676.	AJ G, JO C. Antidepressant effects of flupenthixol. Pharmacotherapy. 1991;11:450-459.
677.	AJ G, PH S. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists - Clinical pharmacology and therapeutic applications. Drugs. 1997;53:20-39.
678.	AJ G, RB L, RL R, Aguiar L, JT H, Salinas E. Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety Disorder - a 6-Month Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2000;283:3082-3088.
679.	AJ H, SE B, KA B, MW K. The effectiveness of citalopram for idiopathic chronic fatigue. Journal of clinical psychiatry. 2003;64:927-935.
680.	AJ K, SB D, JF F, et al. Distressing adverse events after antidepressant switch in the sequenced treatment alternatives to relieve depression (STAR*D) trial: Influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 2012;32:234-243.
681.	AJ L-S, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. British journal of general practice. 2003;53:772-777.
682.	AJ M. The prevention of malaria. Primary Care - Clinics in Office Practice. 2002;29:815-842.
683.	AJ M, EH M. Selective serotonin-reuptake inhibitors in the treatment of premature ejaculation. Annals of pharmacotherapy. 2005;39:1296-1301.
684.	AJ R. New Directions in the Treatment of Antidepressant-Induced Sexual Dysfunction. Clinical therapeutics. 2000;22:A42-A57.
685.	AJ R. Sexual side effects of antidepressants. [Review] [65 refs]. Journal of clinical psychiatry. 2000;61 Suppl 1:28-36.
686.	AJ R. STAR*D: what have we learned? American journal of psychiatry. 2007;164:201-204.
687.	AJ R. The Rothschild Scale for Antidepressant Tachyphylaxis: Reliability and Validity. Comprehensive psychiatry. 2008;49:508-513.
688.	AJ R. Combining antidepressant medications: a good idea? American journal of psychiatry. 2010;167:241-243.
689.	AJ R. Challenges in the treatment of major depressive disorder with psychotic features. Schizophrenia bulletin. 2013;39:787-796.
690.	AJ R, Armitage R, JC G, et al. Comparative Effects of Nefazodone and Fluoxetine on Sleep in Outpatients With Major Depressive Disorder. Biological psychiatry. 1998;44:3-14.
691.	AJ R, Bose A. Escitalopram in Clinical Practice: Results of an Open-Label Trial in a Naturalistic Setting. Depression and anxiety. 2005;21:26-32.
692.	AJ R, BW D, DL D, et al. Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine Er for Two Years (Prevent) Study. Psychopharmacology bulletin. 2009;42:5-20.
693.	AJ R, BW D, DL D, et al. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacology bulletin. 2009;42:5-20.
694.	AJ R, DJ W, MF T, et al. A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features. Journal of clinical psychopharmacology. 2004;24:365-373.
695.	AJ R, EI L. Treatment of premenstrual dysphoric disorder. Women's Health. 2013;9:537-556.
696.	AJ R, Fava M, SR W, et al. Sequenced Treatment Alternatives to Relieve Depression (Star*D): Rationale and Design. Controlled clinical trials. 2004;25:119-142.
697.	AJ R, Fava M, SR W, et al. Sequenced Treatment Alternatives to Relieve Depression (Star*D): Rationale and Design. Controlled clinical trials. 2004;25:119-142.
698.	AJ R, IH B, MH T, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biological psychiatry. 2006;59:493-501.
699.	AJ R, JA M. Premenstrual syndrome in adolescents: Diagnosis and treatment. Pediatric Endocrinology Reviews. 2006;3:132-137.
700.	AJ R, JA M. Premenstrual Syndrome and Premenstrual Dysphoric Disorder in Adolescents. Current opinion in obstetrics & gynecology. 2008;20:455-463.
701.	AJ R, JA M. Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents: Diagnosis and pharmacological treatment. Paediatric drugs. 2013;15:191-202.
702.	AJ R, KA P, Zanardi R, et al. Selective serotonin reuptake inhibitors and delusional depression [16] (multiple letters). American journal of psychiatry. 1999;156:977-978.
703.	AJ R, McDonald M, SA W. Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder. Women's Health. 2007;3:395-408.
704.	AJ R, ME T. Strategies and tactics in the treatment of chronic depression. Journal of clinical psychiatry. 1997;58:14-22.
705.	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression, New England journal of medicine(2006).
706.	AJ R, MH T, TJ C, et al. Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated With Bupropion Sustained Release or Sertraline. Neuropsychopharmacology. 2001;25:131-138.
707.	AJ R, ML C, MG T, et al. Consensus guidelines in the treatment of major depressive disorder. Journal of clinical psychiatry. 1998;59:73-84.
708.	The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder, Comprehensive psychiatry(2014).
709.	AJ R, SA W. The Pharmacologic Management of Premenstrual Dysphoric Disorder. Expert opinion on pharmacotherapy. 2008;9:429-445.
710.	AJ R, SA W. Premenstrual syndrome and premenstrual dysphoric disorder: Quality of life and burden of illness. Expert review of pharmacoeconomics & outcomes research. 2009;9:157-170.
711.	Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features, Archives of general psychiatry(2008).
712.	AJ R, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. American journal of psychiatry. 2003;160:237.
713.	AJ R, Trivedi M, Fava M, Wiesniewski S. CO-MED: Combinations of antidepressant medications to enhance depression outcomes. International journal of neuropsychopharmacology. 2010;Conference:33-34.
714.	AJ S. The Analgesic Effects of Selective Serotonin Reuptake Inhibitors. Journal of psychopharmacology (Oxford, England). 1998;12:407-413.
715.	AJ S, KC A. Binge eating disorder: Disorder or marker? International journal of eating disorders. 2003;34:S107-S116.
716.	AJ S, Oskarsson B, JJ H, Richman D. Current Pharmacologic Management in Selected Neuromuscular Diseases. Physical medicine and rehabilitation clinics of North America. 2012;23:801-820.
717.	AJ vB, E dB, Koele P, Lange A, R vD. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. Journal of nervous and mental disease. 1996;184:133-135.
718.	AJ W, GM K. Anagrelide: A review of its use in the management of essential thrombocythaemia. Drugs. 2006;66:111-131.
719.	AJ W, KL G. Once-weekly fluoxetine. Drugs. 2001;61:2221-2228.
720.	AJ W, KL G. Once-weekly fluoxetine. [Review] [18 refs]. Drugs. 2001;61:2221-2230.
721.	AJ W, Ormrod D, CM S. Tianeptine - a Review of Its Use in Depressive Disorders. CNS drugs. 2001;15:231-259.
722.	AJ W, SM C, AJ M, Ormrod D, KL G. Paroxetine: An update of its use in psychiatric disorders in adults. Drugs. 2002;62:655-703.
723.	AJC M, LC G, FC S. Type III bipolar disorder in children: An infrequent diagnosis. [Spanish]. Revista chilena de pediatria. 2004;75:420-424.
724.	Ajel K, Bhogal K, Baldwin D. Prescribing of the Antidepressant Duloxetine: Can Local Clinical Audit Findings Facilitate Medicines Management Decisions? International journal of psychiatry in clinical practice. 2008;12:156-159.
725.	AJLM VB, P VO, AWA V, R VD, MCE N, HCM V. A meta-analysis on the treatment of obsessive compulsive disorder: A comparison of antidepressants, behavior, and cognitive therapy. Clinical psychology review. 1994;14:359-381.
726.	AK A, BD J, WL W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Current therapeutic research, clinical and experimental. 2005;66:96-106.
727.	AK A, RC R. Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. Journal of sex & marital therapy. 1998;24:191-192.
728.	AK C, HT E, K LL, JS C, MR D. Teaching Evidence-Based Medicine Pediatric Psychopharmacology: Integrating Psychopharmacologic Treatment into the Broad Spectrum of Care. Child and adolescent psychiatric clinics of North America. 2007;16:165-181.
729.	AK D, OM R, SP P. Efficacy of duloxetine compared with imipramine in the treatment of major depressive disorder in Indian patients. International Journal of Pharma and Bio Sciences. 2012;3:133-141.
730.	AK D, PN S, AT K, AG T. Depression and heart failure. Hellenic Journal of Cardiology. 2009;50:410-417.
731.	AK D, Schwartz L, GT G. Behavioral disturbance in dementia. Current psychiatry reports. 2012;14:298-309.
732.	Ak E, SD B, Bulut S, et al. Evaluation of the Effect of Selective Serotonin Reuptake Inhibitors on Bone Mineral Density: an Observational Cross-Sectional Study. Osteoporosis international. 2015;26:273-279.
733.	AK H, Northall A, Zaman R. Stigma and mental health challenges in medical students. BMJ case reports. 2014.
734.	AK J, Soni N, Klysner R, Andersen M. Unethical use of placebo controls [3] (multiple letters). British journal of psychiatry. 2002;181:532-533.
735.	AK L, Zinserling J, Schlosser-Weber G, Berres M, Neuhauser M, Benda N. Estimation of the Treatment Effect in the Presence of Non-Compliance and Missing Data. Statistics in medicine. 2014;33:193-208.
736.	AK M. Fibromyalgia: a Review of Management Options. Formulary (Cleveland, Ohio). 2009;44:362-+.
737.	AK M. The pharmacogenetics of depression: Enter the GWAS. American journal of psychiatry. 2010;167:493-495.
738.	AK M, MH T. The effect of antidepressant therapy on blood pressure and heart rate variability: A review. Psychopharm Review. 2013;48:1-7.
739.	AK T, CC Z, Sajeev G, Arenovich T, DJ M, JL K. Analysis of 34 Candidate Genes in Bupropion and Placebo Remission. International journal of neuropsychopharmacology. 2013;16:771-781.
740.	AK V. A systematic review comparing the functional neuroanatomy of patients with depression who respond to placebo to those who recover spontaneously: Is there a biological basis for the placebo effect in depression? Journal of affective disorders. 2007;98:177-185.
741.	AK Y, Gupta S. Effcacy of escitalopram fuoxetine, paroxetine, and mirtazapine at fexible doses in the outpatient treatment of adults with major depressive disorder a 12-week randomized, open label comparative study. Indian journal of psychiatry. 2012;Conference:S49-S50.
742.	Akca OF. Is it necessary to use antidepressant medication in treatment of depressive disorders in children and adolescents? Bulletin of Clinical Psychopharmacology. 2013;Conference:S21.
743.	Akhondzadeh BA, Esmail M, Ahamad-Ali N, Amir-Hossein J, Hesameddin AS, Shahin A. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:439-442.
744.	Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. Journal of clinical pharmacy and therapeutics. 2003;28:379-384.
745.	Akhondzadeh S, Jafari S. A double-blind, placebo-controlled trial of celecoxib adjunctive treatment to fluoxetine in major depression. British journal of clinical pharmacology. 2010;Conference:291-292.
746.	Akhondzadeh S, PL G, RP B. Nutrients for Prevention and Treatment of Mental Health Disorders. Psychiatric clinics of North America. 2013;36:25-36.
747.	Akimova E. Area-specific occupancy of the serotonin transporter by escitalopram and citalopram in major depressive disorder. European psychiatry. 2011.
748.	Akimova E, Lanzenberger R, Savli M, et al. Serotonin transporter (SERT) availability in raphe nuclei quantified with PET predicts treatment response to S-citalopram in major depressive disorder. European neuropsychopharmacology. 2010;Conference:S62-S63.
749.	Akimova E, Lanzenberger R, Savli M, et al. The serotonin transporter (SERT) occupancy in median raphe nucleus quantified with PET predicts treatment response to SSRIs in major depressive disorder. European neuropsychopharmacology. 2010;Conference:S389.
750.	Akimova E, Lanzenberger R, Savli M, et al. Serotonin transporter availability predicts clinical outcome in patients with major depressive disorder. [11C] DASB PET study. International journal of neuropsychopharmacology. 2010;Conference:70.
751.	Akimova E, Savli M, Haeusler D, et al. Increase of 5-HTT occupancy during escitalopram or citalopram treatment correlates with antidepressant efficacy in major depressive disorder. European neuropsychopharmacology. 2009;Conference:S424-S425.
752.	AL B, Hides L, DI L. Treatment of cannabis use among people with psychotic or depressive disorders: A systemic review. Journal of clinical psychiatry. 2010;71:247-254.
753.	AL B, Saxena S, MA M, LA F, ML H, LR B. Brain Metabolic Changes Associated With Symptom Factor Improvement in Major Depressive Disorder. Biological psychiatry. 2001;50:171-178.
754.	AL B, Saxena S, Stoessel P, et al. Regional Brain Metabolic Changes in Patients With Major Depression Treated With Either Paroxetine or Interpersonal Therapy - Preliminary Findings. Archives of general psychiatry. 2001;58:631-640.
755.	AL D, GA M, NJ W, BJ T, NJ K. Investigation of Consumer Satisfaction With Cognitive-Behaviour Therapy and Sertraline in the Treatment of Adolescent Depression. Australian and New Zealand journal of psychiatry. 2005;39:500-506.
756.	AL H, MM B, KL L, RA C. Is antidepressant use changing? Prevalence and clinical correlates in two New England communities. Pharmacotherapy. 1995;15:78-84.
757.	AL L, GL M, SD H, PD D. A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers. Progress in neuro-psychopharmacology & biological psychiatry. 2014;48:102-111.
758.	AL L, PD D. Saffron (Crocus sativus) for depression: A systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human psychopharmacology. 2014;29:517-527.
759.	AL L, SD H, PD D. Multiple antidepressant potential modes of action of curcumin: A review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. Journal of psychopharmacology (Oxford, England). 2012;26:1512-1524.
760.	AL M. Vitamin C causes cancer! St. John's wort useless for depression! Alternative medicine review. 2001;6:353-354.
761.	AL M. Escitalopram: H Lundbeck. Current opinion in investigational drugs (London, England : 2000). 2002;3:1225-1229.
762.	AL M, Crucitti A, DGS P, et al. Review of Prolactin levels in patients taking duloxetine. International journal of psychiatry in clinical practice. 2009;Conference:38.
763.	AL M, Gilaberte I, Fombellida C, TR H, JA S. Pattern of New Antidepressant's Use in a Clinical Practice Setting. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1998;26:75-81.
764.	AL M, Hjaltason O, Ivarsson O, SB S. The effects of repetitive transcranial magnetic stimulation on depressive symptoms and the P300 event-related potential. Nordic journal of psychiatry. 2006;60:282-285.
765.	AL M, JFW D, CJ H, et al. Better sexual acceptability of agomelatine compared to escitalopram in healthy volunteers during a 9-week placebo-controlled trial. European neuropsychopharmacology. 2014;Conference:S454-S455.
766.	AL M, KT B, TA M, et al. Comparison of Nefazodone and Sertraline for the Treatment of Posttraumatic Stress Disorder. Depression and anxiety. 2004;19:190-196.
767.	AL M, KT B, TA M, et al. Comparison of Nefazodone and Sertraline for the Treatment of Posttraumatic Stress Disorder. Depression and anxiety. 2004;19:190-196.
768.	AL M, Prieto N, Terleira A, et al. Better Sexual Acceptability of Agomelatine (25 and 50 Mg) Compared With Paroxetine (20 Mg) in Healthy Male Volunteers. An 8-Week, Placebo-Controlled Study Using the Prsexdq-Salsex Scale. Journal of psychopharmacology (Oxford, England). 2010;24:111-120.
769.	AL P, JC M, JE B. From the field of play to the field of combat: A review of the pharmacological management of concussion. Neurosurgery. 2012;70:1520-1533.
770.	AL P, Wonnacott S, Hodgson A. Double-Blind Comparative Multicenter Study of Fluvoxamine and Mianserin in the Treatment of Major Depressive Episode in Elderly People. Acta psychiatrica Scandinavica. 1991;83:476-479.
771.	AL R, HK H, Petty F, DB B. Juvenile Rats in the Forced-Swim Test Model the Human Response to Antidepressant Treatment for Pediatric Depression. Psychopharmacology. 2008;197:433-441.
772.	AL R, JC A, DB B, Petty F, H ER, HK H. Treatment With Escitalopram but Not Desipramine Decreases Escape Latency Times in a Learned Helplessness Model Using Juvenile Rats. Psychopharmacology. 2009;205:249-259.
773.	AL S, Bhagwagar Z, Hafizi S, WR W, HJ G, PJ C. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Journal of clinical psychiatry. 2003;64:192-196.
774.	AL S, Hockney R, Mcpeake L, JR G, PJ C. Folic Acid Supplementation for Prevention of Mood Disorders in Young People at Familial Risk: a Randomised, Double Blind, Placebo Controlled Trial. Journal of affective disorders. 2014;167:306-311.
775.	AL S, JD F, Koo J, Steinhoff M. Psychoneuroimmunology of psychological stress and atopic dermatitis: Pathophysiologic and therapeutic updates. Acta dermato-venereologica. 2012;92:7-15.
776.	AL S, Lobel M, Sears S, RS D. Psychosocial aspects of selected issues in women's reproductive health: Current status and future directions. Journal of consulting and clinical psychology. 2002;70:751-770.
777.	AL V, TL S, KR E, AH K. Prevalence and Association of Somatic Symptoms in Patients With Major Depressive Disorder. Journal of affective disorders. 2008;110:270-276.
778.	AL V, TL S, KR E, AH K. Multiple Pain Complaints in Patients With Major Depressive Disorder. Psychosomatic medicine. 2009;71:159-162.
779.	AL VB, DGM B, RH VDH. Changes in EEG power density of NREM sleep in depressed patients during treatment with citalopram. Journal of sleep research. 1993;2:156-162.
780.	AL Z, WH Q, DY H, et al. [Effects of antidepressant therapy in patients with suspected "angina pectoris" and negative coronary angiogram complicating comorbid depression]. [Chinese]. Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases]. 2006;34:1097-1100.
781.	Al-Damluji S. The mechanism of action of antidepressants: A unitary hypothesis based on Transport-P. Current drug targets. CNS and neurological disorders. 2004;3:201-216.
782.	Al-Omari A, Cowan J, Turner L, Cooper C. Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline: a Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology. 2013;27:575-581.
783.	Alagiakrishnan K, Sclater A. Psychiatric disorders presenting in the elderly with type 2 diabetes mellitus. American journal of geriatric psychiatry. 2012;20:645-652.
784.	Alam A, Voronovich Z, JA C. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Primary care companion to the Journal of clinical psychiatry. 2013.
785.	Alamo C, Lopez-Munoz F, Garcia-Garcia P. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert review of neurotherapeutics. 2014;14:593-605.
786.	Alamo C, Lopez-Munoz F, Rubio G, Garcia-Garcia P, Pardo A. Combined Treatment With Reboxetine in Depressed Patients With No Response to Venlafaxine: a 6-Week Follow-up Study. Acta neuropsychiatrica. 2007;19:291-296.
787.	Alan A, Sefi K, David B. Turning darkness into light: A new landmark study on the treatment of adolescent depression. Comments on the TADS study. European Child and Adolescent Psychiatry, Supplement. 2005;14:113-116.
788.	Alan E. Antidepressant use in bipolar disorder: Continuing an age-old debate. American journal of psychiatry. 2010;167:1408.
789.	Alan S, Steven R. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. The American Journal of Geriatric Psychiatry. 2006;14:361-370.
790.	Alan S, Susannah M, Adriane A, et al. Effects of reboxetine and citalopram on appraisal of infant facial expressions and attentional biases. Journal of psychopharmacology (Oxford, England). 2012;26:670-676.
791.	Alan W, M CG, Margaret A, Richard W, Lorna H. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. International clinical psychopharmacology. 2003;18:133-141.
792.	Alan W, Nicolas D, Heldbo RE. Escitalopram in the long-term treatment of major depressive disorder. Annals of clinical psychiatry. 2006;18:83-89.
793.	Alastair F. The impact of treatment resistance on depressive relapse following electroconvulsive therapy. Acta psychiatrica Scandinavica. 1997;96:405.
794.	Albayrak Y, Hashimoto K. Beneficial effects of the sigma-1 agonist fluvoxamine for Tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: Report of 5 cases. Primary care companion to the Journal of clinical psychiatry. 2012.
795.	Albayrak Y, S YO. Beneficial effects of fluvoxamine for tardive dyskinesia: Report of two cases. European psychiatry. 2012.
796.	Albert U, Brunatto C. Obsessive-compulsive disorder in adults: Efficacy of combined and sequential treatments. Clinical Neuropsychiatry. 2009;6:83-93.
797.	Albertazzi P. Management of hot flushes without oestrogen. Journal of the British Menopause Society. 2002;8:147-151.
798.	Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. Journal of the British Menopause Society. 2006;12:7-11.
799.	Albertazzi P. A review of non-hormonal options for the relief of menopausal symptoms. Treatments in endocrinology. 2006;5:101-113.
800.	Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver international. 2009;29:15-18.
801.	Alberti S, Serretti A, Andrisano C, Chiesa A. Insomnia and somnolence induced by second-generation antidepressants during the treatment of major depression: A meta-analysis. European neuropsychopharmacology. 2014;Conference:S69-S70.
802.	Alberto DPJ, Feijo dMA, Florence K-C, et al. Fluvoxamine in the treatment of major depressive disorder: an open multicentric study. [Portuguese]. Jornal brasileiro de psiquiatria. 2007;56:17-22.
803.	Alberto MR, Tung TC, Mathias dAK, Jr TH. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: A randomized double-blind trial in a Brazilian sample. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2006;28:29-32.
804.	Albus C, KH L, Herrmann-Lingen C. Psychocardiology: Clinically Relevant Recommendations Regarding Selected Cardiovascular Diseases. Deutsche medizinische Wochenschrift (1946). 2014;139:596-601.
805.	Alda M, LN Y. Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder? Canadian Journal of Psychiatry. 2009;54:719-725.
806.	Alderman J. Coadministration of Sertraline With Cisapride or Pimozide: an Open-Label, Nonrandomized Examination of Pharmacokinetics and Corrected Qt Intervals in Healthy Adult Volunteers. Clinical therapeutics. 2005;27:1050-1063.
807.	Alderman J. Coadministration of Sertraline With Cisapride or Pimozide: an Open-Label, Nonrandomized Examination of Pharmacokinetics and Corrected Qt Intervals in Healthy Adult Volunteers. Clinical therapeutics. 2005;27:1050-1063.
808.	Alderman J, Wolkow R, Chung M, HF J. Sertraline Treatment of Children and Adolescents With Obsessive-Compulsive Disorder or Depression: Pharmacokinetics, Tolerability and Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:386-394.
809.	Alderman J, Wolkow R, IM F. Drug Concentration Monitoring With Tolerability and Efficacy Assessments During Open-Label, Long-Term Sertraline Treatment of Children and Adolescents. Journal of child and adolescent psychopharmacology. 2006;16:117-129.
810.	Alderton W, Karran E, Ward S. Current and future perspectives in psychiatric drug discovery. Drug news & perspectives. 2009;22:360-364.
811.	Aldosary F, Tremblay P, Hebert C, Blier P. Assessment of norepinephrine and serotonin inhibition by venlafaxine, paroxetine and atomoxetine in depressed patients. Biological psychiatry. 2009;Conference:239S.
812.	Alec C, John B. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. Journal of affective disorders. 2000;60:121-130.
813.	Alec R. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biological psychiatry. 1998;44:633-637.
814.	Alegre P, Nagy B, Nagy J. Economic evaluation of agomelatine in major depresive disorders in Hungary. Value in health. 2010;Conference:A451.
815.	Alejandro D-M, Oscar B, Alfonso O, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 1998;20:467-476.
816.	Aleksandra R-R, Maria S, Aleksandra S, et al. [Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression]. [Polish]. Psychiatria polska. 2008;42:915-923.
817.	Aleksandra R-R, Monika D-W, Pawel K, Maria S, Magdalena K-F, Joanna H. [Association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and the drug response for escitalopram and nortriptyline in depressed patients]. [Polish]. Psychiatria polska. 2008;42:903-914.
818.	Alen F, Orio L, MA G, et al. Increased Alcohol Consumption in Rats After Subchronic Antidepressant Treatment. International journal of neuropsychopharmacology. 2013;16:1809-1818.
819.	Alessandra M, Marco B, Catia S, Beatrice S, Mirko A, Paolo M. Effects of intravenous antidepressant drugs on the excitability of human motor cortex: A study with paired magnetic stimulation on depressed patients. Brain stimulation. 2010;3:15-21.
820.	Alessandro S, Cristina L, Cristina C, et al. SSRIs antidepressant activity is influenced by G beta 3 variants. European neuropsychopharmacology. 2003;13:117-122.
821.	Alessandro S, Enrico L, Raffaella Z, Linda F, Enrico S. Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry research. 2000;94:185-190.
822.	Alessandro S, Raffaella Z, Cristina C, David R, Cristina L, Enrico S. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. European neuropsychopharmacology. 2001;11:375-380.
823.	Alessandro S, Raffaella Z, Cristina C, David R, Cristina L, Enrico S. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. European neuropsychopharmacology. 2001;11:375-380.
824.	Alessandro S, Sara G, Antonio D. Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. [Review]. Journal of affective disorders. 2011;132:14-25.
825.	Alev L, Altin M, Ozbek K, et al. Effect of duloxetine on functional outcomes in patients with major depressive disorder. Klinik Psikofarmakoloji Bulteni. 2011;Conference:S115.
826.	Alex W. Pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39:397-398.
827.	Alexander B, Gerd L, Elisabeth G. Driving Ability of Depressive Patients under Mirtazapine and Reboxetine. [German]. Psychiatrische Praxis. 2007;34:S84-S86.
828.	Alexander B, Gerd L, Irmgard D, Mirijam F, Igor H, Hans-Jurgen M. The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. Journal of clinical psychiatry. 2008;69:1880-1886.
829.	Alexander M, Alain G, Amanda M. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study. Depression and anxiety. 2007;24:487-494.
830.	Alexander M-A, Ricardo P. Does olanzapine have any antidepressant effect? [References]. American journal of psychiatry. 2006;163:1838-1839.
831.	Alexander S, Philip G, Philip B, Ayal S, Hernan P. Depression symptom clusters and their predictive value for treatment outcomes: Results from an individual patient data meta-analysis of duloxetine trials. Journal of psychiatric research. 2014;53:54-61.
832.	Alexander W. Prozac wins new indication: For bulimia nervosa. Drug topics. 1997;141:34.
833.	Alexander W. Pharmacotherapy for Post-traumatic stress disorder in combat veterans: Focus on antidepressants and atypical antipsychotic agents. P and T. 2012;37:32-38.
834.	Alfonso OSdlBJ, Francisco B, Elizabeth B. Double-blind study of fluoxetine vs. amitriptyline in depressive and anxiety symptoms and life quality in adults with major depression. [Spanish]. Salud mental (Mexico City, Mexico). 1998;21:58-63.
835.	Alhaj H, Wisniewski G, RH M-W. The use of the EEG in measuring therapeutic drug action: Focus on depression and antidepressants. Journal of psychopharmacology (Oxford, England). 2011;25:1175-1191.
836.	Ali A, VY N, Northrup V, et al. Intravenous Micronutrient Therapy (Myers' Cocktail) for Fibromyalgia: a Placebo-Controlled Pilot Study. Journal of alternative and complementary medicine (New York, N.Y.). 2009;15:247-257.
837.	Ali C, Yakup A, Karakas UG, Okan E. Beneficial effects of fluvoxamine for hemiballism in a patient with depressive disorder: A case report. Acta neurologica Belgica. 2011;111:62-65.
838.	Ali G, Leila J, Zahra S, et al. Oxybutynin reduces sweating in depressed patients treated with sertraline: A double-blind, placebo-controlled, clinical study. Neuropsychiatric disease and treatment. 2012;8.
839.	Ali G, Moghadasian SK, Saeed A, Nasrin M. Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: A randomized controlled trial. International journal of psychiatry in clinical practice. 2013;17:44-47.
840.	Ali T, Hassanpour MM, Sajadi TSA, Ahmad MS. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial. Journal of affective disorders. 2015;174:51-56.
841.	Alice R, A HJ, Per B. Escitalopram, problem-solving therapy, and poststroke depression. JAMA - Journal of the American Medical Association. 2008;300:1758.
842.	Alice R, Marianne L, Loldrup PD, Karen S, Susanne Q, Per B. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients.[Erratum appears in Psychosomatics. 2004 Jan-Feb;45(1):91]. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2003;44:216-221.
843.	Alice R, Marianne L, Loldrup PD, Karen S, Susanne Q, Per B. Corrections. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2004;45:91.
844.	Alicia D, Trudie C, Simon W. "Randomised, double-blind, placebo-controlled trial of fluoxetine and graded exercise for chronic fatigue syndrome": Commentary. The British Journal of Psychiatry. 1998;172:491-492.
845.	Alison O, James P, J MM, et al. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction (Abingdon, England). 2012;107:131-141.
846.	Alistair B, Eve R, Hilary S-P, Pippa T, Paul ON, Robert B. Sertraline in stroke-associated lability of mood. International journal of geriatric psychiatry. 1999;14:681-685.
847.	Aljeshi A. Obsessive-compulsive disorder. Neurosciences (Riyadh, Saudi Arabia). 2011;16:313-319.
848.	Allan MJ. More on placebo response. Journal of clinical psychiatry. 2007;68:1984.
849.	Allard S, SM S, BF R-S. Coadministration of short-term zolpidem with sertraline in healthy women. Journal of clinical pharmacology. 1999;39:184-191.
850.	Allgulander C. What our patients want and need to know about generalized anxiety disorder?. [Portuguese]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2007;29:172-176.
851.	Allgulander C. Generalized Anxiety Disorder: Between Now and DSM-V. Psychiatric clinics of North America. 2009;32:611-628.
852.	Allgulander C, AA D, Austin C, et al. Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder. American journal of psychiatry. 2004;161:1642-1649.
853.	Allgulander C, AA D, Austin C, et al. Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder. American journal of psychiatry. 2004;161:1642-1649.
854.	Allgulander C, Florea I, AKT H. Prevention of Relapse in Generalized Anxiety Disorder by Escitalopram Treatment. International journal of neuropsychopharmacology. 2006;9:495-505.
855.	Allgulander C, HU W. Pharmacotherapy of generalised anxiety disorder and associated comorbidities. European neuropsychopharmacology. 2008;Conference:S602.
856.	Allgulander C, Jorgensen T, Wade A, et al. Health-Related Quality of Life (Hrqol) Among Patients With Generalised Anxiety Disorder: Evaluation Conducted Alongside an Escitalopram Relapse Prevention Trial. Current medical research and opinion. 2007;23:2543-2549.
857.	Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine Er in Patients With Social Anxiety Disorder: a Double-Blind, Placebo-Controlled, Parallel-Group Comparison With Paroxetine. Human Psychopharmacology-Clinical and Experimental. 2004;19:387-396.
858.	Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine Er in Patients With Social Anxiety Disorder: a Double-Blind, Placebo-Controlled, Parallel-Group Comparison With Paroxetine. Human Psychopharmacology-Clinical and Experimental. 2004;19:387-396.
859.	Allgulander C, Nutt D. Wine and drug evaluations: lessons on making comparisons of noninferiority. Journal of psychopharmacology (Oxford, England). 2008;22:341-342.
860.	Alliot C. Fluoxetine versus placebo in advanced cancer outpatients. Journal of clinical oncology. 2004;22:204-208.
861.	Alliot C. Fluoxetine versus placebo in advanced cancer outpatients. Journal of clinical oncology. 2004;22:204-208.
862.	Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: A double-blind, placebo-controlled study. American journal of psychiatry. 2001;158:1143-1145.
863.	Alosaimi F, Baker B. Are there worthwhile treatments for patients with major depressive disorder and coronary artery disease? Journal of psychosomatic research. 2011;Conference:580-581.
864.	Aloysi A, K VD, Sano M. Women's cognitive and affective health and neuropsychiatry. Mount Sinai Journal of Medicine. 2006;73:967-975.
865.	Alp A, Mehmet A, Levent S, Aytekin O, Yasar K. Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease. [Turkish]. Noropsikiyatri Arsivi / Archives of Neuropsychiatry. 2011;48:201-206.
866.	Alpert M, RR S, ER P. Prediction of treatment response in geriatric depression from baseline folate level: Interaction with an SSRI or a tricyclic antidepressant. Journal of clinical psychopharmacology. 2003;23:309-313.
867.	Alsaadi T. Neuropsychiatric issues in patients with epilepsy: Focus on depression. Therapy. 2010;7:507-515.
868.	Alsultan M, Khurshid F, Alegre P. Economic evaluation of agomelatine in patients attending private hospitals in saudi arabia. European psychiatry. 2012.
869.	Altamura AC, Percudani M, Guercetti G, Invernizzi G. Efficacy and tolerability of fluoxetine in the elderly: A double-blind study versus amitryptiline. International clinical psychopharmacology. 1989;4 Suppl 1:103-106.
870.	Altshuler L, Bookheimer S, Townsend J, et al. Regional brain changes in bipolar I depression: A functional magnetic resonance imaging study. Bipolar disorders. 2008;10:708-717.
871.	Altunoz U, RS I, Hatip E, et al. Retrospective evaluation of the psychotropic prescription patterns in elderly patients with type I bipolar disorder. European neuropsychopharmacology. 2012;Conference:S281.
872.	Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric disease and treatment. 2014;10:1297-1307.
873.	Alvarez E, Vinas F. Mirtazapine in Combination. Actas espanolas de psiquiatria. 2010;38:121-128.
874.	Alves C, Batel-Marques F, AF M. Data sources on drug safety evaluation: A review of recent published meta-analyses. Pharmacoepidemiology and drug safety. 2012;21:21-33.
875.	Alwahhabi F. Anxiety symptoms and generalized anxiety disorder in the elderly: A review. Harvard review of psychiatry. 2003;11:180-193.
876.	Alwan S, Reefhuis J, SA R, RS O, JM F. Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects. New England journal of medicine. 2007;356:2684-2692.
877.	AM A. Pregabalin in the management of partial epilepsy. Neuropsychiatric disease and treatment. 2009;5:407-413.
878.	AM B, JR S, FA P, et al. Quantitative approaches for assessment of white matter hyperintensities in elderly populations. Psychiatry research. 2011;193:101-106.
879.	AM B, Sankaranarayanan J, Wanatabe-Galloway S. Current methodological approaches to the study of sleep disturbances and quality of life in adults with cancer: A systematic review. Psycho-oncology. 2007;16:401-420.
880.	AM B, YF J, EJ S, MA H, RY L, JN Z. Diurnal rhythms of free estradiol and cortisol during the normal menstrual cycle in women with major depression. Hormones and behavior. 2004;45:93-102.
881.	AM C, IR DO, JC A, et al. Double-Blind, Randomized, Placebo-Controlled Trial of Topiramate Plus Cognitive-Behavior Therapy in Binge-Eating Disorder. Journal of clinical psychiatry. 2007;68:1324-1332.
882.	AM D, Kelly J, McDonald C, AM OD, Keane J, Cooney J. A review of the interplay between tuberculosis and mental health. General hospital psychiatry. 2013;35:398-406.
883.	AM D-G, SL W, WC M, Sleath B, Kroenke K, BN G. Depression and comorbid panic in primary care patients. Journal of affective disorders. 2010;123:283-290.
884.	AM De, Zanieri F, Campolmi E, et al. Therapeutic Implications of Adding the Psychotropic Drug Escitalopram in the Treatment of Patients Suffering From Moderate-Severe Psoriasis and Psychiatric Comorbidity: a Retrospective Study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014;28:246-249.
885.	AM G, JS C. Psychiatric comorbidity and depression in older adults. Current psychiatry reports. 2008;10:23-29.
886.	AM H, AF L, IA C, Abrams M. Brain Functional Changes (Qeeg Cordance) and Worsening Suicidal Ideation and Mood Symptoms During Antidepressant Treatment. Acta psychiatrica Scandinavica. 2010;122:461-469.
887.	AM H, AF L, IA C, et al. Brain Functional Changes and Duloxetine Treatment Response in Fibromyalgia: a Pilot Study. Pain medicine (Malden, Mass.). 2009;10:730-738.
888.	AM H, BO M, IA C, AF L. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. Journal of psychiatric research. 2010;44:90-98.
889.	AM H, Butt Z, Umair M. Is depression an inflammatory condition? A review of available evidence. Journal of the Pakistan Medical Association. 2013;63:899-906.
890.	AM H, CC T, JA W. Occurrence of Milnacipran-Associated Morbilliform Rash and Serotonin Toxicity. Annals of pharmacotherapy. 2013;47.
891.	AM H, IA C, Abrams M, AF L. Neurophysiologic Effects of Repeated Exposure to Antidepressant Medication: Are Brain Functional Changes During Antidepressant Administration Influenced by Learning Processes? Medical hypotheses. 2013;81:1004-1011.
892.	AM H, IA C, AF L. Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. Journal of clinical psychopharmacology. 2010;30:748-751.
893.	AM H, IA C, SD G, ML T, KN M, AF L. The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine. Journal of clinical neurophysiology. 2011;28:478-482.
894.	AM H, IA C, SD G, ML T, KN M, AF L. The Antidepressant Treatment Response Index and Treatment Outcomes in a Placebo-Controlled Trial of Fluoxetine. Journal of clinical neurophysiology. 2011;28:478-482.
895.	AM K. Depression in epilepsy: Prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biological psychiatry. 2003;54:388-398.
896.	AM K. Should neurologists be trained to recognize and treat comorbid depression of neurologic disorders? Yes. Epilepsy & behavior. 2005;6:303-311.
897.	AM K. Depression in epilepsy: A complex relation with unexpected consequences. Current opinion in neurology. 2008;21:190-194.
898.	AM K. Psychiatric issues in epilepsy: The complex relation of mood, anxiety disorders, and epilepsy. Epilepsy & behavior. 2009;15:83-87.
899.	AM K. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? The Lancet Neurology. 2012;11:1093-1102.
900.	AM K, Butters M, Begley A, Ogbagaber S, AS W, CF R. Pathways to remission of late life depression, across the spectrum of cognitive functioning. American journal of geriatric psychiatry. 2013;Conference:S65-S66.
901.	AM K, JJ B. The impact of mood disorders in neurological diseases: Should neurologists be concerned? Epilepsy & behavior. 2003;4:S3-S13.
902.	AM K, Karim H, DL T, CF R, Aizenstein H. Emotional processing functional magnetic resonance imaging is associated with treatment response in late life depression. American journal of geriatric psychiatry. 2015;Conference:S132-S133.
903.	AM K, MA B, Begley A, Ogbagaber S, AS W, 3rd RCF. Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning. Journal of clinical psychiatry. 2014;75:e100-107.
904.	AM K, MA B, Begley A, Ogbagaber S, AS W, IIICF R. Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning. Journal of clinical psychiatry. 2014;75:e100-e107.
905.	AM K, MC T. The role of melatonin in psychiatric disorders. Psychopharm Review. 2011;46:49-55.
906.	AM K, ME T. First-Line Pharmacotherapies for Depression - What Is the Best Choice? Polskie Archiwum Medycyny Wewnetrznej-Polish Archives of Internal Medicine. 2009;119:478-485.
907.	AM K, SC A, BR N. Opiate dependence in schizophrenia: Case presentation and literature review. Journal of dual diagnosis. 2014;10:52-57.
908.	AM L, DO A. On chemical imbalances, antidepressants, and the diagnosis of depression. Ethical human psychology and psychiatry. 2009;11:199-214.
909.	AM L, LP R. The empirical status of melancholia: Implications for psychology. Clinical psychology review. 2005;25:25-44.
910.	AM M. Antidepressants for smoking cessation. [Danish]. Ugeskrift for laeger. 2004;166:3697-3699.
911.	AM M. Update on the management of symptoms in schizophrenia: Focus on amisulpride. Neuropsychiatric disease and treatment. 2009;5:267-277.
912.	AM M. Comparative effects of venlafaxine and mirtazapine on sleep physiology measures in patients with major depresive disorder and insomnia. European psychiatry. 2012.
913.	AM M. Healing hearts and minds: Can antidepressants repair the heart? Journal of molecular and cellular cardiology. 2012;53:749-750.
914.	AM M, IO P. The use of antidepressants for chronic pain. U.S.
915.	Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: A randomized pilot study, Journal of clinical psychiatry(2012).
916.	AM P, NC B. Opiates and psychotropics: Pharmacokinetics for practitioners. Current psychiatry. 2011;10:83-86.
917.	AM R. Pharmacological prevention of migraine. Clinical neuroscience (New York, N.Y.). 1998;5:55-59.
918.	AM R, ME B. Preventive migraine therapy: What is new. Neurological sciences. 2004;25:S177-S185.
919.	AM R, ME B. Migraine preventive therapy: Current and emerging treatment options. Neurological sciences. 2005;26:S111-S120.
920.	Obstructive sleep apnea/hypopnea syndrome and poor response to sertraline in patients with coronary heart disease, Journal of clinical psychiatry(2012).
921.	AM S. Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction in Adolescents: a Review. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1071-1079.
922.	AM S. Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction in Adolescents: a Review. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1071-1079.
923.	AM S. A pharmacotherapeutic approach to the management of chronic posttraumatic stress disorder. Journal of pharmacy practice. 2012;25:541-551.
924.	AM T, Hassani J, AT G, Zitzmann M, ML H. Adverse side effects of 5alpha-reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients. Journal of sexual medicine. 2011;8:872-884.
925.	AM T, LM M-W. Credibility of problem-solving therapy and medication for the treatment of depression among primary care patients. Medical science monitor. 2002;8:CR193-196.
926.	AM W, BT L, AJ H, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. American journal of psychiatry. 2004;161:1066-1078.
927.	AM W, DA G. Pharmacological treatment of cannabis dependence. Current pharmaceutical design. 2011;17:1351-1358.
928.	AM W, JJ A. Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK. British journal of clinical practice. 1992;46:21-23.
929.	AM W, Miller H, Bluvstein I, et al. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: A double-blind placebo-controlled study. American journal of drug and alcohol abuse. 2014;40:16-22.
930.	AM W, TM J, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: A systematic review. Canadian Journal of Clinical Pharmacology. 2009;16:e407-e429.
931.	AM Y. Management of anxiety and depression in patients with COPD. Expert review of respiratory medicine. 2008;2:337-347.
932.	AM Y, MJ C. Do antidepressants work in patients with chronic obstructive pulmonary disease with comorbid depression? Expert review of respiratory medicine. 2011;5:727-729.
933.	AM Y, MJ C, RC B. A Feasibility Study of Antidepressant Drug Therapy in Depressed Elderly Patients With Chronic Obstructive Pulmonary Disease. International journal of geriatric psychiatry. 2001;16:451-454.
934.	AM Y, RC B, MJ C. Depression and anxiety in elderly patients with chronic obstructive pulmonary disease. Age and ageing. 2006;35:457-459.
935.	AMA N, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: A systematic review. Journal of affective disorders. 2011;129:14-26.
936.	Amann B, Born C, JM C, Pomarol-Clotet E, McKenna P. Lamotrigine: When and where does it act in affective disorders? A systematic review. Journal of psychopharmacology (Oxford, England). 2011;25:1289-1294.
937.	Delayed amnesic syndrome after riluzole use in major depressive disorder: A case report, Psychosomatics: Journal of Consultation and Liaison Psychiatry(2013).
938.	Ambresin G, Gunn J. Does agomelatine have a place in the treatment of depression? BMJ (Online). 2014.
939.	Ameis S, Feinstein A. Treating depressed multiple sclerosis patients. Therapy. 2007;4:339-347.
940.	Ameli H, TI C, PJ P. Implementation of an algorithm for depression based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial in an ambulatory safety-net clinic. Journal of pharmacy practice. 2012;Conference:284.
941.	AMF W. New concepts concerning the neural mechanisms of amblyopia and their clinical implications. Canadian Journal of Ophthalmology. 2012;47:399-409.
942.	AMG K, Honig A. Treatment of post-myocardial infarction depressive disorder. Expert review of neurotherapeutics. 2008;8:1115-1123.
943.	Ami C, Erik dK, Mark P, M RJ, E SM. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. Journal of clinical psychiatry. 2000;61:928-932.
944.	Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study. European neuropsychopharmacology. 2008;18:455-461.
945.	Amini H, Aghayan S, SA J, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of Mirtazapine and Fluoxetine in the Treatment of Major Depressive Disorder: a Double-Blind, Randomized Trial. Journal of clinical pharmacy and therapeutics. 2005;30:133-138.
946.	Amini H, Aghayan S, SA J, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of Mirtazapine and Fluoxetine in the Treatment of Major Depressive Disorder: a Double-Blind, Randomized Trial. Journal of clinical pharmacy and therapeutics. 2005;30:133-138.
947.	Amir G, M MJ, Sue M, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International clinical psychopharmacology. 2008;23:269-275.
948.	Amirhossein M, Hamid S, Abbas-Ali N, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: Randomized double-blind placebo-controlled trial. Psychopharmacology. 2012;223:381-388.
949.	Amodeo L, Castelli L, Leombruni P, Cipriani D, Biancofiore A, Torta R. Slow Versus Standard up-Titration of Paroxetine for the Treatment of Depression in Cancer Patients: a Pilot Study. Supportive care in cancer. 2012;20:375-384.
950.	Amore M, Bellini M, Berardi D, et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Current therapeutic research, clinical and experimental. 1989;46:815-820.
951.	Amore M, MC J, AMISERTInvestigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. International clinical psychopharmacology. 2001;16:317-324.
952.	Amos T, DJ S, JC I. Pharmacological Interventions for Preventing Post-Traumatic Stress Disorder (Ptsd). Cochrane database of systematic reviews (Online). 2014.
953.	Amr M, El-Mogy A, Shams T, Vieira K, SE L. Efficacy of Vitamin C as an Adjunct to Fluoxetine Therapy in Pediatric Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrition journal. 2013;12.
954.	Amr M, El-Mogy A, Shams T, Vieira K, SE L. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutrition journal. 2013;12:31.
955.	Amrein R, Hetzel W, Stabl M, Schmid-Burgk W. RIMA: A safe concept in the treatment of depression with moclobemide. Canadian Journal of Psychiatry. 1992;37:7-11.
956.	Amrein R, Stabl M, Henauer S, Affolter E, Jonkanski I. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: A clinical overview. Canadian Journal of Psychiatry. 1997;42:1043-1050.
957.	Amy C, Taryn M, Anthony L, et al. Anxiety as a predictor of treatment outcome in children and adolescents with depression. Journal of child and adolescent psychopharmacology. 2010;20:211-216.
958.	Maintenance study for adolescent depression, Journal of child and adolescent psychopharmacology(2008).
959.	Amy F, David M, Maurizio F, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. International clinical psychopharmacology. 2005;20:87-91.
960.	AN A, Agam G, Kaplanski J, Delbar V, ML G. Inositol depletion: A good or bad outcome of valproate treatment? Future neurology. 2008;3:275-286.
961.	AN C, Gunja N, CJ R. A Comparison of Venlafaxine and SSRIs in Deliberate Self-poisoning. Journal of medical toxicology. 2010;6:116-121.
962.	An F, Cui L. A new drug for treatment of major depressive disorder - Desvenlafaxine succinate. [Chinese]. Pharmaceutical Care and Research. 2010;10:47-50.
963.	AN G-P, Yesavage J, Schatzberg A, et al. Personalizing the treatment of depression: Emotional reactivity and early life stress predict antidepressant outcomes. Biological psychiatry. 2015;Conference:243S.
964.	An H, Sohn H, Chung S. Phentermine, sibutramine and affective disorders. Clinical Psychopharmacology and Neuroscience. 2013;11:7-12.
965.	AN S, Arce E, KL L, MB S, MP P. Subchronic Ssri Administration Reduces Insula Response During Affective Anticipation in Healthy Volunteers. International journal of neuropsychopharmacology. 2009;12:1009-1020.
966.	AN T, NA R. A tragic triad: Coronary artery disease, nicotine addiction, and depression. Current opinion in cardiology. 2009;24:447-453.
967.	AN V, AA W, Boovariwala A, et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology. 2007;193:539-545.
968.	Anand A, Malison R, CJ M, LH P. Antiglucocorticoid treatment of refractory depression with metoconazole: A case report. Biological psychiatry. 1995;37:338-340.
969.	Ananth K, Richeimer S, MJ D. Managing chronic pain: Consider psychotropics and other non-opioids. Current psychiatry. 2012;11:38-43.
970.	A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia, Sleep(2010).
971.	Ancoli-Israel S, Ayalon L, Salzman C. Sleep in the elderly: Normal variations and common sleep disorders. Harvard review of psychiatry. 2008;16:279-286.
972.	Anderer P, Saletu B, HV S, RD P-M. Perceptual and cognitive event-related potentials in neuropsychopharmacology: Methodological aspects and clinical applications (pharmaco-ERP topography and tomography). Methods and findings in experimental and clinical pharmacology. 2002;24:121-137.
973.	Anderer P, Saletu B, HV S, RD P-M. Structural and energetic processes related to P300: LORETA findings in depression and effects of antidepressant drugs. Methods and findings in experimental and clinical pharmacology. 2002;24 Suppl D:85-91.
974.	Anders M, Tuma I, Roesslerova H. A Surveillance Study of Escitalopram Treatment of Depressed Patients. Expert opinion on pharmacotherapy. 2008;9:1-6.
975.	Andersen G. Post-stroke depression: Diagnosis and incidence. European psychiatry. 1997;12:255S-260S.
976.	Andersen G, Vestergaard K, JO R. Citalopram for post-stroke pathological crying. Lancet. 1993;342:837-839.
977.	Andersen G, Vestergaard K, Lauritzen L. Effective Treatment of Poststroke Depression With the Selective Serotonin Reuptake Inhibitor Citalopram. Stroke; a journal of cerebral circulation. 1994;25:1099-1104.
978.	Andersen G, Vestergaard K, LU FL. Effective treatment of post-stroke depression. [Danish]. Ugeskrift for laeger. 1995;157:2000-2003.
979.	Andersen G, Vestergaard K, LU L. [Effective treatment of depression following apoplexy with citalopram]. [Danish]. Ugeskrift for laeger. 1995;157:2000-2003.
980.	Anderson B, Brosen K, Christensen P, et al. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. Journal of affective disorders. 1990;18:289-299.
981.	Anderson D, Holmes J. Liaison psychiatry for older people - An overlooked opportunity. Age and ageing. 2005;34:205-207.
982.	Anderson G, Maes M. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: Treatment implications. Current pharmaceutical design. 2014;20:3812-3847.
983.	Anderson I. The New Guidelines From the British Association for Psychopharmacology for Anxiety Disorders. International journal of psychiatry in clinical practice. 2006;10:10-17.
984.	Andersson E, Steneby S, Karlsson K, et al. Long-Term Efficacy of Internet-Based Cognitive Behavior Therapy for Obsessive-Compulsive Disorder With or Without Booster: a Randomized Controlled Trial. Psychological medicine. 2014;44:2877-2887.
985.	Andrade C. Desvenlafaxine. Indian journal of psychiatry. 2009;51:320-323.
986.	Andrade C. Odd odds. Journal of clinical psychiatry. 2011;72:1558-1559; author reply 1559.
987.	Andrade C. A 6-week, multicentre, randomized controlled clinical trial to evaluate the safety and efficacy of placeboxetine hydrochloride in the treatment of major depressive disorder in an Indian setting. Indian journal of psychiatry. 2011;53:69-72.
988.	Andrade C. Placeboxetine for major depressive disorder: Researcher, author, reader, and reviewer perspectives on randomized controlled trials. Indian journal of psychiatry. 2011;53:73-76.
989.	Andrade C. Antidepressant action of atypical antipsychotics: Focus on ziprasidone monotherapy, with a few twists in the tale. Journal of clinical psychiatry. 2013;74:e193-e196.
990.	Andrade C, SG B, NM S. Controversy revisited: Selective serotonin reuptake inhibitors in paediatric depression. [Review] [39 refs]. World journal of biological psychiatry. 2006;7:251-260.
991.	Andraud F, Hardy P. Prognostic factors of recovery. [French]. Encephale. 2005;31:S18-S20.
992.	Andre DN, Stefaan G, Leo R, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. International journal of neuropsychopharmacology. 2002;5:115-120.
993.	Andre T, Dan R, J MM, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatric disease and treatment. 2008;4:269-276.
994.	Andre T, Dan R, J MM, et al. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:1370-1377.
995.	Andre T, Isabella H, Roland M, et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. Journal of affective disorders. 2010;120:86-93.
996.	Andrea C, A FT, Georgia S, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. [Review] [151 refs]. Lancet. 2009;373:746-758.
997.	Andrea C, Corrado B, Paolo B, A FT, Matthew H, R GJ. Are all antidepressants really the same? The case of fluoxetine: a systematic review. [Review] [132 refs]. Journal of clinical psychiatry. 2006;67:850-864.
998.	Andreatini R, ML NP, HM C. The ethics of the use of placebo in clinical studies. [Portuguese]. Jornal brasileiro de psiquiatria. 2001;50:241-245.
999.	Andreescu C, BH M, JE E. Complementary and alternative medicine in the treatment of bipolar disorder - A review of the evidence. Journal of affective disorders. 2008;110:16-26.
1000.	Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features, Journal of clinical psychiatry(2007).
1001.	Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features, Journal of clinical psychiatry(2007).
1002.	Andreescu C, BH M, PR H, et al. Empirically derived decision trees for the treatment of late-life depression. American journal of psychiatry. 2008;165:855-862.
1003.	Andreescu C, CF R. Late-life Depression: Evidence-based Treatment and Promising New Directions for Research and Clinical Practice. Psychiatric clinics of North America. 2011;34:335-355.
1004.	Andreescu C, EJ L, BH M, et al. High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late- life depression. Depression and anxiety. 2009;26:266-272.
1005.	Andreescu C, EJ L, MA D, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: Controlled study. British journal of psychiatry. 2007;190:344-349.
1006.	Andreoli A, Burnand Y, MF C, Marie D, T DC, Ohlendorf P. Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: A randomized clinical study. European psychiatry. 2009;Conference:S93.
1007.	Andres M, S GW, Q BJ, M RJ. Child Psychopharmacology, Effect Sizes, and the Big Bang. American journal of psychiatry. 2005;162:817.
1008.	Andrew R, Derry S, RS T, Straube S, CJ P. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain practice. 2014;14:79-94.
1009.	Andrew W, AIII DN, P MD, M GE, L CJ, A GK. Comparative Effects of Mirtazapine and Fluoxetine on Sleep Physiology Measures in Patients With Major Depression and Insomnia. Journal of clinical psychiatry. 2003;64:1224-1229.
1010.	Andrews G. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Australian and New Zealand journal of psychiatry. 2003;37:641-656.
1011.	Ang D, Myers-Oakes T, Jarvis J, Wang F. Correlation of overall patient impression of improvement with individual items in the Fibromyalgia Impact Questionnaire. Journal of pain. 2010;Conference:S38.
1012.	Angel M, Susana M, J RS, H KS. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. [Review]. Human Psychopharmacology: Clinical and Experimental. 2011;26:537-542.
1013.	Angel-Luis M, S PDG, E SM, et al. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. Journal of sexual medicine. 2011;8:773-782.
1014.	Angela C, J MC, T MR, R HG, H PL. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. Biological psychiatry. 1995;38:765-767.
1015.	Angeletti C, Guetti C, Piroli A, et al. Duloxetine and Pregabalin for Pain Management in Multiple Rheumatic Diseases Associated With Fibromyalgia. Pain practice. 2013;13:657-662.
1016.	Angelini M, Brahmbhatt Y. A review of the pharmacologic options for the treatment of alcohol dependence. Formulary (Cleveland, Ohio). 2007;42:14-31.
1017.	Angelo S, Anna M, Francesca F, Pietro AA, Walter G. Depression treatment selectively modifies arterial stiffness in older participants. The Journals of Gerontology: Series A: Biological Sciences and Medical Sciences. 2013;68A:719-725.
1018.	Angersbach D. Depression: Desvenlafaxine in the treatment of major depression. [German]. Psychopharmakotherapie. 2008;15:224-225.
1019.	Angersbach D. Flouxetine prevents depressive episodes in children and adolescents. [German]. Psychopharmakotherapie. 2008;15:175-176.
1020.	Angersbach D. Acute treatment of depression: Quetiapine monotherapy works. [German]. Psychopharmakotherapie. 2009;16:223-225.
1021.	Angersbach D. Depression: Accompanying pharmacotherapy improves the success of an electroconvulsive therapy. [German]. Psychopharmakotherapie. 2010;17:97-98.
1022.	Anghelescu I. Omega-3 fatty acids for CHD with depression. JAMA - Journal of the American Medical Association. 2010;303:836.
1023.	Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of Hypericum Extract WS 5570 and Paroxetine in Ongoing Treatment after Recovery from an Episode of Moderate to Severe Depression: Results from a Randomized Multicenter Study. Pharmacopsychiatry. 2006;39:213-219.
1024.	Angulo J, Cuevas P, Cuevas B, Bischoff E, IS DT. Antidepressant-Induced Inhibition of Genital Vascular Responses Is Reversed by Vardenafil in Female Rabbits. Journal of sexual medicine. 2006;3:988-995.
1025.	Anita C, Susan K, Apurva P, Craig M, Madelaine W. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. Journal of sexual medicine. 2007;4:917-929.
1026.	Anjana B, Dayong L, Chetan G. Escitalopram in the acute treatment of depressed patients aged 60 years or older. The American Journal of Geriatric Psychiatry. 2008;16:14-20.
1027.	Anjaneyulu M, Chopra K, Kaur I. Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. Journal of medicinal food. 2003;6:391-395.
1028.	Ann-Charlotte A, Finn B, Lisa E, Lars vK. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. International clinical psychopharmacology. 2003;18:347-354.
1029.	Anna A-W, Hans A, Lisa E, Finn B, Ann-Charlotte A. Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy. Journal of clinical psychopharmacology. 2000;20:645-652.
1030.	Anne-Liis vK. Reply to comments by Drs. Holzer and Baumann. Journal of clinical psychopharmacology. 2007;27:326.
1031.	Anne-Liis vK, Ingrid OG, Hove TP, Michael LO, Agnes H. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. Journal of clinical psychopharmacology. 2006;26:311-315.
1032.	Anne-Marie OBL. Critical determinants of the risk-benefit assessment of antidepressants in pregnancy: Pharmacokinetic, safety and economic considerations. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2010;70:6133.
1033.	Annemans L, Brignone M, Druais S, A DP, Gauthier A, Demyttenaere K. Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium. PharmacoEconomics. 2014;32:479-493.
1034.	Annique S, Karly H, Simon S, et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life sciences. 2004;76:637-650.
1035.	Annweiler C, Rastmanesh R, Richard-Devantoy S, Beauchet O. The role of vitamin d in depression: From a curious idea to a therapeutic option. Journal of clinical psychiatry. 2013;74:1121-1122.
1036.	Anonymous. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology. 1986;90:131-138.
1037.	Anonymous. A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. South Wales Antidepressant Drug Trial Group. International clinical psychopharmacology. 1988;3:75-81.
1038.	Anonymous. Novel selective serotonin reuptake inhibitors, Part II. Journal of clinical psychiatry. 1992;53:216-221.
1039.	Anonymous. Safety and efficacy of paroxetine in elderly patients. Geriatrics. 1993;48 Suppl 2:13-15.
1040.	Anonymous. Study addresses question of preferred initial therapy for depression. American journal of health-system pharmacy. 1996;53:1994.
1041.	Anonymous. [Chronic depression in the year 2000: therapeutic hopes. 10th World Congress for Psychiatry. Madrid, 24 August 1996]. [German]. Fortschritte der Neurologie-Psychiatrie. 1996;64:1-4.
1042.	Anonymous. Venlafaxine. (New preparation). Just another antidepressant. Prescrire international. 1998;7:112-114.
1043.	Anonymous. Reboxetine--another new antidepressant. [Review] [9 refs]. Drug and therapeutics bulletin. 1998;36:86-88.
1044.	Anonymous. Citalopram for depression. Medical letter on drugs and therapeutics. 1998;40:113-114.
1045.	Anonymous. Placebos and relapse in depression. Harvard mental health letter / from Harvard Medical School. 1999;15:7.
1046.	Anonymous. Mirtazapine--another new class of antidepressant. [Review] [19 refs]. Drug and therapeutics bulletin. 1999;37:1-3.
1047.	Anonymous. Fluoxetine (Sarafem) for premenstrual dysphoric disorder. Medical letter on drugs and therapeutics. 2001;43:5-6.
1048.	Anonymous. The brain tells: early signs of depression recovery. Harvard mental health letter / from Harvard Medical School. 2002;19:6.
1049.	Anonymous. Treating depression after a heart attack. Harvard heart letter. 2002;13:1.
1050.	Anonymous. [Depression also effects the body]. [German]. Pharmazie in unserer Zeit. 2003;32:74.
1051.	Anonymous. [Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline]. [German]. MMW Fortschritte der Medizin. 2004;146:56.
1052.	Anonymous. [Vital functions at risk. Dealing with depressions rapidly and comprehensively]. [German]. MMW Fortschritte der Medizin. 2004;146 Spec N:93.
1053.	Anonymous. Is Effexor more effective for depression than an SSRI? Medical letter on drugs and therapeutics. 2004;46:15-16.
1054.	Anonymous. Duloxetine (Cymbalta): a new SNRI for depression. Medical letter on drugs and therapeutics. 2004;46:81-82.
1055.	Anonymous. Sertraline and venlafaxine: new indication. Prevention of recurrent depression: no advance. Prescrire international. 2005;14:19-20.
1056.	Anonymous. [Duloxetin effective in depression and pain: high remission rates obtained]. [German]. MMW Fortschritte der Medizin. 2006;148:63.
1057.	Anonymous. About the cover: St. John's wort. [Review] [16 refs]. Journal of the Society for Integrative Oncology. 2006;4:52-55.
1058.	Anonymous. Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire international. 2006;15:168-172.
1059.	Anonymous. Therapeutic alliance and treatment preference. Harvard mental health letter / from Harvard Medical School. 2007;24:7.
1060.	Anonymous. Agomelatine: new drug. Adverse effects and no proven efficacy. Prescrire international. 2009;18:241-245.
1061.	Anonymous. Fibromyalgia: poorly understood; treatments are disappointing. Prescrire international. 2009;18:169-173.
1062.	Anonymous. Treating depression in adolescents. Harvard mental health letter / from Harvard Medical School. 2010;26:7.
1063.	Anonymous. Research indicates antidepressants may be best for severe depression. Mayo Clinic women's healthsource. 2010;14:3.
1064.	Anonymous. [Therapy of moderately severe depressions in daily practice: first patient care research study reinforces clinical data]. [German]. MMW Fortschritte der Medizin. 2011;153:38-39.
1065.	Anonymous. Quetiapine: A me-too neuroleptic; no panacea. Prescrire international. 2011;20:257-261.
1066.	Anonymous. Summaries for Patients. Prevention of depression in patients treated for chronic hepatitis C virus infection with interferon-alpha.[Original report in Ann Intern Med. 2012 Jul 17;157(2):94-103; PMID: 22801672]. Annals of internal medicine. 2012;157:I-40.
1067.	Ansari A, DN O. The psychopharmacology algorithm project at the harvard south shore program: An update on bipolar depression. Harvard review of psychiatry. 2010;18:36-55.
1068.	Ansseau M, Gabriels A, Loyens J, et al. A double-blind comparison of paroxetine and fluvoxamine in major depression. European neuropsychopharmacology. 1993;3:323-324.
1069.	Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology. 1994;114:131-137.
1070.	Ansseau M, R vF, MA G, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. European neuropsychopharmacology. 1991;1:113-121.
1071.	Anstey K, Brodaty H. Antidepressamts amd the elderly: Double-blind trials 1987-1992. International journal of geriatric psychiatry. 1995;10:265-279.
1072.	Antai-Otong D. Social Anxiety Disorder: Characteristics, Course, and Pharmacological Management Prevalence. Perspectives in psychiatric care. 2008;44:48-53.
1073.	Anthony H, Ricardo-Marcelo C, Claudio M, Saiz RJ, Albarran SC, Valentim G. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, double-blind study. International clinical psychopharmacology. 2010;25:305-314.
1074.	Antonini A. Unraveling depression in Parkinson's disease. European journal of neurology. 2008;15:885-886.
1075.	Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinsons disease. CNS drugs. 2010;24:829-841.
1076.	Antonini A, Tesei S, Zecchinelli A, et al. Randomized Study of Sertraline and Low-Dose Amitriptyline in Patients With Parkinson's Disease and Depression: Effect on Quality of Life. Movement disorders. 2006;21:1119-1122.
1077.	Antonio D, Hans M, Alexandra D-S. Moclobemide versus fluoxetine for double depression: A randomized double-blind study. Journal of psychiatric research. 1996;30:453-458.
1078.	Antonio DC, Paolo G, Roberto B, et al. Duloxetine in the treatment of elderly people with major depressive disorder. [Review]. Rivista di psichiatria. 2012;47:479-488.
1079.	Antonucci R, MD P, Atzori L, Fanos V. Pharmaceutical research and metabolomics in the newborn. Journal of maternal-fetal & neonatal medicine. 2012;25:22-26.
1080.	Antonuccio D. Tailoring treatment to parental values: a comment on TADS. Archives of general psychiatry. 2008;65:723; author reply 723-724.
1081.	Antonuccio D. Treating depressed children with antidepressants: More harm than benefit? Journal of clinical psychology in medical settings. 2008;15:92-97.
1082.	Anttila P. Tension-type headache in childhood and adolescence. Lancet neurology. 2006;5:268-274.
1083.	Anttila S, Leinonen E. Duloxetine Eli Lilly. Current opinion in investigational drugs (London, England : 2000). 2002;3:1217-1221.
1084.	Antypa N, Calati R, Serretti A. The neuropsychological hypothesis of antidepressant drug action revisited. CNS and Neurological Disorders - Drug Targets. 2014;13:1722-1739.
1085.	AO M, Rabe T, Kiesel L, Strowitzki T. The use of hormone replacement therapy in patients after breast cancer. Minerva ginecologica. 2007;59:529-541.
1086.	Aouizerate B, Cuny E, JY R, et al. Is Deep Brain Stimulation Able to Make Antidepressants Effective in Resistant Obsessive-Compulsive Disorder? Biological Psychiatry Ri Allard, Michele/D-8538-2014. 2012;71:E43-E44.
1087.	AP A, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. Journal of neuropsychiatry and clinical neurosciences. 1997;9:591-593.
1088.	AP A, TW F. Pain and palliative care pharmacotherapy literature summaries and analyses. [Review] [12 refs]. Journal of pain & palliative care pharmacotherapy. 2009;23:62-68.
1089.	AP C, AL C, JGF C. Clinical trials update from the heart failure society of America and the American heart association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA. European journal of heart failure. 2009;11:214-219.
1090.	AP K, CH K, RE T, Serodio P, LB S, Tannen B. Transient visual loss after right unilateral ECT. Journal of ECT. 2005;21:186-187.
1091.	AP P. Dementia and depression - A treatable condition? Geriatrics. 2003;58:8-12.
1092.	AP S, Trivedi M, DS K. Comparative study of safety and efficacy of desvenlaflexine versus sertraline: A randomised control trial. International Journal of Pharma and Bio Sciences. 2014;5:P762-P769.
1093.	AP W, PM A, DC N, Ecker E, MG F. Pharmacologic management of chronic low back pain: Synthesis of the evidence. Spine. 2011;36:S131-S143.
1094.	AP W, SN G. STAR*D level IV methodology [6]. American journal of psychiatry. 2007;164:681.
1095.	AP W, SN G. STAR*D level IV methodology. American journal of psychiatry. 2007;164:681; author reply 681.
1096.	Apler A. Citalopram for Major Depressive Disorder in Adults: a Systematic Review and Meta-Analysis of Published Placebo-Controlled Trials. Bmj Open. 2011;1.
1097.	Appleby L, Warner R, Whitton A, Faragher B. A Controlled Study of Fluoxetine and Cognitive-Behavioural Counselling in the Treatment of Postnatal Depression. BMJ (Clinical research ed.). 1997;314:932-936.
1098.	Apter A, Lipschitz A, Fong R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. Journal of child and adolescent psychopharmacology. 2006;16:77-90.
1099.	Apter A, Ratzoni G, RA K, et al. Fluvoxamine Open-Label Treatment of Adolescent Inpatients With Obsessive-Compulsive Disorder or Depression. Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33:342-348.
1100.	AR B. Management of Patients with End-Stage Chronic Obstructive Pulmonary Disease. Primary Care - Clinics in Office Practice. 2011;38:277-297.
1101.	AR B, Ferrucci R, Fregni F, PS B, Priori A. Transcranial direct current stimulation for the treatment of major depressive disorder: A summary of preclinical, clinical and translational findings. Progress in neuro-psychopharmacology & biological psychiatry. 2012;39:9-16.
1102.	AR B, Fregni F. Accelerating Response to Antidepressant Treatment in Depression: a Review and Clinical Suggestions. Progress in Neuro-Psychopharmacology & Biological Psychiatry Ri Brunoni, Andre/H-8394-2012 Oi Brunoni, Andre/0000-0002-6310-3571. 2010;34:437-438.
1103.	AR B, IM B, Tcdf A. Therapeutic interventions for vascular depression: a systematic review. [Review]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2011;33:400-409.
1104.	AR B, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. International journal of neuropsychopharmacology. 2008;11:1169-1180.
1105.	AR B, Lopes M, TJ K, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. [Review] [74 refs]. PLoS ONE [Electronic Resource]. 2009;4:e4824.
1106.	AR B, Lopes M, TJ K, Fregni F. Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: a Systematic Review and Meta-Analysis. PloS one. 2009;4.
1107.	AR B, Lopes M, TJ K, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. [Review] [74 refs]. PLoS ONE [Electronic Resource]. 2009;4:e4824.
1108.	Bdnf Plasma Levels After Antidepressant Treatment With Sertraline and Transcranial Direct Current Stimulation: Results From a Factorial, Randomized, Sham-Controlled Trial, European neuropsychopharmacology(2014).
1109.	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis, Progress in neuro-psychopharmacology & biological psychiatry(2015).
1110.	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis, Progress in neuro-psychopharmacology & biological psychiatry(2015).
1111.	AR B, Machado-Vieira R, CA Z, et al. Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology. 2014;231:1315-1323.
1112.	AR B, Machado-Vieira R, CAJr Z, et al. BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, sham-controlled trial. European neuropsychopharmacology. 2014;24:1144-1151.
1113.	AR B, R FJ, Fregni F. Pharmacological and combined interventions for the acute depressive episode: Focus on efficacy and tolerability. Therapeutics and clinical risk management. 2009;5:897-910.
1114.	Differential improvement in depressive symptoms for tDCS alone and combined with pharmacotherapy: An exploratory analysis from the Sertraline Vs. Electrical Current Therapy for Treating Depression Clinical Study, International journal of neuropsychopharmacology(2014).
1115.	Bifrontal tDCS prevents implicit learning acquisition in antidepressant-free patients with major depressive disorder, Progress in neuro-psychopharmacology & biological psychiatry(2013).
1116.	AR B, Tadini L, Fregni F. Changes in Clinical Trials Methodology Over Time: a Systematic Review of Six Decades of Research in Psychopharmacology. PloS one. 2010;5.
1117.	The sertraline vs electrical current therapy for treating depression clinical study, JAMA Psychiatry(2013).
1118.	Sertraline Vs. Electrical Current Therapy for Treating Depression Clinical Trial - Select Tdcs: Design, Rationale and Objectives, Contemporary clinical trials(2011).
1119.	AR B, Valim C, Fregni F. Combination of Noninvasive Brain Stimulation With Pharmacotherapy. Expert review of medical devices. 2011;8:31-39.
1120.	AR E, SB D, RA H, BN G, JF F, Sturmer T. Propensity scores from logistic regression yielded better covariate balance than those from a boosted model: A demonstration using STAR*D data. Pharmacoepidemiology and drug safety. 2011;Conference:S129.
1121.	AR F, PE H, ME K, BW D, WE C, HS M. Pretreatment resting state fMRI predicts differential response to CBT or medication. Biological psychiatry. 2011;Conference:165S.
1122.	AR G, FT M. Pediatric obsessive-compulsive disorder: management in primary care. Current opinion in pediatrics. 2008;20:544-550.
1123.	AR M, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA - Journal of the American Medical Association. 2011;306:1359-1369.
1124.	A Randomised, Double-Blind, Placebo-Controlled, Duloxetine-Referenced Study of the Efficacy and Tolerability of Vortioxetine in the Acute Treatment of Adults With Generalised Anxiety Disorder, International journal of clinical practice(2014).
1125.	A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD, Psychopharmacology(2015).
1126.	AR N, DS D, HB L. Cerebrovascular disease basis of depression: Post-stroke depression and vascular depression. International review of psychiatry. 2006;18:433-441.
1127.	AR P, AB W, RS V, et al. Comparison of the Effectiveness of Trauma-Focused Cognitive Behavioral Therapy and Paroxetine Treatment in Ptsd Patients: Design of a Randomized Controlled Trial. BMC psychiatry. 2012;12.
1128.	AR S, Broadman M. Treatment of the Narcoleptiform Sleep Disorder in Chronic Fatigue Syndrome and Fibromyalgia With Sodium Oxybate. Pain practice. 2010;10:54-59.
1129.	AR S, Budde H, Helmich H, et al. Molecular aspects involved in swimming exercise training reducing anhedonia in a rat model of depression. Neurotoxicity research. 2012;Conference:31.
1130.	AR S, Budde H, Helmich I, et al. Molecular Aspects Involved in Swimming Exercise Training Reducing Anhedonia in a Rat Model of Depression. Neuroscience. 2011;192:661-674.
1131.	AR T, DE B, NS P, LH P, LL C. The neurobiological correlates of childhood adversity and implications for treatment. Acta psychiatrica Scandinavica. 2013;128:434-447.
1132.	AR T, LH P, MF M, AF M, LL C. Psychotic major depression: A benefit-risk assessment of treatment options. Drug safety. 2006;29:491-508.
1133.	Aragona M, Bancheri L, Perinelli D, et al. Randomized Double-Blind Comparison of Serotonergic, (Citalopram) Versus Noradrenergic (Reboxetine) Reuptake Inhibitors in Outpatients With Somatoform, Dsm-Iv-Tr Pain Disorder. European journal of pain (London, England). 2005;9:33-38.
1134.	Aragona M, Bancheri L, Perinelli D, et al. Randomized Double-Blind Comparison of Serotonergic, (Citalopram) Versus Noradrenergic (Reboxetine) Reuptake Inhibitors in Outpatients With Somatoform, Dsm-Iv-Tr Pain Disorder. European journal of pain (London, England). 2005;9:33-38.
1135.	Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple clerosis: A double-blind, placebo controlled, crossover study. Clinical neuropharmacology. 2009;32:41-47.
1136.	Arano I, Sugimoto T, Hamasaki T, Ohno Y. Practical Application of Cure Mixture Model for Long-Term Censored Survivor Data From a Withdrawal Clinical Trial of Patients With Major Depressive Disorder. BMC medical research methodology. 2010;10.
1137.	Arano I, Sugimoto T, Hamasaki T, Ohno Y. Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder. BMC medical research methodology. 2010;10:33.
1138.	Arash M, Ahmad G, Azadeh P. A comparison of the effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder [2]. Journal of clinical psychopharmacology. 2006;26:209-211.
1139.	Arash M, Ehsan K. Topiramate augmentation in patients with resistant major depressive disorder: A double-blind placebo-controlled clinical trial. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:970-973.
1140.	Arato M, O'Connor R, HY M. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: The Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International clinical psychopharmacology. 2002;17:207-215.
1141.	Araya R, Flynn T, Rojas G, Fritsch R, Simon G. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. American journal of psychiatry. 2006;163:1379-1387.
1142.	Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. General hospital psychiatry. 2009;31:478-483.
1143.	Arbaizar B, Gomez-Acebo I, Llorca J. Postural Induced-Tremor in Psychiatry. Psychiatry and clinical neurosciences. 2008;62:638-645.
1144.	Arce E, AN S, KL L, MB S, MP P. Escitalopram Effects on Insula and Amygdala Bold Activation During Emotional Processing. Psychopharmacology. 2008;196:661-672.
1145.	Arendt J, SMW R. Melatonin and its agonists: An update. British journal of psychiatry. 2008;193:267-269.
1146.	Argyris S. Abstract thinking: Treatment response in psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry. 2012;51:561-562.
1147.	Ari K. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. Journal of clinical psychiatry. 1992;53:27-29.
1148.	Ari K, Alan F. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. Journal of clinical psychiatry. 1997;58:146-152.
1149.	Ariane M. Biopsychosocial factors in major depressive disorder. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2003;64:2586.
1150.	Ariane M-M, F LA, Chih-Ping C, James GW, P AS. Predictors of improved mood over time in clinical trials for major depression. Psychiatry research. 2004;127:73-84.
1151.	Arias B, Catal�n R, Gast� C, Guti�rrez B, Fa�an�s L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. Journal of clinical psychopharmacology. 2003;23:563-567.
1152.	Arias E, JJ P, Gilaberte I, et al. Efficacy and Tolerability of New Antidepressants in a Naturalistic Study. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1998;26:351-357.
1153.	Arif K, F KSR, Joy H, et al. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: Role of lithium levels. Journal of psychiatric research. 2011;45:1489-1496.
1154.	Arif K, Kelly S. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: Analysis of the FDA summary basis of approval reports. Annals of clinical psychiatry. 2007;19:31-36.
1155.	Arifulla K, F FL, Richard R. Venlafaxine in depressed outpatients. Psychopharmacology bulletin. 1991;27:141-148.
1156.	Arifulla K, Frances J, H AD, Seth C, Beth S, L DD. DST results in nonpsychotic depressed outpatients. American journal of psychiatry. 1988;145:1153-1156.
1157.	Treatment of vasovagal syncope: An update, Current treatment options in cardiovascular medicine(2010).
1158.	Armand H, Karin K-R, Theresia L-S, et al. Can Bilateral Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) Induce Mania? A Case Report. Journal of clinical psychiatry. 2004;65:1575-1576.
1159.	Armin S, J MM, Ion A, Christoph K, Ralf K, Otto B. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of clinical psychiatry. 2003;64:413-420.
1160.	Armin S, T JW, P vWAP, Egbert vdM, H SH, E TM. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. Journal of clinical psychiatry. 2009;70:344-353.
1161.	Armitage R. The Effects of Antidepressants on Sleep in Patients With Depression. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2000;45:803-809.
1162.	Arnaout B, Batchelder S, RN R, SE H, DJ H. Does a history of alcohol use disorder affect response to antidepressant medication in patients with dysthymic disorder? Journal of dual diagnosis. 2008;4:377-393.
1163.	Arnedt J, Swanson L, Bertram H, et al. Effects of early and late partial sleep deprivation on sleep and slow-wave activity (SWA) in major depressive disorder. Sleep. 2011;Conference:A255.
1164.	Arnheim K. Therapy-refractory depression: Successful augmentation treatment with buspirone. [German]. Nervenheilkunde. 2003;22:93-94.
1165.	Arnim Q, Francesca R, Frank S, et al. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: A randomised, double-blind, placebo-controlled pilot study. Psychiatria Danubina. 2013;25:214-220.
1166.	Arnim Q, Sara Z, Alexander L, et al. Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: A randomized placebo-controlled pilot study. Human Psychopharmacology: Clinical and Experimental. 2010;25:126-132.
1167.	Arnold L, Sarzi-Puttini P, Arsenault P, et al. Pregabalin is effective irrespective of antidepressant class in fibromyalgia patients currently receiving antidepressant medication for comorbid depression. Journal of pain. 2014;Conference:S75.
1168.	Arnone D, Horder J, PJ C, CJ H. Early Effects of Mirtazapine on Emotional Processing. Psychopharmacology. 2009;203:685-691.
1169.	Arns M. First EEG results of the iSPOT study in depression: EEG alpha asymmetry as a gender specific predictor of treatment outcome to sertraline and escitalopram. Biological psychiatry. 2015;Conference:32S-33S.
1170.	Aronson S, Delgado P. Escitalopram. [Review] [32 refs]. Drugs of today (Barcelona, Spain : 1998). 2004;40:121-131.
1171.	Aronson S, Delgado P. Escitalopram. Drugs of today (Barcelona, Spain : 1998). 2004;40:121-131.
1172.	Arpino C, R DC, Donini G, Pasquini P, Raschetti R, Traversa G. Use and misuse of antidepressant drugs in a random sample of the population of Rome, Italy. Acta psychiatrica Scandinavica. 1995;92:7-9.
1173.	Arroll B, CR E, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane database of systematic reviews (Online). 2009.
1174.	Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis. Annals of family medicine. 2005;3:449-456.
1175.	Arthur R, William R. "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial": Comment. JAMA: Journal of the American Medical Association. 2004;292:2577.
1176.	Artigas F. Selective Serotonin Noradrenaline Reuptake Inhibitors (Snris) - Pharmacology and Therapeutic Potential in the Treatment of Depressive-Disorders. CNS drugs. 1995;4:79-89.
1177.	Artigas F. Limitations to enhancing the speed of onset of antidepressants - Are rapid action antidepressants possible? Human psychopharmacology. 2001;16:29-36.
1178.	Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Current drug targets. 2006;7:139-147.
1179.	Artigas F, Dragheim M, Loft H, Perez V, Alvarez E. A randomised, double-blind, placebocontrolled, active-referenced study of Lu AA21004 in patients with major depression. European neuropsychopharmacology. 2009;Conference:S426-S427.
1180.	Arundel C, JH L. Drug-induced liver disease in 2006. Current opinion in gastroenterology. 2007;23:244-254.
1181.	AS A. The Application of Amitriptyline Analog-Amizole in Depressions. Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova. 1996;96:55-58.
1182.	AS B, DM G. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report. [Review] [17 refs]. Journal of clinical pharmacy and therapeutics. 2003;28:69-72.
1183.	AS B, OV P, AV K, ON P. Rexetin in the Therapy of Depressive States. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2005;105:30-34.
1184.	AS B, OV P, AV K, ON P. Rexetin in the Therapy of Depressive States. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2005;105:30-34.
1185.	AS C, Desaiah D, Liu-Seifert H, et al. A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee. Pain practice. 2011;11:33-41.
1186.	AS C, GW K, DJ K. Effects of Rearing Condition on Hpa Axis Response to Fluoxetine and Desipramine Treatment Over Repeated Social Separations in Young Rhesus Monkeys. Psychiatry research. 1998;79:91-104.
1187.	AS C, Littlejohn G, DK K, Scheinberg M, DN Ds, Moldofsky H. A 1-Year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia. Clinical journal of pain. 2009;25:365-375.
1188.	AS C, MH E, DE S, WT M, GW K. Biogenic Amine Activity in Response to Fluoxetine and Desipramine in Differentially Reared Rhesus Monkeys. Biological psychiatry. 1999;46:221-228.
1189.	AS C, MJ O, Liu-Seifert H, et al. Duloxetine, a Centrally Acting Analgesic, in the Treatment of Patients With Osteoarthritis Knee Pain: a 13-Week, Randomized, Placebo-Controlled Trial. Pain. 2009;146:253-260.
1190.	AS D. A little better than placebo is still better than nothing. Nature medicine. 2013;19:962.
1191.	AS G, LK H. Pharmacological targeting of the serotonergic system for the treatment of obesity. Journal of physiology. 2009;587:49-60.
1192.	AS H. Dopamine and the Use of Ssris for Conditions Other Than Depression. Human Psychopharmacology-Clinical and Experimental. 1996;11:S103-S108.
1193.	AS H, Johnstone T, MJ P, GG K, NH K, RJ D. Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. JAMA Psychiatry. 2013;70:1181-1189.
1194.	AS H, Johnstone T, MJ P, GG K, NH K, RJ D. Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. JAMA Psychiatry. 2013;70:1181-1189.
1195.	AS H, Johnstone T, MJ P, GG K, NH K, RJ D. Increased Prefrontal Cortex Activity During Negative Emotion Regulation as a Predictor of Depression Symptom Severity Trajectory Over 6 Months. Jama Psychiatry. 2013;70:1181-+.
1196.	AS H, Johnstone T, SN L, et al. Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment. American journal of psychiatry. 2013;170:197-206.
1197.	AS H, Philippe C, Savli M, et al. Prediction of steady-state occupancy of the serotonin transporter based on single-dose occupancy: A [11C]DASB pet study. European psychiatry. 2011.
1198.	AS K, AM H, IA C, AF L. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clinical neurophysiology. 2009;120:1313-1319.
1199.	AS K, AM H, IA C, AF L. Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. Psychiatry research. 2011;192:188-194.
1200.	AS K, JF R. Efficacy of venlafaxine in the treatment of severe depression. [Review] [36 refs]. Depression and anxiety. 2000;12 Suppl 1:50-54.
1201.	AS L. A review of the pharmacological management of cognition and behaviour problems in older adults with advanced dementia. Geriatrics & aging. 2005;8:16-23.
1202.	AS M, DA M, AB N. Complementary and alternative medicine therapies in mood disorders. Expert review of neurotherapeutics. 2011;11:1049-1056.
1203.	AS N, RL T, LJ S. The Pharmacotherapy of Borderline Personality-Disorder. CNS drugs. 1994;2:347-354.
1204.	AS R, JE C, Sporn J, RY Y, DG V. Sertraline Treatment of Children and Adolescents With Posttraumatic Stress Disorder: a Double-Blind, Placebo-Controlled Trial. Journal of child and adolescent psychopharmacology. 2010;20:463-471.
1205.	AS R, RB O, RE H. Naltrexone as a treatment for repetitive self-injurious behavior: An open-label trial. Journal of clinical psychiatry. 1996;57:233-237.
1206.	AS S. The role of atypical antipsychotic therapy for patients with treatment-resistant bipolar depression. African Journal of Psychiatry (South Africa). 2014.
1207.	Asakura M, Tajima O. A randomized, double-blind study of fluvoxamine maleate in patients with depression or depressive state: A comparison in anticholinergic effects and cardiovascular adverse reactions between fluvoxamine maleate and imipramine hydrochloride. Japanese Pharmacology and Therapeutics. 2005;33:773-787.
1208.	Asakura S, Tajima O, Koyama T. Fluvoxamine Treatment of Generalized Social Anxiety Disorder in Japan: a Randomized Double-Blind, Placebo-Controlled Study. International journal of neuropsychopharmacology. 2007;10:263-274.
1209.	Asanka dSV, Raveen H. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies. International clinical psychopharmacology. 2012;27:8-16.
1210.	Asberg M, Eriksson B, Martensson B. Therapeutic effects of serotonin uptake inhibitors in depression. Journal of clinical psychiatry. 1986;47:23-35.
1211.	Asgharipoor N, AA F, Arshadi H, Sahebi A. A comparative study on the effectiveness of positive psychotherapy and group cognitive-behavioral therapy for the patients suffering from major depressive disorder. Iranian Journal of Psychiatry and Behavioral Sciences. 2012;6:33-41.
1212.	Ashby J, Goldmeier D, Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean journal of urology. 2014;55:9-16.
1213.	Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert review of neurotherapeutics. 2005;5:525-539.
1214.	Ashford JJ. Fluvoxamine-prescription event monitoring. The British Journal of Psychiatry. 1994;164:852-853.
1215.	Ashina S, Bendtsen L, Ashina M. Pathophysiology of tension-type headache. Current pain and headache reports. 2005;9:415-422.
1216.	Ashley S, Kumar JA, Claire B. Sertraline for recurrent major depression [10]. American journal of psychiatry. 2005;162:1025-1026.
1217.	Askey-Jones S, AS D, Silber E, Shaw P, Chalder T. Cognitive behaviour therapy for common mental disorders in people with Multiple Sclerosis: A bench marking study. Behaviour research and therapy. 2013;51:648-655.
1218.	Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: A placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25:677-679.
1219.	Assanangkornchai S, Srisurapanont M. The treatment of alcohol dependence. Current opinion in psychiatry. 2007;20:222-227.
1220.	Asuncion A, Xavier C, Montserrat M-B, Placida M, Francesc S, Juan B. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. Journal of clinical psychopharmacology. 2003;23:509-513.
1221.	AT B, Smit F, ML S, IIICF R, PC C. Preventing depression in high-risk groups. Current opinion in psychiatry. 2010;23:8-11.
1222.	AT C, Maillardet L, Yavin Y. Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence? Thrombosis and haemostasis. 2009;101:422-427.
1223.	AT H, RL R, SH P. Evidence of the dual mechanisms of action of venlafaxine. Archives of general psychiatry. 2000;57:503-509.
1224.	AT P, AA N. Stepping back to step forward: Lessons from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Journal of clinical psychiatry. 2011;72:1429-1431.
1225.	Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. Journal of clinical psychopharmacology. 2009;29:368-371.
1226.	Atar D, Malinin A, Pokov A, et al. Antiplatelet Properties of Escitalopram in Patients With the Metabolic Syndrome: a Dose-Ranging in Vitro Study. Neuropsychopharmacology. 2007;32:2369-2374.
1227.	Atmaca M, Karadag F, Tezcan E. Serum Antioxidant Enzymes and Malondialdehyde Levels in Patients With Premature Ejaculation Before and After Pharmacotherapy. Journal of sexual medicine. 2005;2:254-258.
1228.	Atmaca M, Karadag F, Tezcan E. Serum Antioxidant Enzymes and Malondialdehyde Levels in Patients With Premature Ejaculation Before and After Pharmacotherapy. Journal of sexual medicine. 2005;2:254-258.
1229.	Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H. Antioxidant Enzyme and Malondialdehyde Values in Social Phobia Before and After Citalopram Treatment. European archives of psychiatry and clinical neuroscience. 2004;254:231-235.
1230.	Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H. Antioxidant Enzyme and Malondialdehyde Values in Social Phobia Before and After Citalopram Treatment. European archives of psychiatry and clinical neuroscience. 2004;254:231-235.
1231.	Attal N. Neuropathic pain: Mechanisms, therapeutic approach, and interpretation of clinical trials. CONTINUUM Lifelong Learning in Neurology. 2012;18:161-175.
1232.	Attal N, Mazaltarine G, Perrouin-Verbe B, Albert T. Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous). Annals of physical and rehabilitation medicine. 2009;52:124-141.
1233.	Attard A, Ranjith G, Taylor D. Alternative Routes to Oral Antidepressant Therapy: Case Vignette and Literature Review. Journal of psychopharmacology (Oxford, England). 2010;24:449-454.
1234.	Attari A, Moghaddam Y, Hasanzadeh A, Soltani M, Mahmoodi M. Comparison of efficacy of fluoxetine with nortriptyline in treatment of major depression in children and adolescents: A double-blind study. Journal of research in medical sciences. 2006;11:24-30.
1235.	In the clinic eating disorders, Annals of internal medicine(2012).
1236.	Attia E, Haiman C, BT W, SR F. Does fluoxetine augment the inpatient treatment of anorexia nervosa? American journal of psychiatry. 1998;155:548-551.
1237.	Attia E, Schroeder L. Pharmacologic Treatment of Anorexia Nervosa: Where Do We Go From Here? International journal of eating disorders. 2005;37:S60-S63.
1238.	Attia E, Schroeder L. Pharmacologic Treatment of Anorexia Nervosa: Where Do We Go From Here? International journal of eating disorders. 2005;37:S60-S63.
1239.	Auby P. Ethical, clinical and practical considerations in designing clinical trials in pediatric psychopharmacology. Clinical investigation. 2011;1:45-52.
1240.	Auer J. Management of chronic heart failure. [German]. Journal fur Kardiologie. 2009;16:429-439.
1241.	Augendre-Ferrante B, Picard H, Evans D, et al. Prescribing Patterns of Duloxetine in France: a Prescription Assessment Study in Real-World Conditions. International journal of clinical pharmacology and therapeutics. 2014;52:1-7.
1242.	Aukst-Margetic B, Margetic B. An open-label series using loratadine for the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:754-756.
1243.	Aung T, M HP, M AI. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.[Erratum appears in J Psychopharmacol. 2009 Nov;23(8):1006]. Journal of psychopharmacology (Oxford, England). 2008;22:330-332.
1244.	Aung T, M HP, M AI. "The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: A randomised study": Erratum. Journal of psychopharmacology (Oxford, England). 2009;23:1006.
1245.	Aursnes I, IF T, Gaasemyr J, Natvig B. Suicide attempts in clinical trials with paroxetine randomised against placebo. BMC medicine. 2005.
1246.	Aursnes I, IF T, Gaasemyr J, Natvig B. Suicide attempts in clinical trials with paroxetine randomised against placebo. [Review] [10 refs]. BMC medicine. 2005;3:14.
1247.	Aursnes I, MK G. Common adverse events associated with an SSRI: Meta-analysis of early paroxetine data. Pharmacoepidemiology and drug safety. 2008;17:707-713.
1248.	Autret-Leca E. Information about medicine. [French]. Archives de pediatrie. 2008;15:313-320.
1249.	Autret-Leca E. Drugs news. [French]. Archives de pediatrie. 2010;17:1098-1106.
1250.	AV C, Heldt E, DB B, et al. Cognitive-behavioral group therapy in obsessive-compulsive disorder: A randomized clinical trial. Psychotherapy and psychosomatics. 2003;72:211-216.
1251.	AV D, DL W, JA H. Herbal medicines, other than St. John's Wort, in the treatment of depression: a systematic review. [Review]. Alternative medicine review. 2011;16:40-49.
1252.	AV E. Pharmacologic treatment of adolescent depression. Current opinion in pediatrics. 2002;14:213-218.
1253.	AV P. Review: Bupropion and nortriptyline each increase smoking cessation rates. Evidence-based medicine. 2005;10:88.
1254.	AV R, Al-Subaie A, Abraham G. Quetiapine: Novel uses in the treatment of depressive and anxiety disorders. Expert opinion on investigational drugs. 2010;19:1187-1204.
1255.	AV R, Bradbury C, McKay M, TL dS. Novel uses for risperidone: Focus on depressive, anxiety and behavioral disorders. Expert opinion on pharmacotherapy. 2007;8:1693-1710.
1256.	AV R, Griffiths J, Merali Z, Anisman H. Circulating Lymphocyte Subsets in Obsessive Compulsive Disorder, Major Depression and Normal Controls. Journal of affective disorders. 1999;52:1-10.
1257.	AV R, Griffiths J, Waddell C, Anisman H. Stressful life events and coping styles in relation to dysthymia and major depressive disorder: Variations associated with alleviation of symptoms following pharmacotherapy. Progress in neuro-psychopharmacology & biological psychiatry. 1995;19:637-653.
1258.	AV R, Judge R, BN H, Bray J, NH M. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. Journal of clinical psychiatry. 1997;58:112-118.
1259.	Osmotic-Release Oral System Methylphenidate Augmentation of Antidepressant Monotherapy in Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Trial, Journal of clinical psychiatry(2008).
1260.	AV R, TL DS. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: A systematic review. Journal of affective disorders. 2013;150:707-719.
1261.	Avni-Barron O, Hoagland K, Ford C, LJ M. Preconception planning to reduce the risk of perinatal depression and anxiety disorders. Expert review of obstetrics & gynecology. 2010;5:421-435.
1262.	Avorn J. Drug warnings that can cause fits - Communicating risks in a data-poor environment. New England journal of medicine. 2008;359:991-994.
1263.	Avram S, Buiu C, Duda-Seiman D, Duda-Seiman C, Borcan F, Mihailescu D. Evaluation of the pharmacological descriptors related to the induction of antidepressant activity and its prediction by QSAR/QRAR methods. Mini reviews in medicinal chemistry. 2012;12:467-476.
1264.	AW A, Geretsegger C. Safety and Efficacy of Selective Serotonin Reuptake Inhibitors in the Treatment of Children and Adolescents Compared to Adults. Neuropsychiatrie. 2005;19:34-39.
1265.	AW A, Geretsegger C. Safety and Efficacy of Selective Serotonin Reuptake Inhibitors in the Treatment of Children and Adolescents Compared to Adults. Neuropsychiatrie. 2005;19:34-39.
1266.	AW B, CB W. Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome. Annals of pharmacotherapy. 2014;48:777-784.
1267.	AW M. High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. Journal of clinical psychopharmacology. 2008;28:240-241.
1268.	AY D, BH M, PR H, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of affective disorders. 2007;103:77-82.
1269.	AY D, BH M, RE F, et al. Serotonin Transporter Triallelic Genotype and Response to Citalopram and Risperidone in Dementia With Behavioral Symptoms. International clinical psychopharmacology. 2010;25:37-45.
1270.	Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care, Journal of clinical psychiatry(2010).
1271.	Duloxetine for the treatment of generalized anxiety disorder: A review, Neuropsychiatric disease and treatment(2009).
1272.	AY R. The management of menopausal sequelae in patients with breast cancer. Clinical oncology. 2001;13:174-180.
1273.	Ayal S, Pamela Z, Anthony L. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of affective disorders. 2006;96:95-99.
1274.	Combination of pharmacotherapy with electroconvulsive therapy in prevention of depressive relapse: A pilot controlled trial, Journal of ECT(2010).
1275.	Ayshford H. Risk and reward. Manufacturing Chemist. 2008;79:5.
1276.	Aytekin S, F DSR, Sukru U, et al. Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. Journal of clinical psychiatry. 2005;66:1312-1320.
1277.	AZ E, Singh N, Reddy J, SJ N. Prescriber's guide to using 3 new antidepressants: How do they work? What makes them different? And which patients might benefit most from taking them? Current psychiatry. 2015;14:29 and 32-36.
1278.	AZ F, RT S, JV H. Neuropsychiatric Manifestations of Thyroid Disease. Endocrinology and metabolism clinics of North America. 2013;42:453-476.
1279.	Azizi M, SA B, Baghdasarians A, et al. The role of cognitive group therapy and happiness training on cerebral blood flow using 99mTc-ECD brain perfusion SPECT: A quasi-experimental study of depressed patients. Nuklearmedizin [Nuclear medicine]. 2014;53:205-210.
1280.	B BA, Carl S, Andrew S, Kenneth N, G PB, Tamara G. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depression and anxiety. 2002;15:102-110.
1281.	B BE, L MS, EJr KP, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Journal of clinical psychiatry. 2006;67:1025-1033.
1282.	B CD. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. [Review] [24 refs]. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2004;49:557-563.
1283.	B CJ, Charles W. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. Journal of clinical psychiatry. 1985;46:26-31.
1284.	B CJ, E CJ, S WC, J RP. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacology bulletin. 1990;26:185-189.
1285.	B CJ, Gloria C, Earleen A, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. International clinical psychopharmacology. 1989;4:313-322.
1286.	B CJ, S WC. Paroxetine in major depression: A double-blind trial with imipramine and placebo. Journal of clinical psychiatry. 1992;53:52-56.
1287.	B DM, Diana E. Collaborative care for depression and chronic illnesses. New England journal of medicine. 2011;364:1278.
1288.	B HI, L RN. Novel melatonin-based therapies: potential advances in the treatment of major depression. [Review]. Lancet. 2011;378:621-631.
1289.	Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: A randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo, JAMA Psychiatry(2013).
1290.	B KM. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. [Review] [81 refs]. Journal of clinical psychiatry. 2000;61:896-908.
1291.	B KM. A review of 10 years of European experience and data from U.S. clinical trials. [Hungarian]. Psychiatria Hungarica. 2001;16:41-64.
1292.	B KM, D RN, Michael S, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:762-772.
1293.	B KM, H KJ. "Does venlafaxine maintenance therapy prevent depression recurrences or drug discontinuation reactions?": Drs. Keller and Kocsis Reply. Journal of clinical psychiatry. 2008;69:866.
1294.	B KM, H KJ, E TM, et al. Maintenance Phase Efficacy of Sertraline for Chronic Depression - a Randomized Controlled Trial. JAMA: Journal of the American Medical Association. 1998;280:1665-1672.
1295.	B KM, H KJ, E TM, et al. "Relapse of depressive symptoms after discontinuing sertraline": Reply. JAMA: Journal of the American Medical Association. 1999;282:323-324.
1296.	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases, Journal of clinical psychiatry(2007).
1297.	B KM, H TM, E TM, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.[Erratum appears in Biol Psychiatry. 2012 Feb 15;71(4):387], [Erratum appears in Biol Psychiatry. 2008 Apr;6. Biological psychiatry. 2007;62:1371-1379.
1298.	B KM, H TM, E TM, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the acute and continuation phases: Erratum. Biological psychiatry. 2008;63:721.
1299.	B KM, H TM, E TM, et al. "The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the acute and continuation phases": Erratum. Biological psychiatry. 2012;71:387.
1300.	B KM, J GA, A HRM, et al. The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine. Journal of clinical psychiatry. 1998;59:598-607.
1301.	B ML, J CD, Ernest C, et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: Secondary analyses of four pooled randomized controlled trials of duloxetine. Pain. 2011;152:31-37.
1302.	B NC. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. [Review] [42 refs]. Journal of clinical psychopharmacology. 1993;13:10S-17S.
1303.	B NC, F SA. Pharmacological treatments for unipolar depression. 2002:229-243.
1304.	B NC, F SA. Pharmacological treatments for unipolar depression. 2007:271-287.
1305.	B NC, L ED, Laszlo G, et al. Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression. American journal of psychiatry. 2001;158:906-912.
1306.	B NC, Richard E, Isma B, Mark D, M SD, E TM. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological psychiatry. 2008;63:424-434.
1307.	B PT, B SA, A LS, Harriet S, Caron Z, A BW. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. Journal of clinical psychopharmacology. 1997;17:261-266.
1308.	B QB, Kai-Uwe K, Richard S, Klaus H, Wolfgang M, Michael W. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology. 2004;175:399-406.
1309.	B RK, VS B, BS F, RC T, LK M. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. Journal of child and adolescent psychopharmacology. 1997;7:97-107.
1310.	B RV, Orgaz P, G TS, C BP, A FL, A PT. Subjective experience of illness and treatment received in depressed oncologic patients: A qualitative analysis. Journal of clinical oncology. 2010.
1311.	B RV, P OB, Bayon C, et al. Differences in depressed oncologic patients' narratives after receiving two different therapeutic interventions for depression: a qualitative study. Psycho-oncology. 2012;21:1292-1298.
1312.	B RV, Palao A, Torres G, et al. Combined therapy versus usual care for the treatment of depression in oncologic patients: A randomized controlled trial. Psycho-oncology. 2011;20:943-952.
1313.	B SA, Michael B, Hans-Peter V, et al. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. European archives of psychiatry and clinical neuroscience. 2009;259:329-339.
1314.	B SE, Shirley Y, Ellen C, et al. Combined Dialectical Behavior Therapy and Fluoxetine in the Treatment of Borderline Personality Disorder. Journal of clinical psychiatry. 2004;65:379-385.
1315.	B SK. Invited comment. Acta psychiatrica Scandinavica. 2001;104:236-239.
1316.	B SK, Sona D, Wayne K, Mark S. Response styles among patients with minor depression and dysthymia in primary care. Journal of abnormal psychology. 2002;111:350-356.
1317.	B SM, A HT. Fluoxetine and suicidal ideation in minor depression. Journal of psychiatric research. 2014;48:131-132.
1318.	B SO, A NO, Inger M, et al. Paroxetine and imipramine treatment of depressed patients in a controlled, multicentre study with plasma amino acid measurements. Nordic journal of psychiatry. 1992;46:23-26.
1319.	B SS, F RP, M MC, et al. Compounds containing cytosolic choline in the basal ganglia: A potential biological marker of true drug response to fluoxetine. American journal of psychiatry. 1999;156:1638-1640.
1320.	B TM, Isaac MT. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo. International clinical psychopharmacology. 1998;13:175-182.
1321.	B TM, Isaac MT. One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks. International clinical psychopharmacology. 1998;13:169-174.
1322.	B TM, Robert CC, P WJ, T IM. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: Personality variables and response to paroxetine and pindolol. Journal of affective disorders. 1997;44:101-109.
1323.	B VH. Cosmetic psychiatry. [Dutch]. Tijdschrift voor psychiatrie. 2005;47:507-509.
1324.	B VH, L G-SM. Innovative child and adolescent treatment research for anxiety and depressive disorders. Depression and anxiety. 2009;26:307-308.
1325.	B-W P, HS P. Adjuvant hormonal therapy: Current standard and practical issues. Journal of breast cancer. 2010;13:242-249.
1326.	B-Y Q, J-X Q, Yong J. Meta-analysis of selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) in the efficacy and safety of anti-depression therapy in Parkinson's disease(PD) patients. Iranian Journal of Pharmaceutical Research. 2014;13:1213-1219.
1327.	BA A, Steidtmann D, Blasey C, et al. The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. Journal of consulting and clinical psychology. 2013;81:627-638.
1328.	BA A-W, RH S. Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacology, Biochemistry & Behavior. 2011;100:59-65.
1329.	BA C, Churchill E, JRT D. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Annals of clinical psychiatry. 2004;16:127-132.
1330.	BA D, AA B, PH Y, et al. Longitudinal effect of amitriptyline and fluoxetine treatment on plasma phenylacetic acid concentrations in depression. Biological psychiatry. 1991;30:600-608.
1331.	BA D, AA B, PH Y, et al. Deuterium-labelled p-tyramine challenge test and phenolsulfotransferase activity in depressed patients--failure to replicate decreased p-tyramine conjugation in depression. Progress in neuro-psychopharmacology & biological psychiatry. 1991;15:241-247.
1332.	BA E, Jewell M, Jewell G, Ambrose S, LL D. Treatment of Chronic Posttraumatic Stress Disorder in Combat Veterans With Citalopram - an Open Trial. Journal of clinical psychopharmacology. 2006;26:84-88.
1333.	BA F, AI Q, Laje G, Klein B. Hypochondriasis and its relationship to obsessive-compulsive disorder. Psychiatric clinics of North America. 2000;23:605-616.
1334.	BA F, Petkova E, Skritskaya N, et al. A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis. Journal of clinical psychopharmacology. 2008;28:638-645.
1335.	BA G, JD H. Methodological issues in clinical trials of antidepressant medications: Perspectives from psychotherapy outcome research. Psychotherapy and psychosomatics. 2005;74:17-25.
1336.	BA G, LM W, IW M. Improving treatment adherence in patients with bipolar disorder and substance abuse: Rationale and initial development of a novel psychosocial approach. Journal of psychiatric practice. 2011;17:5-20.
1337.	BA G, RB F, CI K, TW M. Complex partial seizures and depression. Current psychiatry reports. 2003;5:410-416.
1338.	BA H, KJ P. The current state of hormonal therapy for prostate cancer. CA: a cancer journal for clinicians. 2002;52:154-179.
1339.	BA H, PG J, AN H, PM K, Majid I, SIA Z. Flupenthixol and fluvoxamine in mild to moderate depression: A comparison in general practice. Pharmatherapeutica. 1989;5:292-297.
1340.	BA J. Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochemical pharmacology. 2008;75:34-56.
1341.	BA K, AM M. Management of treatment resistance in the depressed geriatric patient. Psychiatric clinics of North America. 1996;19:269-286.
1342.	BA L, Chasuk R, Kendall S. Q/Which complementary therapies can help patients with PMS? Journal of family practice. 2009;58:552+559.
1343.	BA M, GS N-P. Evaluating and treating insomnia in menopausal women. Sexuality, reproduction & menopause. 2010;8:S1-S7.
1344.	BA OL, GB H, MA A. Economic evaluation of agomelatine for major depressive disorder in Australia. Value in health. 2011;Conference:A293-A294.
1345.	BA P, Zhang Q, Desaiah D, DGS P, MJ D, SH K. Long-Term Safety of Duloxetine During Open-Label Compassionate Use Treatment of Patients Who Completed Previous Duloxetine Clinical Trials. Current medical research and opinion. 2010;26:2643-2651.
1346.	BA S, CL H, CS B. Duloxetine for the management of fibromyalgia syndrome. Journal of pain research. 2009;2:99-108.
1347.	BA S, Hazra M, BG P. Desvenlafaxine Succinate for Major Depressive Disorder. Drugs of today (Barcelona, Spain : 1998). 2008;44:475-487.
1348.	BA VdK, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. Journal of clinical psychiatry. 1994;55:517-522.
1349.	BA VDK, Spinazzola J, ME B, et al. A Randomized Clinical Trial of Eye Movement Desensitization and Reprocessing (Emdr), Fluoxetine, and Pill Placebo in the Treatment of Posttraumatic Stress Disorder: Treatment Effects and Long-Term Maintenance. Journal of clinical psychiatry. 2007;68:37-46.
1350.	BA W, AB J, RR C. Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: A controlled, prospective study. Journal of clinical psychiatry. 1996;57:582-587.
1351.	Baas H. Treatment of advanced Parkinson's disease. [German]. Nervenheilkunde. 2005;24:29-35.
1352.	Baastrup C, NB F. Pain in spinal cord injury. Pain management. 2012;2:87-94.
1353.	Babinkostova Z, Stefanovski B. Forms of antipsychotic therapy: Improved individual outcomes under personalised treatment of schizophrenia focused on depression. EPMA journal. 2011;2:391-402.
1354.	Baby S, Nguyen M, Tran D, RB R. Substance P antagonists: The next breakthrough in treating depression? Journal of clinical pharmacy and therapeutics. 1999;24:461-469.
1355.	Baca BE, Giner UJ, Leal CC, Vallejo RJ, Garcia CC, Prieto LR. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depression and anxiety. 2005;22:68-76.
1356.	Baca BE, Rubio-Terres C. [Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review]. [Review] [36 refs] [Spanish]. Actas espanolas de psiquiatria. 2006;34:193-201.
1357.	Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender Differences in Treatment Response to Sertraline Versus Imipramine in Patients With Nonmelancholic Depressive Disorders. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28:57-65.
1358.	Bachawati M. Anticoagulation and psychotropic medications. Current psychiatry reports. 2010;12:265-271.
1359.	Bachmann M, Bachmann C, Rief W, Mattejat F. Efficacy of psychiatric and psychotherapeutic interventions in children and adolescents with psychiatric disorders - A systematic evaluation of meta-analyses and reviews. Part I: Anxiety disorders and depressive disorders. [German]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2008;36:309-320.
1360.	Badowski M, NS P. Pharmacologic Management of Human Immunodeficiency Virus Wasting Syndrome. Pharmacotherapy. 2014;34:868-881.
1361.	Baeken C, M-A V, Remue J, et al. Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients. Journal of affective disorders. 2013;151:625-631.
1362.	Baeken C, R DR, Leyman L, et al. The impact of one HF-rTMS session on mood and salivary cortisol in treatment resistant unipolar melancholic depressed patients. Journal of affective disorders. 2009;113:100-108.
1363.	Baer L, Ball S, JD S, et al. Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). Annals of clinical psychiatry. 2014;26:270-280.
1364.	Baer L, Ball S, Sparks J, et al. Further evidence for the reliability and validity of the massachusetts general hospital Cognitive and Physical Functioning Questionnaire (CPFQ). Neuropsychopharmacology. 2011;Conference:S416-S417.
1365.	When should the sequential parallel comparison design be used in clinical trials?, Clinical investigation(2013).
1366.	Baer L, Ricciardi J, Keuthen N, et al. Discontinuing obsessive-compulsive disorder medication with behavior therapy [6]. American journal of psychiatry. 1994;151:1842.
1367.	BAGB G. Focus on Agomelatine. Current medical research and opinion. 2011;27:745-749.
1368.	Bahl S, Cotterchio M, Kreiger N. Use of antidepressant medications and the possible association with breast cancer risk: A review. Psychotherapy and psychosomatics. 2003;72:185-194.
1369.	Bailer U, HN A, Kasper S. Efficacy of antidepressants in the treatment of severe depression. [German]. Neuropsychiatrie. 2001;15:57-65.
1370.	Bailer U, Praschak-Rieder N, Pezawas L, Kasper S. The Use of Mirtazapine in Depressed Inpatients. Wiener klinische Wochenschrift. 1998;110:646-650.
1371.	Bailly D. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents]. [Review] [49 refs] [French]. Presse medicale. 2006;35:1507-1515.
1372.	Bailly D. [Efficacy of selective serotonin reuptake inhibitor treatment in children and adolescents]. [Review] [72 refs] [French]. Presse medicale. 2006;35:1293-1302.
1373.	Bailly D. Benefits and Risks of Using Antidepressants in Children and Adolescents. Expert opinion on drug safety. 2008;7:9-27.
1374.	Bailly D. Antidepressant use in children and adolescents. [French]. Archives de pediatrie. 2009;16:1415-1418.
1375.	Baird-Bellaire S, JA B, VD P, Patat A, Paul J, AI N. An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine. Clinical therapeutics. 2013;35:782-794.
1376.	Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. Journal of clinical psychopharmacology. 1997;17:15-21.
1377.	Bakim B, UE U, Karamustafalioglu O, et al. The combination of antidepressant drug therapy and high-frequency repetitive transcranial magnetic stimulation in medication-resistant depression. Klinik Psikofarmakoloji Bulteni. 2012;22:244-253.
1378.	Bakish D. Fluvoxamine: A clinical review. Today's Therapeutic Trends. 1992;10:101-109.
1379.	Bakish D. Venlafaxine versus SSRI therapy for major depression. Results of comparative efficacy trials. Postgraduate medicine. 1999;106:24-30.
1380.	Bakish D. The patient with comorbid depression and anxiety: the unmet need. [Review] [29 refs]. Journal of clinical psychiatry. 1999;60 Suppl 6:20-24.
1381.	Bakish D, Cavazzoni P, Chudzik J, Ravindran A, PD H. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biological psychiatry. 1997;41:184-190.
1382.	Bakish D, CL H, MJ F, et al. A Double-Blind Placebo-Controlled Trial Comparing Fluvoxamine and Imipramine in the Treatment of Panic Disorder With or Without Agoraphobia. Psychopharmacology bulletin. 1996;32:135-141.
1383.	Bakish D, Gommoll C, Chen C, et al. Levomilnacipran sr 40mg and 80 mg in major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study. Neuropsychopharmacology. 2012;Conference:S427-S428.
1384.	Bakish D, Habib R, CL H. Mixed Anxiety and Depression - Diagnosis and Treatment Options. CNS drugs. 1998;9:271-280.
1385.	Bakker A, Ajlm VB, R VD. Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder and Agoraphobia. International clinical psychopharmacology. 2000;15:S25-S30.
1386.	Bakker A, AJLM VB, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: A meta-analysis. Acta psychiatrica Scandinavica. 2002;106:163-167.
1387.	Bakker A, R VD, Spinhoven P, Ajlm VB. Paroxetine, Clomipramine, and Cognitive Therapy in the Treatment of Panic Disorder. Journal of clinical psychiatry. 1999;60:831-838.
1388.	Bal R, Legree L, Diwan S. Nonopioid analgesic pipeline: Pharmacology, safety, tolerability, and potential advantages over established agents. Techniques in regional anesthesia & pain management. 2010;14:75-85.
1389.	Balaguer-Martinez E. Complications in the treatment of Parkinson's disease. How should depression be managed in Parkinson's disease?. [Spanish]. Revista de neurologia. 2010;50:S45-S47.
1390.	Balakrishnan P, Rosen H. The causes and treatment of pseudobulbar affect in ischemic stroke. Current treatment options in cardiovascular medicine. 2008;10:216-222.
1391.	Balaratnasingam S, Janca A. Combining sertraline and naltrexone in the treatment of adults with comorbid depression and alcohol dependence. Current psychiatry reports. 2011;13:245-247.
1392.	Baldo P, Doree C, Lazzarini R, Molin P, DJ M. Antidepressants for patients with tinnitus. Cochrane database of systematic reviews (Online). 2006.
1393.	Baldo P, Doree C, Molin P, McFerran D, Cecco S. Antidepressants for patients with tinnitus. [Review][Update of Cochrane Database Syst Rev. 2006;(4):CD003853; PMID: 17054188]. Cochrane database of systematic reviews (Online). 2012;9:CD003853.
1394.	Balducci L. Treating elderly patients with hormone sensitive breast cancer: What do the data show? Cancer treatment reviews. 2009;35:47-56.
1395.	Baldwin D. Anxiety Disorders: Does One Treatment Fit All? International journal of psychiatry in clinical practice. 2004;8:31-35.
1396.	Baldwin D. Tolerability and Safety of Escitalopram in Randomised Controlled Trials in Major Depression and Anxiety Disorders. European neuropsychopharmacology. 2007;17:S317-S318.
1397.	Baldwin D, Bullock T, Montgomery D, Montgomery S. 5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour. [Review] [35 refs]. International clinical psychopharmacology. 1991;6 Suppl 3:46-49.
1398.	Baldwin D, Bullock T, Montgomery D, Montgomery S. 5-Ht Reuptake Inhibitors, Tricyclic Antidepressants and Suicidal-Behavior. International clinical psychopharmacology. 1991;6:49-56.
1399.	Baldwin D, Bullock T, Montgomery D, Montgomery S. 5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour. International clinical psychopharmacology. 1991;6 Suppl 3:49-56.
1400.	Baldwin D, Fineberg N, Montgomery S. Fluoxetine, Fluvoxamine and Extrapyramidal Tract Disorders. International clinical psychopharmacology. 1991;6:51-58.
1401.	Baldwin D, Hutchison J, Donaldson K, Shaw B, Smithers A. Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: Randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. Journal of psychopharmacology (Oxford, England). 2008;22:55-63.
1402.	Baldwin D, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment. European neuropsychopharmacology. 2011;Conference:S390.
1403.	Baldwin D, RA M, Briley M. Resolution of Sexual Dysfunction During Acute Treatment of Major Depression With Milnacipran. Human Psychopharmacology-Clinical and Experimental. 2008;23:527-532.
1404.	Balestrieri M, MG C, Leonetti S, Sebastiani G, Starace F, Bellantuono C. Recognition of depression and appropriateness of antidepressant treatment in Italian primary care. Social psychiatry and psychiatric epidemiology. 2004;39:171-176.
1405.	Ball S, LB M, Lipsius S, JM R. Brain-Derived Neurotrophic Factor in Generalized Anxiety Disorder: Results From a Duloxetine Clinical Trial. Progress in neuro-psychopharmacology & biological psychiatry. 2013;43:217-221.
1406.	Ball S, MA D, DN DS, LB M, JM R, Goldberger C. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. Journal of affective disorders. 2014;167:215-223.
1407.	Ballard C. Agitation and Psychosis in Dementia. American journal of geriatric psychiatry. 2007;15:913-917.
1408.	Ballard C, Aarsland D, Francis P, Corbett A. Neuropsychiatric symptoms in patients with dementias associated with cortical lewy bodies: Pathophysiology, clinical features, and pharmacological management. Drugs & aging. 2013;30:603-611.
1409.	Ballard C, Corbett A. Agitation and aggression in people with Alzheimer's disease. Current opinion in psychiatry. 2013;26:252-259.
1410.	Ballard C, Corbett A. A small proportion of people with dementia and neuropsychiatric symptoms experience clinically significant worsening when antidepressants are discontinued. Evidence-based medicine. 2013;18:27-28.
1411.	Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. [Review] [78 refs]. Current opinion in psychiatry. 2009;22:532-540.
1412.	Ballard C, Corbett A, EL J. Dementia: Challenges and promising developments. The Lancet Neurology. 2011;10:7-9.
1413.	Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia: Importance and treatment considerations. International review of psychiatry. 2008;20:396-404.
1414.	Ballesteros J, LF C. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: A meta-analysis of early and late outcomes from randomised controlled trials. Journal of affective disorders. 2004;79:137-147.
1415.	Ballesteros J, LF C, Gutierrez M. Attaining Remission of Depressive Symptoms in the Pivotal Randomised Clinical Trials of Duloxetine in Major Depression. Which Are the Most Efficacious Doses? Value in health. 2007;10:A288-A289.
1416.	Ballus C, Quiros G, T dF, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. International clinical psychopharmacology. 2000;15:43-48.
1417.	Balogh S, DF F, SE H, SR P. Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacology bulletin. 1993;29:201-206.
1418.	Balon R. Placebo for depression? [1]. Neuropsychopharmacology. 1995;12:355.
1419.	Balon R. Selective serotonin reuptake inhibitors and suicide: Is the evidence, as with beauty, in the eye of the beholder? Psychotherapy and psychosomatics. 2003;72:293-299.
1420.	Balon R. Mood, anxiety, and physical illness: Body and mind, or mind and body? Depression and anxiety. 2006;23:377-387.
1421.	Balon R. Clinical factor 2010. Psychotherapy and psychosomatics. 2011;80:195-198.
1422.	Balon R. Clinical factor 2011. Psychotherapy and psychosomatics. 2012;81:199-205.
1423.	Balon R. Clinical factor 2012. Psychotherapy and psychosomatics. 2013;82:204-212.
1424.	Balon R. Clinical factor 2012. Psychotherapy and psychosomatics. 2013;82:204-212.
1425.	Balon R, Knutson B, OM W, VI R. Alteration of personality by serotonergic intervention [23] (multiple letters). American journal of psychiatry. 1999;156:985.
1426.	Balon R, VK Y, Pohl R, Merlos B, Sherwood P. Changes in Appetite and Weight During the Pharmacological Treatment of Patients With Panic Disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1993;38:19-22.
1427.	Banaschewski T, Roessner V, RW D, PJ S, Rothenberger A. Non-stimulant medications in the treatment of ADHD. European Child and Adolescent Psychiatry, Supplement. 2004;13:I/102-I/116.
1428.	Bandelow B. Nefazodone (Nefadar, Dutonin). [German]. Tagliche Praxis. 2001;42:617-619.
1429.	Bandelow B. Comorbid depression and anxiety - Understanding and treating complex patients. European neuropsychopharmacology. 2009;Conference:S706.
1430.	Bandelow B, Behnke K, Lenoir S, et al. Sertraline Versus Paroxetine in the Treatment of Panic Disorder: an Acute, Double-Blind Noninferiority Comparison. Journal of clinical psychiatry. 2004;65:405-413.
1431.	Bandelow B, Behnke K, Lenoir S, et al. Sertraline Versus Paroxetine in the Treatment of Panic Disorder: an Acute, Double-Blind Noninferiority Comparison. Journal of clinical psychiatry. 2004;65:405-413.
1432.	Extended-Release Quetiapine Fumarate (Quetiapine Xr): a Once-Daily Monotherapy Effective in Generalized Anxiety Disorder. Data From a Randomized, Double-Blind, Placebo- and Active-Controlled Study, International journal of neuropsychopharmacology(2010).
1433.	Bandelow B, DI S, OT D, HF A, DS B. Improvement of Quality of Life in Panic Disorder With Escitalopram, Citalopram, or Placebo. Pharmacopsychiatry. 2007;40:152-156.
1434.	Bandelow B, Kornhuber J. Nefazodone (nefadar, dutonin). [German]. Internistische Praxis. 2001;41:617-619.
1435.	Bandelow B, Meier A. Aripiprazole, a "Dopamine-serotonin system stabilizer" in the treatment of psychosis. German Journal of Psychiatry. 2003;6:9-16.
1436.	Bandelow B, RJ B, Kasper S, et al. Drug Treatment of Generalized Anxiety Disorder (Gad) - a Consensus Statement. Psychopharmakotherapie. 2007;14:136-+.
1437.	Bandyopadhyay U, Bhattacharya R. Adaptive allocation and failure saving in randomised clinical trials. Journal of biopharmaceutical statistics. 2006;16:817-829.
1438.	Bandyopadhyay U, Bhattacharya R. An urn based covariate adjusted response adaptive allocation design. Statistical methods in medical research. 2012;21:135-148.
1439.	Bandyopadhyay U, Biswas A, Bhattacharya R. A covariate adjusted two-stage allocation design for binary responses in randomized clinical trials. Statistics in medicine. 2007;26:4386-4399.
1440.	Banerjee S, Hellier J, Romeo R, et al. Study of the Use of Antidepressants for Depression in Dementia: the Hta-Sadd Trial - a Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial of the Clinical Effectiveness and Cost-Effectiveness of Sertraline and Mirtazapine. Health technology assessment. 2013;17:1-+.
1441.	Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health technology assessment (Winchester, England). 2013;17:1-166.
1442.	Study of the use of antidepressants for depression in dementia: The HTA-SADD trial- A multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine, Health technology assessment(2013).
1443.	Baniasadi M, Hosseini G, MRF B, AR A, HM T. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: A randomized controlled trial. Journal of psychiatric practice. 2014;20:419-427.
1444.	Banti S, Borri C, MS M, et al. Premenstrual disphoric disorder: An update. [Italian]. Journal of Psychopathology. 2012;18:261-272.
1445.	Bao L, Chen J, Huang L, et al. [Effects of Xiaoyao Wan on the behavioral despair and stress depression mice]. [Chinese]. Zhong yao cai = Zhongyaocai [Journal of Chinese medicinal materials]. 2008;31:1360-1364.
1446.	Bao T, Cai L, Snyder C, et al. Patient-Reported Outcomes in Women With Breast Cancer Enrolled in a Dual-Center, Double-Blind, Randomized Controlled Trial Assessing the Effect of Acupuncture in Reducing Aromatase Inhibitor-Induced Musculoskeletal Symptoms. Cancer. 2014;120:381-389.
1447.	Collaborative depression care management and disparities in depression treatment and outcomes, Archives of general psychiatry(2011).
1448.	Bao-Liang Z, Yue-Qin H, Hui-Juan L. The effectiveness and safety of acupuncture for depression: A systematic assessment. [Chinese]. Chinese Mental Health Journal. 2008;22:641-647.
1449.	BAPBK P. Efficacy and Tolerability of Venlafaxine Extended Release in Patients With Major Depressive Disorder. Psychiatria Danubina. 2010;22:413-417.
1450.	BAPBK P. Efficacy and Tolerability of Agomelatine in the Treatment of Depression. Patient preference and adherence. 2014;8:603-612.
1451.	Baptista T, ElFakih Y, Uzcategui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS drugs. 2008;22:477-495.
1452.	Baptista T, S dM, Beaulieu S, Bermudez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: Mechanisms and management. Metabolic syndrome and related disorders. 2004;2:290-307.
1453.	Barak N. Betahistine: What's new on the agenda? Expert opinion on investigational drugs. 2008;17:795-804.
1454.	Barak Y. Co-Prescription of Antidepressants With Other Psychotropics: Distinct Profile of Escitalopram. International journal of psychiatry in clinical practice. 2008;12:31-35.
1455.	Barak Y. Remission: Achieving and sustaining the optimal outcome. International journal of psychiatry in clinical practice. 2009;Conference:8-9.
1456.	Barak Y, Kimhi R, Bodner E, Achiron A. Treatment of depression in patients with multiple sclerosis. Neurologist. 1998;4:99-104.
1457.	Barak Y, Kimhi R, Weizman R. Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients? International clinical psychopharmacology. 2000;15:53-56.
1458.	Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Alzheimer's Disease: a Randomized Double-Blind Pilot Study. International Psychogeriatrics. 2011;23:1515-1519.
1459.	Baraldi S, Hepgul N, Mondelli V, CM P. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. [Review]. Journal of clinical psychopharmacology. 2012;32:531-543.
1460.	Barbara B, Sarah B, Martin K. Evidence of cost-effective treatments for depression: a systematic review. [Review] [75 refs]. Journal of affective disorders. 2005;84:1-13.
1461.	Barbara S, Bettina W-H, Florian L, et al. Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: A randomised open trial. Psychiatry research. 2010;177:109-113.
1462.	Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish Bias" in Antidepressant Drug Trials? Journal of clinical psychopharmacology. 2004;24:126-130.
1463.	Barbui C, Cipriani A, Lintas C, Bertele V, Garattini S. CNS drugs approved by the centralised European procedure: True innovation or dangerous stagnation? Psychopharmacology. 2007;190:265-268.
1464.	Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. CMAJ : Canadian Medical Association journal. 2009;180:291-297.
1465.	Barbui C, Hotopf M. Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials. British journal of psychiatry. 2001;178:129-144.
1466.	Barbui C, Hotopf M, Garattini S. Fluoxetine dose and outcome in antidepressant drug trials. [Review] [103 refs]. European journal of clinical pharmacology. 2002;58:379-386.
1467.	Barbui C, Percudani M, Hotopf M. Economic evaluation of antidepressive agents: A systematic critique of experimental and observational studies. Journal of clinical psychopharmacology. 2003;23:145-154.
1468.	Barbui C, TA F, Cipriani A. The authors respond. CMAJ : Canadian Medical Association journal. 2008;178:1185-1186.
1469.	Barbui C, Violante A, Garattini S. Does placebo help establish equivalence in trials of new antidepressants? European psychiatry. 2000;15:268-273.
1470.	Barcelos R, Faria J, Grossi P, MAM A, CMC B. Vascular depression in elderly: Response to treatment with antidepressant associated to cholinesterase inhibitor. [Portuguese]. Revista de Psiquiatria Clinica. 2007;34:290-293.
1471.	Bardia A, Thompson S, PJ A, et al. Pilot evaluation of aprepitant for the treatment of hot flashes. Supportive cancer therapy. 2006;3:240-246.
1472.	Bares M, Brunovsky M, Novak T, et al. QEEG theta cordance in the prediction of treatment outcome to prefrontal repetitive transcranial magnetic stimulation or venlafaxine ER in patients with major depressive disorder. Clinical EEG and neuroscience. 2015;46:73-80.
1473.	Bares M, Hrdlicka M, Propper L. Atypical neuroleptic drug, olanzapine, in the treatment of impaired mood. [Czech]. Prakticky lekar. 2000;80:329-332.
1474.	Bares M, Kopecek M, Novak T, et al. Right-sided, 1-hz repetitive TMS compared with venlafaxine extended-release in the treatment of resistant depression: A double-blind study. European neuropsychopharmacology. 2009;Conference:S365.
1475.	Bares M, Kopecek M, Sos P, Novak T, Brunovsky M, Stopkova P. Double - blind, parallel, randomized study comparing efficacy of 1 Hz repetitive transcranial magnetic stimulation (rTMS) and venlafaxine ER in the treatment of resistant depression: Discussion on study protocol. [Czech]. Psychiatrie (Stuttgart, Germany). 2008;12:4-7.
1476.	Bares M, Mohr P, Hendrychova Y, Kopecek M, Mohapl M. Vagus nerve stimulation (VNS) in the treatment of resistant depressive disorder - One-year experiences. [Czech]. Psychiatrie (Stuttgart, Germany). 2006;10:18-20.
1477.	Bares M, Novak T. The combinations of antidepressants in the acute treatment of resistant depression: A review of randomized trials. [Czech]. Psychiatrie (Stuttgart, Germany). 2010;14:27-33.
1478.	Bares M, Novak T. Prefrontal cordance in the outcome prediction of 1-Hz, right-sided, prefrontal rTMS in patients with depression. International journal of psychiatry in clinical practice. 2012;Conference:16-17.
1479.	Bares M, Novak T, Kopecek M, et al. The right-sided, low frequency (1 HZ) repetitive transcranial magnetic stimulation (RTMS) in the treatment of resistant depression compared with venlafaxine ER. the results of the double-blind, randomized study. [Czech]. Psychiatrie (Stuttgart, Germany). 2009;13:58.
1480.	Antidepressant Monotherapy Compared With Combinations of Antidepressants in the Treatment of Resistant Depressive Patients: a Randomized, Open-Label Study, International journal of psychiatry in clinical practice(2013).
1481.	Baretic M. Targets for medical therapy in obesity. Digestive diseases (Basel, Switzerland). 2012;30:168-172.
1482.	Barker-Collo S, Starkey N, Theadom A. Treatment for Depression Following Mild Traumatic Brain Injury in Adults: a Meta-Analysis. Brain injury. 2013;27:1124-1133.
1483.	Barker-Collo S, VL F, Dudley M. Post-stroke fatigeu - Where is the evidence to guide practice? New Zealand medical journal. 1264.
1484.	Barnard K, RC P, RIG H. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation. Diabetes care. 2013;36:3337-3345.
1485.	Barnes J. St John's wort is hypericum. Pharmaceutical journal. 2001;266:538-539.
1486.	Barnes J. Quality, efficacy and safety of complementary medicines: Fashions, facts and the future. Part II: Efficacy and safety. British journal of clinical pharmacology. 2003;55:331-340.
1487.	Barnes J, LA A, JD P. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. [Review] [172 refs]. Journal of pharmacy and pharmacology. 2001;53:583-600.
1488.	Barnes K, O'Leary H, Khwaja O. Escitalopram improves mood, anxiety and motor function in adolescent girls with Rett syndrome. Annals of neurology. 2011;Conference:S137-S138.
1489.	Baron R. Detection of neuropathic pain syndromes. [German]. Deutsches Arzteblatt. 2006;103:A2720-2730.
1490.	Barone P. Depressive symptoms in PD - Burden and treatment. European journal of neurology. 2009;Conference:660.
1491.	Barone P, Scarzella L, Marconi R, et al. Pramipexole Versus Sertraline in the Treatment of Depression in Parkinson's Disease - a National Multicenter Parallel-Group Randomized Study. Journal of neurology. 2006;253:601-607.
1492.	Barrelet L, Blajev B, Bolzani L, et al. [Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes]. [French]. Schweizerische Rundschau f�r Medizin Praxis = Revue suisse de m�decine Praxis. 1991;80:524-528.
1493.	Barrett B, Byford S, Knapp M. Evidence of Cost-Effective Treatments for Depression: a Systematic Review. Journal of affective disorders. 2005;84:1-13.
1494.	Barriere J, Cherikh F, Pringuey D, Milano G, JM F. Antidepressants in Oncology: Issues and Clinical Perspectives. Bulletin du cancer. 2008;95:1103-1111.
1495.	Barrot M, Yalcin I, L-H T, M-J F-M. Antidepressant treatment of neuropathic pain: Looking for the mechanism. Future neurology. 2010;5:247-257.
1496.	Bartlett S, Ballard C. Antidepressants in the elderly: A review. Expert opinion on investigational drugs. 1999;8:51-63.
1497.	Barton S, Findlay D, RA B. The management of inappropriate vocalisation in dementia: A heirarchical approach. International journal of geriatric psychiatry. 2005;20:1180-1186.
1498.	Bartzokis G, PH L, Turner J, Mintz J, CS S. Adjunctive Risperidone in the Treatment of Chronic Combat-Related Posttraumatic Stress Disorder. Biological psychiatry. 2005;57:474-479.
1499.	Bartzokis G, PH L, Turner J, Mintz J, CS S. Adjunctive Risperidone in the Treatment of Chronic Combat-Related Posttraumatic Stress Disorder. Biological psychiatry. 2005;57:474-479.
1500.	Baruch S, D SR, Ginette S, Evgeny S, Moshe K, Abraham W. Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-Related Posttraumatic Stress Disorder - a Double-Blind, Fixed-Dosage, Controlled Trial. Journal of clinical psychopharmacology. 2006;26:152-156.
1501.	Baruch Y. Hypericum extract for treatment of depression: what's new?. [Hebrew]. Harefuah. 2009;148:183-185,209,210.
1502.	Baruch Y. [Hypericum extract for treatment of depression: what's new?]. [Review] [8 refs] [Hebrew]. Harefuah. 2009;148:183-185.
1503.	Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatrica Scandinavica, Supplement. 1989;80:141-142.
1504.	Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta psychiatrica Scandinavica. Supplementum. 1989;350:141-142.
1505.	Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitryptyline in depressed patients. Acta neurologica Scandinavica. 1989;80:141-142.
1506.	Baslet G. Psychogenic nonepileptic seizures: A treatment review. What have we learned since the beginning of the millennium? Neuropsychiatric disease and treatment. 2012;8:585-598.
1507.	Bastiaens L, Kennedy M, AC T. Antidepressants and new-onset suicidality in pediatric patients treated in a community mental health center. Primary psychiatry. 2006;13:69-74.
1508.	Bastos O, Busnello E, Calil HM, Campos JA. Evaluation of the efficacy, tolerability, and safety of sertraline (50-200 mg) during 8 wks in the treatment of 150 outpatients with major depression. [Portuguese]. Jornal brasileiro de psiquiatria. 1996;45:105-109.
1509.	Bastos O, Busnello E, HM C, et al. The efficacy, tolerability and safety of sertraline (50-20 mg) during 8 months in the treatment of 150 outpatients with major depression. [Portuguese]. Jornal brasileiro de psiquiatria. 1996;45:105-109.
1510.	Basu M, JRA D. Update on duloxetine for the management of stress urinary incontinence. [Review] [43 refs]. Clinical interventions in aging. 2009;4:25-30.
1511.	Bates B, JY C, PW D, et al. Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive summary. Stroke; a journal of cerebral circulation. 2005;36:2049-2056.
1512.	Bates G. Medication in the treatment of the behavioural sequelae of traumatic brain injury. Developmental medicine and child neurology. 2006;48:697-701.
1513.	Batley M, Walton T, AS AH. Fibromyalgia: Its pathophysiology and treatment. Journal of Functional Syndromes. 2002;2:50-56.
1514.	Battaglia A, Bejor M. Influence of poststroke depression on functional outcome. Europa medicophysica. 2001;37:25-37.
1515.	Battaglia A, Bejor M, Petri M, Beumgarde D, Bartalini B. Analysis of cognitive functions after venlafaxyne treatment in post- stroke depression. [Italian]. Nuova Rivista di Neurologia. 1999;9:15-27.
1516.	Battegay R, Hager M, Rauchfleisch U. Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric outpatient clinic (pilot study). Neuropsychobiology. 1985;13:31-37.
1517.	Bauer M. Making treatment decisions in depression: Balancing efficacy and tolerability among contemporary antidepressant treatment options. European neuropsychopharmacology. 2008;Conference:S610.
1518.	Bauer M. A review of recent advances in evidence-based medicine in MDD: Strategies for the unresponsive patient. European neuropsychopharmacology. 2011;Conference:S638-S639.
1519.	Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: Augmentation of antidepressants. Neuropsychobiology. 2010;62:36-42.
1520.	Bauer M, Bergmann F, Falkai P, et al. State of the art conference "Innovations in antidepressive therapy - Luxury or necessity?" New approaches for a better therapeutic efficacy. [German]. Nervenheilkunde. 2004;23:1-10.
1521.	Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Muller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. American journal of psychiatry. 2000;157:1429-1435.
1522.	Bauer M, Bschor T, Pfennig A, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World journal of biological psychiatry. 2007;8:67-104.
1523.	Bauer M, Bschor T, Pfennig A, et al. Biological treatment of unipolar depressive disorders in the general practitioner's medical care: Guidelines of the World Federation of Societies of Biological Psychiatry (WFSBP). [German]. Psychopharmakotherapie. 2008;15:239-264.
1524.	Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder, Journal of affective disorders(2013).
1525.	Bauer M, DellOsso L, Kasper S, et al. Quetiapine xr monotherapy, quetiapine XR+ongoing antidepressants and lithium+ongoing antidepressants in patients with treatment-resistant major depressive disorder. International journal of neuropsychopharmacology. 2010;Conference:143.
1526.	Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment, International clinical psychopharmacology(2014).
1527.	Bauer M, Demyttenaere K, El-Khalili N, et al. Efficacy of adjunct quetiapine extended-release in major depressive disorder: A pooled analysis of SSRI and SNRI patient subgroups. European neuropsychopharmacology. 2011;Conference:S441-S442.
1528.	Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. Journal of clinical psychopharmacology. 1999;19:427-434.
1529.	Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. Journal of affective disorders. 2010;127:19-30.
1530.	Bauer M, Freemantle N, Tharmanathan P. Meta Analysis of Randomised Controlled Trials of Venlafaxine in the Treatment of Major Depressive Disorder. Der Nervenarzt. 2007;78:115.
1531.	Bauer M, H-J M, Schneider E. Duloxetine: a new selective and dual-acting antidepressant. [Review] [45 refs]. Expert opinion on pharmacotherapy. 2006;7:421-427.
1532.	Bauer M, PC W, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold Revista de Psiquiatria Clinica. 2009;36:58-76.
1533.	Bauer M, PC W, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder. [Portuguese]. Revista de Psiquiatria Clinica. 2009;36:17-57.
1534.	Bauer M, Pfennig A, Linden M, MN S, Neu P, Adli M. Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression. Journal of clinical psychopharmacology. 2009;29:327-333.
1535.	Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World journal of biological psychiatry. 2013;14:334-385.
1536.	Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar disorders. 2012;14:37-50.
1537.	Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy, International journal of neuropsychopharmacology(2013).
1538.	Bauer M, Severus E, Kohler S, PC W, Angst J, H-J M. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: Maintenance treatment of major depressive disorder-update 2015. World journal of biological psychiatry. 2015;16:76-95.
1539.	Bauer M, SM B, Schlagenhauf F, et al. Regional cerebral glucose metabolism and anxiety symptoms in bipolar depression: Effects of levothyroxine. Psychiatry Research - Neuroimaging. 2010;181:71-76.
1540.	Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: Therapeutic Drug Monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
1541.	Baumann P, Nil R, Bertschy G, et al. A double-blind double-dummy study of citalopram comparing infusion versus oral administration. Journal of affective disorders. 1998;49:203-210.
1542.	Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. [Review]. Cochrane database of systematic reviews (Online). 2011;9:CD008012.
1543.	Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. [Review]. Cochrane database of systematic reviews (Online). 2012;12:CD008381.
1544.	Baumeister H, Hutter N, Bengel J. Psychological and Pharmacological Interventions for Depression in Patients With Diabetes Mellitus and Depression. Cochrane database of systematic reviews (Online). 2012.
1545.	Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus: An abridged Cochrane review. Diabetic medicine. 2014;31:773-786.
1546.	Bautovich A, Katz I, Smith M, CK L, SB H. Depression and chronic kidney disease: A review for clinicians. Australian and New Zealand journal of psychiatry. 2014;48:530-541.
1547.	Bay E. Current treatment options for depression after mild traumatic brain injury. Current treatment options in neurology. 2009;11:377-382.
1548.	Baye J. Roflumilast (Daliresp): A novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P and T. 2012;37:149-161.
1549.	Bayer A. Psychogeriatric update. Aging health. 2006;2:547-551.
1550.	Bayes M, Rabasseda X, JR P. Gateways to Clinical Trials. Methods and findings in experimental and clinical pharmacology. 2004;26:723-753.
1551.	Bayes M, Rabasseda X, JR P. Gateways to Clinical Trials. Methods and findings in experimental and clinical pharmacology. 2004;26:129-161.
1552.	Bayes M, Rabasseda X, JR P. Gateways to Clinical Trials. Methods and findings in experimental and clinical pharmacology. 2004;26:129-161.
1553.	BB A, Mikkelsen M, Vesterager A, et al. No influence of the antideprerssant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy research. 1991;10:201-204.
1554.	BB Q, KU K, Stelzenmueller R, Hoenig K, Maier W, Wagner M. Effects of Serotonergic and Noradrenergic Antidepressants on Auditory Startle Response in Patients With Major Depression. Psychopharmacology. 2004;175:399-406.
1555.	BB S. Estrogen and Mood in Women. Endocrinologist. 2005;15:180-185.
1556.	BB S. Estrogen and Mood in Women. Endocrinologist. 2005;15:180-185.
1557.	BC A, Huyser J, Verweij M, et al. Glucocorticoids and relapse of major depression (dexamethasone/ corticotropin-releasing hormone test in relation to relapse of major depression). Biological psychiatry. 2006;59:696-701.
1558.	BC A, JP B, R VD, et al. Triiodothyronine Addition to Paroxetine in the Treatment of Major Depressive Disorder. Journal of clinical endocrinology and metabolism. 2004;89:6271-6276.
1559.	BC A, JP B, R VD, et al. Triiodothyronine Addition to Paroxetine in the Treatment of Major Depressive Disorder. Journal of clinical endocrinology and metabolism. 2004;89:6271-6276.
1560.	BC C, EL F. Painful diabetic neuropathy: Many similarly effective therapies with widely dissimilar costs. Annals of internal medicine. 2014;161:674-675.
1561.	BC G, BC B, BA M. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27:476-479.
1562.	BC H, Jimerson M, Haxton C, DC J. Initial Evaluation, Diagnosis, and Treatment of Anorexia Nervosa and Bulimia Nervosa. American family physician. 2015;91:46-52.
1563.	BD G. Diagnosis and Management of Post-Traumatic Stress Disorder. American family physician. 2003;68:2401-2408.
1564.	BD G. Diagnosis and Management of Post-Traumatic Stress Disorder. American family physician. 2003;68:2401-2408.
1565.	BD G, LH P, SL R, et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: Critical issues. Neurosurgery clinics of North America. 2003;14:199-212.
1566.	BD K. Do new-generation antidepressants work? Irish medical journal. 2008.
1567.	BD K, GJ E, TL M, JL H. Relapse and Recurrence in Pediatric Depression. Child and adolescent psychiatric clinics of North America. 2006;15:1057-1079.
1568.	BD K, GJ E, TL M, et al. Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression. American journal of psychiatry. 2014;171:1083-1090.
1569.	Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome, Journal of the American Academy of Child and Adolescent Psychiatry(2008).
1570.	BD K, SG S, TL M, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. American journal of psychiatry. 2009;166:337-344.
1571.	BD K, SM S, JL H, RB J, GJ E. Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth. Cognitive and behavioral practice. 2008;15:387-399.
1572.	BD T, P DJ, JC C, et al. Depression screening and patient outcomes in cardiovascular care: A systematic review. JAMA - Journal of the American Medical Association. 2008;300:2161-2171.
1573.	BD T, Roseman M, JC C, et al. Does Evidence Support the American Heart Association's Recommendation to Screen Patients for Depression in Cardiovascular Care? An Updated Systematic Review. PloS one. 2013.
1574.	BDS PJ, Tortella G, Lafer B, et al. The bipolar depression electrical treatment trial (better): Design, rationale, and objectives of a randomized, sham-controlled trial and data from the pilot study phase. Neural plasticity. 2015.
1575.	BE C, MJ F. Recognizing and treating depression. Journal of supportive oncology. 2007;5:84-85.
1576.	BE D, SR D, JH P, JF W. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacology bulletin. 1989;25:71-79.
1577.	BE F, LK S, RB L. SSRIs: Implications for women's health across the reproductive life span. Sexuality, reproduction & menopause. 2008;6:27-32.
1578.	BE L. Recent advances in antidepressant medication. Journal of pharmacotherapy. 1979;2:44-49.
1579.	Review article: Current treatment options and management of functional dyspepsia, Alimentary pharmacology & therapeutics(2012).
1580.	Beasley C, Disch D, Prabhakar V, Desaiah D, Tamura R, Perlis R. Potential Predictive Factors for Development of Treatment-Emergent Suicidal Ideation in the Fluoxetine Placebo-Controlled Major Depressive Disorder Database. Neuropsychopharmacology. 2006;31:S100-S101.
1581.	Beaulieu S, Saury S, Sareen J, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Annals of clinical psychiatry. 2012;24:38-55.
1582.	Beaumont G, Baldwin D, Lader M. A criticism of the practice of prescribing subtherapeutic doses of antidepressants for the treatment of depression. Human psychopharmacology. 1996;11:283-291.
1583.	Beauregard M. Mind does really matter: Evidence from neuroimaging studies of emotional self-regulation, psychotherapy, and placebo effect. Progress in neurobiology. 2007;81:218-236.
1584.	Beauregard M. Effect of mind on brain activity: Evidence from neuroimaging studies of psychotherapy and placebo effect. Nordic journal of psychiatry. 2009;63:5-16.
1585.	Bech P. Acute therapy of depression. [Review] [56 refs]. Journal of clinical psychiatry. 1993;54 Suppl:18-27; discussion 28.
1586.	Bech P. The Hamilton disorders. Psychotherapy and psychosomatics. 1993;60:113-115.
1587.	Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: A 20-year review of its use as outcome measure. Acta psychiatrica Scandinavica. 2002;106:252-264.
1588.	Bech P. Modern psychometrics in clinimetrics: Impact on clinical trials of antidepressants. Psychotherapy and psychosomatics. 2004;73:134-138.
1589.	Bech P. Social functioning: Should it become an endpoint in trials of antidepressants? CNS drugs. 2005;19:313-324.
1590.	Bech P. Fifty years with the Hamilton scales for anxiety and depression: A tribute to Max Hamilton. Psychotherapy and psychosomatics. 2009;78:202-211.
1591.	Bech P. Applied psychometrics in clinical psychiatry: The pharmacopsychometric triangle. Acta psychiatrica Scandinavica. 2009;120:400-409.
1592.	Bech P. Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychotherapy and psychosomatics. 2010;79:331-338.
1593.	Bech P, Allerup P, LF G, et al. The Diagnostic Melancholia Scale (DMS): dimensions of endogenous and reactive depression with relationship to the Newcastle Scales. Journal of affective disorders. 1988;14:161-170.
1594.	Bech P, Andersen HF, Wade A. Effective Dose of Escitalopram in Moderate versus Severe DSM-IV Major Depression. Pharmacopsychiatry. 2006;39:128-134.
1595.	Bech P, Ciadella P, Haugh MC, et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. The British Journal of Psychiatry. 2000;176:421-428.
1596.	Bech P, Cialdella P. Citalopram in depression: Meta-analysis of intended and unintended effects. International clinical psychopharmacology. 1992;6 Suppl 5:45-54.
1597.	Bech P, Fava M, MH T, SR W, AJ R. Outcomes on the Pharmacopsychometric Triangle in Bupropion-Sr Vs. Buspirone Augmentation of Citalopram in the Star*D Trial. Acta psychiatrica Scandinavica. 2012;125:342-348.
1598.	Bech P, Gormsen L, Loldrup D, Lunde M. The Clinical Effect of Clomipramine in Chronic Idiopathic Pain Disorder Revisited Using the Spielberger State Anxiety Symptom Scale (Ssass) as Outcome Scale. Journal of affective disorders. 2009;119:43-51.
1599.	Bech P, Haaber A, CR J. Experiments on clinical observation and judgement in the assessment of depression: profiled videotapes and Judgement Analysis. Psychological medicine. 1986;16:873-883.
1600.	Bech P, KF O. Relapse prevention and residual symptoms; further analyses of clinical studies with escitalopram in mdd, GAD, SAD, OCD. European neuropsychopharmacology. 2008;Conference:S308.
1601.	Bech P, Lunde M, Bech-Andersen G, Lindberg L, Martiny K. Psychiatric outcome studies (POS): Does treatment help the patients? A popperian approach to research in clinical psychiatry. 25th anniversary report from the Psychiatric Research Unit, Frederiksborg General Hospital, Denmark. Nordic journal of psychiatry. 2007;61:4-34.
1602.	Bech P, PE S, JF G, GD T. Acute Therapy of Depression. Journal of clinical psychiatry. 1993;54:18-27.
1603.	Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology. 2002;163:20-25.
1604.	Beck J, Brand S, Muheim F, Hatzinger M, Holsboer-Trachsler E. Modafinil reduces microsleep during partial sleep deprivation and improves antidepressant treatment response. Neuropsychobiology. 2009;Conference:69.
1605.	Beck J, Giese M, Brand S, et al. Sleep deprivation: Therapeutic and research tool in depression. European archives of psychiatry and clinical neuroscience. 2010;Conference:S14-S15.
1606.	Beck J, Hemmeter U, Brand S, Muheim F, Hatzinger M, Holsboer-Trachsler E. Modafinil reduces microsleep during partial sleep deprivation in depressed patients. Journal of psychiatric research. 2010;44:853-864.
1607.	Beckmann N, Sharma D, Gulbins E, KA B, Edelmann B. Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons. Frontiers in physiology. 2014.
1608.	Beer K. Cost effectiveness of botulinum toxins for the treatment of depression: Preliminary observations. Journal of drugs in dermatology. 2010;9:27-30.
1609.	Begre S, Traber M, Gerber M, R VK. Physician Speciality and Pain Reduction in Patients With Depressive Symptoms Under Treatment With Venlafaxine. European psychiatry. 2010;25:455-460.
1610.	Behnke K, GS J, H-J G, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Advances in therapy. 2002;19:43-52.
1611.	Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.[Erratum appears in J Clin Psychopharmacol. 2003 Dec;23(6):682]. Journal of clinical psychopharmacology. 2003;23:358-364.
1612.	Belicard-Pernot C, Manckoundia P, Ponavoy E, Rouaud O, Pfitzenmeyer P. Antidepressant use in demented elderly subjects: Current data. [French]. Revue De Medecine Interne. 2009;30:947-954.
1613.	Bell C, Wilson S, Rich A, Bailey J, Nutt D. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology. 2003;166:102-110.
1614.	Bellani M, Dusi N, P-H Y, JC S, Brambilla P. The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:1544-1552.
1615.	Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: A systematic review. Human psychopharmacology. 2007;22:121-128.
1616.	Bellantuono C, Nicoli M, Imperadore G, Vampini C. Quetiapine in Bipolar Disorder: A systematic review of the international studies. [Italian]. Rivista di psichiatria. 2006;41:1-9.
1617.	Bellantuono C, Rizzo R, Vampini C. Guidelines for drug treatment of depression in primary care. [Italian]. Rivista di psichiatria. 1999;34:117-125.
1618.	Belleville G, CM M. Hypnotic Discontinuation in Chronic Insomnia: Impact of Psychological Distress, Readiness to Change, and Self-Efficacy. Health psychology. 2008;27:239-248.
1619.	Belli H, Belli S, MF O, Ural C. Psychopathological dimensions of tinnitus and psychopharmacologic approaches in its treatment. General hospital psychiatry. 2012;34:282-289.
1620.	Bellini M, Merli M. Current drug treatment of patients with bulimia nervosa and binge-eating disorder: Selective serotonin reuptake inhibitors versus mood stabilizers. International journal of psychiatry in clinical practice. 2004;8:235-243.
1621.	Bellino S, Bozzatello P, Blandamura A, Bogetto F. Antidepressants in the treatment of borderline personality disorder: A review of literature data. [Italian]. Italian Journal of Psychopathology. 2009;15:163-176.
1622.	Bellino S, Bozzatello P, Bogetto F. Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: Predictors of response. Psychiatry research. 2015;226:284-288.
1623.	Bellino S, Bozzatello P, Brignolo E, Bogetto F. New antipsychotics in treatment of mood instability and cognitive perceptual symptoms in borderline personality disorder. Current Psychopharmacology. 2012;1:86-96.
1624.	Bellino S, Bozzatello P, Brignolo E, Brunetti C, Bogetto F. Omega-3 fatty acids supplementation in psychiatric disorders: A systematic review. Current Psychopharmacology. 2012;1:353-364.
1625.	Bellino S, Paradiso E, Bogetto F. Efficacy and Tolerability of Aripiprazole Augmentation in Sertraline-Resistant Patients With Borderline Personality Disorder. Psychiatry research. 2008;161:206-212.
1626.	Bellino S, Paradiso E, Bogetto F. Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder. CNS drugs. 2008;22:671-692.
1627.	Bellino S, Paradiso E, Bozzatello P, Bogetto F. Efficacy and Tolerability of Duloxetine in the Treatment of Patients With Borderline Personality Disorder: a Pilot Study. Journal of psychopharmacology (Oxford, England). 2010;24:333-339.
1628.	Bellino S, Rinaldi C, Bogetto F. Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2010;55:74-81.
1629.	Bellino S, Rinaldi C, Bozzatello P, Bogetto F. Recent approaches to pharmacotherapy of personality disorders. Neuropsychiatry. 2011;1:259-273.
1630.	Bellino S, Rinaldi C, Bozzatello P, Bogetto F. Pharmacotherapy of borderline personality disorder: A systematic review. Current medicinal chemistry. 2011;18:3322-3329.
1631.	Bellino S, Zizza M, R DL, et al. Combined therapy of major depressive disorder: A critical review. [Italian]. Italian Journal of Psychopathology. 2002;8:401-416.
1632.	Bellino S, Zizza M, Rinaldi C, Bogetto F. Combined Treatment of Major Depression in Patients With Borderline Personality Disorder: a Comparison With Pharmacotherapy. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2006;51:453-460.
1633.	Belmaker RH. Modafinil add-on in the treatment of bipolar depression. American journal of psychiatry. 2007;164:1143-1145.
1634.	Ben B, E LS, T MR, A KM, R JP. Low red cell folate levels are associated with poor response to nortriptyline in major depression. Acta neuropsychiatrica. 2007;19:204-207.
1635.	Benazzi F. Fluoxetine and olanzapine for resistant depression. American journal of psychiatry. 2002;159:155-156.
1636.	Benazzi F. Bipolar II disorder: Epidemiology, diagnosis and management. CNS drugs. 2007;21:727-740.
1637.	Benazzi F, Healy D. Do SSRIs cause suicide? [2] (multiple letters). Psychotherapy and psychosomatics. 2003;72:358-360.
1638.	Bendjenana G. Mirtazapine (Remeron) in the treatment of severe depression. [French]. Encephale. 1992;18:422.
1639.	Bendtsen L, Jensen R, Olesen J. A Non-Selective (Amitriptyline), but Not a Selective (Citalopram), Serotonin Reuptake Inhibitor Is Effective in the Prophylactic Treatment of Chronic Tension-Type Headache. Journal of neurology, neurosurgery, and psychiatry. 1996;61:285-290.
1640.	Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annual review of pharmacology and toxicology. 2008;48:33-60.
1641.	Benedetti F, Barbini B, Lucca A, Campori E, Colombo C, Smeraldi E. Sleep deprivation hastens the antidepressant action of fluoxetine. European archives of psychiatry and clinical neuroscience. 1997;247:100-103.
1642.	Benedetti F, Bernasconi A, Pontiggia A. Depression and neurological disorders. Current opinion in psychiatry. 2006;19:14-18.
1643.	Benedetti F, Carlino E, Pollo A. How placebos change the Patient's brain. Neuropsychopharmacology. 2011;36:339-354.
1644.	Benedetti F, HS M, TD W, CS S, J-K Z. Neurobiological mechanisms of the placebo effect. Journal of neuroscience. 2005;25:10390-10402.
1645.	Benedetto V. Combined fluoxetine with cognitive-behavioral therapy vs. monotherapy in the treatment of adolescents with major depressive disorder. Directions in Psychiatry. 2007;27:73-82.
1646.	Benedetto V. Treatment of adolescent depression: what we have come to know. [Review] [16 refs]. Depression and anxiety. 2009;26:393-395.
1647.	Benedetto V. Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: Does it improve outcomes compared with monotherapy? [References]. CNS drugs. 2009;23:271-280.
1648.	Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA Sample, Journal of clinical psychiatry(2011).
1649.	Benedetto V, I SR, B PC, et al. Hyperforin Plasma Level as a Marker of Treatment Adherence in the National Institutes of Health Hypericum Depression Trial. Journal of clinical psychopharmacology. 2005;25:243-249.
1650.	Research knowledge among the participants in the treatment for adolescents with depression study (TADS), Journal of the American Academy of Child and Adolescent Psychiatry(2007).
1651.	Benedict A, Arellano J, E DC, Baird J. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. Journal of affective disorders. 2010;120:94-104.
1652.	Benedict A, Naci H, Fahrbach K, et al. Comparative effectiveness of antidepressants (AD) in the treatment of the elderly with major depressive disorder (MDD): A mixed treatment comparison and meta-regression analysis. Value in health. 2010;Conference:A245.
1653.	Bengi Y, Cengiz A, Asli S, Semra A, Saygin ES, Selcuk K. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:1271-1276.
1654.	Benjamas P, Theo V, Melanie B, Stephen L. Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand. Value in health. 2012;15:S3-S8.
1655.	Benjamin B-O, Thomas E, Adrienne E, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. [Review] [39 refs]. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2007;29:918-926.
1656.	Benjamin S, PM D. Review of the Use of Mirtazapine in the Treatment of Depression. Expert opinion on pharmacotherapy. 2011;12:1623-1632.
1657.	Benjelloun G, Pelissolo A. Premenstrual dysphoric disorder: Diagnostic and pharmacological treatment. [French]. Annales medico-psychologiques. 2003;161:351-358.
1658.	Benkelfat C, MF P, Leouffre P, Gay C, Loo H. Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1987;32:175-178.
1659.	Benkert O, Armin S, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response. Acta psychiatrica Scandinavica. 1997;95:288-296.
1660.	Benkert O, Grunder G, Wetzel H. Is There an Advantage to Venlafaxine in Comparison With Other Antidepressants? Human Psychopharmacology-Clinical and Experimental. 1997;12:53-64.
1661.	Benkert O, Muller M, Szegedi A. An overview of the clinical efficacy of mirtazapine. Human psychopharmacology. 2002;17:S23-S26.
1662.	Benkert O, Szegedi A, Kohnen R. Mirtazapine Compared With Paroxetine in Major Depression. Journal of clinical psychiatry. 2000;61:656-663.
1663.	Benkert O, Szegedi A, Philipp M, et al. Mirtazapine Orally Disintegrating Tablets Versus Venlafaxine Extended Release - a Double-Blind, Randomized Multicenter Trial Comparing the Onset of Antidepressant Response in Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2006;26:75-78.
1664.	Bennabi D, Nicolier M, Monnin J, et al. Pilot Study of Feasibility of the Effect of Treatment With Tdcs in Patients Suffering From Treatment-Resistant Depression Treated With Escitalopram. Clinical neurophysiology. 2015;126:1185-1189.
1665.	Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): A review of its development, current version, operating characteristics and uses. Clinical and experimental rheumatology. 2005;23:S154-S162.
1666.	Bennett R, IJ R, Choy E, et al. Evaluation of Patient-Rated Stiffness Associated With Fibromyalgia: a Post-Hoc Analysis of 4 Pooled, Randomized Clinical Trials of Duloxetine. Clinical therapeutics. 2012;34:824-837.
1667.	Bent-Hansen J, Lunde M, Klysner R, et al. The Validity of the Depression Rating Scales in Discriminating between Citalopram and Placebo in Depression Recurrence in the Maintenance Therapy of Elderly Unipolar Patients with Major Depression. Pharmacopsychiatry. 2003;36:313-316.
1668.	Benton T, Blume J, Dube B. Treatment considerations for psychiatric syndromes associated with HIV infection. HIV therapy. 2010;4:231-245.
1669.	Benton T, Staab J, DL E. Medical co-morbidity in depressive disorders. Annals of clinical psychiatry. 2007;19:289-303.
1670.	Benvenuti A, Rucci P, Calugi S, GB C, Miniati M, Frank E. Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression. International clinical psychopharmacology. 2010;25:68-74.
1671.	Benvenuti A, Rucci P, Miniati M, et al. Treatment-emergent mania/hypomania in unipolar patients. Bipolar disorders. 2008;10:726-732.
1672.	Benvenuto A, Battan B, MC P, Curatolo P. Pharmacotherapy of autism spectrum disorders. Brain & development. 2013;35:119-127.
1673.	Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewicz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert review of neurotherapeutics. 2008;8:479-491.
1674.	Benyamina A, Samalin L. Atypical antipsychotic-induced mania/hypomania: A review of recent case reports and clinical studies. International journal of psychiatry in clinical practice. 2012;16:2-7.
1675.	Berend T, Hein vH. Treatment of mild depression in elderly patients. JAMA: Journal of the American Medical Association. 2000;284:2993-2994.
1676.	Berg C. Bupropion also approved as antidepressant. [German]. Pharmazeutische Zeitung. 2007;152:32.
1677.	Berg D, Supprian T, Hofmann E, et al. Depression in Parkinson's disease: Brainstem midline alteration on transcranial sonography and magnetic resonance imaging. Journal of neurology. 1999;246:1186-1193.
1678.	Bergemann N. Antidepressant use during pregnancy. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2009;10:41-47.
1679.	Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial, BMJ (Clinical research ed.)(2012).
1680.	Bergh S, Selbaek G, Engedal K. Discontinuation of Antidepressants in People With Dementia and Neuropsychiatric Symptoms (Desep Study): Double Blind, Randomised, Parallel Group, Placebo Controlled Trial. British medical journal. 2012;344.
1681.	Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): Double blind, randomised, parallel group, placebo controlled trial, BMJ (Online)(7851).
1682.	Berglund M, Thelander S, Salaspuro M, Franck J, Andreasson S, Ojehagen A. Treatment of Alcohol Abuse: An Evidence-Based Review. Alcoholism, clinical and experimental research. 2003;27:1645-1656.
1683.	Bergman J, Miodownik C, Palatnik A, Lerner V. Efficacy of Bupropion Xr in Treatment-Resistant Elderly Patients: a Case Series Study. Clinical neuropharmacology. 2011;34:17-20.
1684.	Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: A meta-analysis of randomized double-blind controlled trials. BMC psychiatry. 2014.
1685.	Berk M. Selective Serotonin Reuptake Inhibitors in Mixed Anxiety - Depression. International clinical psychopharmacology. 2000;15:S41-S45.
1686.	Berk M. Understanding patient needs in the acute setting. European neuropsychopharmacology. 2009;Conference:S711-S712.
1687.	Berk M, AD dP, Birkett M, Richardt D. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. International clinical psychopharmacology. 1997;12:137-140.
1688.	Berk M, Brnabic A, Dodd S, et al. Does Stage of Illness Impact Treatment Response in Bipolar Disorder? Empirical Treatment Data and Their Implication for the Staging Model and Early Intervention. Bipolar disorders. 2011;13:87-98.
1689.	Berk M, Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs. 2005;65:257-269.
1690.	Berk M, Dodd S, Kauer-Sant'Anna M, et al. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder. Acta psychiatrica Scandinavica. 2007;116:41-49.
1691.	Berk M, Hallam K, Lucas N, et al. Health-related quality of life and functioning in bipolar disorder: The impact of pharmacotherapy. Expert review of pharmacoeconomics & outcomes research. 2006;6:509-523.
1692.	Berk M, Ichim C, Brook S. Efficacy of Mirtazapine Add on Therapy to Haloperidol in the Treatment of the Negative Symptoms of Schizophrenia: a Double-Blind Randomized Placebo-Controlled Study. International clinical psychopharmacology. 2001;16:87-92.
1693.	Berk M, Jeavons S, OM D, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS spectrums. 2009;14:357-360.
1694.	Berk M, Kapczinski F, AC A, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and biobehavioral reviews. 2011;35:804-817.
1695.	Berlanga C, Heinze G, Torres M, Apiquian R, Caballero A. Personality and clinical predictors of recurrence of depression. Psychiatric services (Washington, D.C.). 1999;50:376-380.
1696.	Berlin I, Lavergne F. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. European psychiatry. 1998;13:138-142.
1697.	Berlin I, LS C. Pre-Cessation Depressive Mood Predicts Failure to Quit Smoking: the Role of Coping and Personality Traits. Addiction (Abingdon, England). 2006;101:1814-1821.
1698.	Berman J. Clinical development of dietary supplements: The perils of starting at phase III. Fitoterapia. 2011;82:80-84.
1699.	Bernal-Pacheco O, HH F. Apathy in Parkinson's Disease. Parkinson's Disease and Nonmotor Dysfunction. 2013;Current Cl:119-129.
1700.	Berney A, Nishikawa M, Benkelfat C, Debonnel G, Gobbi G, Diksic M. An Index of 5-Ht Synthesis Changes During Early Antidepressant Treatment: Alpha-[C-11]Methyl-L-Tryptophan Pet Study. Neurochemistry international. 2008;52:701-708.
1701.	Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues in clinical neuroscience. 2005;7:249-262.
1702.	Bernik M, TPA S, Gandarela L. Fibromyalgia Comorbid With Anxiety Disorders and Depression: Combined Medical and Psychological Treatment. Current pain and headache reports. 2013;17.
1703.	Bersani G, Rapisarda V, Ciani N, Bertolino A, Sorge G. A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Human Psychopharmacology: Clinical and Experimental. 1994;9:63-68.
1704.	Berthold-Losleben M, Heitmann S, Himmerich H. Anti-inflammatory drugs in psychiatry. Inflammation and Allergy - Drug Targets. 2009;8:266-276.
1705.	Berthold-Losleben M, Himmerich H. The TNF-alpha system: Functional aspects in depression, narcolepsy and psychopharmacology. Current neuropharmacology. 2008;6:193-202.
1706.	Berti C, DP D, NR S, TG D. Sertraline in the treatment of depressive disorders with associated anxiety. Journal of Serotonin Research. 1995;2:151-170.
1707.	Bertsche T, Schulz M. Drug profile: Pure escitalopram. [German]. Pharmazeutische Zeitung. 2004;149:34-38.
1708.	Bertschy G, Ragama-Pardos E, Muscionico M, et al. Trazodone Addition for Insomnia in Venlafaxine-Treated, Depressed Inpatients: a Semi-Naturalistic Study. Pharmacological research. 2005;51:79-84.
1709.	Bertschy G, Ragama-Pardos E, Muscionico M, et al. Trazodone Addition for Insomnia in Venlafaxine-Treated, Depressed Inpatients: a Semi-Naturalistic Study. Pharmacological research. 2005;51:79-84.
1710.	Besancon G, Cousin R, Guitton B, Lavergne F. Mianserin versus fluoxetine in a double blind trial depressed out-patients. [French]. Encephale. 1993;19:341-345.
1711.	Besancon G, Cousin R, Guitton B, Lavergne F. [Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients]. [French]. L'Enc�phale. 1993;19:341-345.
1712.	Besancon G, Cousin R, Guitton B, Lavergne F. A double-blind trial comparing mianserin and fluoxetine in the treatment of outpatients with depression. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1993;19:341-345.
1713.	Besiroglu L, Cetinkaya N, Selvi Y, Atli A. Effects of Selective Serotonin Reuptake Inhibitors on Thought-Action Fusion, Metacognitions, and Thought Suppression in Obsessive-Compulsive Disorder. Comprehensive psychiatry. 2011;52:556-561.
1714.	Besnier N, Casse-Perrot C, Jouve E, et al. Effects of Paroxetine on Emotional Functioning and Treatment Awareness: a 4-Week Randomized Placebo-Controlled Study in Healthy Clinicians. Psychopharmacology. 2010;207:619-629.
1715.	Bessel A, D VK. The psychobiology and psychopharmacology of PTSD. Human psychopharmacology. 2001;16:S49-S64.
1716.	Bet P, Kok R. Withdrawal symptoms with paroxetin. [Dutch]. Pharmaceutisch weekblad. 1998;133:1312-1316.
1717.	Bethoux F. Gait disorders in multiple sclerosis. CONTINUUM Lifelong Learning in Neurology. 2013;19:1007-1022.
1718.	Betry C, AL P, Etievant A, Ebert B, Sanchez C, Haddjeri N. The Rapid Recovery of 5-Ht Cell Firing Induced by the Antidepressant Vortioxetine Involves 5-Ht3 Receptor Antagonism. International journal of neuropsychopharmacology. 2013;16:1115-1127.
1719.	Betry C, Etievant A, Pehrson A, Sanchez C, Haddjeri N. Effect of the Multimodal Acting Antidepressant Vortioxetine on Rat Hippocampal Plasticity and Recognition Memory. Progress in neuro-psychopharmacology & biological psychiatry. 2015;58:38-46.
1720.	Bettencourt C, Lima M. Machado-Joseph disease: From first descriptions to new perspectives. Orphanet journal of rare diseases. 2011.
1721.	Bettina W-H, Jurgen K, Daniel K, et al. Resistin and adiponectin in major depression: The association with free cortisol and effects of antidepressant treatment. Journal of psychiatric research. 2007;41:344-350.
1722.	Bettina W-H, Maria G, Florian L, Isabella H, Michael D. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. Journal of clinical psychiatry. 2006;67:1856-1861.
1723.	Bettocchi C, Verze P, Palumbo F, Arcaniolo D, Mirone V. Ejaculatory disorders: Pathophysiology and management. Nature clinical practice. Urology. 2008;5:93-103.
1724.	Beumont P, Hay P, Beumont R. Summary Australian and New Zealand clinical practice guideline for the management of anorexia nervosa (2003). Australasian psychiatry. 2003;11:129-133.
1725.	Beutler M, Hartmann K, Kuhn M, Gartmann J. Arthralgias and omeprazole [1]. British medical journal. 1994;309:1620.
1726.	Bevan E, Paton C. What evidence there is for the drug treatment of Huntington's disease. Pharmaceutical journal. 2006;277:641-642.
1727.	Beverley B. Memory performance of younger adult outpatients with major depressive disorder before and after antidepressant treatment. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2010;70:5807.
1728.	Beyazyuz M, Albayrak Y, OB E, Albayrak N, Beyazyuz E. Relationship Between Ssris and Metabolic Syndrome Abnormalities in Patients With Generalized Anxiety Disorder: a Prospective Study. Psychiatry investigation. 2013;10:148-154.
1729.	Beyenburg S, Schmidt D. Comorbidity and epilepsy. [German]. Nervenheilkunde. 2004;23:21-30.
1730.	Bezchlibnyk-Butler K, Aleksic I, SH K. Citalopram--a review of pharmacological and clinical effects. [Review] [77 refs]. Journal of psychiatry & neuroscience. 2000;25:241-254.
1731.	BF Y, LE F, SA R. Management of the behavioral manifestations of dementia. Archives of internal medicine. 1995;155:250-260.
1732.	BFS G, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: A randomised double-blind placebo-controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:1393-1396.
1733.	BG A, JA C, MW J. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. [Review] [91 refs]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 1997;17:511-530.
1734.	BG B, Machado M, AV R, TR E. Evidence-Based Review of Clinical Outcomes of Guideline-Recommended Pharmacotherapies for Generalized Anxiety Disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2012;57:470-478.
1735.	BG P. Discontinuation symptoms and SSRIs. Journal of clinical psychiatry. 1998;59:535-537.
1736.	BG P. Citalopram: A comprehensive review. Expert opinion on pharmacotherapy. 2001;2:681-698.
1737.	BG P, BH M, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American journal of geriatric psychiatry. 2007;15:942-952.
1738.	BG P, RE F, BH M, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23:587-590.
1739.	BH G, Gitlin M. New Antidepressants and the Treatment of Depression. Journal of family practice. 1994;38:49-57.
1740.	BH H, JA H, Rasmussen A, J FH, NL TA, Birket-Smith M. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD): Randomised controlled trial. Journal of psychosomatic research. 2010;Conference:630.
1741.	Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD), Trials [Electronic Resource](2009).
1742.	Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD), Trials(2009).
1743.	BH H, JA H, Rasmussen A, JF H, Birket-Smith M. Comparison of participants and non-participants in a randomized study of prevention of depression in patients with acute coronary syndrome. Nordic journal of psychiatry. 2011;65:22-25.
1744.	BH H, JA H, Rasmussen A, JF H, NLT A, Birket-Smith M. Escitalopram prevents depression in patients with acute coronary syndrome (DECARD): A randomized controlled trial. European journal of cardiovascular prevention and rehabilitation. 2010;Conference:S33.
1745.	BH M. Challenges of the treatment of neuropsychiatric symptoms associated with dementia. American journal of geriatric psychiatry. 2014;22:317-320.
1746.	BH M, BG P. Treatment-Resistant Depression in Late Life. Journal of geriatric psychiatry and neurology. 1998;11:186-193.
1747.	BH M, DM B, Ismail Z, Rabheru K, MJ R. A systematic approach to pharmacotherapy for geriatric major depression. Clinics in geriatric medicine. 2014;30:517-534.
1748.	BH M, RA S, Rosen J, et al. A Double-Blind Randomized Comparison of Nortriptyline Plus Perphenazine Versus Nortriptyline Plus Placebo in the Treatment of Psychotic Depression in Late Life. Journal of clinical psychiatry. 2001;62:597-604.
1749.	BH N, Cheu J, Hill N, et al. Single-Blind, Placebo Phase-in Trial of Two Escalating Doses of Selegiline in the Chronic Fatigue Syndrome. Neuropsychobiology. 1998;37:150-154.
1750.	Bhagwagar Z, GM G. The role of lithium in the treatment of bipolar depression. Clinical neuroscience research. 2002;2:222-227.
1751.	Bhagwagar Z, GM G. Lamotrigine in the treatment of bipolar disorder. Expert opinion on pharmacotherapy. 2005;6:1401-1408.
1752.	Bhagwagar Z, GM G. Bipolar disorder: the neglected psychosis. Psychiatry. 2007;6:389-392.
1753.	Bhagwagar Z, PJ C, GM G, CJ H. Normalization of Enhanced Fear Recognition by Acute Ssri Treatment in Subjects With a Previous History of Depression. American journal of psychiatry. 2004;161:166-168.
1754.	Bhagwagar Z, Whale R, PJ C. State and trait abnormalities in serotonin function in major depression. British journal of psychiatry. 2002;180:24-28.
1755.	Bhana N, CM P. Olanzapine - a Review of Its Use in the Treatment of Bipolar I Disorder. CNS drugs. 2001;15:871-904.
1756.	Bhansali P, Dunning J, SE S, David L, Schmauss C. Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q. Journal of neuroscience. 2007;27:1467-1473.
1757.	Bhargava J, ZY K. Comparative evaluation of the effcacy and side effects of imipramine, sertraline and an ayurvedic formulation in patients of depression. Journal of Clinical and Diagnostic Research. 2012;6:220-225.
1758.	Bhat A, AA ES. Management of narcolepsy. Expert opinion on pharmacotherapy. 2008;9:1721-1733.
1759.	Bhatara V, MG A, Warhol P, JM M, Bhatara A. Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: A 10-year follow-up. Journal of child and adolescent psychopharmacology. 2004;14:315-323.
1760.	Bhattacharjee S, Bhattacharya R, GA K, Sambamoorthi U. Antidepressant Use and New-Onset Diabetes: a Systematic Review and Meta-Analysis. Diabetes/metabolism research and reviews. 2013;29:273-284.
1761.	Bhattacharya R. Urn-based response adaptive procedures and optimality. Drug information journal. 2008;42:441-448.
1762.	Bhaumik S, Duggirala C, Bee J, Wildgust H. Economic implications of the use of antidepressants in adults with learning disabilities suffering from affective disorders. Human Psychopharmacology: Clinical and Experimental. 1997;12:47-51.
1763.	Bhidayasiri R, DD T. Therapeutic strategies for nonmotor symptoms in early Parkinson's disease: The case for a higher priority and stronger evidence. Parkinsonism & related disorders. 2012;18:S110-S113.
1764.	Bhuvaneswar C, Spiegel D. An eye for an I: A 35-year-old woman with fluctuating oculomotor deficits and dissociative identity disorder. International journal of clinical and experimental hypnosis. 2013;61:351-370.
1765.	BI G, Diamantouros A, Schaffer A, CA N. Pharmacotherapy of Alcoholism in Patients With Co-Morbid Psychiatric Disorders. Drugs. 2006;66:1229-1237.
1766.	Substance Use and the Treatment of Resistant Depression in Adolescents, Journal of the American Academy of Child and Adolescent Psychiatry(2009).
1767.	BI Y, RJ K, JD F, Hwang S, Mintz J. Antidepressants and Suicidal Behaviour in Unipolar Depression. Acta psychiatrica Scandinavica. 2004;110:452-458.
1768.	BI Y, RJ K, JD F, Hwang S, Mintz J. Antidepressants and Suicidal Behaviour in Unipolar Depression. Acta psychiatrica Scandinavica. 2004;110:452-458.
1769.	Bidzan L, AR M, Jacobsen P, MJ Y, DV S. Vortioxetine (Lu Aa21004) in Generalized Anxiety Disorder: Results of an 8-Week, Multinational, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. European neuropsychopharmacology. 2012;22:847-857.
1770.	Biederman J, Mick E, Spencer T, Surman C, SV F. Is Response to OROS-Methylphenidate Treatment Moderated by Treatment with Antidepressants or Psychiatric Comorbidity? A Secondary Analysis from a Large Randomized Double Blind Study of Adults with ADHD. CNS neuroscience & therapeutics. 2012;18:126-132.
1771.	Biederman J, TJ S. Psychopharmacology of adults with attention-deficit/hyperactivity disorder. Primary psychiatry. 2004;11:57-62.
1772.	Biederman J, TJ S. Psychopharmacological Interventions. Child and adolescent psychiatric clinics of North America. 2008;17:439-458.
1773.	Biglia N, Torta R, Roagna R, et al. Evaluation of Low-Dose Venlafaxine Hydrochloride for the Therapy of Hot Flushes in Breast Cancer Survivors. Maturitas. 2005;52:78-85.
1774.	Bignamini A, Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group. International clinical psychopharmacology. 1992;6 Suppl 4:37-41.
1775.	Disease-modifying therapies in frontotemporal lobar degeneration, Current medicinal chemistry(2012).
1776.	Bijl D. Escitalopram (Cipralex and Lexapro) for the treatment of depression. [Dutch]. Geneesmiddelenbulletin. 2004;38:89-90.
1777.	Bijl D. Agomelatine (Valdoxan), treatment for depression. [Dutch]. Geneesmiddelenbulletin. 2010;44:42-44.
1778.	Bijl D. Antidepressants: Efficacy and severity of depression. [Dutch]. Geneesmiddelenbulletin. 2010;44:46-47.
1779.	Bijl D, HWJ VM, ATF B, M DH, W VT. A randomized controlled trial to improve the recognition, diagnosis and treatment of major depression in elderly people in general practice: Design, first results and feasibility of the West Friesland Study. Primary Care Psychiatry. 2003;8:135-140.
1780.	Bildik T, NB O, Kose S, SK C. Effectiveness and tolerability of aripiprazole in a real-world outpatient population of youth. Klinik Psikofarmakoloji Bulteni. 2012;22:225-234.
1781.	Bildik T, NB O, Kucukkose M, UA A. Aripiprazole use in children and adolescents: A case series. [Turkish]. Klinik Psikofarmakoloji Bulteni. 2010;20:84-93.
1782.	Bilici S, Yigit O, Taskin U, AP G, ED Y. Medium-Term Results of Combined Treatment With Transcranial Magnetic Stimulation and Antidepressant Drug for Chronic Tinnitus. European archives of oto-rhino-laryngology. 2015;272:337-343.
1783.	Bill D, Serdar D. Optimizing antidepressant treatment: Efficacy and tolerability. International clinical psychopharmacology. 2002;17:S13-S24.
1784.	Biller-Andorno N. The use of the placebo effect in clinical medicine - Ethical blunder or ethical imperative? Science and engineering ethics. 2004;10:43-50.
1785.	Billiard M. Narcolepsy: Current treatment options and future approaches. Neuropsychiatric disease and treatment. 2008;4:557-566.
1786.	Billig N. Management of agitation in nursing home patients: Treatment options. Drugs & aging. 1996;9:93-100.
1787.	Bilodeau M, Simon T, MH B, et al. Duloxetine in Adults With Adhd: a Randomized, Placebo-Controlled Pilot Study. Journal of attention disorders. 2014;18:169-175.
1788.	Binder E, Nemeroff C, Schatzberg A, et al. Interaction of pimpamperone augmentation of citalopram and genetic variables in the prediction of antidepressant response. Neuropsychopharmacology. 2010;Conference:S383-S384.
1789.	Bingham K, Whyte E, BS M, et al. The relationships between vascular risk, cognition and outcome in late-life psychotic depression. American journal of geriatric psychiatry. 2015;Conference:S102-S103.
1790.	Biondi M, Picardi A. Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive- behavioural therapy: A follow-up study. Psychotherapy and psychosomatics. 2003;72:34-42.
1791.	Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: A randomized, double blind, parallel group study. Journal of rheumatology. 2000;27:2791-2797.
1792.	Biringer E, Rongve A, Lund A. A review of modern antidepressants' effects on neurocognitive function. Current psychiatry reviews. 2009;5:164-174.
1793.	Birkenhager TK, W vdBW, Mulder PG, Bruijn JA, Moleman P. Comparison of two treatment strategies in inpatients with a depressive disorder: A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition. [Dutch]. Tijdschrift voor psychiatrie. 2006;48:271-281.
1794.	Birkhauser M. Depression, menopause and estrogens: Is there a correlation? Maturitas. 2002;41:S3-S8.
1795.	Birmaher B. Should we use antidepressant medications for children and adolescents with depressive disorders?. [Review] [48 refs]. Psychopharmacology bulletin. 1998;34:35-39.
1796.	Birmaher B. Improving remission and preventing relapse in youths with major depression. American journal of psychiatry. 2014;171:1031-1033.
1797.	Birmaher B, Brent D. Should we use antidepressants for the treatment of major depressive disorder in children and adolescents? Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2005;27:89-90.
1798.	Birmaher B, GS W, Ryan N, et al. Fluoxetine for Childhood Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33:993-999.
1799.	Birmaher B, ND R, DE W, DA B, Kaufman J. Childhood and adolescent depression: a review of the past 10 years. Part II. [Review] [80 refs]. Journal of the American Academy of Child and Adolescent Psychiatry. 1996;35:1575-1583.
1800.	Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatric disease and treatment. 2009;5:483-490.
1801.	Biswas A. Adaptive designs for binary treatment responses in phase III clinical trials: Controversies and progress. Statistical methods in medical research. 2001;10:353-364.
1802.	Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert opinion on drug metabolism & toxicology. 2006;2:1009-1018.
1803.	Bitter I, Filipovits D, Czobor P. Adverse reactions to duloxetine in depression. [Review]. Expert opinion on drug safety. 2011;10:839-850.
1804.	Bittman B, Emanuele S. Fluoxetine - Side-Effects and Efficacy in a Headache Population. Headache Quarterly-Current Treatment and Research. 1992;3:82-85.
1805.	Bixo M, Allard P, Backstrom T, et al. Binding of [H-3]Paroxetine to Serotonin Uptake Sites and of [H-3]Lysergic Acid Diethylamide to 5-Ht2a Receptors in Platelets From Women With Premenstrual Dysphoric Disorder During Gonadotropin Releasing Hormone Treatment. Psychoneuroendocrinology. 2001;26:551-564.
1806.	Bixquert-Jimenez M, Bixquert-Pla L. Antidepressant therapy in functional gastrointestinal disorders. [Spanish]. Gastroenterologia y hepatologia. 2005;28:485-492.
1807.	BJ C. Are SSRI antidepressants clinically homnogeneous? [25]. Lancet. 1994;344:550.
1808.	BJ C. Sertraline and the Cheshire cat in geriatric depression.[Republished in Am J Psychiatry. 2004 Jun;161(6):1145-6; PMID: 15169734]. American journal of psychiatry. 2004;161:759; author reply 759-761.
1809.	BJ C. Sertraline and the Cheshire cat in geriatric depression.[Republished from Am J Psychiatry. 2004 Apr;161(4):759; author reply 759-61; PMID: 15056533]. American journal of psychiatry. 2004;161:1145-1146.
1810.	BJ C. Citalopram and the Curate's egg in geriatric depression. American journal of psychiatry. 2005;162:1762; author reply 1762-1763.
1811.	BJ C. In reply. JAMA Psychiatry. 2013;70:124-125.
1812.	BJ C. Suicide risk and efficacy of antidepressant drugs. JAMA psychiatry (Chicago, Ill.). 2013;70:123-124.
1813.	BJ C, Kassubek J. Comorbidity of depressive disorders - Part I: Role of axis I and II disorders. [German]. Nervenheilkunde. 2004;23:5-12.
1814.	BJ G, PJ G. Selective Serotonin Reuptake Inhibitors in the Treatment of Affective Disorders - Iii. Tolerability, Safety and Pharmacoeconomics. Journal of psychopharmacology (Oxford, England). 1998;12:S55-S87.
1815.	BJ K, Shannon S. Nutritional aspects of child and adolescent psychopharmacology. Pediatric annals. 2007;36:600-609.
1816.	BJ M, JH K, EC R, RB C. A Double-Blind, Placebo-Controlled Trial of Desipramine for Primary Alcohol Dependence Stratified on the Presence or Absence of Major Depression. Jama-Journal of the American Medical Association. 1996;275:761-767.
1817.	BJ M, JM L, DW I, et al. Prophylactic Antidepressant Treatment in Patients With Hepatitis C on Antiviral Therapy: a Double-Blind, Placebo-Controlled Trial. Psychosomatics. 2010;51:401-408.
1818.	BJ M, KL M, MT S, SA W, LM F, Christian K. An Open Study of the Effects of Sertraline on Adolescent Major Depression. Journal of child and adolescent psychopharmacology. 1996;6:41-51.
1819.	BJ M, RO C, KL B, Friedman L, Cottingham E, Nelson D. Newer antidepressants: Beyond selective serotonin reuptake inhibitor antidepressants. Pediatric clinics of North America. 1998;45:1157-1171.
1820.	BJ P, JJ R, Kappler R, et al. Adjunctive osteopathic manipulative treatment in women with depression: A pilot study. Journal of the American Osteopathic Association. 2001;101:517-523.
1821.	BJ R. Treatment of cocaine dependence and depression. Biological psychiatry. 2004;56:803-809.
1822.	BJ S. Depression: A role for omega-3 fish oils and B vitamins? Evidence-Based Integrative Medicine. 2005;2:229-237.
1823.	BJ T. Pharmacotherapy of school refusal. Behaviour change. 1998;15:98-106.
1824.	BJ T, GA M, AL D, MS G. Cognitive behavioural therapy with or without fluoxetine for school refusal: A randomised controlled trial. Australian and New Zealand journal of psychiatry. 2013;Conference:59.
1825.	BJ T, JC E. Posttraumatic headache in military personnel and veterans of the Iraq and Afghanistan conflicts. Current treatment options in neurology. 2012;14:36-49.
1826.	Bjdh C, DL D. A Review of Antidepressant-Induced Hypomania in Major Depression: Suggestions for Dsm-V. Bipolar disorders. 2004;6:32-42.
1827.	Bjdh C, DL D. A Review of Antidepressant-Induced Hypomania in Major Depression: Suggestions for Dsm-V. Bipolar disorders. 2004;6:32-42.
1828.	Bjerkenstedt L, Flyckt L, K FO, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. European journal of clinical pharmacology. 1985;28:553-557.
1829.	Bjork-Linne A, Borg S, Eriksson E, Velin B. Cost effectiveness of premalex (escitalopram) compared to sertraline for treatment of pmdd (premenstrual dysphoric disorder), based upon the CGI-S. Value in health. 2012;Conference:A539.
1830.	BK B, Haque W, MR R, RMA H. Sexual functioning in depressed outpatients taking mirtazapine. Depression and anxiety. 1999;9:175-179.
1831.	BL F, QC W, ZY L. [Influence of Jieyu Huoxue Decoction on rehabilitation of patients with depression after cerebral infarction]. [Chinese][Erratum appears in Zhong Xi Yi Jie He Xue Bao. 2005 Jan;3(1):34]. Zhong xi yi jie he xue bao [Journal of Chinese integrative medicine]. 2004;2:182-184.
1832.	BL G, BH H, KL W, KS P, JM P. Weight Changes in Postpartum Women With Remitted Depression. Journal of clinical psychiatry. 2005;66:291-293.
1833.	BL G, JL K, Chung J, et al. Impact of PTSD comorbidity on one-year outcomes in a depression trial. Journal of clinical psychology. 2006;62:815-835.
1834.	BL G, MM G. Pharmacological and psychological treatments of pathological skin-picking: A preliminary meta-analysis. Journal of Obsessive-Compulsive and Related Disorders. 2013;2:167-175.
1835.	BL H. Adolescent depression: Description, causes, and interventions. Epilepsy & behavior. 2006;8:102-114.
1836.	BL H, DW C, KM A. Association of medically treated depression and age at natural menopause. American journal of epidemiology. 1995;141:1170-1176.
1837.	BL P. Perimenopausal depression. American journal of psychiatry. 2008;165:23-27.
1838.	BL P. Optimal management of perimenopausal depression. International journal of women's health. 2010;2:143-151.
1839.	BL P, AH C, Siegel S, NT M. Rational combination therapy in refractory migraine. Headache. 2008;48:805-819.
1840.	BL P, Daley J. A 45-Year-Old Woman With Premenstrual Dysphoric Disorder. Jama-Journal of the American Medical Association. 1999;281:368-373.
1841.	BL P, EL M. Light treatment of mood disorders. Dialogues in clinical neuroscience. 2003;5:353-365.
1842.	BL P, ML C, CA S, et al. Can Critically Timed Sleep Deprivation Be Useful in Pregnancy and Postpartum Depressions? Journal of affective disorders. 2000;60:201-212.
1843.	BL P, RP N. Chronobiological basis of female-specific mood disorders. [Review] [49 refs]. Neuropsychopharmacology. 2001;25:S102-108.
1844.	BL P, RP N. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology. 2001;25:S102-S108.
1845.	Telephone-delivered collaborative care for treating post-CABG depression: A randomized controlled trial, JAMA - Journal of the American Medical Association(2009).
1846.	BL R, BH B, MS L, Mazumdar S, HC S, CF R. The bypassing the blues treatment protocol: Stepped collaborative care for treating post-CABG depression. Psychosomatic medicine. 2009;71:217-230.
1847.	BL R, SL W, DM VDH, Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: A Cochrane systematic review. Journal of rheumatology. 2012;39:21-27.
1848.	Black B, Muralee S, RR T. Inappropriate sexual behaviors in dementia. Journal of geriatric psychiatry and neurology. 2005;18:155-162.
1849.	Blacker D. Maintenance treatment of major depression: A review of the literature. Harvard review of psychiatry. 1996;4:1-9.
1850.	Blaeser-Kiel G. Mirtazapine - The first NaSSA: Mechanism of action with favorable benefit risk profile. [German]. TW Neurologie Psychiatrie. 1996;10:689-692.
1851.	Blaeser-Kiel G. Antidepressant therapy with bupropion without disturbing the sexual function. [German]. Psychopharmakotherapie. 2007;14:167.
1852.	Blaeser-Kiel G. Bipolar depression: Add-on pramipexole helps resolve mood lows. [German]. Psychopharmakotherapie. 2009;16:94-95.
1853.	Blake J. Menopause: evidence-based practice. Best Practice and Research: Clinical Obstetrics and Gynaecology. 2006;20:799-839.
1854.	Blanco C, Okuda M, Rosenthal H, Lewis-Fernandez R. Duloxetine in the treatment of major depression and other psychiatric disorders. Expert review of clinical pharmacology. 2008;1:195-205.
1855.	Blank S, EJ L, BH M, et al. Outcome of late-life anxiety disorders during 32 weeks of citalopram treatment. Journal of clinical psychiatry. 2006;67:468-472.
1856.	Blardi P, A DL, Urso R, et al. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. Journal of clinical psychopharmacology. 2005;25:262-266.
1857.	Blazquez A, Mas S, MT P, et al. Plasma Fluoxetine Concentrations and Clinical Improvement in an Adolescent Sample Diagnosed With Major Depressive Disorder, Obsessive-Compulsive Disorder, or Generalized Anxiety Disorder. Journal of clinical psychopharmacology. 2014;34:318-326.
1858.	BLC W, RA B. Established and emerging therapies for Huntington's disease. Current molecular medicine. 2007;7:579-587.
1859.	Bleakley S. Review of choice and use of antidepressants. Progress in neurology and psychiatry. 2009;13:14-20.
1860.	Blier P. Possible Neurobiological Mechanisms Underlying Faster Onset of Antidepressant Action. Journal of clinical psychiatry. 2001;62:7-11.
1861.	Blier P. The pharmacology of putative early-onset antidepressant strategies. European neuropsychopharmacology. 2003;13:57-66.
1862.	Blier P. Dual Serotonin and Noradrenaline Reuptake Inhibitors: Focus on Their Differences. International journal of psychiatry in clinical practice. 2006;10:22-32.
1863.	Blier P. The sequenced treatment alternatives to relieve depression (STAR*D): A first look at the initial pharmacotherapy results. Clinical Neuropsychiatry. 2006;3:265-267.
1864.	Blier P. Optimal use of antidepressants: when to act? Journal of psychiatry & neuroscience. 2009;34:80.
1865.	Blier P. New developments in the rational site-directed pharmacotherapy of depression. Journal of affective disorders. 2010;Conference:S8.
1866.	Blier P. Combination of antidepressants from treatment initiation: Neurobiological bases and preliminary double-blind studies. International journal of neuropsychopharmacology. 2010;Conference:34.
1867.	Blier P. Neurotransmitter targeting in the treatment of depression. Journal of clinical psychiatry. 2013;74:19-24.
1868.	Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of clinical psychopharmacology. 1995;15:217-222.
1869.	Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. Journal of clinical psychiatry. 1998;59:16-25.
1870.	Blier P, Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. Journal of affective disorders. 2011;128:S3-S10.
1871.	Blier P, C DM. Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive-Compulsive and Panic Disorders. Neuropsychopharmacology. 1999;21:S91-S98.
1872.	Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/anxiolytic response. Journal of psychiatry & neuroscience. 2004;29:208-218.
1873.	Blier P, Habib R, MF F. Pharmacotherapies in the management of obsessive-compulsive disorder. Canadian Journal of Psychiatry. 2006;51:417-430.
1874.	Blier P, M EM. Aesthetics predict failure. European neuropsychopharmacology. 2011;Conference:S633.
1875.	Blier P, Nutt D. Reply from the editors [2]. Journal of psychopharmacology (Oxford, England). 2007;21:670.
1876.	Blier P, PJ M, Bergeron R, JW S. Comparison of high-dose escitalopram, bupropion, and their combination from treatment initiation in major depressive disorder: A double-blind study. Neuropsychopharmacology. 2011;Conference:S421-S422.
1877.	Bloch M, Meiboom H, Lorberblat M, et al. Treatment of postpartum depression with psychotherapy and add-on sertraline: A double-blind, randomised, placebo-controlled study. European neuropsychopharmacology. 2011;Conference:S359-S360.
1878.	Bloch M, PJ S, DR R. Clinical aspects of premenstrual syndrome. Infertility and Reproductive Medicine Clinics of North America. 1996;7:315-329.
1879.	Blockman M. Selective serotonin reuptake inhibitors in children with major depression [3]. South African medical journal. 2006;96:476-477.
1880.	Blomgren D. Neuropsychiatry. Journal of Pharmacy Practice and Research. 2013;43:74-75.
1881.	Blondel-Hill E, SD S. Treatment of the chronic fatigue syndrome: A review and practical guide. Drugs. 1993;46:639-651.
1882.	Blumberger D, BH M, Kanellopoulos D, et al. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression (STOP-PD). American journal of geriatric psychiatry. 2012;Conference:S116-S118.
1883.	BM D. The effectiveness of the treatment of depression in the physically ill elderly. Aging & mental health. 2000;4:9-20.
1884.	BM G. New on the market: Adalimumab and escitalopram. [German]. Pharmazeutische Zeitung. 2003;148:36.
1885.	BM G. Pregabalin for the treatment of generalized anxiety disorder. [German]. Pharmazeutische Zeitung. 2007;152:32-33.
1886.	BM G, BL C, Richardson R. Bridging the gap: Lessons we have learnt from the merging of psychology and psychiatry for the optimisation of treatments for emotional disorders. Behaviour research and therapy. 2014;62:3-16.
1887.	BM H, JA B, MA B, et al. Exercise Fails to Improve Neurocognition in Depressed Middle-Aged and Older Adults. Medicine and science in sports and exercise. 2008;40:1344-1352.
1888.	BM K. FDA panel seeks to balance risks in warnings for antidepressants. Journal of the American Medical Association. 2007;297:573-574.
1889.	BM K, Dimidjian S, SL R. Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression. Behaviour research and therapy. 2010;48:799-804.
1890.	BM R, EC K. Visual hallucinations associated with varenicline: A case report. Journal of medical case reports. 2009.
1891.	BM S, RD S. A diagnostic approach to dysphagia. Clinics in Family Practice. 2004;6:525-546.
1892.	BM W, EH E, Lorenz R. Augmentation With Atypical Antipsychotics for Depression: a Review of Evidence-Based Support From the Medical Literature. Pharmacotherapy. 2013;33:344-359.
1893.	BN F. Imaging and cognitive tasks in clinical interventions forfemale-specific mood disorders. Biological psychiatry. 2010;Conference:174S.
1894.	BN F, Lord C, CN S. Depression during menopausal transition: A review of treatment strategies and pathophysiological correlates. Menopause international. 2008;14:123-128.
1895.	BN G, AJ R, MH T, et al. Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed With Measurement-Based Care: Results From Star*D. Journal of general internal medicine. 2008;23:551-560.
1896.	BN G, Davis L, AJ R, Trivedi M, Fava M, SR W. The aims and design of the sequenced treatment alternatives to relieve depression (STAR*D) study. Primary psychiatry. 2005;12:36-41.
1897.	BN G, JF F, SB D, et al. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depression and anxiety. 2011;28:989-998.
1898.	BN G, SB D, AR E, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. Journal of clinical psychopharmacology. 2012;32:114-119.
1899.	BN G, Warden D, MH T, SR W, Fava M, AJ R. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric services (Washington, D.C.). 2009;60:1439-1445.
1900.	BO R, JRT D, DJ S, et al. A Pooled Analysis of Gender and Trauma-Type Effects on Responsiveness to Treatment of Ptsd With Venlafaxine Extended Release or Placebo. Journal of clinical psychiatry. 2008;69:1529-+.
1901.	BO R, TK K, JRT D, KT B, KM C, MH H. Placebo-Controlled Trial of Risperidone Augmentation for Selective Serotonin Reuptake Inhibitor-Resistant Civilian Posttraumatic Stress Disorder. Journal of clinical psychiatry. 2008;69:520-525.
1902.	Boath E, Henshaw C. The treatment of postnatal depression: A comprehensive literature review. Journal of reproductive and infant psychology. 2001;19:215-248.
1903.	Boban M. Multifaceted individualities in pharmacological treatments of obesity. Current clinical pharmacology. 2013;8:89-96.
1904.	Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and Plasma Bdnf Levels in Major Depression: a Replication Study and Meta-Analyses. World journal of biological psychiatry. 2010;11:763-773.
1905.	Bochsler L, JS O, TR N. Desvenlafaxine: A new antidepressant. Medicine today. 2010;11:45-46.
1906.	Bochsler L, JS O, TR N. Duloxetine in the Acute and Continuation Treatment of Major Depressive Disorder. Expert review of neurotherapeutics. 2011;11:1525-1539.
1907.	Bocksberger JP, J-P G, Richard J, Dick P. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. European psychiatry. 1993;8:319-324.
1908.	Boessen R, MJ K, RHH G, DE G, KCB R. Increasing Trial Efficiency by Early Reallocation of Placebo Nonresponders in Sequential Parallel Comparison Designs: Application to Antidepressant Trials. Clinical trials (London, England). 2012;9:578-587.
1909.	Boessen R, RHH G, MJ K, DE G, KCB R. Classifying responders and non-responders; does it help when there is evidence of differentially responding patient groups? Journal of psychiatric research. 2012;46:1169-1173.
1910.	Boessen R, RHH G, MJ K, DE G, KCB R. Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials. Journal of affective disorders. 2013;145:363-369.
1911.	Bogetto F, Barzega G, Bellino S, Maina G, Ravizza L. Drug treatment of dysthymia: A clinical study. [Italian]. Rivista di psichiatria. 1997;32:1-5.
1912.	Bogetto F, RB R, Ferro G, Maina G, Ravizza L. Psychopharmacological treatment of burning mouth syndrome (BMS). A study on a sample of 121 patients. [Italian]. Minerva psichiatrica. 1999;40:1-10.
1913.	Boguslaw H, Beata Z. [A double-blind controlled study of the efficacy and acceptability of tianeptine in comparison with fluvoxamine in the treatment of depressed alcoholic patients]. [Polish]. Psychiatria polska. 2006;40:579-597.
1914.	Bokor G, PD A. Attention-deficit/hyperactivity disorder. Journal of pharmacy practice. 2014;27:336-349.
1915.	Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British journal of psychiatry. 1999;174:297-303.
1916.	Bombardier C, Fann J, JS R, et al. Venlafaxine XR for major depressive disorder after spinal cord injury: Rationale, results, and recommendations. Topics in spinal cord injury rehabilitation. 2013;Conference:5.
1917.	Bonaccorso S, A-H L, Verkerk R, et al. Immune markers in fibromyalgia: Comparison with major depressed patients and normal volunteers. Journal of affective disorders. 1998;48:75-82.
1918.	Bonaccorso S, Ricciardi A, Matrisciano F, et al. Activation of serotonin metabolism and bdnf changes in depressed patients with multiple sclerosis during interferon-beta therapy. European psychiatry. 2009;Conference:S618.
1919.	Bondolfi G, JM A, Golaz J, Gex-Fabry M, Gervasoni N, Bertschy G. A Stepwise Drug Treatment Algorithm to Obtain Complete Remission in Depression: a Geneva Study. Swiss medical weekly. 2006;136:78-85.
1920.	Bondy B, Zill P. Molecular methods for individualization of psychotropic drug treatment. Current Pharmacogenomics. 2006;4:177-189.
1921.	Bonne O, JM G, DA L, et al. Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the Cerebrospinal Fluid of Civilians With Posttraumatic Stress Disorder Before and After Treatment With Paroxetine. Journal of clinical psychiatry. 2011;72:1124-1128.
1922.	Bonne O, Krausz Y, Aharon Y, Gelfin Y, Chisin R, Lerer B. Clinical Doses of Fluoxetine and Cerebral Blood Flow in Healthy Volunteers. Psychopharmacology. 1999;143:24-28.
1923.	Bonnet U. Moclobemide: therapeutic use and clinical studies. [Review] [261 refs]. CNS drug reviews. 2003;9:97-140.
1924.	Bonnie S, Neal D, Sherry P, et al. Fluoxetine, smoking, and history of major depression: A randomized controlled trial. Journal of consulting and clinical psychology. 2007;75:85-94.
1925.	Bonnyaud-Fernandez F, Dagens V. The effect of antidepressants on somatic disorders caused by a depressive state: Is it the result of a specific impact? Tianeptine as an example. [French]. Annales de Psychiatrie. 1996;11:56-62.
1926.	Bonuccelli U, Meco G, Fabbrini G, et al. A Non-Comparative Assessment of Tolerability and Efficacy of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease. Expert opinion on pharmacotherapy. 2012;13:2269-2280.
1927.	Booij J, Kemp P. Dopamine transporter imaging with [123I]FP-CIT SPECT: Potential effects of drugs. European journal of nuclear medicine and molecular imaging. 2008;35:424-438.
1928.	Booij L, AJW VDD, PMJ H, WJ R. Acute Tryptophan Depletion in Depressed Patients Treated With a Selective Serotonin-Noradrenalin Reuptake Inhibitor: Augmentation of Antidepressant Response? Journal of affective disorders. 2005;86:305-311.
1929.	Booij L, AJW VDD, PMJ H, WJ R. Acute Tryptophan Depletion in Depressed Patients Treated With a Selective Serotonin-Noradrenalin Reuptake Inhibitor: Augmentation of Antidepressant Response? Journal of affective disorders. 2005;86:305-311.
1930.	Booij L, AJW VDD, WJ R. Monoamine depletion in psychiatric and healthy populations: Review. Molecular psychiatry. 2003;8:951-973.
1931.	Booth S, Bausewein C, Higginson I, SH M. Pharmacological treatment of refractory breathlessness. Expert review of respiratory medicine. 2009;3:21-36.
1932.	Borand L, Madec Y, Laureillard D, et al. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial). PloS one. 2014.
1933.	Borghi J, JF G. Economic Impact of Using Mirtazapine Compared to Amitriptyline and Fluoxetine in the Treatment of Moderate and Severe Depression in the Uk. European psychiatry. 2000;15:378-387.
1934.	Borgne A, H-J A, Berlin I. Current therapeutic strategies in smoking cessation. [French]. Revue du praticien. 2004;54:1883-1893.
1935.	Boris B. Remission of a mother's depression is associated with her child's mental health. American journal of psychiatry. 2011;168:563-565.
1936.	Boris N, Yuly B, Belmaker RH. Controlled Double-Blind Trial of Phenytoin vs. Fluoxetine in Major Depressive Disorder. Journal of clinical psychiatry. 2005;66:586-590.
1937.	Borisovskaya A, Pascualy M, Borson S. Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies. Current psychiatry reports. 2014.
1938.	Borrelli B, Niaura R, NJ K, et al. Development of major depressive disorder during smoking-cessation treatment. Journal of clinical psychiatry. 1996;57:534-538.
1939.	Use of functional imaging across clinical phases in CNS drug development, Translational psychiatry(2013).
1940.	Borsook D, Edwards R, Elman I, Becerra L, Levine J. Pain and analgesia: The value of salience circuits. Progress in neurobiology. 2013;104:93-105.
1941.	Borthwick M, Barnett N. Delirium: A guide to a common condition. Pharmaceutical journal. 2010;285:155-158.
1942.	Bortolotti B, Menchetti M, Bellini F, MB M, Berardi D. Psychological interventions for major depression in primary care: a meta-analytic review of randomized controlled trials. [Review] [56 refs]. General hospital psychiatry. 2008;30:293-302.
1943.	Borwin B, F AH, T DO. Escitalopram in the Treatment of Anxiety Symptoms Associated with Depression. Depression and anxiety. 2007;24:53-61.
1944.	Borwin B, S BD, T DO, Friis AH, J SD. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? [References]. Journal of clinical psychiatry. 2006;67:1428-1434.
1945.	Bosc M. Assessment of social functioning in depression. [Review] [38 refs]. Comprehensive psychiatry. 2000;41:63-69.
1946.	Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European neuropsychopharmacology. 1997;7 Suppl 1:S57-70; discussion S71-53.
1947.	Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European neuropsychopharmacology. 1997;7:S57-S70.
1948.	Bose A, Korotzer A, Gommoll C, DY L. Randomized Placebo-Controlled Trial of Escitalopram and Venlafaxine Xr in the Treatment of Generalized Anxiety Disorder. Depression and anxiety. 2008;25:854-861.
1949.	Early non-response in patients with severe depression: Escitalopram up-titration versus switch to duloxetine, Clinical drug investigation(2012).
1950.	Bottiglieri T. Folate, Vitamin B12, and S-Adenosylmethionine. Psychiatric clinics of North America. 2013;36:1-13.
1951.	Bottlender R, Rudolf D, Strauss A, H-J M. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. Journal of affective disorders. 2001;63:79-83.
1952.	Bouchard JM, Delaunay J, J-P D, et al. Citalopram versus maprotiline: A controlled, clinical, multicentre trial in depressed patients. Acta psychiatrica Scandinavica. 1987;76:583-592.
1953.	Bougerol T, J-C S, Patris M, Strub N, Lemming O, HE HP. Citalopram and fluoxetine in major depression. Comparison of two clinical trials in a psychiatrist setting and in general practice. Clinical drug investigation. 1997;14:77-89.
1954.	Bougerol T, Uchida C, J-P G, Kohler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III): A French/Swiss double-blind trial. Psychopharmacology. 1992;106:102-108.
1955.	Bougerol T, Uchida C, J-P G, Kohler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). Psychopharmacology. 1992;106:S102-S108.
1956.	Bougerol T, Uchida C, JP G, Kohler M, Mikkelsen H. Efficacy and Tolerability of Moclobemide Compared With Fluvoxamine in Depressive Disorder (Dsm Iii) - a French Swiss Double-Blind Trial. Psychopharmacology. 1992;106:S102-S108.
1957.	Bougerol T, Uchida C, JP G, Kohler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial. Psychopharmacology. 1992;106 Suppl:S102-108.
1958.	Bould H, Wiles N, Potokar J, et al. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of psychopharmacology (Oxford, England). 2012;26:663-669.
1959.	Boulenger JP, Hermes A, Huusom AKT, Weiller E. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs paroxetine. Current medical research and opinion. 2010;26:605-614.
1960.	The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: Studies in healthy subjects and in patients with major depressive disorder, Journal of psychopharmacology (Oxford, England)(2010).
1961.	Bourdeaux R, Pannetier P, Younos C, Desor D, PR L, Capolaghi B. Fluoxetine: Relationships Among Plasma Concentrations and Therapeutic Effects in the Treatment of 32 Patients With Major Depressive Disorder at 20 Mg/Day. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 1998;24:57-61.
1962.	Bourgeois J, MM E, L VB, Petrovic M, RH VS. The use of antidepressants in Belgian nursing homes: Focus on indications and dosages in the PHEBE study. Drugs & aging. 2012;29:759-769.
1963.	Bourin M. New pharmacological aspects of antidepressants. [French]. Journal of psychiatry & neuroscience. 1994;19:7-10.
1964.	Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: A review. Human psychopharmacology. 2003;18:185-190.
1965.	Bourin M, Chenu F, Prica C, Hascoet M. Augmentation Effect of Combination Therapy of Aripiprazole and Antidepressants on Forced Swimming Test in Mice. Psychopharmacology. 2009;206:97-107.
1966.	Bourin M, Chue P, Guillon Y. Paroxetine: a Review. CNS drug reviews. 2001;7:25-47.
1967.	Bourin M, Prica C. Melatonin receptor agonist agomelatine: A new drug for treating unipolar depression. Current pharmaceutical design. 2009;15:1675-1682.
1968.	Bourine M, Lambert O. Pharmacotherapy of anxious disorders. Human psychopharmacology. 2002;17:383-400.
1969.	Bowden C. The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: Many questions, few answers. Journal of affective disorders. 2004;79:S9-S14.
1970.	Boyer P. [Proofs of efficacy]. [French]. Encephale. 1999;25 Spec No:25-29.
1971.	Boyer P. Proofs of efficacy. [French]. Encephale. 1999;25:29-31.
1972.	Boyer P, Briley M. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. Drugs of today (Barcelona, Spain : 1998). 1998;34:709-720.
1973.	Boyer P, JM D, JC B, JM H, Troy S. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. PharmacoEconomics. 1998;13:157-169.
1974.	Boyer P, JP T, Falissart B, Troy S. Sequential Improvement of Anxiety, Depression and Anhedonia With Sertraline Treatment in Patients With Major Depression. Journal of clinical pharmacy and therapeutics. 2000;25:363-371.
1975.	Boyer P, Mahe V, Hackett D. Social Adjustment in Generalised Anxiety Disorder: a Long-Term Placebo-Controlled Study of Venlafaxine Extended Release. European psychiatry. 2004;19:272-279.
1976.	Boyer P, Mahe V, Hackett D. Social Adjustment in Generalised Anxiety Disorder: a Long-Term Placebo-Controlled Study of Venlafaxine Extended Release. European psychiatry. 2004;19:272-279.
1977.	Boynton L, Bentley J, Strachan E, Barbato A, Raskind M. Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population. Journal of psychiatric practice. 2009;15:454-459.
1978.	BP B, JI H, JE J, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35:834-846.
1979.	BP B, JL R, KV F, KA R, JM J, JI H. Memantine in the Treatment of Binge Eating Disorder: an Open-Label, Prospective Trial. International journal of eating disorders. 2008;41:520-526.
1980.	BP B, KV F, JL R, KA R, HG PJ, JI H. Duloxetine in the Treatment of Irritable Bowel Syndrome: an Open-Label Pilot Study. Human Psychopharmacology-Clinical and Experimental. 2009;24:423-428.
1981.	BP G, Lanfumey L, AM G. Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (Neurokinin 1) receptor antagonist administration: A review. Current drug targets. 2006;7:187-201.
1982.	BP G, M EM, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: The triple reuptake inhibitors. Current drug targets. 2009;10:1069-1084.
1983.	BP M, Y-C C, T-W P, PD M. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia research. 2006;88:5-25.
1984.	BP Y, YS C, GA M. Is generic fluoxetine effective? Journal of affective disorders. 2004;81:185-186.
1985.	BPV S, Rammohan B, Kumar A. The effective study of aqueous extract of Crocus sativus Linn.(Saffron) in depressed mice. International Journal of PharmTech Research. 2014;6:1143-1152.
1986.	BR B. Involuntary emotional expression disorder: Treating the untreated. CNS spectrums. 2007;12:23-27.
1987.	BR F, BF F. Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease. World journal of gastroenterology. 2014;20:3552-3563.
1988.	BR G, Norbury R, Selvaraj S, PJ C, CJ H. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychological medicine. 2012;42:2609-2617.
1989.	BR M, Pokrajac M, Timotijevi? I, Varagi? V. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. International clinical psychopharmacology. 1997;12:207-212.
1990.	BR R, JR S, JM T, Rindskopf D, BS P, SP R. Deconstructing pediatric depression trials: An analysis of the effects of expectancy and therapeutic contact. Journal of the American Academy of Child and Adolescent Psychiatry. 2011;50:782-795.
1991.	BR R, JR S, SP R. Does Study Design Influence Outcome? The Effects of Placebo Control and Treatment Duration in Antidepressant Trials. Psychotherapy and psychosomatics. 2009;78:172-181.
1992.	BR R, JR S, SP R. Does Differential Drop-Out Explain the Influence of Study Design on Antidepressant Response? A Meta-Analysis. Journal of affective disorders. 2012;140:57-65.
1993.	BR R, MD M, Nelson C, Roose S. The clinical management of late life depression: Implications for signal detection and treatment outcome. American journal of geriatric psychiatry. 2014;Conference:S31-S32.
1994.	BR R, MM W, Glass A, JW S. The Role of Patient Expectancy in Placebo and Nocebo Effects in Antidepressant Trials. Journal of clinical psychiatry. 2014;75:1040-1046.
1995.	BR R, MM W, Glass A, JW S. The role of patient expectancy in placebo and nocebo effects in antidepressant trials. Journal of clinical psychiatry. 2014;75:1040-1046.
1996.	BR R, SM M, Wang P, et al. A Randomized, Prospective Pilot Study of Patient Expectancy and Antidepressant Outcome. Psychological medicine. 2013;43:975-982.
1997.	BR R, Tandler J, PJ B, JR S, SP R. Clinic Visits in Late-Life Depression Trials: Effects on Signal Detection and Therapeutic Outcome. American journal of geriatric psychiatry. 2014;22:1452-1461.
1998.	BR R, TD W, SP R. Expectancy and the treatment of depression: A review of experimental methodology and effects on patient outcome. Current psychiatry reviews. 2010;6:1-10.
1999.	BR R, TM C, Persaud A, PJ B, JR S, SP R. Less is more in antidepressant clinical trials: A meta-analysis of the effect of visit frequency on treatment response and dropout. Journal of clinical psychiatry. 2013;74:703-715.
2000.	Braconnier A, R LC, Cohen D, Group D. Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42:22-29.
2001.	Bradesi S, EA M. Novel therapeutic approaches in IBS. Current opinion in pharmacology. 2007;7:598-604.
2002.	Bradley CM. The relationship among psychiatrists' attitudes toward women and diagnoses and willingness to prescribe anti-depressant medication. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2002;62:4777.
2003.	Bradvik L, Berglund M. Long-Term Treatment and Suicidal Behavior in Severe Depression: Ect and Antidepressant Pharmacotherapy May Have Different Effects on the Occurrence and Seriousness of Suicide Attempts. Depression and anxiety. 2006;23:34-41.
2004.	Bradwejn J, Ahokas A, DJ S, Salinas E, Emilien G, Whitaker T. Venlaflaxine Extended-Release Capsules in Panic Disorder - Flexible-Dose, Double-Blind, Placebo-Controlled Study. British journal of psychiatry. 2005;187:352-359.
2005.	Brady K, Pearlstein T, GM A, et al. Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder - a Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2000;283:1837-1844.
2006.	Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type. Neuropsychobiology. 1995;32:59-63.
2007.	Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa--binge-eating/purging type. Neuropsychobiology. 1995;32:64-67.
2008.	Brambilla F, Samek L, Company M, Lovo F, Cioni L, Mellado C. Multivariate Therapeutic Approach to Binge-Eating Disorder: Combined Nutritional, Psychological and Pharmacological Treatment. International clinical psychopharmacology. 2009;24:312-317.
2009.	Brambilla P, Barale F, JC S. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology. 2003;166:315-332.
2010.	Brambilla P, Cipriani A, Hotopf M, Barbui C. Side-Effect Profile of Fluoxetine in Comparison With Other Ssris, Tricyclic and Newer Antidepressants: a Meta-Analysis of Clinical Trial Data. Pharmacopsychiatry. 2005;38:69-77.
2011.	Brambilla P, Perez J, Barale F, Barbui C. Psychopharmacologal treatment of behavioural problems in autism. [Italian]. Minerva psichiatrica. 2003;44:135-142.
2012.	Brandenburg B, Lesser J, Mangham D, Crow S. Psychopharmacological interventions for adolescents with eating disorders. Adolescent psychiatry. 2011;1:277-285.
2013.	Brasseur R. A multicentre open trial of fluoxetine in depressed out-patients in Belgium. International clinical psychopharmacology. 1989;4 Suppl 1:107-111.
2014.	Brawman-Mintzer O, RG K, Rynn M, RE C, Rickels K. Sertraline Treatment for Generalized Anxiety Disorder: a Randomized, Double-Blind, Placebo-Controlled Study. Journal of clinical psychiatry. 2006;67:874-881.
2015.	Brecht S, Desaiah D, Marechal E, Santini A, Podhorna J, JD G. Efficacy and safety of duloxetine 60-mg and 120-mg daily in patients hospitalised for severe depression. European neuropsychopharmacology. 2009;Conference:S258.
2016.	Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. JNCCN Journal of the National Comprehensive Cancer Network. 2007;5:1081-1091.
2017.	A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression, American journal of psychiatry(2008).
2018.	Brenes GA, Williamson JD, Messier SP, et al. Treatment of minor depression in older adults: A pilot study comparing sertraline and exercise. Aging & mental health. 2007;11:61-68.
2019.	Brenner R, Madhusoodanan S, Puttichanda S, Chandra P. Primary prevention in psychiatry - Adult populations. Annals of clinical psychiatry. 2010;22:239-248.
2020.	Bressa GM, Brugnoli R, Pancheri P. A double-blind study of fluoxetine and imipramine in major depression. International clinical psychopharmacology. 1989;4 Suppl 1:69-73.
2021.	Bressi C, Porcellana M, PM M, EP N, Magri L. Short-term psychodynamic psychotherapy versus treatment as usual for depressive and anxiety disorders: A randomized clinical trial of efficacy. Journal of nervous and mental disease. 2010;198:647-652.
2022.	Bressi C, Sarotti E, Manoussakis C, et al. Depression in the elderly: Risk factors, comorbidity, treatment and prognosis. [Italian]. Rivista di psichiatria. 2008;43:1-14.
2023.	Bretlau LG, Lunde M, Lindberg L, Unden M, Dissing S, Bech P. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression. A double-blind, randomised, sham-controlled trial. Pharmacopsychiatry. 2008;41:41-47.
2024.	Breum L, SE M, Andersen T, Astrup A. Long-Term Effect of Dexfenfluramine on Amino Acid Profiles and Food Selection in Obese Patients During Weight Loss. International journal of obesity. 1996;20:147-153.
2025.	Brian H, Regina P, Bonnie S, et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. Journal of consulting and clinical psychology. 1999;67:547-554.
2026.	Brian KK, R WS, F LJ, et al. Effects of heart disease on depression treatment: Results from the COMED study. General hospital psychiatry. 2012;34:24-34.
2027.	Brian L, David T. Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. [Review]. Journal of psychopharmacology (Oxford, England). 2010;24:1143-1152.
2028.	Bridler R. [Optimal duration of fluoxetine administration for the successful treatment of depression]. [German]. Schweizerische Rundschau fur Medizin Praxis. 1999;88:1777-1778.
2029.	Brietzke E, RB M, Zugman A, et al. Is there a role for curcumin in the treatment of bipolar disorder? Medical hypotheses. 2013;80:606-612.
2030.	Briffault X, Morvan Y, Rouillon F, Dardennes R, Lamboy B. Factors associated with treatment adequacy of major depressive episodes in France. [French]. Encephale. 2010;36:D59-D72.
2031.	Briley M. Milnacipran, a well-tolerated specific serotonin and norepinephrine reuptake inhibiting antidepressant. CNS drug reviews. 1998;4:137-148.
2032.	Briley M. New hope in the treatment of painful symptoms in depression. Current opinion in investigational drugs (London, England : 2000). 2003;4:42-45.
2033.	Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Human psychopharmacology. 2004;19:S21-S25.
2034.	Briley M. Drugs to treat fibromyalgia - The transatlantic difference. Current opinion in investigational drugs (London, England : 2000). 2010;11:16-18.
2035.	Briley M, Moret C. Fibromyalgia syndrome: An overview of potential drug targets. IDrugs : the investigational drugs journal. 2003;6:668-673.
2036.	Briley M, Moret C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. [Review] [40 refs]. CNS spectrums. 2008;13:22-26.
2037.	Brinar V, Franjic J, Podobnik-Sarkanji S, Petelin Z. Recommendations for the diagnosis and treatment of patients with multiple sclerosis. [Croatian, English]. Neurologia Croatica. 2003;52:9-93.
2038.	Brodaty H. Three steps forward, two steps back in helping people with dementia. American journal of geriatric psychiatry. 2009;17:85-87.
2039.	Brodaty H, BM D, L-F L. Behavioural and psychological symptoms of dementia: A seven-tiered model of service delivery. Medical journal of Australia. 2003;178:231-234.
2040.	Brody B, AC L, JH K. Antidepressant clinical trials and subject recruitment: Just who are symptomatic volunteers? American journal of psychiatry. 2011;168:1245-1247.
2041.	Bronisch T. Depression and suicide: Antidepressive therapies in the acute and chronic treatment of unipolar and bipolar affective disorders - Are they preventive according to suicide?. [German]. Krankenhauspsychiatrie, Supplement. 2005;16:S27-S33.
2042.	Bronner G, Elran E, Golomb J, AD K. Female sexuality in multiple sclerosis: The multidimensional nature of the problem and the intervention. Acta neurologica Scandinavica. 2010;121:289-301.
2043.	Broocks A, Ahrendt U, Sommer M. Physical training in the treatment of depressive disorders. [German]. Psychiatrische Praxis, Supplement. 2007;34:S300-S304.
2044.	Brook R. Medicines regulation in the UK: The case for reform. Journal of mental health (Abingdon, England). 2004;13:431-438.
2045.	Brown J, PMS OB, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane database of systematic reviews (Online). 2009.
2046.	Brown MCJ, Nimmerrichter AA, Guest JF. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. European Psychiatry: the Journal of the Association of European Psychiatrists. 1999;14:230-244.
2047.	Brown W, Akiskal H, Angst J, et al. Treatment response in melancholia. Acta psychiatrica Scandinavica. 2007;115:166-168.
2048.	Browne G, Steiner M, Roberts J, et al. Prevalence of Dysthymic Disorder in Primary Care. Journal of affective disorders. 1999;54:303-308.
2049.	Browning M, Grol M, Ly V, GM G, EA H, CJ H. Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety. Neuropsychopharmacology. 2011;36:2689-2697.
2050.	Browning M, Reid C, PJ C, GM G, CJ H. A Single Dose of Citalopram Increases Fear Recognition in Healthy Subjects. Journal of psychopharmacology (Oxford, England). 2007;21:684-690.
2051.	Bruce LR, M SS, Marc H, M HW. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of clinical psychiatry. 1997;58:484-491.
2052.	Bruggeman R, C VdL, JK B, GS G, SM H, JA T. Risperidone versus pimozide in Tourette's disorder: A comparative double-blind parallel-group study. Journal of clinical psychiatry. 2001;62:50-56.
2053.	Brugnoli R, Pacitti F, Arcangeli T. Depression and social adaptation: The role of reboxetine. [Italian]. Rivista di psichiatria. 1999;34:291-299.
2054.	Brugue E, Vieta E. Atypical Antipsychotics in Bipolar Depression: Neurobiological Basis and Clinical Implications. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:275-282.
2055.	Bruhl A, Herwig U, Kaffenberger T. Differential serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychobiology. 2009;Conference:72.
2056.	Bruijn JA, Moleman P, Mulder PGH, W vdBW. Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry. 1999;32:87-92.
2057.	Bruijn JA, Moleman P, Mulder PGH, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology. 1996;127:231-237.
2058.	Brunello N, JA DB, LL J, et al. Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. [Review] [114 refs]. Journal of affective disorders. 2000;60:61-74.
2059.	Brunnauer A, Buschert V, Fric M, et al. Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry. 2015;48:65-71.
2060.	Brunnauer A, Laux G. The Effects of Most Commonly Prescribed Second Generation Antidepressants on Driving Ability: a Systematic Review. Journal of neural transmission. 2013;120:225-232.
2061.	Brunnauer A, Laux G, David I, Geiger E, Weigenand S, Fric M. Driving simulator performance and psychomotor function of depressive inpatients treated with reboxetine or mirtazapine. [German]. Psychopharmakotherapie. 2007;14:157-162.
2062.	Brunnauer A, Laux G, Geiger E. Driving ability of depressive patients under mirtazapine and reboxetine. [German]. Psychiatrische Praxis, Supplement. 2007;34:S84-S86.
2063.	Brunnauer A, Laux G, Geiger E, Soyka M, HJ Ml. Antidepressants and driving ability: results from a clinical study. Journal of clinical psychiatry. 2006;67:1776-1781.
2064.	Bruno D, KJ F. Management of Postmenopausal Symptoms in Breast Cancer Survivors. Seminars in oncology. 2006;33:696-707.
2065.	Bruno F, Nicholas M, Helene V, Jean-Paul A. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. International clinical psychopharmacology. 2007;22:107-115.
2066.	Brunoni A. TDCS as an add-on therapy: The augmentative role of TDCS for the treatment of depression. Biological psychiatry. 2014;Conference:3S.
2067.	Brunoni A, Valiengo L, Baccaro A, et al. Sertraline vs. electrical current therapy for treating depression clinical trial (select tDCS): Results from a factorial, randomized, controlled trial. Biological psychiatry. 2012;Conference:57S.
2068.	Brunoni A, Valiengo L, Baccaro A, et al. Sertraline Vs. Electrical Current Therapy for Treating Depression Clinical Trial (Select Tdcs): Results From a Factorial, Randomized, Controlled Trial. Biological psychiatry. 2012;71:57S.
2069.	Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: Implications for the serotonergic system, European neuropsychopharmacology(2013).
2070.	Brunovsky M, Bares M, Novak T, et al. The reduction of prefrontal QEEG theta cordance as a predictor of treatment response in patients with resistant major depression: A pooled analysis of single-center studies with bupropion, venlafaxine and rTMS. Clinical EEG and neuroscience. 2009;Conference:308.
2071.	Profile of adverse events with duloxetine treatment: A pooled analysis of placebo-controlled studies, Drug safety(2010).
2072.	Bryan C, Songer T, MM B, et al. The Impact of Diabetes on Depression Treatment Outcomes. General hospital psychiatry. 2010;32:33-41.
2073.	Brymer C, CH W. Fluoxetine in Elderly Patients - Is There Cause for Concern. Journal of the American Geriatrics Society. 1992;40:902-905.
2074.	Bryois C, Golaz J, Bondolfi G, J-M A, Bertschy G. Psychiatry. [French]. Medecine et hygiene. 2002;60:135-140.
2075.	BS A, CG L. Rapidly progressive dementias and the treatment of human prion diseases. Expert opinion on pharmacotherapy. 2011;12:1-12.
2076.	BS C, BA B. Fluvoxamine maleate, a serotonergic antidepressant: a comparison with chlorimipramine. Progress in neuro-psychopharmacology & biological psychiatry. 1982;6:475-478.
2077.	Drug treatments for the neuropsychiatric complications of Parkinson's disease, Expert review of neurotherapeutics(2012).
2078.	BS M. Depression and dementia: comorbidities, identification, and treatment. [Review] [65 refs]. Journal of geriatric psychiatry and neurology. 1998;11:201-205.
2079.	BS M. Optimizing the use of data generated by geriatric depression treatment studies during a time of diminishing resources. American journal of geriatric psychiatry. 2007;15:545-552.
2080.	A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).[Erratum appears in Arch Gen Psychiatry. 2011 Jun;68(6):626], Archives of general psychiatry(2009).
2081.	A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).[Erratum appears in Arch Gen Psychiatry. 2011 Jun;68(6):626], Archives of general psychiatry(2009).
2082.	BS M, BH M, Whyte E. Delusional depression in late-life: Treatment effects on mood, psychosis, cognition and the brain. American journal of geriatric psychiatry. 2014;Conference:S10.
2083.	BS M, English J, Gabriele M, et al. A delusion assessment scale for psychotic major depression: Reliability, validity, and utility. Biological psychiatry. 2006;60:1336-1342.
2084.	Bschor T. Therapy-resistant depression. Expert review of neurotherapeutics. 2010;10:77-86.
2085.	Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy: Review. Acta psychiatrica Scandinavica. 2010;121:174-179.
2086.	Bschor T, Bauer M. Efficacy and mechanisms of action of Lithium augmentation in refractory major depression. Current pharmaceutical design. 2006;12:2985-2992.
2087.	BT B. New developments in the management of major depressive disorder and generalized anxiety disorder: Role of quetiapine. Neuropsychiatric disease and treatment. 2008;4:1181-1192.
2088.	BT B, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression - A systematic review. Psychiatry research. 2014;219:25-50.
2089.	A computerized decision support system for depression in primary care, Primary care companion to the Journal of clinical psychiatry(2009).
2090.	BT K, TL G, MH T. Strategies to enhance the therapeutic efficacy of antidepressants: Targeting residual symptoms. Expert review of neurotherapeutics. 2009;9:975-984.
2091.	BT M, Vedrody S. Poststroke depression: A biopsychosocial approach. Current psychiatry reports. 2006;8:25-33.
2092.	BT S. The Prozac boom and its placebogenic counterpart -- a culturally fashioned phenomenon. Medical science monitor. 2002;8:CR389-393.
2093.	BT W. Fluoxetine Treatment of Bulimia-Nervosa. Journal of psychosomatic research. 1991;35:33-40.
2094.	BT W. Psychopharmacologic treatment of bulimia nervosa. Journal of clinical psychiatry. 1991;52:34-38.
2095.	BT W, GT W, KL L, et al. Medication and Psychotherapy in the Treatment of Bulimia Nervosa. American journal of psychiatry. 1997;154:523-531.
2096.	BT W, Sysko R. Placebo Control Groups in Trials of Major Depressive Disorder Among Older Patients. Journal of clinical psychopharmacology. 2005;25:S29-S33.
2097.	BT W, Sysko R. Placebo Control Groups in Trials of Major Depressive Disorder Among Older Patients. Journal of clinical psychopharmacology. 2005;25:S29-S33.
2098.	Budhdeo S, Rajapaksa S. Functional recovery in cerebral palsy may be potentiated by administration of selective serotonin reuptake inhibitors. Medical hypotheses. 2011;77:386-388.
2099.	Budur K, Falcone T, Franco K. Diagnosing and managing posttraumatic stress disorder. Cleveland Clinic journal of medicine. 2006;73:121-129.
2100.	Buhagiar K, Cassar J. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature]. [Review] [25 refs] [Turkish]. Turk psikiyatri dergisi [Turkish journal of psychiatry]. 2007;18:179-183.
2101.	Buhlmann U, Reese H, Golan E, Wilhelm S. Body dysmorphic disorder: Delusions of physical appearance. Current psychosis & therapeutics reports. 2006;4:117-120.
2102.	Bui E, Nadal-Vicens M, NM S. Pharmacological approaches to the treatment of complicated grief: Rationale and a brief review of the literature. Dialogues in clinical neuroscience. 2012;14:149-157.
2103.	Buitrago F. An optimized antidepressant pharmacological treatment combined with pain self-management in patients with depression and chronic musculoskeletal pain. [Spanish]. FMC Formacion Medica Continuada en Atencion Primaria. 2009;16:603.
2104.	Bujoreanu S, Benhayon D, Szigethy E. Treatment of depression in children and adolescents. Pediatric annals. 2011;40:548-555.
2105.	Bulau B. Antidepressant agomelatine approved in Europe: New option for the treatment of depressive episodes. [German]. Neurologie und Rehabilitation. 2009;15:270.
2106.	Bull E. Disease overview - Urinary incontinence. Drugs in Context. 2006;2:89-101.
2107.	Buller R, Legrand V. Novel treatments for depression. Good Clinical Practice Journal. 2001;8:20-24.
2108.	Bullock K, Koran L. Psychopharmacology of compulsive buying. Drugs of today (Barcelona, Spain : 1998). 2003;39:695-700.
2109.	Bunevicius R. Thyroid disorders in mental patients. Current opinion in psychiatry. 2009;22:391-395.
2110.	Bunevicius R, Liutkus S, Kunigelis Z, Kaminskaite T, Gulbinaite N, Mickuviene N. Triiodothyronine effects on treatment of major depression with escitalopram in women. European neuropsychopharmacology. 2012;Conference:S250-S251.
2111.	Buoli M, Dell'osso B, MF B, Altamura C. Slow Vs Standard up-Titration of Paroxetine in the Treatment of Panic Disorder: a Prospective Randomized Trial. Psychiatry and clinical neurosciences. 2010;64:612-619.
2112.	Burgess A, White R, Cortese F, et al. Neural predictors of antidepressant treatment response to quetiapine XR and citalopram in major depressive disorder. Biological psychiatry. 2013;Conference:60S.
2113.	The clinical problem of neuropsychiatric signs and symptoms in dementia, CONTINUUM Lifelong Learning in Neurology(2013).
2114.	Burke D, Shannon J, Beveridge A. Electroconvulsive therapy use in a 97-year-old woman. Australasian psychiatry. 2007;15:427-430.
2115.	Burke W, Schmid K, Lydiatt W. Prevention of depression using escitalopram in patients undergoing treatment for head and neck cancer. American journal of geriatric psychiatry. 2013;Conference:S133.
2116.	Burke W, Schmid K, Sharma A, Theobald J, Lydiatt W. Preventing depression in patients initiating treatment for head and neck cancer. Psycho-oncology. 2013;Conference:32.
2117.	Bursch B, Forgey M. Psychopharmacology for medically ill adolescents topical collection on complex medical-psychiatric issues. Current psychiatry reports. 2013.
2118.	Burt T, RM L. Forced titration as a confound in an SSRI comparator study of sertraline versus citalopram in the treatment of major depressive disorder [1] (multiple letters). Biological psychiatry. 2001;50:66-68.
2119.	Burt T, RM L. Forced Titration as a Confound in an Ssri Comparator Study of Sertraline Versus Citalopram in the Treatment of Major Depressive Disorder. Biological psychiatry. 2001;50:66.
2120.	Burton SW. Symptoms as predictors of response in depression. Journal of psychopharmacology (Oxford, England). 1993;7:135-138.
2121.	Bushell I, Newton W. SSRI or tricyclics for depression? Journal of family practice. 1996;43:345-346.
2122.	Buskila D. Developments in the Scientific and Clinical Understanding of Fibromyalgia. Arthritis research & therapy. 2009;11.
2123.	Buskila D, JN A. Treating juvenile fibromyalgia: Cognitive-behavioral therapy, exercise and pharmacotherapy. Pain management. 2013;3:323-324.
2124.	Bussing R, TK M, EA S, et al. Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD. Psychiatry research. 2013;205:253-261.
2125.	Butler L, Pilkington K. Chinese herbal medicine and depression: The research evidence. Evidence-based Complementary and Alternative Medicine. 2013.
2126.	Butler T, PW S, Greenberg D, et al. Reducing Impulsivity in Repeat Violent Offenders: an Open Label Trial of a Selective Serotonin Reuptake Inhibitor. Australian and New Zealand journal of psychiatry. 2010;44:1137-1143.
2127.	Butterweck V. Mechanism of action of St John's wort in depression: What is known? CNS drugs. 2003;17:539-562.
2128.	BV ON, RJ C, PJ N. The loudness dependence of the auditory evoked potential (LDAEP) as an in iivo biomarker of central serotonergic function in humans: Rationale, evaluation and review of findings. Human psychopharmacology. 2008;23:355-370.
2129.	BW D, Crits-Christoph P, DL E, et al. Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness - a Double-Blind, Placebo-Controlled Study. Journal of clinical psychopharmacology. 2007;27:614-619.
2130.	Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial, Trials [Electronic Resource](2012).
2131.	Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial, Trials [Electronic Resource](2012).
2132.	Predictors of Remission in Depression to Individual and Combined Treatments (Predict): Study Protocol for a Randomized Controlled Trial, Trials(2012).
2133.	BW D, JA D, Marx L, SJ G, CB N, SO L. The effects of sertraline on psychopathic traits. International clinical psychopharmacology. 2011;26:329-337.
2134.	BW D, Li T, SG K, et al. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry research. 2010;177:177-183.
2135.	BW D, Li T, SG K, et al. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. Journal of psychiatric research. 2011;45:96-103.
2136.	How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine, Human psychopharmacology(2014).
2137.	BW D, ME K, TC M, CM V, WE C, HS M. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.[Erratum appears in J Psychiatr Res. 2014 Jul;54:141]. Journal of psychiatric research. 2012;46:375-381.
2138.	BW D, ME T, CC W, et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology. 2012;37:2830-2836.
2139.	BW D, MH A. Response to treatment with placebo, medication or psychotherapy in severe non-psychotic major depressive disorder. Current psychiatry reviews. 2010;6:28-45.
2140.	BW D, PG D. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: A review. Primary care companion to the Journal of clinical psychiatry. 2008;10:222-228.
2141.	BW G. The obesity epidemic: Scope of the problem and management strategies. Journal of midwifery & women's health. 2010;55:568-578.
2142.	BW W. Homeopathic remedies as placebo alternatives - Verification on the example of treatment of menopause-related vegetative and emotional disturbances. Science and engineering ethics. 2004;10:179-188.
2143.	Byford S, Barrett B, Roberts C, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive-behavioural therapy in adolescents with major depression. British journal of psychiatry. 2007;191:521-527.
2144.	Byrne A, Curran S. A systematic review and meta-analysis of sertraline for the treatment of depression in older people. European neuropsychopharmacology. 2009;Conference:S389-S390.
2145.	Byrne C, Browne G, Roberts J, et al. Changes in children's behavior and costs for service use associated with parents' response to treatment for dysthymia. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:239-246.
2146.	Byrne MM. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta neurologica Scandinavica. 1989;80:138-139.
2147.	Byrne N, Regan C, Livingston G. Adherence to treatment in mood disorders. Current opinion in psychiatry. 2006;19:44-49.
2148.	Byrom B, JC M. The value of computer-administered self-report data in central nervous system clinical trials. Current opinion in drug discovery & development. 2005;8:374-383.
2149.	Byrom B, Stein D, Greist J. A hotline to better data. Good Clinical Practice Journal. 2005;12:12-15.
2150.	C BA, Judi W, R GB, et al. Preliminary evidence that sub-chronic citalopram triggers the re-evaluation of value in intimate partnerships. Social cognitive and affective neuroscience. 2014;9:1419-1425.
2151.	C CC, A CL, J FV, et al. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained release and sertraline treatment. Annals of clinical psychiatry. 1999;11:205-215.
2152.	C CC, R KB, Carolyn B-W, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2001;23:1040-1058.
2153.	C CR, D TG, E NM. No gender differences in placebo responses of patients with major depressive disorder. Biological psychiatry. 2001;49:158-160.
2154.	C DB, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, MJ M. Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nature reviews. Drug discovery. 2010;9:628-642.
2155.	C DG. Paroxetine in the elderly: A comparative meta-analysis against standard antidepressant pharmacotherapy. [Hungarian]. Psychiatria Hungarica. 1997;Suppl 1:37-45.
2156.	Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: A randomized, double-blind, placebo-controlled trial, Journal of the American Academy of Child and Adolescent Psychiatry(2015).
2157.	C DM, A OM, M MK, P ES, Shuhua L, John MJ. Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Neuropsychopharmacology. 2001;25:395-401.
2158.	C DM, Carradori S, Chimenti P, et al. New Insights Into the Biological Properties of Crocus Sativus L.: Chemical Modifications, Human Monoamine Oxidases Inhibition and Molecular Modeling Studies. European journal of medicinal chemistry. 2014;82:164-171.
2159.	C DT, S FE. Augmentation Strategies in Star*D: A Review. Primary psychiatry. 2007;14:46-50.
2160.	C FJ, J DR, D HS, Robert G, C SR, D AJ. Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behaviour research and therapy. 2013;51:392-398.
2161.	C FN, G SS, A RM, et al. An exploratory analysis of the impact of family functioning on treatment for depression in adolescents. Journal of clinical child and adolescent psychology. 2009;38:814-825.
2162.	C G-dW, Stoyanova V, Yu Y, Isaac M, Pani L, F dA-T. The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma. European neuropsychopharmacology. 2012;22:804-811.
2163.	The impact of missing data on clinical trials: A re-analysis of a placebo controlled trial of Hypericum perforatum (St Johns wort) and sertraline in major depressive disorder, Psychopharmacology(2014).
2164.	C GD, W BA, Scott M, Meredith W, al e. "Addition of fluoxetine to treatment of schizophrenic patients": Reply. American journal of psychiatry. 1991;148:275-276.
2165.	Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression, Journal of the American Academy of Child and Adolescent Psychiatry(2013).
2166.	Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder, Psychiatry research(2013).
2167.	C KG, C VA, M TJH, Jan P, W vdBW, A BJ. CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. Journal of psychiatric research. 2002;36:391-397.
2168.	C LC, D SA, G SS, et al. The role of readiness to change in response to treatment of adolescent depression. Journal of consulting and clinical psychology. 2009;77:422-428.
2169.	Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS), Journal of the American Academy of Child and Adolescent Psychiatry(2010).
2170.	C LP, Levy E, Ravily V, JN B, Meurgey F. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. Journal of affective disorders. 1994;31:1-18.
2171.	C LS. The efficacy of sertraline treatment for subtypes of alcohol dependence: Advancing individualized treatments. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2010;71:2333.
2172.	Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial, Trials [Electronic Resource](2013).
2173.	C MD, A SR, H MB, et al. Effect of nortriptyline and paroxetine on extrapyrimidal signs and symptoms: A prospective double-blind study in depressed elderly patients. The American Journal of Geriatric Psychiatry. 2000;8:226-231.
2174.	C MD, G PB, Benoit M, et al. Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. The American Journal of Geriatric Psychiatry. 2002;10:199-205.
2175.	C MD, L HS, Alison G. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosomatic medicine. 2003;65:542-547.
2176.	C MJ, H KJ, L BK, J CP, Michael S. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. Journal of affective disorders. 2005;89:167-175.
2177.	C NJ, R DT, L SJ, et al. A pilot randomized controlled trial with paroxetine for subthreshold PTSD in Operation Enduring Freedom/Operation Iraqi Freedom era veterans. Psychiatry research. 2013;206:318-320.
2178.	C PA, Martin B, Suzanne F-B, F HR, F GJ. Fluoxetine versus phenelzine in atypical depression. Biological psychiatry. 1996;40:1017-1020.
2179.	C QL, Filip DF, Jean-Pierre R, H KS, Frederic RP, Michael BR. Dimensional personality traits and treatment outcome in patients with major depressive disorder. Journal of affective disorders. 2008;108:241-250.
2180.	C RD, M QF, F KD. A typological model for estimation of drug and placebo effects in depression. Journal of clinical psychopharmacology. 2002;22:414-418.
2181.	Metabolomic differences in heart failure patients with and without major depression, Journal of geriatric psychiatry and neurology(2010).
2182.	C SJ. Prozac versus placebo: An editorial. Psychology and Education: An Interdisciplinary Journal. 2004;41:40-41.
2183.	C SR. The role of sertraline in the management of depression. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 1994;16:768-782.
2184.	C SR. Dr. Shelton Replies. American journal of psychiatry. 2002;159:155-156.
2185.	C SR. "A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder": Reply. Journal of clinical psychiatry. 2007;68:1619.
2186.	C SR, C AA, H MC, et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. International clinical psychopharmacology. 2007;22:348-355.
2187.	C SR, D TG, Mauricio T, et al. A novel augmentation strategy for treating resistant major depression. American journal of psychiatry. 2001;158:131-134.
2188.	C SR, J WD, A CS, et al. Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance. Journal of clinical psychiatry. 2005;66:1289-1297.
2189.	A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder, Journal of clinical psychiatry(2006).
2190.	C SR, M SS. Risperidone and Paroxetine Given Singly and in Combination for Bipolar Depression. Journal of clinical psychiatry. 2004;65:1715-1719.
2191.	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report, Journal of affective disorders(2015).
2192.	C TA, J MM, W DJ, et al. Does effective depression treatment alone reduce secondary HIV transmission risk? Equivocal findings from a randomized controlled trial. AIDS and behavior. 2013;17:2765-2772.
2193.	C VDF-C. Comorbid diabetes and depression: Do E-health treatments achieve better diabetes control? Diabetes management (London, England). 2013;3:379-388.
2194.	C WK, Marie AA. Parent Involvement in CBT Treatment of Adolescent Depression: Experiences in the Treatment for Adolescents With Depression Study (TADS). Cognitive and behavioral practice. 2005;12:209-220.
2195.	C WS. Depression - Augmentation or switch after initial SSRI treatment [2]. New England journal of medicine. 2006;354:2611-2612.
2196.	C-C H, T-P S, I-H W. Repetitive transcranial magnetic stimulation for treating medication-resistant depression in Taiwan: A preliminary study. Journal of the Chinese Medical Association. 2005;68:210-215.
2197.	C-H S, RW L. Treatment of seasonal affective disorder: Unipolar versus bipolar differences. Current psychiatry reports. 2004;6:478-485.
2198.	C-I H, C-Y L, S-J W, Y-Y J, C-H Y. Somatic Symptoms: an Important Index in Predicting the Outcome of Depression at Six-Month and Two-Year Follow-up Points Among Outpatients With Major Depressive Disorder. Journal of affective disorders. 2010;125:134-140.
2199.	C-J H, T-J C, YW-Y Y, S-J T. Response to Fluoxetine and Serotonin 1a Receptor (C-1019g) Polymorphism in Taiwan Chinese Major Depressive Disorder. Pharmacogenomics journal. 2006;6:27-33.
2200.	C-J H, W-H H, C-C C, C-C H, S-J T, FJL R. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Journal of clinical psychiatry. 2003;64:921-926.
2201.	C-L D, LE R, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane database of systematic reviews (Online). 2008.
2202.	C-S C, N-S T, H-A C, C-C C, T-Y C. Killing two birds with one stone: The potential role of aripiprazole for patients with comorbid major depressive disorder and nicotine dependence via altering brain activity in the anterior cingulate cortex. Medical hypotheses. 2014;83:407-409.
2203.	C-T L, M-H C, C-H J, et al. Efficacy of prefrontal theta-burst stimulation in refractory depression: A randomized sham-controlled study. Brain. 2014;137:2088-2098.
2204.	C-U P. Therapeutic possibility of "semax" for depression [2]. CNS spectrums. 2008;13:20-21.
2205.	C-U P. Desvenlafaxine: a new antidepressant or just another one?. [Review] [57 refs]. Expert opinion on pharmacotherapy. 2009;10:875-887.
2206.	C-U P. Curcumin as an add-on to antidepressive treatment. Clinical neuropharmacology. 2013;36:242-243.
2207.	C-U P. The potential role of scopolamine as antidepressant for mood disorder. Clinical neuropharmacology. 2014;37:67-68.
2208.	C-U P, AA P. Paroxetine: Current status in psychiatry. Expert review of neurotherapeutics. 2007;7:107-120.
2209.	C-U P, AA P, T-Y J, Lee C, PS M, I-H P. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depression and anxiety. 2007;24:522-526.
2210.	C-U P, DC M, Han C, AA P, PS M. Duloxetine: an Emerging Evidence for Fibromyalgia. Biomedicine and Pharmacotherapy. 2009;63:69-71.
2211.	C-U P, DM M, AA P, PS M, Luyten P, Serretti A. Pharmacological treatment of chronic fatigue syndrome: Focusing on the role of antidepressants. Expert opinion on pharmacotherapy. 2009;10:1561-1570.
2212.	C-U P, DM M, Shah M, et al. Milnacipran: beyond a role of antidepressant. [Review] [75 refs]. Clinical neuropharmacology. 2009;32:355-363.
2213.	C-U P, Forbes A, AA P. Aripiprazole as adjunctive therapy for patients with major depressive disorder: Overview and implications of clinical trial data. CNS drugs. 2011;25:109-127.
2214.	C-U P, H-K L, Ajwani N, Lee C, AA P. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert review of neurotherapeutics. 2007;7:603-615.
2215.	C-U P, H-K L, Han C, et al. Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion. Expert review of neurotherapeutics. 2007;7:1251-1263.
2216.	C-U P, Han C, T-Y J. Do We Need More Than One Antidepressant for Patients With Major Depressive Disorder? Expert review of neurotherapeutics. 2011;11:1561-1564.
2217.	C-U P, Luyten P, DM M, et al. The relationship between fibromyalgia and major depressive disorder: A comprehensive review. Current medical research and opinion. 2008;24:2359-2371.
2218.	C-U P, Mandelli L, T-S K, et al. Effectiveness of Antidepressant Treatments in Pre-Menopausal Versus Post-Menopausal Women: a Pilot Study on Differential Effects of Sex Hormones on Antidepressant Effects. Biomedicine and Pharmacotherapy. 2009;63:228-235.
2219.	C-U P, MS S, H-J S, et al. Quetiapine XR: Current status for the treatment of major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:1165-1173.
2220.	An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features, Primary care companion to the Journal of clinical psychiatry(2008).
2221.	C-U P, S-M W, Han C, S-J L, AA P, PS M. Quetiapine augmentation for depression: Dosing pattern in routine practice. International clinical psychopharmacology. 2014;30:54-58.
2222.	C-U P, S-M W, Han C, S-J L, AA P, PS M. Aripiprazole augmentation for major depressive disorder: Dosing patterns in a naturalistic treatment setting. International clinical psychopharmacology. 2014;29:116-119.
2223.	C-U P, S-M W, Han C, S-J L, AA P, PS M. Quetiapine augmentation for depression: Dosing pattern in routine practice. International clinical psychopharmacology. 2015;30:54-58.
2224.	C-U P, S-M W, S-Y L, S-J L. Early Switch Strategy in Patients With Major Depressive Disorder. Expert review of neurotherapeutics. 2012;12:1185-1188.
2225.	C-U P, Serretti A, AA P, PS M. Aripiprazole in the Treatment of Depressive and Anxiety Disorders: a Review of Current Evidence. CNS drugs. 2008;22:367-388.
2226.	C-U P, Tharwani H, DM M, PS M, AA P. Atypical depression: A comprehensive review. CNS drugs. 2009;23:1023-1037.
2227.	CA A, GS G, JN K. Sleep-Related Problems Among Children and Adolescents With Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:224-232.
2228.	CA B, TJ B. Tinnitus assessment and treatment: Integrating clinical experience with the basic science of tinnitus. Seminars in hearing. 2008;29:371-385.
2229.	CA C, HA A, ME T, et al. Azapirones for Generalized Anxiety Disorder. Cochrane database of systematic reviews (Online). 2006.
2230.	CA D, CJ M. Pharmacotherapy to control behavioral symptoms in children with autism. Expert opinion on pharmacotherapy. 2012;13:1615-1629.
2231.	CA D, CJ M. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues in clinical neuroscience. 2012;14:263-279.
2232.	CA D, DJ M, TL P, BD L, DV J. Psychosocial interventions and medication adherence in bipolar disorder. Dialogues in clinical neuroscience. 2008;10:239-250.
2233.	CA DML, Vandel S, Bonin B, Bechtel P, Carron R. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis]. [French]. L'Enc�phale. 1997;23:48-55.
2234.	CA E, DJ P, KA S, CJ M. Pharmacologic treatment of autism and related disorders. Pediatric annals. 2007;36:575-585.
2235.	CA F, Gartlehner G, KA B, et al. Interventions to prevent post-traumatic stress disorder: A systematic review. American journal of preventive medicine. 2013;44:635-650.
2236.	CA F, MG A. Aripiprazole for the treatment of irritability associated with autism. Expert opinion on pharmacotherapy. 2011;12:635-640.
2237.	CA G. A double blind comparison of paroxetine and fluoxetine in patients with major depression. British Journal of Clinical Research. 1993;4:145-152.
2238.	CA G. [Fluoxetine in perspective]. [Afrikaans]. South African medical journal. 1994;Suid-Afrik:361-362.
2239.	CA G. Fluoxetine in perspective. [Afrikaans]. South African medical journal. 1994;84:361-362.
2240.	CA G, PG M, Fourie J, JF LR. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta psychiatrica Scandinavica. Supplementum. 1989;350:130-131.
2241.	CA G, PGM M, Fourie J, JF LR. The therapeutic efficacy of paroxetine: (a) An open study in patients with major depression not responding to antidepressants; (b) A double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatrica Scandinavica, Supplement. 1989;80:130-131.
2242.	CA H, English C. Adverse drug events related to ziprasidone: A meta-analysis of randomized, placebo-controlled trials. Pharmacotherapy. 2011;31:840-849.
2243.	CA H, Sairally J, Starkey N. Self-medication with alcohol appears not to be an effective treatment for the control of depression. Journal of psychopharmacology (Oxford, England). 1998;12:108.
2244.	CA H, Shervin D, Neumeyer A, et al. Retrial of Selective Serotonin Reuptake Inhibitors in Children With Pervasive Developmental Disorders: a Retrospective Chart Review. Journal of child and adolescent psychopharmacology. 2009;19:111-117.
2245.	CA J-R, KO F. Smoking cessation treatment for COPD smokers: The role of counselling. Monaldi Archives for Chest Disease - Pulmonary Series. 2013;79:33-37.
2246.	CA L, AB S, Sood R. Youth with substance abuse and comorbid mental health disorders. Current psychiatry reports. 2008;10:265-271.
2247.	CA M, CF L, LT D, et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. The American Journal of Geriatric Psychiatry. 2012;20:1036-1044.
2248.	CA M, CG L. Cognitive response to sertraline treatment for depression in Alzheimer's disease: A possible sex effect. Research and practice in Alzheimer's disease. 2006;11:361-365.
2249.	CA MaL, Baumann P, Brawand-Amey M, et al. Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:952-956.
2250.	CA N, DM K, KE B. Variations in response to citalopram in men and women with alcohol dependence. Journal of psychiatry & neuroscience. 2000;25:269-275.
2251.	CA O, Fullerton G, Tan R. Male depression: A review of gender concerns and testosterone therapy. Geriatrics. 2004;59:24-30.
2252.	CA O, ME K, Molinari V, RH W. The Use and Tolerability of Fluoxetine in Geropsychiatric Inpatients. Journal of clinical psychiatry. 1996;57:12-16.
2253.	CA R, PJ S, MJ S, MA D, DL M, DR R. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. American journal of psychiatry. 2002;159:1876-1881.
2254.	CA T. Demonstrating drug action. American journal of psychiatry. 2004;161:943-945.
2255.	CA Y, JE F, DO A, Valenstein M, Matuszak J. Meta-analysis of antidepressant augmentation: Piling on in the absence of evidence. Ethical human psychology and psychiatry. 2009;11:171-182.
2256.	CA Z, JC K, Tohen M, MK W, JO C. Does Intolerance or Lack of Response With Fluoxetine Predict the Same Will Happen With Sertraline? Journal of clinical psychiatry. 1996;57:67-71.
2257.	CA Z, JL P, Singh J, et al. Pramipexole for Bipolar Ii Depression: a Placebo-Controlled Proof of Concept Study. Biological psychiatry. 2004;56:54-60.
2258.	CA Z, JL P, Singh J, et al. Pramipexole for Bipolar Ii Depression: a Placebo-Controlled Proof of Concept Study. Biological psychiatry. 2004;56:54-60.
2259.	CA ZJ, HK M. Riluzole in psychiatry: A systematic review of the literature. Expert opinion on drug metabolism & toxicology. 2008;4:1223-1234.
2260.	CA ZJ, JA Q. Combination treatment in bipolar disorder: A review of controlled trials. Bipolar disorders. 2003;5:217-225.
2261.	CA ZJ, Tohen M, RJ B. Clozapine in severe mood disorders. Journal of clinical psychiatry. 1995;56:411-417.
2262.	CAAC A. Novel approaches to treatment of generalized anxiety disorder. [Review] [42 refs]. Current opinion in psychiatry. 2010;23:37-42.
2263.	Caballero J, MC N. Selective serotonin-reuptake inhibitors and suicidal ideation and behavior in children. American journal of health-system pharmacy. 2005;62:864-867.
2264.	CABC B. Pharmacologic Treatment of Bipolar Disorder. CNS spectrums. 2010;15:10-13.
2265.	Cabello M, Mellor-Marsa B, Sabariego C, Cieza A, Bickenbach J, JL A-M. Psychosocial Features of Depression: a Systematic Literature Review. Journal of affective disorders. 2012;141:22-33.
2266.	CAC B, Holmes J, Murray J, et al. Interventions for Treating Anxiety After Stroke. Cochrane database of systematic reviews (Online). 2011.
2267.	CAC C, Dhiman P, Barton G, et al. A Study of the Safety and Harms of Antidepressant Drugs for Older People: a Cohort Study Using a Large Primary Care Database. Health technology assessment. 2011;15:1-+.
2268.	Cacabelos R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatric disease and treatment. 2007;3:303-333.
2269.	Caccia S. N-dealkylation of arylpiperazine derivatives: Disposition and metabolism of the 1-aryl-piperazines formed. Current drug metabolism. 2007;8:612-622.
2270.	Cai L, Li R, Q-Q W, T-N W. [Effect of hesperidin on behavior and HPA axis of rat model of chronic stress-induced depression]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2013;38:229-233.
2271.	Caillard V. Depressive syndromes and antidepressants. [French]. Psychiatrie et Psychobiologie. 1990;5:355-362.
2272.	Caillard V, Rouillon F, JF V, Markabi S. Comparative Effects of Low and High Doses of Clomipramine and Placebo in Panic Disorder: a Double-Blind Controlled Study. Acta psychiatrica Scandinavica. 1999;99:51-58.
2273.	CAL M, DK J. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. British journal of clinical practice. 1991;45:259-262.
2274.	CAL M, Jago W, Pownall R, CP W. Effects of dothiepin and fluoxetine on sleep and morning psychomotor function in depressed patients. European neuropsychopharmacology. 1993;3:353.
2275.	Calabrese J. Recent advances in the short-term management of bipolar disorder. European neuropsychopharmacology. 2008;Conference:S594-S595.
2276.	Calabrese J, KAN M, AH Y, Gustafsson U, Paulsson B. The efficacy of Quetiapine monotherapy in bipolar depression: Combined data from the BOLDER and EMBOLDEN studies. International journal of psychiatry in clinical practice. 2009;Conference:36-37.
2277.	Calabrese JR, Rapport DJ, Kimmel SE, Shelton MD. Controlled trials in bipolar I depression: Focus on switch rates and efficacy. European neuropsychopharmacology. 1999;9:S109-S112.
2278.	Calandra C, Terranova F, Loiacono P, et al. Bupropion in the treatment of major depressive disorder: A comparison with paroxetine. [Italian]. Giornale Italiano di Psicopatologia / Italian Journal of Psychopathology. 2010;16:128-133.
2279.	Calarge C, Kuperman S, GJ E, Nilsson M, Jacobson J, Heiligenstein J. Fluoxetine for depression relapse prevention [2] (multiple letters). Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:966-968.
2280.	CALC-H L. Duloxetine Related Hypersexuality: a Case Report. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:414-415.
2281.	Caldirola D, Dacco S, Grassi M, et al. Effects of cigarette smoking on neuropsychological performance in mood disorders: A comparison between smoking and nonsmoking inpatients. Journal of clinical psychiatry. 2013;74:e130-e136.
2282.	Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline affects subjective sleep quality in major depressive disorder. Sleep medicine. 2005;6:555-559.
2283.	Callari A, Mauri M, Miniati M, et al. Treatment of depression in patients with breast cancer: a critical review. [Review]. Tumori. 2013;99:623-633.
2284.	Callista G, Daneluzzo E. Combined antidepressant and quetiapine therapy in Bipolar I mixed - An open label study. European neuropsychopharmacology. 2008;Conference:S364-S365.
2285.	Callista G, Daneluzzo E. Effects of Duloxetine adjunctive to extendedrelease Quetiapine treatment in Bipolar I mixed - An open label study. International journal of psychiatry in clinical practice. 2009;Conference:25-26.
2286.	Callista G, Daneluzzo E. Combined antidepressant and quetiapine therapy in bipolar I mixed - One-year follow up. European neuropsychopharmacology. 2010;Conference:S409-S410.
2287.	Caltagirone C, Bianchetti A, M DL, et al. Guidelines for the treatment of Alzheimer's disease from the Italian association of psychogeriatrics. Drugs & aging. 2005;22:1-26.
2288.	CAM-WC M-W. Developmental Aspects of Depressive Disorders. Nervenheilkunde. 2012;31:515-523.
2289.	CAMC S, YA H, R WC, TB V. Do antidepressive drugs reduce pain? A literature analysis and critical evaluation. [Dutch]. Pharmaceutisch weekblad. 1994;129:655-659.
2290.	Cameron K, Yuting Z. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population. Journal of mental health policy and economics. 2012;15:171-178.
2291.	Camille WV. Marital status, subtypes and correlates of depression, and response to antidepressant treatment. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008;68:6343.
2292.	Camilleri M. Management of patients with chronic abdominal pain in clinical practice. Neurogastroenterology and motility. 2006;18:499-506.
2293.	Camilleri V, Mauri M. Quetiapine in the treatment of bipolar depression. [Italian]. Italian Journal of Psychopathology. 2005;11:483-493.
2294.	Campbell M, JE C. Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. [Review] [138 refs]. Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34:1262-1272.
2295.	Canavero S, Bonicalzi V, Paolotti R. Reboxetine for central pain: A single-blind prospective study. Clinical neuropharmacology. 2002;25:238-239.
2296.	Candy B, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane database of systematic reviews (Online). 2008.
2297.	Cantrell R, Gillespie W, Altshuler L. Fluoxetine and sertraline dosages in major depression. Depression and anxiety. 1999;9:78-82.
2298.	Cao H, Li X, Han M, Liu J. Acupoint stimulation for fibromyalgia: A systematic review of randomized controlled trials. Evidence-based Complementary and Alternative Medicine. 2013.
2299.	Capaci K, Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clinic. 2002;14:223-228.
2300.	CAPC-U P. Desvenlafaxine in the treatment of major depressive disorder. [Review]. Expert opinion on pharmacotherapy. 2011;12:2923-2928.
2301.	CAPC-U P. Early Versus Conventional Switching of Antidepressant: a Post-Hoc Analysis of Clinical Trial Data for Major Depressive Disorder With Moderate to Severe Pain Symptoms. Expert opinion on pharmacotherapy. 2012;13:2711-2715.
2302.	CAPC-U P. Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder. Expert review of neurotherapeutics. 2014;14:5-8.
2303.	Capehart B, Bass D. Review: Managing posttraumatic stress disorder in combat veterans with comorbid traumatic brain injury. Journal of rehabilitation research and development. 2012;49:789-812.
2304.	Caplan R. Comments on Hankin BL. Adolescent depression: Description, causes, and interventions. Epilepsy & Behavior 2006;8:102-114. Epilepsy & behavior. 2014;40:32-36.
2305.	Capuron L, AH M. Cytokines and Psychopathology: Lessons From Interferon-Alpha. Biological psychiatry. 2004;56:819-824.
2306.	Capuron L, AH M. Cytokines and Psychopathology: Lessons From Interferon-Alpha. Biological psychiatry. 2004;56:819-824.
2307.	Capuron L, FB F, BT K, PD H, PT N, AH M. Does Cytokine-Induced Depression Differ From Idiopathic Major Depression in Medically Healthy Individuals? Journal of affective disorders. 2009;119:181-185.
2308.	Capuron L, Hauser P, Hinze-Selch D, AH M, PJ N. Treatment of cytokine-induced depression. Brain, behavior, and immunity. 2002;16:575-580.
2309.	Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets. European journal of pharmacology. 2010;626:64-71.
2310.	Carandang C, Jabbal R, MacBride A, Elbe D. A Review of Escitalopram and Citalopram in Child and Adolescent Depression. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2011;20:315-324.
2311.	Carandang C, Santor D, DM G, Carrey N, Kutcher S. Data safety monitoring boards and other study methodologies that address subject safety in "high-risk" therapeutic trials in youths. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:489-492.
2312.	Caravaggio F, DM B, Nakajima S, BH M, Graff-Guerrero A. Occupancy of dopamine D3 receptors by aripiprazole in treatment resistant late-life depressed patients depends on length of treatment as evidenced by in vivo imaging with [11C]-(+)-PHNO. American journal of geriatric psychiatry. 2014;Conference:S83-S84.
2313.	Cardamone L, MR S, AS K, Ozturk E, TJ OB, NC J. Chronic antidepressant treatment accelerates kindling epileptogenesis in rats. Neurobiology of disease. 2014;63:194-200.
2314.	Cardona D. Pharmacological Therapy of Cancer Anorexia-Cachexia. Nutricion hospitalaria. 2006;21:17-26.
2315.	Cardoso F. Huntington Disease and Other Choreas. Neurologic clinics. 2009;27:719-736.
2316.	Carl H. An open-label pilot study of fluvoxamine for mixed anxiety-depression. Psychopharmacology bulletin. 1998;34:225-227.
2317.	Carl S, David J, Russell V, Eric W, Jennifer G. Response to SSRI antidepressants correlates with reduction in plasma HVA: Pilot study. Biological psychiatry. 1993;34:569-571.
2318.	Carl S, N WA, Alan S, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of clinical psychopharmacology. 1995;15:23-29.
2319.	Carlat D. Evidence-based somatic treatment of depression in adults. [Review]. Psychiatric clinics of North America. 2012;35:131-142.
2320.	Carlo AA, A MS, Wernicke JF. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. The British Journal of Psychiatry. 1988;153:109-112.
2321.	Carlo AA, Bernardo DO, Massimiliano B, Monica B, Emanuela M. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: A randomized placebo-controlled study. International clinical psychopharmacology. 2008;23:198-202.
2322.	Carlo AA, Bernardo DO, Massimiliano B, Silvia Z, Emanuela M. Intravenous Augmentative Citalopram Versus Clomipramine in Partial/Nonresponder Depressed Patients - a Short-Term, Low Dose, Randomized, Placebo-Controlled Study. Journal of clinical psychopharmacology. 2008;28:406-410.
2323.	Carlo C, Rekha J, Angela M, Dean E. A review of escitalopram and citalopram in child and adolescent depression. Journal of the Canadian Academy of Child and Adolescent Psychiatry / Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent. 2011;20:315-414.
2324.	Carlo L, Claudio A, Carlo G. Fluoxetine versus imipramine. International clinical psychopharmacology. 1989;4 Suppl 1:75-79.
2325.	Carlo M, Ceccherininelli A, Rossi A, Maggini C. Is anxious-agitated major depression responsive to fluoxetine? A double- blind comparison with amitriptyline. Pharmacopsychiatry. 1998;31:216-221.
2326.	Carlos A, Isabel C, Jose B. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry. 1999;5:57-63.
2327.	Carlos B, Beatriz A, Gerardo H, et al. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. Salud mental (Mexico City, Mexico). 1997;20:1-8.
2328.	Carlos B, Danelia M, Guadalupe A, Maria DCL. Failure of Tibolone to Potentiate the Pharmacological Effect of Fluoxetine in Postmenopausal Major Depression. Journal of women's health (2002). 2003;12:33-39.
2329.	Carlos B, Monica F-R. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Journal of affective disorders. 2006;95:119-123.
2330.	Carney C. Diabetes mellitus and major depressive disorder: An overview of prevalence, complications, and treatment. Depression and anxiety. 1998;7:149-157.
2331.	Carney C. Treating insomnia in those with depression: A randomized controlled trial. Sleep. 2014;Conference:A175.
2332.	Carol M, Gary K, I CC, David G. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. The American Journal of Geriatric Psychiatry. 2000;8:66-74.
2333.	Caroli F, Baldacci-Epinette C, Ribeyre P. [Antidepressant treatment of schizophrenic patients]. [Review] [22 refs] [French]. Encephale. 1993;19 Spec No:393-396.
2334.	Caroli F, Baldacci-Epinette C, Ribeyre P. Depression and schizophrenia. [French]. Encephale. 1993;19:393-396.
2335.	Carota A. Poststroke depression: Certainties and uncertainties. Schweizer Archiv fur Neurologie und Psychiatrie. 2006;157:186-187.
2336.	Carpiniello B, MG C. Quality of life and depression: Methodological problems and impact of treatments. [Italian]. Italian Journal of Psychopathology. 2004;10:199-207.
2337.	Carr A. Depression in young people: Description, assessment and evidence-based treatment. Developmental neurorehabilitation. 2008;11:3-15.
2338.	Carrillo-Roa T, CL M, AS Z, et al. Polygenic predictors of antidepressant treatment-specific response. Biological psychiatry. 2015;Conference:222S.
2339.	Carroll S, Hides L, Catania L, Mathias S, Greenwood-Smith C, Lubman D. Integrated Cognitive Behaviour Therapy for Co-Occurring Substance Misuse and Major Depression: Lessons From a Youth Mental Health Service. Australasian psychiatry. 2009;17:365-370.
2340.	Carvalho L, MF J, AS P, Poon L, AJ C, CM P. Four days of citalopram increase in vitro glucocorticoid receptor function in healthy volunteers. European neuropsychopharmacology. 2009;Conference:S399.
2341.	Carvalho LA, Gorenstein C, Moreno R, Pariante C, Markus RP. Effect of antidepressants on melatonin metabolite in depressed patients. Journal of psychopharmacology (Oxford, England). 2009;23:315-321.
2342.	Casamassima F, AC H, Benedetti A, Lattanzi L, GB C, RH P. L-type calcium channels and psychiatric disorders: A brief review. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2010;153:1373-1390.
2343.	Casamassima F, Fava M, GB C, Clain A, MS CK, RH P. Predictive value of bipolar-spectrum clinical features in a large cohort of fluoxetine treated patients with major depressive disorder. Bipolar disorders. 2011;Conference:34.
2344.	Casamassima F, Huang J, Fava M, et al. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2010;153B:303-309.
2345.	Casamassima F, Huang J, Fava M, et al. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. American journal of medical genetics. 2010;Part B, Ne:the Official Publication of the International Soci.
2346.	Casciano J, Arikian S, J-E T, JJ D, Casciano R. A pharmacoeconomic evaluation of major depressive disorder (Italy). Epidemiologia e psichiatria sociale. 1999;8:220-231.
2347.	Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: A multinational study. International journal of clinical practice. 2001;55:292-299.
2348.	Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Managed care interface. 2003;Suppl B:16-21.
2349.	Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Managed care interface. 2003;16:16-21.
2350.	Casey C, L-M C, MW R. Symptom management in gynecologic malignancies. Expert review of anticancer therapy. 2011;11:1077-1089.
2351.	Cass H. Natural remedies for treating depression. Alternative and Complementary Therapies. 2007;13:199-206.
2352.	Cassano P, CN S, Cusin C, Mascarini A, LS C, Fava M. Antidepressant Response and Well-Being in Pre-, Peri- and Postmenopausal Women With Major Depressive Disorder Treated With Fluoxetine. Psychotherapy and psychosomatics. 2005;74:362-365.
2353.	Cassano P, CN S, Cusin C, Mascarini A, LS C, Fava M. Antidepressant Response and Well-Being in Pre-, Peri- and Postmenopausal Women With Major Depressive Disorder Treated With Fluoxetine. Psychotherapy and psychosomatics. 2005;74:362-365.
2354.	Cassano P, Lattanzi L, MI F, et al. Ropinirole in Treatment-Resistant Depression: a 16-Week Pilot Study. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:357-360.
2355.	Cassano P, Lattanzi L, MI F, et al. Ropinirole in Treatment-Resistant Depression: a 16-Week Pilot Study. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:357-360.
2356.	Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in Treatment-Resistant Depression: an Extended Follow-up. Depression and anxiety. 2004;20:131-138.
2357.	Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in Treatment-Resistant Depression: an Extended Follow-up. Depression and anxiety. 2004;20:131-138.
2358.	Cassidy F. Antidepressant treatment practice in the face of STAR*D and STEP-BD. Bipolar disorders. 2008;10:973-974.
2359.	Castanheira L, Fresco P, AF M. Guidelines for the management of chronic medication in the perioperative period: Systematic review and formal consensus. Journal of clinical pharmacy and therapeutics. 2011;36:446-467.
2360.	Castano J, Garnier C, Corcoles D, et al. Efficacy of duloxetine in painful symptoms with major depressive disorder. European neuropsychopharmacology. 2008;Conference:S298-S299.
2361.	Castiel M, WJ G, PJ D. Management of menopausal symptoms in the cancer patient. Oncology. 1999;13:1363-1383.
2362.	Castren E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry. 2013;70:983-989.
2363.	Castren E, Rantamaki T. Role of brain-derived neurotrophic factor in the aetiology of depression: Implications for pharmacological treatment. CNS drugs. 2010;24:1-7.
2364.	Catalano G, SM H, MC C. Sertraline-Induced Panic Attacks. Clinical neuropharmacology. 2000;23:164-168.
2365.	Catapano F, Perris F, Masella M, et al. Obsessive-Compulsive Disorder: a 3-Year Prospective Follow-up Study of Patients Treated With Serotonin Reuptake Inhibitors Ocd Follow-up Study. Journal of psychiatric research. 2006;40:502-510.
2366.	Catena-Dell'Osso M, Marazziti D, Rotella F, Bellantuono C. Emerging targets for the pharmacological treatment of depression: Focus on melatonergic system. Current medicinal chemistry. 2012;19:428-437.
2367.	Catena-Dell'Osso M, Rotella F, Dell'Osso A, Fagiolini A, Marazziti D. Inflammation, Serotonin and Major Depression. Current drug targets. 2013;14:571-577.
2368.	Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. International journal of neuropsychopharmacology. 2010;13:103-108.
2369.	Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology. 2013;38:377-385.
2370.	Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology. 2013;38:377-385.
2371.	Cavazzuti E, Bertolini A, AV V, et al. L-Sulpiride, at a Low, Non Neuroleptic Dose, Prevents Conditioned Fear Stress Induced Freezing Behavior in Rats. Psychopharmacology. 1999;143:20-23.
2372.	CB B. Traumatized refugees: morbidity, treatment and predictors of outcome. [Review]. Danish medical journal. 2014;61:B4871.
2373.	CB B. Traumatized refugees: Morbidity, treatment and predictors of outcome. Danish Medical Journal. 2014.
2374.	CB B, Tweedie R, Duval S, SW W. Evidence that the SSRI dose response in treating major depression should be reassessed: A meta-analysis. Depression and anxiety. 2003;17:1-9.
2375.	CB M. Recognition and Treatment of Depression in a Primary-Care Setting. Journal of clinical psychiatry. 1994;55:18-34.
2376.	CB N. Paroxetine - an Overview of the Efficacy and Safety of a New Selective Serotonin Reuptake Inhibitor in the Treatment of Depression. Journal of clinical psychopharmacology. 1993;13:S10-S17.
2377.	CB N. Evolutionary Trends in the Pharmacotherapeutic Management of Depression. Journal of clinical psychiatry. 1994;55:3-15.
2378.	CB N. Evolutionary trends in the pharmacotherapeutic management of depression. [Review] [78 refs]. Journal of clinical psychiatry. 1994;55 Suppl:3-7.
2379.	CB N. Progress in the battle with the black dog: Advances in the treatment of depression. American journal of psychiatry. 2001;158:1555-1557.
2380.	CB N. New directions in the development of antidepressants: The interface of neurobiology and psychiatry. Human psychopharmacology. 2002;17:S13-S16.
2381.	CB N. Improving antidepressant adherence. [Review] [26 refs]. Journal of clinical psychiatry. 2003;64 Suppl 1:25-30.
2382.	CB N. Use of Atypical Antipsychotics in Refractory Depression and Anxiety. Journal of clinical psychiatry. 2005;66:13-21.
2383.	CB N. Use of atypical antipsychotics in refractory depression and anxiety. [Review] [66 refs]. Journal of clinical psychiatry. 2005;66 Suppl 8:13-21.
2384.	CB N. Prevalence and management of treatment-resistant depression. Journal of clinical psychiatry. 2007;68:17-25.
2385.	CB N. Psychopharmacology and the future of personalized treatment. Depression and anxiety. 2014;31:906-908.
2386.	CB N, ME T, Group ES. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Journal of psychiatric research. 2007;41:351-359.
2387.	CB N, PJ G-C. Heartache and heartbreak-the link between depression and cardiovascular disease. Nature reviews. Cardiology. 2012;9:526-539.
2388.	CB N, PT N, Ballenger J, et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression. 1995;3:163-169.
2389.	CB S, Reichmann H. Treatment of depression in Parkinson's disease. [German]. Arzneimitteltherapie. 2009;27:383-387.
2390.	CB T, ME Y, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Archives of general psychiatry. 2005;62:792-798.
2391.	CC H, CW C, CH P, CS L. Rapid Management of Trigeminal Neuralgia and Comorbid Major Depressive Disorder With Duloxetine. Annals of pharmacotherapy. 2014;48:1090-1092.
2392.	CC H, IS S, HK C, WC M, YW Y. Adjunctive Use of Methylphenidate in the Treatment of Psychotic Unipolar Depression. Clinical neuropharmacology. 2008;31:245-247.
2393.	CC H, JE B. Sleepiness and Fatigue in Patients with Psychiatric Disorders. Sleep medicine clinics. 2008;3:205-215.
2394.	CC L, DM M. Non-cardiac comorbidities in chronic heart failure. Heart (British Cardiac Society). 2007;93:665-671.
2395.	CC M, JC P, CA M, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004;29:2258-2265.
2396.	CC R. The Importance of Nutrition as the Best Medicine for Eating Disorders. Explore: The Journal of Science and Healing. 2007;3:153-157.
2397.	CC S-M, H-H A. Care of depressive patients in general practice: How, why and with how much success? A systematic review. [German]. Zeitschrift fur Allgemeinmedizin. 2008;84:327-335.
2398.	CC W. Neo-psychoanalysis: A paradigm for the 21st century. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry. 2006;34:603-627.
2399.	CC W, GJ T. Cognitive impairment in patients with Aids - Prevalence and severity. HIV/AIDS - Research and Palliative Care. 2015;7:35-47.
2400.	CCJr E, EA W, AL E, Bullis J, Armstrong A. A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. Journal of psychosomatic research. 1998;44:203-207.
2401.	CD A. Antidepressants: Update on benefits and risks. Current Psychopharmacology. 2012;1:203-213.
2402.	CD B, KL A, DA M. Milnacipran for Fibromyalgia: a Useful Addition to the Treatment Armamentarium. Expert opinion on pharmacotherapy. 2013;14:905-916.
2403.	CD C, Hernandez-Diaz S, LJ VM, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England journal of medicine. 2006;354:579-587.
2404.	CD H, AH C. Sertraline in the Treatment of Panic Disorder. Drugs of today (Barcelona, Spain : 1998). 2009;45:351-361.
2405.	CD K, AG W, HF A, TE S. Baseline Severity of Depression Predicts Antidepressant Drug Response Relative to Escitalopram. Expert opinion on pharmacotherapy. 2009;10:927-936.
2406.	CD M, CWP H, WR B-J. Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease. Movement disorders. 2014;29:1556-1561.
2407.	CD M, Jr WJW, Trivedi M, et al. Evidence report on: Treatment of depression - Newer pharmacotherapies. Psychopharmacology bulletin. 1998;34:409-795.
2408.	CD M, JW WJ, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. American journal of medicine. 2000;108:54-64.
2409.	CD M, Walter M, Graf H, Abler B. SSRI-related modulation of sexual functioning is predicted by pre-treatment resting state functional connectivity in healthy men. Archives of sexual behavior. 2013;42:935-947.
2410.	CD R, DM L, CT N, JTD R. Efficacy of Exercise in Reducing Depressive Symptoms Across 5-Httlpr Genotypes. Medicine and science in sports and exercise. 2010;42:2141-2147.
2411.	Rationale and Design of a Randomised, Controlled, Multicenter Trial Investigating the Effects of Selective Serotonin Re-Uptake Inhibition on Morbidity, Mortality and Mood in Depressed Heart Failure Patients (Mood-Hf), European journal of heart failure(2007).
2412.	CE C, ZV S, JD E, AD K. A Comparison of Rates of Residual Insomnia Symptoms Following Pharmacotherapy or Cognitive-Behavioral Therapy for Major Depressive Disorder. Journal of clinical psychiatry. 2007;68:254-260.
2413.	CE D. The Use of Herbs and Dietary Supplements in Gynecology:An Evidence-Based Review. Journal of midwifery & women's health. 2006;51:402-409.
2414.	CE D. Psychopharmacology: A house divided. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:1-10.
2415.	CE F, MC W, MM W, et al. Remission of maternal depression: Relations to family functioning and youth internalizing and externalizing symptoms. Journal of clinical child and adolescent psychology. 2008;37:714-724.
2416.	CE LF, RZ L, CL R, DH M, IM S, AI G. Pharmacological Treatment of Alcohol Abuse/Dependence with Psychiatric Comorbidity. Alcoholism, clinical and experimental research. 2004;28:302-312.
2417.	CE N, LR D. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. [Review] [43 refs]. Annals of pharmacotherapy. 2001;35:1608-1613.
2418.	CE OC, AV R, Majumdar B. Violence in older people with mental illness. Advances in Psychiatric Treatment. 2010;16:339-348.
2419.	CE R, AJ F, Clenet F, Hascoet M, Bourin M. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology. 2001;159:42-50.
2420.	CE R, Coli E, Marazziti D, et al. Therapeutic options for binge eating disorder. [Review]. Eating & Weight Disorders: EWD. 2013;18:3-9.
2421.	CEB D, JRM D, Broocks A. How reliably can general practitioners diagnose depression using ICD-10 criteria? German Journal of Psychiatry. 2008;11:146-148.
2422.	Celik C, Ozdemir B, KN O, et al. Efficacy of Paroxetine and Amitriptyline in Posttraumatic Stress Disorder: an Open-Label Comparative Study. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2011;21:179-185.
2423.	Cengiz A, Asli S, Yusuf SE, Bengi Y, Selcuk K. Comparison of effects of sertraline-reboxetine combination and venlafaxine on the loss of social functioning in major depressive disorder: A randomized, open-labeled study. [Turkish]. Yeni Symposium: psikiyatri, noroloji ve davranis bilimleri dergisi. 2007;45:28-34.
2424.	Cengiz A, Selcuk K, Saygin ES, Sengul C, Mustafa C, Asli S. Comparison of the efficacy and safety of sertraline, reboxetine, and venlafaxine in patients with major depressive disorder: A pooled analysis of four randomized, open-label trials. Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology. 2010;20:274-287.
2425.	Cengiz A, Yusuf SE, Semra A, Saygin ES, Selcuk K. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study. Human Psychopharmacology: Clinical and Experimental. 2006;21:337-345.
2426.	Cengiz B, Alpay AM, Ayhan A, et al. Adjuvant folate with escitalopram treatment and homocystein, folate, vitamin B-12 levels in patients with major depressive disorder. Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology. 2009;19:135-142.
2427.	Centorrino F, SL C, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Comprehensive psychiatry. 2008;49:65-69.
2428.	Ceravolo R, Rossi C, Kiferle L, Bonuccelli U. Nonmotor symptoms in Parkinsons disease: The dark side of the moon. Future neurology. 2010;5:851-871.
2429.	Cerda P, Cervell� E, Cocca A, Viciana J. Effect of an aerobic training program as complementary therapy in patients with moderate depression. Perceptual and motor skills. 2011;112:761-769.
2430.	Cervera-Enguix S, Baca-Baldomero E, Garcia-Calvo C, Prieto-Lopez R. Depression in Primary Care: Effectiveness of Venlafaxine Extended-Release in Elderly Patients - Observational Study. Archives of gerontology and geriatrics. 2004;38:271-280.
2431.	Cervera-Enguix S, Baca-Baldomero E, Garcia-Calvo C, Prieto-Lopez R. Depression in Primary Care: Effectiveness of Venlafaxine Extended-Release in Elderly Patients - Observational Study. Archives of gerontology and geriatrics. 2004;38:271-280.
2432.	Ceskova E. The pitfalls of long-term treatment of depression. Homeostasis in health and disease. 2000;40:76-83.
2433.	Cetin M, Aricioglu F, CH A, Kilic S. Today's psychopharmacological treatments: Results, problems, new perspectives. Klinik Psikofarmakoloji Bulteni. 2012;22:198-204.
2434.	Cetin M, Tarhan N, ME C, Burkovik Y. A double-blind comparison of the effects and side-effects of fluoxetine and placebo in the treatment of depression. [Turkish]. Bulletin of Gulhane Military Medical Academy. 1994;36:170-173.
2435.	CF B, Hosey A, Coello J. Bipolar depression: An evidence-based approach. Current psychiatry reports. 2011;13:483-487.
2436.	CF B, RH P. Treatment of Bipolar Depression. CNS spectrums. 2003;8:1-11.
2437.	CF B, SM D, Littman L, MA L. What Drugs Are Best for Bipolar Depression? Annals of clinical psychiatry. 2003;15:225-232.
2438.	CF C. The use of SSRIs in depressed patients with Parkinson's disease [2]. Irish journal of psychological medicine. 1998;15:41-42.
2439.	CF C, SS W. Paroxetine: a selective serotonin reuptake inhibiting antidepressant. [Review] [63 refs]. Annals of pharmacotherapy. 1993;27:1212-1222.
2440.	CF R, GS S, MA D, et al. Accelerating Symptom-Reduction in Late-Life Depression - a Double-Blind, Randomized, Placebo-Controlled Trial of Sleep Deprivation. American journal of geriatric psychiatry. 2005;13:353-358.
2441.	CF S, Bitsika V. Differences in neurobiological pathways of four "clinical content" subtypes of depression. Behavioural brain research. 2013;256:368-376.
2442.	CF Z. Selective serotonin re-uptake inhibitors for children and adolescents. European child & adolescent psychiatry. 2000;9:I20-I26.
2443.	CG A, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. Journal of ECT. 2012;28:157-161.
2444.	CG B, Gauthier S, JL C, et al. Management of agitation and aggression associated with alzheimer disease. Nature reviews. Neurology. 2009;5:245-255.
2445.	CG B, Singh V, PM T. Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders. Expert opinion on drug safety. 2008;7:435-445.
2446.	CG D, AM C, SM C, et al. The Addition of Fluoxetine to Cognitive Behavioural Therapy for Youth Depression (Yoda-C): Study Protocol for a Randomised Control Trial. Trials. 2014;15.
2447.	CG G. Depression in the elderly: Treatment strategies. Nordic Journal of Psychiatry, Supplement. 1993;47:75-81.
2448.	CG G. Scandinavian experience with citalopram in the elderly. International clinical psychopharmacology. 1996;11:41-44.
2449.	CG G. Recognition and management of depression in the elderly. [Review] [16 refs]. International clinical psychopharmacology. 1997;12 Suppl 7:S31-36.
2450.	CG G. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Movement disorders. 2010;25:S104-S109.
2451.	Initial management of Parkinson's disease, BMJ (Online)(2014).
2452.	CG G, RR W. A Double-Blind, Placebo-Controlled Trial of the Effect of Fluoxetine on Dietary Intake in Overweight Women With and Without Binge-Eating Disorder. American journal of clinical nutrition. 1996;64:267-273.
2453.	CG G, WC K, Poewe W, et al. Treatment of depression in idiopathic Parkinson's disease. Movement disorders. 2002;17:S112-S119.
2454.	CG L. The interface between depression and dementia: Where are we with this important frontier? American journal of geriatric psychiatry. 2010;18:95-97.
2455.	CG L, MC C, JM R, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's & dementia. 2011;7:532-539.
2456.	CG L, Weiller E, Katona C, Gorwood P. Are Old-Old Patients With Major Depression More Likely to Relapse Than Young-Old Patients During Continuation Treatment With Escitalopram? BMC geriatrics. 2011;11.
2457.	CG L, Weiller E, Katona C, Gorwood P. Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram? BMC geriatrics. 2011;11:2.
2458.	CG M, Jannini E, Waldinger M, Rowland D. Standard Operating Procedures in the Disorders of Orgasm and Ejaculation. Journal of sexual medicine. 2013;10:204-229.
2459.	CG N, MPM B, NZ Z, NJ DW. The prevalence and pharmacotherapy of depression in cancer patients. Journal of affective disorders. 2011;131:1-7.
2460.	CG O, Paradiso S, RG R. Gender differences in depression associated with neurologic illness: Clinical correlates and pharmacologic response. Journal of gender-specific medicine. 2001;4:65-72.
2461.	CH B. Venlafaxine XR for depression and pain in spinal cord injury: Major outcomes. Journal of spinal cord medicine. 2013;Conference:551.
2462.	CH B, JR F, CS W, et al. A Randomized Controlled Trial of Venlafaxine Xr for Major Depressive Disorder After Spinal Cord Injury: Methods and Lessons Learned. Journal of spinal cord medicine. 2014;37:247-263.
2463.	CH K, GS W, ND R, et al. A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry. 1996;35:1139-1144.
2464.	CH K, LS L, Nazarian R, et al. Efficacy of right unilateral ultrabrief pulse electroconvulsive therapy (ECT): Data from phase 1 of the pride study. American journal of geriatric psychiatry. 2013;Conference:S131.
2465.	CH L, BG P, CG L, et al. Population pharmacokinetic modeling of sertraline treatment in patients with alzheimer disease : The DIADS-2 study. Journal of clinical pharmacology. 2013;53:234-239.
2466.	CH L, CC C, Wong J, RS M. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. Journal of affective disorders. 2014;161:123-126.
2467.	CH L, HY L, CC C, SHH J, CF Y. Pain Has a Strong Negative Impact on the Fluoxetine Response in Hospitalized Patients With Major Depressive Disorder. Clinical journal of pain. 2011;27:805-810.
2468.	CH L, HY L, CC C, SHH J, CF Y. Early Prediction of Fluoxetine Response for Han Chinese Inpatients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2011;31:187-193.
2469.	CH L, MJ L, Wong J, CC C. Comparison of Physician-Rating and Self-Rating Scales for Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2014;34:716-721.
2470.	CH M, AL M, Prakash A, DE F, MJ D. Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacology bulletin. 2007;40:101-114.
2471.	CH M, JG W, CF L, MM W, Raskin J. Duloxetine in the Treatment of Major Depressive Disorder: a Comparison of Efficacy in Patients With and Without Melancholic Features. BMC psychiatry. 2005;5.
2472.	CH M, JG W, Liu C, MM W, Raskin J. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. BMC psychiatry. 2005;5:1.
2473.	CH M, Lin Q, Lipkovich I, Molenberghs G. A Structured Approach to Choosing Estimands and Estimators in Longitudinal Clinical Trials. Pharmaceutical statistics. 2012;11:456-461.
2474.	CH M, MJ D, WR P, SJ R, Molenberghs G. Considerations for Comparing a Test Drug With Standard of Care in Phase 2 Clinical Trials of Central Nervous System Disorders. Drug information journal. 2010;44:443-452.
2475.	CH M, MJ D, WR P, SJ R, Molenberghs G. Considerations for Using Positive Controls in Phase 2 Clinical Trials of Central Nervous System Disorders. Drug information journal. 2010;44:431-441.
2476.	CH M, MJ D, WR P, SJ R, Molenberghs G. Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders. Drug information journal. 2010;44:421-430.
2477.	CH M, Raskin J, MM W, JG W, MJ D. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC psychiatry. 2004;4:26.
2478.	CH M, Raskin J, MM W, JG W, MJ D. The Efficacy of Duloxetine: a Comprehensive Summary of Results From Mmrm and Locf_Ancova in Eight Clinical Trials. BMC psychiatry. 2004;4.
2479.	CH S. Current immunomodulatory therapies for multiple sclerosis. Formulary (Cleveland, Ohio). 2004;39:4-10.
2480.	Chabrol H, Callahan S. Prevention and treatment of postnatal depression. Expert review of neurotherapeutics. 2007;7:557-576.
2481.	Chadi C, Samuel K. Fluoxetine For Depression Relapse Prevention. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:966-967.
2482.	Chaichan W. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry and clinical neurosciences. 2004;58:364-368.
2483.	Chakos M, JK P, Rosenheck R, et al. Concomitant psychotropic medication use during treatment of schizophrenia patients: Longitudinal results from the CATIE study. Clinical schizophrenia & related psychoses. 2011;5:124-134.
2484.	Chakraborty K, Basu D. Management of anorexia and bulimia nervosa: An evidence-based review. Indian journal of psychiatry. 2010;52:174-186.
2485.	Chalon S, Pereira A, Lainey E, et al. Comparative Effects of Duloxetine and Desipramine on Sleep Eeg in Healthy Subjects. Psychopharmacology. 2005;177:357-U355.
2486.	Chalon S, Pereira A, Lainey E, et al. Comparative Effects of Duloxetine and Desipramine on Sleep Eeg in Healthy Subjects. Psychopharmacology. 2005;177:357-U355.
2487.	Chambers C, Moses-Kolko E, KL W. Antidepressant use in pregnancy: New concerns, old dilemmas. Expert review of neurotherapeutics. 2007;7:761-764.
2488.	The future of psychopharmacology of depression, Journal of clinical psychiatry(2010).
2489.	Chang V, Gonzalez P, Akuthota V. Evidence-informed management of chronic low back pain with adjunctive analgesics. Spine journal. 2008;8:21-27.
2490.	Changsu H, Sheng-Min W, Masaki K, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. [Review]. Expert review of neurotherapeutics. 2013;13:851-870.
2491.	Chantal M, Mike B. Antidepressants in the treatment of fibromyalgia. Neuropsychiatric disease and treatment. 2006;2:537-548.
2492.	Chaplin S, Krishnadas R. Properties and use of SSRIs for depressive disorders. Prescriber. 2014;25:24-26.
2493.	The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial, BMC psychiatry(2008).
2494.	Charakida M, Finer N. Drug treatment of obesity in cardiovascular disease. American journal of cardiovascular drugs. 2012;12:93-104.
2495.	Charles D, Brent SH, Jennifer P, Ellen K, F SA. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. Journal of clinical psychopharmacology. 2003;23:27-30.
2496.	Charles D, Gustavo K, Daniel H, et al. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. Journal of psychiatric research. 2011;45:64-75.
2497.	Charles F. Effect of fluoxetine on the electrocardiogram. Journal of clinical psychiatry. 1985;46:42-44.
2498.	Charles M, Anita H, Andrew H. Depressing research: Comment. Lancet. 2004;363:2087.
2499.	Charles S, Richard E, Krishna PS, E VP. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. International clinical psychopharmacology. 2005;20:233-238.
2500.	Charyton C, JO E, JL M, ET K. Is it time to consider cognitive behavioral therapy for persons with epilepsy? Clues from pathophysiology, treatment and functional neuroimaging. Expert review of neurotherapeutics. 2010;10:1911-1927.
2501.	Chatterjee A, Fayyad R. Efficacy of venlafaxine compared with Selective Serotonin Reuptake Inhibitors (SSRI) in severe Major Depressive Disorder (MDD): A retrospective pooled analysis. European psychiatry. 2012.
2502.	Chaudhari K, Khanzode S, Dakhale G, Saoji A, Sarode S. Clinical correlation of alteration of endogenous antioxidant-uric acid level in major depressive disorder. Indian journal of clinical biochemistry. 2010;25:77-81.
2503.	Chavda N, ND K, Jaykaran. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. Journal of pharmacology & pharmacotherapeutics. 2011;2:11-16.
2504.	Chavez B, Chavez-Brown M, MA SJ, JA R. Atypical antipsychotics in children with pervasive developmental disorders. Pediatric Drugs. 2007;9:249-266.
2505.	Chavez-Leon E. Pharmacological treatment of the bipolar disorder, depressive phase (bipolar depression). Part II. [Spanish]. Salud mental (Mexico City, Mexico). 2004;27:8-16.
2506.	Chavez-Leon E. Pharmacological treatment of the bipolar disorder, depressive phase (bipolar depression). First part. [Spanish]. Salud mental (Mexico City, Mexico). 2004;27:33-43.
2507.	Check E. Trial analysis questions use of antidepressants in children. Nature. 2004;428:682.
2508.	Check E. Antidepressant reputation falls to new lows. Nature medicine. 2004;10:439.
2509.	Chee N, Jerome S, Ajeet S, et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Human Psychopharmacology: Clinical and Experimental. 2013;28:516-522.
2510.	Chelminski I, Zisook S. Recognition and treatment of depression with or without comorbid anxiety disorders. CNS spectrums. 2006;11:1-14.
2511.	Chemali Z, LM C, Fricchione G. The use of selective serotonin reuptake inhibitors in elderly patients. Harvard review of psychiatry. 2009;17:242-253.
2512.	Chemerinski E, SR L. Neuropsychiatric disorders following vascular brain injury. Mount Sinai Journal of Medicine. 2006;73:1006-1014.
2513.	Chen C, W-P X, Huang Y, et al. Efficacy and safety of Duloxetine versus paroxetine for adults' depression: A meta-analysis. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2012;12:320-325.
2514.	Chen C, W-P X, Huang Y, et al. Efficacy and safety of Duloxetine versus paroxetine for adults' depression: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2012;12:320-325.
2515.	Chen F, TJ H, NT W. Do SSRIs Play a Role in Decreasing Bone Mineral Density? Journal of the American Medical Directors Association. 2012;13:413-417.
2516.	Chen H, TJ L, RH R, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clinic proceedings. 2004;79:1533-1545.
2517.	Chen H, Wu J, Zhang J, Hashimoto K. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Current drug abuse reviews. 2010;3:222-238.
2518.	Chen J, JA R. Racial and ethnic disparities in antidepressant drug use. Journal of mental health policy and economics. 2008;11:155-165.
2519.	Chen J, YR F, DE K, JR C, KM G. Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms. Current psychiatry reports. 2010;12:512-521.
2520.	Chen Q, Liu W, Li H, Zhang H, Tian M. Molecular imaging in patients with mood disorders: A review of PET findings. European journal of nuclear medicine and molecular imaging. 2011;38:1367-1380.
2521.	Depression care management for adults older than 60 years in primary care clinics in urban China: A cluster-randomised trial, The Lancet Psychiatry(2015).
2522.	Depression care management for late-life depression in China primary care: Protocol for a randomized controlled trial, Trials(2011).
2523.	Chen W, G-F W, X-H C, Y-L S, Zhu H. Effects of paroxetine on function recovery in patients with poststroke depression. Chinese Journal of Clinical Rehabilitation. 2002;6:2014-2015.
2524.	Chen Y, Deutsch A, MJ D, et al. Current research outcomes from the spinal cord injury model systems. Archives of physical medicine and rehabilitation. 2011;92:329-331.
2525.	Chen Y, HI W, JP Or, et al. Quantification of Cerebral Blood Flow as Biomarker of Drug Effect: Arterial Spin Labeling Phmri After a Single Dose of Oral Citalopram. Clinical pharmacology and therapeutics. 2011;89:251-258.
2526.	Chen Y, JJ G, SY Z, NC P. Treatment Effects of Antidepressants in Patients With Post-Stroke Depression: a Meta-Analysis. Annals of pharmacotherapy. 2006;40:2115-2122.
2527.	Chen Y, NC P, JJ G, SY Z. Antidepressant Prophylaxis for Poststroke Depression: a Meta-Analysis. International clinical psychopharmacology. 2007;22:159-166.
2528.	Chen Z, Yang J, Tobak A. Designing new treatments for depression and anxiety. IDrugs : the investigational drugs journal. 2008;11:189-197.
2529.	Chen-Jee H, Wei-Herng H, Chwen-Cheng C, Cheng-Cheng H, Shih-Jen T, L RFJ. A Double-Blind, Randomized, Group-Comparative Study of the Tolerability and Efficacy of 6 Weeks' Treatment With Mirtazapine or Fluoxetine in Depressed Chinese Patients. Journal of clinical psychiatry. 2003;64:921-929.
2530.	Cheng F, Shao G, Bao S. Study of effect on neurologic function rehabilitation in patient with post-stroke depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2003;7:108-109.
2531.	Chernoloz O, M EM, Blier P. Electrophysiological Studies in the Rat Brain on the Basis for Aripiprazole Augmentation of Antidepressants in Major Depressive Disorder. Psychopharmacology. 2009;206:335-344.
2532.	Cherri M, Eileen B, Susan M, Jill G, Madelaine W. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2002;24:417-433.
2533.	Chetty S, Baalbergen E, AI B, et al. Clinical practice guidelines for management of neuropathic pain: Expert panel recommendations for South Africa. South African family practice. 2013;55:143-158.
2534.	Chetty S, Baalbergen E, IBhigjee A, et al. Clinical practice guidelines for management of neuropathic pain: Expert panel recommendations for South Africa. Samj South African Medical Journal. 2012;102:312-325.
2535.	Chi-Un P. Comments on 'What is a rational antidepressant treatment for major depression in patients with Parkinson's disease'? [References]. Psychiatry and clinical neurosciences. 2013;67:65-66.
2536.	Chi-Un P, S MP, M MD, et al. History of depressive and/or anxiety disorders as a predictor of treatment response: A post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:996-1002.
2537.	Chiappedi M, S dV, Bejor M. Nutraceuticals in psychiatric practice. Recent patents on CNS drug discovery. 2012;7:163-172.
2538.	Chibuzo U, Burton BJ, J CN. What drugs are best for bipolar depression? [References]. Journal of family practice. 2008;57:606-608.
2539.	Chien-Ho L, Shih-Hsien L, Fong-Lin J. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: A randomized, double-blind, controlled study. Journal of clinical psychopharmacology. 2011;31:563-568.
2540.	Chiesa A, Chierzi F, D DR, Serretti A. Quetiapine for bipolar depression: A systematic review and meta-analysis. International clinical psychopharmacology. 2012;27:76-90.
2541.	Chiesa A, Serretti A. Antidepressants and sexual dysfunction: Epidemiology, mechanisms and management. [Italian]. Italian Journal of Psychopathology. 2010;16:104-113.
2542.	Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression, Biological psychiatry(2013).
2543.	Chilman-Blair K, Castaner J, Bayes M, JS S. Agomelatine. Antidepressant treatment of bipolar disorder melatonin agonist/5-HT2C antagonist. Drugs of the future. 2003;28:7-13.
2544.	Ching-Hua L, Keng-Shin L, Chang-Yi L, Ming-Chao C, Hsien-Yuan L. Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. Journal of clinical psychiatry. 2008;69:54-59.
2545.	Cho D, Jee H, Je H. Treatment of glossodynia (burning mouth syndrome) with quetiapine. European neuropsychopharmacology. 2012;Conference:S323-S324.
2546.	Chocron S, Vandel P, Durst C, et al. Antidepressant Therapy in Patients Undergoing Coronary Artery Bypass Grafting: the Motiv-Cabg Trial. Annals of thoracic surgery. 2013;95:1609-1618.
2547.	Choi E, Zmarlicka M, MJ E. Vilazodone: A novel antidepressant. American journal of health-system pharmacy. 2012;69:1551-1557.
2548.	Choi-Kwon S, Choi J, SU K, D-W K, JS K. Fluoxetine is not effective in the treatment of post-stroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular diseases (Basel, Switzerland). 2007;23:103-108.
2549.	Choi-Kwon S, Choi J, SU K, DW K, JS K. Fluoxetine Improves the Quality of Life in Patients With Poststroke Emotional Disturbances. Cerebrovascular diseases (Basel, Switzerland). 2008;26:266-271.
2550.	Choi-Kwon S, JS K. Poststroke fatigue: an emerging, critical issue in stroke medicine. International journal of stroke. 2011;6:328-336.
2551.	Choi-Kwon S, SU K, DW K, JS K. Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke; a journal of cerebral circulation. 2009;Conference:e282.
2552.	Choi-Kwon S, SW H, SU K, D-W K, JM C, JS K. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke; a journal of cerebral circulation. 2006;37:156-161.
2553.	Chojnacki C, Walecka-Kapica E, Mokwinska M, et al. Influence of Tianeptine on Melatonin Homeostasis and Psychosomatic Symptoms in Patients With Irritable Bowel Syndrome. Journal of physiology and pharmacology. 2013;64:177-183.
2554.	Chollet F, Acket B, Raposo N, JF A, Loubinoux I, Pariente J. Use of antidepressant medications to improve outcomes after stroke topical collection on stroke. Current neurology and neuroscience reports. 2013.
2555.	Chollet F, J-F A. Strategies to augment recovery after stroke. Current treatment options in neurology. 2012;14:531-540.
2556.	Chollet F, Tardy J, JF A, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.[Erratum appears in Lancet Neurol. 2011 Mar;10(3):205]. The Lancet. Neurology. 2011;10:123-130.
2557.	Chopra K, Kuhad A, Arora V. Neoteric Pharmacotherapeutic Targets in Fibromyalgia. Expert opinion on therapeutic targets. 2011;15:1267-1281.
2558.	Chosak A, Marques L, JL G, Jenike E, DD D, Wilhelm S. Body dysmorphic disorder and obsessive-compulsive disorder: Similarities, differences and the classification debate. Expert review of neurotherapeutics. 2008;8:1209-1218.
2559.	Chouinard G. Sertraline in the treatment of obsessive compulsive disorders: Two double-blind, placebo-controlled studies. International clinical psychopharmacology. 1992;7:37-41.
2560.	Chouinard G. The Search for New Off-Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs. Journal of psychiatry & neuroscience. 2006;31:168-176.
2561.	Chouinard G, BM S, NPV N, et al. A Canadian Multicenter Placebo-Controlled Study of a Fixed-Dose of Brofaromine, a Reversible Selective Mao-a Inhibitor, in the Treatment of Major Depression. Journal of affective disorders. 1994;32:105-114.
2562.	Chouinard G, MC B, Beauclair L, Sultan S, BEP M. Potentiation of Fluoxetine by Aminoglutethimide, an Adrenal Steroid Suppressant, in Obsessive-Compulsive Disorder Resistant to Ssris: a Case Report. Progress in neuro-psychopharmacology & biological psychiatry. 1996;20:1067-1079.
2563.	Chouinard G, V-A C. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and psychosomatics. 2008;77:69-77.
2564.	Choy E, Marshall D, ZL G, SA M, Gylee E, HA D. A Systematic Review and Mixed Treatment Comparison of the Efficacy of Pharmacological Treatments for Fibromyalgia. Seminars in arthritis and rheumatism. 2011;41:335-345.
2565.	Choy E, Richards S, Bowrin K, et al. Cost Effectiveness of Pregabalin in the Treatment of Fibromyalgia From a Uk Perspective. Current medical research and opinion. 2010;26:965-975.
2566.	Chris D, Malcolm J, Chris S, Francis C. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2000;41:490-499.
2567.	Chris T. Onset of action of antidepressants: Results of different analyses. Human Psychopharmacology: Clinical and Experimental. 2002;17:S27-S32.
2568.	Chrisman A, Egger H, SN C, Curry J, DB G. Assessment of childhood depression. Child and adolescent mental health. 2006;11:111-116.
2569.	Christensen H, AJ G, AJ M, et al. Protocol for a Randomised Controlled Trial Investigating the Effectiveness of an Online E-Health Application Compared to Attention Placebo or Sertraline in the Treatment of Generalised Anxiety Disorder. Trials. 2010;11.
2570.	Christensen H, AJ M, PJ B, et al. The effectiveness of an online e-health application compared to attention placebo or Sertraline in the treatment of Generalised Anxiety Disorder. Internet Interventions. 2014;1:169-174.
2571.	Christensen H, AJ M, PJ B, et al. The effectiveness of an online e-health application compared to attention placebo or Sertraline in the treatment of generalised Anxiety disorder. Internet Interventions. 2014;1:169-174.
2572.	Christensen H, L-F L, KJ A. Prevalence, risk factors and treatment for substance abuse in older adults. Current opinion in psychiatry. 2006;19:587-592.
2573.	Christian D, Michael N, Andrea S. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. [Review]. Drugs & aging. 2010;27:625-640.
2574.	Christian G, Waltraud B, Renate S, Christoph S, Brigitta B, Wolfgang A. Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. European neuropsychopharmacology. 2008;18:141-146.
2575.	Christian GJ, Mark R, K EM, Andrew W. "A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-related measures of sleep in depressed patients: A double-blind, 8-week clinical trial": Correction. Journal of clinical psychiatry. 1997;58:275.
2576.	Christian GJ, Mark R, K EM, Andrew W, J AB. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.[Erratum appears in J Clin Psychiatry 1997 Jun;58(6):275]. Journal of clinical psychiatry. 1997;58:185-192.
2577.	Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study, Journal of psychiatric research(2010).
2578.	Christmas D, Hood S, Nutt D. Potential novel anxiolytic drugs. Current pharmaceutical design. 2008;14:3534-3546.
2579.	Christophe L, Christophe S, Ivan N, Jean F. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: A prospective, naturalistic, 8-week study. International journal of psychiatry in clinical practice. 2006;10:131-137.
2580.	Christophe L, Patrice V, Lieven A, Nicolas D, Clement F. Escitalopram in major depressive disorder: Clinical benefits and cost effectiveness versus citalopram. International journal of psychiatry in clinical practice. 2007;11:44-52.
2581.	Christopher L, Geoffrey D. An overview of studies comparing the efficacy, safety, and tolerability of paroxetine and clomipramine. Nordic journal of psychiatry. 1992;46:17-22.
2582.	Christopher T, C PR, Deborah S, Jan M. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: A randomized comparison of fluoxetine and a tricyclic antidepressant. American journal of psychiatry. 2000;157:338-343.
2583.	Chuluunkhuu G, Nakahara N, Yanagisawa S, Kamae I. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. The Kobe journal of medical sciences. 2008;54:E147-E158.
2584.	Chung H, Culpepper L, JN DW, et al. Recognizing, managing, and treating bipolar disorder at the interface of primary care and psychiatric medicine. Part 4: Treatment by phase: Pharmacologic management of bipolar disorder. Journal of family practice. 2007;56:S19-S27.
2585.	CHY F. Structural and functional MRI predictors of treatment response in depression. Biological psychiatry. 2015;Conference:16S.
2586.	CHY F, Steiner H, SG C. Predictive neural biomarkers of clinical response in depression: A meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiology of disease. 2013;52:75-83.
2587.	CI J, AM L, AK M. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Annals of pharmacotherapy. 2008;42:967-978.
2588.	CI S. Long-Term Management of Major Depressive Disorder: Are Differences Among Antidepressant Treatments Meaningful? Journal of clinical psychiatry. 2004;65:29-33.
2589.	Cialdella P. A Reply to Perron Regarding the Inserm Report "Psychotherapy. The Assessment of Three Approaches". Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2007;33:783-790.
2590.	Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: A case series. Neuropsychiatric disease and treatment. 2009;5:1-4.
2591.	Ciapparelli A, Dell'Osso L, AB DP, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: A naturalistic 48-month follow-up study. Journal of clinical psychiatry. 2003;64:451-458.
2592.	Ciara M, Zevic M. Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. NeuroImage. 2011;57:1317-1323.
2593.	Ciara M, Zevic M, J CP, J HC. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biological psychiatry. 2010;67:439-445.
2594.	Ciaramella A, Grosso S, Poli P. [Fluoxetine versus fluvoxamine for treatment of chronic pain]. [Italian]. Minerva anestesiologica. 2000;66:55-61.
2595.	Ciaran M, Gerard L, J KD, J CS. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. Journal of psychopharmacology (Oxford, England). 2003;17:107-112.
2596.	Cicogni A, Castagnoli A, Domenichetti S, Perone R, Sestini S. Asperger Syndrome, a diagnostic therapeutic paradox. [Italian]. Italian Journal of Psychopathology. 2008;14:356-366.
2597.	Ciotta L, Ando A, Pagano I, Stracquadanio M, Formuso C. Long-term treatment with vitex agnus castus (VAC) in premenstrual dysphoric disorders (PMDD). International journal of gynaecology and obstetrics. 2012;Conference:S605.
2598.	Cipriani A, Brambilla P, Furukawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. [Review] [198 refs][Update in Cochrane Database Syst Rev. 2013;7:CD004185; PMID: 24353997]. Cochrane database of systematic reviews (Online). 2005:CD004185.
2599.	Cipriani A, Brambilla P, TA F, et al. Fluoxetine Versus Other Types of Pharmacotherapy for Depression. Cochrane database of systematic reviews (Online). 2005.
2600.	Cipriani A, Brambilla P, TA F, et al. Fluoxetine Versus Other Types of Pharmacotherapy for Depression. Cochrane database of systematic reviews (Online). 2005.
2601.	Cipriani A, Hawton K, Stockton S, JR G. Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ (Online). 7916.
2602.	Cipriani A, JR G. Placebo for Depression: We Need to Improve the Quality of Scientific Information but Also Reject Too Simplistic Approaches or Ideological Nihilism. BMC medicine. 2014;12.
2603.	Cipriani A, JR G. Placebo for depression: We need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. BMC medicine. 2014.
2604.	Cipriani A, JR G. Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. BMC medicine. 2014;12:105.
2605.	Cipriani A, JR G, TA F, Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: An evidence-based approach to inform clinical practice. Canadian Journal of Psychiatry. 2007;52:553-562.
2606.	Cipriani A, Koesters M, TA F, et al. Duloxetine Versus Other Anti-Depressive Agents for Depression. Cochrane database of systematic reviews (Online). 2012.
2607.	Cipriani A, Koesters M, TA F, et al. Duloxetine versus other anti-depressive agents for depression. [Review]. Cochrane database of systematic reviews (Online). 2012;10:CD006533.
2608.	Cipriani A, Malvini L, TA F, Barbui C. Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: systematic review, meta-analysis, and meta-regression analysis. [Review] [29 refs]. Journal of clinical psychopharmacology. 2007;27:352-356.
2609.	Cipriani A, Pontarollo F, Signoretti A, et al. Escitalopram versus other anti-depressive agents for depression. Cochrane database of systematic reviews (Online). 2007.
2610.	Cipriani A, Purgato M, TA F, et al. Citalopram versus other anti-depressive agents for depression. [Review]. Cochrane database of systematic reviews (Online). 2012;7:CD006534.
2611.	Cipriani A, Purgato M, TA F, et al. Citalopram Versus Other Anti-Depressive Agents for Depression. Cochrane database of systematic reviews (Online). 2012.
2612.	Cipriani A, Santilli C, TA F, et al. Escitalopram versus other antidepressive agents for depression. [Review] [99 refs]. Cochrane database of systematic reviews (Online). 2009:CD006532.
2613.	Cipriani A, Santilli C, TA F, et al. Escitalopram versus other antidepressive agents for depression. Cochrane database of systematic reviews (Online). 2009.
2614.	Cipriani A, Santilli C, TA F, et al. Escitalopram Versus Other Antidepressive Agents for Depression. Cochrane database of systematic reviews (Online). 2009.
2615.	Cipriani A, Santilli C, TA F, et al. Escitalopram versus other antidepressive agents for depression. [Review] [99 refs]. Cochrane database of systematic reviews (Online). 2009:CD006532.
2616.	Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane database of systematic reviews (Online). 2006.
2617.	Cipriani A, T LF, TA F, et al. Sertraline versus other antidepressive agents for depression. [Review] [139 refs][Update in Cochrane Database Syst Rev. 2010;(1):CD006117; PMID: 20091586]. Cochrane database of systematic reviews (Online). 2009:CD006117.
2618.	Cipriani A, T LF, TA F, et al. Sertraline Versus Other Antidepressive Agents for Depression. Cochrane database of systematic reviews (Online). 2009.
2619.	Cipriani A, T LF, TA F, et al. Sertraline versus other antidepressive agents for depression. [Review] [140 refs][Update in Cochrane Database Syst Rev. 2010;(4):CD006117; PMID: 20393946], [Update of Cochrane Database Syst Rev. 2009;(2):CD006117; PMID: 19370626]. Cochrane database of systematic reviews (Online). 2010:CD006117.
2620.	Cipriani A, T LF, TA F, et al. Sertraline versus other antidepressive agents for depression. [Review] [140 refs][Update in Cochrane Database Syst Rev. 2010;(4):CD006117; PMID: 20393946], [Update of Cochrane Database Syst Rev. 2009;(2):CD006117; PMID: 19370626]. Cochrane database of systematic reviews (Online). 2010:CD006117.
2621.	Cipriani A, T LF, TA F, et al. Sertraline versus other antidepressive agents for depression. Cochrane database of systematic reviews (Online). 2010;4:xxx.
2622.	Cipriani A, T LF, TA F, et al. Sertraline Versus Other Antidepressive Agents for Depression. Cochrane database of systematic reviews (Online). 2010.
2623.	Cipriani A, T LF, TA F, et al. Sertraline versus other antidepressive agents for depression. [Review] [140 refs][Update of Cochrane Database Syst Rev. 2010;(1):CD006117; PMID: 20091586]. Cochrane database of systematic reviews (Online). 2010:CD006117.
2624.	Cipriani A, T LF, TA F, et al. Sertraline Versus Other Antidepressive Agents for Depression. Cochrane database of systematic reviews (Online). 2010.
2625.	Cipriani A, TA F, JR G, et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. [Review] [93 refs]. Journal of clinical psychiatry. 2008;69:1732-1742.
2626.	Cipriani A, TA F, Veronese A, et al. Paroxetine versus other anti-depressive agents for depression. Cochrane database of systematic reviews (Online). 2007.
2627.	Cipriani R, GI P, Rampinelli S. Paroxetine in alopecia areata. International journal of dermatology. 2001;40:600-601.
2628.	Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. Journal of pharmacology & pharmacotherapeutics. 2013;4:S94-S98.
2629.	Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatric disease and treatment. 2006;2:427-443.
2630.	Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. [Review] [20 refs]. Acta psychiatrica Scandinavica. 2008;117:412-419.
2631.	Citrome L. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Current drug safety. 2009;4:229-237.
2632.	Citrome L. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Expert review of neurotherapeutics. 2010;10:1031-1037.
2633.	Citrome L. Drug safety evaluation of ziprasidone. Expert opinion on drug safety. 2011;10:437-448.
2634.	Citrome L. Iloperidone, asenapine, and lurasidone: A brief overview of 3 new second-generation antipsychotics. Postgraduate medicine. 2011;123:153-162.
2635.	Vilazodone for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antidepressant - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?, International journal of clinical practice(2012).
2636.	A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach, CNS drugs(2013).
2637.	Citrome L. Treatment of bipolar depression: making sensible decisions. [Review]. CNS spectrums. 2014;19 Suppl 1:3-4.
2638.	Citrome L. Treatment of Bipolar Depression: Making Sensible Decisions. CNS spectrums. 2014;19:4-12.
2639.	Citrome L. Treatment of bipolar depression: making sensible decisions. CNS spectrums. 2014;19:3-4,12.
2640.	Citrome L, HA N. On-label on the table: What the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert opinion on pharmacotherapy. 2012;13:1599-1613.
2641.	Citrome L, JT K. Olanzapine dosing above the licensed range is more efficacious than lower doses: Fact or fiction? Expert review of neurotherapeutics. 2009;9:1045-1058.
2642.	Citrome L, TA K. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. International journal of clinical practice. 2013;67:407-411.
2643.	Citrome L, TA K, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Neuropsychopharmacology. 2013;Conference:S359-S361.
2644.	A systematic review of duloxetine for osteoarthritic pain: What is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?, Postgraduate medicine(2012).
2645.	Depression, Child and adolescent psychiatric clinics of North America(2012).
2646.	CJ G, CA Y. Assessing and managing depression and fatigue in motor neuron disease. Neurodegenerative disease management. 2012;2:401-409.
2647.	CJ H. Cost-effectiveness of eszopiclone for the treatment of chronic insomnia. Expert review of pharmacoeconomics & outcomes research. 2007;7:9-17.
2648.	CJ H. Emotional Processing and Antidepressant Action. Behavioral Neurobiology of Depression and Its Treatment. 2013;Current To:209-222.
2649.	CJ H, Bhagwagar Z, PJ C, GM G. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology. 2002;163:106-110.
2650.	CJ H, HA P, SJ Q, et al. A Protocol for the Pharmacologic Treatment of Major Depression - a Field Test of a Potential Prototype. Journal of affective disorders. 1998;47:87-96.
2651.	CJ H, NA F. Commentary on Star*D: a Summary and Uk Perspective. Journal of psychopharmacology (Oxford, England). 2009;23:620-621.
2652.	CJ H, NC S, PJ C, GM G. Increased Positive Versus Negative Affective Perception and Memory in Healthy Volunteers Following Selective Serotonin and Norepinephrine Reuptake Inhibition. American journal of psychiatry. 2004;161:1256-1263.
2653.	CJ H, NC S, PJ C, GM G. Increased Positive Versus Negative Affective Perception and Memory in Healthy Volunteers Following Selective Serotonin and Norepinephrine Reuptake Inhibition. American journal of psychiatry. 2004;161:1256-1263.
2654.	CJ H, PJ C, GM G. Efficacy markers in depression. Journal of psychopharmacology (Oxford, England). 2011;25:1148-1158.
2655.	CJ H, PJ L, SJ Q, et al. Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: A review of the current evidence. International clinical psychopharmacology. 2000;15:197-206.
2656.	CJ K, HEH P, KF O. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depression and anxiety. 1998;8:147-153.
2657.	CJ L. Anaemia, fatigue and quality of life in advanced malignancy: Potential therapeutic role for epoetin. Erythropoiesis: New Dimensions in the Treatment of Anaemia. 1997;8:63-73.
2658.	CJ L, JF L, Young C, Martin A. Antidepressant-Induced Manic Conversion: a Developmentally Informed Synthesis of the Literature. International Review of Neurobiology, Vol 65. 2005;65:25-52.
2659.	CJ L, JF L, Young C, Martin A. Antidepressant-Induced Manic Conversion: a Developmentally Informed Synthesis of the Literature. International Review of Neurobiology, Vol 65. 2005;65:25-52.
2660.	CJ M, CN E, LH P, Gelernter J. Evidence for Linkage Disequilibrium Between Serotonin Transporter Protein Gene (Slc6a4) and Obsessive Compulsive Disorder. Molecular psychiatry. 1998;3:270-273.
2661.	CJ M, LH P, WK G, DS C, GR H. A Controlled Trial of Lithium Augmentation in Fluvoxamine-Refractory Obsessive-Compulsive Disorder - Lack of Efficacy. Journal of clinical psychopharmacology. 1991;11:175-184.
2662.	CJ M, PJ S. Diagnosis and management of motor neurone disease. BMJ (Clinical research ed.). 2008;336:658-662.
2663.	Psychological interventions for postnatal depression: Cluster randomised trial and economic evaluation. The PoNDER trial, Health technology assessment(2009).
2664.	CJ M, WK G, JF L, et al. Limited Therapeutic Effect of Addition of Buspirone in Fluvoxamine-Refractory Obsessive-Compulsive Disorder. American journal of psychiatry. 1993;150:647-649.
2665.	CJ M, WK G, JF L, LC B, GR H, LH P. The Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder - Effects of Comorbid Chronic Tic Disorder. Journal of clinical psychopharmacology. 1993;13:354-358.
2666.	CJ M, WK G, JF L, NC L, GR H, LH P. Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder - a Double-Blind, Placebo-Controlled Study in Patients With and Without Tics. Archives of general psychiatry. 1994;51:302-308.
2667.	CJ SJ, Ancoli-Israel S. Sleep and Its Disorders in Seniors. Sleep medicine clinics. 2008;3:281-293.
2668.	CJ T, JMA S, LP D. Clinical Pharmacokinetics of Mirtazapine. Clinical pharmacokinetics. 2000;38:461-474.
2669.	CJ V, DS C, DJ K. Pharmaceutical Therapy for Radiculopathy. Physical medicine and rehabilitation clinics of North America. 2011;22:127-137.
2670.	CJ VdS, Gal S, WJ G, MBH Y. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert opinion on investigational drugs. 2006;15:873-886.
2671.	CJ W, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective Serotonin Reuptake Inhibitors in Childhood Depression: Systematic Review of Published Versus Unpublished Data. Lancet. 2004;363:1341-1345.
2672.	CJ W, Kendall T, Fonagy P, EJ G. Review: Most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children. Evidence-based medicine. 2004;9:181.
2673.	CJ Z, JF W, ZW Q, LM C, JT Z. Bioequivalence Evaluation of Two Sertraline Tablet Formulations in Healthy Male Volunteers After a Single Dose Administration. International journal of clinical pharmacology and therapeutics. 1999;37:120-124.
2674.	CK B, Meeker G, ES B. Examination of a Possible Interaction Between Prednisone and Newer Antidepressants. Primary care & community psychiatry. 2005;10:143-147.
2675.	CK B, Meeker G, ES B. Examination of a Possible Interaction Between Prednisone and Newer Antidepressants. Primary care & community psychiatry. 2005;10:143-147.
2676.	CK C, DS R, DL R, UE S, O'Brien K, JR I. Responders to antidepressant drug treatment: A study comparing nefazodone, imipramine, and placebo in patients with major depression. Journal of clinical psychiatry. 1996;57:15-18.
2677.	CK C, Shrivastava R, Mendels J, et al. Double-Blind, Multicenter Comparison of Sertraline and Amitriptyline in Elderly Depressed-Patients. Journal of clinical psychiatry. 1990;51 Suppl B:28-33.
2678.	CK F, Mcelroy S. Predictive Factors for Relapse After an Integrated Inpatient Treatment Programme for Unipolar Depressed and Bipolar Alcoholics. Alcohol and Alcoholism. 2010;45:527-533.
2679.	CK J, BJ E, AB N, HE S. Analgesic Effects of Serotonergic, Noradrenergic or Dual Reuptake Inhibitors in the Carrageenan Test in Rats: Evidence for Synergism Between Serotonergic and Noradrenergic Reuptake Inhibition. Neuropharmacology. 2006;51:1172-1180.
2680.	CK L, PB M, VM C, et al. Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. Psychological medicine. 2003;33:33-40.
2681.	CK V. Treating depression in children and adolescents: What options now? CNS drugs. 2006;20:1-13.
2682.	CK V. Commentary by an academic child psychiatrist on the relationship of the pharmaceutical industry, academia, psychiatric practice, and the food and drug administration. Journal of child and adolescent psychopharmacology. 2007;17:292-294.
2683.	CK V, CJ S. Anxiety disorders in the child and teen. Pediatric clinics of North America. 2003;50:1107-1138.
2684.	CL A, YWF L, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. Journal of clinical pharmacology. 2000;40:58-66.
2685.	CL B. Role of newer medications for bipolar disorder. Journal of clinical psychopharmacology. 1996;16:48S-55S.
2686.	CL B. Improving identification of treatment effectiveness in bipolar disorders. Bipolar disorders. 2003;5:77-78.
2687.	CL B. Relationship of acute mania symptomatology to maintenance treatment response. Current psychiatry reports. 2004;6:473-477.
2688.	CL B. Makinig Optimal Use of Combination Pharmacotherapy in Bipolar Disorder. Journal of clinical psychiatry. 2004;65:21-24.
2689.	CL B. Makinig Optimal Use of Combination Pharmacotherapy in Bipolar Disorder. Journal of clinical psychiatry. 2004;65:21-24.
2690.	CL B. Treatment options for bipolar depression. [Review] [23 refs]. Journal of clinical psychiatry. 2005;66 Suppl 1:3-6.
2691.	CL B. Spectrum of effectiveness of valproate in neuropsychiatry. Expert review of neurotherapeutics. 2007;7:9-16.
2692.	CL B. Anticonvulsants in bipolar disorders: Current research and practice and future directions. Bipolar disorders. 2009;11:20-33.
2693.	CL B. Pharmacological treatments for bipolar disorder: Present recommendations and future prospects. Behavioral Neurobiology of Bipolar Disorder and its Treatment. 2011;Current To:263-283.
2694.	CL B, AF S, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. Journal of clinical psychopharmacology. 1993;13:305-310.
2695.	CL B, Edwards S, Evoniuk G. Open-label, concomitant use of lamotrigine and other medications for bipolar disorder. CNS spectrums. 2008;13:75-83.
2696.	CL B, GM A, LD G, Bentley B, Leadbetter R, White R. Safety and Tolerability of Lamotrigine for Bipolar Disorder. Drug safety. 2004;27:173-184.
2697.	CL B, MC tD, Spijker J, et al. Continuation and maintenance use of antidepressants in recurrent depression. Psychotherapy and psychosomatics. 2008;77:17-26.
2698.	CL B, RH P, ME T, et al. Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). CNS neuroscience & therapeutics. 2012;18:243-249.
2699.	CL B, Singh V. Lamotrigine (Lamictal Ir) for the Treatment of Bipolar Disorder. Expert opinion on pharmacotherapy. 2012;13:2565-2571.
2700.	CL D. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Human psychopharmacology. 1995;10:S185-S193.
2701.	CL D. Nefazodone - Pharmacology and efficacy of a new antidepressant agent: Formulary considerations. P and T. 1995;20:363+367-370+373-374.
2702.	CL D. The Place of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder. Pharmacotherapy. 1997;17:282-292.
2703.	CL D. Pharmacology and efficacy of citalopram: Formulary considerations. P and T. 1999;24:338-346.
2704.	CL D. Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child and adolescent psychiatric clinics of North America. 2003;12:251-269.
2705.	CL D, FR S. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. [Review] [103 refs]. Journal of clinical psychiatry. 1996;57:55-66.
2706.	CL E, JF G. Antisuicide Properties of Psychotropic Drugs: A Critical Review. Harvard review of psychiatry. 2004;12:14-41.
2707.	CL H-K, Leggio L, GA K. Pharmacological approaches to reducing craving in patients with alcohol use disorders. CNS drugs. 2014;28:343-360.
2708.	CL K, CP K. New generation multi-modal antidepressants: Focus on vortioxetine for major depressive disorder. Neuropsychiatric disease and treatment. 2014;10:349-354.
2709.	CL L. Preliminary results in women seeking HRT alternative. Oncology Report. 2005:132.
2710.	Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression, Biological psychiatry(2014).
2711.	Toward a neuroimaging treatment selection biomarker for major depressive disorder, JAMA Psychiatry(2013).
2712.	CL M, PE H, ME K, et al. Pretreatment resting state FDG-PET predicts differential response to CBT or medication. Biological psychiatry. 2011;Conference:168S.
2713.	CL M, SL G. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. Annals of pharmacotherapy. 2012;46:599-605.
2714.	CL P. Advances in the treatment of interstitial cystitis. Expert opinion on pharmacotherapy. 2006;7:411-419.
2715.	CL R, AH M. Depression in cancer: New developments regarding diagnosis and treatment. Biological psychiatry. 2003;54:283-294.
2716.	CL R, AH M. Malaise, melancholia and madness: The evolutionary legacy of an inflammatory bias. Brain, behavior, and immunity. 2013;31:1-8.
2717.	Role of inflammation in depression: Implications for phenomenology, pathophysiology and treatment, Inflammation in Psychiatry(2013).
2718.	Paroxetine for Prevention of Depressive Symptoms Induced by Interferon-Alpha and Ribavirin for Hepatitis C, Alimentary pharmacology & therapeutics(2007).
2719.	CL R, JA O, MS S, DG G. Pharmacotherapy for pediatric sleep disturbances: Current patterns of use and target populations for controlled clinical trials. Current therapeutic research, clinical and experimental. 2002;63:B53-B66.
2720.	CL S. Growing increase in the <<off label>> use of psychotropic drugs. [French]. Information psychiatrique. 2005;81:120-124.
2721.	CL W, SD M, RL R, KD J. Duloxetine for the Treatment of Fibromyalgia. Expert review of clinical immunology. 2010;6:745-756.
2722.	Claghorn J. A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. International clinical psychopharmacology. 1992;6 Suppl 4:25-30.
2723.	Clapham E, Berg J, Ekman M, Jonsson L. Economic evaluation of agomelatine for major depressive disorder in Sweden. Value in health. 2009;Conference:A176.
2724.	Clarice G, Andrade L, Moreno RA, Artes R. Social adjustment in depressed patients treated with venlafaxine and amitriptyline. International clinical psychopharmacology. 2002;17:171-175.
2725.	Clark L, SR C, BJ S. Neurocognitive mechanisms in depression: Implications for treatment. Annual review of neuroscience. 2009;32:57-74.
2726.	Clarke G, AG H. The complex role of sleep in adolescent depression. [Review]. Child and adolescent psychiatric clinics of North America. 2012;21:385-400.
2727.	Clarke G, Debar L, Lynch F, et al. A Randomized Effectiveness Trial of Brief Cognitive-Behavioral Therapy for Depressed Adolescents Receiving Antidepressant Medication. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:888-898.
2728.	Classi P, Milton D, JM W, Shelton R, Matza L. Reliability and validity of the fatigue associated with depression (FAsD) questionnaire in a clinical trial of patients with major depressive disorder who partially respond to SSRI treatment. Neuropsychopharmacology. 2011;Conference:S346-S347.
2729.	Claudia C, Cornelius K, Kostas L, et al. A systematic review of treatments for refractory depression in older people. [Review]. American journal of psychiatry. 2011;168:681-688.
2730.	Claudia W. Depressing news. Nature reviews. Neuroscience. 2008;9:252.
2731.	Claus N, Barbara H, O SL, Marion H, Heinz G, Jorg W. Lamotrigine as adjunct to paroxetine in acute depression: A placebo-controlled, double-blind study. Journal of clinical psychiatry. 2002;63:337-344.
2732.	Clausius N, Born C, Grunze H. The relevance of dopamine agonists in the treatment of depression. [German]. Neuropsychiatrie. 2009;23:15-25.
2733.	Clavenna A, Andretta M, Pilati P, et al. Antidepressant and Antipsychotic Use in an Italian Pediatric Population. BMC pediatrics. 2011;11.
2734.	Clayton A, Guico-Pabia C. Recognition of depression among women presenting with menopausal symptoms. Menopause (New York, N.Y.). 2008;15:758-767.
2735.	CLE K. Refractory depression: A review with particular reference to the use of lithium augmentation. European neuropsychopharmacology. 1995;5 Suppl:109-113.
2736.	CLE K, KK S. Depression in old age. Reviews in clinical gerontology. 2004;14:283-306.
2737.	Clerc G, Group MFS. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine. International clinical psychopharmacology. 2001;16:145-151.
2738.	Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. International clinical psychopharmacology. 1994;9:139-143.
2739.	CM B, CB P, Bradwejn J, JRT D, Vitiello B, KM G. Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression. Depression and anxiety. 2004;20:114-122.
2740.	CM B, DJ C. Fibromyalgia: A primer for the anesthesia community. Current opinion in anaesthesiology. 2011;24:532-539.
2741.	CM B, KA B, JR S. Diagnosis and management of binge eating disorder. World psychiatry. 2007;6:142-148.
2742.	CM B, LJ S. Quetiapine extended release: In schizophrenia. CNS drugs. 2009;23:261-269.
2743.	CM B, SC K, ME N, JS G. Adverse Events and Treatment Discontinuations in Clinical Trials of Fluoxetine in Major Depressive Disorder: an Updated Meta-Analysis. Clinical therapeutics. 2000;22:1319-+.
2744.	CM B, TS B, JK B, RL R. Efficacy and safety of mifepristone for the treatment of psychotic depression. Journal of clinical psychopharmacology. 2011;31:436-440.
2745.	CM BJ, BE D, JA P, JC B, ME S. Fluoxetine versus trazodone: Efficacy and activating-sedating effects. Journal of clinical psychiatry. 1991;52:294-299.
2746.	CM BJ, BE D, JC B, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.[Erratum appears in BMJ 1991 Oct 19;303(6808):968]. BMJ (Clinical research ed.). 1991;303:685-692.
2747.	CM BJ, JH P, DN M, DE W, BE D, LA G. Fluoxetine - No Association With Suicidality in Obsessive-Compulsive Disorder. Journal of affective disorders. 1992;24:1-10.
2748.	CM C, JC H. Depression and cardiac disease: A review. Cardiology in review. 2011;19:130-142.
2749.	CM C, LJ S. Asenapine: A review of its use in the management of mania in adults with bipolar i disorder. CNS drugs. 2011;25:251-267.
2750.	CM D. Antidepressant augmentation and combinations. Psychiatric clinics of North America. 2000;23:743-755.
2751.	CM D, Fisher L, Papakostas G, et al. A double-blind, randomized, pilot dose-finding study of maca root (L. Meyenii) for the management of SSRI-induced sexual dysfunction. CNS neuroscience & therapeutics. 2008;14:182-191.
2752.	CM D, Mischoulon D, TM G, et al. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: Prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS spectrums. 2010;15:515-521.
2753.	CM D, Sinicropi-Yao L, Papakostas G, et al. The Response of Psychotic-Like Symptoms to Fluoxetine Monotherapy in Non-Psychotic Major Depressive Disorder. Nordic journal of psychiatry. 2009;63:420-425.
2754.	CM D-B, JFW D, Mckie S, et al. The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: an Fmri Study. Neuropsychopharmacology. 2005;30:1724-1734.
2755.	CM G, PB M, Thilges S, PJ S. Comparison of early quality of life outcomes in autologous and allogeneic transplant patients. Bone marrow transplantation. 2012;47:1577-1582.
2756.	CM G, RD C, GT W, RM M. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. Journal of consulting and clinical psychology. 2012;80:1108-1113.
2757.	CM G, RM M, RD C. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. Journal of consulting and clinical psychology. 2012;80:897-906.
2758.	CM M. A Randomized, Placebo-Controlled, Crossover Study of Ephedrine for SSRI-Induced Female Sexual Dysfunction. Journal of sex & marital therapy. 2004;30:57-68.
2759.	CM Oc, AH G, DJ H. Pharmacoeconomic Analysis of Sertraline Treatment of Depression in Patients With Unstable Angina or a Recent Myocardial Infarction. Journal of clinical psychiatry. 2005;66:346-352.
2760.	Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (Sertraline against depression and heart disease in chronic heart failure) trial, Journal of the American College of Cardiology(2010).
2761.	CM P, AS P, Poon L, et al. Four Days of Citalopram Increase Suppression of Cortisol Secretion by Prednisolone in Healthy Volunteers. Psychopharmacology. 2004;177:200-206.
2762.	CM P, AS P, Poon L, et al. Four Days of Citalopram Increase Suppression of Cortisol Secretion by Prednisolone in Healthy Volunteers. Psychopharmacology. 2004;177:200-206.
2763.	CM S, MI W. Milnacipran. A review of its use in depression. [Review] [79 refs]. Drugs. 1998;56:405-427.
2764.	CM VdF-C. Treatment of interictal psychiatric disorder in epilepsy. I. Affective and anxiety disorders. Acta neuropsychiatrica. 2002;14:39-43.
2765.	CM W. Clinical research on traditional drugs and food items - The potential of comparative effectiveness research for interdisciplinary research. Journal of ethnopharmacology. 2013;147:254-258.
2766.	CMC B, Barcelos-Ferreira R, SRI R. Treatment of depression in older adults. Current psychiatry reports. 2012;14:289-297.
2767.	CN H, LM Y, LA M. Fibromyalgia: Diagnosis and Management for the Primary Healthcare Provider. Journal of women's health. 2008;17:1379-1387.
2768.	CN S. Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women. Evidence-based medicine. 2011;16:159-160.
2769.	CN S, Arsenio H, Joffe H, et al. Escitalopram Versus Ethinyl Estradiol and Norethindrone Acetate for Symptomatic Peri- and Postmenopausal Women: Impact on Depression, Vasomotor Symptoms, Sleep, and Quality of Life. Menopause-the Journal of the North American Menopause Society. 2006;13:780-786.
2770.	CN S, BJ M. Sleep Disturbances in Women: Psychiatric Considerations. Sleep medicine clinics. 2008;3:295-306.
2771.	CN S, BN F. Challenges and Opportunities to Manage Depression During the Menopausal Transition and Beyond. Psychiatric clinics of North America. 2010;33:295-308.
2772.	CN S, HC A, Cassano P, LS C. Impact of Escitalopram Versus Norethindrone Acetate and Ethinyl Estradiol on Depression, Vasomotor Symptoms, and Quality of Life in Peri and Postmenopausal Women: an Eight-Week, Randomized Trial. Biological psychiatry. 2004;55:93S.
2773.	CN S, HC A, Cassano P, LS C. Impact of Escitalopram Versus Norethindrone Acetate and Ethinyl Estradiol on Depression, Vasomotor Symptoms, and Quality of Life in Peri and Postmenopausal Women: an Eight-Week, Randomized Trial. Biological psychiatry. 2004;55:93S.
2774.	CN S, Joffe H, AC V, et al. Paroxetine Versus Placebo for Women in Midlife After Hormone Therapy Discontinuation. American journal of medicine. 2008;121:159-162.e151.
2775.	CN S, Joffe H, AC V, et al. Paroxetine Versus Placebo for Women in Midlife After Hormone Therapy Discontinuation. American journal of medicine. 2008;121:159-U112.
2776.	CN S, LS C. Perimenopause and mood disturbance: An update. CNS spectrums. 2001;6:167-174.
2777.	CN S, ME T, Clayton A, et al. Desvenlafaxine and Escitalopram for the Treatment of Postmenopausal Women With Major Depressive Disorder. Menopause-the Journal of the North American Menopause Society. 2010;17:700-711.
2778.	CN S, RS F, CJ G-P. Early Improvement in Depressive Symptoms With Desvenlafaxine 50 Mg/D as a Predictor of Treatment Success in Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2014;34:57-65.
2779.	CN S, S DP. Hormones in the treatment of depression. Women's Health. 2006;2:435-445.
2780.	CN S, YCJ R, Kandavel T, et al. Clinical Predictors of Drug Nonresponse in Obsessive-Compulsive Disorder. Journal of clinical psychiatry. 2005;66:1517-1523.
2781.	CN W, JL G. Does bupropion exacerbate anxiety? Current psychiatry. 2012;11:E3-E4.
2782.	CO L, DJ N, KA R, Loughhead A, ZN S. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depression and anxiety. 2005;22:94-97.
2783.	Cobb C, Crichlow R. Duloxetine (Cymbalta) for Treatment of Major Depressive Disorder. American family physician. 2005;72:1099-1101.
2784.	Cobb C, Crichlow R. Duloxetine (Cymbalta) for treatment of major depressive disorder. American family physician. 2005;72:1099-1102.
2785.	Coghill D. Evidence-based psychopharmacology for children and adolescents. Current opinion in psychiatry. 2002;15:361-368.
2786.	Coghill D. Current issues in child and adolescent psychopharmacology. Part 1: Attention-deficit hyperactivity and affective disorders. Advances in Psychiatric Treatment. 2003;9:86-94.
2787.	Coghill D. Pragmatic measures in paediatric psychopharmacology - Are we getting it right? European neuropsychopharmacology. 2011;21:571-583.
2788.	Cohen A, PR H, Szanto K, MA D, SE G, CF R. Social Inequalities in Response to Antidepressant Treatment in Older Adults. Archives of general psychiatry. 2006;63:50-56.
2789.	Cohen D, Deniau E, Maturana A, et al. Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials. PloS one. 2008;3:1-8.
2790.	Cohen D, Deniau E, Maturana A, et al. Are Child and Adolescent Responses to Placebo Higher in Major Depression Than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials. PloS one. 2008;3.
2791.	Cohen D, DH J. Randomized controlled trials of antidepressants: Clinically and scientifically irrelevant. Journal of Mind and Behavior. 2010;31:1-22.
2792.	Cohen D, Gerardin P, Mazet P, Purper-Ouakil D, MF F. Pharmacological Treatment of Adolescent Major Depression. Journal of child and adolescent psychopharmacology. 2004;14:19-31.
2793.	Cohen D, Hoeller K. Screening for depression: Preventive medicine or telemarketing? Ethical human sciences and services. 2003;5:3-6.
2794.	Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia: Incidence, mechanisms and management. CNS drugs. 2010;24:563-574.
2795.	Coleman N, Spiller R. New pharmaceutical approaches to the treatment of IBS: Future development & research. Annals of Gastroenterology. 2002;15:278-289.
2796.	Colla M, Kronenberg G, Deuschle M, et al. Hippocampal volume reduction and HPA-system activity in major depression. Journal of psychiatric research. 2007;41:553-560.
2797.	Collazos F, Ramos M, Qureshi A, et al. Effectiveness and Tolerability of Duloxetine in 2 Different Ethnic Samples a Prospective Observational Cohort Study. Journal of clinical psychopharmacology. 2013;33:254-256.
2798.	Colloca L, FG M. Role of expectations in health. Current opinion in psychiatry. 2011;24:149-155.
2799.	Colloca L, Lopiano L, Benedetti F, Lanotte M. The placebo response in conditions other than pain. Seminars in Pain Medicine. 2005;3:43-47.
2800.	Colman I, Zeng Y, Ataullahjan A, Senthilselvan A, SB P. The association between antidepressant use and depression eight years later: A national cohort study. Journal of psychiatric research. 2011;45:1012-1018.
2801.	Colonna L, HF A, EH R. A Randomized, Double-Blind, 24-Week Study of Escitalopram (10 Mg/Day) Versus Citalopram (20 Mg/Day) in Primary Care Patients With Major Depressive Disorder. Current medical research and opinion. 2005;21:1659-1668.
2802.	Colotto M, Vinci F, N VH, et al. [Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art]. [Review] [Italian]. Clinica terapeutica. 2012;163:e41-45.
2803.	Colotto M, Vinci F, N VH, et al. [Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art]. [Italian]. Clinica terapeutica. 2012;163:e41-45.
2804.	Colotto M, Vinci F, NV H, et al. Effect of Treatment With Selective Serotonin Reuptake Inhibitors on Lipid Profile: State of the Art. Clinica terapeutica. 2012;163:E41-E45.
2805.	Colotto M, Vinci F, NV H, et al. Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: State of the art. [Italian]. Clinica terapeutica. 2013;163:e41-e45.
2806.	Combs S, BM K, JS K. Research priorities in geriatric palliative care: Nonpain symptoms. Journal of palliative medicine. 2013;16:1001-1007.
2807.	Compare A, Germani E, Proietti R, Janeway D. Clinical psychology and cardiovascular disease: An up-to-date clinical practice review for assessment and treatment of anxiety and depression. Clinical practice and epidemiology in mental health. 2011;7:148-156.
2808.	Conca A, Koppi S, Konig P, Swoboda E, Krecke N. Transcranial magnetic stimulation: A novel antidepressive strategy? Neuropsychobiology. 1996;34:204-207.
2809.	Conca A, Swoboda E, Konig P, et al. Clinical Impacts of Single Transcranial Magnetic Stimulation (Stms) as an Add-on Therapy in Severely Depressed Patients Under Ssri Treatment. Human Psychopharmacology-Clinical and Experimental. 2000;15:429-438.
2810.	Condat A, MC M-S. Selective Serotonin Reuptake Inhibitors in the Treatment of Child and Adolescent Depression. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2000;26:53-60.
2811.	Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health technology assessment. 2007;11:iii-75.
2812.	Connor C, Attai D. Adjuvant endocrine therapy for the surgeon: Options, side effects, and their management. Annals of surgical oncology. 2013;20:3188-3193.
2813.	Constantinescu R. Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatric disease and treatment. 2008;4:337-352.
2814.	Conti L, Dell'Osso L. Clinical predictors of response to fluvoxamine, imipramine, and placebo. New Trends in Experimental & Clinical Psychiatry. 1989;5:221-229.
2815.	Conti L, Placidi GF, Dell'Osso L, Lenzi A, al e. Therapeutic response in subtypes of major depression. New Trends in Experimental & Clinical Psychiatry. 1987;3:101-107.
2816.	Cookson J. Side-Effects of Antidepressants. British journal of psychiatry. 1993;163:20-24.
2817.	Cookson J, Duffett R. Fluoxetine: Therapeutic and Undesirable Effects. Hospital medicine (London, England : 1998). 1998;59:622-+.
2818.	Cookson J, PE K, TA K, Macfadden W. Number Needed to Treat and Time to Response/Remission for Quetiapine Monotherapy Efficacy in Acute Bipolar Depression: Evidence From a Large, Randomized, Placebo-Controlled Study. International clinical psychopharmacology. 2007;22:93-100.
2819.	Coombs A. A matter of the heart. Nature medicine. 2008;14:231-233.
2820.	Cooper C, Mukadam N, Katona C, et al. Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia. American journal of geriatric psychiatry. 2013;21:173-183.
2821.	Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. International journal of neuropsychopharmacology. 2008;11:685-699.
2822.	Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine, Journal of affective disorders(2009).
2823.	Coppen A. Depression as a lethal disease: Prevention strategies. Journal of clinical psychiatry. 1994;55:37-45.
2824.	Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer's disease. Current treatment options in neurology. 2012;14:113-125.
2825.	Corcos M, Flament M, Atger F, Jeammet P. [Pharmacologic treatment of bulimia]. [Review] [37 refs] [French]. Encephale. 1996;22:133-142.
2826.	Corcos M, Pham-Scottez A. Atypical antipsychotics and borderline personality disorder. [French]. Encephale. 2008;34:S219-S222.
2827.	Corey-Bloom J, Yaari R, Weisman D. Managing patients with Alzheimer's disease. Practical neurology. 2006;6:78-89.
2828.	Coric V, HH F, DA O, et al. Multicenter, Randomized, Double-Blind, Active Comparator and Placebo-Controlled Trial of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Generalized Anxiety Disorder. Depression and anxiety. 2010;27:417-425.
2829.	Coric V, Kelmendi B, Pittenger C, Wasylink S, MH B, Green J. Beneficial Effects of the Antiglutamatergic Agent Riluzole in a Patient Diagnosed With Trichotillomania. Journal of clinical psychiatry. 2007;68:170-171.
2830.	Corne SJ, Hall JR. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. International clinical psychopharmacology. 1989;4:245-254.
2831.	Cornelius J, Douaihy A, Chung T, et al. Four-year follow-up of double-blind fluoxetine trial in comorbid mddaud adolescents. Alcoholism, clinical and experimental research. 2011;Conference:20A.
2832.	Cornelius J, Ferrell R, Chung T, et al. Double-blind fluoxetine trial of comorbid MDD-CUD youth and pharmacogenetics data. Alcoholism, clinical and experimental research. 2010;Conference:175A.
2833.	A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder, International clinical psychopharmacology(2012).
2834.	Cornelius S, Christian S, Juergen H, Gregor L. Mirtazapine inhibits salivary cortisol concentrations in anorexia nervosa. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:1015-1019.
2835.	Cornish S, Mehl-Madrona L. The role of vitamins and minerals in psychiatry. Integrative medicine insights. 2008;2008:33-42.
2836.	Corrado B, A FT, Andrea C. Effectiveness of paroxetine in the treatment of acute major depression in adults: A systematic re-examination of published and unpublished data from randomized trials. CMAJ : Canadian Medical Association journal. 2008;178:296-305.
2837.	Corrado B, Andrea C, Lara M, Michele T. Validity of the Impact Factor of Journals as a Measure of Randomized Controlled Trial Quality. Journal of clinical psychiatry. 2006;67:37-40.
2838.	Corrado B, Andrea C, Paolo B, Matthew H. "Wish bias" in antidepressant drug trials?. [Review] [44 refs]. Journal of clinical psychopharmacology. 2004;24:126-130.
2839.	Corrado B, Andrea C, Vikram P, L A-MJ, Mark vO. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. [Review]. The British Journal of Psychiatry. 2011;198:11-16.
2840.	Correa R, Akiskal H, Gilmer W, AA N, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? Journal of affective disorders. 2010;127:10-18.
2841.	Correll CU. The role of antipsychotics and mood stabilizers in the treatment of bipolar disorder. Giornale Italiano di Psicopatologia / Italian Journal of Psychopathology. 2011;17:341-351.
2842.	Corruble E, Belaidi C, GM G. Agomelatine Versus Escitalopram in Major Depressive Disorders : a Randomized Double-Blind, Long Term Study Focusing on Sleep Satisfaction and Emotional Blunting. European psychiatry. 2011;26.
2843.	Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: A 24-wk randomized, controlled, double-blind trial, International journal of neuropsychopharmacology(2013).
2844.	Corruble E, J-D G. Is there a relationship between clinical efficacy and antidepressant dosage in major depression?. [French]. Encephale. 1999;25:39-43.
2845.	Corruble E, JD G. [Is there a relationship between clinical efficacy and antidepressant dosage in major depression?]. [Review] [9 refs] [French]. Encephale. 1999;25 Spec No:36-39.
2846.	Corruble E, JD G. Does Increasing Dose Improve Efficacy in Patients With Poor Antidepressant Response: a Review. Acta psychiatrica Scandinavica. 2000;101:343-348.
2847.	Corruble E, Sabran V, Payan C, AJ P, Fermanian J, JD G. Rating antidepressant efficacy with naturalistic live versus structured videotaped interviews. European psychiatry. 1998;13:225-230.
2848.	Coryell W, Rickels H. Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: A placebo-controlled, crossover study. Journal of clinical psychopharmacology. 2009;29:174-178.
2849.	Coskun M, Karakoc S, Kircelli F, NM M. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. Journal of child and adolescent psychopharmacology. 2009;19:203-206.
2850.	Coskunol H, Gokden O, ES E, Bayraktar E, Tuglular I, Saygili R. Long-term efficacy of sertraline in the prevention of alcoholic relapses in alcohol-dependent patients: A single-center, double-blind, randomized, placebo-controlled, parallel-group study. Current therapeutic research, clinical and experimental. 2002;63:759-771.
2851.	Coss-Adame E, Erdogan A, SSC R. Treatment of Esophageal (Noncardiac) Chest Pain: An Expert Review. Clinical gastroenterology and hepatology. 2014;12:1224-1245.
2852.	Costa-Campos L, AP H, LK P, Michels M, Noetzold G, Elisabetsky E. Interactive Effects of N-Acetylcysteine and Antidepressants. Progress in neuro-psychopharmacology & biological psychiatry. 2013;44:125-130.
2853.	Cotgrove A, Timimi S. Should young people be given antidepressants? British medical journal. 2007;335:750-751.
2854.	Cotter G, Milo-Cotter O, Rubinstein D, Shemesh E. Posttraumatic Stress Disorder: a Missed Link Between Psychiatric and Cardiovascular Morbidity? CNS spectrums. 2006;11:129-136.
2855.	Cotterchio M, Kreiger N, Darlington G, Steingart A. Comparison of self-reported and physician-reported antidepressant medication use. Annals of epidemiology. 1999;9:283-289.
2856.	Cottraux J, Mollard E, Bouvard M, Marks I. Exposure Therapy, Fluvoxamine, or Combination Treatment in Obsessive-Compulsive Disorder - One-Year Follow-up. Psychiatry research. 1993;49:63-75.
2857.	Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International clinical psychopharmacology. 1990;5:17-30.
2858.	Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant Use and Risk of Suicide and Attempted Suicide or Self Harm in People Aged 20 to 64: Cohort Study Using a Primary Care Database. Bmj-British Medical Journal. 2015;350.
2859.	Court A, Mulder C, Kerr M, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study. Journal of psychiatric research. 2010;44:1027-1034.
2860.	Court A, Mulder C, SE H, Purcell R, PD M. What is the scientific evidence for the use of antipsychotic medication in anorexia nervosa? Eating disorders. 2008;16:217-223.
2861.	Courtet P, Guillaume S, Seneque M, Olie E. Current indications of lithium: Suicide risk prevention. [French]. Annales medico-psychologiques. 2014;172:182-185.
2862.	Couturier J, Lock J. Psychopharmacology update: A review of medication use for children and adolescents with eating disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2007;16:173-176.
2863.	Cowen P, AC S. The role of serotonin in cognitive function: Evidence from recent studies and implications for understanding depression. Journal of psychopharmacology (Oxford, England). 2013;27:575-583.
2864.	CP A. Debate continues over the use of combination antidepressants in patients with treatment-resistant depression. Drugs and Therapy Perspectives. 2012;28:23-25.
2865.	CP A, AC A, Loutchkina D, JE H. Psychotropic drug-related problems in the elderly. Aging health. 2012;8:147-159.
2866.	CP A, JT C, AL G. An Open-Label Study of Mirtazapine as Treatment for Combat-Related Ptsd. Annals of pharmacotherapy. 2009;43:1220-1226.
2867.	CP A, Loutchkina D, AC A. Psychotropic drug safety issues: Continuing vigilance is needed. Expert review of clinical pharmacology. 2010;3:427-432.
2868.	CP C, Kumar A. Treatment of overweight and obesity: Lifestyle, pharmacologic, and surgical options. Clinical cornerstone. 2009;9:55-71.
2869.	CP C, Schmidt D, CM S, JD M, RM S. Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry research. 2013;206:213-216.
2870.	CP F. Psychological and drug therapies for post-traumatic stress disorder. Psychiatry. 2009;8:301-309.
2871.	CP F, LWA vH, JA M, et al. Antiglucocorticoids, neurogenesis and depression. Mini reviews in medicinal chemistry. 2009;9:249-264.
2872.	CP H, Mitchell K, Barlotta K, RB F. Toxicity and drug interactions associated with herbal products: Ephedra and St. John's Wort. Medical clinics of North America. 2005;89:1225-1257.
2873.	CP K, AC K, JT W. Pediatric generalized anxiety disorder: Epidemiology, diagnosis, and management. Pediatric Drugs. 2009;11:171-183.
2874.	CP M, ML M. Fibromyalgia: Helping your patient while maintaining your sanity. Primary Care - Clinics in Office Practice. 2010;37:743-755.
2875.	CP OB. Adapting treatment to patient problems. American journal of psychiatry. 2011;168:670-671.
2876.	CP P, Watson L, Doucette D, Dolovich L. Sertraline-associated bruxism. Canadian Journal of Clinical Pharmacology. 1996;3:123-125.
2877.	CPN W, Gilron I, Sawynok J, ME L. Nontricyclic Antidepressant Analgesics and Pain: Are Serotonin Norepinephrine Reuptake Inhibitors (Snris) Any Better? Pain. 2011;152:2206-2210.
2878.	CR A, JH K, GD B, et al. Electrophysiological Evidence for Rapid 5-Ht1a Autoreceptor Inhibition by Vilazodone, a 5-Ht1a Receptor Partial Agonist and 5-Ht Reuptake Inhibitor. European journal of pharmacology. 2013;714:359-365.
2879.	CR C, JT C, Cumming P, et al. Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study. Psychiatry research. 2014;221:231-239.
2880.	CR C, JT C, Cumming P, et al. Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET study. Psychiatry Research - Neuroimaging. 2014;221:231-239.
2881.	CR C, YI S, JT C, et al. Using functional neuroimaging to study dopaminergic effects of adjunctive aripiprazole on the brain in treatment-resistant major depression. Biological psychiatry. 2011;Conference:161S.
2882.	CR C, YI S, JT C, et al. Positron emission tomography and functional MRI to assess mechanism of action ofaripiprazole as an antidepressant augmentation agent. Biological psychiatry. 2010;Conference:136S.
2883.	CR D, MH N, CA I. The effects of mirtazapine on sleep in patients with major depressive disorder. [Review]. Annals of clinical psychiatry. 2012;24:215-224.
2884.	CR D, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. [Review] [65 refs]. Annals of pharmacotherapy. 2008;42:1822-1831.
2885.	CR H, GS S, PR H, et al. The Clinical Response to Total Sleep Deprivation and Recovery Sleep in Geriatric Depression: Potential Indicators of Antidepressant Treatment Outcome. Psychiatry research. 2000;97:41-49.
2886.	CR J, Shwetha H, Rajarathna K. A cross sectional study to evaluate the non-epileptic uses of antiepileptic drugs at a tertiary care hospital. International Journal of Pharmaceutical and Phytopharmacological Research. 2014;4:199-200.
2887.	CR M, DR T. Depression in coronary heart disease patients: Etiological and screening issues. Current psychiatry reviews. 2006;2:245-254.
2888.	Craig M, Abel K. Prescribing for psychiatric disorders in pregnancy and lactation. Best Practice and Research: Clinical Obstetrics and Gynaecology. 2001;15:1013-1030.
2889.	Craig NJ. Anxiety does not predict response to duloxetine in major depression: Results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depression and anxiety. 2010;27:12-18.
2890.	Craig NJ. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression. Journal of clinical psychopharmacology. 2011;31:682-684.
2891.	Craig NJ, Kevin D, Lon S. Suicidal thinking and behavior during treatment with sertraline in late-life depression. The American Journal of Geriatric Psychiatry. 2007;15:573-580.
2892.	Craig NJ, Laura P, C LA. Residual Symptoms in Depressed Patients After Treatment With Fluoxetine or Reboxetine. Journal of clinical psychiatry. 2005;66:1409-1414.
2893.	Craig NJ, Laura P, C LA. Are There Differences in the Symptoms that Respond to a Selective Serotonin or Norepinephrine Reuptake Inhibitor? [References]. Biological psychiatry. 2005;57:1535-1542.
2894.	Craig NJ, M MC, BJr BM, I JP, H PL. Reply. Biological psychiatry. 2004;56:535-536.
2895.	Craig NJ, M MC, I JP, BJr BM, H PL. Combining Norepinephrine and Serotonin Reuptake Inhibition Mechanisms for Treatment of Depression: A Double-Blind, Randomized Study. Biological psychiatry. 2004;55:296-300.
2896.	Craig NJ, M WM, H MC, J DM, G WJ, S KJ. Duloxetine for the Treatment of Major Depressive Disorder in Older Patients. The American Journal of Geriatric Psychiatry. 2005;13:227-235.
2897.	Craig NJ, Qianyi Z, Katarina K, Elias E, Walter D, Michael B. Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants. Current medical research and opinion. 2013;29:827-833.
2898.	Craig NJ, S KJ, G PB, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American journal of psychiatry. 1999;156:1024-1028.
2899.	Crawford A, Lewis S, Hodgson K, et al. Genome-wide association study of antidepressant-induced sexual dysfunction in depressed males. European neuropsychopharmacology. 2014;Conference:S373-S374.
2900.	Crawford-Faucher A. Escitalopram effective for reducing hot flashes in menopausal women. American family physician. 2011;84:1293-1294.
2901.	Creed F. How Do Ssris Help Patients With Irritable Bowel Syndrome? Gut. 2006;55:1065-1067.
2902.	Creed F, Guthrie E, Ratcliffe J, et al. Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Australian and New Zealand journal of psychiatry. 2005;39:807-815.
2903.	Crespo-Facorro B, Perez-Iglesias R, Mata I, et al. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: Results of a 6-week, randomized, flexible-dose, open-label comparison. Journal of clinical psychopharmacology. 2013;33:215-220.
2904.	Creswell C, Waite P, PJ C. Assessment and management of anxiety disorders in children and adolescents. Archives of disease in childhood. 2014;99:674-678.
2905.	Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: A 12-week, randomized, double-blind, placebo-controlled trial, Journal of clinical psychiatry(2011).
2906.	Cristobal G, Victor N, Teodoro M, J PM, Merce T, Miquel R. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. Journal of clinical psychopharmacology. 2003;23:21-26.
2907.	Crone C, GM G. Comprehensive review of hepatitis C for psychiatrists: Risks, screening, diagnosis, treatment, and interferon-based therapy complications. Journal of psychiatric practice. 2003;9:93-110.
2908.	Croydon L. American Chemical Society - 235th national meeting: Part 1. IDrugs : the investigational drugs journal. 2008;11:387-390.
2909.	Crucitti A, Zhang Q, Nilsson M, Brecht S, CR Y, Wernicke J. Duloxetine Treatment and Glycemic Controls in Patients With Diagnoses Other Than Diabetic Peripheral Neuropathic Pain: a Meta-Analysis. Current medical research and opinion. 2010;26:2579-2588.
2910.	Cruz N, JM G, Sanchez-Moreno J, Vieta E. Efficacy of modern antipsychotics in placebocontrolled trials in bipolar depression: A meta-analysis. European neuropsychopharmacology. 2008;Conference:S427.
2911.	Cruz N, Vieta E. Antidepressants in acute bipolar depression: An inconclusive meta-analysis. Journal of clinical psychiatry. 2011;72:415-416.
2912.	CS A, RL B. A multi-hit endocrine model of intrinsic adult-onset asthma. Ageing research reviews. 2008;7:114-125.
2913.	CS B. Depression and anxiety disorders. Obstetrics and gynecology clinics of North America. 2001;28:241-268.
2914.	CS B. First pregabalin and now duloxetine for fibromyalgia syndrome: Closer to a brave new world? Nature clinical practice. Rheumatology. 2008;4:636-637.
2915.	CS B, AS F, Wan J, FW L. Citalopram in the Treatment of Women With Chronic Pelvic Pain - an Open-Label Trial. Journal of reproductive medicine. 2008;53:191-195.
2916.	CS B, EW F, FW L. An Update on the Treatment of Premenstrual Syndrome. American journal of managed care. 1998;4:266-274.
2917.	CS H, DM M, CU P, et al. Paroxetine for Patients With Undifferentiated Somatoform Disorder: a Prospective, Open-Label, 8-Week Pilot Study. Current therapeutic research, clinical and experimental. 2008;69:221-231.
2918.	CS L, Accordino R, Howard J, Koo J. Psychopharmacology in Dermatology. Dermatologic therapy. 2008;21:69-82.
2919.	CS P. [Therapeutic action lag time and resistance to treatment]. [Review] [17 refs] [French]. Encephale. 1999;25 Spec No:49-54.
2920.	CS P. Time to therapeutic action onset and resistance to treatment. [French]. Encephale. 1999;25:49-54.
2921.	CS P, Martin P, Bayle F, Banzet S. Definitions and recommendations for studying the delay of antidepressant action. Part 3: Methodological aspects. [French]. Encephale. 2003;29:313-321.
2922.	CS P, Perugi G. Eating disorders, obesity and bipolar spectrum. [Italian]. Italian Journal of Psychopathology. 2005;11:326-346.
2923.	CS P, PK L. Bayesian meta-analyses of the tolerability of selective serotonin reuptake inhibitors and tricyclic antidepressants for treating patients with depression. Singapore General Hospital Proceedings. 2005;14:17-27.
2924.	CS T, CL W, SY C, HY T, TH H, JA S. Prevention of Poststroke Depression With Milnacipran in Patients With Acute Ischemic Stroke: a Double-Blind Randomized Placebo-Controlled Trial. International clinical psychopharmacology. 2011;26:263-267.
2925.	CS V, Corruble E, Naveau S, Perlemuter G. Antidepressant-Induced Liver Injury: a Review for Clinicians. American journal of psychiatry. 2014;171:404-415.
2926.	CS W, JB C, RD L, et al. Predictors of placebo response: A retrospective analysis. Psychopharmacology bulletin. 1992;28:157-162.
2927.	CT G, LG J. Antidepressant Side Effects in Children and Adolescents. Journal of child and adolescent psychopharmacology. 2006;16:147-157.
2928.	CT M, KM G, KM H. Naltrexone/bupropion: An investigational combination for weight loss and maintenance. Obesity facts. 2011;4:489-494.
2929.	CU C, CJ K, JS M. Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants, and antipsychotics. Journal of clinical psychiatry. 2011;72:655-670.
2930.	CU C, RR P, JP M, et al. Paroxetine in the treatment of adolescent major depression [1] (multiple letters). Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1269-1271.
2931.	CU P, DM M, Han C, PS M, AA P. Pregabalin Augmentation of Antidepressants in Patients With Accident-Related Posttraumatic Stress Disorder: an Open Label Pilot Study. International clinical psychopharmacology. 2009;24:29-33.
2932.	CU P, MH P, DM M, Han C, AA P, PS M. Desvenlafaxine, a Serotonin-Norepinephrine Uptake Inhibitor for Major Depressive Disorder, Neuropathic Pain and the Vasomotor Symptoms Associated With Menopause. Current opinion in investigational drugs (London, England : 2000). 2009;10:75-90.
2933.	CU P, PS M, DM M, et al. History of Early Abuse as a Predictor of Treatment Response in Patients With Fibromyalgia: a Post-Hoc Analysis of a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine Controlled Release. World journal of biological psychiatry. 2009;10:435-441.
2934.	CU P, SM W, Han C, et al. Vortioxetine: a Meta-Analysis of 12 Short-Term, Randomized, Placebo-Controlled Clinical Trials for the Treatment of Major Depressive Disorder. Journal of psychiatry & neuroscience. 2015;40:174-186.
2935.	Cui Z, DE F, Shen W, SL A, Novick D. Longitudinal analysis of patient level health care costs in patients with major depressive disorder treated with duloxetine. Value in health. 2012;Conference:A335-A336.
2936.	Cui Z, DE F, Shen W, SL A, Novick D. Longitudinal analysis of healthcare costs: A case study of patients with major depressive disorder treated with duloxetine. Journal of medical economics. 2013;16:623-632.
2937.	Cuijpers P, A VS, P VO, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. Journal of clinical psychiatry. 2008;69:1675-1685.
2938.	Cuijpers P, A vS, Schuurmans J, P vO, SD H, Andersson G. Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clinical psychology review. 2010;30:51-62.
2939.	Cuijpers P, A VS, SD H, Andersson G. The Contribution of Active Medication to Combined Treatments of Psychotherapy and Pharmacotherapy for Adult Depression: a Meta-Analysis. Acta psychiatrica Scandinavica. 2010;121:415-423.
2940.	Cuijpers P, A VS, Warmerdam L. Are individual and group treatments equally effective in the treatment of depression in adults? A meta-analysis. European Journal of Psychiatry. 2008;22:38-51.
2941.	Cuijpers P, Dekker J, SD H, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: A meta-analysis. Journal of clinical psychiatry. 2009;70:1219-1229.
2942.	Cuijpers P, RA S. Increased mortality in depressive disorders: A review. Current psychiatry reports. 2004;6:430-437.
2943.	Cuijpers P, SD H, A VS, Bockting C, Berking M, Andersson G. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open. 2013.
2944.	Culpepper L. Secondary insomnia in the primary care setting: Review of diagnosis, treatment, and management. Current medical research and opinion. 2006;22:1257-1268.
2945.	Culpepper L. Does screening for depression in primary care improve outcome? Current psychiatry reports. 2012;14:345-352.
2946.	Culpepper L. The diagnosis and treatment of bipolar disorder: Decision-making in primary care. Primary care companion to the Journal of clinical psychiatry. 2014.
2947.	Culpepper L, LJ K. A review of the literature on the selegiline transdermal system: An effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Primary care companion to the Journal of clinical psychiatry. 2008;10:25-30.
2948.	Cumyn L, Kolar D, Keller A, Hechtman L. Current issues and trends in the diagnosis and treatment of adults with ADHD. Expert review of neurotherapeutics. 2007;7:1375-1390.
2949.	Curatolo E, Brasil H. Depression in childhood: Peculiarities in diagnosis and pharmacological treatment. [Portuguese]. Jornal brasileiro de psiquiatria. 2005;54:170-176.
2950.	Curran G, Ravindran A. Lithium for bipolar disorder: A review of the recent literature. Expert review of neurotherapeutics. 2014;14:1079-1098.
2951.	Curran S, Rampat R, Spencer R, Minogue V, Warns J. Paroxetine for the treatment of old age depression: A systematic review. European neuropsychopharmacology. 2009;Conference:S403-S404.
2952.	Currie H, Cochrane R. The menopause: Risks and benefits of available treatments. Prescriber. 2013;24:17-32.
2953.	Curry J, Rohde P, Simons A, et al. Predictors and Moderators of Acute Outcome in the Treatment for Adolescents With Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1427-1439.
2954.	Curry J, Silva S, Rohde P, et al. Onset of alcohol or substance use disorders following treatment for adolescent depression. Journal of consulting and clinical psychology. 2012;80:299-312.
2955.	Curry J, Silva S, Rohde P, et al. Recovery and recurrence following treatment for adolescent major depression. Archives of general psychiatry. 2011;68:263-269.
2956.	Curry P, O'Brien M. The male heart and the female mind: A study in the gendering of antidepressants and cardiovascular drugs in advertisements in Irish medical publication. Social science & medicine. 2006;62:1970-1977.
2957.	Cusin C, Iovieno N, DV I, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder. Journal of clinical psychiatry. 2013;74:E636-E641.
2958.	Cusin C, Serretti A, Zanardi R, et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. International journal of neuropsychopharmacology. 2002;5:27-35.
2959.	Cutler A, Ball S, SM S. Dosing atypical antipsychotics. CNS spectrums. 2008;13:3-14.
2960.	CV FL, LT D, CE F, et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? depression in alzheimer's disease study 2. American journal of geriatric psychiatry. 2014;22:14-24.
2961.	CV FL, LT D, CE F, et al. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. American journal of geriatric psychiatry. 2014;22:14-24.
2962.	CW B, CM M, SM dCT, MF J. Early life stress in depressive patients: HPA axis response to GR and MR agonist. Frontiers in Psychiatry. 2014.
2963.	CW H, GJ E, ML C, et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:1442-1454.
2964.	CW H, GJ E, ML C, et al. Texas Children's Medication Algorithm Project: Update From Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:667-686.
2965.	CW L. (S)-(+)-mecamylamine (TC-5214): A neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for major depressive disorder (MDD). ACS chemical neuroscience. 2010;1:530-531.
2966.	CW T, SD O, Sondergaard S, Bech P. The WHO-5 well-being index: A systematic review of the literature. Psychotherapy and psychosomatics. 2015;84:167-176.
2967.	CY C, SI F, MB M, EM R. Recruitment and enrollment of elderly persons with depression into a clinical drug trial. International Journal of Geriatric Psychopharmacology. 1999;2:23-27.
2968.	CY L, GE T, HS W, et al. Effectiveness of Aripiprazole, Olanzapine, Quetiapine, and Risperidone Augmentation Treatment for Major Depressive Disorder: a Nationwide Population-Based Study. Journal of clinical psychiatry. 2014;75:E924-U947.
2969.	Cynthia LM, Katherine W, H HB. Does maternal role functioning improve with antidepressant treatment in women with postpartum depression? [References]. Journal of women's health (2002). 2009;18:85-90.
2970.	Cynthia LM, Katherine W, H HB, Amanda P. Role functioning and symptom remission in women with postpartum depression after antidepressant treatment. Archives of psychiatric nursing. 2003;17:276-283.
2971.	CZG DC, Rmcb DM, DMT Z, et al. Comparison Among Clomipramine, Fluoxetine, and Placebo for the Treatment of Anxiety Disorders in Children and Adolescents. Journal of child and adolescent psychopharmacology. 2013;23:687-692.
2972.	Czlonkowska A, Lesniak M. Pharmacotherapy in stroke rehabilitation. Expert opinion on pharmacotherapy. 2009;10:1249-1259.
2973.	Czobor P, Skolnick P, Beer B, Lippa A. A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study of Efficacy and Safety of Ocinaplon (Dov 273,547) in Generalized Anxiety Disorder. CNS neuroscience & therapeutics. 2010;16:63-75.
2974.	D AJ. "Antidepressants in rapid-cycling bipolar disorder": Response. The British Journal of Psychiatry. 2013;203:75.
2975.	D AJ, B HM, Jess A. Once- versus twice-daily venlafaxine therapy in major depression: A randomized, double-blind study. Journal of clinical psychiatry. 1998;59:236-240.
2976.	D AJ, Chia-Hao W, Michelle S, Justine S. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: A randomized, parallel group, open-label trial. Journal of affective disorders. 2009;112:219-230.
2977.	D AJ, David W, David M, et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology. 2009;59:227-233.
2978.	D AJ, Felipe G-E. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. Journal of affective disorders. 2000;59:225-229.
2979.	D AJ, Felipe G-E, Jan F, et al. Blood pressure changes during short-term fluoxetine treatment. Journal of clinical psychopharmacology. 1999;19:9-14.
2980.	D AJ, Felipe G-E, Jan F, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. Journal of clinical psychopharmacology. 1998;18:435-440.
2981.	D AJ, J BD. Site variability in treatment outcome in antidepressant trials. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:989-993.
2982.	D AJ, Justine S. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. International clinical psychopharmacology. 2005;20:257-264.
2983.	D AJ, Justine S. Comparison of Fluoxetine, Olanzapine, and Combined Fluoxetine Plus Olanzapine Initial Therapy of Bipolar Type I and Type Ii Major Depression - Lack of Manic Induction. Journal of affective disorders. 2005;87:121-130.
2984.	D AJ, Justine S. Comparison for short-term venlafaxine versus lithium monotherapy for bipolar II major depression episode: A randomized open-label study. Journal of clinical psychopharmacology. 2008;28:171-181.
2985.	D AJ, Justine S. Does tachyphylaxis occur after repeated antidepressant exposure in patients with bipolar II major depressive episode? [References]. Journal of affective disorders. 2009;115:234-240.
2986.	Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study, American journal of psychiatry(2010).
2987.	D AJ, Justine S, J BD, Miriam H. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar disorders. 2004;6:75-81.
2988.	D AJ, Justine S, Nancy R. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:100-106.
2989.	Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder, The British Journal of Psychiatry(2013).
2990.	D AJ, Maurizio F, Greg M, Jerrold R, Mady H-R. TRH stimulation test as a predictor of acute and long-term antidepressant response in major depression. Journal of affective disorders. 1996;38:165-172.
2991.	A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder, Journal of child and adolescent psychopharmacology(2014).
2992.	D BJ. Fluoxetine in depressed patients: A comparison with imipramine. Journal of clinical psychiatry. 1984;45:414-419.
2993.	D DB, CM C, Marini S, et al. Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data. International journal of immunopathology and pharmacology. 2013;26:299-304.
2994.	D dB, G DI, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine. CNS and Neurological Disorders - Drug Targets. 2011;10:119-132.
2995.	D DB, Marini S, Fornaro M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: Implications for clinical practice. International journal of molecular sciences. 2013;14:12458-12483.
2996.	D DB, Marini S, Serroni N, et al. S-Adenosyl-L-Methionine Augmentation in Patients With Stage Ii Treatment-Resistant Major Depressive Disorder: an Open Label, Fixed Dose, Single-Blind Study. TheScientificWorldJournal. 2013.
2997.	D DB, Serroni N, Carano A, et al. The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatric disease and treatment. 2008;4:929-935.
2998.	D DE, M KG. Spotlight on olanzapine/fluoxetine in acute bipolar depression. CNS drugs. 2008;22:793-795.
2999.	D DM, FN J. The clinical efficacy of reboxetine in the treatment of depression. Reviews in Contemporary Pharmacotherapy. 2000;11:303-320.
3000.	D DR, Rucci P, Lodi M, Ravaglia G, Forti P, Volterra V. Fluoxetine and amitriptyline in elderly depressed patients: A 10-week, double-blind study on course of neurocognitive adverse events and depressive symptoms. Archives of gerontology and geriatrics. 1998;Suppl 6:125-140.
3001.	D DW, HO S. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotoxicity research. 2002;4:453-468.
3002.	D FA, F FM, Patrice B, A GJ. Sertraline versus fluoxetine in the treatment of major depression: A combined analysis of five double-blind comparator studies. International clinical psychopharmacology. 2003;18:203-210.
3003.	D GB, Jonathan B, D MJ, et al. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology. 1998;140:434-444.
3004.	D GJ, Carla W, David H, Y GJ, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of clinical psychiatry. 1995;56:450-458.
3005.	D GR, Hendricks BC, Kwan H, M DJ, John MJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.[Erratum appears in Arch Gen Psychiatry.2013 Aug;70(8):881]. Archives of general psychiatry. 2012;69:580-587.
3006.	D GR, Hendricks BC, Kwan H, M DJ, John MJ. "Suicidal thoughts and behavior with antidepressant treatment: Reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine": Correction. JAMA Psychiatry. 2013;70:881.
3007.	D GR, Kwan H, Hendricks BC, M DJ, John MJ. Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Archives of general psychiatry. 2012;69:572-579.
3008.	D HJ, E FM, B FE, T DJR. Study refusal and exclusion from a randomized treatment study of generalized social phobia. Journal of anxiety disorders. 2003;17:683-693.
3009.	D HK, B NC. Paroxetine. 2004:259-281.
3010.	Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, Jama Psychiatry(2014).
3011.	D HS, Judy G, C SR. Treatment of Depression in Adolescents With Cognitive Behavior Therapy and Medications: A Commentary on the TADS Project. Cognitive and behavioral practice. 2005;12:149-155.
3012.	D JR, S FE, R BS, L FA, H HR, E TM. Effects of Sertraline on Sleep Architecture in Patients with Depression. Journal of clinical psychopharmacology. 2003;23:540-548.
3013.	Remission and recovery in the Treatment for Adolescents With Depression Study (TADS): Acute and long-term outcomes, Journal of the American Academy of Child and Adolescent Psychiatry(2009).
3014.	D KB, J EG, L MT, et al. Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression. American journal of psychiatry. 2014;171:1083-1090.
3015.	Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder, Journal of the American Academy of Child and Adolescent Psychiatry(2008).
3016.	D KB, N CG, Robin WV, et al. Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: Preliminary findings. Journal of consulting and clinical psychology. 2009;77:1033-1041.
3017.	D lG, Lock J. New and emerging treatment options for adolescent bulimia nervosa. Therapy. 2007;4:841-849.
3018.	D LNA. Self-concept and attributional style in the treatment of depression. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2002;63:533.
3019.	D LP, T SW, Vincent G, R PJ. Short-term cotherapy with clonazepam and fluoxetine: Anxiety, sleep disturbance and core symptoms of depression. Journal of affective disorders. 2000;61:73-79.
3020.	D LR, Jian-Hua S, Ripu J, S DH, H KS, M SC. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.[Erratum appears in J Psychiatry Neurosci. 2000 Nov;25(5):439]. Journal of psychiatry & neuroscience. 2000;25:337-346.
3021.	D LR, Jian-Hua S, Ripu J, S DH, H KS, M SC. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: Antidepressant and hypnotic effects. Journal of psychiatry & neuroscience. 2000;25:439.
3022.	D LR, S WC, F HJ, Elaine C, Wisselink PG. Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives? Psychopharmacology bulletin. 1994;30:151-156.
3023.	D LT, Falorni A. Pharmacological causes of hyperprolactinemia. Therapeutics and clinical risk management. 2007;3:929-951.
3024.	D LY, Browne M, Horn E, et al. Treatment of major affective disorder with fluvoxamine. Journal of clinical psychiatry. 1987;48:65-68.
3025.	D MJ, A BK, M PL, et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analyses. Journal of clinical psychiatry. 2002;63:1164-1170.
3026.	D MR, M JC, Y CP, Helen S, A KD, J DC. Bupropion and sertraline combination treatment in refractory depression. Journal of psychopharmacology (Oxford, England). 1995;9:284-286.
3027.	D NR, G PB, R HP, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine. Journal of psychiatric research. 2003;37:99-108.
3028.	D PE, Gabriel T, Reneh K, Demetria P, William IW. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up. Psychiatry research. 2015;225:680-686.
3029.	D PE, Michael S, Ann-Marie F, Faouzia B, Goodnick P, Fieve RR. The predictive value of the dexamethasone suppression test: A placebo-controlled study. The British Journal of Psychiatry. 1989;155:667-672.
3030.	D PR, G PA, L RR. Can improvement in well-being and functioning be distinguished from depression improvement in antidepressant clinical trials? [References]. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation. 2002;11:9-17.
3031.	D RN. Continuation treatment with antidepressants in child and adolescent major depression. American journal of psychiatry. 2008;165:411-412.
3032.	D SA, CNathan M, Paul R, C LC, John C, John M. Does homework "matter" in cognitive behavioral therapy for adolescent depression? [References]. Journal of cognitive psychotherapy. 2012;26:390-404.
3033.	D SB, W MS, MA C, Siegelman J. Which drug for which patient? is there a Fluoxetine responding versus a Bupropion responding personality profile? Clinical practice and epidemiology in mental health. 2013;9:142-147.
3034.	D SM, A SD, J AB, et al. Persistence of Antidepressant Treatment Effects in a Pharmacotherapy Plus Psychotherapy Trial for Active Injection Drug Users. American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2005;14:346-357.
3035.	Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons, Journal of substance abuse treatment(2010).
3036.	D TB, C ZR. When prevention is a bad idea: Problems with the DECARD trial and the premise behind it. Journal of psychosomatic research. 2012;72:333-335.
3037.	D TG, H GJ, W JJ, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: A comparative trial of fluoxetine versus imipramine. Journal of clinical psychopharmacology. 1994;14:385-391.
3038.	D TG, H HJ, L TS, A BM, L KD, B NC. Is there a relationship between baseline and treatment-associated changes in [-3H]-IMI platelet binding and clinical response in major depression? Neuropsychopharmacology. 1996;14:47-53.
3039.	D TG, H RA, G EG, H PJ. Does pharmacotherapy induce paradoxical worsening in some patients? Depression. 1993;1:105-107.
3040.	D TG, H RA, M BC, G EG, H PJ. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. Journal of clinical psychopharmacology. 1994;14:163-169.
3041.	D TG, Jan F, George W, et al. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. [Review] [81 refs]. Annals of clinical psychiatry. 1993;5:209-224.
3042.	D TG, L HS. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. International clinical psychopharmacology. 1993;8:253-259.
3043.	D TG, L HS, E SM, H PJ. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Journal of clinical psychiatry. 1994;55:50-59.
3044.	D TG, L HS, E SM, H PJ. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Journal of Clinical Psychiatry Monograph Series. 1995;13:13-22.
3045.	D TW, Murali DP. A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. [Review] [95 refs]. Neuropsychopharmacology. 2004;29:2285-2299.
3046.	D vC, Zobel I, Dykierek P, et al. Time course of response to antidepressants: Predictive value of early improvement and effect of additional psychotherapy. Journal of affective disorders. 2009;114:243-253.
3047.	D VW, Maes M. Neuroendocrine and immune aspects of fibromyalgia. BioDrugs. 2001;15:521-531.
3048.	D WD, T AJ, A HJ, et al. The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients. Annals of clinical psychiatry. 1996;8:139-151.
3049.	D WK, J WC, Ruoyong Y. "Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder": Reply. JAMA: Journal of the American Medical Association. 2004;291:42.
3050.	D-L Q, Y-H H, G-S Y. Cost-effectiveness analysis of three drugs in treatment of patients with depression. [Chinese]. Pharmaceutical Care and Research. 2004;4:136-138.
3051.	D-M D, Tu Y, L-P C, Z-J W. Efficacy Evaluation for Depression With Somatic Symptoms Treated by Electroacupuncture Combined With Fluoxetine. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2009;29:167-173.
3052.	D-Q D, Y-B W. Living ability and cognitive function ameliorated by low frequency repetitive transcranial magnetic stimulation in patients with post-stroke depression: Comparison with drug plus psychological treatment. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:22-23.
3053.	D'Agostino A, CD E, JA R. Vortioxetine (brintellix): A new serotonergic antidepressant. P and T. 2015;40:36-40.
3054.	D'Amico D. Controversies in migraine: Monotherapy. Neurological sciences. 2012;33:S141-S145.
3055.	D'Amico D, Leone M, Grazzi L, Bussone G. When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis? Neurological sciences. 2008;29:S55-S58.
3056.	D'Empaire I, CJ G-P, SH P. Antidepressant treatment and altered CYP2D6 activity Are pharmacokinetic variations clinically relevant? Journal of psychiatric practice. 2011;17:330-339.
3057.	DA A, Birmaher B. Relation between anxiety and depressive disorders in childhood and adolescence. Depression and anxiety. 2001;14:67-78.
3058.	DA A, JM P, Birmaher B, et al. Platelet Serotonin Reuptake Inhibition and Response to Ssris in Depressed Adolescents. American journal of psychiatry. 2005;162:802-804.
3059.	DA A, JM P, Birmaher B, et al. Platelet Serotonin Reuptake Inhibition and Response to Ssris in Depressed Adolescents. American journal of psychiatry. 2005;162:802-804.
3060.	DA B. Is the medication bottle for pediatric and adolescent depression half-full or half-empty? Journal of adolescent health. 2005;37:431-433.
3061.	DA B. Glad for what TADS adds, but many TADS grads still sad. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1461-1464.
3062.	DA B. Selective serotonin reuptake inhibitors and suicidality: A guide for the perplexed. Canadian Journal of Psychiatry. 2009;54:72-74.
3063.	DA B. Youth depression and suicide: Selective serotonin reuptake inhibitors treat the former and prevent the latter. Canadian Journal of Psychiatry. 2009;54:76-77.
3064.	DA B. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depression and anxiety. 2009;26:871-874.
3065.	DA B, Birmaher B. British warnings on SSRIs questioned [1]. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:379-380.
3066.	DA B, Birmaher B. Treatment-Resistant Depression in Adolescents: Recognition and Management. Child and adolescent psychiatric clinics of North America. 2006;15:1015-1034.
3067.	DA B, Cameron J, DA L. A primate model of the effects of childhood antidepressant treatment. American journal of psychiatry. 2014;171:252-255.
3068.	DA B, JA B, Lambert G. Recent advances in late-life mood disorders. Current Geriatrics Reports. 2014;3:245-252.
3069.	DA C. Do antidepressant medications work? P and T. 2013;38:162-163.
3070.	DA C. Pharmacotherapy of neuropsychiatric symptoms of dementia. P and T. 2015;40:284-287.
3071.	DA C, Knapp C, Rotrosen J, et al. Nefazodone Treatment of Cocaine Dependence With Comorbid Depressive Symptoms. Addiction (Abingdon, England). 2005;100:23-31.
3072.	DA C, Knapp C, Rotrosen J, et al. Nefazodone Treatment of Cocaine Dependence With Comorbid Depressive Symptoms. Addiction (Abingdon, England). 2005;100:23-31.
3073.	DA C, Sarris J, Berk M. Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:887-895.
3074.	DA D, Danilewitz M, Naesdal J, Hwang C, Adler J, DG S. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. American journal of gastroenterology. 2008;103:2562-2569.
3075.	DA F. Polypharmacy treatment approaches to the psychiatric and somatic comorbidities found in patients with chronic pain. American journal of physical medicine & rehabilitation. 2005;84:S56-S63.
3076.	DA F. Duloxetine Status - Introduction. Pain medicine (Malden, Mass.). 2007;8:S25-S26.
3077.	DA F. Duloxetine status. Pain medicine (Malden, Mass.). 2007;8:S25-S26.
3078.	DA F, Cole B, JE L, JR G. Does Pain Interfere With Antidepressant Depression Treatment Response and Remission in Patients With Depression and Pain? An Evidence-Based Structured Review. Pain medicine (Malden, Mass.). 2014;15:1522-1539.
3079.	DA F, Hall J, AL M, Gonzales J, Mallinckrodt C. Does Pain Mediate the Pain Interference with Sleep Problem in Chronic Pain? Findings from Studies for Management of Diabetic Peripheral Neuropathic Pain with Duloxetine. Journal of pain and symptom management. 2008;36:639-647.
3080.	DA F, MB B. A survey of clinician's practice in the symptomatic treatment of ALS. Amyotrophic lateral sclerosis and other motor neuron disorders. 2003;4:258-263.
3081.	DA G, Paredes A. Effect of Fluoxetine on Alcohol-Consumption in Male Alcoholics. Alcoholism, clinical and experimental research. 1992;16:261-265.
3082.	DA G, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS drugs. 2008;22:563-586.
3083.	DA G, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiology of disease. 2012;46:581-589.
3084.	DA G, SL H, JH H, et al. Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: a Placebo-Controlled Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:773-779.
3085.	DA H. New drug update: 2008. Consultant pharmacist. 2009;24:268-280.
3086.	DA H, Debattista C, RJ V, DV I. Measuring Severe Adverse Events and Medication Selection Using a "Peer Report" for Nonpsychotic Patients: a Retrospective Chart Review. Neuropsychiatric disease and treatment. 2012;8:277-284.
3087.	DA H, F RL, LM R, et al. Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial. Journal of consulting and clinical psychology. 2015;83:359-369.
3088.	DA H, Schiller M, JM G, DV I. Polypharmacy or medication washout: An old tool revisited. Neuropsychiatric disease and treatment. 2011;7:639-648.
3089.	DA K, GS S, DJ P, Carpenter D, JP D, Ross R. Expert consensus guidelines for the medication treatment of bipolar disorder: A new treatment tool. Economics of Neuroscience. 2001;3:49-57.
3090.	DA K, RL F. Randomized trial of the effect of research design and publication characteristics on physician change. Primary care companion to the Journal of clinical psychiatry. 2006;8:32-38.
3091.	DA M, Mago R, EJ SK. Depression, cognition, and anxiety among postmenopausal women with breast cancer. Psychiatric services (Washington, D.C.). 2005;56:1353-1355.
3092.	DA P. Frontocingulate dysfunction in depression: Toward biomarkers of treatment response. Neuropsychopharmacology. 2011;36:183-206.
3093.	DA R, JS C. Steroid psychosis: A review for neurosurgeons. Journal of neuro-oncology. 2012;109:439-447.
3094.	DA R, LC P, AM R. Incorporating pharmacoeconomic and health outcomes into randomized clinical trials. Expert review of pharmacoeconomics & outcomes research. 2005;5:695-703.
3095.	DA R, Siddique J, JY C, et al. Cost-Effectiveness of Evidence-Based Pharmacotherapy or Cognitive Behavior Therapy Compared With Community Referral for Major Depression in Predominantly Low-Income Minority Women. Archives of general psychiatry. 2005;62:868-875.
3096.	DA R, W-H C, Frank L, Feltner D, Morlock R. Development and analysis of item response theory-based short-form depression severity scales based on the HDRS and MADRS. Health outcomes research in medicine. 2010;1:e111-e122.
3097.	DA R, Wood M. Patient-Assigned Health State Utilities for Depression-Related Outcomes: Differences by Depression Severity and Antidepressant Medications. Journal of affective disorders. 1998;48:25-36.
3098.	DA S, HS M, AR M, et al. Limbic-frontal circuitry in major depression: A path modeling metanalysis. NeuroImage. 2004;22:409-418.
3099.	DA S, JA M, AL H, DR H, DJ N, Henry B. Comparison of Alterations in C-Fos and Egr-1 (Zif268) Expression Throughout the Rat Brain Following Acute Administration of Different Classes of Antidepressant Compounds. Neuropsychopharmacology. 2005;30:1278-1287.
3100.	DA S, MS B. Continuation and maintenance pharmacotherapy for unipolar and bipolar mood disorders. Psychiatric clinics of North America. 1993;16:515-540.
3101.	DA S, Pharm B, TL S, Pharm D, LM R. Antidepressant pharmacotherapy: A review of pharmacoeconomic research. [French]. Encephale. 1999;25:373-380.
3102.	DA S, RY J, Liu N, et al. Effects of Bd1047, a Sigma(1) Receptor Antagonist, on the Expression of Mtor, Camk2 Gamma and Gsk-3 Beta in Fluvoxamine-Treated N2a Cells. Experimental and therapeutic medicine. 2014;7:435-438.
3103.	DA S, SA S, TJ B. An Open Trial of Fluvoxamine Therapy for Panic Disorder Complicated by Depression. Journal of clinical psychiatry. 1996;57:37-41.
3104.	DA S, Sheridan R. Second-generation antidepressants for depression in adults. American family physician. 2013;88:687-689.
3105.	DA S, TL S, LM R, JK S. Economic appraisal of antidepressant pharmacotherapy: Critical review of the literature and future directions. Depression and anxiety. 1998;8:121-127.
3106.	DA S, TL S, LM R, RS G, RF L, NL N. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. Journal of clinical psychiatry. 1998;59 Suppl 2:13-17.
3107.	DA S, TM S, Niazi R, LH T, TT P. Depression after delivery: Risk factors, diagnostic and therapeutic considerations. TheScientificWorldJournal. 2007;7:1670-1682.
3108.	DA W, CM G, Petty F, BW H, MV M, AJ R. Tridimensional Personality Questionnaire and serotonin in bulimia nervosa. Psychiatry research. 1993;48:9-15.
3109.	Dag A, P LJ, Geok LN, Lene W, Per B. alpha2-Adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson disease and depression. Nordic journal of psychiatry. 2000;54:411-415.
3110.	Dai W, WD L, Lu J. [Effect of electroacupuncture on hippocampal apoptosis and JNK signal pathway in chronic stress depression rats]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2010;35:330-334.
3111.	DAKDJ K, Hlt CPSM. Use of Selective Serotonin Reuptake Inhibitor Medications for the Treatment of Child and Adolescent Mental Illness. Paediatrics & child health. 2013;18:487-491.
3112.	Dalery J, Aubin V. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence]. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2001;27:71-81.
3113.	Dalery J, Bouhassira M, J-P K, Lancrenon S, Tafani A, Hantouche EG. Agitated-anxious versus blunted-retarded major depressions: Different clinical effects of fluoxetine. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1995;21:217-225.
3114.	Dalery J, Bouhassira M, JP K, Lancrenon S, Tafani A, EG H. [Major agitated-anxious versus blunted-retarded depression: differential effects of fluoxetine]. [French]. L'Enc�phale. 1995;21:217-225.
3115.	Dalery J, Rochat C, Peyron E, Bernard G. [Comparative study of the efficacy and acceptability of amineptine and fluoxetine in patients with major depression]. [French]. L'Enc�phale. 1992;18:257-262.
3116.	Dalery J, Rochat C, Peyron E, Bernard G. Comparative study of the efficacy and the acceptability of amineptine versus fluoxetine in major depressive episodes. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1992;18:257-262.
3117.	Dalery J, Rochat C, Peyron E, Bernard G. The efficacy and acceptability of amineptine versus fluoxetine in major depression. International clinical psychopharmacology. 1997;12 Suppl 3:S35-38.
3118.	Exercise and depression: A review of reviews, Journal of clinical psychology in medical settings(2008).
3119.	Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry. 1998;31:48-54.
3120.	Dam M, Tonin P, A DB, et al. Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy. Stroke; a journal of cerebral circulation. 1996;27:1211-1214.
3121.	DAMDA M. Duloxetine Use in Painful Conditions. Expert opinion on pharmacotherapy. 2011;12:1333-1340.
3122.	Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Archives of general psychiatry. 2007;64:170-176.
3123.	Damsa C, Bumb A, Bianchi-Demicheli F, et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. [Review] [62 refs]. Journal of clinical psychiatry. 2004;65:1064-1068.
3124.	Danchenko N, Despiegel N, Marteau F, S HdR. Economic benefits of escitalopram versus duloxetine in Spain. Value in health. 2009;Conference:A354.
3125.	Danial K, Mehdi F, Amirhossein M, et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: A randomized, double-blind, placebo-controlled study. Journal of clinical psychiatry. 2012;73:1428-1433.
3126.	Daniel D, Aurora S, Viorel L, Doina C. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: A randomized clinical trial, posttreatment outcomes, and six-month follow-up. Journal of clinical psychology. 2008;64:728-746.
3127.	Daniel S, Alessandro S, Raffaella C, et al. Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. The World Journal of Biological Psychiatry. 2011;12:364-375.
3128.	Daniel S, Pierre V, Emmanuel W, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of affective disorders. 2004;83:233-236.
3129.	Danielsson L, Papoulias I, E-L P, Carlsson J, Waern M. Exercise or basic body awareness therapy as add-on treatment for major depression: A controlled study. Journal of affective disorders. 2014;168:98-106.
3130.	Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. International clinical psychopharmacology. 1995;10:15-20.
3131.	Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. [Review] [7 refs]. International clinical psychopharmacology. 1995;10 Suppl 2:15-20.
3132.	Danovitch I, DA G. State of the Art Treatments for Cannabis Dependence. Psychiatric clinics of North America. 2012;35:309-326.
3133.	Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: A systematic review. Journal of psychosomatic obstetrics and gynaecology. 2011;32:42-51.
3134.	Danuta L, Eva M, Johanna S, et al. Neural correlates of treatment outcome in major depression. International journal of neuropsychopharmacology. 2011;14:521-534.
3135.	Daoyuan Y, Wenqin C, Zhengming G. A study of depressive patients with psychological marital disorder and their treatment. [Chinese]. Psychological Science (China). 1999;22:259-260.
3136.	Dara S, Boris B. Developmentally informed pharmacotherapy for child and adolescent depressive disorders. [Review]. Child and adolescent psychiatric clinics of North America. 2012;21:313-325.
3137.	Darby-Stewart A, Dachs R, MA G. Antidepressants for initial treatment of depression. American family physician. 2010;81:1205-1212.
3138.	Darius R, -F AJ, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta psychiatrica Scandinavica. 1996;94:205-210.
3139.	DASDJ S. Obsessive Compulsive Disorder. South African Journal of Psychiatry Ri Stein, Dan/a-1752-2008 Oi Stein, Dan/0000-0001-7218-7810. 2013;19:180-186.
3140.	Dasgupta K. Treatment of Depression in Elderly Patients - Recent Advances. Archives of family medicine. 1998;7:274-280.
3141.	Dashtipour K, JJ C, MF L. Rasagiline for the management of Parkinson's disease. Therapy. 2008;5:203-214.
3142.	Datta V, AJ C. Recent advances in bipolar disorder pharmacotherapy: Focus on bipolar depression and rapid cycling. Expert review of clinical pharmacology. 2009;2:423-434.
3143.	David A. Tailoring treatment to parental values: A comment on TADS. Archives of general psychiatry. 2008;65:723.
3144.	David A, David B. "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial": Comment. JAMA: Journal of the American Medical Association. 2004;292:2577.
3145.	David B. Anxiety disorders: Does one treatment fit all? [References]. International journal of psychiatry in clinical practice. 2004;8:31-35.
3146.	David B, Arun R, Cynthia H, Yvon L. Psychopharmacological treatment response of patients with a DSM-III diagnosis of dysthymic disorder. Psychopharmacology bulletin. 1994;30:53-59.
3147.	Switching to Another Ssri or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With Ssri-Resistant Depression - the Tordia Randomized Controlled Trial, JAMA - Journal of the American Medical Association(2008).
3148.	David B, Kevin B, Christel B. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of psychopharmacology (Oxford, England). 2006;20:91-96.
3149.	Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study, American journal of psychiatry(2010).
3150.	David C. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?. [Review] [71 refs]. Psychotherapy and psychosomatics. 2006;76:5-14.
3151.	David C, Priscille G, Philippe M, Diane P-O, F FM. Pharmacological treatment of adolescent major depression. [Review] [75 refs]. Journal of child and adolescent psychopharmacology. 2004;14:19-31.
3152.	David F. When common clinical practice meets evidence-based medicine. Psychiatry. 2006;3:36-38.
3153.	David H. Reboxetine: Its effects as measured by the Social Adaptation Self-evaluation Scale. Acta psychiatrica Scandinavica. 2001;104:45-51.
3154.	David M. Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression. Journal of clinical psychiatry. 1999;60:338-339.
3155.	David M, A AL, D AJ, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double-blind, placebo-controlled study. Journal of clinical psychiatry. 2007;68:582-587.
3156.	A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-l-methionine (SAMe) versus escitalopram in major depressive disorder, Journal of clinical psychiatry(2014).
3157.	David M, Jay A, Jeffrey A, et al. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology. 2000;25:169-177.
3158.	David M, Mark S, Julia L, Rosalinda T. Changes in sexual function during acute and six-month fluoxetine therapy: A prospective assessment. Journal of sex & marital therapy. 2001;27:289-302.
3159.	David MK. The efficacy of treatments for childhood depression: An integrative review. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2000;60:5784.
3160.	David P. "Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder": Comment. JAMA: Journal of the American Medical Association. 2004;291:40-41.
3161.	David R, Alessandro S, Linda F, et al. Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression - a Double-Blind, Randomized Trial. Journal of clinical psychopharmacology. 2005;25:471-475.
3162.	David S, C DG, L FD. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacology bulletin. 1992;28:139-143.
3163.	David S, Carrie D, Julie G, Nick F, Ian A. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. The British Journal of Psychiatry. 2002;180:396-404.
3164.	David W. "Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial." Comment. JAMA: Journal of the American Medical Association. 2002;288:446.
3165.	David W. St John's Wort in depression: The patient's dilemma. Primary care & community psychiatry. 2006;11:137-142.
3166.	David Z. Evidence needs to be presented. Deutsches Arzteblatt international. 2013;110:11-12.
3167.	Davidson, Stewart, Rapaport, Thase. Established therapies for atypical depression. Journal of clinical psychiatry. 2007;68:30.
3168.	Davidson J. Vintage treatments for PTSD: A reconsideration of tricyclic drugs. Journal of psychopharmacology (Oxford, England). 2015;29:264-269.
3169.	Davidson J, Allgulander C, MH P, et al. Efficacy and Tolerability of Duloxetine in Elderly Patients With Generalized Anxiety Disorder: a Pooled. Analysis of Four Randomized, Double-Blind, Placebo-Controlled Studies. Human Psychopharmacology-Clinical and Experimental. 2008;23:519-526.
3170.	Davidson J, Baldwin D, DJ S, et al. Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release - a 6-Month Randomized Controlled Trial. Archives of general psychiatry. 2006;63:1158-1165.
3171.	Davidson J, DS B, DJ S, et al. A 6-Month Study of Venlafaxine Xr Versus Placebo in the Treatment of Posttraumatic Stress Disorder. European neuropsychopharmacology. 2005;15:S545.
3172.	Davis A, Gilhooley M, Agius M. Using non-steroidal anti-inflammatory drugs in the treatment of depression. Psychiatria Danubina. 2010;22 Suppl 1:S49-52.
3173.	Davis A, Gilhooley M, Agius M. Using Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Depression. Psychiatria Danubina. 2010;22:S49-S52.
3174.	Davis J, RL B. Clinical pharmacology of mirtazapine: Revisited [1]. American family physician. 1999;60:1101.
3175.	Davis L, Howland R, Zisook S, et al. Substance use disorder does not impair recovery from major depression with combination antidepressant treatment compared to SSRI monotherapy. Neuropsychopharmacology. 2010;Conference:S98-S99.
3176.	Davis R, Faulds D. Dexfenfluramine: An updated review of its therapeutic use in the management of obesity. Drugs. 1996;52:696-724.
3177.	Davis R, MI W. Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS drugs. 1996;5:389-402.
3178.	Davis R, Whittington X, HM B. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. [Review] [110 refs]. Drugs. 1997;53:608-636.
3179.	Davis V, AL R. Metabolic effects of antipsychotic drugs. Pediatric diabetes. 2006;7:176-186.
3180.	Day C, CJ B. Pharmacological approaches to reduce adiposity. British Journal of Diabetes and Vascular Disease. 2006;6:121-125.
3181.	Dayan J, Graignic-Philippe R, Seligmann C, Andro G. Use of antipsychotics and breastfeeding. Current women's health reviews. 2011;7:37-45.
3182.	DB C. Selective Serotonin Reuptake Inhibitor and Venlafaxine Use in Children and Adolescents With Major Depressive Disorder: a Systematic Review of Published Randomized Controlled Trials. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2004;49:557-563.
3183.	DB C. Pharmacotherapy for adolescent alcohol use disorder. CNS drugs. 2012;26:559-569.
3184.	DB C, Birmaher B, Axelson D, et al. Fluoxetine for the Treatment of Childhood Anxiety Disorders: Open-Label, Long-Term Extension to a Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:1263-1270.
3185.	DB D, Walker K, CI P, Twisselmann B. Rethinking childhood depression [1]. British medical journal. 2005;330:418-419.
3186.	DB F, C DP, JS K, SV L, Hindmarch I. Citalopram compared to dothiepin and placebo: Effects on cognitive function and psychomotor performance. Human psychopharmacology. 1997;12:119-126.
3187.	DB K, Ward S. Spectrum of Anxiety Disorders: Diagnosis and Pharmacologic Treatment. Journal of midwifery & women's health. 2011;56:266-281.
3188.	DB M, Roberts A, Green M, Bullock T, Baldwin D, SA M. Lack of Efficacy of Fluoxetine in Recurrent Brief Depression and Suicidal Attempts. European archives of psychiatry and clinical neuroscience. 1994;244:211-215.
3189.	DB M, Taghavi E, PA M, RC H. Fluoxetine's spectrum of action in premenstrual syndrome. International clinical psychopharmacology. 1993;8:95-102.
3190.	DB M, Taghavi E, PA M, RC H. Fluoxetine Spectrum of Action in Premenstrual-Syndrome. International clinical psychopharmacology. 1993;8:95-102.
3191.	DB R, MC Z, KA B. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International clinical psychopharmacology. 2009;24:270-275.
3192.	DC G, KK M, Sarid-Segal O, JW H, Amico E. A Placebo-Controlled Trial of Fluoxetine Added to Neuroleptic in Patients With Schizophrenia. Psychopharmacology. 1995;117:417-423.
3193.	DC H. QEEG-guided neurofeedback in the treatment of obsessive compulsive disorder. Journal of neurotherapy. 2003;7:25-52.
3194.	DC H. Hypnosis, placebos, and systematic research bias in biological psychiatry. American journal of clinical hypnosis. 2007;50:37-47.
3195.	DC M. A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression. Journal of managed care pharmacy. 2007;13:S8-S18.
3196.	DC M. A budget-impact and cost-effectiveness model for second-line treatment of major depression. Journal of managed care pharmacy. 2007;13:S8-18.
3197.	DC M, AC B, DE G, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. Journal of consulting and clinical psychology. 2001;69:942-949.
3198.	DC M, Classen C, Barrera M. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychological medicine. 2004;34:533-541.
3199.	DC M, DE G, Islar J, SL H, CP G. Treatment of Depression Is Associated With Suppression of Nonspecific and Antigen-Specific T(H)1 Responses in Multiple Sclerosis. Archives of neurology. 2001;58:1081-1086.
3200.	DC M, EM R, MJ N, DF I, JJ R, CA ZJ. Neurobiological aspects of suicide and suicide attempts in bipolar disorder. Translational neuroscience. 2013;4:203-216.
3201.	DC M, Epstein L, TL L, et al. Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. Journal of consulting and clinical psychology. 2003;71:1017-1024.
3202.	DC M, RA S, BH M, et al. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. American journal of geriatric psychiatry. 2000;8:226-231.
3203.	DC S. Antidepressant efficacy. Ethical human sciences and services. 2000;2:215-216.
3204.	DC S. Research in geriatric depression: A model for mental health research in the 21st century? American journal of geriatric psychiatry. 2005;13:829-833.
3205.	DC S, DR M, KRR K. Partial response as a predictor of outcome in geriatric depression. American journal of geriatric psychiatry. 2003;11:340-348.
3206.	DC S, KRR K, MJ H. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta- analysis. Depression and anxiety. 1997;6:10-18.
3207.	DC S, Nashelsky J. Counseling or antidepressants for treating depression? American family physician. 2005.
3208.	DC S, Snowden M, MY F, Hendrie H, WJ K, Unutzer J. Cognitive Impairment and Depression Outcomes in the Impact Study. American journal of geriatric psychiatry. 2006;14:401-409.
3209.	DC T, CJ V, Scarbrough E, LJ C, NJ R, JA P. Fibromyalgia: Combining Pharmacological and Nonpharmacological Approaches to Treating the Person, Not Just the Pain. Journal of pain. 2008;9:99-104.
3210.	DC W, BD K. Bipolar affective disorder: Advances in genetics and mood-stabilising medication. Irish journal of psychological medicine. 2006;23:24-28.
3211.	DD B, Faiz S, Bashoura L, Manzullo E. Cancer-related fatigue and sleep disorders. Sleep medicine clinics. 2013;8:229-234.
3212.	DD C. Rational Antidepressant Selection in the Elderly. Geriatrics. 1995;50:S41-S50.
3213.	DD D, AK C, Chou T, et al. Open-Label Study of Duloxetine for the Treatment of Obsessive-Compulsive Disorder. International journal of neuropsychopharmacology. 2015;18.
3214.	DD D, Jameson M, Deckersbach T, et al. Open-Label Study of High (30 Mg) and Moderate (20 Mg) Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder. International clinical psychopharmacology. 2009;24:306-311.
3215.	DD D, Loh R, MA J, NJ K. Single Modality Versus Dual Modality Treatment for Trichotillomania: Sertraline, Behavioral Therapy, or Both? Journal of clinical psychiatry. 2006;67:1086-1092.
3216.	DD L, LK H. Serotonin and energy balance: Molecular mechanisms and implications for type 2 diabetes. Expert reviews in molecular medicine. 2007;9:1-24.
3217.	DD M, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: A meta-analysis. Psychiatry research. 2014;215:82-86.
3218.	DD T. The efficacy of nutrition and lifestyle approaches in the treatment of depression. Topics in clinical nutrition. 2009;24:55-66.
3219.	DE A, AB D, Guler A, Acarer A. Inappropriate sexual behaviors in dementia and treatment approaches. [Turkish]. Yeni Symposium. 2007;45:62-73.
3220.	DE A, Kotlyar M. Premature Ejaculation Associated With Citalopram Withdrawal. Annals of pharmacotherapy. 2003;37:1804-1806.
3221.	DE A, Kotlyar M. Premature Ejaculation Associated With Citalopram Withdrawal. Annals of pharmacotherapy. 2003;37:1804-1806.
3222.	DE A, MG K, TA F. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. Journal of affective disorders. 2005;86:99-104.
3223.	Genotype-Based Ancestral Background Consistently Predicts Efficacy and Side Effects across Treatments in CATIE and STAR*D, PloS one(2013).
3224.	DE C. Striking a balance between safety and efficacy: experience with the SSRI sertraline. [Review] [32 refs]. International clinical psychopharmacology. 1994;9 Suppl 3:5-12.
3225.	Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy, International journal of clinical practice(2014).
3226.	DE F, Harness J, Brock J, Sambunaris A, JC C, Morlock R. Clinical Evaluation of the Daily Assessment of Symptoms-Anxiety (Das-a): a New Instrument to Assess the Onset of Symptomatic Improvement in Generalized Anxiety Disorder. CNS neuroscience & therapeutics. 2009;15:12-18.
3227.	DE F, JH H, GD T, WZ P. The double-blind variable placebo lead-in period: Results from two antidepressant clinical trials. Journal of clinical psychopharmacology. 2001;21:561-568.
3228.	DE G, LA B, Feucht C. Pharmacotherapy for Obese Adolescents. Pediatric clinics of North America. 2011;58:139-153.
3229.	Managing the side effects associated with commonly used treatments for bipolar depression, Journal of affective disorders(2014).
3230.	DE K, DJ M, RS M, JR C. Bipolar depression: Trial-based insights to guide patient care. Dialogues in clinical neuroscience. 2008;10:181-192.
3231.	DE K, Ismail-Beigi F, JR C. Antidepressant response associated with pioglitazone: Support for an overlapping pathophysiology between major depression and metabolic syndrome. American journal of psychiatry. 2009;166:619.
3232.	DE M. The meaning response and the ethics of avoiding placebos. Evaluation & the health professions. 2002;25:399-409.
3233.	Meaningful placebos - Controlling the uncontrollable, New England journal of medicine(2011).
3234.	DE M. Against the " placebo effect" : A personal point of view. Complementary therapies in medicine. 2013;21:125-130.
3235.	DE M, BD Z, DE E, LJ B, RC E, DK J. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. Journal of clinical psychopharmacology. 1997;17:451-459.
3236.	A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents with Depression Study (TADS), Journal of the American Academy of Child and Adolescent Psychiatry(2007).
3237.	de MHV, Geurts ACH, Van LJ. Pharmacologic treatment of poststroke depression: a systematic review of the literature. [Review] [66 refs]. Topics in stroke rehabilitation. 2003;10:79-92.
3238.	DE S. Depression during pregnancy. Obstetrical & gynecological survey. 2012;67:141-143.
3239.	DE S, Fairman M, Barbadoro S, Zownir P, Steiner M. Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder. Biological psychiatry. 1994;36:201-202.
3240.	DE T. Identifying Potentially Inappropriate Drugs for Geriatric Patients: Updating the Beers List. More Evidence for Treating Systolic Hypertension in the Elderly. Hospital pharmacy. 2004;39:210-214.
3241.	DE T, JS A, GJ D. Defining Response in Clinical Trials for Obsessive-Compulsive Disorder: a Signal Detection Analysis of the Yale-Brown Obsessive Compulsive Scale. Journal of clinical psychiatry. 2005;66:1549-1557.
3242.	DE T, KL K, Holtsclaw E, Donaghy K, SD P. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. Journal of pain and symptom management. 2002;23:442-447.
3243.	DE T, KL K, Holtsclaw E, Donaghy K, SD P. An open label pilot study of citalopram for depression and boredom in ambulatory cancer patients. Palliative & supportive care. 2003;1:71-77.
3244.	DE V, VG S. Depressions in Hematological Patients. Part 2. Therapy of Depressive Disorders in Patients With Hematological Malignancies. Gematologiya I Transfuziologiya. 2005;50:37-41.
3245.	DE W, AH RJ, VL T, JH P, DN M, CM BJ. Lack of Association Between Fluoxetine and Suicidality in Bulimia-Nervosa. Journal of clinical psychiatry. 1992;53:235-241.
3246.	Deahl M. Pharmacological treatment of depression: the role of paroxetine. [Review] [39 refs]. Hospital medicine (London, England : 1998). 2001;62:38-42.
3247.	Deakin B, Dursun S. Optimizing antidepressant treatment: efficacy and tolerability. [Review] [82 refs]. International clinical psychopharmacology. 2002;17 Suppl 1:S13-24.
3248.	Deakin B, Williams S, Downey D, et al. A non-competitive nmda antagonist AZD6765 compared with ketamine and placebo on pharmaco-mri and cognitive mechanistic biomarkers in untreated major depressive disorder; a randomized double-blind controlled trial. Neuropsychopharmacology. 2012;Conference:S209-S210.
3249.	Deakin J, O'Loughlin C. STAR*D: A summary and UK perspective. Journal of psychopharmacology (Oxford, England). 2009;23:622-624.
3250.	Deakin J, Williams S, Downey D, et al. PharmacoMRI and cognitive effects of the potential antidepressant AZD6765 compared with ketamine in untreated major depressive disorder. European neuropsychopharmacology. 2012;Conference:S264.
3251.	Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. Journal of psychiatry & neuroscience. 2011;36:78-86.
3252.	Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain injury. 2004;18:1-31.
3253.	DeBattista C. Augmentation and combination strategies for depression. Journal of psychopharmacology (Oxford, England). 2006;20:11-18.
3254.	DeBattista C, Doghramji K, MA M, MH R, RR F. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. Journal of clinical psychiatry. 2003;64:1057-1064.
3255.	Debattista C, Hawkins J. Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression. CNS drugs. 2009;23:369-377.
3256.	DeBattista C, Lembke A. Update on augmentation of antidepressant response in resistant depression. Current psychiatry reports. 2005;7:435-440.
3257.	Debattista C, Lembke A, HB S, Ghebremichael R, Poirier J. A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression. Journal of clinical psychopharmacology. 2004;24:87-90.
3258.	Debattista C, Lembke A, HB S, Ghebremichael R, Poirier J. A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression. Journal of clinical psychopharmacology. 2004;24:87-90.
3259.	Debattista C, Sofuoglu M, AF S. Serotonergic synergism: The risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biological psychiatry. 1998;44:341-347.
3260.	Deberdt W, JC N, IA L, et al. Evaluating predictors for remission with placebo using integrated data from patients with major depressive disorder. European psychiatry.
3261.	Deboer M, WO D, PJR F, JE H, JHM D, Vanduijn H. Fluvoxamine Treatment for Chronic Ptsd - a Pilot-Study. Psychotherapy and psychosomatics. 1992;57:158-163.
3262.	Deborah D, L RC, S RJ, F AR. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: A pilot study. Human Psychopharmacology: Clinical and Experimental. 2000;15:461-469.
3263.	Deborah H, Christopher N. Psychiatric Dispatches: Noteworthy Briefs From the Field. Primary psychiatry. 2003;10:19,24-28.
3264.	Deborah R, Jeffrey M, Harnett SK, V SD. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Progress in neuro-psychopharmacology & biological psychiatry. 1990;14:929-939.
3265.	Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P. Adjunctive Trazodone in the Treatment of Negative Symptoms of Schizophrenia. Hospital & community psychiatry. 1994;45:1220-1223.
3266.	DeFronzo DR, Matthew M, A AL, et al. Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Annals of clinical psychiatry. 2009;21:70-76.
3267.	The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease, Journal of neuropsychiatry and clinical neurosciences(2010).
3268.	Depression in Parkinson's disease: Symptom improvement and residual symptoms after acute pharmacologic management, The American Journal of Geriatric Psychiatry(2011).
3269.	DEJ L, Habes I, SJ J, et al. Real-time self-regulation of emotion networks in patients with depression. PloS one. 2012.
3270.	Dejonge P, Ormel J. Heterogeneity off patients with coronary artery disease and distress and the need to identify relevant subtypes. Archives of general psychiatry. 2008;65:851-852.
3271.	Dejonghe F, Tuynmanqua H, Mager J. Fluoxetin and Depression in the Dutch Psychiatric Practice - a Report of an Open Study. Tgo-Tijdschrift Voor Therapie Geneesmiddel En Onderzoek Jdr-Journal for Drugtherapy and Research. 1991;16:76-80.
3272.	Dekel R, DA D, AD S. The Use of Psychotropic Drugs in Irritable Bowel Syndrome. Expert opinion on investigational drugs. 2013;22:329-339.
3273.	Dekker J, HL V, Hendriksen M, et al. What is the best sequential treatment strategy in the treatment of depression? adding pharmacotherapy to psychotherapy or vice versa? Psychotherapy and psychosomatics. 2013;82:89-98.
3274.	Dekker J, PJ M, Kool S, G VA, Peen J, F dJ. Dose-effect relations in time-limited combined psycho-pharmacological treatment for depression. Psychological medicine. 2005;35:47-58.
3275.	Delate T, AJ G, VA S, BR M. Trends in the Use of Antidepressants in a National Sample of Commercially Insured Pediatric Patients, 1998 to 2002. Psychiatric services (Washington, D.C.). 2004;55:387-391.
3276.	Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P. Brain effects of antidepressants in major depression: A meta-analysis of emotional processing studies. Journal of affective disorders. 2011;130:66-74.
3277.	DelBello M, HC D, Landry J, Usher R, Schroer R, Dingankar M. Safety and efficacy of olanzapine/fluoxetine combination versus placebo in patients aged 10 to 17 in the acute treatment of major depressive episodes associated with bipolar i disorder. Neuropsychopharmacology. 2012;Conference:S99-S100.
3278.	Delecluse F, JA E, J-M G. A case of tardive tremor successfully treated with clozapine. Movement disorders. 1998;13:846-847.
3279.	Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: Diagnosis and management. Neuroendocrinology. 2013;98:267-280.
3280.	Delini-Stula A. Milnacipran: An antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Human psychopharmacology. 2000;15:255-260.
3281.	Delini-Stula A, Cameron A, Angst J. Comparative Efficacy of Antidepressants on Anxiety Features in Depression: a Meta-Analysis of Double-Blind Studies of Imipramine and Moclobemide Against Placebo. International journal of psychiatry in clinical practice. 2000;4:111-117.
3282.	Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS drugs. 2009;23:739-753.
3283.	Dell'Aica I, Garbisa S, Caniato R. The renaissance of hypericum perforatum: Bio-medical research catches up with folk medicine. Current bioactive compounds. 2007;3:109-119.
3284.	Dell'osso B, AC A, Mundo E, Marazziti D, Hollander E. Diagnosis and Treatment of Obsessive-Compulsive Disorder and Related Disorders. International journal of clinical practice. 2007;61:98-104.
3285.	Dell'Osso B, Allen A, AC A, Buoli M, Hollander E. Impulsive - Compulsive buying disorder: Clinical overview. Australian and New Zealand journal of psychiatry. 2008;42:259-266.
3286.	Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: A critical review. Clinical practice and epidemiology in mental health. 2005.
3287.	Dell'osso B, Arici C, Dobrea C, Camuri G, Benatti B, AC A. Escitalopram Tolerability as Mono- Versus Augmentative Therapy in Patients With Affective Disorders: a Naturalistic Study. Neuropsychiatric disease and treatment. 2013;9:205-209.
3288.	Dell'Osso B, Buoli M, Albano A, et al. Duloxetine versus iv citalopram in partial/non responder depressed patients: A randomized placebo-controlled study. European neuropsychopharmacology. 2009;Conference:S408-S409.
3289.	Dell'Osso B, Buoli M, DS B, AC A. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: A comprehensive review of their clinical efficacy. Human Psychopharmacology-Clinical and Experimental. 2010;25:17-29.
3290.	Dell'Osso B, Cremaschi L, MC P, et al. Use of asenapine as add-on therapy in the treatment of bipolar disorder: A comprehensive review and case series. Expert opinion on drug safety. 2014;13:1199-1208.
3291.	Dell'Osso B, Dobrea C, Arici C, et al. Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: A follow-up study. CNS spectrums. 2014;19:347-354.
3292.	Dell'Osso B, Dobrea C, Arici C, et al. Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: A follow-up study. CNS spectrums. 2014;19:347-354.
3293.	Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase, Journal of clinical psychiatry(2008).
3294.	Dell'Osso B, Marazziti D, Hollander E, AC A. Traditional and newer impulse control disorders: A clinical update. Clinical Neuropsychiatry. 2007;4:30-38.
3295.	Dell'osso B, MC P, Oldani L, AC A. The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects. CNS neuroscience & therapeutics. 2011;17:723-732.
3296.	DellaGioia N, Hannestad J. Citalopram pre-treatment does not reduce endotoxin-induced depressive symptoms. Biological psychiatry. 2010;Conference:242S.
3297.	Delorme R, Chabane N, Callebert J, et al. Platelet Serotonergic Predictors of Clinical Improvement in Obsessive Compulsive Disorder. Journal of clinical psychopharmacology. 2004;24:18-23.
3298.	Delorme R, Chabane N, Callebert J, et al. Platelet Serotonergic Predictors of Clinical Improvement in Obsessive Compulsive Disorder. Journal of clinical psychopharmacology. 2004;24:18-23.
3299.	DeMarchi R, Bansal V, Hung A, et al. Review of awakening agents. Canadian Journal of Neurological Sciences. 2005;32:4-17.
3300.	Demily C, Thibaut F. Recovery Criteria of a Major Depressive Episode. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:S8-S12.
3301.	Demling J. Experiences with new antidepressant agents: Comment. [German]. Fortschritte der Medizin. 1993;111:10.
3302.	Demyttenaere K. Quality of Life in Depression and Anxiety: Does It Matter? International journal of psychiatry in clinical practice. 2006;10:27-30.
3303.	Demyttenaere K. Agomelatine: a narrative review. [Review]. European neuropsychopharmacology. 2011;21 Suppl 4:S703-709.
3304.	Demyttenaere K. Evidence-based antidepressant efficacy of agomelatine. European neuropsychopharmacology. 2011;Conference:S636.
3305.	Demyttenaere K, Adelin A, Patrick M, Walthere D, DB K, Michele S. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. International clinical psychopharmacology. 2008;23:36-42.
3306.	Demyttenaere K, Albert A, Mesters P, Dewe W, K DB, Sangeleer M. What Happens With Adverse Events During 6 Months of Treatment With Selective Serotonin Reuptake Inhibitors? Journal of clinical psychiatry. 2005;66:859-863.
3307.	Demyttenaere K, Albert A, Mesters P, Dewe W, K DB, Sangeleer M. What Happens With Adverse Events During 6 Months of Treatment With Selective Serotonin Reuptake Inhibitors? Journal of clinical psychiatry. 2005;66:859-863.
3308.	Demyttenaere K, Corruble E, Hale A, MA Q-S, Picarel-Blanchot F, Kasper S. A Pooled Analysis of Six Month Comparative Efficacy and Tolerability in Four Randomized Clinical Trials: Agomelatine Versus Escitalopram, Fluoxetine, and Sertraline. CNS spectrums. 2013;18:163-170.
3309.	Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder, Primary care companion to the Journal of clinical psychiatry(2009).
3310.	Demyttenaere K, Desaiah D, Raskin J, Cairns V, Brecht S. Suicidal thoughts and reasons for living in hospitalized patients with severe depression: Post hoc analyses of a double-blind randomized trial of duloxetine. International journal of neuropsychopharmacology. 2012;Conference:183.
3311.	Suicidal thoughts and reasons for living in hospitalized patients with severe depression: Post-hoc analyses of a double-blind randomized trial of duloxetine, Primary care companion to the Journal of clinical psychiatry(2014).
3312.	Demyttenaere K, E VG, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. International clinical psychopharmacology. 1998;13:11-17.
3313.	Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatrica Scandinavica, Supplement. 2000;101:50-56.
3314.	Demyttenaere K, J DF. Getting what you ask for: On the selectivity of depression rating scales. Psychotherapy and psychosomatics. 2003;72:61-70.
3315.	Demyttenaere K, J DF, Sienaert P. Psychotropics and Sexuality. International clinical psychopharmacology. 1998;13:S35-S41.
3316.	Demyttenaere K, J DF, SM S. The Many Faces of Fatigue in Major Depressive Disorder. International journal of neuropsychopharmacology. 2005;8:93-105.
3317.	Demyttenaere K, J DF, SM S. The Many Faces of Fatigue in Major Depressive Disorder. International journal of neuropsychopharmacology. 2005;8:93-105.
3318.	Demyttenaere K, Jaspers L. Review: Bupropion and SSRI-induced side effects. Journal of psychopharmacology (Oxford, England). 2008;22:792-804.
3319.	Demyttenaere K, MEA H, Hudry J, Annemans L. A Cost-Effectiveness Model of Escitalopram, Citalopram, and Venlafaxine as First-Line Treatment for Major Depressive Disorder in Belgium. Clinical therapeutics. 2005;27:111-124.
3320.	Demyttenaere K, MEA H, Hudry J, Annemans L. A Cost-Effectiveness Model of Escitalopram, Citalopram, and Venlafaxine as First-Line Treatment for Major Depressive Disorder in Belgium. Clinical therapeutics. 2005;27:111-124.
3321.	Deng Y, CH Z, HN Z. [Effects of chaihu shugan powder on the behavior and expressions of BDNF and TrkB in the hippocampus, amygdala, and the frontal lobe in rat model of depression]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2011;31:1373-1378.
3322.	Denizot H, Laporte F, P-M L. Pharmacotherapy of children with depressive disorders. [French]. Archives de pediatrie. 2009;16:1208-1212.
3323.	Dennerstein L, CN S. The unique challenges of managing depression in mid-life women. World psychiatry. 2008;7:137-142.
3324.	Denys D, AA K, HGM W. Synergistic Dopamine Increase in the Rat Prefrontal Cortex With the Combination of Quetiapine and Fluvoxamine. Psychopharmacology. 2004;176:195-203.
3325.	Denys D, AA K, HGM W. Synergistic Dopamine Increase in the Rat Prefrontal Cortex With the Combination of Quetiapine and Fluvoxamine. Psychopharmacology. 2004;176:195-203.
3326.	Denys D, F VN, Deforce D, HGM W. Prediction of Response to Paroxetine and Venlafaxine by Serotonin-Related Genes in Obsessive-Compulsive Disorder in a Randomized, Double-Blind Trial. Journal of clinical psychiatry. 2007;68:747-753.
3327.	Denys D, Fluitman S, Kavelaars A, Heijnen C, HGM W. Effects of Paroxetine and Venlafaxine on Immune Parameters in Patients With Obsessive Compulsive Disorder. Psychoneuroendocrinology. 2006;31:355-360.
3328.	Deranja E. When medications fail. Using psychotherapy in the psychopharmacology setting. Clinical Neuropsychiatry. 2011;8:81-94.
3329.	Derivan A, AR E, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacology bulletin. 1995;31:439-447.
3330.	DeRogatis L. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) in women with major depression. Journal of sexual medicine. 2010;Conference:140.
3331.	DeRogatis L, CS B. Gepirone-er treatment of symptoms of sexual dysfunction in women with major depressive disorder (MDD). Journal of sexual medicine. 2010;Conference:43.
3332.	Derry S, RA A. Atypical antipsychotics in bipolar disorder: Systematic review of randomised trials. BMC psychiatry. 2007.
3333.	Deshauer D, Grimshaw J. "Can discontinuation trials inform the use of antidepressants in depressed children?": Reply. American journal of psychiatry. 2008;165:1205.
3334.	Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J. Selective Serotonin Reuptake Inhibitors for Unipolar Depression: a Systematic Review of Classic Long-Term Randomized Controlled Trials. CMAJ : Canadian Medical Association journal. 2008;178:1293-1301.
3335.	Deshmukh R, Franco K. Talking to patients about St. John's wort. Cleveland Clinic journal of medicine. 2003;70:985-989.
3336.	Despiegel N, Danchenko N, Maman K. Cost-effectiveness of escitalopram versus venlafaxine in second-line treatment of major depressive disorder (MDD) in Sweden. Value in health. 2009;Conference:A177.
3337.	Dessaulles A, SM J, WH D. Emotion-focused therapy for couples in the treatment of depression: A pilot study. American journal of family therapy. 2003;31:345-353.
3338.	Dettling M, Opgen-Rhein C, Quante A, Anghelescu I. Fluoxetine for treatment of anorexia nervosa [11]. Journal of the American Medical Association. 2006;296:2439-2440.
3339.	Dettore D, CF G. Body dysmorphic disorder: Clinical features, aetiopathogenesis and treatment. [Italian]. Psicoterapia Cognitiva e Comportamentale. 2007;13:139-166.
3340.	Deuschle M. [Stabilizing affective symptoms without adverse cardiac effects. Myocardial infarct risk after depression--and vice versa]. [German]. MMW Fortschritte der Medizin. 2002;144:54-55.
3341.	Deuschle M, Angermeier T, Westphal S, et al. Venlafaxine, but not mirtazapine lowers retinol-binding protein 4 serum concentrations in nondiabetic depressed patients. Psychotherapy and psychosomatics. 2010;79:123-125.
3342.	Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R. Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: Role of medication and response to treatment. Pharmacopsychiatry. 2013;46:54-58.
3343.	Deuschle M, Hamann B, Meichel C, et al. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. Journal of clinical psychopharmacology. 2003;23:201-205.
3344.	Deuschle M, Kniest A, Niemann H, et al. Impaired declarative memory in depressed patients is slow to recover: clinical experience. Pharmacopsychiatry. 2004;37:147-151.
3345.	Deuschle M, Krumm B, Bindeballe N, et al. Open-label non-randomized versus double-blind randomized antidepressive treatment: What are the advantages of clinical decision over randomization? Pharmacopsychiatry. 2004;37:299-302.
3346.	Deuschle M, Luppa P, Gilles M, Hamann B, Heuser I. Antidepressant treatment and dehydroepiandrosterone sulfate: Different effects of amitriptyline and paroxetine. Neuropsychobiology. 2004;50:252-256.
3347.	Deuschle M, Luppa P, Hamann B, Nonell A, Heuser I. Increased concentration of corticosteroid-binding globulin due to antidepressant treatment with amitritpyline, but not paroxetine. Journal of psychiatric research. 2003;37:85-87.
3348.	Deuschle M, Mase E, Zink M. Dyskinesia During Treatment With Duloxetine. Pharmacopsychiatry. 2006;39:237-238.
3349.	Deuschle M, Sander P, Herpfer I, BL F, Heuser I, Lieb K. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment. Psychiatry research. 2005;136:1-6.
3350.	Devanand DP, Nicole J, S NM, et al. An Open Treatment Trial of Venlafaxine for Elderly Patients With Dysthymic Disorder. Journal of geriatric psychiatry and neurology. 2004;17:219-224.
3351.	Devanand DP, S NM, Jocelyn C, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Fluoxetine Treatment for Elderly Patients With Dysthymic Disorder. The American Journal of Geriatric Psychiatry. 2005;13:59-68.
3352.	Devasahayam A, JD S, Curran S. Systematic review of the efficacy of duloxetine in major depressive disorder of the elderly. European neuropsychopharmacology. 2011;Conference:S404.
3353.	Devi S. Antidepressant-suicide link in children questioned. Lancet. 2012;379:791.
3354.	Devi V, Shankar P. Ramelteon: A melatonin receptor agonist for the treatment of insomnia. JK Science. 2008;10:99-100.
3355.	Devos D, Dujardin K, Poirot I, et al. Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease: a Double-Blind, Randomized, Placebo-Controlled Study. Movement disorders. 2008;23:850-857.
3356.	Devrim BA, Kemal Y, Eda A, et al. Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:281-285.
3357.	Devrim BA, Kemal Y, Visal B, et al. Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: A flow cytometric analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:70-75.
3358.	Dewilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A Double-Blind, Comparative, Multicenter Study Comparing Paroxetine With Fluoxetine in Depressed-Patients. Acta psychiatrica Scandinavica. 1993;87:141-145.
3359.	Dewilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A Double-Blind, Comparative, Multicenter Study Comparing Paroxetine With Fluoxetine in Depressed-Patients (Reprinted From Acta Psychiatr Scand, Vol 87, Pg 141-145, 1993). Hospital formulary. 1993;28:36-40.
3360.	Dewulf L, Hendrickx B, Lesaffre E. Epidemiological data of patients treated with fluvoxamine: results from a 12 week non-comparative multicentre study. International clinical psychopharmacology. 1995;9 Suppl 4:67-72.
3361.	Dezsi L, Vecsei L. Established therapies and novel targets in the treatment of Parkinson's disease. Expert review of clinical pharmacology. 2009;2:631-644.
3362.	DF A, CM D, GD C, JH P, Olivier S. Desvenlafaxine for the Treatment of Vasomotor Symptoms Associated With Menopause: a Double-Blind, Randomized, Placebo-Controlled Trial of Efficacy and Safety. American journal of obstetrics and gynecology. 2009;200.
3363.	DF A, DW S, Baber R, et al. Menopausal hot flushes and night sweats: Where are we now? Climacteric. 2011;14:515-528.
3364.	DF A, Seidman L, GD C, JH P, Olivier S. A Double-Blind, Randomly Assigned, Placebo-Controlled Study of Desvenlafaxine Efficacy and Safety for the Treatment of Vasomotor Symptoms Associated With Menopause. American journal of obstetrics and gynecology. 2009;200.
3365.	DF H. Follow-up of patients with early breast cancer. New England journal of medicine. 2007;356:2505-2513.
3366.	DF I, MJ N, EM R, CA ZJ. Pharmacologic treatment of dimensional anxious depression: A review. Primary care companion to the Journal of clinical psychiatry. 2014.
3367.	DF K. Light Treatment for Nonseasonal Depression: Speed, Efficacy, and Combined Treatment. Journal of affective disorders. 1998;49:109-117.
3368.	DF K. Flawed meta-analyses comparing psychotherapy with pharmacotherapy. American journal of psychiatry. 2000;157:1204-1211.
3369.	DF K. Greater Incidence of Depression With Hypnotic Use Than With Placebo. BMC psychiatry. 2007;7.
3370.	DF M, RW P. Reply to Magalhaes regarding 'Selective serotonin reuptake inhibitors and the utility of the borderline-bipolar distinction' [2]. Bipolar disorders. 2007;9:547.
3371.	DF S, BS S, Wegener G, et al. Receptor Occupancy of Mirtazapine Determined by Pet in Healthy Volunteers. Psychopharmacology. 2007;195:131-138.
3372.	DF T, Maltby N, GJ D, SE H, Worhunsky P. Cognitive-Behavioral Therapy for Medication Nonresponders With Obsessive-Compulsive Disorder: a Wait-List-Controlled Open Trial. Journal of clinical psychiatry. 2004;65:922-931.
3373.	DF T, Maltby N, GJ D, SE H, Worhunsky P. Cognitive-Behavioral Therapy for Medication Nonresponders With Obsessive-Compulsive Disorder: a Wait-List-Controlled Open Trial. Journal of clinical psychiatry. 2004;65:922-931.
3374.	DF T-W, KA J. Diagnosis and management of dementia in Parkinson's disease. Geriatrics & aging. 2004;7:49-54.
3375.	DG A, AS C, TK L, et al. Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evaluation of Functional Outcomes. Pain medicine (Malden, Mass.). 2007;8:410-418.
3376.	DG C, DL E, MJ R, Gettes D, SD D, JM P. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biological psychiatry. 2003;54:307-316.
3377.	DG P, Gilaberte I, FJ W, et al. Duloxetine in the Prevention of Relapse of Major Depressive Disorder - Double-Blind Placebo-Controlled Study. British journal of psychiatry. 2006;188:346-353.
3378.	DG P, ME B, Zhang Q, et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): Analysis of placebo-controlled trials and post-marketing adverse event reports. Drug, healthcare and patient safety. 2013;5:211-219.
3379.	DG T, Bombardier C, Heinemann A, Fann J, Barber J, Forchheimer M. Factors influencing quality of life following a multisite trial for major depression disorder in SCI. Archives of physical medicine and rehabilitation. 2012;Conference:E57.
3380.	DG T, Forchheimer M, CH B, AW H, HD N, JR F. Differences in quality of life outcomes among depressed spinal cord injury trial participants. Archives of physical medicine and rehabilitation. 2015;96:340-348.
3381.	DG T, Ratti E, Bye A. Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists. Journal of Receptors and Signal Transduction. 2013;33:333-337.
3382.	DGS P, DK K, DJ W, Raskin J, Tylee A. Duloxetine 60 Mg Once Daily in the Treatment of Milder Major Depressive Disorder. International journal of clinical practice. 2006;60:613-620.
3383.	DGS P, Quail D, Gandhi P, DJ W, RC P. A Randomized, Controlled Trial of Duloxetine Alone Vs. Duloxetine Plus a Telephone Intervention in the Treatment of Depression. Journal of affective disorders. 2008;108:33-41.
3384.	DH A, PE H, Fawaz W, et al. Transcranial Magnetic Stimulation Reduces Pain in Patients With Major Depression a Sham-Controlled Study. Journal of nervous and mental disease. 2007;195:378-381.
3385.	DH O, AH R, Djouma E, Parsian A, AJ L. Depressive-like behavior and high alcohol drinking co-occur in the FH/WJD rat but appear to be under independent genetic control. Neuroscience and biobehavioral reviews. 2007;31:103-114.
3386.	DH O, Hlavka J, JP F, Nicolau G, JS F. Antidepressant-Like Effects of a Novel Pentapeptide, Nemifitide, in an Animal Model of Depression. Psychopharmacology. 2004;175:303-309.
3387.	DH O, Hlavka J, JP F, Nicolau G, JS F. Antidepressant-Like Effects of a Novel Pentapeptide, Nemifitide, in an Animal Model of Depression. Psychopharmacology. 2004;175:303-309.
3388.	DH R. Medicating the obese patient. Endocrinology and metabolism clinics of North America. 1996;25:989-1004.
3389.	DH R, JT W. Ssris, Adolescents, and Aggression: Tempering Human Implications Regarding Ssri-Induced Aggression in Hamsters: Comment on Ricci and Melloni (2012). Behavioral neuroscience. 2012;126:742-747.
3390.	DH R, TM S. Medical management of obesity in women: Office-based approaches to weight management. Clinical obstetrics and gynecology. 2004;47:914-927.
3391.	DH VZ, PC G, MF J. The comparative effects of remifentanil or magnesium sulfate versus placebo on attenuating the hemodynamic responses after electroconvulsive therapy. Anesthesia and analgesia. 2005;101:1651-1655.
3392.	Dharmshaktu P, Tayal V, BS K. Efficacy of Antidepressants as Analgesics: a Review. Journal of clinical pharmacology. 2012;52:6-17.
3393.	Dhillon S, LJ S, GL P. Escitalopram - a Review of Its Use in the Management of Anxiety Disorders. CNS drugs. 2006;20:763-790.
3394.	Dhillon S, LPH Y, MP C. Bupropion: a review of its use in the management of major depressive disorder. [Review] [85 refs][Erratum appears in Drugs. 2008;68(7):980]. Drugs. 2008;68:653-689.
3395.	Dhingra S, Parle M. Herbal remedies and nutritional supplements in the treatment of depression: Areview. Klinik Psikofarmakoloji Bulteni. 2012;22:286-292.
3396.	Dhippayom T, Chaiyakunapruk N, Jongchansittho T. Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: A systematic review and meta-analysis. Drug safety. 2011;34:199-210.
3397.	DI B, Davidson C. Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment. Progress in neuro-psychopharmacology & biological psychiatry. 2012;39:263-272.
3398.	DI S, Miller M, JJ K. Modeling the risks and benefits of depression treatment for children and young adults. Value in health. 2012;15:724-729.
3399.	Adherence to antidepressant combinations and monotherapy for major depressive disorder: A CO-MED report of measurement-based care, Journal of psychiatric practice(2014).
3400.	Diaper A, AS R, SJ W, et al. Changes in Cardiovascular Function After Venlafaxine but Not Pregabalin in Healthy Volunteers: a Double-Blind, Placebo-Controlled Study of Orthostatic Challenge, Blood Pressure and Heart Rate. Human Psychopharmacology-Clinical and Experimental. 2013;28:562-575.
3401.	Diaz A, Fouilloux C, Ortiz S. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients. Proceedings of the Western Pharmacology Society. 2002;45:154-155.
3402.	Diaz-Marsa M, Palomares N, MD M, et al. Psychological Factors Affecting Response to Antidepressant Drugs in Fibromyalgia. Psychosomatics. 2011;52:237-244.
3403.	DiazGranados N, CA ZJ. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Current psychiatry reports. 2008;10:510-519.
3404.	A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression, Archives of general psychiatry(2010).
3405.	Dick P, Ferrero E. A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. British journal of clinical pharmacology. 1983;15 Suppl 3:419S-425S.
3406.	Dickstein D. In this issue/abstract thinking: The costs of mental illness. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48:459-460.
3407.	Diedrich A, Voderholzer U. Obsessive-Compulsive Personality Disorder: a Current Review. Current psychiatry reports. 2015.
3408.	Dieneke H. Identifying responders in randomised controlled trials for depression. The British Journal of Psychiatry. 2012;200:430.
3409.	Dierick M. A review of the efficacy and tolerability of venlafaxine. European psychiatry. 1997;12:307s-313s.
3410.	Diez-Quevedo C, Masnou H, Castellvi P, et al. Efficacy and Safety of Escitalopram for Prevention of Depressive Symptoms Induced by Peginterferon Alpha-2a and Ribavirin in Chronic Hepatitis C. A Double-Blind, Randomized, Placebo-Controlled Trial. Journal of hepatology. 2009;Conference:S223.
3411.	Difede J, Cukor J, Lee F, Yurt R. Treatments for common psychiatric conditions among adults during acute, rehabilitation, and reintegration phases. International review of psychiatry. 2009;21:559-569.
3412.	Diflorio A, Jones I. Is sex important Gender differences in bipolar disorder. International review of psychiatry. 2010;22:437-452.
3413.	Digvijay SG. Clinical outcomes associated with depression, anxiety and social support among cardiac rehabilitation attendees. Australian and New Zealand journal of psychiatry. 2010;44:1055.
3414.	Dilbaz N, SY C. Augmentation Strategies for Inadequate Response in Major Depressive Disorder. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2010;20:S4-S14.
3415.	Dilley M, Fleminger S. Advances in neuropsychiatry: Clinical implications. Advances in Psychiatric Treatment. 2006;12:23-33.
3416.	Dillon C, CM S, Castro D, PP L, SL H, FE T. Behavioral symptoms related to cognitive impairment. Neuropsychiatric disease and treatment. 2013;9:1443-1455.
3417.	Dimidjian S, Goodman S. Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clinical obstetrics and gynecology. 2009;52:498-515.
3418.	Dimidjian S, KJ D. Newer variations of cognitive-behavioral therapy: Behavioral activation and mindfulness-based cognitive therapy. Current psychiatry reports. 2009;11:453-458.
3419.	Pharmacotherapy or untreated antenatal depression: A false dichotomy, Journal of clinical psychiatry(2009).
3420.	Dimidjian S, SD H, KS D, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of consulting and clinical psychology. 2006;74:658-670.
3421.	Early effect of NEURAPAS balance on current source density (CSD) of human EEG, BMC psychiatry(2011).
3422.	Dinan T. Treatment approaches to therapy-resistant depression. Journal of psychopharmacology (Oxford, England). 1995;9:199-204.
3423.	Dinan T. Antidepressants in clinical practice: Limitations of assessment methods and drug response. Human psychopharmacology. 2001;16:105-114.
3424.	Dinan T. Therapeutic Options: Addressing the Current Dilemma. European neuropsychopharmacology. 2006;16:S119-S127.
3425.	Dineen WK. Pharmacotherapy for major depression in children and adolescents. [Review] [42 refs]. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:819-826.
3426.	Dineen WK, Jeffrey J, L FR, Daniel V, Khalil S. A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:280-288.
3427.	Out of the black box: Treatment of resistant depression in adolescents and the antidepressant controversy, Journal of child and adolescent psychopharmacology(2012).
3428.	Dineen WK, S RA, L FR, Jianqing J. Dr. Wagner and Colleagues Reply. American journal of psychiatry. 2005;162:818-819.
3429.	Dineen WK, S RA, L FR, Jianqing J, M GM, E HW. A Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents. American journal of psychiatry. 2004;161:1079-1083.
3430.	Dingemanse J. Nemifitide Innapharma. Current opinion in investigational drugs (London, England : 2000). 2003;4:859-862.
3431.	Dingemanse J, Wallnofer A, Gieschke R, Guentert T, Amrein R. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigtion of development of the 'serotonin syndrome'. Clinical pharmacology and therapeutics. 1998;63:403-413.
3432.	Dinger U, Zilcha-Mano S, KS M, MS B, JP B. Interpersonal problems as predictors of alliance, symptomatic improvement and premature termination in treatment of depression. Journal of affective disorders. 2013;151:800-803.
3433.	Dinuzzo F. Learning output kernels for multi-task problems. Neurocomputing. 2013;118:119-126.
3434.	Dirk E, Monika L, Ulrich G, et al. Reboxetine for acute treatment of major depression: Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ: British Medical Journal. 2010;341:1-14.
3435.	Divyashree M, CR J, Chandrashekar H. A comparative study of efficacy and safety of conventional versus newer antidepressants in patients with depressive episode in a tertiary care hospital. Journal of chemical and pharmaceutical research. 2014;6:516-524.
3436.	DJ A, Manuel C, Davis E. Diagnosis and treatment of aggression in individuals with developmental disabilities. Psychiatric quarterly. 2008;79:225-247.
3437.	DJ A, NJ L, DA R. Preliminary trial of photic stimulation for premenstrual syndrome. Journal of obstetrics and gynaecology. 1997;17:76-79.
3438.	DJ B. Depression in Parkinson's disease. European journal of neurology. 2002;9:44-54.
3439.	DJ B. Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease. Movement disorders. 2002;17:445-454.
3440.	DJ B, DJ K, Cherry C, Stapf D, Frank E. Effects of Prior Fluoxetine Treatment on Eeg Sleep in Women With Recurrent Depression. Neuropsychopharmacology. 1999;21:258-267.
3441.	DJ B, Hadjipavlou G, RW L, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. [Review]. Annals of clinical psychiatry. 2012;24:23-37.
3442.	DJ B, Hall M, Begley A, et al. Sleep and treatment response in depression: new findings using power spectral analysis. Psychiatry research. 2001;103:51-67.
3443.	DJ B, JD A, Fawcett J, et al. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy [1]. Journal of clinical psychopharmacology. 2001;21:616-618.
3444.	DJ B, NM W. Toward future therapies in progressive supranuclear palsy. Movement disorders. 2005;20:S92-S98.
3445.	DJ B, SH G, IS W. The cardiovascular toll of stress. Lancet. 2007;370:1089-1100.
3446.	DJ B, XM T, CR C, et al. Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biological psychiatry. 1999;45:205-213.
3447.	DJ C. Paroxetine may increase risk of suicidal behavior in young adults. P and T. 2006;31:728.
3448.	DJ C. Pharmacotherapy for patients with fibromyalgia. [Review] [42 refs]. Journal of clinical psychiatry. 2008;69 Suppl 2:25-29.
3449.	DJ C. Pain management: Fibromyalgia drugs are 'as good as it gets' in chronic pain. Nature reviews. Rheumatology. 2010;6:439-440.
3450.	DJ C. St. John's Wort and s-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: What is the evidence for clinically relevant benefit? Alternative medicine review. 2011;16:17-39.
3451.	DJ C, Fong R, JE K, JT D, Moore C, ME T. Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: a Complete Set of Randomized Placebo-Controlled Trials. Journal of clinical psychiatry. 2011;72:1503-1514.
3452.	DJ C, Levien T, DE B. Aprepitant. Hospital pharmacy. 2003;38:763-771.
3453.	DJ C, Rossell S, Kyrios M. Body Dysmorphic Disorder. Psychiatric clinics of North America. 2006;29:521-538.
3454.	DJ C, TL L, DE B. Milnacipran. Hospital pharmacy. 2009;44:604-615.
3455.	DJ C, TL L, DE B. Formulary drug reviews - Roflumilast. Hospital pharmacy. 2011;46:597-610.
3456.	DJ G, AC F. IBS-like symptoms in patients with ulcerative colitis. Clinical and experimental gastroenterology. 2015;8:101-109.
3457.	DJ G, AH RJ, JH P, DN M, CM BJ. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Journal of clinical psychiatry. 1993;54:309-316.
3458.	DJ G, Lu Y, MJ D, TC L, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.
3459.	DJ G, YL L, MJ D, Hudson J, Iyengar S, MA D. Effects of Duloxetine on Painful Physical Symptoms Associated With Depression. Psychosomatics. 2004;45:17-28.
3460.	DJ G, YL L, MJ D, Wiltse C, Mallinckrodt C, MA D. Duloxetine in the Treatment of Depression - a Double-Blind-Placebo-Controlled Comparison With Paroxetine. Journal of clinical psychopharmacology. 2004;24:389-399.
3461.	ContraveTM: Novel treatment for obesity, Future lipidology(2009).
3462.	DJ H. Dysthymic disorder reviewed: Treating chronic depression in the age of DSM-5. Minerva psichiatrica. 2011;52:125-144.
3463.	DJ H, Batchelder S, Hyler S, et al. Aripiprazole as an Adjunctive Treatment for Refractory Unipolar Depression. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:744-750.
3464.	DJ H, Batchelder S, Kreditor D, Fedak M. Bupropion Sustained-Release for the Treatment of Dysthymic Disorder: an Open-Label Study. Journal of clinical psychopharmacology. 2001;21:325-329.
3465.	DJ H, Batchelder S, Miozzo R, et al. Citalopram in the Treatment of Dysthymic Disorder. International clinical psychopharmacology. 2004;19:143-148.
3466.	DJ H, Batchelder S, Miozzo R, et al. Citalopram in the Treatment of Dysthymic Disorder. International clinical psychopharmacology. 2004;19:143-148.
3467.	DJ H, Erickson G, JW S, et al. Behavioral activation therapy for return to work in medication-responsive chronic depression with persistent psychosocial dysfunction. Comprehensive psychiatry. 2015;57:140-147.
3468.	Vilazodone for the treatment of major depressive disorder: An evidence-based review of its place in therapy, Core evidence(2015).
3469.	DJ H, JH K, Chapman D, JW S, Harrison W. Double-Blind Comparison of Sertraline, Imipramine, and Placebo in the Treatment of Dysthymia: Effects on Personality. American journal of psychiatry. 2000;157:1436-1444.
3470.	DJ H, ST B, SAS L, MJ F, Kreditor D, Rosenthal J. Venlafaxine in the Treatment of Dysthymia: an Open-Label Study. Journal of clinical psychiatry. 1999;60:845-849.
3471.	DJ H, VL K, Kang S, DA H. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. [Review]. Laryngoscope. 2011;121:1555-1564.
3472.	DJ H, Yanowitch P, Rosenthal J, et al. Long-term treatment of double depression: a preliminary study with serotonergic antidepressants. Progress in neuro-psychopharmacology & biological psychiatry. 1994;18:139-147.
3473.	DJ K. Management of recurrent depression. [Review] [16 refs]. Journal of clinical psychiatry. 1993;54 Suppl:25-29.
3474.	DJ K. The depressions of Alzheimer's disease: Sorting, pharmacotherapy, and clinical advice. Journal of geriatric psychiatry and neurology. 1995;8:S40-S51.
3475.	DJ K. The pharmacological management of depression. Dialogues in clinical neuroscience. 2005;7:191-205.
3476.	DJ K. Use of selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness. Paediatrics and Child Health (Canada). 2013;18:1-6.
3477.	DJ K, Frank E. The Interaction of Drug- and Psychotherapy in the Long-Term Treatment of Depression. Journal of affective disorders. 2001;62:131-137.
3478.	DJ K, Frank E. Placebo in clinical trials for depression: complexity and necessity.[Erratum appears in JAMA 2002 Jun 19;287(23):3083]. Journal of the American Medical Association. 2002;287:1853-1854.
3479.	DJ K, GE S, SD P, et al. Randomized trial of a depression management program in high utilizers of medical care. Archives of family medicine. 2000;9:345-351.
3480.	DJ K, KA K, JH G, JW J, JM M, RC S. Sertraline for Social Phobia - a Double-Blind, Placebo-Controlled Crossover Study. American journal of psychiatry. 1995;152:1368-1371.
3481.	DJ K, KNR C, AJ G, et al. Citalopram as adjunctive therapy in bipolar depression. Journal of clinical psychiatry. 2001;62:985-990.
3482.	DJ K, MB K. Management of recurrent depression. Journal of clinical psychiatry. 1993;54:29-35.
3483.	DJ M. Treatment and prevention of mania in bipolar I disorder: Focus on aripiprazole. Neuropsychiatric disease and treatment. 2009;5:279-288.
3484.	DJ M. Genetic variation of inflammatory markers (IL-1beta, IL-2, IL6, TSPO) and BDNF in response to treatment with duloxetine and placebo. Biological psychiatry. 2015;Conference:224S.
3485.	DJ M, DE K, RS M. Differentiating bipolar disorders from major depressive disorders: Treatment implications. Annals of clinical psychiatry. 2007;19:305-312.
3486.	DJ M, DM B. The efficacy of treatments for depression used in the management of tinnitus. Audiological medicine. 2008;6:40-47.
3487.	DJ M, JS C, TA C, et al. Adjunctive aripiprazole for depression: Predictive value of early assessment. American journal of managed care. 2011;17:793-801.
3488.	Intensive psychosocial intervention enhances functioning in patients with bipolar depression: Results from a 9-month randomized controlled trial, American journal of psychiatry(2007).
3489.	DJ N. Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. [Review] [9 refs]. Depression and anxiety. 1998;7 Suppl 1:7-10.
3490.	DJ N. Care of depressed patients with anxiety symptoms. [Review] [26 refs]. Journal of clinical psychiatry. 1999;60 Suppl 1:23-28.
3491.	DJ N. Tolerability and safety aspects of mirtazapine. Human psychopharmacology. 2002;17:S37-S41.
3492.	DJ N. Death by tricyclic: The real antidepressant scandal? Journal of psychopharmacology (Oxford, England). 2005;19:123-124.
3493.	DJ N. Misplaced trust? Gaping flaws in drug approval and licensing. South African medical journal. 2010;100:399.
3494.	DJ N, AL M. Why does the world have such a 'down' on antidepressants? Journal of psychopharmacology (Oxford, England). 2008;22:223-226.
3495.	DJ N, Forshall S, Bell C, et al. Mechanisms of Action of Selective Serotonin Reuptake Inhibitors in the Treatment of Psychiatric Disorders. European neuropsychopharmacology. 1999;9:S81-S86.
3496.	DJ N, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues in clinical neuroscience. 2008;10:329-336.
3497.	DJ P, AM K, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Effects of Low-Dose Paroxetine 7.5 Mg on Weight and Sexual Function During Treatment of Vasomotor Symptoms Associated With Menopause. Menopause-the Journal of the North American Menopause Society. 2014;21:1082-1090.
3498.	DJ R, NT P. Roflumilast: A novel treatment for chronic obstructive pulmonary disease. Annals of pharmacotherapy. 2012;46:521-529.
3499.	DJ S. Algorithms for primary care: An evidence-based approach to the pharmacotherapy of depression and anxiety disorders. Primary psychiatry. 2004;11:55-78.
3500.	DJ S. Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders? Pediatrics. 2006;118:1248-1251.
3501.	DJ S. Evidence-based treatment of anxiety disorders. International journal of psychiatry in clinical practice. 2006;10:16-21.
3502.	DJ S, AG L. Effects of Escitalopram on Sleep Problems in Patients With Major Depression or Generalized Anxiety Disorder. Advances in therapy. 2011;28:1021-1037.
3503.	DJ S, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine Prevents Relapse in Generalized Anxiety Disorder: a 6-Month Randomized, Double-Blind, Placebo-Controlled Discontinuation Study. Journal of clinical psychiatry. 2012;73:1002-1008.
3504.	DJ S, Ahokas A, MS M, et al. Agomelatine in Generalized Anxiety Disorder: an Active Comparator and Placebo-Controlled Study. Journal of clinical psychiatry. 2014;75:362-U383.
3505.	DJ S, Bandelow B, Hollander E, et al. WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. CNS spectrums. 2003;8:31-39.
3506.	DJ S, Berk M, Els C, et al. A Double-Blind Placebo-Controlled Trial of Paroxetine in the Management of Social Phobia (Social Anxiety Disorder) in South Africa. South African medical journal. 1999;89:402-406.
3507.	A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: The RESPOND trial, Health technology assessment(2010).
3508.	DJ S, Davidson J, Seedat S, Beebe K. Paroxetine in the treatment of post-traumatic stress disorder: Pooled analysis of placebo-controlled studies. Expert opinion on pharmacotherapy. 2003;4:1829-1838.
3509.	DJ S, DJ C, SH K. Efficacy of the antidepressant agomelatine for the anxiety symptoms of depression in patients with major depressive disorder. Australian and New Zealand journal of psychiatry. 2012;Conference:31-32.
3510.	DJ S, DS B, Baldinetti F, Mandel F. Efficacy of Pregabalin in Depressive Symptoms Associated With Generalized Anxiety Disorder: a Pooled Analysis of 6 Studies. European neuropsychopharmacology. 2008;18:422-430.
3511.	DJ S, HF A, WK G. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes. Annals of clinical psychiatry. 2005;17:71-75.
3512.	DJ S, Hollander E, LS M, CM D, MR L. Comparison of Clomipramine, Alprazolam and Placebo in the Treatment of Obsessive-Compulsive Disorder. Human Psychopharmacology-Clinical and Experimental. 1992;7:389-395.
3513.	DJ S, Ipser J, Mcanda N. Pharmacotherapy of Posttraumatic Stress Disorder: a Review of Meta-Analyses and Treatment Guidelines. CNS spectrums. 2009;14:25-31.
3514.	DJ S, JC I. Combined pharmacotherapy and psychotherapy for social anxiety disorder. Current psychiatry reports. 2010;12:273-275.
3515.	DJ S, JC I, Seedat S. Pharmacotherapy for Post Traumatic Stress Disorder (Ptsd). Cochrane database of systematic reviews (Online). 2006.
3516.	DJ S, JM Z. Treatment-Emergent Adverse Events From Selective Serotonin Reuptake Inhibitors by Age Group: Children Versus Adolescents. Journal of child and adolescent psychopharmacology. 2006;16:159-169.
3517.	DJ S, Kasper S, EW A, Nil R, Lader M. Escitalopram in the Treatment of Social Anxiety Disorder: Analysis of Efficacy for Different Clinical Subgroups and Symptom Dimensions. Depression and anxiety. 2004;20:175-181.
3518.	DJ S, Kasper S, EW A, Nil R, Lader M. Escitalopram in the Treatment of Social Anxiety Disorder: Analysis of Efficacy for Different Clinical Subgroups and Symptom Dimensions. Depression and anxiety. 2004;20:175-181.
3519.	DJ S, Koen N, Fineberg N, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Current psychiatry reports. 2012;14:211-219.
3520.	DJ S, PD C, Lochner C, Seedat S, Fineberg N, EW A. Escitalopram in Obsessive-Compulsive Disorder: Response of Symptom Dimensions to Pharmacotherapy. CNS spectrums. 2008;13:492-498.
3521.	DJ S, RB L, BK H, FS M. Impact of Gastrointestinal Symptoms on Response to Pregabalin in Generalized Anxiety Disorder: Results of a Six-Study Combined Analysis. International clinical psychopharmacology. 2009;24:126-132.
3522.	DJ S, SH K. Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression. European neuropsychopharmacology. 2011;Conference:S383.
3523.	DJ T, P DB. New indications of fluoxetine: A survey. [Dutch]. Pharmaceutisch weekblad. 1995;130:330-332.
3524.	DJA D, PJ B, Patelis-Siotis I, et al. Changes in Self-Schema Structure in Cognitive Therapy for Major Depressive Disorder: A Randomized Clinical Trial. Journal of consulting and clinical psychology. 2009;77:1078-1088.
3525.	Djamshidian A, JH F. Anxiety and depression in Parkinson's disease. Current treatment options in neurology. 2014.
3526.	DJLG S, J vH. An endocrine perspective on the role of steroid hormones in the antidepressant treatment efficacy of transcranial magnetic stimulation. Psychoneuroendocrinology. 2010;35:171-178.
3527.	DJP D, Bourin M, Hascoet M, MC C, GB B, Jolliet P. Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: Involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology. 2001;153:443-449.
3528.	DK A, AK C, Fass R, Falck-Ytter Y. Systematic review with meta-analysis: Selective serotonin reuptake inhibitors for noncardiac chest pain. Alimentary pharmacology & therapeutics. 2015;41:167-176.
3529.	DK B, Matreja P, Deswal R. Focused Conference Group: P01 - Clinical pharmacology in the emerging countries efficacy and safety of add-on mirtazapine in depression. Basic & clinical pharmacology & toxicology. 2010;Conference:187.
3530.	DK B, PP K, RS D, PS M. Safety and efficacy of duloxetine versus venlafaxine in major depression in Indian patients. JK Science. 2006;8:195-199.
3531.	DK C, Gibson M, Feldman S, et al. National guidelines for seniors' mental health: The Assessment and Treatment of Mental Health Issues in Long-Term Care Homes (focus on mood and behaviour symptoms). Canadian Journal of Geriatrics. 2006;9:S59-S64.
3532.	DK K, Iyengar S, Desaiah D, et al. Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings From Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies. Clinical therapeutics. 2007;29:2536-2546.
3533.	DK P, SK Y, Mahesh R, Rajkumar R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety? Behavioural brain research. 2009;205:436-442.
3534.	DK S, JD M, FJ K, MP K. Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometric Method for the Determination of the Major Metabolites of Duloxetine in Human Plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007;852:582-589.
3535.	DK T, DW J, SS S. Kaleidoscope. British journal of psychiatry. 2015;206:259-260.
3536.	DKY S, KL W. Identification of postpartum depression. Clinical obstetrics and gynecology. 2009;52:456-468.
3537.	DL A, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. Journal of clinical psychopharmacology. 2002;22:309-317.
3538.	DL A, Greenland S, Bystritsky A. Clinical Characteristics of Response to Fluoxetine Treatment of Obsessive-Compulsive Disorder. Journal of clinical psychopharmacology. 1998;18:185-192.
3539.	DL A, Greenland S, Bystritsky A. Side Effects as Predictors of Drug Response in Obsessive-Compulsive Disorder. Journal of clinical psychopharmacology. 1999;19:459-465.
3540.	DL D. Therapeutic Considerations in Treating Depression in the Elderly. Journal of clinical psychiatry. 1994;55:48-58.
3541.	DL D. Treatment of dysthymic disorder. Depression and anxiety. 1998;8:54-58.
3542.	DL D. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar disorders. 2005;7:307-325.
3543.	DL D. Dysthymia and double depression. International review of psychiatry. 2005;17:3-8.
3544.	DL D, Blier P, MB K, MH P, ME T, JM Z. Preventing recurrent depression: Long-term treatment for major depressive disorder. Primary care companion to the Journal of clinical psychiatry. 2007;9:214-223.
3545.	DL D, Blier P, MB K, MH P, ME T, JM Z. Preventing recurrent depression: Long-term treatment for major depressive disorder. Journal of clinical psychiatry. 2007;68:619-630.
3546.	DL D, DN Ds, DK K, MJ D, JM R. Is Treatment-Associated Hypomania Rare With Duloxetine: Secondary Analysis of Controlled Trials in Non-Bipolar Depression. Journal of affective disorders. 2005;87:115-119.
3547.	DL D, HE H, Bea C, CB B. Venlafaxine in Dysthymic Disorder. Journal of clinical psychiatry. 1997;58:528-531.
3548.	DL D, HE H, Bea C, CB B, O'connor E. Dysthymic Disorder: Treatment With Mirtazapine. Depression and anxiety. 1999;10:68-72.
3549.	DL D, JB C, IIIT W, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Journal of clinical psychiatry. 1992;53 Suppl:57-60.
3550.	DL D, JB C, Walshe T, et al. 2 Combined, Multicenter Double-Blind Studies of Paroxetine and Doxepin in Geriatric-Patients With Major Depression. Journal of clinical psychiatry. 1992;53:57-60.
3551.	DL D, KB S, Hendrickson H, Becker J, Lehman A, Bea C. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression. 1996;4:34-41.
3552.	Beneficial effects of adjunctive Aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: A post hoc analysis of 3 randomized, double-blind, placebo-controlled trials, Primary care companion to the Journal of clinical psychiatry(2012).
3553.	DL D, MM W, CH M, JG W, Fava M. Clinical Consequences of Initial Duloxetine Dosing Strategies: Comparison of 30 and 60 Mg Qd Starting Doses. Current therapeutic research, clinical and experimental. 2005;66:522-540.
3554.	DL D, Wilson M, Fava M, et al. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depression and anxiety. 2008;25:E1-8.
3555.	DL E, DS C, Lewis L, et al. Mood disorders in the medically ill: Scientific review and recommendations. Biological psychiatry. 2005;58:175-189.
3556.	DL E, KG L, Benton T, et al. Selective Serotonin Reuptake Inhibitor and Substance P Antagonist Enhancement of Natural Killer Cell Innate Immunity in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. Biological psychiatry. 2008;63:899-905.
3557.	DL E, Staab J, Ward H, et al. Depression in the medically ill: Management considerations. Depression and anxiety. 1997;4:199-208.
3558.	DL F, Alvarado I, ML W, Licinio J, Flockhart D. Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans. Annals of internal medicine. 2004;140:W71.
3559.	DL G. Chromium Picolinate Treatment of Atypical Depression. Primary psychiatry. 2003;10:23-24.
3560.	DL G. Mecamylamine augmentation of SSRIs for refractory depression. Primary psychiatry. 2004;11:23-24.
3561.	DL G. Vardenafil treatment of sertraline-induced anorgasmia in a woman. Primary psychiatry. 2005;12:17-18.
3562.	DL G. Sertraline for severe tinnitus. Primary psychiatry. 2006;13:32-33.
3563.	DL G. Pharmacological Treatment of Fibromyalgia and Other Chronic Musculoskeletal Pain. Best Practice & Research in Clinical Rheumatology. 2007;21:499-511.
3564.	DL G, Bhigjee A, Retief C, et al. Guideline for the diagnosis and management of multiple sclerosis: A Southern African perspective. South African medical journal. 2013;103:670-691.
3565.	DL G, DJ C, M-A F. New Concepts in Pain Research and Pain Management of the Rheumatic Diseases. Seminars in arthritis and rheumatism. 2011;41:319-334.
3566.	DL G, DJ C, RH P, Mease P, Chen W, RM G. Durability of Therapeutic Response to Milnacipran Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension Study. Pain medicine (Malden, Mass.). 2010;11:180-194.
3567.	DL G, HS A, PE KJ, et al. Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data. CNS spectrums. 2005;10:1-14.
3568.	DL G, Russell, Smythe, Wolfe. Medications/clinical trials in fibromyalgia. Journal of musculoskeletal pain. 1994;2:135-142.
3569.	DL G, SP R, EJ L, GS A, Hollander E. Depression in the elderly: The unique features related to diagnosis and treatment. CNS spectrums. 2005;10:i1-i14.
3570.	DL K, RR C, WT C. First-episode schizophrenia: A focus on pharmacological treatment and safety considerations. Drugs. 2005;65:1113-1138.
3571.	DL L, ME T, RL R, RL O, TW C. Appropriateness of prescribing practices for serotonergic antidepressants. Psychiatric services (Washington, D.C.). 2002;53:179-184.
3572.	DL M, Betan E, Larsen H, LS P. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. Biological psychiatry. 2003;54:317-329.
3573.	Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression, Journal of the American Academy of Child and Adolescent Psychiatry(2012).
3574.	Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression, Journal of the American Academy of Child and Adolescent Psychiatry(2012).
3575.	DL M, UM M, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings. Archives of general psychiatry. 2000;57:875-882.
3576.	DL M, Wang M, Long Q, et al. Impact of escitalopram on IL-2-induced behavioral, neuroendocrineand immunechanges in malignant melanoma patients: Preliminary findings. Biological psychiatry. 2012;Conference:62S.
3577.	DL M, WI S, Guo Y, et al. A Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (Stages I, Ii, Iii, and Iv) With Major Depression. Journal of clinical psychiatry. 2006;67:288-296.
3578.	DL R. Off-label prescription of quetiapine in psychiatric disorders. Expert review of neurotherapeutics. 2007;7:841-852.
3579.	DL R. Psychological impact of premature ejaculation and barriers to its recognition and treatment. Current medical research and opinion. 2011;27:1509-1518.
3580.	DL R, CM G. Current and emerging drug treatments for binge eating disorder. Expert opinion on emerging drugs. 2014;19:99-142.
3581.	DL S. Selective Serotonin Reuptake Inhibitors and Trazodone for Treatment of Depression, Psychosis, and Behavioral Symptoms in Patients With Dementia. International Psychogeriatrics. 2000;12:245-251.
3582.	DL S, AM D, Lock J. Use of Mirtazapine in an Adult With Refractory Anorexia Nervosa and Comorbid Depression: a Case Report. International journal of eating disorders. 2011;44:178-181.
3583.	DL T, DB C. Adolescent alcohol abuse and dependence: Development, diagnosis, treatment and outcomes. Current psychiatry reviews. 2006;2:159-177.
3584.	DL W, Gordon B, TW M, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. Journal of neurotrauma. 2006;23:1468-1501.
3585.	DM B, BH M, Emeremni C, et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of psychiatric research. 2011;45:896-901.
3586.	The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression, Journal of clinical psychopharmacology(2013).
3587.	What is the role of brain stimulation therapies in the treatment of depression? Topical collection on mood disorders, Current psychiatry reports(2013).
3588.	DM B, Shir Y, MA W. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain medicine (Malden, Mass.). 2006;7:25-29.
3589.	DM C, Fallon D, Hill M, JA F. The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings. Harvard review of psychiatry. 2013;21:219-247.
3590.	DM C, Fallon D, Hill M, JA F. The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings. Harvard review of psychiatry. 2013;21:219-247.
3591.	DM C, KC C. Depression, anxiety and their relationship with chronic diseases: A review of the epidemiology, risk and treatment evidence. Medical journal of Australia. 2009;190:S54-S60.
3592.	DM C, SJ B, DM C, et al. Screening, referral and treatment for depression in patients with coronary heart disease: A consensus statement from the national heart foundation of Australia. Medical journal of Australia. 2013;198:1-7.
3593.	DM D, Tu Y, LP C. [Assessment of effectiveness of electroacupuncture and fluoxetine for treatment of depression with physical symptoms]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2008;28:167-170.
3594.	DM D, Tu Y, LP C. [Effects of electroacupuncture at different acupoint groups on behavior activity and p-CREB expression in hippocampus in the rat of depression]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2008;28:369-373.
3595.	DM D, Tu Y, LP C, ZJ W. [Study on electroacupuncture treatment of depression by magnetic resonance imaging]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2009;29:139-144.
3596.	DM D, Tu Y, SA J, Qin W. The Relevance Between Symptoms and Magnetic Resonance Imaging Analysis of the Hippocampus of Depressed Patients Given Electro-Acupuncture Combined With Fluoxetine Intervention - a Randomized, Controlled Trial. Chinese journal of integrative medicine. 2011;17:190-199.
3597.	DM F, ME C, RG H, et al. The Liebowitz Social Anxiety Scale: a Comparison of the Psychometric Properties of Self-Report and Clinician-Administered Formats. Psychological medicine. 2001;31:1025-1035.
3598.	DM F, ZV S, Buis T, Kennedy S. Relationship of Posttreatment Decentering and Cognitive Reactivity to Relapse in Major Depression. Journal of consulting and clinical psychology. 2007;75:447-455.
3599.	DM G. Evidence-based decisions about herbal products for treating mental disorders. Journal of psychiatry & neuroscience. 2002;27:324-333.
3600.	DM G, AL M, Kutcher S, et al. Evidence review and clinical guidance for the use of ziprasidone in Canada. Annals of general psychiatry. 2013.
3601.	DM G, CL C, Zhu L, et al. Risk Factors for Obesity in Adult Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor Study. Journal of clinical oncology. 2012;30:246-255.
3602.	DM H, Bezemer G, BE H, et al. Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. Journal of clinical psychiatry. 2014;75:1069-1077.
3603.	DM H, JA B, CH C. Diagnostic and treatment interventions for hypochondriasis in the neurology setting. Current treatment options in neurology. 2006;8:401-409.
3604.	DM M, AA P, PS M, C-U P. Does pregabalin have neuropsychotropic effects?: A short perspective. Psychiatry investigation. 2009;6:55-58.
3605.	DM M, C-U P, AA P. Triple reuptake inhibitors: The next generation of antidepressants. Current neuropharmacology. 2008;6:338-343.
3606.	DM M, C-U P, AA P. Triple reuptake inhibitors: A premise and promise. Psychiatry investigation. 2008;5:142-147.
3607.	DM M, FR L, AM S, EV N. Venlafaxine treatment of cocaine abusers with depressive disorders. American journal of drug and alcohol abuse. 2000;26:25-31.
3608.	History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: Post hoc analysis from a placebo-controlled study, Primary care companion to the Journal of clinical psychiatry(2008).
3609.	DM M, M-H P, B-J H, et al. Paroxetine: Safety and Tolerability Issues. Expert opinion on drug safety. 2008;7:783-794.
3610.	DM M, MJ S, AA P, PS M, G-Y P, C-U P. Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise. Current neuropharmacology. 2009;7:331-336.
3611.	DM M, Mogg A, Eranti S, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: A multicentre pragmatic randomised controlled trial and economic analysis. Health technology assessment. 2007;11:iii-35.
3612.	DM N, Devine R, Bicer S, et al. Fluoxetine Prevents the Development of Depressive-Like Behavior in a Mouse Model of Cancer Related Fatigue. Physiology & behavior. 2015;140:230-235.
3613.	DM P. Electroconvulsive therapy for depressive episodes: A brief review. Geriatrics. 2009;64:9-12.
3614.	DM R, Edmonds L. Assessing the role of drugs in suicidal ideation and suicidality. CNS drugs. 2007;21:463-472.
3615.	DM R, GM K. Sodium oxybate: A review of its use in the management of narcolepsy. CNS drugs. 2007;21:337-354.
3616.	DM S, AR S. Gender differences in depression. Women's Health. 2006;2:425-434.
3617.	DM S, DR T, MH B, et al. A comparison of the antidepressant action of citalopram and amitriptyline. The British Journal of Psychiatry. 1986;149:515-517.
3618.	DM S, JS M, Helbok C, Muck R. Efficacy of Sertraline for Bulimia Nervosa. International journal of eating disorders. 2004;36:48-54.
3619.	DM S, JS M, Helbok C, Muck R. Efficacy of Sertraline for Bulimia Nervosa. International journal of eating disorders. 2004;36:48-54.
3620.	DM U, JL H, WWJJ A, Roland M, MW VT. Antidepressants for non-specific low back pain. Cochrane database of systematic reviews (Online). 2008.
3621.	DN A. Treating depression in old age: The reasons to be positive. Age and ageing. 2001;30:13-17.
3622.	DN J. Antidepressants, antiplatelets and bleeding: One more thing to worry about? CMAJ : Canadian Medical Association journal. 2011;183:1819-1820.
3623.	DN J, MM M, Kopp A, DA R. The Risk of Suicide With Selective Serotonin Reuptake Inhibitors in the Elderly. American journal of psychiatry. 2006;163:813-821.
3624.	DN J, Wright T, Berti C. Is there an economic advantage in the use of SSRIs over TCAs in the treatment of depression? Journal of Serotonin Research. 1996;2:225-235.
3625.	Social problem solving and depressive symptoms over time: A randomized clinical trial of cognitive-behavioral analysis system of psychotherapy, brief supportive psychotherapy, and pharmacotherapy, Journal of consulting and clinical psychology(2011).
3626.	DN K, AC L, PA A. Psychosocial Interventions for Late-life Major Depression: Evidence-Based Treatments, Predictors of Treatment Outcomes, and Moderators of Treatment Effects. Psychiatric clinics of North America. 2011;34:377-401.
3627.	DN K, AF S, JP M, et al. Early- versus late-onset dythymic disorder: comparison in out-patients with superimposed major depressive episodes. Journal of affective disorders. 1999;52:187-196.
3628.	DN K, PA A, Teri L, GS A. Home-delivered problem adaptation therapy (PATH) for depressed, cognitively impaired, disabled elders: A preliminary study. American journal of geriatric psychiatry. 2010;18:988-998.
3629.	DN M. Fluoxetine-induced breast astrophy [3]. Australian and New Zealand journal of psychiatry. 2004;38:382.
3630.	DN N. Pharmacologic approaches for the treatment of chronic insomnia. Clinical cornerstone. 2003;5:16-23.
3631.	DN N, KN F. Chronic insomnia. Seminars in neurology. 2009;29:340-353.
3632.	DN O, LR D. The psychopharmacology algorithm project at the harvard south shore program. Psychopharm Review. 2010;45:91-99.
3633.	DN R, CJ J. Effects of topical essential oil on exercise volume after a 12-week exercise program for women with fibromyalgia: A pilot study. Journal of alternative and complementary medicine (New York, N.Y.). 2007;13:1099-1106.
3634.	DN T, Thor S, JA K. Treatment of Irritable Bowel Syndrome in Women. Gastroenterology clinics of North America. 2011;40:265-290.
3635.	DO A, Thomas M, WG D. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behavior therapy. 1997;28:187-210.
3636.	Dobry Y, Novakovic V, RL B, VK S. Management of auditory hallucinations as a sequela of traumatic brain injury: A case report and a relevant literature review. American journal of therapeutics. 2014;21:e1-e6.
3637.	Dodd S, Berk M. Predictors of antidepressant response: A selective review. International journal of psychiatry in clinical practice. 2004;8:91-100.
3638.	Dodd S, Berk M. Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. [Review] [103 refs]. Expert review of neurotherapeutics. 2008;8:1299-1306.
3639.	Dodd S, Berk M. Duloxetine for major depressive disorder. Medicine today. 2008;9:65-66.
3640.	Application of the Gradient Boosted Method in Randomised Clinical Trials: Participant Variables That Contribute to Depression Treatment Efficacy of Duloxetine, Ssris or Placebo, Journal of affective disorders(2014).
3641.	Dodd S, Horgan D, GS M, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. Journal of affective disorders. 2005;89:1-11.
3642.	Dodd S, Maes M, Anderson G, OM D, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Progress in neuro-psychopharmacology & biological psychiatry. 2013;42:135-145.
3643.	Dodick D, Blumenfeld A, SD S. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Clinics in dermatology. 2004;22:76-81.
3644.	Dogterom P, Hulskotte E, Gerrits M, et al. Asenapine pharmacokinetics: Influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition. European neuropsychopharmacology. 2008;Conference:S452-S453.
3645.	Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: Are all agents the same? CNS drugs. 2007;21:389-405.
3646.	Dolle K, Schulte-Korne G. The treatment of depressive disorders in children and adolescents. [Review]. Deutsches Arzteblatt international. 2013;110:854-860.
3647.	Dolle K, Schulte-Korne G. The treatment of depressive disorders in children and adolescents. [German, English]. Deutsches Arzteblatt international. 2013;110:854-860+858-811+I-II.
3648.	Dolle K, Schulte-Korne G. The Treatment of Depressive Disorders in Children and Adolescents. Deutsches Arzteblatt international. 2013;110:854-+.
3649.	Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. International journal of neuropsychopharmacology. 2010;13:93-101.
3650.	Domschke K, Stevens S, Pfleiderer B, AL G. Interoceptive sensitivity in anxiety and anxiety disorders: An overview and integration of neurobiological findings. Clinical psychology review. 2010;30:1-11.
3651.	Domschke K, Zwanzger P. GABAergic and endocannabinoid dysfunction in anxiety - Future therapeutic targets? Current pharmaceutical design. 2008;14:3508-3517.
3652.	Donald A, Jean A, Scott P, et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. Journal of clinical psychopharmacology. 2002;22:20-25.
3653.	Dongfeng M, Zhijun Z, Xiangrong Z, Lingjiang L. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: A multiple-treatments meta-analysis. Current medical research and opinion. 2014;30:971-995.
3654.	Donnelly A, Paton C. Safety of selective serotonin reuptake inhibitors in pregnancy. Psychiatric bulletin (London, England). 2007;31:183-186.
3655.	Donoghue J. Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. [Review] [28 refs]. Acta psychiatrica Scandinavica. Supplementum. 2000;403:57-61.
3656.	Donoghue J, Judge R. Antidepressant use patterns in clinical practices: Comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, Supplement. 2000;101:57-61.
3657.	Donoghue J, TR H. Antidepressant use in clinical practice: Efficacy v. effectiveness. British journal of psychiatry. 2001;179:s9-s17.
3658.	Donovan S. The efficacy and tolerability of dothiepin versus serotonin specific reuptake inhibitors in the treatment of depression. European neuropsychopharmacology. 1993;3:331-332.
3659.	Donovan S, McGrady H, Pownall R, Rees JA. The efficacy and tolerability of dothiepin and three selective serotonin reuptake inhibitors in the treatment of major depression: A review of six double-blind studies. Current therapeutic research, clinical and experimental. 1993;54:275-289.
3660.	Doogan DP. Toleration and safety of sertraline: experience worldwide. [Review] [14 refs]. International clinical psychopharmacology. 1991;6 Suppl 2:47-56.
3661.	Doogan DP, Caillard V. Sertraline in the prevention of depression. The British Journal of Psychiatry. 1992;160:217-222.
3662.	Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. International clinical psychopharmacology. 1994;9:95-100.
3663.	Dorian D. Review of Let Them Eat Prozac. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2004;49:639-640.
3664.	Dorman T. Sleep and paroxetine: A comparison with mianserin in elderly depressed patients. International clinical psychopharmacology. 1992;6 Suppl 4:53-58.
3665.	Doron M, Baruch S, Alex A, Hanna Z, Yoram B. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. International clinical psychopharmacology. 2007;22:371-375.
3666.	Doroudgar S, Lackey G, Alsop J, Albertson T. A 10-year retrospective review of venlafaxine ingestions in children under 4 years of age. Clinical toxicology. 2012;Conference:596-597.
3667.	Dorst J, Kuehnlein P, AD S, AC L. Therapy options in amyotrophic lateral sclerosis (ALS). [German]. Nervenheilkunde. 2007;26:362-367.
3668.	Doruk D, Gray Z, GL B, Pascual-Leone A, Fregni F. Effects of Tdcs on Executive Function in Parkinson's Disease. Neuroscience letters. 2014;582:27-31.
3669.	Doshi P. Putting GlaxoSmithKline to the test over paroxetine. BMJ (Online). 2013.
3670.	Doshi P, Zito J, dosReis S. Digging for data on harms in duloxetine trials. BMJ (Clinical research ed.). 2014;348:g3578.
3671.	Dossey L. Memory Management: A Gathering Ethical Storm. Explore: The Journal of Science and Healing. 2006;2:185-188.
3672.	Douaihy A, Cornelius J, RT C, et al. One-year follow-up of double-blind fluoxetine trial in comorbid mddcud youth. Alcoholism, clinical and experimental research. 2011;Conference:20A.
3673.	Doug W, Eileen B, H PR, Jonna A, W BR, Mauricio T. Clinical relevance of depressive symptom improvement in bipolar I depressed patients. Journal of affective disorders. 2006;92:261-266.
3674.	Douglas F, John H, Jyoti R, David D, Mark D, Z PW. The responsiveness of the Hamilton Depression Rating Scale. Journal of psychiatric research. 2000;34:3-10.
3675.	Dove D, Warren Z, ML M, JL T, NA S, Veenstra-VanderWeele J. Medications for adolescents and young adults with autism spectrum disorders: A systematic review. Pediatrics. 2012;130:717-726.
3676.	Dove M, Eskes G, Klein R, Shore D. A left attentional bias in chronic neglect: A case study using temporal order judgments. Neurocase. 2007;13:37-49.
3677.	Dowrick C. Advances in psychiatric treatment in primary care. Advances in Psychiatric Treatment. 2001;7:1-8.
3678.	DP A. Chronic back pain with possible prescription opioid misuse. JAMA - Journal of the American Medical Association. 2013;309:919-925.
3679.	DP C, SR P-P, GM B. Sleep and circadian dysregulation in depressive illness. Pharmacological implications. Clinical Neuropsychiatry. 2011;8:321-338.
3680.	DP C, SR P-P, Srinivasan V, DW S, Trakht I. Therapeutic potential of melatonin agonists. Expert review of endocrinology & metabolism. 2008;3:269-279.
3681.	DP C, Srinivasan V, Brzezinski A, GM B. Melatonin and its analogs in insomnia and depression. Journal of pineal research. 2012;52:365-375.
3682.	DP C-F, TL L. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert review of clinical pharmacology. 2011;4:363-377.
3683.	DP D. Dysthymic disorder in the elderly population. International Psychogeriatrics. 2014;26:39-48.
3684.	DP D, Garvey M, AG P, et al. Neurologic examination abnormalities in children with bipolar disorder or attention-deficit/hyperactivity disorder. Biological psychiatry. 2005;58:517-524.
3685.	DP D, Juszczak N, MS N, et al. Open Treatment Trial of Venlafaxine for Elderly Patients With Dysthymic Disorder. Journal of geriatric psychiatry and neurology. 2004;17:219-224.
3686.	DP D, Juszczak N, MS N, et al. Open Treatment Trial of Venlafaxine for Elderly Patients With Dysthymic Disorder. Journal of geriatric psychiatry and neurology. 2004;17:219-224.
3687.	DP D, MK K, MS N. Fluoxetine discontinuation in elderly dysthymic patients. American journal of geriatric psychiatry. 1997;5:83-87.
3688.	DP D, MS N, Cheng J, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Fluoxetine Treatment for Elderly Patients With Dysthymic Disorder. American journal of geriatric psychiatry. 2005;13:59-68.
3689.	DP D, SP R. Antidepressants in older adults: Complexities, confounds and clinical effects. American journal of geriatric psychiatry. 2014;22:1-3.
3690.	DP S, JR C, Alpert J, Fava M. Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder. CNS neuroscience & therapeutics. 2012;18:441-451.
3691.	DP W, JR L. Approach to the patient with Raynaud's phenomenon. Clinics in Family Practice. 2005;7:321-334.
3692.	DP W, M VM, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. Journal of clinical psychiatry. 1998;59:306-312.
3693.	DR C, RJ H. SSRIs for anxiety and depression in children and adolescents. Pediatric annals. 2013;42:62-66.
3694.	DR G, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. [Review] [59 refs]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 2004;24:621-629.
3695.	DR G, Scheckner B, Albano D. Treatment of Pain Syndromes With Venlafaxine. Pharmacotherapy. 2004;24:621-629.
3696.	DR G, Scheckner B, Albano D. Treatment of Pain Syndromes with Venlafaxine. Pharmacotherapy. 2004;24:621-629.
3697.	DR K, CN E, AR W, KL W. Pharmacotherapy of postpartum depression: An update. Expert opinion on pharmacotherapy. 2014;15:1223-1234.
3698.	DR K, Joffe H. Use of antidepressants during perimenopause. Women's Health. 2006;2:627-637.
3699.	DR L, JD H, EB F, JRT D, FJ K, NLS P. Impact of Depressieve Symptoms on the Treatment of Generalized Social Anxiety Disorder. Depression and anxiety. 2005;22:161-167.
3700.	DR L, JD H, EB F, JRT D, FJ K, NLS P. Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and anxiety. 2005;22:161-167.
3701.	DR L, JD H, EB F, JRT D, FJ K, NLS P. Impact of Depressieve Symptoms on the Treatment of Generalized Social Anxiety Disorder. Depression and anxiety. 2005;22:161-167.
3702.	DR L, RG H, DA H, et al. Efficacy of a Manualized and Workbook-Driven Individual Treatment for Social Anxiety Disorder. Behavior therapy. 2009;40:414-424.
3703.	DR P, DE G, JL C, HD P. Developmental disabilities across the lifespan. Disease-a-month. 2010;56:305-397.
3704.	DR P, DL B, KM S, CL L. Troublesome symptoms in cancer survivors: Fatigue, insomnia, neuropathy, and pain. Journal of clinical oncology. 2012;30:3687-3696.
3705.	DR S, Grenoble S. Pharmacotherapies for Adolescent Substance Use Disorders. Child and adolescent psychiatric clinics of North America. 2010;19:591-608.
3706.	DR S, MO S, SD H, et al. Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression. Psychological medicine. 2010;40:1379-1387.
3707.	Persistence on a stress-challenge task before initiating buprenorphine treatment was associated with successful transition from opioid use to early abstinence, Journal of addiction medicine(2012).
3708.	DR W, Vallortigara J, Alghamdi A, et al. Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia With Lewy Bodies, and Parkinson Disease Dementia. American journal of geriatric psychiatry. 2015;23:141-148.
3709.	Drago A. SSRIs impact on sleep architecture: Guidelines for clinician use. Clinical Neuropsychiatry. 2008;5:115-131.
3710.	Dreher T, Hauser W, Schiltenwolf M. Fibromyalgia Syndrome - Updated S3 Guidelines. Zeitschrift fur Orthopadie und Unfallchirurgie. 2013;151:603-609.
3711.	Dreimuller N, Lieb K, Tadic A. Combination of Antidepressants. Nervenheilkunde. 2009;28:298-+.
3712.	Dreimuller N, Lieb K, Tadic A. Combination of antidepressants. [German]. Nervenheilkunde. 2009;28:298-303.
3713.	Dremencov E, M EM, Blier P. Effects of Sustained Serotonin Reuptake Inhibition on the Firing of Dopamine Neurons in the Rat Ventral Tegmental Area. Journal of psychiatry & neuroscience. 2009;34:223-229.
3714.	Drieling T, NC B, LO S, Strobl N, JM L. Psychotropic Drug-Induced Change of Weight: a Review. Fortschritte der Neurologie-Psychiatrie. 2007;75:65-80.
3715.	Cognitive behavioral therapy versus short psychodynamic supportive psychotherapy in the outpatient treatment of depression: A randomized controlled trial, BMC psychiatry(2007).
3716.	Driessen E, SD H. Cognitive behavioral therapy for mood disorders: Efficacy, moderators and mediators. Psychiatric clinics of North America. 2010;33:537-555.
3717.	Drohomirecka A, EA J, Banasiak W, Ponikowski P. Depression in patients with chronic heart failure. [Polish]. Kardiologia polska. 2008;66:1325-1332.
3718.	DRP G. Geriatric pharmacotherapy updates. American Journal Geriatric Pharmacotherapy. 2006;4:287-291.
3719.	DRP G. Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson's disease. American Journal Geriatric Pharmacotherapy. 2006;4:330-346.
3720.	DRS J, AE J. Depression in Patients With Parkinson's Disease: Identification and Treatment. British journal of hospital medicine. 2007;68:485-488.
3721.	Drtilkova I. Antidepressants in child psychiatry. [Czech]. Ceska a Slovenska Psychiatrie. 1999;95:36.
3722.	Drtilkova I. Developmental aspects of antidepressant treatment. [Czech]. Psychiatrie (Stuttgart, Germany). 2003;7:184-187.
3723.	Drtilkova I. Current view on the suicide risk during treatment of antidepressants in children. [Czech]. Ceska a Slovenska Psychiatrie. 2007;103:22-27.
3724.	Druais S, Gauthier A, Demyttenaere K, et al. An assessement of the cost-effectiveness of escitalopram versus multiple comparators as first line antidepressant in patients with major depressive disorder (MDD) in belgium. Value in health. 2012;Conference:A338.
3725.	Drueke B, Baetz J, Boecker M, et al. Differential effects of escitalopram on attention: A placebo-controlled, double-blind cross-over study. Psychopharmacology. 2009;207:213-223.
3726.	DS B. Depression and Sexual Function. Journal of psychopharmacology (Oxford, England). 1996;10:30-34.
3727.	DS B. Monoamine systems in depression: Towards better understanding of the disorder and improved treatment options. Human psychopharmacology. 1998;13:293-295.
3728.	DS B. Venlafaxine. Prescribers' journal. 1999;39:242-247.
3729.	DS B. Clinical Experience With Paroxetine in Social Anxiety Disorder. International clinical psychopharmacology. 2000;15:S19-S24.
3730.	DS B. Unmet needs in the pharmacological management of depression. Human psychopharmacology. 2001;16:S93-S99.
3731.	DS B. Escitalopram: efficacy and tolerability in the treatment of depression. [Review] [15 refs]. Hospital medicine (London, England : 1998). 2002;63:668-671.
3732.	DS B. Recurrent brief depression - More investigations in clinical samples are now required. Psychological medicine. 2003;33:383-386.
3733.	DS B. Serotonin Noradrenaline Reuptake Inhibitors: a New Generation of Treatment for Anxiety Disorders. International journal of psychiatry in clinical practice. 2006;10:12-15.
3734.	DS B. The Importance of Long-Term Tolerability in Achieving Recovery. International journal of psychiatry in clinical practice. 2006;10:31-37.
3735.	DS B. Room for Improvement in the Pharmacological Treatment of Anxiety Disorders. Current pharmaceutical design. 2008;14:3482-3491.
3736.	DS B. Where is the room for improvement in the drug treatment of depression and anxiety? Human psychopharmacology. 2011;26:1-3.
3737.	DS B. The treatment of cognitive deficits in major depressive disorder. International journal of psychiatry in clinical practice. 2013;Conference:4.
3738.	DS B, Ajel K, VG M, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: An update. Neuropsychiatric disease and treatment. 2013;9:883-892.
3739.	DS B, AKT H, Maehlum E. Escitalopram and Paroxetine in the Treatment of Generalised Anxiety Disorder - Randomised, Placebo-Controlled, Double-Blind Study. British journal of psychiatry. 2006;189:264-272.
3740.	DS B, AT L. Agomelatine in the Treatment of Mood and Anxiety Disorders. British journal of hospital medicine. 2010;71:153-156.
3741.	DS B, Buis C, Carabal E. Tolerability and safety of reboxetine. Reviews in Contemporary Pharmacotherapy. 2000;11:321-330.
3742.	DS B, CJ H, Mellors K, Group C-S. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: Safety, tolerability and efficacy in continuation phase treatment. Journal of psychopharmacology (Oxford, England). 2001;15:161-165.
3743.	DS B, CJ H, RT A, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Journal of clinical psychiatry. 1996;57 Suppl 2:46-52.
3744.	DS B, DJ N. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European neuropsychopharmacology. 2012;22:841-843.
3745.	DS B, EH R, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. [Review] [59 refs]. Annals of pharmacotherapy. 2007;41:1583-1592.
3746.	DS B, EK B, Meron D. The overlap of obsessive-compulsive disorder and social phobia and its treatment. CNS spectrums. 2008;13:47-53.
3747.	DS B, Foong T. Antidepressant Drugs and Sexual Dysfunction. British journal of psychiatry. 2013;202:396-397.
3748.	DS B, GI P. Symptoms of Fatigue and Sleepiness in Major Depressive Disorder. Journal of clinical psychiatry. 2006;67:9-15.
3749.	Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder, Current medical research and opinion(2012).
3750.	DS B, Hansen T, Florea I. Lu AA21004, a multimodal psychotropic agent, in the open-label, long-term treatment of major depressive disorder. European neuropsychopharmacology. 2012;Conference:S227-S228.
3751.	DS B, IM A, DJ N, et al. Evidence-Based Pharmacological Treatment of Anxiety Disorders, Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder: a Revision of the 2005 Guidelines From the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England). 2014;28:403-439.
3752.	DS B, KI A, Garner M. Pharmacological treatment of generalized anxiety disorder. Behavioral Neurobiology of Anxiety and Its Treatment. 2010;Current To:453-467.
3753.	DS B, Kosky N. Off-label prescribing in psychiatric practice. Advances in Psychiatric Treatment. 2007;13:414-422.
3754.	DS B, Loft H, Florea I. Lu Aa21004, a Multimodal Psychotropic Agent, in the Prevention of Relapse in Adult Patients With Generalized Anxiety Disorder. International clinical psychopharmacology. 2012;27:197-207.
3755.	DS B, Polkinghorn C. Evidence-Based Pharmacotherapy of Generalized Anxiety Disorder. International journal of neuropsychopharmacology. 2005;8:293-302.
3756.	DS B, PT C. Chronic Fatigue Syndrome - Psychotropic or Immunological Therapy. CNS drugs. 1994;1:348-355.
3757.	DS B, RV N. Escitalopram in the treatment of generalized anxiety disorder. [Review] [50 refs]. Expert review of neurotherapeutics. 2005;5:443-449.
3758.	DS B, Serenko M, Palo W, Lophaven S, Matz J. The safety and tolerability of vortioxetine (Lu AA21004) in the treatment of adults with major depressive disorder (MDD): A pooled analysis. International journal of psychiatry in clinical practice. 2013;Conference:16-17.
3759.	DS B, Tiwari N. The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going? CNS spectrums. 2009;14:5-12.
3760.	Vortioxetine in the treatment of major depressive disorder, Future neurology(2015).
3761.	DS B, Waldman S, Allgulander C. Evidence-Based Pharmacological Treatment of Generalized Anxiety Disorder. International journal of neuropsychopharmacology. 2011;14:697-710.
3762.	Major depressive disorder and type II diabetes mellitus: Mechanisms underlying risk for Alzheimer's disease, CNS and Neurological Disorders - Drug Targets(2014).
3763.	DS C, DR G, SL S. The course of major depressive disorder. Journal of clinical psychiatry. 2002;63:4-5.
3764.	DS G, Fujioka K, Devine W, GA B. A randomized double-blind clinical trial of fluoxetine in obese diabetics. International journal of obesity. 1992;16:S67-S72.
3765.	DS G, Fujioka K, Devine W, GA B. Fluoxetine treatment of the obese diabetic. International journal of obesity. 1992;16:193-198.
3766.	DS G, MP O. Pharmacotherapy of Bulimia-Nervosa With Fluoxetine - Assessment of Clinically Significant Attitudinal Change. American journal of psychiatry. 1993;150:770-774.
3767.	DS J. Depression and dysphoria effects on the interpersonal perception of negative and positive moods and caring relationships: Effects of antidepressants, amphetamine, and methylphenidate. Current psychiatry reports. 2003;5:451-459.
3768.	DS J. Current issues in the treatment of depression in bipolar disorder patients. Current psychiatry reports. 2005;7:485-486.
3769.	DS J. Recent depression updates: Relevant presentations. Current psychiatry reports. 2006;8:470-472.
3770.	DS J. Bipolar disorder-relevant abstracts of posters from the 2008 CINP congress. Current psychiatry reports. 2008;10:525-527.
3771.	DS J, Shetty M, Barnhill J, Elamir B, JM D. Serotonergic Antidepressant Effects on Aggressive, Self-Injurious and Destructive/Disruptive Behaviours in Intellectually Disabled Adults: a Retrospective, Open-Label, Naturalistic Trial. International journal of neuropsychopharmacology. 2005;8:37-48.
3772.	DS J, Shetty M, Barnhill J, Elamir B, JM D. Serotonergic Antidepressant Effects on Aggressive, Self-Injurious and Destructive/Disruptive Behaviours in Intellectually Disabled Adults: a Retrospective, Open-Label, Naturalistic Trial. International journal of neuropsychopharmacology. 2005;8:37-48.
3773.	DS M, SN Y. Ecological momentary assessment: What it is and why it is a method of the future in clinical psychopharmacology. Journal of psychiatry & neuroscience. 2006;31:13-20.
3774.	DS P, JA C. Trauma in children and adolescents: Risk and treatment of psychiatric sequelae. Biological psychiatry. 2002;51:519-531.
3775.	DS R. Remission of depression: How effective are antidepressants? Primary psychiatry. 2005;12:17-18.
3776.	DS R. Antidepressant drugs: Early onset of therapeutic effect. Primary psychiatry. 2007;14:23-24.
3777.	DS R. The role of dopamine and norepinephrine in depression. Primary psychiatry. 2007;14:21-23.
3778.	DS R. Fibromyalgia Treatment Update. Current opinion in rheumatology. 2007;19:111-117.
3779.	DS R, DL R, JM S, et al. The safety profile of nefazodone. [Review] [20 refs]. Journal of clinical psychiatry. 1996;57 Suppl 2:31-38.
3780.	DS R, JD A. The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability. Journal of affective disorders. 2008;105:15-23.
3781.	DS S, KE F, RN G, RP M. ENRICHD and SADHART: Implications for future biobehavioral intervention efforts. Psychosomatic medicine. 2003;65:1-4.
3782.	DS T, CC C, FW L, CY Y. Maoa Gene Polymorphisms and Response to Mirtazapine in Major Depression. Human Psychopharmacology-Clinical and Experimental. 2009;24:293-300.
3783.	DT B, GG M, Niederauer K, AV C. Full Remission and Relapse of Obsessive-Compulsive Symptoms After Cognitive-Behavioral Group Therapy: a Two-Year Follow-up. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2010;32:164-168.
3784.	Fluoxetine treatment of alcoholic perpetrators of domestic violence: A 12-week, double-blind, randomized, placebo-controlled intervention study, Journal of clinical psychiatry(2011).
3785.	DT W, FP B. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?. [Review] [147 refs]. Progress in drug research. 2002;58:169-222.
3786.	DTS L, TKH C. Postnatal depression: an update. Best Practice and Research in Clinical Obstetrics and Gynaecology. 2007;21:183-191.
3787.	Du L, Bakish D, AV R, PD H. Does fluoxetine influence major depression by modifying five-factor personality traits? Journal of affective disorders. 2002;71:235-241.
3788.	Dua T, Barbui C, Clark N, et al. Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: Summary of WHO recommendations. PLoS medicine. 2011.
3789.	Duan D, Tu Y, Jiao S, Chen L. Combined effects of electroacupuncture and anti-depression drugs on the hippocampus and frontal lobe. Neural Regeneration Research. 2010;5:1723-1727.
3790.	Dube S, MA D, Jones M, et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. Biological psychiatry. 2009;Conference:242S.
3791.	Dube S, MA D, Jones M, et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. Journal of psychiatric research. 2010;44:356-363.
3792.	Dubicka B, Elvins R, Roberts C, Chick G, Wilkinson P, IM G. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. [Review]. British journal of psychiatry. 2010;197:433-440.
3793.	Dubicka B, Goodyer I. Should we prescribe antidepressants to children? Psychiatric bulletin (London, England). 2005;29:164-167.
3794.	Dubicka B, Hadley S, Roberts C. Suicidal Behaviour in Youths With Depression Treated With New-Generation Antidepressants - Meta-Analysis. British journal of psychiatry. 2006;189:393-398.
3795.	Dubicka B, Wilkinson P, RG K, IM G. Pharmacological treatment of depression and bipolar disorder in children and adolescents. Advances in Psychiatric Treatment. 2010;16:402-412.
3796.	Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? European neuropsychopharmacology. 1997;7:S49-S55.
3797.	Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. Journal of psychopharmacology (Oxford, England). 1997;11:S17-23.
3798.	Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? European neuropsychopharmacology. 1997;7 Suppl 1:S49-55; discussion S71-43.
3799.	Dubois O. [Indications for crenotherapy]. [Review] [21 refs] [French]. Encephale. 2009;35 Suppl 4:S133-136.
3800.	Dubois O, Salamon R, M-F P, J-P O. Crenotherapy in anxiety disorder. [French]. Annales medico-psychologiques. 2008;166:109-114.
3801.	Ducasse D, Courtet P, Olie E. Burning mouth syndrome: Current clinical, physiopathologic, and therapeutic data. Regional anesthesia and pain medicine. 2013;38:380-390.
3802.	Ducher JL, Terra JL. Is the suicidal risk assessment scale RSD of predictive value? [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2006;32:738-745.
3803.	Duckett J. Duloxetine as a treatment for stress incontinence - Where are we now? International urogynecology journal and pelvic floor dysfunction. 2008;19:1-3.
3804.	Ducrotte P. Irritable bowel syndrome: dietary and pharmacological therapeutic options. [French]. Gastroenterologie clinique et biologique. 2009;33:S68-S78.
3805.	Dudra-Jastrzebska M, MM A-M, JJ L, SJ C. Mood Disorders in Patients With Epilepsy. Pharmacological Reports. 2007;59:369-378.
3806.	Duenas H, AJM B, Lee A, et al. Treatment-Emergent Sexual Dysfunction With Ssris and Duloxetine: Effectiveness and Functional Outcomes Over a 6-Month Observational Period. International journal of psychiatry in clinical practice. 2011;15:242-254.
3807.	Dufour H. Treatment of recurrent unipolar depressions: psychological and biological aspects. Bibliotheca psychiatrica. 1994:79-85.
3808.	Dumortier G, Welniarz B, Sauvebois C, et al. Prescription of Psychotropic Drugs in Paediatry : Approved Indications and Therapeutic Perspectives. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:477-489.
3809.	Dumortier G, Welniarz B, Sauvebois C, et al. Prescription of Psychotropic Drugs in Paediatry : Approved Indications and Therapeutic Perspectives. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:477-489.
3810.	Dumortier G, Welniarz B, Sauvebois C, et al. Prescription of psychotropic drugs in paediatry: Approved indications and therapeutic perspectives. [French]. Encephale. 2005;31:477-489.
3811.	Dunai A, Novak M, SA C, et al. Moderate Exercise and Bright Light Treatment in Overweight and Obese Individuals. Obesity (Silver Spring, Md.). 2007;15:1749-1757.
3812.	Dunbar G, Hosford D. The potential of the nicotinic channel blocker tc-5214 as augmentation treatment in patients with major depression. European neuropsychopharmacology. 2010;Conference:S334.
3813.	Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. The British Journal of Psychiatry. 1991;159:394-398.
3814.	Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. International clinical psychopharmacology. 1992;6 Suppl 4:81-90.
3815.	Dunbar GC, L CJ, Kiev A, Rickels K, Smith WT. A comparison of paroxetine and placebo in depressed outpatients. Acta psychiatrica Scandinavica. 1993;87:302-305.
3816.	Duncko R, Novakova L, Notova P, Stepankova O, Jezova D. Behavioral and Neuroendocrine Changes During Mental Stress and Repeated Treatment With Antidepressants in Healthy Men.1018:524-532.
3817.	Duncko R, Novakova L, Notova P, Stepankova O, Jezova D. Behavioral and Neuroendocrine Changes During Mental Stress and Repeated Treatment With Antidepressants in Healthy Men.1018:524-532.
3818.	Dundar Y, Boland A, Strobl J, et al. Newer hypnotic drugs for the short-term management of insomnia: A systematic review and economic evaluation. Health technology assessment. 2004;8:iii-68.
3819.	Dunkin J, Rasgon N, Zeller M, et al. Estrogen replacement and cognition in postmenopausal women: Effect of years since menopause on response to treatment. Drug development research. 2005;66:150-159.
3820.	Dunlop B, DeFife J, Marx L, et al. The effect of sertraline on psychopathic traits. Neuropsychopharmacology. 2010;Conference:S391-S392.
3821.	Dunner D, Kumar R. Paroxetine: A review of clinical experience. Pharmacopsychiatry. 1998;31:89-101.
3822.	Dunner DL, Dunbar GC. Managing the patient with depression and anxiety. European psychiatry. 1993;8:9S-12S.
3823.	Duong S, Chung K, SB W. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD. Expert opinion on drug metabolism & toxicology. 2012;8:543-552.
3824.	Durand G, Girodon J, Debiais F. Medical management of failed back surgery syndrome in Europe: Evaluation modalities and treatment proposals. Neuro-Chirurgie. 2015;61:S57-S65.
3825.	Durmaz O, MA A, Gunay H, Basoglu C. One year follow-up of repetitive TMS efficacy in treatment-resistant major depression: Report of two cases. European neuropsychopharmacology. 2012;Conference:S300-S301.
3826.	Durrance A. Depression & Anxiety - SMi Conference: Shining light into dark corners 12-13 May 2003, London, UK. IDrugs : the investigational drugs journal. 2003;6:664-667.
3827.	Dursun S. Initial Effectiveness, Partial Remission, and Full Remission in Depression: Focus on Long-Term Treatment With Snris. CNS spectrums. 2008;13:10-14.
3828.	Duru G, Fantino B. The Clinical Relevance of Changes in the Montgomery-Asberg Depression Rating Scale Using the Minimum Clinically Important Difference Approach. Current medical research and opinion. 2008;24:1329-1335.
3829.	Dusouchet T, MC B, Bret P. Antidepressants: Characteristics and usage recommendations for SSRI, NaSRI and NaSSA. [French]. Pharmacien Hospitalier. 2006;41:25-31.
3830.	Dusseldorp E, Spinhoven P, Bakker A, R VD, Ajlm VB. Which Panic Disorder Patients Benefit From Which Treatment: Cognitive Therapy or Antidepressants? Psychotherapy and psychosomatics. 2007;76:154-161.
3831.	Dutta A, McKie S, JFW D. Are the acute effects of citalopram mediated by the dopamine system. European neuropsychopharmacology. 2014;Conference:S308.
3832.	Dutta A, McKie S, JFW D. Ketamine and other potential glutamate antidepressants. Psychiatry research. 2015;225:1-13.
3833.	Dutta V. Psychostimulants for chemotherapy induced cognitive changes in cancer, Ockham's razor, anyone. Journal of cancer research and therapeutics. 2012;8:326-329.
3834.	Duval F, MC M, MA C, et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Archives of general psychiatry. 1996;53:833-840.
3835.	DV H, CR R, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: Preclinical, human laboratory, and clinical studies. Addiction Reviews 2. 2010;Annals of 76-100.
3836.	DV I. Prediction of Response to Antidepressants: Is Quantitative Eeg (Qeeg) an Alternative ? CNS neuroscience & therapeutics. 2008;14:263-265.
3837.	DV I. Electroencephalography-derived biomarkers of antidepressant response. Harvard review of psychiatry. 2011;19:144-154.
3838.	DV I. EEG biomarkers of treatment response in major depression. Biological psychiatry. 2015;Conference:17S.
3839.	DV I, AA N, JE A, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. American journal of psychiatry. 2003;160:2122-2127.
3840.	DV I, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Current psychiatry reports. 2004;6:193-201.
3841.	DV J, CR D. Treatment of non-schizophrenic disorders: Focus on atypical antipsychotics. Journal of psychiatric research. 2004;38:73-103.
3842.	DV J, TW M, DS K, GS Z. Research agenda for DSM-V: Diagnostic categories and criteria for neuropsychiatric syndromes in dementia. Journal of geriatric psychiatry and neurology. 2006;19:160-171.
3843.	DV S. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. Journal of clinical psychiatry. 1999;60:23-28.
3844.	DV S. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. [Review] [26 refs]. Journal of clinical psychiatry. 1999;60 Suppl 2:23-28.
3845.	DV S. Current Concepts in the Treatment of Panic Disorder. Journal of clinical psychiatry. 1999;60:16-21.
3846.	DV S. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. [Review] [30 refs]. Journal of clinical psychiatry. 2001;62 Suppl 1:26-31.
3847.	DV S, AL M, Ahl J, Prakash A, TMM O, Kelin K. Efficacy of duloxetine on functional impairment in patients with major depressive disorder. Australian and New Zealand journal of psychiatry. 2011;Conference:A63.
3848.	The Relationship Between Functional Outcomes and the Treatment of Anxious and Painful Somatic Symptoms in Patients With Generalized Anxiety Disorder, Current medical research and opinion(2008).
3849.	DV S, BA R, RR T, EL K. Serotonin in panic disorder and social phobia. International clinical psychopharmacology. 1993;8:63-77.
3850.	DV S, CB N, ME T, Entsuah R, Group ES. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. International clinical psychopharmacology. 2009;24:61-86.
3851.	DV S, CK D, RK D. An analysis of the effects of three commonly prescribed antidepressant agents on memory function. Drugs and Therapy Perspectives. 2014;30:112-116.
3852.	DV S, CK D, RK D, DJ D. An analysis of the effects of three commonly prescribed antidepressant agents on psychomotor function. Drugs and Therapy Perspectives. 2013;29:324-328.
3853.	DV S, DB B, MK I, Perera P. Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder. Journal of clinical psychiatry. 2005;66:34-40.
3854.	DV S, DB B, MK I, Perera P. Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder. Journal of clinical psychiatry. 2005;66:34-40.
3855.	DV S, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation: A comparison between controlled-release and immediate-release paroxetine. Journal of clinical psychopharmacology. 2004;24:544-548.
3856.	DV S, Harnett-Sheehan K. The role of SSRIs in panic disorder. Journal of clinical psychiatry. 1996;57:51-60.
3857.	DV S, MB K. Optimizing Therapeutic Options in the Treatment of Bipolar Disorder. Primary psychiatry. 2003;10:1-10.
3858.	DV S, Svedsater H, JC L, Eriksson H. Effects of Extended-Release Quetiapine Fumarate on Long-Term Functioning and Sleep Quality in Patients With Generalized Anxiety Disorder (Gad): Data From a Randomized-Withdrawal, Placebo-Controlled Maintenance Study. Journal of affective disorders. 2013;151:906-913.
3859.	DV V, RJ B. Anticonvulsants in the treatment of major depressive disorder: An overview. Harvard review of psychiatry. 2009;17:231-241.
3860.	DW B, DP M, WJ B, MC S, Allen J. An Open-Label Trial of Acamprosate in the Treatment of Pathological Gambling. Annals of clinical psychiatry. 2011;23:250-256.
3861.	DW B, Gabel J, Hansen J, Schlosser S. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Annals of clinical psychiatry. 2000;12:205-211.
3862.	DW B, Monahan P, Gabel J. Fluvoxamine in the treatment of compulsive buying. Journal of clinical psychiatry. 1997;58:159-163.
3863.	DW B, RB W, Gabel J, Bowers W, Monahan P. Predictors of Short-Term Treatment Response in 66 Patients With Panic Disorder. Journal of affective disorders. 1994;30:233-241.
3864.	DW B, Shaw M, Mccormick B, JD B, Allen J. Neuropsychological Performance, Impulsivity, Adhd Symptoms, and Novelty Seeking in Compulsive Buying Disorder. Psychiatry research. 2012;200:581-587.
3865.	DW C. Drug repurposing: Identify, develop and commercialize new uses for existing or abandoned drugs. Part II. 31 January - 1 February 2005, Philadelphia, PA, USA. IDrugs : the investigational drugs journal. 2005;8:310-313.
3866.	DW D. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache. 2003;43:S25-S33.
3867.	DW G, ME T. Recognizing ADHD in adults with comorbid mood disorders: Implications for identification and management. Postgraduate medicine. 2009;121:20-30.
3868.	DW H, BL B, DA S, Godfrey K, AM L. The Efficacy of Selective Serotonin Reuptake Inhibitors in Adult Social Anxiety Disorder: a Meta-Analysis of Double-Blind, Placebo-Controlled Trials. Journal of psychopharmacology (Oxford, England). 2007;21:102-111.
3869.	DW H, FLM W. An emerging role for escitalopram in the treatment of obsessive-compulsive disorder. Neuropsychiatric disease and treatment. 2007;3:455-461.
3870.	DW M, MH T, AJ R. Folate and unipolar depression. Journal of alternative and complementary medicine (New York, N.Y.). 2008;14:277-285.
3871.	DW M, MH T, Fava M, et al. Diurnal Mood Variation in Outpatients With Major Depressive Disorder. Depression and anxiety. 2009;26:851-863.
3872.	TNF-alpha antagonist infliximab in the treatment of depression in older adults: Results of a prematurely ended, randomized, placebo-controlled trial, Journal of clinical psychopharmacology(2010).
3873.	DW O. Treatment of late-life depression complicated by alcohol dependence. American journal of geriatric psychiatry. 2005;13:491-500.
3874.	DW O. Treatment of late-life depression complicated by alcohol dependence. American journal of geriatric psychiatry. 2005;13:491-500.
3875.	DY J, DL D, Henry M, et al. Sporadic jakob-creutzfeldt disease presenting as primary progressive aphasia. JAMA Neurology. 2013;70:254-257.
3876.	DY L, KW K, JH J, et al. A multicenter, randomized, placebocontrolled, double-blind clinicaltrial of escitalopram on its atrophydelaying effect in Alzheimer's disease. Alzheimer's & dementia. 2012;Conference:P603.
3877.	DZ L, FK G. Use of olanzapine in the treatment of bipolar I disorder. Expert review of neurotherapeutics. 2004;4:759-767.
3878.	DZ L, FK G. Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. Current psychiatry reports. 2004;6:459-465.
3879.	DZ L, SH M. Desvenlafaxine in major depressive disorder: An evidence-based review of its place in therapy. Core evidence. 2009;4:67-82.
3880.	E AJ, George P, David M, et al. S-Adenosyl-L-Methionine (Same) as an Adjunct for Resistant Major Depressive Disorder - an Open Trial Following Partial or Nonresponse to Selective Serotonin Reuptake Inhibitors or Venlafaxine. Journal of clinical psychopharmacology. 2004;24:661-664.
3881.	E AJ, Kurt K, EJr ND, S KM, Ananda S. Trajectories of improvement for six depression-related outcomes. General hospital psychiatry. 2008;30:26-31.
3882.	E BG, E AJ, Daniel A, et al. Neurocognitive predictors of antidepressant clinical response. Journal of affective disorders. 2014;166:108-114.
3883.	E BJ, WJr WJ, E OT, et al. Treatment of Dysthymia and Minor Depression in Primary Care - a Randomized Trial in Patients Aged 18 to 59 Years. Journal of family practice. 2001;50:405-412.
3884.	E BJ, WJr WJ, E OT, et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. [Review] [59 refs]. General hospital psychiatry. 1999;21:260-273.
3885.	E BL. Prozac and placebo: There's a pony in there somewhere. Prevention & Treatment. 1998;1:No Pagination Specified.
3886.	E BM, A PT, Mark-David J. Floxetine-induced memory impairment in an adolesccent. Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33:1303-1306.
3887.	E CM, R SJ, G KJ, et al. Change in cognitive functioning following acute antidepressant treatment in late-life depression. The American Journal of Geriatric Psychiatry. 2009;17:881-888.
3888.	E DC. Mortality and poststroke depression. American journal of psychiatry. 2004;161:1506.
3889.	E DCM-C, Llanes-Gonzalez L, Aguilar-Faisal L, Asbun-Bojalil J. Individualized Homeopathic Treatment and Fluoxetine for Moderate to Severe Depression in Peri- and Postmenopausal Women (Homdep-Menop Study): a Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Trial. PloS one. 2015;10.
3890.	E DK. Patient Compliance With Enteric-Coated Weekly Fluoxetine During Continuation Treatment of Major Depressive Disorder. Journal of clinical psychiatry. 2001;62 Suppl 2:43-47.
3891.	E DS, W PB, Thomas M, et al. Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression? [References]. Neuropsychobiology. 2012;65:168-172.
3892.	E dWJ, Doogan DP. Fluvoxamine and chlorimipramine in endogenous depression. Journal of affective disorders. 1982;4:249-259.
3893.	E FJ, H FR. Pregabalin - in the Treatment of Generalised Anxiety Disorder. CNS drugs. 2006;20:685-693.
3894.	E FJ, L PG. Duloxetine: a review of its use in the treatment of major depressive disorder. [Review] [124 refs]. CNS drugs. 2007;21:581-609.
3895.	E FW, F RJ, W OM, M ZP, B WJ, A NR. Fluoxetine versus trazodone in depressed geriatric patients. Journal of geriatric psychiatry and neurology. 1989;2:208-214.
3896.	E HM, Brian B, Nancy F-S, et al. First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial. Journal of psychosomatic research. 2010;69:133-141.
3897.	E HM, E PM, M CK, et al. Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. Journal of substance abuse treatment. 2012;42:366-372.
3898.	E HM, J KM, John H, et al. Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biological psychiatry. 2003;53:100-105.
3899.	E HM, M MC, J KM, et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: A fluorine MRS study. American journal of psychiatry. 2000;157:1506-1508.
3900.	E HM, T SB, L BT, Lynn CM. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. [Review] [42 refs]. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2005;27:1126-1143.
3901.	E JK, M OCC. Lessons From SADHART, ENRICHD, and Other Trials. Psychosomatic medicine. 2005;67:S63-S66.
3902.	E JR, G RR, Stephan A. Drs. Jorge and Robinson reply. American journal of psychiatry. 2004;161:1507-1508.
3903.	E JR, G RR, Stephan A, Sergio S. Mortality and Poststroke Depression: A Placebo-Controlled Trial of Antidepressants. American journal of psychiatry. 2003;160:1823-1829.
3904.	E KCL. New antidepressants in elderly patients. 1993:157-167.
3905.	E KCL, N HB, Julia B. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. International journal of geriatric psychiatry. 1998;13:100-108.
3906.	E KCL, T A-SM, A HD, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.[Erratum appears in Br J Psychiatry 1995 Apr;166(4):544]. The British Journal of Psychiatry. 1995;166:80-86.
3907.	E KD, J GS, Martin B, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. Journal of affective disorders. 2011;130:171-179.
3908.	E KD, J MD, Kerning G, R CJ. Pharmacological treatments for bipolar depression: Focus on atypical antipsychotics. Directions in Psychiatry. 2007;27:99-112.
3909.	E KD, S GW, Jenelle F, L SJ, L DP, Melissa K. Aripiprazole augmentation in treatment-resistant bipolar depression: Early response and development of akathisia. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:574-577.
3910.	E KE, N GB, Gerald G, et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. [Review] [32 refs]. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2008;49:191-198.
3911.	E KJ. Clinician perspective on achieving and maintaining remission in depression. Journal of clinical psychiatry. 2001;62:16-21.
3912.	E KM, David M, B BD. The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment. Neuropharmacology. 2008;54:251-257.
3913.	E KS, A KR, A YE, Jon-Kar Z. Dysregulation of Endogenous Opioid Emotion Regulation Circuitry in Major Depression in Women. Archives of general psychiatry. 2006;63:1199-1206.
3914.	E LS, R JP, T MR. Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning? Journal of psychopharmacology (Oxford, England). 2001;15:257-264.
3915.	E ME, Greg M, J LA, et al. Quality of life as an outcome indicator in patients with seasonal affective disorder: Results from the Can-SAD study. Psychological medicine. 2007;37:727-736.
3916.	E MM, MV RC, P MR, A MI. Adjuvant drugs in the treatment of oncological pain. [Spanish]. DOLOR. 2009;24:89-95.
3917.	E MS, Beurs P, Timmerman L, et al. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline: A preliminary study. Psychopharmacology. 1986;88:96-100.
3918.	E OT, E BJ, Anjana S, et al. Status of minor depression or dysthymia in primary care following a randomized controlled treatment. General hospital psychiatry. 2001;23:301-310.
3919.	E PK. Plasma BDNF in women with anorexia nervosa compared to healthy controls before and after short-term SSRI administration. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2014;74:No Pagination Specified.
3920.	E SA. "Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder": Comment. JAMA: Journal of the American Medical Association. 2004;291:41-42.
3921.	E SB, Bobadilla L, A JR. Ketoconazole in bipolar patients with depressive symptoms: A case series and literature review. Bipolar disorders. 2001;3:23-29.
3922.	E SD, M WM, H MC, G WJ, G KS. Duloxetine in the treatment of major depressive disorder: Comparisons of safety and tolerability in male and female patients. Journal of affective disorders. 2006;94:183-189.
3923.	E SG, H HJ, Louis G, Wayne K, Dennis R. Should anxiety and insomnia influence antidepressant selection: A randomized comparison of fluoxetine and imipramine. Journal of clinical psychiatry. 1998;59:49-55.
3924.	E SG, Michael V, H HJ, et al. Initial Antidepressant Choice in Primary Care - Effectiveness and Cost of Fluoxetine Vs Tricyclic Antidepressants. JAMA: Journal of the American Medical Association. 1996;275:1897-1902.
3925.	E SM, Maurizio F, M RJ, Rajinder J. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. Journal of clinical psychiatry. 2000;61:851-857.
3926.	E SM, Maurizio F, Shuyu Z, Jill G, J RN, Rajinder J. Treatment approaches to major depressive disorder relapse - Part 1: Dose increase. Psychotherapy and psychosomatics. 2002;71:190-194.
3927.	E SP. The changing horizon in the treatment of depression: Scientific/clinical publication overview. Journal of clinical psychiatry. 1991;52:35-43.
3928.	E SS, Romina M, D PB. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. [Review] [33 refs]. International review of psychiatry. 2008;20:382-388.
3929.	E SS, Simone B, Brad H. Depression after stroke. 2013:51-64.
3930.	E TF, G LC, A MC, F AR, Enrique C-D. A double-blind, randomized, fixed dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 1997;38:246-252.
3931.	E TM. "Sertraline and imipramine for the treatment of dysthymia": Reply. Archives of general psychiatry. 1997;54:973.
3932.	E TM. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. Journal of clinical psychiatry. 1997;58:393-398.
3933.	E TM. Redefining antidepressant efficacy toward long-term recovery. Journal of clinical psychiatry. 1999;60 Suppl 6:15-19.
3934.	E TM. Quetiapine monotherapy for bipolar depression. Neuropsychiatric disease and treatment. 2008;4:21-31.
3935.	E TM. Reply to comments by Dr. Rifkin and Dr. Dawdy. Journal of clinical psychopharmacology. 2008;28:368.
3936.	E TM. Antidepressants and rapid-cycling bipolar II disorder: Dogma, definitions and deconstructing discrepant data. The British Journal of Psychiatry. 2013;202:251-252.
3937.	A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder, Journal of clinical psychiatry(2007).
3938.	E TM, A NA, Peter V, J vOHJ, Albert-Jan S, H SJ. Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. International clinical psychopharmacology. 2010;25:189-198.
3939.	E TM, Alan G, G KS, et al. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study. Journal of psychiatric research. 2011;45:412-420.
3940.	E TM, B NC. "Regarding 'Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs'": Reply. Biological psychiatry. 2009;66:e9-e10.
3941.	E TM, C SR, Arifulla K. Treatment With Venlafaxine Extended Release After Ssri Nonresponse or Intolerance - a Randomized Comparison of Standard- and Higher-Dosing Strategies. Journal of clinical psychopharmacology. 2006;26:250-258.
3942.	E TM, G LK, H KS. Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: Use of a mixture model. The British Journal of Psychiatry. 2011;199:501-507.
3943.	E TM, John RA, H HR, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of general psychiatry. 2002;59:233-239.
3944.	E TM, Lu PY, J OM, W SR, Jimmy X, J DM. Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors - Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2007;27:672-676.
3945.	E TM, Maurizio F, Uriel H, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Archives of general psychiatry. 1996;53:777-784.
3946.	E TM, Richard E, Marc C, G KS. Relative Antidepressant Efficacy of Venlafaxine and SSRIs: Sex-Age Interactions. Journal of women's health. 2005;14:609-616.
3947.	E TM, Richard EA, L RR. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. The British Journal of Psychiatry. 2001;178:234-241.
3948.	E TM, S FE, L FA, et al. Treatment of men with major depression: A comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. Journal of clinical psychiatry. 2000;61:466-472.
3949.	E TM, S FE, M BM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR*D report. American journal of psychiatry. 2007;164:739-752.
3950.	E TM, V TP, Curtis W, A PB, Craig M, J DM. Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine. Journal of clinical psychopharmacology. 2005;25:132-140.
3951.	E WA, Julia N, B WW, J FM. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: Did unpublished studies influence the efficacy/safety debate? [References]. Journal of child and adolescent psychopharmacology. 2006;16:37-58.
3952.	E WM, D MM, Katherine S, et al. Fluvoxamine pharmacotherapy of anxiety disorders in later life: Preliminary open-trial data. Journal of geriatric psychiatry and neurology. 2000;13:43-48.
3953.	E-A O. The efficacy of fluvoxamine in patients with severe depression. [French]. Psychologie medicale. 1991;23:1639-1644.
3954.	E-A O. The efficacy of fluvoximine in patients with severe depression. [French]. Psychologie medicale. 1991;23:1639-1644.
3955.	E-L B, Merkl A, Wilbertz G, et al. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: A randomized controlled trial. Biological psychiatry. 2014;76:194-202.
3956.	EA D. Long-term treatment of major depressive disorder with paroxetine. Journal of clinical psychopharmacology. 1993;13:28S-33S.
3957.	EA D, MM B. Treatment of depression in patients with coronary artery disease [5]. Journal of the American Medical Association. 2007;297:1879-1880.
3958.	EA E, JS P. Depression in the early stages of Huntington disease. Neurodegenerative disease management. 2011;1:407-414.
3959.	EA F, Keilp J, Song I, et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and psychosomatics. 2012;81:38-43.
3960.	EA F, SE S. Treatment of Depression in Patients With Dementia - Epidemiology, Pathophysiology and Treatment. CNS drugs. 2000;14:191-201.
3961.	EA H, Ivkovic A, GL F. Generalized anxiety disorder: Diagnosis and treatment. BMJ (Online). 7885.
3962.	EA J, AM I, Aversa A, Lenzi A, SE A. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. Journal of sexual medicine. 2013;10:2359-2369.
3963.	EA M, Tillisch K, Bradesi S. Review article: Modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Alimentary pharmacology & therapeutics. 2006;24:919-933.
3964.	EA N, 3rd RCF, ME T, et al. REM sleep enhancement by bupropion in depressed men. American journal of psychiatry. 1995;152:274-276.
3965.	EA O. A meta-analysis of published fluvoxamine studies in hospitalized depressed patients: A comparison with tri- and tetracyclic antidepressants. European neuropsychopharmacology. 1993;3:327.
3966.	EA O. Fluvoxamine superior to imipramine in suicidal depressed patients. European neuropsychopharmacology. 1993;3:362-363.
3967.	EA O. Fluvoxamine and Clomipramine in Depressed Hospitalized-Patients - Results From a Randomized, Double-Blind-Study. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 1995;21:317-321.
3968.	EA OC, EP W, TL B, BN G. Screening for depression in adult patients in primary care settings: a systematic evidence review. [Review] [105 refs]. Annals of internal medicine. 2009;151:793-803.
3969.	EA Oc, EP W, TL B, BN G. Screening for Depression in Adult Patients in Primary Care Settings: a Systematic Evidence Review. Annals of internal medicine. 2009;151:793-W265.
3970.	EA P, B TG, Wong C, Ortega M, PS J. A review of the growing evidence base for pediatric psychopharmacology. Child and adolescent psychiatric clinics of North America. 2004;13:817-855.
3971.	EA S, DJ G, Miyamoto H, EM M. Androgen deprivation therapy for prostate cancer. Expert opinion on pharmacotherapy. 2008;9:211-228.
3972.	EA S, ME S, BG P, et al. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of pharmacokinetics and pharmacodynamics. 2012;39:393-414.
3973.	EA S, MJ L, NA S, et al. Clinical Predictors of Early Fluoxetine Treatment Response in Obsessive-Compulsive Disorder. Depression and anxiety. 2006;23:429-433.
3974.	EA Y, Altemus M, JF L, et al. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology. 2004;29:1198-1204.
3975.	EA Z, SE W, PM C, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: A systematic review. Cost effectiveness and resource allocation. 2012.
3976.	Eaddy M, Bramley T, Regan T. Time to Antidepressant Discontinuation: A Comparison of Controlled-Release Paroxetine and Immediate-Release Selective Serotonin-Reuptake Inhibitors. Managed care interface. 2003;16:22-27.
3977.	EAHES H. Acute and Chronic Pain Management in Fibromyalgia: Updates on Pharmacotherapy. American journal of therapeutics. 2011;18:487-509.
3978.	EAKE K. Escitalopram for the Management of Major Depressive Disorder: a Review of Its Efficacy, Safety, and Patient Acceptability. Patient preference and adherence. 2012;6:853-861.
3979.	Eapen V, Crncec R. Strategies and challenges in the management of adolescent depression. Current opinion in psychiatry. 2012;25:7-13.
3980.	EB B, JG U, CL C, JV R, CG C, RP L. Venlafaxine Extended Release Versus Conventional Antidepressants in the Remission of Depressive Disorders After Previous Antidepressant Failure: Argos Study. Depression and anxiety. 2005;22:68-76.
3981.	EB C. Diabetic peripheral neuropathic pain: Recognition and management. Pain medicine (Malden, Mass.). 2007;8:S27-S32.
3982.	The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder, Journal of clinical psychiatry(2009).
3983.	EB F. Social Anxiety Disorder Treatments: Psychosocial Therapies. Journal of clinical psychiatry. 2006;67:27-30.
3984.	EB F, JCN C, Nan H, Sartorius N, Oldenburg B. Co-occurrence of diabetes and depression: Conceptual considerations for an emerging global health challenge. Journal of affective disorders. 2012;142:S56-S66.
3985.	EB F, MR L, MJ K, et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder. American journal of psychiatry. 2005;162:151-161.
3986.	EB F, MR L, MJ K, et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder. American journal of psychiatry. 2005;162:151-161.
3987.	EB N. Psychotic depression - Beyond the antidepressant/antipsychotic combination. Current psychiatry reports. 2012;14:619-623.
3988.	EB P, RM B, Sanacora G, Anand A, Lynch-Colonese K, DS C. Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors: a Double-Blind, Randomized, Controlled Trial. Journal of clinical psychiatry. 2004;65:238-243.
3989.	EB P, RM B, Sanacora G, Anand A, Lynch-Colonese K, DS C. Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors: a Double-Blind, Randomized, Controlled Trial. Journal of clinical psychiatry. 2004;65:238-243.
3990.	EB S, BA L. Case series: Extrapyramidal symptoms associated with use of aripiprazole in older adults. International journal of geriatric psychiatry. 2013;28:1208-1210.
3991.	EB S, Yen S, Costello E, et al. Combined Dialectical Behavior Therapy and Fluoxetine in the Treatment of Borderline Personality Disorder. Journal of clinical psychiatry. 2004;65:379-385.
3992.	EB W, AK D, RA W. Somatic treatment of bipolar disorder in children and adolescents. Psychiatric clinics of North America. 2004;27:155-178.
3993.	EB W, RA W. Treatment options in the management of adolescent depression. Journal of affective disorders. 2000;61:S23-S28.
3994.	EB W, RA W. Treatment Options in the Management of Adolescent Depression. Journal of affective disorders. 2000;61:23-28.
3995.	EB W, RA W. Relapse prevention in childhood depression. Current psychiatry reports. 2010;12:85-87.
3996.	EB W, Tucker S, RA W. The selective serotonin reuptake inhibitors controversy in the treatment of depression in children. Current psychiatry reports. 2005;7:87-90.
3997.	Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: Safety considerations. Drug safety. 2005;28:695-706.
3998.	Ebert D, Albert R, May A, Stosiek I, Kaschka W. Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology. 1995;119:342-344.
3999.	Ebner K, SB S, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Current pharmaceutical design. 2009;15:1647-1674.
4000.	Ebrahim I. Ramelteon: A new approach to managing insomnia. Future neurology. 2008;3:9-18.
4001.	EC B, DL M. Depression, alterations in platelet function, and ischemic heart disease. Psychosomatic medicine. 2005;67:S34-S36.
4002.	EC D, CE D. Buspirone Augmentation of Antidepressant Therapy. Journal of clinical psychopharmacology. 1998;18:465-469.
4003.	EC J-S, RG H. Social Phobia: An Update on Treatment. Psychiatric clinics of North America. 2009;32:641-663.
4004.	EC L. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Medical hypotheses. 2012;78:693-702.
4005.	EC L, SD S, Victoroff J, KL C, MF M. Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications. Journal of neuropsychiatry and clinical neurosciences. 2010;22:130-154.
4006.	EC P, LN B, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Annals of pharmacotherapy. 2014;48:1030-1039.
4007.	EC W. Examining differential treatment effects for depression in racial and ethnic minority women: A qualitative systematic review. Journal of the National Medical Association. 2007;99:265-274.
4008.	EC-H L, RCS S. What is the place for placebo in the management of psychogenic disease? Journal of the Royal Society of Medicine. 2007;100:60-61.
4009.	Effect of pharmacological treatment of depression on A1C and quality of life in low-income hispanics and African Americans with diabetes: A randomized, double-blind, placebo-controlled trial, Diabetes care(2009).
4010.	Eckert A, Giese M, Beck J, et al. Serum brain-derived neurotrophic factor levels as predictor of antidepressant therapy response. European neuropsychopharmacology. 2010;Conference:S384-S385.
4011.	Eckert L, Falissard B. Using Meta-Regression in Performing Indirect-Comparisons: Comparing Escitalopram With Venlafaxine Xr. Current medical research and opinion. 2006;22:2313-2321.
4012.	Eckert L, Lancon C. Duloxetine Compared With Fluoxetine and Venlafaxine: Use of Meta-Regression Analysis for Indirect Comparisons. BMC psychiatry. 2006;6.
4013.	Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. [Review] [55 refs]. BMC psychiatry. 2006;6:30.
4014.	ECW N, MJDL vdV, Blauwhoff-Buskermolen S, HMW V. Aiming for a better understanding and management of cancer-related fatigue. Oncologist. 2013;18:1135-1143.
4015.	ED D. Risperidone long-acting injection: In bipolar i disorder. Drugs. 2010;70:1001-1012.
4016.	ED D, CM P. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (atripla): A review of its use in the management of HIV infection. Drugs. 2010;70:2315-2338.
4017.	ED D, GM K. Olanzapine/Fluoxetine - a Review of Its Use in the Treatment of Acute Bipolar Depression. Drugs. 2008;68:1115-1137.
4018.	ED H, KT P, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17-22.
4019.	ED H, LM S, Bertram H, et al. Neuropsychological functioning following fluoxetine and repeated partial sleep deprivation in adults with major depressive disorder. Sleep. 2014;Conference:A284.
4020.	ED L, Heathman M, HY K, et al. Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data From Phase Ii/Iii Trials. Clinical pharmacokinetics. 2010;49:311-321.
4021.	ED L, Loghin C, MP K, et al. Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women. Clinical pharmacokinetics. 2008;47:103-109.
4022.	ED L, Quinlan T, O'brien L, MP K, Heathman M. Population pharmacokinetics of Orally administered duloxetine in patients: Implications for dosing recommendation. Clinical pharmacokinetics. 2009;48:189-197.
4023.	Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents With Major Depressive Disorder, Clinical pharmacokinetics(2014).
4024.	Efficacy of Individualized Homeopathic Treatment and Fluoxetine for Moderate to Severe Depression in Peri- and Postmenopausal Women (Homdep-Menop): Study Protocol for a Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Trial, Trials(2013).
4025.	ED P, A-M F, Goodnick P, Barouche F, RR F. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacology bulletin. 1989;25:267-271.
4026.	ED P, A-M F, Goodnick P, Barouche F, RR F. The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacology bulletin. 1989;25:272-276.
4027.	ED P, Lautin A, Wolkin A, et al. The dexamethasone suppression test and response to placebo. Journal of clinical psychopharmacology. 1986;6:286-291.
4028.	ED P, MP S, Difiglia C, RR F. Melancholic/endogenous depression and response to somatic treatment and placebo. [Review] [52 refs]. American journal of psychiatry. 1992;149:1324-1334.
4029.	ED P, MP S, RR F. Patients' and informants' reports of personality traits during and after major depression. Journal of abnormal psychology. 1994;103:819-824.
4030.	ED P, MP S, RR F, CJ R, Block P. Sociotropy and autonomy: Relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. Journal of abnormal psychology. 1992;101:479-486.
4031.	ED P, Robins C, Block P, Barouche F, RR F. Dysfunctional attitudes in depressed patients before and after clinical treatment and in normal control subjects. American journal of psychiatry. 1990;147:439-444.
4032.	ED P, RR F. Depressive attributional style and the dexamethasone suppression test: Relationship to the endogenous/melancholic distinction and to each other. Psychopathology. 1992;25:173-182.
4033.	ED W, Steptoe A. The role of depression in the etiology of acute coronary syndrome. Current psychiatry reports. 2007;9:486-492.
4034.	Eden J. Vitex agnus-castus and premenstrual syndrome. Medicine today. 2013;14:71-72.
4035.	Edgar F, Robert G, Timothy L, John T, Robyn J. A double-blind, multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in Australian general practice. Australian and New Zealand journal of psychiatry. 1999;33:416-421.
4036.	Edmonds M, McGuire H, Price J. Exercise therapy for chronic fatigue syndrome. [Review] [31 refs][Update in Cochrane Database Syst Rev. 2015;2:CD003200; PMID: 25674924]. Cochrane database of systematic reviews (Online). 2004:CD003200.
4037.	Eduard M, Anu T, Kristi K, et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European neuropsychopharmacology. 2009;19:451-456.
4038.	Eduard V, Anabel M-A, Manuel GJ, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of clinical psychiatry. 2002;63:508-512.
4039.	Eduard V, Carolina F, Nuria C. Antipsychotics in bipolar depression: In reply. International journal of neuropsychopharmacology. 2010;13:969.
4040.	Eduard V, Julie L, Oliver G, et al. Treatment options for bipolar depression: A systematic review of randomized, controlled trials. Journal of clinical psychopharmacology. 2010;30:579-590.
4041.	Eduard V, R CJ, John H, et al. Comparison of Rapid-Cycling and Non-Rapid-Cycling Bipolar I Manic Patients During Treatment With Olanzapine: Analysis of Pooled Data. Journal of clinical psychiatry. 2004;65:1420-1428.
4042.	Edward S. Before Prozac: The troubled history of mood disorders in psychiatry. 2009.
4043.	Edward S, Charles W, Cathryn C, Ira F, Karl R. Placebo-controlled trial of venlafaxine for the treatment of major depression. Journal of clinical psychopharmacology. 1991;11:233-236.
4044.	Edward S, John F, A ML, Karl R. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of clinical psychiatry. 1994;55:104-108.
4045.	Edward S, Karl R, D AJ, Ira F, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? Journal of clinical psychiatry. 1990;51:8-11.
4046.	Edwards E, Mischoulon D, Rapaport M, Stussman B, Weber W. Building an evidence base in complementary and integrative healthcare for child and adolescent psychiatry. Child and adolescent psychiatric clinics of North America. 2013;22:509-529.
4047.	Edwin W, Lawrence S. Use of antidepressants in children: Is it time for a comparative effectiveness trial? [References]. Journal of the American Academy of Child and Adolescent Psychiatry. 2010;49:184-185.
4048.	EE B. Serotonergic modulation of basal ganglia circuits: Complexity and therapeutic opportunities. Neurology. 2009;73:880-886.
4049.	EE K, JB G, Seltman H, Kelleher K. Do Antidepressants Cause Suicidality in Children? A Bayesian Meta-Analysis. Clinical trials (London, England). 2006;3:73-90.
4050.	EE M, LN Y, DDC W, RW L. Perceived Quality of Life in Patients With Bipolar Disorder. Does Group Psychoeducation Have an Impact? Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:95-100.
4051.	EE M, LN Y, DDC W, RW L. Perceived Quality of Life in Patients With Bipolar Disorder. Does Group Psychoeducation Have an Impact? Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:95-100.
4052.	EE M, Murray G, AH Y, RW L. Burden of bipolar depression: Impact of disorder and medications on quality of life. CNS drugs. 2008;22:389-406.
4053.	EE M, RW L. Breaking the myths: New treatment approaches for chronic depression. Canadian Journal of Psychiatry. 2002;47:635-643.
4054.	EE M, Wilkinson C, Dowrick C, Wilkinson G. Seasonal affective disorder: Prevalence, detection and current treatment in North Wales. British journal of psychiatry. 2001;179:31-34.
4055.	EE Y, Guler J, Incesu C. Sexual Side Effects Caused by Psychotropic Medications. Noropsikiyatri Arsivi-Archives of Neuropsychiatry. 2011;48:7-15.
4056.	EF C, RJ K. Fluoxetine and Impulsive Aggressive Behavior in Personality-Disordered Subjects. Archives of general psychiatry. 1997;54:1081-1088.
4057.	EF C, RJ L, RJ K. A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Patients With Intermittent Explosive Disorder. Journal of clinical psychiatry. 2009;70:653-662.
4058.	EF H, CM M, HS S. Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome. Pediatric neurology. 2009;40:420-425.
4059.	EF L. Assessing the impact of heart failure therapeutics on quality of life and functional capacity. Current treatment options in cardiovascular medicine. 2013;15:425-436.
4060.	EF P, JA M. Vortioxetine for the Treatment of Depression. Annals of pharmacotherapy. 2014;48:758-765.
4061.	EF S, AC T. Male erectile dysfunction: Integrating psychopharmacology and psychotherapy. General hospital psychiatry. 2013;35:33-38.
4062.	EF T, DH K, PN D, DA A, Bystritsky A, FI F. Structured group therapy and fluoxetine to treat depression in HIV- positive persons. Psychosomatics. 1994;35:132-137.
4063.	EF T, JM D. Adjunct treatments for schizophrenia and bipolar disorder: What to try when you are out of ideas. Clinical schizophrenia & related psychoses. 2012;5:208-216C.
4064.	EFH S, KR S. Personality Trait Dimensions and the Pharmacological Treatment of Borderline Personality Disorder. Journal of clinical psychopharmacology. 2009;29:461-467.
4065.	EFH S, MG M, JF G. Evidence for the need of long-term treatment of major depression. Primary psychiatry. 2007;14:60-65.
4066.	EG B-W, MA R, RH J, Martinovich Z, SG S, JS M. Predictors of hopelessness among clinically depressed youth. Behavioural and cognitive psychotherapy. 2009;37:267-291.
4067.	EG B-W, RH J, MA R, SG S, JS M. Social problem-solving among adolescents treated for depression. Behaviour research and therapy. 2010;48:11-18.
4068.	EG H, Bouhassira M, Lancrenon S, Lancrenon S. Prospective Naturalistic Follow-up During 12 Months of a Cohort of 155 Patients Suffering From Obsessive-Compulsive Disorder. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2000;26:73-83.
4069.	EG H, Lancrenon S, J-M C. Evaluation of discontrol change under psychotropic treatments: Preliminary evidence for an opposite effect of benzodiazepines and antidepressants on discontrol. [French]. Encephale. 1995;21:59-65.
4070.	EG I, MV Z, AG Se. Efficacy of Medical-Psychological Rehabilitation of Combatants. Neuroscience and behavioral physiology. 2014;44:933-938.
4071.	EG K, GM G, LA A, OV S, SN M. Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. 2003;Korsakova 24-29.
4072.	EG K, GM G, LA A, OV S, SN M. [Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 2003;Korsakova.:24-29.
4073.	EG K, OV S, MIa L, SN M. [A comparative study of efficacy and safety of torin and zoloft]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 2008;Korsakova.:34-38.
4074.	EG S. Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: confirmatory analysis and research implications. Journal of affective disorders. 2009;114:143-148.
4075.	Antidepressant augmentation using the N-methyl-d-aspartate antagonist memantine: A randomized, double-blind, placebo-controlled trial, Journal of clinical psychiatry(2013).
4076.	Egemen S, E MS, Andreas B, Andre S, Hartmut S. Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. International journal of neuropsychopharmacology. 2008;11:381-388.
4077.	EH C, LM A, DJ C, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. Journal of rheumatology. 2009;36:2330-2334.
4078.	EH H, Myllyla V. Safety of selegiline (Deprenyl) in the treatment of Parkinson's disease. Drug safety. 1998;19:11-22.
4079.	EH L, M VK, EJ L, et al. Enhancing adherence to prevent depression relapse in primary care. General hospital psychiatry. 2003;25:303-310.
4080.	EH M. Women and insomnia. Clinical cornerstone. 2004;6:S6-S18.
4081.	EH T. Publication bias, with a focus on psychiatry: Causes and solutions. CNS drugs. 2013;27:457-468.
4082.	EH T, AD B. 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. Medical hypotheses. 2005;65:138-144.
4083.	EH T, AM M, Linardatos E, RA T, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England journal of medicine. 2008;358:252-260.
4084.	EH T, JM L, AD B. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & therapeutics. 2006;109:325-338.
4085.	EH U, Matuzas W, TD W, Paine S, RB L, MH P. Do Antidepressants Selectively Suppress Spontaneous (Unexpected) Panic Attacks? A Replication. Journal of clinical psychopharmacology. 2000;20:622-627.
4086.	Ehret M, DM S. Prevention of Interferon-Alpha-Associated Depression With Antidepressant Medications in Patients With Hepatitis C Virus: a Systematic Review and Meta-Analysis. International journal of clinical practice. 2014;68:255-261.
4087.	EHS C, PJ M, DK K, et al. Safety and Tolerability of Duloxetine in the Treatment of Patients With Fibromyalgia: Pooled Analysis of Data From Five Clinical Trials. Clinical rheumatology. 2009;28:1035-1044.
4088.	EI P, OW B. Polycythaemia vera and essential thrombocythaemia: Current treatment strategies. Drugs. 2006;66:2173-2187.
4089.	EIII HP, W MT, E KM, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. International journal of geriatric psychiatry. 2008;23:625-631.
4090.	Eiji H, Alexander S, Tsukasa K, B ML, Toshinaga T, Rodrigo E. Efficacy comparison of duloxetine and SSRIs at doses approved in Japan. Neuropsychiatric disease and treatment. 2015;11.
4091.	Eileen B, L DD, L MS, et al. Olanzapine/fluoxetine combination vs. Lamotrigine in the 6-month treatment of bipolar I depression. International journal of neuropsychopharmacology. 2009;12:773-782.
4092.	Einarson A. Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.[Erratum appears in Can Fam Physician. 2010 Nov;56(11):1112]. Canadian Family Physician. 2010;56:767-768.
4093.	Einarson A. Publishing statistically significant results with questionable clinical importance: focus on antidepressant use in pregnancy. Journal of clinical psychiatry. 2012;73:1443-1446.
4094.	Eiser N, Harte R, Karvounis S, Phillips C, MT I. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005;2:233-241.
4095.	EJ B, KF V. Antidepressant Therapy in High-Risk Patients. South African medical journal. 1999;89:995-1000.
4096.	EJ C, JM E, FR N, CM C, E DP. Pharmacology and therapeutic potential of sigma1 receptor ligands. Current neuropharmacology. 2008;6:344-366.
4097.	EJ D. Neurotoxicity of cancer chemotherapy. Seminars in neurology. 2004;24:419-426.
4098.	EJ D, MH T. A review of quetiapine in combination with antidepressant therapy in patients with depression. Neuropsychiatric disease and treatment. 2007;3:855-867.
4099.	EJ G. New developments in pharmacotherapy of pediatric anxiety disorders. Expert review of neurotherapeutics. 2002;2:203-211.
4100.	EJ G, Kutcher S, Virani A. 2008 position paper on using SSRIs in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2009;18:160-165.
4101.	EJ K, JF C, Spielman L, Pupo C, Abrams R, GS A. Late-life depression and functional disability: The role of goal-focused group psychotherapy. International journal of geriatric psychiatry. 1998;13:707-716.
4102.	EJ L, AM G, Nowotny P, et al. Relation of Serotonin Transporter Genetic Variation to Efficacy of Escitalopram for Generalized Anxiety Disorder in Older Adults. Journal of clinical psychopharmacology. 2010;30:672-677.
4103.	EJ L, BH M, MA D, et al. Good treatment outcomes in late-life depression with comorbid anxiety. Journal of affective disorders. 2003;77:247-254.
4104.	EJ L, BH M, MK S, et al. Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial. American journal of psychiatry. 2005;162:146-150.
4105.	EJ L, BH M, MK S, et al. Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial. American journal of psychiatry. 2005;162:146-150.
4106.	Escitalopram for older adults with generalized anxiety disorder: A randomized controlled trial, JAMA - Journal of the American Medical Association(2009).
4107.	EJ L, Dixon D, Nowotny P, et al. Escitalopram Reduces Attentional Performance in Anxious Older Adults With High-Expression Genetic Variants at Serotonin 2a and 1b Receptors. International journal of neuropsychopharmacology. 2013;16:279-288.
4108.	EJ L, Dixon D, RC M, et al. Treatment-Related Alteration of Cortisol Predicts Change in Neuropsychological Function During Acute Treatment of Late-Life Anxiety Disorder. International journal of geriatric psychiatry. 2012;27:454-462.
4109.	EJ L, JF K, BH M, et al. Somatic Symptoms in Late-Life Anxiety: Treatment Issues. Journal of geriatric psychiatry and neurology. 2005;18:89-96.
4110.	EJ L, JF K, BH M, et al. Somatic symptoms in late-life anxiety: treatment issues. [Review] [59 refs]. Journal of geriatric psychiatry and neurology. 2005;18:89-96.
4111.	EJ L, JL W. A Lifespan view of anxiety disorders. Dialogues in clinical neuroscience. 2011;13:381-399.
4112.	EJ L, RC M, PC S, et al. Elevated Cortisol in Older Adults With Generalized Anxiety Disorder Is Reduced by Treatment: a Placebo-Controlled Evaluation of Escitalopram. American journal of geriatric psychiatry. 2011;19:482-490.
4113.	EJ L, Sheffrin M, HC D, et al. Incomplete response in late-life depression: Getting to remission. Dialogues in clinical neuroscience. 2008;10:419-430.
4114.	EJ M, Kanters S, Keohane D, Thorlund K. Comparative efficacy and safety of antidepressant use among elderly patients-a network meta-analysis. Journal of the American Geriatrics Society. 2014;Conference:S38-S39.
4115.	EJ P, SL S, PJ M, JA K, SP H. Investigation of Serotonin-Related Genes in Antidepressant Response. Molecular psychiatry. 2004;9:879-889.
4116.	EJ S. Combining desloratadine and pseudoephedrine in the treatment of seasonal allergic rhinitis. Expert review of clinical immunology. 2006;2:519-531.
4117.	EJ S, PM D, GL C, et al. Citalopram and Quality of Life in Lung Transplant Recipients [1]. Psychosomatics. 2004;45:271-272.
4118.	EJ S, TA H. Cost-utility of agomelatine, venlafaxine and placebo in the treatment of major depressive disorder (MDD) in finland - economic modelling study using representative population data. Value in health. 2009;Conference:A359.
4119.	EJ S, TA H. Cost-Utility of Agomelatine, Venlafaxine and Placebo in the Treatment of Major Depressive Disorder (Mdd) in Finland-Economic Modelling Study Using Representative Population Data. Value in health. 2009;12:A359.
4120.	Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: Study protocol for a pragmatic randomized controlled trial (CYSCEtrial), Trials(2015).
4121.	EJM M. A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes. Neurotherapeutics. 2012;9:739-752.
4122.	EJr KP. Bipolar depression: a new role for atypical antipsychotics?. [Review] [32 refs]. Bipolar disorders. 2005;7 Suppl 4:34-40.
4123.	EJr KP, A CS, L AL, et al. Analyses of Treatment-Emergent Mania With Olanzapine/Fluoxetine Combination in the Treatment of Bipolar Depression. Journal of clinical psychiatry. 2005;66:611-616.
4124.	EJr KP, L MS. Pharmacological treatments for bipolar disorder. 2002:277-299.
4125.	EJr KP, L MS. Pharmacological treatments for bipolar disorder. 2007:323-350.
4126.	EK B, DS B. Anxiety disorders. Medicine (United Kingdom). 2012;40:599-606.
4127.	EK G, Maruff P, GO L. Clinical Characteristics of 150 Consecutive Fibromyalgia Patients Attending an Australian Public Hospital Clinic. International journal of rheumatic diseases. 2012;15:348-357.
4128.	EK M, Bang-Andersen B. Serotonin reuptake inhibitors: The cancer stone in treatment of depression for half a century - A medicinal chemistry survey. Current topics in medicinal chemistry. 2006;6:1801-1823.
4129.	Ekinci O, JB T, AA R, Berkem M, Trevathan E. Depression and anxiety in children and adolescents with epilepsy: Prevalence, risk factors, and treatment. Epilepsy & behavior. 2009;14:8-18.
4130.	EKJ P. The folate puzzle. Part IV: Folate and depression. Drugs of the future. 2008;33:591-595.
4131.	Ekkekakis P. The genetic tidal wave finally reached our shores: Will it be the catalyst for a critical overhaul of the way we think and do science? Mental health and physical activity. 2008;1:47-52.
4132.	Ekkekakis P. Honey, i shrunk the pooled SMD! Guide to critical appraisal of systematic reviews and meta-analyses using the Cochrane review on exercise for depression as example. Mental health and physical activity. 2015;8:21-36.
4133.	EKL S, Gao Y, RS E-M. Pharmacotherapy of bipolar disorder: Current status and emerging options. Clinical Practice. 2014;11:39-48.
4134.	Ekman M, Lindgren P, Miltenburger C, Meier G, JC L, ML C. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. PharmacoEconomics. 2012;30:513-530.
4135.	Eknoyan D, RA H, KH T. The neurobiology of placebo and nocebo: How expectations influence treatment outcomes. Journal of neuropsychiatry and clinical neurosciences. 2013;25:250-254.
4136.	EKO W, Krishnadas R, Cavanagh J. The interface between neurology and psychiatry: The case of multiple sclerosis. Advances in Psychiatric Treatment. 2013;19:370-377.
4137.	Ekselius L, L vK. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International clinical psychopharmacology. 1998;13:205-211.
4138.	Ekselius L, L VK. Effect on Sexual Function of Kong-Term Treatment With Selective Serotonin Reuptake Inhibitors in Depressed Patients Treated in Primary Care. Journal of clinical psychopharmacology. 2001;21:154-160.
4139.	Ekselius L, L vK, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. International clinical psychopharmacology. 1997;12:323-331.
4140.	EL C. Importance of duloxetine (Cymbalta) in daily clinical practice. [French]. Louvain medical. 2007;126:35-38.
4141.	EL C, Lauderdale S, JI S. Mixed Anxiety and Depression in Older Adults: Clinical Characteristics and Management. Journal of geriatric psychiatry and neurology. 2005;18:83-88.
4142.	EL C, Lauderdale S, JI S. Mixed Anxiety and Depression in Older Adults: Clinical Characteristics and Management. Journal of geriatric psychiatry and neurology. 2005;18:83-88.
4143.	Transdermal estradiol for postpartum depression: A promising treatment option, Clinical obstetrics and gynecology(2009).
4144.	EL P, Hallett M. Psychogenic Movement Disorders. Neurologic clinics. 2009;27:801-819.
4145.	EL S, KS P. Psychopharmacologic treatment of chronic pain in children and adolescents. Psychopharm Review. 2011;46:73-80.
4146.	EL SO, SA M. Pain associated with diabetic peripheral neuropathy: A review of available treatments. P and T. 2008;33:166-179.
4147.	EL T, Street D, AM H, Vermeeren A, A VO, JG R. A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu Aa21004), on Actual Driving and Cognition. Clinical pharmacology and therapeutics. 2013;93:493-501.
4148.	El-Armouche A, Zolk O, Eschenhagen T. Citalopram. [German]. Deutsche medizinische Wochenschrift (1946). 2003;128:2253-2256.
4149.	El-Giamal N, M DZ, Bailer U, et al. Reboxetine in the Treatment of Bulimia Nervosa: a Report of Seven Cases. International clinical psychopharmacology. 2000;15:351-356.
4150.	El-Hage W, Leman S, Camus V, Belzung C. Mechanisms of antidepressant resistance. Frontiers in pharmacology. 2013.
4151.	Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study, International journal of neuropsychopharmacology(2010).
4152.	el-Yazigi A, Chaleby K, Gad A, DA R. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. Journal of clinical pharmacology. 1995;35:17-21.
4153.	Elahi B, Elahi B, Chen R. Effect of Transcranial Magnetic Stimulation on Parkinson Motor Function-Systematic Review of Controlled Clinical Trials. Movement disorders. 2009;24:357-363.
4154.	Elderon L, MA W. Depression and cardiovascular disease. Progress in cardiovascular diseases. 2013;55:511-523.
4155.	Elena DM, J BB, G SS, et al. Cost-effectiveness of treatments for adolescent depression: Results from TADS. American journal of psychiatry. 2008;165:588-596.
4156.	Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial, Journal of the American Academy of Child and Adolescent Psychiatry(2009).
4157.	Elena U-FR, Francisco dlP-O, Ines N-l. The multimodal treatment for children and adolescents with depression. [Spanish]. Salud mental (Mexico City, Mexico). 2011;34:403-407.
4158.	Elgamal S, MacQueen G. Galantamine as an adjunctive treatment in major depression. Journal of clinical psychopharmacology. 2008;28:357-359.
4159.	Elias E, Agneta E, Suzanne S, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Journal of clinical psychopharmacology. 2008;28:195-202.
4160.	Elie C. Treatment of premenstrual dysphoria with antidepressants: Review of controlled clinical trials. [Portuguese]. Jornal brasileiro de psiquiatria. 2006;55:142-147.
4161.	Elizabeth B, Mauricio T, Olawale O, John L, E TM. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 2014;39:2549-2559.
4162.	Elizabeth W, Jacqueline S, G PB, et al. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: A double-blind randomized trial. The American Journal of Geriatric Psychiatry. 2000;8:245-250.
4163.	Elkashef A, Vocci F, Huestis M, et al. Marijuana neurobiology and treatment. Substance abuse. 2008;29:17-29.
4164.	Ellen F, Paola R, Wayne K, et al. Correlates of remission in primary care patients treated for minor depression. General hospital psychiatry. 2002;24:12-19.
4165.	Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:445-450.
4166.	Ellis P, Hickie I, Bushnell J, Hirini P, Stevens S, DAR S. Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand journal of psychiatry. 2004;38:389-407.
4167.	Elmansari M, Bouchard C, Blier P. Alteration of Serotonin Release in the Guinea-Pig Orbitofrontal Cortex by Selective Serotonin Reuptake Inhibitors - Relevance to Treatment of Obsessive-Compulsive Disorder. Neuropsychopharmacology. 1995;13:117-127.
4168.	Elvins R, Green J. Pharmacological management of core and comorbid symptoms in autism-spectrum disorder. Advances in Psychiatric Treatment. 2010;16:349-360.
4169.	EM C, Ambrosino N. Nonpharmacological treatment and relief of symptoms in COPD. European respiratory journal. 2008;32:218-228.
4170.	EM C, Loi S. Depression and dementia. Medical journal of Australia. 2012;1:40-43.
4171.	EM C, Whale R, Sharp T, PJ C. Effect of Penbutolol on Neuroendocrine Responses to Buspirone and Mood in Ssri-Refractory Patients: a Preliminary Study. Human Psychopharmacology-Clinical and Experimental. 1999;14:273-277.
4172.	EM H. A Review of the Assessment of Antidepressant-Induced Sexual Dysfunction Used in Randomized, Controlled Clinical Trials. Pharmacopsychiatry. 2007;40:173-182.
4173.	EM H, DC L. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophrenia research. 2012;134:202-206.
4174.	EM J, Whyte E, BH M, et al. Cardiovascular Changes Associated With Venlafaxine in the Treatment of Late-Life Depression. American journal of geriatric psychiatry. 2006;14:796-802.
4175.	EM K. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study. Clinical therapeutics. 2002;24:1194-1200.
4176.	EM K, AM B, TY D, et al. Effects of citalopram treatment of protracted withdrawal (syndrome of Anhedonia) in patients with heroin addiction. Addictive disorders & their treatment. 2002;1:29-33.
4177.	EM K, SM Y, VA B, et al. Double Blind Placebo Controlled Randomized Clinical Trial of Escitalopram for Alcoholism Comorbid With Affective Disorders (Depression and Anxiety). Alcoholism, clinical and experimental research. 2010;34:167A.
4178.	EM M, WE F. Diagnosis and pharmacotherapy of anxiety in older patients. Geriatrics & aging. 2005;8:37-41.
4179.	EM P, Gomeni R. Including a priori knowledge to define under-performing recruiting centres could help to improve "signal detection" in antidepressant multicenter trials: A clinical trial simulation study. Neuropsychopharmacology. 2010;Conference:S210-S211.
4180.	EM Q. Is the selective serotonin reuptake inhibitor fluoxetine a fountain of youth? Future neurology. 2008;3:385-389.
4181.	EM S, Cilasun J, JG E. Paroxetine and the electroencephalogram. Journal of psychopharmacology (Oxford, England). 1987;1:31-34.
4182.	EM S, GMP C, PE M, DR R, PJ S. Rapid Response to Fluoxetine in Women With Premenstrual Dysphoric Disorder. Depression and anxiety. 2012;29:531-540.
4183.	EM S, HJ M. Facet theoretic analysis of the Hamilton-D scale. Journal of affective disorders. 1992;25:53-61.
4184.	EM T, RA C. Asenapine: A novel atypical antipsychotic agent for schizophrenia and bipolar I disorder. Journal of pharmacy technology. 2010;26:352-361.
4185.	EM T, RW L, AJ L. Treatment of Seasonal Affective-Disorder - a Review. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1995;40:457-466.
4186.	EM U, Falconieri L. Treatment options for vasomotor symptoms in menopause: Focus on desvenlafaxine. International journal of women's health. 2012;4:305-319.
4187.	EM W, AI R, Kohn B, et al. Acupuncture Versus Venlafaxine for the Management of Vasomotor Symptoms in Patients With Hormone Receptor-Positive Breast Cancer: a Randomized Controlled Trial. Journal of clinical oncology. 2010;28:634-640.
4188.	EM W, Basinski J, Farhi P, et al. Geriatric Depression Treatment in Nonresponders to Selective Serotonin Reuptake Inhibitors. Journal of clinical psychiatry. 2004;65:1634-1641.
4189.	EM W, Basinski J, Farhi P, et al. Geriatric Depression Treatment in Nonresponders to Selective Serotonin Reuptake Inhibitors. Journal of clinical psychiatry. 2004;65:1634-1641.
4190.	EM W, BH M, BW R, CF R. Preventing depression after stroke. International review of psychiatry. 2006;18:471-481.
4191.	Emanuel S, Nadine S, Hans-Jurgen M. State of the art: Treatment of bipolar disorders. CNS neuroscience & therapeutics. 2012;18:214-218.
4192.	Emens J, Powell L, Lewy A. Circadian misalignment in major depression. Sleep. 2012;Conference:A325.
4193.	Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.[Erratum appears in J Clin Psychopharmacol. 2012 Apr;32(2):185], Journal of clinical psychopharmacology(2011).
4194.	Emilien G, JM M, Seghers A, Charles G. Use of a placebo in clinical trials. European psychiatry. 1998;13:254-263.
4195.	Emilien G, Septien L, Brisard C, Corruble E, Bourin M. Bipolar disorder. How far are we from a rigorous definition and effective management? Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:975-996.
4196.	Emilio S, B CG, Gaetano P, et al. Paroxetine versus amitriptyline in patients with recurrent major depression: A double-blind trial. International journal of psychiatry in clinical practice. 2002;6:23-29.
4197.	Emily P, L BD, Denada H, D CJ, L WK. Sertraline and breastfeeding: Review and meta-analysis. Archives of women's mental health. 2015;18:139-146.
4198.	Emin O, Umit T. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. Journal of affective disorders. 2003;76:223-227.
4199.	EML S, Pang H, Cirrincione C, et al. Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy a Randomized Clinical Trial. Jama-Journal of the American Medical Association. 2013;309:1359-1367.
4200.	EMM Q, BE L. Overlap of functional dyspepsia and GERD - Diagnostic and treatment implications. Nature Reviews Gastroenterology and Hepatology. 2013;10:175-186.
4201.	Emmanuelle C, Celine G, Melissa S. Relationship between TSH levels in the normal range and short-term duloxetine efficacy. Journal of affective disorders. 2010;123:312-316.
4202.	Emre M, PJ F, Bilgic B, EY U. Cognitive impairment and dementia in Parkinson's disease: Practical issues and management. Movement disorders. 2014;29:663-672.
4203.	Emsley R, Hawkridge S. Clinical trials in psychiatry: Obtaining the evidence. South African Journal of Psychiatry. 2004;10:4-7.
4204.	Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection, International clinical psychopharmacology(2008).
4205.	Emslie G. Clinical guidelines vs. clinical trials. Journal of child and adolescent psychopharmacology. 2004;14:v-vii.
4206.	Emslie G. Pediatric MDD: Sequential treatment with fluoxetine and relapse prevention CBT. European child & adolescent psychiatry. 2013;Conference:S112-S113.
4207.	Emslie G, Judge R. Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors: Use During Pregnancy, in Children/Adolescents and in the Elderly. Acta Psychiatrica Scandinavica, Supplement. 2000;101:26-34.
4208.	Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents With Depression Study (TADS): Safety Results. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1440-1455.
4209.	Enache D, Winblad B, Aarsland D. Depression in dementia: Epidemiology, mechanisms, and treatment. Current opinion in psychiatry. 2011;24:461-472.
4210.	Ender AA, Nabi Z, Hakan C, Fisun A, Gul K. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: A randomized, double-blind study. Human Psychopharmacology: Clinical and Experimental. 2008;23:313-319.
4211.	Endicott J. Diagnosis and psychopharmacologic treatment of premenstrual dysphoric disorder. Economics of Neuroscience. 2001;3:44-47.
4212.	Endicott J, Amsterdam J, Eriksson E, et al. Is Premenstrual Dysphoric Disorder a Distinct Clinical Entity? Journal of women's health & gender-based medicine. 1999;8:663-679.
4213.	Endicott J, JM R, Raskin J, et al. Duloxetine Treatment for Role Functioning Improvement in Generalized Anxiety Disorder: Three Independent Studies. Journal of clinical psychiatry. 2007;68:518-524.
4214.	Endicott J, Nee J, RY Y, Wohlberg C. Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (Pq-Les-Q): Reliability and Validity. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:401-407.
4215.	Endicott J, Svedsater H, JC L. Effects of Once-Daily Extended Release Quetiapine Fumarate on Patient-Reported Outcomes in Patients With Generalized Anxiety Disorder. Neuropsychiatric disease and treatment. 2012;8:301-311.
4216.	Engelman W, FM H, JF M. Diagnosing Pseudobulbar affect in traumatic brain injury. Neuropsychiatric disease and treatment. 2014;10:1903-1910.
4217.	Engin E, Treit D, CT D. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.[Erratum appears in Neuroscience. 2009 Sep 15;162(4):1438-9]. Neuroscience. 2009;161:359-369.
4218.	Englisch S, Fritzinger M, Zink M. Urinary Retention During Combined Treatment of Postpsychotic Depression With Duloxetine and Olanzapine. Clinical neuropharmacology. 2008;31:307-309.
4219.	Duloxetine for major depressive episodes in the course of psychotic disorders: An observational clinical trial, Journal of psychopharmacology (Oxford, England)(2009).
4220.	Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:1386-1392.
4221.	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder, International journal of neuropsychopharmacology(2012).
4222.	Enrico S. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: A double-blind, comparative study. Journal of affective disorders. 1998;48:47-56.
4223.	Enrico T, Yeciel L, Nadia l, E AV, Craig NJ, I PG. Efficacy of antidepressants for late-life depression: A meta-analysis and meta-regression of placebo-controlled randomized trials. Journal of clinical psychiatry. 2011;72:1660-1668.
4224.	Enrique B, Manuel GdC, Mauro G-T, Francisco P-A, Alberto P-C. Sertraline is more effective than imipramine in the treatment of non-melancholic depression: Results from a multicentre, randomized study. Progress in neuro-psychopharmacology & biological psychiatry. 2003;27:493-500.
4225.	Enrique B, Margarida G-G, Alberto P-C. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28:57-65.
4226.	Entsuah AR, Rudolf RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates. International clinical psychopharmacology. 1996;11:137-145.
4227.	Entsuah R. Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. [Review] [30 refs]. Journal of biopharmaceutical statistics. 1996;6:457-475.
4228.	Entsuah R. Complete Remission of Severe Individual Symptoms of Depression: a Comparison of Venlafaxine, Ssris, and Placebo. European neuropsychopharmacology. 2004;14:S183.
4229.	Entsuah R. Complete Remission of Individual Symptoms of Depression: a Comparison of Venlafaxine, Ssris, and Placebo. International journal of neuropsychopharmacology. 2004;7:S180.
4230.	Entsuah R. Complete Remission of Individual Symptoms of Depression: a Comparison of Venlafaxine, Ssris, and Placebo. International journal of neuropsychopharmacology. 2004;7:S180.
4231.	Entsuah R. Complete Remission of Severe Individual Symptoms of Depression: a Comparison of Venlafaxine, Ssris, and Placebo. European neuropsychopharmacology. 2004;14:S183.
4232.	Entsuah R, DV S, ME T, Zhang Y. A Comparison of Etrank, Mmrm and Locf Analyses of Eighteen Placebo-Controlled Venlafaxine Clinical Trials for the Treatment of Major Depressive Disorder. Neuropsychopharmacology. 2005;30:S109.
4233.	Entsuah R, Gao B. Global benefit-risk evaluation of antidepressant action: Comparison of pooled data for venlafaxine, SSRIs, and placebo. CNS spectrums. 2002;7:882-888.
4234.	Entsuah R, Sheehan D, Thase M, Zhang Y. A Comparison of Analytical Methods - Etrank, Mmrm and Locf - in 18 Placebo-Controlled Venlafaxine Clinical Trials for the Treatment of Major Depressive Disorder. International journal of neuropsychopharmacology. 2006;9:S231-S232.
4235.	Entsuah R, Upton GV, Rudolph R. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Human Psychopharmacology: Clinical and Experimental. 1995;10:195-200.
4236.	Entsuah R, Vinall P. Potential Predictors of Placebo Response: Lessons From a Large Database. Drug information journal. 2007;41:315-330.
4237.	Enver A, Orhan D, Gamze A. The role of folic acid in the treatment of major depressive disorder. [Turkish]. Anadolu Psikiyatri Dergisi. 2000;1:5-12.
4238.	EP A. Critical evaluation of a decision-analytic model of major depression treatment. Formulary (Cleveland, Ohio). 1999;34:683-687.
4239.	EP A, GH S, M HE. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Current medical research and opinion. 2007;23:251-258.
4240.	EP C. Would the elderly be better off if they were given more placebos? Geriatrics & gerontology international. 2010;10:131-137.
4241.	EP C, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS drugs. 2012;26:135-153.
4242.	EP C, Rico-Villademoros F, CM R-L. Monotherapy or combination therapy for fibromyalgia treatment. Current rheumatology reports. 2012;14:568-575.
4243.	EP C, Rico-Villademoros F, Galan J, et al. Quetiapine Extended-Release (Seroquel-Xr) Versus Amitriptyline Monotherapy for Treating Patients With Fibromyalgia: a 16-Week, Randomized, Flexible-Dose, Open-Label Trial. Psychopharmacology. 2014;231:2525-2531.
4244.	EP K, HB F, DG W, Fox B. Should we use SSRIs to treat adolescents with depression? Journal of family practice. 2007;56:759-760.
4245.	EP L, Lidonnici D. Economic evaluation of agomelatine for major depressive disorders relative to other antidepressants in the Italian setting. Value in health. 2014;Conference:A460.
4246.	EP M, DA C, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. Journal of clinical psychopharmacology. 2003;23:193-196.
4247.	EP P. Suicidality and antidepressants in the elderly. Clinical geriatrics. 2007;15:23-28.
4248.	Progress in corticotropin-releasing factor-1 antagonist development, Drug discovery today(2010).
4249.	Epling J. Is Fluoxetine an Effective Therapy for Weight Loss in Obese Patients? American family physician. 2003;68:2437-2438.
4250.	ER E, Kudrow D, AM R. A Prospective, Open-Label Study of Milnacipran in the Prevention of Headache in Patients With Episodic or Chronic Migraine. Neurological sciences. 2014;35:429-435.
4251.	ER M. Postoperative delirium: A 76-year-old woman with delirium following surgery. JAMA - Journal of the American Medical Association. 2012;308:73-81.
4252.	ER N, Burke K, JR C, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Adjunctive Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder. Journal of affective disorders. 2013;144:141-147.
4253.	ER P. Management of depression in long-term care of patients with Alzheimer's disease. Journal of the American Medical Directors Association. 2003;4:S141-S145.
4254.	A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression, American journal of psychiatry(2007).
4255.	Erdinc A, Gurates B, Celik H, Polat A, Kumru S, Simsek M. The Efficacy of Venlafaxine in the Treatment of Women With Stress Urinary Incontinence. Archives of gynecology and obstetrics. 2009;279:343-348.
4256.	Eren I. Maintenance treatment in bipolar disorder, Iki uclu bozuklukta koruma tedavisi. [Turkish, English]. Klinik Psikofarmakoloji Bulteni. 2012;Conference:S11.
4257.	Eren I, Demirdas A, IC I. Evaluating the Antidepressant Efficacy of Aripiprazole Using a Chronic Mild Stress Model: an Experimental Study. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2014;24:15-22.
4258.	Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochemical research. 2007;32:1188-1195.
4259.	Eren I, Naziroglu M, Demirdas A, et al. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochemical research. 2007;32:497-505.
4260.	Erfurth A, Loew M, Wendler G, Floreanu A. Treatment of depressive disorders in neurological rehabilitation: Effects of paroxetine. [German]. Psychiatrische Praxis. 2001;28:43-44.
4261.	Erfurth A, Loew M, Wendler G, Floreanu A. [Depressive disorders in neurologic rehabilitation: therapy with paroxetine]. [German]. Psychiatrische Praxis. 2001;28:43-44.
4262.	Eric W. Paroxetine (Paxil, Seroxat): Increased risk of suicide in pediatric patients. Canadian Medical Association journal. 2003;169:446.
4263.	Erickson G, DJ H. Behavioral activation therapy for remediating persistent social deficits in medication-responsive chronic depression. Journal of psychiatric practice. 2011;17:161-169.
4264.	Erik dK. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. Journal of clinical psychiatry. 2001;62:43-47.
4265.	Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. International clinical psychopharmacology. 1999;14:S27-S33.
4266.	Eriksson E, Andersch B, H-P H, et al. Premenstrual dysphoria: An illustrative example of how serotonin modulates sex-steroid - Related behavior. CNS spectrums. 2001;6:141-149.
4267.	Eriksson E, Andersch B, HP H, Landen M, Sundblad C. Diagnosis and treatment of premenstrual dysphoria. Journal of clinical psychiatry. 2002;63:16-23.
4268.	Eriksson E, MA H, Andersch B, Sundblad C. The Serotonin Reuptake Inhibitor Paroxetin Is Superior to the Noradrenaline Reuptake Inhibitor Maprotiline in the Treatment of Premenstrual-Syndrome. Neuropsychopharmacology. 1995;12:167-176.
4269.	Eriksson H. The role of atypical antipsychotics in treating bipolar and unipolar depression. International journal of psychiatry in clinical practice. 2009;Conference:16-17.
4270.	Eriksson M, Berggren U, Fahlke C, Hard E, Balldin J. Mental well-being in subjects with long-term excessive alcohol consumption: An experimental study. Alcohol (Fayetteville, N.Y.). 2002;27:99-105.
4271.	Erin RM. Change in cognitive functioning following acute antidepressant treatment in late-life depression. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2014;74:No Pagination Specified.
4272.	Erkul E, Cingi C, M OK, et al. Effects of escitalopram on symptoms and quality of life in patients with allergic rhinitis. American journal of rhinology & allergy. 2012;26:e142-146.
4273.	Erkul E, Cingi C, MO K, et al. Effects of escitalopram on symptoms and quality of life in patients with allergic rhinitis. American journal of rhinology & allergy. 2012;26:e142-e146.
4274.	Ermer J, MB H, Richards C, et al. An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults. Clinical drug investigation. 2013;33:243-254.
4275.	Ernst E. Herbal remedies for depression and anxiety. Advances in Psychiatric Treatment. 2007;13:312-316.
4276.	Ertekin E. Recurrence of Major Depressive Disorder Following a Switch From Escitalopram to St. John's Wort: a Case Report. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2014;24:180-183.
4277.	Ertekin YA, Pervin E, Abdullah E, et al. Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: An open placebo-controlled study. [Turkish]. Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology. 2012;22:23-30.
4278.	ES B. Effects of glucocorticoids on mood, memory, and the hippocampus: Treatment and preventive therapy. Glucocorticoids and Mood Clinical Manifestations, Risk Factors, and Molecular Mechanisms. 2009;Annals of 41-55.
4279.	ES B, DA K, Vigil L, AJ R. A Randomized, Double-Blind, Placebo-Controlled Trial of Citalopram in Outpatient Adults With Asthma and Major Depressive Disorder. Neuropsychopharmacology. 2004;29:S92.
4280.	ES B, DA K, Vigil L, AJ R. A Randomized, Double-Blind, Placebo-Controlled Trial of Citalopram in Outpatient Adults With Asthma and Major Depressive Disorder. Neuropsychopharmacology. 2004;29:S92.
4281.	ES B, DA K, Vigil L, JDM L, TJ C, AJ R. A Randomized, Double-Blind, Placebo-Controlled Trial of Citalopram in Outpatient Adults With Asthma and Major Depressive Disorder. Biological psychiatry. 2005;57:118S.
4282.	ES B, DA K, Vigil L, JDM L, TJ C, AJ R. A Randomized, Double-Blind, Placebo-Controlled Trial of Citalopram in Outpatient Adults With Asthma and Major Depressive Disorder. Biological psychiatry. 2005;57:118S.
4283.	ES B, LA V, DA K, AJ R. Bupropion in the treatment of outpatients with asthma and major depressive disorder. International journal of psychiatry in medicine. 2007;37:23-28.
4284.	ES B, Murray M, TJ C, et al. The Quick Inventory of Depressive Symptomatology-Self-report: A psychometric evaluation in patients with asthma and major depressive disorder. Annals of Allergy, Asthma and Immunology. 2008;100:433-438.
4285.	ES C, Ozalp E, Soygur H, DI A, Turhan L, Alkis N. Mirtazapine Improves Sleep and Lowers Anxiety and Depression in Cancer Patients: Superiority Over Imipramine. Supportive care in cancer. 2008;16:1291-1298.
4286.	ES F, LL D, Zisook S, et al. Baseline Depression Severity as a Predictor of Single and Combination Antidepressant Treatment Outcome: Results From the Co-Med Trial. European neuropsychopharmacology. 2012;22:183-199.
4287.	ES F, SR W, Gilmer W, et al. Sociodemographic, Clinical, and Treatment Characteristics Associated With Worsened Depression During Treatment With Citalopram: Results of the Nimh Star*D Trial. Depression and anxiety. 2009;26:612-621.
4288.	ES H. A Comparative Analysis of Antidepressants and Stimulants for the Treatment of Adults With Attention-Deficit Hyperactivity Disorder. Journal of family practice. 1999;48:15-20.
4289.	ES J, RL T. St. John's wort: A new alternative for depression? International journal of clinical pharmacology and therapeutics. 1999;37:111-119.
4290.	ES K. Treatment of depression in patients with epilepsy: Problems, pitfalls, and some solutions. Epilepsy & behavior. 2003;4:S46-S54.
4291.	ES P. Recent Developments in Antidepressants. Current therapeutic research, clinical and experimental. 1993;54:811-819.
4292.	ES P. Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression. Acta Psychiatrica Scandinavica, Supplement. 1995;91:22-27.
4293.	ES P. Achieving gains beyond response. Acta Psychiatrica Scandinavica, Supplement. 2002;106:12-17.
4294.	ES P. Cognitive therapy in relapse prevention in depression. International journal of neuropsychopharmacology. 2007;10:131-136.
4295.	ES P, Scott J, JD T. Antidepressants plus cognitive therapy reduced relapse in residual depression: Commentary. Evidence-based medicine. 2000;5:87.
4296.	ES P, Scott J, JD T, et al. Prevention of Relapse in Residual Depression by Cognitive Therapy - a Controlled Trial. Archives of general psychiatry. 1999;56:829-835.
4297.	ES P, Scott J, PL C, et al. Duration of relapse prevention after cognitive therapy in residual depression: Follow-up of controlled trial. Psychological medicine. 2005;35:59-68.
4298.	Esa L, Heikki N. The influence of educational information on depressed outpatients treated with escitalopram: A semi-naturalistic study. Nordic journal of psychiatry. 2007;61:109-114.
4299.	Esa L, Jon S, Kirsten B, Hans A, Th HJ. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. International clinical psychopharmacology. 1999;14:329-337.
4300.	Escalona R, JM C, LA C, JRT D. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depression and anxiety. 2002;15:29-33.
4301.	Escamilla M, LaVoy M, BA M, Krakow B. Management of post-traumatic nightmares: A review of pharmacologic and nonpharmacologic treatments since 2010. Current psychiatry reports. 2012;14:529-535.
4302.	Escande M, Gentil V, Frexinos M. The delay of antidepressant effect: Clinical data. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 1995;21:3-8.
4303.	Eser D, TC B, H-J M. Evidence of agomelatine's antidepressant efficacy: The key points. International clinical psychopharmacology. 2007;22:S15-S19.
4304.	Eser D, TC B, H-J M. Agomelatine: The evidence for its place in the treatment of depression. Core evidence. 2009;4:171-179.
4305.	Eser D, TC B, H-J M. Clinical data on the efficacy of agomela tine. [German]. Psychopharmakotherapie. 2009;16:6-10.
4306.	Eser D, TC B, HJ M. Clinical Data on the Efficacy of Agomelatine. Psychopharmakotherapie. 2009;16:A6-A10.
4307.	Espinosa-Aguilar A, Caraveo-Anduaga J, Zamora-Olvera M, et al. Clinical guideline for diagnosis and treatment of depression in eldery. [Spanish]. Salud mental (Mexico City, Mexico). 2007;30:69-80.
4308.	Esposito D, Wahl P, Daniel G, MA S, MH E, TW C. Results of a Retrospective Claims Database Analysis of Differences in Antidepressant Treatment Persistence Associated With Escitalopram and Other Selective Serotonin Reuptake Inhibitors in the United States. Clinical therapeutics. 2009;31:644-656.
4309.	Esposito E, LW J, CE A, et al. Frequency and adequacy of depression treatment in a Canadian population sample. Canadian Journal of Psychiatry. 2007;52:780-789.
4310.	Esposito K, Goodnick P. Predictors of response in depression. Psychiatric clinics of North America. 2003;26:353-365.
4311.	Essali A, N A-HH, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane database of systematic reviews (Online). 2009.
4312.	Esteve G-F, Ixchel H-G, Beatriz C, et al. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. Journal of affective disorders. 2010;127:343-351.
4313.	Esteve G-F, Ixchel H-G, Beatriz C, et al. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms. Human Psychopharmacology: Clinical and Experimental. 2012;27:577-586.
4314.	Esteve G-F, Joan G-O, Maribel P-C, et al. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables. Journal of affective disorders. 2013;150:1082-1090.
4315.	ET M, KM S, Moyer A, NF C. Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: A framework for personalized risk assessment and counseling. Journal of cancer education. 2007;22:10-14.
4316.	ET O, Vahip S. Bipolar depression: An overview. IDrugs : the investigational drugs journal. 2004;7:846-850.
4317.	ET OK, Turan E. Anxiety disorders in elderly people. [Turkish]. Turk Geriatri Dergisi. 2007;10:150-155.
4318.	Etain B, Bonnet-Perrin E. Interest of Fluoxetine in Obsessive-Compulsive Disorders in Adults: a Review. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2001;27:280-289.
4319.	Etchegaray M, Hardy P. Treatment of Generalized Anxiety Disorders. Presse medicale. 2008;37:859-866.
4320.	Etievant A, Betry C, Haddjeri N. Partial dopamine D2/serotonin 5-HT1a receptor agonists as new therapeutic agents. Open neuropsychopharmacology journal. 2010;3:1-12.
4321.	Etkin A. Large-scale pre-treatment prediction of remission with antidepressants for individual patients based on cognitive and emotional test performance, as well as its neuroimaging correlates. Neuropsychopharmacology. 2013;Conference:S8.
4322.	Etkin A, Patenaude B, YJC S, et al. A Cognitive-Emotional Biomarker for Predicting Remission With Antidepressant Medications: a Report From the Ispot-D Trial. Neuropsychopharmacology. 2015;40:1332-1342.
4323.	Vitamin B12 supplementation in treating major depressive disorder: A randomized controlled trial, Open neurology journal(2013).
4324.	Eun-Ho K, In-Soo L, Sang-Keun C, et al. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial. Psychiatry research. 2009;169:118-123.
4325.	EV N. Commentary on Zhou Et Al. (2015): Treating Psychiatric Comorbidity in Adolescents-an Important Problem. Addiction (Abingdon, England). 2015;110:49-50.
4326.	Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). [Review], Nephrology, dialysis, transplantation(2012).
4327.	EV N, FR L. Treatment of Depression in Patients with Alcohol or Other Drug Dependence: A Meta-analysis. Journal of the American Medical Association. 2004;291:1887-1896.
4328.	No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression, Journal of neuroimmunology(2012).
4329.	Evans J, Sun Y, McGregor A, Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology. 2012;63:1315-1326.
4330.	Evans R, Rosen N. Expert Opinion - Migraine, Psychiatric Comorbidities, and Treatment. Headache. 2008;48:952-958.
4331.	Even C, Weintraub D. Case for and against specificity of depression in Alzheimer's disease. Psychiatry and clinical neurosciences. 2010;64:358-366.
4332.	Even C, Weintraub D. Is depression in Parkinson's Disease (PD) a specific entity? Journal of affective disorders. 2012;139:103-112.
4333.	Everitt BS. Analysis of drop-out data in treatment trials. The British Journal of Psychiatry. 1998;173:271.
4334.	Evers S. Treatment of Migraine With Prophylactic Drugs. Expert opinion on pharmacotherapy. 2008;9:2565-2573.
4335.	Evian G, John RA, M PD, A BT, William R. Toward an online cognitive and emotional battery to predict treatment remission in depression. Neuropsychiatric disease and treatment. 2015;11.
4336.	Evliyaoglu Y, Yelsel K, Kobaner M, Alma E, Saygili M. Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Urology. 2011;77:1137-1141.
4337.	EW dH, Dekker J, JF vEvdS, et al. Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled m. BMC psychiatry. 2013;13:147.
4338.	EW F. Treatment of depression associated with the menstrual cycle: Premenstrual dysphoria, postpartum depression, and the perimenopause. Dialogues in clinical neuroscience. 2002;4:177-191.
4339.	EW F. Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder. CNS drugs. 2004;18:453-468.
4340.	EW F. Effects of Antidepressants on Quality of Life in Women With Pre-Menstrual Dysphoric Disorder. PharmacoEconomics. 2005;23:433-444.
4341.	EW F. Effects of Antidepressants on Quality of Life in Women With Pre-Menstrual Dysphoric Disorder. PharmacoEconomics. 2005;23:433-444.
4342.	EW F. Therapeutic management of premenstrual syndrome. [Review]. Expert opinion on pharmacotherapy. 2010;11:2879-2889.
4343.	EW F, CA F, Rickels K, PAG M, SS S. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. Journal of clinical psychopharmacology. 2002;22:516-520.
4344.	EW F, Jabara S, SJ S, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study. Journal of women's health. 2002;11:459-464.
4345.	EW F, KA G, Caan B, et al. Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women a Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2011;305:267-274.
4346.	EW F, Kroll R, Rapkin A, et al. Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder. Journal of women's health & gender-based medicine. 2001;10:561-569.
4347.	EW F, MD S, Lin H, Rickels K, SJ S. Clinical Subtypes of Premenstrual Syndrome and Responses to Sertraline Treatment. Obstetrics and gynecology. 2011;118:1293-1300.
4348.	EW F, Rickels K, KA Y, NR K, MK M, GV U. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics and gynecology. 2001;98:737-744.
4349.	Time to Relapse After Short- or Long-Term Treatment of Severe Premenstrual Syndrome With Sertraline, Archives of general psychiatry(2009).
4350.	EW F, Rickels K, SJ S. Fluvoxamine for Premenstrual Dysphoric Disorder: a Pilot Study. Journal of clinical psychiatry. 1996;57:56-60.
4351.	EW F, Rickels K, SJ S, Denis A, Pfeifer S, Weil S. Nefazodone in the Treatment of Premenstrual-Syndrome - a Preliminary-Study. Journal of clinical psychopharmacology. 1994;14:180-186.
4352.	EW F, Rickels K, SJ S, FM W. Sertraline Versus Desipramine in the Treatment of Premenstrual Syndrome: an Open-Label Trial. Journal of clinical psychiatry. 1996;57:7-11.
4353.	EW F, Rickels K, SJ S, Polansky M. Differential Response to Antidepressants in Women With Premenstrual Syndrome/Premenstrual Dysphoric Disorder - a Randomized Controlled Trial. Archives of general psychiatry. 1999;56:932-939.
4354.	EW F, Rickels K, SJ S, Polansky M, Xiao S. Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder. American journal of psychiatry. 2004;161:343-351.
4355.	EW F, SJ S, MD S, Ferdousi T, Lin H. A Preliminary Study of Luteal Phase Versus Symptom-Onset Dosing With Escitalopram for Premenstrual Dysphoric Disorder. Journal of clinical psychiatry. 2005;66:769-773.
4356.	EW F, SJ S, MD S, Ferdousi T, Lin H. A Preliminary Study of Luteal Phase Versus Symptom-Onset Dosing With Escitalopram for Premenstrual Dysphoric Disorder. Journal of clinical psychiatry. 2005;66:769-773.
4357.	EW F, SJ S, Polansky M, Garcia-Espagna B. Predictors of response to sertraline treatment of severe premenstrual syndromes. Journal of clinical psychiatry. 2000;61:579-584.
4358.	EW F, SJ S, Rickels K, PG M. A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome [6]. Journal of clinical psychopharmacology. 2004;24:351-353.
4359.	EWW L. Optimizing the psychopharmacotherapy of depression and medication adherence in primary care. Hong Kong Practitioner. 2007;29:16-23.
4360.	EY S, MA G, JW L, et al. Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. Journal of pharmacokinetics and pharmacodynamics. 2009;36:63-80.
4361.	Eyal S, Vilma G. Inflammatory depressive bowel diseases: The new era. Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53:720-722.
4362.	Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for Acute Treatment of Major Depression: Systematic Review and Meta-Analysis of Published and Unpublished Placebo and Selective Serotonin Reuptake Inhibitor Controlled Trials. Bmj-British Medical Journal. 2010;341.
4363.	Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ (Online). 2010;341:816.
4364.	Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. [Review]. BMJ (Clinical research ed.). 2010;341:c4737.
4365.	F AT, A DA. Pharmacotherapy for bipolar depression: A review of the evidence. Current psychiatry reviews. 2008;4:145-156.
4366.	F BW, W RF, R WD, I GB. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. Journal of clinical psychopharmacology. 1988;8:112-115.
4367.	F CJ, C WK. Striving for Effectiveness in the Treatment of Adolescent Depression: Cognitive Behavior Therapy for Multisite Community Intervention. Cognitive and behavioral practice. 2005;12:177-185.
4368.	F CK, M PC, L PG. Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS drugs. 2009;23:427-452.
4369.	F DC, Perelli F, Armando M, Vicari S. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials. [Review]. Journal of affective disorders. 2014;152-154:39-44.
4370.	F dJ, Dekker J, Kool S, G vA, Peen J, C GvW. Psychotherapy and/or antidepressants with depression: A randomised study. [Dutch]. Tijdschrift voor psychiatrie. 2002;44:237-248.
4371.	F dJ, Hendricksen M, G vA, et al. Psychotherapy Alone and Combined With Pharmacotherapy in the Treatment of Depression. British journal of psychiatry. 2004;185:37-45.
4372.	F DJ, Kool S, G VA, Dekker J, Peen J. Combining psychotherapy and antidepressants in the treatment of depression. Journal of affective disorders. 2001;64:217-229.
4373.	F dJ, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 1991;24:62-67.
4374.	F DJ, Swinkels J. Selective serotonin reuptake inhibitors: Relevance of differences in their pharmacological and clinical profiles. CNS drugs. 1997;7:452-467.
4375.	F dJ, Swinkels J, Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry. 1991;24:21-27.
4376.	F DJ, Tuynmann-Qua H, Mager J. Fluoxetin and depression in the Dutch psychiatric practice; a report of an open study. [Dutch]. TGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek. 1991;16:76-81.
4377.	F DP, Orsi R, Settembre R. Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression. Journal of multidisciplinary healthcare. 2015;8:39-45.
4378.	F FL. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Journal of clinical psychiatry. 1992;53:40-43.
4379.	F FL, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biological psychiatry. 1995;38:592-602.
4380.	F FL, Lynn C. Efficacy of fluoxetine in outpatients with major depression. Current therapeutic research, clinical and experimental. 1985;37:115-123.
4381.	F FL, S BC, C SL, R DL. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. Journal of sexual medicine. 2011;8:1411-1419.
4382.	F GJ. The modern pharmacopoeia: A return to depressive realism? [References]. Bipolar disorders. 2008;10:969-972.
4383.	SSRI versus bupropion effects on symptom clusters in suicidal depression: Post hoc analysis of a randomized clinical trial, Journal of clinical psychiatry(2013).
4384.	F GM, P ES, Naihua D, K BA, A OM, JJohn M. Pilot randomized clinical trial of an SSRI vs bupropion: Effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology. 2012;37:697-706.
4385.	F GW, Peter V, Hermes K, Ralf K. Moclobemide versus fluoxetine in the treatment of inpatients with major depression. Journal of clinical psychopharmacology. 1995;15:35S-40S.
4386.	F KJ, L RB, FIII RC, et al. Addressing both depression and pain in late life: The methodology of the adapt study. Pain medicine (Malden, Mass.). 2012;13:405-418.
4387.	F LA, A CI, A WE, Melinda M, Michelle A. Changes in brain function of depressed subjects during treatment with placebo. American journal of psychiatry. 2002;159:122-129.
4388.	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study, Psychiatry research(2009).
4389.	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder, Psychiatry research(2009).
4390.	F LA, Melinda M, A CI, Jennifer D, Michelle A, Elise W. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology. 2004;177:15-22.
4391.	F LJ, Verin M, N'diaye K, et al. Decrease of Prefrontal Metabolism After Subthalamic Stimulation in Obsessive-Compulsive Disorder: a Positron Emission Tomography Study. Biological psychiatry. 2010;68:1016-1022.
4392.	F RJ, Maurizio F, L HS, C AR, B KW. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological psychiatry. 1998;44:77-87.
4393.	F SA. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. [Review] [32 refs]. Journal of clinical psychiatry. 1998;59 Suppl 1:15-18.
4394.	F SA. Clinical efficacy of reboxetine in major depression. Journal of clinical psychiatry. 2000;61:31-38.
4395.	F VDL, WCM WS, H VDW, JH SVL. The premenstrual syndrome. [Dutch]. Nederlands tijdschrift voor geneeskunde. 2010;154:1504-1508.
4396.	F VH, Wauters A, Vandoolaeghe E, Neels H, Demedts P, Maes M. Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: Effects of antidepressant treatments. Psychiatry research. 1996;65:159-169.
4397.	F-H H, G-M J, Y-M L, et al. The long-term effects of psychotherapy added to pharmacotherapy on morning to evening diurnal cortisol patterns in outpatients with major depression. Psychotherapy and psychosomatics. 2011;80:166-172.
4398.	F-T Z, S-M X, Q-H Z, X-L W, H-H L. Citalopiam versus venlafaxine for the improvement of post-stroke depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:12-13.
4399.	F-Y T, X-W X, S-Y H, S-H S. Effect of BST on synapse protein SYT and SYN in the hippocampus of chronic stress depression in rats. [Chinese]. Journal of Central South University (Medical Sciences). 2006;31:687-691.
4400.	Predictive socioeconomic and clinical profiles of antidepressant response and remission, Depression and anxiety(2013).
4401.	FA M, AJ G, Bachar K, PL D. Pindolol augmentation of treatment-resistant depressed patients. Journal of clinical psychiatry. 1997;58:437-439.
4402.	FA M, AJ G, GR H, et al. Tryptophan depletion and depressive vulnerability. Biological psychiatry. 1999;46:498-505.
4403.	FA M, Parkinson D, Palmer C, et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. European neuropsychopharmacology. 2010;20:18-24.
4404.	Fabbri C, Gurwitz D, Stingl J, et al. CHL1 gene: A new promising antidepressant response marker in major depression. European neuropsychopharmacology. 2013;Conference:S168-S169.
4405.	Fabbri C, Marsano A, Serretti A. Genetics of serotonin receptors and depression: State of the art. Current drug targets. 2013;14:531-548.
4406.	Fabbri S, GA F, Rafanelli C, Tomba E. Family intervention approach to loss of clinical effect during long-term antidepressant treatment: A pilot study. Journal of clinical psychiatry. 2007;68:1348-1351.
4407.	Fabre L. The effect of major depression, SSRI and gepirone-extended-release treatment on sexual function in women. European neuropsychopharmacology. 2010;Conference:S372-S373.
4408.	Fabre L, LC S, LR D. The effect of gepirone-er, fluoxetine, and paroxetine (SSRIS) compared to placebo on sexual function in subjects with and without sexual dysfunction prior to treatment as measured by the derogatis inventory of sexual function (DISF). Journal of sexual medicine. 2012;Conference:327.
4409.	Fabre L, LJ B, BA Z, LF W, BM K. Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients. International clinical psychopharmacology. 1996;11:119-127.
4410.	Fagiolini A, Bossini L. Treating major depressive disorder to remission. Looking for a complete remission. [Italian]. Journal of Psychopathology. 2012;18:292-303.
4411.	Fagiolini A, Casamassima F, Mostacciuolo W, Forgione R, Goracci A, BI G. Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar i disorder. Expert opinion on pharmacotherapy. 2010;11:1727-1740.
4412.	Fagiolini A, Comandini A, MC DO, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS drugs. 2012;26:1033-1049.
4413.	Fagiolini A, Frank E, DA A, et al. Enhancing outcomes in patients with bipolar disorder: Results from the Bipolar Disorder Center for Pennsylvanians Study. Bipolar disorders. 2009;11:382-390.
4414.	Fagiolini A, KNR C. Weight gain and metabolic issues of medicines used for bipolar disorder. Current psychiatry reports. 2007;9:521-528.
4415.	Fagiolini A, Maina G. Aripiprazole: A discussion on its clinical use in mania associated with bipolar I disorder. Drugs and Therapy Perspectives. 2008;24:1-4.
4416.	Fagiolini A, Nitti M, RN F, FS M, Casamassima F. Aripiprazole for the treatment of bipolar disorder: A review of current evidence. Expert opinion on pharmacotherapy. 2011;12:473-488.
4417.	Fahlen T. Personality Traits in Social Phobia .2. Changes During Drug Treatment. Journal of clinical psychiatry. 1995;56:569-573.
4418.	Fairweather DB, Kerr JS, Harrison DA, Moon CA, Hindmarch I. A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients. Human Psychopharmacology: Clinical and Experimental. 1993;8:41-47.
4419.	Fairweather DB, Stanley N, Yoon JS, Hindmarch I. The effects of fluoxetine and dothiepin on cognitive function in depressed patients in general practice. Human Psychopharmacology: Clinical and Experimental. 1999;14:325-332.
4420.	Fakra E, D DF, Livolsi S, Destoppeleire C, Lancon C. Long term studies of depression: What is relevant for the physician? European Journal of Psychiatry. 2006;20:242-257.
4421.	Falkai P. Mirtazapine: Other indications. Journal of clinical psychiatry. 1999;60:36-40.
4422.	Falkai P. What was new, interesting and frequently cited in 2009? European archives of psychiatry and clinical neuroscience. 2010;260:87-89.
4423.	Faller H, CE A. Depression in chronic heart failure: Complication, risk factor or autonomous disease?. [German]. Internist. 2008;49:394-404.
4424.	Faludi G, Gonda X, Bagdy G, Dome P. Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: A brief review. Neuropsychopharmacologia Hungarica. 2012;14:221-229.
4425.	FAM D, Simoens S, Laekeman G. The impact of informing psychiatric patients about their medication: A systematic review. Pharmacy World and Science. 2006;28:329-341.
4426.	Fan L, Fu W, Xu N, Liu J, Ou A, Wang Y. Meta-analysis of 20 clinical, randomized, controlled trials of acupuncture for depression. Neural Regeneration Research. 2010;5:1862-1869.
4427.	Fan L, W-B F, C-R M, et al. Effect of acupuncture at routine acupoint and non-acupoint on depressive neurosis evaluated with Hamilton depression scale. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:14-16.
4428.	Fang Y, Yuan C, Xu Y, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Journal of clinical psychopharmacology. 2011;31:638-642.
4429.	Fang Y, Yuan C, Xu Y, et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: A double-blind, randomized pilot study in a Chinese population. Journal of clinical psychopharmacology. 2010;30:357-364.
4430.	Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: A proposal for clinical management. European heart journal. 2014;35:1306-1315b.
4431.	Fantino B, Moore N. The self-reported Montgomery-Asberg depression rating scale is a useful evaluative tool in major depressive disorder. BMC psychiatry. 2009.
4432.	Fanton J, MM G. Psychopharmacology and Preschoolers: A Critical Review of Current Conditions. Child and adolescent psychiatric clinics of North America. 2009;18:753-771.
4433.	Farabaugh A, Mischoulon D, Fava M, et al. The Relationship Between Early Changes in the Hamd-17 Anxiety/Somatization Factor Items and Treatment Outcome Among Depressed Outpatients. International clinical psychopharmacology. 2005;20:87-91.
4434.	Farabaugh A, Mischoulon D, Schwartz F, Pender M, Fava M, Alpert J. Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD. Depression and anxiety. 2007;24:433-439.
4435.	Farace E, Sheehan J, Bonneau R, Glantz M. Prophylactic use of paroxetine prevents the development of de novo depression in patients with primary brain tumors. Neuro-oncology. 2011;Conference:iii125.
4436.	Farace E, Sheehan J, VM C, Hegarty J. Pilot study of paroxetine to prevent development of depression in primary brain tumors. Neuro-oncology. 2009;Conference:656.
4437.	Farahani A, CU C. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. Journal of clinical psychiatry. 2012;73:486-496.
4438.	Faramarzi M, Kheirkhah F, Esmaelzadeh S, Alipour A, Hjiahmadi M, Rahnama J. Is psychotherapy a reliable alternative to pharmacotherapy to promote the mental health of infertile women? A randomized clinical trial. European journal of obstetrics, gynecology, and reproductive biology. 2008;141:49-53.
4439.	Faramarzi M, Pasha H, Esmailzadeh S, Kheirkhah F, Heidary S, Afshar Z. The effect of the cognitive behavioral therapy and pharmacotherapy on infertility stress: A randomized controlled trial. International Journal of Fertility and Sterility. 2013;7:199-206.
4440.	Faria V, Fredrikson M, Furmark T. Imaging the placebo response: A neurofunctional review. European neuropsychopharmacology. 2008;18:473-485.
4441.	Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: Results from a double-blind, randomized, and placebo-controlled clinical trial, Neuropsychiatric disease and treatment(2015).
4442.	Farooq S, Ahmad B. Depression and coronary artery disease - Real heart break? Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2001;11:263-271.
4443.	Farrokhi F. Depression among dialysis patients: Barriers to good care. Iranian journal of kidney diseases. 2012;6:403-406.
4444.	Fassino S, Leombruni P, GA D, et al. Efficacy of citalopram in anorexia nervosa: A pilot study. European neuropsychopharmacology. 2002;12:453-459.
4445.	Fasullo S. Post heart attack depression and antidepressants. [Italian]. Quaderni Italiani di Psichiatria. 2008;27:68-76.
4446.	Fava M. Anger attacks in unipolar depressive disorders. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 1997;23:39-42.
4447.	Fava M. Psychopharmacologic treatment of pathologic aggressio n. Psychiatric clinics of North America. 1997;20:427-451.
4448.	Fava M. Anger attacks in unipolar depressive disorders. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1997;23:39-42.
4449.	Fava M. [Anger outbursts in unipolar depressive disorders]. [Review] [19 refs] [French]. Encephale. 1997;23 Spec No:39-42.
4450.	Fava M. Depression with anger attacks. [Review] [31 refs]. Journal of clinical psychiatry. 1998;59 Suppl 1:18-22.
4451.	Fava M. Weight Gain and Antidepressants. Journal of clinical psychiatry. 2000;61:37-41.
4452.	Fava M. Diagnosis and definition of treatment-resistant depression. Biological psychiatry. 2003;53:649-659.
4453.	Fava M. Prospective Studies of Adverse Events Related to Antidepressant Discontinuation. Journal of clinical psychiatry. 2006;67:14-21.
4454.	Fava M. Augmenting antidepressants with folate: A clinical perspective. Journal of clinical psychiatry. 2007;68:4-7.
4455.	Fava M, AA N, FM Q, et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacology bulletin. 1997;33:101-103.
4456.	Fava M, Alpert J, AA N, et al. Fluoxetine treatment of anger attacks: a replication study. Annals of clinical psychiatry. 1996;8:7-10.
4457.	Fava M, Bouffides E, JA P, MK M, RJ S, JF R. Personality-Disorder Comorbidity With Major Depression and Response to Fluoxetine Treatment. Psychotherapy and psychosomatics. 1994;62:160-167.
4458.	Fava M, CH M, MJ D, JG W, MM W. The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients: Do Improvements in These Symptoms Result in Higher Remission Rates? Journal of clinical psychiatry. 2004;65:521-530.
4459.	Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: A post hoc analysis of 3 randomized, double-blind, placebo-controlled studies, Primary care companion to the Journal of clinical psychiatry(2011).
4460.	Fava M, DL D, JH G, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. Journal of clinical psychiatry. 2001;62:413-420.
4461.	Fava M, GM A, Shrivastava R, et al. Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder. Journal of clinical psychopharmacology. 2009;29:222-230.
4462.	Fava M, JF R. Anger attacks in depression. [Review] [24 refs]. Depression and anxiety. 1998;8 Suppl 1:59-63.
4463.	Fava M, JF R, McCarthy M, Pava J, Steingard R, Bless E. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacology bulletin. 1991;27:275-279.
4464.	Fava M, JM M, Greist J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Annals of clinical psychiatry. 2007;19:187-195.
4465.	Fava M, LA L, ME A, JF R. Hypothyroidism and hyperthyroidism in major depression revisited. Journal of clinical psychiatry. 1995;56:186-192.
4466.	Fava M, LA U, JE A, AA N, JA P, JF R. Major Depressive Subtypes and Treatment Response. Biological psychiatry. 1997;42:568-576.
4467.	Fava M, MA R, JE A, AA N, JJ W. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychotherapy and psychosomatics. 1998;67:328-331.
4468.	Fava M, ME T, Debattista C. A Multicenter, Placebo-Controlled Study of Modafinil Augmentation in Partial Responders to Selective Serotonin Reuptake Inhibitors With Persistent Fatigue and Sleepiness. Journal of clinical psychiatry. 2005;66:85-93.
4469.	Fava M, ME T, Debattista C. A Multicenter, Placebo-Controlled Study of Modafinil Augmentation in Partial Responders to Selective Serotonin Reuptake Inhibitors With Persistent Fatigue and Sleepiness. Journal of clinical psychiatry. 2005;66:85-93.
4470.	Fava M, Mischoulon D. Folate in depression: Efficacy, safety, differences in formulations, and clinical issues. Journal of clinical psychiatry. 2009;70:12-17.
4471.	A randomized, double-blind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression is there a relationship to leptin levels?, Journal of clinical psychopharmacology(2015).
4472.	Fava M, RD V, EC W, AA N, JE A, JF R. Fenfluramine Challenge in Unipolar Depression With and Without Anger Attacks. Psychiatry research. 2000;94:9-18.
4473.	Fava M, SD T, AA N, et al. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. Journal of psychiatric research. 2012;46:1553-1563.
4474.	Fava M, SM R, JA P, AA N, JE A, JF R. Relapse in Patients on Long-Term Fluoxetine Treatment - Response to Increased Fluoxetine Dose. Journal of clinical psychiatry. 1995;56:52-55.
4475.	Fava M, SR W, ME T, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies. Journal of clinical psychopharmacology. 2009;29:362-367.
4476.	Fawcett J. Antidepressants: Partial response in chronic depression. British journal of psychiatry. 1994;165:37-41.
4477.	Fawcett J, JM Z, HM K, Edwards J, Jeffriess H, Scorza E. Fluoxetine versus amitriptyline in adult outpatients with major depression. Current therapeutic research, clinical and experimental. 1989;45:821-832.
4478.	Fawcett J, RL B. Efficacy issues with antidepressants. [Review] [32 refs]. Journal of clinical psychiatry. 1997;58 Suppl 6:32-39.
4479.	Fawcett J, RN M, SF A, O'Brien K, Schwiderski U. Response of Anxiety and Agitation Symptoms During Nefazodone Treatment of Major Depression. Journal of clinical psychiatry. 1995;56:37-42.
4480.	Fazzino F, Montes C, Urbina M, Carreira I, Lima L. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation. Journal of neuroimmunology. 2008;196:173-180.
4481.	FB A, NO T. Intermittent Versus Continuous Sertraline Therapy in the Treatment of Premenstrual Dysphoric Disorders. International journal of fertility and women's medicine. 2001;46:228-231.
4482.	FC F. Treatment of psychotic depression. [Spanish]. Psiquiatria Biologica. 2004;11:144-153.
4483.	FC J, Zhang J. Metabolic Kinetics of 5-Hydroxytryptamine and the Research Targets of Functional Gastrointestinal Disorders. Digestive diseases and sciences. 2014;59:2642-2648.
4484.	FC L-H, MG W, RG T, SC K. Fluoxetine Vs. Tricyclic Antidepressants in Women With Major Depressive Disorder. Journal of women's health. 1997;6:337-343.
4485.	FD A, Baker B. Clinical review of treatment options for major depressive disorder in patients with coronary heart disease. [Review]. Saudi medical journal. 2012;33:1159-1168.
4486.	FD E, Bertschy G. The lactate provocation test to investigate the relationships between panic attacks and psychosis: A report of two cases. World journal of biological psychiatry. 2008;9:154-158.
4487.	FE B, TG D. The clinical efficacy of venlafaxine in the treatment of depression. Reviews in Contemporary Pharmacotherapy. 1998;9:303-320.
4488.	FE B, TG D. Venlafaxine. Pharmacology and therapeutic potential in the treatment of depression. Human psychopharmacology. 1998;13:153-162.
4489.	FE F. Akathisia: Is restlessness a primary condition or an adverse drug effect? Current psychiatry. 2015;14:14-18.
4490.	FE L. Major depression during interferon-alpha treatment: Vulnerability and prevention. Dialogues in clinical neuroscience. 2009;11:417-425.
4491.	FE L, BG P. Aging and clinical pharmacology: Implications for antidepressants. Journal of clinical pharmacology. 2005;45:1106-1122.
4492.	FE M. Strategies for the rapid treatment of depression. Human psychopharmacology. 2001;16:125-132.
4493.	FE T, Allegri R, Vicario A, Bagnatti P, CG L. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. International journal of geriatric psychiatry. 2001;16:254-260.
4494.	Feetam C. Managing bipolar depression: A therapeutic challenge? Progress in neurology and psychiatry. 2011;15:21-25.
4495.	Feetam C. Are two antidepressants always better than one? Progress in neurology and psychiatry. 2012;16:5-8.
4496.	Feiger A, Kiev A, RK S, PG W, CS W. Nefazodone Versus Sertraline in Outpatients With Major Depression: Focus on Efficacy, Tolerability, and Effects on Sexual Function and Satisfaction. Journal of clinical psychiatry. 1996;57:53-62.
4497.	Feighner JP. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. International clinical psychopharmacology. 1992;6 Suppl 4:31-35.
4498.	Feighner JP, Cohn JB, Fabre LF, et al. A study comparing paroxetine placebo and imipramine in depressed patients. Journal of affective disorders. 1993;28:71-79.
4499.	Feil D, Weinreb J, Sultzer D. Psychiatric disorders and psychotropic medication use in elderly persons with diabetes. Annals of long-term care. 2006;14:39-47.
4500.	Feinberg M. Bupropion: new therapy for depression. American family physician. 1990;41:1787-1790.
4501.	Feinstein A. Multiple Sclerosis, Disease Modifying Treatments and Depression: a Critical Methodological Review. Multiple sclerosis (Houndmills, Basingstoke, England). 2000;6:343-348.
4502.	Feinstein A. The Neuropsychiatry of Multiple Sclerosis. Canadian Journal of Psychiatry. 2004;49:157-163.
4503.	Feinstein A. Neuropsychiatric syndromes associated with multiple sclerosis. Journal of neurology. 2007;254:II/73-II/76.
4504.	Feinstein A. Multiple sclerosis and depression. Multiple sclerosis (Houndmills, Basingstoke, England). 2011;17:1276-1281.
4505.	Feinstein A, Magalhaes S, J-F R, Audet B, Moore C. The link between multiple sclerosis and depression. Nature reviews. Neurology. 2014;10:507-517.
4506.	Felicia I, Elena P, Simona S, Daniel D. Rational-emotive and cognitive-behavior therapy (REBT/CBT) versus pharmacotherapy versus REBT/CBT plus pharmacotherapy in the treatment of major depressive disorder in youth; A randomized clinical trial. Psychiatry research. 2015;225:687-694.
4507.	Felix J, Almeida J, Varandas P. A discrete event simulation model in major depressive disorder - cost-effectiveness analysis of agomelatine. Value in health. 2009;Conference:A223.
4508.	Felmet K, Zisook S, JW K. Elderly patients with schizophrenia and depression: Diagnosis and treatment. Clinical schizophrenia & related psychoses. 2011;4:239-250E.
4509.	Feltner D, HU W, Kavoussi R, Brock J, Baldinetti F, AC P. Long-Term Efficacy of Pregabalin in Generalized Anxiety Disorder. International clinical psychopharmacology. 2008;23:18-28.
4510.	Feng X, Nicolas D, Natalya D, Karina H. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International journal of psychiatry in clinical practice. 2009;13:59-69.
4511.	Feng Y, BG P, RE F, MA K, 3rd RCF, RR B. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British journal of clinical pharmacology. 2006;61:558-569.
4512.	Feng Y, XY W, SD L, et al. Clinical research of acupuncture on malignant tumor patients for improving depression and sleep quality. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2011;31:199-202.
4513.	Fenton C, LJ S. Risperidone: A review of its use in the treatment of bipolar mania. CNS drugs. 2005;19:429-444.
4514.	Ferenc M. Post-traumatic stress disorder - Neurobiology, symptoms and pharmacological treatment. [Hungarian]. Psychiatria Hungarica. 2000;15:276-293.
4515.	Ferenc M, Martin D, Karin M, Stephen M. Gender differences in the efficacy of fluoxetime and maprotiline in depressed patients: A double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. European neuropsychopharmacology. 2001;11:227-232.
4516.	Fernandez A, SE B, Srivathsan K, WVR V. Cardiovascular side effects of newer antidepressants. Anadolu Kardiyoloji Dergisi. 2007;7:305-309.
4517.	Fernandez M. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study. [Spanish]. Revista de neurologia. 2009;48:S23.
4518.	Fernandez-De-Las-Penas C, Schoenen J. Chronic tension-type headache: What is new? Current opinion in neurology. 2009;22:254-261.
4519.	Fernandez-Prieto M, Lens M, Lopez-Real A, Puy A, JJ D-S, MJ S. Disorders affecting the emotional sphere and impulse control in Parkinson's disease. [Spanish]. Revista de neurologia. 2010;50:S41-S49.
4520.	Fernando CE, Felipe F, Martins MF, et al. rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex. International journal of neuropsychopharmacology. 2008;11:173-183.
4521.	Fernando K, JD C, CMA F, et al. Childhood-, Teenage-, and Adult-Onset Depression: Diagnostic and Individual Characteristics in a Clinical Sample. Comprehensive psychiatry. 2011;52:623-629.
4522.	Fernando R-V, Jeronimo S-R. Fluvoxamine in the treatment of late-life depression: How much we know coming from randomized controlled trials: Comment on article by Dr Rossini and colleagues [7]. Journal of clinical psychopharmacology. 2007;27:98-99.
4523.	Ferraro L, Antonelli T, Beggiato S, MC T, Fuxe K, Tanganelli S. The vigilance promoting drug modafinil modulates serotonin transmission in the rat prefrontal cortex and dorsal raphe nucleus. possible relevance for its postulated antidepressant activity. Mini reviews in medicinal chemistry. 2013;13:478-492.
4524.	Ferreri F, Agbokou C, Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ : Canadian Medical Association journal. 2006;175:1545-1552.
4525.	Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta psychiatrica Scandinavica. 2001;103:66-72.
4526.	Fessler B. Testing of St John's wort: Also for atypical depression. [German]. Deutsche Apotheker-Zeitung. 2006;146:34-35.
4527.	FG F. Newer aspects of migraine preventive therapies. Drug development research. 2007;68:315-320.
4528.	FH C, HD C, CL G, WF R. Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil). American journal of obstetrics and gynecology. 1999;181:1166-1171.
4529.	FHR C, ALZ R, Maultasch H, DH N, MB V. Depression in Parkinson's disease: Diagnosis and treatment. Arquivos de neuro-psiquiatria. 2012;70:617-620.
4530.	FI T, SM S. Iloperidone, asenapine and lurasidone: A primer on their current status. Expert opinion on pharmacotherapy. 2012;13:1911-1922.
4531.	FI T, ZT S, Pleskow J, SA M. Asperger's syndrome: Diagnosis, comorbidity and therapy. Expert review of neurotherapeutics. 2015;15:281-293.
4532.	Fichter MM, Leibl C, Kruger R, Rief W. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry. 1997;30:85-92.
4533.	Figueroa G. Psychotherapy and pharmacotherapy in the treatment of major depression. [Spanish]. Revista chilena de neuro-psiquiatria. 2002;40:77-95.
4534.	Maintenance Treatment of Major Depression in Old Age, New England journal of medicine(2006).
4535.	Treating depression to remission in older adults: A controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management, International journal of geriatric psychiatry(2010).
4536.	FIII RC, S SG, Amanda DM, et al. Accelerating Symptom-Reduction in Late-Life Depression - a Double-Blind, Randomized, Placebo-Controlled Trial of Sleep Deprivation. The American Journal of Geriatric Psychiatry. 2005;13:353-358.
4537.	Filip M, Bader M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacological Reports. 2009;61:761-777.
4538.	Filippo B, Giulio B, Silvio B, Giuseppe M, Luigi R. Il trattamento farmacologico della distimia: uno studio clinico. / Drug treatment of dysthymia: A clinical study. [Italian]. Rivista di psichiatria. 1997;32:1-5.
4539.	Filippov G, PF C. Vortioxetine (Lu AA21004) 15 and 20 mg/day: Open-label long-term safety and tolerability in major depressive disorder. European neuropsychopharmacology. 2013;Conference:S325.
4540.	Findling R, Bose A, Aquino D, Tourkodimitris S. 24-week double-blind escitalopram treatment of depressed adolescents. Journal of child and adolescent psychopharmacology. 2009;Conference:783.
4541.	Fineberg N, Chamberlain S, Hollander E, Boulougouris V, Robbins T. Translational approaches to obsessive-compulsive disorder: From animal models to clinical treatment. British journal of pharmacology. 2011;164:1044-1061.
4542.	Fini C, Mirigliani A, Biondi M. Gender differences in responses to pharmacological therapy for depressive disorder. [Italian]. Rivista di psichiatria. 2007;42:235-246.
4543.	Fink M, Irwin P. Pharmaco-EEG study of 6-azamianserin (ORG 3770): Dissociation of EEG and pharmacologic predictors of antidepressant activity. Psychopharmacology. 1982;78:44-48.
4544.	Fink M, Irwin P. Pharmaco-EEG study of 6-azamianserin (ORG 3770): dissociation of EEG and biochemical predictors of antidepressant activity. Psychopharmacology bulletin. 1983;19:96.
4545.	Finkenzeller W, Zobel I, Rietz S, Schramm E, Berger M. [Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness]. [German]. Der Nervenarzt. 2009;80:805-812.
4546.	Fiorentino L, Rissling M, Liu L, Ancoli-Israel S. The symptom cluster of sleep, fatigue and depressive symptoms in breast cancer patients: Severity of the problem and treatment options. Drug discovery today. Disease models. 2011;8:167-173.
4547.	Fisch C, SB K. Electrocardiographic findings in sertraline depression trials. Drug Investigation. 1992;4:305-312.
4548.	Fisch M. Use of antidepressants for depression in patients with advanced cancer. Lancet oncology. 2007;8:567-568.
4549.	Fischer K, Goetghebeur E, Vrijens B, IR W. A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments. Biostatistics. 2011;12:247-257.
4550.	Fishbain D, Johnson S, Webster L, Greene L, Faysal J. Review of regulatory programs and new opioid technologies in chronic pain management: Balancing the risk of medication abuse with medical need. Journal of managed care pharmacy. 2010;16:276-287.
4551.	Fishbain D, JR G, Lewis J, Bruns D, LJ M, JM D. Examination of Symptom Clusters in Acute and Chronic Pain Patients. Pain physician. 2014;17:E349-E357.
4552.	Fisher P. Commentary. Focus on Alternative and Complementary Therapies. 2012;17:173-174.
4553.	Fisher S, TA K, SG B. Postmarketing Surveillance by Patient Self-Monitoring - Preliminary Data for Sertraline Versus Fluoxetine. Journal of clinical psychiatry. 1995;56:288-296.
4554.	Fitch K, FJ M, Power B, Wilkins D, Man-Son-Hing M. Antidepressant use in older people: family physicians' knowledge, attitudes, and practices. Canadian family physician Medecin de famille canadien. 2005;51:80-81.
4555.	Fitelson E, Kim S, AS B, Leight K. Treatment of postpartum depression: Clinical, psychological and pharmacological options. International journal of women's health. 2011;3:1-14.
4556.	Fitton A, Faulds D, KL G. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. [Review] [220 refs][Erratum appears in Drugs 1992 Sep;44(3):374], [Erratum appears in Drugs 1993 Jun;45(6):894]. Drugs. 1992;43:561-596.
4557.	Fitzgerald P, SM OB, Scully P, Rijkers K, LV S, TG D. Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychological medicine. 2006;36:37-43.
4558.	Fiuzat M, Jiang W, Oken H, et al. Polyunsaturated fatty acids and omega-3 as predictors of mortality in depressed heart failure (HF) patients. Journal of the American College of Cardiology. 2010;Conference:A25.E233.
4559.	Fiuzat M, Jiang W, Spertus J, et al. Effects of successful depression intervention on health status in patients with chronic heart failure and major depressive disorder: Findings from the SADHART-CHF randomized controlled trial. Journal of cardiac failure. 2009;Conference:S86.
4560.	FJ A, Ros S. Effects of Comorbidity and Polypharmacy on the Clinical Usefulness of Sertraline in Elderly Depressed Patients: an Open Multicentre Study. Journal of affective disorders. 1997;46:285-291.
4561.	FJ C-A. [Post-stroke depression (II): its differential diagnosis, complications and treatment]. [Review] [107 refs] [Spanish]. Revista de neurologia. 2006;42:238-244.
4562.	FJ C-A. Post-stroke depression: Can prediction help prevention? Future neurology. 2010;5:569-580.
4563.	FJ dA, LA G-R. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Archives of general psychiatry. 2008;65:795-803.
4564.	FJ F, LD P, JJ J, AB J, LA Z, PP R-B. Pharmacological treatment of anxiety disorders: Current treatments and future directions. Journal of anxiety disorders. 2012;26:833-843.
4565.	FJ F, Schmauss M. The role of venlafaxine in psychiatric pharmacotherapy. [German]. Psychopharmakotherapie. 1996;3:152-157.
4566.	FJ H, WA Z, Kupka R. The applicability of antidepressants in the depressed medically ill: an open clinical trial with fluoxetine. Journal of psychosomatic research. 1994;38:695-703.
4567.	FJ K, RA S, TJ S, et al. Effects of coping skills training and sertraline in patients with non-cardiac chest pain: A randomized controlled study. Pain. 2011;152:730-741.
4568.	FJ O, Hernandez-Herrero C, M-J M-A, Garrido J, Armenteros S, Velasco J. Fluoxetine Bentazepam Combination in the Treatment of Dysthymic Disorders. Current therapeutic research, clinical and experimental. 1994;55:519-531.
4569.	FJ P. Developmental risks associated with use of psychoactive drugs during pregnancy are largely unknown. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2014;36:359.
4570.	FJ S, Freemantle N, TA S, et al. Selective Serotonin Reuptake Inhibitors - Metaanalysis of Efficacy and Acceptability. British medical journal. 1993;306:683-687.
4571.	FJ SJ, Luthra R, EA S, et al. A Randomized Controlled Trial of Sertraline to Prevent Posttraumatic Stress Disorder in Burned Children. Journal of child and adolescent psychopharmacology. 2011;21:469-477.
4572.	FJ VA, ME T, PPA M, et al. A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up. Journal of clinical psychiatry. 2010;71:574-586.
4573.	FJ VA, Wjpj VH, Ppamm H, et al. Is a Combined Therapy More Effective Than Either Cbt or Ssri Alone? Results of a Multicenter Trial on Panic Disorder With or Without Agoraphobia. Acta psychiatrica Scandinavica. 2008;117:260-270.
4574.	FJ VB. Mirtazapine - A new activity principle. [German]. Therapie und Erfolg Neurologie Psychiatrie. 1997;11:921-924.
4575.	FJ W, SJ R, PJ G, AN H, LM A. Early Improvement in Pain Predicts Pain Response at Endpoint in Patients With Fibromyalgia. Journal of pain. 2011;12:1088-1094.
4576.	FJE V, Solinas C. Current approaches to management of depression in Parkinson's Disease. Journal of clinical neuroscience. 2005;12:739-743.
4577.	FK G. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Journal of clinical psychiatry. 2003;64:18-24.
4578.	FK G, MA G. Optimizing lithium treatment in bipolar disorder: A review of the literature and clinical recommendations. Journal of psychiatric practice. 2003;9:333-343.
4579.	FK J, Moore K, TR N, GD B, RK G, Parker G. A Multicenter Double-Blind Trial of Fluoxetine Versus Amitriptyline in the Treatment of Depressive-Illness. Australian and New Zealand journal of psychiatry. 1993;27:49-55.
4580.	Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings, Archives of general psychiatry(2011).
4581.	FL R, MGR M, BP S, Hara C, Fuzikawa C. Antidepressants for Depression in Parkinson's Disease: Systematic Review and Meta-Analysis. Journal of psychopharmacology (Oxford, England). 2013;27:417-423.
4582.	Flaster M, Meresh E, Rao M, Biller J. Central poststroke pain: Current diagnosis and treatment. Topics in stroke rehabilitation. 2013;20:116-123.
4583.	Flaster M, Sharma A, Rao M. Poststroke depression: A review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery. Topics in stroke rehabilitation. 2013;20:139-150.
4584.	Flechtner-Mors M, CP J, Alt A, Adler G, HH D. Metabolism in Adipose Tissue in Response to Citalopram and Trimipramine Treatment - an in Situ Microdialysis Study. Journal of psychiatric research. 2008;42:578-586.
4585.	Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacology bulletin. 2011;44:57-90.
4586.	Fleurence R, Williamson R, YH J, et al. A systematic review of augmentation strategies for patients with major depressive disorder. [Review]. Psychopharmacology bulletin. 2009;42:57-90.
4587.	Flint A. The impact of treatment resistance on depressive relapse following electroconvulsive therapy. Acta psychiatrica Scandinavica. 1997;96:405-406.
4588.	Flock A, Zobel A, Bauriedel G, et al. Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. Thrombosis research. 2010;126:e83-87.
4589.	Flock A, Zobel A, Bauriedel G, et al. Antiplatelet Effects of Antidepressant Treatment: a Randomized Comparison Between Escitalopram and Nortriptyline. Thrombosis research. 2010;126:E83-E87.
4590.	Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: Open-label long-term safety and tolerability study in major depressive disorder. European neuropsychopharmacology. 2012;Conference:S255-S256.
4591.	Flores RM, Ontiveros UM, Cortes SJ. Continuous versus intermittent treatment with citalopram in premenstrual dysphoric disorder. [Spanish]. Salud mental (Mexico City, Mexico). 2003;26:37-45.
4592.	Florian N, Solene MA, Bruno F. Antidepressant response in major depressive disorder: A meta-regression comparison of randomized controlled trials and observational studies. PloS one. 2011;6.
4593.	Florkowski A, Gruszczy?ski W, Ga?ecki P, Zboralski K, Ko?odziejska I, Miko?ajczyk I. [Trazodone and venlafaxine in treatment of depressive disorders]. Polski merkuriusz lekarski. 2005;18:556-559.
4594.	Flory R, Ametepe J, Bowers B. A Randomized, Placebo-Controlled Trial of Bright Light and High-Density Negative Air Ions for Treatment of Seasonal Affective Disorder. Psychiatry research. 2010;177:101-108.
4595.	Flynn LCV, T DL, E FC, et al. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's disease study 2. The American Journal of Geriatric Psychiatry. 2014;22:14-24.
4596.	FM E, Aydin N, Sati-Kirkan T. Chewing gum may be an effective complementary therapy in patients with mild to moderate depression. Appetite. 2013;65:31-34.
4597.	FM M. Monitoring treatment in neuropsychiatry. Neurology. 2006;66:1615.
4598.	FM Q. Placebos, Drug Effects, and Study Design: a Clinician's Guide. American journal of psychiatry. 1999;156:829-836.
4599.	FM Q, BP T, Kremer C. Does Mirtazapine Have a More Rapid Onset Than Ssris? Journal of clinical psychiatry. 2001;62:358-361.
4600.	FM Q, JW S, PJ M, et al. Are there differences between women's and men's antidepressant responses? American journal of psychiatry. 2002;159:1848-1854.
4601.	FM Q, PJ M, JW S, et al. Remission Rates With 3 Consecutive Antidepressant Trials: Effectiveness for Depressed Outpatients. Journal of clinical psychiatry. 2005;66:670-676.
4602.	FM Q, PJ M, JW S, et al. Chronological Milestones to Guide Drug Change - When Should Clinicians Switch Antidepressants? Archives of general psychiatry. 1996;53:785-792.
4603.	FM V. An 8-Week, Open-Label Trial of Duloxetine for Comorbid Major Depressive Disorder and Chronic Headache. Journal of clinical psychiatry. 2008;69:1449-+.
4604.	Fogden E, Neuberger J. Alternative medicines and the liver. Liver international. 2003;23:213-220.
4605.	Foley P, Lawler A, Chandran S, Mead G. Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: Systematic review and meta-analysis. Journal of neurology, neurosurgery, and psychiatry. 2014;85:709-710.
4606.	Folkerts HW, Michael N, Tolle R, Schonauer K, Mucke S, Schulze-Monking H. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study. Acta psychiatrica Scandinavica. 1997;96:334-342.
4607.	Foltz R. The mistreatment of mood disorders in youth. Ethical human psychology and psychiatry. 2006;8:147-155.
4608.	Fonagy P, Roth A, Higgitt A. Psychodynamic psychotherapies: Evidence-based practice and clinical wisdom. Bulletin of the Menninger Clinic. 2005;69:1-58.
4609.	Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: A systematic qualitative review. Acta psychiatrica Scandinavica. 2014;129:163-179.
4610.	Fonseca L, Rodrigues M, Machado A. Psychogenic movement disorder after a venlafaxine-induced dystonia. Movement disorders. 2010;25:506-507.
4611.	Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clinical neuropharmacology. 1993;16:S45-S50.
4612.	Fontenelle L, Marques C, Figueira I, AE N, Versiani M. The effect-size of clomipramine in obsessive-compulsive disorder. [Portuguese]. Jornal brasileiro de psiquiatria. 1998;47:131-143.
4613.	Fooladi E, RJ B, SR D. Management strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric. 2012;15:306-316.
4614.	Fora F, Galvez-Ortiz V, Cardoner-Alvarez N, et al. Tolerability and Profile of the Side Effects of Bupropion. Actas espanolas de psiquiatria. 2011;39:20-26.
4615.	Forbes D, Creamer M, Phelps A, et al. Australian guidelines for the treatment of adults with acute stress disorder and post-traumatic stress disorder. Australian and New Zealand journal of psychiatry. 2007;41:637-648.
4616.	Forchheimer M, DG T, Kalpakjian C, Chiodo A. Subject retention in a clinical trial of an antidepressant for treatment of mild to moderate depressive symptoms in people with SCI. Topics in spinal cord injury rehabilitation. 2013;Conference:25-26.
4617.	Ford N. The treatment of major depression in adolescents. Australian Journal of Psychopharmacology. 1999;9:36-42.
4618.	Fornaro M. A systematic review on agomelatine. [Italian]. Italian Journal of Psychopathology. 2009;15:302-309.
4619.	Fornaro M. Beyond monoamines towards the development of novel antidepressants. Journal of Psychopathology. 2012;18:226-233.
4620.	Fornaro M, Giosue P. Current nosology of Treatment Resistant Depression: A controversy resistant to revision. Clinical practice and epidemiology in mental health. 2010;6:20-24.
4621.	Fornaro M, Martino M, C DP, Moussaoui D. The argument of antidepressant drugs in the treatment of bipolar depression: Mixed evidence or mixed states? Expert opinion on pharmacotherapy. 2012;13:2037-2051.
4622.	Fornaro M, Martino M, Mattei C, et al. Duloxetine-Bupropion Combination for Treatment-Resistant Atypical Depression: a Double-Blind, Randomized, Placebo-Controlled Trial. European neuropsychopharmacology. 2014;24:1269-1278.
4623.	Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Current neuropharmacology. 2010;8:287-304.
4624.	Fornaro P, Lippi P, Allegretti M. The dexamethasone suppression test in the selection of the treatment and in the choice of antidepressant drug. [Italian]. Minerva psichiatrica. 1992;33:177-183.
4625.	Fornaro P, Venuti S, Fornaro M, Sartore F, Gabrielli F. Ophthalmological side effects of antidepressant, anxiolytic and mood stabilizer agents. [Italian]. Minerva psichiatrica. 2005;46:301-313.
4626.	Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: A randomized controlled trial. Journal of orofacial pain. 2004;18:131-137.
4627.	Forsthoff A, Born C, Grunze H. Puzzling bipolar disorder. [German]. MMW Fortschritte der Medizin. 2005;147:32-38.
4628.	Fountoulakis K, Kantartzis S, Siamouli M, et al. Peripheral thyroid dysfunction in depression. World journal of biological psychiatry. 2006;7:131-137.
4629.	Fournier JP, Lane RM, Chouinard G, et al. A double-blind comparison of sertraline and imipramine in outpatients with major depression: Acute (8 weeks) and continuation (16 weeks) treatment. Human Psychopharmacology: Clinical and Experimental. 1997;12:203-215.
4630.	Fouzia L-T, G PB, C MM, H MB, Linda A, S FM. Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Psychopharmacology bulletin. 1995;31:659-663.
4631.	FP B, RK M, PV T. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert opinion on investigational drugs. 2003;12:531-543.
4632.	FP B, TC L, MP K, MJ D, Iyengar S. The Dual Transporter Inhibitor Duloxetine: a Review of Its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression. Current pharmaceutical design. 2005;11:1475-1493.
4633.	FP B, TC L, MP K, MJ D, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. [Review] [132 refs]. Current pharmaceutical design. 2005;11:1475-1493.
4634.	FR C, KA F. Switching antidepressant drug therapy helps some patients some of the time - What TORDIA, STAR*D, and observational research have taught us about treatment-resistant depression. Journal of managed care pharmacy. 2008;14:468-473.
4635.	FR L, Mariani J, DJ B, et al. A Randomized Double-Blind, Placebo-Controlled Trial of Venlafaxine-Extended Release for Co-Occurring Cannabis Dependence and Depressive Disorders. Addiction (Abingdon, England). 2013;108:1084-1094.
4636.	FR S, JB S, Campeas R, et al. Buspirone in Social Phobia. Journal of clinical psychopharmacology. 1993;13:251-256.
4637.	FR S, KD B, Kishon R, Amsel L, HB S. Escitalopram for persistent symptoms of generalized anxiety disorder after CBT: a pilot study. Journal of nervous and mental disease. 2010;198:458-461.
4638.	FR T. Kleptomania and potential exacerbating factors: A review and case report. Innovations in clinical neuroscience. 2011;8:35-39.
4639.	FR W. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology. 2013;67:304-317.
4640.	Fraguas R, RM dST, TCTF A, et al. A Double-Blind, Placebo-Controlled Treatment Trial of Citalopram for Major Depressive Disorder in Older Patients With Heart Failure: the Relevance of the Placebo Effect and Psychological Symptoms. Contemporary clinical trials. 2009;30:205-211.
4641.	Francesco B, Cristina C, Adriana P, Alessandro B, Marcello F, Enrico S. Morning light treatment hastens the antidepressant effect of citalopram: A placebo-controlled trial. Journal of clinical psychiatry. 2003;64:648-653.
4642.	Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. Journal of clinical psychiatry. 1997;58:104-107.
4643.	Franchini L, Gasperini M, Smeraldi E. A 24-month follow-up study of unipolar subjects: A comparison between lithium and fluvoxamine. Journal of affective disorders. 1994;32:225-231.
4644.	Franchini L, Gasperini M, Zanardi R, Smeraldi E. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. Journal of affective disorders. 2000;58:233-236.
4645.	Franchini L, Rossini D, Bongiorno F, Spagnolo C, Smeraldi E, Zanardi R. Will a Second Prophylactic Treatment With a Higher Dosage of the Same Antidepressant Either Prevent or Delay New Depressive Episodes? Psychiatry research. 2000;96:81-85.
4646.	Franchini L, Zanardi R, Gasperini M, Smeraldi E. Two-Year Maintenance Treatment With Citalopram, 20 Mg, in Unipolar Subjects With High Recurrence Rate. Journal of clinical psychiatry. 1999;60:861-865.
4647.	Franciskovic T, Sukovic Z, Janovic S, et al. Tianeptine in the Combined Treatment of Combat Related Posttraumatic Stress Disorder. Psychiatria Danubina. 2011;23:257-263.
4648.	Franco B. Fluoxetine and olanzapine for resistant depression. American journal of psychiatry. 2002;159:155.
4649.	Franco B. How to treat bipolar II depression and bipolar II mixed depression? [References]. International journal of neuropsychopharmacology. 2004;7:105-106.
4650.	Franco B, Michael B, A FM, Wei W, Alessandra B, Mauricio T. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: A post hoc analysis. Journal of clinical psychiatry. 2009;70:1424-1431.
4651.	Franco K, Malhotra S. Poststroke depression. American journal of psychiatry. 2001;158:658-660.
4652.	Franco K, Malhotra S, RG R. Poststroke depression [11] (multiple letters). American journal of psychiatry. 2001;158:658-660.
4653.	Francois C, Pierre S. "Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data": Comment. Lancet. 2004;364:660.
4654.	Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: Comparison of cost-effectiveness between the other SSRIS and SNRI for the treatment of depression and estimation of the budgetary impact. Journal of medical economics. 2002;5:91-107.
4655.	Francois L, Nancy F-S. Sertraline for treatment of depression in acute coronary syndromes: Comment. JAMA: Journal of the American Medical Association. 2002;288:2403.
4656.	Francomano A, Bonanno B, Fuca L, M lP, D lB. The role of antidepressant treatments on cognitive deficits a review of recent literature. Clinical Neuropsychiatry. 2011;8:354-366.
4657.	Frank E, Cassano GB, Rucci P, et al. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychological medicine. 2011;41:151-162.
4658.	Frank E, DJ K, Rucci P, et al. Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach. Psychological medicine. 2012;42:865-873.
4659.	Frank E, JF K, AJ R. Efficacy of treatments for major depression. Psychopharmacology bulletin. 1993;29:457-475.
4660.	Frank E, JM C, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Archives of general psychiatry. 2002;59:905-911.
4661.	Frank E, Maggi L, Miniati M, Benvenuti A. The rationale for combining interpersonal and social rhythm therapy (IPRST) and pharmacotherapy for the treatment of bipolar disorders. Clinical Neuropsychiatry. 2009;6:63-74.
4662.	Frank E, MK S, Rucci P, et al. Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. American journal of psychiatry. 2000;157:1101-1107.
4663.	Frank L, DA R, SV S, YC S. The economics of selective serotonin reuptake inhibitors in depression: a critical review. [Review] [97 refs]. CNS drugs. 2001;15:59-83.
4664.	Frank MG, Hendricks SE, Burke WJ, Johnson DR. Clinical response augments NK cell activity independent of treatment modality: A randomized double-blind placebo controlled antidepressant trial. Psychological medicine. 2004;34:491-498.
4665.	Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controll, BMC psychiatry(2013).
4666.	Frans dJ. Sertraline and imipramine for the treatment of dysthymia. Archives of general psychiatry. 1997;54:973.
4667.	Frans dJ, Marielle H, Gerda vA, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. The British Journal of Psychiatry. 2004;185:37-45.
4668.	Frantz S. Antidepressant use in children questioned. Nature reviews. Drug discovery. 2003;2:939.
4669.	Frantz S. Pharma faces major challenges after a year of failures and heated battles. Nature reviews. Drug discovery. 2007;6:5-7.
4670.	Fratucci DGJI, Mieko OAC, Ferreira ST, Shigueto ML, Goi RM, Bojikian MB. Antidepressant treatment decreases daily salt intake and prevents heart dysfunction following subchronic aortic regurgitation in rats. Physiology & behavior. 2015;144:124-128.
4671.	Frazer A, MM K. Mechanisms of antidepressant action: Is onset early or late? Drug discovery today. Disease mechanisms. 2004;1:429-433.
4672.	Frazzetto G. The drugs don't work for everyone. Doubts about the efficacy of antidepressants renew debates over the medicalization of common distress. EMBO reports. 2008;9:605-608.
4673.	Genetic polymorphisms in the treatment of depression: Speculations from an augmentation study using atomoxetine, Psychiatry research(2010).
4674.	Freedman R, DA L, Michels R, et al. 2012 in review. American journal of psychiatry. 2012;169:1233-1237.
4675.	Freeman C. Psychological and drug therapies for post-traumatic stress disorder. Psychiatry. 2006;5:231-237.
4676.	Freeman C, Lewis I, JM H. Neuropsychiatric Symptoms in Patients With Thymoma-Associated and Non-Thymoma Myasthenia Gravis. South African Journal of Psychiatry. 2014;20:50-53.
4677.	Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic Analysis of Antidepressants for Major Depressive Disorder in the United Kingdom. PharmacoEconomics. 2000;18:143-148.
4678.	Freeman M. Omega-3 fatty acids: Complementary and alternative medicine in psychiatry. Primary psychiatry. 2009;16:25-27.
4679.	Freemantle N. The review by Weinmann and colleagues. Psychopharmacology. 2008;199:131-134.
4680.	Freemantle N, Drummond M. Should clinical trials with concurrent economic analyses be blinded? Journal of the American Medical Association. 1997;277:63-64.
4681.	Freemantle N, IM A, Young P. Predictive Value of Pharmacological Activity for the Relative Efficacy of Antidepressant Drugs - Meta-Regression Analysis. British journal of psychiatry. 2000;177:292-302.
4682.	Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. PharmacoEconomics. 1997;12:10-16.
4683.	Freemantle N, Tharmanathan P. Meta Analysis of Randomised Controlled Trials Describing the Effectiveness of Venlafaxine in the Treatment of Major Depressive Disorder. European psychiatry. 2007;22:S229.
4684.	Freemantle N, Tharmanathan P, Bauer M, HJ M. Meta Analysis of Randomised Controlled Trials of Venlafaxine in the Treatment of Major Depressive Disorder. European neuropsychopharmacology. 2007;17:S359.
4685.	Fregni F, Ono CR, Santos CM, et al. Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology. 2006;66:1629-1637.
4686.	Fregni F, Pascual-Leone A. Transcranial magnetic stimulation for the treatment of depression in neurologic disorders. Current psychiatry reports. 2005;7:381-390.
4687.	Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry. 2004;75:1171-1174.
4688.	French L. Approach to the perimenopausal patient. Journal of family practice. 2002;51:271-276.
4689.	Frenette E, CA K. Primary hypersomnias of central origin. Seminars in neurology. 2009;29:354-367.
4690.	Frenk P, Marcus H, Jeffrey R, et al. The clinical effectiveness of evidence-based interventions for depression: A pragmatic trial in routine practice. Journal of affective disorders. 2013;145:349-355.
4691.	Freudenreich O, HW G, KL C, et al. Psychiatric Treatment of Persons With Hiv/Aids: an Hiv-Psychiatry Consensus Survey of Current Practices. Psychosomatics. 2010;51:480-488.
4692.	Freudenstein U, Jagger C, Arthur A, Donner-Banzhoff N. Treatments for late life depression in primary care - A systematic review. Family practice. 2001;18:321-327.
4693.	Freund N, BS T, Denormandie J, Vaccarro K, SL A. Windows of vulnerability: maternal separation, age, and fluoxetine on adolescent depressive-like behavior in rats. Neuroscience. 2013;249:88-97.
4694.	Freynhagen R, Muth-Selbach U, Lipfert P, et al. The Effect of Mirtazapine in Patients With Chronic Pain and Concomitant Depression. Current medical research and opinion. 2006;22:257-264.
4695.	Fric M, Pfuhimann B, Laux G, et al. The Influence of Smoking on the Serum Level of Duloxetine. Pharmacopsychiatry. 2008;41:151-155.
4696.	Friede M, HH HvZ, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry. 2001;34 Suppl 1:S38-41.
4697.	Friedrich M, SE G, GC W. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. [Review]. Clinical therapeutics. 2010;32:1221-1233.
4698.	Frieri M, Argyriou A. Is there a relationship between fibromyalgia and rhinitis? Allergy and asthma proceedings. 2012;33:443-449.
4699.	Friess E, Kuempfel T, Modell S, et al. Paroxetine Treatment Improves Motor Symptoms in Patients With Multiple System Atrophy. Parkinsonism & related disorders. 2006;12:432-437.
4700.	Fritze J. Prescribing patterns of psychotropic drugs in Germany: Results and comments to the Drug Prescription Report 2009. [German]. Psychopharmakotherapie. 2010;17:240-250.
4701.	Fritze J, H-J M. Design of clinical trials of antidepressants: Should a placebo control arm be included? CNS drugs. 2001;15:755-764.
4702.	Fritze J, JB A, Bergmann F, Maier W, H-J M. Antidepressants: Life threatening placebos?. [German]. PsychoNeuro. 2005;31:480-484.
4703.	Fritze J, Schneider B, Weber B. Venlafaxine is not a selective serotonin reuptake inhibitor, but a serotonin norepinephrine reuptake inhibitors, and that is relevant. [German]. Psychoneuro. 2003;29:240-244.
4704.	Froehlich W. Making a case to continue considering treatment with selective serotonin reuptake inhibitors for children with autism spectrum disorders. Current psychiatry reports. 2011;13:170-173.
4705.	Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine's anti-aggressive effects. International journal of neuropsychopharmacology. 2012;15:1351-1371.
4706.	Frohlich P, CM M. Fluoxetine-induced changes in tactile sensation and sexual functioning among clinically depressed women. Journal of sex & marital therapy. 2005;31:113-128.
4707.	Frolich L, Hausner L. Therapy of Dementia With Antipsychotics and Antidepressives. Der Nervenarzt. 2015;86:461-467.
4708.	Frommberger U, RD S, Nyberg E, et al. Comparison Between Paroxetine and Behaviour Therapy in Patients With Posttraumatic Stress Disorder (Ptsd): a Pilot Study. International journal of psychiatry in clinical practice. 2004;8:19-23.
4709.	Frommberger U, RD S, Nyberg E, et al. Comparison Between Paroxetine and Behaviour Therapy in Patients With Posttraumatic Stress Disorder (Ptsd): a Pilot Study. International journal of psychiatry in clinical practice. 2004;8:19-23.
4710.	Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression: A three-month double-blind placebo-controlled study with an open-label long-term follow up. Journal of neurology. 2003;250:347-351.
4711.	FS B, Iannitelli A, Pacitti F, Bersani G. Sleep and biorythm disturbances in schizophrenia, mood and anxiety disorders: A review. Rivista di psichiatria. 2012;47:365-375.
4712.	FS G, EE M, Birmaher B, DR R. Manic Behaviors Associated With Fluoxetine in Three 12- to 18-Year-Olds With Obsessive-Compulsive Disorder. Journal of child and adolescent psychopharmacology. 1998;8:73-80.
4713.	FS M. Fluoxetine - a Spectrum of Clinical-Applications and Postulates of Underlying Mechanisms. Neuroscience and biobehavioral reviews. 1993;17:385-396.
4714.	FS R, J VDB, BCJM VDH, KCB R, JF OH. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. Journal of clinical psychopharmacology. 2000;20:531-537.
4715.	FS W. Anxiety and depression in COPD: A call (and need) for further research. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005;2:199-201.
4716.	FSD C, VL B, JS V, Data-Franca J, JA R, LV L. Escitalopram improves memory deficits induced by maternal separation in the rat. European journal of pharmacology. 2012;695:71-75.
4717.	FT B, Benaur M, Henchcliffe C. Late-life depression: A neuropsychiatric approach. Expert review of neurotherapeutics. 2006;6:65-72.
4718.	FT C, Mabf V, Andreatini R. Dual Monoamine Modulation for the Antidepressant-Like Effect of Lamotrigine in the Modified Forced Swimming Test. European neuropsychopharmacology. 2006;16:451-458.
4719.	FT L, Evers-Casey S. Behavioral Interventions in Tobacco Dependence. Primary Care - Clinics in Office Practice. 2009;36:489-507.
4720.	FT L, Evers-Casey S, BA T, Vachani A. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143:e61S-e77S.
4721.	FT M, DA B. Child and adolescent depression intervention overview: what works, for whom and how well?. [Review]. Child and adolescent psychiatric clinics of North America. 2012;21:299-312.
4722.	Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study, Journal of affective disorders(2012).
4723.	Fu C, Costafreda S, MM R, Donati R, Liu P, Marangell L. Neuroimaging predictors of clinical response and potential markers of treatment with duloxetine in major depressive disorder. Neuropsychopharmacology. 2013;Conference:S344.
4724.	Fu J, Liu Y, Wang Q, Zhao J. Effect of Shuganjieyu capsules on neuronal apoptosis in hippocampal CA3 area and the expression of caspase-3 in the brain of rat depression model. [Chinese]. Journal of Central South University (Medical Sciences). 2012;37:1198-1204.
4725.	Fu J, Liu Y, Wang Q, Zhao J. [Effect of Shuganjieyu capsules on neuronal apoptosis in hippocampal CA3 area and the expression of caspase-3 in the brain of rat depression model]. [Chinese]. Zhong Nan da Xue Xue Bao. 2012;Yi Xue Ban:1198-1204.
4726.	Fu J, YM C. The Efficacy and Safety of 5 Mg/D Vortioxetine Compared to Placebo for Major Depressive Disorder: a Meta-Analysis. Psychopharmacology. 2015;232:7-16.
4727.	Fukui N, Suzuki Y, Sugai T, et al. Promoter Variation in the Catechol-O-Methyltransferase Gene Is Associated With Remission of Symptoms During Fluvoxamine Treatment for Major Depression. Psychiatry research. 2014;218:353-355.
4728.	Fukushima K, Kobuchi S, Shibata M, Takada K, Sugioka N. Decrease in Brain Distribution of Fluvoxamine in Experimental Hyperlipidemic Rats. Journal of pharmacy & pharmaceutical sciences. 2011;14:414-424.
4729.	Fulton B, Benfield P, Chouinard G, et al. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996;52:450-474.
4730.	Fulton B, Mctavish D. Fluoxetine - an Overview of Its Pharmacodynamic and Pharmacokinetic Properties and Review of Its Therapeutic Efficacy in Obsessive-Compulsive Disorder. CNS drugs. 1995;3:305-322.
4731.	Funda G, Okan C, Erdal V, Cengiz T, Ercan A. [Combination therapy using sertraline with sleep deprivation and light therapy compared to sertraline monotherapy for major depressive disorder]. [Turkish]. Turk psikiyatri dergisi [Turkish journal of psychiatry]. 2005;16:245-251.
4732.	Fung K, C-L D. Postpartum depression among immigrant women. Current opinion in psychiatry. 2010;23:342-348.
4733.	Furmark T, Appel L, Michelgard A, et al. Cerebral Blood Flow Changes After Treatment of Social Phobia With the Neurokinin-1 Antagonist Gr205171, Citalopram, or Placebo. Biological psychiatry. 2005;58:132-142.
4734.	Furmark T, Appel L, Michelgard A, et al. Cerebral Blood Flow Changes After Treatment of Social Phobia With the Neurokinin-1 Antagonist Gr205171, Citalopram, or Placebo. Biological psychiatry. 2005;58:132-142.
4735.	Furukawa T, DL S, LT Y. Review: Antidepressants plus benzodiazepines lead to fewer drop outs and less depression severity in major depression. Evidence-based medicine. 2001;6:184.
4736.	Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: The potential role of sigma-1 receptors. International journal of neuropsychopharmacology. 2010;Conference:73-74.
4737.	Fusar-Poli P, Lazzaretti M, Ceruti M, et al. Depression after lung transplantation: causes and treatment. [Review] [70 refs]. Lung. 2007;185:55-65.
4738.	Fusar-Poli P, Picchioni M, Martinelli V, et al. Anti-depressive therapies after heart transplantation. [Review] [110 refs]. Journal of heart and lung transplantation. 2006;25:785-793.
4739.	Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. Journal of psychiatric research. 2004;38:323-325.
4740.	Fux M, Taub M, Zohar J. Emergence of Depressive Symptoms During Treatment for Panic Disorder With Specific 5-Hydroxytryptophan Reuptake Inhibitors. Acta psychiatrica Scandinavica. 1993;88:235-237.
4741.	FV K, Leibenluft E, Stringaris A, GV P. Irritability in children and adolescents: Past concepts, current debates, and future opportunities. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2013;35:S32-S39.
4742.	FW L. Recognizing and Treating Premenstrual Dysphoric Disorder in the Obstetric, Gynecologic, and Primary Care Practices. Journal of clinical psychiatry. 2000;61:9-16.
4743.	FW L, Rickels K. Desvenlafaxine Succinate for the Treatment of Major Depressive Disorder. Expert opinion on pharmacotherapy. 2008;9:2129-2136.
4744.	FW L, TN F. Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010;11:423-439.
4745.	FW R, Chouinard G, CK C, et al. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of clinical psychiatry. 1990;51 Suppl B:18-27.
4746.	FW R, DR W, Byerley B, Brainard J, BI G. Characteristics of responders to fluoxetine. Psychopharmacology bulletin. 1984;20:70-72.
4747.	FW R, LA C, SR B, JA J, JA A. A Multicenter Evaluation of the Efficacy and Safety of 150 and 300 Mg/D Sustained-Release Bupropion Tablets Versus Placebo in Depressed Outpatients. Clinical therapeutics. 1998;20:505-516.
4748.	FW R, MF W, WF B. The introductory placebo washout: A retrospective evaluation. Psychiatry research. 1989;30:191-199.
4749.	FW R, RE S, BK M, DW H, PH W. Factors Affecting Return of Symptoms 1 Year After Treatment in a 62-Week Controlled Study of Fluoxetine in Major Depression. Journal of clinical psychiatry. 2001;62 Suppl 2:16-23.
4750.	FW R, WF B, MF W, BJ L, PH W. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacology bulletin. 1988;24:200-205.
4751.	FY T, XW X, SY H, SH S. [Effect of BST on synapse protein SYT and SYN in the hippocampus of chronic stress depression in rats]. [Chinese]. Zhong Nan da Xue Xue Bao. 2006;Yi Xue Ban:687-691.
4752.	G AB, K SE, E KT, Olli-Pekka M, T MT, H NH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Journal of clinical psychiatry. 2001;62:448-452.
4753.	G AD, Gianotti L, Mondelli V, Quartesan R, Fassino S. The psychopharmacotherapy of anorexia nervosa: Clinical, neuroendocrine and metabolic aspects. Journal of endocrinological investigation. 2004;27:975-981.
4754.	A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression, Journal of clinical psychiatry(2011).
4755.	G DI, Matarazzo I, L DT, Martinotti G. Treatment-resistant insomnia treated with pregabalin. European review for medical and pharmacological sciences. 2013;17:1552-1554.
4756.	G dI, Stefano M, Tiziano A, et al. Antidepressants and Sleep: Neurophysiology and Clinical Correlates. Current psychiatry reviews. 2012;8:2-13.
4757.	G DT. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. Journal of clinical psychiatry. 2001;62:48-52.
4758.	G ET, I HW, C-C H, K-H H, H-Y L. N-methyl-D-aspartate mechanism of depression and a glycine transporter-I inhibitor, N-methylglycine (sarcosine) for the treatment of depression. Neuropsychopharmacology. 2011;Conference:S304.
4759.	G FJ, Kenji T, G RR. Risk factors for and correlates of poststroke depression following discontinuation of antidepressants. Journal of neuropsychiatry and clinical neurosciences. 2007;19:399-405.
4760.	G FM. Immunologic dimensions in major depressive disorder: An evaluation of clinical predictors and antidepressant immunomodulation in vivo and in vitro. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2002;62:5019.
4761.	G GA, R HP, H MB, et al. Course and rate of antidepressant response in the very old. Journal of affective disorders. 2002;69:177-184.
4762.	G GC. Recognition and management of depression in the elderly. International clinical psychopharmacology. 1997;12:S31-S36.
4763.	G KD, Young-Hoon S, L HT, et al. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: A 31-phosphorus magnetic resonance spectroscopy study. Journal of affective disorders. 2011;135:354-361.
4764.	G KS. Beyond remission: Rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study. CNS spectrums. 2006;11:28-34.
4765.	G KS, Anjana B, Dayong L, Khalil S, Chetan G. Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial. Journal of clinical psychiatry. 2006;67:1767-1775.
4766.	Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: Analysis of data from the PREVENT study, Journal of clinical psychiatry(2014).
4767.	G KS, Dayong L, Yongcai M, Sara L, F AH, I PG. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS spectrums. 2009;14:326-333.
4768.	G KS, F SA, E TM, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. American journal of psychiatry. 2000;157:1445-1452.
4769.	G KS, H KJ, Saeeduddin A, et al. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: A secondary analysis of data from the PREVENT study. International clinical psychopharmacology. 2008;23:357-363.
4770.	A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy, Journal of clinical psychiatry(2008).
4771.	G KS, M WM, H MC, G WJ, E SD. Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials. Journal of clinical psychiatry. 2006;67:761-770.
4772.	G LC, E SJ-M, D SC, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study. American journal of psychiatry. 2000;157:1686-1689.
4773.	G LC, Lourdes D, Martin S, et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Archives of general psychiatry. 2003;60:737-746.
4774.	G MV, Panagiotis O, A KN, Constantin P, V KA, R SC. Remission of migraine attacks in a patient with depression who is taking pregabalin. Clinical neuropharmacology. 2008;31:238-240.
4775.	G PA. Citalopram and suicidality in adult major depression and anxiety disorders. Nordic journal of psychiatry. 2006;60:392-399.
4776.	G PB, Fouzia L-T, R WW. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of clinical psychopharmacology. 2000;20:137-140.
4777.	G PB, H MB, Robert N, et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. American journal of psychiatry. 1998;155:1110-1112.
4778.	G PD, Inmaculada G, Fujun W, et al. Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study: Double-blind placebo-controlled study. The British Journal of Psychiatry. 2006;188:346-353.
4779.	G PD, K KD, Durisala D, M HP. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of affective disorders. 2005;89:207-212.
4780.	G PS, T TP, Gustavo A, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Journal of clinical psychopharmacology. 2002;22:174-182.
4781.	G PY, Manolis M, M ZI, Maria T, Nikos V, Michael D. Administration of citalopram before ECT: Seizure duration and hormone responses. Journal of ECT. 2000;16:356-360.
4782.	Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder, Psychoneuroendocrinology(2015).
4783.	Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: A functional magnetic resonance imaging study, Journal of clinical psychiatry(2012).
4784.	G RH, Jochanan H, A SJ, H SA. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. [Review] [140 refs]. Journal of clinical psychiatry. 2006;67:1836-1855.
4785.	G RJ, J WG, C MM, Richard R, Hsing LS. Testosterone Versus Fluoxetine for Depression and Fatigue in Hiv/Aids - a Placebo-Controlled Trial. Journal of clinical psychopharmacology. 2004;24:379-385.
4786.	G RJ, J WG, Richard R. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. American journal of psychiatry. 1999;156:101-107.
4787.	G RR. Dr. Robinson replies. American journal of psychiatry. 2001;158:659-660.
4788.	G RR. Psychiatric management of stroke. Psychiatric annals. 2002;32:121-127.
4789.	G RR. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. [Review] [103 refs]. Biological psychiatry. 2003;54:376-387.
4790.	Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.[Erratum appears in JAMA. 2009 Mar 11;301(10):1024], JAMA - Journal of the American Medical Association(2008).
4791.	G RR, E JR, J MD, et al. "Escitalopram and problem-solving therapy for prevention of poststroke depression: A randomized controlled trial": Correction. JAMA: Journal of the American Medical Association. 2009;301:1024.
4792.	G RR, E JR, Stephan A. "Escitalopram, problem-solving therapy, and poststroke depression": In reply. JAMA - Journal of the American Medical Association. 2008;300:1758-1759.
4793.	G RR, K SS, Carlos C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo-controlled, double-blind study. American journal of psychiatry. 2000;157:351-359.
4794.	G RR, Stephan A. "Incomplete financial disclosure in a study of escitalopram and problem-solving therapy for prevention of post stroke depression": Comment. JAMA: Journal of the American Medical Association. 2009;301:1023-1024.
4795.	G RR, Veselin T, E JR. Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression. The American Journal of Geriatric Psychiatry. 2009;17:682-687.
4796.	G SA, Paolo O, Emanuele B, Marco B, Diana DR. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. The World Journal of Biological Psychiatry. 2011;12:501-515.
4797.	G SJ, F DV, Bruce FH, Copping W. Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Progress in neuro-psychopharmacology & biological psychiatry. 1990;14:791-795.
4798.	G SW, Douglas F. The effects of fluoxetine on symptoms of insomnia in depressed patients. Psychopharmacology bulletin. 1995;31:227-237.
4799.	G VD, Evan B, Ilan F, E KCM. A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. Journal of clinical psychiatry. 2009;70:674-683.
4800.	G VDL, B VH, Warwick J, et al. Functional Brain Imaging and Pharmacotherapy in Social Phobia: Single Photon Emission Computed Tomography Before and After Treatment With the Selective Serotonin Reuptake Inhibitor Citalopram. Progress in neuro-psychopharmacology & biological psychiatry. 2000;24:419-438.
4801.	G VG, GB M, LN H, McCusker J, Bellavance F. St. John's wort or sertraline? Randomized controlled trial in primary care. Canadian family physician M�decin de famille canadien. 2002;48:905-912.
4802.	G VV, Tervonen T, Zhao J, B DB, HL H, Postmus D. Multicriteria benefit-risk assessment using network meta-analysis. Journal of clinical epidemiology. 2012;65:394-403.
4803.	G WA, Idris T, H HME. A Pharmacoeconomic Evaluation of Escitalopram Versus Citalopram in the Treatment of Severe Depression in the United Kingdom. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2005;27:486-496.
4804.	G WA, Jose-Luis F, Clement F, Karina H, Natalya D, Nicolas D. Escitalopram and duloxetine in major depressive disorder: A pharmacoeconomic comparison using UK cost data. PharmacoEconomics. 2008;26:969-981.
4805.	A comparison of initial duloxetine dosing strategies in patients with major depressive disorder, Journal of clinical psychiatry(2007).
4806.	G ZF, E CJ. Chronic benzodiazepine use in general practice patients with depression: An evaluation of controlled treatment and taper-off - Report on behalf of the Dutch Chronic Benzodiazepine Working Group. The British Journal of Psychiatry. 2001;178:317-324.
4807.	G-C Z, W-B F, N-G X, et al. Meta analysis of the curative effect of acupuncture on post-stroke depression. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2012;32:6-11.
4808.	G-J Z, Z-Y S, Liu S, S-H G, J-Q L, J-S L. Clinical Observation on Treatment of Depression by Electro-Acupuncture Combined With Paroxetine. Chinese journal of integrative medicine. 2007;13:228-230.
4809.	G-M C, J-Y Z, Kang B, Lu L, T-D Y, Y-M Q. Application of double syndrome differentiation treatment for depressive neurosis in open wards. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:2815-2817.
4810.	G-Y Z, Y-H P. The efficacy of mirtazapine for acute postroke depression and its effect on post stroke rehabilitation. [Chinese]. Chinese Journal of Cerebrovascular Diseases. 2007;4:164-167.
4811.	GA B. Medications for Obesity: Mechanisms and Applications. Clinics in chest medicine. 2009;30:525-538.
4812.	GA B. Medications for Weight Reduction. Medical clinics of North America. 2011;95:989-1008.
4813.	GA B, CM B, AR P. Anxiety disorders in children and adolescents: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry. 1996;35:1110-1119.
4814.	GA B, DH R. Medical therapy for the patient with obesity. Circulation. 2012;125:1695-1703.
4815.	GA B, FL G. Pharmacological treatment of the overweight patient. Pharmacological reviews. 2007;59:151-184.
4816.	GA B, JM H, CM B, MH M. Treatment of School Refusal: One-Year Follow-up. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:206-213.
4817.	GA B, LK A, JM H, GM R. Imipramine Compliance in Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39:284-291.
4818.	GA B, PWH P. Duloxetine: A review of its pharmacology and use in chronic pain management. Regional anesthesia and pain medicine. 2010;35:294-303.
4819.	GA C. The challenge of diagnosing depression in childhood and adolescence. Journal of affective disorders. 2000;61:S3-S8.
4820.	GA C, SE M. Phenomenology and diagnosis of bipolar disorder in children, adolescents, and adults: Complexities and developmental issues. Development and psychopathology. 2006;18:939-969.
4821.	GA C, SJ C. The Characterization and Treatment of Trichotillomania. Journal of clinical psychiatry. 1996;57:42-49.
4822.	GA C, TB M, JE M, AL C. A Placebo-Controlled, Double-Blind Crossover Study of Fluoxetine in Trichotillomania. American journal of psychiatry. 1991;148:1566-1571.
4823.	GA DC, S-C B, Boeving A, Graf H. Effects of Selective Serotonin Reuptake Inhibitors on Thyroid Function in Depressed Patients With Primary Hypothyroidism or Normal Thyroid Function. Thyroid. 2009;19:691-697.
4824.	GA F. Rational use of antidepressant drugs. Psychotherapy and psychosomatics. 2014;83:197-204.
4825.	GA F, Bernardi M, Tomba E, Rafanelli C. Effects of Gradual Discontinuation of Selective Serotonin Reuptake Inhibitors in Panic Disorder With Agoraphobia. International journal of neuropsychopharmacology. 2007;10:835-838.
4826.	GA F, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms After Selective Serotonin Reuptake Inhibitor Discontinuation: a Systematic Review. Psychotherapy and psychosomatics. 2015;84:72-81.
4827.	GA F, JF G, JC N, et al. Regarding "combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind randomized study": Optimizing initial interventions (multiple letters). Biological psychiatry. 2004;56:535-536.
4828.	GA F, Offidani E. The mechanisms of tolerance in antidepressant action. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:1593-1602.
4829.	GA F, Rafanelli C, Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy: Preliminary findings. Archives of general psychiatry. 1998;55:816-820.
4830.	GA F, Rafanelli C, Silvana G, Canestrari R, MA M. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. American journal of psychiatry. 1998;155:1443-1445.
4831.	GA F, Ruini C. What is the optimal treatment of mood and anxiety disorders? Clinical Psychology: Science and Practice. 2005;12:92-96.
4832.	GA F, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. American journal of psychiatry. 2004;161:1872-1876.
4833.	GA F, Ruini C, Rafanelli C, Grandi S. Cognitive behavior approach to loss of clinical effect during long-term antidepressant treatment: A pilot study. American journal of psychiatry. 2002;159:2094-2095.
4834.	GA F, Ruini C, Tossani E, PM E. How long should drug treatment of depression last? (multiple letters). Medical journal of Australia. 2003;178:526-527.
4835.	GA F, SK P, Sonino N. Treatment of recurrent depression. Expert review of neurotherapeutics. 2006;6:1735-1740.
4836.	GA F, Tomba E. New modalities of assessment and treatment planning in depression: The sequential approach. CNS drugs. 2010;24:453-465.
4837.	GA F, Tomba E, Tossani E. Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Progress in neuro-psychopharmacology & biological psychiatry. 2013;40:306-311.
4838.	GA F, Visani D. Psychosocial determinants of recovery in depression. Dialogues in clinical neuroscience. 2008;10:461-472.
4839.	GA K. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Current pharmaceutical design. 2010;16:2126-2135.
4840.	GA K, Roder-Hanna N, Leggio L, et al. Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: Review of psychopathology and pharmacotherapy. Pharmacogenomics and personalized medicine. 2012;5:19-35.
4841.	GA L. Whither "chronic prostatitis"? Sexually transmitted infections. 2005;81:96-97.
4842.	GA M, MS G, BM F. Assessment of suicidal ideation and behavior in clinical trials: Challenges and controversies. Clinical investigation. 2012;2:265-273.
4843.	GA N, NS W. Quality indicators for the care of depression in vulnerable elders. Journal of the American Geriatrics Society. 2007;55:S302-S311.
4844.	GA VW, Tendolkar I, Urner M, et al. Short-Term Antidepressant Administration Reduces Default Mode and Task-Positive Network Connectivity in Healthy Individuals During Rest. NeuroImage. 2014;88:47-53.
4845.	Ga?ecka E, Kedziora J, Florkowski A, Ga?ecki P. [Copper-zinc superoxide dismutase activity in platelets in patients with depressive disorder treated by fluoxetine--preliminary study]. Polski merkuriusz lekarski. 2007;22:182-185.
4846.	Gabaldon L, Fuentes B, Frank-Garcia A, Diez-Tejedor E. Poststroke depression: Importance of its detection and treatment. Cerebrovascular diseases (Basel, Switzerland). 2007;24:181-188.
4847.	Gabarron E, Garcia-Bayo I, Soler-Vila M, et al. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: A six-month randomised study comparing fluoxetine to imipramine. Journal of affective disorders. 2006;91:153-163.
4848.	Gabor F. Fluvoxamine: A role in the treatment of psychiatric disorders. [Hungarian]. Psychiatria Hungarica. 1993;8:179-190.
4849.	Gabriel DVCU, Alves VE, Avila DMR, Lopes RF. Pharmacological treatment of depression associated with dementia. [Portuguese]. Jornal brasileiro de psiquiatria. 2005;54:236-241.
4850.	Gabriel dVCU, Lopes RF, Avila dMR, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia and geriatric cognitive disorders. 2007;24:36-41.
4851.	Gabriela R, Philipp S, Meline S, et al. Functional neuroanatomy of emotion processing in major depressive disorder is altered after successful antidepressant therapy. Journal of psychopharmacology (Oxford, England). 2012;26:1424-1433.
4852.	Gaffney M. Factor analysis of treatment response in posttraumatic stress disorder. Journal of traumatic stress. 2003;16:77-80.
4853.	GAFG F. Using second-generation antidepressants (SGA) in daily practice. [French]. Annales medico-psychologiques. 2013;171:198-203.
4854.	Gagiano CA, Muller PG, Fourie J, LeRoux JF. The therapeutic efficacy of paroxetine: (a) An open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta neurologica Scandinavica. 1989;80:130-131.
4855.	Gahimer J, Wernicke J, Yalcin I, MJ O, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23 983 subjects. Current medical research and opinion. 2007;23:175-184.
4856.	Gahimer J, Wernicke J, Yalcin I, MJ O, Wulster-Radcliffe M, Viktrup L. A Retrospective Pooled Analysis of Duloxetine Safety in 23 983 Subjects. Current medical research and opinion. 2007;23:173-184.
4857.	Gahr M. Agomelatine in the Treatment of Major Depressive Disorder: an Assessment of Benefits and Risks. Current neuropharmacology. 2014;12:387-398.
4858.	Gahr M, RW F, BJ C, Hiemke C, Schonfeldt-Lecuona C. Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived From Spontaneous Reports of Adverse Drug Reactions. Pharmacopsychiatry. 2013;46:214-220.
4859.	Gaillard R. Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis "Cipriani". [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2009;35:499-504.
4860.	Gaillard R, Salvador A, Vinckier F, et al. Effects of agomelatine compared to escitalopram on motivation in healthy male and female volunteers after 9 weeks of treatment. European neuropsychopharmacology. 2014;Conference:S458-S459.
4861.	Gajwani P. Treatment-refractory bipolar disorder: Classification to aid in clinical management. Expert opinion on pharmacotherapy. 2009;10:1907-1915.
4862.	Gajwani P, DJ M, DE K, Gao K, JR C. Update on quetiapine in the treatment of bipolar disorder: Results from the BOLDER studies. Neuropsychiatric disease and treatment. 2007;3:847-853.
4863.	Gala C, Peirone A, Bellodi S, Pasquare L, Redaelli C. Depression and cognitive impairment in the elderly. [Italian]. Giornale di gerontologia. 2008;56:25-33.
4864.	Galanter M, Glickman L, Singer D. An overview of outpatient treatment of adolescent substance abuse. Substance abuse. 2007;28:51-58.
4865.	Gale S, BL H. Postpartum mood disorders: A review of clinical and epidemiological factors. Journal of psychosomatic obstetrics and gynaecology. 2003;24:257-266.
4866.	Gale S, Croasdell G. 28th annual JPMorgan healthcare conference - Forest laboratories and icagen. IDrugs : the investigational drugs journal. 2010;13:145-148.
4867.	GALG L, Grp V. The Antidepressant Agomelatine in Daily Practice: Results of the Non-Interventional Study Vivaldi. Pharmacopsychiatry. 2012;45:284-291.
4868.	GALG L, VIVALDI-Studiengrp. Treatment of Depression With Agomelatine in Psychiatric Practice: Results of the Vivaldi Study. Psychopharmakotherapie. 2011;18:18-+.
4869.	Gallagher P, AH Y. Mifepristone (RU-486) treatment for depression and psychosis: A review of the therapeutic implications. Neuropsychiatric disease and treatment. 2006;2:33-42.
4870.	Gallagher P, Malik N, Newham J, AH Y, IN F, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane database of systematic reviews (Online). 2008.
4871.	Gallagher P, Watson S, MS S, IN F, AH Y. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biological psychiatry. 2005;57:155-161.
4872.	Galletly C. Sunshine, supplements, CBT and more. Australian and New Zealand journal of psychiatry. 2013;47:199-200.
4873.	Galvez V, O'Keefe E, Cotiga L, et al. Long-lasting effects of a single subcutaneous dose of Ketamine for treating melancholic depression: A case report. Biological psychiatry. 2014;76:e1-e2.
4874.	Gambi F, D DB, Campanella D, et al. Mirtazapine Treatment of Generalized Anxiety Disorder: a Fixed Dose, Open Label Study. Journal of psychopharmacology (Oxford, England). 2005;19:483-487.
4875.	Gang W, Alexander M, R EW, R RS, Hans E. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatric disease and treatment. 2014;10.
4876.	Gang W, Mette G, Gleb F, Stuart M. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: A randomized, double-blind study. Current medical research and opinion. 2015;31:785-794.
4877.	Gao F, AK M, Chen S. Non-parametric estimation for baseline hazards function and covariate effects with time-dependent covariates. Statistics in medicine. 2007;26:857-868.
4878.	Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder, Bipolar disorders(2008).
4879.	Gao K, Gajwani P, Elhaj O, JR C. Typical and atypical antipsychotics in bipolar depression. Journal of clinical psychiatry. 2005;66:1376-1385.
4880.	Gao K, Muzina D, Gajwani P, JR C. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review. Journal of clinical psychiatry. 2006;67:1327-1340.
4881.	Gao X, JM S, JA C, Haider S, VK R. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert review of pharmacoeconomics & outcomes research. 2012;12:335-343.
4882.	Gao Y, GA N, WP J, et al. Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Neuropathic Pain in China. Chinese medical journal. 2010;123:3184-3192.
4883.	GAPGI P. Surrogate Markers of Treatment Outcome in Major Depressive Disorder. International journal of neuropsychopharmacology. 2012;15:841-854.
4884.	Gara N, MG G. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clinical infectious diseases. 2013;56:1629-1636.
4885.	Garattini S. Scientific information: What kind of credibility?. [Italian]. Geriatric and Medical Intelligence. 2004;13:65-66.
4886.	Garattini S, Barbui C, Saraceno B. Antidepressant agents: From tricyclics to serotonin uptake inhibitors. Psychological medicine. 1998;28:1169-1178.
4887.	Garber J. Depression in Children and Adolescents. Linking Risk Research and Prevention. American journal of preventive medicine. 2006;31:104-125.
4888.	Garcia G, GE L, Gonzalez-Heydrich J. Management of Psychotropic Medication Side Effects in Children and Adolescents. Child and adolescent psychiatric clinics of North America. 2012;21:713-738.
4889.	Garcia-Amador M, Pacchiarotti I, Valenti M, RF S, JM G, Vieta E. Role of aripiprazole in treating mood disorders. Expert review of neurotherapeutics. 2006;6:1777-1783.
4890.	Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, Trials [Electronic Resource](2009).
4891.	Effectiveness of the Psychological and Pharmacological Treatment of Catastrophization in Patients With Fibromyalgia: a Randomized Controlled Trial, Trials(2009).
4892.	Garcia-Carrasco M, Jimenez-Hernandez M, RO E, et al. Treatment of Raynaud's phenomenon. Autoimmunity reviews. 2008;8:62-68.
4893.	Garcia-Martin I, EM M-V, CA S. Duloxetine in the Treatment of Adolescents With Somatoform Disorders: a Report of Two Cases. Actas espanolas de psiquiatria. 2012;40:165-168.
4894.	Garcia-Morales I, PDLP M, AM K. Psychiatric comorbidities in epilepsy: Identification and treatment. Neurologist. 2008;14:S15-S25.
4895.	Garcia-Toro M, Mayol A, Arnillas H, et al. Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression. Journal of affective disorders. 2001;64:271-275.
4896.	Garcia-Toro M, Pascual-Leone A, Romera M, et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment for depression. Journal of neurology, neurosurgery, and psychiatry. 2001;71:546-548.
4897.	Gareri P, P DF, S DF, Marigliano N, GF I, G DS. Adverse effects of atypical antipsychotics in the elderly: A review. Drugs & aging. 2006;23:937-956.
4898.	Garland J, O'Rourke L, Robertson D. Autism spectrum disorder in adults: Clinical features and the role of the psychiatrist. Advances in Psychiatric Treatment. 2013;19:378-391.
4899.	Garlow S, Ninan P, Nemeroff C. The first time is best: Highest remission rate to SSRI antidepressant in first episode of treatment for depression. Neuropsychopharmacology. 2010;Conference:S102-S103.
4900.	Garnier C, Diaz B, Alvaro P, et al. Use of antidepressants in the treatment of major depressive disorder in an outpatient mental health center. European neuropsychopharmacology. 2009;Conference:S390-S391.
4901.	Garrett C, Doherty A. Diabetes and mental health. Clinical Medicine, Journal of the Royal College of Physicians of London. 2014;14:669-672.
4902.	Garrett D, Vaughn A, Miller S. Citalopram: A meta-analysis comparing efficacy, dosing and titration. Journal of pharmacy practice. 2012;Conference:276-277.
4903.	Garrido-Mesa N, Zarzuelo A, Galvez J. What is behind the non-antibiotic properties of minocycline? Pharmacological research. 2013;67:18-30.
4904.	Gartlehner G, BN G, RA H, et al. Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians. Annals of internal medicine. 2008;149:734-U313.
4905.	Gartlehner G, BN G, RA H, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. [Review] [319 refs][Summary for patients in Ann Intern Med. 2008 Nov 18;149(10):I56; PMID: 19017586]. Annals of internal medicine. 2008;149:734-750.
4906.	Gartlehner G, CG M. Direct Versus Indirect Comparisons: a Summary of the Evidence. International journal of technology assessment in health care. 2008;24:170-177.
4907.	Gartlehner G, Chapman A, Strobelberger M, Thaler K. Differences in Efficacy and Safety of Pharmaceutical Treatments Between Men and Women: an Umbrella Review. PloS one. 2010;5.
4908.	Gartlehner G, RA H, LC M, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Annals of internal medicine. 2011;155:772-785.
4909.	Gartlehner G, RA H, LC M, et al. Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder an Updated Meta-Analysis. Annals of internal medicine. 2011;155:772-U112.
4910.	Gartlehner G, RA H, TS C, KN L, BN G, LC R. Discontinuation Rates for Selective Serotonin Reuptake Inhibitors and Other Second-Generation Antidepressants in Outpatients With Major Depressive Disorder: a Systematic Review and Meta-Analysis. International clinical psychopharmacology. 2005;20:59-69.
4911.	Gartlehner G, RA H, TS C, KN L, BN G, LC R. Discontinuation Rates for Selective Serotonin Reuptake Inhibitors and Other Second-Generation Antidepressants in Outpatients With Major Depressive Disorder: a Systematic Review and Meta-Analysis. International clinical psychopharmacology. 2005;20:59-69.
4912.	Gartlehner G, Thaler K, Hill S, RA H. How Should Primary Care Doctors Select Which Antidepressants to Administer? Current psychiatry reports. 2012;14:360-369.
4913.	Gartlehner G, Thaler K, RA H, BN G. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. [Review] [69 refs]. Drug safety. 2009;32:1159-1173.
4914.	Gartlehner G, Thieda P, RA H, et al. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. [Review] [136 refs]. Drug safety. 2008;31:851-865.
4915.	Garvey C. Depression in patients with chronic obstructive pulmonary disease. Postgraduate medicine. 2012;124:101-109.
4916.	Garza I, JW S. Prophylaxis of migraine. Neuropsychiatric disease and treatment. 2006;2:281-291.
4917.	Gastpar M. The value of tricyclic antidepressants in modern antidepressive therapy. [German]. Psychopharmakotherapie, Supplement. 2005;12:24-25.
4918.	Gastpar M, Singer A, Zeller K. Efficacy and Tolerability of Hypericum Extract Stw3 in Long-Term Treatment With a Once-Daily Dosage in Comparison With Sertraline. Pharmacopsychiatry. 2005;38:78-86.
4919.	Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: A double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry. 2006;39:66-75.
4920.	Gastpar M, Zeller K. Comparison of hypericum extract STW3 and sertraline in the treatment of mode-rate depression: A double-blind randomized 24-week-study. [German]. Psychopharmakotherapie. 2005;12:146-153.
4921.	Gatti F, Nasta P, Matti A, et al. Treating hepatitis C virus in HIV patients: Are side effects a real obstacle? AIDS reviews. 2007;9:16-24.
4922.	Gaur V, Kumar A. Behavioral, biochemical and cellular correlates in the protective effect of sertraline against transient global ischemia induced behavioral despair: possible involvement of nitric oxide-cyclic guanosine monophosphate study pathway. Brain research bulletin. 2010;82:57-64.
4923.	Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics. 2010;22:346-372.
4924.	Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics. 2002;14:389-404.
4925.	Gawel K. Irritable bowel syndrome: Pathogenesis, symptoms, diagnosis and pharmacotherapy. Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia. 2011;24:177-182.
4926.	Gawlik S, Reck C, Sohn C, Schlehe B. Postpartum depression. Which care is necessary?. [German]. Geburtshilfe und Frauenheilkunde. 2010;70:512-514.
4927.	Gaynor P, Mccarberg B, Zheng W, Shoemaker S, Duenas H. Weight Change With Long-Term Duloxetine Use in Chronic Painful Conditions: an Analysis of 16 Clinical Studies. International journal of clinical practice. 2011;65:341-349.
4928.	GB C, Conti L, Massimetti G, Mengali F, JS W, Levine J. Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo. Psychopharmacology bulletin. 1986;22:52-58.
4929.	GB C, MC J, AMIMAJORGroup. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: A randomized, double-blind, parallel group study. International clinical psychopharmacology. 2002;17:27-32.
4930.	GB L. Coronary artery disease: Exercise or medication keeps patients with coronary heart disease UPBEAT. Nature reviews. Cardiology. 2012;9:553.
4931.	GB P, TM H, WF W, et al. Timing Is Everything: the Onset of Depression and Acute Coronary Syndrome Outcome. Biological psychiatry. 2008;64:660-666.
4932.	GC B, Tyagi A, Huda N, DS M, Sharma P. Comparative efficacy and safety of a herbal preparation along with Shirodhara therapy and fluoxetine in the treatment of major depressive disorder. Indian journal of psychiatry. 2013;Conference:S36.
4933.	GC D. Paroxetine in the Elderly - a Comparative Metaanalysis Against Standard Antidepressant Pharmacotherapy. Pharmacology. 1995;51:137-144.
4934.	GD B, CME K. Mirtazapine: Clinical Advantages in the Treatment of Depression. Journal of clinical psychopharmacology. 1997;17:S34-S39.
4935.	GD B, TR N. Suicide, violent behaviour and fluoxetine: Meta-analysis of clinical trials shows that fluoxetine does not cause or increase suicidal behaviour or violent acts. Medical journal of Australia. 1994;161:404-405.
4936.	GD E, Fass R. Functional gastrointestinal disorders: Venlafaxine is a potential therapy for functional chest pain. Nature Reviews Gastroenterology and Hepatology. 2011;8:14-16.
4937.	GD G, GM L. Factors Affecting Prescribing of the Newer Antidepressants. Annals of pharmacotherapy. 2000;34:10-14.
4938.	GD K, Pacchiarotti I, Manfredi G, et al. Ethical Questions in Human Clinical Psychopharmacology: Should the Focus Be on Placebo Administration? Journal of psychopharmacology (Oxford, England). 2008;22:590-597.
4939.	GD K, Whitmore S, Gottfried B, et al. Fibromyalgia/chronic pain syndrome: An alternative medicine perspective. Critical Reviews in Physical and Rehabilitation Medicine. 2005;17:1-30.
4940.	GD L. Placebo as good as paroxetine for treating acute moderate-to-severe major depression. Medscape journal of medicine. 2008;10:79.
4941.	GD L. Placebo as good as paroxetine for treating acute moderate-to-severe major depression. MedGenMed : Medscape general medicine. 2008.
4942.	GD T, AH R, JH P, et al. A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-Compulsive Disorder. Archives of general psychiatry. 1994;51:559-567.
4943.	GD T, Birkett M, Koran L, et al. Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. Journal of clinical psychiatry. 1994;55:69-78.
4944.	GD T, JC B, JH H, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. International psychogeriatrics / IPA. 1995;7:89-104.
4945.	GD T, ME S. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine. [Review] [55 refs]. Depression and anxiety. 1997;4:294-311.
4946.	GD T, SL T, ME S, MG L. Absence of emergent suicidal ideation during treatment: A comparative, controlled, double-blind analysis employing several distinct antidepressants. Depression. 1994;2:73-79.
4947.	GD T, Souetre E, Thomander L, JH P. Comorbid Anxious Signs and Symptoms in Major Depression - Impact on Functional Work Capacity and Comparative Treatment Outcomes. International clinical psychopharmacology. 1993;8:281-293.
4948.	GE A, IM A, AJ vB, et al. The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up. Journal of affective disorders. 2011;135:201-207.
4949.	Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings, Biological psychiatry(2008).
4950.	Dosing quetiapine in drug-naive first-episode psychosis: A controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years, Journal of clinical psychiatry(2008).
4951.	GE G, CR M, RB K. Omega-3 fatty acids influence mood in healthy and depressed individuals. Nutrition reviews. 2013;71:727-741.
4952.	GE M, C-F H, Hackett M. Selective serotonin reuptake inhibitors for stroke recovery. JAMA - Journal of the American Medical Association. 2013;310:1066-1067.
4953.	GE M, C-F H, Lee R, et al. Selective serotonin reuptake inhibitors for stroke recovery: A systematic review and meta-analysis. Stroke; a journal of cerebral circulation. 2013;44:844-850.
4954.	GE M, CF H, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. [Review]. Cochrane database of systematic reviews (Online). 2012;11:CD009286.
4955.	GE M, Dennis M, Lundstrom E, Murray V, Hackett M, GJ H. Letter by mead et al regarding article, "selective serotonin reuptake inhibitors for stroke: More trials are needed". Stroke; a journal of cerebral circulation. 2013;44:e40-e41.
4956.	GE M, Morley W, Campbell P, CA G, McMurdo M, DA L. Exercise for depression. Cochrane database of systematic reviews (Online). 2008.
4957.	GE R. Place of Psychoactive-Drugs in the Treatment of Premenstrual-Syndrome. CNS drugs. 1994;2:453-464.
4958.	GE R. Depression in the Patient With Chronic Pain. Journal of family practice. 1996;43:S25-S33.
4959.	GE R. Psychotic and Mood Disorders Associated With the Perimenopausal Period - Epidemiology, Aetiology and Management. CNS drugs. 2001;15:175-184.
4960.	GE R. Migraine: Effective pharmacologic strategies for prevention and treatment. Headache and Pain: Diagnostic Challenges, Current Therapy. 2004;15:75-82.
4961.	GE S. The antidepressant quandary - Considering suicide risk when treating adolescent depression. New England journal of medicine. 2006;355:2722-2723.
4962.	GE S. How can we know whether antidepressants increase suicide risk? American journal of psychiatry. 2006;163:1861-1863.
4963.	GE S, EJ L, Tutty S, Operskalski B, M VK. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: A randomized controlled trial. Journal of the American Medical Association. 2004;292:935-942.
4964.	GE S, Heiligenstein J, Revicki D, et al. Long-Term Outcomes of Initial Antidepressant Drug Choice in a "Real World" Randomized Trial. Archives of family medicine. 1999;8:319-325.
4965.	GE S, ML C, RL D. Outcomes of prenatal antidepressant exposure. American journal of psychiatry. 2002;159:2055-2061.
4966.	GE S, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. General hospital psychiatry. 2000;22:153-162.
4967.	GE S, WG M, DJ K, SD P, HJ H, CP H. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Archives of general psychiatry. 2001;58:181-187.
4968.	GE T, JL J, PG OM, Balden E, JE S. Treatment of chronic headache with antidepressants: A meta-analysis. American journal of medicine. 2001;111:54-63.
4969.	Geerts S, Bruynooghe F, H DC, Demeulemeester F, Haazen L. Moclobemide versus fluoxetine for major depressive episodes. Clinical neuropharmacology. 1994;17 Suppl 1:S50-57.
4970.	Geerts S, Bruynooghe F, H DC, Demeulemeester F, Haazen L. Moclobemide versus fluoxetine for major depressive episodes. Clinical neuropharmacology. 1994;17:S50-S57.
4971.	Geller B, Reising D, HL L, MA R, B TW. Critical review of tricyclic antidepressant use in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:513-516.
4972.	Generali J, DJ C. Paroxetine: Hot Flashes. Hospital pharmacy. 2004;39:130-137+190.
4973.	Gentil V, Lotufoneto F, Andrade L, et al. Clomipramine, a Better Reference Drug for Panic/Agoraphobia .1. Effectiveness Comparison With Imipramine. Journal of psychopharmacology (Oxford, England). 1993;7:316-324.
4974.	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection, Therapeutics and clinical risk management(2014).
4975.	Gentile S. SSRIs in pregnancy and lactation: Emphasis on neurodevelopmental outcome. CNS drugs. 2005;19:623-633.
4976.	Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug safety. 2005;28:137-152.
4977.	Gentile S. Serotonin reuptake inhibitor-induced perinatal complications. Pediatric Drugs. 2007;9:97-106.
4978.	Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. Journal of clinical psychopharmacology. 2007;27:35-45.
4979.	Gentile S. Atypical antipsychotics for the treatment of bipolar disorder: More shadows than lights. CNS drugs. 2007;21:367-387.
4980.	Gentile S. A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: Focus on aripiprazole. Neuropsychiatric disease and treatment. 2009;5:117-125.
4981.	Gentile S. Antidepressant use in children and adolescents diagnosed with major depressive disorder: what can we learn from published data?. [Review] [112 refs]. Reviews on recent clinical trials. 2010;5:63-75.
4982.	Georg J, Oliver P, Holger A, et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. Journal of clinical psychiatry. 2007;68:1206-1212.
4983.	Georg N, A MA, Adelheid C, et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology. 2005;181:751-760.
4984.	George H, Hiram M, N YL. Pharmacotherapy of bipolar II disorder: A critical review of current evidence. Bipolar disorders. 2004;6:14-25.
4985.	Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression, Journal of psychopharmacology (Oxford, England)(2011).
4986.	Georgios P, Peter L, Maria G, et al. Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment. Journal of psychiatric research. 2010;44:556-560.
4987.	Gerard S, M BR, Angela C, et al. Addition of the Alpha 2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology. 2004;29:1166-1171.
4988.	Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: Randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. International clinical psychopharmacology. 1994;9:25-29.
4989.	Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology. 1995;119:277-281.
4990.	Gerhard T, Akincigil A, CU C, NJ F, Crystal S, Olfson M. National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression. Journal of clinical psychiatry. 2014;75:490-U206.
4991.	Germain A, DJ K. Circadian rhythm disturbances in depression. Human psychopharmacology. 2008;23:571-585.
4992.	Gerra G, Fertonani G, Zaimovic A, et al. Hostility in Heroin Abusers Subtypes: Fluoxetine and Naltrexone Treatment. Progress in neuro-psychopharmacology & biological psychiatry. 1995;19:1225-1237.
4993.	Gerretsen P, BG P. Pharmacogenetics and the serotonin transporter in late-life depression. [Review] [107 refs]. Expert opinion on drug metabolism & toxicology. 2008;4:1465-1478.
4994.	Gerretsen P, DJ M, Tiwari A, Mamo D, BG P. The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues in clinical neuroscience. 2009;11:363-376.
4995.	Gerrits M, Dogterom P, Hulskotte E, R DG, PAM P. The pharmacokinetics of single dose asenapine during steady-state conditions of cyp450 and UGT modulators. British journal of clinical pharmacology. 2010;Conference:924.
4996.	Gersel PA. Escitalopram and suicidality in adult depression and anxiety. International clinical psychopharmacology. 2005;20:139-143.
4997.	Gerson S, TR B, Kaufman A, Mintz J, Jarvik L. Pharmacological and psychological treatments for depressed older patients: A meta-analysis and overview of recent findings. Harvard review of psychiatry. 1999;7:1-28.
4998.	Gertsik L, RE P, Bresee C, MH R. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. Journal of clinical psychopharmacology. 2012;32:61-64.
4999.	Gervasoni N, Bertschy G. The major depression with psychotic symptoms. [French]. Revue medicale suisse. 2008;4:1984-1987.
5000.	Gervasoni N, Legendre-Simon P, JM A, Gex-Fabry M, Bertschy G, Bondolfi G. Early telephone intervention for psychiatric outpatients starting antidepressant treatment. Nordic journal of psychiatry. 2010;64:265-267.
5001.	Gex-Fabry M, AE B-G, LP B, Rudaz S, JL V, Bertschy G. Time Course of Clinical Response to Venlafaxine: Relevance of Plasma Level and Chirality. European journal of clinical pharmacology. 2004;59:883-891.
5002.	Gex-Fabry M, AE B-G, LP B, Rudaz S, JL V, Bertschy G. Time Course of Clinical Response to Venlafaxine: Relevance of Plasma Level and Chirality. European journal of clinical pharmacology. 2004;59:883-891.
5003.	GF H, Fellerer K, Zochling R, Zentz A, GC D. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta psychiatrica Scandinavica. Supplementum. 1989;350:81-84.
5004.	GF K, G KL, BJ M. Development of pharmacotherapies for drug addiction: A Rosetta stone approach. Nature reviews. Drug discovery. 2009;8:500-515.
5005.	GG K, Lovato J, McQuellon R, Robinson E, HB M. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast journal. 2006;12:114-122.
5006.	GG P, DC S. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007;13:105-117.
5007.	GH G, WD G. SSRIs vs tricyclic antidepressants. Journal of family practice. 1996;42:110.
5008.	GH P, OL H, MH T, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: A pilot study. International journal of geriatric psychiatry. 2008;23:670-676.
5009.	GH V, Tondo L, Undurraga J, RJ B. Overview of antidepressant treatment of bipolar depression. International journal of neuropsychopharmacology. 2013;16:1673-1685.
5010.	GH V, Tondo L, Undurraga J, Zaratiegui R, Selle V, RJ B. Pharmacological treatment of bipolar depression. Advances in Psychiatric Treatment. 2014;20:193-201.
5011.	Ghaeli P, Shahsavand E, Mesbahi M, MZ K, Sadeghi M, Dashti-Khavidaki S. Comparing the Effects of 8-Week Treatment With Fluoxetine and Imipramine on Fasting Blood Glucose of Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2004;24:386-388.
5012.	Ghaleiha A, Jahangard L, Sherafat Z, et al. Oxybutynin Reduces Sweating in Depressed Patients Treated With Sertraline: a Double-Blind, Placebo-Controlled, Clinical Study. Neuropsychiatric disease and treatment. 2012;8:407-412.
5013.	Ghanizadeh A. Nail biting; etiology, consequences and management. Iranian Journal of Medical Sciences. 2011;36:73-79.
5014.	Ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Anti-inflammatory & anti-allergy agents in medicinal chemistry. 2013;12:223-228.
5015.	Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial, Anti-inflammatory & anti-allergy agents in medicinal chemistry(2014).
5016.	Ghasemi M, MH K, Yoosefi A, et al. Rapid Antidepressant Effects of Repeated Doses of Ketamine Compared With Electroconvulsive Therapy in Hospitalized Patients With Major Depressive Disorder. Psychiatry research. 2014;215:355-361.
5017.	Ghaziuddin N, MW N, CA K. Fluoxetine in tricyclic refractory depression in adolescents. Depression. 1995;2:287-291.
5018.	Ghio L, Natta W, Rossi P, et al. Combined venlafaxine and olanzapine prescription in women with psychotic major depression: A case series. Case reports in medicine. 2011.
5019.	Ghio L, Vaggi M, Amore M, Ferrannini L, Natta W. Unmet needs and research challenges for late-life mood disorders. Aging clinical and experimental research. 2014;26:101-114.
5020.	Ghoge H, Sharma S, Sonawalla S, Parikh R. Cerebrovascular diseases and depression. Current psychiatry reports. 2003;5:231-238.
5021.	Ghosh A, JSE H. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert opinion on investigational drugs. 2007;16:1999-2004.
5022.	GI K, AK M. Management of treatment-resistant depression. Psychiatric clinics of North America. 2012;35:249-265.
5023.	GI K, CE R, DA S. Realistic expectations and a disease management model for depressed patients with persistent symptoms. Journal of clinical psychiatry. 2006;67:1412-1421.
5024.	GI K, SJ G, CE R, et al. A Randomized, Placebo-Controlled Trial of Risperidone Augmentation for Patients With Difficult-to-Treat Unipolar, Non-Psychotic Major Depression. Journal of psychiatric research. 2008;43:205-214.
5025.	GI P. Dopaminergic-based pharmacotherapies for depression. European neuropsychopharmacology. 2006;16:391-402.
5026.	GI P. Examining the Evidence on Augmentation With Atypical Antipsychotics. CNS spectrums. 2007;12:10-12.
5027.	GI P. Limitations of Contemporary Antidepressants: Tolerability. Journal of clinical psychiatry. 2007;68:11-17.
5028.	The use of atypical antipsychotics as augmentation for treatment-resistant major depressive disorder, Primary psychiatry(2008).
5029.	GI P. Managing Partial Response or Nonresponse: Switching, Augmentation, and Combination Strategies for Major Depressive Disorder. Journal of clinical psychiatry. 2009;70:16-25.
5030.	GI P. Switching Antidepressants Vs. Conventional Augmentation Strategies. CNS spectrums. 2009;14:11-14.
5031.	GI P. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. Journal of clinical psychiatry. 2009;70:18-22.
5032.	Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice, Journal of clinical psychiatry(2014).
5033.	GI P, CF C, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Canadian Journal of Psychiatry. 2012;57:406-413.
5034.	GI P, Charles D, Fava M. Are Typical Starting Doses of the Selective Serotonin Reuptake Inhibitors Sub-Optimal? A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies in Major Depressive Disorder. World journal of biological psychiatry. 2010;11:300-307.
5035.	GI P, CM C, MJ S, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder: A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology. 2007;56:132-137.
5036.	GI P, Cooper-Kazaz R, BC A, et al. Simultaneous Initiation (Coinitiation) of Pharmacotherapy With Triiodothyronine and a Selective Serotonin Reuptake Inhibitor for Major Depressive Disorder: a Quantitative Synthesis of Double-Blind Studies. International clinical psychopharmacology. 2009;24:19-25.
5037.	GI P, Culpepper L, RS F, Musgnung J, CJ G-P. Efficacy of Desvenlafaxine 50 Mg Compared With Placebo in Patients With Moderate or Severe Major Depressive Disorder: a Pooled Analysis of Six Randomized, Double-Blind, Placebo-Controlled Studies. International clinical psychopharmacology. 2013;28:312-321.
5038.	GI P, DJ N, LA H, VL T, Krishen A, Fava M. Resolution of Sleepiness and Fatigue in Major Depressive Disorder: a Comparison of Bupropion and the Selective Serotonin Reuntake Inhibitors. Biological psychiatry. 2006;60:1350-1355.
5039.	GI P, Fava M. A Metaanalysis of Clinical Trials Comparing Moclobemide With Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2006;51:783-790.
5040.	GI P, Fava M. A Meta-Analysis of Clinical Trials Comparing the Serotonin (5ht)-2 Receptor Antagonists Trazodone and Nefazodone With Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder. European psychiatry. 2007;22:444-447.
5041.	GI P, Fava M. A Meta-Analysis of Clinical Trials Comparing Milnacipran, a Serotonin-Norepinephrine Reuptake Inhibitor, With a Selective Serotonin Reuptake Inhibitor for the Treatment of Major Depressive Disorder. European neuropsychopharmacology. 2007;17:32-36.
5042.	GI P, Fava M. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues in clinical neuroscience. 2008;10:439-451.
5043.	GI P, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European neuropsychopharmacology. 2009;19:34-40.
5044.	GI P, JC N, Kasper S, HJ M. A Meta-Analysis of Clinical Trials Comparing Reboxetine, a Norepinephrine Reuptake Inhibitor, With Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder. European neuropsychopharmacology. 2008;18:122-127.
5045.	GI P, JE A, Fava M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Current psychiatry reports. 2003;5:460-466.
5046.	GI P, Mcgrath P, Stewart J, et al. Psychic and Somatic Anxiety Symptoms as Predictors of Response to Fluoxetine in Major Depressive Disorder. Psychiatry research. 2008;161:116-120.
5047.	GI P, MH T, JE A, et al. Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Anxiety Symptoms in Major Depressive Disorder: a Meta-Analysis of Individual Patient Data From 10 Double-Blind, Randomized Clinical Trials. Journal of psychiatric research. 2008;42:134-140.
5048.	S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial, American journal of psychiatry(2010).
5049.	GI P, Petersen T, DV I, et al. Obesity among outpatients with major depressive disorder. International journal of neuropsychopharmacology. 2005;8:59-63.
5050.	GI P, Petersen T, JW D, et al. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Annals of clinical psychiatry. 2003;15:187-192.
5051.	GI P, Petersen T, Mahal Y, Mischoulon D, AA N, Fava M. Quality of life assessments in major depressive disorder: A review of the literature. General hospital psychiatry. 2004;26:13-17.
5052.	GI P, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. Journal of clinical psychiatry. 2004;65:1096-1098.
5053.	GI P, Petersen T, Mischoulon D, et al. Serum Folate, Vitamin B-12, and Homocysteine in Major Depressive Disorder, Part I: Predictors of Clinical Response in Fluoxetine-Resistant Depression. Journal of clinical psychiatry. 2004;65:1090-1095.
5054.	GI P, RC S. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Current psychiatry reports. 2008;10:481-486.
5055.	Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by Biomarker levels and genotype: Results from a randomized clinical trial, Journal of clinical psychiatry(2014).
5056.	GI P, RC S, JM Z, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind,,parallel-sequential trials. American journal of psychiatry. 2012;169:1267-1274.
5057.	GI P, RC S, Smith J, Fava M. Augmentation of Antidepressants With Atypical Antipsychotic Medications for Treatment-Resistant Major Depressive Disorder: a Meta-Analysis. Journal of clinical psychiatry. 2007;68:826-831.
5058.	GI P, RH P, MJ S, TJ P, Fava M. A Meta-Analysis of Early Sustained Response Rates Between Antidepressants and Placebo for the Treatment of Major Depressive Disorder. Journal of clinical psychopharmacology. 2006;26:56-60.
5059.	GI P, RH P, Seifert C, Fava M. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychotherapy and psychosomatics. 2007;76:266-270.
5060.	GI P, SG K, AH C, et al. Relative Antidepressant Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder: Gender-Age Interactions. International clinical psychopharmacology. 2007;22:226-229.
5061.	GI P, SM S, Krishen A, et al. Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression): a Pooled Analysis of 10 Studies. Journal of clinical psychiatry. 2008;69:1287-1292.
5062.	GI P, TJ P, Green C, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Annals of clinical psychiatry. 2005;17:161-165.
5063.	GI S, Gerwig K. The efficacy of antidepressants on overall well-being and self-reported depression symptom severity in youth: A meta-analysis. Psychotherapy and psychosomatics. 2014;83:158-164.
5064.	GI S, JP M. A Comparative Meta-Analysis of Clinical Global Impressions Change in Antidepressant Trials. Journal of nervous and mental disease. 2006;194:845-852.
5065.	GI S, Jureidini J, Healy D, Purssey R. Inappropriate data and measures lead to questionable conclusions. JAMA psychiatry (Chicago, Ill.). 2013;70:121-122.
5066.	GI S, Jureidini J, Healy D, Purssey R. Inappropriate data and measures lead to questionable conclusions. JAMA Psychiatry. 2013;70:121-122.
5067.	GI S, Kirsch I. Drug approval and drug effectiveness. Annual review of clinical psychology. 2014;10:741-766.
5068.	GI S, MI B, AN U. Psychotherapy versus second-generation antidepressants in the treatment of depression: A meta-analysis. Journal of nervous and mental disease. 2011;199:142-149.
5069.	GI S, MI B, Linardatos E, NZ R, Perry A, AC T. Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: a Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. PLoS medicine. 2013;10.
5070.	GI S, MI B, Linardatos E, NZ R, Perry A, AC T. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Medicine / Public Library of Science. 2013;10:e1001403.
5071.	GI S, TL B, DL S. A case study of salami slicing: pooled analyses of duloxetine for depression. Psychotherapy and psychosomatics. 2010;79:97-106.
5072.	Giacobbe P, Flint A. Pharmacological treatment of post-stroke pathological laughing and crying. Journal of psychiatry & neuroscience. 2007;32:384.
5073.	Giacobbe P, Flint A. Panic disorder in the elderly. Aging health. 2007;3:245-255.
5074.	Giacomelli C, Talarico R, Bombardieri S, Bazzichi L. The Interaction Between Autoimmune Diseases and Fibromyalgia: Risk, Disease Course and Management. Expert review of clinical immunology. 2013;9:1069-1076.
5075.	Gianfranco S, Carlo C. Sertraline treatment of post-stroke major depression: An open study in patients with moderate to severe symptoms. Functional neurology. 2003;18:227-232.
5076.	Giannantoni A, Porena M, Gubbiotti M, Maddonni S, SM DS. The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2014;83:400-405.
5077.	Gibiino S, Marsano A, Serretti A. Specificity profile of venlafaxine and sertraline in major depression: Metaregression of double-blind, randomized clinical trials. International journal of neuropsychopharmacology. 2014;17:1-8.
5078.	Gibiino S, Porcelli S, Mori E, D DR, Serretti A. Potential benefits of slow titration of paroxetine treatment in elderly population. International journal of neuropsychopharmacology. 2012;Conference:146.
5079.	Gibiino S, Serretti A. Paroxetine for the Treatment of Depression: a Critical Update. Expert opinion on pharmacotherapy. 2012;13:421-431.
5080.	Giese M, Beck J, Brand S, et al. Increase of serum BDNF level in depressive patients identifies therapy response and correlates with mood improvement. Pharmacopsychiatry.
5081.	Giese M, Beck J, Brand S, et al. Increased serum BDNF levels after partial sleep deprivation correlate with therapy response and mood improvement in depressive patients. European neuropsychopharmacology. 2011;Conference:S263.
5082.	Giese M, Beck J, Muheim F, Hatzinger M, Holsboer-Trachsler E, Eckert A. Presence of diurnal pattern of serum BDNF before partial sleep deprivation is associated with therapy response in major depression. European neuropsychopharmacology. 2012;Conference:S271-S272.
5083.	Gijs S, Roberto G, Meindert D, Oscar DP. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. Journal of psychiatric research. 2008;42:1000-1009.
5084.	Gilaberte I, AL M, J DLG, et al. Fluoxetine in the prevention of depressive recurrences: A double-blind study. Journal of clinical psychopharmacology. 2001;21:417-424.
5085.	Gilaberte I, Romera I, Perez-Sola V, JM M, Schacht A. Different levels of lack of improvement at 4 weeks of escitalopram treatment as predictors of poor 8-week outcome in MDD. Journal of affective disorders. 2013;146:433-437.
5086.	Gilbert G. Adults with both anxiety and depression respond poorly to treatment. Journal of the National Medical Association. 2008;100:870-871.
5087.	Gili M, Roca M, Armengol S, Asensio D, Garcia-Campayo J, Parker G. Clinical Patterns and Treatment Outcome in Patients With Melancholic, Atypical and Non-Melancholic Depressions. PloS one. 2012;7.
5088.	Gill D, Hatcher S. A Systematic Review of the Treatment of Depression With Antidepressant Drugs in Patients Who Also Have a Physical Illness. Journal of psychosomatic research. 1999;47:131-143.
5089.	Gill J, Luckenbaugh D, Charney D, Vythilingam M. Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. Biological psychiatry. 2010;68:999-1006.
5090.	Gill P, AC D, RD N, Smith N, Heywood P, AE W. Evidence based general practice: A retrospective study of interventions in one training practice. British medical journal. 1996;312:819-821.
5091.	Gillabert C, Desmeules J, Vogt-Ferrier N, Dayer P. Behavioural and psychological symptoms of dementia (BPSD): Pharmacological management. [French]. Revue medicale suisse. 2006;2:970-975.
5092.	Gilliam F, AM K. Treatment of depressive disorders in epilepsy patients. Epilepsy & behavior. 2002;3:S2-S9.
5093.	Gilligan P, Shepherd M, Lumsden G, et al. SOCRATES 11 (synopsis of Cochrane reviews applicable to emergency services). Emergency medicine journal. 2005;22:656-657.
5094.	Gilron I, CPN W, CM C, DE M. Neuropathic pain: A practical guide for the clinician. CMAJ : Canadian Medical Association journal. 2006;175:265-275.
5095.	Gina B, Meir S, Jacqueline R, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. Journal of affective disorders. 2002;68:317-330.
5096.	Giner L, CM N, Zalsman G, MA O. Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: An update. International journal of adolescent medicine and health. 2005;17:211-220.
5097.	Ginestet D, Alby JM, Besancon G, Carrier G, al e. Fluoxetine in endogenous depression and melancholia versus clomipramine. International clinical psychopharmacology. 1989;4 Suppl 1:37-40.
5098.	Giordano DU, Antonio M, Marco M, Alberto P, Giovanni M. Transcranial direct current stimulation and cognitive-behavioral therapy: Evidence of a synergistic effect in treatment-resistant depression. Brain stimulation. 2013;6:465-467.
5099.	Giovanni M, Gianna S, Francesco G, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. Journal of clinical psychopharmacology. 2012;32:487-491.
5100.	Gitlin M, LL A, MA F, et al. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors. Journal of psychiatry & neuroscience. 2004;29:383-386.
5101.	Giuliano F. 5-Hydroxytryptamine in Premature Ejaculation: Opportunities for Therapeutic Intervention. Trends in neurosciences. 2007;30:79-84.
5102.	Giunta B, Somboonwit C, WV N, et al. Psychiatric implications of hepatitis-C infection. Critical reviews in neurobiology. 2007;19:79-118.
5103.	Giuseppe B, Anna S, Stefano P, Enrico S, Pietro T. Clinical variables and response to citalopram in major depression: An open multicentric study. [Italian]. Rivista di psichiatria. 1997;32:260-267.
5104.	Giuseppe B, Giuseppe M, Alessandro D, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: A double-blind, multicenter, controlled randomized study vs. fluoxetine. European neuropsychopharmacology. 2013;23:1219-1225.
5105.	Giuseppe M, Gianluca R, Chiara C, Filippo B. Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: A pilot study. Psychotherapy and psychosomatics. 2007;76:298-305.
5106.	Given C, Given B, Rahbar M, et al. Does a symptom management intervention affect depression among cancer patients: Results from a clinical trial. Psycho-oncology. 2004;13:818-830.
5107.	GJ B, NA P. Anxiety and depression in the elderly: Do we know any more? Current opinion in psychiatry. 2010;23:504-509.
5108.	GJ E. Dr. Emslie replies. American journal of psychiatry. 2008;165:1205.
5109.	GJ E. Understanding placebo response in pediatric depression trials. American journal of psychiatry. 2009;166:1-3.
5110.	GJ E. The psychopharmacology of adolescent depression. Journal of child and adolescent psychopharmacology. 2012;22:2-4.
5111.	GJ E. Are adults just big children? American journal of psychiatry. 2012;169:248-250.
5112.	GJ E, AJ R, WA W. Fluoxetine decreased depressive symptoms in children and adolescents with nonpsychotic major depressive disorder. Evidence-based medicine. 1998;3:105.
5113.	GJ E, AJ R, WA W, RA K, Carmody T, TL M. Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depression and anxiety. 1998;7:32-39.
5114.	GJ E, BD K, TL M. Predictors of treatment response in adolescent depression. Pediatric annals. 2011;40:300-306.
5115.	GJ E, JH H, KD W, et al. Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1205-1215.
5116.	GJ E, JH H, SL H, et al. Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents: a Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1397-1405.
5117.	GJ E, ND R, KD W. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. [Review] [62 refs]. Journal of clinical psychiatry. 2005;66 Suppl 7:14-20.
5118.	GJ E, PP Y, NR K. Long-Term, Open-Label Venlafaxine Extended-Release Treatment in Children and Adolescents With Major Depressive Disorder. CNS spectrums. 2007;12:223-233.
5119.	A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder, Journal of child and adolescent psychopharmacology(2014).
5120.	GJ E, TL M, CW H. Updates in the pharmacologic treatment of childhood depression. Psychiatric clinics of North America. 2000;23:813-835.
5121.	GJ E, WA W, TL M. Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors. Depression and anxiety. 1998;8 Suppl 1:13-17.
5122.	GJ H. Selective serotonin reuptake inhibitors and risk of cerebral bleeding. Stroke; a journal of cerebral circulation. 2014;45:1917-1918.
5123.	GJ K. Addressing the unmet promise of antidepressant trials in older adults. Primary psychiatry. 2006;13:24-27+36.
5124.	GJ K. Advances in the treatment of late-life psychotic depression. Primary psychiatry. 2008;15:27-29.
5125.	GJ K, Marcus P. Use of antidepressants in older patients with co-morbid medical conditions: Guidance from studies of depression in somatic illness. Drugs & aging. 2005;22:273-287.
5126.	GJ L, Nashed A, Manzini C, MC C. Does sleep differ among patients with common musculoskeletal pain disorders? Current rheumatology reports. 2011;13:535-542.
5127.	GJ L, Shprecher D, Coffey B, Kurlan R. Tourette's disorder. Current treatment options in neurology. 2010;12:274-286.
5128.	GJ W, HBF Z, MA T, Hackett D. Estimation of Symptom-Free Days in Generalized Anxiety Disorder. Current medical research and opinion. 2006;22:587-591.
5129.	GJ W, Rabkin R. Effects of Dextroamphetamine on Depression and Fatigue in Men With Hiv: a Double-Blind, Placebo-Controlled Trial. Journal of clinical psychiatry. 2000;61:436-440.
5130.	GJG A, JS A, AA R, Whedon M. Health anxiety: Current perspectives and future directions. Current psychiatry reports. 2010;12:306-312.
5131.	GK B, Biswas A, Volkov S. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments. Journal of biopharmaceutical statistics. 2009;19:838-856.
5132.	GK Z. Eszopiclone: A nonbenzodiazepine that effectively improves sleep maintenance and initiation in patients with insomnia. Future neurology. 2007;2:249-257.
5133.	GL A, JG Ob, PG T, LS K. Increased Aripiprazole Concentrations in an Hiv-Positive Male Concurrently Taking Duloxetine, Darunavir, and Ritonavir. Annals of pharmacotherapy. 2010;44:1850-1854.
5134.	GL H, DJ F, TE F. Separation anxiety disorder and school refusal in children and adolescents. Pediatrics in review. 2006;27:56-63.
5135.	GL P. Quetiapine: A Pharmacoeconomic Review of its Use in Bipolar Disorder. PharmacoEconomics. 2012;30:611-631.
5136.	GL S, DM S, WA C. Focus on Fluvoxamine - a Serotonin Reuptake Inhibitor for Major Depression and Obsessive-Compulsive Disorder. Hospital formulary. 1991;26:635-&.
5137.	GL S, JA D, SM S. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. [Review] [60 refs]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 1997;17:10-21.
5138.	GL S, JC H. The impact of mental illness on cardiac outcomes: A review for the cardiologist. International journal of cardiology. 2009;132:30-37.
5139.	GL X, Fiuzat M, Kuchibhatla M, et al. Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. Circulation. Heart failure. 2012;5:688-692.
5140.	GL Z, HG PJ. Treatment of depression in bipolar disorder: New directions for research. Journal of clinical psychopharmacology. 1993;13:397-408.
5141.	Glassman A. Depression and cardiovascular disease. Pharmacopsychiatry. 2008;41:221-225.
5142.	Glenda M, Leslie B, Meir S. The selective serotonin reuptake inhibitor sertraline: Its profile and use in psychiatric disorders. CNS drug reviews. 2001;7:1-24.
5143.	Glue P, MR D, Kolluri S, Emir B. Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders. Australian and New Zealand journal of psychiatry. 2010;44:697-705.
5144.	GM A, CS B, Lindell S, AC D, Shifrovich I, JD H. Time Course of the Effects of the Serotonin-Selective Reuptake Inhibitor Sertraline on Central and Peripheral Serotonin Neurochemistry in the Rhesus Monkey. Psychopharmacology. 2005;178:339-346.
5145.	GM A, CS B, Lindell S, AC D, Shifrovich I, JD H. Time Course of the Effects of the Serotonin-Selective Reuptake Inhibitor Sertraline on Central and Peripheral Serotonin Neurochemistry in the Rhesus Monkey. Psychopharmacology. 2005;178:339-346.
5146.	GM A, FA H, AW G, et al. Fluvoxamine in the Treatment of Panic Disorder: a Multi-Center, Double-Blind, Placebo-Controlled Study in Outpatients. Psychiatry research. 2001;103:1-14.
5147.	GM A, MA H. Levomilnacipran for the Treatment of Major Depressive Disorder: a Review. Neuropsychiatric disease and treatment. 2015;11:125-135.
5148.	GM C, DV I, MH P, SD T, Fava M. Validation of the massachusetts general hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS neuroscience & therapeutics. 2010;16:322-325.
5149.	GM G. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England). 2003;17:149-173.
5150.	GM G. Innovation translates into antidepressant effectiveness. [Review] [17 refs]. Journal of psychopharmacology (Oxford, England). 2008;22:9-12.
5151.	GM G. Clinical Studies on the Efficacy of Agomelatine on Depressive Symptoms. CNS drugs. 2009;23:35-39.
5152.	GM G. Agomelatine: A new insight into antidepressant efficacy. International journal of neuropsychopharmacology. 2012;Conference:251.
5153.	GM G. Brain imaging in understanding the action of psychotropic drugs: The drugs for depression. Annales medico-psychologiques. 2015;173:259-262.
5154.	GM G, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. European neuropsychopharmacology. 2008;18:535-549.
5155.	GM G, Boyer P, Emsley R, Rouillon F, C DB. Is It Time to Shift to Better Characterization of Patients in Trials Assessing Novel Antidepressants? An Example of Two Relapse Prevention Studies With Agomelatine. International clinical psychopharmacology. 2013;28:20-28.
5156.	GM G, Emsey R, Rembry S, Rouillon F. Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. Journal of clinical psychiatry. 2009;70:1128-1137.
5157.	GM K. Loxapine inhalation powder: A review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS drugs. 2013;27:479-489.
5158.	GM K, KA L-W, SM H. Rasagiline: A guide to its use in parkinsons disease. CNS drugs. 2012;26:781-785.
5159.	GM M. ABCB1 genetic variation and clinical outcomes in the international study to predict optimized treatment for depression (iSPOT-D). Biological psychiatry. 2014;Conference:23S-24S.
5160.	GM M, CM F, Christofides J, et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clinical and experimental pharmacology & physiology. 2009;36:425-435.
5161.	GM M, Kremer C, Rodrigues H, AF S, Group MvpS. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biological psychiatry. 2003;54:665-673.
5162.	GM M, Reynolds A, Andersen C, Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry. 1998;4:127-132.
5163.	GM MJ, JE S, HS R, O'Hara R, AF S, LC L. Bdnf and Creb1 Genetic Variants Interact to Affect Antidepressant Treatment Outcomes in Geriatric Depression. Pharmacogenetics and genomics. 2013;23:301-313.
5164.	GM P, Avraam G, Andreou E, Dimou S, Gkoutzamanis G, Goulas O. Outpatients' prescription patterns from the psychiatric department of a general hospital: Preliminary results. European neuropsychopharmacology. 2014;Conference:S358-S359.
5165.	GM S, SJ K. Drs. Simpson and Kingsbury reply [5]. Journal of clinical psychiatry. 2005;66:1615-1616.
5166.	GM S-Z, Arnold O, Saletu B, Anderer P. The key-lock principle in the diagnosis and treatment of nonorganic insomnia related to psychiatric disorders: Sleep laboratory investigations. Methods and findings in experimental and clinical pharmacology. 2002;24:37-49.
5167.	Mirtazapine to reduce methamphetamine use: A randomized controlled trial, Archives of general psychiatry(2011).
5168.	GN S, Th C, Kho D, HR, Ce C. Therapies for depression in Parkinson's disease. [Review] [56 refs]. Cochrane database of systematic reviews (Online). 2003:CD003465.
5169.	GO L. Balanced Treatments for Fibromyalgia. Arthritis and rheumatism. 2004;50:2725-2729.
5170.	GO L. Balanced Treatments for Fibromyalgia. Arthritis and rheumatism. 2004;50:2725-2729.
5171.	GO L, EK G. Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose. Current pharmaceutical design. 2006;12:3-9.
5172.	Goder R, Seeck-Hirschner M, Koch J, Stingele K, Weinhold S. Sleep in major depression: Effects of pharmacological REM sleep suppression on performance in neuropsychological tasks. Sleep medicine. 2011;Conference:S52.
5173.	Godlewska B, Norbury R, Cowen P, CJ H. Early changes in neural responses to emotional information predict clinical response to SSRI treatment in depression. Neuropsychopharmacology. 2013;Conference:S446.
5174.	Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychological medicine. 2012;42:2609-2617.
5175.	Goesling J, DJ C, AL H. Pain and depression: An integrative review of neurobiological and psychological factors. Current psychiatry reports. 2013.
5176.	Goettems BA, Pinto GLS, Marceli TC. Neurocognitive changes in depressed patients in psychodynamic psychotherapy, therapy with fluoxetine and combination therapy. Journal of affective disorders. 2013;151:1066-1075.
5177.	Goikolea J. Use of antidepressants in long treatment of bipolar depression. European neuropsychopharmacology. 2008;Conference:S192-S193.
5178.	Gois C, Dias VV, Carmo I, et al. Treatment response in type 2 diabetes patients with major depression. Clinical psychology & psychotherapy. 2014;21:39-48.
5179.	Goldberg D. The "NICE Guideline" on the treatment of depression. Epidemiologia e psichiatria sociale. 2006;15:11-15.
5180.	Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and rheumatism. 1996;39:1852-1859.
5181.	Goldman S. Developmental Epidemiology of Depressive Disorders. Child and adolescent psychiatric clinics of North America. 2012;21:217-235.
5182.	Goldsmith M, Singh M, Chang K. Antidepressants and psychostimulants in pediatric populations: Is there an association with mania? Pediatric Drugs. 2011;13:225-243.
5183.	Goldstein-Piekarski A, Schatzberg A, Korgaonkar M, Grieve S, Etkin A, Williams L. Corticotrophin-releasing hormone genotype interacts with pre-treatment anxiety status and amygdala reactivity to predict treatment outcomes in major depressive disorder. Neuropsychopharmacology. 2014;Conference:S249.
5184.	Golomb M, Fava M, Abraham M, JF R. The relationship between age and personality disorders in depressed outpatients. Journal of nervous and mental disease. 1995;183:43-44.
5185.	Gomeni R, Merlo-Pich E. Bayesian Modelling and Roc Analysis to Predict Placebo Responders Using Clinical Score Measured in the Initial Weeks of Treatment in Depression Trials. British journal of clinical pharmacology. 2007;63:595-613.
5186.	Gommans J, JA B, TH H, et al. Stimulus Properties of Fluvoxamine in a Conditioned Taste Aversion Procedure. Psychopharmacology. 1998;140:496-502.
5187.	Gonella G, Baignoli G, Ecari U. Fluvoxamine and imipramine in the treatment of depressive patients: A double-blind controlled study. Current medical research and opinion. 1990;12:177-184.
5188.	Gonner S, Limbacher K, Ecker W. Inpatient cognitive behavior therapy for obsessive-compulsive disorder: Effectiveness and predictors of response in routine clinical practice. [German]. Verhaltenstherapie. 2012;22:17-26.
5189.	Gonsalves L, Schuermeyer I. Treating depression in pregnancy: Practical suggestions. Cleveland Clinic journal of medicine. 2006;73:1098-1104.
5190.	Gonzalez A, Mata S, Sanchez P, et al. Omega-3 fatty acids as adjunctive of antidepressant therapy and its effects on brain-derived neurotrophic factor in serum, monocytes and lymphocytes. Archivos Venezolanos de Farmacologia y Terapeutica. 2011;30:72-78.
5191.	Good P, Stafford B. Inpatient palliative medicine is evidence based. Palliative medicine. 2001;15:493-498.
5192.	Goodman M, Vail L, West S, New A, Siever L. The pharmacological and psychological treatment of personality disorders - From neurobiology to treatment strategies. Journal of family psychotherapy. 2006;17:53-81.
5193.	Goodwin G. Innovation translates into antidepressant effectiveness. European neuropsychopharmacology. 2008;Conference:S591-S592.
5194.	Goodwin G. Agomelatine: Demonstrated efficacy on the complete range of depressive symptoms. European neuropsychopharmacology. 2009;Conference:S719.
5195.	Goodwin G. Agomelatine: Superior antidepressant efficacy at each step of depression. International journal of neuropsychopharmacology. 2010;Conference:248.
5196.	Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial. British medical journal. 2007;335:142-146.
5197.	Goodyer I, Kutcher S. CBT plus an SSRI was as effective as an SSRI alone for adolescents with moderate to severe depression: Commentary. Evidence-based medicine. 2008;13:13.
5198.	Gopalakrishnan R, Ross J, O'brien C, Oslin D. Course of Late-Life Depression With Alcoholism Following Combination Therapy. Journal of studies on alcohol and drugs. 2009;70:237-241.
5199.	Gordon C, JN G. Fibromyalgia syndrome: Fact, fiction, and future remedies. Critical Reviews in Physical and Rehabilitation Medicine. 2006;18:343-369.
5200.	Gordon E, AJ R, DM P, TA B, Rekshan W. Toward an online cognitive and emotional battery to predict treatment remission in depression. Neuropsychiatric disease and treatment. 2015;11:517-531.
5201.	Gordon P, M AI, Peter H. Clinical trials of antidepressant medications are producing meaningless results. The British Journal of Psychiatry. 2003;183:102-104.
5202.	Gorenstein C, Gentil V, Melo M, Lotufo-Neto F, Lauriano V. Mood Improvement in 'normal' Volunteers. Journal of psychopharmacology (Oxford, England). 1998;12:246-251.
5203.	Gorlyn M, Keilp J, Burke A, Oquendo M, JJ M, Grunebaum M. No superiority in cognitive improvement with bupropion XL vs. Paroxetine CR treatment in suicidal MDD patients. Biological psychiatry. 2014;Conference:125S.
5204.	Gorwood P. Restoring circadian rhythms: A new way to successfully manage depression. European neuropsychopharmacology. 2010;Conference:S646.
5205.	Gorwood P, Bayle F, Vaiva G, Courtet P, Corruble E, P-M L. Is It Worth Assessing Progress as Early as Week 2 to Adapt Antidepressive Treatment Strategy? Results From a Study on Agomelatine and a Global Meta-Analysis. European psychiatry. 2013;28:362-371.
5206.	Gorwood P, Katona C, Lyketsos C, Steinberg M, Weiller E. Are old-old patients with MDD more likely to relapse than the young-old after open label treatment with escitalopram? American journal of geriatric psychiatry. 2010;Conference:S60.
5207.	Gothelf D, Rubinstein M, Shemesh E, et al. Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents With Cancer. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:1258-1262.
5208.	Goto F, Tsutsumi T, Oishi N, Mimura M. Hidden depression in otolaryngology patients with medically unexplained symptoms. General hospital psychiatry. 2012;34:206-208.
5209.	Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. [Review] [20 refs]. International clinical psychopharmacology. 1992;6 Suppl 5:55-64.
5210.	Gourion D. [Antidepressants and their onset of action: a major clinical, methodological and pronostical issue]. [Review] [29 refs] [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2008;34:73-81.
5211.	Gourion D, Galinowski A, Baraille L, Picard H. Switch Antidepressants: When? How? Why? Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2011;37:S50-S57.
5212.	Gourion D, Perrin E, Ph Q. [Fluoxetine: an update of its use in major depressive disorder in adults]. [Review] [57 refs] [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:392-399.
5213.	Gourion D, Perrin E, Quintin PH. Fluoxetine: An update of its use in major depressive disorder in adults. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2004;30:392-399.
5214.	Gournellis R, Lykouras L. Psychotic (delusional) major depression in the elderly: A review. Current psychiatry reviews. 2006;2:235-244.
5215.	Gouvea F, Lopes A, Greenberg B, et al. Response to sham and active gamma ventral capsulotomy in otherwise intractable obsessive-compulsive disorder. Stereotactic and functional neurosurgery. 2010;88:177-182.
5216.	Gowan J, Roller L. Women's health and irritable bowel syndrome. Australian Journal of Pharmacy. 2013;94:70-74.
5217.	Gowers S, Claxton M, Rowlands L, et al. Drug Prescribing in Child and Adolescent Eating Disorder Services. Child and adolescent mental health. 2010;15:18-22.
5218.	GP O, DG B, Kasckow J, JA C, Mohamed S. Review of assessment and treatment of PTSD among elderly American armed forces veterans. International journal of geriatric psychiatry. 2005;20:1118-1130.
5219.	GP P, AN K, MM K, IV O, VG K. Peculiarities of Paxil Clinical Action in Endogenous Depressions. Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova. 1998;98:26-31.
5220.	GP R, OO M, CF D. Pharmacogenomics in psychiatry: The relevance of receptor and transporter polymorphisms. British journal of clinical pharmacology. 2014;77:654-672.
5221.	GR B, HB K, MA Q. Role of fluoxetine and nortriptyline in major depressive disorders. Rawal Medical Journal. 2011;36:38-40.
5222.	GR M, JT H, JA R, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of clinical oncology. 2003;21:4635-4641.
5223.	GR M, JT H, JA R, et al. Differential Effects of Paroxetine on Fatigue and Depression: a Randomized, Double-Blind Trial From the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of clinical oncology. 2003;21:4635-4641.
5224.	GR M, JT H, JA R, et al. Differential Effects of Paroxetine on Fatigue and Depression: a Randomized, Double-Blind Trial From the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of clinical oncology. 2003;21:4635-4641.
5225.	GR P, RP A, Phadnis P, Paliwal A, Vyas S, Solanki P. Evaluation of Antidepressant Like Property of Amisulpride Per Se and Its Comparison With Fluoxetine and Olanzapine Using Forced Swimming Test in Albino Mice. Acta poloniae pharmaceutica. 2009;66:327-331.
5226.	GR V. CRF receptos as a potential target in the development of novel pharmacotherapies for depression. Current pharmaceutical design. 2009;15:1587-1594.
5227.	Grabois M. Management of chronic low back pain. American journal of physical medicine & rehabilitation. 2005;84:S29-S41.
5228.	Grace W, FIII RC, H MB, G PB. Continuation and maintenance pharmacotherapy in geriatric depression: An open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Journal of clinical psychiatry. 1999;60 Suppl 2:21-25.
5229.	Grady D. Management of menopausal symptoms. New England journal of medicine. 2006;355:2338-2347.
5230.	Graf H, Abler B, Hartmann A, CD M, Walter M. Modulation of Attention Network Activation Under Antidepressant Agents in Healthy Subjects. International journal of neuropsychopharmacology. 2013;16:1219-1230.
5231.	Graf H, Walter M, CD M, Abler B. Antidepressant-Related Sexual Dysfunction - Perspectives From Neuroimaging. Pharmacology, biochemistry, and behavior. 2014;121:138-145.
5232.	Graf H, Wiegers M, CD M, Walter M, Gron G, Abler B. Erotic Stimulus Processing Under Amisulpride and Reboxetine: a Placebo-Controlled Fmri Study in Healthy Subjects. International journal of neuropsychopharmacology. 2015;18.
5233.	Graham E, Dineen WK, Stan K, et al. Paroxetine Treatment in Children and Adolescents With Major Depressive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:709-719.
5234.	Graham K, Massak A. Alcohol consumption and the use of antidepressants. CMAJ : Canadian Medical Association journal. 2007;176:633-637.
5235.	Gram L. Fluoxetine. [Review] [102 refs][Erratum appears in N Engl J Med 1995 Feb 2;332(5):343]. New England journal of medicine. 1994;331:1354-1361.
5236.	Grant L, Roblin D. The placebo effect and the pharmaceutical industry. International Journal of Pharmaceutical Medicine. 2005;19:219-225.
5237.	Gras J, Llenas J, JM J, Jauregui J, Cabarrocas X, JM P. Almotriptan, a new anti-migraine agent: A review. CNS drug reviews. 2002;8:217-234.
5238.	Grassi L, Biancosino B, Marmai L, Righi R. Effect of Reboxetine on Major Depressive Disorder in Breast Cancer Patients: an Open-Label Study. Journal of clinical psychiatry. 2004;65:515-520.
5239.	Grassi L, Biancosino B, Marmai L, Righi R. Effect of Reboxetine on Major Depressive Disorder in Breast Cancer Patients: an Open-Label Study. Journal of clinical psychiatry. 2004;65:515-520.
5240.	Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta psychiatrica Scandinavica. 1987;75:478-486.
5241.	Gray J, HHA A, Beilby J, Holton C, Banham D, Karnon J. Practice Nurse Involvement in Primary Care Depression Management: an Observational Cost-Effectiveness Analysis. BMC family practice. 2014;15.
5242.	Graziottin A, Serafini A. Depression and the menopause: Why antidepressants are not enough? Menopause international. 2009;15:76-81.
5243.	Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy. 2007;18:437-443.
5244.	Greco T, Eckert G, Kroenke K. The Outcome of Physical Symptoms With Treatment of Depression. Journal of general internal medicine. 2004;19:813-818.
5245.	Green A, Crawford A, KS B, et al. Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. Journal of affective disorders. 2014;163:40-46.
5246.	Green A, Crawford A, KS B, et al. Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. Journal of affective disorders. 2014;163:40-46.
5247.	Green A, Nightingale S, Curran S. Review of pharmacological treatment of depression in the older people. CPD Bulletin Old Age Psychiatry. 2003;3:79-83.
5248.	Post-traumatic stress disorder: New directions in pharmacotherapy, Advances in Psychiatric Treatment(2013).
5249.	Green B. Prazosin in the treatment of PTSD. Journal of psychiatric practice. 2014;20:253-259.
5250.	Green B, DL D, MH R. Paroxetine controlled release. CNS drugs. 2004;18:365-366.
5251.	Green T, Steingart L, Frisch A, Zarchi O, Weizman A, Gothelf D. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: A double-blind placebo-controlled trial. Journal of neural transmission (Vienna, Austria : 1996). 2012;119:1417-1423.
5252.	Greenberg P, PK C-L, Birnbaum H, Marynchenko M, Claxton A. Economic Implications of Treatment-Resistant Depression Among Employees. PharmacoEconomics. 2004;22:363-373.
5253.	Greenberg P, PK C-L, Birnbaum H, Marynchenko M, Claxton A. Economic Implications of Treatment-Resistant Depression Among Employees. PharmacoEconomics. 2004;22:363-373.
5254.	Greene J, Banasr M, Lee B, Warner-Schmidt J, RS D. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology. 2009;34:2459-2468.
5255.	Greene J, Banasr M, Lee B, Warner-Schmidt J, RS D. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology. 2009;34:2459-2468.
5256.	Greener M. Agomelatine: A new approach to depression. Progress in neurology and psychiatry. 2009;13:29-31.
5257.	Greener M. Treating generalised anxiety disorder: Room to improve. Progress in neurology and psychiatry. 2009;13:28-29.
5258.	Greener M. Managing the double burden of depression and Parkinson's disease. Progress in neurology and psychiatry. 2012;16:16-17.
5259.	Greenes D, Fava M, Cioffi J, DB H. The relationship of depression to dissociation in patients with bulimia nervosa. Journal of psychiatric research. 1993;27:133-137.
5260.	Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: Systematic reviews and economic modelling studies. Health technology assessment. 2005;9:iii-94.
5261.	Greenlee A, JF K, MA D, Houck P, Andreescu C, 3rd RCF. Anxiety impairs depression remission in partial responders during extended treatment in late-life. Depression and anxiety. 2010;27:451-456.
5262.	Greetfeld M, Cuntz U, Voderholzer U. Pharmacotherapy for Anorexia Nervosa and Bulimia Nervosa. Fortschritte der Neurologie-Psychiatrie. 2012;80:9-16.
5263.	Greeven A, AJLM VB, Visser S, et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: A randomized controlled trial. American journal of psychiatry. 2007;164:91-99.
5264.	Greg M, E ME, J LA, et al. Therapeutic mechanism in seasonal affective disorder: Do fluoxetine and light operate through advancing circadian phase? [References]. Chronobiology international. 2005;22:937-943.
5265.	Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic Trends in 2231 Psychiatric Inpatients With Bipolar Depression From the International Amsp Project Between 1994 and 2009. Journal of affective disorders. 2012;136:534-542.
5266.	Greist J, RK M, CH M, JN R, Raskin J. Incidence and Duration of Antidepressant-Induced Nausea: Duloxetine Compared With Paroxetine and Fluoxetine. Clinical therapeutics. 2004;26:1446-1455.
5267.	Grelotti DJ, Hammer GP, Dilley JW, et al. Does Substance Use Compromise Depression Treatment? A Randomized Trial of Homeless HIV+ Persons. Topics in antiviral medicine. 2014;Conference:541-542.
5268.	Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: The end of the beginning? Nature reviews. Drug discovery. 2012;11:462-478.
5269.	Griebel G, Stahl S, Arvanitis L. The V1b receptor antagonist ssr149415 in the treatment of major depressive and generalized anxiety disorders: Results from three double-blind, placebo-controlled studies. Neuropsychopharmacology. 2011;Conference:S351.
5270.	Grigoriadis S, BA B, Kennedy S, RM B, RT J. A Comparison of Desipramine Response in Younger and Older Women. Journal of clinical psychopharmacology. 2010;30:80-82.
5271.	Grigoriadis S, EH V, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis. Journal of clinical psychiatry. 2013;74:e309-e320.
5272.	Grigoriadis S, EH V, Mamisashvili L, et al. The Effect of Prenatal Antidepressant Exposure on Neonatal Adaptation: a Systematic Review and Meta-Analysis. Journal of clinical psychiatry. 2013;74:E309-+.
5273.	Grigoriadis S, EH V, Mamisashvili L, et al. Antidepressant Exposure During Pregnancy and Congenital Malformations: Is There an Association? A Systematic Review and Meta-Analysis of the Best Evidence. Journal of clinical psychiatry. 2013;74:E293-+.
5274.	Grigoriadis S, GE R. Gender issues in depression. Annals of clinical psychiatry. 2007;19:247-255.
5275.	Grigoriadis S, Ravitz P. An Approach to Interpersonal Psychotherapy for Postpartum Depression. Canadian Family Physician. 2007;53:1469-1475.
5276.	Grillon C, Levenson J, DS P. A Single Dose of the Selective Serotonin Reuptake Inhibitor Citalopram Exacerbates Anxiety in Humans: a Fear-Potentiated Startle Study. Neuropsychopharmacology. 2007;32:225-231.
5277.	Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. Journal of clinical endocrinology and metabolism. 2000;85:60-65.
5278.	Groban L, DW K, TC R, CA S. Effect of depression and sertraline treatment on cardiac function in female nonhuman primates. Psychosomatic medicine. 2014;76:137-146.
5279.	Groban L, DW K, TC R, CA S. Effect of depression and sertraline treatment on cardiac function in female nonhuman primates. Psychosomatic medicine. 2014;76:137-146.
5280.	Grosjean B. From synapse to psychotherapy: The fascinating evolution of neuroscience. American journal of psychotherapy. 2005;59:181-197.
5281.	Grossman H, Bergmann C, Parker S. Dementia: A brief review. Mount Sinai Journal of Medicine. 2006;73:985-992.
5282.	Routine pharmacogenetic testing in clinical practice: Dream or reality?, Pharmacogenomics(2007).
5283.	Grossman R, Reynolds D, Goodman M, et al. Efficacy of Open-Label Venlafaxine in Subjects With Major Depressive Disorder: Associations With Neuroendocrine Response to Serotonergic and Noradrenergic Probes. Psychiatry research. 2004;128:203-206.
5284.	Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: A comprehensive meta-analysis of randomized clinical trials. PloS one. 2014.
5285.	Group HDTS. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807-1814.
5286.	Grover M, Camilleri M. Effects on Gastrointestinal Functions and Symptoms of Serotonergic Psychoactive Agents Used in Functional Gastrointestinal Diseases. Journal of gastroenterology. 2013;48:177-181.
5287.	Grover M, DA D. Psychotropic agents in functional gastrointestinal disorders. Current opinion in pharmacology. 2008;8:715-723.
5288.	Grover M, DA D. Psychopharmacologic and Behavioral Treatments for Functional Gastrointestinal Disorders. Gastrointestinal endoscopy clinics of North America. 2009;19:151-170.
5289.	Grunder G, Wetzel H, Schlosser R, Benkert O. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: Assessment by automatic 24-hour monitoring. Pharmacopsychiatry. 1996;29:72-78.
5290.	Grunze H. Reevaluating therapies for bipolar depression. Journal of clinical psychiatry. 2005;66:17-25.
5291.	Grunze H. Switch to mania and antidepressants: The case for caution? European neuropsychopharmacology. 2008;Conference:S193.
5292.	Grunze H. Long-term management of bipolar disorder. European neuropsychopharmacology. 2009;Conference:S720.
5293.	Grunze H. "How to manage mania not responding to a first-step 2 weeks treatment with quetiapine-A report from a prematurely discontinued randomised clinical trial": Comment on Licht and Bech. Acta psychiatrica Scandinavica. 2009;120:335.
5294.	Stimulants for treating bipolar disorder: Pro and con, Harvard review of psychiatry(2014).
5295.	Grunze H, Adli M, Bauer M, et al. Clinical standing of valproate treatment of bipolar disorders. [German]. Fortschritte der Neurologie-Psychiatrie. 2007;75:220-235.
5296.	Grunze H, Dargel S. Acute and long-term treatment for bipolar depression. [German]. Der Nervenarzt. 2010;81:539-548.
5297.	Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. World journal of biological psychiatry. 2004;5:120-135.
5298.	The World Federation of Societies of Biological Psychiatry (Wfsbp) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the Long-Term Treatment of Bipolar Disorder, World journal of biological psychiatry(2013).
5299.	Grunze H, Vieta E, GM G, et al. The World Federation of Societies of Biological Psychiatry (Wfsbp) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. World journal of biological psychiatry. 2010;11:81-109.
5300.	Gruwez B, Gury C, M-F P, et al. Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:425-432.
5301.	Gruwez B, Gury C, MF P, et al. Comparison of Two Assessment Tools of Antidepressant Side-Effects : Uku Scale Versus Spontaneous Notification. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:425-432.
5302.	Gryglewski G, Lanzenberger R, GS K, Cumming P. Meta-Analysis of Molecular Imaging of Serotonin Transporters in Major Depression. Journal of cerebral blood flow and metabolism. 2014;34:1096-1103.
5303.	GS A. The treatment of depressed demented patients. Journal of clinical psychiatry. 1996;57:14-20.
5304.	GS A, DN K, JA S, et al. Untangling therapeutic ingredients of a personalized intervention for patients with depression and severe copd. American journal of geriatric psychiatry. 2014;22:1316-1324.
5305.	GS A, Gordon J, DZ Z. A Placebo-Controlled Trial of Escitalopram and Sertraline in the Treatment of Major Depressive Disorder. Neuropsychopharmacology. 2004;29:S87.
5306.	GS A, Gordon J, DZ Z. A Placebo-Controlled Trial of Escitalopram and Sertraline in the Treatment of Major Depressive Disorder. Neuropsychopharmacology. 2004;29:S87.
5307.	GS A, Kanellopoulos D, Murphy C, Gunning-Dixon F, Katz R, Heo M. Placebo Response and Antidepressant Response. American journal of geriatric psychiatry. 2007;15:149-158.
5308.	GS A, PJ R, JA S, PA A. Developing an intervention for depressed, chronically medically ill elders: A model from COPD. International journal of geriatric psychiatry. 2008;23:447-453.
5309.	GS A, Streim J, Carpenter D, JP D. Introduction: Methods, Commentary, and Summary. Journal of clinical psychiatry. 2004;65:5-99.
5310.	GS A, Streim J, Carpenter D, JP D. Introduction: Methods, Commentary, and Summary. Journal of clinical psychiatry. 2004;65:5-99.
5311.	GS D, AJ T, CM F, Addington S, RC S. Do Venlafaxine Xr and Paroxetine Equally Influence Negative and Positive Affect? Journal of affective disorders. 2005;85:333-339.
5312.	GS D, JN F, MJ S. The effects of Brief Behavioral Activation Therapy for Depression on cognitive control in affective contexts: An fMRI investigation. Journal of affective disorders. 2010;126:236-244.
5313.	GS G, AM A, RL F, Kratochvil C, Walkup J. Integrating cognitive behavioral therapy and pharmacotherapy in the treatment of adolescent depression. Cognitive and behavioral practice. 2005;12:252-262.
5314.	Naturalistic Follow-up of Youths Treated for Pediatric Anxiety Disorders, Jama Psychiatry(2014).
5315.	GS G, SG S, RH J, et al. Cognitive measures of adolescent depression: Unique or unitary constructs? Journal of clinical child and adolescent psychology. 2009;38:790-802.
5316.	GS M, Adams D, Berk M. Medicating mood with maintenance in mind: Bipolar depression pharmacotherapy. Bipolar disorders. 2009;11:55-76.
5317.	GS M, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Australian and New Zealand journal of psychiatry. 2009;43:1096-1104.
5318.	GS M, Adams D, Berk M. The pharmacological treatment of bipolar disorder in primary care. Medical journal of Australia. 2010;193:S24-S30.
5319.	GS M, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta psychiatrica Scandinavica. 2009;119:27-46.
5320.	GS M, Adams D, Porter R, et al. Clinical practice recommendations for depression. Acta psychiatrica Scandinavica. 2009;119:8-26.
5321.	GS M, DM B, Mcintyre R, et al. Balanced Efficacy, Safety, and Tolerability Recommendations for the Clinical Management of Bipolar Disorder. Bipolar disorders. 2012;14:1-21.
5322.	GS S. Decision tree for the treatment of bipolar disorder. Journal of clinical psychiatry. 2003;64:35-40.
5323.	GS S, 3rd RCF, PR H, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry research. 2009;171:1-9.
5324.	Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression, New England journal of medicine(2007).
5325.	GS S, BD G, Gutierrez-Esteinou R, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. Journal of clinical psychiatry. 2007;68:1377-1383.
5326.	GS S, DJ P, DA K, Carpenter D, JP D. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgraduate medicine. 2000;Spec No:1-104.
5327.	GS S, JM D, CW W. The pharmacologic treatment of bipolar disorder. Journal of clinical psychiatry. 2011;72:704-715.
5328.	GS S, Ma Y, Dhawan V, et al. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse (New York, N.Y.). 2002;45:105-112.
5329.	GS S, ME T, MW O, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological psychiatry. 2003;53:1028-1042.
5330.	GS Y, FM G, Woods E, MJ H, GS A. Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. Biological psychiatry. 2013;Conference:196S.
5331.	GS Y, FM G, Woods E, SA K, MJ H, GS A. Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. Journal of affective disorders. 2014;166:179-186.
5332.	GS Y, FM G, Woods E, SA K, MJ H, GS A. Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. Journal of affective disorders. 2014;166:179-186.
5333.	GS Y, Gunning-Dixon F, Woods E, Hoptman M, GS A. Neuroanatomical correlates of apathy in late life depression and antidepressant treatment response. Neuropsychopharmacology. 2012;Conference:S96.
5334.	GT B, Chavez B. Safety and Efficacy of Quetiapine in Bipolar Depression. Annals of pharmacotherapy. 2009;43:1848-1856.
5335.	GT B, HK W. Difficult Behaviors in Long-term Care Patients With Dementia. Journal of the American Medical Directors Association. 2007;8:e101-e113.
5336.	GT P, Petersen T, JW D, et al. Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine. Journal of clinical psychopharmacology. 2004;24:507-511.
5337.	GT P, Petersen T, JW D, et al. Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine. Journal of clinical psychopharmacology. 2004;24:507-511.
5338.	GT W. Treatment of binge eating disorder. Psychiatric clinics of North America. 2011;34:773-783.
5339.	Psychological Treatments of Binge Eating Disorder, Archives of general psychiatry(2010).
5340.	Guaiana G, Barbui C, Hotopf M. Amitriptyline for depression. Cochrane database of systematic reviews (Online). 2007.
5341.	Guaiana G, Gupta S, Chiodo D, SJ D, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. [Review]. Cochrane database of systematic reviews (Online). 2013;12:CD008851.
5342.	Guaiana G, Gupta S, Chiodo D, SJC D, Haederle K, Koesters M. Agomelatine Versus Other Antidepressive Agents for Major Depression. Cochrane database of systematic reviews (Online). 2013.
5343.	Gual A, Balcells M, Torres M, Madrigal M, Diez T, Serrano L. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: A randomized controlled trial. Alcohol and alcoholism (Oxford, Oxfordshire). 2003;38:619-625.
5344.	Guan NC, M BMP, B RKC, et al. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: A four-week, randomized, double-blinded, placebo-controlled study. European neuropsychopharmacology. 2014;24:491-498.
5345.	Guardia D, Rolland B, Karila L, Cottencin O. Gabaergic and glutamatergic modulation in binge eating: Therapeutic approach. Current pharmaceutical design. 2011;17:1396-1409.
5346.	Guastella V, Mick G. Strategies for the Diagnosis and Treatment of Neuropathic Pain Secondary to Diabetic Peripheral Sensory Polyneuropathy. Diabetes & metabolism. 2009;35:12-19.
5347.	Guazzi M, Arena R, Ascione A, Piepoli M, MD G. Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: An unfavorable combination with high prognostic value. American heart journal. 2007;153:859-867.
5348.	Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International clinical psychopharmacology. 1998;13:121-128.
5349.	Guelfi JD, Bouhassira M, Bonett-Perrin E, Lancrenon S. Study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients, followed in general practice. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1999;25:265-270.
5350.	Guelfi JD, Dreyfus JF, Pichot P. Fluvoxamine and imipramine: Results of a long-term controlled trial. International clinical psychopharmacology. 1987;2:103-109.
5351.	Guelfi JD, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression: Safety and efficacy data from a double-blind, double-dummy trial. Journal of affective disorders. 2000;58:201-209.
5352.	Guenter H, Moeller O, Erfurth A, et al. The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients. Pharmacopsychiatry. 2004;37:200-205.
5353.	Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses, Archives of general psychiatry(2011).
5354.	Guico-Pabia CJ, Jiang Q, Ninan PT, Thase ME. Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. Current medical research and opinion. 2011;27:1815-1826.
5355.	Guille C, Newman R, LD F, CK L, CN E. Management of postpartum depression. Journal of midwifery & women's health. 2013;58:632-642.
5356.	Guille C, Spencer S, Cavus I, CN E. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: Implications for diagnosis and treatment. Epilepsy & behavior. 2008;13:12-24.
5357.	Guille V, RJ C, BV On, Illic S, KL P, PJ N. An Examination of Acute Changes in Serotonergic Neurotransmission Using the Loudness Dependence Measure of Auditory Cortex Evoked Activity: Effects of Citalopram, Escitalopram and Sertraline. Human Psychopharmacology-Clinical and Experimental. 2008;23:231-241.
5358.	Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta neurologica Scandinavica. 1989;80:132-134.
5359.	Guillibert E, Pelicier Y, JC A, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatrica Scandinavica, Supplement. 1989;80:132-134.
5360.	Guillibert E, Pelicier Y, JC A, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta psychiatrica Scandinavica. Supplementum. 1989;350:132-134.
5361.	Guirguis-Blake J. Effectiveness of antidepressants compared with placebo for depression in primary care. American family physician. 2010;82:42.
5362.	Gulrez G, DK B, RS D, Sharma A. Bupropion as an Augmenting Agent in Patients of Depression With Partial Response. Basic & clinical pharmacology & toxicology. 2012;110:227-230.
5363.	Gulseren L, Gulseren S, Hekimsoy Z, Mete L. Comparison of Fluoxetine and Paroxetine in Type Ii Diabetes Mellitus Patients. Archives of medical research. 2005;36:159-165.
5364.	Gulseren L, Gulseren S, Hekimsoy Z, Mete L. Comparison of Fluoxetine and Paroxetine in Type Ii Diabetes Mellitus Patients. Archives of medical research. 2005;36:159-165.
5365.	Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. British medical journal. 2005;330:385-388.
5366.	Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Journal of urology. 2006;175:1433-1434.
5367.	Gunning-Dixon F, Cheng J, Acuna J, et al. Anterior cingulate regional volumes and treatment remission of geriatric depression. American journal of geriatric psychiatry. 2009;Conference:A63.
5368.	Gunter M. Pure gold of psychoanalysis or pure chemistry? How can we handle the counter-transference and the psychoanalyst's super-ego conflicts in combined treatment? Psychoanalytic psychotherapy. 2005;19:193-204.
5369.	Gunther T, Holtkamp K, Jolles J, Herpertz-Dahlmann B, Konrad K. The Influence of Sertraline on Attention and Verbal Memory in Children and Adolescents With Anxiety Disorders. Journal of child and adolescent psychopharmacology. 2005;15:608-618.
5370.	Gunther T, Holtkamp K, Jolles J, Herpertz-Dahlmann B, Konrad K. The Influence of Sertraline on Attention and Verbal Memory in Children and Adolescents With Anxiety Disorders. Journal of child and adolescent psychopharmacology. 2005;15:608-618.
5371.	Guo H-R, Ren Y-M, Li S-Y. Controlled Study of Mirtazapine and Mianserine in the Treatment of Senile Depression. [Chinese]. Chinese Mental Health Journal. 2005;19:489-491.
5372.	Guo J-H, Cao C-A, Liao C-P. Effect of Mirtazapine and Clomipramine on the Life Quality of Patients. [Chinese]. Chinese Mental Health Journal. 2006;20:413-415.
5373.	Guo T, Wang Y, Sun L, Zhang W, Ma W. Acupuncture combined with an antidepressant has a better effect on major depression: A multi-center, randomized, controlled clinical trial. BMC complementary and alternative medicine. 2012.
5374.	Gupta A, Pansari K, Shetty H. Post-stroke depression. International journal of clinical practice. 2002;56:531-537.
5375.	Gupta D, Radhakrishnan M, Kurhe Y. Ondansetron, a 5ht(3) Receptor Antagonist Reverses Depression and Anxiety-Like Behavior in Streptozotocin-Induced Diabetic Mice: Possible Implication of Serotonergic System. European journal of pharmacology. 2014;744:59-66.
5376.	Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2- methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models. European journal of pharmacology. 2014;735:59-67.
5377.	Gupta P, MS OM. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: Recommendations for prescribing. Drugs & aging. 2008;25:415-443.
5378.	Gupta S. Review of herbal drug of interactions to consolidate clinical and pharmacologic aspects. International Journal of Advances in Pharmaceutical Research. 2013;4:1517-1523.
5379.	Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. Journal of clinical pharmacology. 2004;44:1252-1259.
5380.	Gupta S, Masand P. Aripiprazole: Review of its pharmacology and therapeutic use in psychiatric disorders. Annals of clinical psychiatry. 2004;16:155-166.
5381.	Gustafson Y, Nilsson I, Mattsson M, Astrom M, Bucht G. Epidemiology and treatment of post-stroke depression. [Review] [45 refs]. Drugs & aging. 1995;7:298-309.
5382.	Guthrie E, Barlow J, Fernandes L, et al. Changes in Tolerance to Rectal Distension Correlate With Changes in Psychological State in Patients With Severe Irritable Bowel Syndrome. Psychosomatic medicine. 2004;66:578-582.
5383.	Guthrie E, Barlow J, Fernandes L, et al. Changes in Tolerance to Rectal Distension Correlate With Changes in Psychological State in Patients With Severe Irritable Bowel Syndrome. Psychosomatic medicine. 2004;66:578-582.
5384.	Guy C. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. Journal of clinical psychiatry. 1985;46:32-37.
5385.	Guy C, Bishan S, Marie-Claire B, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. Journal of affective disorders. 1999;54:39-48.
5386.	Guy D, Elise S-A, Chantal H, Claude dM, Normand L, Pierre B. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International journal of neuropsychopharmacology. 2007;10:51-61.
5387.	Guy EJ, Ann G. Placebo-controlled trial of paroxetine in depressive illness. Human Psychopharmacology: Clinical and Experimental. 1993;8:203-209.
5388.	The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies, Journal of clinical psychiatry(2012).
5389.	Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. Journal of clinical psychiatry. 1990;51 Suppl B:37-39.
5390.	Guy W, Manov G, WH W. Double-blind dose determination study of a new antidepressant-sertraline. Drug development research. 1986;9:267-272.
5391.	Guy W, WH W, TA B. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Drug development research. 1984;4:143-153.
5392.	Guy W, WH W, TA B, DL K, Manov G, OK F. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacology bulletin. 1984;20:73-78.
5393.	GV O, RA M, TP Y. Thyroid hormone augmentation in treatment-refractory depression. Clinical Psychopharmacology and Neuroscience. 2008;6:3-10.
5394.	GV P. Management and current treatment of irritable bowel syndrome. Annals of Gastroenterology. 2002;15:271-277.
5395.	GV P, IE K, AV K, NA E, ID S. [Clinical efficacy of escitalopram in patients with ischemic heart disease and comorbid depression]. [Russian]. Kardiologiia. 2009;49:4-8.
5396.	GV P, OA G, IuM I, EA T. [Clinical efficacy of citalopram in patients with hypertension and concomitant depression]. [Russian]. Kardiologiya. 2004;44:49-53.
5397.	GV P, OA G, YM Y, EA T. Clinical Efficacy of Citalopram in Patients With Hypertension and Concomitant Depression. Kardiologiya. 2004;44:49-53.
5398.	GV Z, Fabiano V, Manfredini V. Neonates born to mothers using antidepressant drugs. Early human development. 2012;88:S84-S85.
5399.	GW B, TO H, Kendrick T, et al. Antidepressants, social adversity and outcome of depression in general practice. Journal of affective disorders. 2010;121:239-246.
5400.	GW B-W, GW M. Major Depression: Does a Gender-Based Down-Rating of Suicide Risk Challenge Its Diagnostic Validity? Australian and New Zealand journal of psychiatry. 2001;35:322-328.
5401.	GW E, Vonthein R, Bode R, et al. Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): A short-term randomised controlled trial in pharmaco-resistant major depression. Journal of affective disorders. 2007;101:149-157.
5402.	GW S, Birkett M, BS M, et al. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. Journal of the American Geriatrics Society. 1996;44:1220-1225.
5403.	GW S, LS S, SH H, Bystritsky A, BS M, CB N. Site variability in a multisite geriatric depression trial. International journal of geriatric psychiatry. 1996;11:1089-1095.
5404.	GW S, SH H, Bystritsky A, BS M, CB N. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. International psychogeriatrics / IPA. 1995;7 Suppl:41-53.
5405.	GWD L. Escitalopram for the prevention of peginterferon-alpha2a - Associated depression. Annals of internal medicine. 2013;158:139-140.
5406.	Gyllenhaal C, FA H. Research briefings. Integrative cancer therapies. 2002;1:417-424.
5407.	Gysling E. Bupropion as antidepressant. [German]. Pharma-Kritik. 2007;29:45-47.
5408.	Gysling E. Depression in alcoholics. [German]. Pharma-Kritik. 2007;29:58-59.
5409.	G�mez-Gil E, Navin�s R, MJ MnDO, et al. Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment. Psychoneuroendocrinology. 2010;35:481-489.
5410.	H BE, M MJ, J MJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Journal of clinical psychiatry. 1995;56:229-237.
5411.	H CA, A CH, P HJ, et al. Bupropion Extended Release Compared With Escitalopram: Effects on Sexual Functioning and Antidepressant Efficacy in 2 Randomized, Double-Blind, Placebo-Controlled Studies. Journal of clinical psychiatry. 2006;67:736-746.
5412.	H CA, John Z, M FJ, K F-RJ, T BM, E SG. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International clinical psychopharmacology. 2003;18:151-156.
5413.	H FA, B SS, Maurizio F, et al. Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Human Psychopharmacology: Clinical and Experimental. 2006;21:221-225.
5414.	H GA, Jr BJT. Antidepressants in coronary heart disease: SSRIs reduce depression, but do they save lives? [References]. JAMA: Journal of the American Medical Association. 2007;297:411-412.
5415.	H GA, Jr BJT, Michael G. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: Seven-year follow-up of SADHART participants. Archives of general psychiatry. 2009;66:1022-1029.
5416.	H GA, M OCC. Sertraline for treatment of depression in acute coronary syndromes: Reply. JAMA: Journal of the American Medical Association. 2002;288:2403-2404.
5417.	H GA, Thomas BJ, Michael G, A SP, Robert SJ. Onset of Major Depression Associated With Acute Coronary Syndromes - Relationship of Onset, Major Depressive Disorder History, and Episode Severity to Sertraline Benefit. Archives of general psychiatry. 2006;63:283-288.
5418.	H GA, Thomas BJ, Michael G, T VZL. Heart rate variability in acute coronary syndrome patients with major depression: Influence of sertraline and mood improvement. Archives of general psychiatry. 2007;64:1025-1031.
5419.	H GL, Carbone F, Holvoet L, et al. Mirtazapine improves early satiation, nutrient intake, weight recovery and quality of life in functional dyspepsia with weight loss: A double-blind, randomized, placebo-ontrolled pilot study. Gastroenterology. 2013;Conference:S37.
5420.	H HJ, D TG, E FD. Response patterns of depressed outpatients with and without melancholia: A double-blind, placebo-controlled trial of fluoxetine versus placebo. Journal of affective disorders. 1994;30:163-173.
5421.	H HJ, D TG, Faries DE. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. International clinical psychopharmacology. 1993;8:247-251.
5422.	H HJ, E FD, John RA, et al. Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry research. 1994;52:327-339.
5423.	H HJ, EJr WJ, M BK, J RP, Carol A, D TG. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. International Psychogeriatrics. 1995;7:125-137.
5424.	H HJ, L HS, Dineen WK, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: A pilot study. Journal of child and adolescent psychopharmacology. 2006;16:207-217.
5425.	H HR. Electroencephalography technology for predicting response to antidepressant medications. Journal of psychosocial nursing and mental health services. 2006;44:11-14.
5426.	H HR. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design. [Review] [12 refs]. Journal of psychosocial nursing and mental health services. 2008;46:21-24.
5427.	H HR. Novel melatonin-based treatments for major depression: Comment. Lancet. 2012;379:215-216.
5428.	H HR. Mortality risk of mirtazapine: Guilt by association? [References]. JAMA Psychiatry. 2014;71:585-586.
5429.	H JR, G B-WE, A RM, et al. Treating depression and oppositional behavior in adolescents. Journal of clinical child and adolescent psychology. 2010;39:559-567.
5430.	H JR, G SS, A RM, et al. Dysfunctional Attitudes Scale perfectionism: A predictor and partial mediator of acute treatment outcome among clinically depressed adolescents. Journal of clinical child and adolescent psychology. 2009;38:803-813.
5431.	H KA, S QD, A GM, L FK, Kerri B, M GJ. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. [Review] [75 refs]. Biological psychiatry. 2010;67:1067-1074.
5432.	H KJ. Questions raised by the failure of a trial of short-term psychodynamic therapy versus pharmacotherapy for major depressive disorder. Journal of clinical psychiatry. 2012;73:64-65.
5433.	H KJ, Alan S, John RA, et al. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Archives of general psychiatry. 2002;59:723-728.
5434.	Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study, Journal of clinical psychiatry(2007).
5435.	H KJ, Sidney Z, Jonathan D, et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes. American journal of psychiatry. 1997;154:390-395.
5436.	H KS. Treatment guidelines for mania. Journal of psychiatry & neuroscience. 2006;31:144.
5437.	H KS. Agomelatine: efficacy at each phase of antidepressant treatment. [Review] [27 refs]. CNS drugs. 2009;23 Suppl 2:41-47.
5438.	H KS, A FK, Michael BR, L GA, L CN, Shahryar R-T. Sexual Function During Bupropion or Paroxetine Treatment of Major Depressive Disorder. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2006;51:234-242.
5439.	H KS, F AH, E TM. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current medical research and opinion. 2009;25:161-175.
5440.	H KS, F AH, W LR. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.[Erratum appears in J Psychiatry Neurosci. 2006 Jul;31(4):228]. Journal of psychiatry & neuroscience. 2006;31:122-131.
5441.	H KS, F AH, W LR. Efficacy of Escitalopram in the Treatment of Major Depressive Disorder Compared With Conventional Selective Serotonin Reuptake Inhibitors and Venlafaxine Xr: a Meta-Analysis. (Vol 31, Pg 122, 2006). Journal of psychiatry & neuroscience. 2006;31:228.
5442.	H KS, J RS. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. [Review] [85 refs]. CNS drugs. 2010;24:479-499.
5443.	H KS, Sakina R, Kari F, Jill R. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of clinical psychopharmacology. 2008;28:329-333.
5444.	H KS, Z KJ, V SZ, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. American journal of psychiatry. 2007;164:778-788.
5445.	H MB, G PB, D NR, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Journal of clinical psychiatry. 1999;60 Suppl 2:16-20.
5446.	H MB, G PB, Robert N, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. The American Journal of Geriatric Psychiatry. 2001;9:406-414.
5447.	H MC, Apurva P, C AA, G WJ, M WM. Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range. Journal of psychiatric research. 2006;40:337-348.
5448.	H MC, Apurva P, P HJ, Ralph S, J DM, Maurizio F. Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 2007;56:73-85.
5449.	H MC, G WJ, Chaofeng L, M WM, Joel R. Duloxetine in the treatment of major depressive disorder: A comparison of efficacy in patients with and without melancholic features. BMC psychiatry. 2005;5.
5450.	H MC, Joel R, M WM, G WJ, J DM. The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC psychiatry. 2004;4.
5451.	H MD, F AR, K LP, E VK, L WR, Ramon D-A. Sertraline and cognitive behavioral therapy for depressed alcoholics: Results of a placebo-controlled trial. Journal of clinical psychopharmacology. 2003;23:553-562.
5452.	H MJ. A novel placebo lead-in behavior strategy for sertraline dosing in a depressed patient highly sensitive to medication side effects [4]. Journal of clinical psychiatry. 1997;58:405-406.
5453.	H MJ, L SJ, S CW, S MR, C TL. Platelet activation in depression and effects of sertraline treatment: An open-label study. American journal of psychiatry. 2000;157:1006-1008.
5454.	H ML, Jari L, David S, Jouko L, Hannu A. Treatment of alcohol dependence in patients with co-morbid major depressive disorder-Predictors for the outcomes with memantine and escitalopram medication. Substance abuse treatment, prevention, and policy. 2008;3.
5455.	H ML, Jari L, Hannu A, Jouko L, Jari H, T SS. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence. Psychiatry research. 2011;186:53-57.
5456.	Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence, Psychiatry research(2009).
5457.	Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence, Journal of clinical psychiatry(2008).
5458.	H PM, JIII WJ, W OM, et al. Clinical trials-Anxiety disorders. Psychopharmacology bulletin. 1996;32:667-670.
5459.	H PR, A NA, E AJ, et al. The effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. Journal of clinical psychopharmacology. 2002;22:474-480.
5460.	H PR, Alpert J, Nierenberg AA, et al. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta psychiatrica Scandinavica. 2003;108:432-438.
5461.	H PR, Bonnie F, H AD, K SV, H TM, P HJ. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological psychiatry. 2009;65:785-791.
5462.	H PR, H AD, Bonnie F, et al. Genetic association of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. Journal of clinical psychiatry. 2010;71:599-605.
5463.	H PR, Rudolf U, Michael O, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Archives of general psychiatry. 2011;68:351-360.
5464.	H PR, Rudolf U, Nader P, Maurizio F. Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial? [References]. Journal of clinical psychiatry. 2012;73:1439-1442.
5465.	H PR, V ID, Jonathan A, A NA, F RJ, Maurizio F. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2004;45:224-229.
5466.	H PS, Beryl S, Jorge B, Cameron D. Antidepressant response and plasma concentrations of fluoxetine. Annals of clinical psychiatry. 1991;3:147-151.
5467.	H PS, Bryan B, Sheela K, S MF, Michael K, W LJ. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of clinical psychopharmacology. 2008;28:631-637.
5468.	H RD. Joy returns last: Anhedonia and treatment resistance in depressed adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 2012;51:353-355.
5469.	H SC, Christian G, B WA, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. Journal of clinical psychopharmacology. 1994;14:241-246.
5470.	H SJJM, Adriaan H, Edwin K, Jeanette D, Jelle J. Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta neuropsychiatrica. 2006;18:1-6.
5471.	H SJJM, Adriaan H, Richel L, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: Findings from a double-blind, placebo-controlled trial. Psychosomatic medicine. 2000;62:783-789.
5472.	H SJJM, M vPH, Adriaan H. [Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment]. [Dutch]. Tijdschrift voor gerontologie en geriatrie. 2003;34:104-112.
5473.	H SP, Arun R. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. Journal of clinical psychiatry. 1999;60:22-28.
5474.	H SP, Eliseo S. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Journal of clinical psychiatry. 2001;62:523-529.
5475.	H TJ, Caryl B, John J, Sami M, G DT. Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry research. 1997;73:27-32.
5476.	H TJ, G DT. Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: A double-blind, placebo-controlled study. American journal of psychiatry. 1995;152:616-618.
5477.	H TM, A PT, Philip P, E DK, L CM, D PC. Effectiveness of Low Doses of Paroxetine Controlled Release in the Treatment of Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:1356-1364.
5478.	H TM, E TM, Olawale O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. Journal of clinical psychiatry. 2009;70:387-396.
5479.	A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram, Journal of clinical psychiatry(2013).
5480.	H TM, J WG, Rajiv M, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. Journal of clinical psychopharmacology. 2004;24:497-506.
5481.	H TM, John RA, J CT, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? [References]. Journal of clinical psychiatry. 2001;62:776-781.
5482.	H TM, John RA, T KB, A NA, R WS, Maurizio F. "Combined treatments for depression as for other medical disorders": Reply. American journal of psychiatry. 2012;169:95-96.
5483.	H TM, K C-LP, Zhenchao G, D LR, Andrei P, Edward K. Remission, response without remission, and nonresponse in major depressive disorder: Impact on functioning. International clinical psychopharmacology. 2009;24:133-138.
5484.	H TM, L DD, G KS, et al. Psychosocial Outcomes in Patients With Recurrent Major Depressive Disorder During 2 Years of Maintenance Treatment With Venlafaxine Extended Release. Journal of affective disorders. 2010;126:420-429.
5485.	H YLP, J SL. Escitalopram in the treatment of major depressive disorder in adolescent patients: Profile report. CNS drugs. 2010;24:621-623.
5486.	H-B R. Are antidepressants also effective in fibromyalgia without accompanying depression?. [German]. MMW Fortschritte der Medizin. 2007;149:21-24.
5487.	H-B R, Ehrentraut S, G VD, et al. Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Journal of clinical psychiatry. 2000;61:750-755.
5488.	H-C K, R-B L, I-S S, C-C H. Plasma free 3-methpxy-4-hydroxyphenylglycol predicts response to fluoxetine. Biological psychiatry. 1997;41:774-781.
5489.	H-Ch D. Pharmacological approaches to migraine. Journal of Neural Transmission, Supplement. 2003:35-63.
5490.	H-D S, Richter P, Fritzsche M, A VT, Barnett W. Neurophysiologic tests during antidepressive treatment - An exploratory study. Pharmacopsychiatry. 2000;33:229-233.
5491.	H-G H. Depression: Treatment in the Family Doctor's Office. [German]. MMW Fortschritte der Medizin. 2008;150:56-58.
5492.	H-H C, P-S C, P-W G. Association between ABCB1 polymorphisms and fluoxetine/venlafaxine treatment response in taiwanese major depressive patients. Biological psychiatry. 2011;Conference:150S.
5493.	H-H T, Tsong Y, J-T L, Dong X, Wu Y. Weighted evidence approach of bridging study. Journal of biopharmaceutical statistics. 2012;22:952-965.
5494.	H-J A. Management of emergent psychiatric symptoms during smoking cessation. Current medical research and opinion. 2009;25:519-525.
5495.	Smoking, quitting, and psychiatric disease: A review, Neuroscience and biobehavioral reviews(2012).
5496.	H-J C, C-J H, C-H C. Paroxetine in the treatment of Chinese patients with depressive episode: A double-blind randomized comparison with imipramine. Zhonghua yi xue za zhi [Chinese medical journal; Free China ed]. 1996;57:418-423.
5497.	Antidepressants for neuro-regeneration: From depression to Alzheimer's disease, Archives of pharmacal research(2013).
5498.	Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies, International journal of cardiology(2015).
5499.	Predictors of depressive disorder following acute coronary syndrome: Results from K-DEPACS and EsDEPACS, Journal of affective disorders(2015).
5500.	H-J M. The influence of antidepressants on the suicidality of depressive patients. [German]. Fortschritte der Neurologie-Psychiatrie. 1994;62:19-23.
5501.	H-J M. Are all antidepressants the same? Journal of clinical psychiatry. 2000;61:24-28.
5502.	H-J M. Anxiety associated with comorbid depression. Journal of clinical psychiatry. 2002;63:22-26.
5503.	H-J M. SSRIs justly on trial?. [German]. Psychopharmakotherapie. 2004;11:69-70.
5504.	H-J M. SSRIs: Are the accusations justified? World journal of biological psychiatry. 2004;5:174-175.
5505.	H-J M. Resistance to antidepressant therapy. Definition, frequency, predictive factors, and medical strategies. [German]. Der Nervenarzt. 2004;75:499-517.
5506.	H-J M. Antidepressive effects of traditional and second generation antipsychotics: A review of the clinical data. European archives of psychiatry and clinical neuroscience. 2005;255:83-93.
5507.	H-J M. Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: Conceptual and treatment issues. World journal of biological psychiatry. 2005;6:247-263.
5508.	H-J M. Duloxetine - A new option for the treatment of depression and painful somatic symptoms. [German]. Psychopharmakotherapie, Supplement. 2005;12:12-14.
5509.	H-J M. Sertraline in the maintenance therapy and relapse prevention of unipolar depressive diseases. [German]. Psychopharmakotherapie. 2006;13:2-11.
5510.	H-J M. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. European archives of psychiatry and clinical neuroscience. 2006;256:329-343.
5511.	H-J M. Drug treatment of depressive symptoms in schizophrenia. Clinical schizophrenia & related psychoses. 2008;1:328-340.
5512.	H-J M. Critical comment on the results of the metaanalysis of Kirsch et al. 2008 regarding the efficacy of SSRIs. [German]. Psychopharmakotherapie. 2008;15:164-168.
5513.	H-J M. Psychopharmacological treatment of suicidal ideation and behaviour in the frame of mental disorders. Clinical Neuropsychiatry. 2011;8:277-286.
5514.	H-J M, Berzewski H, Eckmann F, et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry. 1993;26:75-78.
5515.	H-J M, Bitter I, Bobes J, Fountoulakis K, Hoschl C, Kasper S. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European psychiatry. 2012;27:114-128.
5516.	H-J M, DS B, Goodwin G, et al. Do Ssris or Antidepressants in General Increase Suicidality? Wpa Section on Pharmacopsychiatry: Consensus Statement. European archives of psychiatry and clinical neuroscience. 2008;258:3-23.
5517.	H-J M, Fuger J, Kasper S. Efficacy of New-Generation Antidepressants - Metaanalysis of Imipramine-Controlled Studies. Pharmacopsychiatry. 1994;27:215-223.
5518.	H-J M, Gallinat J, Hegerl U, et al. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry. 1998;31:170-177.
5519.	H-J M, Glaser K, Leverkus F, Gobel C. Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry. 2000;33:206-212.
5520.	H-J M, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. European archives of psychiatry and clinical neuroscience. 2006;256:1-16.
5521.	H-J M, H-P V. Drug treatment of depression in the 1990s: An overview of achievements and future possibilities. Drugs. 1996;52:625-638.
5522.	H-J M, Seemuller F, Schennach-Wolff R, Stubner S, Ruther E, Grohmann R. History, background, concepts and current use of comedication and polypharmacy in psychiatry. International journal of neuropsychopharmacology. 2014;17:983-996.
5523.	H-J M, Steinmeyer EM. Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. European neuropsychopharmacology. 1994;4:55-59.
5524.	H-J R, Zeitler C, Schreiber H, Wild A. [Additional treatment in chronic pain syndrome due to hip and knee arthritis with the selective serotonin reuptake inhibitor fluvoxamine (Fevarin]. [German]. Zeitschrift fur Orthopadie und Unfallchirurgie. 2008;146:742-746.
5525.	H-J S, MS S, AA P, PS M, C-U P. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. [Review] [42 refs]. Postgraduate medicine. 2010;122:125-138.
5526.	H-M W, M-H Y, Liu Y, S-D L, Li M. Effectiveness of Bushen Huoxue Granule () on 5-serotonin and norepinephrine in the brain of Parkinson's disease patients with depressive state. Chinese journal of integrative medicine. 2014;20:944-948.
5527.	H-M W, M-H Y, Liu Y, S-D L, Li M. Effectiveness of Bushen Huoxue Granule () on 5-serotonin and norepinephrine in the brain of Parkinson's disease patients with depressive state. Chinese journal of integrative medicine. 2014;20:944-948.
5528.	H-N C, Alonzo A, DM M, PB M, Sachdev P, CK L. Augmenting transcranial direct current stimulation with D-cycloserine for depression: A pilot study. Journal of ECT. 2013;29:196-200.
5529.	H-N C, PB M, CK L, SB H. Pharmacological treatment approaches to difficult-to-treat depression. Medical journal of Australia. 2012;1:44-47.
5530.	H-P S, Kuhs H, LH R, et al. Platelet 5-HT transport in depressed patients under double-blind treatment with paroxetine versus amitriptyline. Acta Psychiatrica Scandinavica, Supplement. 1989;80:149-151.
5531.	H-P S, Kuhs H, Rolf LH, et al. Platelet 5-HT transport in depressed patients under double-blind treatment with paroxetine versus amitriptyline. Acta neurologica Scandinavica. 1989;80:149-151.
5532.	H-P V. Is there evidence for a stage-dependent dosage of antidepressants?. [German]. Psychopharmakotherapie, Supplement. 1997;4:12-16.
5533.	H-P V. Chances and opportunities of new antidepressants. [German]. Psychopharmakotherapie, Supplement. 2005;12:45-50.
5534.	H-P V. Is there a clinical benefit from antidepressant pharmacotherapy? Pro. [German]. Psychopharmakotherapie. 2008;15:157-159.
5535.	H-P V. Escitalopram-Data concerning long-term efficacy. [German]. Die Psychiatrie: Grundlagen & Perspektiven. 2009;6:97-101.
5536.	H-P V. Duloxetine - Current data and practical use. [German]. Psychopharmakotherapie. 2009;16:239-245.
5537.	H-P V. Duloxetine. [German]. Die Psychiatrie: Grundlagen & Perspektiven. 2010;7:107-117.
5538.	H-P V. Efficacy differences between escitalopram and citalopram: A systematic survey. [German]. Psychopharmakotherapie. 2011;18:172-178.
5539.	H-P V, Faltus F, Magyar I, H-J M. Brofaromine in treatment-resistant depressed patients a comparative trial versus tranylcypromine. Journal of affective disorders. 1994;30:209-217.
5540.	H-P V, H-J M. Antidepressant drug therapy in the elderly - A critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry. 1994;27:93-100.
5541.	H-P V, Laux P. Antidepressive pharmacotherapy in mild to moderate depression - A comparison of extracts of St. John's wort and fluoxetine. [German]. Psychopharmakotherapie. 1999;6:138-142.
5542.	H-P V, Laux P. Potential Treatment for Subthreshold and Mild Depression: a Comparison of St. John's Wort Extracts and Fluoxetine. Comprehensive psychiatry. 2000;41:133-137.
5543.	H-Q Z, D-G L, G-H S. Effect of paroxetine hydrochloride and pinaverium bromide therapy in patients with irritable bowel syndrome. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2002;6:3576-3577.
5544.	Association of PDE11A global haplotype with major depression and antidepressant drug response, Neuropsychiatric disease and treatment(2009).
5545.	H-T W, Liu H, A-J X, Kan Q, Li R. Effect of fluoxetine on expression of phosphorylated microtubule-associated protein -2 in amygdala of depressional rats. [Chinese]. Journal of Jilin University Medicine Edition. 2012;38:713-716.
5546.	H-X G, Xue R, Y-F L, H-W W, Y-Z Z. Long term regular physical exercise improve chronic unpredictable stress induced depression and cognitive impairment in rats. Acta pharmacologica Sinica. 2013;Conference:103.
5547.	H-Y D, W-M Y, Zhang B, H-T Y. Anxiolytic intervention for coronary heart disease patients combined with anxiety disorder. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:23-25.
5548.	H-Y H, M-N T, Ma C, G-D M, W-S H, H-B Z. Evaluation on the effects of community management mode in improving the quality of life in patients with dementia. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:3-6.
5549.	H-Y L. Treatment of NMDA agonist, glycine transporter i Inhibitor and D-Amino acid oxidase inhibitor for mental disorders. International journal of neuropsychopharmacology. 2012;Conference:37.
5550.	H-Y T, Wu J, L-F B, et al. [Effects of Betel shisanwei ingredients pill on AC-cAMP-PKA signal transduction pathways in hippocampus and prefrontal cortex of depressive rats]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2014;39:1946-1950.
5551.	H-Z L, J-L M, Y-L Z. Venlafaxine extended release and lithium salt for major depressive disorder in nonresponders to selective serotonin reuptake inhibitors. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:4-6.
5552.	HA E, Air T, Proctor S, Rositano S, BT B. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Progress in neuro-psychopharmacology & biological psychiatry. 2015;57:11-16.
5553.	HA F. Natural course, placebo effect, and sham electroconvulsive therapy. Journal of ECT. 2010;26:76.
5554.	HA G, SP H. Genetic studies of drug response and side effects in the STAR*D study, part 2. Journal of clinical psychiatry. 2009;70:1323-1325.
5555.	HA H, Emre M. Treatment of behavioural symptoms and dementia in Parkinson's disease. Fundamental & clinical pharmacology. 2005;19:133-146.
5556.	HA H, Saha D, PJ D, SD A. Saffron (Crocus sativus L.) and major depressive disorder: A meta-analysis of randomized clinical trials. Journal of Integrative Medicine. 2013;11:377-383.
5557.	HA S. Convulsant and anticonvulsant properties of electroconvulsive therapy: Towards a focal form of brain stimulation. Clinical neuroscience research. 2004;4:39-57.
5558.	HA S, EM D, Prudic J, et al. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: Short-term efficacy and adverse effects. Archives of general psychiatry. 2009;66:729-737.
5559.	HA S, Frank E, Zuckoff A, et al. Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment. American journal of psychiatry. 2008;165:1155-1162.
5560.	HA S, LJ B. Etiology and treatment of overactive bladder in women. Southern medical journal. 2011;104:34-39.
5561.	HA S, ME T. Pharmacotherapy for the treatment of acute bipolar II Depression: Current evidence. Journal of clinical psychiatry. 2011;72:356-366.
5562.	HA S, SP R, PW L. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biological psychiatry. 2006;59:483-492.
5563.	Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial, General hospital psychiatry(2015).
5564.	Hachisu M, Ichimaru Y. Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan. [Japanese]. Folia Pharmacologica Japonica. 2000;115:271-279.
5565.	Hackett D. Comparing Onset of Effect of Antidepressants: Pragmatic Considerations on Methods and End-Points. European psychiatry. 1998;13:117-123.
5566.	Hackett D. Venlafaxine Xr in the Treatment of Anxiety. Acta psychiatrica Scandinavica. Supplementum. 2000;102:30-35.
5567.	Haddad P. Do Antidepressants Have Any Potential to Cause Addiction? Journal of psychopharmacology (Oxford, England). 1999;13:300-307.
5568.	Hadine J, N SC, F PL, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. Journal of clinical psychiatry. 2007;68:943-950.
5569.	Hadjipavlou G, Mok H, LN Y. Pharmacotherapy of Bipolar Ii Disorder: a Critical Review of Current Evidence. Bipolar disorders. 2004;6:14-25.
5570.	Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and Combination Drug Therapies in Hospitalized Patients With Bipolar Depression. Data From the European Drug Surveillance Program Amsp. BMC psychiatry. 2012;12.
5571.	Haen E, Schneider E, Waldeck B. Tolerability and Safety of Duloxetine in the Treatment of Depressive Patients. Psychopharmakotherapie. 2008;15:115-+.
5572.	Hafizi S. Depression: Epidemic or pseudo-epidemic? [6]. Journal of the Royal Society of Medicine. 2006;99:436.
5573.	Hafizi S, Chandra P, PJ C. Neurokinin-1 receptor antagonists as novel antidepressants: Trials and tribulations. British journal of psychiatry. 2007;191:282-284.
5574.	Haggstrom L, RZ N, Danchenko N, Poulsen L. A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. European neuropsychopharmacology. 2013;Conference:S412.
5575.	Hahm W. An open label study of mirtazapine in the treatment of depression with Alzheimer's disease. European neuropsychopharmacology. 2010;Conference:S552.
5576.	Haider A, DR M, JL C, AG C, RD S. Clinical effect of converting antidepressant therapy from fluoxetine to sertraline. American journal of health-system pharmacy. 1995;52:1317-1319.
5577.	Haimov-Kochman R, Hochner-Celnikier D. Hot flashes revisited: Pharmacological and herbal options for hot flashes management. What does the evidence tell us? Acta obstetricia et gynecologica Scandinavica. 2005;84:972-979.
5578.	Hainer V, Kabrnova K, Aldhoon B, Kunesova M, Wagenknecht M. Serotonin and norepinephrine reuptake inhibition and eating behavior. Stress, Obesity, and Metabolic Syndrome. 2006;Annals of 252-269.
5579.	Haj-Mirzaian A, Amiri S, Kordjazy N, et al. Blockade of NMDA receptors reverses the depressant, but not anxiogenic effect of adolescence social isolation in mice. European journal of pharmacology. 2015;750:160-166.
5580.	Hajak G, Landgrebe M. Therapeutic options in depression and pain: Review with special reference to duloxetine. [German]. Psychopharmakotherapie, Supplement. 2005;12:5-11.
5581.	Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Hoschl C. Amygdala volumes in mood disorders - Meta-analysis of magnetic resonance volumetry studies. Journal of affective disorders. 2009;115:395-410.
5582.	Hajiaghaee R, Akhondzadeh S. Evidence based herbal medicine and mental health. Journal of Medicinal Plants. 2012;11:1-8.
5583.	Hajiaghaee R, Heidari M, Akhondzadeh S. Saffron a prototype example for evidence based herbal medicine. Journal of Medicinal Plants. 2013;12:1-7.
5584.	Hajos M, JC F, JK F-R, MT B, EHF W. The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile. CNS drug reviews. 2004;10:23-44.
5585.	Hakanson R. S-enantiomer of the selective serotonin reuptake inhibitor citalopram compared with racemate citalopram (S+R). Pharmacology & toxicology. 2001;89:153-155.
5586.	Hakanson R. Letter to the Editor. Pharmacology & toxicology. 2002;90:3-4.
5587.	HAKHP K. Psychopharmacological Treatment in Patients With Somatoform Disorders and Functional Body Syndromes. Der Nervenarzt. 2012;83:1128-+.
5588.	Halaris A. Antiinflammatory augmentation strategy reverses treatment resistant bipolar depression. Biological psychiatry. 2015;Conference:297S.
5589.	Halaris A, Alvi N, Meresh E, Sharma A. Inflammation control reverses treatment-resistance in bipolar depression. Neurology Psychiatry and Brain Research. 2014;Conference:12-13.
5590.	Halaris A, Meresh E, Sharma A, Alvi N, Sinacore J. Inflammation control augments antidepressant response in bipolar depression. Brain, behavior, and immunity. 2013;Conference:e26.
5591.	Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: Effective but not enough. CNS spectrums. 2008;13:566-572.
5592.	Halbreich U, Bergeron R, KA Y, Freeman E, AL S, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics and gynecology. 2002;100:1219-1229.
5593.	Halbreich U, JW S. Intermittent Luteal Phase Sertraline Treatment of Dysphoric Premenstrual Syndrome. Journal of clinical psychiatry. 1997;58:399-402.
5594.	Halbreich U, LS K. Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline. Expert opinion on pharmacotherapy. 2003;4:2065-2078.
5595.	Halbreich U, PMS OB, Eriksson E, Backstrom T, KA Y, EW F. Are There Differential Symptom Profiles That Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder? CNS drugs. 2006;20:523-547.
5596.	Hale A. Agomelatine: More than just another antidepressant. Progress in neurology and psychiatry. 2010;14:28-29.
5597.	Hale A, Corral R, Mencacci O, JS R, Albarransevero C, Gentil V. Superior Antidepressant Efficacy of Agomelatine Vs Fluoxetine in Severe Major Depressive Disorder Patients: a Randomised, Double-Blind Study. European neuropsychopharmacology. 2009;Conference:S418-S419.
5598.	Hale T, Cialdella P, RA F, et al. Effective and acceptable treatment for depression [4]. British medical journal. 1993;306:1124-1127.
5599.	Hall E, BN F, CN S. Non-hormonal treatment strategies for vasomotor symptoms: A critical review. Drugs. 2011;71:287-304.
5600.	Hall J. Fluoxetine: efficacy against placebo and by dose--an overview. British Journal of Psychiatry - Supplementum. 1988:59-63.
5601.	Hall J, CA N, BA S, Herrmann N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. Journal of clinical psychopharmacology. 2003;23:349-357.
5602.	Hall W. Feeling 'better than well'. EMBO reports. 2004;5:1105-1109.
5603.	Haller E. Depression during and after pregnancy: What does the primary care physician need to know? Advanced Studies in Medicine. 2005;5:21-26.
5604.	Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues in clinical neuroscience. 2007;9:47-59.
5605.	HAM M. Collegium Internationale Neuro-Psychopharmacologicum - 23rd Congress: Localization and function of 5-HT2 receptors: 23-27 June 2002, Montreal, QB, Canada. IDrugs : the investigational drugs journal. 2002;5:776-778.
5606.	HAMH M. Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome. [Review]. Therapeutic drug monitoring. 2012;34:607-614.
5607.	Hamid H, AM K. Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs? Epilepsy & behavior. 2013;26:261-265.
5608.	Hammerness P, Basch E, Ulbricht C, et al. St. John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44:271-282.
5609.	Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review. Neuropsychiatric disease and treatment. 2009;5:215-226.
5610.	Hamrin V, MA M, Moffett J, Durso S. Psychopharmacological treatment of non-comorbid and comorbid pervasive developmental disorder and pediatric bipolar disorder. Minerva pediatrica. 2008;60:87-101.
5611.	Hamrin V, Scahill L. Selective serotonin reuptake inhibitors for children and adolescents with major depression: Current controversies and recommendations. Issues in mental health nursing. 2005;26:433-450.
5612.	Han C, C-U P. Oral scopolamine augmentation for major depression. Expert review of neurotherapeutics. 2013;13:19-21.
5613.	Han C, CU P, BH L, et al. Fluoxetine Versus Sertraline in the Treatment of Patients With Undifferentiated Somatoform Disorder: a Randomized, Open-Label, 12-Week, Parallel-Group Trial. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:437-444.
5614.	Han C, CU P, BH L, et al. Venlafaxine Versus Mirtazapine in the Treatment of Undifferentiated Somatoform Disorder - a 12-Week Prospective, Open-Label, Randomized, Parallel-Group Trial. Clinical drug investigation. 2008;28:251-261.
5615.	Han C, PS M, Krulewicz S, et al. Childhood Abuse and Treatment Response in Patients With Irritable Bowel Syndrome: a Post-Hoc Analysis of a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine Controlled Release. Journal of clinical pharmacy and therapeutics. 2009;34:79-88.
5616.	Han C, S-J L, S-Y L, et al. Available therapies and current management of fibromyalgia: Fcusing on pharmacological agents. Drugs of today (Barcelona, Spain : 1998). 2011;47:539-557.
5617.	Han D, ECY W. Remission From Depression - a Review of Venlafaxine Clinical and Economic Evidence. PharmacoEconomics. 2005;23:567-581.
5618.	Han D, ECY W. Remission From Depression - a Review of Venlafaxine Clinical and Economic Evidence. PharmacoEconomics. 2005;23:567-581.
5619.	Han L, McCusker J, Cole M, Capek R, Abrahamowicz M. Antidepressant use and cognitive functioning in older medical patients with major or minor depression: a prospective cohort study with database linkage. Journal of clinical psychopharmacology. 2011;31:429-435.
5620.	Han L, McCusker J, Cole M, Capek R, Abrahamowicz M. Antidepressant use and cognitive functioning in older medical patients with major or minor depression: a prospective cohort study with database linkage. Journal of clinical psychopharmacology. 2011;31:429-435.
5621.	Hanci N, OC E, Miraloglu O, MA U, Ozkaya G, SS E. Relationship Between Antidepressant Prescription Rates and Features of Schizophrenic Patients and Its Outcome in Schizophrenia Treatment. Noropsikiyatri Arsivi-Archives of Neuropsychiatry. 2015;52:64-68.
5622.	Handoko H-P. Use of fluvoxamine and amitriptyline for the management of chronic pain in depressed patients. Primary care & community psychiatry. 2007;12:17-22.
5623.	Hanken K, Eling P, Hildebrandt H. Is There a Cognitive Signature for Ms-Related Fatigue? Multiple Sclerosis Journal. 2015;21:376-381.
5624.	Hanna N, Karabelnik L, Ranga J. Risk of suicide and SSRIs. Connecticut medicine. 2005;69:541-546.
5625.	Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Human psychopharmacology. 2001;16:495-505.
5626.	Hansenne M, Pitchot W, Pinto E, et al. 5-HT1A dysfunction in borderline personality disorder. Psychological medicine. 2002;32:935-941.
5627.	Hansson M, Bodlund O, Chotai J. Patient education and group counselling to improve the treatment of depression in primary care: A randomized controlled trial. Journal of affective disorders. 2008;105:235-240.
5628.	Hantsoo L, Ward-O'Brien D, KA C, Gueorguieva R, LH P, CN E. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology. 2014;231:939-948.
5629.	Harada E, Schacht A, Koyama T, LB M, Tsuji T, Escobar R. Efficacy Comparison of Duloxetine and Ssris at Doses Approved in Japan. Neuropsychiatric disease and treatment. 2015;11:115-123.
5630.	Harada Y, Kohara N, Imaeda T. [Pharmacological, pharmacokinetic, and clinical profile of sertraline hydrochloride (J ZOLOFT)]. [Review] [43 refs] [Japanese]. Nippon Yakurigaku Zasshi - Folia Pharmacologica Japonica. 2006;128:417-424.
5631.	Harald M, Maurizio F, Jonathan A, et al. Hypericum extract in patients with MDD and reversed vegetative signs: Re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. International journal of neuropsychopharmacology. 2005;8:215-221.
5632.	Harbottle L, Schonfelder N. Nutrition and depression: A review of the evidence. Journal of mental health (Abingdon, England). 2008;17:576-587.
5633.	Hardeland R. Cognitive enhancers in moderate to severe Alzheimer's disease. Clinical Medicine Insights: Therapeutics. 2011;3:459-476.
5634.	Haria M, Fitton A, Mctavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. [Review] [200 refs]. Drugs & aging. 1994;4:331-355.
5635.	Harley J, Luty S, Carter J, Mulder R, Joyce P. Elevated C-reactive protein in depression: A predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. Journal of psychopharmacology (Oxford, England). 2010;24:625-626.
5636.	Harley J, Roberts R, Joyce P, et al. Orosomucoid influences the response to antidepressants in major depressive disorder. Journal of psychopharmacology (Oxford, England). 2010;24:531-535.
5637.	Harm-Pieter S, Pascal S, Filip B, et al. Speed of remission in elderly patients with depression: Electroconvulsive therapy V. medication. The British Journal of Psychiatry. 2015;206:67-71.
5638.	Harmark L, E VP, K VG. Intensive Monitoring of Duloxetine: Results of a Web-Based Intensive Monitoring Study. European journal of clinical pharmacology. 2013;69:209-215.
5639.	Harmer CJ, Heinzen J, O'Sullivan U, Ayres RA, Cowen PJ. Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers. Psychopharmacology. 2008;199:495-502.
5640.	Haro R, Drucker-Colin R. A Two-Year Study on the Effects of Nicotine and Its Withdrawal on Mood and Sleep. Pharmacopsychiatry. 2004;37:221-227.
5641.	Haro R, Drucker-Colin R. Effects of Long-Term Administration of Nicotine and Fluoxetine on Sleep in Depressed Patients. Archives of medical research. 2004;35:499-506.
5642.	Haro R, Drucker-Colin R. A Two-Year Study on the Effects of Nicotine and Its Withdrawal on Mood and Sleep. Pharmacopsychiatry. 2004;37:221-227.
5643.	Haro R, Drucker-Colin R. Effects of Long-Term Administration of Nicotine and Fluoxetine on Sleep in Depressed Patients. Archives of medical research. 2004;35:499-506.
5644.	Haroon E, CL R, AH M. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37:137-162.
5645.	Haroon E, Kumar A. The clinical neuroscience of post stroke depression. Current neuropharmacology. 2004;2:353-362.
5646.	Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittel-Forschung/Drug Research. 1999;49:289-296.
5647.	Harris A, Boyce P, Rekshan W, et al. Does personality predict outcome in major depression. Biological psychiatry. 2013;Conference:159S.
5648.	Harris S. Clinical Trials in CNS - SMi Conference. IDrugs : the investigational drugs journal. 2005;8:25-28.
5649.	Harry C, Jr SE, Trisha H, R BS, J DRM, A AJ. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 1999;21:643-658.
5650.	Hart JR. The role of change in dysfunctional attitudes and extreme thinking in failure to maintain remission among adolescents treated for depression. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2009;70:2575.
5651.	Hart S, Fonareva I, Merluzzi N, DC M. Treatment for Depression and Its Relationship to Improvement in Quality of Life and Psychological Well-Being in Multiple Sclerosis Patients. Quality of life research. 2005;14:695-703.
5652.	Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an Snri Treatment for Generalized Anxiety Disorder: Results From a Placebo and Active-Controlled Trial. International clinical psychopharmacology. 2007;22:167-174.
5653.	Harth W, Hermes B, Niemeier V, Gieler U. Clinical pictures and classification of somatoform disorders in dermatology. European journal of dermatology. 2006;16:607-614.
5654.	Harth W, Seikowski K, Hermes B, Gieler U. Lifestyle drugs in medicine. [German]. Wiener medizinische Wochenschrift (1946). 2008;158:110-115.
5655.	Hartikainen S, Rahkonen T, Kautiainen H, Sulkava R. Use of psychotropics among home-dwelling nondemented and demented elderly. International journal of geriatric psychiatry. 2003;18:1135-1141.
5656.	Hartmann U. Depression and sexual dysfunction. Journal of men's health & gender. 2007;4:18-25.
5657.	Hartvig P, Bergstrom M, Antoni G, Langstrom B. Positron emission tomography and brain monoamine neurotransmission - Entries for study of drug interactions. Current pharmaceutical design. 2002;8:1417-1434.
5658.	Haruka M, W KC, L BE, et al. Effects of depression history and sex on the efficacy of sequential versus standard fluoxetine for smoking cessation in elevated depressive symptom smokers. Addictive disorders & their treatment. 2015;14:29-39.
5659.	Haruka M, W KC, Litvin BE, et al. Effects of sequential fluoxetine and gender on prequit depressive symptoms, affect, craving, and quit day abstinence in smokers with elevated depressive symptoms: A growth curve modeling approach. Experimental and clinical psychopharmacology. 2014;22:392-406.
5660.	Hasbroucq T, Rihet P, Blin O, C-A P. Serotonin and human information processing: Fluvoxamine can improve reaction time performance. Neuroscience letters. 1997;229:204-208.
5661.	Hasenburg A, Gabriel B, E-M E. Sexuality after ovarian cancer therapy. [German]. Geburtshilfe und Frauenheilkunde. 2008;68:994-997.
5662.	Hasey G, MacCrimmon D, Abraham G, Milev R, Lawson S. Bilateral transcranial magnetic stimulation: Does adding right low frequency diminish the antidepressant effect of left high frequency treatment. Biological psychiatry. 2009;Conference:221S.
5663.	Hashemian F, Majd M, SM H, Sharifi A, MVS P, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klinik Psikofarmakoloji Bulteni. 2011;Conference:S183-S184.
5664.	Hashemian F, MS T, Sharifi A, Majd M. Comparison of the effects of bupropion and fluoxetine on reaction time in adults with major depressive disorder in a 4-week, single-blind study. Klinik Psikofarmakoloji Bulteni. 2011;Conference:S113.
5665.	Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain research reviews. 2009;61:105-123.
5666.	Hashimoto K. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder". Journal of clinical psychopharmacology. 2009;29:411-412; author reply 412.
5667.	Hashimoto K. Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert review of neurotherapeutics. 2011;11:33-36.
5668.	Hashimoto K. Therapeutic implications for NMDA receptors in mood disorders. Expert review of neurotherapeutics. 2013;13:735-737.
5669.	Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. Journal of pharmacological sciences. 2015;127:6-9.
5670.	Hashimoto T, Shiina A, Hasegawa T, et al. Effect of Mirtazapine for Benzodiazepines Use Compared With Selective Serotonin Reuptake Inhibitors in Patients With Major Depressive Disorder: a Multicenter, Open-Label, Randomized, Controlled Trial. International journal of neuropsychopharmacology. 2014;17:56.
5671.	Haslam C, Nurmikko T. Pharmacological treatment of neuropathic pain in older persons. Clinical interventions in aging. 2008;3:111-120.
5672.	Hasnain M, WVR V. Weight Considerations in Psychotropic Drug Prescribing and Switching. Postgraduate medicine. 2013;125:117-129.
5673.	Hasnain M, WVR V. Qtc Interval Prolongation and Torsade De Pointes Associated With Second-Generation Antipsychotics and Antidepressants: a Comprehensive Review. CNS drugs. 2014;28:887-920.
5674.	Hasnain M, WVR V, Hollett B. Weight Gain and Glucose Dysregulation With Second-Generation Antipsychotics and Antidepressants: a Review for Primary Care Physicians. Postgraduate medicine. 2012;124:154-167.
5675.	Hassan A, WE H. Appropriateness of timing of drug administration in electronic prescriptions. Pharmacy World and Science. 2010;32:162-171.
5676.	Hassler F, Duck A, Reis O, Buchmann J. Alternative agents used in ADHD. [German]. Psychopharmakotherapie. 2007;14:229-236.
5677.	Hatcher S. The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light? Evidence-based mental health. 2008;11:97-99.
5678.	Hatcher S, Arroll B. Newer antidepressants for the treatment of depression in adults. BMJ (Online). 7841.
5679.	Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer. 2008;112:982-994.
5680.	Hauser W. Fibromyalgia-what really works? From ancient to recent managements. Annals of the rheumatic diseases. 2014;73.
5681.	Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA - Journal of the American Medical Association. 2009;301:198-209.
5682.	Hauser W, Petzke F, Sommer C. Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome. Journal of pain. 2010;11:505-521.
5683.	Hauser W, Petzke F, Uceyler N, Sommer C. Comparative Efficacy and Acceptability of Amitriptyline, Duloxetine and Milnacipran in Fibromyalgia Syndrome: a Systematic Review With Meta-Analysis. Rheumatology. 2011;50:532-543.
5684.	Hauser W, Sarzi-Puttini P, TR T, Wolfe F. Placebo and Nocebo Responses in Randomised Controlled Trials of Drugs Applying for Approval for Fibromyalgia Syndrome Treatment: Systematic Review and Meta-Analysis. Clinical and experimental rheumatology. 2012;30:S78-S87.
5685.	Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B. Serotonin and Noradrenaline Reuptake Inhibitors (Snris) for Fibromyalgia Syndrome (Review). Cochrane database of systematic reviews (Online). 2013.
5686.	Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis. CNS drugs. 2012;26:297-307.
5687.	Hausmann A, Kemmler G, Walpoth M, et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: A prospective, single centre, randomised, double blind, sham controlled "add on" trial. Journal of neurology, neurosurgery, and psychiatry. 2004;75:320-322.
5688.	HAVH-P V. Efficacy Differences Between Escitalopram and Citalopram: a Systematic Survey. Psychopharmakotherapie. 2011;18:172-+.
5689.	Haw C, Stubbs J. Off-label use of antipsychotics: Are we mad? Expert opinion on drug safety. 2007;6:533-545.
5690.	Haw C, Stubbs J. Medication for borderline personality disorder: A survey at a secure hospital. International journal of psychiatry in clinical practice. 2011;15:280-285.
5691.	Hawgood J, D DL. Anxiety disorders and suicidal behaviour: An update. Current opinion in psychiatry. 2008;21:51-64.
5692.	Hawley C, Feetam C. In depression one size does not fit all - Antidepressants are not all equal. Pharmaceutical journal. 2010;284:160-161.
5693.	Hay P. Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Australian and New Zealand journal of psychiatry. 2004;38:659-670.
5694.	Hayasaka Y, Purgato M, LR M, et al. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Journal of affective disorders. 2015;180:179-184.
5695.	Hayee B, Forgacs I. Psychological approach to managing irritable bowel syndrome. British medical journal. 2007;334:1105-1109.
5696.	Hayes D. Recent developments in antidepressant therapy in special populations. [Review] [56 refs]. American journal of managed care. 2004;10:S179-185.
5697.	Hayes D. Recent Developments in Antidepressant Therapy in Special Populations. American journal of managed care. 2004;10:S179-S185.
5698.	Hayes D. Recent Developments in Antidepressant Therapy in Special Populations. American journal of managed care. 2004;10:S179-S185.
5699.	Hayley S, Litteljohn D. Neuroplasticity and the next wave of antidepressant strategies. Frontiers in cellular neuroscience. 2013.
5700.	Hazell P. Pharmacological management of attention-deficit hyperactivity disorder in adolescents: Special considerations. CNS drugs. 2007;21:37-46.
5701.	Hazell P. Prescribing psychotropic medication in children and adolescents. Medicine today. 2008;9:42-47.
5702.	HB S, Husain M, PB F, et al. Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: Acute and six month outcomes. Brain stimulation. 2014;7:219-225.
5703.	HB S, KS G, MR L. Cognitive-Behavioral Therapy as an Adjunct to Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: an Open Trial. Journal of clinical psychiatry. 1999;60:584-590.
5704.	HC D, Basinski J, BH M, et al. Late-onset major depression: Clinical and treatment-response variability. International journal of geriatric psychiatry. 2005;20:661-667.
5705.	HC K, DF M, AM M. Cerebrovascular disease and late-life depression. American journal of geriatric psychiatry. 2005;13:88-98.
5706.	HC K, GT W, CG F, WS A. Mediators and moderators of treatment effects in randomized clinical trials. Archives of general psychiatry. 2002;59:877-883.
5707.	HC K, LN G, CG L. Assessment and management of behavioral and psychological symptoms of dementia. BMJ (Online). 2015.
5708.	HC K, RB L, IS S, CC H. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Biological psychiatry. 1997;41:774-781.
5709.	HC S, BH B, PR H, Mazumdar S, 3rd RCF, BL R. Treating post-CABG depression with telephone-delivered collaborative care: does patient age affect treatment and outcome? American journal of geriatric psychiatry. 2011;19:871-880.
5710.	HC S, BH B, PR H, Mazumdar S, 3rd RCF, BL R. Treating post-CABG depression with telephone-delivered collaborative care: does patient age affect treatment and outcome? American journal of geriatric psychiatry. 2011;19:871-880.
5711.	HC S, Katon W, GE S, AJ R. Treating major depression in primary care practice: An update of the agency for health care policy and research practice guidelines. Archives of general psychiatry. 1998;55:1121-1127.
5712.	HC W, PS C. Genetic polymorphisms of CYP2C19 influence treatment response to antidepresants in a taiwanese population with major depressive disorder. Biological psychiatry. 2011;Conference:155S.
5713.	HCR G. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues in clinical neuroscience. 2008;10:77-89.
5714.	HCR G. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: Fact or overinterpretation? CNS spectrums. 2008;13:790-795.
5715.	HD N. Menopause. Lancet. 2008;371:760-770.
5716.	HD R. Phytopharmaceutics and phytotherapy - Research and practice. [German]. Zeitschrift fur Phytotherapie. 2003;24:126-135.
5717.	HE G, Rosenthal B. Post-launch clinical investigator drug prescribing in the US: The behaviour of clinical trial investigators after participating in phase III trials. International Journal of Pharmaceutical Medicine. 2005;19:97-104.
5718.	He H, JS R. Nefazodone: A review of its neurochemical mechanisms, pharmacokinetics, and therapeutic use in major depressive disorder. CNS drug reviews. 1997;3:34-48.
5719.	He J, Entsuah R. A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trials. Pharmaceutical statistics. 2014;13:327-336.
5720.	HE K, Ackl N, Hatzinger M, et al. Outcome in Delusional Depression Comparing Trimipramine Monotherapy With a Combination of Amitriptyline and Haloperidol - a Double-Blind Multicenter Trial. Journal of psychiatric research. 2009;43:702-710.
5721.	HE P. STAR*D: A tale and trail of bias. Ethical human psychology and psychiatry. 2011;13:6-28.
5722.	HE P, AM L, GS A, JJ B. Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and psychosomatics. 2010;79:267-279.
5723.	HE P, GS A. In response to 'do pharmacotherapy and/or psychotherapy work in depression? it depends!' and 'widespread methodological problems limit validity of meta-analytic results'. Psychotherapy and psychosomatics. 2011;80:247-248.
5724.	He P, Kong Y, L-Z X. Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:6016-6017.
5725.	He W, Cai D, Lin L, Fang Y, Zheng X. Clinical studies on event-related potentials (ERPs) N400 and the related factors in patients with poststroke depression (PSD). International journal of psychiatry in medicine. 2010;40:349-359.
5726.	Healy D. Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trials: Implications. Primary Care Psychiatry. 1998;4:81-89.
5727.	Healy D. The three faces of the antidepressants: A critical commentary on the clinical-economic context of diagnosis. Journal of nervous and mental disease. 1999;187:174-180.
5728.	Healy D. Clinical trials and legal jeopardy. Bulletin of medical ethics. 1999:13-18.
5729.	Healy D. Reboxetine: Its effects as measured by the social adaptation self- evaluation scale. Acta Psychiatrica Scandinavica, Supplement. 2000;101:45-51.
5730.	Healy D. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale. [Review] [36 refs]. Acta psychiatrica Scandinavica. Supplementum. 2000;402:45-51.
5731.	Healy D. Emergence of antidepressant induced suicidality. Primary Care Psychiatry. 2000;6:23-28.
5732.	Healy D. The Assessment of Outcomes in Depression: Measures of Social Functioning. Reviews in Contemporary Pharmacotherapy. 2000;11:295-301.
5733.	Healy D. The dilemmas posed by new and fashionable treatments. Advances in Psychiatric Treatment. 2001;7:322-327.
5734.	Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and psychosomatics. 2003;72:71-79.
5735.	Healy D. Drug Regulation - Did Regulators Fail Over Selective Serotonin Reuptake Inhibitors? British medical journal. 2006;333:92-95.
5736.	Healy D. Did regulators fail over selective serotonin reuptake inhibitors? British medical journal. 2006;333:92-95.
5737.	Healy D. The new anecdotes. Ethical human psychology and psychiatry. 2007;9:131-137.
5738.	Healy D. Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide? Canadian Journal of Psychiatry. 2009;54:69-71.
5739.	Healy D, Aldred G. Antidepressant drug use & the risk of suicide. International review of psychiatry. 2005;17:163-172.
5740.	Healy D, Bechthold K, Tolias P. Antidepressant-Induced Suicidality: How Translational Epidemiology Incorporating Pharmacogenetics Into Controlled Trials Can Improve Clinical Care. Personalized medicine. 2014;11:79-88.
5741.	Healy D, Healy H. The clinical pharmacologic profile of reboxetine: Does it involve the putative neurobiological substrates of wellbeing? Journal of affective disorders. 1998;51:313-322.
5742.	Healy D, Langmaak C, Savage M. Suicide in the course of the treatment of depression. Journal of psychopharmacology (Oxford, England). 1999;13:94-99.
5743.	Healy D, Mangin D, Antonuccio D. Data based medicine and clinical judgement. International journal of risk & safety in medicine. 2013;25:111-121.
5744.	Healy D, Mangin D, Mintzes B. The ethics of randomized placebo controlled trials of antidepressants with pregnant women. International journal of risk & safety in medicine. 2010;22:7-16.
5745.	Healy D, Whitaker C. Antidepressants and suicide: Risk-benefit conundrums. Journal of psychiatry & neuroscience. 2003;28:331-337.
5746.	Healy E, McKeon P. Dopaminergic sensitivity and prediction of antidepressant response. Journal of psychopharmacology (Oxford, England). 2000;14:152-156.
5747.	Hebebrand J. Commentary on 'Forum: Use of antidepressants in children and adolescents'. Current opinion in psychiatry. 2010;23:62-63.
5748.	Hector D, Arier L, M BAJ, et al. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. International journal of psychiatry in clinical practice. 2011;15:80-90.
5749.	Hedegaard HB, Abed HJ, Alice R, et al. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). Journal of psychosomatic research. 2012;72:11-16.
5750.	Hegerl U. The MIND-Study: A randomized placebo-controlled trial on the acute treatment of primary care patients with mild and minor depressive symptoms. European psychiatry.
5751.	Hegerl U. Antidepressants and suicidality. Risk-benefit analysis. [German]. Der Nervenarzt. 2007;78:7-14.
5752.	Hegerl U, A-K A, Henkel V, Mergl R. Can effects of antidepressants in patients with mild depression be considered as clinically significant? Journal of affective disorders. 2012;138:183-191.
5753.	Hegerl U, Mergl R. The Clinical Significance of Antidepressant Treatment Effects Cannot Be Derived From Placebo-Verum Response Differences. Journal of psychopharmacology (Oxford, England). 2010;24:445-448.
5754.	Hegerl U, Mergl R. Depression and suicidality in COPD: Understandable reaction or independent disorders? European respiratory journal. 2014;44:734-743.
5755.	Hegerl U, Mergl R, Quail D, Schneider E, HP H, Linden M. Does Pain Improve Earlier Than Mood in Depressed Patients With Painful Physics Symptoms Treated With Duloxetine? Pharmacopsychiatry. 2012;45:114-118.
5756.	Hegerl U, Schonknecht P. Subdiagnostic depression : Are there treatments with clinically relevant effects?. [German]. Der Nervenarzt. 2009;80:532-539.
5757.	Hegerl U, Schonknecht P, Mergl R. Are antidepressants useful in the treatment of minor depression: A critical update of the current literature. Current opinion in psychiatry. 2012;25:1-6.
5758.	Heijnen WTCJ, W vdBW, Mulder PGH, Birkenhager TK. Prevalence of trait anxiety in a sample of depressed inpatients and its influence on response to antidepressants. Journal of psychopharmacology (Oxford, England). 2010;24:559-563.
5759.	Heikki V, Esa L. Double-bind study of mirtazapine and placebo in hospitalized patients with major depression. European neuropsychopharmacology. 1994;4:145-150.
5760.	Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clinical pharmacology and therapeutics. 2002;72:184-191.
5761.	Heim T. Advantages of mirtazapine in long-term therapy: Alternative in recurrent depression and chronic pain?. [German]. Nervenheilkunde. 2002;21:84-85.
5762.	Heinemann A, Williams R, Bombardier C, Forchheimer M, Fan J, Neumann H. Improving the measurement properties of depressive symptom instruments for use after spinal cord injury. Topics in spinal cord injury rehabilitation. 2013;Conference:5-6.
5763.	Heinrich S, Sabine H-H, Wilfried D. Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry. 2003;36:169-175.
5764.	Heiser P, Remschmidt H. The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry. [German]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2002;30:173-183.
5765.	Heiser P, Remschmidt H. [Selective serotonin reuptake inhibitors and newer antidepressive substances in child and adolescent psychiatry]. [Review] [70 refs] [German]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2002;30:173-183.
5766.	Heitzman J, Solak M. Antidepressant Discontinuation Syndrome - a Problem for the Clinician and the Patient. Psychiatria polska. 2007;41:601-613.
5767.	Helen B, Nicola W, John P, et al. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of psychopharmacology (Oxford, England). 2012;26:663-669.
5768.	Helen L, L AL, E OR, et al. Complementary use of Tai Chi Chih augments escitalopram treatment of geriatric depression: A randomized controlled trial. The American Journal of Geriatric Psychiatry. 2011;19:839-850.
5769.	Helen L, Prabha S, Anand K, FIII RC. The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatments response in geriatric depression: A pilot study. International journal of geriatric psychiatry. 2008;23:55-59.
5770.	Helen L, Prabha S, R IM. Improving depression and enhancing resilience in family dementia caregivers: A pilot randomized placebo-controlled trial of escitalopram. The American Journal of Geriatric Psychiatry. 2010;18:154-162.
5771.	Helen L, Susan P, Prabha S, Anand K, FIII RC. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. The American Journal of Geriatric Psychiatry. 2006;14:181-185.
5772.	Hella B, GA B. Panic Disorder and School Refusal. Child and adolescent psychiatric clinics of North America. 2012;21:593-606.
5773.	Hellmann-Regen J, Piber D, Hinkelmann K, et al. Depressive syndromes in neurological disorders. European archives of psychiatry and clinical neuroscience. 2013;263:S123-136.
5774.	Hellweg R, Ziegenhorn A, Heuser I, Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry. 2008;41:66-71.
5775.	Hellwig B. Drugs under development: New melatonin agonists before introduction. [German]. Deutsche Apotheker-Zeitung. 2009;149:49-52.
5776.	Helmreich I, Wagner S, Mergl R, et al. Sensitivity to changes during antidepressant treatment: A comparison of unidimensional depression rating scales in patients with minor depression. European psychiatry. 2012.
5777.	Hemerson P, MA C, Wald M, MR B. Erectile dysfunction: Beyond the phosphodiesterase inhibitors. U.S.
5778.	Hemlock C, JS R, Winston A. Fluoxetine-induced psoriasis. Annals of pharmacotherapy. 1992;26:211-212.
5779.	Henderson P. Comments on "postpartum depression" article by Dr Wisner and colleagues [17]. Journal of clinical psychopharmacology. 2007;27:321.
5780.	Henderson S. The July issue: An exegesis. Australian and New Zealand journal of psychiatry. 2012;46:593-594.
5781.	Hendin H, JT M, Szanto K. The Psychosocial Context of Trauma in Treating Ptsd Patients. American journal of psychiatry. 2008;165:28-32.
5782.	Hendrick V. Treatment of postnatal depression. British medical journal. 2003;327:1003-1004.
5783.	Hendrickx B, M VM, Spiers R, R VFJ. The Treatment of Psychocutaneous Disorders - a New Approach. Current therapeutic research, clinical and experimental. 1991;49:111-119.
5784.	Henkel V, Althaus D, Hegerl U, Symons L, Thompson C. Lessons from the Hampshire Depression Project (multiple letters). Lancet. 2000;355:1641-1642.
5785.	Henkel V, Mergl R, A-K A, et al. Treatment of atypical depression: Post-hoc analysis of a randomized controlled study testing the efficacy of sertraline and cognitive behavioural therapy in mildly depressed outpatients. European Psychiatry: the Journal of the Association of European Psychiatrists. 2010;25:491-498.
5786.	Henkel V, Mergl R, AK A, Kohnen R, HJ M, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry research. 2006;141:89-101.
5787.	Henkel V, Seemuller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? - Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Journal of affective disorders. 2009;115:439-449.
5788.	Henning O, Niedermaier N, Kniest A, Heuser I, Deuschle M. Amitriptyline and paroxetine: Effects upon peripheral nervous system (PNS) [4]. Journal of clinical psychopharmacology. 2002;22:229-230.
5789.	Henningsen P, Lowe B. Depression, pain, and somatoform disorders. Current opinion in psychiatry. 2006;19:19-24.
5790.	Henri L, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. International clinical psychopharmacology. 2002;17:239-247.
5791.	Henry A, MD K, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Molecular psychiatry. 2012;17:1186-1193.
5792.	Henry B. Antidepressant treatment in Alzheimer's disease. Lancet. 2011;378:375-376.
5793.	Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-Induced Mania in Bipolar Patients: Identification of Risk Factors. Journal of clinical psychiatry. 2001;62:249-255.
5794.	Henry G, Williamson D, RR T. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. [Review]. American journal of Alzheimer's disease and other dementias. 2011;26:169-183.
5795.	Henze T. What is new in symptom management? International MS Journal. 2007;14:22-27.
5796.	Heo M, AC L, BS M, GS A. Problems in statistical analysis of attrition in randomized controlled clinical trials of antidepressant for geriatric depression. Current psychiatry reviews. 2007;3:178-185.
5797.	Heo M, CF M, BS M. Relationship Between the Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale in Depressed Elderly: a Meta-Analysis. American journal of geriatric psychiatry. 2007;15:899-905.
5798.	Heras P, Kritikos K, Hatzopoulos A, Kritikos N, Heras V, Mitsibounas D. The role of paroxetine in fatigue and depression of patients under chemotherapeutic treatment. American journal of therapeutics. 2013;20:254-256.
5799.	Herbert J. Neurogenesis and depression: Breakthrough or blind alley? Journal of neuroendocrinology. 2008;20:413-414.
5800.	Heresco-Levy U, DC J, Gelfin Y, et al. Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. Journal of affective disorders. 2006;93:239-243.
5801.	Hermanns N, Caputo S, Dzida G, Khunti K, LF M, Snoek F. Screening, evaluation and management of depression in people with diabetes in primary care. Primary care diabetes. 2013;7:1-10.
5802.	Hermens M, H VH, Terluin B, et al. Are antidepressants helpful in minor and mild-major depression?. [Dutch]. Huisarts en wetenschap. 2008;51:361-369.
5803.	Herng-Nieng C, Angelo A, M MD, et al. Treatment of major depressive disorder by transcranial random noise stimulation: Case report of a novel treatment. Biological psychiatry. 2012;72:e9-e10.
5804.	Herpertz-Dahlmann B. Commentary on 'Forum: Use of antidepressants in children and adolescents'. Current opinion in psychiatry. 2010;23:65-66.
5805.	Herrera J, Gomez-Herrera C. Duloxetine for the treatment of other painful conditions. [Spanish]. Revista de la Sociedad Espanola del Dolor. 2006;13:42-54.
5806.	Herrera-Arellano A, JE J-F, Zamilpa A, Garcia-Alonso G, Herrera-Alvarez S, Tortoriello J. Therapeutic Effectiveness of Galphimia Glauca Vs. Lorazepam in Generalized Anxiety Disorder. A Controlled 15-Week Clinical Trial. Planta medica. 2012;78:1529-1535.
5807.	Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, JE H-A. Effects of Selective Serotonin Reuptake and Dual Serotonergic-Noradrenergic Reuptake Treatments on Memory and Mental Processing Speed in Patients With Major Depressive Disorder. Journal of psychiatric research. 2009;43:855-863.
5808.	Herrera-Guzman I, JE H-A, Gudayol-Ferre E, et al. Effects of Selective Serotonin Reuptake and Dual Serotonergic-Noradrenergic Reuptake Treatments on Attention and Executive Functions in Patients With Major Depressive Disorder. Psychiatry research. 2010;177:323-329.
5809.	Herring C, AJ M, Jamerson B. Treatment of comorbid depression in medical illness. Journal of pharmacy practice. 2010;23:274-276.
5810.	Herrmann N. Post stroke depression. Primary Care Psychiatry. 1999;5:81-87.
5811.	Herrmann N. An update on the neuropsychiatric symptoms of dementia. Neurodegenerative disease management. 2011;1:335-340.
5812.	Herrmann N, Gauthier S, PG L. Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's & dementia. 2007;3:385-397.
5813.	Herrmann N, KL L. Pharmacologic Management of Neuropsychiatric Symptoms of Alzheimer Disease. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2007;52:630-646.
5814.	Herrmann N, KL L, LR K. The role of norepinephrine in the behavioral and psychological symptoms of dementia. Journal of neuropsychiatry and clinical neurosciences. 2004;16:261-276.
5815.	Herwig U, AJ F, Hoppner J, et al. Antidepressant Effects of Augmentative Transcranial Magnetic Stimulation - Randomised Multicentre Trial. British journal of psychiatry. 2007;191:441-448.
5816.	Hesslinger B, Harter M, Barth J, et al. Comorbidity of depressive disorders and cardiovascular disease. Implications for diagnosis, pharmacotherapy, and psychotherapy. [German]. Der Nervenarzt. 2002;73:205-218.
5817.	Hetland A, DB C. Medications and Impaired Driving. Annals of pharmacotherapy. 2014;48:494-506.
5818.	Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. [Review] [127 refs][Update in Cochrane Database Syst Rev. 2012;11:CD004851; PMID: 23152227]. Cochrane database of systematic reviews (Online). 2007:CD004851.
5819.	Hetrick S, Simmons M, Merry S. SSRIs and depression in children and adolescents: The imperative for shared decision-making. Australasian psychiatry. 2008;16:354-358.
5820.	Hetzel G, Moeller O, Evers S, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology. 2005;178:161-166.
5821.	Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V. The Efficacy of Agomelatine in Elderly Patients With Recurrent Major Depressive Disorder: a Placebo-Controlled Study. Journal of clinical psychiatry. 2013;74:587-594.
5822.	Heuzenroeder L, Donnelly M, MM H, et al. Cost-Effectiveness of Psychological and Pharmacological Interventions for Generalized Anxiety Disorder and Panic Disorder. Australian and New Zealand journal of psychiatry. 2004;38:602-612.
5823.	Heuzenroeder L, Donnelly M, MM H, et al. Cost-Effectiveness of Psychological and Pharmacological Interventions for Generalized Anxiety Disorder and Panic Disorder. Australian and New Zealand journal of psychiatry. 2004;38:602-612.
5824.	Hewer W, Rost W, WF G. Effects of fluvoxamine and maprotiline on ECG parameters. [German]. Nervenheilkunde. 1994;13:375-380.
5825.	Hewett K, Chrzanowski W, Jokinen R, et al. Double-Blind, Placebo-Controlled Evaluation of Extended-Release Bupropion in Elderly Patients With Major Depressive Disorder. Journal of psychopharmacology (Oxford, England). 2010;24:521-529.
5826.	Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of psychopharmacology (Oxford, England). 2009;23:531-538.
5827.	HEY-S, WUY-S, OUYANGM-F, LIG-X, LIH-J, XIEH-E. Efficacy observation of depression in nicotine withdrawal treated with acupuncture. World Journal of Acupuncture - Moxibustion. 2012;22:13-16.
5828.	Heyman I, Mataix-Cols D, NA F. Obsessive-compulsive disorder. British medical journal. 2006;333:424-429.
5829.	HF K, MJ F. Antidepressant use in ambulatory cancer patients. Current oncology reports. 2006;8:275-281.
5830.	HF L, Li T, GJ L, JF L. Citalopram and Escitalopram in the Treatment of Major Depressive Disorder: a Pooled Analysis of 3 Clinical Trials. Annals of clinical psychiatry. 2014;26:281-287.
5831.	HF Z, Khandker R. Improvement of Fatigue in Patients With Major Depressive Disorder Treated With Venlafaxine, Sertraline, or Placebo. Value in health. 2005;8:392.
5832.	HF Z, Khandker R. Improvement of Fatigue in Patients With Major Depressive Disorder Treated With Venlafaxine, Sertraline, or Placebo. Value in health. 2005;8:392.
5833.	HG K, Kolpe M. Pharmacologic treatment of psychiatric conditions during and after pregnancy. Primary psychiatry. 2007;14:46-53.
5834.	HG N. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs of today (Barcelona, Spain : 1998). 2008;44:147-168.
5835.	HG N, Fava M, AJ G, PL H, Paine S. Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction. International journal of impotence research. 2007;19:167-175.
5836.	HG N, Gelenberg A, TB H, WM H, RL S, MD S. Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. American journal of psychiatry. 2001;158:1926-1928.
5837.	HG N, Lauriello J, PL H, LM P, SJ K. Sildenafil for iatrogenic serotonergic antidepressant medication- induced sexual dysfunction in 4 patients. Journal of clinical psychiatry. 1999;60:33-35.
5838.	HG N, PL H. Selective phosphodiesterase type-5 inhibitor treatment of serotonergic reuptake inhibitor antidepressant-associated sexual dysfunction: A review of diagnosis, treatment, and relevance. CNS spectrums. 2003;8:194-202.
5839.	HG N, PL H, AJ G, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: A randomized controlled trial. Journal of the American Medical Association. 2003;289:56-64.
5840.	Sildenafil treatment of women with antidepressant-associated sexual dysfunction: A randomized controlled trial, JAMA - Journal of the American Medical Association(2008).
5841.	HG N, PM T, PL H. Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. Journal of clinical psychiatry. 1999;60:574-579.
5842.	HG PJ, Amiaz R, BP B, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. Journal of clinical psychopharmacology. 2010;30:126-134.
5843.	HG R. Suicide risk due to antidepressants once again under the magnifying glass. [Dutch]. Tijdschrift voor psychiatrie. 2006;48:494-495.
5844.	HG R. Serotonin transporter promoter polymorphism is not associated to response, but to side-effects of citalopram treatment. [Dutch]. Nederlands tijdschrift voor geneeskunde. 2007;151:2641.
5845.	HG R, Booij J, DJ V, JB R, MC M, AH S. The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI. European neuropsychopharmacology. 2008;Conference:S332-S333.
5846.	Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.[Erratum appears in Neuropsychopharmacology. 2009 Mar;34(4):1088], Neuropsychopharmacology(2009).
5847.	Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.[Erratum appears in Neuropsychopharmacology. 2009 Mar;34(4):1088], Neuropsychopharmacology(2009).
5848.	HG R, G VR, DJ V, AH S. Twelve weeks of paroxetine treatment improves prefrontal brain activity. An fMRI study using the Tower of London. European neuropsychopharmacology. 2010;Conference:S380.
5849.	HG R, Huyser J, JA S, AH S. Dose Escalation for Insufficient Response to Standard-Dose Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder - Systematic Review. British journal of psychiatry. 2006;189:309-316.
5850.	HG R, Miedema E, Booij J, MWA C, DJ V, AH S. Volumetric changes in amygdala and hippocampus after three months of paroxetine treatment for major depressive disorder. European neuropsychopharmacology. 2012;Conference:S267-S268.
5851.	HG R, NS M, AH S. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Molecular psychiatry. 2007;12:331-359.
5852.	HGeorge N, SN S, AJ G, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: Clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology. 2002;60:58-66.
5853.	HGM W. Developments in the Drug Treatment of Panic Disorder: What Is the Place of the Selective Serotonin Reuptake Inhibitors? Journal of affective disorders. 1996;40:85-93.
5854.	HGM W. Facing the Challenge of Social Anxiety Disorder. European neuropsychopharmacology. 1999;9:S93-S99.
5855.	HGM W, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. International journal of clinical practice. 2006;60:482-491.
5856.	HH F, BR S, TA K, Alldredge B. Safety and tolerability of mood-stabilising anticonvulsants in the elderly. Expert opinion on drug safety. 2006;5:401-416.
5857.	HH F, Merello M. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone? The Lancet Neurology. 2010;9:556-557.
5858.	HH S, Angst J. Delayed onset of action of antidepressants: Fact or fiction? CNS drugs. 1998;9:177-184.
5859.	HH S, Angst J, Delini-Stula A. Onset of improvement under fluoxetine and moclobemide. European psychiatry. 1998;13:128-133.
5860.	HH S, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of clinical psychiatry. 2007;68:1195-1205.
5861.	HH S, Kuny S, Hell D. The Speech Analysis Approach to Determining Onset of Improvement Under Antidepressants. European neuropsychopharmacology. 1998;8:303-310.
5862.	HHA A, Karnon J, Gray J. A Critical Review of Model-Based Economic Studies of Depression Modelling Techniques, Model Structure and Data Sources. PharmacoEconomics. 2012;30:461-482.
5863.	HI L, Sen A, CO C, RRSH G. Difficulty in walking 10 years after gastric surgery. European journal of gastroenterology & hepatology. 2011;23:952-953.
5864.	HI W, Soares H, JF W. Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression. Biomarkers in medicine. 2012;6:119-129.
5865.	Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Annals of oncology. 2008;19:1669-1680.
5866.	Hickie J, Wilson A. A catecholamine model of fatigue [5]. British journal of psychiatry. 1994;164:275-276.
5867.	Hicks P, XP H. Depression severity and effect of antidepressant medications [5]. JAMA - Journal of the American Medical Association. 2010;303:1598.
5868.	Hida E, Tango T. On the three-arm non-inferiority trial including a placebo with a prespecified margin. Statistics in medicine. 2011;30:224-231.
5869.	Hida E, Tango T. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints. Journal of biopharmaceutical statistics. 2013;23:774-789.
5870.	Hidalgo R, MA H, Mellman T, et al. Nefazodone in Post-Traumatic Stress Disorder: Results From Six Open-Label Trials. International clinical psychopharmacology. 1999;14:61-68.
5871.	Hieber R, Dellenbaugh T, LA N. Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia. Annals of pharmacotherapy. 2008;42:841-846.
5872.	Hiemke C, Hampel C, Weigmann H. Pharmacology of duloxetine. A therapeutic option for different indications. [German]. Psychopharmakotherapie. 2006;13:12-18.
5873.	Hiemke C, Hartter S. Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Pharmacology & therapeutics. 2000;85:11-28.
5874.	Higgins A, Nash M, AM L. Antidepressant-associated sexual dysfunction: Impact, effects, and treatment. Drug, healthcare and patient safety. 2010;2:141-150.
5875.	Higuchi T, Briley M. Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan. Neuropsychiatric disease and treatment. 2007;3:41-58.
5876.	Hilas O, Avena-Woods C. Neurocardiogenic syncope: A focus on the management of vasovagal episodes. U.S. 2011;Pharmacist:HS2-HS11.
5877.	Hilger E, Praschak-Rieder N, Willeit M, et al. Pharmacotherapy of seasonal affective disorder. [German]. Der Nervenarzt. 2002;73:22-31.
5878.	Hill A, Briken P, Kraus C, Strohm K, Berner W. Differential pharmacological treatment of paraphilias and sex offenders. International journal of offender therapy and comparative criminology. 2003;47:407-421.
5879.	Hill K, Geist R, RS G, Lacasse Y. Anxiety and depression in end-stage COPD. European respiratory journal. 2008;31:667-677.
5880.	Hill L, KC L. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. [Review]. Annals of pharmacotherapy. 2013;47:75-89.
5881.	Hillemacher T, Wilhelm J, Heberlein A. Depression and Alcohol Addiction. Nervenheilkunde. 2012;31:305-+.
5882.	Hilton P. Of porcupines and poodles - A joint challenge to industry and the profession. International urogynecology journal and pelvic floor dysfunction. 2007;18:3-11.
5883.	Himelhoch S, DR M. Efficacy of antidepressant medication among HIV-positive individuals with depression: A systematic review and meta-analysis. AIDS patient care and STDs. 2005;19:813-822.
5884.	Himelhoch S, Slade E, Kreyenbuhl J, Medoff D, Brown C, Dixon L. Antidepressant Prescribing Patterns Among Va Patients With Schizophrenia. Schizophrenia research. 2012;136:32-35.
5885.	Hindi F, MA D, SM A, FE L, CF R. Preventing Depression in Later Life: State of the Art and Science Circa 2011. Psychiatric clinics of North America. 2011;34:67-78.
5886.	Hindmarch I. A review of the psychomotor effects of paroxetine. [Review] [3 refs]. International clinical psychopharmacology. 1992;6 Suppl 4:65-67.
5887.	Hindmarch I. The effects of antidepressants on psychomotor function with particular reference to reboxetine. European neuropsychopharmacology. 1997;7:S17-S21.
5888.	Hindmarch I. Expanding the horizons of depression: Beyond the monoamine hypothesis. Human psychopharmacology. 2001;16:203-218.
5889.	Hindmarch I, Kimber S, SM C. Abrupt and Brief Discontinuation of Antidepressant Treatment: Effects on Cognitive Function and Psychomotor Performance. International clinical psychopharmacology. 2000;15:305-318.
5890.	Hindmarsh I, JS K. Effects of paroxetine on cognitive function in depressed patients, volunteers and elderly volunteers. Medical science research. 1994;22:669-670.
5891.	Hinkelmann K, Moritz S, Botzenhardt J, et al. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: A longitudinal study. Psychoneuroendocrinology. 2012;37:685-692.
5892.	Hinz M, Stein A, Uncini T. Monoamine depletion by reuptake inhibitors. Drug, healthcare and patient safety. 2011;3:69-77.
5893.	Hiroyuki U, Hiroyoshi T, Takefumi S, Kensuke N, Koichiro W, Haruo K. Combined treatment with Sulpiride and paroxetine for accelerated response in patients with major depressive disorder. Journal of clinical psychopharmacology. 2005;25:545-551.
5894.	Hirschmann S, PN D, Iancu I, OT D, Zohar J, Grunhaus L. Pindolol Augmentation in Patients With Treatment-Resistant Panic Disorder: a Double-Blind, Placebo-Controlled Trial. Journal of clinical psychopharmacology. 2000;20:556-559.
5895.	Hirschowitz J, Kolevzon A, Garakani A. The pharmacological treatment of bipolar disorder: The question of modern advances. Harvard review of psychiatry. 2010;18:266-278.
5896.	Hitiris N, JA B, MJ B. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: Five case reports. Epilepsy & behavior. 2006;8:418-421.
5897.	Hitsman B, Spring B, Pingitore R, Munafo M, Hedeker D. Effect of Tryptophan Depletion on the Attentional Salience of Smoking Cues. Psychopharmacology. 2007;192:317-324.
5898.	Hitsman B, Spring B, Wolf W, Pingitore R, JW C, Hedeker D. Effects of Acute Tryptophan Depletion on Negative Symptoms and Smoking Topography in Nicotine-Dependent Schizophrenics and Nonpsychiatric Controls. Neuropsychopharmacology. 2005;30:640-648.
5899.	Hitsman B, Spring B, Wolf W, Pingitore R, JW C, Hedeker D. Effects of Acute Tryptophan Depletion on Negative Symptoms and Smoking Topography in Nicotine-Dependent Schizophrenics and Nonpsychiatric Controls. Neuropsychopharmacology. 2005;30:640-648.
5900.	Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial, Journal of the American Academy of Child and Adolescent Psychiatry(2011).
5901.	HJ A, IIICF R. The treatment of geriatric depression: Progress and challenges. Economics of Neuroscience. 2001;3:58-62.
5902.	HJ A, Tilikete S, Barrucand D. Depression and Smoking. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 1996;22:17-22.
5903.	HJ C, Hotopf M, Wessely S. The placebo response in the treatment of chronic fatigue syndrome: A systematic review and meta-analysis. Psychosomatic medicine. 2005;67:301-313.
5904.	HJ D, ER H, FH DK, Janknegt R, OH K, AC E. The Association Between Antidepressant Use and Hypoglycaemia in Diabetic Patients: a Nested Case-Control Study. Pharmacoepidemiology and drug safety. 2008;17:336-344.
5905.	HJ G, JR G, JM R, WA N, GM G. Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. American journal of psychiatry. 2004;161:1537-1547.
5906.	HJ J, Fava M, Mischoulon D, et al. Psychomotor Symptoms and Treatment Outcomes of Ziprasidone Monotherapy in Patients With Major Depressive Disorder: a 12-Week, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Trial. International clinical psychopharmacology. 2014;29:332-338.
5907.	HJ J, JM W, SH L, et al. Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: Tianeptine versus escitalopram. European neuropsychopharmacology. 2013;Conference:S320-S321.
5908.	HJ K, Raschka C, Hannak D. Pindolol can be effectively given once or twice daily for augmentation in psychiatric patients. European neuropsychopharmacology. 2000;10:511-512.
5909.	HJ L, BL Z, YP F, HT H. [Acupuncture for post-stroke depression: a randomized controlled trial]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2011;31:3-6.
5910.	HJ M. Suicide, suicidality and suicide prevention in affective disorders. Acta psychiatrica Scandinavica. 2003;108:73-80.
5911.	HJ M. Duloxetine - a New Option for the Treatment of Depression and Painful Somatic Symptoms. Psychopharmakotherapie. 2005;12:12-14.
5912.	HJ M. Is There Evidence for Negative Effects of Antidepressants on Suicidality in Depressive Patients? A Systematic Review. European archives of psychiatry and clinical neuroscience. 2006;256:476-496.
5913.	HJ M. Sertraline does not improve well-being in patients with advanced cancer who do not have depression. Journal of clinical outcomes management. 2007;14:488+491.
5914.	HJ M, Brasser M, Kasper S, HP V, RJ B, Bandelow B. Effectiveness and Tolerability of Pregabalin in Patients With Generalized Anxiety Disorders in Routine Clinical Care. Psychopharmakotherapie. 2009;16:211-+.
5915.	HJ M, Langer S, Schmauss M. Escitalopram in Clinical Practice: Results of an Open-Label Trial in Outpatients With Depression in a Naturalistic Setting in Germany. Pharmacopsychiatry. 2007;40:53-57.
5916.	HJ M, Schneider E. Duloxetine - a New Selective and Dual Acting Antidepressant: Good Effectiveness Not Only on Psychiatric but Also on Bodily Symptoms of Depression. Psychopharmakotherapie. 2006;13:19-23.
5917.	HJ P, EJ G, Verburg C. Fluvoxamine-ritanserin combination in the treatment of panic anxiety with avoidance behavior. European neuropsychopharmacology. 1993;3:377.
5918.	HJ S, BC L, JH S, et al. An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients With Major Depressive Disorder With Atypical Features. Pharmacopsychiatry. 2013;46:221-226.
5919.	HJ S, HR S, Jeong S, et al. Does Comorbid Subthreshold Anxiety Predict Treatment Response in Depression? Results From a Naturalistic Cohort Study (the Crescend Study). Journal of affective disorders. 2014;152:352-359.
5920.	HJ S, YE J, Jeong S, et al. Persistence and Resolution of Suicidal Ideation During Treatment of Depression in Patients With Significant Suicidality at the Beginning of Treatment: the Crescend Study. Journal of affective disorders. 2014;155:208-215.
5921.	HJ S, YE J, YS W, TY J, JH C, WM B. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Human psychopharmacology. 2009;24:135-143.
5922.	HJ W, RW D. Therapeutic Efficacy of Fluoxetine in Routine Practice. Psychopharmakotherapie. 1997;4:23-27.
5923.	Hjalmarsson L, Corcos M, Jeammet P. Biological treatment and prescription in children and adolescents suffering from a major depressive episode. [French]. Information psychiatrique. 2005;81:803-810.
5924.	Hjalmarsson L, Corcos M, Jeammet P. Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder in Children and Adolescents (Ratio of Benefits/Risks). Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:309-316.
5925.	Hjalmarsson L, Corcos M, Jeammet P. Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder in Children and Adolescents (Ratio of Benefits/Risks). Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:309-316.
5926.	Hjalmarsson L, Corcos M, Ph J. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)]. [French]. Encephale. 2005;31:309-316.
5927.	HJF VM, Tendolkar I, Urner M, RJ V, Fernandez G, G VW. Subchronic Duloxetine Administration Alters the Extended Amygdala Circuitry in Healthy Individuals. NeuroImage. 2011;55:825-831.
5928.	HK G, RA P, GW B. Looking forward in geriatric anxiety and depression: Implications of basic science for the future. American journal of geriatric psychiatry. 2005;13:1027-1040.
5929.	HL G, CC S, PM C. Patient preferences for treatment of major depressive disorder and the impact on health outcomes: A systematic review. Primary care companion to the Journal of clinical psychiatry. 2011.
5930.	HL K, JM K, FS H, et al. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature reviews. Clinical oncology. 2013;10:588-598.
5931.	HL L, SE S, MC L, et al. A Double-Blind Desipramine Substitution During Long-Term Clomipramine Treatment in Children and Adolescents With Obsessive-Compulsive Disorder. Archives of general psychiatry. 1991;48:922-927.
5932.	HL M, MS S. Double-blind comparison of fluoxetine and amitryptyline in the treatment of major depressive illness. Advances in therapy. 1985;2:275-284.
5933.	HL M, PL D, RM S, et al. Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression. Archives of general psychiatry. 1996;53:117-128.
5934.	HL T. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. Journal of women's health. 2011;20:1007-1016.
5935.	HL V, Dekker J, Koelen J, et al. Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression. Psychotherapy research. 2009;19:205-212.
5936.	HL V, Dekker J, Peen J, G vA, RA S. Identifying patients at risk of complete nonresponse in the outpatient treatment of depression. Psychotherapy and psychosomatics. 2008;77:358-364.
5937.	HL V, RA S, Dekker J. Predicting the outcome of antidepressants and psychotherapy for depression: A qualitative, systematic review. Harvard review of psychiatry. 2008;16:225-234.
5938.	HL Z, Haddjeri N, Sanchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. [Review]. Psychopharmacology. 2012;219:1-13.
5939.	HM A, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: Dilemmas, achievements, applications, and future scope. American journal of pharmacogenomics. 2005;5:149-160.
5940.	HM C. Fluoxetine: a Suitable Long-Term Treatment. Journal of clinical psychiatry. 2001;62:24-29.
5941.	HM C, UC A, NMP P, et al. Homeopathic individualized Q-potencies versus fluoxetine for moderate to severe depression: Double-blind, randomized non-inferiority trial. Evidence-based Complementary and Alternative Medicine. 2011.
5942.	HM E, Berger M, Riemann D, D VZ. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: A double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry. 1987;20:60-63.
5943.	HM H, DN O. The psychopharmacology algorithm project at the Harvard south shore program: An update on psychotic depression. Harvard review of psychiatry. 2008;16:235-247.
5944.	HM J. Low dosage tricyclic antidepressants in depression. Giving low dose tricyclics is not justified by evidence. BMJ (Clinical research ed.). 2003;326:499; author reply 499.
5945.	HM J, IM A, JE M, TA F, Barbui C, McGuire H. Low dosage tricyclic antidepressants in depression [3]. British medical journal. 2003;326:499-501.
5946.	HM K, Zivin K, HM C, et al. Predictors of Start of Different Antidepressants in Patient Charts Among Patients With Depression. Journal of managed care pharmacy. 2015;21:424-430.
5947.	HM P. The Use of Selective Serotonin Reuptake Inhibitors in Treating Alcoholic Subtypes. Journal of clinical psychiatry. 2001;62:26-31.
5948.	HM P. Antidepressant Treatment of Co-Occurring Depression and Alcohol Dependence. Biological psychiatry. 2004;56:785-792.
5949.	HM P. Antidepressant Treatment of Co-Occurring Depression and Alcohol Dependence. Biological psychiatry. 2004;56:785-792.
5950.	HM P, AR L, WD D. Sertraline treatment in subtypes of alcohol dependence: A replication. Alcoholism, clinical and experimental research. 2012;Conference:245A.
5951.	HM P, CP OB, AR R, et al. The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. Journal of clinical psychopharmacology. 2006;26:610-625.
5952.	HM P, CP OB, WD D. Current status of co-occurring mood and substance use disorders: a new therapeutic target. [Review]. American journal of psychiatry. 2013;170:23-30.
5953.	HM P, Oslin D, Decker K. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS spectrums. 2000;5:33-46.
5954.	HM R, SD H. Social anxiety disorder - A review of pharmacological treatments. Current psychiatry reviews. 2007;3:95-122.
5955.	HM T, Yerramsetty P, Mannelli P, Patkar A, Masand P. Recent advances in poststroke depression. Current psychiatry reports. 2007;9:225-231.
5956.	HM V, RC vdM. Bipolar disorder, antidepressants and induction of hypomania or mania. A systematic review. World journal of biological psychiatry. 2005;6:231-241.
5957.	HM V, RC VDM, Blom A. Bipolar disorder, antidepressants and induction of (hypo)mania. A systematic review. [Dutch]. Tijdschrift voor psychiatrie. 2002;44:599-608.
5958.	HM VP. Combination of antidepressant drugs: The case of inositol. Human psychopharmacology. 2001;16:37-43.
5959.	HM VP. Disappointments. Why did antidepressants have so little influence on suicide frequency?. [Dutch]. Tijdschrift voor psychiatrie. 2002;44:693-702.
5960.	HN A. Dysthymia: A chronic disease and its treatment. [German]. Wiener medizinische Wochenschrift (1946). 1999;149:503-510.
5961.	HN C, Fam J, B-Y N. Use of antidepressants in the treatment of chronic pain. Annals of the Academy of Medicine, Singapore. 2009;38:974-979.
5962.	Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Depression: Study Protocol for a Randomized Controlled Trial, Trials(2013).
5963.	HO O-S. Safe treatment of depression with mirtazapine. [German]. Psychopharmakotherapie. 2000;7:1-4.
5964.	Ho R. Cytokines in depressive disorder. Annals of the Academy of Medicine, Singapore. 2014;Conference:S8.
5965.	Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression. [Hungarian]. Psychiatria Hungarica. 2001;16:87-100.
5966.	Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic Effect of Citalopram in Unipolar, Recurrent Depression - Placebo-Controlled Study of Maintenance Therapy. The British Journal of Psychiatry. 2001;178:304-310.
5967.	Hodes M, Garralda E. NICE guidelines on depression in children and young people: Not always following the evidence. Psychiatric bulletin (London, England). 2007;31:361-362.
5968.	Hodgson K, Uher R, AA C, et al. Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of psychopharmacology (Oxford, England). 2014;28:142-150.
5969.	Hoehn-Saric R, DR M, PA H. Effect of Fluvoxamine on Panic Disorder. Journal of clinical psychopharmacology. 1993;13:321-326.
5970.	Hoehn-Saric R, TE S, BD G, DR M, GD P, SH W. Cerebral blood flow in obsessive-compulsive patients with major depression: Effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Research - Neuroimaging. 2001;108:89-100.
5971.	Hoehnsaric R, DR M, WD Z, PA H. Symptoms and Physiological Manifestations in Obsessive-Compulsive Patients Before and After Treatment With Clomipramine. Journal of clinical psychiatry. 1993;54:272-276.
5972.	Hoeppner J, Padberg F, Domes G, et al. Influence of repetitive transcranial magnetic stimulation on psychomotor symptoms in major depression. European archives of psychiatry and clinical neuroscience. 2010;260:197-202.
5973.	Hoertel N, P DM, Katz J, et al. Are Participants in Pharmacological and Psychotherapy Treatment Trials for Social Anxiety Disorder Representative of Patients in Real-Life Settings? Journal of clinical psychopharmacology. 2014;34:697-703.
5974.	Hoertel N, Y LS, Blanco C, Lavaud P, Dubertret C. Generalizability of Clinical Trial Results for Generalized Anxiety Disorder to Community Samples. Depression and anxiety. 2012;29:614-620.
5975.	Hoffbrand S, Howard L, Crawley H. Antidepressant drug treatment for postnatal depression. [Review] [34 refs][Update in Cochrane Database Syst Rev. 2014;9:CD002018; PMID: 25211400]. Cochrane database of systematic reviews (Online). 2001:CD002018.
5976.	Hofler-Speckner S. Agomelatine in the treatment of major depression and depression-associated sleep disorders. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2009;10:95-96.
5977.	Hoflich G, Kasper S, Danos P, Schmidt R. Thyroid hormones, body temperature, and antidepressant treatment. Biological psychiatry. 1992;31:859-862.
5978.	Hogg S, Michan L, Jessa M. Prediction of Anti-Panic Properties of Escitalopram in the Dorsal Periaqueductal Grey Model of Panic Anxiety. Neuropharmacology. 2006;51:141-145.
5979.	Hohagen F, Winkelmann G, Rasche-Rauchle H, et al. Combination of Behaviour Therapy With Fluvoxamine in Comparison With Behaviour Therapy and Placebo - Results of a Multicentre Study. British Journal of Psychiatry - Supplementum. 1998;173:71-78.
5980.	Hohn P, Menne-Lothmann C, Peeters F, et al. Moment-to-Moment Transfer of Positive Emotions in Daily Life Predicts Future Course of Depression in Both General Population and Patient Samples. PloS one. 2013.
5981.	Hojo M, Miwa H, Yokoyama T, et al. Treatment of Functional Dyspepsia With Antianxiety or Antidepressive Agents: Systematic Review. Journal of gastroenterology. 2005;40:1036-1042.
5982.	Holden C. NIH to explore St. John's wort. Science (New York, N.Y.). 1997;278:391.
5983.	Holden C. FDA Weighs Suicide Risk in Children on Antidepressants. Science (New York, N.Y.). 2004;303:745.
5984.	Holger J, Mildred S, Falk K, Michael K, Alexander Y, Klaus W. Metyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial. Archives of general psychiatry. 2004;61:1235-1244.
5985.	Hollander E. Perspectives on suicide and depression in children and adolescents and beyond. CNS spectrums. 2007;12:91-92.
5986.	Hollander E. Differential treatment response, neuroinflammation, and psychosis associated with chromosome deletion. CNS spectrums. 2008;13:459-460.
5987.	Hollander E, Allen A, Kwon J, et al. Clomipramine Vs Desipramine Crossover Trial in Body Dysmorphic Disorder - Selective Efficacy of a Serotonin Reuptake Inhibitor in Imagined Ugliness. Archives of general psychiatry. 1999;56:1033-1039.
5988.	Hollander E, Allen A, RP L, et al. A Preliminary Double-Blind, Placebo-Controlled Trial of Divalproex Sodium in Borderline Personality Disorder. Journal of clinical psychiatry. 2001;62:199-203.
5989.	Hollander E, Allen A, Steiner M, DE W, Oakes R, DB B. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Journal of clinical psychiatry. 2003;64:1113-1121.
5990.	Hollander E, CM W. Body dysmorphic disorder, pathological gambling, and sexual compulsions. Journal of clinical psychiatry. 1995;56:7-13.
5991.	Hollander E, DJ S, NA F, Marteau F, Legault M. Quality of Life Outcomes in Patients With Obsessive-Compulsive Disorder: Relationship to Treatment Response and Symptom Relapse. Journal of clinical psychiatry. 2010;71:784-792.
5992.	Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American journal of psychiatry. 2012;169:292-299.
5993.	Holsboer F. The role of peptides in treatment of psychiatric disorders. Journal of Neural Transmission, Supplement. 2003:17-34.
5994.	Holsboer-Trachsler E. Therapy of depression in neurorehabilitation and neurobiological mechanisms of action. [German]. Schweizer Archiv fur Neurologie und Psychiatrie. 2003;154:431-439.
5995.	Holsboer-Trachsler E, Baumann P, Hock P, et al. Escitalopram in Clinical Practice: Results of an Observational Study in Patients With Depression and Anxiety. Psychopharmakotherapie. 2011;18:59-+.
5996.	Holt S. Is evidence-based complementary and alternative medicine a contradiction in terms? -'No'. Focus on Alternative and Complementary Therapies. 2011;16:117-119.
5997.	Holtkamp K, Herpertz-Dahlmann B. SSRI and SNRI treatment in children and adolescents. Current views of the benefits and risks. [German]. Der Nervenarzt. 2008;79:1237-1248.
5998.	Holtkamp K, Konrad K, Kaiser N, et al. A Retrospective Study of Ssri Treatment in Adolescent Anorexia Nervosa: Insufficient Evidence for Efficacy. Journal of psychiatric research. 2005;39:303-310.
5999.	Holtkamp K, Konrad K, Kaiser N, et al. A Retrospective Study of Ssri Treatment in Adolescent Anorexia Nervosa: Insufficient Evidence for Efficacy. Journal of psychiatric research. 2005;39:303-310.
6000.	Holtmann M, Bolte S, Poustka F. Suicidality in depressive children and adolescents during treatment with selective serotonin reuptake inhibitors. Review and meta-analysis of the available randomised, placebo controlled trials. [German]. Der Nervenarzt. 2006;77:1332-1337.
6001.	Holtmann M, Bolte S, Poustka F. [Suicidality in depressive children and adolescents during treatment with selective serotonin reuptake inhibitors. Review and meta-analysis of the available randomised, placebo controlled trials]. [Review] [30 refs] [German]. Der Nervenarzt. 2006;77:1332-1337.
6002.	Holtmann M, Bolte S, Poustka F. Suicidality in Depressive Children and Adolescents During Treatment With Selective Serotonin Reuptake Inhibitors. Review and Meta-Analysis of the Available Randomised, Placebo Controlled Trials. Der Nervenarzt. 2006;77:1332-+.
6003.	Holzer M, Langer A, Muller N. Consequences of public discussion on the ineffectiveness of antidepressives: Attempted suicide after stopping medication. [German]. Der Nervenarzt. 2008;79:1074-1075.
6004.	Holzinger E. Insomnia. IDrugs : the investigational drugs journal. 2005;8:410-415.
6005.	Hongfen C, Weidong J, Guoquan Z, Chuang Y, Tianyou G. A randomized and double-blind clinical trial of venlafaxine hydrochloride sustained release capsules for treating juvenile depression. European psychiatry. 2009;Conference:S502.
6006.	Hongjie Z, B BM, H BS, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - Possible role for methoxyindole pathway. PloS one. 2013;8.
6007.	Honig A, AM K, AH S, et al. Treatment of post-myocardial infarction depressive disorder: A randomized, placebo-controlled trial with mirtazapine. Psychosomatic medicine. 2007;69:606-613.
6008.	Hood S, Stein D, Marquez M, et al. Efficacy of the antidepressant agomelatine in generalised anxiety disorder: A randomised, double-blind, placebocontrolled trial versus active comparator. Australian and New Zealand journal of psychiatry. 2013;Conference:49.
6009.	Hoog S, Tepner R, ME N, Romano S, JS K. Changes in anxiety, agitation, and insomnia during treatment of depression for patients age 55 years and older: Analysis from fluoxetine double-blind, placebo-controlled trials. International Journal of Geriatric Psychopharmacology. 1999;2:33-39.
6010.	Hoppner J, Schulz M, Irmisch G, Mau R, Schlafke D, Richter J. Antidepressant efficacy of two different rTMS procedures: High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. European archives of psychiatry and clinical neuroscience. 2003;253:103-109.
6011.	Horacek J, Brunovsky M, Novak T, et al. Subanesthetic Dose of Ketamine Decreases Prefrontal Theta Cordance in Healthy Volunteers: Implications for Antidepressant Effect. Psychological medicine. 2010;40:1443-1451.
6012.	Hornyak M, Feige B, Riemann D, Voderholzer U. Periodic leg movements in sleep and periodic limb movement disorder: Prevalence, clinical significance and treatment. Sleep medicine reviews. 2006;10:169-177.
6013.	Horrillo I, JE O, JJ M. Long-term fluoxetine reverses alpha2-adrenoceptors desensitization induced by chronic corticosterone treatment. European neuropsychopharmacology. 2010;Conference:S14-S15.
6014.	Horsley L. ACP guideline on second-generation antidepressants for depression treatment. American family physician. 2009;80:291-294.
6015.	Horstmann S, Dose T, Lucae S, et al. Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action. Psychoneuroendocrinology. 2009;34:238-248.
6016.	Hosak L, Tuma I. Comparative study of three antidepressants: Preliminary results. Homeostasis in health and disease. 1996;37:138-139.
6017.	Hoschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert review of neurotherapeutics. 2008;8:537-552.
6018.	Hosenbocus S, Chahal R. SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2011;20:60-67.
6019.	Hosenbocus S, Chahal R. Memantine: A review of possible uses in child and adolescent psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2013;22:166-171.
6020.	Hosford D, Kuchibhatla R, Dunbar G. Mecamylamine improved disability of depressed subjects who did not respond adequately to citalopram. European neuropsychopharmacology. 2009;Conference:S404-S405.
6021.	Hosseinzadeh H, Nassiri-Asl M. Avicenna's (Ibn Sina) the canon of medicine and saffron (Crocus sativus): A review. Phytotherapy research : PTR. 2013;27:475-483.
6022.	Hotho D, Bezemer G, BE H, et al. A prognostic model to select patients for prophylactic ssri therapy during antiviral treatment for chronic hepatitis C infection. Hepatology (Baltimore, Md.). 2011;Conference:850A-851A.
6023.	Hotopf M, Hardy R, Lewis G. Discontinuation Rates of Ssris and Tricyclic Antidepressants: a Meta-Analysis and Investigation of Heterogeneity. British journal of psychiatry. 1997;170:120-127.
6024.	Hotopf M, Lewis G, Normand C. Are Ssris a Cost-Effective Alternative to Tricyclics? British journal of psychiatry. 1996;168:404-409.
6025.	Hotopf M, Lewis G, Normand C. Putting Trials on Trial - the Costs and Consequences of Small Trials in Depression: a Systematic Review of Methodology. Journal of epidemiology and community health. 1997;51:354-358.
6026.	Hough S. Depression after spinal cord injury and medication: The journey continues. Journal of spinal cord medicine. 2014;37:246.
6027.	Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women, Psychiatry research(2011).
6028.	Houston J, Fijal B, DH A. Replicated genetic association study of dopamine receptor D2 gene variants and serum prolactin increase. European neuropsychopharmacology. 2008;Conference:S442.
6029.	Houston J, Zou W, Aris V, et al. Association of genetic variants with baseline pain in patients with major depressive disorder. Neuropsychopharmacology. 2011;Conference:S123-S124.
6030.	Hovaguimian A, CH G. Clinical approach to the treatment of painful diabetic neuropathy. Therapeutic advances in endocrinology and metabolism. 2011;2:27-38.
6031.	Howard P, Knight C. A clinical- and cost-effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIs) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fund. Journal of medical economics. 2004;7:93-106.
6032.	HP B, Mulleroerlinghausen B, Nickelsen T, PR H. Pharmacokinetic Interactions Between Lithium and Fluoxetine After Single and Repeated Fluoxetine Administration in Young Healthy-Volunteers. International journal of clinical pharmacology and therapeutics. 1995;33:415-419.
6033.	HP S, Kasper S, Danos P, Hoflich G, HJ M. Selective Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Symptoms in Schizophrenia. Der Nervenarzt. 1994;65:478-481.
6034.	HP S, Kuhs H, LH R, et al. Platelet 5-HT transport in depressed patients under double-blind treatment with paroxetine versus amitriptyline. Acta psychiatrica Scandinavica. Supplementum. 1989;350:149-151.
6035.	HP V. Chances and Possibilities of New Antidepressiva. Psychopharmakotherapie. 2005;12:45-50.
6036.	HP V. Chances and Possibilities of New Antidepressiva. Psychopharmakotherapie. 2005;12:45-50.
6037.	HP V. Duloxetine - Current Data and Practical Use. Psychopharmakotherapie. 2009;16:239-+.
6038.	HR B, JY L, KH M. Patterns of early adherence to the antidepressant citalopram among older primary care patients: The prospect study. International journal of psychiatry in medicine. 2006;36:103-119.
6039.	Diabetes, depression, and death: A randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT), Diabetes care(2007).
6040.	HR B, MS C, ML B, et al. The role of medical comorbidity in outcome of major depression in primary care: The PROSPECT study. American journal of geriatric psychiatry. 2005;13:861-868.
6041.	HR C, Qureshi Z, IAK T, Yazdani I. Efficacy and tolerability of paroxetine 20 mg daily in the treatment of depression and depression associated anxiety. JPMA - Journal of the Pakistan Medical Association. 2002;52:518-525.
6042.	HR K, Armeli S, Tennen H, et al. A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence Moderation by Age and 5-Hydroxytryptamine Transporter-Linked Promoter Region Genotype. Journal of clinical psychopharmacology. 2011;31:22-30.
6043.	HR K, F DB, Korner P, Brown J. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. Journal of substance abuse treatment. 1993;10:283-287.
6044.	HR K, JA B, Brown J, TF B. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism, clinical and experimental research. 1996;20:1534-1541.
6045.	HR K, JA B, Korner P, et al. Placebo-Controlled Trial of Fluoxetine as an Adjunct to Relapse Prevention in Alcoholics. American journal of psychiatry. 1995;152:391-397.
6046.	HR K, RF A. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. Journal of consulting and clinical psychology. 1994;62:1116-1126.
6047.	HR N-P, Broy P, Berard A. Use of Antidepressants During Pregnancy and the Risk of Spontaneous Abortion. CMAJ : Canadian Medical Association journal. 2010;182:1031-1037.
6048.	HR W, YS W, W-M B. Atypical antipsychotics in the treatment of posttraumatic stress disorder. Clinical neuropharmacology. 2013;36:216-222.
6049.	HR W, YS W, WM B. The Potential Role of Atypical Antipsychotics in the Treatment of Panic Disorder. Human Psychopharmacology-Clinical and Experimental. 2014;29:405-413.
6050.	Hritzak K, NS C. Sertraline effective for children and adolescents with major depression. Journal of family practice. 2004;53:11-12.
6051.	HS A. Toward an Innovative Classification of Depression: Temperament and Pharmacological Response. Drugs of today (Barcelona, Spain : 1998). 1997;33:183-190.
6052.	HS A-A. Olanzapine-induced diabetic ketoacidosis in a Saudi female. Bahrain Medical Bulletin. 2009.
6053.	HS K. Efficacy and safety of antidepressant drugs in patients with dementia. Current neurology and neuroscience reports. 2011;11:520-522.
6054.	HS K. From the editor-in-chief's desk. Journal of child and adolescent psychopharmacology. 2014;24:169.
6055.	HS L, Davidson J, JA B. Nonpharmacologic treatments for depression in patients with coronary heart disease. Psychosomatic medicine. 2005;67:S58-S62.
6056.	HS L, JA B, MA B, et al. Depression as a risk factor for coronary artery disease: Evidence, mechanisms, and treatment. Psychosomatic medicine. 2004;66:305-315.
6057.	HS M. Targeted electrode-based modulation of neural circuits for depression. Journal of clinical investigation. 2009;119:717-725.
6058.	HS M, PE H. Targeted modulation of neural circuits: A new treatment strategy for neuropsychiatric disease. Electrophysiological Recording Techniques. 2011;Neurometho:257-279.
6059.	HS M, SK B, JL T, et al. Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biological psychiatry. 2000;48:830-843.
6060.	HS S, Bracken D, JM S. Pharmacotherapy for fibromyalgia. Frontiers in pharmacology. 2011.
6061.	HS S, EJ S, BR S. Duloxetine in the management of chronic musculoskeletal pain. Therapeutics and clinical risk management. 2012;8:267-277.
6062.	HS S, Harris R, Clauw D. Fibromyalgia: an Afferent Processing Disorder Leading to a Complex Pain Generalized Syndrome. Pain physician. 2011;14:E217-E245.
6063.	HS S, RL B. Fibromyalgia Syndrome: a Discussion of the Syndrome and Pharmacotherapy. American journal of therapeutics. 2010;17:418-439.
6064.	HS S, RL B. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Dm Disease-a-Month. 2011;57:248-285.
6065.	HS S, RL B, SJ B. Personalized pharmacotherapy for treatment approaches focused at primary insomnia. American journal of therapeutics. 2011;18:227-240.
6066.	Hsuan-Chi W, Lieh YT, Hua CH, et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology. 2011;213:773-779.
6067.	Hsyoerg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta psychiatrica Scandinavica. 1996;93:184-190.
6068.	Hu Q, SY Z, Liu F, et al. Influence of Gnb3 C825t Polymorphism on the Efficacy of Antidepressants in the Treatment of Major Depressive Disorder: a Meta-Analysis. Journal of affective disorders. 2015;172:103-109.
6069.	Hua B, R-F C, Jing J, et al. Antidepressant effect of licorice flavonoids from Glycyrrhiza uralensis on stress-induced depression and the key protein SYP/PSD95 associated with synaptic plasticity in rats. [Chinese]. Chinese Journal of New Drugs. 2014;23:1180-1187.
6070.	Hua CH, Hung CM, IHui L, et al. The change of insulin levels after six weeks antidepressant use in drug-naive major depressive patients. Journal of affective disorders. 2013;150:295-299.
6071.	Hua S, Hui Z, Chi M, et al. Effects of electroacupuncture on depression and the production of glial cell line-derived neurotrophic factor compared with fluoxetine: A randomized controlled pilot study. Journal of alternative and complementary medicine (New York, N.Y.). 2013;19:733-739.
6072.	Huafang L, Ting L, Yifeng S. Pharmacokinetics and safety of duloxetine enteric-coated tablets in Chinese healthy volunteers: A randomized, open-label, single- and multiple-dose study. Clinical Psychopharmacology and Neuroscience. 2013;11:28-33.
6073.	Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine, Annals of general psychiatry(2010).
6074.	Huaiyu Y, Sarah C, Lara S-Y, et al. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. European archives of psychiatry and clinical neuroscience. 2010;260:145-150.
6075.	Huang J, D-H P, C-M Y, et al. Clinical effects of venlafaxine in treatment of depressive disorder associated with anxiety and its impact factors. [Chinese]. Journal of Shanghai Jiaotong University (Medical Science). 2012;32:746-750+760.
6076.	Huang X, Li C, YL L, JL J, Wang B. Efficacy of venlafaxine extended release monotherapy for first episode depression with painful physical symptoms. European neuropsychopharmacology. 2012;Conference:S254-S255.
6077.	Huang X, Li C, YL L, Wang B, JL J. Efficacy of Venlafaxine Extended-Release Monotherapy for First-Episode Depression With Painful Physical Symptoms. Neuroreport. 2013;24:364-369.
6078.	Huang X, Yu T, Cao Y, et al. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013;14:1723-1730.
6079.	Comparison of escitalopram and paroxetine in the treatment of major depressive disorder, International clinical psychopharmacology(2013).
6080.	Hud-Aleem R, Ladson D. Generalized anxiety disorder in adults. Journal of clinical outcomes management. 2008;15:353-362.
6081.	Huezo-Diaz P, Perroud N, EP S, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of psychopharmacology (Oxford, England). 2012;26:398-407.
6082.	Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. British journal of psychiatry. 2009;195:30-38.
6083.	Huff W, Ruhrmann S, Sitzer M. Post-stroke depression: Diagnosis and therapy. [German]. Fortschritte der Neurologie-Psychiatrie. 2001;69:581-591.
6084.	Hughes J, Gabbay M, Funnell E, Dowrick C. Exploratory Review of Placebo Characteristics Reported in Randomised Placebo Controlled Antidepressant Drug Trials. Pharmacopsychiatry. 2012;45:20-27.
6085.	Hughes S, Cohen D. Can Online Consumers Contribute to Drug Knowledge? A Mixed-Methods Comparison of Consumer-Generated and Professionally Controlled Psychotropic Medication Information on the Internet. Journal of medical Internet research. 2011;13.
6086.	Huh J, Goebert D, Takeshita J, BY L, Kang M. Treatment of generalized anxiety disorder: A comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Primary care companion to the Journal of clinical psychiatry. 2011.
6087.	Hulisz D, Moore N. Chronic pain management. U.S. 2007;Pharmacist:55-61.
6088.	Hulkova M, Hosak L. Psychiatric aspects of hepatic encephalopathy, hepatitis C and liver transplantation. Scripta Medica Facultatis Medicae Universitatis Brunensis Masarykianae. 2009;82:256-261.
6089.	Humayun F, TM S, JA T, RJ F. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. Journal of medical case reports. 2007.
6090.	Humble M. Noradrenaline and Serotonin Reuptake Inhibition as Clinical Principles: a Review of Antidepressant Efficacy. Acta psychiatrica Scandinavica. 2000;101:28-36.
6091.	Humble M, Bejerot S, PBF B, Bengtsson F. Reactivity of Serotonin in Whole Blood: Relationship With Drug Response in Obsessive-Compulsive Disorder. Biological psychiatry. 2001;49:360-368.
6092.	Hung CM, Hua CH, Sheng-Yu L, et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. Journal of affective disorders. 2010;126:430-435.
6093.	Hunter AM, Ravikumar S, Cook IA, Leuchter AF. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression. Acta psychiatrica Scandinavica. 2009;119:266-273.
6094.	Huntley E, Swanson L, Bertram H, et al. Diurnal variability in negative affect following fluoxetine and repeated partial sleep deprivation in adults with major depressive disorder. Sleep. 2013;Conference:A316.
6095.	Huot P, SH F. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Experimental Brain Research. 2013;230:463-476.
6096.	Huppert D, Strupp M, Muckter H, Brandt T. Which medication do i need to manage dizzy patients? Acta oto-laryngologica. 2011;131:228-241.
6097.	Hurst M, HM L. Fluoxetine - a Review of Its Use in Anxiety Disorders and Mixed Anxiety and Depression. CNS drugs. 2000;14:51-80.
6098.	Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: A double-blind comparison with amitriptyline. International clinical psychopharmacology. 1992;6 Suppl 4:43-51.
6099.	Hutchinson K, Cruickshank K, Wylie K. A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation. Drug safety. 2012;35:359-372.
6100.	Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J. Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatric disease and treatment. 2012;8:95-104.
6101.	HV K, AF L, IA C, Abrams M. Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the Treatment of Fibromyalgia and Chronic Low Back Pain. Psychosomatics. 2005;46:379-384.
6102.	HW G. Low-dose doxepin for the treatment of insomnia: Emerging data. Expert opinion on pharmacotherapy. 2009;10:1649-1653.
6103.	HW K, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. Journal of clinical psychiatry. 2003;64:628-634.
6104.	HW vM, Ader H, M dH, Beekman A. Primary care management of major depression in patients aged > or =55 years: outcome of a randomised clinical trial. British journal of general practice. 2008;58:680-686, I-II; discussion 687.
6105.	HW X, CY B, Yi Y, et al. [Observation on therapeutic effect of acupuncture of five Shu-points of the liver meridian combined with bloodletting for depression patients and concomitant changes of blood rheology]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2012;37:140-144.
6106.	HW Z, CY W, HN X, et al. [Clinical study on effect of fluoxetine combined with Chinese medicine or tibetan drugs in treating senile depression in plateau district]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2006;26:202-204.
6107.	HWH T, EP C, WM C. Effects of mindful and non-mindful exercises on people with depression: A systematic review. British journal of clinical psychology. 2008;47:303-322.
6108.	HWJ R, JF OH. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. European neuropsychopharmacology. 1995;5:35-42.
6109.	HWJ vM, Ader H, M dH, Beekman A. Primary care management of major depression in patients aged >55 years: Outcome of a randomised clinical trial. British journal of general practice. 2008;58:680-686.
6110.	HY C. Assessing the Quality of Evidence From Randomized, Controlled Drug and Nutritional Supplement Trials Conducted Among Nursing Home Residents Between 1968 and 2004: What Can We Learn? Journal of the American Medical Directors Association. 2009;10:28-35.
6111.	HY J, Kim Y. Clinical experience with the escitalopram in Korean children and adolescents. International journal of neuropsychopharmacology. 2010;Conference:76.
6112.	HY L, CH L. Glycine transporter-1 and D-amino acid oxidase based modulation of NMDAR neurotransmission: Diagnostic and therapeutic implications. Journal of neurochemistry. 2014;Conference:37.
6113.	HY L, YK K. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology. 2008;57:194-199.
6114.	HY M. Paroxetine - a Safe and Effective Once-Daily Oral Antidepressant Agent. Hospital formulary. 1993;28:4-13.
6115.	HY M, Young M, Metz J. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. Journal of neural transmission. General section. 1979;45:165-175.
6116.	HY P, BJ L, JH K, JN B, BJ H. Rapid Improvement of Depression and Quality of Life With Escitalopram Treatment in Outpatients With Breast Cancer: a 12-Week, Open-Label Prospective Trial. Progress in neuro-psychopharmacology & biological psychiatry. 2012;36:318-323.
6117.	HY W, Chen M, BH Z. Effect of different therapies of Chinese medicine on the expressions of c-Fos and c-Jun proteins in hippocampus of rats with post-stroke depression. Neural Regeneration Research. 2006;1:234-238.
6118.	HY X, Chen Z, He J, et al. Synergetic Effects of Quetiapine and Venlafaxine in Preventing the Chronic Restraint Stress-Induced Decrease in Cell Proliferation and Bdnf Expression in Rat Hippocampus. Hippocampus. 2006;16:551-559.
6119.	HY Y, Cusin C, Fava M. Is There a Placebo Problem in Antidepressant Trials? Current topics in medicinal chemistry. 2005;5:1077-1086.
6120.	HY Y, Cusin C, Fava M. Is There a Placebo Problem in Antidepressant Trials? Current topics in medicinal chemistry. 2005;5:1077-1086.
6121.	Hyeran K, Shinn-Won L, Seonwoo K, et al. Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression. JAMA: Journal of the American Medical Association. 2006;296:1609-1618.
6122.	Hyman RM, A NA, Robert H, Christina D, J SP, David M. The treatment of minor depression with St. John's wort or citalopram: Failure to show benefit over placebo. Journal of psychiatric research. 2011;45:931-941.
6123.	Hyman RM, Anjana B, Hongjie Z. Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes. Journal of clinical psychiatry. 2004;65:44-49.
6124.	Hyman RM, Bruce LR, D PC, et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: A randomized, placebo-controlled trial. Journal of clinical psychiatry. 2009;70:46-57.
6125.	Hyman RM, M GG, M CC, et al. Corrigendum: Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. Neuropsychopharmacology. 2006;31:2514.
6126.	Hyman RM, M GG, M CC, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.[Erratum appears in Neuropsychopharmacology. 2007 May;32(5):1208], [Erratum appears in Neuropsychoph. Neuropsychopharmacology. 2006;31:2505-2513.
6127.	Hyman RM, M GG, M CC, et al. Corrigendum: "Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation". Neuropsychopharmacology. 2007;32:1208.
6128.	Hymie A, V RA, Jenna G, Zul M. Interleukin-1 Beta Production in Dysthymia Before and After Pharmacotherapy. Biological psychiatry. 1999;46:1649-1655.
6129.	Hymowitz N. Smoking and weight. Current respiratory medicine reviews. 2008;4:137-149.
6130.	Hyun HD, Mi KS, Eun CJ, Joon MK, F RP. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence. Journal of psychopharmacology (Oxford, England). 2013;27:282-291.
6131.	HZ M, Radziwon-Zaleska M, ML S, Ryszewska-Pokrasniewicz B, Nowak G, Pilc A. Complementary to TDM biomarkers of therapeutic response to antidepressants. Therapeutic drug monitoring. 2011;Conference:525-526.
6132.	I CC, H NC, Fernandes L. Aging, circadian rhythms and depressive disorders: A review. American Journal of Neurodegenerative Diseases. 2013;2:228-246.
6133.	I FS, M RE, M CC. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. International psychogeriatrics / IPA. 1999;11:85-99.
6134.	I GA, L MS, L WE, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial. International journal of eating disorders. 2012;45:281-289.
6135.	I GL, F TM, S TB, A AM. Update in the multidisciplinary treatment of fibromyalgia. [Spanish]. DOLOR. 2008;23:194-206.
6136.	I HJ, M WM, K KD, H MC, G WJ, V MO. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. [Review] [46 refs]. Human Psychopharmacology: Clinical and Experimental. 2005;20:327-341.
6137.	I PG. Serotonin norepinephrine reuptake inhibitors: Spectrum of efficacy in major depressive disorder. Primary psychiatry. 2009;16:16-24.
6138.	I PG, A MS, E TM, R KJ, Alok K, L TV. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: A pooled survival analysis of 7 double-blind, randomized clinical trials. Journal of clinical psychiatry. 2007;68:1907-1912.
6139.	I PG, Alisabet C, E AV, et al. Fluoxetine-clonazepam cotherapy for anxious depression: An exploratory, post-hoc analysis of a randomized, double blind study. International clinical psychopharmacology. 2010;25:17-21.
6140.	I PG, E TM, Maurizio F, Craig NJ, C SR. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. [Review] [141 refs. Biological psychiatry. 2007;62:1217-1227.
6141.	I PG, Hua F, Enrico T. Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. European neuropsychopharmacology. 2012;22:347-355.
6142.	I PG, Klaus L. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. European archives of psychiatry and clinical neuroscience. 2011;261:147-156.
6143.	I PG, Maurizio F, E TM. Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches. Biological psychiatry. 2008;63:699-704.
6144.	I PG, Timothy P, B SS, et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003;47:146-151.
6145.	I PG, Timothy P, David M, et al. Serum Folate, Vitamin B-12, and Homocysteine in Major Depressive Disorder, Part I: Predictors of Clinical Response in Fluoxetine-Resistant Depression. Journal of clinical psychiatry. 2004;65:1090-1095.
6146.	I PG, Timothy P, G SK, A NA, E AJ, Maurizio F. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry research. 2007;149:195-200.
6147.	I PG, Timothy P, H HC, et al. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Annals of clinical psychiatry. 2007;19:5-8.
6148.	I PG, Timothy P, J WJ, et al. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. International clinical psychopharmacology. 2003;18:293-296.
6149.	I PG, V lD, Timothy P, et al. Serum Cholesterol in the Continuation Phase of Pharmacotherapy With Fluoxetine in Remitted Major Depressive Disorder. Journal of clinical psychopharmacology. 2004;24:467-469.
6150.	I PM, L FM, C MG. The impact of the efficacy and the safety warnings of antidepressants in the treatment of childhood depression. changes in patterns of use and scientific evidences. European psychiatry. 2011.
6151.	I SC. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?. [Review] [39 refs]. Journal of clinical psychiatry. 2004;65 Suppl 1:29-33.
6152.	I SD. Sertraline for treatment of depression in acute coronary syndromes: Comment. JAMA: Journal of the American Medical Association. 2002;288:2403.
6153.	I SG. "Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial." Comment. JAMA: Journal of the American Medical Association. 2002;288:446-447.
6154.	I SG. "Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder": Comment. JAMA: Journal of the American Medical Association. 2004;291:41.
6155.	I SG. Duloxetine does not relieve painful physical symptoms in depression: A meta-analysis. Psychotherapy and psychosomatics. 2007;77:12-16.
6156.	I SG. False conclusions regarding duloxetine's purported efficacy in pain among depressed patients. Psychiatria Danubina. 2010;22:550.
6157.	I SJ, L CE, Murali DP, et al. Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness.[Erratum appears in J Am Geriatr Soc. 2004 Jul;52(7):1228]. Journal of the American Geriatrics Society. 2004;52:86-92.
6158.	I SY, E BM, G CJ. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reputake inhibitors. Journal of clinical psychopharmacology. 1997;17:11-14.
6159.	Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms, Pain(2011).
6160.	I-C L, C-J H, S-J T. Expression of cAMP response element-binding protein in major depression before and after antidepressant treatment. Neuropsychobiology. 2003;48:182-185.
6161.	I-G A, Dierkes W, H-P V, P-A L, AB S. [Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients]. [German]. Fortschritte der Neurologie-Psychiatrie. 2009;77:646-654.
6162.	I-M B, RG M. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. British journal of psychiatry. 1997;171:328-334.
6163.	IA C. Quantitative EEG measures of frontal activity as biomarkers for predicting treatment outcomes in major depression. Biological psychiatry. 2010;Conference:98S.
6164.	IA C, AF L, Witte E, et al. Neurophysiologic predictors of treatment response to fluoxetine in major depression.[Erratum appears in Psychiatry Res 2000 Jul 24;95(1):87]. Psychiatry research. 1999;85:263-273.
6165.	IA C, AM H, Abrams M, Siegman B, AF L. Midline and Right Frontal Brain Function as a Physiologic Biomarker of Remission in Major Depression. Psychiatry Research - Neuroimaging. 2009;174:152-157.
6166.	Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial, Journal of clinical psychiatry(2013).
6167.	IA L, EH C, P VW, Deberdt W, Sagman D. Typology of Patients With Fibromyalgia: Cluster Analysis of Duloxetine Study Patients. BMC musculoskeletal disorders. 2014;15.
6168.	IA N, PE R, Sennef C. Factors That Influence the Outcome of Placebo-Controlled Antidepressant Clinical Trials. Psychopharmacology bulletin. 1997;33:41-51.
6169.	IA S, AD S, Lohr J, AN S. Too hard to control: Compromised pain anticipation and modulation in mild traumatic brain injury. Translational psychiatry. 2014.
6170.	Ian R. Review of Before Prozac. The troubled history of mood disorders in psychiatry. The British Journal of Psychiatry. 2009;195:183-184.
6171.	Iancu I, Tschernihovsky E, Bodner E, AS P, Lowengrub K. Escitalopram in the Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: a Randomized Double-Blind Placebo-Controlled Trial. Psychiatry research. 2010;179:19-23.
6172.	Iannitelli A, Pancheri P. Citalopram: Pharmacological profile and clinical efficacy of the most selective among SSRI. [Italian]. Italian Journal of Psychopathology. 2002;8:435-459.
6173.	Iavarone L, Gomeni R. Analysis of longitudinal clinical scores in major depressive disorder trials: Comparison of linear and non-linear mixed effect modelling. European neuropsychopharmacology. 2009;Conference:S406-S407.
6174.	IB H. An Approach to Managing Depression in General Practice. Medical journal of Australia. 2000;173:106-110.
6175.	IB H, AJ W, JM W, BK B, Wakefield D, AR L. A randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. Journal of clinical psychiatry. 2000;61:643-648.
6176.	IB K. Mood and anxiety disorders in patients with myasthenia gravis: Aetiology, diagnosis and treatment. CNS drugs. 2007;21:473-481.
6177.	IC G, SL C, Finkenzeller D, PJ C. Interventional therapies for controlling pelvic pain: What is the evidence? Current pain and headache reports. 2010;14:22-32.
6178.	Ichiro M, J RM. Effects of antidepressants on functional recovery following stroke: A double-blind study. Journal of neurologic rehabilitation. 1998;12:5-13.
6179.	Icick R, Desage A, Gard S, Guillaume S, J-P L, Bellivier F. Comorbid addiction in bipolar affective disorder. Neuropsychiatry. 2012;2:531-541.
6180.	ICK W, FMC B, PJ S, ML M. Use of selective serotonin reuptake inhibitors in children and adolescents. [Review] [42 refs]. Drug safety. 2004;27:991-1000.
6181.	ID G, Suppes T, Debattista C, RJ H, Marder S. Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia. Annals of internal medicine. 2001;134:47-60.
6182.	ID M, Svikis D, SC M, Suarez A, Tanielian T, HA P. Psychiatric care of patients with depression and comorbid substance use disorders. Journal of clinical psychiatry. 2000;61:698-705.
6183.	IE L, AK B. Epilepsy in the elderly. The Year in Neurology 2. 2010;Annals of 208-224.
6184.	IG A, Regen F. [St. John's wort in depression. The question is not whether it is effective but how do we use it]. [German]. MMW Fortschritte der Medizin. 2005;147:17.
6185.	Iga J, Ueno S, Yamauchi K, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neuroscience letters. 2005;389:12-16.
6186.	Iga J, Ueno S, Yamauchi K, et al. Gene expression and association analysis of LIM (PDLIM5) in major depression. Neuroscience letters. 2006;400:203-207.
6187.	Iglesias C, Pato E, Ocio S, et al. [Treatment with venlafaxine extended release for climacteric women with depression or anxiety diagnosis. An open-label study]. [Spanish]. Actas espanolas de psiquiatria. 2009;37:137-142.
6188.	Igor F, Branimir M, Ivona S, Miro J. Depression treatment and its impact upon the quality of life in patients with diabetes type 2 - The Croatian study. Psychiatria Danubina. 2010;22:231-235.
6189.	Igor S, Chawki B, Paul G, et al. Decreased [F-18]Mppf Binding Potential in the Dorsal Raphe Nucleus After a Single Oral Dose of Fluoxetine: a Positron-Emission Tomography Study in Healthy Volunteers. Biological psychiatry. 2008;63:1135-1140.
6190.	IH R. Depression and apathy in Parkinson's disease. Current neurology and neuroscience reports. 2007;7:295-301.
6191.	IH R. Paroxetine (Paxil) and venlafaxine (Effexor) relieve depression in Parkinson's disease. P and T. 2010;35:637.
6192.	IH R, McDermott M, WM M. A multicenter randomized, double-blind, placebo-controlled trial of paroxetine and venlafaxine extended release for depression in Parkinson's disease. Movement disorders. 2010;Conference:S680.
6193.	A Randomized, Double-Blind, Placebo-Controlled Trial of Antidepressants in Parkinson Disease, Neurology(2012).
6194.	Ihl R, Frolich L, Winblad B, Schneider L, Burns A, H-J M. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World journal of biological psychiatry. 2011;12:2-32.
6195.	II B, MY K. Use of Pregabalin and Sertraline in Complex Treatment of Patients With Partial Epilepsy Comorbid With Depressive and Anxiety Disorders. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2012;112:29-36.
6196.	IIE D, Schlegel E. The management of amyotrophic lateral sclerosis. U.S. 2009;Pharmacist:HS10-HS12.
6197.	IIICF R. Treatment of depression in special populations. Journal of clinical psychiatry. 1992;53:45-53.
6198.	IIICF R, Cuijpers P, Patel V, et al. Early intervention to reduce the global health and economic burden of major depression in older adults. Annual review of public health. 2012;33:123-135.
6199.	IIICF R, Degenholtz H, LS P, et al. Treatment as usual (TAU) control practices in the PROSPECT study: Managing the interaction and tension between research design and ethics. International journal of geriatric psychiatry. 2001;16:602-608.
6200.	Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy, Archives of general psychiatry(2011).
6201.	IIIJO B, JC H. Neurocognitive costs and benefits of psychotropic medications in older adults. Journal of geriatric psychiatry and neurology. 2007;20:199-214.
6202.	IIIJO B, Karnik N, Hoblyn J. High initial dosing of olanzapine for stabilization of acute agitation: A retrospective case series. Journal of pharmacy technology. 2008;24:7-11.
6203.	IIIL F, KR S. State of the art in the pharmacologic treatment of borderline personality disorder. Current psychiatry reports. 2011;13:69-75.
6204.	IIIPE H, CB N. Emerging treatments for depression. Expert opinion on pharmacotherapy. 2006;7:2323-2339.
6205.	IIRL P, Lindenfeld J. The comorbidity conundrum: A focus on the role of noncardiovascular chronic conditions in the heart failure patient. Current cardiology reports. 2012;14:276-284.
6206.	IJ R. Fibromyalgia Syndrome: Approach to Management. CNS spectrums. 2008;13:27-33.
6207.	IJ R, LJ C, Leon T, et al. The Effects of Pregabalin on Sleep Disturbance Symptoms Among Individuals With Fibromyalgia Syndrome. Sleep medicine. 2009;10:604-610.
6208.	IJ R, PJ M, TR S, DK K, MM W, MJ D. Comments. Journal of musculoskeletal pain. 2008;16:331.
6209.	IJ T, CH M. Carbohydrate-based drugs in the treatment of epilepsy, depression and other affective disorders. Current topics in medicinal chemistry. 2008;8:159-170.
6210.	IJon R. The promise of substance P inhibitors in fibromyalgia. Rheumatic Disease Clinics of North America. 2002;28:329-342.
6211.	Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Ueda N, Nakamura J. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:1451-1453.
6212.	IL P, Ralevski E, Desai N, et al. Noradrenergic Vs Serotonergic Antidepressant With or Without Naltrexone for Veterans With Ptsd and Comorbid Alcohol Dependence. Neuropsychopharmacology. 2012;37:996-1004.
6213.	Ilhan YL, Aytul C, Nese K, Ayten E, Gulsah K, Dilek Y. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International journal of psychiatry in clinical practice. 2004;8:205-211.
6214.	Illescas-Rico R, Paez-Agraz F, Arreola-Chavez F, Verduzco-Fragoso W, FA G-R, Luna-Soria F. [Effectiveness and security of venlafaxine XR in the treatment of major depression]. [Spanish]. Revista medica del Instituto Mexicano del Seguro Social. 2005;43:473-478.
6215.	IM A. SSRIS versus tricyclic antidepressants in depressed inpatients: A meta- analysis of efficacy and tolerability. Depression and anxiety. 1998;7:11-17.
6216.	IM A. Meta-analytical studies on new antidepressants. [Review] [32 refs]. British medical bulletin. 2001;57:161-178.
6217.	IM A. Drug treatment of depression: Reflections on the evidence. Advances in Psychiatric Treatment. 2003;9:11-20.
6218.	IM A. Commentary on 'Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: Meta-analysis' by Weinmann et al. Psychopharmacology. 2008;196:521-522.
6219.	IM A. Commentary on STAR*D: A summary and UK perspective. Journal of psychopharmacology (Oxford, England). 2009;23:613-614.
6220.	IM A. Pharmacological Treatment of Unipolar Depression. Behavioral Neurobiology of Depression and Its Treatment. 2013;Current To:263-289.
6221.	IM A, BM T. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. Journal of psychopharmacology (Oxford, England). 1994;8:238-249.
6222.	IM A, BM T. Treatment Discontinuation With Selective Serotonin Reuptake Inhibitors Compared With Tricyclic Antidepressants - a Metaanalysis. Bmj-British Medical Journal. 1995;310:1433-1438.
6223.	IM A, DJ N, JFW D. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. Journal of psychopharmacology (Oxford, England). 2000;14:3-20.
6224.	IM A, GE A, AJ vB, JH S, Hermesh H, P vO. Sudden gains in the treatment of obsessive-compulsive disorder. Psychotherapy and psychosomatics. 2012;81:44-51.
6225.	IM A, GE A, AJ vB, et al. Differences between early and late drop-outs from treatment for obsessive-compulsive disorder. Journal of anxiety disorders. 2011;25:918-923.
6226.	IM A, PM H, Scott J. Bipolar disorder. BMJ (Online). 7889.
6227.	IM C, IC R, SA M. Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder. Journal of affective disorders. 2014;166:48-58.
6228.	IM C, Trinder J, GE S. The impact of smoking cessation on objective and subjective markers of sleep: Review, synthesis, and recommendations. Nicotine & tobacco research. 2004;6:913-925.
6229.	IM G. Author's reply [2]. British medical journal. 2007;335:221.
6230.	IM G, Dubicka B, Wilkinson P, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health technology assessment. 2008;12:iii-60.
6231.	IM G, Dubicka B, Wilkinson P, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health technology assessment (Winchester, England). 2008;12:iii-iv, ix-60.
6232.	Improving Mood With Psychoanalytic and Cognitive Therapies (Impact): a Pragmatic Effectiveness Superiority Trial to Investigate Whether Specialised Psychological Treatment Reduces the Risk for Relapse in Adolescents With Moderate to Severe Unipolar Depres, Trials(2011).
6233.	Improving mood with psychoanalytic and cognitive therapies (IMPACT): a pragmatic effectiveness superiority trial to investigate whether specialised psychological treatment reduces the risk for relapse in adolescents with moderate to severe unipolar depres, Trials [Electronic Resource](2011).
6234.	IM L, AF L, MH T, et al. Insured and non-insured depressed outpatients: how do they compare? Annals of clinical psychiatry. 2007;19:73-82.
6235.	IM L, HF M, KM L, et al. Ethnic differences in antidepressant response: A prospective multi-site clinical trial. Depression and anxiety. 2010;27:56-62.
6236.	IM O, Watanabe N, Nakagawa A, et al. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. [Review] [54 refs]. Journal of psychopharmacology (Oxford, England). 2009;23:539-550.
6237.	IM O, Watanabe N, Nakagawa A, et al. Fluvoxamine Versus Other Anti-Depressive Agents for Depression. Cochrane database of systematic reviews (Online). 2010.
6238.	IM O, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. [Review] [205 refs]. Cochrane database of systematic reviews (Online). 2010:CD006114.
6239.	IM O, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. [Review] [205 refs]. Cochrane database of systematic reviews (Online). 2010;3:CD006114.
6240.	IM S, JM P, JR C, et al. Therapeutic drug monitoring (TDM) and treatment response in major depression with comorbid alcoholism. Neuropsychopharmacology. 2010;Conference:S314-S315.
6241.	IM S, JR C, Douaihy A, Caceda R, Miao F, Kirisci L. Differential impact of cannabis abuse on depression remission in comorbid depression and alcoholism. Alcoholism, clinical and experimental research. 2012;Conference:299A.
6242.	IM S, JR C, Douaihy A, et al. Longstanding cannabis abuse is associated with decreased likelihood of remission from major depression. Neuropsychopharmacology. 2011;Conference:S300-S301.
6243.	IM S, JR C, Douaihy A, DC D. Predicting medication adherence and treament completion among depressed alcoholics. Alcoholism, clinical and experimental research. 2013;Conference:198A.
6244.	IM S, JR C, Douaihy A, Kirisci L. Gender difference in alcohol treatment response in patients with comorbid alcoholism and depression. Alcoholism, clinical and experimental research. 2011;Conference:19A.
6245.	IM S, JR C, ME T, DC D, Kirisci L, Spotts C. Naltrexone Utility in Depressed Alcoholics. Psychopharmacology bulletin. 1998;34:111-115.
6246.	IM S, YO J. Efficacy of pharmacotherapy for comorbid major depression and substance use disorders: A review. Current psychiatry reviews. 2008;4:14-27.
6247.	IM V, BR S, HGM W, JA D. Behavioral, Neuroendocrine and Biochemical Effects of Different Doses of 5-Htp in Panic Disorder. European neuropsychopharmacology. 1996;6:103-110.
6248.	IM V, HGM W, JA D. Mao Inhibitors in Panic Disorder - Clinical Effects of Treatment With Brofaromine - a Double Blind Placebo Controlled Study. Psychopharmacology. 1993;112:483-489.
6249.	IM VV, JA DB, HGM W, KL HP. Clinical effects of buspirone in social phobia: A double-blind placebo- controlled study. Journal of clinical psychiatry. 1997;58:164-168.
6250.	Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: From pathology and genetics to potential therapies. Biochemical journal. 2008;412:191-209.
6251.	Imaz A, Cayuela N, Niubo J, et al. Short Communication: Focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS research and human retroviruses. 2014;30:984-987.
6252.	IMM VH, WA VK, HJ D, CJ K, TCG E. Selective Serotonin Reuptake Inhibitors and Intraoperative Blood Pressure. American journal of hypertension. 2012;25:223-228.
6253.	Impey B, DS B. On 'cognitive Dysfunction' as a Novel Target for Antidepressant Treatment. Human Psychopharmacology-Clinical and Experimental. 2013;28:535-537.
6254.	Imran N. Attention deficit hyperactivity syndrome: An update on assessment and management. Pakistan Journal of Medical Sciences. 2007;23:9-15.
6255.	IN F. Characterizing the ideal antidepressant therapy to achieve remission. Journal of clinical psychiatry. 2001;62:10-15.
6256.	Inanli I, Kurkcu A, Ozbek S, Varsak N, Eren I. Severe extrapyramidal symptoms associated with the use of aripiprazole. Bulletin of Clinical Psychopharmacology. 2013;Conference:S164.
6257.	Inanli I, Kurkcu A, Ozbek S, Varsak N, Eren I. Severe extrapyramidal symptoms associated with the use of aripiprazole. Klinik Psikofarmakoloji Bulteni. 2013;Conference:S164.
6258.	indicated Na. Abstracts. South African Psychiatry Review. 2006;9:45-58.
6259.	indicated Na. Treating pain in depression is associated with higher rates of remission. African journal of psychiatry. 2008;11:149.
6260.	indicated Na. Duloxetine in elderly patients with depression: Improvement in cognition, painful symptoms and mood. African journal of psychiatry. 2008;11:226.
6261.	indicated Na. Alleviation of painful physical symptoms in depressed patients will increase remission. African journal of psychiatry. 2009;12:84.
6262.	indicated Na. Review of Before Prozac: The troubled history of mood disorders in psychiatry. Journal of the history of the behavioral sciences. 2010;46:333-334.
6263.	Induruwa I, CS C, Gran B. Fatigue in multiple sclerosis - a brief review. [Review]. Journal of the neurological sciences. 2012;323:9-15.
6264.	Indusekhar R, SB U, O'Brien S. Psychological aspects of premenstrual syndrome. Best Practice and Research in Clinical Obstetrics and Gynaecology. 2007;21:207-220.
6265.	Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. Journal of clinical psychiatry. 2010;71:14-25.
6266.	Ingvar K, Jan G, Augusto DMLC, et al. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. International journal of geriatric psychiatry. 2000;15:295-305.
6267.	Inoue T, Kitaichi Y, Masui T, et al. Pramipexole for Stage 2 Treatment-Resistant Major Depression: an Open Study. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:1446-1449.
6268.	Ioannidis K, Serfontein J, Muller U. Bulimia nervosa patient diagnosed with previously unsuspected ADHD in adulthood: Clinical case report, literature review, and diagnostic challenges. International journal of eating disorders. 2014;47:431-436.
6269.	Ionescu D, Dehelean C, S TF, Dumache R. A comparative evaluation of therapy escitalopram versus memantine in the case of patients with alcohol dependence and co-morbid major depressive disorder. Toxicology letters. 2011;Conference:S89.
6270.	Iovieno N, GI P. Does the Presence of an Open-Label Antidepressant Treatment Period Influence Study Outcome in Clinical Trials Examining Augmentation/Combination Strategies in Treatment Partial Responders/Nonresponders With Major Depressive Disorder? Journal of clinical psychiatry. 2012;73:676-683.
6271.	Iovieno N, Tedeschini E, KH B, AE E, GI P. Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: a Meta-Analysis of Placebo-Controlled Randomized Trials. Journal of clinical psychiatry. 2011;72:1144-1151.
6272.	Iovieno N, Tedeschini E, Levkovitz Y, VE A, GI P. Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials. International journal of neuropsychopharmacology. 2012;15:289-296.
6273.	Iovieno N, Tedeschini E, VE A, Rigatelli M, GI P. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: A meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. International clinical psychopharmacology. 2011;26:69-74.
6274.	IP P, AR R, LM M, Colom F, Tohen M, Vieta E. Predominant polarity as an outcome predictor in a clinical trial for bipolar depression. European neuropsychopharmacology. 2009;Conference:S448-S449.
6275.	Ipser J, Seedat S, DJ S. Pharmacotherapy for Post-Traumatic Stress Disorder - a Systematic Review and Meta-Analysis. Samj South African Medical Journal. 2006;96:1088-1096.
6276.	IR K. Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. Journal of clinical psychiatry. 1998;59:38-44.
6277.	IR K, IIICF R, GS A, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials. Journal of the American Geriatrics Society. 2002;50:18-25.
6278.	Iranikhah M, TM W, AR T. Vilazodone for the treatment of major depressive disorder. Pharmacotherapy. 2012;32:958-965.
6279.	Irena N, Joanne R, E SD, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. American journal of psychiatry. 2002;159:1889-1895.
6280.	Irene R, MA L, DC H, David P, DJ R, Inmaculada G. Switching to Duloxetine From Selective Serotonin Reuptake Inhibitors in Non- or Partial Responders: Results From a Spanish Sample. International journal of psychiatry in clinical practice. 2009;13:100-108.
6281.	Irene R, Victor P, Manuel MJ, et al. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: A double-blind randomized study. Journal of affective disorders. 2012;143:47-55.
6282.	Early switch strategy in patients with major depression disorder: A double-blind, randomized study, Journal of clinical psychopharmacology(2012).
6283.	Irmisch G, Richter J, Schulz M, Schlafke D, Herpertz S, Hoppner J. Fatty acid concentrations in depressive patients during a repetitive transcranial magnetic stimulation (rTMS). [German]. Nervenheilkunde. 2005;24:310-316.
6284.	Irving K. The emperor's new drugs: Exploding the antidepressant myth. 2010.
6285.	Irving K, Guy S. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention & Treatment. 1998;1:No Pagination Specified.
6286.	IS H, Brne M, Juckel G. Psychopathology in multiple sclerosis: Diagnosis, prevalence and treatment. Therapeutic advances in neurological disorders. 2009;2:13-29.
6287.	IS K, JJ W, Gajwani P, RE F. Depression and coronary artery disease: The association, mechanisms and therapeutic implications. Psychiatry. 2009.
6288.	IS S, LN Y, Srisurapanont M, RW L, EM T, AP Z. Does the Addition of Pindolol Accelerate the Response to Electroconvulsive Therapy in Patients With Major Depression? A Double-Blind, Placebo-Controlled Pilot Study. Journal of clinical psychopharmacology. 2000;20:373-378.
6289.	Isaac M. Where Are We Going With Ssris? European neuropsychopharmacology. 1999;9:S101-S106.
6290.	Isaac S, Kay M, Chee N. Sexual side-effects of contemporary antidepressants: review. [Review] [40 refs]. Australian and New Zealand journal of psychiatry. 2009;43:795-808.
6291.	Isabella H, Stefanie W, Jochem K, et al. Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. Journal of affective disorders. 2015;175:199-208.
6292.	Isabella H, Stefanie W, Roland M, et al. The Inventory Of Depressive Symptomatology (IDS-C(28)) is more sensitive to changes in depressive symptomatology than the Hamilton Depression Rating Scale (HAMD(17)) in patients with mild major, minor or subsyndromal depression. European archives of psychiatry and clinical neuroscience. 2011;261:357-367.
6293.	Sensitivity to changes during antidepressant treatment: A comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depre, European archives of psychiatry and clinical neuroscience(2012).
6294.	Ischaki E, Gratziou C. Smoking and depression: Is smoking cessation effective? Therapeutic advances in respiratory disease. 2009;3:31-38.
6295.	Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. Journal of receptor, ligand and channel research. 2010;3:25-36.
6296.	Ishikawa M, Ishiwata K, Ishii K, et al. High Occupancy of Sigma-1 Receptors in the Human Brain After Single Oral Administration of Fluvoxamine: a Positron Emission Tomography Study Using [C-11]Sa4503. Biological psychiatry. 2007;62:878-883.
6297.	Ishikawa M, Sakata M, Ishii K, et al. Estimating sigma-1 receptor occupancy by PET. Neuroscience research. 2011;Conference:e34.
6298.	Ising M, Holsboer F. CRH1 Receptor Antagonists for the Treatment of Depression and Anxiety. Experimental and clinical psychopharmacology. 2007;15:519-528.
6299.	Isingrini E, Belzung C, JL F, MC M, Camus V. Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice. Psychosomatic medicine. 2012;74:63-72.
6300.	Isingrini E, JL F, MC M, Camus V, Belzung C. Endothelial dysfunction in a rodent model of depression may underlie atherosclerosis formation. European neuropsychopharmacology. 2009;Conference:S392.
6301.	Iskedjian M, TR E, FF F. Pharmacoeconomic Aspects of Venlafaxine. Reviews in Contemporary Pharmacotherapy. 1998;9:345-353.
6302.	Iskedjian M, TR E, FF F. Pbarmacoeconomic aspects of venlafaxine. Reviews in Contemporary Pharmacotherapy. 1998;9:345-353.
6303.	Ismail K. Depression and diabetes. Psychiatry. 2009;8:203-207.
6304.	Ismene P, M CK, Charla N, Lynn G, Thomas K, Bruce R. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug and alcohol dependence. 1998;50:221-226.
6305.	Isolan L, Pheula G, GA SJ, Oswald S, LA R, GG M. An Open-Label Trial of Escitalopram in Children and Adolescents With Social Anxiety Disorder. Journal of child and adolescent psychopharmacology. 2007;17:751-759.
6306.	Italiano D, Spina E, J DL. Pharmacokinetic and Pharmacodynamic Interactions Between Antiepileptics and Antidepressants. Expert opinion on drug metabolism & toxicology. 2014;10:1457-1489.
6307.	Itil TM, Bhattachyaryya A, Polvan N, Huque M, Menon GN. Fluvoxamine (DU-23,000), a new antidepressant: Quantitative pharmaco-electroencephalography and pilot clinical trials. Progress in neuro-psychopharmacology. 1977;1:309-322.
6308.	IV K, AS Sk, KM R, SO M. [Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment]. [Ukrainian]. Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy. 2014:58-64.
6309.	IV V, NM L, Golshan S, et al. Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms. Indian journal of psychiatry. 2013;55:144-148.
6310.	Ivan B, Henian C, S CL. Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day. Addiction (Abingdon, England). 2010;105:2209-2216.
6311.	Ivana D. The position of sertraline among SSRI's from the aspect of paedopsychiatry. [Czech]. Ceska a Slovenska Psychiatrie. 2001;97:171-175.
6312.	Ivkovic M, Damjanovic A, Jovanovic A, Cvetic T, Jasovic-Gasic M. Lamotrigine Versus Lithium Augmentation of Antidepressant Therapy in Treatment-Resistant Depression: Efficacy and Tolerability. Psychiatria Danubina. 2009;21:187-193.
6313.	IW M, GI K, AF S, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Journal of clinical psychiatry. 1998;59:608-619.
6314.	Cognitive and psychosocial aspects of caring for elderly patients with diabetes, Current diabetes reports(2009).
6315.	Iwona C, Mark Z, I MJ. Diagnosing melancholia. Journal of clinical psychiatry. 2000;61:874-875.
6316.	Izakova L, Andre I, Halaris A. Combination Therapy or Monotherapy for the Depressed Type of Schizoaffective Disorder. Neuropsychiatric disease and treatment. 2009;5:91-101.
6317.	J AM, CJr CR, J KE. Divalproex sodium in substance abusers with mood disorder. Journal of clinical psychiatry. 2000;61:916-921.
6318.	J AP. A review of pharmacotherapy of major depression in children and adolescents. [Review] [48 refs]. Psychiatric services (Washington, D.C.). 2000;51:627-633.
6319.	A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression, Journal of clinical psychopharmacology(2015).
6320.	J BA, J L-SA. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. [Review]. Journal of psychopharmacology (Oxford, England). 2013;27:740-758.
6321.	J BD, D AJ, Jan F, et al. Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. Journal of affective disorders. 2002;68:243-249.
6322.	J BD, M NM, Marcia K-SA, W LR, N YL. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. [Review] [44 refs]. Journal of clinical psychiatry. 2008;69:1589-1601.
6323.	J BD, P GDB, P ORJ, Mohit C, D AJ. Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjects. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28:477-480.
6324.	J BD, P GDB, P ORJ, Mohit C, D AJ. Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjects. Neuropsychopharmacology. 2004;29:477-480.
6325.	J BM, L RR, J EG, E SP, W CT, Kurt K. Impact of Pain on Depression Treatment Response in Primary Care. Psychosomatic medicine. 2004;66:17-22.
6326.	J BMC, T vLJM, F GJ. Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France. The European Journal of Psychiatry. 1999;13:197-208.
6327.	J BP, L HL, T BR, et al. Treatment-specific changes in decentering following mindfulness-based cognitive therapy versus antidepressant medication or placebo for prevention of depressive relapse. Journal of consulting and clinical psychology. 2012;80:365-372.
6328.	J BR, C VA. Relapse of depressive symptoms after discontinuing sertraline. JAMA: Journal of the American Medical Association. 1999;282:323.
6329.	J BR, Daniel V, Chung-Chi C. A Double-Blind Comparison of Escitalopram and Venlafaxine Extended Release in the Treatment of Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:1190-1196.
6330.	J BS, P KS, Stan K. The Kutcher Adolescent Depression Scale: Assessment of Its Evaluative Properties over the Course of an 8-Week Pediatric Pharmacotherapy Trial. Journal of child and adolescent psychopharmacology. 2003;13:337-349.
6331.	J BW, A M-MD. Exploring treatment alternatives: Weekly dosing of fluoxetine for the continuation phase of major depressive disorder. Journal of clinical psychiatry. 2001;62:38-42.
6332.	J BW, E HS, Delores M-C, Daniel J, Stull T. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacology bulletin. 1996;32:27-32.
6333.	J BW, E HS, Delores M-M, et al. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placebo-controlled, randomized clinical trial. Journal of clinical psychopharmacology. 2000;20:423-427.
6334.	J BW, Ivan G, Anjana B. Fixed-dose trial of the single isomer SSRI Escitalopram in depressed outpatients. Journal of clinical psychiatry. 2002;63:331-336.
6335.	Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.[Erratum appears in J Clin Psychiatry. 2009 Dec;70(12):1729], Journal of clinical psychiatry(2009).
6336.	J CA, A MS, David F, Arthur L, Mikael A, Martin B. Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder: a Placebo- and Duloxetine-Controlled Study (Vol 70, Pg 526, 2009). Journal of clinical psychiatry. 2009;70:1729.
6337.	J CB. "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial": Comment. JAMA: Journal of the American Medical Association. 2004;292:2578.
6338.	J CB. Citalopram and the Curate's Egg in Geriatric Depression. American journal of psychiatry. 2005;162:1762.
6339.	J CB, P SR, Brent M, S LP. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: A meta-analysis. Journal of behavior therapy and experimental psychiatry. 1993;24:149-153.
6340.	J CN. Safety and Tolerability of the New Antidepressants. Journal of clinical psychiatry. 1997;58:26-31.
6341.	J CP, Daniel W. Agomelatine-Is it another reboxetine? Another case of publication bias. Authors' response. The Psychiatric Bulletin. 2014;38:88.
6342.	J DA, James B, J MD, Gordon P, J CM. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. Journal of affective disorders. 2002;72:85-90.
6343.	J DB. The choice of treatment in severe depression. The severe depression meta analysis. Primary Care Psychiatry. 1999;5:S21-S24.
6344.	J DB, Robaeys G, Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice. Acta gastro-enterologica Belgica. 2005;68:68-80.
6345.	J dD-A, MJ P, Puigdemont D, Perez-Egea R, Alvarez E, Perez V. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. Journal of affective disorders. 2010;120:221-225.
6346.	J DF, Demyttenaere K. Quality of life measurement in antidepressant trials. Is there an added value?. [Review] [58 refs]. Psychotherapy and psychosomatics. 2009;78:212-219.
6347.	J DF, Deschepper E, Audenaert K, et al. Second Generation Antipsychotics in the Treatment of Bipolar Depression: a Systematic Review and Meta-Analysis. Journal of psychopharmacology (Oxford, England). 2012;26:603-617.
6348.	J DF, Sienaert P, Demyttenaere K. Doubt on the efficacy of antidepressants: What's the evidence?. [Dutch]. Tijdschrift voor geneeskunde. 2009;65:768-775.
6349.	J DJ, Julian C, Steven A, Jean-Eric T, A GM, Roman C. A multinational pharmacoeconomic evaluation of acute major depressive disordere (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in health. 2001;4:16-31.
6350.	J DL. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: Part II: Focus on bipolar disorder. Journal of clinical psychopharmacology. 2014;34:291-296.
6351.	J DL, MT S, Murray-Carmichael E. The AmpliChipTM CYP450 genotyping test: Integrating a new clinical tool. Molecular diagnosis & therapy. 2006;10:135-151.
6352.	J DL, NB S, KL C. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part I. Psychosomatics. 2008;49:258-270.
6353.	J DM, G WC, H MC, K MR, A DM, Istvan B. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. European neuropsychopharmacology. 2004;14:457-470.
6354.	J DM, Yili L, J GD, K MR, A DM. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of psychiatric research. 2002;36:383-390.
6355.	J DM, Yili L, J GD, R HJ, A DM. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. Journal of clinical psychiatry. 2002;63:308-315.
6356.	J DR, D HS, D AJ, et al. Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression. Archives of general psychiatry. 2005;62:409-416.
6357.	J dW, Mertens C, K FO, E HPH. Citalopram versus mianserin: A controlled, double-blind trial in depressed patients. Acta psychiatrica Scandinavica. 1985;72:89-96.
6358.	J dW, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta psychiatrica Scandinavica. 1993;87:141-145.
6359.	J DW, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. [Hungarian]. Psychiatria Hungarica. 1997;Suppl 1:47-54.
6360.	J EA, Joan R, P R-BP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. General hospital psychiatry. 2002;24:43-47.
6361.	J EA, K UK, Karen B, Joan R, Keith C, P R-BP. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. American journal of psychiatry. 1998;155:367372.
6362.	J EC, B NC. Paroxetine. 2009:321-352.
6363.	J EG. Le Mieux Est I'Ennemi du Bien: Dr. Emslie replies. Journal of the American Academy of Child and Adolescent Psychiatry. 2010;49:185-186.
6364.	A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder, Journal of child and adolescent psychopharmacology(2014).
6365.	J EG, D KB, L MT. Predictors of treatment response in adolescent depression. Psychiatric annals. 2011;41:213-219.
6366.	J EG, D KB, L MT, et al. Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth. Journal of child and adolescent psychopharmacology. 2012;22:21-28.
6367.	J EG, D KB, L MT, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. American journal of psychiatry. 2008;165:459-467.
6368.	Escitalopram in the treatment of adolescent depression: A randomized placebo-controlled multisite trial, Journal of the American Academy of Child and Adolescent Psychiatry(2009).
6369.	J EG, H HJ, Dineen WK, et al. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1205-1214.
6370.	J EG, H HJ, L HS, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A double-blind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1397-1405.
6371.	J EG, John R, A WW, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of general psychiatry. 1997;54:1031-1037.
6372.	J EG, L FR, P YP, R KN, Yunfeng L. Venlafaxine ER for the treatment of pediatric subjects with depression: Results of two placebo-controlled trials. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:479-488.
6373.	J EG, Mary N, Jennie J, John H. "Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents.": Dr. Emslie et al. reply. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:967-968.
6374.	J EG, T WJ, R PS, Monique E. Nontricyclic antidepressants: current trends in children and adolescents. [Review] [108 refs]. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:517-528.
6375.	Treatment of resistant depression in adolescents (TORDIA): Week 24 outcomes, American journal of psychiatry(2010).
6376.	Sustaining remission of psychotic depression: Rationale, design and methodology of STOP-PD II, BMC psychiatry(2013).
6377.	J G-OJ, Josefina R-G, Maria dLG-A, Edgar M-T, Ernesto R-Z, Gabriela A-C. Electroencephalographic source analysis in patients receiving transcranial magnetic stimulation as antidepressant treatment. [Spanish]. Salud mental (Mexico City, Mexico). 2013;36:235-240.
6378.	J GA, L DD, J RA, Ron P, M DK, T NP. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. Journal of nervous and mental disease. 2013;201:266-273.
6379.	J GD. Duloxetine in the treatment of major depressive disorder. Neuropsychiatric disease and treatment. 2007;3:193-209.
6380.	J GD, C WM, C AR, Mahir A-B. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. International journal of eating disorders. 1999;25:19-27.
6381.	J GD, Craig M, Yili L, A DM. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. Journal of clinical psychiatry. 2002;63:225-231.
6382.	J GD, H HS, N MD, M BC. Fluoxetine in medically stable, depressed geriatric patients: effects on weight. Journal of clinical psychopharmacology. 1997;17:365-369.
6383.	J GD, Yili L, J DM, Curtis W, Craig M, A DM. Duloxetine in the Treatment of Depression - a Double-Blind-Placebo-Controlled Comparison With Paroxetine. Journal of clinical psychopharmacology. 2004;24:389-399.
6384.	J GD, Yili L, J DM, James H, Smriti I, A DM. Effects of Duloxetine on Painful Physical Symptoms Associated With Depression. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2004;45:17-28.
6385.	J GJ, C CJ. The challenge of depression in late life: Bridging science and service in primary care. JAMA: Journal of the American Medical Association. 2000;284:1570-1572.
6386.	J GP, Adarsh K, H HJ, V BVM, B GR. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacology bulletin. 1997;33:261-264.
6387.	A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms, Current medical research and opinion(2011).
6388.	Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: A replication study, Current medical research and opinion(2011).
6389.	J GS. Response to the letter from Marc B Stone, MD; Tarek A Hammad, MD, PHD, MSc, MS. Journal of psychiatric research. 2014;48:133-134.
6390.	J GS, Becky K, E TM, et al. Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. Journal of psychiatric research. 2013;47:1199-1203.
6391.	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder, Journal of psychiatric research(2012).
6392.	J HC, E MC, B RC, J CP, M GG. Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues. Biological psychiatry. 2006;59:816-820.
6393.	J HC, R DG, T DC, et al. Combined NK1 antagonism and serotonin reuptake inhibition: Effects on emotional processing in humans. Journal of psychopharmacology (Oxford, England). 2013;27:435-443.
6394.	J HD, H KJ, Douglass C, W SJ, Wilma H. Double-blind comparison of sertaline, imipramine, and placebo in the treatment of dysthymia: Effects on personality. American journal of psychiatry. 2000;157:1436-1444.
6395.	J HD, H KJ, Douglass C, W SJ, Wilma H. Dr. Hellerstein and colleagues reply. American journal of psychiatry. 2002;159:156.
6396.	J HD, Philip Y, Jesse R, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. American journal of psychiatry. 1993;150:1169-1175.
6397.	J HD, S LSA, Wallner SL, et al. Adding group psychotherapy to medication treatment in dysthymia: A randomized prospective pilot study. Journal of psychotherapy practice and research. 2001;10:93-103.
6398.	J HD, T BS, Steven H, et al. Escitalopram versus placebo in the treatment of dysthymic disorder. International clinical psychopharmacology. 2010;25:143-148.
6399.	A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression, Journal of clinical psychiatry(2012).
6400.	J IW, R PTC, T MR, A DR, R JP. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology. 2001;156:73-78.
6401.	J JM, E SM, Maurizio F, et al. Long-Term Treatment Outcomes of Depression With Associated Anxiety: Efficacy of Continuation Treatment With Fluoxetine. Journal of clinical psychiatry. 2004;65:373-378.
6402.	J KC, Anne S, Benedetto V, et al. A Multisite Psychotherapy and Medication Trial for Depressed Adolescents: Background and Benefits. Cognitive and behavioral practice. 2005;12:159-165.
6403.	J KC, Benedetto V, John W, et al. Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable?. [Review] [40 refs]. Journal of child and adolescent psychopharmacology. 2006;16:11-24.
6404.	Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study, Journal of child and adolescent psychopharmacology(2009).
6405.	J KC, H NJ, Eugene AL, et al. Atomoxetine Alone or Combined With Fluoxetine for Treating ADHD With Comorbid Depressive or Anxiety Symptoms. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:915-924.
6406.	J KD, Ellen F. "Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial." Reply. JAMA: Journal of the American Medical Association. 2002;288:449.
6407.	J KD, M PJ, G PB, et al. Fluvoxamine versus desipramine: Comparative polysomnographic effects. Biological psychiatry. 1991;29:23-40.
6408.	J KL. [Mirtazapine versus other antidepressive agents for depression]. [Danish]. Ugeskrift for laeger. 2012;174:2864-2866.
6409.	J KR, L HR, F CE. Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors. Biological psychiatry. 1999;45:295-299.
6410.	J KR, Taylor S, R HA, A AJ, Andrew JJ. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. Journal of clinical psychiatry. 1997;58:532-537.
6411.	J KV, D LY. Computerized EEG correlates of depression and antidepressant treatment. Progress in neuro-psychopharmacology & biological psychiatry. 1987;11:213-221.
6412.	J KW, B LEH, Michael VK. The authors reply: "Collaborative care for depression and chronic illnesses." [References]. New England journal of medicine. 2011;364:1278-1279.
6413.	J L-SA, Qin J. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. International clinical psychopharmacology. 2008;23:113-119.
6414.	J LP, E CR, D NB, et al. Sertraline for Prevention of Depression Recurrence in Diabetes Mellitus: A Randomised, Double-blind, Placebo-Controlled Trial. Archives of general psychiatry. 2006;63:521-529.
6415.	J MB, Aly RM, M LJ, W ID, Kelly MJ, Peter H. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.[Erratum appears in J Affect Disord. 2009 Feb;113(1-2):201]. Journal of affective disorders. 2007;103:83-90.
6416.	J MB, Aly RM, M LJ, W ID, Kelly MJ, Peter H. "A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C": Erratum. Journal of affective disorders. 2009;113:201.
6417.	J MD, R CJ. Recent placebo-controlled acute trials in bipolar depression: focus on methodology. [Review] [28 refs]. International journal of neuropsychopharmacology. 2003;6:285-291.
6418.	J MM, Janette M, P CM, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. Journal of clinical psychopharmacology. 2014;34:234-239.
6419.	J MP. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. [Review]. Journal of Alzheimer's disease. 2010;21:1077-1087.
6420.	J MP. Facebook enhances antidepressant pharmacotherapy effects. TheScientificWorldJournal. 2014.
6421.	J MP, W SJ, Eva P, et al. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. Journal of clinical psychiatry. 2000;61:518-524.
6422.	J MP, W SJ, M QF. The use of monoamine oxidase inhibitors for treating atypical depression. Psychiatric annals. 2001;31:371-375.
6423.	J MP, W SJ, M QF, et al. Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression. American journal of psychiatry. 2006;163:1542-1548.
6424.	J MP, W SJ, Maurizio F, et al. Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. American journal of psychiatry. 2006;163:1531-1541.
6425.	J MP, W SJ, N JM, Eva P, M QF, F KD. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. American journal of psychiatry. 2000;157:344-350.
6426.	J MR. Brain changes and placebo. American journal of psychiatry. 2003;160:389-390.
6427.	J ND. Care of depressed patients with anxiety symptoms. Journal of clinical psychiatry. 1999;60:23-27.
6428.	J OM, Stan K, S SJ, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33:3201-3212.
6429.	J PM, Javier dD-A, Dolors P, et al. Pindolol augmentation enhances response outcomes in first depressive episodes. European neuropsychopharmacology. 2009;19:516-519.
6430.	Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression, Journal of clinical psychiatry(2011).
6431.	J PP, J GM, W KM, L CB, Dunner FJ, Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. Journal of clinical psychiatry. 1989;50:290-294.
6432.	J PP, Massano J. Clinical, genetic and neuropathological features of frontotemporal dementia: An update and guide. Acta medica portuguesa. 2013;26:392-401.
6433.	J PR, T MR, R JP, E LS. Tryptophan and tyrosine availability and response to antidepressant treatment in major depression. Journal of affective disorders. 2005;86:129-134.
6434.	J PT, A PJ, Jacqueline B, et al. The role of cognitive-behavioral therapy and fluoxetine in prevention of recurrence of major depressive disorder. Cognitive therapy and research. 2010;34:13-23.
6435.	J PT, Greg F, Rebecca H, et al. Extreme response style in recurrent and chronically depressed patients: Change with antidepressant administration and stability during continuation treatment. Journal of consulting and clinical psychology. 2007;75:145-153.
6436.	J RA, J WD, F TM, et al. A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features. Journal of clinical psychopharmacology. 2004;24:365-373.
6437.	J RJ, Nassir GS. Is aripiprazole an efficacious adjunct for unipolar depression? [References]. Journal of clinical psychiatry. 2008;69:1021.
6438.	J RJ, W DB. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: A review. Journal of clinical psychiatry. 2011;72:81-90.
6439.	A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury, Journal of clinical psychiatry(2010).
6440.	J RM, David S, J GP, et al. Relationship between major depressive disorder and associated painful physical symptoms: Analysis of data from two pooled placebo-controlled, randomized studies of duloxetine. International clinical psychopharmacology. 2013;28:330-338.
6441.	J RP, C SH, Moonseong H, Sibel K, L BM. Patients' depression treatment preferences and initiation, adherence, and outcome: A randomized primary care study. Psychiatric services (Washington, D.C.). 2009;60:337-343.
6442.	J RS, G TR, R BB. Changes in insomnia during the treatment of depression: An analysis of double-blind, placebo-controlled trials of fluoxetine hydrochloride. Psychiatric annals. 1999;29:562-567.
6443.	J SD, Francoise P-B, H KS. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Human Psychopharmacology: Clinical and Experimental. 2013;28:151-159.
6444.	J SD, M PJ, J EG, et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Journal of clinical psychopharmacology. 2011;31:92-97.
6445.	J SD, S BD, T DO, Nicolas D, Borwin B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. [Review] [74 refs]. Journal of clinical psychiatry. 2006;67:1741-1746.
6446.	J SD, S BD, T DO, Nicolas D, Borwin B. "More on placebo response": Reply. Journal of clinical psychiatry. 2007;68:1984-1985.
6447.	J SM, A GC, FX MC. Psychological treatment of obsessive-compulsive disorder in Europe: A meta-analytic study. [Spanish]. Psicologia conductual. 2003;11:213-237.
6448.	J SR, JM MR. The role of mood stabilizers in the prophylaxis of relapses and recurrences of depression. [Spanish]. Psiquiatria Biologica. 2004;11:58-63.
6449.	J SS, F BM, Kendyl S, Phillip S, Nadine B, Simon PA. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. Journal of mental health policy and economics. 2010;13:27-35.
6450.	J TK, C ML, Megan VN, et al. Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. [Review]. Depression and anxiety. 2012;29:495-505.
6451.	J TM, R GB, Ray N, Sudhakar S, Jamie N, J CP. Early Increase in Marker of Neuronal Integrity With Antidepressant Treatment of Major Depression: H-1-Magnetic Resonance Spectroscopy of N-Acetyl-Aspartate. International journal of neuropsychopharmacology. 2012;15:1541-1546.
6452.	J TM, R GB, Ray N, Sudhakar S, Jamie N, J CP. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. International journal of neuropsychopharmacology. 2012;15:1541-1546.
6453.	J WA, K MR, Ricky M, et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. The British Journal of Psychiatry. 1998;172:485-490.
6454.	J WA, M CS, J MA, Douglas O, L GK. Spotlight on paroxetine in psychiatric disorders in adults. [Review] [103 refs]. CNS drugs. 2002;16:425-434.
6455.	J WC, Tim K, Peter F, David C, Andrew C, Ellen B. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. [Review] [29 refs]. Lancet. 2004;363:1341-1345.
6456.	J WC, Tim K, Steve P. Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Current opinion in psychiatry. 2005;18:21-25.
6457.	J WG, G RJ, Richard R. A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Comprehensive psychiatry. 1996;37:402-408.
6458.	J WG, Shira M, G RJ. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatric services (Washington, D.C.). 1998;49:239-240.
6459.	Severity of depression and response to antidepressants: GENPOD randomised controlled trial, The British Journal of Psychiatry(2012).
6460.	J-A S, H-Y T. Comparison of weight changes in patients treated with different antidepressants: Clinical experiences in Taiwanese patients. Chang Gung medical journal. 2006;29:154-161.
6461.	J-B Z, L-L W, Lu M, L-Y L, Li D. Effects of acupuncture on monoamine neurotransmitter in frontal cortex of depressed model rats. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:129-131.
6462.	J-C B. Clinical utility of milnacipran in comparison with other antidepressants. International clinical psychopharmacology. 2002;17:S43-S50.
6463.	J-C P, Y-Z L, H-Y L. Efficacy of Venlafaxine in treatment of non-erosive gastroesophageal reflux disease with depression and anxiety. [Chinese]. World Chinese Journal of Digestology. 2009;17:2508-2511.
6464.	J-F H, C-J C, X-L B, et al. [Effect of early intervention of liver-smoothing and blood-activating decoction combined with acupuncture on patients with post-stroke depression]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2013;38:2403-2405.
6465.	J-F L, CJ B, Zumbach S, Bugnon O. Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton. Journal of the American Medical Directors Association. 2008;9:439-448.
6466.	J-F L, CJ B, Zumbach S, Bugnon O. Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton (DOI:10.1016/j.jamda.2008.04.003). Journal of the American Medical Directors Association. 2008;9:611-611.e610.
6467.	J-G S, Z-H Z, X-H W, J-L M. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation. 2006;10:160-162.
6468.	J-H A, AA P. Escitalopram for the treatment of major depressive disorder in youth. [Review]. Expert opinion on pharmacotherapy. 2011;12:2235-2244.
6469.	J-H H, C-K W. Pharmacologic treatment of depression in patients with myocardial infarction. Journal of Geriatric Cardiology. 2011;8:121-126.
6470.	Predictors and Mediators of Add-on Mirtazapine-Induced Cognitive Enhancement in Schizophrenia - a Path Model Investigation, Neuropharmacology(2013).
6471.	J-L D, Dalery J. [Concurrent validation of the suicidal risk assessment scale (R.S.D.) with the Beck's suicidal ideation scale]. [French]. Encephale. 2004;30:249-254.
6472.	J-L D, Dalery J. Correlations between Beck's suicidal ideation scale, suicidal risk assessment scale RSD and Hamilton's depression rating scale. [French]. Encephale. 2008;34:132-138.
6473.	J-L J, W-J L, Zhang N, et al. [Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study]. [Chinese]. National Medical Journal of China. 2007;87:1585-1589.
6474.	J-L M. Simulating the anhedonia symptom of depression in animals. Dialogues in clinical neuroscience. 2002;4:351-360.
6475.	J-M A, Delini-Stula A, Gervasoni N, et al. Psychiatry. [French]. Revue medicale suisse. 2007;3:161-167.
6476.	J-M A, Kaladjian A. An Update on the Treatment of Bipolar Depression. Expert opinion on pharmacotherapy. 2009;10:161-172.
6477.	J-M A, P-M L, Despiegel N, Verpillat P. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:158-166.
6478.	J-M K, K-Y B, H-J K, et al. Design and Methodology for the Korean Observational and Escitalopram Treatment Studies of Depression in Acute Coronary Syndrome: K-Depacs and Esdepacs. Psychiatry investigation. 2014;11:89-94.
6479.	J-M S, Hao Q, Li Y, Li H, Peng M. Efficacy assessment of mirtazapine in the treatment of severe functional dyspepsia: An analysis of 22 cases. World Chinese Journal of Digestology. 2011;19:2895-2899.
6480.	J-M V, Attar-Levy D, M-F P, Bouhassira M, Blin P, J-P O. Controlled efficacy study of fluoxetine in dysthymia. British journal of psychiatry. 1997;170:345-350.
6481.	J-P B. Use of antidepressants in the treatment of generalized anxiety. [French]. Neuro-Psy. 2000;15:210-215.
6482.	J-P B. Antidepressant therapy: Criteria for the evaluation of treatment outcome. [French]. Encephale. 2007;33:S666-S671.
6483.	J-P B, AKT H, Florea I, Baemadraskdal T, Sarchiapone M. A Comparative Study of the Efficacy of Long-Term Treatment With Escitalopram and Paroxetine in Severely Depressed Patients. Current medical research and opinion. 2006;22:1331-1341.
6484.	J-P B, Canva V, Tran A, et al. Assessment of paroxetine in the prevention of depression in patients with chronic hepatitis C treated by PEG-interferon-ribavirin.: A double-blinded, randomized study. ANRS HC18 paropeg. Journal of hepatology. 2010;Conference:S104.
6485.	J-P B, Canva V, Tran A, et al. Assessment of paroxetine in the prevention of depression in patients with chronic hepatitis C treated by PEG-interferon alpha plus ribavirin: A multicentric, double-blinded, randomized study. ANRS HC18 paropeg. Gastroenterology. 2010;Conference:S790.
6486.	J-P D, J DR, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: A comparison with lithium. Current medical research and opinion. 2007;23:333-341.
6487.	J-P K. Mood stabilisers. Australian Prescriber. 2012;35:164-168.
6488.	J-P O. Dysthymia study. Round Table Series - Royal Society of Medicine. 1998:5-9.
6489.	J-P O, Bayle F, Kasper S. [A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression]. [French]. Encephale. 2003;29:322-328.
6490.	J-P O, Gourion D, Montagne A, Rostin M, M-F P. Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomised, double blind exploratory study. [French]. Encephale. 2009;36:595-604.
6491.	J-P O, Gourion D, Montagne A, Rostin M, M-F P. Milnacipran and Venlafaxine at Flexible Doses (up to 200 Mg/Day) in the Outpatient Treatment of Adults With Moderate-to-Severe Major Depressive Disorder: a 24-Week Randomized, Double-Blind Exploratory Study. Neuropsychiatric disease and treatment. 2010;6:71-79.
6492.	J-Q T. Jieyu pill versus venlafaxine extended release in the treatment of depression at different levels of severity. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:1-3.
6493.	J-R Z, Li J. Antidepressive characteristics of escitalopram oxalate. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:128-130.
6494.	J-S H, Berlin I. Cardiovascular effects of selective serotonin reuptake inhibitors. [French]. Sang Thrombose Vaisseaux. 2004;16:302-308.
6495.	J-W L, L-P L, He Y. Clinical study of Paroxetine combined with psychotherapy in treating post-stroke emotion disorder. [Chinese]. Journal of Clinical Neurology (China). 2008;21:18-20.
6496.	J-X C, L-H Y, H-L W, et al. Effects of fluoxetine on changes of GLT-1 in rat prefrontal cortex after chronic unpredictable stress. [Chinese]. Chinese Pharmacological Bulletin. 2015;31:256-260.
6497.	J-X X, J-W T, L-M O. A comparative study of fluoxetine with a little dose of amitriptyline in treating depressive neurosis. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2002;6:1312-1313.
6498.	J-X X, J-W T, L-M O. Comparison of the effect of fluoxetine and amitriptyline in treating comorbid depression disorder and anxiety disorder. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:2812-2814.
6499.	J-Y N. Can one reasonably prescribe an antidepressant to a child? (2). [French]. Revue medicale suisse. 2006;2:881.
6500.	JA B. Targeting lifestyle change in patients with depression. Journal of the American College of Cardiology. 2013;61:631-634.
6501.	JA B, Allgulander C, PM L, et al. Predictors of Relapse in a Study of Duloxetine Treatment for Patients With Generalized Anxiety Disorder. Human Psychopharmacology-Clinical and Experimental. 2011;26:258-266.
6502.	JA B, BD R, Williamson M. Complementary medicines: Hospital pharmacists' attitude, knowledge and information seeking behaviour. Journal of Pharmacy Practice and Research. 2009;39:281-285.
6503.	JA B, CB S, Birmaher B, AG A, DA B. The Risks and Benefits of Antidepressant Treatment for Youth Depression. Annals of medicine. 2005;37:404-412.
6504.	JA B, CB S, Birmaher B, AG A, DA B. The Risks and Benefits of Antidepressant Treatment for Youth Depression. Annals of medicine. 2005;37:404-412.
6505.	JA B, DA A. The contribution of pharmacoepidemiology to the antidepressant-suicidality debate in children and adolescents. International review of psychiatry. 2008;20:209-214.
6506.	Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials, Journal of the American Medical Association(2007).
6507.	JA B, MA B, KA M, et al. Effects of Exercise Training on Older Patients With Major Depression. Archives of internal medicine. 1999;159:2349-2356.
6508.	JA B, Moleman P, PGH M, WW VDB. Treatment of mood-congruent psychotic depression with imipramine. Journal of affective disorders. 2001;66:165-174.
6509.	JA B, Moleman P, WW VDB, PGH M. Trait anxiety and the effect of a single high dose of diazepam in unipolar depression. Journal of psychiatric research. 2001;35:331-337.
6510.	JA B, P MD. To the editor. JAMA - Journal of the American Medical Association. 2014;312:2166-2167.
6511.	JA B, RA L, JD W, DM G, RJ B. Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy. Journal of clinical psychiatry. 1997;58:137-145.
6512.	JA B, Sherwood A, LL W, Hinderliter A. Reply. Journal of the American College of Cardiology. 2012;60:2425-2426.
6513.	Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: Results from the UPBEAT (understanding the prognostic benefits of exercise and antidepressant therapy) study, Journal of the American College of Cardiology(2012).
6514.	JA B, Sherwood A, MA B, PM D, BM H. Response to letters to the editor [3]. Psychosomatic medicine. 2008;70:264-265.
6515.	JA B, Sherwood A, SD R, et al. Understanding Prognostic Benefits of Exercise and Antidepressant Therapy for Persons With Depression and Heart Disease: the Upbeat Study - Rationale, Design, and Methodological Issues. Clinical trials (London, England). 2007;4:548-559.
6516.	JA BB, Jarvis B. Venlafaxine Extended-Release - a Review of Its Clinical Potential in the Management of Generalised Anxiety Disorder. CNS drugs. 2000;14:483-503.
6517.	JA C, AP M, JM P, Staron V. A Pilot Randomized Controlled Trial of Combined Trauma-Focused Cbt and Sertraline for Childhood Ptsd Symptoms. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:811-819.
6518.	Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group, Asian journal of psychiatry(2015).
6519.	JA CE. The effect of milnacipran on depressive symptoms. International journal of psychiatry in clinical practice. 1999;3:S21-S27.
6520.	JA CE. Overview of the field. Metabolism: clinical and experimental. 2005;54:5-9.
6521.	JA D. Psychopharmacology of Comorbid Obsessive-Compulsive Disorder and Depression. Journal of clinical psychiatry. 1997;58:17-19.
6522.	JA D, Arakawa R, JH G, AH C. Assessing the Onset of Antidepressant-Induced Sexual Dysfunction Using Interactive Voice Response Technology. Journal of clinical psychiatry. 2007;68:525-532.
6523.	JA D, SR P. Attention-deficit-hyperactivity disorder: An update. Pharmacotherapy. 2009;29:656-679.
6524.	JA DB. Pharmacotherapy of Panic Disorder: Differential Efficacy From a Clinical Viewpoint. Journal of clinical psychiatry. 1998;59:30-38.
6525.	JA DB, BR S. Review of Current Treatment in Panic Disorder. International clinical psychopharmacology. 1998;13:S25-S30.
6526.	JA dB, FJ B, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. International clinical psychopharmacology. 2006;21 Suppl 1:S21-24.
6527.	JA DB, FJ B, Meesters Y. Clinical Efficacy of Agomelatine in Depression: the Evidence. International clinical psychopharmacology. 2006;21:S21-S24.
6528.	JA DB, HGM W. Serotonergic Compounds in Panic Disorder, Obsessive-Compulsive Disorder and Anxious Depression - a Concise Review. Human Psychopharmacology-Clinical and Experimental. 1995;10:S173-S183.
6529.	JA F. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Journal of clinical psychiatry. 2003;64:32-37.
6530.	OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients, Pharmacogenetics and genomics(2015).
6531.	JA G, Bernardy K, Hauser W. Efficacy of EMG- and EEG-biofeedback in fibromyalgia syndrome: A meta-analysis and a systematic review of randomized controlled trials. Evidence-based Complementary and Alternative Medicine. 2013.
6532.	JA G-D, HP S. Reduction of Parkinsonism and Psychosis With Mirtazapine: a Case Report. Pharmacopsychiatry. 2014;47:81-83.
6533.	JA H. Antidepressants and Overdoses. Postgraduate medical journal. 1994;70:S9-S12.
6534.	JA H. Depression in elderly people. CME Journal Geriatric Medicine. 2002;4:28-33.
6535.	JA H, BH H, JF H, OW N, Rasmussen A, Birket-Smith M. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: Results from the DEpression in Patients with Coronary ARtery Disease (DECARD) trial. Journal of cardiovascular pharmacology. 2012;60:397-405.
6536.	JA H, Brecht S, Chappell A, MJ D. Duloxetine and the Control of Pain. Annals of the rheumatic diseases. 2006;65:554-555.
6537.	JA H, LA K, WF G, Kilgore E, Shah P. Sertraline Response in Adults With Mental Retardation and Autistic Disorder. Journal of clinical psychiatry. 1996;57:333-336.
6538.	JA H, MG A. Pharmacological treatment of sleep disturbance in developmental disabilities: A review of the literature. Research in developmental disabilities. 2011;32:939-962.
6539.	JA H, SV A, AS R, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. British journal of psychiatry. 2002;180:528-535.
6540.	JA K, Cortes J. Black box warnings incite red flags. Pharmacy times. 2008;74:16-17.
6541.	JA L. 23rd Congress of Collegium Internationale Neuropsychopharmacologicum. Journal of Pharmacy Practice and Research. 2003;33:48-49.
6542.	JA L, JH S, P VO, Ajlm VB. Assignment Refusal and Its Relation to Outcome in a Randomized Controlled Trial Comparing Cognitive Therapy and Fluvoxamine in Treatment-Resistant Patients With Obsessive Compulsive Disorder. Psychiatry research. 2015;226:198-203.
6543.	JA M, Ma AM. Seasonal Affective Disorder. Drugs of the future. 2007;32:457-462.
6544.	JA M, MaA M. Therapy of somatoform disorders. Drugs of the future. 2006;31:695-703.
6545.	JA M, MaA M. Personality disorders. Drugs of the future. 2007;32:713-721.
6546.	JA O, Moturi S. Pharmacologic Treatment of Pediatric Insomnia. Child and adolescent psychiatric clinics of North America. 2009;18:1001-1016.
6547.	JA R, GR M, JT H, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast cancer research and treatment. 2005;89:243-249.
6548.	JA R, GR M, JT H, et al. Effect of Paroxetine Hydrochloride (Paxil((R))) on Fatigue and Depression in Breast Cancer Patients Receiving Chemotherapy. Breast cancer research and treatment. 2005;89:243-249.
6549.	JA R, GR M, JT H, et al. Effect of Paroxetine Hydrochloride (Paxil((R))) on Fatigue and Depression in Breast Cancer Patients Receiving Chemotherapy. Breast cancer research and treatment. 2005;89:243-249.
6550.	JA R, LA M, FW L, Rickels K. Evidence for the use of vilazodone in the treatment of major depressive disorder. Expert opinion on pharmacotherapy. 2012;13:2215-2224.
6551.	JA R, LA M, Rickels K, FW L. Pharmacological Treatment of Generalized Anxiety Disorder. Expert opinion on pharmacotherapy. 2011;12:2457-2467.
6552.	JA R, Warden D, SR W, et al. STAR*D: Revising conventional wisdom. CNS drugs. 2009;23:627-647.
6553.	JA S. Fluoxetine in Parkinson's disease. Movement disorders. 1996;11:581-582.
6554.	JA S. Experience is a biochemical intervention: Reconceptualizing the "biologically based mental illness". Bulletin of the Menninger Clinic. 2005;69:157-171.
6555.	JA S. Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Women's Health. 2007;3:29-37.
6556.	JA S. Low sexual desire - Is it all in her head? Pathophysiology, diagnosis, and treatment of Hypoactive sexual desire disorder. Postgraduate medicine. 2010;122:128-136.
6557.	JA S, BL D. Do no harm: A critical risk/benefit analysis of child psychotropic medication. Journal of family psychotherapy. 2008;19:1-19.
6558.	JA S, DA D, DJ H, PJ M, JW S. Can People With Nonsevere Major Depression Benefit From Antidepressant Medication? Journal of clinical psychiatry. 2012;73:518-525.
6559.	JA S, Dejonghe F. Safety of Antidepressants. International clinical psychopharmacology. 1995;9:19-25.
6560.	JA S, Gilaberte I, TR H, et al. [The costs of treatment with the new antidepressants in clinical practice]. [Spanish]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 1999;23:15-16.
6561.	JA S, Gilaberte I, TR H, et al. The costs of treatment with the new antidepressants in clinical practice. [Spanish]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 1999;23:15-16,18,20-25.
6562.	JA S, JG R, MJ K, MP vB, EF V, WJ R. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. Journal of psychopharmacology (Oxford, England). 2002;16:207-214.
6563.	JA S, Soto J, Galende I, TR H. Randomized database studies: A new method to assess drugs' effectiveness. Journal of clinical epidemiology. 1998;51:713-715.
6564.	JA S-L, Lewis-Fernandez R, Goetz D, et al. Open Trial of Nefazodone Among Hispanics With Major Depression: Efficacy, Tolerability, and Adherence Issues. Depression and anxiety. 2001;13:118-124.
6565.	JA V, Grudnikoff E, AJ S, et al. Antidepressants for cognitive impairment in schizophrenia - A systematic review and meta-analysis. Schizophrenia research. 2014;159:385-394.
6566.	JAA dD, SD B. New and Unconventional Treatments for Obstructive Sleep Apnea. Neurotherapeutics. 2012;9:702-709.
6567.	Jaap W, Huibert B, W vdBW, et al. Long-term response to successful acute pharmacological treatment of psychotic depression. Journal of affective disorders. 2010;123:238-242.
6568.	JAC D, BE O, RL M, BM P. Estimating ethnic differences in self-reported new use of antidepressant medications: Results from the Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiology and drug safety. 2009;18:545-553.
6569.	JAC-GJ-C C-G. Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: Data from the ''Boulenger'' study. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2010;36:425-432.
6570.	Jack D, Frans dJ, Hanneke T. The use of anti-depressants after recovery from depression. The European Journal of Psychiatry. 2000;14:207-212.
6571.	Jackowski L, Worthley D, Phillips P. Cardioprotective aspirin in type 2 diabetes. Medicine today. 2012;13:44-47.
6572.	Jackson G, Gillies H, Osterloh I. Past, present, and future: A 7-year update of Viagra (sildenafil citrate). International journal of clinical practice. 2005;59:680-691.
6573.	Jacob P, Esben H. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. [Review]. Clinical psychology review. 2011;31:1032-1040.
6574.	Jacobi C, Dahme B, Dittmann R. Cognitive-behavioural, fluoxetine and combined treatment for bulimia nervosa: Short- and long-term results. European eating disorders review. 2002;10:179-198.
6575.	Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. British journal of general practice. 2003;53:120-125.
6576.	Jacqueline H, Paul C, A JJ, Henri C, Katherine S, J SD. Escitalopram treatment of depression in human immunodeficiency virus/acquired immunodeficiency syndrome: A randomized, double-blind, placebo-controlled study. Journal of nervous and mental disease. 2014;202:133-137.
6577.	JADO C, Iacoponi E, PEL M. Brazilian multicenter study of sertraline for the treatment of depression associated with anxiety. [Portuguese]. Revista brasileira de medicina. 2007;64:31-35.
6578.	Jaehne A, Loessl B, Barkai Z, Riemann D, Hornyak M. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep medicine reviews. 2009;13:363-377.
6579.	Jager A, Sleijfer S, CCD vdR. The pathogenesis of cancer related fatigue: Could increased activity of pro-inflammatory cytokines be the common denominator? European journal of cancer. 2008;44:175-181.
6580.	Jager M, Frasch K, Becker T. Adjustment disorders - Nosological state and treatment options. [German]. Psychiatrische Praxis. 2008;35:219-225.
6581.	JAGJF G. Expanding the Bipolar Construct While Preserving Its Diagnostic Integrity: Are We Keeping the Baby or the Bathwater? World psychiatry. 2011;10:187-188.
6582.	Jain N, MH T, AJ R, et al. Rationale and Design of the Chronic Kidney Disease Antidepressant Sertraline Trial (Cast). Contemporary clinical trials. 2013;34:136-144.
6583.	Jain N, MH T, AJ R, et al. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemporary clinical trials. 2013;34:136-144.
6584.	Jain R, DL C, Edwards J, Mathews M. Early and Sustained Improvement With Vilazodone in Adult Patients With Major Depressive Disorder: Post Hoc Analyses of Two Phase Iii Trials. Current medical research and opinion. 2014;30:263-270.
6585.	Jain R, J SM, Garlow S, TG S. Managing bipolar disorder from urgent situations to maintenance therapy, part 1: Urgent situations. Journal of clinical psychiatry. 2007;68:1129-1138.
6586.	Jain R, Jain S, CL R, Maletic V. Painful Diabetic Neuropathy Is More Than Pain Alone: Examining the Role of Anxiety and Depression as Mediators and Complicators. Current diabetes reports. 2011;11:275-284.
6587.	Jain S. Journal Watch review of Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. Journal of the American Psychoanalytic Association. 2014;62:113-115.
6588.	Jain S, Jain R, Islam J. How to lower suicide risk in depressed children and adolescents. Current psychiatry. 2012;11:21-31.
6589.	Jainer AK, Soni N. Unethical use of placebo controls. The British Journal of Psychiatry. 2002;181:532-533.
6590.	JAJ S, JS M. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: A pilot study. Depression and anxiety. 1999;9:70-74.
6591.	Jakovcevska-Kujundziska M, Lazarova V, Filovska V, Cadikovska N. Alprazolam/Venlafaxine versus Venlafaxine in the treatment of mixed depression and anxiety. European neuropsychopharmacology. 2009;Conference:S589.
6592.	Jakovljevic M, Reiner Z, Milicic D. Mental disorders, treatment response, mortality and serum cholesterol: A new holistic look at old data. Psychiatria Danubina. 2007;19:270-281.
6593.	Jakubovski E, JB D, Valerio C, et al. Clinical predictors of long-term outcome in obsessive-compulsive disorder. Depression and anxiety. 2013;30:763-772.
6594.	Jalenques I, Legrand G, Vaille-Perret E, Tourtauchaux R, Galland F. Therapeutic efficacy and safety of repetitive Transcranial Magnetic Stimulation in depressions of the elderly: A review. [French]. Encephale. 2010;36:D105-D118.
6595.	James A. Pharmacotherapy and child psychiatry: Is there a way forward? Advances in Psychiatric Treatment. 2008;14:10-16.
6596.	James A, Soler A, Weatherall R. Cognitive Behavioural Therapy for Anxiety Disorders in Children and Adolescents. Cochrane database of systematic reviews (Online). 2005.
6597.	James A, Soler A, Weatherall R. Cognitive Behavioural Therapy for Anxiety Disorders in Children and Adolescents. Cochrane database of systematic reviews (Online). 2005.
6598.	James R. Personality change after treatment. American journal of psychiatry. 2002;159:156.
6599.	James R, Joel R, Curtis W, Daniel W, Olga B-M. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. Psychiatry. 2007;4:33-45.
6600.	Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.[Erratum appears in Curr Med Res Opin. 2011 Sep;27(9):1708], Current medical research and opinion(2011).
6601.	Jamie H, Paul M, Robert W. Placebo, prozac and PLoS: significant lessons for psychopharmacology. [Review]. Journal of psychopharmacology (Oxford, England). 2011;25:1277-1288.
6602.	Jan F, L BR. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. [Review] [79 refs]. Journal of affective disorders. 1998;51:267-285.
6603.	Jan F, L BR. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. Journal of clinical psychiatry. 1998;59:123-127.
6604.	Jan J, Karolina G, Jerzy M, Joanna H. Comparison of the effects of escitalopram and nortriptyline on painful symptoms in patients with major depression. General hospital psychiatry. 2015;37:36-39.
6605.	Jan L-H. Treatment of mild depression in elderly patients. JAMA: Journal of the American Medical Association. 2000;284:2993.
6606.	Jana H, Sabine W, Bettina W-H, et al. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: A randomized open-label prospective trial. Journal of clinical psychiatry. 2011;72:885-891.
6607.	Jana S, Stefan W, Rudolf U, et al. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. The World Journal of Biological Psychiatry. 2011;12:528-538.
6608.	Jane G. Facing the evidence: Antidepressant treatment in children and adolescents. Canadian Medical Association journal. 2004;170:489-491.
6609.	Janelle G-B, Andrew W, Joanne R. Which drugs are most effective for moderate to severe depression in adolescents? [References]. Journal of family practice. 2008;57:330-332.
6610.	A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Journal of clinical psychopharmacology(2012).
6611.	Jang S, Jung S, Pae C, KB P, JC N, AA P. Predictors of Relapse in Patients With Major Depressive Disorder in a 52-Week, Fixed Dose, Double Blind, Randomized Trial of Selegiline Transdermal System (Sts). Journal of affective disorders. 2013;151:854-859.
6612.	Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E. Effects of Fluoxetine at Antidepressant Doses on Short-Term Outcome of Detoxified Alcoholics. International clinical psychopharmacology. 1996;11:109-117.
6613.	Jansen I, Molenberghs G, Aerts M, Thijs H, K VS. A local influence approach applied to binary data from a psychiatric study. Biometrics. 2003;59:410-419.
6614.	Janssen J, HE HP, HG S, et al. Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression. International journal of geriatric psychiatry. 2007;22:468-474.
6615.	Jaracz J, Rybakowski J. Depression and pain: Novel clinical, neurobiological and psychopharmacological data. [Polish]. Psychiatria polska. 2005;39:937-950.
6616.	Jarema M. [A test for using meta-analysis to evaluate antidepressive effects of fluoxetine]. [Polish]. Psychiatria polska. 1996;30:569-581.
6617.	Jarema M. The use of meta-analysis in the evaluation of antidepressive effects of fluoxetine. [Polish]. Psychiatria polska. 1996;30:569-581.
6618.	Jarema M. Atypical antipsychotics in the treatment of mood disorders. Current opinion in psychiatry. 2007;20:23-29.
6619.	Jarema M. Herbal drug treatment. Neuro endocrinology letters. 2008;29:93-104.
6620.	Jariani M, Saaki M, Nazari H, Birjandi M. The Effect of Olanzapine and Sertraline on Personality Disorder in Patients With Methadone Maintenance Therapy. Psychiatria Danubina. 2010;22:544-547.
6621.	Jaroslaw S, Magdalena J, Teodor HR, et al. Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression. Journal of affective disorders. 2010;123:321-326.
6622.	Jaurrieta N, Jimenez-Murcia S, JM M, et al. Individual versus group cognitive-behavioral treatment for obsessive-compulsive disorder: A controlled pilot study. Psychotherapy research. 2008;18:604-614.
6623.	Javad A, Reza AH, Ali GB. Effectiveness of CBT, pharmacotherapy and combined approach in improvement of symptoms depression anger in borderline personality disorder. [Farsi (Iranian)]. Journal of psychology. 2009;13:342-359.
6624.	Javier B, F CL, Miguel G. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder [10]. Journal of clinical psychopharmacology. 2007;27:219-221.
6625.	Jaworska N, Blondeau C, Tessier P, et al. Response Prediction to Antidepressants Using Scalp and Source-Localized Loudness Dependence of Auditory Evoked Potential (Ldaep) Slopes. Progress in neuro-psychopharmacology & biological psychiatry. 2013;44:100-107.
6626.	Jaworska N, E DS, Blondeau C, et al. Auditory P3 in antidepressant pharmacotherapy treatment responders, non-responders and controls. European neuropsychopharmacology. 2013;23:1561-1569.
6627.	Jay A. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. Journal of clinical psychopharmacology. 1998;18:414-417.
6628.	Jay A, Felipe G-E, Jan F, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. Journal of affective disorders. 1999;55:11-17.
6629.	Jazayeri S, SA K, Tehrani-Doost M, et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry research. 2010;178:112-115.
6630.	JAZJM Z. Medical management of trigeminal neuropathic pains. Expert opinion on pharmacotherapy. 2010;11:1239-1254.
6631.	JB B, NV F, LV T. [Modern approaches to the synchronization of circadian rhythms in treatment of depression]. [Review] [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. 2014;Korsakova 124-128.
6632.	JB B, Russo J, MB S, et al. Does Occasional Cannabis Use Impact Anxiety and Depression Treatment Outcomes?: Results From a Randomized Effectiveness Trial. Depression and anxiety. 2007;24:392-398.
6633.	JB B, SC L. Clinical pearls in general internal medicine. Mayo Clinic proceedings. 2011;86:70-74.
6634.	JB C, CS W. Paroxetine in major depression: A double-blind trial with imipramine and placebo. Journal of clinical psychiatry. 1992;53 Suppl:52-56.
6635.	JB G, EE K, Kelleher K, Seltman H, Gardner W. Generalizing from clinical trial data: A case study. The risk of suicidality among pediatric antidepressant users. Statistics in medicine. 2008;27:1801-1813.
6636.	JB J, SM S. Childhood depression. Current opinion in psychiatry. 1991;4:535-541.
6637.	JB K, EJ P, SL S, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biological psychiatry. 2007;61:734-742.
6638.	JB K, EJ P, SL S, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biological psychiatry. 2007;61:734-742.
6639.	JB N, Sarinopoulos I, DJ O, et al. Anticipatory Activation in the Amygdala and Anterior Cingulate in Generalized Anxiety Disorder and Prediction of Treatment Response. American journal of psychiatry. 2009;166:302-310.
6640.	JB R, Papaioannou A, JD A, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Archives of internal medicine. 2007;167:188-194.
6641.	JB S, AC N, Bogers W, et al. Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biological psychiatry. 2011;69:336-343.
6642.	JB S, CA ZJ. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: A review of controlled trials. Bipolar disorders. 2006;8:696-709.
6643.	JB S, Cronholm P. Are paroxetine, fluoxetine, and sertraline equally effective for depression? Journal of family practice. 2002;51:285.
6644.	JB S, HH H. Drugs under investigation for attention-deficit hyperactivity disorder. Current opinion in investigational drugs (London, England : 2000). 2002;3:1207-1211.
6645.	JB W, RM K, S-L Y. Type II error and antidepressants [2]. Journal of clinical psychiatry. 2001;62:373-374.
6646.	JB W, RM K, SL Y. Type II error and antidepressants. Journal of clinical psychiatry. 2001;62:373-375.
6647.	JC A, JR B, Coutinho W. Psychotropic drugs in the treatment of obesity: what promise?. [Review] [163 refs]. CNS drugs. 2004;18:629-651.
6648.	JC A, JR B, Coutinho W. Psychotropic Drugs in the Treatment of Obesity. CNS drugs. 2004;18:629-651.
6649.	JC B. Clinical evaluation of venlafaxine. [Review] [12 refs]. Journal of clinical psychopharmacology. 1996;16:29S-35S; discussion 35S-36S.
6650.	JC B. Clinical Evaluation of Venlafaxine. Journal of clinical psychopharmacology. 1996;16:S29-S35.
6651.	JC B. Clinical evaluation of venlafaxine. Journal of clinical psychopharmacology. 1996;16:29S-36S.
6652.	JC B. Recognizing the Patient With Social Anxiety Disorder. International clinical psychopharmacology. 2000;15:S1-S5.
6653.	JC B. Overview of Different Pharmacotherapies for Attaining Remission in Generalized Anxiety Disorder. Journal of clinical psychiatry. 2001;62:11-19.
6654.	JC B. Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine. Journal of clinical psychiatry. 2004;65:1696-1707.
6655.	JC B. Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine. Journal of clinical psychiatry. 2004;65:1696-1707.
6656.	JC B, AM T, MR C, Filipe A. Pirlindole in the treatment of depression and fibromyalgia syndrome. Clinical drug investigation. 2011;31:675-689.
6657.	JC B, DE W, Steiner M, Bushnell W, IP G. Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder. American journal of psychiatry. 1998;155:36-42.
6658.	JC B, JRT D, Lecrubier Y, et al. Consensus Statement on the Primary Care Management of Depression From the International Consensus Group on Depression and Anxiety. Journal of clinical psychiatry. 1999;60:54-61.
6659.	JC B, Kafantaris V. Pharmacological treatment of bipolar disorder among children and adolescents. Expert review of neurotherapeutics. 2007;7:259-270.
6660.	JC B, RM L, MF F, et al. A Double-Blind Comparison of Sertraline and Clomipramine in Outpatients With Obsessive-Compulsive Disorder. European psychiatry. 1997;12:82-93.
6661.	JC C, Eisenhofer G, MJ O, et al. Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects. Journal of clinical psychopharmacology. 2014;34:9-16.
6662.	JC C, HR S. The BDI of the beholder. Journal of psychopharmacology (Oxford, England). 2002;16:103.
6663.	JC C, Kovacs R, Haber H, et al. Evaluation of the Effects of Duloxetine and Escitalopram on 24-Hour Heart Rate Variability a Mechanistic Study Using Heart Rate Variability as a Pharmacodynamic Measure. Journal of clinical psychopharmacology. 2013;33:236-239.
6664.	JC C, MP C, DG M, et al. Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: evidence for the involvement of monoaminergic systems. European journal of pharmacology. 2010;643:232-238.
6665.	JC C-K, LC E. Scientific misconduct, the pharmaceutical industry, and the tragedy of institutions. Medicine and law. 2007;26:431-446.
6666.	JC D. Why psychiatric drugs "work": The attribution of positive effects due to psychological factors. Ethical human psychology and psychiatry. 2008;10:10-15.
6667.	JC F, FE L. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199-229.
6668.	JC F, RJ D, Amsterdam J, RC S, SD H. Gains in Employment Status Following Antidepressant Medication or Cognitive Therapy for Depression. British journal of psychiatry. 2015;206:332-338.
6669.	JC F, RJ D, RC S, Gallop R, JD A, SD H. Antidepressant Medications V. Cognitive Therapy in People With Depression With or Without Personality Disorder. British journal of psychiatry. 2008;192:124-129.
6670.	JC F, RJ D, RC S, Gallop R, JD A, SD H. Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder. British journal of psychiatry. 2008;192:124-129.
6671.	JC F, RJ D, RC S, SD H, JD A, Gallop R. Prediction of Response to Medication and Cognitive Therapy in the Treatment of Moderate to Severe Depression. Journal of consulting and clinical psychology. 2009;77:775-787.
6672.	JC F, RJ D, SD H, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA - Journal of the American Medical Association. 2010;303:47-53.
6673.	JC F, RJ D, SD H, Gallop R, RC S, JD A. Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behaviour research and therapy. 2013;51:392-398.
6674.	JC G. Emerging pharmacologic treatments for alcohol dependence. Journal of clinical psychiatry. 2006;67:35-40.
6675.	JC G, RA S, RFJ C, MK A, Astl D, Seljan P. The Effect of Dose Titration and Dose Tapering on the Tolerability of Desvenlafaxine in Women With Vasomotor Symptoms Associated With Menopause. Journal of women's health. 2012;21:188-198.
6676.	JC H, CA M, SR B, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: The management of sadness and anxiety in cardiology (MOSAIC) randomized clinical trial. JAMA Internal Medicine. 2014;174:927-935.
6677.	JC H, SJ R, JH H, RG T, MG W. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology. 1998;7:291-300.
6678.	JC H, SR B, Suarez L, et al. Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial. Contemporary clinical trials. 2013;36:488-501.
6679.	JC I, DJ S, Hawkridge S, Hoppe L. Pharmacotherapy for Anxiety Disorders in Children and Adolescents (Review). Cochrane database of systematic reviews (Online). 2009.
6680.	Pharmacotherapy and Psychotherapy for Body Dysmorphic Disorder, Cochrane database of systematic reviews (Online)(2009).
6681.	JC I, Wilson D, TO A, Sager C, DJ S. Pharmacotherapy for Anxiety and Comorbid Alcohol Use Disorders. Cochrane database of systematic reviews (Online). 2015.
6682.	JC J, JL H, Simonsen E, Gluud C. The effect of interpersonal psychotherapy and other psychodynamic therapies versus 'treatment as usual' in patients with major depressive disorder. PloS one. 2011.
6683.	JC J, JL H, Simonsen E, Gluud C. The effect of adding psychodynamic therapy to antidepressants in patients with major depressive disorder. A systematic review of randomized clinical trials with meta-analyses and trial sequential analyses. Journal of affective disorders. 2012;137:4-14.
6684.	JC L, AA M, JG C. Treatment of violent behavior in patients with Combined psychiatric illness and cognitive impairment: A case series. Mental Health Aspects of Developmental Disabilities. 2009;12:8-16.
6685.	JC L, Svedsater H, Datto C, Endicott J. Effects of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine Xr) on Quality of Life and Sleep in Elderly Patients With Major Depressive Disorder. Journal of affective disorders. 2013;149:189-195.
6686.	Vocal acoustic biomarkers of depression severity and treatment response, Biological psychiatry(2012).
6687.	JC M, BL M. What to do when a psychotherapy fails. The Lancet Psychiatry. 2015;2:186-190.
6688.	JC M, JH G, JW J, et al. Is it easier to find what you are looking for if you think you know what it looks like? Journal of clinical psychopharmacology. 2007;27:121-125.
6689.	JC M, KM E, Unger M, Odin P, KR C, WH O. Clinical risk-benefit assessment of dopamine agonists. European journal of neurology. 2008;15:15-23.
6690.	JC M, Levi M, Thompson C. The compliance with antidepressants in general practice. Journal of psychopharmacology (Oxford, England). 1994;8:48-53.
6691.	JC MA, Gonzalez LC. Antidepressives and Suicide. [Spanish]. Revista chilena de pediatria. 2007;78:461-471.
6692.	JC N. Treatment of refractory depression. Depression and anxiety. 1997;5:165-174.
6693.	JC N. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biological psychiatry. 1999;46:1301-1308.
6694.	JC N. The STAR*D study: A four-course meal that leaves us wanting more. American journal of psychiatry. 2006;163:1864-1866.
6695.	JC N. Recent findings and current status of augmentation strategies. Primary psychiatry. 2007;14:6-9.
6696.	JC N. Anxious depression and response to treatment. [Review] [9 refs]. American journal of psychiatry. 2008;165:297-299.
6697.	JC N. The evolving story of folate in depression and the therapeutic potential of L-methylfolate. American journal of psychiatry. 2012;169:1223-1225.
6698.	JC N, CM C, AC L, LS S. Symptoms of Late-Life Depression - Frequency and Change During Treatment. American journal of geriatric psychiatry. 2005;13:520-526.
6699.	JC N, CM C, AC L, LS S. Symptoms of Late-Life Depression - Frequency and Change During Treatment. American journal of geriatric psychiatry. 2005;13:520-526.
6700.	JC N, DC S, Yang H, et al. Subpopulation analysis of adjunctive aripiprazole in MDD patients aged = >50 years (CN138-139/163/165). American journal of geriatric psychiatry. 2009;Conference:A55-A56.
6701.	JC N, Delucchi K, LS S. Efficacy of second generation antidepressants in late-life depression: A meta-analysis of the evidence. American journal of geriatric psychiatry. 2008;16:558-567.
6702.	JC N, Delucchi K, LS S. Anxiety Does Not Predict Response to Antidepressant Treatment in Late Life Depression: Results of a Meta-Analysis. International journal of geriatric psychiatry. 2009;24:539-544.
6703.	JC N, DP D. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. Journal of the American Geriatrics Society. 2011;59:577-585.
6704.	JC N, GI P. Atypical Antipsychotic Augmentation in Major Depressive Disorder: a Meta-Analysis of Placebo-Controlled Randomized Trials. American journal of psychiatry. 2009;166:980-991.
6705.	JC N, KL D, LS S. Moderators of outcome in late-life depression: A patient-level meta-analysis. American journal of psychiatry. 2013;170:651-659.
6706.	JC N, LH P, Fava M, et al. Lithium or desipramine augmentation of fluoxetine treatment [10]. American journal of psychiatry. 1995;152:1538-1539.
6707.	JC N, Mankoski R, RA B, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies. Journal of affective disorders. 2010;120:133-140.
6708.	JC N, ME T, EE B, et al. Efficacy of Adjunctive Aripiprazole in Patients With Major Depressive Disorder Who Showed Minimal Response to Initial Antidepressant Therapy. International clinical psychopharmacology. 2012;27:125-133.
6709.	JC N, ME T, Khan A. Are Antidepressants effective? What's a clinician to think? Journal of clinical psychiatry. 2008;69:1014-1015.
6710.	Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163), Primary care companion to the Journal of clinical psychiatry(2009).
6711.	JC N, MM W, CH M, MJ D, JG W, JS K. Duloxetine for the Treatment of Major Depressive Disorder in Older Patients. American journal of geriatric psychiatry. 2005;13:227-235.
6712.	JC N, Pikalov A, RM B. Augmentation treatment in major depressive disorder: Focus on aripiprazole. Neuropsychiatric disease and treatment. 2008;4:937-948.
6713.	JC N, Portera L, AC L. Are There Differences in the Symptoms That Respond to a Selective Serotonin or Norepinephrine Reuptake Inhibitor? Biological psychiatry. 2005;57:1535-1542.
6714.	JC N, Rahman Z, KK L, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS spectrums. 2013;19:528-534.
6715.	JC N, Rahman Z, KK L, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS spectrums. 2014;19:528-534.
6716.	JC N, SB H, Betzel J, et al. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. International journal of geriatric psychiatry. 2006;21:898-901.
6717.	Assessment of falls in older patients treated with duloxetine: A secondary analysis of a 24-week randomized, placebo-controlled trial, Primary care companion to the Journal of clinical psychiatry(2013).
6718.	JC N, YL P, Martynov O, JY Y, CH M, MJ D. The safety and tolerability of duloxetine compared with paroxetine and placebo: A pooled analysis of 4 clinical trials. Primary care companion to the Journal of clinical psychiatry. 2006;8:212-219.
6719.	JC P, DN B. Fatigue in Rheumatologic Diseases. Physical medicine and rehabilitation clinics of North America. 2009;20:373-387.
6720.	JC P, KL S, JR S, et al. Management of Depression in Rheumatoid Arthritis: A Combined Pharmacologic and Cognitive-Behavioral Approach. Arthritis care and research. 2003;49:766-777.
6721.	JC P, RA K, MP D. The use of antipsychotics in children and adolescents with bipolar disorders. Expert opinion on pharmacotherapy. 2007;8:2673-2687.
6722.	JC P, RA K, MP D. Pharmacotherapy of bipolar disorder in children and adolescents: Recent progress. CNS drugs. 2010;24:575-593.
6723.	JC R, JS P. Sleep and headache. Current treatment options in neurology. 2010;12:1-15.
6724.	Nocebo Effect in Randomized Clinical Trials of Antidepressants in Children and Adolescents: Systematic Review and Meta-Analysis, Frontiers in behavioral neuroscience(2014).
6725.	JC S, Cox S, CM H, ML HK, SS G. Use of Fluoxetine in Anorexia Nervosa Before and After Weight Restoration. Annals of pharmacotherapy. 2013;47:1201-1205.
6726.	JC S, Gershon S. Prospects for the development of new treatments with a rapid onset of action in affective disorders. Drugs. 1996;52:477-482.
6727.	JC S, MH P. Pharmacologic treatment of panic disorder. CNS spectrums. 2005;10:25-31.
6728.	JC V, AJAE VDL, Roth T. Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. European journal of pharmacology. 2015;753:252-256.
6729.	JC V, ER V. Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature. CNS drug reviews. 2004;10:45-76.
6730.	JC W, JR K, Schachat C, et al. Rapid and Sustained Antidepressant Response with Sleep Deprivation and Chronotherapy in Bipolar Disorder. Biological psychiatry. 2009;66:298-301.
6731.	JCG R, SA M, LV J, Tanghoj P. Dose and profile of citalopram in the management of depressive illness. European neuropsychopharmacology. 1993;3:325-326.
6732.	JD A. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. Journal of psychopharmacology (Oxford, England). 1998;12:S99-S111.
6733.	JD A. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. [Review] [109 refs]. Journal of psychopharmacology (Oxford, England). 1998;12:S99-111.
6734.	JD A, DJ B. Antidepressant monotherapy for bipolar type II major depression. Bipolar disorders. 2003;5:388-395.
6735.	JD A, DJ B, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A - A putative, new antidepressant. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:1333-1338.
6736.	JD A, Fawcett J, FM Q, et al. Fluoxetine and Norfluoxetine Plasma Concentrations in Major Depression: a Multicenter Study. American journal of psychiatry. 1997;154:963-969.
6737.	JD A, LB M. The paroxetine 352 bipolar trial: A study in medical ghostwriting. International journal of risk & safety in medicine. 2012;24:221-231.
6738.	JD A, LL L, Shults J. Effectiveness and Mood Conversion Rate of Short-Term Fluoxetine Monotherapy in Patients With Rapid Cycling Bipolar Ii Depression Versus Patients With Nonrapid Cycling Bipolar Ii Depression. Journal of clinical psychopharmacology. 2013;33:420-424.
6739.	JD A, Luo L, Shults J. Authors' reply. British journal of psychiatry. 2013;203:75.
6740.	JD A, Maislin G, Potter L. Fluoxetine Efficacy in Treatment-Resistant Depression. Progress in neuro-psychopharmacology & biological psychiatry. 1994;18:243-261.
6741.	JD A, Shults J. Comparison of Fluoxetine, Olanzapine, and Combined Fluoxetine Plus Olanzapine Initial Therapy of Bipolar Type I and Type Ii Major Depression - Lack of Manic Induction. Journal of affective disorders. 2005;87:121-130.
6742.	JD A, Shults J. Comparison of Short-Term Venlafaxine Versus Lithium Monotherapy for Bipolar Ii Major Depressive Episode - a Randomized Open-Label Study. Journal of clinical psychopharmacology. 2008;28:171-181.
6743.	JD A, Shults J, DJ B, Hundert M. Short-Term Fluoxetine Monotherapy for Bipolar Type Ii or Bipolar Nos Major Depression - Low Manic Switch Rate. Bipolar disorders. 2004;6:75-81.
6744.	JD A, Shults J, Rutherford N, Schwartz S. Safety and Efficacy of S-Citalopram in Patients With Co-Morbid Major Depression and Diabetes Mellitus. Neuropsychobiology. 2006;54:208-214.
6745.	JD A, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta psychiatrica Scandinavica. 2010;121:201-208.
6746.	JD B. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Journal of clinical psychiatry. 1995;56:519-525.
6747.	JD B. Double-blind comparison of mirtazapine, amitriptyline and placebo in major depression. [German]. Nervenheilkunde. 1996;15:533-540.
6748.	JD B, JP F. Cost analysis of paroxetine versus imipramine in major depression. PharmacoEconomics. 1995;8:223-232.
6749.	JD B, MF J, Honore P, CS S. Fibromyalgia: Mechanisms, Current Treatment and Animal Models. Current pharmaceutical biotechnology. 2011;12:1613-1626.
6750.	JD B, TI C. Identification, treatment, and clinical outcomes of neuropathic pain for the primary care physician. Journal of clinical outcomes management. 2010;17:37-54.
6751.	JD B, WT S. Org 3770 VS amitriptyline in the continuation treatment of depression: A placebo controlled trial. European Journal of Psychiatry. 1996;10:5-15.
6752.	JD C, Gopinath S, CG A, BR B. A neurobiological hypothesis of treatment-resistant depression-mechanisms for selective serotonin reuptake inhibitor non-efficacy. Frontiers in behavioral neuroscience. 2014.
6753.	JD E, Lavretsky H, O'Hara R, Gildengers A. Cognition and mood disorder: Is there a connection to neurodegeneration and cognitive decline? American journal of geriatric psychiatry. 2013;Conference:S8-S9.
6754.	JD F, PR P, MW W, WJ B. Psychostimulants for older adults. Current psychiatry. 2012;11:23-32.
6755.	JD F, TG B, Steinhoff M. Innovative management of pruritus. Dermatologic clinics. 2010;28:467-478.
6756.	JD G, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. Journal of clinical psychopharmacology. 2001;21:425-431.
6757.	JD G, Bouhassira M, Bonett-Perrin E, Lancrenon S. [The study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice]. [French]. L'Enc�phale. 1999;25:265-270.
6758.	JD G, JF D, Pichot P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. British journal of clinical pharmacology. 1983;15 Suppl 3:411S-417S.
6759.	JD G, Loo H, CS P, MF P, Bourin M, Lecrubier Y. Delay in action and treatment resistance. [French]. Encephale. 1999;25:58-61.
6760.	JD G, Slayton P, K dG. Vilazodone (viibryd) for the treatment of depression. American family physician. 2013;88:263-264.
6761.	JD K, SP F, AF S, et al. Nicotine patch and paroxetine for smoking cessation. Journal of consulting and clinical psychology. 2000;68:883-889.
6762.	JD K, SP F, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment for nicotine dependence. Addictive behaviors. 2003;28:461-470.
6763.	JD K, SP F, Varady A, HC K. Do men outperform women in smoking cessation trials? Maybe, but not by much. Experimental and clinical psychopharmacology. 2002;10:295-301.
6764.	JD M, Fava M. Risk of suicidality in depression with serotonergic antidepressants. Annals of clinical psychiatry. 2000;12:43-50.
6765.	JD N. Treating late-life depression. Primary psychiatry. 2006;13:33-36.
6766.	JD R. Commentary on Comparison of Alcoholism Subtypes as Moderators of the Response to Sertraline Treatment. Alcoholism, clinical and experimental research. 2012;36:561-563.
6767.	JD S. A Critique of Recent Studies on Placebo Effects of Antidepressants: Importance of Research on Active Placebos. Psychopharmacology. 2000;152:1-6.
6768.	JD S, Currie J, SM L, Reid I. Prefrontal Cortical Functional Abnormality in Major Depressive Disorder: a Stereotactic Meta-Analysis. Journal of affective disorders. 2007;101:1-11.
6769.	JD T, BH M, PR H, et al. Impact of Prior Treatment Exposure on Response to Antidepressant Treatment in Late Life. American journal of geriatric psychiatry. 2006;14:957-965.
6770.	JD T, BH M, RF H, Joan P, AE B, HA S. Relapse during continuation pharmacotherapy after acute response to ECT: A comparison of usual care versus protocolized treatment. Annals of clinical psychiatry. 2007;19:1-4.
6771.	JD V, SH K, RM B. Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Canadian Journal of Psychiatry. 2002;47:174-180.
6772.	JE A, DA F, SB H, Fava M. Gepirone Extended-Release Treatment of Anxious Depression: Evidence From a Retrospective Subgroup Analysis in Patients With Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:1069-1075.
6773.	JE A, DA F, SB H, Fava M. Gepirone Extended-Release Treatment of Anxious Depression: Evidence From a Retrospective Subgroup Analysis in Patients With Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:1069-1075.
6774.	JE A, Kroenke K, RW S, GJ E. Nine-Month Predictors and Outcomes of Ssri Antidepressant Continuation in Primary Care. General hospital psychiatry. 2005;27:229-236.
6775.	JE A, Kroenke K, RW S, GJ E. Nine-Month Predictors and Outcomes of Ssri Antidepressant Continuation in Primary Care. General hospital psychiatry. 2005;27:229-236.
6776.	JE A, LA U, NE M, Abraham M, JF R, Fava M. The Mini-Mental State Examination among adult outpatients with major depressive disorder. Psychotherapy and psychosomatics. 1995;63:207-211.
6777.	JE A, Maddocks A, JF R, Fava M. Childhood psychopathology retrospectively assessed among adults with early onset major depression. Journal of affective disorders. 1994;31:165-171.
6778.	JE A, Papakostas G, Mischoulon D, et al. S-Adenosyl-L-Methionine (Same) as an Adjunct for Resistant Major Depressive Disorder - an Open Trial Following Partial or Nonresponse to Selective Serotonin Reuptake Inhibitors or Venlafaxine. Journal of clinical psychopharmacology. 2004;24:661-664.
6779.	JE B. Behavioral symptoms in patients with breast cancer and survivors. Journal of clinical oncology. 2008;26:768-777.
6780.	JE B, DJF vS, MC dB, et al. Are psychological treatments for depression in primary care cost-effective? Journal of mental health policy and economics. 2008;11:3-15.
6781.	JE B, Potokar J, Coupland N, DJ N. The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. Journal of psychopharmacology (Oxford, England). 1995;9:137-141.
6782.	JE D, KJ L. Managing menopausal symptoms and depression in tamoxifen users: Implications of drug and medicinal interactions. Maturitas. 2010;67:296-308.
6783.	JE DW, Mertens C, JS W. Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. British journal of clinical pharmacology. 1983;15 Suppl 3:427S-431S.
6784.	JE F. Vilazodone: In major depressive disorder. CNS drugs. 2011;25:615-627.
6785.	JE F, GL P. Selegiline transdermal system: In the treatment of major depressive disorder. Drugs. 2007;67:257-265.
6786.	JE G, Schreiber L, BL O, SW K. Pathologic Gambling and Bankruptcy. Comprehensive psychiatry. 2010;51:115-120.
6787.	JE J. Treating anxiety disorders in children and adolescents with epilepsy: What do we know? Epilepsy & behavior. 2014;39:137-142.
6788.	JE K. Venlafaxine in Social Phobia. Psychopharmacology bulletin. 1995;31:767-771.
6789.	JE K. Dose-response relationship with venlafaxine. Journal of clinical psychopharmacology. 1996;16:21S-28S.
6790.	JE K. Clinician perspective on achieving and maintaining remission in depression. [Review] [65 refs]. Journal of clinical psychiatry. 2001;62 Suppl 2:16-21.
6791.	JE K. Treatment strategies in achieving remission in major depressive disorder. Acta Psychiatrica Scandinavica, Supplement. 2002;106:18-23.
6792.	JE K. Remission as the goal of treatment in major depressive disorder. Managed care interface. 2003;16:4-8.
6793.	JE K, BB S, Cook A, Reviere R, JA L. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Journal of clinical psychiatry. 2005;66:1564-1568.
6794.	JE K, JP H, DJ C, Fong R, PS B, JT D. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. Journal of affective disorders. 2010;120:40-47.
6795.	JE K, SJ Y, Kim J, et al. Efficacy and Tolerability of Mirtazapine in Treating Major Depressive Disorder With Anxiety Symptoms: an 8-Week Open-Label Randomised Paroxetine-Controlled Trial. International journal of clinical practice. 2011;65:323-329.
6796.	JE M. The search for better noncholinergic treatment options for Alzheimer's disease. Journal of clinical psychiatry. 2003;64:18-22.
6797.	JE M. Depression in nursing home residents. Journal of the American Medical Directors Association. 2010;11:301-303.
6798.	Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomised trial, British journal of psychiatry(2011).
6799.	Stepped Care and Cognitive Behavioural Therapy for Bulimia Nervosa: Randomised Trial, British journal of psychiatry(2011).
6800.	JE M, Agras S, Wonderlich S. Treatment of Bulimia Nervosa: Where Are We and Where Are We Going? International journal of eating disorders. 2007;40:95-101.
6801.	JE M, Koen L, Seedat S, DJ S. Social anxiety disorder: Current treatment recommendations. CNS drugs. 2005;19:377-391.
6802.	JE M, Raymond N, Specker S. A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. International journal of eating disorders. 1993;14:229-247.
6803.	JE M, Wentzel I, Koen L, DJH N, Seedat S, DJ S. Escitalopram in the Treatment of Multisomatoform Disorder: a Double-Blind, Placebo-Controlled Trial. International clinical psychopharmacology. 2008;23:43-48.
6804.	JE S, DE M. Fibromyalgia: Presentation and Management With a Focus on Pharmacological Treatment. Pain research & management. 2008;13:477-483.
6805.	JE S, LC L, HS R, AF S, GM MJ. FKBP5 polymorphisms and antidepressant response in geriatric depression. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2010;Part B, Ne:the Official Publication of the International Soci.
6806.	JE S, LC L, HS R, AF S, GM MJ. FKBP5 polymorphisms and antidepressant response in geriatric depression. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2010;153:554-560.
6807.	JE S, LC L, HS R, BD E, AF S, GM M. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenetics and genomics. 2010;20:467-475.
6808.	JE S, Sysko R, Mayer L, et al. Pre-Meal Anxiety and Food Intake in Anorexia Nervosa. Appetite. 2010;55:214-218.
6809.	JE T, Debonnel G, C DM, Hebert C, Blier P. Assessment of the Serotonin and Norepinephrine Reuptake Blocking Properties of Duloxetine in Healthy Subjects. Neuropsychopharmacology. 2001;24:511-521.
6810.	JEA M, Honig A, FRJ V, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: A qualitative analysis of the literature on their efficacy and side-effects. International clinical psychopharmacology. 1996;11:165-175.
6811.	Jean D, Adriaan H. Fluvoxamine versus fluoxetine in major depressive episode: A double-blind randomized comparison. Human Psychopharmacology: Clinical and Experimental. 2003;18:379-384.
6812.	Jean D, Catherine R, Eric P, Genevieve B. The efficacy and acceptability of amineptine versus fluoxetine in major depression. International clinical psychopharmacology. 1997;12:S35-S38.
6813.	Jean T. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. Journal of clinical psychopharmacology. 1993;13:18S-22S.
6814.	Jean-Marie V, Dominique A-L, Marie-France P, Myriam B, Blin P, Olie JP. Controlled efficacy study of fluoxetine in dysthymia. The British Journal of Psychiatry. 1997;170:345-350.
6815.	Jean-Michel M, Jorge P-P. Selective serotonin reuptake inhibitors (SSRIs) and depression after myocardial infarction (MI). Journal of psychiatry & neuroscience. 2005;30:152.
6816.	Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder, International clinical psychopharmacology(2014).
6817.	Jean-Pierre L, Vincent C, Jean-Claude B, Sylvie T, Jean-Michel H, Patrice B. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder.[Erratum appears in Am J Psychiatry. 2004 Jul;161(7):1320]. American journal of psychiatry. 2004;161:836-842.
6818.	Jean-Pierre O, David G, Agnes M, Michel R, Marie-France P. Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomized, double-blind exploratory study. Neuropsychiatric disease and treatment. 2010;6.
6819.	Jean-Pierre P, GR M, JA R, et al. A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Clinical Trial of the Effect of Modafinil on Cancer-Related Fatigue Among 631 Patients Receiving Chemotherapy. Cancer. 2010;116:3513-3520.
6820.	Jeanne M, Y CJ, L GB, et al. Treating Depression in Predominantly Low-Income Young Minority Women: A Randomized Controlled Trial. JAMA: Journal of the American Medical Association. 2003;290:57-65.
6821.	Jeannette M, W GA, Jennifer E, Graham B, Anne B, John R. Treatment of postnatal depression with cognitive behavioural therapy, sertraline and combination therapy: A randomised controlled trial. Australian and New Zealand journal of psychiatry. 2015;49:236-245.
6822.	Jefferies K. Treatment of neuropathic pain. Seminars in neurology. 2010;30:425-432.
6823.	Jeffrey L, Jonathan L. Escitalopram, problem-solving therapy, and poststroke depression. JAMA: Journal of the American Medical Association. 2008;300:1757-1758.
6824.	Jeffreys M, Capehart B, MJ F. Pharmacotherapy for Posttraumatic Stress Disorder: Review With Clinical Applications. Journal of rehabilitation research and development. 2012;49:703-715.
6825.	Jen-Ping H, Cheng-Hung Y, Shih-Jen T. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. International journal of geriatric psychiatry. 2004;19:189-190.
6826.	Jeong H, HW Y, S-J J, et al. The effects of care management on depression treatment in a psychiatric clinic: A randomized controlled trial. International journal of geriatric psychiatry. 2013;28:1023-1030.
6827.	Jerome S, A NA, Isaac S, et al. Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. Journal of clinical psychopharmacology. 2013;33:827-830.
6828.	S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response, Journal of affective disorders(2014).
6829.	Jesper B-H, Per B. Validity of the definite and Semidefinite Questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale. Part I. European archives of psychiatry and clinical neuroscience. 2011;261:37-46.
6830.	Jesper N, Helge V, Bente D-S. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445-449.
6831.	Jesper S, M LR, Paul L, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. Journal of psychopharmacology (Oxford, England). 1999;13:406-414.
6832.	Jespersen S, Berk M, C VW, et al. A Pilot Randomized, Double-Blind, Placebo-Controlled Study of Granisetron in the Treatment of Sexual Dysfunction in Women Associated With Antidepressant Use. International clinical psychopharmacology. 2004;19:161-164.
6833.	Jespersen S, Berk M, C VW, et al. A Pilot Randomized, Double-Blind, Placebo-Controlled Study of Granisetron in the Treatment of Sexual Dysfunction in Women Associated With Antidepressant Use. International clinical psychopharmacology. 2004;19:161-164.
6834.	Jew R. Lesson from the saga of selective serotonin-reuptake inhibitors. American journal of health-system pharmacy. 2005;62:806.
6835.	Jezukaitis P, Kapur D. Management of occupation-related musculoskeletal disorders. Best Practice and Research: Clinical Rheumatology. 2011;25:117-129.
6836.	JF G. New Drugs in Psychiatry. Emergency medicine clinics of North America. 2000;18:211-+.
6837.	JF G. When do antidepressants worsen the course of bipolar disorder? Journal of psychiatric practice. 2003;9:181-194.
6838.	JF G. What psychotherapists should know about pharmacotherapies for bipolar disorder. Journal of clinical psychology. 2007;63:475-490.
6839.	JF G. Psychosis with bipolar mania. Annals of clinical psychiatry. 2008;20:S9-S13.
6840.	JF G. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. Journal of clinical psychiatry. 2008;69:11-19.
6841.	JF G. A practical approach to subtyping depression among your patients. Current psychiatry. 2014;13:41-46.
6842.	JF G. The first of 2 parts: A practical approach to subtyping depression among your patients. Current psychiatry. 2014;13:43-47+65.
6843.	JF G, CJ T. Antidepressant-induced mania: An overview of current controversies. Bipolar disorders. 2003;5:407-420.
6844.	JF G, Ghaemi N. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disorders, Supplement. 2005;7:3-12.
6845.	JF G, KE B, CJ E. Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression. American journal of psychiatry. 2004;161:564-566.
6846.	JF G, RH P, SN G, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: Findings from the STEP-BD. American journal of psychiatry. 2007;164:1348-1355.
6847.	JF K. Major Depressive Disorder, Antidepressants and Sexual Dysfunction. Neuropsychiatrie. 2009;23:134-138.
6848.	JF K, BL R, 3rd RCF, et al. Addressing both depression and pain in late life: the methodology of the ADAPT study. Pain medicine (Malden, Mass.). 2012;13:405-418.
6849.	JF K, DK W, MA D, Begley A, MD M, CF R. Duloxetine and Care Management Treatment of Older Adults With Comorbid Major Depressive Disorder and Chronic Low Back Pain: Results of an Open-Label Pilot Study. International journal of geriatric psychiatry. 2010;25:633-642.
6850.	JF K, Lenze E, Solai L, Rosen J, IIICF R. Preventing depression in older adults. Clinical Neuropsychiatry. 2006;3:69-80.
6851.	JF K, Skidmore E, Lotz M, Lenze E, MA D, 3rd RCF. Use of the late-life function and disability instrument to assess disability in major depression. Journal of the American Geriatrics Society. 2009;57:1612-1619.
6852.	JF K, Skidmore E, Lotz M, Lenze E, MA D, 3rd RCF. Use of the late-life function and disability instrument to assess disability in major depression. Journal of the American Geriatrics Society. 2009;57:1612-1619.
6853.	JF K, Weiner D, Seligman K, et al. Body pain and treatment response in late-life depression. American journal of geriatric psychiatry. 2005;13:188-194.
6854.	JF L. The risks and benefits of antidepressants to treat pediatric-onset depression and anxiety disorders: A developmental perspective. Psychotherapy and psychosomatics. 2013;82:129-131.
6855.	JF L. The risks and benefits of antidepressants to treat pediatric-onset depression and anxiety disorders: A developmental perspective. Psychotherapy and psychosomatics. 2013;82:129-131.
6856.	JF L, RA K. A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. American journal of psychiatry. 2007;164:1304-1306.
6857.	JF M, BB S, EA S. The phenomenology, assessment and treatment of pediatric obsessive-compulsive disorder. Minerva psichiatrica. 2011;52:51-60.
6858.	JF M, Bruno A. Post-stroke complications: Epidemiology and prospects for pharmacological intervention during rehabilitation. CNS drugs. 1998;9:357-370.
6859.	JF M, Scott C, Hodge J. Appraisal of the Clinical-Value of Serotoninergic Drugs. American journal of clinical nutrition. 1992;55:189-192.
6860.	JF M, Ung D, RR S, et al. Treating trichotillomania: A meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of psychiatric research. 2014;58:76-83.
6861.	JF W. Safety and side effect profile of fluoxetine. Expert opinion on drug safety. 2004;3:495-504.
6862.	JF W, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert opinion on drug safety. 2005;4:987-993.
6863.	JF W, Iyengar S, MD F-G. Treatment of chronic pain with drugs that modulate central nervous system serotonin and norepinephrine. Current drug therapy. 2007;2:161-167.
6864.	JF W, ME S, SC K, DK P, GD T. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior. Depression and anxiety. 1997;6:31-39.
6865.	JF W, SR D, BE D, JC B, Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacology bulletin. 1988;24:183-188.
6866.	JF W, SR D, BE D, RL Z. Fixed-dose fluoxetine therapy for depression. Psychopharmacology bulletin. 1987;23:164-168.
6867.	JF W, Wang F, YL P, et al. An Open-Label 52-Week Clinical Extension Comparing Duloxetine With Routine Care in Patients With Diabetic Peripheral Neuropathic Pain. Pain medicine (Malden, Mass.). 2007;8:503-513.
6868.	JG B, FA W, Tverdal A. The sales of antidepressants and suicide rates in Norway and its counties 1980-2004. Journal of affective disorders. 2007;102:1-9.
6869.	JG E. Selective serotonin reuptake inhibitors in the treatment of depression. Prescribers' journal. 1994;34:197-204.
6870.	JG E. Drug Choice in Depression - Selective Serotonin Reuptake Inhibitors or Tricyclic Antidepressants. CNS drugs. 1995;4:141-159.
6871.	JG E. Newer v. older antidepressants in long-term pharmacotherapy. Revisiting: Prevention of relapse and recurrence of depression. Advances in Psychiatric Treatment. 2005;11:184-194.
6872.	JG E, Anderson I. Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors. Drugs. 1999;57:507-533.
6873.	JG E, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology. 1989;97:96-98.
6874.	JG E, Goldie A, Papayanni-Papasthatis S, Punter J, EM S. The effect of paroxetine on the electroencephalogram, electrocardiogram, and blood pressure. Acta psychiatrica Scandinavica. Supplementum. 1989;350:124.
6875.	JG E, WHW I, Wilton L, GL P. Prescription-Event Monitoring of 10401 Patients Treated With Fluvoxamine. British journal of psychiatry. 1994;164:387-395.
6876.	JG F, Hale N, AA S, WH C. Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. Annals of clinical psychiatry. 2010;22:157-163.
6877.	JG I, M-H C, Lakshminarayanan M, GF L, JF H. Bayesian probability of success for clinical trials using historical data. Statistics in medicine. 2014;34:249-264.
6878.	JG I, M-H C, Lakshminarayanan M, GF L, JF H. Bayesian probability of success for clinical trials using historical data. Statistics in medicine. 2015;34:249-264.
6879.	JG M, NE R, AE H, et al. Seasonal Affective Disorder and Its Prevention by Anticipatory Treatment With Bupropion Xl. Biological psychiatry. 2005;58:658-667.
6880.	JG R. Antidepressants: Pharmacological Profile and Clinical Consequences. International journal of psychiatry in clinical practice. 2001;5:S19-S28.
6881.	JG R. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. [Review] [34 refs]. Journal of clinical psychiatry. 2003;64:20-29.
6882.	JG R. [Further evidence of the efficacy of the antidepressant Valdoxan (agomelatine) compared with conventional antidepressive drugs (from the ECNP held in Istanbul, 15 September 2009)]. [French]. Encephale. 2009;35:611.
6883.	JG R, GJ W, MC M, Rabkin R, SH L. Testosterone Versus Fluoxetine for Depression and Fatigue in Hiv/Aids - a Placebo-Controlled Trial. Journal of clinical psychopharmacology. 2004;24:379-385.
6884.	JG R, GJ W, Rabkin R. Immunologiceffects of psychotropic drugs in HIV+ patients [4]. Journal of acquired immune deficiency syndromes and human retrovirology. 1996;13:465.
6885.	JG R, Lourenco C. Deterministic dynamics of daily mood over five years in a patient with affective disorder. International clinical psychopharmacology. 2012;Conference:e23.
6886.	JG R, MJ G, LL A. Lamotrigine in psychiatric disorders. Journal of clinical psychiatry. 2013;74:675-684.
6887.	JG R, Rabkin R, Wagner G. Effects of Fluoxetine on Mood and Immune Status in Depressed-Patients With Hiv Illness. Journal of clinical psychiatry. 1994;55:92-97.
6888.	JG R, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: An open trial. Journal of clinical psychiatry. 1994;55:433-439.
6889.	JG R, Wagner G, Rabkin R. Treatment of depression in HIV+ men: Literature review and report of an ongoing study of testosterone replacement therapy. Annals of behavioral medicine. 1996;18:24-29.
6890.	JG S, BJ VZ, HDB V, Wohlfarth T, W VDB. Relapse and recurrence prevention in major depression: A critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. European psychiatry. 2001;16:327-335.
6891.	JG S, NB A. Mood and Personality Effects in Healthy Participants After Chronic Administration of Sertraline. Journal of affective disorders. 2011;134:377-385.
6892.	JG S, PJ N, Berger G, NB A. Chronic Modulation of Serotonergic Neurotransmission With Sertraline Attenuates the Loudness Dependence of the Auditory Evoked Potential in Healthy Participants. Psychopharmacology. 2011;217:101-110.
6893.	JG S, VF D, HB F, Copping W. Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Progress in neuro-psychopharmacology & biological psychiatry. 1990;14:790-795.
6894.	JH A, MA S, DR W, et al. Effects of Noradrenergic and Serotonergic Antidepressants on Chronic Low Back Pain Intensity. Pain. 1999;83:137-145.
6895.	JH A, MA S, EV C, et al. Efficacy of Noradrenergic and Serotonergic Antidepressants in Chronic Back Pain - a Preliminary Concentration-Controlled Trial. Journal of clinical psychopharmacology. 2007;27:135-142.
6896.	JH A, SM P, JM M, MA S, Zisook S, Capparelli E. Is there a therapeutic window with some antidepressants for analgesic response? Current pain and headache reports. 2009;13:93-99.
6897.	JH B, E-S K, Fava M, et al. Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. Journal of affective disorders. 2014;169:112-117.
6898.	JH B, EE B, AA N. One-carbon metabolism and bipolar disorder. Australian and New Zealand journal of psychiatry. 2013;47:1013-1018.
6899.	JH B, LC H, IJ C, BJ C. Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep. Psychopharmacology. 2004;171:450-457.
6900.	JH B, TA N, Brunner R, Renfroe S, H-Y L, Meythaler J. Impact of early administration of sertraline on cognitive and behavioral recovery in the first year after moderate to severe traumatic brain injury. Journal of head trauma rehabilitation. 2010;25:357-361.
6901.	JH C, Seri S, AE C. Clinical guidelines on long-term pharmacotherapy for bipolar disorder in children and adolescents. Journal of Clinical Medicine. 2014;3:135-143.
6902.	JH D. Pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in adults. Current psychiatry reviews. 2006;2:317-331.
6903.	JH D, Kornhuber J. Sertralin (Gladem, Zoloft, Tresleen). Chirurgische Praxis. 2002;59:549-554.
6904.	JH F. Fatigue in Parkinson's disease patients. Current treatment options in neurology. 2009;11:186-190.
6905.	JH F, Weintraub D. Glad about SAD (PD). Neurology. 2012;78:1198-1199.
6906.	JH G. An Integrated Approach to Treatment of Obsessive-Compulsive Disorder. Journal of clinical psychiatry. 1992;53:38-41.
6907.	JH G. New developments in behaviour therapy for obsessive-compulsive disorder. International clinical psychopharmacology. 1996;11:63-73.
6908.	JH G, JW J, KA K, DJ K, RC S. Efficacy and Tolerability of Serotonin Transport Inhibitors in Obsessive-Compulsive Disorder - a Metaanalysis. Archives of general psychiatry. 1995;52:53-60.
6909.	JH H, CM BJ, JH P. Fluoxetine Not Associated With Increased Aggression in Controlled Clinical-Trials. International clinical psychopharmacology. 1993;8:277-280.
6910.	JH H, EF C, JH P, CM BJ, BE D, DN M. Fluoxetine not associated with increased violence or aggression in controlled clinical trials. Annals of clinical psychiatry. 1992;4:285-295.
6911.	JH H, JEJr W, KM B, PJ R, Andrejasich C, GD T. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. International psychogeriatrics / IPA. 1995;7 Suppl:125-137.
6912.	JH H, WW S. Male sexual side effects associated with antidepressants: A descriptive clinical study of 32 patients. International journal of psychiatry in medicine. 1995;25:191-201.
6913.	JH J, KH M, HF DV, JJ G. Disparity in use of psychotherapy offered in primary care between older African-American and white adults: Results from a practice-based depression intervention trial. Journal of the American Geriatrics Society. 2010;58:154-160.
6914.	JH K. Geriatric dysthymia. [Review] [5 refs]. Journal of clinical psychiatry. 1998;59 Suppl 1:13-15.
6915.	JH K. New Strategies for Treating Chronic Depression. Journal of clinical psychiatry. 2000;61:42-45.
6916.	JH K. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS and Neurological Disorders - Drug Targets. 2007;6:163-182.
6917.	Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: The REVAMP trial, Archives of general psychiatry(2009).
6918.	JH K, CK C. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models. Pharmacology & therapeutics. 2010;128:460-487.
6919.	JH K, GD M. CRF1 receptor antagonists: treatment of stress-related disorders. Drug discovery today. Therapeutic strategies. 2008;5:161-168.
6920.	JH K, Gueorguieva R, Cramer J, Collins J, Rosenheck R. Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From Va Cooperative Study No. 425, "Naltrexone in the Treatment of Alcoholism". Alcoholism, clinical and experimental research. 2008;32:85-91.
6921.	JH K, RA F, JC M, et al. Maintenance therapy for chronic depression: A controlled clinical trial of desipramine. Archives of general psychiatry. 1996;53:769-776.
6922.	JH K, RA R, JA C, et al. Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related Ptsd a Randomized Trial. Jama-Journal of the American Medical Association. 2011;306:493-502.
6923.	JH M. Imaging the Serotonin Transporter During Major Depressive Disorder and Antidepressant Treatment. Journal of psychiatry & neuroscience. 2007;32:86-102.
6924.	JH M. Molecular imaging of mood episodes. Molecular Imaging in the Clinical Neurosciences. 2012;Neurometho:273-303.
6925.	JH M. Neuroimaging markers of cellular function in major depressive disorder: Implications for therapeutics, personalized medicine, and prevention. Clinical pharmacology and therapeutics. 2012;91:201-214.
6926.	JH M, AA W, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. American journal of psychiatry. 2001;158:1843-1849.
6927.	JH N. Comorbidity of ADHD and disruptive behavior disorders: Prevalence, impact, and management options. Drug Benefit Trends. 2004;16:431-436.
6928.	JH N. Selective serotonin reuptake inhibitor treatment of major depressive disorder in children and adolescents. Current psychiatry reports. 2004;6:85-87.
6929.	JH S, SA C, Kayumov L, et al. Polysomnographic and Symptomatological Analyses of Major Depressive Disorder Patients Treated With Mirtazapine. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2006;51:27-34.
6930.	JH S, SH K, RD L, Kayumov L, CM S. The Effects of Nefazodone on Women With Seasonal Affective Disorder: Clinical and Polysomnographic Analyses. Journal of psychiatry & neuroscience. 2005;30:11-16.
6931.	JH S, SH K, RD L, Kayumov L, CM S. The Effects of Nefazodone on Women With Seasonal Affective Disorder: Clinical and Polysomnographic Analyses. Journal of psychiatry & neuroscience. 2005;30:11-16.
6932.	JH SvL, RR L, AF J, WJ C, Viktrup L. Efficacy and Safety of Duloxetine in Elderly Women With Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence. Maturitas. 2008;60:138-147.
6933.	JH T. Stabilisation of the hypothalamic-pituitary-adrenal axis as a treatment modality for mood disorders. Human psychopharmacology. 1998;13:77-81.
6934.	JH T, AC V, WW vdB, JA B. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression. Journal of clinical psychopharmacology. 2006;26:542-544.
6935.	JH T, JA B, KJ dM, Pepplinkhuizen L, AH vdM, AJ MitV. Cardiovascular Variability in Major Depressive Disorder and Effects of Imipramine or Mirtazapine (Org 3770). Journal of clinical psychopharmacology. 1996;16:135-145.
6936.	JH W, JD M, DP M, HE H. Early clinical trial of clovoxamine: A new antidepressant. Current therapeutic research, clinical and experimental. 1981;29:148-155.
6937.	JH W, YB Z, HY X, et al. Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble Beta-Amyloid in App/Ps1 Mice. Current Alzheimer research. 2014;11:672-680.
6938.	JHK V, SF B, RB C, et al. Integrating complementary medicine into cardiovascular medicine: A report of the american college of cardiology foundation task force on clinical expert consensus documents (Writing Committee to Develop an Expert Consensus Document on Complementary and In. Journal of the American College of Cardiology. 2005;46:184-221.
6939.	JHMM V, CMA S, FG Z, et al. Randomised, Double-Blind, Placebo-Controlled Study of Fluoxetine in Chronic Fatigue Syndrome. Lancet. 1996;347:858-861.
6940.	JHMM V, FG Z, JFM F, JMD G, JWM VDM, Bleijenberg G. No effect of fluoxetine in chronic fatigue syndrome; randomized double-blind placebo-controlled trial. [Dutch]. Nederlands tijdschrift voor geneeskunde. 1997;141:1531-1535.
6941.	JI E. Overview of somatization: Diagnosis, epidemiology, and management. Psychopharmacology bulletin. 1996;32:589-596.
6942.	JI H, DG P, Gilaberte I, Wang F, JG W, MJ D. Duloxetine in the Treatment of Major Depressive Disorder: an Open-Label Study. BMC psychiatry. 2007;7.
6943.	JI H, HG P. The Concept of Affective Spectrum Disorder - Relationship to Fibromyalgia and Other Syndromes of Chronic Fatigue and Chronic Muscle Pain. Bailliere's clinical rheumatology. 1994;8:839-856.
6944.	JI H, LM A, LA B, et al. What Makes Patients With Fibromyalgia Feel Better? Correlations Between Patient Global Impression of Improvement and Changes in Clinical Symptoms and Function: a Pooled Analysis of 4 Randomized Placebo-Controlled Trials of Duloxetine. Journal of rheumatology. 2009;36:2517-2522.
6945.	JI H, MM W, DK K, CH M, JG W, OV M. Safety and Tolerability of Duloxetine in the Treatment of Major Depressive Disorder: Analysis of Pooled Data From Eight Placebo-Controlled Clinical Trials. Human Psychopharmacology-Clinical and Experimental. 2005;20:327-341.
6946.	JI H, SL M, NC R, et al. Fluvoxamine in the Treatment of Binge-Eating Disorder: a Multicenter Placebo-Controlled, Double-Blind Trial. American journal of psychiatry. 1998;155:1756-1762.
6947.	JI H, WP C, HG PJ. Antidepressant treatment of binge-eating disorder: Research findings and clinical guidelines. Journal of clinical psychiatry. 1996;57:73-79.
6948.	Ji Q, ZG L, YS T, YP M, HJ Y, CK S. [Effect of electroacupuncture intervention on behavioral changes and hippocampal excitatory amino acid transporter mRNA expression in depression rats]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2013;38:202-207,219.
6949.	Ji Q, ZG L, YS T, YP M, HJ Y, CK S. [Effect of electroacupuncture intervention on behavioral changes and hippocampal excitatory amino acid transporter mRNA expression in depression rats]. [Chinese]. Chen Tzu Yen Chiu Acupuncture Research. 2013;38:202-207.
6950.	JI R, Park C. The psychiatric management of patients with alcohol dependence. Current treatment options in neurology. 2007;9:381-392.
6951.	JI S, EL C, PM D, et al. Efficacy, Safety, and Tolerability of Sertraline in Patients With Late-Life Depression and Comorbid Medical Illness. Journal of the American Geriatrics Society. 2004;52:86-92.
6952.	JI S, Londborg P, CM C, Fayyad R. The Efficacy of Sertraline in Panic Disorder: Combined Results From Two Fixed-Dose Studies. International clinical psychopharmacology. 2000;15:335-342.
6953.	JI T, BJ A, DR S, MD S. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: A longitudinal study. American journal of drug and alcohol abuse. 2014;40:163-169.
6954.	Jia W, X-L Z, D-B Z, M-Y L. Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:4-5.
6955.	Jiahui Z, Peng S. Clinical observation on acupuncture treatment of depressive neurosis in 30 cases. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2006;26:191-192.
6956.	Jian-Jun O, Guang-Lei X, Ren-Rong W, et al. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology. 2011;213:639-646.
6957.	Jiancheng L, Yuhua C, Wentian D. Effect of Sertraline in Treatment of Dysthymia. [Chinese]. Chinese Mental Health Journal. 2004;18:265-266.
6958.	Jiang H, Deng M, Zhang Y, Chen H, Chen Q, Ruan B. Specific serotonin reuptake inhibitors prevent interferon-alpha-induced depression in patients with hepatitis c: A meta-analysis. Clinical gastroenterology and hepatology. 2014;12:1452-1460.
6959.	Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial, American heart journal(2012).
6960.	Jiang W, JA B. Depression and ischemic heart disease: Overview of the evidence and treatment implications. Current psychiatry reports. 2003;5:47-54.
6961.	Jiang W, Krishnan R, Kuchibhatla M, et al. Characteristics of Depression Remission and Its Relation With Cardiovascular Outcome Among Patients With Chronic Heart Failure (From the Sadhart-Chf Study). American journal of cardiology. 2011;107:545-551.
6962.	Safety and Efficacy of Sertraline for Depression in Patients With Chf (Sadhart-Chf): a Randomized, Double-Blind, Placebo-Controlled Trial of Sertraline for Major Depression With Congestive Heart Failure, American heart journal(2008).
6963.	Jiang W, Oken H, Fiuzat M, et al. Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients With Chronic Heart Failure and Major Depressive Disorder. Journal of cardiovascular translational research. 2012;5:92-99.
6964.	Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: A prospective, randomized trial of 28 patients, Journal of clinical psychiatry(2009).
6965.	Jianxue Y, Yonggan Z, Shufeng B. Controlled study on antidepressant treatment of patients with post-stroke depression. [Chinese]. Chinese Mental Health Journal. 2002;16:871-872.
6966.	Jiao S, C-S Y, Qin W, X-Y Y, Tu Y. Cerebral volume and magnetization transfer ratio indices in treatment evaluation on chronic stress model rats. [Chinese]. Chinese Journal of Medical Imaging Technology. 2007;23:1429-1432.
6967.	Jimenez F, Velasco F, Salin-Pascual R, et al. A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery. 2005;57:585-592.
6968.	Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. Expert Opinion on Orphan Drugs. 2013;1:423-436.
6969.	Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus excitalopram, the CAMPION study, Journal of clinical psychopharmacology(2014).
6970.	Jin Y, BG P, Frank E, et al. The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram. Journal of clinical pharmacology. 2009;49:176-184.
6971.	Jin Y, BG P, Frank E, et al. Effect of age on escitalopram exposure. Clinical pharmacology and therapeutics. 2009;Conference:S38.
6972.	A pilot study of the use of EEG-based synchronized Transcranial Magnetic Stimulation (sTMS) for treatment of Major Depression, BMC psychiatry(2014).
6973.	Jing D, Xu M, Chen Z, et al. Emotional disorders and tretment in patients with refractory irritable bowel syndrome. [Chinese]. Chinese Journal of Gastroenterology. 2004;9:90-93.
6974.	Jing L, Hua-Qing M, Wei D. Mirtazapine and Fluoxetine in the Treatment of Cardiovascular Neurosis with Depression. [Chinese]. Chinese Mental Health Journal. 2005;19:637-639.
6975.	Jingping Z, Qiuqing A, Jijun W, et al. A Comparative Efficacy of Fluoxetine and Trazodone in Depression with Remarkable Retardation and Loss of Energy: A Randomized Open-Label Trial. International Medical Journal. 2006;13:25-30.
6976.	JJ B, AB E, Friel P, et al. Consensus statement: The evaluation and treatment of people with epilepsy and affective disorders. Epilepsy & behavior. 2008;13:S1-S29.
6977.	JJ B, Anderson B, FA K, et al. Acute and long-term VNS effects on pain perception in a case of treatment-resistant depression. Neurocase. 2006;12:216-220.
6978.	JJ C, LS K, Wollner D, BA P. The Potential Role of 5-Hydroxytryptophan for Hot Flash Reduction: a Hypothesis. Alternative medicine review. 2005;10:216-221.
6979.	JJ C, Marsh L. Depression in parkinson's disease: Identification and management. Pharmacotherapy. 2013;33:972-983.
6980.	JJ C, MF L, Siderowf A. Treatment strategies and quality-of-care indicators for patients with Parkinson's disease. Journal of managed care pharmacy. 2009;15:S1-S21.
6981.	JJ C, WG O, Dashtipour K, DM S. Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature. Clinical therapeutics. 2012;34:1487-1504.
6982.	JJ D, AF L, IA C, JE K-G, Abrams M, Rosenberg-Thompson S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. Journal of affective disorders. 2000;60:13-23.
6983.	JJ G, CL T, CR AJ. Is there a link between aripiprazole and treatment-emergent psychosis? Current psychiatry. 2011;10:53-60.
6984.	JJ H, Teng E. Depressive symptoms in clinical and incipient Alzheimer's disease. Neurodegenerative disease management. 2013;3:147-155.
6985.	JJ J, LA Z, NC F. Sudden Gains in Prolonged Exposure and Sertraline for Chronic Ptsd. Depression and anxiety. 2013;30:607-613.
6986.	JJ L, Saiz J, Cottraux J, et al. Double-Blind Comparison of Fluoxetine Versus Clomipramine in the Treatment of Obsessive Compulsive Disorder. European neuropsychopharmacology. 1996;6:111-118.
6987.	JJ L, XR Y, SB S, et al. Effect and mechanism of fluoxetine on electrophysiology in vivo in a rat model of postmyocardial infarction depression. Drug design, development and therapy. 2015;9:763-772.
6988.	JJ L-IJ. Reduced suicidality with paroxetine. European psychiatry. 1993;8:17S-19S.
6989.	JJ M, Emslie G, RJ B, et al. Acnp Task Force Report on Ssris and Suicidal Behavior in Youth. Neuropsychopharmacology. 2006;31:473-492.
6990.	JJ M, FR L. Pharmacotherapy for alcohol-related disorders: What clinicians should know. Harvard review of psychiatry. 2004;12:351-366.
6991.	JJ M, FR L. Treatment strategies for co-occurring ADHD and substance use disorders. American Journal on Addictions. 2007;16:45-56.
6992.	JJ M, MS M, Sabai M, JW K. Serotonin-Selective Reuptake Inhibitors in the Treatment of Geriatric Depression and Related Disorders. International journal of neuropsychopharmacology. 1999;2:121-127.
6993.	JJ M, SV F. Estimating the size of treatment effects: Moving beyond P values. Psychiatry. 2009;6:21-29.
6994.	JJ M, SX X, Zee J, et al. Rhodiola Rosea Versus Sertraline for Major Depressive Disorder: a Randomized Placebo-Controlled Trial. Phytomedicine. 2015;22:394-399.
6995.	JJ N, MP D. Selegiline transdermal system: A novel treatment option for major depressive disorder. Expert opinion on pharmacotherapy. 2009;10:1665-1673.
6996.	JJ N, MP D, Kowatch R. Pharmacologic Treatment of Pediatric Bipolar Disorder. Child and adolescent psychiatric clinics of North America. 2009;18:455-469.
6997.	JJ P. Failure to treat tobacco use in mental health and addiction treatment settings: A form of harm reduction? Drug and alcohol dependence. 2010;110:177-182.
6998.	JJ P, DH M. Co-morbid bipolar and alcohol use disorders: A treatment-focused review. Journal of dual diagnosis. 2010;6:171-188.
6999.	JJ R, Harrison R. Successful treatment of bipolar disorder II and ADHD with a micronutrient formula: A case study. CNS spectrums. 2010;15:289-295.
7000.	JJ S, Kashkin K, Jasinsky O, Kardatzke D, Kennedy S, NR C. Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder. Depression. 1995;3:199-203.
7001.	JJ S, NR C. The Impact of gender on antidepressants. Biological Basis of Sex Differences in Psychopharmacology. 2011;Current To:231-249.
7002.	JJ S, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Journal of clinical psychiatry. 1996;57:287-291.
7003.	JJ T, TJ W, RK L, PG L, AE B. Cognitive-behavioral treatment of body image disturbance in a congenitally blind patient with anorexia nervosa. American journal of psychiatry. 2012;169:16-20.
7004.	JJ X, MJ C, YC Y. Fluoxetine as a Treatment for Post-Traumatic Stress Disorder. Neurosciences (Riyadh, Saudi Arabia). 2011;16:257-262.
7005.	Jjdl M. Premenstrual Dysphoric Disorder: Fluoxetine Long-Term Treatment and Discontinuation. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1997;25:235-242.
7006.	JJG M, RIR M, Briz O, et al. Cholestasis during pregnancy: Aetiopathogenesis, foetal-maternal repercussions and pharmacological treatments. Current women's health reviews. 2007;3:235-247.
7007.	JJL I, JL C, Prieto R, Garcia-Calvo C. Effectiveness and Safety of Venlafaxine Extended Release in Elderly Depressed Patients. Archives of gerontology and geriatrics. 2008;46:317-326.
7008.	JJM D, JA K, HL V, et al. Speed of action: The relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. Journal of affective disorders. 2008;109:183-188.
7009.	JK B. Treatment of adolescent depression: Some substantive issues. International journal of neuropsychopharmacology. 2012;Conference:6.
7010.	JK C, Kohli S, KM M, JA R, GR M. Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007;12:43-51.
7011.	JK G, LE A, BJ A. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: Current evidence and practice. Journal of child and adolescent psychopharmacology. 2008;18:413-447.
7012.	JK H. Two studies confirm the efficacy of sertraline for the treatment of depression in children and adolescents. [Dutch]. Pharmaceutisch weekblad. 2003;138:1616-1617.
7013.	JK M, HJ W, Harper E, McCormack J, Nguyen T. Psychotropic drug prescribing in an Australian specialist child and adolescent eating disorder service: A retrospective study. Journal of Eating Disorders. 2013.
7014.	JK R. Long-term pharmacological treatment of bipolar disorders. Neuro endocrinology letters. 2007;28:71-93.
7015.	JK R. Bipolar mood disorder and treatment-resistant depression. Annals of general psychiatry. 2010;Conference:S14.
7016.	JK R. Antidepressant activity of mood stabilizers. Clinical Neuropsychiatry. 2012;9:157-165.
7017.	JK R, DL M, CB N. The relationship of depression and diabetes: Pathophysiological and treatment implications. Psychoneuroendocrinology. 2011;36:1276-1286.
7018.	JK R, TA S, KA H, DL M. Diagnosis and treatment of depression in patients with congestive heart failure: A review of the literature. Primary care companion to the Journal of clinical psychiatry. 2013.
7019.	JK S, JF P, SE L, et al. Measures of temperament and character are differentially impacted on by depression severity. Journal of affective disorders. 2010;126:140-146.
7020.	Novel therapeutic targets in depression: Minocycline as a candidate treatment, Behavioural brain research(2012).
7021.	The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression?, Neurotoxicology(2009).
7022.	JK T, Kar S. Focus issues in dysthymia. Neuropsychiatry. 2011;1:291-297.
7023.	JK W, JC B, DW M. Depressive symptoms associated with gonadotropin-releasing hormone agonists. [Review] [45 refs]. Depression and anxiety. 1998;7:171-177.
7024.	JK W, JClark B, DW M. Depressive Mood Symptoms Associated With Ovarian Suppression. Fertility and sterility. 2000;74:984-986.
7025.	JK Z, AC P, MA D. Two year follow-up of atypical depression. Journal of psychiatric research. 1999;33:23-29.
7026.	Treating depression within the HIV medical home: A guided algorithm for antidepressant management by HIV clinicians, AIDS patient care and STDs(2012).
7027.	JL A-G. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World journal of biological psychiatry. 2005;6:31-37.
7028.	JL B. Managing depression in geriatric populations. Annals of clinical psychiatry. 2007;19:221-238.
7029.	JL B, IIR LP, JM R. Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors. Neurologic clinics. 2008;26:85-96.
7030.	JL B, SP W, WJ B. Depression in Parkinson's Disease: An Update. Parkinson's Disease and Nonmotor Dysfunction. 2013;Current Cl:3-15.
7031.	JL C. The safety and efficacy of paroxetine compared with placebo in a double- blind trial of depressed outpatients. Journal of clinical psychiatry. 1992;53 Suppl:33-35.
7032.	JL C. Mirtazapine: A novel noradrenergic and specific serotonergic antidepressant. Today's Therapeutic Trends. 1996;14:141-164.
7033.	JL C. Progress in neurotherapeutics and neuropsychopharmacology 2008. Progress in Neurotherapeutics and Neuropsychopharmacology. 2008;3:1-11.
7034.	JL C. Psychopharmacologic Control of Aggression and Violence in Children and Adolescents. Pediatric clinics of North America. 2011;58:73-84.
7035.	JL C, CQ E, DD W, et al. Fluvoxamine maleate in the treatment of depression: A single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. Journal of clinical psychopharmacology. 1996;16:113-120.
7036.	JL C, Diaz-Marsa M, Saiz J. [Sertraline in the treatment of mixed anxiety and depression disorder]. [Spanish]. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1997;25:141-145.
7037.	JL C, EE J, SL S, SA A. The effectiveness of 6-azamianserin (Org 3770) in depressed outpatients. Psychopharmacology bulletin. 1987;23:160-161.
7038.	JL C, JP F. A Double-Blind Comparison of Paroxetine With Imipramine in the Long-Term Treatment of Depression. Journal of clinical psychopharmacology. 1993;13:S23-S27.
7039.	JL C, LB M, FD F. The Efficacy of the Combination of Sertraline With Buspirone for Smoking Cessation - a Randomized Clinical Trial in Nondepressed Smokers. European archives of psychiatry and clinical neuroscience. 2007;257:383-388.
7040.	JL C, Mcrae T, Zhang R. Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders. American journal of geriatric psychiatry. 2006;14:605-612.
7041.	JL C, MD L. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. Journal of affective disorders. 1995;34:165-171.
7042.	JL C, Sandner C. Clinical Effects of Pharmacological Variations in Selective Serotonin Reuptake Inhibitors: an Overview. International journal of clinical practice. 2005;59:1428-1434.
7043.	JL D, JL T. [Is the suicidal risk assessment scale RSD of predictive value?]. [French]. L'Enc�phale. 2006;32:738-745.
7044.	JL D, JL T. Is the suicidal risk assessment scale RSD of predictive value?. [French]. Encephale. 2006;32:738-745.
7045.	JL E, KK K, CK M. Benefits and harms of pediatric antidepressant medications [8]. Journal of the American Medical Association. 2007;298:626-627.
7046.	JL F, Montgomery S, Francois C. Evaluation of the Cost Effectiveness of Escitalopram Versus Venlafaxine Xr in Major Depressive Disorder. PharmacoEconomics. 2005;23:155-167.
7047.	JL F, PJ P, MJ G, MW K. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. Journal of affective disorders. 1990;18:275-280.
7048.	JL G. Antidepressants use in pediatric populations. Expert opinion on drug safety. 2008;7:223-225.
7049.	JL G, SS G. Hormone Replacement Therapy in the Treatment of Perimenopausal Depression. Current psychiatry reports. 2014.
7050.	JL H, Karachi C, Mallet L, et al. Tourette's syndrome and deep brain stimulation. Journal of neurology, neurosurgery, and psychiatry. 2005;76:992-995.
7051.	JL H, KP M, MH P, PA S. Disseminated intravascular coagulation, meningococcal infection, and ischemic changes affecting the lower extremities: A case study. Journal of foot and ankle surgery. 2010;49:489.e485-489.e489.
7052.	JL J, PG OM, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS spectrums. 2006;11:212-222.
7053.	JL K, FW R. Effects of placebo washout and dose in a comparison of sertraline and amitriptyline [1]. Journal of clinical psychiatry. 1991;52:386.
7054.	JL K, JL G. Duloxetine: An antidepressant that inhibits both norepinephrine and serotonin uptake. Formulary (Cleveland, Ohio). 2003;38:29-37.
7055.	JL K, JL G. Duloxetine: a Dual Serotonin-Norepinephrine Reuptake Inhibitor for Treatment of Major Depressive Disorder. Pharmacotherapy. 2005;25:396-410.
7056.	JL K, JL G. Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. [Review] [69 refs]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 2005;25:396-410.
7057.	JL M, CS B. The Use of Monoamine Pharmacological Agents in the Treatment of Sexual Dysfunction: Evidence in the Literature. Journal of sexual medicine. 2011;8:956-970.
7058.	JL M, Ruff D, Ahl J, MM W. Safety and Efficacy of Duloxetine Treatment in Older and Younger Patients With Osteoarthritis Knee Pain: a Post Hoc, Subgroup Analysis of Two Randomized, Placebo-Controlled Trials. BMC musculoskeletal disorders. 2013;14.
7059.	JL P. Antidepressant use in the postpartum period: Practical considerations. American journal of psychiatry. 2007;164:1329-1332.
7060.	JL R. Initial conditions of psychotropic drug response: Studies of serotonin transporter long promoter region (5-HTTLPR), serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:1046-1051.
7061.	JL R. Depression later in life - An approach for the family practitioner. South African family practice. 2008;50:38-43.
7062.	JL R, Lencer R, JR B, Keedy S, JA S. Pharmacological treatment effects on eye movement control. Brain and cognition. 2008;68:415-435.
7063.	JL R, Lencer R, ME T, JA S. Effects of sertraline on neurocognition in outpatients with major depressive disorder. Neuropsychopharmacology. 2011;Conference:S117-S118.
7064.	JL R, Weston S, Plouffe L. Role of Psychotropic Medication in the Treatment of Affective Symptoms in Premenstrual-Syndrome. Clinical obstetrics and gynecology. 1992;35:667-678.
7065.	JL S. Fibromyalgia syndrome in women. Nursing clinics of North America. 2004;39:195-204.
7066.	JL T, SA M. Fluvoxamine prevents recurrence of depression: Results of a long-term, double-blind, placebo-controlled study. International clinical psychopharmacology. 1998;13:55-62.
7067.	Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults, American journal of psychiatry(2013).
7068.	JL W, CR A, JT S, et al. Modular psychotherapy for anxiety in older primary care patients. American journal of geriatric psychiatry. 2009;17:483-492.
7069.	JL W, JA S, KS W, et al. Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study. International journal of geriatric psychiatry. 2011;26:869-875.
7070.	JL W, XC L, CD M. Treatment Adherence and Persistence With Duloxetine, Venlafaxine Xr, and Escitalopram Among Patients With Major Depressive Disorder and Chronic Pain-Related Diseases. Current medical research and opinion. 2011;27:1303-1313.
7071.	JM A, Cabane J, Ferreri M, Bougerol T. Efficacy and acceptability of tianeptine in major depressive disorder and in dysthymia (DSM-IIIR) with somatic complaints: Double blind study versus fluoxetine. European neuropsychopharmacology. 1993;3:333.
7072.	JM A, Ferreri M, Cabane J, C DB, Dagens V. Efficacy of tianeptine (Stablon) for the treatment of major depression and dysthymia with somatic complaints. A comparative study versus fluoxetine (Prozac). [French]. Annales de Psychiatrie. 1993;8:136-144.
7073.	JM A, SJ M. Glutamate and anxiety disorders. Current psychiatry reports. 2007;9:278-283.
7074.	JM B. Tired of the questions: Deciphering cancer-related fatigue. Journal of supportive oncology. 2006;4:520-521.
7075.	JM B. A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clinic proceedings. 2010;85:538-550.
7076.	JM B, BF J, Steurer J, Held U, MM W. Treatment efficacy for non-cardiovascular chest pain: A systematic review and meta-analysis. PloS one. 2014.
7077.	JM B, Enning F, FM L. Repurposed drugs for the treatment of schizophrenia and bipolar disorders. Current topics in medicinal chemistry. 2013;13:2364-2385.
7078.	JM B, MacESE, PL H, AM D, RD G, CR W. Children's mental health emergencies-part 2: Emergency department evaluation and treatment of children with mental health disorders. Pediatric emergency care. 2008;24:485-498.
7079.	JM B, Strub N, Nil R, et al. Citalopram and viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial. Journal of affective disorders. 1997;46:51-58.
7080.	JM B-R, Zhong C, Kohnken R, et al. Comparison of Mechanical Allodynia and the Affective Component of Inflammatory Pain in Rats. Neuropharmacology. 2010;58:537-543.
7081.	JM C, Frank E, Winter E, et al. Personality pathology and outcome in recurrently depressed women over 2 years of maintenance interpersonal psychotherapy. Psychological medicine. 2004;34:659-669.
7082.	JM C, LA C, Y-F C, DA H, Unutzer J. The presentation, recognition and management of bipolar depression in primary care. Journal of general internal medicine. 2013;28:1648-1656.
7083.	JM C, RD C, LA C, Qualls C, VB T. Bupropion Treatment in Veterans With Posttraumatic Stress Disorder: an Open Study. Journal of clinical psychopharmacology. 1998;18:379-383.
7084.	JM D. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: A naturalistic follow up study. Journal of Serotonin Research. 1996;2:267-270.
7085.	JM D, MJ O, Huffman J, RH P, AA N. A critical review of pharmacotherapy for major depressive disorder. International journal of neuropsychopharmacology. 2011;14:1417-1431.
7086.	JM D, Wilens T. The use of tricyclic antidepressants in children and adolescents. Pediatric clinics of North America. 1998;45:1123-1135.
7087.	JM E. A 60-year-old woman with mild memory impairment: Review of mild cognitive impairment. JAMA - Journal of the American Medical Association. 2008;300:1566-1574.
7088.	JM E, TK M, Croarkin P, SM M. A systematic overview of measurement-based care in the treatment of childhood and adolescent depression. Journal of psychiatric practice. 2010;16:217-234.
7089.	JM F. The effects of antidepressants on sexual functioning in depressed patients: a review. [Review] [25 refs]. Journal of clinical psychiatry. 2001;62 Suppl 3:22-34.
7090.	JM F. Depression treatment with SSRI in child and adolescent psychiatry. A debacle of research or information?. [German]. Nervenheilkunde. 2004;23:60-64.
7091.	JM F, Canhao P. Acute treatment of cerebral venous and dural sinus thrombosis. Current treatment options in neurology. 2008;10:126-137.
7092.	JM F, Janhsen K, Boge I. Drug therapy of depression in childhood and adolescence. What to do in face of multiple warning against SSRI and SNRI?. [German]. Psychopharmakotherapie. 2006;13:84-94.
7093.	JM F, Janhsen K, Boge I. Drug Therapy of Depression in Childhood and Adolescence. What to Do in Face of Multiple Warning Against Ssri and Snri? Psychopharmakotherapie. 2006;13:84-+.
7094.	JM F, JP F. Fluoxetine-induced weight loss in overweight non-depressed humans. International journal of obesity. 1987;11 Suppl 3:163-170.
7095.	JM F, KA T, GR R. High-Dose Desvenlafaxine in Outpatients With Major Depressive Disorder. CNS spectrums. 2012;17:121-130.
7096.	JM F, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. Journal of clinical psychiatry. 2007;68:58-68.
7097.	JM F, Mendels J, NR M. Dothiepin Versus Doxepin in Major Depression - Results of a Multicenter, Placebo-Controlled Trial. Journal of clinical psychiatry. 1994;55:258-263.
7098.	JM G. Mirtazapine: clinical overview. [Review] [24 refs]. Journal of clinical psychiatry. 1999;60 Suppl 1:8-9.
7099.	JM G. Ever-present adverse effects. CNS spectrums. 2004;9:796.
7100.	JM G. Gender differences in depression and response to psychotropic medication. Gender medicine. 2006;3:93-109.
7101.	JM G, Bogousslavsky J. Post-stroke depression. Expert review of neurotherapeutics. 2008;8:75-92.
7102.	JM G, CB N, DS C. The role of norepinephrine in the treatment of depression. Journal of clinical psychiatry. 1999;60:623-631.
7103.	JM G, JM K. Ssris and Snris: Broad Spectrum of Efficacy Beyond Major Depression. Journal of clinical psychiatry. 1999;60:33-39.
7104.	JM G, JP H, DG S. Measurement of pain and medication effect in a study of duloxetine. Journal of clinical psychiatry. 2008;69:1022.
7105.	JM G, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS spectrums. 2002;7:40-44.
7106.	JM G, LA B, PS C, JR M, JW W. Smoking cessation interventions for patients with depression: A systematic review and meta-analysis. Journal of general internal medicine. 2012;27:351-360.
7107.	JM G, LA P. Efficacy of venlafaxine in mixed depression-anxiety states. Depression and anxiety. 2000;12:77-80.
7108.	JM G, PM T, TA M. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient preference and adherence. 2011;5:333-341.
7109.	JM G, Sullivan G. Noradrenergic Approaches to Antidepressant Therapy. Journal of clinical psychiatry. 2000;61:13-16.
7110.	JM G-V. Treatment of non cognitive symptoms of Alzheimer's disease. [Spanish]. Revista de neurologia. 2006;42:482-488.
7111.	JM H. On the usefulness of clinical case studies. Bipolar disorders. 2003;5:69-71.
7112.	JM H, Schaaf L, Fulda S. Glucose metabolism and antidepressant medication. Current pharmaceutical design. 2012;18:5900-5919.
7113.	JM H, Schaaf L, Fulda S. Glucose metabolism and antidepressant medication. [Review]. Current pharmaceutical design. 2012;18:5900-5919.
7114.	JM J, AE H. Alprazolam and Suicidal Ideation: a Meta-Analysis of Controlled Trials in the Treatment of Depression. Journal of clinical psychopharmacology. 1996;16:208-211.
7115.	JM J, RS M. Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: A retrospective cohort study. Primary care companion to the Journal of clinical psychiatry. 2010;12:e1-e8.
7116.	JM K, KY B, Stewart R, et al. Escitalopram Treatment for Depressive Disorder Following Acute Coronary Syndrome: a 24-Week Double-Blind, Placebo-Controlled Trial. Journal of clinical psychiatry. 2015;76:62-U138.
7117.	Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial, Journal of clinical psychiatry(2015).
7118.	JM K, Stewart R, KY B, et al. Effects of Depression Co-Morbidity and Treatment on Quality of Life in Patients With Acute Coronary Syndrome: the Korean Depression in Acs (K-Depacs) and the Escitalopram for Depression in Acs (Esdepacs) Study. Psychological medicine. 2015;45:1641-1652.
7119.	JM K, WW F, Hansen L, Perlis R, IIIA P, Assuncao-Talbott S. Akathisia: An updated review focusing on second-generation antipsychotics. Journal of clinical psychiatry. 2009;70:627-643.
7120.	JM KH, PMC DJ, DP D, Montgomery S. Sertraline in the prevention of depression [3]. British journal of psychiatry. 1992;161:270-272.
7121.	Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate, Journal of clinical psychopharmacology(2008).
7122.	JM L, Huckans M, BJ M. Neuroimmune mechanisms of cytokine-induced depression: Current theories and novel treatment strategies. Neurobiology of disease. 2010;37:519-533.
7123.	JM LM, Mailo K, Lara N, et al. Paroxetine-Induced Increase in Ldl Cholesterol Levels. Journal of psychopharmacology (Oxford, England). 2009;23:826-830.
7124.	JM M. Review of the efficacy and safety of available antidepressants in the treatment of depression in patients with comorbid medical illness. Primary care companion to the Journal of clinical psychiatry. 2006;7:290-293.
7125.	JM M, JP M, AM R, et al. Prospective relationship between obsessive-compulsive and depressive symptoms during multimodal treatment in pediatric obsessive-compulsive disorder. Child psychiatry and human development. 2014;45:163-172.
7126.	JM M, NS S, LA Z. Tinnitus-related distress: A review of recent findings. Current psychiatry reports. 2011;13:31-36.
7127.	JM M, Schneck N, GJ S, et al. fMRI response to negative words and SSRI treatment outcome in major depressive disorder: a preliminary study.[Erratum appears in Psychiatry Res. 2014 Jun 30;222(3):173-5]. Psychiatry research. 2013;214:296-305.
7128.	JM M, Schneck N, GJ S, et al. An emotional words fmri task predicts treatment outcome with standardized pharmacotherapy for depression. Biological psychiatry. 2012;Conference:244S.
7129.	JM M, SR P-P. Eszopiclone: Its use in the treatment of insomnia. Neuropsychiatric disease and treatment. 2007;3:441-453.
7130.	JM M, VR P-G, AM W. A Double-Blind Comparison of Fluvoxamine and Dothiepin in the Treatment of Major Affective-Disorder. British journal of clinical practice. 1988;42:51-55.
7131.	JM N, BE B, R VH, RV H, Kwok Y, WE C. Heart Failure. Clinical Problem and Management Issues. Primary Care - Clinics in Office Practice. 2013;40:17-42.
7132.	JM P. Medical disease offset versus medical cost offset. Drug Benefit Trends. 2001;13:22-23.
7133.	JM P. The diabetes and depression connection. Drug Benefit Trends. 2001;13:2BH-3BH.
7134.	JM P. Patient noncompliance with medication: Antidepressants. Drug Benefit Trends. 2002;14:22-23.
7135.	JM P. Viagra and medical necessity. Drug Benefit Trends. 2002;14:33+40.
7136.	JM P. SSRIs require thoughtful prescribing, careful monitoring. Drug Benefit Trends. 2003;15:44-46.
7137.	JM P. Pramipexole as a psychiatric medication. Drug Benefit Trends. 2003;15:25-26.
7138.	JM P. Lithium treatment of bipolar disorder: Still the gold standard. Drug Benefit Trends. 2004;16:325-326.
7139.	JM P. Neuroimaging opens window on biologic manifestations of depression and recovery. Drug Benefit Trends. 2004;16:429-430.
7140.	JM P. Eating disorders: When is medication use appropriate? Drug Benefit Trends. 2005;17:364-365.
7141.	JM P. Atypical antipsychotics for treating major depression. Drug Benefit Trends. 2009;21:244-245.
7142.	JM P. Weighing the benefits of reformulated medications. Drug Benefit Trends. 2009;21:29-30.
7143.	JM P, DJ K, RM Y, Stubbs B, Bradizza N. Impact of cognitive behaviour therapy via mail for cessation of benzodiazepine use: A series of case reports. Behaviour change. 2013;30:74-83.
7144.	JM P, Fernandez-Lorente G, Ortiz C, et al. Conformational engineering of lipases via directed immobilisation: Improving the resolution of chiral drugs. Medicinal Chemistry Reviews - Online. 2005;2:369-378.
7145.	A Comparison of Low-Dose Risperidone to Paroxetine in the Treatment of Panic Attacks: a Randomized, Single-Blind Study, BMC psychiatry(2009).
7146.	JM R, MJ D. Depressed youth, suicidality and antidepressants. No cause for panic, but an incentive to improve clinical practice. Medical journal of Australia. 2005;182:378-379.
7147.	JM R, Salzman C. Update: New uses for lithium and anticonvulsants. CNS spectrums. 2007;12:831-841.
7148.	JM R-T. The hypersensitive esophagus: Pathophysiology, evaluation, and treatment options. Current gastroenterology reports. 2010;12:417-426.
7149.	JM T, Gomez G, Barrios R, Holguin J, Adrianzen C. Differential time course efficacy on dysphoric and physical symptoms of the intermittent dosing of fluoxetine in the premenstrual dysphoric disorder [14]. Journal of clinical psychopharmacology. 2004;24:469-471.
7150.	JM T, Mejia-Rodriguez D, AM N-M, LM A-A, Vazquez G, Vieta E. Therapy of no-type I bipolar spectrum disorders: A systematic review. Current psychiatry reviews. 2013;9:41-50.
7151.	JM T, MH G. TCAs or SSRIs as initial therapy for depression? Journal of family practice. 1999;48:845-846.
7152.	JM T, Payakachat N. Progress in measuring family spillover effects for economic evaluations. Expert review of pharmacoeconomics & outcomes research. 2015;15:195-198.
7153.	JM V, MF P, Benkelfat C, et al. Diagnostic and therapeutic value of testing stimulation of thyroid-stimulating hormone by thyrotropin-releasing hormone in 100 depressed patients. Acta psychiatrica Scandinavica. 1990;81:156-161.
7154.	JM W, GJ M, BG J, DD S. Metabotropic glutamate receptors in the control of mood disorders. CNS and Neurological Disorders - Drug Targets. 2007;6:87-100.
7155.	JM Z. The Effect of Nefazodone on Comorbid Anxiety Symptoms Associated With Depression: Experience in Family Practice and Psychiatric Outpatient Settings. Journal of clinical psychiatry. 1996;57:10-14.
7156.	JM Z. Treating Depression to Remission. Journal of clinical psychiatry. 2003;64:7-12.
7157.	JM Z, Albano D. SNRIs in the management of acute major depressive disorder. [Review] [68 refs]. Journal of clinical psychiatry. 2004;65 Suppl 1:11-18.
7158.	JM Z, Albano D. Snris in the Management of Acute Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:11-18.
7159.	JM Z, AT D, CJ K, DJ S, JM F, LL G. Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child and adolescent psychiatry and mental health. 2008.
7160.	JM Z, DJ S, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121:e157-e163.
7161.	JMA S, Zivkov M. Mirtazapine. Clinical profile. CNS drugs. 1995;4:39-48.
7162.	JMW B. The role of serotonin in the future of forensic psychiatry. Bulletin of the American Academy of Psychiatry and the Law. 1996;24:57-72.
7163.	JMX dA, PTM S, VM P, ACO eS, AE N. The carbon dioxide challenge test in panic disorder: A systematic review of preclinical and clinical research. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2013;35:318-331.
7164.	JN A, Buskila D. Emerging Therapies for Fibromyalgia: an Update. Expert opinion on emerging drugs. 2010;15:521-533.
7165.	JN B. [Current methodologies and clinical research]. [Review] [6 refs] [French]. Encephale. 1996;22 Spec No:57-61.
7166.	JN C, Merlet B, Ciofu C, et al. Duloxetine for Mild to Moderate Postprostatectomy Incontinence: Preliminary Results of a Randomised, Placebo-Controlled Trial. European urology. 2011;59:148-154.
7167.	JN F, TL S. Obsessive-compulsive disorder: Diagnosis and management. American family physician. 2009;80:239-245.
7168.	JN J, AL T. Clinical practice guidelines for depression in young people. Medical journal of Australia. 2003;178:300; author reply 300-302.
7169.	JN J, AL T, RTW C, JM R, PL H. Clinical practice guidelines for depression in young people (multiple letters). Medical journal of Australia. 2003;178:300-302.
7170.	JN J, CJ D, PR M, MM H, DB M, AL T. Efficacy and Safety of Antidepressants for Children and Adolescents. British medical journal. 2004;328:879-883.
7171.	JN J, CJ D, PR M, MM H, DB M, AL T. Efficacy and Safety of Antidepressants for Children and Adolescents. British medical journal. 2004;328:879-883.
7172.	JN J, LB M. Key opinion leaders and paediatric antidepressant overprescribing. Psychotherapy and psychosomatics. 2009;78:197-201.
7173.	JN J, LB M, PR M. Clinical trials and drug promotion: Selective reporting of study 329. International journal of risk & safety in medicine. 2008;20:73-81.
7174.	JN K, HO K, GS G, et al. Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample. Journal of clinical child and adolescent psychology. 2009;38:768-780.
7175.	JN R, ESR E, LA N. Ramelteon: A novel approach in the treatment of insomnia. Annals of pharmacotherapy. 2008;42:1262-1271.
7176.	JN W. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophrenia bulletin. 1997;23:215-228.
7177.	JN W, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Annals of pharmacotherapy. 2009;43:707-713.
7178.	JO B, Spigset O. Psychiatric disorders during pregnancy and lactation: Recent advances in treatment. [Norwegian]. Tidsskrift for den Norske laegeforening. 2003;123:2037-2040.
7179.	Joakim R, Christian A, Martin H. Effectiveness and cost-effectiveness of antidepressants in primary care: A multiple treatment comparison meta-analysis and cost-effectiveness model. PloS one. 2012;7.
7180.	Dynamic prediction of treatment response in late-life depression, The American Journal of Geriatric Psychiatry(2014).
7181.	Dynamic prediction of treatment response in late-life depression, American journal of geriatric psychiatry(2014).
7182.	Joel I, Begley A, BH M, et al. Dynamic treatment response prediction in late-life depression. American journal of geriatric psychiatry. 2012;Conference:S75-S77.
7183.	Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial, American journal of psychiatry(2007).
7184.	Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder, Journal of clinical psychopharmacology(2008).
7185.	Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: Outcomes following randomized switch to either duloxetine or escitalopram, Journal of psychiatric research(2012).
7186.	Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder, International psychogeriatrics / IPA(2008).
7187.	Joffe H, LF P, AC V, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report. Journal of clinical psychiatry. 2007;68:1954-1962.
7188.	Joffe H, Partridge A, Giobbie-Hurder A, et al. Augmentation of Venlafaxine and Selective Serotonin Reuptake Inhibitors With Zolpidem Improves Sleep and Quality of Life in Breast Cancer Patients With Hot Flashes: a Randomized, Double-Blind, Placebo-Controlled Trial. Menopause-the Journal of the North American Menopause Society. 2010;17:908-916.
7189.	Joffe R, Sokolov S, Streiner D. Antidepressant Treatment of Depression: a Metaanalysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1996;41:613-616.
7190.	Johansson D, Falk A, MM M, TH S. Celecoxib Enhances the Effect of Reboxetine and Fluoxetine on Cortical Noradrenaline and Serotonin Output in the Rat. Progress in neuro-psychopharmacology & biological psychiatry. 2012;39:143-148.
7191.	John C, Inmaculada G, Durisala D, K KD. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. International clinical psychopharmacology. 2006;21:267-273.
7192.	John C, Susan S, Paul R, et al. Onset of alcohol or substance use disorders following treatment for adolescent depression. Journal of consulting and clinical psychology. 2012;80:299-312.
7193.	John C, Susan S, Paul R, et al. Recovery and recurrence following treatment for adolescent major depression. Archives of general psychiatry. 2011;68:263-270.
7194.	John G, K MR, H MC, N RJ, Joel R. Incidence and Duration of Antidepressant-lnduced Nausea: Duloxetine Compared with Paroxetine and Fluoxetine. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2004;26:1446-1455.
7195.	John K, Ian F, Shahrokh G, Ellen S, Thomas M, Sidney Z. Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: Effect of age on response. The American Journal of Geriatric Psychiatry. 2010;18:853-857.
7196.	John K, Nicole L, Thomas P, et al. Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: Effect on functioning. International journal of geriatric psychiatry. 2010;25:183-190.
7197.	John L, Thomas P, Elias T, Andreas R. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:55-60.
7198.	John M, Adrian L, Ernest B, Robin M, Singh BG, George F. A multicentre, double-blind, amitriptyline controlled study of mirtazapine in patients with major depression. Journal of psychopharmacology (Oxford, England). 1996;10:235-240.
7199.	John RA, Anjana B. Escitalopram in Clinical Practice: Results of an Open-Label Trial in a Naturalistic Setting. Depression and anxiety. 2005;21:26-32.
7200.	John RA, Diane W, R WS, et al. STAR*D: Revising conventional wisdom. CNS drugs. 2009;23:627-647.
7201.	John RA, H TM, J CT, et al. Response in related to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology. 2001;25:131-138.
7202.	John RA, H TM, R WS. Depression--Augmentation or Switch after Initial SSRI Treatment: Reply. New England journal of medicine. 2006;354:2612-2613.
7203.	John RA, H TM, W SJ, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. 2013:85-97.
7204.	Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study, American journal of psychiatry(2011).
7205.	John RA, M KL, B KM, et al. The treatment of chronic depression, Part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Journal of clinical psychiatry. 1998;59:589-597.
7206.	John RA, R BS, J DRM, A AJ, J CT, Alan M. Does pretreatment anxiety predict response to either bupropion SR or sertraline? [References]. Journal of affective disorders. 2001;64:81-87.
7207.	Selecting among second-step antidepressant medication monotherapies: Predictive value of clinical, demographic, or first-step treatment features, Archives of general psychiatry(2008).
7208.	John S. Tailored treatment for depression with co-morbid dementia. Australian and New Zealand journal of psychiatry. 2012;46:678-679.
7209.	John S-F, Rita S-F. Efficacy of antidepressant medication with depressed youth: What psychologists should know. Professional psychology, research and practice. 1996;27:145-153.
7210.	John W, L GK. Escitalopram : a review of its use in the management of major depressive and anxiety disorders. [Review] [64 refs]. CNS drugs. 2003;17:343-362.
7211.	John Z, Jan F, Jay A, et al. Safety of abrupt discontinuation of fluoxetine: A randomized, placebo- controlled study. Journal of clinical psychopharmacology. 1998;18:193-197.
7212.	Jon J, Barbara M. Does venlafaxine maintenance therapy prevent depression recurrences or drug discontinuation reactions? [References]. Journal of clinical psychiatry. 2008;69:865-866.
7213.	Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial, Pain(2008).
7214.	Jonas H, Nicole D, Nyrma O, Brian P, Zubin B. Citalopram reduces endotoxin-induced fatigue. Brain, behavior, and immunity. 2011;25:256-259.
7215.	Jonas J, Bose A, GS A, Gommoll C, DY L, Gandhi C. Double-Blind Comparison of Escitallopram and Duloxetine in the Acute Treatment of Major Depressive Disorder. Neuropsychopharmacology. 2006;31:S166.
7216.	Jonas W, Wheatley D, GI S, et al. St John's wort and depression [1] (multiple letters). Journal of the American Medical Association. 2002;288:446-449.
7217.	Jonassen R, Chelnokova O, Harmer C, Leknes S, Landro NI. A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology. 2015;232:953-958.
7218.	Jonathan C, Harald A, Kurt H. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: A one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug and alcohol dependence. 2004;74:61-70.
7219.	Jonathan D, Lana W, Michael O, et al. Effects of Paroxetine and Venlafaxine XR on Heart Rate Variability in Depression. Journal of clinical psychopharmacology. 2005;25:480-484.
7220.	Jonathan P, J HD, Inbal G, et al. Antidepressants normalize the default mode network in patients with dysthymia. JAMA Psychiatry. 2013;70:373-382.
7221.	Jong E, LA O, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS (London, England). 2010;24:1387-1405.
7222.	Jonsson B, PE B. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British journal of psychiatry. 1994;164:665-673.
7223.	Jorge CeS. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Journal of clinical psychiatry. 1998;59:352-357.
7224.	Jorge CeS. "Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression": Reply. Journal of clinical psychiatry. 1999;60:339-340.
7225.	Jose-Luis F, Stuart M, Clement F. Evaluation of the Cost Effectiveness of Escitalopram versus Venlafaxine XR in Major Depressive Disorder. PharmacoEconomics. 2005;23:155-167.
7226.	Joseph B, Chanoch M, Yuly B, et al. Curcumin as an add-on to antidepressive treatment: A randomized, double-blind, placebo-controlled, pilot clinical study. Clinical neuropharmacology. 2013;36:73-77.
7227.	Joseph M, Robert J, A MJ, Robert R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology bulletin. 1993;29:169-174.
7228.	Joseph Z. Fluvoxamine in the treatment of severe depression. Primary Care Psychiatry. 2004;9:115-119.
7229.	Joseph Z, Harman K, Lucien B. Fluvoxamine as effective as clomipramine against symptoms of severe depression: Results from a multicentre, double-blind study. Human Psychopharmacology: Clinical and Experimental. 2003;18:113-119.
7230.	Josephine NL. The impact of childhood trauma on treatment response of depressed adolescents. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2007;68:1316.
7231.	Jost W. Duloxetine (Yentreve, Cymbalta). [German]. Tagliche Praxis. 2006;47:429-434.
7232.	Jost W. Duloxetin. [German]. Chirurgische Praxis. 2006;65:735-740.
7233.	Jost W. Duloxetin (Yentreve, Cymbalta). [German]. Padiatrische Praxis. 2006;68:333-338.
7234.	Jotwani V, KG H. Postconcussion syndrome in athletes. Current sports medicine reports. 2010;9:21-26.
7235.	Jouvent R. Dihydrergocryptine plus caffeine in treatment of migraine: A randomized double-blind trial against placebo. [French]. Gazette Medicale. 1989;96:41-46.
7236.	Joyce W, Arnold L, Bernard B. Clinical development of citalopram. Journal of clinical psychopharmacology. 1999;19:36S-46S.
7237.	JP A, RZ L. Alcoholics with collateral psychopathology: Issues and research findings. Alcoholism. 1998;34:47-56.
7238.	JP B. Other indication for escitalopram: Interest of long-term studies. [French]. Encephale. 2008;34:S115-S119.
7239.	JP B, BC A, EF vR, et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology. 2006;31:1154-1163.
7240.	JP B, BC A, RP P, et al. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. European journal of endocrinology / European Federation of Endocrine Societies. 2006;154:819-825.
7241.	JP B, LJ B. Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee. Therapeutic advances in musculoskeletal disease. 2013;5:291-304.
7242.	JP B, NJ P, JM F, RD M. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regulatory Toxicology and Pharmacology. 2008;50:420-427.
7243.	JP D, Deplanque G, Montheil V, et al. Efficacy of Venlafaxine for the Prevention and Relief of Oxaliplatin-Induced Acute Neurotoxicity: Results of Effox, a Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial. Annals of oncology. 2012;23:200-U217.
7244.	JP F. The new generation of antidepressants. [Review] [61 refs]. Journal of clinical psychiatry. 1983;44:49-55.
7245.	JP F. Clinical overview of serotonin re-uptake inhibitors. Nordic Journal of Psychiatry, Supplement. 1992;46:7-16.
7246.	JP F. The role of venlafaxine in rational antidepressant therapy. [Review] [19 refs]. Journal of clinical psychiatry. 1994;55 Suppl A:62-70.
7247.	JP F. Clinical effects of selective serotonin reuptake inhibitors - A survey. [German]. Fortschritte der Neurologie-Psychiatrie. 1994;62:9-15.
7248.	JP F. [Clinical effects of serotonin reuptake inhibitors--a review]. [Review] [22 refs] [German]. Fortschritte der Neurologie-Psychiatrie. 1994;62 Suppl 1:9-15.
7249.	JP F. Cardiovascular safety in depressed patients: focus on venlafaxine. [Review] [44 refs]. Journal of clinical psychiatry. 1995;56:574-579.
7250.	JP F. Citalopram: A new selective serotonin reuptake inhibitor for the treatment of depression. Today's Therapeutic Trends. 1999;17:257-272.
7251.	JP F. Overview of Antidepressants Currently Used to Treat Anxiety Disorders. Journal of clinical psychiatry. 1999;60:18-22.
7252.	JP F. Mechanism of action of antidepressant medications. Journal of clinical psychiatry. 1999;60:4-13.
7253.	JP F, LA C, SP R, Richelson E, SH P. The role of venlafaxine in rational antidepressant therapy. Journal of clinical psychiatry. 1994;55:62-70.
7254.	JP F, Sorisio D, Kirshner M, BG P. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. Journal of chromatography. B, Biomedical applications. 1997;693:147-151.
7255.	JP F, WF B. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta psychiatrica Scandinavica. Supplementum. 1989;350:125-129.
7256.	JP F, WF B. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Acta Psychiatrica Scandinavica, Supplement. 1989;80:125-129.
7257.	JP F, WF B. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Journal of clinical psychiatry. 1992;53 Suppl:44-47.
7258.	JP F, WF B, CH M, Hendrickson G. An overview of fluoxetine in geriatric depression. British Journal of Psychiatry - Supplementum. 1988:105-108.
7259.	JP G, FA Z. A systematic review of chronic fatigue syndrome: Don't assume it's depression. Primary care companion to the Journal of clinical psychiatry. 2008;10:120-128.
7260.	JP H, Ahl J, AL M, CJ K, Tohen M, RJ B. Reduced Suicidal Ideation in Bipolar I Disorder Mixed-Episode Patients in a Placebo-Controlled Trial of Olanzapine Combined With Lithium or Divalproex. Journal of clinical psychiatry. 2006;67:1246-1252.
7261.	JP H, Fijal B, AN H, DH A. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry research. 2010;175:171-172.
7262.	JP J, Lukose A, Manjunath S. Off-label use of memantine as adjunctive treatment in schizophrenia: A retrospective case series study. Pharmacopsychiatry. 2014;47:202-209.
7263.	JP L. A Randomized, Placebo-Controlled Trial of Sertraline for Prophylactic Treatment of Highly Recurrent Major Depressive Disorder (Vol 161, Pg 836, 2004). American journal of psychiatry. 2004;161:1320.
7264.	JP L. A Randomized, Placebo-Controlled Trial of Sertraline for Prophylactic Treatment of Highly Recurrent Major Depressive Disorder (Vol 161, Pg 836, 2004). American journal of psychiatry. 2004;161:1320.
7265.	JP L, Caillard V, JC B, Troy S, JM H, Boyer P. A Randomized, Placebo-Controlled Trial of Sertraline for Prophylactic Treatment of Highly Recurrent Major Depressive Disorder. American journal of psychiatry. 2004;161:836-842.
7266.	JP L, Khan A. Pharmacological treatment strategies for schizophrenia. Expert review of neurotherapeutics. 2004;4:705-723.
7267.	JP M. Current and future pharmacotherapeutic strategies in treatment of premature ejaculation. Urology. 2006;67:9-16.
7268.	JP O, Gourion D, Montagne A, Rostin M, MF P. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. [French]. L'Enc�phale. 2009;35:595-604.
7269.	JP O, KP G, Katz E. A Double-Blind Placebo-Controlled Multicentre Study of Sertraline in the Acute and Continuation Treatment of Major Depression. European psychiatry. 1997;12:34-41.
7270.	JP O, Tonnoir B, Menard F, Galinowski A. A Prospective Study of Escitalopram in the Treatment of Major Depressive Episodes in the Presence or Absence of Anxiety. Depression and anxiety. 2007;24:318-324.
7271.	JP OR, JF F, MA C, Newman S. Unexpected reduction in migraine and psychogenic headaches following rTMS treatment for major depression: A report of two cases. CNS spectrums. 2007;12:921-925.
7272.	JP OR, MP C, Bergan A, Gallop R, RJ D, Crits-Christoph P. Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants. Biological psychiatry. 2004;55:957-959.
7273.	JP P. Clinical challenges of bipolar depression. British journal of hospital medicine. 2007;68:530-537.
7274.	JP S, DL E. Efficacy of venlafaxine in geriatric depression. [Review] [73 refs]. Depression and anxiety. 2000;12 Suppl 1:63-68.
7275.	JP V. [What is the "best" treatment of depression in general practice?]. [French]. Presse medicale (Paris, France : 1983). 2000;29:1765-1766.
7276.	JP VM, P DJ, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. British journal of psychiatry. 2007;190:460-466.
7277.	JP VM, P DJ, MP VDB, HJ P, DJ VV. Treatment of Depression in Acute Coronary Syndromes With Selective Serotonin Reuptake Inhibitors. Drugs. 2006;66:2095-2107.
7278.	JP W. [Clinical observation on acupuncture treatment of 150 cases of post-stroke depression according to syndrome differentiation]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2010;35:303-306.
7279.	JP W, Blizard R. How to appraise clinical guidelines. Psychiatric bulletin (London, England). 1998;22:759-761.
7280.	JP Y, S VDL, VV T, et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obesity surgery. 2013;23:819-825.
7281.	JP Z, Chen J, JQ C, et al. Early filiform needle acupuncture for poststroke depression: A meta-analysis of 17 randomized controlled clinical trials. Neural Regeneration Research. 2014;9:773-784.
7282.	JPR J, Plenge P, BD S, et al. The Interaction of Escitalopram and R-Citalopram at the Human Serotonin Transporter Investigated in the Mouse. Psychopharmacology. 2014;231:4527-4540.
7283.	JPR Y, Coleman A, MH L. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. British journal of psychiatry. 1987;151:337-340.
7284.	JPT N, ACL P, Arap S. Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. International braz j urol. 2002;28:116-122.
7285.	JPT N, ACL P, Arap S. Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology. 2002;28:116-122.
7286.	JQ B, DH R, Prince J, Schlozman S. Treatment of depression in children and adolescents. Journal of psychiatric practice. 2005;11:141-154.
7287.	JQ B, Wilens T, Spencer T, Biederman J. Juvenile mood disorders and office psychopharmacology. Pediatric clinics of North America. 1997;44:1487-1503.
7288.	JQ C, WR L, SX W, et al. Acupuncture/Electroacupuncture Enhances Anti-Depressant Effect of Seroxat: the Symptom Checklist-90 Scores. Neural Regeneration Research. 2014;9:213-222.
7289.	JR A, LH J, Duan N, et al. Effectiveness of a Quality Improvement Intervention for Adolescent Depression in Primary Care Clinics - a Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2005;293:311-319.
7290.	JR A, LH J, Duan N, et al. Effectiveness of a Quality Improvement Intervention for Adolescent Depression in Primary Care Clinics - a Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2005;293:311-319.
7291.	JR B, Mattos P. Double-action antidepressants: Correlations between mechanisms of action and clinical use. [Portuguese]. Jornal brasileiro de psiquiatria. 2001;50:313-323.
7292.	JR C. Acute bipolar depression trials: How they have failed to inform the treatment of real world patients. Bipolar disorders. 2010;Conference:11.
7293.	JR C, AH Y, Gustafsson U, Paulsson B. The efficacy of quetiapine monotherapy in bipolar depression: Combined data from the BOLDER and EMBOLDEN studies. Bipolar disorders. 2009;Conference:26.
7294.	JR C, AN C, DK L. Intravenous ketamine for treatment-resistant major depressive disorder. Annals of pharmacotherapy. 2012;46:117-123.
7295.	JR C, Chung T, OG B, Douaihy A, Hayes J, DS W. Two-year follow-up of double-blind fluoxetine trial in comorbid MDD-AUD adolescents. Alcoholism, clinical and experimental research. 2010;Conference:175A.
7296.	JR C, CL B, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of clinical psychiatry. 2003;64:1013-1024.
7297.	JR C, DB C, OG B, Birmaher B, IM S, SA B. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. [Review] [29 refs]. Addictive behaviors. 2005;30:1824-1833.
7298.	JR C, DJ R, MD S, SE K. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology. 1998;38:185-191.
7299.	JR C, Douaihy A, DB C. Mirtazapine pilot trial in depressed alcoholics. American Journal on Addictions. 2012;Conference:392.
7300.	JR C, Douaihy A, DB C, et al. Mirtazapine pilot trial in comorbid MDD-aud. Alcoholism, clinical and experimental research. 2012;Conference:296A.
7301.	JR C, Douaihy A, OG B, et al. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addictive behaviors. 2011;36:843-848.
7302.	JR C, Elhaj O, Gajwani P, KM G. Clinical Highlights in Bipolar Depression: Focus on Atypical Antipsychotics. Journal of clinical psychiatry. 2005;66:26-33.
7303.	JR C, HJ A, AR H. Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. Addictive behaviors. 2010;35:644-646.
7304.	JR C, IM S, JG E, et al. Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacology bulletin. 1997;33:165-170.
7305.	JR C, IM S, Lynch K, DB C, J JM. Treating the Substance-Abusing Suicidal Patient. Annals of the New York Academy of Sciences. 2001;932:78-93.
7306.	JR C, IM S, Lynch K, DB C, JJ M. Treating the substance-abusing suicidal patient. Annals of the New York Academy of Sciences. 2001;932:73-78.
7307.	JR C, JD G, Perdrizet-Chevallier C. Agomelatine Adjunctive Therapy for Acute Bipolar Depression: Preliminary Open Data. Bipolar disorders. 2007;9:628-635.
7308.	JR C, OG B, IM S, TM K, DS W. Long-term follow-up of double-blind fluoxetine trial in comorbid MDD-AUD adolescents. Alcoholism, clinical and experimental research. 2009;Conference:117A.
7309.	JR C, OG B, IM S, TM K, DS W, DB C. Fluoxetine in Depressed Aud Adolescents: a 1-Year Follow-up Evaluation. Journal of child and adolescent psychopharmacology. 2004;14:33-38.
7310.	JR C, OG B, IM S, TM K, DS W, DB C. Fluoxetine in Depressed Aud Adolescents: a 1-Year Follow-up Evaluation. Journal of child and adolescent psychopharmacology. 2004;14:33-38.
7311.	JR C, PH S, George A, RF U, JM P. Haloperidol Vs Phenelzine in Continuation Therapy of Borderline Disorder. Psychopharmacology bulletin. 1993;29:333-337.
7312.	JR C, PH S, JM P, RF U. A Preliminary Trial of Fluoxetine in Refractory Borderline Patients. Journal of clinical psychopharmacology. 1991;11:116-120.
7313.	JR D, Zhang W, KM C, et al. Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). Journal of psychopharmacology (Oxford, England). 2010;24:3-26.
7314.	JR D, Zhang W, KM C, et al. A Psychopharmacological Treatment Algorithm for Generalised Anxiety Disorder (Gad). Journal of psychopharmacology (Oxford, England). 2010;24:3-26.
7315.	JR F, AM T-R, WJ K, et al. Major depression after breast cancer: a review of epidemiology and treatment. General hospital psychiatry. 2008;30:112-126.
7316.	JR G. Toward optimal health: Diagnosis and management of disordered sleep in women. Journal of women's health. 2009;18:147-152.
7317.	JR G, Cipriani A. Selective serotonin reuptake inhibitors. British medical journal. 2004;329:809-810.
7318.	JR G, DJ M. Treatment of bipolar disorder. Lancet. 2013;381:1672-1682.
7319.	JR G, Wahed M, DS R. Management of stress in inflammatory bowel disease: A therapeutic option? Expert review of gastroenterology & hepatology. 2009;3:661-679.
7320.	JR H. Depression during tobacco abstinence. Nicotine & tobacco research. 2007;9:443-446.
7321.	JR H, LF S, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for Smoking Cessation. Cochrane database of systematic reviews (Online). 2014.
7322.	JR H, LF S, Lancaster T. Antidepressants for Smoking Cessation. Cochrane database of systematic reviews (Online). 2007.
7323.	JR K, JY Y, MH J, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. American journal of the medical sciences. 2005;329:1-5.
7324.	JR M, BD K, TL M. Cognitive behavioral treatment of depression in youth. Pediatric annals. 2011;40:307-313.
7325.	JR M, DW G, Wimberg S, RJ M. Down-Regulation of Human Platelet Tritiated Imipramine Binding-Sites Is Associated With the Antidepressant Response to Etoperidone Hydrochloride. Current therapeutic research, clinical and experimental. 1992;51:299-308.
7326.	JR N, SE E, RD M, et al. Tridimensional personality questionnaire and treatment response in major depressive disorder: a negative study. Journal of affective disorders. 2000;57:241-247.
7327.	JR S. Quality of life in patients with coronary artery disease and the impact of depression. Current psychiatry reports. 2004;6:438-445.
7328.	JR S, AE L, SJ T. Nefazodone for Chronic Daily Headache Prophylaxis: an Open-Label Study. Headache. 2001;41:465-474.
7329.	JR S, BL M, IM L, AL D. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.[Erratum appears in J Clin Psychiatry 1997 Jun;58(6):275]. Journal of clinical psychiatry. 1997;58:212-216.
7330.	JR S, BR R, Rindskopf D, DT L, HA S, SP R. Design makes a difference: A meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. American journal of geriatric psychiatry. 2008;16:65-73.
7331.	JR S, CB B, SW W. Mood-stabilizer-maintained, remitted bipolar patients: Taper and discontinuation of adjunctive antipsychotic medication. General hospital psychiatry. 2004;26:233-236.
7332.	JR S, CM Oc, Barton D, et al. Influence of Depression and Effect of Treatment With Sertraline on Quality of Life After Hospitalization for Acute Coronary Syndrome. American journal of cardiology. 2003;92:1271-1276.
7333.	JR S, CM OC, Barton D, et al. Influence of Depression and Effect of Treatment With Sertraline on Quality of Life After Hospitalization for Acute Coronary Syndrome. American journal of cardiology. 2003;92:1271-1276.
7334.	JR S, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: A systematic review of randomized trials. Canadian Journal of Psychiatry. 2006;51:923-929.
7335.	JR S, JA W, AM W, Keeshin B, MA R. Efficacy and Tolerability of Antidepressants in Pediatric Anxiety Disorders: a Systematic Review and Meta-Analysis. Depression and anxiety. 2015;32:149-157.
7336.	JR S, JG K, AM B, SP R. The specificity of neuropsychological impairment in predicting antidepressant non-response in the very old depressed. International journal of geriatric psychiatry. 2008;23:319-323.
7337.	JR S, Leggio L, Zywiak W, et al. Effects of sertraline on alcohol craving and consumption in the late luteal phase of non-treatment seeking alcohol dependent women. Alcoholism, clinical and experimental research. 2012;Conference:245A.
7338.	JR S, Prakash A, Zhang Q, et al. A Randomized, Placebo-Controlled Study of Duloxetine for the Treatment of Children and Adolescents With Generalized Anxiety Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54:283-293.
7339.	JR S, Rindskopf D, DC S, KRR K, SP R. The Vascular Depression Subtype: Evidence of Internal Validity. Biological psychiatry. 2008;64:491-497.
7340.	JR S, SD S, 3rd LAE, ME W. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994;34:497-502.
7341.	JR T, Fava M, LA U, JE A, AA N, JF R. Are study dropouts different from completers? Biological psychiatry. 1996;40:668-670.
7342.	JR W, KD K. Fear: the Impact and Treatment of Social Phobia. Journal of psychopharmacology (Oxford, England). 2000;14:S13-S23.
7343.	JR WJ. The contribution of medications to hypoglycemia unawareness. Diabetes spectrum. 2007;20:77-80.
7344.	JR Y, Lumbad J. Opioid antagonists for the treatment of alcohol dependence. American family physician. 2011;84:990-992.
7345.	JR Z, AM G, JM N, AB N. Update in women's health 2006-2007. Journal of general internal medicine. 2008;23:93-99.
7346.	JRI D, Bose A, Wang Q. Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety Disorder. Journal of clinical psychiatry. 2005;66:1441-1446.
7347.	JRT D. Sexual dysfunction and antidepressants. Depression. 1995;2:233-240.
7348.	JRT D. Defining an Appropriate Management Strategy for Social Anxiety Disorder. International clinical psychopharmacology. 2000;15:S13-S17.
7349.	JRT D. Social Anxiety Disorder Under Scrutiny. Depression and anxiety. 2000;11:93-98.
7350.	JRT D. Pharmacotherapy of Generalized Anxiety Disorder. Journal of clinical psychiatry. 2001;62:46-52.
7351.	JRT D. First-Line Pharmacotherapy Approaches for Generalized Anxiety Disorder. Journal of clinical psychiatry. 2009;70:25-31.
7352.	JRT D, Bose A, Korotzer A, HJ Z. Escitalopram in the Treatment of Generalized Anxiety Disorder: Double-Blind, Placebo Controlled, Flexible-Dose Study. Depression and anxiety. 2004;19:234-240.
7353.	JRT D, Bose A, Korotzer A, HJ Z. Escitalopram in the Treatment of Generalized Anxiety Disorder: Double-Blind, Placebo Controlled, Flexible-Dose Study. Depression and anxiety. 2004;19:234-240.
7354.	JRT D, Brady K, TA M, MB S, MH P. The Efficacy and Tolerability of Tiagabine in Adult Patients With Post-Traumatic Stress Disorder. Journal of clinical psychopharmacology. 2007;27:85-88.
7355.	JRT D, DJ S, AY S, Yehuda R. Posttraumatic Stress Disorder: Acquisition, Recognition, Course, and Treatment. Journal of neuropsychiatry and clinical neurosciences. 2004;16:135-147.
7356.	JRT D, DJ S, AY S, Yehuda R. Posttraumatic Stress Disorder: Acquisition, Recognition, Course, and Treatment. Journal of neuropsychiatry and clinical neurosciences. 2004;16:135-147.
7357.	JRT D, H-U W, P-M L, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. European neuropsychopharmacology. 2008;18:673-681.
7358.	JRT D, KM C. Bupropion sustained release: a therapeutic overview. [Review] [22 refs]. Journal of clinical psychiatry. 1998;59 Suppl 4:25-31.
7359.	JRT D, KM G, JA F, et al. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial. Journal of the American Medical Association. 2002;287:1807-1814.
7360.	JRT D, RH W, MI B, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial. Biological psychiatry. 2003;53:188-191.
7361.	JRT D, RL D, Hedges D, JT H. Efficacy, Safety, and Tolerability of Venlafaxine Extended Release and Buspirone in Outpatients With Generalized Anxiety Disorder. Journal of clinical psychiatry. 1999;60:528-535.
7362.	JRT D, Zhang W. Treatment of post-stroke depression with antidepressants. Journal of alternative and complementary medicine (New York, N.Y.). 2008;14:795-796.
7363.	JS A. Hypochondriasis: Conceptualization, treatment, and relationship to obsessive compulsive disorder. Annals of clinical psychiatry. 2005;17:211-217.
7364.	JS A, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374:491-499.
7365.	JS C, Ha K, IY Y, et al. Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine. Progress in neuro-psychopharmacology & biological psychiatry. 2012;39:136-142.
7366.	JS C, KA G, JC L, et al. Effect of Escitalopram on Hot Flash Interference: a Randomized, Controlled Trial. Fertility and sterility. 2012;97:1399-+.
7367.	JS K, DB F, Hindmarch I. Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients. International clinical psychopharmacology. 1993;8:341-343.
7368.	JS K, DB F, Mahendran R, Hindmarch I. The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. International clinical psychopharmacology. 1992;7:101-108.
7369.	JS K, Hindmarch I. Citalopram and other antidepressants: Comparative effects on cognitive function and psychomotor performance. Journal of Serotonin Research. 1996;3:123-129.
7370.	JS K, JM M, BJ K, RH A. The results of a 6-month treatment for depression on symptoms, life satisfaction, and community activities among individuals aging with a disability. Rehabilitation psychology. 2006;51:13-22.
7371.	JS K, PD K. Update on oral treatments for male erectile dysfunction. Journal of the European Academy of Dermatology and Venereology : JEADV. 2004;18:267-274.
7372.	JS K, Youn T, HY J. Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. Journal of affective disorders. 1996;40:169-173.
7373.	JS M. Difficult-to-treat depressions: A primary care perspective. Journal of clinical psychiatry. 2003;64:24-31.
7374.	JS M. Burden of illness in bipolar depression. Primary care companion to the Journal of clinical psychiatry. 2006;7:259-267.
7375.	JS M, AR E, Rynn M, AM A, KA T. A Randomized Controlled Trial of Venlafaxine Er Versus Placebo in Pediatric Social Anxiety Disorder. Biological psychiatry. 2007;62:1149-1154.
7376.	JS M, HA K, NL R. Insulin resistance in major depressive disorder and the effects of psychotropic medications. Clinical Practice. 2012;9:579-589.
7377.	JS M, RO T, MS S, PA S. The role of palliative care in the current HIV treatment era in developed countries. Topics in antiviral medicine. 2013;21:20-26.
7378.	JS M, SG S, Compton S, et al. The child and adolescent psychiatry trials network (CAPTN). Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:515-518.
7379.	The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.[Erratum appears in Arch Gen Psychiatry. 2008 Jan;65(1):101], Archives of general psychiatry(2007).
7380.	The Treatment for Adolescents With Depression Study (Tads) - Long-Term Effectiveness and Safety Outcomes, Archives of general psychiatry(2007).
7381.	JS M, Silva S, Petrycki S, Dubicka B, Ramchandani P. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder. Evidence-based medicine. 2005;10:46.
7382.	JS M, TADSGroup. Authors of TADS study reply to letter raising concerns [2]. BMJ (Clinical research ed.). 2005;330:730-731.
7383.	JS N, JW S, SR W, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Journal of clinical psychiatry. 2005;66:1002-1011.
7384.	JS O, GD B, TR N. Discontinuation syndromes with selective serotonin reuptake inhibitors are there clinically relevant differences? CNS drugs. 1999;12:171-177.
7385.	JS O, GD B, TR N. Third-Generation Antidepressants - Do They Offer Advantages Over the Ssris? CNS drugs. 2001;15:941-954.
7386.	JS O, JF C, GD B, TR N. Pindolol augmentation of antidepressants: A review and rationale. Australian and New Zealand journal of psychiatry. 2000;34:71-79.
7387.	JS P, PC W, SM W, AVP M. A Comparison of the Post-Marketing Safety of Four Selective Serotonin Re-Uptake Inhibitors Including the Investigation of Symptoms Occurring on Withdrawal. British journal of clinical pharmacology. 1996;42:757-763.
7388.	JS R, CH B, CS W, et al. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: A randomized, controlled trial. Archives of physical medicine and rehabilitation. 2015;96:680-689.
7389.	JS R, PG J, MA W, et al. Depression Predicts Mortality and Hospitalization in Patients With Myocardial Infarction Complicated by Heart Failure. American heart journal. 2005;150:961-967.
7390.	JS S, LM A, NR K, Lei D. Extended-Release Venlafaxine in Relapse Prevention for Patients With Major Depressive Disorder. Journal of psychiatric research. 2004;38:249-257.
7391.	JS VW. Night eating syndrome: A critical review of the literature. Clinical psychology review. 2012;32:49-59.
7392.	JS VW. The Treatment of Night Eating Syndrome: A Review and Theoretical Model. Current Obesity Reports. 2014;3:137-144.
7393.	JT A, DA C, KJ B. Treatment options for sleep disturbances during alcohol recovery. Journal of addictive diseases. 2007;26:41-54.
7394.	JT C. Premenstrual syndrome in primary care: An update. Primary Care Psychiatry. 2001;7:85-90.
7395.	JT C. Premenstrual Syndrome in Primary Care: an Update. Primary care & community psychiatry. 2006;11:129-135.
7396.	JT F, YL P, Robinson M, Prakash A, Chappell A. The Clinical Importance of Changes in the 0 to 10 Numeric Rating Scale for Worst, Least, and Average Pain Intensity: Analyses of Data From Clinical Trials of Duloxetine in Pain Disorders. Journal of pain. 2010;11:109-118.
7397.	JT K, Citrome L. Olanzapine: Review of safety 2008. Expert opinion on drug safety. 2008;7:761-769.
7398.	JT K, Epstein M, Beggel O, et al. Modulation of N-methyl-D-aspartate (NMDAR)-type glutamate receptors in psychiatric disorders. Neuropsychopharmacology. 2013;Conference:S376-S377.
7399.	JT K, RR T. Risk of Psychosis Exacerbation by Tricyclic Antidepressants in Unipolar Major Depressive Disorder With Psychotic Features. Journal of affective disorders. 2008;106:279-284.
7400.	JT L, TA K, TA K, et al. Venlafaxine or Bupropion Responders but Not Nonresponders Show Baseline Prefrontal and Paralimbic Hypometabolism Compared With Controls. Psychopharmacology bulletin. 1996;32:629-635.
7401.	JT L, TA K, TA K, et al. Bupropion and Venlafaxine Responders Differ in Pretreatment Regional Cerebral Metabolism in Unipolar Depression. Biological psychiatry. 2005;57:220-228.
7402.	JT P, Fountoulaki K, Filippatos G, Adamopoulos S, Paraskevaidis I, Kremastinos D. Depression in coronary artery disease: Novel pathophysiologic mechanisms and therapeutic implications. International journal of cardiology. 2007;116:153-160.
7403.	JT P, Fountoulaki K, Paraskevaidis I, Kremastinos D. Depression in chronic heart failure: Novel pathophysiological mechanisms and therapeutic approaches. Expert opinion on investigational drugs. 2005;14:567-577.
7404.	JT P, LJ C. Chronic opioid use in fibromyalgia syndrome: A clinical review. Journal of clinical rheumatology. 2013;19:72-77.
7405.	JT R. Omega fatty acids in major depression. Psychopharm Review. 2009;44:33-40.
7406.	JT W, Hoffman B, JA B. Management of depression in patients with coronary heart disease: Association, mechanisms, and treatment implications for depressed cardiac patients. Expert opinion on pharmacotherapy. 2011;12:85-98.
7407.	JT W, MJ L, MA R, et al. Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents. New England journal of medicine. 2001;344:1279-1285.
7408.	Ju-Wei H, Tung-Ping S, Chen-Ying H, Ying-Sheue C, Yuan-Hwa C. Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naive first-episode major depressive disorder in a Chinese population: A 6-week double-blind, randomized comparative study. Journal of clinical psychopharmacology. 2011;31:577-581.
7409.	Juan M. Reboxetine versus fluoxetine: An overview of efficacy and tolerability. Journal of clinical psychiatry. 1998;59 Suppl 1:8-10.
7410.	Juan M, H-J M, Burrows GD, Montenegro RM. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder. International clinical psychopharmacology. 1999;14:73-80.
7411.	Juckel G, Schule C, Pogarell O, Rupp D, Laakmann G, Hegerl U. Epileptiform EEG patterns induced by mirtazapine in both psychiatric patients and healthy volunteers [6]. Journal of clinical psychopharmacology. 2003;23:421-422.
7412.	Judge R. Depression with anxiety. Round Table Series - Royal Society of Medicine. 1998:33-36.
7413.	Judge R, BE W. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety. Journal of clinical psychiatry. 1999;60:795-796.
7414.	Judge R, Parry MG, Quail D, G JJ. Discontinuation symptoms: Comparison of brief interruption in fluoxetine and paroxetine treatment. International clinical psychopharmacology. 2002;17:217-225.
7415.	Judith B, Martine dB, Hein vH, et al. Cost-Effectiveness of a Disease Management Program for Major Depression in Elderly Primary Care Patients. Journal of general internal medicine. 2006;21:1020-1026.
7416.	Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression, Psychiatry research(2012).
7417.	Low-vs high-frequency repetitive transcranial magnetic stimulation as an add-on treatment for refractory depression, Frontiers in Psychiatry(2012).
7418.	Julien M. Efficacy of fluvoxamine in severe depression. [French]. Psychologie medicale. 1992;24:1225-1234.
7419.	Jun C, Keming G, E KD. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. [Review]. Current opinion in psychiatry. 2011;24:10-17.
7420.	Juned S, Y CJ, Hendricks BC, Jeanne M. Comparative effectiveness of medication versus cognitive-behavioral therapy in a randomized controlled trial of low-income young minority women with depression. Journal of consulting and clinical psychology. 2012;80:995-1006.
7421.	Jurcic J, JA P, Kavanaugh D. St John's wort versus paroxetine for depression. Canadian Family Physician. 2007;53:1511-1513.
7422.	Jureidini J, Tonkin A, Jureidini E. Combination pharmacotherapy for psychiatric disorders in children and adolescents: Prevalence, efficacy, risks and research needs. Pediatric Drugs. 2013;15:377-391.
7423.	Jureidini J, Tonkin A, PR M. TADS study raises concerns [3]. British medical journal. 2004;329:1343-1344.
7424.	Jurica J, Zourkova A. Dynamics and persistence of CYP2D6 inhibition by paroxetine. Journal of clinical pharmacy and therapeutics. 2013;38:294-300.
7425.	Jussi H, Jarmo H, Jaana K, et al. Effects of Antidepressant Drug Treatment and Psychotherapy on Striatal and Thalamic Dopamine D-2/3 Receptors in Major Depressive Disorder Studied With [C-11]Raclopride Pet. Journal of psychopharmacology (Oxford, England). 2011;25:1329-1336.
7426.	Justine S, D AJ. "Antidepressant use in bipolar disorder: Continuing an age-old debate": Response to Eppel letter. American journal of psychiatry. 2010;167:1408-1409.
7427.	JV C, Perel J, Lucas A, et al. Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: an Exploratory Study. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1234-1242.
7428.	JV C, Perel J, Lucas A, et al. Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: an Exploratory Study. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1234-1242.
7429.	JV L, JA G, Aguado J, et al. Effectiveness of group acceptance and commitment therapy for fibromyalgia: A 6-month randomized controlled trial (EFFIGACT study). Pain. 2014;155:693-702.
7430.	JV P, GC S, SA S, et al. High-dose olanzapine/fluoxetine (O/F) combination therapy for treatment-resistant depression (TRD) decreases ventromedial prefrontal and right amygdala metabolism: Relationship to clinical response. Neuropsychopharmacology. 2010;Conference:S357.
7431.	JV P, RB R, Taylor R, Rodriguez G, Nalamachu S, Langley P. A Review of Duloxetine 60mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain. Pain practice. 2013;13:239-252.
7432.	JW C, Spring B, DE M, et al. Influence of Fluoxetine on Positive and Negative Affect in a Clinic-Based Smoking Cessation Trial. Psychopharmacology. 2004;173:153-159.
7433.	JW C, Spring B, DE M, et al. Influence of Fluoxetine on Positive and Negative Affect in a Clinic-Based Smoking Cessation Trial. Psychopharmacology. 2004;173:153-159.
7434.	JW D, GI P, Mahal Y, et al. Somatic Symptoms in Outpatients With Major Depressive Disorder Treated With Fluoxetine. Psychosomatics. 2006;47:348-352.
7435.	JW J. Social phobia: A pharmacologic treatment overview. Journal of clinical psychiatry. 1995;56:18-24.
7436.	JW J. Antidepressants in panic disorder. Journal of clinical psychiatry. 1997;58:20-24.
7437.	JW J. Lamotrigine in psychiatry: Pharmacology and therapeutics. CNS spectrums. 2005;10:224-232.
7438.	JW J. Bupropion extended-release for depressive disorders. Expert review of neurotherapeutics. 2008;8:715-722.
7439.	JW J. Herbal psychopharmacology: Show me the data. Psychopharm Review. 2009;44:25-32.
7440.	JW J. Clinical and pharmacologic perspectives on the treatment of major depressive disorder. CNS spectrums. 2011.
7441.	JW K, Mohamed S, Thallasinos A, Carroll B, Zisook S, DV J. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International journal of geriatric psychiatry. 2001;16:1163-1167.
7442.	JW K, Zisook S. Co-Occurring Depressive Symptoms in the Older Patient With Schizophrenia. Drugs & aging. 2008;25:631-647.
7443.	Is there anything really novel on the antidepressant horizon?, Current psychiatry reports(2012).
7444.	A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine, Journal of clinical psychiatry(2008).
7445.	JW S. Treating depression with atypical features. Journal of clinical psychiatry. 2007;68:25-29.
7446.	JW S, FM Q, DF K. The pharmacotherapy of minor depression. [Review] [33 refs]. American journal of psychotherapy. 1992;46:23-36.
7447.	JW S, PJ M, FM Q, DF K. Dsm-Iv Depression With Atypical Features: Is It Valid? Neuropsychopharmacology. 2009;34:2625-2632.
7448.	JW U, JG E, Goldie A, DG W. Comparative effects of fluoxetine and amitriptyline on cardiac function. British journal of clinical pharmacology. 1988;26:399-402.
7449.	JW WJ. Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people. Evidence-based medicine. 2006;11:111.
7450.	JW WJ, CD M, Chiquette E, PH N, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Annals of internal medicine. 2000;132:743-756.
7451.	JW WJ, Holsinger T. St John's for depression, worts and all. BMJ (Clinical research ed.). 2005;330:E350-351.
7452.	JWG T, Bouwer C, Behnke K. Moclobemide for Anxiety Disorders: a Focus on Moclobemide for Panic Disorder. International clinical psychopharmacology. 1997;12:S27-S30.
7453.	JWG T, GFS J, GD B. Moclobemide for depression: An Australian psychiatric practice study. Journal of clinical psychopharmacology. 1995;15:31S-34S.
7454.	JWJ B, Berenbaum F, FPJG L. Osteoarthritis: An update with relevance for clinical practice. Lancet. 2011;377:2115-2126.
7455.	JWJr W, Holsinger T. St John's for depression, worts and all. BMJ (Clinical research ed.). 2005;330:E350-351.
7456.	JY L, Gismondi R, McQuade R, Carson W, Berman R. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: Pooled data from 3 short-term studies. European neuropsychopharmacology. 2009;Conference:S421-S422.
7457.	JY L, MK F, ME C. Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Annals of pharmacotherapy. 2007;41:1005-1012.
7458.	JY L, MY J, ZM K, Chu Y. Influence of 5-Htr2a Genetic Polymorphisms on the Efficacy of Antidepressants in the Treatment of Major Depressive Disorder: a Meta-Analysis. Journal of affective disorders. 2014;168:430-438.
7459.	JY T, GM L. Citalopram in the treatment of depression and other potential uses in psychiatry. [Review] [76 refs]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 1999;19:675-689.
7460.	JY W. New mechanisms of action provide alternative therapies. Consultant pharmacist. 2005;20:404-414.
7461.	Jylha P, Ketokivi M, Mantere O, et al. Do antidepressants change personality? - A five-year observational study. Journal of affective disorders. 2012;142:200-207.
7462.	JZ K, SH K, ZV S, et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. Journal of psychiatry & neuroscience. 2009;34:175-180.
7463.	JZ R, Boyer P, Vialet C, Hwang E, KA T. Efficacy and Safety of Desvenlafaxine 50 Mg/D for Prevention of Relapse in Major Depressive Disorder: a Randomized Controlled Trial. Journal of clinical psychiatry. 2013;74:158-166.
7464.	K AM, W LR. Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric disease and treatment. 2011;7.
7465.	K ASA, J LEV. A review of the pharmacological and clinical profile of mirtazapine. CNS drug reviews. 2001;7:249-264.
7466.	K BR, H MC, M WM, G WJ, M PJ. Duloxetine in the Treatment of Major Depressive Disorder: Comparisons of Safety and Efficacy. Journal of the National Medical Association. 2006;98:437-447.
7467.	K BS, H MC, B BE, M WM, G WJ, F SA. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of psychiatric research. 2005;39:43-53.
7468.	K BT, W vdBW, G MP, A BJ, Peter M. Efficacy and Tolerability of Tranylcypromine Versus Phenelzine: a Double-Blind Study in Antidepressant- Refractory Depressed Inpatients. Journal of clinical psychiatry. 2004;65:1505-1510.
7469.	K BT, W vdBW, G MP, A BJ, Peter M. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. American journal of psychiatry. 2004;161:2060-2065.
7470.	K BV, M WM, H MC, J DM, G WJ, E SD. Duloxetine for the Treatment of Major Depressive Disorder in Women Ages 40 to 55 Years. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2005;46:345-354.
7471.	K CC, Ram S, Joseph M, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. Journal of clinical psychiatry. 1990;51:28-33.
7472.	K DE, H JH, Susan T, Michael C. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: An analysis of 2 adult studies in treatment-resistant depression. Journal of clinical psychopharmacology. 2011;31:337-340.
7473.	K GW, H PL, A RS, L DP, R HG, S CD. Efficacy of fluvoxamine in obsessive-compulsive disorder: A double-blind comparison with placebo. Archives of general psychiatry. 1989;46:36-44.
7474.	K JF, Kate M, R NT, D BG, al e. "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness": Erratum. Australian and New Zealand journal of psychiatry. 1993;27:732.
7475.	K JF, Kate M, R NT, D BG, Gupta RK, Parker G. A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Australian and New Zealand journal of psychiatry. 1993;27:49-55.
7476.	K LJ, Sintonen H, Syvalahti E, et al. Antidepressant Efficacy and Quality-of-Life in Depression - a Double-Blind-Study With Moclobemide and Fluoxetine. Acta psychiatrica Scandinavica. 1994;89:363-369.
7477.	K LL, Bruce LR. Imipramine-related tinnitus. Journal of clinical psychiatry. 1989;50:146.
7478.	K LL, Bruce LR, Alexander MW, et al. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Journal of clinical psychiatry. 1993;54:224-228.
7479.	K LL, Chidgey J, Addington-Hall J, Hotopf M. Depression in palliative care: A systematic review: Part 2. Treatment. Palliative medicine. 2002;16:279-284.
7480.	Design of Depression in Alzheimer's Disease Study-2, The American Journal of Geriatric Psychiatry(2006).
7481.	K MH, M WM, G WM, et al. Using daily interactive voice response assessments to measure onset of symptom improvement with duloxetine. Psychiatry. 2007;4:30-37.
7482.	K SJ, Hasse K, Jarmo H, et al. Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: A randomized comparative study. Psychotherapy and psychosomatics. 2008;77:351-357.
7483.	The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial, Psychiatry research(2014).
7484.	K SL, G PB, H MB, et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. Journal of clinical psychopharmacology. 2002;22:481-486.
7485.	K SR, Patel SS, Norbert O, L BC. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. Journal of clinical psychiatry. 1992;53:48-51.
7486.	K VC. Psychopharmacological treatment of major depressive disorder in children and adolescents: Comment. JAMA: Journal of the American Medical Association. 2003;290:1091-1093.
7487.	K-L C, Campayo A, DJ M, Arndt S, RG R. Aggressive Behavior in Patients With Stroke: Association With Psychopathology and Results of Antidepressant Treatment on Aggression. Archives of physical medicine and rehabilitation. 2006;87:793-798.
7488.	K-L H, W-C L, Y-Y W, et al. Comparison of Agomelatine and Selective Serotonin Reuptake Inhibitors/Serotonin-Norepinephrine Reuptake Inhibitors in Major Depressive Disorder: a Meta-Analysis of Head-to-Head Randomized Clinical Trials. Australian and New Zealand journal of psychiatry. 2014;48:663-671.
7489.	K-N C, S-L C, Luo F, Y-Y T. Changes of neurotransmitter in patients with post-stroke depression observed with encephalofluctuography technology. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:118-119.
7490.	K-P S, S-M W, C-U P. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert opinion on investigational drugs. 2013;22:1519-1534.
7491.	K-S N, KJ L, JS L, YS C, H-Y J. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2014;48:79-85.
7492.	K-U K, BB Q, Riedel M, Krampe O, Maier W. Safety and efficacy of citalopram in the treatment of depressive disorders. [German]. Psychopharmakotherapie. 2005;12:83-90.
7493.	K-U K, BB Q, Thiel M, Falkai P, Maier W, CE E. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy & behavior. 2003;4:674-679.
7494.	K-W H. Antidepressants and traffic safety. [German]. Fortschritte der Neurologie-Psychiatrie. 1994;62:24-28.
7495.	K-Y P, X-Y L, J-Z Y, Zhu L, X-M W, S-M Y. Cost-effectiveness analysis of depression treatment with paroxetine, venlafaxine and citalopram. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:16-18.
7496.	K-Y W, C-Y L, M-C H. Six-Month Paroxetine Treatment of Premenstrual Dysphoric Disorder: Continuous Versus Intermittent Treatment Protocols. Psychiatry and clinical neurosciences. 2008;62:109-114.
7497.	K-Z B, H-Q Y, Z-F H, Gong K, Qu B, S-T W. Chronic pain and emotional disorders as well as the effect of interventional treatment. Chinese Journal of Clinical Rehabilitation. 2006;10:190-192.
7498.	KA B, CM P, M LV, CM B. Pharmacological Approaches to the Management of Binge Eating Disorder. Drugs. 2015;75:9-32.
7499.	KA B, ND B, JA S, KN L, CM B. Binge eating disorder treatment: A systematic review of randomized controlled trials. International journal of eating disorders. 2007;40:337-348.
7500.	KA B, TM E, JA B. Exercise as a treatment for depression and other psychiatric disorders: A review. Journal of cardiopulmonary rehabilitation and prevention. 2007;27:359-367.
7501.	KA C, RR K. Postherpetic neuralgia in an elderly patient. Consultant pharmacist. 2007;22:593-598.
7502.	KA C, VY X, TL P, JV M, LM R, LM C. An Indirect Comparison of the Efficacy and Safety of Desvenlafaxine and Venlafaxine Using Placebo as the Common Comparator. CNS spectrums. 2012;17:131-141.
7503.	KA G, DJ S. Pharmacotherapy of social anxiety disorder. Behavioral Neurobiology of Anxiety and Its Treatment. 2010;Current To:487-503.
7504.	KA G, JC I, DJ S. Augmentation of cognitive behavioral therapy with pharmacotherapy. [Review] [85 refs]. Psychiatric clinics of North America. 2010;33:687-699.
7505.	KA H. Perplexities of treatment resistence in eating disorders. BMC psychiatry. 2013.
7506.	KA H, G-M S, Vittinghoff E, Santos D, Colfax G, Coffin P. Event-Level Relationship Between Methamphetamine Use Significantly Associated With Non-Adherence to Pharmacologic Trial Medications in Event-Level Analyses. Drug and alcohol dependence. 2014;143:277-280.
7507.	KA K, AD F, JD L. Interview quality and signal detection in clinical trials. American journal of psychiatry. 2005;162:628.
7508.	KA K, JH G, JW J, DJ K. Computer-administered clinical rating scales. Psychopharmacology. 1996;127:291-301.
7509.	KA K, JM K, ME T, AA N. Why do clinical trials fail?: The problem of measurement error in clinical trials: Time to test new paradigms? Journal of clinical psychopharmacology. 2007;27:1-5.
7510.	KA K, Leuchter A, DeBrota D, et al. Site versus centralized raters in a clinical depression trial: Impact on patient selection and placebo response. Journal of clinical psychopharmacology. 2010;30:193-197.
7511.	KA L. Sleep dysfunction in women and its management. Current treatment options in neurology. 2006;8:376-386.
7512.	KA L, SM D, Kaciroti N, AR K, CR NJ, DM V. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: A meta-analysis. Journal of perinatology. 2005;25:595-604.
7513.	KA M, BG G. Self-compliance at 'Prozac campus'. Anthropology & medicine. 2010;17:173-185.
7514.	KA P. Smoking cessation in women: Special considerations. CNS drugs. 2001;15:391-411.
7515.	KA P, JM S, SL M. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatric quarterly. 2004;75:309-320.
7516.	KA P, ME T. A review of Vilazodone, Serotonin, and Major Depressive Disorder. Primary care companion to the Journal of clinical psychiatry. 2014.
7517.	KA P, Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS spectrums. 2009;14:252-260.
7518.	KA P, MM K. Suicidality in a Placebo-Controlled Fluoxetine Study of Body Dysmorphic Disorder. International clinical psychopharmacology. 2009;24:26-28.
7519.	KA P, RS A, SA R. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of general psychiatry. 2002;59:381-388.
7520.	KA P, SA R. Change in Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder Treated With Fluoxetine: a Placebo-Controlled Study. Psychosomatics. 2004;45:438-444.
7521.	KA P, SA R. Change in Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder Treated With Fluoxetine: a Placebo-Controlled Study. Psychosomatics. 2004;45:438-444.
7522.	KA P, SL M, JI H, HG PJ. Body dysmorphic disorder: An obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? Journal of clinical psychiatry. 1995;56:41-52.
7523.	KA P, WH K. The relationship of body dysmorphic disorder and eating disorders to obsessive-compulsive disorder. CNS spectrums. 2007;12:347-358.
7524.	KA P-G, Torres-Ruiz A, Ramirez-Bermudez J, Velazquez-Moctezuma J, Arana-Lechuga Y, Teran-Perez G. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial. Journal of clinical psychiatry. 2006;67:1820.
7525.	KA S, LE P, EM S. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clinical drug investigation. 2012;32:157-169.
7526.	KA T, Jiang Q, PT N. Analysis of the Effect of Desvenlafaxine on Anxiety Symptoms Associated With Major Depressive Disorder: Pooled Data From 9 Short-Term, Double-Blind, Placebo-Controlled Trials. CNS spectrums. 2010;15:187-193.
7527.	KA T, Pitrosky B, SK P, GR R. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Primary care companion to the Journal of clinical psychiatry. 2011.
7528.	Desvenlafaxine 50 and 100 Mg/D in the Treatment of Major Depressive Disorder: an 8-Week, Phase Iii, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial and a Post Hoc Pooled Analysis of Three Studies, Clinical therapeutics(2009).
7529.	KA V, BL M. New approaches to the treatment of frontotemporal lobar degeneration. Current opinion in neurology. 2008;21:708-716.
7530.	KA VO, AE B, Conwell Y, IIICF R. Does reducing social disconnectedness represent a mechanism whereby depression treatment reduces suicide risk? American journal of geriatric psychiatry. 2014;Conference:S134-S135.
7531.	KA Y. Antidepressants in the Treatment of Premenstrual Dysphoric Disorder. Journal of clinical psychiatry. 1997;58:4-13.
7532.	KA Y. The Association Between Premenstrual Dysphoric Disorder and Other Mood Disorders. Journal of clinical psychiatry. 1997;58:19-25.
7533.	KA Y, ER N, MV S, et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology (Cambridge, Mass.). 2012;23:677-685.
7534.	KA Y, GA H, Poschman K, HB H. Symptom-Onset Treatment for Women With Premenstrual Dysphoric Disorder. Journal of clinical psychopharmacology. 2006;26:198-202.
7535.	KA Y, Lieberman, Rickels, Brawmanmintzer, Lydiard. Anxiety Symptoms and Anxiety Disorders: How Are They Related to Premenstrual Disorders? Journal of clinical psychiatry. 1997;58:62-69.
7536.	KA Y, Pearlstein T, Fayyad R, JA G. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. Journal of affective disorders. 2005;85:317-321.
7537.	KA Y, RH C, MH T. The Psychopharmacological Treatment of Nonmajor Mood Disorders. Mood Disorders. 1997;25:146-166.
7538.	KA Y, TB P, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. Journal of clinical psychopharmacology. 2013;33:614-620.
7539.	Kaan A, T DM, PFJ S. Treatment of depression in Parkinson's disease: Paroxetine, venlafaxine extended release and placebo. [Dutch]. Tijdschrift voor psychiatrie. 2013;55:220-221.
7540.	Kachowski L, DR O, M KQ. Medications for weight loss in patients with type 2 diabetes mellitus. American family physician. 2012;85:633-635.
7541.	Kacinski M, Leskiewicz M, Jaworska-Feil L, et al. Pseudo-Epileptic Seizures in Children Are Not Associated With Enhanced Plasma Level of Allopregnanolone. Pharmacological Reports. 2007;59:683-690.
7542.	Kaddurah-Daouk R. Pharmacometabolomic analysis of depression and treatment outcomes. Biological psychiatry. 2013;Conference:107S-108S.
7543.	Kaddurah-Daouk R, Matson W, Sharma S, et al. Metabolomic signatures for response to sertraline and placebo. Neuropsychopharmacology. 2010;Conference:S278.
7544.	Kaddurah-Daouk R, MB B, WR W, et al. Pharmacometabolomic Mapping of Early Biochemical Changes Induced by Sertraline and Placebo. Translational psychiatry. 2013;3.
7545.	Kaddurah-Daouk R, MB B, WR W, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry Psychiatry. 2013;3:e223.
7546.	Kaddurah-Daouk R, SH B, Matson W, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Translational psychiatry. 2011;1:e26.
7547.	Kaddurah-Daouk R, SH B, Matson W, et al. Pretreatment Metabotype as a Predictor of Response to Sertraline or Placebo in Depressed Outpatients: a Proof of Concept. Translational psychiatry. 2011;1.
7548.	Kaddurah-Daouk R, SH B, Matson W, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry Psychiatry. 2011;1:1.
7549.	KADK D. Agomelatine in Treating Generalized Anxiety Disorder. Expert opinion on investigational drugs. 2014;23:857-864.
7550.	Kadoguchi N, Okabe S, Yamamura Y, et al. Mirtazapine Has a Therapeutic Potency in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (Mptp)-Induced Mice Model of Parkinson's Disease. BMC neuroscience. 2014;15.
7551.	KAHK H. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. [Review]. Progress in neurobiology. 2013;100:15-29.
7552.	Kajander J, Vilkman H, Syvalahti E, Nagren K, Hietala J. Effects of repeated fluoxetine treatment on striatal D2 dopamine binding in humans, measured with positron emission tomography. Nordic journal of psychiatry. 1998;52:121-122.
7553.	Kalali A, Montgomery S, Earley W, Szamosi J, Eriksson H. Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy and adjunct therapy in patients with major depressive disorder. International journal of neuropsychopharmacology. 2010;Conference:151.
7554.	Kamalipour M, AH J, Akhondzadeh S. Antidepressant effect of Crocus sativus: An evidence based review. Journal of Medicinal Plants. 2010;9:35-38.
7555.	Kamalipour M, SH A, Sh R. Herbal medicines in the treatment of depression and anxiety. Journal of Medicinal Plants. 2008;7:1-7.
7556.	Kamath J, DeMartinis N, Handratta V. Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. Future neurology. 2007;2:361-371.
7557.	Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: A critical review of the evidence. Expert review of neurotherapeutics. 2008;8:1787-1797.
7558.	Kamenov K, Mellor-Marsa B, Leal I, JL A-M, Cabello M. Analysing Psychosocial Difficulties in Depression: a Content Comparison Between Systematic Literature Review and Patient Perspective. Biomed Research International. 2014.
7559.	Kamijima K, Hashimoto S, Nagayoshi E, Koyama T. Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression. Neuropsychiatric disease and treatment. 2013;9:555-565.
7560.	Kamijima K, Hashimoto S, Nagayoshi E, Koyama T. Double-Blind, Comparative Study of Milnacipran and Paroxetine in Japanese Patients With Major Depression. Neuropsychiatric disease and treatment. 2013;9:555-564.
7561.	Kamijima K, Hashimoto T, Fujiwara A, et al. Phase I study of sertraline hydrochloride (CP-51, 974-1): Multiple dose study. Japanese Journal of Neuropsychopharmacology. 1997;19:425-447.
7562.	Kamijima K, Koyama T, Mita T, et al. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of depression and depressive state: A double-blind, group comparison study of sertraline by hydrochloride vs amitriptyline hydrochloride. [Japanese]. Japanese Journal of Neuropsychopharmacology. 1997;19:529-548.
7563.	Kamijima K, Koyama T, Mita T, et al. Clinical Evaluation of Sertraline Hydrochloride, a Selective Serotonin Reuptake Inhibitor in the Treatment of Depression and Depressive State - a Double-Blind, Group Comparison Study of Sertraline Hydrochloride Vs Amitriptyline Hydrochloride. Japanese Journal of Neuropsychopharmacology. 1997;19:529-548.
7564.	Kamijima K, Kuboki T, Kumano H, et al. A Placebo-Controlled, Randomized Withdrawal Study of Sertraline for Panic Disorder in Japan. International clinical psychopharmacology. 2005;20:265-273.
7565.	Kamijima K, Otsubo T, Ota A, et al. Phase I study of sertraline hydrochloride (CP-51, 974 1): Single dose study. [Japanese]. Japanese Journal of Neuropsychopharmacology. 1997;19:395-423.
7566.	Kamijima K, Yamashita I, Yamauchi T, et al. Clinical Evaluation of Sertraline Hydrochloride, a Selective Serotonin Reuptake Inhibitor for Depression and Depressive State. Japanese Journal of Neuropsychopharmacology. 1997;19:471-485.
7567.	Kampman O, Poutanen O. Can onset and recovery in depression be predicted by temperament? A systematic review and meta-analysis. Journal of affective disorders. 2011;135:20-27.
7568.	Kanba S, Kato T, Terao T, Yamada K. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry and clinical neurosciences. 2013;67:285-300.
7569.	Kandasamy M, Tripathy K, Ravi S, et al. Unsuspected Poor Metabolizer Phenotypes of Fluoxetine in Bioavailability/Bioequivalence Studies From an Indian Population Perspective Retrospective Pharmacokinetic Data Evaluation. Arzneimittel-Forschung-Drug Research. 2010;60:12-21.
7570.	Kaneda A, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S. The influence of the personality factor on the treatment with paroxetine in patient with major depressive disorders. International journal of neuropsychopharmacology. 2010;Conference:151.
7571.	Kaneda A, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S. The influence of personality factors on paroxetine response time in patients with major depression. Journal of affective disorders. 2011;135:321-325.
7572.	Kanemaru K, Hasegawa S, Nishi K, Diksic M. Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation. Brain research bulletin. 2008;77:214-220.
7573.	Kanemoto K, Matsubara M, Yamashita K, Tarao Y, Inada E, Sekine T. Controlled Comparison of Two Different Doses of Milnacipran in Major Depressive Outpatients. International clinical psychopharmacology. 2004;19:343-346.
7574.	Kanemoto K, Matsubara M, Yamashita K, Tarao Y, Inada E, Sekine T. Controlled Comparison of Two Different Doses of Milnacipran in Major Depressive Outpatients. International clinical psychopharmacology. 2004;19:343-346.
7575.	Kanemoto K, Tadokoro Y, AJ S, Oshima T. Lack of data on depression-like states and antidepressant pharmacotherapy in patients with epilepsy: Randomised controlled trials are badly needed. Current pharmaceutical design. 2012;18:5828-5836.
7576.	Kannan S, MM H, ES L, JY K. The role of tumor necrosis factor-alpha and other cytokines in depression: What dermatologists should know. Journal of dermatological treatment. 2013;24:148-152.
7577.	Kano O, Ikeda K, Cridebring D, Takazawa T, Yoshii Y, Iwasaki Y. Neurobiology of depression and anxiety in parkinson's disease. Parkinson's disease. 2011.
7578.	Kant R, Smith-Seemiller L, Zeiler D. Treatment of Aggression and Irritability After Head Injury. Brain injury. 1998;12:661-666.
7579.	Kapczinski F, FK G, Frey B, Kauer-SanT'Anna M, Tramontina J. Pharmacological treatment of bipolar disorder: Evidence from randomized clinical trials. [Portuguese]. Revista de Psiquiatria Clinica. 2005;32:34-38.
7580.	KAPK P. Anxiety, Depression and Acupuncture: a Review of the Clinical Research. Autonomic Neuroscience-Basic & Clinical. 2010;157:91-95.
7581.	Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatric services (Washington, D.C.). 2003;54:1111-1118.
7582.	Kaplan C, Zhang Y. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US medicare population. Journal of mental health policy and economics. 2012;15:171-202.
7583.	Kaplan G, Ivanov I. Pharmacotherapy for Substance Abuse Disorders in Adolescence. Pediatric clinics of North America. 2011;58:243-258.
7584.	Kaplan G, JH N. Pharmacotherapy for Child and Adolescent Attention-deficit Hyperactivity Disorder. Pediatric clinics of North America. 2011;58:99-120.
7585.	Kaplan G, JT M. Psychopharmacology of autism spectrum disorders. Pediatric clinics of North America. 2012;59:175-187.
7586.	Kapornai K, Vetro A. Depression in Children. Current opinion in psychiatry. 2008;21:1-7.
7587.	Kapur S, Mieczkowski T, JJ M. Antidepressant Medications and the Relative Risk of Suicide Attempt and Suicide. Jama-Journal of the American Medical Association. 1992;268:3441-3445.
7588.	Kara H, Aydin S, MY A, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study. Journal of urology. 1996;156:1631-1632.
7589.	Karabekiroglu K, MN K, Yuce M, GNT S. Fluoxetine for the Treatment of Childhood and Adolescence Social Phobia: Factors Playing a Role in Efficacy. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2011;21:317-324.
7590.	Karabi G. Tolerance and side-effects of paroxetine in elderly depressed patients. Archives of gerontology and geriatrics. 1997;24:35-45.
7591.	Karabulut V, YC C, Ozcelik B, et al. Comparison of six antidepressants in terms of time to discontinuation. European neuropsychopharmacology. 2009;Conference:S384-S385.
7592.	Karaiskos D, Tzavellas E, Ilias I, Liappas A, Liappas I, Paparrigopoulos T. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. European psychiatry. 2013.
7593.	Karaiskos D, Tzavellas E, Ilias I, Liappas I, Paparrigopoulos T. Agomelatine and Sertraline for the Treatment of Depression in Type 2 Diabetes Mellitus. International journal of clinical practice. 2013;67:257-260.
7594.	Karakaya T, Fusser F, Prvulovic D, Hampel H. Treatment options for tauopathies. Current treatment options in neurology. 2012;14:126-136.
7595.	Karakus G, Tamam L. Impulse Control Disorder Comorbidity Among Patients With Bipolar I Disorder. Comprehensive psychiatry. 2011;52:378-385.
7596.	Karamustafalioglu O, Bozkurt S. Pharmacotherapeutic treatment choices of of post-traumatic stress disorder. [Turkish]. Klinik Psikofarmakoloji Bulteni. 2009;19:S94-S97.
7597.	Karamustafalioglu O, Cevik M, Tankaya O, et al. Effects of add-on rTMS on response and remission in moderate to severe depressive disorder. Clinical EEG and neuroscience. 2011;Conference:67.
7598.	Karanges E, IS M. Antidepressants and adolescent brain development. Future neurology. 2011;6:783-808.
7599.	Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: A review of systematic reviews. Frontiers in pharmacology. 2013.
7600.	Karen H, D GM, Alok K, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of psychopharmacology (Oxford, England). 2010;24:1209-1216.
7601.	Karen H, Rudolf U, A CA, et al. Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the genome-based therapeutic drugs for depression (GENDEP) study. Journal of psychopharmacology (Oxford, England). 2014;28:142-150.
7602.	Karen OF, Veronica OK, V LJ, G DT. Effect of fluoxetine on noradrenergic mediated growth hormone release: A double blind, placebo-controlled study. Biological psychiatry. 1991;30:377-382.
7603.	Pharmacological approaches to methamphetamine dependence: A focused review, British journal of clinical pharmacology(2010).
7604.	Karl R, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta neurologica Scandinavica. 1989;80:117-123.
7605.	Karl R, D AJ, F AM. Fluoxetine in major depression: A controlled study. Current therapeutic research, clinical and experimental. 1986;39:559-563.
7606.	Karlovic D, Serretti A. Serotonin Transporter Gene (5-Httlpr) Polymorphism and Efficacy of Selective Serotonin Reuptake Inhibitors - Do We Have Sufficient Evidence for Clinical Practice. Acta clinica Croatica. 2013;52:353-362.
7607.	Karlsson H. Remission in depression--is it a realistic goal? Nordic journal of psychiatry. 2008;62:421-422.
7608.	Karlsson H, Hirvonen J, Kajander J, et al. Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychological medicine. 2010;40:523-528.
7609.	Karlsson H, Hirvonen J, Kajander J, et al. Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychological medicine. 2010;40:523-528.
7610.	Karlsson H, Hirvonen J, Salminen J, Hietala J. Increased serotonin receptor 1A binding in major depressive disorder after psychotherapy, but not after SSRI pharmacotherapy, is related to improved social functioning capacity. Psychotherapy and psychosomatics. 2013;82:260-261.
7611.	Karlsson H, Hirvonen J, Salminen J, Hietala J. Increased serotonin receptor 1A binding in major depressive disorder after psychotherapy, but not after SSRI pharmacotherapy, is related to improved social functioning capacity. Psychotherapy and psychosomatics. 2013;82:260-261.
7612.	Karlsson I. Pharmacologic Treatment of Noncognitive Symptoms of Dementia. Acta Neurologica Scandinavica, Supplement. 1996;93:101-104.
7613.	Karvelas D, SV V. Fibromyalgia syndrome. Pain management. 2011;1:557-570.
7614.	Kasckow J, Felmet K, Zisook S. Managing suicide risk in patients with schizophrenia. CNS drugs. 2011;25:129-143.
7615.	Kasckow J, Montross L, Prunty L, Fox L, Zisook S. Suicidal behavior in the older patient with schizophrenia. Aging health. 2011;7:379-393.
7616.	Kasper S. Is severe depression a different illness? The pharmacological evidence. European neuropsychopharmacology. 1993;3:215-217.
7617.	Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. [Review] [45 refs][Erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153]. International clinical psychopharmacology. 1995;10 Suppl 4:25-35.
7618.	Kasper S. Citalopram - Profile of a modern antidepressant agent. [German]. Psychopharmakotherapie. 1996;3:146-151.
7619.	Kasper S. Treatment of Seasonal Affective Disorder (Sad) With Hypericum Extract. Pharmacopsychiatry. 1997;30:89-93.
7620.	Kasper S. Effectiveness of antidepressants in the treatment of severe depression - The position of mirtazapine. [German]. Psychopharmakotherapie. 1998;5:99-108.
7621.	Kasper S. Pharmacological Treatment of Seasonal Affective Disorder - the Role of Hypericum Extract. Psychopharmakotherapie. 1998;5:21-25.
7622.	Kasper S. Pharmacological treatment of seasonal affective disorder - The role of hypericum extract. [German]. Psychopharmakotherapie, Supplement. 1998;5:21-25.
7623.	Kasper S. Unique Mechanism of Action for Escitalopram: Does It Hold the Promise? International journal of psychiatry in clinical practice. 2004;8:15-18.
7624.	Kasper S. Anxiety Disorders: Under-Diagnosed and Insufficiently Treated. International journal of psychiatry in clinical practice. 2006;10:3-9.
7625.	Kasper S. The psychiatrist confronted with a fibromyalgia patient. Human psychopharmacology. 2009;24:S25-S30.
7626.	Kasper S. Anxiety: A common theme in psychiatric disorders? European neuropsychopharmacology. 2009;Conference:S715.
7627.	Kasper S. The World Journal of Biological Psychiatry vol. 11, issue 7. World journal of biological psychiatry. 2010;11:843.
7628.	Kasper S. EDITORIAL. World journal of biological psychiatry. 2010;11:1.
7629.	Kasper S. Treatment-resistant depression: A challenge for future research. Acta neuropsychiatrica. 2014;26:131-133.
7630.	Kasper S, Baldwin D. International Journal of Psychiatry in Clinical Practice: Editorial. International journal of psychiatry in clinical practice. 2003;7:229.
7631.	Kasper S, Baldwin D, JP B. Pooled Analysis of Two Randomised Clinical Trials of Escitalopram and Paroxetine Fit the Treatment of Major Depressive Disorder (Mdd). International journal of neuropsychopharmacology. 2008;11:193.
7632.	Kasper S, Baldwin D, JP B. Pooled Analysis: 2 Randomised Clinical Trials Confirms Superiority of Escitalopram Over Paroxetine in Treatment of Major Depressive Disorder. European neuropsychopharmacology. 2008;Conference:S297-S298.
7633.	Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R. How Well Do Randomized Controlled Trial Data Generalize to 'real-World' Clinical Practice Settings? A Comparison of Two Generalized Anxiety Disorder Studies. European neuropsychopharmacology. 2014;24:125-132.
7634.	Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. European neuropsychopharmacology. 2010;20:747-765.
7635.	Kasper S, Corruble E, Hale A, Lemoine P, SA M, M-A Q-S. Antidepressant Efficacy of Agomelatine Versus Ssri/Snri: Results From a Pooled Analysis of Head-to-Head Studies Without a Placebo Control. International clinical psychopharmacology. 2013;28:12-19.
7636.	Kasper S, Dienel A, Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression - Rationale and study design. International journal of methods in psychiatric research. 2004;13:176-183.
7637.	Kasper S, DJ S, Loft H, Nil R. Escitalopram in the Treatment of Social Anxiety Disorder - Randomised, Placebo-Controlled, Flexible-Dosage Study. British journal of psychiatry. 2005;186:222-226.
7638.	Kasper S, DJ S, Loft H, Nil R. Escitalopram in the Treatment of Social Anxiety Disorder - Randomised, Placebo-Controlled, Flexible-Dosage Study. British journal of psychiatry. 2005;186:222-226.
7639.	Kasper S, Ebert B, Larsen K, Tonnoir B. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. European neuropsychopharmacology. 2011;Conference:S408.
7640.	Kasper S, Fuger J, H-J M. Comparative efficacy of antidepressants. Drugs. 1992;43:11-23.
7641.	Kasper S, Fuger J, HJ M. Comparative efficacy of antidepressants. [Review] [113 refs]. Drugs. 1992;43 Suppl 2:11-13.
7642.	Kasper S, Gastpar M, WE M. Efficacy of antidepressants: Rather differentiated assessment than overall criticism. [German]. Psychopharmakotherapie. 2005;12:193-194.
7643.	Kasper S, Gastpar M, WE M, H-P V, Dienel A, H-J M. Treatment of depression with St. John's wort extract WS 5570. No influence on patients' weight. [German]. Psychopharmakotherapie. 2008;15:6-10.
7644.	Kasper S, Gastpar M, WE M, HP V, Dienel A, HJ M. Treatment of Depression With St. John's Wort Extract Ws (R) 5570. No Influence on Patients' Weight. Psychopharmakotherapie. 2008;15:6-+.
7645.	Kasper S, Gastpar M, WE M, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. International journal of neuropsychopharmacology. 2014;17:859-869.
7646.	Kasper S, H dS, H FA. Escitalopram in the treatment of depressed elderly patients. American journal of geriatric psychiatry. 2005;13:884-891.
7647.	Kasper S, H-J M, Montgomery SA, Zondag E. Antidepressant efficacy in relation to item analysis and severity of depression: A placebo-controlled trial of fluvoxamine versus imipramine. International clinical psychopharmacology. 1995;9 Suppl 4:3-12.
7648.	Kasper S, Hajak G. The efficacy of agomelatine in previously treated depressed patients. International journal of psychiatry in clinical practice. 2010;Conference:26-27.
7649.	Kasper S, Hajak G, Wulff K, et al. Efficacy the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. Zhurnal Nevrologii i Psihiatrii imeni S.S. 2011;Korsakova.:92-94.
7650.	Kasper S, Hale A, Lemoine P, MA QS. Superior efficacy results of agomelatine in a pooled analysis versus SSRI/SNRI. European neuropsychopharmacology. 2010;Conference:S348-S349.
7651.	Kasper S, Heiden A. Citalopram in depressive male patients - A drug surveillance. [German]. Psychopharmakotherapie. 2002;9:95-99.
7652.	Kasper S, Herman B, Nivoli G, et al. Efficacy of Pregabalin and Venlafaxine-Xr in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 8-Week Trial. International clinical psychopharmacology. 2009;24:87-96.
7653.	Kasper S, Hernandez-Ribas R. Prof. Siegfried Kasper's speech on agomelatine: Clinical efficacy of the first melatonergic antidepressant. [Spanish]. Revista de Psiquiatria y Salud Mental. 2010;3:12-14.
7654.	Kasper S, Hesselmann B, Wein W. [Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients]. [German]. Wiener klinische Wochenschrift. 1997;109:197-201.
7655.	Kasper S, Hesselmann B, Wein W. Continuation treatment with fluoxetine (20 mg daily). An application study on 1737 patients with depression. [German]. Wiener klinische Wochenschrift. 1997;109:197-201.
7656.	Kasper S, Hoflich G, H-P S, H-J M. Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Human Psychopharmacology: Clinical and Experimental. 1994;9:1-12.
7657.	Kasper S, Hoflich G, H-P S, H-J M. "Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors": Erratum. Human Psychopharmacology: Clinical and Experimental. 1994;9:226.
7658.	Kasper S, HP V, HJ M, Dienel A, Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. European neuropsychopharmacology. 2008;18:803-813.
7659.	Kasper S, Iglesias-Garcia C, Schweizer E, et al. Pregabalin Long-Term Treatment and Assessment of Discontinuation in Patients With Generalized Anxiety Disorder. International journal of neuropsychopharmacology. 2014;17:685-695.
7660.	Kasper S, JP O. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. European Psychiatry: the Journal of the Association of European Psychiatrists. 2002;17 Suppl 3:331-340.
7661.	Kasper S, JP O. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. European psychiatry. 2002;17:331-340.
7662.	Kasper S, JR C, Johnson G, et al. International consensus group on the evidence-based pharmacologic treatment of bipolar I and II depression. Journal of clinical psychiatry. 2008;69:1632-1646.
7663.	Kasper S, Kick H, Voll G, Vieira A. Therapeutic sleep deprivation and antidepressant medication in patients with major depression. European neuropsychopharmacology. 1991;1:107-111.
7664.	Kasper S, Laigle L, Bayle F. Superior Antidepressant Efficacy of Agomelatine Versus Sertraline: a Randomised, Double-Blind Study. European neuropsychopharmacology. 2008;Conference:S336-S337.
7665.	Kasper S, Lemoine P. Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline. European neuropsychopharmacology. 2008;Conference:S331-S332.
7666.	Kasper S, Meshkat D, Kutzelnigg A. Improvement of the noradrenergic symptom cluster following treatment with milnacipran. Neuropsychiatric disease and treatment. 2011;7:21-27.
7667.	Kasper S, Muller-Spahn F. Intravenous antidepressant treatment: focus on citalopram. [Review] [31 refs]. European archives of psychiatry and clinical neuroscience. 2002;252:105-109.
7668.	Kasper S, Olie JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. European psychiatry. 2002;17:331s-340s.
7669.	Kasper S, Olivieri L, G DL, Dionisio P. A Comparative, Randomised, Double-Blind Study of Trazodone Prolonged-Release and Paroxetine in the Treatment of Patients With Major Depressive Disorder. Current medical research and opinion. 2005;21:1139-1146.
7670.	Kasper S, Olivieri L, G DL, Dionisio P. A Comparative, Randomised, Double-Blind Study of Trazodone Prolonged-Release and Paroxetine in the Treatment of Patients With Major Depressive Disorder. Current medical research and opinion. 2005;21:1139-1146.
7671.	Kasper S, Pail G. Milnacipran: a Unique Antidepressant? Neuropsychiatric disease and treatment. 2010;6:23-31.
7672.	Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. [Review] [65 refs][Erratum appears in Drug Saf 1998 Feb;18(2):123]. Drug safety. 1997;17:251-264.
7673.	Kasper S, RD T-S. St John's wort extract: An effective and well-tolerated antidepressant. Primary Care Psychiatry. 2001;7:39-42.
7674.	Kasper S, RD T-S. St. John's Wort - A well tolerated and effective antidepressant. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2004;5:48-55.
7675.	Kasper S, SA M, H-J M, et al. Longitudinal Analysis of the Suicidal Behaviour Risk in Short-Term Placebo-Controlled Studies of Mirtazapine in Major Depressive Disorder. World journal of biological psychiatry. 2010;11:36-44.
7676.	Kasper S, Sacher J, Klein N, et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International clinical psychopharmacology. 2009;24:119-125.
7677.	Kasper S, Voll G, Vieira A, Kick H. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression - results of a double-blind study. Pharmacopsychiatry. 1990;23:135-142.
7678.	Kasper S, Zivkov M, KCB R, AG P. Pharmacological treatment of severely depressed patients: A meta-analysis comparing efficacy of mirtazapine and amitriptyline. [German]. Nervenheilkunde. 1997;16:294-302.
7679.	Kasper S, Zivkov M, Roes KCB, Pols AG. Pharmacological treatment of severely depressed patients: A meta- analysis comparing efficacy of mirtazapine and amitriptyline. European neuropsychopharmacology. 1997;7:115-124.
7680.	Kassam-Adams N, ML M, Hildenbrand A, Winston F. Posttraumatic stress following pediatric injury update on diagnosis, risk factors, and intervention. JAMA Pediatrics. 2013;167:1158-1165.
7681.	Effects of antidepressant medication on emotion regulation in depressed patients: An iSPOT-D report, Journal of affective disorders(2014).
7682.	Kates N. Attention deficit disorder in adults. Management in primary care. Canadian Family Physician. 2005;51:53-59.
7683.	Kathleen F, Shishuka M. Poststroke depression. American journal of psychiatry. 2001;158:658-659.
7684.	Kathleen P, Donald A, Jean A, Scott P. Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2006;51:715-718.
7685.	Kathryn DL, M WS, M MP, M CC, B SA. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology. 2004;174:525-529.
7686.	Kathryn L, N JV, Yueping Z, Kathleen R, Chunfu Q, Bruce C. Validation of the Sleep Impact Scale in patients with major depressive disorder and insomnia. Current medical research and opinion. 2009;25:1699-1710.
7687.	Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine Xr) Monotherapy in Elderly Patients With Major Depressive Disorder. American journal of geriatric psychiatry. 2013;21:769-784.
7688.	Kato M. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment]. [Review] [15 refs] [Japanese]. Nihon shinkei seishin yakurigaku zasshi [Japanese journal of psychopharmacology]. 2010;30:83-92.
7689.	Kato M. Pharmacogenetical approach to prediction and personalized medication in major depressive disorder treatment. International journal of neuropsychopharmacology. 2010;Conference:6.
7690.	Kato M. [Choosing the adequate antidepressant focusing on efficacy, tolerability and its predictors]. [Japanese]. Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica. 2012;114:589-600.
7691.	Kato M, C-M C. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS drugs. 2013;27:S11-S119.
7692.	Kato M, CM C. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. [Review]. CNS drugs. 2013;27 Suppl 1:S11-19.
7693.	Kato M, CM C. Augmentation Treatments With Second-Generation Antipsychotics to Antidepressants in Treatment-Resistant Depression. CNS drugs. 2013;27:S11-S19.
7694.	Kato M, Ikenaga Y, Wakeno M, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International clinical psychopharmacology. 2005;20:151-156.
7695.	Kato M, Kimura T, Kimura T, Hara T. Safety and Effectiveness of Controlled-Release Paroxetine in Routine Clinical Practice: Results of a Postmarketing Surveillance Study of Patients With Depression. Neuropsychiatric disease and treatment. 2015;11:435-452.
7696.	Kato M, Nonen S, Serretti A, et al. 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: A randomized, controlled trial. Journal of clinical psychopharmacology. 2013;33:131-132.
7697.	Kato M, Sakai S, Koshikawa Y, et al. Randomised clinical trial of mirtazapine versus SSRIs. Interim report of genetic utility needed for depression antidepressant medication (GUNDAM) study. European neuropsychopharmacology. 2014;Conference:S457.
7698.	Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular psychiatry. 2010;15:473-500.
7699.	Kato M, Serretti A, Nonen S, et al. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: The result of two pooled RCTs. Translational psychiatry. 2015.
7700.	Kato M, Tetsuo S, Wakeno M, et al. New functional variant in SLC6A4 gene as candidate of the individualised treatment of depression - The result of an RCT. European neuropsychopharmacology. 2010;Conference:S374-S375.
7701.	Kato M, Wakeno M, Okugawa G, et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology. 2007;56:167-171.
7702.	Kato M, Wakeno M, Takekita Y, Okugawa G, Sakai S, Kinoshita T. Efficacy and tolerability of paroxetine, fluvoxamine and milnacipran in depression: A result of two pooled open label randomized controlled trial. International journal of neuropsychopharmacology. 2012;Conference:148.
7703.	Kato M, Wakeno M, Tetsuo S, et al. Early partial improvement in combination with genetic variants as a predictor in major depressive disorder treatment: The result of two RCTs. European neuropsychopharmacology. 2011;Conference:S361-S362.
7704.	Kato S. [Review of placebo effect and re-evaluation of psychotherapy focusing on depressive disorders]. [Review] [Japanese]. Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica. 2013;115:887-900.
7705.	Katoh Y, Uchida S, Kawai M, et al. Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients. Biological & pharmaceutical bulletin. 2010;33:1999-2002.
7706.	Katon W, M vK, Lin E, Bush T, Ormel J. Adequacy and Duration of Antidepressant Treatment in Primary Care. Medical care. 1992;30:67-76.
7707.	Katon W, M VK, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: A randomized trial. Archives of general psychiatry. 1999;56:1109-1115.
7708.	Katon W, M VK, Lin E, et al. Collaborative management to achieve treatment guidelines: Impact on depression in primary care. Journal of the American Medical Association. 1995;273:1026-1031.
7709.	Katona C. Optimizing treatment for the elderly depressive: New antidepressants in the elderly. Journal of psychopharmacology (Oxford, England). 1993;7:131-134.
7710.	Katona C. Managing Depression and Anxiety in the Elderly Patient. European neuropsychopharmacology. 2000;10:S427-S432.
7711.	Katona C. New Antidepressants for Older People: A Critical Review of the Evidence Base. Encephale. 2008;34:S71-S76.
7712.	Katona C, CG L, Steinberg M, Qureshi S, Weiller E, Gorwood P. Are old-old patients with MDD more likely to relapse than the young-old after open label treatment with escitalopram? International journal of psychiatry in clinical practice. 2009;Conference:42.
7713.	Katona C, DC B, CP K. Antidepressants for older people: What can we learn from the current evidence base? Maturitas. 2014;79:174-178.
7714.	Katona C, Hansen T, CK O. A randomised, double-blind, placebocontrolled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European neuropsychopharmacology. 2012;Conference:S258-S259.
7715.	Katona C, Livingston G. How well do antidepressants work in older people? A systematic review of Number Needed to Treat. Journal of affective disorders. 2002;69:47-52.
7716.	Katona CL, Robertson MM, Abou-Saleh MT, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. International clinical psychopharmacology. 1993;8:323.
7717.	Katsarava Z, DC B, AN M, RB L. Defining the differences between episodic migraine and chronic migraine. Current pain and headache reports. 2012;16:86-92.
7718.	Katz T, Fisher P, Katz A, Davidson J, Feder G. The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. Homeopathy: the Journal of the Faculty of Homeopathy. 2005;94:145-152.
7719.	Kauer-Sant' AM, Flavio K, Eduard V. Epidemiology and management of anxiety in patients with bipolar disorder. CNS drugs. 2009;23:953-964.
7720.	Kaufeler R, Meier B, Brattstrom A. Clinical studies with St. John's worth extract Ze 117. [German]. Praxis. 2001;90:1138-1139.
7721.	Kaufeler R, Meier B, Brattstrom A. Efficacy and tolerability of Ze 117 St. John's wort extract in comparison with placebo, imipramine, and fluoxetine for the treatment of mild to moderate depression according to ICD-10: An overview. Pharmacopsychiatry. 2001;34:S49-S50.
7722.	Kaufeler R, Meier B, Brattstrom A. Efficacy and tolerability of Ze 117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview. [Review] [3 refs]. Pharmacopsychiatry. 2001;34 Suppl 1:S49-50.
7723.	Kaufmann C, Panayiotou P, Dossenbach M, GS B. Treatment of accompanying depression. [German]. Wiener medizinische Wochenschrift (1946). 1992;142:145-152.
7724.	Kaufmann C, Panayiotou P, Dossenbach M, GS B. [Concomitant depression and its treatment]. [German]. Wiener medizinische Wochenschrift (1946). 1992;142:145-152.
7725.	Kaur A, Kumar A, SL H, Navis S. Immensed risk of diabetes associated with the use of antidepressants. International Journal of Advances in Pharmaceutical Research. 2013;4:2200-2207.
7726.	Kavirajan H. Venlafaxine and SSRI remission data revisited [2]. British journal of psychiatry. 2004;184:452-453.
7727.	Kavirajan H, [Ed] IK. Venlafaxine and SSRI remission data revisited. The British Journal of Psychiatry. 2004;184:452-453.
7728.	Kaye W, Gendall K, Strober M. Serotonin Neuronal Function and Selective Serotonin Reuptake Inhibitor Treatment in Anorexia and Bulimia Nervosa. Biological psychiatry. 1998;44:825-838.
7729.	Kayiran S, Dursun E, Dursun N, Ermutlu N, Karamursel S. Neurofeedback intervention in fibromyalgia syndrome; A randomized, controlled, rater blind clinical trial. Applied psychophysiology and biofeedback. 2010;35:293-302.
7730.	Kaymaz N, J VO, AJM L, WA N. Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation: a Meta-Analysis of Placebo-Controlled Randomized Trials. Journal of clinical psychiatry. 2008;69:1423-+.
7731.	Kaymaz N, J VO, AJM L, WA N. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: A meta-analysis of placebo-controlled randomized trials. Journal of clinical psychiatry. 2008;69:1423-1436.
7732.	Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The Effects of Trazodone on Sleep in Patients Treated With Stimulant Antidepressants. Sleep medicine. 2004;5:15-20.
7733.	Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The Effects of Trazodone on Sleep in Patients Treated With Stimulant Antidepressants. Sleep medicine. 2004;5:15-20.
7734.	KB J, Petzke F, Carville S, et al. Anxiety and Depressive Symptoms in Fibromyalgia Are Related to Poor Perception of Health but Not to Pain Sensitivity or Cerebral Processing of Pain. Arthritis and rheumatism. 2010;62:3488-3495.
7735.	KB S, Bech P, LF G, Kragh-Sorensen P, Rosenberg C, Ohrberg S. Are in-Patient Depressives More Often of the Melancholic Subtype? Acta psychiatrica Scandinavica. 1998;98:432-436.
7736.	KB T, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. [Review] [57 refs]. International journal of clinical practice. 2007;61:1349-1355.
7737.	KB W, LQ T, GA C, JR A. Treatment of Youth Depression in Primary Care Under Usual Practice Conditions: Observational Findings From Youth Partners in Care. Journal of child and adolescent psychopharmacology. 2012;22:80-90.
7738.	KB W, Sherbourne C, Schoenbaum M, et al. Impact of Disseminating Quality Improvement Programs for Depression in Managed Primary Care - a Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2000;283:212-220.
7739.	KC A, AJ S. Obesity and eating disorders. Psychiatric clinics of North America. 2005;28:55-67.
7740.	KC A, EP T. Treatment of night eating syndrome. Psychiatric clinics of North America. 2011;34:785-796.
7741.	KC D, DelDotto D. The role of olanzapine in the treatment of anorexia nervosa. Annals of pharmacotherapy. 2007;41:111-115.
7742.	KC H, Ostrander R, JT W, SG S, JS M. Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS). Journal of consulting and clinical psychology. 2007;75:716-728.
7743.	KC L, JJ C. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatric disease and treatment. 2007;3:527-537.
7744.	KC L, MD F, PR F. Beyond depression: Evaluation of newer indications and off-label uses for SSRIs. Formulary (Cleveland, Ohio). 2002;37:312-319.
7745.	KCM W, PG M, Ashworth L, MT A-S. Older community residents with depression: Long-term treatment with sertraline: Randomised, double-blind, placebo-controlled study. British journal of psychiatry. 2003;182:492-497.
7746.	KD B, HG R. Behavioral activation is effective in the treatment of depression. [Dutch]. Tijdschrift voor psychiatrie. 2007;49:411.
7747.	KD C. Neurodegeneration in pediatric mood disorders: Supporting evidence and the case for neuroprotection. Clinical Neuropsychiatry. 2006;3:184-193.
7748.	KD C. The use of atypical antipsychotics in pediatric bipolar disorder. Journal of clinical psychiatry. 2008;69:4-8.
7749.	KD C. Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues in clinical neuroscience. 2009;11:73-80.
7750.	KD G, VK H. Adjunctive therapy in parkinson's disease: The role of rasagiline. Neuropsychiatric disease and treatment. 2012;8:285-294.
7751.	KD H, Ho T, KB B, MC R. Narcotic withdrawal syndrome following gastric bypass - A difficult diagnosis. Obesity surgery. 2001;11:631-634.
7752.	KD K, JE C, JM L. Duloxetine pharmacology: profile of a dual monoamine modulator. [Review] [65 refs]. CNS drug reviews. 2002;8:361-376.
7753.	KD M, SL C. How effective are treatments for child and adolescent depression? A meta-analytic review. [Review] [112 refs]. Clinical psychology review. 2002;22:247-269.
7754.	KD W. Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacology bulletin. 2003;37 Suppl 1:167-175.
7755.	KD W. Pharmacotherapy for Major Depression in Children and Adolescents. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:819-826.
7756.	KD W. Predictors, criteria, and treatment response. Journal of clinical psychiatry. 2009;70:730-731.
7757.	KD W, Ambrosini P, Rynn M, March J. Sertraline reduced the severity of patients' depressive symptoms in major depressive disorder. Evidence-based medicine. 2004;9:46.
7758.	KD W, Ambrosini P, Rynn M, et al. Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder: Two Randomized Controlled Trials. JAMA: Journal of the American Medical Association. 2003;290:1033-1041.
7759.	KD W, AS R, RL F, JQ J, MM G, WE H. A Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents. American journal of psychiatry. 2004;161:1079-1083.
7760.	KD W, Berard R, MB S, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine in Children and Adolescents With Social Anxiety Disorder. Archives of general psychiatry. 2004;61:1153-1162.
7761.	KD W, Berard R, MB S, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine in Children and Adolescents With Social Anxiety Disorder. Archives of general psychiatry. 2004;61:1153-1162.
7762.	KE C, LA R. Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug and alcohol dependence. 2014;143:11-21.
7763.	KE E, Joffe H, KA G, et al. Effect of Escitalopram on Insomnia Symptoms and Subjective Sleep Quality in Healthy Perimenopausal and Postmenopausal Women With Hot Flashes: a Randomized Controlled Trial. Menopause-the Journal of the North American Menopause Society. 2012;19:848-855.
7764.	KE F, RM C. Depression as a risk factor for adverse outcomes in coronary heart disease. BMC medicine. 2013.
7765.	KE H, PB F. Introducing magnetic seizure therapy: A novel therapy for treatment resistant depression. Australian and New Zealand journal of psychiatry. 2010;44:591-598.
7766.	KE J, CM Oc. Lessons From Sadhart, Enrichd, and Other Trials. Psychosomatic medicine. 2005;67:S63-S66.
7767.	KE J, CM OC. Lessons from SADHART, ENRICHD, and other trials. [Review] [30 refs]. Psychosomatic medicine. 2005;67 Suppl 1:S63-66.
7768.	KE J, DJ W, CM OC. Depression and cardiovascular disease: Mechanisms of interaction. Biological psychiatry. 2003;54:248-261.
7769.	KE L, WM L, Denman D, WJ B. Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head & neck. 2009;31:888-892.
7770.	KE T, Guipponi M, Perroud N, et al. Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS medicine. 2012.
7771.	KEA S, GM G. New Approaches in the Treatment of Bipolar Depression. Behavioral Neurobiology of Depression and Its Treatment. 2013;Current To:291-307.
7772.	Keating C, Tilbrook A, Kulkarni J. Oestrogen: An overlooked mediator in the neuropsychopharmacology of treatment response? International journal of neuropsychopharmacology. 2011;14:553-566.
7773.	Keefe B. Interferon-induced depression in hepatitis C: An update. Current psychiatry reports. 2007;9:255-261.
7774.	Keefe R, Mahableshwarkar A, Zajecka J, Jacobson W, YZ C. Efficacy of Vortioxetine on Cognitive Function in Patients With Major Depressive Disorder: Cognitive Test Performance Results: From a Randomized, Double-Blind, Duloxetine-Referenced, Placebo-Controlled. Neuropsychopharmacology. 2014;Conference:S389-S390.
7775.	Keegan D, Bowen RC, Blackshaw S, et al. A comparison of fluoxetine and amitriptyline in the treatment of major depression. International clinical psychopharmacology. 1991;6:117-124.
7776.	Keers R, Bonvicini C, Scassellati C, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of psychopharmacology (Oxford, England). 2011;25:867-874.
7777.	Keers R, Ingelman-Sundberg M, Hauser J, et al. CYP2D6 and CYP2C19 genotypes predict antidepressant dose in the GENDEP project. European neuropsychopharmacology. 2010;Conference:S70-S71.
7778.	Keers R, Ingelman-Sundberg M, Hauser J, et al. CYP2D6 genotype predicts antidepressant dose in the GENDEP project. European neuropsychopharmacology. 2010;Conference:S172-S173.
7779.	Keers R, KJ A. Gender differences in antidepressant drug response. International review of psychiatry. 2010;22:485-500.
7780.	Keers R, KJ A. Pharmacogenetics of antidepressant response. Expert review of neurotherapeutics. 2011;11:101-125.
7781.	Keers R, Uher R, Gupta B, et al. Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of affective disorders. 2010;127:337-342.
7782.	Keers R, Uher R, Huezo-Diaz P, et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics journal. 2011;11:138-145.
7783.	Keers R, Uher R, Huezo-Diaz P, et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics journal. 2011;11:138-145.
7784.	Kei N, Taro K, Masatsugu M, et al. Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: A 4-week open-label, parallel-group study of major depressive disorder. Neuropsychiatric disease and treatment. 2013;9.
7785.	Kelin K, Berk M, Spann M, et al. Duloxetine 60 Mg/Day for the Prevention of Depressive Recurrences: Post Hoc Analyses From a Recurrence Prevention Study. International journal of clinical practice. 2010;64:719-726.
7786.	Kellner M, Muhtz C, Demiralay C, et al. The Selective Serotonin Re-Uptake Inhibitor Escitalopram Modulates the Panic Response to Cholecystokinin Tetrapeptide in Healthy Men Depending on 5-Httlpr Genotype. Journal of psychiatric research. 2009;43:642-648.
7787.	Kelly K, Posternak M, JE A. Toward achieving optimal response: Understanding and managing antidepressant side effects. Dialogues in clinical neuroscience. 2008;10:409-418.
7788.	Kelly O, Matheson K, Ravindran A, Merali Z, Anisman H. Rumfnative-Coping Among Patients With Dysthymia Before and After Pharmacotheraty. Depression and anxiety. 2007;24:233-243.
7789.	Kelsall D. Clinical shorts. CMAJ : Canadian Medical Association journal. 2011;183:1403.
7790.	Keming G, R CJ. Newer treatment studies for bipolar depression. Bipolar disorders. 2005;7:13-23.
7791.	Keming G, V SD, R CJ. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert review of neurotherapeutics. 2009;9:1147-1158.
7792.	Kendall T, Glover N, Taylor C, Pilling S. Quality, bias and service user experience in healthcare: 10 Years of mental health guidelines at the UK National Collaborating Centre for Mental Health. International review of psychiatry. 2011;23:342-351.
7793.	Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care, Health technology assessment (Winchester, England)(2009).
7794.	Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care, Health technology assessment(2009).
7795.	Kendrick T, Peveler R, Longworth L, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: Randomised controlled trial. British journal of psychiatry. 2006;188:337-345.
7796.	Kendrick T, Simons L, Mynors-Wallis L, et al. A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study. Health technology assessment. 2005;9:iii-59.
7797.	Kenji H. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-Methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder". Journal of clinical psychopharmacology. 2009;29:411-412.
7798.	Kenji N, Keen-Loong C, T KJ, G RR. Does Cognitive Recovery After Treatment of Poststroke Depression Last? A 2-Year Follow-Up of Cognitive Function Associated With Poststroke Depression. American journal of psychiatry. 2003;160:1157-1162.
7799.	Kenji N, Todd KJ, G RR. Preventing poststroke depression: A 12-week double-blind randomized treatment trial and 21-month follow-up. Journal of nervous and mental disease. 2002;190:296-303.
7800.	Kennard B, Silva S, Vitiello B, et al. Remission and Residual Symptoms After Short-Term Treatment in the Treatment of Adolescents with Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1404-1411.
7801.	Kennedy N, ES P. Treatment and response in refractory depression: results from a specialist affective disorders service. Journal of affective disorders. 2004;81:49-53.
7802.	Kennedy S. Shortcomings of Current Antidepressant Therapies. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2007;107:87-93.
7803.	Kennedy S. Symptom relief achieved at every stage of depression treatment. European neuropsychopharmacology. 2009;Conference:S719.
7804.	Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. Journal of psychiatry & neuroscience. 2002;27:269-280.
7805.	Kenneth K, C FM, Hsiao-hui W, John P, Rajinder J. Meta-analysis of safety of fluoxetine in Asian patients. 1999:221-238.
7806.	Kenny M, Jabbar F. Sexual dysfunction and antidepressants: A review with emphasis on treatment. Irish journal of psychological medicine. 2011;28:165-167.
7807.	Keowkase R, Aboukhatwa M, YA L. Fluoxetine Protects Against Amyloid-Beta Toxicity, in Part Via Daf-16 Mediated Cell Signaling Pathway, in Caenorhabditis Elegans. Neuropharmacology. 2010;59:358-365.
7808.	Keowkase R, Luo Y. Mechanism of CNS drugs and their combinations for Alzheimer's disease. Central nervous system agents in medicinal chemistry. 2008;8:241-248.
7809.	Keri W, M PC. Venlafaxine extended-release: a review of its use in the management of major depression. [Review] [125 refs]. CNS drugs. 2001;15:643-669.
7810.	Kerner N, Prudic J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry. 2014;4:33-54.
7811.	Kerrin W, Whitney W, Lee TL, Lon S, Zemansky M. Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatric Journal of the University of Ottawa. 1990;15:156-158.
7812.	Ketter T, Amchin J, Yang R, MA F. Adjunctive armodafinil 150 mg/d in combination with lamotrigine, olanzapine, or quetiapine maintenance therapy for bipolar I depression: A pooled sub-group analysis of efficacy from phase 3 studies. Neuropsychopharmacology. 2014;Conference:S383-S384.
7813.	KF C, GL P. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS drugs. 2004;18:469-473.
7814.	KF H, WC B. Smoking cessation through the utilization of pharmacotherapy. Expert review of respiratory medicine. 2009;3:475-485.
7815.	KF Q, AA S, CH N, CB C. Prevalence of Sexual Problems and Its Association With Social, Psychological and Physical Factors Among Men in a Malaysian Population: a Cross-Sectional Study. Journal of sexual medicine. 2008;5:70-76.
7816.	KG DJ, JB J, Sanchez C, AL P. Vortioxetine Dose-Dependently Reverses 5-Ht Depletion-Induced Deficits in Spatial Working and Object Recognition Memory: a Potential Role for 5-Ht1a Receptor Agonism and 5-Ht3 Receptor Antagonism. European neuropsychopharmacology. 2014;24:160-171.
7817.	Randomized, Double-Blind, Placebo-Controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence, Drug and alcohol dependence(2010).
7818.	KG K, Lampen-Inkamp S, Gollner K, et al. Pharmacotherapy for Depression in Diabetics. Diabetologe. 2010;6:280-+.
7819.	KG M. Duloxetine Treatment of Pediatric Chronic Pain and Co-Morbid Major Depressive Disorder. Journal of child and adolescent psychopharmacology. 2007;17:121-127.
7820.	KG R, Mueller M, RG K, et al. Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: A report from the consortium for research in electroconvulsive therapy. Journal of clinical psychiatry. 2007;68:1701-1706.
7821.	KG Y, SG P. Current and future treatments for Alzheimer's disease. Therapeutic advances in neurological disorders. 2013;6:19-33.
7822.	KH K, Krause J, GE T. Hyperkinetic Syndrome (Attention Deficit Hyperactivity Disorder) in Adulthood. Der Nervenarzt. 1998;69:543-556.
7823.	KH N, DEC L, JI S. Treatment of Depression in Patients With Epilepsy. Current treatment options in neurology. 2011;13:371-379.
7824.	KH S, DV S. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. International clinical psychopharmacology. 2008;23:70-83.
7825.	KH T, RM M, Potokar J, Pirmohamed M, Gunnell D. Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacology & Toxicology. 2014;15:54.
7826.	KH W, CJ M. Psychotherapy and medication management strategies for obsessive-compulsive disorder. Neuropsychiatric disease and treatment. 2011;7:485-494.
7827.	Khalid-Khan S, M-P S, McMicken C, MA R. Social anxiety disorder in children and adolescents: Epidemiology, diagnosis, and treatment. Pediatric Drugs. 2007;9:227-237.
7828.	Khan A. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert review of neurotherapeutics. 2008;8:1435-1447.
7829.	Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert opinion on investigational drugs. 2009;18:1753-1764.
7830.	Khan A, AE B, KA S, RL K, WA B. Sex differences in antidepressant response in recent antidepressant clinical trials. Journal of clinical psychopharmacology. 2005;25:318-324.
7831.	Khan A, AE B, RL K, WA B. Severity of Depressive Symptoms and Response to Antidepressants and Placebo in Antidepressant Trials. Journal of psychiatric research. 2005;39:145-150.
7832.	Khan A, AE B, RL K, WA B. Severity of Depressive Symptoms and Response to Antidepressants and Placebo in Antidepressant Trials. Journal of psychiatric research. 2005;39:145-150.
7833.	Khan A, Bhat A. Is the problem of a high placebo response unique to antidepressant trials? Journal of clinical psychiatry. 2008;69:1979-1980.
7834.	Khan A, Bhat A, Faucett J, Kolts R, WA B. Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: Role of baseline severity. Psychopharmacology. 2011;214:961-965.
7835.	Khan A, Bose A, GS A, Gommoll C, DY L, Gandhi C. Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder. Clinical drug investigation. 2007;27:481-492.
7836.	Khan A, Cohen S, Dager S, DH A, DL D. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. Journal of affective disorders. 1989;17:33-38.
7837.	Khan A, Detke M, SRF K, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. Journal of nervous and mental disease. 2003;191:211-218.
7838.	Khan A, Faucett J, Morrison S, WA B. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/ hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry. 2013;70:1091-1099.
7839.	Khan A, Gommoll C, Mathews M, Chen D, Nunez R. Efficacy and safety of vilazodone 20mg and 40mg in major depressive disorder (MDD): A randomised, double-blind, placebo- and active-controlled trial. European neuropsychopharmacology. 2014;Conference:S386-S387.
7840.	Khan A, GV U, RL R, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. Journal of clinical psychopharmacology. 1998;18:19-25.
7841.	Khan A, HA W, WA B. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the food and drug administration database. Archives of general psychiatry. 2000;57:311-317.
7842.	Khan A, KA S, RL K, WA B. BMI, sex, and antidepressant response. Journal of affective disorders. 2007;99:101-106.
7843.	Khan A, Khan S. Placebo in mood disorders: The tail that wags the dog. Current opinion in psychiatry. 2003;16:35-39.
7844.	Khan A, LF F, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacology bulletin. 1991;27:141-144.
7845.	Khan A, MH M, Claypoole K, et al. Effects of low-dose TRH on cognitive deficits in the ECT postictal state. American journal of psychiatry. 1994;151:1694-1696.
7846.	Khan A, Redding N, WA B. The Persistence of the Placebo Response in Antidepressant Clinical Trials. Journal of psychiatric research. 2008;42:791-796.
7847.	Khan A, RL K, ME T, KRR K, Brown W. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. American journal of psychiatry. 2004;161:2045-2049.
7848.	Khan A, RL K, MH R, K RRK, AE B, WA B. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychological medicine. 2005;35:743-749.
7849.	Khan A, Schwartz K. Design Features That Affect Psychopharmacology Trials. Letters in drug design & discovery. 2005;2:546-550.
7850.	Khan A, Schwartz K, Redding N, RL K, WA B. Psychiatric diagnosis and clinical trial completion rates: Analysis of the FDA SBA reports. Neuropsychopharmacology. 2007;32:2422-2430.
7851.	Khan A, Schwartz K, RL K, Ridgway D, Lineberry C. Relationship Between Depression Severity Entry Criteria and Antidepressant Clinical Trial Outcomes. Biological psychiatry. 2007;62:65-71.
7852.	Khan A, SR K, EB S, NL P. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. International clinical psychopharmacology. 2002;17:281-285.
7853.	Khan A, SR K, RM L, WA B. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration Database. International journal of neuropsychopharmacology. 2001;4:113-118.
7854.	Khan A, SRF K, Hobus J, et al. Changes in suicide risk and depressive symptoms with low dose lithium combined with citalopram compared to citalopram with placebo in a group of severely ill depressed patients. Neuropsychopharmacology. 2011;Conference:S300.
7855.	Khan MC. A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Human Psychopharmacology: Clinical and Experimental. 1995;10:S119-S124.
7856.	Pioglitazone adjunctive therapy for moderate-to-severe major depression disorder: Randomized double-blind placebo-controlled trial, Neuropsychopharmacology(2012).
7857.	Khazaie H, Rahimi M, Tatari F, Rezaei M, Najafi F, Tahmasian M. Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? Neurosciences (Riyadh, Saudi Arabia). 2011;16:42-45.
7858.	Khedmatgozar H, Birashk B, Ashayeri H, AA F. Comparing the effectiveness of paroxetine, attention modification program and combination of both on improving social anxiety symptoms. Basic and Clinical Neuroscience. 2012;3:36-44.
7859.	Khodayari-Rostamabad A, JP R, GM H, H dB, DJ M. A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder. Clinical neurophysiology. 2013;124:1975-1985.
7860.	Khoza S, JC B. Glucose Dysregulation Associated With Antidepressant Agents: an Analysis of 17 Published Case Reports. International journal of clinical pharmacy. 2011;33:484-492.
7861.	Khrista B, Soledad R, Boris B. Psychopharmacologic treatment of pediatric major depressive disorder. [Review] [103 refs]. Psychopharmacology. 2007;191:27-38.
7862.	KI A, Dorssos T, SJ H. Mood and behavior disorder in pediatric epilepsy. Journal of Pediatric Epilepsy. 2013;2:157-172.
7863.	Kiefer D, Ali-Akbarian L. A brief evidence-based review of two gastrointestinal illnesses: Irritable bowel and leaky gut syndromes. Alternative therapies in health and medicine. 2004;10:22-31+92.
7864.	Kiejna A, Pacan P, Trypka E, et al. Standards in dementia care. [Polish]. Psychogeriatria Polska. 2008;5:59-94.
7865.	Kienzle-Horn S. Herbal medicines for neurological diseases. Current opinion in investigational drugs (London, England : 2000). 2002;3:763-767.
7866.	Kierlin L, MR L. Parasomnias and antidepressant therapy: A review of the literature. Frontiers in Psychiatry. 2011.
7867.	Kieser M, Friede T. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Statistics in medicine. 2007;26:253-273.
7868.	Kieser M, Szegedi A. Predicting Stable Treatment Response in Patients With Major Depression Treated With Hypericum Extract Ws 5570/5572. Pharmacopsychiatry. 2005;38:194-200.
7869.	Kieser M, Szegedi A. Predicting Stable Treatment Response in Patients With Major Depression Treated With Hypericum Extract Ws 5570/5572. Pharmacopsychiatry. 2005;38:194-200.
7870.	Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. Journal of clinical psychiatry. 1992;53 Suppl:27-29.
7871.	Kilian R, JP L, Koster J, Brand P, Frasch K, Becker T. Factors influencing the effectiveness of sertraline in routine outpatient treatment of affective disorders. Multi level analysis in an internet supported post marketing surveillance. [German]. Psychopharmakotherapie. 2005;12:57-63.
7872.	Kilian R, JP L, Koster J, Brand P, Frasch K, Becker T. Factors Influencing the Effectiveness of Sertraline in Routine Outpatient Treatment of Affective Disorders. Multi Level Analysis in an Internet Supported Post Marketing Surveillance. Psychopharmakotherapie. 2005;12:57-63.
7873.	Killingley B, Pozniak A. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs of today (Barcelona, Spain : 1998). 2007;43:427-442.
7874.	Killoran A, KM B. Therapeutics in Huntington's disease. Current treatment options in neurology. 2012;14:137-149.
7875.	Kilzieh N, HS A. Rapid-cycling bipolar disorder: An overview of research and clinical experience. Psychiatric clinics of North America. 1999;22:585-607.
7876.	Kim E, Levy R, Pikalov A. Personalized treatment with atypical antipsychotic medications. Advances in therapy. 2007;24:721-740.
7877.	Kim H, Alexander Y, Michael K, Holger J, Klaus W, J RT. No effects of antidepressants on negative symptoms in schizophrenia. Journal of clinical psychopharmacology. 2013;33:686-690.
7878.	Kim H, KJ L. Effect of duloxetine on chronic tension-type headache in patients with major depressive disorder. European neuropsychopharmacology. 2010;Conference:S382.
7879.	Kim H, KJ L. Escitalopram for chronic tension-type headache in patients with major depressive disorder. European neuropsychopharmacology. 2012;Conference:S255.
7880.	Kim H, KJ L. An open clinical trial of adjunctive therapy with aripiprazole in patients with partial remission of major depressive disorder. European neuropsychopharmacology. 2013;Conference:S410.
7881.	Kim K, K SJ, Jarmo H, et al. Does defense style or psychological mindedness predict treatment response in major depression? [References]. Depression and anxiety. 2009;26:689-695.
7882.	Kim K, K SJ, Jarmo H, et al. Personality traits and recovery from major depressive disorder. Nordic journal of psychiatry. 2011;65:52-57.
7883.	Kim L, Lipton S, Deodhar A. Pregabalin for Fibromyalgia: Some Relief but No Cure. Cleveland Clinic journal of medicine. 2009;76:255-261.
7884.	Kim W, BR J, WS Y, et al. Treatment With Selective Serotonin Reuptake Inhibitors and Mirtapazine Results in Differential Brain Activation by Visual Erotic Stimuli in Patients With Major Depressive Disorder. Psychiatry investigation. 2009;6:85-95.
7885.	Kim W, CU P, JH C, TY J, WM B. The Effectiveness of Mirtazapine in the Treatment of Post-Traumatic Stress Disorder: a 24-Week Continuation Therapy. Psychiatry and clinical neurosciences. 2005;59:743-747.
7886.	Kim Y, Asukai N, Konishi T, et al. Clinical Evaluation of Paroxetine in Post-Traumatic Stress Disorder (Ptsd): 52-Week, Non-Comparative Open-Label Study for Clinical Use Experience. Psychiatry and clinical neurosciences. 2008;62:646-652.
7887.	Kim Y, JT H, Morrow G. Fatigue and Depression in Cancer Patients Undergoing Chemotherapy: An Emotion Approach. Journal of pain and symptom management. 2006;32:311-321.
7888.	Kimberlie D. Highlights of this issue. The British Journal of Psychiatry. 2013;202:A7.
7889.	Kimhy D, Corcoran C. Use of Palm computer as an adjunct to cognitive-behavioural therapy with an ultra-high-risk patient: A case report. Early intervention in psychiatry. 2008;2:234-241.
7890.	Kimiko GK. Pulling back the curtain on placebo: The search for a relationship between anxiety and placebo response. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008;68:7663.
7891.	Kimura H, Ozaki N. Diagnosis and treatment of depression in dialysis patients. Therapeutic apheresis and dialysis. 2006;10:328-332.
7892.	Kind P, Sorensen J. Modeling the Cost-Effectiveness of the Prophylactic Use of Ssris in the Treatment of Depression. International clinical psychopharmacology. 1995;10:41-48.
7893.	King M, Nazareth I, Lampe F, et al. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. Health technology assessment. 2005;9:iii-68.
7894.	Kinrys G, Coleman E, Rothstein E. Natural remedies for anxiety disorders: potential use and clinical applications. Depression and anxiety. 2009;26:259-265.
7895.	Kirby M, KB T. Is duloxetine safe and effective for the treatment of overactive bladder? Commentary. Nature clinical practice. Urology. 2008;5:188-189.
7896.	Kirk R. Clinical trials in CNS - SMi's eighth annual conference. IDrugs : the investigational drugs journal. 2010;13:66-69.
7897.	Kirli S, Caliskan M. A Comparative Study of Sertraline Versus Imipramine in Postpsychotic Depressive Disorder of Schizophrenia. Schizophrenia research. 1998;33:103-111.
7898.	Kirsch I. St John's wort, conventional medication, and placebo: An egregious double standard. Complementary therapies in medicine. 2003;11:193-195.
7899.	Kirsch I. Medication and suggestion in the treatment of depression. Contemporary hypnosis. 2005;22:59-66.
7900.	Kirsch I. Antidepressants and the placebo response. Epidemiologia e psichiatria sociale. 2009;18:318-322.
7901.	Kirsch I, BJ D, TB H-M, Scoboria A, TJ M, BT J. Initial Severity and Antidepressant Benefits: a Meta-Analysis of Data Submitted to the Food and Drug Administration. PLoS medicine. 2008;5:260-268.
7902.	Kirsch I, BJ D, TB H-M, Scoboria A, TJ M, BT J. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. PLoS medicine. 2008;5:260-268.
7903.	Kishi T, Hirota T, Iwata N. Add-on Fluvoxamine Treatment for Schizophrenia: an Updated Meta-Analysis of Randomized Controlled Trials. European archives of psychiatry and clinical neuroscience. 2013;263:633-641.
7904.	Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. European neuropsychopharmacology. 2013;Conference:S434.
7905.	Kishi T, Iwata N. Meta-Analysis of Noradrenergic and Specific Serotonergic Antidepressant Use in Schizophrenia. International journal of neuropsychopharmacology. 2014;17:343-354.
7906.	Kishi T, Kawashima K, Moriwaki M, et al. A randomized study of escitalopram and paroxetine controlled-release in the treatment of Japanese patients with major depressive disorder. European neuropsychopharmacology. 2013;Conference:S338.
7907.	Kishi T, Tsunoka T, Ikeda M, et al. Serotonin 1a Receptor Gene and Major Depressive Disorder: an Association Study and Meta-Analysis. Journal of human genetics. 2009;54:629-633.
7908.	Kitago T, RS M. Strategies for Early Stroke Recovery: What Lies Ahead? Current treatment options in cardiovascular medicine. 2014.
7909.	Kitaichi Y, Inoue T, Izurni T, et al. Effect of Co-Administration of a Serotonin-Noradrenaline Reuptake Inhibitor and a Dopamine Agonist on Extracellular Monoamine Concentrations in Rats. European journal of pharmacology. 2008;584:285-290.
7910.	Kitamura H, Yokoyama T, Someya T. A Pharmacotherapy Algorithm for the Treatment of Dysthymia in Japan. Psychiatry and clinical neurosciences. 1999;53:S49-S53.
7911.	KJ A. Clinical lessons from GENDEP for the treatment of depression. Annals of general psychiatry. 2010;Conference:S6.
7912.	KJ A, AK M. The Ninth Annual Pharmacogenetics in Psychiatry Meeting report. Psychiatric genetics. 2011;21:112-113.
7913.	KJ A, Bienroth M, Cookson J, et al. A UK consensus on the administration of aripiprazole for the treatment of mania. Journal of psychopharmacology (Oxford, England). 2009;23:231-240.
7914.	KJ A, Noble W, Montejo A, et al. Efficacy and Safety of Duloxetine in the Treatment of Older Adult Patients With Generalized Anxiety Disorder: a Randomized, Double-Blind, Placebo-Controlled Trial. International journal of geriatric psychiatry. 2014;29:978-986.
7915.	KJ B, Terhaar J, MK B, Boettger S, Berger S, Weiss T. Pseudohypoalgesia on the Skin a Novel View on the Paradox of Pain Perception in Depression. Journal of clinical psychopharmacology. 2011;31:103-107.
7916.	KJ G, JM O, SJ C, RC M. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clinical therapeutics. 1994;16:306-315.
7917.	KJ H, CM S. Reboxetine: A review of its use in depression. CNS drugs. 1999;12:65-83.
7918.	KJ H, Jarvis B, RH F. Mirtazapine. A pharmacoeconomic review of its use in depression. [Review] [85 refs]. PharmacoEconomics. 2000;17:515-534.
7919.	KJ H, Markham A. Mirtazapine: a review of its use in major depression. [Review] [107 refs]. Drugs. 1999;57:607-631.
7920.	KJ K, Maloney K, RL R, SF S, WJ J, ST C. Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and Its Active O-Desmethyl Metabolite. Journal of clinical pharmacology. 1992;32:716-724.
7921.	KJ L, PR J, SE L, et al. An association study of DRD2 and COMT polymorphisms with novelty seeking and harm avoidance scores, in two independent samples of depressed patients. Behavioral and brain functions. 2007.
7922.	KJ M, GS A, Banerjee S, et al. Executive functioning complaints and escitalopram treatment response in late-life depression. American journal of geriatric psychiatry. 2015;23:440-445.
7923.	KJ P, Benfield P. Fluvoxamine - an Overview of Its Pharmacological Properties and Review of Its Therapeutic Potential in Non-Depressive Disorders. CNS drugs. 1994;1:57-87.
7924.	KJ P, JL R, JE M. Towards the pharmacotherapy of eating disorders. Expert opinion on pharmacotherapy. 2003;4:1659-1678.
7925.	KJ S, JL R, JE M, Uppala S. Emerging drugs for eating disorder treatment. Expert opinion on emerging drugs. 2006;11:315-336.
7926.	KJ S, SW W. Identification of a Treatment-Resistant, Ketamine-Sensitive Genetic Line in the Chick Anxiety-Depression Model. Pharmacology, biochemistry, and behavior. 2013;113:63-67.
7927.	KJ T, LC M, M VN, et al. A case study of pooled-studies publications indicated potential for both valuable information and bias. Journal of clinical epidemiology. 2013;66:1082-1092.
7928.	KJ T, M VN, LC M, et al. The comparative effectiveness of second-generation antidepressants for the accompanying symptoms of depression: A systematic review. European psychiatry. 2012.
7929.	Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Therapeutics and clinical risk management. 2007;3:59-69.
7930.	KK K, SK R, Azorina V, Loo C. Durability of the Antidepressant Effect of the High-Frequency Repetitive Transcranial Magnetic Stimulation (Rtms) in the Absence of Maintenance Treatment in Major Depression: a Systematic Review and Meta-Analysis of 16 Double-Blind, Randomized, Sham-Contr. Depression and anxiety. 2015;32:193-203.
7931.	KK S, LM S, CL A, Reed K, MM K, CR S. Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2004;13:438-446.
7932.	KL B, BG P, BA S, RR B. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: An updated review. Gender medicine. 2009;6:522-543.
7933.	KL B, BG P, HJ A, PM F, RR B, AR H. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology. 2008;33:3221-3225.
7934.	KL B, BG P, HJ A, PM F, RR B, AR H. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology. 2008;33:3221-3225.
7935.	KL B, DJ H, RS H. Management of osteoarthritis of the knee. BMJ (Online). 7868.
7936.	KL D. Issues and controversies surrounding the diagnosis and treatment of social anxiety disorder. Expert review of neurotherapeutics. 2012;12:993-1009.
7937.	KL D, RT J, SL B. Measurement properties of quantitative urine benzoylecgonine in clinical trials research. Addiction (Abingdon, England). 1997;92:297-302.
7938.	KL D, SP C. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. [Review] [96 refs]. Drugs. 1991;41:225-253.
7939.	KL F, EK G, GO L. Targeting fibromyalgia pain: Brain-spinal cord and peripheral contributions. International journal of clinical rheumatology. 2011;6:463-474.
7940.	KL H, R MB, SH K. Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder. Journal of consulting and clinical psychology. 2012;80:342-353.
7941.	KL H, SD H. Ethical Considerations for Cognitive-Behavioral Therapists in Psychotherapy Research Trials. Cognitive and behavioral practice. 2009;16:153-163.
7942.	KL P, AD S, Auinger P, et al. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Movement disorders. 2012;27:880-887.
7943.	KL P, Lee R, EF C. Personality Predictors of Antiaggressive Response to Fluoxetine: Inverse Association With Neuroticism and Harm Avoidance. International clinical psychopharmacology. 2011;26:278-283.
7944.	KL P, Waters C. Zydis selegiline in the management of Parkinson's disease. Expert opinion on pharmacotherapy. 2007;8:2615-2624.
7945.	KL S, NC F, Zhu L, JW J, RW T. Prevention of poststroke depression: Does prophylactic pharmacotherapy work? Journal of stroke and cerebrovascular diseases. 2013;22:1243-1251.
7946.	KL S, Stain-Mahngren R, Andersson A, berg-Wistedt A, Schenck-Gustafsson K. High frequency of anxiety and angina pectoris in depressed women with coronary heart disease. Gender medicine. 2007;4:146-156.
7947.	KL W. Should estradiol be prescribed for postpartum depression? Biological psychiatry. 2014;Conference:299S.
7948.	KL W, BH H, JM P, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. Journal of clinical psychopharmacology. 2006;26:353-360.
7949.	KL W, Costantino M, DK S, CS F, McShea M, Prairie E. Transdermal estradiol for postpartum major depression. Archives of women's mental health. 2011;Conference:S86.
7950.	Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes, American journal of psychiatry(2009).
7951.	KL W, SR B, TL H, RMJ D, JA A. Type Ii Error and Antidepressants - Dr. Weihs and Colleagues Reply. Journal of clinical psychiatry. 2001;62:374-375.
7952.	Klasik A, Krysta K, Krzystanek M. Impact of psychotherapy and antidepressive treatment on cognitive functions in patients treated for depression. Psychiatria Danubina. 2012;24 Suppl 1:S130-134.
7953.	Klaus L, Levente K, Gerta R, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis. Annals of family medicine. 2015;13:69-79.
7954.	Klaus L, Walden J, Grunze H, Fiebich BL, Berger M, Normann C. Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry. 2004;37:238-239.
7955.	Klaus M. Adjunctive Bright Light in Non-Seasonal Major Depression. Acta psychiatrica Scandinavica. 2004;110:7-28.
7956.	Klaus M, Else R, Vibeke L, et al. A 9-week randomized trial comparing chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. Journal of clinical psychiatry. 2012;73:1234-1242.
7957.	Klaus M, Lunde M, Unden M, Dam H, Bech P. Adjunctive bright light in non-seasonal major depression: Results from clinician-rated depression scales. Acta psychiatrica Scandinavica. 2005;112:117-125.
7958.	Klaus M, Lunde M, Unden M, Dam H, Bech P. Adjunctive bright light in non-seasonal major depression: Results from patient-reported symptom and well-being scales. Acta psychiatrica Scandinavica. 2005;111:453-459.
7959.	Klaus M, Marianne L, Mogens U, Henrik D, Per B. The lack of sustained effect of bright light, after discontinuation, in non-seasonal major depression.[Erratum appears in Psychol Med. 2006 Sep;36(9):1336]. Psychological medicine. 2006;36:1247-1252.
7960.	Klaus M, Marianne L, Mogens U, Henrik D, Per B. "The lack of sustained effect of bright light, after discontinuation, in non-seasonal major depression": Corrigendum. Psychological medicine. 2006;36:1336.
7961.	A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression, Nordic journal of psychiatry(2012).
7962.	Kleijn J, TIFH C, CM H, BHC W. CB1 receptors modulate the effect of the selective serotonin reuptake inhibitor, Citalopram on extracellular serotonin levels in the rat prefrontal cortex. [Dutch]. Pharmaceutisch weekblad. 2014;149:194-198.
7963.	Kleimann A, Theilmann W, Brandt C, et al. Effects of electroconvulsive stimulation on p11 promoter methylation in humans and rats. European neuropsychopharmacology. 2014;Conference:S170-S171.
7964.	Klein N, Sacher J, Geiss-Granadia T, et al. In Vivo Imaging of Serotonin Transporter Occupancy by Means of Spect and [I-123]Adam in Healthy Subjects Administered Different Doses of Escitalopram or Citalopram. Psychopharmacology. 2006;188:263-272.
7965.	Klein N, Sacher J, Wallner H, Tauscher J, Kasper S. Therapy of treatment resistant depression: Focus on the management of TRD with atypical antipsychotics. CNS spectrums. 2004;9:823-832.
7966.	Kleinstauber M, Witthoft M, Hiller W. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis. [Review]. Journal of clinical psychology in medical settings. 2012;19:308-319.
7967.	Klenke S, Kussmann M, Siffert W. The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenetics and genomics. 2011;21:594-606.
7968.	Klieser E, Lehmann E, Heinrich K. Fluoxetine in Patients With Major Depressive Disorder - a Responder Analysis. Pharmacopsychiatry. 1995;28:14-19.
7969.	Klinger G, Merlob P. SSRIs and congenital defects: SSRIs and heart defects in neonates. BMJ (Online). 2009;339:933.
7970.	Kloiber S, Ripke S, MA K, et al. Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. European neuropsychopharmacology. 2013;23:653-662.
7971.	Klok CJ, Brouwer GJ, M VPH, Doogan D. Fluvoxamine and clomipramine in depressed patients: A double-blind clinical study. Acta psychiatrica Scandinavica. 1981;64:1-11.
7972.	Kluge M, Schussler P, Steiger A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. European neuropsychopharmacology. 2007;17:527-531.
7973.	Klysner R, Bent-Hansen J, HL H, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: Placebo-controlled study of maintenance therapy. British journal of psychiatry. 2002;181:29-35.
7974.	KM A, PJ R, AR N. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. American journal of clinical nutrition. 2010;91:757-770.
7975.	KM B, DP B, RN R, et al. Evaluation of an information exchange program for primary care patients with depression. Disease management. 2000;3:1-9.
7976.	KM B, Hays P. Phototherapy is a useful adjunct in the treatment of depressed in- patients. Acta psychiatrica Scandinavica. 1997;95:424-427.
7977.	KM B, RG H. A review of pramipexole and its clinical utility in Parkinson's disease. Expert opinion on pharmacotherapy. 2002;3:197-210.
7978.	KM B, Steinwald B, JEJr W. Usefulness of the Sf-36 Health Survey in Measuring Health Outcomes in the Depressed Elderly. Journal of geriatric psychiatry and neurology. 1996;9:13-21.
7979.	KM C, AC B, SK V, EV N. The Effect of Sertraline and Environmental Context on Treating Depression and Illicit Substance Use Among Methadone Maintained Opiate Dependent Patients: a Controlled Clinical Trial. Drug and alcohol dependence. 2004;74:123-134.
7980.	KM C, CC S, AC-F H, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. American journal of medicine. 2002;112:191-197.
7981.	KM C, JRT D, RH W, Ahearn E. A Pilot Study of Mirtazapine in Post-Traumatic Stress Disorder. International clinical psychopharmacology. 1999;14:29-31.
7982.	KM C, JRT D, RH W, Zhang W, Abraham K. Tiagabine for Posttraumatic Stress Disorder: Effects of Open-Label and Double-Blind Discontinuation Treatment. Psychopharmacology. 2006;184:21-25.
7983.	KM C, JRT D, Sutherland S, Weisler R. Social Phobia: Issues in Assessment and Management. Epilepsia. 1999;40:S60-S65.
7984.	KM C, Zhang W. Resilience: Determinants, measurement, and treatment responsiveness. CNS spectrums. 2006;11:5-12.
7985.	A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (Stop-Pd): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body Mass Index and Metabolic Measures, Journal of clinical psychiatry(2013).
7986.	A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures, Journal of clinical psychiatry(2013).
7987.	KM D, MP F. Complementary and Alternative Medicine for the Treatment of Depressive Disorders in Women. Psychiatric clinics of North America. 2010;33:441-463.
7988.	KM D, RJ P, CM F, Gallagher P, AH Y. Abnormal Response to Failure in Unmedicated Major Depression. Journal of affective disorders. 2009;119:92-99.
7989.	KM D, Rothschild A, BA B, et al. A gender analysis of the nimh study of the pharmacotherapy of psychotic depression (STOP-PD). Neuropsychopharmacology. 2010;Conference:S405.
7990.	KM G, DE K, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. Journal of clinical psychiatry. 2011;72:1063-1071.
7991.	KM G, JR C. Newer Treatment Studies for Bipolar Depression. Bipolar Disorders, Supplement. 2005;7:13-23.
7992.	KM H-P, Vuola T, Lahelma L, Marttunen M. Mirtazapine in the Treatment of Adolescents With Major Depression: an Open-Label, Multicenter Pilot Study. Journal of child and adolescent psychopharmacology. 2004;14:175-184.
7993.	KM H-P, Vuola T, Lahelma L, Marttunen M. Mirtazapine in the Treatment of Adolescents With Major Depression: an Open-Label, Multicenter Pilot Study. Journal of child and adolescent psychopharmacology. 2004;14:175-184.
7994.	KM K, Jamali F. Drug disease interactions: Role of inflammatory mediators in depression and variability in antidepressant drug response. Journal of pharmacy & pharmaceutical sciences. 2006;9:292-306.
7995.	KM K, Mago R, Duffany S, EJS K. Psycho-oncology: Review and update. Current psychiatry reports. 2006;8:246-252.
7996.	KM L, CLE K, MT A-S, et al. Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine. Psychopharmacology. 1994;115:261-264.
7997.	KM N, JS C, KA G, et al. Methods for the design of vasomotor symptom trials: The Menopausal Strategies: Finding lasting answers to symptoms and health network. Menopause (New York, N.Y.). 2014;21:45-58.
7998.	Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: Effects on nonmotor symptoms and tolerability, JAMA Neurology(2015).
7999.	KM S, KE M, Watson K. Impact and Clinical Management of Depression in Patients With Coronary Artery Disease. Pharmacotherapy. 2010;30:304-322.
8000.	KM S, KF H, Yaffe K. Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia - a Review of the Evidence. Jama-Journal of the American Medical Association. 2005;293:596-608.
8001.	KM S, LJM S, Jsag S, Fpml P, MH P. Does Pretreatment Testing for Serotonin Transporter Polymorphisms Lead to Earlier Effects of Drug Treatment in Patients With Major Depression? A Decision-Analytic Model. Clinical therapeutics. 2007;29:691-702.
8002.	KM S, Zeiss A. The treatment of depression in older adults in the primary care setting: An evidence-based review. Health psychology. 2006;25:665-674.
8003.	KM W, MW B. Complementary therapies as adjuncts in the treatment of postpartum depression. Journal of midwifery & women's health. 2004;49:96-104.
8004.	KML H, CM vdF-C, HWJ vM, FJ dJ, DAWM vdW, ATF B. Negative association of concomitant physical symptoms with the course of major depressive disorder: A systematic review. Journal of psychosomatic research. 2010;68:511-519.
8005.	KMM C, MA M, Santin A, Kapczinski F. Pilot-project of implantation of pharmaceutical care close to the program of bipolar mood disorder of the Hospital of Clinics of Porto Alegre. Brazilian Journal of Pharmaceutical Sciences. 2009;45:249-256.
8006.	KN B, Geller B. Refractory depression in children and adolescents. Depression and anxiety. 1997;5:212-223.
8007.	KN F. The contemporary face of bipolar illness: Complex diagnostic and therapeutic challenges. CNS spectrums. 2008;13:763-779.
8008.	KN F. Pharmaceutical treatment of acute bipolar depression. F1000 medicine reports. 2010.
8009.	KN F. An update of evidence-based treatment of bipolar depression: where do we stand?. [Review] [81 refs]. Current opinion in psychiatry. 2010;23:19-24.
8010.	Refractoriness in Bipolar Disorder: Definitions and Evidence-Based Treatment, CNS neuroscience & therapeutics(2012).
8011.	Class effect of pharmacotherapy in bipolar disorder: Fact or misbelief?, Annals of general psychiatry(2011).
8012.	KN F, Grunze H, Panagiotidis P, Kaprinis G. Treatment of Bipolar Depression: an Update. Journal of affective disorders. 2008;109:21-34.
8013.	KN F, H-J M. Antidepressants vs. placebo: Not merely a quantitative difference in response. International journal of neuropsychopharmacology. 2011;14:1435-1437.
8014.	KN F, H-J M. Are antidepressants clinically useful? Conclusion of a decade of debate. World psychiatry. 2014;13:201-202.
8015.	KN F, HJ M. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. [Review]. International journal of neuropsychopharmacology. 2011;14:405-412.
8016.	Receptor targets for antidepressant therapy in bipolar disorder: An overview, Journal of affective disorders(2012).
8017.	Efficacy of Pharmacotherapy in Bipolar Disorder: a Report by the Wpa Section on Pharmacopsychiatry, European archives of psychiatry and clinical neuroscience(2012).
8018.	KN F, Kontis D, Gonda X, LN Y. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar disorders. 2013;15:115-137.
8019.	KN F, Kontis D, Gonda X, Siamouli M, LN Y. Treatment of mixed bipolar states. International journal of neuropsychopharmacology. 2012;15:1015-1026.
8020.	KN F, Messinger-Rapport B. Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: a Review of the Evidence. Journal of the American Medical Directors Association. 2006;7:201-202.
8021.	KN F, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: A systematic review. Annals of general hospital psychiatry. 2004.
8022.	KN F, Tsolaki M, Kazis A. Target Symptoms for Fluvoxamine in Old Age Depression. International journal of psychiatry in clinical practice. 2000;4:127-134.
8023.	Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. [Review] [280 refs], International journal of neuropsychopharmacology(2008).
8024.	KN F, Vieta E, Siamouli M, et al. Treatment of bipolar disorder: A complex treatment for a multi-faceted disorder. Annals of general psychiatry. 2007.
8025.	KN G, JA D. Psychotropic Medication Use at a Private Eating Disorders Treatment Facility: a Retrospective Chart Review and Descriptive Data Analysis. Current therapeutic research, clinical and experimental. 2005;66:572-588.
8026.	KN S. Adjunctive aripiprazole in bipolar I depression. Annals of pharmacotherapy. 2007;41:35-40.
8027.	KN S, JC C, BJ B, EM D. Once-Daily High-Dose Pindolol for Ssri-Refractory Depression. Psychiatry research. 2004;125:81-86.
8028.	Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: A health economics analysis, Advances in therapy(2009).
8029.	Knable M, Bowman M. Scientific and economic benefits of sequential parallel comparative design (SPCD), a novel clinical trial methodology. Neurotherapeutics. 2011;Conference:530-531.
8030.	Knorr U, LV K. The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nordic journal of psychiatry. 2010;64:153-163.
8031.	Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: a randomized trial, PLoS ONE [Electronic Resource](2012).
8032.	Knorr U, Vinberg M, Gade A, et al. A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression. Therapeutic Advances in Psychopharmacology. 2011;1:133-144.
8033.	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients - a Randomized Placebo-Controlled Trial, PLoS ONE [Electronic Resource](2011).
8034.	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: The effect of escitalopram versus Trials(2009).
8035.	Knorr U, Vinberg M, Klose M, et al. Rationale and Design of the Participant, Investigator, Observer, and Data-Analyst-Blinded Randomized Agenda Trial on Associations Between Gene-Polymorphisms, Endophenotypes for Depression and Antidepressive Intervention: the Effect of Escitalopram Versus Trials. 2009;10.
8036.	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus Trials [Electronic Resource](2009).
8037.	KNR C, Hennen J, RJ B, et al. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar disorders. 2005;7:68-76.
8038.	KNR C, LK S, JF H, Xiang J, NR R. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. Journal of clinical psychiatry. 2006;67:1698-1706.
8039.	KNR C, RK K, Perkins K, et al. Bupropion Sustained Release as a Smoking Cessation Treatment in Remitted Depressed Patients Maintained on Treatment With Selective Serotonin Reuptake Inhibitor Antidepressants. Journal of clinical psychiatry. 2001;62:503-508.
8040.	Kocmur M, Vodopivec Z. Reappearance of catatonia. A case report. Neuro endocrinology letters. 2006;27:260-262.
8041.	Kocourkova J, Soltysova M, Mohaplova M, Hrdlicka M. Anorexia nervosa in a blind girl. Neuro endocrinology letters. 2011;32:748-750.
8042.	Kodish I, Rockhill C, Ryan S, Varley C. Pharmacotherapy for Anxiety Disorders in Children and Adolescents. Pediatric clinics of North America. 2011;58:55-72.
8043.	Koelch M, AK P, Kliegl K, et al. Therapeutic Drug Monitoring of Children and Adolescents Treated With Fluoxetine. Pharmacopsychiatry. 2012;45:72-76.
8044.	Koelch M, Pfalzer A, Keller F, Plener P, Gerlach M. Therapeutic drug monitoring (TDM) of fluoxetine in children and adolescents. European neuropsychopharmacology. 2013;Conference:S608-S609.
8045.	Koen D. Agomelatine: A narrative review. European neuropsychopharmacology. 2011;21:S703-S709.
8046.	Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo, Current medical research and opinion(2012).
8047.	Koen D, Friis AH, Heldbo RE. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. International clinical psychopharmacology. 2008;23:276-286.
8048.	Koen D, Patrick M, Bruno B, et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. Journal of affective disorders. 2001;65:243-252.
8049.	Koen N, DJ S. Pharmacotherapy of anxiety disorders: A critical review. Dialogues in clinical neuroscience. 2011;13:423-437.
8050.	Koesters M, Becker T, Weinmann S. Regarding "Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs". Biological psychiatry. 2009;66:e7; authour reply e9-10.
8051.	Kohatsu W. Nutrition and Depression. Explore: The Journal of Science and Healing. 2005;1:474-476.
8052.	Kohen I, PE L, Lam S. Antipsychotic treatments for the elderly: Efficacy and safety of aripiprazole. Neuropsychiatric disease and treatment. 2010;6:47-58.
8053.	Kohler S, Gaus S, Bschor T. The challenge of treatment in bipolar depression: Evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry. 2014;47:53-59.
8054.	Kohler S, Hoffmann S, Unger T, Steinacher B, Fydrich T. Adherence to guidelines and effectiveness of inpatient treatment for unipolar depression. International journal of psychiatry in clinical practice. 2012;16:103-112.
8055.	Kohler S, Unger T, Hoffmann S, Steinacher B, Fydrich T, Bschor T. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: A naturalistic study. Pharmacopsychiatry. 2013;46:69-76.
8056.	Kohler S, Wiethoff K, Ricken R, et al. Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. Journal of affective disorders. 2014;173:126-133.
8057.	Kohn R, Epstein-Lubow G. Course and outcomes of depression in the elderly. Current psychiatry reports. 2006;8:34-40.
8058.	Koike S, Nishimura Y, Takizawa R, Yahata N, Kasai K. Near-infrared spectroscopy in schizophrenia: A possible biomarker for predicting clinical outcome and treatment response. Frontiers in Psychiatry. 2013.
8059.	Kok R, Heeren T, Nolen W. Treatment of psychotic depression in the elderly compared with nonpsychotic depression. Journal of clinical psychopharmacology. 2010;30:465-467.
8060.	Kok R, HP S, J VDB. The speed of response to electroconvulsive therapy versus medication in elderly depressed inpatients. International Psychogeriatrics. 2013;Conference:S148-S149.
8061.	Kok R, Nolen W, Heeren T. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. American journal of geriatric psychiatry. 2007;15:725; author reply 726.
8062.	Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. Acta psychiatrica Scandinavica. 2009;119:274-281.
8063.	KoKoAung E, Aromataris E. The association between suicidality and treatment with selective serotonin reuptake inhibitors in older people with major depression: A systematic review. JBI Database of Systematic Reviews and Implementation Reports. 2012;10:S313-S324.
8064.	KoKoAung E, Aromataris E. The association between suicidality and treatment with selective serotonin reuptake inhibitors in older people with major depression: A systematic review. JBI Library of Systematic Reviews. 2012;10:S313-S324.
8065.	Koks S, Vasar E. Deramciclane: Egis. Current opinion in investigational drugs (London, England : 2000). 2002;3:289-294.
8066.	Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatric disease and treatment. 2008;4:389-403.
8067.	Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatric disease and treatment. 2008;4:107-121.
8068.	Kolch M, PL P, AG L, JM F. Pediatric psychopharmacoepidemiology in Germany. [German]. Psychopharmakotherapie. 2010;17:112-118.
8069.	Kolevzon A, KA M, Hollander E. Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability. Journal of clinical psychiatry. 2006;67:407-414.
8070.	Kolshus E, Douglas L, Dunne R. Antidepressant augmentation and combination in unipoiar depression: Strong guidance, wealt foundations. Irish journal of psychological medicine. 2011;28:i-viii.
8071.	Komorousova J, Beran J, Rusavy Z, Jankovec Z. Glycemic Control Improvement Through Treatment of Depression Using Antidepressant Drugs in Patients With Diabetes Mellitus Type 1. Neuro endocrinology letters. 2010;31:801-806.
8072.	Komorousova J, Beran J, Rusavy Z, Jankovec Z. Glycemic control improvement through treatment of depression using antidepressant drugs in patients with diabetes mellitus type 1. Neuro endocrinology letters. 2010;31:801-805.
8073.	Komossa K, AM D, Gaudchau A, Kissling W, Leucht S. Second-Generation Antipsychotics for Major Depressive Disorder and Dysthymia. Cochrane database of systematic reviews (Online). 2010.
8074.	Kong S. Day Treatment Programme for Patients With Eating Disorders: Randomized Controlled Trial. Journal of advanced nursing. 2005;51:5-14.
8075.	Kong S. Day Treatment Programme for Patients With Eating Disorders: Randomized Controlled Trial. Journal of advanced nursing. 2005;51:5-14.
8076.	Kong Y, WL D, CF L. Fluoxetine for poststroke depression: A randomized placebo controlled clinical trial. Neural Regeneration Research. 2007;2:162-165.
8077.	Kongsakon R, KI P, Saguansiritham R. Mirtazapine in Amphetamine Detoxification: a Placebo-Controlled Pilot Study. International clinical psychopharmacology. 2005;20:253-256.
8078.	Konstantin L. Predictors and moderators of treatment adherence in depressed youths. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2012;72:7691.
8079.	Konstantinidis A, Hrubos W, Nirnberger G, et al. Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:242-247.
8080.	Kontorinis N, Agarwal K, DT D. Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Reviews in gastroenterological disorders. 2004;4:S39-S47.
8081.	Konuk N. Are antidepressants no better than placebo? Getting a true readings and interpretations on Kirsch's meta-analyses. [Turkish]. Klinik Psikofarmakoloji Bulteni. 2009;19:S57-S58.
8082.	Konuk N, Atasoy N, Atik L, Akay O. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Advances in therapy. 2006;23:646-654.
8083.	Konuk N, Ortancil O, Bostanci B, Kiran S, Sapmaz P. A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome With Co-Morbid Depressive Symptoms: an Open-Label Preliminary Study. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2010;20:29-37.
8084.	Kool S, Dekker J, IJ D, F dJ, Puite B. Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients. Journal of personality disorders. 2003;17:60-72.
8085.	Kool S, Schoevers R, Duijsens IJ, et al. [Treatment of depressive disorder and comorbid personality pathology: combined therapy versus pharmacotherapy]. [Dutch]. Tijdschrift voor psychiatrie. 2007;49:361-372.
8086.	Kool S, Schoevers R, S DM, et al. Efficacy of Pharmacotherapy in Depressed Patients With and Without Personality Disorders: a Systematic Review and Meta-Analysis. Journal of affective disorders. 2005;88:269-278.
8087.	Koopman C, SF W, Whitsell S, Westrup D, RA M. Relationships of alcohol use, stress, avoidance coping, and other factors with mental health in a highly educated workforce. American journal of health promotion. 2003;17:259-268.
8088.	Kopecek M, Bares M, Novak T, Brunovsky M. The place of rTMS in the treatment of depressive disorder and a possibility of treatment response prediction - The Czech experience. [Czech]. Psychiatrie (Stuttgart, Germany). 2009;13:160-164.
8089.	Kopecek M, Brunovsky M, Bares M, et al. QEEG prediction of response to rTMS and/or venlafaxine in patients with depressive disorder. A double-blind, single-centre, randomized study. Biological psychiatry. 2009;Conference:222S.
8090.	Kopecek M, Brunovsky M, Bares M, et al. Qeeg Prediction of Response to Rtms and/or Venlafaxine in Patients With Depressive Disorder. A Double-Blind, Single-Centre, Randomized Study. Biological psychiatry. 2009;65:222S.
8091.	Kopecek M, Cerna L, Sulak J, Raszka M, Bares M, Seifertova D. Depressed Patients Perception of the Efficacy of Electroconvulsive Therapy and Venlafaxine Therapy. Neuro endocrinology letters. 2007;28:889-894.
8092.	Koren G, MacLeod S, Davis D. Drugs in pregnancy: Acknowledging challenges - Finding solutions. Canadian Journal of Clinical Pharmacology. 2007;14:e2-e4.
8093.	Koren G, Nickel C. Perpetuating fears: Bias against the null hypothesis in fetal safety of drugs as expressed in scientific citations. Canadian Journal of Clinical Pharmacology. 2011;18:e28-e32.
8094.	Korszun A, MP F. Stress - The battle for hearts and minds: Links between depression, stress and ischemic heart disease. Future cardiology. 2006;2:571-578.
8095.	Kory C, J SP, Andrew S, et al. Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression. Journal of nervous and mental disease. 2014;202:167-171.
8096.	Kos K, Baker C, Kumar S. Current treatment strategies for obesity. Therapy. 2005;2:955-967.
8097.	Kos M, Calado F. Pharmacoeconomic perspective on depressive disorder treatment with antidepressants. Farmacevtski vestnik. 2006;57:268-273.
8098.	Kosel M, Frick C, SH L, H-U F, TE S. Magnetic Seizure Therapy Improves Mood in Refractory Major Depression. Neuropsychopharmacology. 2003;28:2045-2048.
8099.	Kosova J. Treatment of anxiety disorders. [Czech]. Psychiatrie (Stuttgart, Germany). 2011;15:13-20.
8100.	Kostic V, Dzoljic E, Todorovic Z, et al. Fluoxetine Does Not Impair Motor Function in Patients With Parkinson's Disease: Correlation Between Mood and Motor Functions With Plasma Concentrations of Fluoxetine/Norfluoxetine. Vojnosanitetski pregled. Military-medical and pharmaceutical review. 2012;69:1067-1075.
8101.	Koszycki D, Lafontaine S, Frasure-Smith N, Swenson R, Lesperance F. An open-label trial of interpersonal psychotherapy in depressed patients with coronary disease. Psychosomatics. 2004;45:319-324.
8102.	Kotagal S, Chopra A. Pediatric Sleep-Wake Disorders. Neurologic clinics. 2012;30:1193-1212.
8103.	Kotzailias N, Marker M, Jilma B. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: A randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology. 2004;24:536-539.
8104.	Koukopoulos A, SN G. The Primacy of Mania: a Reconsideration of Mood Disorders. European psychiatry. 2009;24:125-134.
8105.	KP E, LL H. TMS - The beginning of the end or the end of the beginning? Psychological medicine. 2008;38:319-321.
8106.	KP G, EGTM H. Oxybutynin for antidepressant-induced hyperhidrosis. European neuropsychopharmacology. 2011;Conference:S385.
8107.	KP G-J. Dextromethorphan/Quinidine: In pseudobulbar affect. CNS drugs. 2011;25:435-445.
8108.	KP G-J. Vortioxetine: a Review of Its Use in Major Depressive Disorder. CNS drugs. 2014;28:855-874.
8109.	KP G-J. Vortioxetine: A review of its use in major depressive disorder. CNS drugs. 2015;28:855-874.
8110.	KP G-J, GM K. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatric Drugs. 2009;11:203-226.
8111.	KP Oc, Aardema F, Robillard S, et al. Cognitive Behaviour Therapy and Medication in the Treatment of Obsessive-Compulsive Disorder. Acta psychiatrica Scandinavica. 2006;113:408-419.
8112.	KP R. Sildenafil. Journal of sex & marital therapy. 1999;25:271-279.
8113.	KPM C, S-F H. Depression in children and adolescents. Hong Kong Practitioner. 2006;28:31-39.
8114.	KR C, AH S. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. The Lancet Neurology. 2009;8:464-474.
8115.	KR C, ME T. The clinical management of bipolar disorder: A review of evidence-based guidelines. Primary care companion to the Journal of clinical psychiatry. 2011;13:6.
8116.	KR C, ME T. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. [Review]. Drugs. 2011;71:43-64.
8117.	KR C, ME T. Emerging Drugs for Major Depressive Disorder. Expert opinion on emerging drugs. 2012;17:105-126.
8118.	KR E, Sills T, GR W, HP M. Worsening of Depressive Symptoms Prior to Randomization in Clinical Trials: a Possible Screen for Placebo Responders? Journal of psychiatric research. 2004;38:437-444.
8119.	KR K. Revisiting monoamine oxidase inhibitors. Journal of clinical psychiatry. 2007;68:35-41.
8120.	KR K, PJ G. Depression, chronic fatigue syndrome, and fibromyalgia: An update. Journal of Chronic Fatigue Syndrome. 2006;13:77-106.
8121.	KR S, AM B. Dementia syndromes: Evaluation and treatment. Expert review of neurotherapeutics. 2007;7:407-422.
8122.	KR S, GW P, JM W, et al. Sb-649915-B, a Novel 5-Ht1a/B Autoreceptor Antagonist and Serotonin Reuptake Inhibitor, Is Anxiolytic and Displays Fast Onset Activity in the Rat High Light Social Interaction Test. Neuropsychopharmacology. 2007;32:2163-2172.
8123.	KR S, KL W, BH H, JM P. Postpartum Depression Recurrence Versus Discontinuation Syndrome: Observations From a Randomized Controlled Trial. Journal of clinical psychiatry. 2004;65:1266-1268.
8124.	Kradin R. The placebo response: Its putative role as a functional salutogenic mechanism of the central nervous system. Perspectives in biology and medicine. 2004;47:328-338.
8125.	Kraft K. [New developments in hypericum extracts: data on efficacy and interactions]. [Review] [27 refs] [German]. Wiener medizinische Wochenschrift (1946). 2007;157:284-287.
8126.	Kragh-Sorensen P, KB S. The concept of melancholia and antidepressant treatment. Salud mental (Mexico City, Mexico). 2004;27:1-7.
8127.	Kramer D, A-K A, Fejtkova S, Mergl R, Hegerl U. Depression in nursing homes: Prevalence, recognition, and treatment. International journal of psychiatry in medicine. 2009;39:345-358.
8128.	Krapivensky N, Lewis D. Escitalopram monotherapy in managing depressive and pain symptoms in patients with depression and fibromyalgia. European psychiatry. 2012.
8129.	Kratochvil C, Emslie G, Silva S, et al. Acute Time to Response in the Treatment for Adolescents with Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1412-1418.
8130.	Kraus C, Ganger S, Losak J, et al. Gray Matter and Intrinsic Network Changes in the Posterior Cingulate Cortex After Selective Serotonin Reuptake Inhibitor Intake. NeuroImage. 2014;84:236-244.
8131.	Krawczyk K, Rybakowski J. Augmentation of Antidepressants With Unsaturated Fatty Acids Omega-3 in Drug-Resistant Depression. Psychiatria polska. 2012;46:585-598.
8132.	Krebs G, Heyman I. Treatment-resistant obsessive-compulsive disorder in young people: Assessment and treatment strategies. Child and adolescent mental health. 2010;15:2-11.
8133.	Kretzchmar A. After successful therapy of mania, olanzapine is also approved for phase prophylaxis in bipolar disorders. [German]. Nervenheilkunde. 2004;23:105-106.
8134.	Kretzschmar A. Safe treatment of depression in women with fluoxetine. [German]. Nervenheilkunde. 2000;19:102.
8135.	Kretzschmar A. Disturbed Chronobiology Favours Depression Agomelatin as New Therapy Option With Innovative Effective Profile. Nervenheilkunde. 2009;28:410-411.
8136.	Kreutzkamp B. Metaanalysis: The effectiveness of antidepressant agents is only clinically relevant in very severe symptoms. [German]. Medizinische Monatsschrift fur Pharmazeuten. 2010;33:103-104.
8137.	Kripalani M, Suleman M. Results for behavioural activation are overstated. British journal of psychiatry. 2013;202:466.
8138.	Kris K, Sara A, Bradley P. Premenstrual dysphoric disorder: Treatment with sertraline, neuropsychological effects, and flight status. Aviation, space, and environmental medicine. 2007;78:B138-B143.
8139.	A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function, International journal of geriatric psychiatry(2008).
8140.	Kroenke K, Bair M, Damush T, et al. Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study. Design and practical implications of an intervention for comorbid pain and depression. General hospital psychiatry. 2007;29:506-517.
8141.	Kroenke K, EE K, MJ B. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. [Review] [131 refs]. General hospital psychiatry. 2009;31:206-219.
8142.	Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: A randomized controlled trial, JAMA - Journal of the American Medical Association(2009).
8143.	Kroenke K, SL W, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial. JAMA: Journal of the American Medical Association. 2001;286:2947-2955.
8144.	Kroenke K, Theobald D, Norton K, et al. The Indiana Cancer Pain and Depression (INCPAD) trial. Design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. General hospital psychiatry. 2009;31:240-253.
8145.	Krogias C, Hoffmann K, Eyding J, et al. Evaluation of basal ganglia, brainstem raphe and ventricles in bipolar disorder by transcranial sonography. Psychiatry Research - Neuroimaging. 2011;194:190-197.
8146.	Krogias C, Strassburger K, Eyding J, et al. Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. Journal of psychiatry & neuroscience. 2011;36:187-194.
8147.	Kroll R, AJ R. Treatment of Premenstrual Disorders. Journal of reproductive medicine. 2006;51:359-370.
8148.	Kronenberg S, Apter A, Brent D, et al. Serotonin Transporter Polymorphism (5-Httlpr) and Citalopram Effectiveness and Side Effects in Children With Depression and/or Anxiety Disorders. Journal of child and adolescent psychopharmacology. 2007;17:741-750.
8149.	Kronenberg S, Frisch A, Rotberg B, Carmel M, Apter A, Weizman A. Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics. 2008;9:1725-1736.
8150.	Kronfeld-Schor N, Einat H. Circadian rhythms and depression: Human psychopathology and animal models. Neuropharmacology. 2012;62:101-114.
8151.	Kronfol Z, HJ L, Back-Madruga C, et al. No Increase in Depression With Low-Dose Maintenance Peginterferon in Prior Non-Responders With Chronic Hepatitis C. Journal of affective disorders. 2011;129:205-212.
8152.	KRR K. Treatment of depression in the medically III. Journal of clinical psychopharmacology. 2005;25:S14-S18.
8153.	Krstic J, Buzadzic I, SD M, NV I, Pajic S, TV I. Low-frequency repetitive transcranial magnetic stimulation in the right prefrontal cortex combined with partial sleep deprivation in treatment-resistant depression: A randomized sham-controlled trial. Journal of ECT. 2014;30:325-331.
8154.	Kruger S, Braunig P. Pharmacotherapy of manic-depressive mixed states. [German]. Nervenheilkunde. 2008;27:145-154.
8155.	Kruger S, LT Y, Braunig P. Pharmacotherapy of bipolar mixed states. Bipolar disorders. 2005;7:205-215.
8156.	Krupitsky EM, Yerish SM, Kiselev AS, et al. A double-blind, placebo-controlled, randomized clinical trial of escitalopram for the treatment of affective disorders in alcohol dependent patients in early remission. 2013:239-256.
8157.	Krupp L, Patel Y, Bhise V. Pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders. 2011;Current Cl:157-177.
8158.	Krystal A. Addressing co-morbidities in insomnia. European neuropsychopharmacology. 2008;Conference:S603-S604.
8159.	Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. Journal of clinical sleep medicine. 2007;3:48-55.
8160.	KS B, DS B. Pharmacological treatment of social phobia. Psychiatry. 2007;6:217-223.
8161.	KS D, SD H, Dimidjian S, et al. Randomized Trial of Behavioral Activation, Cognitive Therapy, and Antidepressant Medication in the Prevention of Relapse and Recurrence in Major Depression. Journal of consulting and clinical psychology. 2008;76:468-477.
8162.	KS H. Milnacipran: A new treatment for fibromyalgia syndrome. Journal of pharmacy technology. 2010;26:129-135.
8163.	KS P, KL W. Successful recruitment strategies for women in postpartum mental health trials. Journal of psychiatric research. 2003;37:117-125.
8164.	KS R, JA B, AM M, Roderick P, SA W, Daly C. Physical Measures for Treating Depression in Dialysis Patients. Cochrane database of systematic reviews (Online). 2005.
8165.	KS R, JA B, AM M, Roderick P, SA W, Daly C. Physical measures for treating depression in dialysis patients. [Review] [41 refs]. Cochrane database of systematic reviews (Online). 2005:CD004541.
8166.	KS R, JA B, AM M, Roderick P, SA W, Daly C. Physical Measures for Treating Depression in Dialysis Patients. Cochrane database of systematic reviews (Online). 2005.
8167.	KT B, BK T, ML V. Alcohol use and anxiety: Diagnostic and management issues. American journal of psychiatry. 2007;164:217-221.
8168.	KT B, EW F, SJ S. A Clinician Guide to the Premenstrual-Syndrome. Medical clinics of North America. 1995;79:1457-&.
8169.	KT B, Kaltsounis-Puckett J. Major depressive disorder with anxiety symptoms or sleep disturbance. Journal of clinical psychiatry. 2002;63:5-7.
8170.	KT B, ML V, BK T. Treatment of patients comorbid for addiction and other psychiatric disorders. Current psychiatry reports. 2007;9:374-380.
8171.	KT B, Sonne S, RF A, CL R, SE B, Simpson K. Sertraline in the Treatment of Co-Occurring Alcohol Dependence and Posttraumatic Stress Disorder. Alcoholism, clinical and experimental research. 2005;29:395-401.
8172.	KT B, Sonne S, RF A, CL R, SE B, Simpson K. Sertraline in the Treatment of Co-Occurring Alcohol Dependence and Posttraumatic Stress Disorder. Alcoholism, clinical and experimental research. 2005;29:395-401.
8173.	KT M. Antidepressant-related adverse effects improve with time. American family physician. 2010;81:1030.
8174.	KU K, BB Q, Riedel M, Krampe O, Maier W. Safety and Efficacy of Citalopram in the Treatment of Depressive Disorders. Psychopharmakotherapie. 2005;12:83-90.
8175.	Kucukgoncu S, Midura M, Tek C. Optimal management of night eating syndrome: Challenges and solutions. Neuropsychiatric disease and treatment. 2015;11:751-760.
8176.	Kugaya A, Sanacora G, JK S, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological psychiatry. 2004;56:497-502.
8177.	Kuha S, O-P M, Henttonen A, Naarala M. The efficacy of fluoxetine versus maprotiline in depressed patients and by dose. Nordisk Psykiatrisk Tidsskrift. 1991;45:109-117.
8178.	Kuhad A, Bishnoi M, Chopra K. Anti-Nociceptive Effect of Duloxetine in Mouse Model of Diabetic Neuropathic Pain. Indian journal of experimental biology. 2009;47:193-197.
8179.	Kuhl H. Venlafaxin for hot flushes - Side-effects and interactions, contraindications. [German]. Gynakologische Praxis. 2004;28:536.
8180.	Kuhl H. Venlafaxin for hot flushes - Side-effects and interactions, contraindications. [German]. Tagliche Praxis. 2004;45:802.
8181.	Kuhs H, GA R. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta psychiatrica Scandinavica. Supplementum. 1989;350:145-146.
8182.	Kuhs H, GAE R. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatrica Scandinavica, Supplement. 1989;80:145-146.
8183.	Kuhs H, GAE R. Cardiovascular effects of paroxetine. Psychopharmacology. 1990;102:379-382.
8184.	Kuhs H, H-P S, Rolf LH, Rudolf GA. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta psychiatrica Scandinavica. 1992;85:364-369.
8185.	Kuhs H, Rudolf GA. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta neurologica Scandinavica. 1989;80:145-146.
8186.	Kulp W, J-M GVDS, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. European journal of health economics. 2005;6:317-321.
8187.	Kumar A, Aggarwal A, Gaur V. Post-stroke depression: Pathologlogy, diagnosis and treatment strategy. International Journal of Pharmaceutical Sciences and Research. 2011;2:483-493.
8188.	Kumar A, Garg R, Gaur V, Kumar P. Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain research. 2010;1311:73-80.
8189.	Kumar B, Prakash A, RK S, Medhi B, Modi M. Drug therapy in autism: A present and future perspective. Pharmacological Reports. 2012;64:1291-1304.
8190.	Kumar P, Waiter G, Ahearn T, Milders M, Reid I, JD S. Abnormal temporal difference reward-learning signals in major depression. Brain. 2008;131:2084-2093.
8191.	Kumar R. Approved and investigational uses of modafinil: An evidence-based review. Drugs. 2008;68:1803-1839.
8192.	Kumar R, PS S. Akathisia and Second-Generation Antipsychotic Drugs. Current opinion in psychiatry. 2009;22:293-299.
8193.	Kumar S. Prophylaxis of depression in older people. British journal of psychiatry. 2003;183:365; author reply 365.
8194.	Kumar S, [Ed] ZS. Prophylaxis of depression in older people: Comment. The British Journal of Psychiatry. 2003;183:365.
8195.	Kumar S, Kodela S, JG D, KY K, MB D. Bupropion-induced psychosis: Folklore or a fact? A systematic review of the literature. General hospital psychiatry. 2011;33:612-617.
8196.	Kumar S, MH S, LR C. Medical complications after stroke. The Lancet Neurology. 2010;9:105-118.
8197.	Kumar S, Oakley-Browne M, Zanardi R, Rossini D, Serretti A. Problems with ensuring a double blind [2]. Journal of clinical psychiatry. 2001;62:295-296.
8198.	Kumar V. Post-stroke depression and treatment strategies including Aniracetam. International Journal of Geriatric Psychopharmacology. 1999;2:40-46.
8199.	Kummer A, AL T. Neuropsychiatry of Parkinson's disease. Arquivos de neuro-psiquiatria. 2009;67:930-939.
8200.	Kunitoshi K, Shinji H, Eiichi N, Tsukasa K. Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression. Neuropsychiatric disease and treatment. 2013;9.
8201.	Kunitoshi K, Tal B, Guy C, Ichiro A, Toshimitsu H. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. International clinical psychopharmacology. 2006;21:1-9.
8202.	Kunwar A, Dewan M, SV F. Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder. Expert opinion on pharmacotherapy. 2007;8:555-562.
8203.	Kuper H, Nicholson A, Kivimaki M, et al. Evaluating the causal relevance of diverse risk markers: Horizontal systematic review. BMJ (Online). 2009;339:1240.
8204.	Kurt B, Joseph C. Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: A case report and review literature. Turk Psikiyatri Dergisi. 2007;18:1-5.
8205.	Kurt K, III MN, Isma B, Jay G, Jeff M. Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder. Journal of clinical psychiatry. 2006;67:72-80.
8206.	Kushwaha V, RK C, Mehta M. Psychotherapeutic Intervention in Somatisation Disorder: Results of a Controlled Study From India. Psychology, health & medicine. 2013;18:445-450.
8207.	Kusnick C. Treatment of depression and anxiety: Rapid improvement with escitalopram. [German]. Deutsche Apotheker-Zeitung. 2003;143:38-40.
8208.	Kusnick C. Extended approval: Duloxetine for generalized anxiety disorder. [German]. Deutsche Apotheker-Zeitung. 2008;148:39-40.
8209.	Kusnick C. Benefit analysis of antidepressants: Venlafaxine and duloxetine are superior to placebo. [German]. Deutsche Apotheker-Zeitung. 2009;149:32-33.
8210.	Kusnick C, H-P H. Mental disorders: Are antidepressants effective only in severe depression?. [German]. Deutsche Apotheker-Zeitung. 2010;150:42-43.
8211.	Kuspinar A, AM R, NE M. The effects of clinical interventions on health-related quality of life in multiple sclerosis: A meta-analysis. Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18:1686-1704.
8212.	Kusumoto M, Ueno K, Oda A, et al. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Clinical pharmacology and therapeutics. 2001;69:104-107.
8213.	A combination of cognitive-behavioural therapy and sertraline reduced anxiety in children more than either treatment alone, Evidence-based medicine(2009).
8214.	Kutcher S, DM G. Use of selective serotonin reuptake inhibitors and youth suicide: Making sense from a confusing story. Current opinion in psychiatry. 2008;21:65-69.
8215.	Kutcher S, Leblanc J, Maclaren C, Hadrava V. A randomized trial of a specific adherence enhancement program in sertraline-treated adults with major depressive disorder in a primary care setting. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:591-596.
8216.	KV R. Cortical blindness after electroconvulsive therapy. Journal of the American Board of Family Practice. 1997;10:141-143.
8217.	Receptor-binding and pharmacokinetic properties of dopaminergic agonists, Current topics in medicinal chemistry(2008).
8218.	KW C. New SSRI approved in last quarter of 2013. Drug topics. 2014.
8219.	KW D, DJ K, JT B, et al. Assessment and Treatment of Depression in Patients With Cardiovascular Disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosomatic medicine. 2006;68:645-650.
8220.	Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: Coronary psychosocial evaluation studies randomized controlled trial, Archives of internal medicine(2010).
8221.	KW M, Favaron E, Hafizi S, et al. Effects of erythropoietin on emotional processing biases in patients with major depression: An exploratory fMRI study. Psychopharmacology. 2009;207:133-142.
8222.	KW M, Favaron E, Hafizi S, et al. Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology. 2010;210:419-428.
8223.	KW O. Treatment of noncardiac chest pain of psychological origin. Current treatment options in gastroenterology. 2006;9:51-58.
8224.	KW O, AR B. Treatment of the severe refractory irritable bowel patient. Current treatment options in gastroenterology. 2006;9:324-330.
8225.	KW W, Harnam N, DA R, JC L, Svedsater H, Endicott J. Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form Responder Thresholds in Generalized Anxiety Disorder and Bipolar Disorder Studies. International clinical psychopharmacology. 2011;26:121-129.
8226.	A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder, American journal of psychiatry(2012).
8227.	L AD, Sander G, Alexander B, W SG. Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression. Psychopharmacology bulletin. 1997;33:707-714.
8228.	L AD, Sander G, Alexander B, W SG. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. Journal of clinical psychopharmacology. 2000;20:658-665.
8229.	L BA, Sanjaya S, S SDH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Research - Neuroimaging. 1999;91:127-139.
8230.	L BB, C FL, Anne-Catherine R-L, Y MC, D ES, I BS. Treatment of depression associated with age-related macular degeneration: A double-blind, randomized, controlled study. Annals of clinical psychiatry. 2011;23:277-284.
8231.	L BC. Treatment Options for Bipolar Depression. Journal of clinical psychiatry. 2005;66:3-6.
8232.	L BC, F SA, Alan R, et al. Fluoxetine and desipramine in major depressive disorder. Journal of clinical psychopharmacology. 1993;13:305-311.
8233.	L CG. The safety of fluoxetine: An update. The British Journal of Psychiatry. 1988;153:77-86.
8234.	L CJ. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Journal of clinical psychiatry. 1992;53:33-35.
8235.	L CJ, Ari K, Karl R, T SW, Dunbar GC. Paroxetine Versus Placebo - a Double-Blind Comparison in Depressed-Patients. Journal of clinical psychiatry. 1992;53:434-438.
8236.	L CJ, P FJ. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. Journal of clinical psychopharmacology. 1993;13:23S-27S.
8237.	L CL, R TA, K LJ, P TA, W WC, H PL. A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. Psychopharmacology. 2011;218:371-379.
8238.	L CL, Sarah Y, H PL. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological psychiatry. 2002;51:183-188.
8239.	L DA, A MG, J WN, J TB, J KN. Investigation of consumer satisfaction with cognitive-behaviour therapy and sertraline in the treatment of adolescent depression. Australian and New Zealand journal of psychiatry. 2005;39:500-506.
8240.	L DC, Dineen WK, Moira R, et al. Sertraline in Children and Adolescents With Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1162-1170.
8241.	L DD, Alan L, D PC, T DJ. Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Severe Depression: Post hoc Analysis of Pooled Data from a Subset of Subjects in Four Double-Blind Clinical Trials. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2005;27:1901-1911.
8242.	L DD, B CJ, Thomas W, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Journal of clinical psychiatry. 1992;53:57-60.
8243.	L DD, D AJ, C SR, Antony L, J RS. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study. Journal of clinical psychiatry. 2007;68:1071-1077.
8244.	L DD, E HH, Carolyn B, B BC, Friedman SD. Dysthymic disorder: Treatment with citalopram. Depression and anxiety. 2002;15:18-22.
8245.	L DD, J GD, Craig M, Yili L, J DM. Duloxetine in treatment of anxiety symptoms associated with depression. Depression and anxiety. 2003;18:53-61.
8246.	L DD, N DSD, K KD, J DM, M RJ. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. [Review] [27 refs]. Journal of affective disorders. 2005;87:115-119.
8247.	L DL, Patricia P, R WS, et al. Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: An exploratory analysis of a single-blind randomized trial. Depression and anxiety. 2012;29:111-122.
8248.	L DP, H PL, S CD, R HG. Efficacy of fluvoxamine in treatment-refractory depression. Journal of affective disorders. 1988;15:55-60.
8249.	L DP, K BS, H MC, et al. Sexual Functioning Assessed in 4 Double-Blind Placebo- and Paroxetine-Controlled Trials of Duloxetine for Major Depressive Disorder. Journal of clinical psychiatry. 2005;66:686-692.
8250.	L DP, L MH, M SR, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biological psychiatry. 1999;46:212-220.
8251.	L DP, L MH, M SR, et al. Monoamines and the mechanism of antidepressant action: Effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacology bulletin. 1993;29:389-396.
8252.	Escitalopram in the treatment of adolescent depression: A randomized, double-blind, placebo-controlled extension trial, Journal of child and adolescent psychopharmacology(2013).
8253.	L FR, E PM, K MN, et al. The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: A pilot randomized placebo-controlled trial. Child and adolescent psychiatry and mental health. 2009;3.
8254.	L FR, Jacqui L, M RB, K MN, R CJ. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. Journal of child and adolescent psychopharmacology. 2008;18:615-621.
8255.	L FR, K MN, J SR, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. [Review] [42 refs]. Journal of child and adolescent psychopharmacology. 2006;16:131-145.
8256.	L GB, H HB, L WK, S PK, M PJ. Weight Changes in Postpartum Women With Remitted Depression. Journal of clinical psychiatry. 2005;66:291-293.
8257.	L GD. Mirtazapine treatment of neuroleptic-lnduced akathisia. Primary psychiatry. 2005;12:27-28.
8258.	L GM, J OM, B NC. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. American journal of psychiatry. 2002;159:1702-1710.
8259.	L GM, J OM, B NC. "Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine": Erratum. American journal of psychiatry. 2003;160:204.
8260.	The Clinical Relevance of Self-Reported Premenstrual Worsening of Depressive Symptoms in the Management of Depressed Outpatients: a Star(Star)D Report, Journal of women's health (2002)(2013).
8261.	L HC, C SS, John RA, et al. The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: A STAR*D report. Journal of women's health. 2013;22:219-229.
8262.	L HP. Treatment of bereavement-related depression and traumatic grief. [Review] [49 refs]. Journal of affective disorders. 2006;92:117-124.
8263.	L JL, Hyman RM, A YK, et al. Randomized, Placebo-Controlled Trial of Fluoxetine for Acute Treatment of Minor Depressive Disorder. American journal of psychiatry. 2004;161:1864-1871.
8264.	L LB. Selective serotonin reuptake inhibitors for treatment of depression and suicide in youth: What's a doctor to do? Journal of child and adolescent psychopharmacology. 2012;22:315.
8265.	Toward a neuroimaging treatment selection biomarker for major depressive disorder, JAMA Psychiatry(2013).
8266.	L MD, H LD, F GJ, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. New England journal of medicine. 2001;344:961-966.
8267.	L MD, I SW, Ying G, et al. Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (stages I, II, III, and IV) With Major Depression. Journal of clinical psychiatry. 2006;67:288-296.
8268.	L MH, David ER, A MG, Bruce LR, N GR. Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology. 2001;24:617-623.
8269.	L MM, FJ GS, I HG, CF SP, MC BP, M EI. Geriatric depression therapy in residential homes. [Spanish]. Anales de Psiquiatria. 2008;24:184-189.
8270.	L MM, J RA, Giovanni B, Mariangela S, Giuseppina PM, Natalie R. Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women. Archives of women's mental health. 2010;13:91-98.
8271.	A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II), Journal of clinical psychiatry(2010).
8272.	L NA, G GC. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A nordic mulitcentre study. The British Journal of Psychiatry. 1990;157:894-901.
8273.	L PY, D MM, K C-LP, A BR, Durisala D, J DM. Use of effect size to determine optimal dose of duloxetine in major depressive disorder. Journal of psychiatric research. 2007;41:311-318.
8274.	L RJ, E JM, You-Jun F, et al. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biological psychiatry. 2002;51:723-732.
8275.	L RK. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review. [Review] [19 refs]. Journal of cardiovascular nursing. 2008;23:489-496.
8276.	L RN, Jennifer D, Lynn F, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: A pilot study. Journal of psychiatric research. 2007;41:338-343.
8277.	L RR, D FA. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of affective disorders. 1999;56:171-181.
8278.	L RR, F FL, P FJ, Karl R, Richard E, T DA. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of clinical psychiatry. 1998;59:116-122.
8279.	L RR, Richard E, Rohini C. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. Journal of clinical psychopharmacology. 1998;18:136-144.
8280.	L SV, F SR, B CT, et al. Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression. American journal of psychiatry. 2005;162:1165-1170.
8281.	L TA, M VH, Rosenberg J, Gogenur I. Pharmacological treatment of depression in women with breast cancer: a systematic review. [Review]. Breast cancer research and treatment. 2013;141:325-330.
8282.	L vBA, H vdHR, M BDG, L BA. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology. 1993;113:225-230.
8283.	L vK, A-C A, Bengtsson F, Carlsson A, Ekselius L. Cost of depression: Effect of adherence and treatment response. European Psychiatry: the Journal of the Association of European Psychiatrists. 2006;21:349-354.
8284.	L VK, Ekselius L. Idiopathic pain and depression. Quality of life research. 1994;3:S57-S68.
8285.	L VO, Aziz Q. Recent insights on central processing and psychological processes in functional gastrointestinal disorders. Digestive and liver disease. 2009;41:781-787.
8286.	L VO, Tack J. Authors' response [2]. Gut. 2007;56:733.
8287.	L VO, Tack J. Is the Antidepressant Venlafaxine Effective for the Treatment of Functional Dyspepsia? Nature clinical practice. Gastroenterology & hepatology. 2009;6:74-75.
8288.	L WK, CJr SE, R BS, L HT, J DRM, A AJ. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Journal of clinical psychiatry. 2000;61:196-202.
8289.	L WK, H HB, M PJ, et al. Postpartum Depression - a Randomized Trial of Sertraline Versus Nortriptyline. Journal of clinical psychopharmacology. 2006;26:353-360.
8290.	L WK, M PJ, S PK, H HB, M PC, L FR. Prevention of postpartum depression: A pilot randomized clinical trial. American journal of psychiatry. 2004;161:1290-1292.
8291.	L WK, Y SDK, H HB, L M-KE, M PJ. Reply to Drs. Henderson and Vale. Journal of clinical psychopharmacology. 2007;27:322-325.
8292.	L-H G, Wang S, He R. Poststroke depression. Chinese Journal of Clinical Rehabilitation. 2005;9:230-231.
8293.	L-H T, Kjellman B, Arned M, Lindwall-Sundel K, Walinder J, Wetterberg L. Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. International clinical psychopharmacology. 1999;14:S7-S11.
8294.	L-H W, R-L Z, J-F M, Y-Z S. Comparison of the clinical efficacy and safety of domestic duloxetine with imported duloxetine in treating depression. [Chinese]. Chinese Journal of New Drugs. 2012;21:1647-1650.
8295.	L-J X, P-K W, H-M L, Pang B. Effects of Xiaotan Jieyu Recipe on behaviors of tumor-bearing rats with chronic mild stress and the mechanism. [Chinese]. Zhong xi yi jie he xue bao [Journal of Chinese integrative medicine]. 2010;8:138-144.
8296.	L-K W, J-J Z, J-X W, et al. [Effects of pingyu capsule on signal transduction of rats with chronic stress-induced depression]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2008;33:1743-1746.
8297.	L-L H. Comparison of therapeutic effects and side effects between fluoxetine hydrochloride and clomipramine in patients with vascular depression. Chinese Journal of Clinical Rehabilitation. 2005;9:226-228.
8298.	L-S Z, X-Y H, L-Y Y, et al. Prophylactic effects of duloxetine on post-stroke depression symptoms: An open single-blind trial. European neurology. 2013;69:336-343.
8299.	L-T L, S-H W, H-Y G, Chen J, S-W Y, Yu M. The Beneficial Effects of the Herbal Medicine Free and Easy Wanderer Plus (Fewp) and Fluoxetine on Post-Stroke Depression. Journal of alternative and complementary medicine (New York, N.Y.). 2008;14:841-846.
8300.	L-X Y, Wang H, Y-D W, Zhang L, D-S L, Guo Y. Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:6826-6828.
8301.	L-X Y, Y-D W, Wang H, D-S L. Effect of Paxil and berhomine on poststroke anxiety-depression and neurological recovery. Chinese Journal of Clinical Rehabilitation. 2006;10:153-155.
8302.	L'Eilde-Balcon C, Lemonnier E, Chamoux F, Borgnis-Desbordes N. Pharmacological treatments of childhood and adolescent depression. [French]. Journal de Pharmacie Clinique. 2001;20:171-177.
8303.	LA A, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Bailliere's Best Practice and Research in Clinical Rheumatology. 2003;17:563-574.
8304.	LA A, Resnick S, Kunz M, Devinsky O. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacology bulletin. 1995;31:785-788.
8305.	LA B, AN T, DN O. The psychopharmacology algorithm project at the harvard south shore program: An update on posttraumatic stress disorder. Harvard review of psychiatry. 2011;19:240-258.
8306.	LA B, Bennett R, IJ R, et al. Effect of Duloxetine in Patients With Fibromyalgia: Tiredness Subgroups. Arthritis research & therapy. 2010;12.
8307.	LA B, MM W, FJ W, et al. Pain Response Profile of Patients With Fibromyalgia Treated With Duloxetine. Clinical journal of pain. 2010;26:498-504.
8308.	LA C. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Annals of clinical psychiatry. 1997;9:157-164.
8309.	LA C, JK G, CK Y, Odouli R, Hendrick V. Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders. Archives of general psychiatry. 2011;68:1104-1112.
8310.	LA C, SH P, JP F, MJ B, SP R. Depression in the medically ill: Choosing an antidepressant. Journal of clinical psychiatry. 1994;55:90-100.
8311.	LA D, SM B. 5-HT1 receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders. Current topics in medicinal chemistry. 2008;8:1008-1023.
8312.	LA F, AH F, CD B, OP A. Memory loss. Medical journal of Australia. 2012;196:114-117.
8313.	LA J, Banupriya R, MR A. Antidepressant effect of tramadol on balb-c mice in animal models of depression. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2013;4:1435-1441.
8314.	LA L, HA C, MA O. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. [Review] [82 refs]. Journal of clinical psychiatry. 2003;64 Suppl 1:11-19.
8315.	LA L, SC S, CL R, RF A, KT B. Does Comorbid Anxiety or Depression Affect Clinical Outcomes in Patients With Post-Traumatic Stress Disorder and Alcohol Use Disorders? Comprehensive psychiatry. 2004;45:304-310.
8316.	LA M, MF B, BJ M, RM V, Luckoor R, SD R. Hepatitis C treatment for people with severe mental illness. Psychosomatics. 2006;47:93-107.
8317.	LA N, JR A-S. Management of depression in patients with comorbid cardiovascular disease. Journal of pharmacy practice. 2001;14:526-539.
8318.	LA O, MS G, MG O. Pharmacotherapy of post-traumatic stress disorder. Drugs of today (Barcelona, Spain : 1998). 2006;42:803-809.
8319.	LA P. Nutritional interventions for treatment of seasonal affective disorder. CNS neuroscience & therapeutics. 2010;16:3-5.
8320.	LA P, JC M, JH K, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: A pilot study. American journal of psychiatry. 1997;154:1757-1759.
8321.	LA R, KE H, Tartter M. Application of human laboratory models to pharmacotherapy development for alcohol dependence. Current pharmaceutical design. 2010;16:2149-2158.
8322.	LA S, Rabasseda X, Silvestre J, Castaner J. Vilazodone hydrochloride. Drugs of the future. 2001;26:247-252.
8323.	LA S, RM C, Castaner J. Duloxetine oxalate: Treatment of stress urinary incontinence antidepressant norepinephrine reuptake inhibitor 5-HT reuptake inhibitor. Drugs of the future. 2000;25:907-916.
8324.	LA V, RMA H. Bipolar disorder: Quality of life and the impact of atypical antipsychotics. American journal of managed care. 2005;11:S275-S280.
8325.	LA V, SM S, KE T. A Systematic Review of the Efficacy of Venlafaxine for the Treatment of Fibromyalgia. Journal of clinical pharmacy and therapeutics. 2015;40:1-6.
8326.	LA vK, RJ L, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clinical gastroenterology and hepatology. 2008;6:746-752; quiz 718.
8327.	LA Z, Busto U, HL K, EM S. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. Journal of clinical psychopharmacology. 1995;15:117-124.
8328.	Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. British Journal of Psychiatry - Supplementum. 1988:64-68.
8329.	Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. The British Journal of Psychiatry. 1988;153:64-68.
8330.	Laakmann G, Jahn G, Schule C. Hypericum perforatum extracts in the treatment of mild to moderate depression - Clinical and pharmacological aspects. [German]. Der Nervenarzt. 2002;73:600-612.
8331.	Laakmann G, Schule C, Baghai T, Waldvogel E, Bidlingmaier M, Strasburger C. Mirtazapine: An inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion [3]. Journal of clinical psychopharmacology. 2000;20:101-103.
8332.	Laan E, AH R, Barnes T. Standard Operating Procedures for Female Orgasmic Disorder: Consensus of the International Society for Sexual Medicine. Journal of sexual medicine. 2013;10:74-82.
8333.	Labuschagne I, RJ C, KL P, PJ N. Augmenting serotonin neurotransmission with citalopram modulates emotional expression decoding but not structural encoding of moderate intensity sad facial emotional stimuli: an event-related potential (ERP) investigation. Journal of psychopharmacology (Oxford, England). 2010;24:1153-1164.
8334.	Lacasse J, Leo J. Escitalopram, problem-solving therapy, and poststroke depression [3]. JAMA - Journal of the American Medical Association. 2008;300:1757-1758.
8335.	Lacasse Y, Beaudoin L, Rousseau L, Maltais F. Randomized trial of paroxetine in end-stage COPD. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universit� di Napoli, Secondo ateneo. 2004;61:140-147.
8336.	Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: an Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed, Postgraduate medicine(2010).
8337.	LACL C. Olanzapine-Fluoxetine Combination for the Treatment of Bipolar Depression. Expert opinion on pharmacotherapy. 2011;12:2751-2758.
8338.	Levomilnacipran for Major Depressive Disorder: a Systematic Review of the Efficacy and Safety Profile for This Newly Approved Antidepressant - What Is the Number Needed to Treat, Number Needed to Harm and Likelihood to Be Helped or Harmed?, International journal of clinical practice(2013).
8339.	Vortioxetine for Major Depressive Disorder: a Systematic Review of the Efficacy and Safety Profile for This Newly Approved Antidepressant - What Is the Number Needed to Treat, Number Needed to Harm and Likelihood to Be Helped or Harmed?, International journal of clinical practice(2014).
8340.	LACLJ C. Pain Management in Fibromyalgia. Current opinion in rheumatology. 2008;20:246-250.
8341.	Citalopram Provides Little or No Benefit in Nondepressed Patients With Irritable Bowel Syndrome, Clinical gastroenterology and hepatology(2010).
8342.	Ladan K, Firoozeh R, Sepideh S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: Randomized double-blind placebo-controlled study. Human Psychopharmacology: Clinical and Experimental. 2013;28:54-60.
8343.	Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. Journal of clinical psychiatry. 1983;44:20-24.
8344.	Lader M. Limitations of current medical treatments for depression: Disturbed circadian rhythms as a possible therapeutic target. European neuropsychopharmacology. 2007;17:743-755.
8345.	Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients. Human Psychopharmacology: Clinical and Experimental. 2005;20:349-354.
8346.	Lader M, HF A, Baekdal T. The Effect of Escitalopram on Sleep Problems in Depressed Patients. Human Psychopharmacology-Clinical and Experimental. 2005;20:349-354.
8347.	Lader M, Stender K, Burger V, Nil R. Efficacy and Tolerability of Escitalopram in 12-and 24-Week Treatment of Social Anxiety Disorder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study. Depression and anxiety. 2004;19:241-248.
8348.	Lader M, Stender K, Burger V, Nil R. Efficacy and Tolerability of Escitalopram in 12-and 24-Week Treatment of Social Anxiety Disorder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study. Depression and anxiety. 2004;19:241-248.
8349.	Ladislav H, Tuma I, Hanus H. A comparative study of three antidepressants with a different mechanism of action in hospitalized patients. [Czech]. Ceska a Slovenska Psychiatrie. 1999;95:146-156.
8350.	Ladislav H, Tuma I, Hanus H. D-fenfluramine test in depression: Final results. [Czech]. Ceska a Slovenska Psychiatrie. 2000;96:126-130.
8351.	LADLA D. The Discovery and Development of Vilazodone for the Treatment of Depression: a Novel Antidepressant or Simply Another Ssri? Expert opinion on drug discovery. 2013;8:1529-1539.
8352.	LADLM D. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia - Common features and differences. [German]. Psychopharmakotherapie. 2010;17:20-26.
8353.	Laederach-Hofmann K, Graf C, Horber F, et al. Imipramine and Diet Counseling With Psychological Support in the Treatment of Obese Binge Eaters: a Randomized, Placebo-Controlled Double-Blind Study. International journal of eating disorders. 1999;26:231-244.
8354.	Laenen A, Alonso A, Molenberghs G, Vangeneugden T, CH M. Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales. Journal of psychiatric research. 2009;43:730-738.
8355.	Lafer B, Fava M, Hammerness P, JF R. The influence of DST and TRH test administration on depression assessments: a controlled study. Biological psychiatry. 1993;34:650-653.
8356.	Lahti T, JT H, Pankakoski M, Sinclair D, Alho H. Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention: a Pilot Study. Psychopharmacology bulletin. 2010;43:35-44.
8357.	Lai H, Tolat R. Paroxetine-related tremor: While this SSRI can significantly improve mood, its adverse effect warrants second look. Geriatrics. 2005;60:18-20.
8358.	Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. Journal of clinical psychiatry. 2006;67:421-424.
8359.	Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clinical neuropharmacology. 1997;20:419-433.
8360.	Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. American journal of psychiatry. 2007;164:1530-1538.
8361.	Laje G, RH P, AJ R, FJ M. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatric services (Washington, D.C.). 2009;60:1446-1457.
8362.	Lam D, DA G, Patten S, Pringsheim T. The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada From 2005 to 2009: a Database Analysis. Pediatric Drugs. 2013;15:319-327.
8363.	LAM G. Sex and stress hormone effects in animal models of postpartum depression. Biological psychiatry. 2014;Conference:298S.
8364.	Lam R, Parikh S, Ramasubbu R, Michalak E. Measuring work productivity with depression treatment: A novel methodology. International journal of neuropsychopharmacology. 2012;Conference:149.
8365.	Lam RW, Andersen HF. The Influence of Baseline Severity on Efficacy of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: An Extended Analysis. Pharmacopsychiatry. 2006;39:180-184.
8366.	Lamarre-Cliche M. Drug treatment of orthostatic hypotension because of autonomic failure or neurocardiogenic syncope. American journal of cardiovascular drugs. 2002;2:23-35.
8367.	LAML M. Antidepressant Therapy With Milnacipran and Venlafaxine. Neuropsychiatric disease and treatment. 2010;6:17-22.
8368.	Lampe L. Social anxiety disorder: Common, disabling and often untreated. Medicine today. 2009;10:54-64.
8369.	Lanche M. FDA approves duloxetine for maintenance treatment of major depressive disorder. CNS spectrums. 2008;13:23.
8370.	Landaverde C, Saab S. Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations. Current hepatitis reports. 2009;8:43-51.
8371.	Landen M, Eriksson O, Sundblad C, Andersch B, Naessen T, Eriksson E. Compounds With Affinity for Serotonergic Receptors in the Treatment of Premenstrual Dysphoria: a Comparison of Buspirone, Nefazodone and Placebo. Psychopharmacology. 2001;155:292-298.
8372.	Landen M, Hogberg P, ME T. Incidence of Sexual Side Effects in Refractory Depression During Treatment With Citalopram or Paroxetine. Journal of clinical psychiatry. 2005;66:100-106.
8373.	Landen M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E. Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder. Neuropsychopharmacology. 2007;32:153-161.
8374.	Landy S, McGinnis J, Curlin D, SC L. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache. 1999;39:28-32.
8375.	Lane R. The Long-Term Management of Depression. Journal of psychopharmacology (Oxford, England). 1995;9:191-198.
8376.	Lane R, Baldwin D, Preskorn S. The Ssris - Advantages, Disadvantages and Differences. Journal of psychopharmacology (Oxford, England). 1995;9:163-178.
8377.	Langan J, Shajahan P, Martin D, Carleton R. Agomelatine in unipolar depression in clinical practice: A retrospective chart review. Therapeutic Advances in Psychopharmacology. 2011;1:175-180.
8378.	Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache. 1994;34:20-24.
8379.	Langenstrass J. Therapy of severe forms of depression with sertralin. [German]. Nervenheilkunde. 1999;18:153-155.
8380.	Langguth B, AB E. Emerging pharmacotherapy of tinnitus. Expert opinion on emerging drugs. 2011;16:603-606.
8381.	Langguth B, AB E. Current pharmacological treatments for tinnitus. Expert opinion on pharmacotherapy. 2012;13:2495-2509.
8382.	Langguth B, Landgrebe M, Kleinjung T, GP S, Hajak G. Tinnitus and depression. World journal of biological psychiatry. 2011;12:489-500.
8383.	Laniado-Laborin R. Smoking cessation intervention: An evidence-based approach. Postgraduate medicine. 2010;122:74-82.
8384.	Lanza dST, H HB, L WK. Sexual function in postpartum women treated for depression: Results from a randomized trial of nortriptyline versus sertraline. Journal of clinical psychiatry. 2009;70:423-428.
8385.	Lapierre Y, Bentkover J, Schainbaum S, Manners S. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1995;40:370-377.
8386.	Lapierre YD. Controlling acute episodes of depression. International clinical psychopharmacology. 1991;6 Suppl 2:23-35.
8387.	Larauche M, Mulak A, Tache Y. Stress and visceral pain: From animal models to clinical therapies. Experimental neurology. 2012;233:49-67.
8388.	LaRocco-Cockburn A, SD R, Melville J, et al. Improving depression treatment for women: Integrating a collaborative care depression intervention into OB-GYN care. Contemporary clinical trials. 2013;36:362-370.
8389.	Lars B, Edman G, Flyckt L, Hagenfeldt L, Sedvall G, Wiesel FA. Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor - A dose-response study in depressed patients. Psychopharmacology. 1985;87:253-259.
8390.	Lars B, V EG, Gisberth AR, Marcus M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: A randomized, placebo-controlled multi-center study in outpatients. European archives of psychiatry and clinical neuroscience. 2005;255:40-47.
8391.	Lars E. Safety aspects of treatment of the elderly with dementia and/or depression: Side effect profile of a specific 5-HT uptake inhibitor. [Danish]. Nordisk Psykiatrisk Tidsskrift. 1991;45:29-35.
8392.	Larsson B. [Cognitive outcome of childhood depression using cognitive behavior therapy]. [Review] [55 refs] [Swedish]. Lakartidningen. 1815;99:1810-1812.
8393.	Larsson B. Cognitive outcome of childhood depression using cognitive behavior therapy. [Swedish]. Lakartidningen. 2002;99:1810-1812,1815-1819.
8394.	LAS VK, RJF L, Aparicio N, et al. Effect of the Antidepressant Venlafaxine in Functional Dyspepsia: a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical gastroenterology and hepatology. 2008;6:746-752.
8395.	Lastra-Gonzalez G, Manrique-Acevedo C, Lastra-Lastra G. Central obesity and the cardiometabolic syndrome in Hispanics. Therapy. 2007;4:609-621.
8396.	Laszlo G, L BC, L MS, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology. 2003;28:1374-1382.
8397.	Lata G, H-J M. Agomelatine - depression - circadian rhythmicity: Antidepressant with innovative effect mechanism. [German]. Psychopharmakotherapie. 2009;16:1.
8398.	Latalova K, Prasko J. Aggression in Borderline Personality Disorder. Psychiatric quarterly. 2010;81:239-251.
8399.	Latoo J, Mistry M, FJ D. Depression in Parkinson's Disease: Diagnosis and Management. British journal of hospital medicine. 2012;73:331-334.
8400.	Lattanzio F, Cherubini A, Furneri G, M DB, Marchionni N. Sertraline Treatment for Depression Associated With Acute Coronary Syndromes: a Cost Analysis From the Viewpoint of the Italian Healthcare System. Aging clinical and experimental research. 2008;20:76-80.
8401.	Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders, International journal of molecular sciences(2014).
8402.	Laugharne J, Cowan N, Peet M. When fluoxetine fails, what next? A national survey controlling for age. Journal of mental health (Abingdon, England). 1997;6:409-415.
8403.	Laura B, Michael B, Merryll V. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of clinical psychiatry. 2003;64:403-407.
8404.	Laurent H, Pierre B. Selective serotonin reuptake inhibitors in adolescent depression still controversial [20]. Journal of clinical psychopharmacology. 2007;27:325-326.
8405.	Lauretani F, Saginario A, GP C, et al. Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation. Current drug targets. 2014;15:943-947.
8406.	Lauritzen L, Odgaard K, Clemmesen L, et al. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: A comparison with imipramine and placebo in medium-term continuation therapy. Acta psychiatrica Scandinavica. 1996;94:241-251.
8407.	Lauritzen L, Odgaard K, Clemmeson L, et al. The impact of treatment resistance on depressive relapse following electroconvulsive therapy: Reply. Acta psychiatrica Scandinavica. 1997;96:406.
8408.	Laux G. Controlled comparative studies with moclobemide in antidepressive treatment. [German]. Munchener medizinische Wochenschrift (1950). 1995;137:296-300.
8409.	Laux G. Pharmacoeconomics of the new antidepressants and antipsychotics. [German]. Psychiatrische Praxis, Supplement. 2003;30:S90-S93.
8410.	Laux G. Tolerability of Agomelatine. Psychopharmakotherapie. 2009;16:A11-A14.
8411.	Laux G, Brunnauer A. Everyday suitability of antidepressants: Road traffic safety/driving ability. [German]. Psychopharmakotherapie, Supplement. 2005;12:36-38.
8412.	Laux G, Brunnauer A. Fitness to drive under selective antidepressants. European neuropsychopharmacology. 2009;Conference:S424.
8413.	Laux G, Friede M. Treatment of Comorbid Anxiety and Depression With Escitalopram. Psychopharmakotherapie. 2009;16:106-112.
8414.	Laux G, Friede M, Muller WE. Treatment of comorbid anxiety and depression with escitalopram: Results of a post marketing surveillance study. Pharmacopsychiatry. 2013;46:16-22.
8415.	Laux G, NA H. Subgroup analysis of the non-interventional study VIVALDI: Agomelatine in treatment-naive patients, in combination therapy and after treatment switch. International journal of psychiatry in clinical practice. 2014;18:86-96.
8416.	Laux G, Ulrich S. Tranylcypromine: A review. [German]. Psychopharmakotherapie. 2006;13:130-141.
8417.	Lavretsky H. Therapy of depression in dementia. Expert review of neurotherapeutics. 2003;3:631-639.
8418.	Lavretsky H. Neuropsychiatric symptoms in alzheime disease and related disorders: Why do treatments work in clinical practice but not in the randomized trials? American journal of geriatric psychiatry. 2008;16:523-527.
8419.	Lavretsky H. Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders. Aging health. 2009;5:61-78.
8420.	Lavretsky H. Update on geriatric psychiatry. Aging health. 2009;5:287-290.
8421.	Lavretsky H. Combination of methylpehnidate with citalopram is superior to either drug alone in improving clinical and cognitive outcomes in geriatric depression. Neuropsychopharmacology. 2013;Conference:S90.
8422.	Lavretsky H, Eskin A, Nelson S, Cole S. Genomic predictors of response to antidepressant treatment in geriatric depression using genome-wide expression analyses: A pilot study. Neuropsychopharmacology. 2012;Conference:S314-S315.
8423.	Lavretsky H, Irwin M. Complementary use of Tai Chi improves resilience, quality of life, and cognitive function in depressed older adults. Biological psychiatry. 2010;Conference:58S-59S.
8424.	Lavretsky H, LL A, RE O, et al. Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial. American journal of geriatric psychiatry. 2011;19:839-850.
8425.	Lavretsky H, M-D K, Kumar A, IIICF R. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: An open trial. Journal of clinical psychiatry. 2003;64:1410-1414.
8426.	Lavretsky H, MR I. Resilience and aging. Aging health. 2007;3:309-323.
8427.	Lavretsky H, MR I. Enhancing resilience and quality of life in depressed family dementia caregivers: A randomized placebo-controlled trial of escitalopram. Biological psychiatry. 2009;Conference:236S.
8428.	Lavretsky H, MR I. Enhancing resilience and quality of life in depressed family dementia caregivers: A randomized placebo-controlled trial of escitalopram. American journal of geriatric psychiatry. 2009;Conference:A87-A88.
8429.	Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta psychiatrica Scandinavica. 1990;81:185-189.
8430.	Lawson K. Therapeutic applications of anti-depressant drugs in fibromyalgia syndrome. Physiotherapy. 1999;85:197-200.
8431.	Lawson K. Emerging Pharmacological Therapies for Fibromyalgia. Current opinion in investigational drugs (London, England : 2000). 2006;7:631-636.
8432.	Lawson K. Pharmacological Treatments of Fibromyalgia: Do Complex Conditions Need Complex Therapies? Drug discovery today. 2008;13:333-340.
8433.	Lawvere S, MC M. St. John's wort. American family physician. 2005;72:2249-2254.
8434.	Layous K, Chancellor J, Lyubomirsky S, LH W, PM D. Delivering Happiness: Translating Positive Psychology Intervention Research for Treating Major and Minor Depressive Disorders. Journal of alternative and complementary medicine (New York, N.Y.). 2011;17:675-683.
8435.	LB A, AJ D, KA K, et al. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. European neuropsychopharmacology. 2011;Conference:S417.
8436.	LB D, JM B. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clinic proceedings. 2014;89:817-834.
8437.	LB K. Management of pediatric multiple sclerosis. Therapy. 2008;5:641-651.
8438.	LB M. Switching Antidepressants for Treatment-Resistant Major Depression. Journal of clinical psychiatry. 2001;62:12-17.
8439.	LB M, JH C, FA C. The ethics of randomized placebo-controlled trials of antidepressants with pregnant women: A systematic review. Obstetrics and gynecology. 2008;112:1361-1368.
8440.	LB M, JM M, Martinez M, HA Z, R AJ. Suicide risk and prevention in bipolar disorder. Current psychosis & therapeutics reports. 2006;4:167-170.
8441.	LB M, MS G, AM C, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Archives of general psychiatry. 1997;54:214-222.
8442.	LB M, Suppes T, HA Z, et al. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. Journal of clinical psychiatry. 2008;69:183-189.
8443.	LB O, LJ H. Investigating CAM [7] (multiple letters). CMAJ : Canadian Medical Association journal. 2003;168:1527-1528.
8444.	LB Z, HH F. Pathophysiology and Treatment of Psychosis in Parkinson's Disease - a Review. Drugs & aging. 2008;25:665-682.
8445.	LC A, JU A, R VS, LK M. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000;40:572-580.
8446.	LC B, GR H, Goodman W, DS C, LH P. Effects of Fluoxetine Administration on Mood Response to Tryptophan Depletion in Healthy Subjects. Biological psychiatry. 1997;41:949-954.
8447.	LC B, SR M, JA J. Type of Antidepressant Therapy and Risk of Type 2 Diabetes in People With Depression. Diabetes research and clinical practice. 2008;79:61-67.
8448.	LC B, WK G, Anand A, CJ M, LH P. Addition of Desipramine to Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder. American journal of psychiatry. 1997;154:1293-1295.
8449.	LC B, WK G, CJ M, et al. Tryptophan Depletion in Patients With Obsessive-Compulsive Disorder Who Respond to Serotonin Reuptake Inhibitors. Archives of general psychiatry. 1994;51:309-317.
8450.	LC C, DJ C, FJ K. Persistent pain and depression: A biopsychosocial perspective. Biological psychiatry. 2003;54:399-409.
8451.	LC D, GG G. Ontogeny and regulation of the serotonin transporter: Providing insights into human disorders. Pharmacology & therapeutics. 2011;131:61-79.
8452.	LC L, Giaroli G, Taylor D, DK T. Bipolar depression: Clinically missed, pharmacologically mismanaged. Therapeutic Advances in Psychopharmacology. 2011;1:153-162.
8453.	LC M, Gartlehner G, HA R. Comparative effectiveness of second generation antidepressants in the pharmacologic treatment of adult depression. European psychiatry. 2012.
8454.	LC Q, KM G, SH K, RM B. Harm avoidance as a mediator of treatment response to antidepressant treatment of patients with major depression. Psychotherapy and psychosomatics. 2010;79:116-122.
8455.	LC Q, L-AC M, RM B. Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. Journal of affective disorders. 2008;111:67-73.
8456.	LC Q, McBride C, RM B. Evidence for the cognitive mediational model of cognitive behavioural therapy for depression. Psychological medicine. 2008;38:1531-1541.
8457.	LCL V, IM B, PA L, R FJ, AR B. Transcranial direct current stimulation and repetitive transcranial magnetic stimulation in consultation-liaison psychiatry. Brazilian Journal of Medical and Biological Research. 2013;46:815-823.
8458.	LCS T. Mood disorders in Parkinson's disease. Parkinsonism & related disorders. 2012;18:S74-S76.
8459.	LD A, AM S, AG H. Circadian rhythms and psychiatric illness. Current opinion in psychiatry. 2013;26:566-571.
8460.	LD G. Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder. CNS spectrums. 2009;14:8-14.
8461.	LD W, JJ N, SM S, EK D. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. [Review]. American journal of geriatric pharmacotherapy. 2010;8:294-315.
8462.	LDCL V, LP DJ, MV Z. Antidepressants in bipolar depression: Risk versus efficacy. [Portuguese]. Revista de Psiquiatria Clinica. 2009;36:248-249.
8463.	LE E, Ellis C. Diabetes and depression: Global perspectives. Diabetes research and clinical practice. 2010;87:302-312.
8464.	LE E, MA H-T. Effect of comorbid depression on quality of life in adults with Type 2 diabetes. Expert review of pharmacoeconomics & outcomes research. 2013;13:83-91.
8465.	LE G, JJ S, ER H, HLI N, Olivier B, TCG E. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. Journal of clinical psychiatry. 2006;67:1013-1024.
8466.	LE K, VA N, XS R, Lee A, Selim A, DR M. Medication effectiveness studies in the United States Veterans Administration health care system: A model for large integrated delivery systems. Drug development research. 2006;67:217-226.
8467.	LE L, BH J, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: A double-blind, randomised, cross-over trial. Palliative medicine. 2009;23:731-738.
8468.	LE N. Therapy: Nonhormonal treatment of hot flashesa viable alternative? Nature reviews. Endocrinology. 2010;6:66-67.
8469.	LE S, CN E, JP B. A meta-analysis of treatments for perinatal depression. Clinical psychology review. 2011;31:839-849.
8470.	LE S, CN E, JP B. Preventing postpartum depression: A meta-analytic review. Clinical psychology review. 2013;33:1205-1217.
8471.	LE T. Depression and Alzheimer's disease. Depression and anxiety. 1998;8:91-95.
8472.	LE V, PO A, RF C. A close look at fenfluramine and dexfenfluramine. Journal of emergency medicine. 1998;16:197-205.
8473.	Lea R, PJ W. New insights into the psychosocial aspects of irritable bowel syndrome. Current gastroenterology reports. 2003;5:343-350.
8474.	Lea R, PJ W. Benefit-risk assessment of tegaserod in irritable bowel syndrome. Drug safety. 2004;27:229-242.
8475.	Leah G. Social and vocational functioning in chronic depression. Dissertation Abstracts International: Section B: The Sciences and Engineering. 1999;60:829.
8476.	Leanne T, Neil S, Una R, Ian H. A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in Journal of psychopharmacology (Oxford, England). 2004;18:205-214.
8477.	Lebert F. [Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias]. [Review] [30 refs] [French]. Presse medicale. 2003;32:1181-1186.
8478.	Lebert F, Pasquier F. Management of a patient with frontotemporal dementia. [French]. Revue de geriatrie. 2007;32:21-26.
8479.	Lebert F, Robert P, AS R. Management of Behavioral Disorders in Dementia Patients. Revue neurologique. 2000;156:767-772.
8480.	Leblhuber F. [Citalopram in treatment of behavioral disorders in demented patients]. [German]. Acta medica Austriaca. 1994;21:104-106.
8481.	Lecei O, Lederbogen F, Gronau W, et al. Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients. Journal of clinical psychopharmacology. 2012;32:574-576.
8482.	Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline - A novel MAO B inhibitor in Parkinson's disease therapy. Therapeutics and clinical risk management. 2007;3:467-474.
8483.	Lecrubier Y. Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug safety. 1994;10:292-300.
8484.	Lecrubier Y. Clinical utility of venlafaxine in comparison with other antidepressants. International clinical psychopharmacology. 1995;10:29-35.
8485.	Lecrubier Y. Pharmacological interventions in dysthymia. European psychiatry. 1996;11:129s-133s.
8486.	Lecrubier Y. Milnacipran: The clinical properties of a selective serotonin and noradrenaline reuptake inhibitor (SNRI). Human psychopharmacology. 1997;12:S127-S134.
8487.	Lecrubier Y. How do you define remission? Acta Psychiatrica Scandinavica, Supplement. 2002;106:7-11.
8488.	Lecrubier Y, Bech P. The Ham D-6 Is More Homogenous and as Sensitive as the Ham D-17. European psychiatry. 2007;22:252-255.
8489.	Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta psychiatrica Scandinavica. 1997;95:485-493.
8490.	Lederbogen F, H�rer E, Hellweg R, Heuser I, Deuschle M. Platelet counts in depressed patients treated with amitriptyline or paroxetine. European psychiatry. 2003;18:89-91.
8491.	Lederbogen F, Weber B, Colla M, Heuser I, Deuschle M, C-E D. Antidepressant treatment and global tests of coagulation and fibrinolysis [6]. Journal of clinical psychiatry. 2001;62:130.
8492.	Lee H, JH K, B-H M, et al. Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. American journal of gastroenterology. 2010;105:1504-1512.
8493.	Lee H, Kim S, Kim J, Shin I, Yang S, Yoon J. Comparing Effects of Methylphenidate, Sertraline and Placebo on Depressive Symptoms and Psychomotor Function in Patients With Traumatic Brain Injury. International journal of neuropsychopharmacology. 2004;7:S274.
8494.	Lee H, Kim S, Kim J, Shin I, Yang S, Yoon J. Comparing Effects of Methylphenidate, Sertraline and Placebo on Depressive Symptoms and Psychomotor Function in Patients With Traumatic Brain Injury. International journal of neuropsychopharmacology. 2004;7:S274.
8495.	Lee H, SW K, JM K, IS S, SJ Y, JS Y. Comparing Effects of Methylphenidate, Sertraline and Placebo on Neuropsychiatric Sequelae in Patients With Traumatic Brain Injury. Human Psychopharmacology-Clinical and Experimental. 2005;20:97-104.
8496.	Lee H, SW K, JM K, IS S, SJ Y, JS Y. Comparing Effects of Methylphenidate, Sertraline and Placebo on Neuropsychiatric Sequelae in Patients With Traumatic Brain Injury. Human Psychopharmacology-Clinical and Experimental. 2005;20:97-104.
8497.	Lee S, JR W, Jakul L, Sexton K. Does Elimination of Placebo Responders in a Placebo Run-in Increase the Treatment Effect in Randomized Clinical Trials? A Meta-Analytic Evaluation. Depression and anxiety. 2004;19:10-19.
8498.	Lee S, JR W, Jakul L, Sexton K. Does Elimination of Placebo Responders in a Placebo Run-in Increase the Treatment Effect in Randomized Clinical Trials? A Meta-Analytic Evaluation. Depression and anxiety. 2004;19:10-19.
8499.	Lee Y, Han D, Kim S, Park D, Na C. Augmentation therapy of aripiprazole with escitalopram in patients with co-occurrence of depression and alcohol dependence. European neuropsychopharmacology. 2012;Conference:S389.
8500.	Leelahanaj T. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder. Chotmaihet thangphaet [Journal of the Medical Association of Thailand]. 2010;93 Suppl 6:S35-42.
8501.	Leelahanaj T. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial. Chotmaihet thangphaet [Journal of the Medical Association of Thailand]. 2012;95 Suppl 5:S29-37.
8502.	Leentjens A. Mood and motivational syndromes in Parkinson's disease: An update. Journal of psychosomatic research. 2011;Conference:604-605.
8503.	Leentjens AFG, Vreeling FW, G-J L, Verhey FRJ. SSRIs in the treatment of depression in Parkinson's disease. International journal of geriatric psychiatry. 2003;18:552-554.
8504.	Leff J, Vearnals S, CR B, et al. The London depression intervention trial. Randomised controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: Clinical outcome and costs. British journal of psychiatry. 2000;177:95-100.
8505.	Leibenluft E, BM N, TA W. Diurnal variation: reliability of measurement and relationship to typical and atypical symptoms of depression. Journal of affective disorders. 1992;26:199-204.
8506.	Leibenluft E, DE M, PJ S, PA M, TA W. A clinical trial of sleep deprivation in combination with antidepressant medication. Psychiatry research. 1993;46:213-227.
8507.	Leibenluft E, Feldman-Naim S, EH T, TA W, NE R. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. Journal of clinical psychiatry. 1997;58:383-388.
8508.	Leichsenring F, Leibing E, Kruse J, AS N, Leweke F. Borderline personality disorder. Lancet. 2011;377:74-84.
8509.	Leichsenring F, Schauenburg H. Empirically supported methods of short-term psychodynamic therapy in depression - Towards an evidence-based unified protocol. Journal of affective disorders. 2014;169:128-143.
8510.	Leigh E, Smith P, Milavic G, Stringaris A. Mood regulation in youth: Research findings and clinical approaches to irritability and short-lived episodes of mania-like symptoms. Current opinion in psychiatry. 2012;25:271-276.
8511.	Leigh MJ. The "ignored common factor": The role of expectancy in the treatment of adolescent depression. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2012;73:1855.
8512.	Leinonen E, Lepola U, Koponen H, Turtonen J, Wade A, Lehto H. Citalopram Controls Phobic Symptoms in Patients With Panic Disorder: Randomized Controlled Trial. Journal of psychiatry & neuroscience. 2000;25:24-32.
8513.	Lejoyeux M. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol and Alcoholism. 1996;31:69-75.
8514.	Lejoyeux M. Compulsive buying: Psychological and biological treatment. [French]. Encephale. 2007;33:873-875.
8515.	Lejoyeux M, Matharan S, C DB. How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine. CNS spectrums. 2015;20:29-38.
8516.	Lejoyeux M, Picarel-Blanchot F, C DB. How to switch to agomelatine after an initial treatment failure of paroxetine or venlafaxine? European neuropsychopharmacology. 2013;Conference:S341-S342.
8517.	Lekakis J, Ikonomidis I, Papoutsi Z, et al. Selective Serotonin Re-Uptake Inhibitors Decrease the Cytokine-Induced Endothelial Adhesion Molecule Expression, the Endothelial Adhesiveness to Monocytes and the Circulating Levels of Vascular Adhesion Molecules. International journal of cardiology. 2010;139:150-158.
8518.	Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biological psychiatry. 2008;63:1103-1110.
8519.	Lelas S, YW L, TL W-B, et al. Nk1 Receptor Antagonism Lowers Occupancy Requirement for Antidepressant-Like Effects of Ssris in the Gerbil Forced Swim Test. Neuropharmacology. 2013;73:232-240.
8520.	Lembke A, Johnson K, DeBattista C. Depression and smoking cessation: Does the evidence support psychiatric practice? Neuropsychiatric disease and treatment. 2007;3:487-493.
8521.	Lemke MR. Antidepressant effects of dopamine agonists. Experimental and clinical findings. [German]. Der Nervenarzt. 2007;78:31-38.
8522.	Lemond L, LA A. Palliative Care and Hospice in Advanced Heart Failure. Progress in cardiovascular diseases. 2011;54:168-178.
8523.	Lenox-Smith A, Conway P, Knight C. Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the Uk. PharmacoEconomics. 2004;22:311-319.
8524.	Lenox-Smith A, Conway P, Knight C. Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the Uk. PharmacoEconomics. 2004;22:311-319.
8525.	Lenox-Smith A, Greenstreet L, Burslem K, Knight C. Cost Effectiveness of Venlafaxine Compared With Generic Fluoxetine or Generic Amitriptyline in Major Depressive Disorder in the Uk. Clinical drug investigation. 2009;29:173-184.
8526.	Lenox-Smith A, Kelin K, Brnabic A. Efficacy of duloxetine vs venlafaxine - An updated non-inferiority analysis in major depressive disorder. International journal of psychiatry in clinical practice. 2011;Conference:30.
8527.	Lenz B, Sidiropoulos C, Bleich S, Kornhuber J. Frontotemporal Dementia: Neurotransmitter and Clinical Symptoms With Focus on Therapeutic Targets. Fortschritte der Neurologie-Psychiatrie. 2009;77:289-294.
8528.	Lenz K, Coderre K, MD W. Overview of depression and its management in children and adolescents. Formulary (Cleveland, Ohio). 2009;44:172-180.
8529.	Lenzer J. Truly independent research? BMJ (Clinical research ed.). 2008;337:602-606.
8530.	Lenzinger E, Diamant K, Vytiskabinstorfer E, Kasper S. Premenstrual Dysphoric Disorder (Pmdd). A Review of the Diagnosis, Epidemiology, and Therapy Modes. Der Nervenarzt. 1997;68:708-718.
8531.	Leo J. The healy dilemma: A reply to the American college of neuropsychopharmacology's report on SSRIs and suicidal behavior in children. Ethical human psychology and psychiatry. 2004;6:147-151.
8532.	Leo J. The SSRI trials in children: Disturbing implications for academic medicine. Ethical human psychology and psychiatry. 2006;8:29-41.
8533.	Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. Citalopram Versus Fluoxetine for the Treatment of Patients With Bulimia Nervosa: a Single-Blind Randomized Controlled Trial. Advances in therapy. 2006;23:481-494.
8534.	Leombruni P, Lavagnino L, Gastaldi F, Vasile A, Fassino S. Duloxetine in Obese Binge Eater Outpatients: Preliminary Results From a 12-Week Open Trial. Human Psychopharmacology-Clinical and Experimental. 2009;24:483-488.
8535.	Leombruni P, Miniotti M, Colonna F, et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and experimental rheumatology. 2015;33:S82-85.
8536.	Leombruni P, Miniotti M, Colonna F, et al. A Randomised Controlled Trial Comparing Duloxetine and Acetyl L-Carnitine in Fibromyalgic Patients: Preliminary Data. Clinical and experimental rheumatology. 2015;33:S82-S85.
8537.	Leon G, Schmuel H, T DO, Shaul S, N DP. Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT. Journal of ECT. 2001;17:124-128.
8538.	Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neuroscience and biobehavioral reviews. 2012;36:764-785.
8539.	Leonard B, Taylor D. Review: Escitalopram-translating molecular properties into clinical benefit: Reviewing the evidence in major depression. Journal of psychopharmacology (Oxford, England). 2010;24:1143-1152.
8540.	Leong C. Antidepressants for depression in patients with dementia: a review of the literature. [Review]. Consultant pharmacist. 2014;29:254-263.
8541.	Lepine JP, Goger J, Blashko C, et al. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. International clinical psychopharmacology. 2000;15:263-271.
8542.	Lepola U, Alan W, Friis AH. Do Equivalent Doses of Escitalopram and Citalopram Have Similar Efficacy? A Pooled Analysis of Two Positive Placebo-Controlled Studies in Major Depressive Disorder (Vol 19, Pg 149, 2004). International clinical psychopharmacology. 2004;19:256-257.
8543.	Lepola U, Bergtholdt B, J SL, KL D, Ruggiero L. Controlled-Release Paroxetine in the Treatment of Patients With Social Anxiety Disorder. Journal of clinical psychiatry. 2004;65:222-229.
8544.	Lepola U, Bergtholdt B, J SL, KL D, Ruggiero L. Controlled-Release Paroxetine in the Treatment of Patients With Social Anxiety Disorder. Journal of clinical psychiatry. 2004;65:222-229.
8545.	Lepola U, Wade A, HF A. Do Equivalent Doses of Escitalopram and Citalopram Have Similar Efficacy? A Pooled Analysis of Two Positive Placebo-Controlled Studies in Major Depressive Disorder. International clinical psychopharmacology. 2004;19:149-155.
8546.	Lepola U, Wade A, HF A. Do Equivalent Doses of Escitalopram and Citalopram Have Similar Efficacy? A Pooled Analysis of Two Positive Placebo-Controlled Studies in Major Depressive Disorder (Vol 19, Pg 149, 2004). International clinical psychopharmacology. 2004;19:256-257.
8547.	Lerer B, Gelfin Y, Gorfine M, Allolio B, KP L, ME N. 5-Ht1a Receptor Function in Normal Subjects on Clinical Doses of Fluoxetine: Blunted Temperature and Hormone Responses to Ipsapirone Challenge. Neuropsychopharmacology. 1999;20:628-639.
8548.	Lerman C, MG L, KA P, et al. Translational research in medication development for nicotine dependence. Nature reviews. Drug discovery. 2007;6:746-762.
8549.	Lerman C, Patterson F, Berrettini W. Treating Tobacco Dependence: State of the Science and New Directions. Journal of clinical oncology. 2005;23:311-323.
8550.	Lerman C, Patterson F, Berrettini W. Treating Tobacco Dependence: State of the Science and New Directions. Journal of clinical oncology. 2005;23:311-323.
8551.	LES M, BT W. The Use of Selective Serotonin Reuptake Inhibitors in Eating Disorders. Journal of clinical psychiatry. 1998;59:28-34.
8552.	Lesemann A, Reinel C, Huhnchen P, et al. MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice.[Erratum appears in Brain Res. 2013 May 13;1510:89]. Brain research. 2012;1457:51-69.
8553.	Leshno M, Ben-Amnon Y, Brignone M, Marteau F, Hansen K. Cost-utility analysis of escitalopram versus citalopram in major depressive disorder in Israel. Value in health. 2010;Conference:A453.
8554.	Leslie C, A KT, Josephine C, Antony L. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of affective disorders. 2014;155:20-27.
8555.	Lesperance F, Frasure-Smith N, DI S, AH G, CM OC. Sertraline for treatment of depression in acute coronary syndromes [1] (multiple letters). Journal of the American Medical Association. 2002;288:2403-2404.
8556.	Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.[Erratum appears in JAMA. 2007 Jul 4;298(1, JAMA: Journal of the American Medical Association(2007).
8557.	Letizia C, Kapik B, WD F. Suicidal Risk During Controlled Clinical Investigations of Fluvoxamine. Journal of clinical psychiatry. 1996;57:415-421.
8558.	Lev G, E PR, Catherine B, Hyman RM. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. Journal of clinical psychopharmacology. 2012;32:61-64.
8559.	Lev-Ran S, Balchand K, Lefebvre L, KF A, B LF. Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: A review. Canadian Journal of Psychiatry. 2012;57:342-349.
8560.	Levente K, Alessa vW, Annika W, P HL, Martin H. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. [Review]. Depression and anxiety. 2014;31:621-630.
8561.	Levey L, Ragan K, Hower-Hartley A, DJ N, ZN S. Psychiatric disorders in pregnancy. Neurologic clinics. 2004;22:863-893.
8562.	Levin T, DW K. Psychooncology - The state of its development in 2006. European Journal of Psychiatry. 2006;20:183-197.
8563.	Levine J, BD G. Fatigue in Parkinson Disease, Stroke, and Traumatic Brain Injury. Physical medicine and rehabilitation clinics of North America. 2009;20:347-361.
8564.	Levine J, Gonsalves M, Babur I, et al. Inositol 6 g daily may be effective in depression but not in schizophrenia. Human psychopharmacology. 1993;8:49-53.
8565.	Levine J, KNR C, Gershon S, Drevets W. Differentiating primary pathophysiologic from secondary adaptational processes. Depression and anxiety. 2001;14:105-111.
8566.	Levine J, Mishori A, Susnosky M, Martin M, RH B. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biological psychiatry. 1999;45:270-273.
8567.	Levine R, Fink M. The case against evidence-based principles in psychiatry. Medical hypotheses. 2006;67:401-410.
8568.	Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. British journal of psychiatry. 1987;150:653-655.
8569.	Levitan. Preliminary Randomized Double-Blind Placebo-Controlled Trial of Tryptophan Combined With Fluoxetine to Treat Major Depressive Disorder: Antidepressant and Hypnotic Effects (Vol 25, Pg 337, 2000). Journal of psychiatry & neuroscience. 2000;25:439.
8570.	Levy D, Kimhi R, Barak Y, Aviv A, Elizur A. Antidepressant-Associated Mania: a Study of Anxiety Disorders Patients. Psychopharmacology. 1998;136:243-246.
8571.	Levy K, KL L, SB F, Li A, Herrmann N. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimers disease relieve caregiver burden? Drugs & aging. 2012;29:167-179.
8572.	Levy M. Cancer fatigue: a review for psychiatrists. General hospital psychiatry. 2008;30:233-244.
8573.	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial, British journal of psychiatry(2011).
8574.	Polymorphism of the 5-Ht Transporter and Response to Antidepressants: Randomised Controlled Trial, British journal of psychiatry(2011).
8575.	Lewis-Fernandez R, AK D, Alfonso C, MM W, Olfson M. Depression in US Hispanics: Diagnostic and management considerations in family practice. Journal of the American Board of Family Practice. 2005;18:282-296.
8576.	Leyla G, Seref G, Zeliha H, Zeynep B, Savas K. Efficacy of fluoxetine and paroxetine on depression-anxiety, quality of life, disability and metabolic control in diabetic patients with major depressive disorder: A single-blind, comparative study. [Turkish]. Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology. 2001;11:1-10.
8577.	LF D, Zacny J, Klafta J, Karrison T. The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. Journals of gerontology. Series A, Biological sciences and medical sciences. 2001;56:M36-M41.
8578.	LF F. Buspirone in the management of major depression: A placebo-controlled comparison. Journal of clinical psychiatry. 1990;51:55-61.
8579.	LF F. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Journal of clinical psychiatry. 1992;53 Suppl:40-43.
8580.	LF F, 3rd PHP. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Journal of clinical psychiatry. 1987;48:406-408.
8581.	LF F, AH C, LC S, Goldstein I, LR D. The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men. Journal of sexual medicine. 2012;9:821-829.
8582.	LF F, AL N, MV M, RG S, Versiani M. An update on the pharmacological treatment of obsessive-compulsive disorder. Expert opinion on pharmacotherapy. 2007;8:563-583.
8583.	LF F, LC S. The effect of SSRIs on total cholesterol levels in subjects with major depression. Journal of clinical lipidology. 2012;Conference:268.
8584.	LF F, LC S, LR D. Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis. Journal of sexual medicine. 2011;8:2569-2581.
8585.	LF F, MB S, TM I. Comparative Efficacy and Safety of Nortriptyline and Fluoxetine in the Treatment of Major Depression - a Clinical-Study. Journal of clinical psychiatry. 1991;52 Suppl:62-67.
8586.	LF F, MV M, EC M, Versiani M. Citalopram Plus Reboxetine in Treatment-Resistant Obsessive-Compulsive Disorder. World journal of biological psychiatry. 2005;6:57-59.
8587.	LF F, MV M, EC M, Versiani M. Citalopram Plus Reboxetine in Treatment-Resistant Obsessive-Compulsive Disorder. World journal of biological psychiatry. 2005;6:57-59.
8588.	LF G. Drug-Therapy - Fluoxetine. New England journal of medicine. 1994;331:1354-1361.
8589.	LF G, KB S. Dose, drop-out and symptomatology: Important methodological problems in testing new antidepressants. [Danish]. Nordic Journal of Psychiatry, Supplement. 1997;51:27-31.
8590.	LF G, NA R, PM A, et al. Acute and continuation therapy in unipolar depression: Observations from the run-in phase of a maintenance trial. Acta psychiatrica Scandinavica. 2008;118:123-129.
8591.	LF Z, Wang J, ZJ W. [Study on clinical intervention of jiawei shengdan louxie sini fang on coronary heart disease with depression]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2012;37:3150-3154.
8592.	LG A-M, Friederichsen A. Treatment of major depressive disorder with fluoxetine in children and adolescents. A double-blind, placebo-controlled study. [Spanish]. Psiquiatria Biologica. 2005;12:198-205.
8593.	LG M. Drug interactions known or potentially associated with St. John's Wort. Journal of herbal pharmacotherapy. 2001;1:51-64.
8594.	LG S, RC S, DE K, et al. Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar disorders. 2015;17:212-223.
8595.	Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication, Substance abuse treatment, prevention, and policy(2008).
8596.	LH P, DS C, GR H. Variability of response to lithium augmentation in refractory depression. American journal of psychiatry. 1986;143:1387-1392.
8597.	LH P, DS C, PL D, GM A, GR H. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Archives of general psychiatry. 1989;46:625-631.
8598.	LH P, LL C, AR T. Lithium augmentation for refractory depression: A critical reappraisal. Primary psychiatry. 2008;15:35-42.
8599.	LH R. Clinical psychopharmacology of borderline personality disorder: An update on the available evidence in light of the Diagnostic and Statistical Manual of Mental Disorders - 5. Current opinion in psychiatry. 2012;25:52-58.
8600.	LH R. Psychopharmacologic treatment of borderline personality disorder. Dialogues in clinical neuroscience. 2013;15:213-224.
8601.	LH T, KA K. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. Journal of clinical psychiatry. 2000;61:575-578.
8602.	LH T, Kjellman B, Arned M, Lindwall-Sundel K, Walinder J, Wetterberg L. Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. International clinical psychopharmacology. 1999;14 Suppl 2:S7-11.
8603.	LHM C. Functional disorders continue to pose diagnostic and therapeutic challenges to neurologists. Arquivos de neuro-psiquiatria. 2014;72:745-746.
8604.	LHW L, GH S, AA F, MR W, CH T, WY O. Lipidomic Analyses of the Mouse Brain After Antidepressant Treatment: Evidence for Endogenous Release of Long-Chain Fatty Acids? International journal of neuropsychopharmacology. 2009;12:953-964.
8605.	Li G, Mbuagbaw L, Samaan Z, et al. Efficacy of vitamin D supplementation in depression in adults: A systematic review. Journal of clinical endocrinology and metabolism. 2014;99:757-767.
8606.	Li H, Zhou D, Song Y. Effect on Platelet Protein Kinase C of Electro-Acupuncture and Fluoxetine Treatment in Patients with Major Depressive Disorder. [Chinese]. Chinese Mental Health Journal. 2004;18:688-691.
8607.	Li J, Q-Y H, M-F H. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:1208-1209.
8608.	Li J, W-W S, Liu Y, Xu L, S-M L, W-H K. The effectiveness and safety of escitalopram in the treatment of major depression: A randomized double-blind active-drug controlled trial. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2006;6:552-556.
8609.	Li M, BMY C. Pharmacotherapy for obesity. British journal of clinical pharmacology. 2009;68:804-810.
8610.	Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. Journal of clinical oncology. 2012;30:1187-1196.
8611.	Li M, JK S, SH K. Inflammatory biomarkers in depression: An opportunity for novel therapeutic interventions. Current psychiatry reports. 2011;13:316-320.
8612.	LI S, DM C, SD H, et al. Antidepressant-Induced Jitteriness/Anxiety Syndrome: Systematic Review. British journal of psychiatry. 2009;194:483-490.
8613.	Li W, D-R M. A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:20-21.
8614.	Li X, Q-S T, X-J H, Luo B. Changes in brain monoamine neurotransmitters of rats with poststroke depression and the interventional effect of Chinese herb of Yinao Jieyu presciption. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:49-51.
8615.	Li X, RS M, LC T, WT J, JM FJ, LR BJ. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover study. Journal of clinical psychiatry. 2005;66:736-743.
8616.	LI Y, Corapcioglu A, Kocabasoglu N, Erdogan A, Koroglu G, Yilmaz D. A Prospective Randomized Single-Blind, Multicenter Trial Comparing the Efficacy and Safety of Paroxetine With and Without Quetiapine Therapy in Depression Associated With Anxiety. International journal of psychiatry in clinical practice. 2004;8:205-211.
8617.	Li Y, S-L Z, Zhu J, X-N D, Z-F H, Huang F. [Impact of duloxetine on depression and anxiety in patients with ankylosing spondylitis: a case-control study]. [Chinese]. National Medical Journal of China. 2013;93:966-969.
8618.	Li Y, X-N Z, Z-M W. Comparative study on the effects of paroxetine and venlafaxine in treating depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:4174-4175.
8619.	Li-San Z, Xing-Yue H, Lin-Yan Y, et al. Prophylactic effects of duloxetine on post-stroke depression symptoms: An open single-blind trial. European neurology. 2013;69:336-343.
8620.	Lian-Tao L, Shu-Hua W, Hong-You G, Jing C, Shou-Wei Y, Mei Y. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. The Journal of Alternative and Complementary Medicine. 2008;14:841-846.
8621.	Liang Y, KC C. Stratified and randomized play-the-winner rule. Statistical methods in medical research. 2008;17:581-593.
8622.	Liang Z, Tang S, Liu J. Clinical efficacy of Fluoxine in treatment of patients with depression after acute stroke. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2003;7:1924-1925.
8623.	Liappas J, Paparrigopoulos T, Malitas P, Tzavellas E, Christodoulou G. Mirtazapine improves alcohol detoxification. Journal of psychopharmacology (Oxford, England). 2004;18:88-93.
8624.	Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and Venlafaxine in the Management of Collateral Psychopathology During Alcohol Detoxification. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:55-60.
8625.	Liashko V, Manassis K. Medicated Anxious Children: Characteristics and Cognitive-Behavioural Treatment Response. Canadian Journal of Psychiatry. 2003;48:741-748.
8626.	Liborio R, Alessandro A, Santina C, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology. 2004;50:322-328.
8627.	Liborio R, Santina C, Giovanni N, et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology. 2004;173:73-78.
8628.	Licinio J. Sequence variability in ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1, NTRK2 and BDNF: Novel variations and association with depression and antidepressant response. Biological psychiatry. 2010;Conference:193S-194S.
8629.	Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response, Archives of general psychiatry(2009).
8630.	Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response, Archives of general psychiatry(2009).
8631.	Licinio J, M-L W. Depression, antidepressants and suicidality: A critical appraisal. Nature reviews. Drug discovery. 2005;4:165-171.
8632.	Licinio J, O'Kirwan F, Irizarry K, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Molecular psychiatry. 2004;9:1075-1082.
8633.	Lidia GM, Carlo M, A AJ, Pierre B, J HD, W SJ. Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant? [References]. Journal of clinical psychiatry. 2014;75:e939-e944.
8634.	Lieb K. [What will not be publicized]. [German]. MMW Fortschritte der Medizin. 2014;156:38.
8635.	Lieb K, Vollm B, Rucker G, Timmer A, JM S. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British journal of psychiatry. 2010;196:4-12.
8636.	Lieberman J. Borderline personality disorder: Interface with mood and other Axis I disorders. Advanced Studies in Medicine. 2004;4:S965-S969.
8637.	Liepert J. New therapies in neurorehabilitation. [German]. Aktuelle Neurologie. 2003;30:209-214.
8638.	Bright light in elderly subjects with nonseasonal major depressive disorder: A double blind randomised clinical trial using early morning bright blue light comparing dim red light treatment, Trials(2008).
8639.	Lifschytz T, Segman R, Shalom G, et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Current drug targets. 2006;7:203-210.
8640.	Liisa H, Deborah W-OB, A CK, Ralitza G, H PL, Neill EC. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology. 2014;231:939-948.
8641.	Lilue M, Palacios S. Non-hormonal treatment for vasomotor symptoms during menopause: Role of desvenlafaxine. [Spanish]. Ginecologia y obstetricia de Mexico. 2009;77:475-481.
8642.	Limin W, Zhuoyuan Z, Jingyang H, et al. Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: A randomized controlled trial. BMC psychiatry. 2015;15.
8643.	Limosin F, Ades J. Psychiatric and psychologic aspects of premenstrual syndrome. [French]. Encephale. 2001;27:501-508.
8644.	Limosin F, J-C S, Rouillon F. Multicenter double-blind study of the efficacy of paroxetine versus clomipramine in elderly patients with major depression. Journal of Aging and Pharmacotherapy. 2007;13:7-19.
8645.	Limosin F, J-Y L, Zylberman-Bouhassira M, ME S, Perrin E, Rouillon F. The Course of Depressive Illness in General Practice. Canadian Journal of Psychiatry. 2004;49:119-123.
8646.	Lin D, Mok H, LN Y. Polytherapy in Bipolar Disorder. CNS drugs. 2006;20:29-42.
8647.	Lin J, DS T. Treating premenstrual dysphoric disorder using serotonin agents. Journal of women's health & gender-based medicine. 2001;10:745-750.
8648.	Linazasoro G. Rasagiline in Parkinson's disease. [Spanish]. Neurologia (Barcelona, Spain). 2008;23:238-245.
8649.	Lind RS, F OK, Per T. Cardiac safety of citalopram: Prospective trials and retrospective analyses. Journal of clinical psychopharmacology. 1999;19:407-415.
8650.	Linda F, Mariangela G, Jorge P, Enrico S, Raffaella Z. Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study. Journal of clinical psychiatry. 1998;59:229-232.
8651.	Linde K. St. John's Wort - An overview. Forschende Komplementarmedizin. 2009;16:146-155.
8652.	Linde K, Berner M, Egger M, Mulrow C. St John's wort for depression: Meta-analysis of randomised controlled trials. British journal of psychiatry. 2005;186:99-107.
8653.	Linde K, G tR, Hondras M, Vickers A, Saller R, Melchart D. Systematic reviews of complementary therapies - An annotated bibliography. Part 2: Herbal medicine. BMC complementary and alternative medicine. 2001.
8654.	Linde K, Gastpar M. Long-term comparison of hypericum and sertraline. [German]. Forschende Komplementarmedizin und klassische Naturheilkunde [Research in complementary and natural classical medicine]. 2005;12:227-228.
8655.	Linde K, MM B, Kriston L. St John's wort for major depression. Cochrane database of systematic reviews (Online). 2008.
8656.	Linde K, MM B, Kriston L. St John's wort for major depression. Cochrane database of systematic reviews (Online). 2009.
8657.	Linde K, Sigterman K. Is the efficacy of antidepressants truly a Myth? Global Advances In Health and Medicine. 2012;1:12-13.
8658.	Linden M, Christof T, Rentzsch C. Contents of General Practitioner-Patient Consultations in the Treatment of Depression. Journal of general internal medicine. 2008;23:1567-1570.
8659.	Linden M, Westram A. What Do Psychiatrists Talk About With Their Depressed Patients Parallel to Prescribing an Antidepressant? International journal of psychiatry in clinical practice. 2011;15:35-41.
8660.	Linden M, Westram A, LG S, Haag C. Impact of the WHO depression guideline on patient care by psychiatrists: A randomized controlled trial. European Psychiatry: the Journal of the Association of European Psychiatrists. 2008;23:403-408.
8661.	Lindsay M, Crino R, Andrews G. Controlled trial of exposure and response prevention in obsessive- compulsive disorder. British journal of psychiatry. 1997;171:135-139.
8662.	Lindsey O, J VR, J HE, et al. Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits. Biological psychiatry. 2011;70:568-574.
8663.	Ling W, Mooney L, Haglund M. Treating methamphetamine abuse disorder. Current psychiatry. 2014;13:37-44.
8664.	Ling W, Mooney L, L-T W. Advances in Opioid Antagonist Treatment for Opioid Addiction. Psychiatric clinics of North America. 2012;35:297-308.
8665.	Lingjaerde O. Reports from WHO Collaborative Reference Centers for the Study of Psychotropic Drugs in Norway and Yugoslavia. Current research in Norway. Psychopharmacology bulletin. 1979;15:8-10.
8666.	Link C, Dunbar G. An overview of studies comparing the efficacy, safety, and tolerability of paroxetine and clomipramine. Nordic Journal of Psychiatry, Supplement. 1992;46:17-22.
8667.	Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. Journal of clinical endocrinology and metabolism. 2004;89:5003-5012.
8668.	Linka T, Wiltfang J, Sartory G, BW M. Effects of antidepressant treatment on the intensity dependence of auditory evoked potential components. European neuropsychopharmacology. 2008;Conference:S321-S322.
8669.	Linkowski P, Kerkhofs M, Kempenaers C, Staner L, Mendlewicz J. Sleep architecture effects as predictors of response to treatment. European neuropsychopharmacology. 1993;3:316-317.
8670.	Linnet K, OV O. [Citalopram and desmethylcitalopram for psychiatric patients]. [Danish]. Ugeskrift for laeger. 1996;158:4920-4923.
8671.	Lionel W, Lucia S, Paul A. Efficacy and safety of tianeptine in major depression: Evidence from a 3-month controlled clinical trial versus paroxetine. CNS drugs. 2002;16:65-75.
8672.	Lipari M, Benipal H, Kale-Pradhan P. Roflumilast in the management of chronic obstructive pulmonary disease. American journal of health-system pharmacy. 2013;70:2087-2095.
8673.	Liperoti R, Landi F, Fusco O, Bernabei R, Onder G. Omega-3 polyunsaturated fatty acids and depression: A review of the evidence. Current pharmaceutical design. 2009;15:4165-4172.
8674.	Lipkovich I, CH M, Prakash A, AA N. Addressing Methodological Issues in Studying Antidepressant Onset Efficacy Using Prespecified Sensitivity Analyses. Psychopharmacology bulletin. 2008;41:40-54.
8675.	Lisa E, Bengtsson F, L vK. Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality. International clinical psychopharmacology. 2000;15:273-278.
8676.	Lisa E, von KL. Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care. Journal of clinical psychopharmacology. 2001;21:154-160.
8677.	Little J, Sharp L, MJ K, Bradley L, Gwinn M. The epidemiologic approach to pharmacogenomics. American journal of pharmacogenomics. 2005;5:1-20.
8678.	Liu J, Dong J, Wang L, Su Y, Yan P, Sun S. Comparative Efficacy and Acceptability of Antidepressants in Parkinson's Disease: A Network Meta-Analysis. PloS one. 2013.
8679.	Liu J, HX J, JQ W, Xu Y, JZ T, Shi J. [Treatment of refractory depression patients of yin deficiency inner heat syndrome by jieyu granule combined paroxetine: an efficacy observation]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2013;33:462-465.
8680.	Liu J, JC G, Bronner J, CS K, Zhang W, XY L. Acute Administration of Leptin Produces Anxiolytic-Like Effects: a Comparison With Fluoxetine. Psychopharmacology. 2010;207:535-545.
8681.	Liu J, Zhang Y, Han M, Liu Z, Wang J, He Q. Chinese herbal formula Xiao Yao San for treatment of depression: A systematic review of randomized controlled trials. Evidence-based Complementary and Alternative Medicine. 2012.
8682.	Liu M, Yan J, Zhou X, Hu Y, Liu P. [Effect of Kaixin San on learning and memory in chronic stress depression model rats]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2012;37:2439-2443.
8683.	Liu P, F-F H, W-P B, et al. Menopausal Depression: Comparison of Hormone Replacement Therapy and Hormone Replacement Therapy Plus Fluoxetine. Chinese medical journal. 2004;117:189-194.
8684.	Liu P, FF H, WP B, et al. Menopausal Depression: Comparison of Hormone Replacement Therapy and Hormone Replacement Therapy Plus Fluoxetine. Chinese medical journal. 2004;117:189-194.
8685.	Liu T, MN P. Problematic internet use: Clinical implications. CNS spectrums. 2007;12:453-466.
8686.	Liu Y, YH Z, Jin M, WJ L. [Study on clinical effect enhancement of acupuncture for depression with chronic pain treated with SSRI antidepressants]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2013;33:689-691.
8687.	Liu Y, Zhou X, Qin B, C DG, Zhang Y, Xie P. Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: Protocol for a systematic review and network meta-analysis. Systematic Reviews. 2014.
8688.	Liu Z, Qin L, Xu G. Meta-analysis on effectiveness and safety of bupropion hydrochloride sustained-release tablets and fluoxetine tablets in treatment of depression. [Chinese]. Journal of Jilin University Medicine Edition. 2015;41:140-144.
8689.	Liu-Seifert H, Siemers E, Sundell K, et al. Cognitive and Functional Decline and Their Relationship in Patients With Mild Alzheimer's Dementia. Journal of Alzheimer's disease. 2015;43:949-955.
8690.	Lizheng S, A NM, Ralph S, et al. Effects of Olanzapine Alone and Olanzapine/Fluoxetine Combination on Health-Related Quality of Life in Patients With Bipolar Depression: Secondary Analyses of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2004;26:125-134.
8691.	LJ A, KR S. Weight gain in the treatment of mood disorders. Journal of clinical psychiatry. 2003;64:22-29.
8692.	LJ A, Musenga A, MA R. Iloperidone: A new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert opinion on investigational drugs. 2008;17:61-75.
8693.	LJ B, GR L, Olden K, et al. An evidence-based approach to the management of irritable bowel syndrome in North America. American journal of gastroenterology. 2002;97:S1-S26.
8694.	LJ B, O'connor D, Watts R, MS D, PH H. Evidence for Accelerated Desensitisation of 5-Ht2c Receptors Following Combined Treatment With Fluoxetine and the 5-Ht1a Receptor Antagonist, Way 100,635, in the Rat. Neuropharmacology. 2000;39:1222-1236.
8695.	Results of the citalopram to enhance cognition in Huntington disease trial, Movement disorders(2014).
8696.	Results of the Citalopram to Enhance Cognition in Huntington Disease Trial, Movement disorders(2014).
8697.	LJ C. Rational Drug Use in the Treatment of Depression. Pharmacotherapy. 1997;17:45-61.
8698.	LJ G, SA P, RK C. Sexual dysfunction in inflammatory bowel disease. Inflammatory bowel diseases. 2015;21:939-947.
8699.	LJ K. Psychopharmacology in a globalizing world: The use of antidepressants in Japan. Transcultural psychiatry. 2002;39:295-322.
8700.	LJ M. Management of atypical antipsychotic drug-induced weight gain: Focus on metformin. Pharmacotherapy. 2009;29:725-735.
8701.	LJ M, EM L. Preventing Postpartum Depression. Psychiatric clinics of North America. 2011;34:53-65.
8702.	LJ M, Girgis C, Gupta R. Depression and related disorders during the female reproductive cycle. Women's Health. 2009;5:577-587.
8703.	LJ R, WS G, JP OR. T3 augmentation in major depressive disorder: Safety considerations. American journal of psychiatry. 2011;168:1035-1040.
8704.	LJ R-T, DD M. Genetic screening for SSRI drug response among those with major depression: Great promise and unseen perils. Depression and anxiety. 2007;24:350-357.
8705.	LJ S. The third annual meeting of the International Society of Pharmacogenetics (ISP): A joint meeting with the International Union of Nutritional Sciences (IUNS) task force on genetics and nutrition. Pharmacogenomics journal. 2005;5:146-148.
8706.	LJ S. Tetrabenazine: For chorea associated with huntingtons disease. CNS drugs. 2011;25:1073-1085.
8707.	LJ S, Dhillon S. Risperidone: A review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Pediatric Drugs. 2007;9:343-354.
8708.	LJ S, Dhillon S. Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents. CNS drugs. 2008;22:259-262.
8709.	Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: The CoBalT randomised controlled trial protocol, Contemporary clinical trials(2012).
8710.	LJ VO, PM VD, DR S, et al. A Novel Class of 3-(Phenoxy-Phenyl-Methyl)-Pyrrolidines as Potent and Balanced Norepinephrine and Serotonin Reuptake Inhibitors: Synthesis and Structure-Activity Relationships. Bioorganic & medicinal chemistry letters. 2013;23:1456-1461.
8711.	Ljubicic D, MV P, Vitezic D, Peitl V, Grbac J. Psychopharmacotherapy and spirituality. Psychiatria Danubina. 2007;19:216-221.
8712.	LK B, DL D, JW D, PS G. Antidepressant Medication Use and Restless Legs Syndrome in Patients Presenting With Insomnia. Sleep medicine. 2005;6:443-450.
8713.	LK B, DL D, JW D, PS G. Antidepressant Medication Use and Restless Legs Syndrome in Patients Presenting With Insomnia. Sleep medicine. 2005;6:443-450.
8714.	LK D, SM W, PM M, CM C, AB S. The Serotonin Transporter Polymorphism, 5httlpr, Is Associated With a Faster Response Time to Sertraline in an Elderly Population With Major Depressive Disorder. Psychopharmacology. 2004;174:525-529.
8715.	LK K, PA S. Depression and related psychological factors in heart disease. Harvard review of psychiatry. 2009;17:377-388.
8716.	LK L, Townsend B, ER H, Jokic R, R DT, Milev R. Sleep Architecture and Cognitive Changes in Olanzapine-Treated Patients With Depression: a Double Blind Randomized Placebo Controlled Trial. BMC psychiatry. 2014;14.
8717.	LKK S, BH M, BG P. Selective Serotonin Reuptake Inhibitors for Late-Life Depression - a Comparative Review. Drugs & aging. 2001;18:355-368.
8718.	LL A, MA F, MJ G. Acceleration and augmentation strategies for treating bipolar depression. Biological psychiatry. 2003;53:691-700.
8719.	LL A, RM P, Hellemann G, et al. Impact of Antidepressant Continuation After Acute Positive or Partial Treatment Response for Bipolar Depression: a Blinded, Randomized Study. Journal of clinical psychiatry. 2009;70:450-457.
8720.	LL A, Suppes T, DO B, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. American journal of psychiatry. 2006;163:313-315.
8721.	LL C, JM S, AR T, et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. Journal of clinical psychiatry. 2006;67:66-71.
8722.	LL C, Yasmin S, LH P. A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine. Biological psychiatry. 2002;51:183-188.
8723.	LL D, Carrollmichals L, SJ B, CP L. Fluoxetines Effect on Weight-Loss in Obese Subjects. American journal of clinical nutrition. 1991;54:321-325.
8724.	LL D, Frazier E, MM H, et al. Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2006;15:278-285.
8725.	LL D, JA R, SR W, et al. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. Comprehensive psychiatry. 2005;46:81-89.
8726.	LL D, ME J, Ambrose S, et al. A Placebo-Controlled Study of Nefazodone for the Treatment of Chronic Posttraumatic Stress Disorder - a Preliminary Study. Journal of clinical psychopharmacology. 2004;24:291-297.
8727.	LL D, ME J, Ambrose S, et al. A Placebo-Controlled Study of Nefazodone for the Treatment of Chronic Posttraumatic Stress Disorder - a Preliminary Study. Journal of clinical psychopharmacology. 2004;24:291-297.
8728.	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes, Drug and alcohol dependence(2010).
8729.	LL I-D, Proietto J, AM T, JJ M. Safety of drug therapies used for weight loss and treatment of obesity. Drug safety. 2006;29:277-302.
8730.	LL J, MH R. Effect of pharmacotherapy on suicidal ideation and behavior. Depression. 1995;2:169-172.
8731.	LL J, MH R, KA Y, et al. Randomized, Placebo-Controlled Trial of Fluoxetine for-Acute Treatment of Minor Depressive Disorder. American journal of psychiatry. 2004;161:1864-1871.
8732.	LL O, HS S, WK G, BL M. Tourette syndrome: Diagnosis, strategies, therapies, pathogenesis, and future research directions. Journal of child neurology. 2006;21:630-641.
8733.	Novel melatonin-based treatments for major depression, Lancet(2012).
8734.	Lloyd-Williams M. Are antidepressants effective in cancer patients? Progress in palliative care. 2004;12:217-219.
8735.	Lluch E, Torres R, Nijs J, J VO. Evidence for central sensitization in patients with osteoarthritis pain: A systematic literature review. European Journal of Pain (United Kingdom). 2014;18:1367-1375.
8736.	LM A. Management of psychiatric comorbidity in fibromyalgia. Current psychiatry reports. 2006;8:241-245.
8737.	LM A. Biology and Therapy of Fibromyalgia - New Therapies in Fibromyalgia. Arthritis research & therapy. 2006;8.
8738.	LM A. Duloxetine and Other Antidepressants in the Treatment of Patients With Fibromyalgia. Pain medicine (Malden, Mass.). 2007;8:S63-S74.
8739.	LM A. The pathophysiology, diagnosis and treatment of fibromyalgia. [Review] [223 refs]. Psychiatric clinics of North America. 2010;33:375-408.
8740.	LM A, AL M, Sunderajan P, et al. The Effect of Pain on Outcomes in a Trial of Duloxetine Treatment of Major Depressive Disorder. Annals of clinical psychiatry. 2008;20:187-193.
8741.	LM A, AM A, AS A, KM A. Long term antidepressants prescribing in the psychiatry department at Riyadh military hospital: Cross-sectional study. Saudi medical journal. 2011;32:1051-1054.
8742.	LM A, Chatamra K, Hirsch I, Stoker M. Safety and Efficacy of Esreboxetine in Patients With Fibromyalgia: an 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Clinical therapeutics. 2010;32:1618-1632.
8743.	LM A, Clauw D, FJ W, Ahl J, PJ G, MM W. Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of rheumatology. 2010;37:2578-2586.
8744.	LM A, Hirsch I, Sanders P, Ellis A, Hughes B. Safety and Efficacy of Esreboxetine in Patients With Fibromyalgia: a Fourteen-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. Arthritis and rheumatism. 2012;64:2387-2397.
8745.	LM A, JC C, Clair A, ET M. Interpreting Effect Sizes and Clinical Relevance of Pharmacological Interventions for Fibromyalgia. Pain and Therapy. 2013;2:65-71.
8746.	LM A, Leon T, Whalen E, Barrett J. Relationships Among Pain and Depressive and Anxiety Symptoms in Clinical Trials of Pregabalin in Fibromyalgia. Psychosomatics. 2010;51:489-497.
8747.	LM A, Maletic V. Management of painful physical symptoms associated with depression and mood disorders. Primary psychiatry. 2005;12:1-14.
8748.	LM A, RH P, RM G, Chen W. Relationships Among Pain, Depressed Mood, and Global Status in Fibromyalgia Patients: Post Hoc Analyses of a Randomized, Placebo-Controlled Trial of Milnacipran. Psychosomatics. 2012;53:371-379.
8749.	LM A, SY Z, BA P. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: A randomized, double-blind, placebo-controlled study. Clinical journal of pain. 2012;28:775-781.
8750.	LM A, Wang F, Ahl J, Gaynor P, Wohlreich M. Improvement in multiple dimensions of fatigue in fibromyalgia patients treated with duloxetine. Arthritis and rheumatism. 2010;Conference:105.
8751.	Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: Secondary analysis of a randomized, placebo-controlled trial, Arthritis research & therapy(2011).
8752.	Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial, Arthritis research & therapy(2011).
8753.	LM A, YL L, LJ C, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine With Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder. Arthritis and rheumatism. 2004;50:2974-2984.
8754.	LM A, YL L, LJ C, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine With Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder. Arthritis and rheumatism. 2004;50:2974-2984.
8755.	LM A, YL P, DN Ds, DK K, Iyengar S, JF W. Duloxetine for the Treatment of Fibromyalgia in Women: Pooled Results From Two Randomized, Placebo-Controlled Clinical Trials. Journal of women's health. 2007;16:1145-1156.
8756.	LM A, Zhang S, Pangallo B. A randomized, double-blind comparison of duloxetine 30 mg once daily (QD) and placebo in adult patients with fibromyalgia. Arthritis and rheumatism. 2011.
8757.	LM B, GM K. Paroxetine Controlled Release. CNS drugs. 2004;18:355-364.
8758.	LM B, GM K. Paroxetine controlled release. [Review] [34 refs]. CNS drugs. 2004;18:355-356.
8759.	LM B, KL W. Nutrition and depression: Implications for improving mental health among childbearing-aged women. Biological psychiatry. 2005;58:679-685.
8760.	LM C, Acar D, Chemali Z. The elderly safety imperative and antipsychotic usage. Harvard review of psychiatry. 2010;18:158-172.
8761.	LM D. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia - Common features and differences. [German]. Medizinische Monatsschrift fur Pharmazeuten. 2011.
8762.	LM H, Boath E, Henshaw C. Antidepressant prevention of postnatal depression. PLoS medicine. 2006;3:1741-1742.
8763.	LM H, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of postnatal depression. [Review] [31 refs]. Cochrane database of systematic reviews (Online). 2005:CD004363.
8764.	LM H, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant Prevention of Postnatal Depression. Cochrane database of systematic reviews (Online). 2005.
8765.	LM H, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant Prevention of Postnatal Depression. Cochrane database of systematic reviews (Online). 2005.
8766.	LM H, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of postnatal depression (Cochrane review). Chinese Journal of Evidence-Based Medicine. 2005;5:735-742.
8767.	LM K, EN A, Solvason B, NN G, EH S. Escitalopram for compulsive buying disorder: A double-blind discontinuation study [13]. Journal of clinical psychopharmacology. 2007;27:225-227.
8768.	LM K, GL H, Hollander E, Nestadt G, HB S. Practice guideline for the treatment of patients with obsessive-compulsive disorder work group on obsessive-compulsive disorder. American journal of psychiatry. 2007;164:1-53.
8769.	LM K, HW C, KD B, SC S. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Journal of clinical psychiatry. 2003;64:793-798.
8770.	LM K, SL M, JRT D, SA R, Hollander E, MA J. Fluvoxamine Versus Clomipramine for Obsessive-Compulsive Disorder: a Double-Blind Comparison. Journal of clinical psychopharmacology. 1996;16:121-129.
8771.	LM M, RN G, Szigethy E, Herzer M, Deer K, KA H. Psychosocial issues in pediatric inflammatory bowel disease: Report of the north american society for pediatric gastroenterology, hepatology, and nutrition. Journal of pediatric gastroenterology and nutrition. 2013;56:449-458.
8772.	LM M, Schulz R, IIICF R, JF K, AG G, EM W. Treatment of late-life depression alleviates caregiver burden. Journal of the American Geriatrics Society. 2010;58:23-29.
8773.	LM M-W, DH G, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ (Clinical research ed.). 2000;320:26-30.
8774.	LM N, 3rd MCA, SM S, DS C. Open Prospective Trial of Fluoxetine for Posttraumatic-Stress-Disorder. Journal of clinical psychopharmacology. 1993;13:107-113.
8775.	LM P. The 56th annual meeting of the American Academy of Neurology. P and T. 2004;29:450-453+460.
8776.	LM P. Depression and suicide in children and adolescents. Pediatrics in review. 2009;30:199-206.
8777.	LM P, SL P. 130th Annual Meeting of the American Neurological Association. P and T. 2005;30:679-682.
8778.	LM S, JA DP. Atypical antipsychotics in treatment refractory depression. [Portuguese]. Jornal brasileiro de psiquiatria. 2009;58:73-78.
8779.	LM T, CN T, AP T. Pharmacotherapy of Fibromyalgia. American journal of health-system pharmacy. 2011;68:1307-1319.
8780.	LM W. RS110402 variation mediates neural activation to emotional faces and response to treatment. Biological psychiatry. 2015;Conference:155S-156S.
8781.	LM W, AJ R, Koslow S, et al. Identifying gene, brain, cognition and emotion markers for response to antidepressants: The iSPOT-D trial. Biological psychiatry. 2011;Conference:135S.
8782.	International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol, Trials [Electronic Resource](2011).
8783.	International Study to Predict Optimized Treatment for Depression (Ispot-D), a Randomized Clinical Trial: Rationale and Protocol, Trials(2011).
8784.	LM W, Korgaonkar M, Paton R, SG G, Etkin A. Amygdala activation to subliminal sad and happy faces is a general and specific predictor of acute treatment outcomes in major depressive disorder. Biological psychiatry. 2014;Conference:234S.
8785.	LN C, AJ R, Huitron-Resendiz S, PB H. Effects of Lurasidone in Behavioral Models of Depression. Role of the 5-Ht7 Receptor Subtype. Neuropharmacology. 2013;70:211-217.
8786.	LN F-R, Moye J, AD N. Improving the recognition and treatment of cancer-related posttraumatic stress disorder. Journal of psychiatric practice. 2011;17:270-276.
8787.	LN R, BS E, SH K. Combining Mirtazapine and Duloxetine in Treatment-Resistant Depression Improves Outcomes and Sexual Function. Journal of clinical psychopharmacology. 2008;28:107-108.
8788.	LN R, MB S. The pharmacologic treatment of anxiety disorders: A review of progress. Journal of clinical psychiatry. 2010;71:839-854.
8789.	LN V, Arcelus A, Birnbaum H, et al. The impact of antidepressant use on social functioning: Reboxetine versus fluoxetine. International clinical psychopharmacology. 2000;15:279-289.
8790.	LN Y. Diagnosis and management of patients with bipolar II disorder. Journal of clinical psychiatry. 2005;66:13-17.
8791.	LN Y, SH K, O'donovan C, et al. Canadian Network for Mood and Anxiety Treatments (Canmat) Guidelines for the Management of Patients With Bipolar Disorder: Update 2007. Bipolar disorders. 2006;8:721-739.
8792.	LN Y, SH K, RW L. Advances in treatment of mood and anxiety disorders: Focus on atypical antipsychotics. Bipolar Disorders, Supplement. 2003;5:5-6.
8793.	LN Y, SH K, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar disorders. 2009;11:225-255.
8794.	Lo V. How should we treat major depression combined with anxiety? Commentary. Journal of family practice. 2007;56:306-308.
8795.	Lo V, Maggio L. What's Best When a Patient Doesn't Respond to the Maximum Dose of an Antidepressant? Journal of family practice. 2010;59:173-175.
8796.	Lo V, Maggio L. Q / what's best when a patient doesn't respond to the maximum dose of an antidepressant? Journal of family practice. 2010;59:173-175.
8797.	Lobello K, C GP, Jiang Q, Nichols A, Preskorn S. Venlafaxine efficacy varies with cytochrome P450 2D6 phenotype in patients treated for depression. International journal of neuropsychopharmacology. 2010;Conference:155-156.
8798.	Lobello K, Reddy S, Musgnung J, Pedersen R, PT N. Patient outcomes with education, drug therapy, and support: A study of venlafaxine ER-treated outpatients with major depressive disorder. Psychopharmacology bulletin. 2010;43:28-44.
8799.	Lochner C, Seedat S, DJH N, DJ S. Topiramate in the Treatment of Trichotillomania: an Open-Label Pilot Study. International clinical psychopharmacology. 2006;21:255-259.
8800.	Lochner C, Simmons C, Kidd M, et al. Differential Effects of Escitalopram Challenge on Disgust Processing in Obsessive-Compulsive Disorder. Behavioural brain research. 2012;226:274-280.
8801.	Loeffler T, JL K. Treatment options for Anorexia nervosa. U.S. 2007;Pharmacist:63-70.
8802.	Lofthouse N, Gilchrist R, Splaingard M. Mood-related Sleep Problems in Children and Adolescents. Child and adolescent psychiatric clinics of North America. 2009;18:893-916.
8803.	Loibl S, Schwedler K, G VM, Strohmeier R, KM M, Kaufmann M. Venlafaxine Is Superior to Clonidine as Treatment of Hot Flashes in Breast Cancer Patients - a Double-Blind, Randomized Study. Annals of oncology. 2007;18:689-693.
8804.	Lois K, Kumar S. Pharmacotherapy of obesity. Therapy. 2008;5:223-235.
8805.	Loj J, GD S. Migraine prophylaxis: Who, why, and how. Cleveland Clinic journal of medicine. 2006;73:793-816.
8806.	Lolak S, Suwannarat P, RH L. Epigenetics of depression. Progress in molecular biology and translational science. 2014;128:103-137.
8807.	Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O. Moclobemide and fluoxetine in atypical depression: A double-blind trial. Journal of affective disorders. 1994;32:169-177.
8808.	Lonnqvist J, Sihvo S, Syvalahti E, Sintonen H, Kiviruusu O, Pitkanen H. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta psychiatrica Scandinavica. 1995;91:189-194.
8809.	Loo C, McFarquhar T, Walter G. Transcranial magnetic stimulation in adolescent depression. Australasian psychiatry. 2006;14:81-85.
8810.	Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. American journal of psychiatry. 1999;156:946-948.
8811.	Loo H, Saiz-Ruiz J, A CaSJ, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. Human Psychopharmacology: Clinical and Experimental. 2001;16:S31-S38.
8812.	Loo H, Saiz-Ruiz J, JA CE, et al. Efficacy and Safety of Tianeptine in the Treatment of Depressive Disorders in Comparison With Fluoxetine. Human Psychopharmacology-Clinical and Experimental. 2001;16:S31-S38.
8813.	Loonen AJM, Doorschot CH, Oostelbos MCJM, Sitsen JMA. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: A pilot study. European neuropsychopharmacology. 1999;10:51-57.
8814.	Lopes RF, Cintia F, Rachel R, Claudia H. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. [Review]. Journal of clinical psychopharmacology. 2012;32:278-281.
8815.	Lopes RF, Cintia F, Rachel R, Guarieiro RM, Claudia H. Antidepressant combination for major depression in incomplete responders--a systematic review. [Review]. Journal of affective disorders. 2013;144:1-6.
8816.	Lopez C, Dauchy S. Bipolar syndromes and cancer: Particular aspects of management. [French]. Psycho-Oncologie. 2010;4:28-35.
8817.	Lopez RJ, Lopez BMA, Vargas TBE, Villamil SV. Double blind study with antidepressant, brief psychotherapy and placebo in patients with mild to moderate depression. [Spanish]. Salud mental (Mexico City, Mexico). 2004;27:53-61.
8818.	Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. [Review] [32 refs]. International clinical psychopharmacology. 1996;11 Suppl 4:41-46.
8819.	Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today. Current pharmaceutical design. 2009;15:1563-1586.
8820.	Lopez-Munoz F, Alamo C, Rubio G, Garcia-Garcia P, Pardo A. Reboxetine Combination in Treatment-Resistant Depression to Selective Serotonin Reuptake Inhibitors. Pharmacopsychiatry. 2007;40:14-19.
8821.	Lorenz M, Prause S, Eidens M, et al. Translation of CYP2D6 human genetic variation into medical practice: Lessons learned and the way forward. Current pharmacogenomics and personalized medicine. 2010;8:306-319.
8822.	Lori A, C-R T, EB B, et al. Association of rare variants in ADRA1a with response to treatment for major depressive disorder (MDD). Biological psychiatry. 2015;Conference:227S.
8823.	Los I, Jacob R. Metabolic complications with aripiprazole. German Journal of Psychiatry. 2010;13:49-50.
8824.	Lothgren M, Hemels M, Francois C, Jonsson B. A Cost-Effectiveness Analysis of Escitalopram as First Line Treatment of Depression in Sweden. Primary Care Psychiatry. 2004;9:153-161.
8825.	Lotrich F. Management of psychiatric disease in hepatitis C treatment candidates. Current hepatitis reports. 2010;9:113-118.
8826.	Lotufo-Neto F, Trivedi M, ME T. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226-247.
8827.	Loux G. The new antidepressant agomelatine: A review. [German]. Arzneimitteltherapie. 2011;29:211-217.
8828.	Lovell N, Ward J. The role of mirtazapine in treating multiple symptoms in patients with cancer. Focus on Cancer Medicine. 2011;2:60-63.
8829.	Lovenberg T, Bonaventure P, Kramer M, et al. Preclinical and clinical evaluation of JNJ-18038683, a selective 5-HT7 receptor antagonist, in the physiology of sleep and in major depressive disorder. Neuropsychopharmacology. 2010;Conference:S281.
8830.	Lowe B, Schenkel I, MJ B, Gobel C. Efficacy, Predictors of Therapy Response, and Safety of Sertraline in Routine Clinical Practice: Prospective, Open-Label, Non-Interventional Postmarketing Surveillance Study in 1878 Patients. Journal of affective disorders. 2005;87:271-279.
8831.	Lowe B, Schenkel I, MJ B, Gobel C. Efficacy, Predictors of Therapy Response, and Safety of Sertraline in Routine Clinical Practice: Prospective, Open-Label, Non-Interventional Postmarketing Surveillance Study in 1878 Patients. Journal of affective disorders. 2005;87:271-279.
8832.	Lowenstein L, ER M, Sharma S, MP F. Urinary Hesitancy and Retention During Treatment With Sertraline. International urogynecology journal. 2007;18:827-829.
8833.	Lowry F, Wachter K, Worcester S. Lung cancer and younger patients most plagued by insomnia. Oncology Report. 2008:101.
8834.	Lowry F, Wachter K, Worcester S. Citalopram reduces hot flashes in randomized phase III trial. Oncology Report. 2008:104.
8835.	Lowry F, Wachter K, Worcester S. Meta-analysis supports gabapentin/new antidepressants. Oncology Report. 2008:104.
8836.	LP C, Sun Y, FW W, DM D, YZ H. [Effect of Shuyusan on neuropeptide Y and serotonin expression in the hippocampal neurons of rats with chronic mild unpredictable stress-induced depression]. [Chinese]. Nan fang yi ke da xue xue bao [Journal of Southern Medical University]. 2011;31:113-116.
8837.	LP D, AS R, KA K-P, MT B. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS drug reviews. 2006;12:178-207.
8838.	LP G. Depression in the elderly. [Portuguese]. Revista brasileira de medicina. 2006;63:317-330.
8839.	LP G. Depression in the elderly. [Portuguese]. Revista brasileira de medicina. 2007;64:14-29.
8840.	LP P, RS G, EB L. Treatment of Mood Disorders in Multiple Sclerosis. Current treatment options in neurology. 2015;17.
8841.	LP R. Diabetes as a chronic metabolic stressor: Causes, consequences and clinical complications. Experimental neurology. 2012;233:68-78.
8842.	LP R, AM RC, JRC J, OIF L. Pharmaceutical surveillance of sertraline in Cuban patients affected by major depression episode. [Spanish]. Revista Cubana de Farmacia. 2011;45:69-75.
8843.	LP S. Androgens and menopause: more fuel for the fire. Menopause (New York, N.Y.). 2006;13:168-170.
8844.	LP S. Gynecological management of premenstrual symptoms. Current pain and headache reports. 2010;14:367-375.
8845.	LP Y, LJ S. Escitalopram: in the treatment of major depressive disorder in adolescent patients. [Review] [36 refs][Erratum appears in Paediatr Drugs. 2010 Jun;12(3):163]. Paediatric drugs. 2010;12:155-163.
8846.	LPH Y. Oral paliperidone: A review of its use in the management of schizoaffective disorder. CNS drugs. 2011;25:523-538.
8847.	LPH Y, GL P. Desvenlafaxine Extended Release. CNS drugs. 2008;22:1061-1069.
8848.	LPH Y, LJ S. Escitalopram: In the treatment of major depressive disorder in adolescent patients. Pediatric Drugs. 2010;12:155-162.
8849.	Lpmm W, Nazareth I, Petersen I. Trends in Depression and Antidepressant Prescribing in Children and Adolescents: a Cohort Study in the Health Improvement Network (Thin). PloS one. 2012;7.
8850.	LR D. Short and long term effects of gepirone-ER on sexual desire in women with major depression. Journal of sexual medicine. 2010;Conference:143.
8851.	LR D, Laan E, Brauer M, et al. Responses to the proposed DSM-V changes. Journal of sexual medicine. 2010;7:1998-2014.
8852.	LR J. Hyperforin: A potent anti-depressant natural drug. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5:9-13.
8853.	LR L, HG PJ, GG E, et al. Fluoxetine in the Treatment of Bulimia-Nervosa - a Multicenter, Placebo-Controlled, Double-Blind Trial. Archives of general psychiatry. 1992;49:139-147.
8854.	LR M. On the observed specific and non-specific effects of complex therapeutic interventions: Truly separate or complementary? Advances in experimental medicine and biology. 2015;821:79-92.
8855.	LR M, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane database of systematic reviews. 2013;7:CD004185.
8856.	LR M, Purgato M, Gastaldon C, et al. Fluoxetine Versus Other Types of Pharmacotherapy for Depression. Cochrane database of systematic reviews (Online). 2013.
8857.	LR M, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. [Review][Update of Cochrane Database Syst Rev. 2005;(4):CD004185; PMID: 16235353]. Cochrane database of systematic reviews (Online). 2013;7:CD004185.
8858.	LRN S, BL O, JE G. Diagnosis and treatment of trichotillomania. Neuropsychiatry. 2011;1:123-132.
8859.	LS B, SJ M. Mutual influences between paroxysmal hypertension and psychiatric disturbance [5] (multiple letters). Archives of internal medicine. 1999;159:2091-2092.
8860.	LS C. Gender-Specific Considerations in the Treatment of Mood Disorders in Women Across the Life Cycle. Journal of clinical psychiatry. 2003;64:18-29.
8861.	LS C, AH G, Stetner F, Rivelli S, Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. American journal of psychiatry. 2002;159:1731-1737.
8862.	LS C, CN S, KA Y, KM B, IM B, Steiner M. Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: a Double-Blind, Placebo-Controlled Trial. Psychosomatic medicine. 2004;66:707-713.
8863.	LS C, CN S, KA Y, KM B, IM B, Steiner M. Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: a Double-Blind, Placebo-Controlled Trial. Psychosomatic medicine. 2004;66:707-713.
8864.	LS C, CN S, Lyster A, Cassano P, Brandes M, GA L. Efficacy and Tolerability of Premenstrual Use of Venlafaxine (Flexible Dose) in the Treatment of Premenstrual Dysphoric Disorder. Journal of clinical psychopharmacology. 2004;24:540-543.
8865.	LS C, CN S, Lyster A, Cassano P, Brandes M, GA L. Efficacy and Tolerability of Premenstrual Use of Venlafaxine (Flexible Dose) in the Treatment of Premenstrual Dysphoric Disorder. Journal of clinical psychopharmacology. 2004;24:540-543.
8866.	LS C, Hitsman B, Spring B, Borrelli B, McChargue D, Niaura R. Comments on "History of depression and smoking cessation outcome: A meta-analysis" (multiple letters). Nicotine & tobacco research. 2004;6:743-749.
8867.	LS C, Miner C, Brown E, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-controlled, clinical trial using computerized diaries. Obstetrics and gynecology. 2002;100:435-444.
8868.	LS M, Blanco C, SC V, Vaughan R, SP R. Defense mechanisms and personality in depression. Depression and anxiety. 1999;10:168-174.
8869.	LS M, Morlock R, Sexton C, Malley K, Feltner D. Identifying Ham-a Cutoffs for Mild, Moderate, and Severe Generalized Anxiety Disorder. International journal of methods in psychiatric research. 2010;19:223-232.
8870.	LS R, Herrmann N, KL L. Post-stroke depression. Geriatrics & aging. 2007;10:415-424.
8871.	LS S. Efficacy of Treatment for Geropsychiatric Patients With Severe Mental-Illness. Psychopharmacology bulletin. 1993;29:501-524.
8872.	LS S, GW S, CM C. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. American journal of geriatric psychiatry. 2001;9:393-399.
8873.	LS S, JC N, CM C, et al. An 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression. American journal of psychiatry. 2003;160:1277-1285.
8874.	LS S, JT O. Efficacy of acute treatment for geriatric depression. [Review] [75 refs]. International Psychogeriatrics. 1995;7 Suppl:7-25.
8875.	LS S, PB S. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: A selective review. International journal of geriatric psychiatry. 1991;6:691-708.
8876.	LS S, SM M. Postpartum mood disorders. International review of psychiatry. 2003;15:231-242.
8877.	LS V, Colasanti A, Cerveri G, et al. Clinical Outcome and Tolerability of Duloxetine in the Treatment of Major Depressive Disorder: a 12-Week Study With Plasma Levels. Journal of psychopharmacology (Oxford, England). 2010;24:1193-1199.
8878.	LS W, Kroenke K, Bakas T, et al. Care management of poststroke depression: A randomized, controlled trial. Stroke; a journal of cerebral circulation. 2007;38:998-1003.
8879.	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study +/- 2 (DIADS-2)? [References], International journal of geriatric psychiatry(2011).
8880.	LT D, Ismail Z, AP P, et al. Citalopram for Agitation in Alzheimer's Disease: Design and Methods. Alzheimer's & dementia. 2012;8:121-130.
8881.	LT R. Episode of Major Depression Refractory to Pharmacotherapy. West Indian medical journal. 2006;55:455-456.
8882.	LT R. Obstinate Gambling Addiction. Pakistan Journal of Medical Sciences. 2007;23:293-295.
8883.	LT R. An Uncontrollable Gambling Addiction. Bratislava Medical Journal-Bratislavske Lekarske Listy. 2008;109:459-460.
8884.	LT vZ, Lesperance F, Frasure-Smith N, et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. Journal of thrombosis and thrombolysis. 2009;27:48-56.
8885.	LT W, SL R, DJ C. Body dysmorphic disorder: A review of current nosological issues and associated cognitive deficits. Current psychiatry reviews. 2009;5:261-270.
8886.	Lu NZ, Eshleman AJ, Janowsky A, Bethea CL. Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques. Molecular psychiatry. 2003;8:353-360.
8887.	Lubarsky M, JL J. Progressive supranuclear palsy: A current review. Neurologist. 2008;14:79-88.
8888.	Lubomira I, Ivan A, Angelos H. Combination therapy or monotherapy for the depressed type of schizoaffective disorder. Neuropsychiatric disease and treatment. 2009;5.
8889.	Luca C, Carlo C, Gianfranco S. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Human Psychopharmacology: Clinical and Experimental. 2009;24:331-336.
8890.	Luca M, Luca A, Calandra C. Borderline personality disorder and depression: An update. Psychiatric quarterly. 2012;83:281-292.
8891.	Lucchetti G, AB O, JPP M, MFP P. Anxiety and fear-avoidance in musculoskeletal pain. Current pain and headache reports. 2012;16:399-406.
8892.	Luciano C, Liliana DO, Fosca R, Laura M, al e. Fluvoxamine maleate: Double-blind clinical trial vs placebo in hospitalized depressed patients. Current therapeutic research, clinical and experimental. 1988;43:468-480.
8893.	Lucile C, F GJ, L MD, et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652.
8894.	Lucile C, Gabriele N, L MD, et al. Interferon-Alpha-Induced Changes in Tryptophan Metabolism: Relationship to Depression and Paroxetine Treatment. Biological psychiatry. 2003;54:906-914.
8895.	Ludman E, M VK, Katon W, et al. The design, implementation, and acceptance of a primary care-based intervention to prevent depression relapse. International journal of psychiatry in medicine. 2000;30:229-245.
8896.	Luis S, Belen A. Mirtazapine: Only for depression? [References]. Acta neuropsychiatrica. 2006;18:130-143.
8897.	Lukacova-Zib I, Gopalakrishnan G. Therapeutic options for the prevention of type 2 diabetes mellitus in the metabolic syndrome. Mount Sinai Journal of Medicine. 2010;77:524-532.
8898.	Lundberg J, JS C, KB P, Loft H, Halldin C, Farde L. Pet Measurement of Serotonin Transporter Occupancy: a Comparison of Escitalopram and Citalopram. International journal of neuropsychopharmacology. 2007;10:777-785.
8899.	Lupi M, Martinotti G, Acciavatti T, et al. Pharmacological treatments in gambling disorder: A qualitative review. BioMed Research International. 2014.
8900.	Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacology bulletin. 1996;32:637-646.
8901.	Lutz M, Morali A, JP L. Atypical Depression: Clinical Perspectives. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2013;39:258-264.
8902.	Luzny J. Treating pharmacoresistant depression in psychogeriatry-should electroconvulsive therapy or intravenous seropram be used? European neuropsychopharmacology. 2013;Conference:S400-S401.
8903.	LV T. Depression in cardiac patients: Underrecognized and undertreated. U.S. 2012;Pharmacist:HS-12-HS-15.
8904.	LX Z, SF X, Chun-Zhi T. [Effects of different intervention methods on behavior changes in depression rats]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2007;32:93-97.
8905.	LY L, Lu Q, LL W. Influence of electro-acupuncture on the side effects of fluoxetine on depression patients. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2009;29:271-274.
8906.	LY W, Borisovskaya A, AL M, Pascualy M. Common psychiatric problems in cognitively impaired older patients. Causes and management. Clinics in geriatric medicine. 2014;30:443-467.
8907.	Lyketsos C, Mintzer J, Rosenberg P, Schneider L, Weintraub D. Depression in Alzheimer's disease study-2: Methods and initial presentation of results. American journal of geriatric psychiatry. 2009;Conference:A28-A29.
8908.	Lykouras L, Gournellis R. Psychotic (delusional) major depression: New vistas. Current psychiatry reviews. 2009;5:1-28.
8909.	Lynch A, CA G, Fitzgerald F. Psychopharmacologic treatment of adolescent depression. [Review] [30 refs]. Archives of psychiatric nursing. 2001;15:41-47.
8910.	Lynch S, Fraser J. "Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome": Commentary. The British Journal of Psychiatry. 1998;173:353.
8911.	Lynch S, Fraser J, Morris R. Fluoxetine and graded exercise in chronic fatigue syndrome [5] (multiple letters). British journal of psychiatry. 1998;173:353.
8912.	LZ S, JA L, Campbell C, Zhao Y. Factors Associated With Duloxetine Treatment Among Patients With Major Depressive Disorder in Veterans Health Administration: a Retrospective Study. Current medical research and opinion. 2010;26:2715-2721.
8913.	LZ S, MA N, Swindle R, et al. Effects of Olanzapine Alone and Olanzapine/Fluoxetine Combination on Health-Related Quality of Life in Patients With Bipolar Depression: Secondary Analyses of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clinical therapeutics. 2004;26:125-134.
8914.	L�o H, Saiz-Ruiz J, null CeSJ, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. Journal of affective disorders. 1999;56:109-118.
8915.	M AG, A HM. Levomilnacipran for the treatment of major depressive disorder: A review. Neuropsychiatric disease and treatment. 2015;11.
8916.	M AG, Amal C, A DE, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. Journal of clinical psychiatry. 1999;60:668-676.
8917.	M AI. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. Journal of affective disorders. 2000;58:19-36.
8918.	M AI. "Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: Meta-analysis": Comment. Psychopharmacology. 2008;196:521-522.
8919.	M AL, Amy R, Lu PY, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
8920.	M AL, I HJ, Fujun W, et al. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Clinical journal of pain. 2009;25:461-468.
8921.	M AM, A RM, G SS, S MJ. Parental marital discord and treatment response in depressed adolescents. Journal of abnormal child psychology. 2011;39:401-411.
8922.	M BC, C BJ, F WJ. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology bulletin. 1990;26:18-24.
8923.	M BC, E DB, C BJ, et al. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. International clinical psychopharmacology. 1992;6:35-57.
8924.	M BC, E NM, C KS, S GJ. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose. Journal of clinical psychiatry. 2000;61:722-728.
8925.	M BC, E SM, C BJ, Wernicke JF. High-Dose Fluoxetine - Efficacy and Activating-Sedating Effects in Agitated and Retarded Depression. Journal of clinical psychopharmacology. 1991;11:166-174.
8926.	M BC, E SM, E CG, M WA, N MD. Fluoxetine in tricyclic refractory major depressive disorder. Journal of affective disorders. 1990;20:193-200.
8927.	M BC, E SM, M WA, H PJ. Fluoxetine - Activating and Sedating Effects at Multiple Fixed Doses. Journal of clinical psychopharmacology. 1992;12:328-333.
8928.	M BC, H PJ. Fluoxetine: activating and sedating effects. [Review] [13 refs]. International clinical psychopharmacology. 1993;8:271-275.
8929.	M BC, L HS, H PJ. Fluoxetine compared with imipramine in the treatment of inpatient depression: A multicenter trial. Annals of clinical psychiatry. 1993;5:199-207.
8930.	M BC, Sayler ME, H PJ. Fluoxetine Versus Amitriptyline in the Treatment of Major Depression - a Multicenter Trial. International clinical psychopharmacology. 1993;8:143-149.
8931.	M BD, H MB, Chetachi E, et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of psychiatric research. 2011;45:896-901.
8932.	The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression, Journal of clinical psychopharmacology(2013).
8933.	M BG, H MB, G PB, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depression and anxiety. 2001;13:38-44.
8934.	M BL, M KG. Paroxetine Controlled Release. CNS drugs. 2004;18:355-364.
8935.	M BR, Amit A, Angela C, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biological psychiatry. 1999;45:1170-1177.
8936.	M BR, K WG, P KH. Huntington's disease: Present treatments and future therapeutic modalities. International clinical psychopharmacology. 2004;19:51-62.
8937.	M BR, M DA, L MH, Amit A, S CD. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial. American journal of psychiatry. 1997;154:37-43.
8938.	The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study, Journal of clinical psychiatry(2007).
8939.	Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants, CNS spectrums(2009).
8940.	M CJ, Ellen F, Christine C, Patricia H, J KD. Prospective assessment of sexual function in women treated for recurrent major depression. Journal of psychiatric research. 2004;38:267-273.
8941.	M CK, C BA, K VS, V NE. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: A controlled clinical trial. Drug and alcohol dependence. 2004;74:123-134.
8942.	M CR, E FK, C SB. "Omega-3 fatty acids for CHD with depression": Reply. JAMA: Journal of the American Medical Association. 2010;303:836.
8943.	Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: A randomized controlled trial, JAMA - Journal of the American Medical Association(2009).
8944.	M CR, E FK, K SP, et al. Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosomatic medicine. 2010;72:748-754.
8945.	M D-BC, William DJF, Shane M, et al. The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study. Neuropsychopharmacology. 2005;30:1724-1734.
8946.	M DB, F DF, LC Q, JP R, Decuyper M, RM B. Does personality disorder co-morbidity impact treatment outcome for patients with major depression? A multi-level analysis. Journal of personality disorders. 2011;25:1-15.
8947.	M DB, JG J, F DF. Patient and clinician perceptions of therapeutic alliance as predictors of improvement in depression. Psychotherapy and psychosomatics. 2010;79:378-385.
8948.	M DF, Iannuccelli C, Atzeni F, et al. Pharmacological Treatment of Fibromyalgia. Clinical and experimental rheumatology. 2010;28:S110-S116.
8949.	M DG, Martinotti G. Anhedonia and major depression: the role of agomelatine. [Review]. European neuropsychopharmacology. 2012;22 Suppl 3:S505-510.
8950.	M DH, JM D, Wood D, KG K, RIG H, H-J M. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC. European psychiatry. 2009;24:412-424.
8951.	M dKEC, Moleman P, Hoogduin CAL, et al. Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders. Psychopharmacology. 2002;160:67-73.
8952.	M DL. Experts disagree on affect of anti-depressives: Nut fluoxetine for children under discussion. [Dutch]. Pharmaceutisch weekblad. 2009;144:40-41.
8953.	M DR. "Listening to Prozac but hearing placebo": Commentary on Kirsch and Saperstein. Prevention & Treatment. 1998;1:No Pagination Specified.
8954.	M DS, Doallo S, Costoloni G, Rohenkohl G, AC N, CJ H. "Look me in the face!": Short-term SSRI administration reverts avoidant ocular face exploration in subjects at risk for psychopathology. European neuropsychopharmacology. 2012;Conference:S178-S179.
8955.	M DS, Norbury R, Harmer CJ. Short-term antidepressant administration reduces negative self-referential processing in the medial prefrontal cortex in subjects at risk for depression. Molecular psychiatry. 2012;17:503-510.
8956.	M DS, Western D, Hanson B, Taggart P, Harmer C. Short-term antidepressant administration modulates cardiovascular response during emotion regulation in subjects at risk for psychopathology. Biological psychiatry. 2012;Conference:289S-290S.
8957.	M DT, Sardaro M, Vecchio E, Serpino C, Stasi M, Ranieri M. Central Sensitisation Phenomena in Primary Headaches: Overview of a Preventive Therapeutic Approach. CNS & neurological disorders drug targets. 2008;7:524-535.
8958.	M ED, H KG, Lydia C, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. General hospital psychiatry. 2008;30:40-48.
8959.	M EM, BP G, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS neuroscience & therapeutics. 2010;16:e1-e17.
8960.	M FA, L WW, J M-HJ, et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:279-283.
8961.	M FA, M SS, J BR, Gho-zhu Z, Wesley LJ, B NC. Tritiated platelet imipramine binding and treatment response in depressed outpatients. Depression. 1993;1:20-23.
8962.	M FDM, J DJM, Bacaltchuk J, Verdeli H, Neugebauer R. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. European archives of psychiatry and clinical neuroscience. 2005;255:75-82.
8963.	M FJ, A WK, E SG. Reboxetine versus paroxetine versus placebo: Effects on cognitive functioning in depressed patients. International clinical psychopharmacology. 2003;18:9-14.
8964.	M FJ, K SR, M SS, et al. Reemergence of sexual dysfunction in patients with major depressive disorder: Double-blind comparison of nefazodone and sertraline. Journal of clinical psychiatry. 2001;62:24-29.
8965.	M FM, ML F, Petrov P, et al. Quetiapine XR monotherapy and quetiapine XR+ongoing antidepressant versus lithium+ongoing AD for Stage II treatment-resistant major depressive disorder. European neuropsychopharmacology. 2010;Conference:S347.
8966.	M G-DF, Michael W, Janice C, et al. MRI signal hyperintensities and treatment remission of geriatric depression. Journal of affective disorders. 2010;126:395-401.
8967.	M GF, Janice C, F MC, et al. Anterior cingulate cortical volumes and treatment remission of geriatric depression. International journal of geriatric psychiatry. 2009;24:829-836.
8968.	M GI, Paul W, Bernadka D, Raphael K. Forum: The use of selective serotonin reuptake inhibitors in depressed children and adolescents: Commentary on the meta-analysis by Hetrick et al. Current opinion in psychiatry. 2010;23:58-61.
8969.	M GJ. Mirtazapine: Clinical overview. Journal of clinical psychiatry. 1999;60:9-13.
8970.	M HA, A CI, F LA. Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. Journal of clinical psychopharmacology. 2010;30:748-750.
8971.	M HA, A CI, F LA. Does prior antidepressant treatment of major depression impact brain function during current treatment? [References]. European neuropsychopharmacology. 2012;22:711-720.
8972.	M HA, F LA, A PR, et al. A genome-wide association study of a sustained pattern of antidepressant response. Journal of psychiatric research. 2013;47:1157-1165.
8973.	M HA, F LA, L MM, A CI. Changes in Brain Function (Quantitative EEG Cordance) During Placebo Lead-in and Treatment Outcomes in Clinical Trials for Major Depression. American journal of psychiatry. 2006;163:1426-1432.
8974.	M HA, F LA, L MM, et al. Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo. Neuropsychopharmacology. 2005;30:792-799.
8975.	M HA, O MB, A CI, F LA. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. Journal of psychiatric research. 2010;44:90-98.
8976.	Rostral anterior cingulate activity in major depressive disorder: State or trait marker of responsiveness to medication? [References], Journal of neuropsychiatry and clinical neurosciences(2013).
8977.	M HB, A BM, Andrew S, et al. Effects of aerobic exercise on sexual functioning in depressed adults. Mental health and physical activity. 2009;2:23-28.
8978.	Exercise and pharmacotherapy in patients with major depression: One-year follow-up of the SMILE Study, Psychosomatic medicine(2011).
8979.	M HH, Kanter D, Houser VP. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: One years experience. Pharmacopsychiatry. 1995;28:253-256.
8980.	M IB, Scott MK, S BM, Moira R, Robert G, P BJ. Treatment preferences affect the therapeutic alliance: Implications for randomized controlled trials. Journal of consulting and clinical psychology. 2007;75:194-198.
8981.	M IP, M LF, G CM. Suicide risk in pediatric populations treated with antidepressives: Impact of the 2003 alert in prescription and research in efficacy and safety. Revista chilena de pediatria. 2011;82:277-288.
8982.	M JJ, E LS, D CJ, T MR, A FCM, R JP. Childhood neglect and abuse as predictors of antidepressant response in adult depression. Depression and anxiety. 2009;26:711-717.
8983.	Extreme nonresponse to acute phase cognitive therapy for depression: An attempt to replicate and extend, Behavior therapy(2014).
8984.	M KL, H HS, Marc H, et al. Predicting response to fluoxetine in geriatric patients with major depression. Journal of clinical psychopharmacology. 1995;15:421-427.
8985.	M KL, J GA, G KS, et al. Sertraline versus imipramine to prevent relapse in chronic depression. Journal of affective disorders. 2001;65:27-36.
8986.	Duloxetine treatment of dysthymia and double depression: An open-label trial, Journal of clinical psychiatry(2007).
8987.	M KM, L TJ, L BC, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566-579.
8988.	M KR, A NW, J HT. Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: A randomised, double-blind, controlled trial. International journal of geriatric psychiatry. 2007;22:1247-1254.
8989.	M KR, Carlijn vB, A NW, J HT. Early response as predictor of final remission in elderly depressed patients. International journal of geriatric psychiatry. 2009;24:1299-1303.
8990.	Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: An open, randomized, controlled trial, Journal of clinical psychiatry(2007).
8991.	M KR, Marja A, A NW, J HT. The course of adverse effects of nortriptyline and venlafaxine in elderly patients with major depression. Journal of the American Geriatrics Society. 2009;57:2112-2117.
8992.	M LI, Sidney Z, N GB, et al. Effects of race and ethnicity on depression treatment outcomes: The CO-MED trial. Psychiatric services (Washington, D.C.). 2011;62:1167-1179.
8993.	M LI, W SM, Marcy W, Ismael M, Mark MC, Keh-Ming L. Brain imaging, antidepressants, and ethnicity: Preliminary observations. Psychopharmacology bulletin. 1996;32:235-242.
8994.	M LJ, M WJ, L PR, Peter H. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology. 2006;31:1289-1294.
8995.	M LU, Henrik L, Heldbo RE. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. International clinical psychopharmacology. 2003;18:211-217.
8996.	M NB, Behnke K, Arup P, et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta psychiatrica Scandinavica. 1993;87:269-272.
8997.	M OCC, H GA, J HD. Pharmacoeconomic Analysis of Sertraline Treatment of Depression in Patients With Unstable Angina or a Recent Myocardial Infarction. Journal of clinical psychiatry. 2005;66:346-352.
8998.	Safety and tolerability of duloxetine in elderly patients with major depressive disorder: A pooled analysis of two placebo-controlled studies, International clinical psychopharmacology(2013).
8999.	M PG, Eran C, E SS. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. International psychogeriatrics / IPA. 2001;13:233-240.
9000.	M PH, R VJ, Gary L, R KH, R RM, Avital C. Double-blind clinical trial of sertraline treatment for alcohol dependence. Journal of clinical psychopharmacology. 2001;21:143-153.
9001.	A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence, American journal of psychiatry(2010).
9002.	M PR, A NW, W KR, et al. The Stanley Foundation Bipolar Network: 1. Rationale and methods. The British Journal of Psychiatry. 2001;178:s169-s176.
9003.	M PR, L AL, A FM, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar disorders. 2001;3:259-265.
9004.	M PR, S LG. Treatment of bipolar illness: A casebook for clinicians and patients. 2008.
9005.	M QF, Eva P, J MP, et al. When should a trial of fluoxetine for major depression be declared failed? [References]. American journal of psychiatry. 2003;160:734-740.
9006.	M QF, J MP, W SJ, et al. Remission Rates With 3 Consecutive Antidepressant Trials: Effectiveness for Depressed Outpatients. Journal of clinical psychiatry. 2005;66:670-676.
9007.	M RJ, G KS, Tracie SM, et al. Chronic depression and comorbid personality disorders: Response to sertraline versus imipramine. Journal of clinical psychiatry. 2003;64:554-561.
9008.	M RJ, M KL, John R, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depression and anxiety. 2001;13:18-27.
9009.	M RM, T A-SM, Harrison DA, et al. A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. Journal of psychopharmacology (Oxford, England). 1994;8:98-103.
9010.	M SJ, Patricia A, L SA, Gerard MF, M RH, John G. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug and alcohol dependence. 2001;63:207-214.
9011.	M SK, F HK, Kristine Y. Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia - a Review of the Evidence. JAMA: Journal of the American Medical Association. 2005;293:596-608.
9012.	M SM, Kazemi-shishvan M. The effectiveness of clomiphene citrate(CC) + metformin vs CC + metformin + fuoxetine in PCOS CC-resistant patients. Human reproduction (Oxford, England). 2010;Conference:i288.
9013.	M SM, M MG. "Antidepressants in acute bipolar depression: An inconclusive meta-analysis." Reply. Journal of clinical psychiatry. 2011;72:416.
9014.	M SN, M CK, T LR, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: Preliminary findings. Psychopharmacology. 2008;197:675-681.
9015.	M SS. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biological psychiatry. 2000;48:894-901.
9016.	M SS. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertaline. [Hungarian]. Psychiatria Hungarica. 2001;16:29-40.
9017.	M SS. Bioenergetics for depression: Something different for depression. American journal of psychiatry. 2012;169:891-893.
9018.	M SS, Richard E, L RR. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biological psychiatry. 2002;52:1166-1174.
9019.	M ST, L GS, Joseph GP, A NM, G GM, F TM. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. Journal of clinical psychiatry. 2001;62:273-281.
9020.	M ST, Marcin M, Iwona K. Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease. International journal of geriatric psychiatry. 2001;16:1108-1109.
9021.	M TE, Federico S, Leonardo T, J BR. Efficacy of antidepressants in juvenile depression: meta-analysis. [Review] [81 refs][Erratum appears in Br J Psychiatry. 2008 Oct;193(4):346], [Erratum appears in Br J Psychiatry. 2008 Aug;193(2):169]. The British Journal of Psychiatry. 2008;193:10-17.
9022.	M TE, Federico S, Leonardo T, J BR. "Efficacy of anti-depressants in juvenile depression: Meta-analysis": Erratum. The British Journal of Psychiatry. 2008;193:169.
9023.	Effectiveness and safety of the combination of fluoxentine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico, Journal of clinical psychopharmacology(2009).
9024.	M VA, Mancini C, DL S. Fluoxetine Efficacy in Social Phobia. Journal of clinical psychiatry. 1993;54:27-32.
9025.	M VA, Mancini C, JM O. Nefazodone in Social Phobia. Journal of clinical psychiatry. 1999;60:96-100.
9026.	M VA, Mancini C, Oakman J, et al. Nefazodone in the Treatment of Generalized Social Phobia: a Randomized, Placebo-Controlled Trial. Journal of clinical psychiatry. 2007;68:288-295.
9027.	M VA, Mancini C, Patterson B, Bennett M. Symptom relapse following switch from Celexa to generic citalopram: An anxiety disorders case series. Journal of psychopharmacology (Oxford, England). 2007;21:472-476.
9028.	M VA, Mancini C, Patterson B, Bennett M, Oakman J. A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania. Journal of clinical psychiatry. 2010;71:1336-1343.
9029.	M VA, Mancini C, Pipe B, Oakman J, Bennett M. An Open Trial of Topiramate in the Treatment of Generalized Social Phobia. Journal of clinical psychiatry. 2004;65:1674-1678.
9030.	M VA, Mancini C, Pipe B, Oakman J, Bennett M. An Open Trial of Topiramate in the Treatment of Generalized Social Phobia. Journal of clinical psychiatry. 2004;65:1674-1678.
9031.	M VA, Oakman J, Mancini C, Pipe B, Chung H. Predictors of Response in Generalized Social Phobia: Effect of Age of Onset. Journal of clinical psychopharmacology. 2004;24:42-48.
9032.	M VA, Oakman J, Mancini C, Pipe B, Chung H. Predictors of Response in Generalized Social Phobia: Effect of Age of Onset. Journal of clinical psychopharmacology. 2004;24:42-48.
9033.	M VB, PMJ V, TR E. Cost Effectiveness of Duloxetine Compared With Venlafaxine-Xr in the Treatment of Major Depressive Disorder. Current medical research and opinion. 2005;21:1271-1279.
9034.	M VB, PMJ V, TR E. Cost Effectiveness of Duloxetine Compared With Venlafaxine-Xr in the Treatment of Major Depressive Disorder. Current medical research and opinion. 2005;21:1271-1279.
9035.	M vBAJL, G EPM, Merijn E, W HA, H SJ, Patricia vO. Cognitive Therapy Versus Fluvoxamine as a Second-Step Treatment in Obsessive-Compulsive Disorder Nonresponsive to First-Step Behavior Therapy. Psychotherapy and psychosomatics. 2012;81:366-374.
9036.	M vdF-CC, Jasper N, Corinne S, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. [Review][Erratum appears in Gen Hosp Psychiatry. 2010 Nov-Dec;32(6):645]. General hospital psychiatry. 2010;32:380-395.
9037.	M vdF-CC, Jasper N, Corinne S, et al. Erratum to "Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: A systematic review and meta-analysis": [General Hospital Psychiatry 32 (2010) 380-395]. General hospital psychiatry. 2010;32:645.
9038.	Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine, Acta psychiatrica Scandinavica(2010).
9039.	Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: A randomized, placebo-controlled trial with a novel design, Bipolar disorders(2011).
9040.	M VM, Bartholome F, Cosyns P, AR DN, Mertens C. A Controlled Comparison of Sertraline and Fluoxetine in Acute and Continuation Treatment of Major Depression. Human Psychopharmacology-Clinical and Experimental. 1995;10:393-405.
9041.	M vM, J dW, Vereecken A, et al. Mirtazapine Is More Effective Than Trazodone - a Double-Blind Controlled-Study in Hospitalized-Patients With Major Depression. International clinical psychopharmacology. 1995;10:3-9.
9042.	M WA, Yuyan J, G PB, et al. Adherence to escitalopram treatment in depression: A study of electronically compiled dosing histories in the 'Depression: The search for phenotypes' study. International clinical psychopharmacology. 2012;27:291-297.
9043.	M WM, D SM, H MC, et al. Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: Treatment outcomes in patients with comorbid arthritis. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2009;50:402-412.
9044.	Duloxetine for the Treatment of Major Depressive Disorder: Safety and Tolerability Associated with Dose Escalation, Depression and anxiety(2007).
9045.	M WM, M MJ, H MC, Apurva P, G WJ, Maurizio F. An Open-Label Study of Duloxetine for the Treatment of Major Depressive Disorder - Comparison of Switching Versus Initiating Treatment Approaches. Journal of clinical psychopharmacology. 2005;25:552-560.
9046.	M-A B, JE S. Two overlooked mood disorders in women: Subsyndromal depression and prenatal depression. Nursing clinics of North America. 2004;39:83-95.
9047.	M-A E. Pharmacogenomics of alcohol response and addiction. American journal of pharmacogenomics. 2003;3:217-232.
9048.	M-A F, PA S-M, Shir Y, Lussier D. Management of fibromyalgia in older adults. Drugs & aging. 2014;31:711-719.
9049.	Therapeutic effects of non-invasive brain stimulation with direct currents (tDCS) in neuropsychiatric diseases, NeuroImage(2014).
9050.	M-F OC, JE B, HJ C, et al. To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers. Brain, behavior, and immunity. 2009;23:887-897.
9051.	M-F P, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.[Erratum appears in Br J Psychiatry 1999 Oct;175:394]. The British Journal of Psychiatry. 1999;175:12-16.
9052.	M-J F, Leblanc J, Gravel P. The new dual-action antidepressant, duloxetine: A review of the literature. Today's Therapeutic Trends. 2003;21:277-293.
9053.	M-J K, J-X C. Integrated traditional and Western medicine for treatment of depression based on syndrome differentiation: A meta-analysis of randomized controlled trials based on the Hamilton depression scale. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2012;32:1-5.
9054.	M-L C, VP S, Ganes D, et al. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: Workshop summary report. AAPS journal. 2010;12:371-377.
9055.	M-L W, Dong C, Flores D, et al. Clinical and pharmacogenetic outcomes of a double-blind antidepressant treatment study. Neuropsychopharmacology. 2014;Conference:S395-S396.
9056.	M-L W, Licinio J. From monoamines to genomic targets: A paradigm shift for drug discovery in depression. Nature reviews. Drug discovery. 2004;3:136-151.
9057.	M-L W, Whelan F, Deloukas P, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:15124-15129.
9058.	M-M B, Serra J. Pharmacologic management part 1: Better-studied neuropathic pain diseases. Pain medicine (Malden, Mass.). 2004;5:S28-S47.
9059.	M-MG W. Menopause. Clinics in geriatric medicine. 2003;19:483-506.
9060.	M-S L. Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants. Drugs of today (Barcelona, Spain : 1998). 2007;43:569-581.
9061.	M-S L. Pharmacogenetic treatment of depressive disorders. Future neurology. 2007;2:329-338.
9062.	M-S L, BJ H, BS K, et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Current medical research and opinion. 2005;21:1369-1375.
9063.	M-S L, S-G K. Geriatric depression. Psychiatry investigation. 2007;4:2-5.
9064.	The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients With Major Depressive Disorder, Psychiatry investigation(2012).
9065.	The effect of initial duloxetine dosing strategy on nausea in Korean patients with major depressive disorder, Psychiatry investigation(2013).
9066.	MA A, Algul A, Yilmaz O, et al. Adjuvant folate treatment to essitalopram and serum homocystein, folate, vitamin B-12 levels in patients with major depressive disorder. [Turkish]. Klinik Psikofarmakoloji Bulteni. 2009;19:S151-S152.
9067.	MA B. Keeping our depressed patients in the right treatment long enough for them to get better: some hopeful findings. American journal of psychiatry. 2007;164:1136-1139.
9068.	MA B, Hierholzer R, HR K, Barlow A, O'Toole S. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007;70:167-174.
9069.	MA B, JT B, RD N, et al. Changes in cognitive functioning following treatment of late-life depression. American journal of psychiatry. 2000;157:1949-1954.
9070.	MA B, ML S, Klomp A, et al. The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. BMC psychiatry. 2014;14:48.
9071.	MA B, MLJ S, Klomp A, et al. The Effects of Psychotropic Drugs on Developing Brain (Epod) Study: Methods and Design. BMC psychiatry. 2014;14.
9072.	MA B, RK B, Andreescu C, et al. Changes in Neuropsychological Functioning Following Treatment for Late-Life Generalised Anxiety Disorder. British journal of psychiatry. 2011;199:211-218.
9073.	MA B, RK B, BH M, et al. Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: Is there a relationship? American journal of geriatric psychiatry. 2004;12:387-394.
9074.	MA C, ME T. The Role of Quetiapine Extended Release in the Treatment of Bipolar Depression. Advances in therapy. 2010;27:774-784.
9075.	MA C, ME T. Drug Safety Evaluation of Olanzapine/Fluoxetine Combination. Expert opinion on drug safety. 2014;13:1133-1141.
9076.	MA C, SM S. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. [Review]. CNS spectrums. 2013;18:199-208.
9077.	MA D, BA J. Pharmacotherapeutic trials in adolescent alcohol use disorders: Opportunities and challenges. Alcohol and Alcoholism. 2004;39:166-177.
9078.	MA D, ME T. Clinical Significance of Transcranial Magnetic Stimulation (Tms) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data. Psychopharmacology bulletin. 2009;42:5-38.
9079.	MA D, Zhang L, JC C, et al. The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate. Journal of cardiovascular pharmacology. 2007;49:384-393.
9080.	MA DV, Berard A. Antidepressant Use During Pregnancy and the Risk of Pregnancy-Induced Hypertension. British journal of clinical pharmacology. 2012;74:362-369.
9081.	MA F, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. Journal of clinical psychiatry. 2011;72:1295-1310.
9082.	MA F, Helleman G, SL M, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. American journal of psychiatry. 2009;166:164-172.
9083.	MA F, JB D-B, HE L, Horne R, GI K, IW M. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clinical Psychology: Science and Practice. 2004;11:47-68.
9084.	MA F, LE F, Fernandez M, et al. Ciguatera fish poisoning: Treatment, prevention and management. Marine drugs. 2008;6:456-479.
9085.	MA F, ML P, WV B, et al. Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of affective disorders. 2014;169:S17-S23.
9086.	MA F, Sajatovic M, Handiwala L. Clinical perspectives on the influence of drug formulation on patient tolerability and use of commonly prescribed antidepressants in major depressive disorder. Archives of Pharmacy Practice. 2013;4:83-92.
9087.	MA F, Suppes T, Swann A. The International Society for Bipolar Disorder (ISBD) work group on mixed states and treatment response. Bipolar disorders. 2010;Conference:21.
9088.	MA G, Dachs R, Darby-Stewart A. Aripiprazole as adjunctive therapy in patients with major depressive disorder. American family physician. 2008;78:308-311.
9089.	MA G, GL S, JY A. Venlafaxine: A 2003 update. Clinical therapeutics. 2003;25:2138-2154.
9090.	MA G, MA R. Obsessive-Compulsive Disorder in Children and Adolescents - Treatment Guidelines. CNS drugs. 1999;12:257-277.
9091.	MA H, ME F, JC B, JRT D. Trial Trazodone for Posttraumatic Stress Disorder Using a Multiple Baseline Group Design. Journal of clinical psychopharmacology. 1996;16:294-298.
9092.	MA H, Watson L. Use of psychotropic drugs in cerebrovascular disease. Clinical geriatrics. 2005;13:37-45.
9093.	MA J. Psychiatric illnesses in the elderly: A review. Journal of geriatric psychiatry and neurology. 1996;9:57-82.
9094.	MA J-A, Fernandez I, Vidal J, et al. Selective Serotonin Reuptake Inhibitors: Use in Children and Adolescents With Major Depressive Disorder. Actas espanolas de psiquiatria. 2007;35:342-350.
9095.	Ma J-J, Li X, Feng Y. Effect of mirtazapine on depression after cerebral infarction and rehabilitation of neurological functions. [Chinese]. Chinese Mental Health Journal. 2006;20:486-489.
9096.	MA K. Management of obesity. Current respiratory medicine reviews. 2008;4:122-130.
9097.	MA K. Current Considerations in the Treatment of Generalized Anxiety Disorder. CNS drugs. 2009;23:103-120.
9098.	MA K. Aripiprazole: A clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. Journal of affective disorders. 2011;128:S11-S20.
9099.	MA K, Bleau P, Blier P, Chokka P, Kjernisted K, M VA. Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic Stress and Obsessive-Compulsive Disorders. BMC psychiatry. 2014;14.
9100.	MA K, Jacobs L. Venlafaxine in the treatment of panic disorder. Neuropsychiatric disease and treatment. 2007;3:59-67.
9101.	MA K, Pavlicova M, Glass A, et al. Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? Drug and alcohol dependence. 2014;144:42-46.
9102.	MA K, VH C, Schulkin J. Glucocorticoid inhibition in the treatment of depression: Can we think outside the endocrine hypothalamus? Depression and anxiety. 2009;26:641-649.
9103.	MA M. The placebo effect and randomized trials: Analysis of conventional medicine. Urologic clinics of North America. 2002;29:125-133.
9104.	MA M. Lifestyle changes, nutritional supplements, and general preventive medicine recommendations that can simultaneously improve heart and urologic health: Part I. What do I tell patients? Seminars in Preventive and Alternative Medicine. 2007;3:74-87.
9105.	Efficacy of ECT in chronic, severe, antidepressant- and CBT-refractory PTSD: an open, prospective study, Brain stimulation(2010).
9106.	MA M, KR K, Castellanos A. Modafinil Augmentation of Antidepressant Treatment in Depression. Journal of clinical psychiatry. 2000;61:378-381.
9107.	MA N. Translational use of tdcs in major depressive disorder: Focus on neuroplasticity. Biological psychiatry. 2014;Conference:2S-3S.
9108.	MA N, CG L, PB R. Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. Alzheimer's research & therapy. 2015.
9109.	Epidemiology, Assessment, and Treatment of Dementia, Psychiatric clinics of North America(2011).
9110.	MA O, HC G, Currier D, et al. Treatment of suicide attempters with bipolar disorder: A randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. American journal of psychiatry. 2011;168:1050-1056.
9111.	MA O, McGrath P, MM W. Biomarker studies and the future of personalized treatment for depression. Depression and anxiety. 2014;31:902-905.
9112.	Response rates to fluoxetine in subjects who initially show no improvement, Journal of clinical psychiatry(2011).
9113.	MA P, Gray G, Lange M. The impact of sertraline on psychomotor performance. Aviation, space, and environmental medicine. 2002;73:964-970.
9114.	MA P, GW G, RJ L, Lange M. Ssri Effects on Pyschomotor Performance: Assessment of Citalopram and Escitalopram on Normal Subjects. Aviation, space, and environmental medicine. 2007;78:693-697.
9115.	MA P, ME R, LC J, Garcon E, JR S, SP R. The external validity of MRI-defined vascular depression. American journal of geriatric psychiatry. 2013;Conference:S66-S67.
9116.	MA P, Zimmerman M. Dual Reuptake Inhibitors Incur Lower Rates of Tachyphylaxis Than Selective Serotonin Reuptake Inhibitors: a Retrospective Study. Journal of clinical psychiatry. 2005;66:705-707.
9117.	MA P, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of clinical psychiatry. 2005;66:148-158.
9118.	MA P, Zimmerman M. Dual Reuptake Inhibitors Incur Lower Rates of Tachyphylaxis Than Selective Serotonin Reuptake Inhibitors: a Retrospective Study. Journal of clinical psychiatry. 2005;66:705-707.
9119.	MA P, Zimmerman M. Therapeutic Effect of Follow-up Assessments on Antidepressant and Placebo Response Rates in Antidepressant Efficacy Trials - Meta-Analysis. British journal of psychiatry. 2007;190:287-292.
9120.	Ma Q, DA Z, LP W. [Clinical curative effect and factor analysis of depression treated by acupuncture]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2011;31:875-878.
9121.	MA Q-S, Hajak G, S K-LG, Nutt D. Efficacy and Safety of Agomelatine in Patients With Major Depressive Disorder Compared to Escitalopram: a Randomized, Double-Blind Study. International journal of neuropsychopharmacology. 2010;Conference:82.
9122.	MA QS, Hartley S, Barbot F, JC A, Lofaso F, Guilleminault C. Circadian rhythms, melatonin and depression. Current pharmaceutical design. 2011;17:1459-1470.
9123.	MA R. Diagnosis and Treatment of Depression Comorbid with Neurologic Disorders. American journal of medicine. 2008;121:S28-S37.
9124.	MA R, Brawman-Mintzer O. Generalized Anxiety Disorder: Acute and Chronic Treatment. CNS spectrums. 2004;9:716-723.
9125.	MA R, Brawman-Mintzer O. Generalized Anxiety Disorder: Acute and Chronic Treatment. CNS spectrums. 2004;9:716-723.
9126.	MA R, EA R, JA Y-T, et al. Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: a Randomized, Controlled, Multicenter Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:222-229.
9127.	MA R, ER P. Alzheimer's disease and related disorders. [Review] [66 refs]. Medical clinics of North America. 2001;85:803-817.
9128.	Ma R, H-Y Y, B-S K, R-Q Q, X-L Z, J-G G. Difference of the antidepressant effects between Jieyu wan and its components in mouse models of depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:115-117.
9129.	MA R, JT W, SN C, et al. Child/Adolescent Anxiety Multimodal Study: Evaluating Safety. Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54:180-190.
9130.	MA R, MA R, PP Y, NR K. Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials. American journal of psychiatry. 2007;164:290-300.
9131.	MA R, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. American journal of psychiatry. 2013;170:1003-1010.
9132.	MA R, Scahill L, RA K, et al. Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents With Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31:1062-1069.
9133.	MA R, SR B. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Annals of pharmacotherapy. 2001;35:1024-1027.
9134.	MA S, AM L, BB B, ER G, Kirsch I. The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: a Meta-Analysis of Change on the Hamilton Rating Scales. PloS one. 2014;9.
9135.	MA S, EM L. Depression in children and adolescents: When "moodiness" merits special attention. Postgraduate medicine. 2002;112:53-61.
9136.	MA S, EM L. Depression in children and adolescents. [Turkish]. SENDROM. 2003;15:45-52.
9137.	MA S, Hara C, BLP S, FL R. Treatment-resistant depression: Review of pharmacologic antidepressant strategies. [Portuguese]. Jornal brasileiro de psiquiatria. 2006;55:232-242.
9138.	Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: A randomized controlled trial, Archives of general psychiatry(2009).
9139.	MA S, JK B, AC S, EB F, Reich L. Fluvoxamine Treatment of Trichotillomania. Journal of clinical psychopharmacology. 1997;17:278-283.
9140.	MA S, LS C. Nicotine dependence: The role for antidepressants and anxiolytics. Current opinion in investigational drugs (London, England : 2000). 2002;3:262-271.
9141.	MA S, MJ E, Grgas M. Desvenlafaxine: Another "Me Too" Drug? Annals of pharmacotherapy. 2008;42:1439-1446.
9142.	MA S, Osborne D, MJ B, Blizard R, PW R. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6MG) or placebo for sleep disturbance and depressed mood. International clinical psychopharmacology. 2010;25:132-142.
9143.	MA S, PS S, Gattis W. Therapeutic options for treating major depression, and the role of venlafaxine. Pharmacotherapy. 1996;16:352-365.
9144.	MA S, SM T. Current status of pharmacological and behavioral treatment of obsessive- compulsive disorder. Behavior therapy. 1995;26:163-186.
9145.	MA S, VN B, LA P, Rasmussen K. Chronic Coadministration of Olanzapine and Fluoxetine Activates Locus Coeruleus Neurons in Rats: Implications for Bipolar Disorder. Psychopharmacology. 2005;181:126-133.
9146.	MA S, VN B, LA P, Rasmussen K. Chronic Coadministration of Olanzapine and Fluoxetine Activates Locus Coeruleus Neurons in Rats: Implications for Bipolar Disorder. Psychopharmacology. 2005;181:126-133.
9147.	MA VN, TOC K. The Effect of Acute Serotonergic Modulation on Rectal Motor Function in Diarrhea-Predominant Irritable Bowel Syndrome and Healthy Controls. European journal of gastroenterology & hepatology. 2012;24:1259-1265.
9148.	MA W. Mind your heart. Annals of internal medicine. 2006;144:858-860.
9149.	MA W, C DB, Kalak N, et al. Facing depression with botulinum toxin: A randomized controlled trial. Journal of psychiatric research. 2012;46:574-581.
9150.	MA W, CM G. Bupropion for Overweight Women With Binge-Eating Disorder: a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of clinical psychiatry. 2013;74:400-406.
9151.	MA W, GE S. Primary Care - Managing Depression in Medical Outpatients. New England journal of medicine. 2000;343:1942-1950.
9152.	MA W, JM W. Depression and cardiovascular disorders. Annual review of clinical psychology. 2013;9:327-354.
9153.	Ma X, Gao C, Tan Q, et al. Bupropion SR and fluoxetine in treatment of depression in multicenter clinical trial. [Chinese]. Journal of Xi'an Jiaotong University (Medical Sciences). 2007;28:533-536+543.
9154.	Ma Y, Koesters M, Zhang Y, Weinmann S, Becker T, Jin W. Systematic review and meta-analysis of Chinese Venlafaxine trials. Psychiatrische Praxis. 2011.
9155.	Ma-Li W, Chuanhui D, L FD, et al. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. American journal of psychiatry. 2014;171:1297-1309.
9156.	Ma-Li W, Chuanhui D, L FD, et al. "Association of a brain methylation site with clinical outcomes in depression does not replicate across populations": Response to Uher et al. American journal of psychiatry. 2015;172:396-398.
9157.	Maalouf M, JM R, Shi J. An update on the diagnosis and management of dementing conditions. Reviews in neurological diseases. 2011;8:e68-e87.
9158.	Maayan L, CU C. Management of antipsychotic-related weight gain. Expert review of neurotherapeutics. 2010;10:1175-1200.
9159.	MacAluso M, SH P. CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: Is it more than just drug metabolism? Journal of clinical psychopharmacology. 2011;31:143-145.
9160.	MacAluso M, WC D, SH P. How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression. Journal of psychiatric practice. 2012;18:281-286.
9161.	Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. [Review] [84 refs]. Expert opinion on pharmacotherapy. 2000;1:917-933.
9162.	MacEdo A, Leiria E, Filipe A. Pirlindole in the treatment of depression: A meta-analysis. Clinical drug investigation. 2011;31:61-71.
9163.	Macgillivray L, KB R, PI R, MF M. The comparative effects of environmental enrichment with exercise and serotonin transporter blockade on serotonergic neurons in the dorsal raphe nucleus. Synapse (New York, N.Y.). 2012;66:465-470.
9164.	Machado M, Iskedjian M, IA R, TR E. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: Cost-effectiveness and budget-impact analyses. PharmacoEconomics. 2007;25:979-990.
9165.	Machado M, Iskedjian M, Ruiz I, TR E. Remission, Dropouts, and Adverse Drug Reaction Rates in Major Depressive Disorder: a Meta-Analysis of Head-to-Head Trials. Current medical research and opinion. 2006;22:1825-1837.
9166.	Machado M, TR E. Comparison of Ssris and Snris in Major Depressive Disorder: a Meta-Analysis of Head-to-Head Randomized Clinical Trials. Journal of clinical pharmacy and therapeutics. 2010;35:177-188.
9167.	Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: A comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel, Switzerland). 2010;3:19-41.
9168.	MacHado-Vieira R, HK M, CA Z. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist. 2009;15:525-539.
9169.	Machado-Vieira R, Salvadore G, DiazGranados N, CA ZJ. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacology & therapeutics. 2009;123:143-150.
9170.	Machado-Vieira R, Salvadore G, DiazGranados N, et al. New therapeutic targets for mood disorders. TheScientificWorldJournal. 2010;10:713-726.
9171.	Machado-Vieira R, Salvadore G, LA I, Diaz-Granados N, CA ZJ. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Current pharmaceutical design. 2009;15:1595-1611.
9172.	Mackin P, Gallagher P, Watson S, Young A, IN F. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Australian and New Zealand journal of psychiatry. 2007;41:321-326.
9173.	Macoveanu J, Knorr U, Skimminge A, et al. Altered reward processing in the orbitofrontal cortex and hippocampus in healthy first-degree relatives of patients with depression. Psychological medicine. 2014;44:1183-1195.
9174.	Macoveanu J, PM F, ME H, VG F, GM K, HR S. Effects of Selective Serotonin Reuptake Inhibition on Neural Activity Related to Risky Decisions and Monetary Rewards in Healthy Males. NeuroImage. 2014;99:434-442.
9175.	MacPhee E. Dissociative disorders in medical settings topical collection on complex medical-psychiatric issues. Current psychiatry reports. 2013.
9176.	MacQueen G, Chokka P. Special Issues in the Management of Depression in Women. Canadian Journal of Psychiatry. 2004;49:27S-40S.
9177.	Madaan V, DR W. Neuropeptides: Relevance in treatment of depression and anxiety disorders. Drug news & perspectives. 2009;22:319-324.
9178.	Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. European journal of clinical pharmacology. 2006;62:225-233.
9179.	Madhusoodanan S, Shah P, Brenner R, Gupta S. Pharmacological treatment of the psychosis of Alzheimer's disease: What is the best approach? CNS drugs. 2007;21:101-115.
9180.	MADM D. Effects of Antidepressants on Glucose Metabolism and Diabetes Mellitus Type 2 in Adults. Current opinion in psychiatry. 2013;26:60-65.
9181.	MAE Z. Nebivolol: New beta-blocker for hypertension. U.S.
9182.	Maeng S, CA ZJ. The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current psychiatry reports. 2007;9:467-474.
9183.	Maercker A, Lalor J. Diagnostic and clinical considerations in prolonged grief disorder. Dialogues in clinical neuroscience. 2012;14:167-176.
9184.	Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:664-675.
9185.	Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: Inflammatory, cell-mediate immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. and new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20:127-150.
9186.	Maes M, Leonard B, Fernandez A, et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:659-663.
9187.	Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta psychiatrica Scandinavica. 1998;97:302-308.
9188.	Magdalena I-K. Poststroke depression. 2013:64-70.
9189.	MAGM G. Hypericum Extract Ws (R) 5570 for Depression - an Overview. International journal of psychiatry in clinical practice. 2013;17:1-7.
9190.	Mago R. Proposed strategies for successful clinical management with aripiprazole. Expert opinion on pharmacotherapy. 2008;9:1279-1290.
9191.	Mago R, Mahajan R, ME T. Medically serious adverse effects of newer antidepressants. Current psychiatry reports. 2008;10:249-257.
9192.	Mago R, Monti D. Antiadrenergic treatment of antidepressant-induced excessive sweating in 3 patients [6]. Journal of clinical psychiatry. 2007;68:639-640.
9193.	Mago R, Tripathi N, Andrade C. Cardiovascular Adverse Effects of Newer Antidepressants. Expert review of neurotherapeutics. 2014;14:539-551.
9194.	Mahajan B, Kaushal S, SC C. Ramelteon: A new melatonin receptor agonist. Journal of anaesthesiology, clinical pharmacology. 2008;24:463-465.
9195.	Mahbobeh F, Ahmad A, Seddigheh E, Farzan K, Karamolah P, Hagar P. Treatment of depression and anxiety in infertile women: Cognitive behavioral therapy versus fluoxetine. Journal of affective disorders. 2008;108:159-164.
9196.	Mahe V, Feline A. Late mania: I - Late-onset bipolar illness. [French]. Annales medico-psychologiques. 1996;154:217-225.
9197.	Mahmoud F, RR T. Pharmacotherapy for neuropathic pain in the elderly: Focus on painful diabetic peripheral neuropathy. Clinical geriatrics. 2011;19:36-41.
9198.	Maier C, H-H G, Gruhn K, EK K, M-A E. Increased risk of suicide under intrathecal ziconotide treatment? - A warning. Pain. 2011;152:235-237.
9199.	Maier S, Balasa R, Buruian M, Maier A, Bajko Z. Depression in multiple sclerosis - Review. Romanian Journal of Neurology/ Revista Romana de Neurologie. 2015;14:22-29.
9200.	Maina G, Albert U, Salvi V, Bogetto F. Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder: a Prospective Comparison Between Serotonin Reuptake Inhibitors. Journal of clinical psychiatry. 2004;65:1365-1371.
9201.	Maina G, Albert U, Salvi V, Bogetto F. Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder: a Prospective Comparison Between Serotonin Reuptake Inhibitors. Journal of clinical psychiatry. 2004;65:1365-1371.
9202.	Maina G, Pessina E, GF A, Micari J, Bogetto F. Pharmacologic treatment of obsessive-compulsive disorder: Which choice beyond serotonin re-uptake inhibitors?. [Italian]. Italian Journal of Psychopathology. 2007;13:209-221.
9203.	Maina G, Picco C, Saracco P, Ziero S, Ceregato A, Bogetto F. Combined therapy in minor depressive disorders: Unique therapist or split treatment?. [Italian]. Italian Journal of Psychopathology. 2004;10:38-44.
9204.	Maina G, Rosso G, Rigardetto S, S CP, Bogetto F. No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression. Psychotherapy and psychosomatics. 2010;79:295-302.
9205.	Maina G, Salvi V, Rigardetto S, Bogetto F. Complex drug therapies in bipolar disorders: The role of atypical antipsychotics and antidepressants. [Italian]. Minerva psichiatrica. 2006;47:25-34.
9206.	Maity N, MK G, Gupta A, Sil A, Chakraborty S, Chatterjee S. Clinical Effectiveness and Safety of Escitalopram and Desvenlafaxine in Patients of Depression With Anxiety: a Randomized, Open-Label Controlled Trial. Indian journal of pharmacology. 2014;46:433-437.
9207.	Maju M, Babatunde A, Joanne M, et al. To the editor. American journal of psychiatry. 2005;162:818.
9208.	Maju M, Manu M, Joanne M. "Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder": Comment. JAMA: Journal of the American Medical Association. 2004;291:40.
9209.	Makela P, Hammerbeck U, DN R. Rehabilitation of the younger adult stroke patient. Therapy. 2006;3:273-289.
9210.	Makhlouf A, Kparker A, CS N. Depression and Erectile Dysfunction. Urologic clinics of North America. 2007;34:565-574.
9211.	MAKM K. Statement of the Agnp-Work Group "Child and Adolescent Pharmacology" on the Decision of the Joint Federal Committee (Gba) of the 17/02/2011 to Combine Escitalopram With Citalopram Into a Fixed Amount Group. Pharmacopsychiatry. 2012;45:III-IV.
9212.	Malan-Muller S, SM JH, Seedat S. Big effects of small RNAs: A review of MicroRNAs in anxiety. Molecular neurobiology. 2013;47:726-739.
9213.	Malaty W. St. John's wort for depression. American family physician. 2005;71:1375-1376.
9214.	Malatynska E, Goldenberg R, Shuck L, et al. Reduction of submissive behavior in rats: A test for antidepressant drug activity. Pharmacology. 2002;64:8-17.
9215.	Malatynska E, Pinhasov A, CJ C, et al. Assessing activity onset time and efficacy for clinically effective antidepressant and antimanic drugs in animal models based on dominant-submissive relationships. Neuroscience and biobehavioral reviews. 2007;31:904-919.
9216.	Malcolm P. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. The British Journal of Psychiatry. 1994;164:549-550.
9217.	Malek-Ahmadi P. Gabapentin and posttraumatic stress disorder. Annals of pharmacotherapy. 2003;37:664-666.
9218.	Malhotra S, GE T, Franco K. The relationship between depression and cardiovascular disorders. [Review] [19 refs]. Current psychiatry reports. 2000;2:241-246.
9219.	Malhotra S, PP D. Understanding childhood depression. Indian journal of medical research. 2007;125:115-128.
9220.	Malik M, Lake J, WB L, SV J. Culturally adapted pharmacotherapy and the integrative formulation. Child and adolescent psychiatric clinics of North America. 2010;19:791-814.
9221.	Malin E-G, Anne E, Stein O. Use of Psychotropic Medications in Treating Mood Disorders During Lactation - Practical Recommendations. CNS drugs. 2006;20:187-198.
9222.	Malin P, SP W, WJ B. Escitalopram: better treatment for depression is through the looking glass. [Review] [63 refs]. Expert review of neurotherapeutics. 2004;4:769-779.
9223.	Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants, Biological psychiatry(2011).
9224.	Malki K, Uher R, Paya-Cano J, et al. Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. Biological psychiatry. 2011;69:360-365.
9225.	Mallarkey G, PB M. Looking at the causes of, and possible treatments for, psychiatric diseases: Gene-environment interactions, circadian rhythms and neuronal dysfunction. Therapeutic advances in chronic disease. 2011;2:5-8.
9226.	Mallick R, Zhang H. Improvement of Fatigue-Related Symptoms in Patients With Major Depression Treated With Venlafaxine, Ssris, or Placebo. International journal of neuropsychopharmacology. 2004;7:S336.
9227.	Mallick R, Zhang H. Improvement of Fatigue-Related Symptoms in Patients With Major Depression Treated With Venlafaxine, Ssris, or Placebo. International journal of neuropsychopharmacology. 2004;7:S336.
9228.	Mallinckrodt C, Chuang-Stein C, Mcsorley P, et al. A Case Study Comparing a Randomized Withdrawal Trial and a Double-Blind Long-Term Trial for Assessing the Long-Term Efficacy of an Antidepressant. Pharmaceutical statistics. 2007;6:9-22.
9229.	Mallinckrodt C, Roger J, Chuang-Stein C, et al. Missing Data: Turning Guidance Into Action. Statistics in biopharmaceutical research. 2013;5:369-382.
9230.	Malling D, MN P, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. British journal of clinical pharmacology. 2005;60:287-290.
9231.	Malsert J, Chauvin A, Guyader N, et al. Oculometry as indicator of treatment efficacy in MDD. European archives of psychiatry and clinical neuroscience. 2010;Conference:S49-S50.
9232.	Malsert J, Guyader N, Chauvin A, et al. Antisaccades as a follow-up tool in major depressive disorder therapies: A pilot study. Psychiatry research. 2012;200:1051-1053.
9233.	Maltsman-tseikhin A, Moricca P, Niv D. Burning mouth syndrome: Will better understanding yield better management? Pain practice. 2007;7:151-162.
9234.	Mamdani F, MT B, MM B, Labbe A, Merette C, Turecki G. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Translational psychiatry. 2011;1:e13.
9235.	Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Progress in neurobiology. 2009;89:193-219.
9236.	Oxytocin nasal spray in fibromyalgic patients, Rheumatology international(2014).
9237.	Man C, Li C, Gong D, Xu J, Fan Y. Meta-analysis of Chinese herbal Xiaoyao formula as an adjuvant treatment in relieving depression in Chinese patients. Complementary therapies in medicine. 2014;22:362-370.
9238.	Man-li H, Ben-yan L, Jian-bo H, et al. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: A double-blind, randomized, sham-controlled trial. Australian and New Zealand journal of psychiatry. 2012;46:257-264.
9239.	Manas A, JP C, MC F, et al. Post Hoc Analysis of Pregabalin Vs. Non-Pregabalin Treatment in Patients With Cancer-Related Neuropathic Pain: Better Pain Relief, Sleep and Physical Health. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes & of the National Cancer Institute of Mexico. 2011;13:656-663.
9240.	Manber R, AS C. Insomnia and depression: A multifaceted interplay. Current psychiatry reports. 2009;11:437-442.
9241.	Manber R, Buysse D, JD E, et al. Treating insomnia in depression (TRIAD): Impact on insomnia severity and depression remission. Sleep. 2015;Conference:A341.
9242.	Manber R, JJB A, MM M. Alternative treatments for depression: Empirical support and relevance to women. Journal of clinical psychiatry. 2002;63:628-640.
9243.	Mancano M. ISMP adverse drug reactions-telaprevir-related dermatitis; Neuroleptic malignant syndrome with risperidone long-acting injection; Tigecycline-related pancreatitis; Venlafaxine-related psychosis; Neurologic adverse effects of ranolazine. Hospital pharmacy. 2013;48:360-365.
9244.	Mancini C, Vanameringen M. Paroxetine in Social Phobia. Journal of clinical psychiatry. 1996;57:519-522.
9245.	Mancini M, Gianni W, Rossi A, Amore M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. [Review] [57 refs]. Expert opinion on pharmacotherapy. 2009;10:847-860.
9246.	Mancini M, Perna G, Rossi A, Petralia A. Use of Duloxetine in Patients With an Anxiety Disorder, or With Comorbid Anxiety and Major Depressive Disorder: a Review of the Literature. Expert opinion on pharmacotherapy. 2010;11:1167-1181.
9247.	Mandrioli R, Mercolini L, MA S, MA R. Selective Serotonin Reuptake Inhibitors (Ssris): Therapeutic Drug Monitoring and Pharmacological Interactions. Current medicinal chemistry. 2012;19:1846-1863.
9248.	Maneeton N, Maneeton B, Eurviriyanukul K, Srisurapanont M. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine. [Review]. Drug design, development and therapy. 2013;7:1053-1062.
9249.	Maneeton N, Maneeton B, Srisurapanont M, SD M. Quetiapine Monotherapy in Acute Phase for Major Depressive Disorder: a Meta-Analysis of Randomized, Placebo-Controlled Trials. BMC psychiatry. 2012;12.
9250.	Maneeton N, Thongkam A, Maneeton B. Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study. Chotmaihet thangphaet [Journal of the Medical Association of Thailand]. 2010;93:337-342.
9251.	Manglick M, SM R, Taffe J, Tonge B, Melvin G. Persistent sleep disturbance is associated with treatment response in adolescents with depression. Australian and New Zealand journal of psychiatry. 2013;47:556-563.
9252.	Maniadakis N, Kourlaba G, Mougiakos T, Chatzimanolis I, Jonsson L. Economic Evaluation of Agomelatine Relative to Other Antidepressants for Treatment of Major Depressive Disorders in Greece. BMC health services research. 2013;13.
9253.	The bi-directional relationship between parent-child conflict and treatment outcome in treatment-resistant adolescent depression, Journal of the American Academy of Child and Adolescent Psychiatry(2013).
9254.	Mann K. Pharmacotherapy of alcohol dependence: A review of the clinical data. CNS drugs. 2004;18:485-504.
9255.	Mann K, Pankok J, Leissner J, Benkert O. Effects of Moclobemide on Sexual Performance and Nocturnal Erections in Psychogenic Erectile Dysfunction. Psychopharmacology. 2001;156:86-91.
9256.	Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St. John's Wort Extract Li160 for the Treatment of Depression With Atypical Features - a Double-Blind, Randomized, and Placebo-Controlled Trial. Journal of psychiatric research. 2010;44:760-767.
9257.	Mannu P, Rinaldi S, Fontani V, Castagna A, ML M. Radio electric treatment vs. Es-Citalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study. Acupuncture & electro-therapeutics research. 2009;34:135-149.
9258.	Manoela F, C SJ, P HJ, P SA, Flavio K. An Open Trial of Adjunctive Escitalopram in Bipolar Depression. Journal of clinical psychiatry. 2006;67:81-86.
9259.	Mansfield P, MK R, JN J, JM R, MJ D, Topliss D. Letter to the Editor (multiple letters) [2]. Medical journal of Australia. 2005;183:275-276.
9260.	Mansoor B, Rengasamy M, Hilton R, et al. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. Journal of child and adolescent psychopharmacology. 2013;23:458-467.
9261.	Mansuy L. Using flexible dosing with Milnacipran and Venlafaxine. International journal of psychiatry in clinical practice. 2009;Conference:14-15.
9262.	Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression, Journal of affective disorders(2013).
9263.	Mantovani A, Pavlicova M, Avery D, et al. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatmnt-resistant depression. Depression and anxiety. 2012;29:883-890.
9264.	Manus A. [Clinical criteria for choosing an antidepressive drug]. [Review] [26 refs] [French]. Encephale. 1995;21 Spec No:19-21.
9265.	Manus A. Clinical Criteria for the Selection of an Antidepressant. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 1995;21:19-21.
9266.	Mao J, Zee J, Xie S, et al. A randomized placebo controlled trial of rhodiola rosea and sertraline for major depressive disorder. Journal of alternative and complementary medicine (New York, N.Y.). 2014;Conference:A26-A27.
9267.	Maquet D, Demoulin C, J-M C. Chronic fatigue syndrome: a systematic review. Annales de readaptation et de medecine physique. 2006;49:418-427.
9268.	Mar A, Spreekmeester E, Rochford J. Antidepressants Preferentially Enhance Habituation to Novelty in the Olfactory Bulbectomized Rat. Psychopharmacology. 2000;150:52-60.
9269.	Marandi T, Vasar V, Rago L. The patterns of use of antidepressants in Estonia in 1996. Nordic journal of psychiatry. 1998;52:465-473.
9270.	Marano G, Harnic D, Lotrionte M, et al. Depression and the cardiovascular system: Increasing evidence of a link and therapeutic implications. Expert review of cardiovascular therapy. 2009;7:1123-1147.
9271.	Marazziti D, Baroni S, Giannaccini G, et al. Plasma Fluvoxamine Levels and Ocd Symptoms/Response in Adult Patients. Human Psychopharmacology-Clinical and Experimental. 2012;27:397-402.
9272.	Marazziti D, Golia F, Consoli G, et al. Effectiveness of Long-Term Augmentation With Citalopram to Clomipramine in Treatment-Resistant Ocd Patients. CNS spectrums. 2008;13:971-976.
9273.	Marazziti D, Mungai F, Vivarelli L, Presta S, Dell'Osso B. Pain and psychiatry: A critical analysis and pharmacological review. Clinical practice and epidemiology in mental health. 2006.
9274.	March J, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (Tads): Demographic and Clinical Characteristics. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:28-40.
9275.	March J, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. [Review] [57 refs]. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:28-40.
9276.	March J, Silva S, Petrycki S, et al. Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression - Treatment for Adolescents With Depression Study (Tads) Randomized Controlled Trial. JAMA: Journal of the American Medical Association. 2004;292:807-820.
9277.	March J, Silva S, Petrycki S, et al. Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression - Treatment for Adolescents With Depression Study (Tads) Randomized Controlled Trial. Jama-Journal of the American Medical Association. 2004;292:807-820.
9278.	March J, Silva S, Petrycki S, et al. Treatment for Adolescents with Depression Study (TADS): Rationale, design, and methods. Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42:531-542.
9279.	March J, Silva S, Vitiello B, TADSTeam. The Treatment for Adolescents with Depression Study (TADS): Methods and Message at 12 Weeks. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1393-1403.
9280.	Marchehi F, Travan L, Lazzerini M. Use of antidepressant drugs in children and adolescents: Risks and benefits. [Italian]. Medico e Bambino. 2005;24:377-382.
9281.	Marchesi C. Pharmacological management of panic disorder. Neuropsychiatric disease and treatment. 2008;4:93-106.
9282.	Marchesi C, C DP, Cantoni A, Fonto S, MR G, Maggini C. Personality Disorders and Response to Medication Treatment in Panic Disorder: a 1-Year Naturalistic Study. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:1240-1245.
9283.	Marchesi C, C DP, Tonna M, Ossola P. Is placebo useful in the treatment of major depression in clinical practice? Neuropsychiatric disease and treatment. 2013;9:915-920.
9284.	Marchesi C, Cantoni A, Fonto S, MR G, Maggini C. Predictors of Symptom Resolution in Panic Disorder After One Year of Pharmacological Treatment: a Naturalistic Study. Pharmacopsychiatry. 2006;39:60-65.
9285.	Marchionni N, Vampini C. Depression and cardiovascular diseases in the elderly: A complex relationship. [Italian]. Giornale di gerontologia. 2003;51:131-144.
9286.	Marcia V, Myra KH, Dara G, et al. Antidepressant agents and suicide death among US Department of Veterans Affairs patients in depression treatment. Journal of clinical psychopharmacology. 2012;32:346-353.
9287.	Marcio V. Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. [Review] [69 refs]. Journal of affective disorders. 1998;51:323-332.
9288.	Marcio V. Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients. International journal of psychiatry in clinical practice. 2000;4:201-208.
9289.	Marcio V, Alfonso O, Guido M, et al. A double-blind comparison of fluoxetine and amitriptyline in the treatment of major depression with associated anxiety ('anxious depression'). 1999:249-258.
9290.	Marga K, Z DM, Rok T. Effect of paroxetine on intermittent brief depression episodes and suicide attempts among patients with personality disorders: A double-blind, placebo-controlled study. Psychiatria Danubina. 1998;10:283-286.
9291.	Maria-Antonia Q-S, Goeran H, Pierre P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International clinical psychopharmacology. 2011;26:252-262.
9292.	Maria-Antonia Q-S, Patrick L, Christian G. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. [Review] [40 refs]. Human Psychopharmacology: Clinical and Experimental. 2010;25:222-229.
9293.	Mariangela G, Flavia G, Laura B, Roberta A, Smeraldi E. Perspectives in Clinical Psychopharmacology of Amitriptyline and Fluvoxamine - a Double-Blind-Study in Depressed Inpatients. Neuropsychobiology. 1992;26:186-192.
9294.	Marianna P, Andrea C, Corrado B. Randomized trials published in Chinese or Western journals: comparative empirical analysis. [Review]. Journal of clinical psychopharmacology. 2012;32:354-361.
9295.	Marianne G, John K, Ainsley B, Maria O, John MJ, Michael G. Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: Paroxetine vs. bupropion. Psychiatry research. 2015;225:407-412.
9296.	Marianne K, F TI, Jorund G, Bent N, Ivar A. Meta-regression analysis of paroxetine clinical trial data: Does reporting scale matter? [References]. Journal of clinical psychopharmacology. 2011;31:201-206.
9297.	Marie BA. Measuring severity by self-report in the pharmacological treatment of childhood and adolescent depression: Psychometric properties of the Short Form of the Weinberg Scale of Affective Severity (WSAS-SF). Dissertation Abstracts International: Section B: The Sciences and Engineering. 2004;65:3215.
9298.	Marie T, Yola M, Ralph C, Galbaud dFG, Thierry D. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. Journal of affective disorders. 2009;115:160-166.
9299.	Marie-Mitchell A, AF L, CP C, WJ G, SP A. Predictors of Improved Mood Over Time in Clinical Trials for Major Depression. Psychiatry research. 2004;127:73-84.
9300.	Marinescu V, Vrabie M. Treatment of depressive disorder: A focus on drug interactions via uridine 5'-diphosphate-glucuronosyltransferase enzymatic system. European neuropsychopharmacology. 2011;Conference:S401.
9301.	Marinescu V, Vrabie M. Treatment of bipolar disorder with somatic comorbidities-an overview of drug-drug interactions. European neuropsychopharmacology. 2011;Conference:S140-S141.
9302.	Marino J, English C, Caballero J, Harrington C. The role of paliperidone extended release for the treatment of bipolar disorder. Neuropsychiatric disease and treatment. 2012;8:181-189.
9303.	Marino S, Sessa E, G DL, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurological sciences. 2008;29:391-395.
9304.	Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression, Journal of psychosomatic research(2011).
9305.	Mark A, Jenny G, Kathy L, Rashid Z. An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications. Psychiatria Danubina. 2010;22:346-349.
9306.	Mark A, Jenny G, Kathy L, Rashid Z. An audit to compare discharge rates and suicidality between antidepressant monotherapies prescribed for unipolar depression. Psychiatria Danubina. 2010;22:350-353.
9307.	Mark R, Emil C, Yvette S, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. Journal of clinical psychopharmacology. 1996;16:373-378.
9308.	Mark S, Ayal S, Anthony L. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. [Review] [46 refs]. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2010;55:126-135.
9309.	Mark T, Guy EJ, Sedgwick EM. Fluoxetine, amitriptyline and the electroencephalogram. Journal of affective disorders. 1993;29:7-10.
9310.	Markou A, AA H, Chevrette J, Hoyer D. Paroxetine Combined With a 5-Ht1a Receptor Antagonist Reversed Reward Deficits Observed During Amphetamine Withdrawal in Rats. Psychopharmacology. 2005;178:133-142.
9311.	Markou A, AA H, Chevrette J, Hoyer D. Paroxetine Combined With a 5-Ht1a Receptor Antagonist Reversed Reward Deficits Observed During Amphetamine Withdrawal in Rats. Psychopharmacology. 2005;178:133-142.
9312.	Markowitz JS, Lindsay DC, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. International clinical psychopharmacology. 2000;15:329-333.
9313.	Marks S, Heinrich T. Assessing and treating depression in palliative care patients. Current psychiatry. 2013;12:35-40.
9314.	Markus G. Hypericum extract WS  5570 for depression--an overview. [Review]. International journal of psychiatry in clinical practice. 2013;17 Suppl 1:1-7.
9315.	Markus G, Singer A, Zeller K. Efficacy and Tolerability of Hypericum Extract STW3 in Long-term Treatment with a Once-daily Dosage in Comparison with Sertraline. Pharmacopsychiatry. 2005;38:78-86.
9316.	Markus K, Thomas B, Stefan W. Regarding "Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs." [References]. Biological psychiatry. 2009;66:e7.
9317.	Markus K, Ying Z, Chun MY, Stefan W, Thomas B, Dong JW. What can we learn from Chinese randomized controlled trials? A systematic review and meta-analysis of Chinese venlafaxine studies. [Review]. Journal of clinical psychopharmacology. 2011;31:194-200.
9318.	Marlijn V, G MP, W vdBW, A BJ, K BT. A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients. Journal of psychiatric research. 2013;47:1337-1342.
9319.	Marlijn V, M KA, E VM, W vdBW, K BT. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology. 2015;232:1347-1356.
9320.	MARMA R. Antidepressant Treatment in Old Age: What Is the Evidence Base? Psychopharmakotherapie. 2010;17:69-+.
9321.	Maron E, Tammiste A, Kallassalu K, et al. Serotonin transporter promoter polymorphism does not influence treatment response to escitalopram in depression. European neuropsychopharmacology. 2008;Conference:S331.
9322.	Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: Results of a pilot randomized, placebo-controlled trial. Alcoholism, clinical and experimental research. 2002;26:1545-1552.
9323.	Marrocco J, ML R, Gatta E, et al. The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders. Journal of neuroscience. 2014;34:2015-2024.
9324.	Marsalek M. Suicidal tendencies induced by antidepressants. [Czech]. Psychiatrie (Stuttgart, Germany). 2006;10:160-171.
9325.	Marsano A, Gibiino S, Serretti A. Specificity profile of venlafaxine and sertraline in major depression: Meta-regression of double-blind, randomized clinical trials. European neuropsychopharmacology. 2013;Conference:S409-S410.
9326.	Marsden J, Sacks N. The role of hormone replacement therapy and alternative treatments: The management of estrogen deficiency symptoms in breast cancer survivors. American journal of cancer. 2004;3:67-78.
9327.	Marsh L. Depression and parkinson's disease: Current knowledge topical collection on movement disorders. Current neurology and neuroscience reports. 2013.
9328.	Marshall E. Antidepressants and children. Buried data can be hazardous to a company's health. Science (New York, N.Y.). 2004;304:1576-1577.
9329.	Marshall E. Buried data can be hazardous to a company's health. Science (New York, N.Y.). 2004;304:1576-1577.
9330.	Martiadis V, Castaldo E, Monteleone P, Maj M. The role of psychopharmacotherapy in the treatment of eating disorders. Clinical Neuropsychiatry. 2007;4:51-60.
9331.	Martignoni E, Calandrella D. Mental manifestations in Parkinson's disease. Minerva psichiatrica. 2009;50:27-44.
9332.	Martin A, WS G, JQ B, JM R. Child psychopharmacology, effect sizes, and the big bang. American journal of psychiatry. 2005;162:817; author reply 818-819.
9333.	Martin A, WS G, JQ B, JM R. Child psychopharmacology, effect sizes, and the big bang. American journal of psychiatry. 2005;162:817; author reply 818-819.
9334.	Martin A, WS G, JQ B, et al. Child psychopharmacology, effect sizes, and the big bang [14] (multiple letters). American journal of psychiatry. 2005;162:817-819.
9335.	Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: A double-blind, single-centre, randomized study, Journal of affective disorders(2009).
9336.	Martin K, Stuart M, William B, et al. Lack of Efficacy of the Substance P (Neurokinin(1) Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biological psychiatry. 2006;59:216-223.
9337.	Martin P. Coadministration benzodiazepine and antidepressant drugs: The state of art. [French]. Encephale. 2006;32:753-766.
9338.	Martin P, Laporte AM, Soubrie P, S EM, Hamon M. Reversal of helpless behaviour in rats by serotonin uptake inhibitors. 1989:231-233.
9339.	Martin S, A MC, Quincy S, V RP, Jason B, G LC. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International journal of geriatric psychiatry. 2004;19:144-150.
9340.	Martin-Araguz A, Bustamante-Martinez C, JM DP-P. Treatment of chronic tension-type headache with mirtazapine and amitriptyline. [Spanish]. Revista de neurologia. 2003;37:101-105.
9341.	Martin-Facklam M, Kostrzewa M, Schubert F, Gasse C, WE H. Quality markers of drug information on the internet: An evaluation of sites about St. John's wort. American journal of medicine. 2002;113:740-745.
9342.	Martina DS, Sonia D, Giulia C, Gustavo R, C NA, J HC. 'Can you look me in the face?' Short-term SSRI administration reverts avoidant ocular face exploration in subjects at risk for psychopathology. Neuropsychopharmacology. 2014;39:3059-3066.
9343.	Martinez D, Broft A, Laruelle M. Pindolol augmentation of antidepressant treatment: Recent contributions from brain imaging studies. Biological psychiatry. 2000;48:844-853.
9344.	Martinez D, Mawlawi O, DR H, et al. Positron Emission Tomography Study of Pindolol Occupancy of 5-Ht1a Receptors in Humans: Preliminary Analyses. Nuclear medicine and biology. 2000;27:523-527.
9345.	Martinez J, Trivedi M, Prakash A, Meyers A, Mallinckrodt C. What does remission look like in major depressive disorder? Comparisons of symptom resolution and functional impairment in remitters vs. non-remitters. American journal of geriatric psychiatry. 2009;Conference:A102-A103.
9346.	Martinez-Aran A, Vieta E, KNR C, Gershon S, Mullen J, Paulsson B. Reporting outcomes in clinical trials for bipolar disorder: A commentary and suggestions for change. Bipolar disorders. 2008;10:566-579.
9347.	Martinez-Martin P, MM K. Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. Parkinsonism & related disorders. 2010;15:S58-S64.
9348.	Martini B. Antidepressants versus psychotherapy: Successful treatment in patients with coronary heart disease. [German]. Deutsche Apotheker-Zeitung. 2007;147:50-52.
9349.	Martini B, Rosso G, DF C, D dC, Maina G. Brief dynamic therapy combined with pharmacotherapy in the treatment of panic disorder with concurrent depressive symptoms. Clinical Neuropsychiatry. 2011;8:204-211.
9350.	Martinotti G, Sepede G, M DN, et al. Agomelatine versus venlafaxine in the treatment of anhedonia in major depressive subjects: A pilot study. European psychiatry. 2012.
9351.	Martinotti G, Sepede G, Signorelli M, Aguglia E, M DG. Efficacy and Safety of Fluoxetine Monotherapy in Bipolar Depression: a Systematic Review. Expert opinion on pharmacotherapy. 2013;14:1065-1075.
9352.	Martinotti G, Tedeschi D, Fiori F, Janiri L, M DG. Agomelatine vs. venlafaxine in major depression: Focus on anhedonia and tolerability. International journal of neuropsychopharmacology. 2012;Conference:189.
9353.	Martiny K. Adjunctive Bright Light in Non-Seasonal Major Depression. Acta psychiatrica Scandinavica. 2004;110:7-28.
9354.	Martiny K. Adjunctive bright light in non-seasonal major depression. Acta Psychiatrica Scandinavica, Supplement. 2004;110:7-28.
9355.	Martiny K. Adjunctive bright light in non-seasonal major depression. Acta psychiatrica Scandinavica. Supplementum. 2004;Supplement:7-28.
9356.	Martiny K, Lunde M, Simonsen C, et al. Relapse Prevention by Citalopram in Sad Patients Responding to 1 Week of Light Therapy. A Placebo-Controlled Study. Acta psychiatrica Scandinavica. 2004;109:230-234.
9357.	Martiny K, Lunde M, Simonsen C, et al. Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta psychiatrica Scandinavica. 2004;109:230-234.
9358.	Martiny K, Lunde M, Unden M, Dam H, Bech P. Adjunctive Bright Light in Non-Seasonal Major Depression: Results From Clinician-Rated Depression Scales. Acta psychiatrica Scandinavica. 2005;112:117-125.
9359.	Martiny K, Lunde M, Unden M, Dam H, Bech P. Adjunctive Bright Light in Non-Seasonal Major Depression: Results From Patient-Reported Symptom and Well-Being Scales. Acta psychiatrica Scandinavica. 2005;111:453-459.
9360.	Martiny K, Lunde M, Unden M, Dam H, Bech P. High cortisol awakening response is associated with an impairment of the effect of bright light therapy. Acta psychiatrica Scandinavica. 2009;120:196-202.
9361.	Martiny K, Refsgaard E, Lund V, Lunde M, Bech P. Wake therapy yields sustained response and remission. A rater-blind 9 weeks controlled study using a chronotherapeutic intervention compared to exercise. European psychiatry. 2011.
9362.	A 9-Week Randomized Trial Comparing a Chronotherapeutic Intervention (Wake and Light Therapy) to Exercise in Major Depressive Disorder Patients Treated With Duloxetine, Journal of clinical psychiatry(2012).
9363.	The Day-to-Day Acute Effect of Wake Therapy in Patients with Major Depression Using the HAM-D6 as Primary Outcome Measure: Results from a Randomised Controlled Trial, PloS one(2013).
9364.	Martocchia A, Curto M, Toussan L, Stefanelli M, Falaschi P. Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Recent patents on CNS drug discovery. 2011;6:196-204.
9365.	Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. European neuropsychopharmacology. 1995;5:441-446.
9366.	Marutani T, Yahata N, Ikeda Y, et al. Functional Magnetic Resonance Imaging Study on the Effects of Acute Single Administration of Paroxetine on Motivation-Related Brain Activity. Psychiatry and clinical neurosciences. 2011;65:191-198.
9367.	Mary N, Melissa J, M MC, B BE, H HJ. Safety of Subchronic Treatment with Fluoxetine for Major Depressive Disorder in Children and Adolescents. Journal of child and adolescent psychopharmacology. 2004;14:412-417.
9368.	Maryam A, M KC, Ofra S-S, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. American journal of drug and alcohol abuse. 2012;38:181-186.
9369.	Marzolini S, Jensen B, Melville P. Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with severe schizophrenia: A multidisciplinary approach. Mental health and physical activity. 2009;2:29-36.
9370.	Masaki K, Chia-Ming C. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS drugs. 2013;27:11-19.
9371.	Masaki K, Tsuyoshi F, Masataka W, et al. Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. Neuropsychobiology. 2006;53:186-195.
9372.	Masana M, Castane A, Santana N, Bortolozzi A, Artigas F. Noradrenergic Antidepressants Increase Cortical Dopamine: Potential Use in Augmentation Strategies. Neuropharmacology. 2012;63:675-684.
9373.	Masand P, Narasimhan M. Major depressive disorder and medical illness: STAR*D outcomes. Current psychiatry reports. 2006;8:165-166.
9374.	Masataka W, Masaki K, Gaku O, et al. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Journal of clinical psychopharmacology. 2008;28:518-524.
9375.	Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal Outcome Following Pregnancy Exposure to Antidepressants: a Prospective Controlled Cohort Study. Bjog-an International Journal of Obstetrics and Gynaecology. 2008;115:283-289.
9376.	Maschio M, Jandolo B. Supportive therapy in neuro-oncology. Journal of experimental & clinical cancer research. 2005;24:17-24.
9377.	Masi G. Pharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents. CNS drugs. 2004;18:1031-1052.
9378.	Masi G. Pharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents. CNS drugs. 2004;18:1031-1052.
9379.	Masi G, Liboni F, Brovedani P. Pharmacotherapy of major depressive disorder in adolescents. [Review] [73 refs]. Expert opinion on pharmacotherapy. 2010;11:375-386.
9380.	Masi G, Millepiedi S, Mucci M, Bertini N, Milantoni L, Arcangeli F. A Naturalistic Study of Referred Children and Adolescents With Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:673-681.
9381.	Masi G, Millepiedi S, Mucci M, Bertini N, Milantoni L, Arcangeli F. A Naturalistic Study of Referred Children and Adolescents With Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:673-681.
9382.	Masi G, Millepiedi S, Perugi G, et al. Pharmacotherapy in paediatric obsessive-compulsive disorder: A naturalistic, retrospective study. CNS drugs. 2009;23:241-252.
9383.	Masi G, Pari C, Millepiedi S. Pharmacological treatment options for panic disorder in children and adolescents. Expert opinion on pharmacotherapy. 2006;7:545-554.
9384.	MASM S. Fibromyalgia Syndrome Treatment From a Multidimensional Perspective. Journal of musculoskeletal pain. 2010;18:373-379.
9385.	MASMR S. Analysis of Association Between the 5-Httlpr and Stin2 Polymorphisms in the Serotonin-Transporter Gene and Clinical Response to a Selective Serotonin Reuptake Inhibitor (Sertraline) in Patients With Premature Ejaculation (Retracted Article. See Vol. 115, . BJU international. 2010;105:73-78.
9386.	Massimiliano B, Cumerlato MC, Alice C, Carlo AA. Are antidepressants equally effective in the long-term treatment of major depressive disorder? [References]. Human Psychopharmacology: Clinical and Experimental. 2015;30:21-27.
9387.	Massimo DG, Giovanni M. Anhedonia and major depression: The role of agomelatine. European neuropsychopharmacology. 2012;22:S505-S510.
9388.	Massimo M. Reboxetine: A review of antidepressant tolerability. Journal of psychopharmacology (Oxford, England). 1997;11:S33-S37.
9389.	Massiou H. Prophylactic treatments of migraine. [French]. Revue neurologique. 2000;156:4S79-74S86.
9390.	Masterman D. Treatment of the neuropsychiatric symptoms in Alzheimer's disease. Journal of the American Medical Directors Association. 2003;4:S146-S154.
9391.	Mastrogiannis D, Giamouzis G, Dardiotis E, et al. Depression in patients with cardiovascular disease. Cardiology research and practice. 2012.
9392.	Mastrogiannis D, Giamouzis G, Dardiotis E, et al. Depression in patients with cardiovascular disease. Cardiology research and practice. 2012.
9393.	Mastropasqua L, Steardo L, Testa N. Fluoxetine oral administration increases intraocular pressure [1]. British journal of ophthalmology. 1996;80:678.
9394.	Mathew J. Clinical features, diagnosis and treatment of narcolepsy. Progress in neurology and psychiatry. 2008;12:10-15.
9395.	Mathews J, KS G, MA M, YI S. Antidepressant Efficacy of Olanzapine as Monotherapy in Major Depressive Disorder, Without Psychosis: a Pilot Study. Psychiatry Research-Neuroimaging. 2006;146:149-155.
9396.	Mathews M, Adetunji B, Mathews J, et al. Child psychopharmacology, effect sizes, and the big bang. American journal of psychiatry. 2005;162:818; author reply 818-819.
9397.	Efficacy and Safety of Vilazodone 20 and 40 Mg in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Trial, International clinical psychopharmacology(2015).
9398.	Mathys M, BG M. Targeting treatment-resistant depression. Journal of pharmacy practice. 2011;24:520-533.
9399.	Matias J, JM M, JL S, JL C, Llorca G, Ledesma A. Seasonal Affective Disorder and Light Therapy. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1996;24:204-208.
9400.	MATME T. Antidepressant Combinations: Widely Used, but Far From Empirically Validated. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2011;56:317-323.
9401.	MATME T. Combined Antidepressant Strategies Are Not More Effective Than Vigorous Escitalopram Monotherapy: Results of the Co-Med Study. Current psychiatry reports. 2011;13:434-436.
9402.	Matrisciano F, Bonaccorso S, Ricciardi A, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. Journal of psychiatric research. 2009;43:247-254.
9403.	Matsumoto S, Shimodozono M, Noma T, Kawahira K. A comparative study of duloxetine and paroxetine in Japanese patients with poststroke depression. Brain injury. 2014;Conference:738.
9404.	Matthew H, Corrado B. Bias in the evaluation of antidepressants. Epidemiologia e psichiatria sociale. 2005;14:55-57.
9405.	Matuzany-Ruban A, Golan M, Miroshnik N, Schreiber G, Avissar S. Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants. International journal of neuropsychopharmacology. 2010;13:83-91.
9406.	Matuzany-Ruban A, Schreiber G, Farkash P, Avissar S. Phosducin-like protein levels in leukocytes of patients with major depression and in rat cortex: the effect of chronic treatment with antidepressants. Psychiatry research. 2006;141:287-294.
9407.	Maudsley S, Martin B, JM E. To be or not to be - Obese. Endocrinology. 2011;152:3592-3596.
9408.	Maund E, Tendal B, Hrobjartsson A, et al. Benefits and Harms in Clinical Trials of Duloxetine for Treatment of Major Depressive Disorder: Comparison of Clinical Study Reports, Trial Registries, and Publications. Bmj-British Medical Journal. 2014;348.
9409.	Maund E, Tendal B, Hrobjartsson A, et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. [Review]. BMJ (Clinical research ed.). 2014;348:g3510.
9410.	Maund E, Tendal B, Hrobjartsson A, et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. [Review]. BMJ (Clinical research ed.). 2014;348:g3510.
9411.	Maund E, Tendal B, Hrobjartsson A, Lundh A, PC G. Coding of Adverse Events of Suicidality in Clinical Study Reports of Duloxetine for the Treatment of Major Depressive Disorder: Descriptive Study. Bmj-British Medical Journal. 2014;348.
9412.	Maund E, Tendal B, Hrobjartsson A, Lundh A, PC G. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. BMJ (Clinical research ed.). 2014;348:g3555.
9413.	Maund E, Tendal B, Hrobjartsson A, Lundh A, PC G. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. BMJ (Clinical research ed.). 2014;348:g3555.
9414.	Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: Current understanding, unanswered questions, and research needs. Chest. 2008;134:43S-56S.
9415.	Mauri M, Miniati M. Antidepressants heterogeneity: Venlafaxine vs SSRIs through the lens of the metanalysis. [Italian]. Italian Journal of Psychopathology. 2002;8:369-372.
9416.	Maurice F, Barte H, Blauwblomme JF, Fabiani JM, al e. Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. International clinical psychopharmacology. 1989;4 Suppl 1:97-101.
9417.	Maurice T, T-P S. The pharmacology of sigma-1 receptors. Pharmacology & therapeutics. 2009;124:195-206.
9418.	Mauricio T, Eduard V, Joseph C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.[Erratum appears in Arch Gen Psychiatry. 2004 Feb;61(2):176]. Archives of general psychiatry. 2003;60:1079-1088.
9419.	Mauricio T, Joseph C, Eduard V, et al. Effect of comorbid anxiety on treatment response in bipolar depression. Journal of affective disorders. 2007;104:137-146.
9420.	Mauricio T, Yen LD. "Does olanzapine have any antidepressant effect?": Drs. Tohen and Lin reply. American journal of psychiatry. 2006;163:1839.
9421.	Maurizio F, Curtis W, Daniel W, Stephan B, Andrew C, David P. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. Journal of affective disorders. 2009;113:263-271.
9422.	Maurizio F, D AJ, A DJ, Carl S, Michael S, L DD. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Annals of clinical psychiatry. 1998;10:145-150.
9423.	Maurizio F, E SM, Shuyu Z, Jill G, J RN, Rajinder J. Treatment approaches to major depressive disorder relapse - Part 2: Reinitiation of antidepressant treatment. Psychotherapy and psychosomatics. 2002;71:195-199.
9424.	Maurizio F, F RJ, J MP, W SJ, D AJ, M QF. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. American journal of psychiatry. 1994;151:1372-1374.
9425.	Maurizio F, F RJ, L HS, G TR, B KJ, E NM. Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in anxious depression. Journal of affective disorders. 2000;59:119-126.
9426.	Maurizio F, H MC, J DM, G WJ, M WM. The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? [References]. Journal of clinical psychiatry. 2004;65:521-530.
9427.	Maurizio F, J DM, Matteo B, Fujun W, Joel R, David P. Management of depression relapse: Re-initiation of duloxetine treatment or dose increase. Journal of psychiatric research. 2006;40:328-336.
9428.	Maurizio F, John RA, E AJ, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. American journal of psychiatry. 2008;165:342-351.
9429.	Maurizio F, John RA, R WS, et al. A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American journal of psychiatry. 2006;163:1161-1172.
9430.	Maurizio F, Jonathan A, A NA, et al. A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. Journal of clinical psychopharmacology. 2005;25:441-447.
9431.	Maurizio F, Jonathan A, Andrew N, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. Journal of clinical psychopharmacology. 2002;22:379-387.
9432.	Maurizio F, Kendyl S, Holly H, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. Journal of clinical psychiatry. 2011;72:473-479.
9433.	Maurizio F, L HS, A JR, B KJ, E NM, S GJ. Acute Efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline Insomnia. Journal of clinical psychopharmacology. 2002;22:137-147.
9434.	Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: A randomized controlled trial, Journal of clinical psychiatry(2011).
9435.	Maurizio F, Rajinder J, L HS, E NM, C KS. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. Journal of clinical psychiatry. 2000;61:863-867.
9436.	Maurizio F, Rosemarie M, Jonathan A, A NA, F RJ. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. American journal of psychiatry. 1997;154:1760-1762.
9437.	Maurizio F, Vaughn MW, Andrew K, et al. Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. Biological psychiatry. 2006;59:1052-1060.
9438.	Mavis E, Margaret H, Ken W, Michael L, John C. Treatment of depression in the elderly: Effect of physical illness on response. International journal of geriatric psychiatry. 1997;12:1189-1194.
9439.	Mavis E, Margaret H, Kenneth W, Michael L, John C. Placebo-controlled treatment trial of depression in elderly physically ill patients. International journal of geriatric psychiatry. 1997;12:817-824.
9440.	Mavranezouli I, Meader N, Cape J, Kendall T. The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder. PharmacoEconomics. 2013;31:317-333.
9441.	Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. Depression and anxiety. 2013;30:328-341.
9442.	Mavridis D, Sutton A, Cipriani A, Salanti G. A fully Bayesian application of the Copas selection model for publication bias extended to network meta-analysis. Statistics in medicine. 2013;32:51-66.
9443.	Maximilian P, Roland W, Christine W, Ute L, Michael B. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: A reanalysis of a randomized, double-blind study. Journal of affective disorders. 2010;126:453-457.
9444.	Mayberg H. CBT or medication? Putative pet and FMRI biomarkers for optimizing treatment selection for MDD. Biological psychiatry. 2013;Conference:139S.
9445.	Mayer G, Jennum P, Riemann D, Dauvilliers Y. Insomnia in central neurologic diseases - occurrence and management. Sleep medicine reviews. 2011;15:369-378.
9446.	Mazumdar S, Tang G, PR H, et al. Statistical analysis of longitudinal psychiatric data with dropouts. Journal of psychiatric research. 2007;41:1032-1041.
9447.	Mazurek MB. A Focus on the Mental Health of Adults and Older Adults. Worldviews on evidence-based nursing / Sigma Theta Tau International, Honor Society of Nursing. 2005;2:103-106.
9448.	Mazza M, Harnic D, Catalano V, Janiri L, Bria P. Duloxetine for Premenstrual dysphoric disorder. European neuropsychopharmacology. 2008;Conference:S295.
9449.	Mazza M, Harnic D, Catalano V, Janiri L, Bria P. Duloxetine for Premenstrual Dysphoric Disorder: a Pilot Study. Expert opinion on pharmacotherapy. 2008;9:517-521.
9450.	Mazza M, Lotrionte M, Biondi-Zoccai G, Abbate A, Sheiban I, Romagnoli E. Selective Serotonin Reuptake Inhibitors Provide Significant Lower Re-Hospitalization Rates in Patients Recovering From Acute Coronary Syndromes: Evidence From a Meta-Analysis. Journal of psychopharmacology (Oxford, England). 2010;24:1785-1792.
9451.	Mazza M, M DN, Martinotti G, et al. Oxcarbazepine in bipolar disorder: A critical review of the literature. Expert opinion on pharmacotherapy. 2007;8:649-656.
9452.	Mazza M, Marano G. Current understanding of comorbidity in anxiety disorders: An integrative approach. Minerva psichiatrica. 2009;50:231-263.
9453.	MB C, CB N. Inflammation and mood disorders: Proinflammatory cytokines and the pathogenesis of depression. Anti-inflammatory & anti-allergy agents in medicinal chemistry. 2010;9:212-220.
9454.	MB C, CB N. Depression as a risk factor for cancer: From pathophysiological advances to treatment implications. Annual review of medicine. 2014;65:203-221.
9455.	MB C, Molina G, Kato M. Citalopram Treatment of Major Depressive Disorder in Hispanic Hiv and Aids Patients: a Prospective Study. Psychosomatics. 2004;45:210-216.
9456.	MB C, Molina G, Kato M. Citalopram Treatment of Major Depressive Disorder in Hispanic Hiv and Aids Patients: a Prospective Study. Psychosomatics. 2004;45:210-216.
9457.	MB D, Echeverry D. Collaborative care for depression and chronic illnesses. New England journal of medicine. 2011;364:1278; author reply 1278-1279.
9458.	MB F, EE P, AM D, CR L, PB DP, JD H. The Effects of Fluoxetine and Buspirone on Self-Injurious and Stereotypic Behavior in Adult Male Rhesus Macaques. Comparative medicine. 2005;55:67-74.
9459.	MB F, EE P, AM D, CR L, PB DP, JD H. The Effects of Fluoxetine and Buspirone on Self-Injurious and Stereotypic Behavior in Adult Male Rhesus Macaques. Comparative medicine. 2005;55:67-74.
9460.	MB F, MW M, RM M, GM A. Dose-Finding Study of Fluoxetine and Venlafaxine for the Treatment of Self-Injurious and Stereotypic Behavior in Rhesus Macaques (Macaca Mulatta). Journal of the American Association for Laboratory Animal Science. 2009;48:176-184.
9461.	MB H, Robert S, BC F. Treatment-Resistant Posttraumatic Stress Disorder: Strategies for Intervention. CNS spectrums. 2004;9:740-752.
9462.	MB H, Robert S, BC F. Treatment-Resistant Posttraumatic Stress Disorder: Strategies for Intervention. CNS spectrums. 2004;9:740-752.
9463.	MB H, Uvnas-Moberg K, Engstrom I, Bejerot S. Plasma Oxytocin Changes and Anti-Obsessive Response During Serotonin Reuptake Inhibitor Treatment: a Placebo Controlled Study. BMC psychiatry. 2013;13.
9464.	MB K. The long-term treatment of depression. Journal of clinical psychiatry. 1999;60:41-45.
9465.	MB K. Long-Term Treatment of Recurrent and Chronic Depression. Journal of clinical psychiatry. 2001;62 Suppl 2:3-5.
9466.	MB K. Long-term treatment strategies in affective disorders. [Review] [33 refs]. Psychopharmacology bulletin. 2002;36 Suppl 2:36-48.
9467.	MB K. Rationale and options for the long-term treatment of depression. Human psychopharmacology. 2002;17:S43-S46.
9468.	MB K. Issues in Treatment-Resistant Depression. Journal of clinical psychiatry. 2005;66:5-12.
9469.	MB K. Issues in Treatment-Resistant Depression. Journal of clinical psychiatry. 2005;66:5-12.
9470.	MB K, Cooper C, MJ B, et al. Ctn-194 (Picco): Design of a Trial of Citalopram for the Prevention of Depression and Its Consequences in Hiv-Hepatitis C Co-Infected Individuals Initiating Pegylated Interferon/Ribavirin Therapy. Contemporary clinical trials. 2008;29:617-630.
9471.	MB K, Harrison W, JA F, et al. Treatment of Chronic Depression With Sertraline or Imipramine - Preliminary Blinded Response Rates and High-Rates of Undertreatment in the Community. Psychopharmacology bulletin. 1995;31:205-212.
9472.	MB K, JP M, DN K, et al. A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. New England journal of medicine. 2000;342:1462-1470.
9473.	Citalopram for the Prevention of Depression and Its Consequences in Hiv-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: a Multicenter Randomized Double-Blind Placebo-Controlled Trial, HIV clinical trials(2014).
9474.	MB K, RJ B. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biological psychiatry. 1998;44:348-360.
9475.	MB M, SA L, Muir J, SE S, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New England journal of medicine. 1992;326:1250-1256.
9476.	MB S. Sodium oxybate for narcolepsy. Expert review of neurotherapeutics. 2006;6:1139-1146.
9477.	MB S, DJ S. Social Anxiety Disorder. Lancet. 2008;371:1115-1125.
9478.	MB S, Keshaviah A, SA H, et al. Influence of Rgs2 on Sertraline Treatment for Social Anxiety Disorder. Neuropsychopharmacology. 2014;39:1340-1346.
9479.	MB S, NA K, JL M. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. American journal of psychiatry. 2002;159:1777-1779.
9480.	MB VI, SU Z, RTCM K, FRJ V, MGMO R. Antipsychotics for behavioural and psychological problems in elderly people with dementia: A systematic review of adverse events. Drugs & aging. 2005;22:845-858.
9481.	MC B. Women's mental health research: The emergence of a biomedical field. Annual review of clinical psychology. 2006;2:135-160.
9482.	MC H, Schubiner H, MA L, JS S, DJ C, DA W. Sustained Pain Reduction Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial. Journal of general internal medicine. 2010;25:1064-1070.
9483.	MC H, Wohlreich M, Gaynor P, Hanna S, Risser R. Clinically Relevant Outcomes Based on Analysis of Pooled Data From 2 Trials of Duloxetine in Patients With Knee Osteoarthritis. Journal of rheumatology. 2012;39:352-358.
9484.	MC J-S, Bauer A, Godemann F, FM R, Selig F, Schlattmann R. Negative Symptoms of Schizophrenia Are Improved by the Addition of Paroxetine to Neuroleptics: a Double-Blind Placebo-Controlled Study. International clinical psychopharmacology. 2005;20:27-31.
9485.	MC J-S, Bauer A, Godemann F, FM R, Selig F, Schlattmann R. Negative Symptoms of Schizophrenia Are Improved by the Addition of Paroxetine to Neuroleptics: a Double-Blind Placebo-Controlled Study. International clinical psychopharmacology. 2005;20:27-31.
9486.	MC K. A Randomized, Double-Blind, Placebo-Controlled, 5-Weeks Study of Org-3770 (Mirtazapine) in Major Depression. Human Psychopharmacology-Clinical and Experimental. 1995;10:S119-S124.
9487.	MC K, KJ R, Zatzick D, BO R. Early interventions for PTSD: A review. Depression and anxiety. 2012;29:833-842.
9488.	MC M. Duloxetine - Three birds with one stone? International journal of clinical practice. 2007;61:1247-1248.
9489.	MC M, DH M, Minarzyk A, Schwerdtner I, Quail D, Gross A. Safety and tolerability of duloxetine in the treatment of female stress urinary incontinence (SUI) in general practice in Germany - Results from a large observational study. Neurourology and urodynamics. 2009;Conference:783-784.
9490.	MC M, Ferrara A, Fabiano L, Ricci C, Invernizzi G. A double blind study on fluvoxamine vs. placebo in depressed HIV positive patients: Short-term and perspective results. Integrative psychiatry. 1994;10:199-201.
9491.	MC M, Minarzyk A, Schwerdtner I, Quail D, HD M, HJ W. Observational Study on Safety and Tolerability of Duloxetine in the Treatment of Female Stress Urinary Incontinence in German Routine Practice. British journal of clinical pharmacology. 2013;75:1098-1108.
9492.	Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment, British journal of pharmacology(2012).
9493.	MC S, SL B. The Ethics of Paediatric Anti-Depressant Use: Erring on the Side of Caution. Journal of medical ethics. 2008;34:710-714.
9494.	MC T, KD B, JR A. Enhancing the Developmental Appropriateness of Treatment for Depression in Youth: Integrating the Family in Treatment. Child and adolescent psychiatric clinics of North America. 2012;21:345-384.
9495.	MC Z. Update on pharmacotherapy of borderline personality disorder. Current psychiatry reports. 2004;6:66-70.
9496.	MC Z, FR F, EA P. A Preliminary, Randomized Trial of Fluoxetine, Olanzapine, and the Olanzapine-Fluoxetine Combination in Women With Borderline Personality Disorder. Journal of clinical psychiatry. 2004;65:903-907.
9497.	MC Z, FR F, EA P. A Preliminary, Randomized Trial of Fluoxetine, Olanzapine, and the Olanzapine-Fluoxetine Combination in Women With Borderline Personality Disorder. Journal of clinical psychiatry. 2004;65:903-907.
9498.	Mcardle P. Comments on NICE guidelines for 'Depression in children and young people'. Child and adolescent mental health. 2007;12:66-69.
9499.	McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. British journal of psychiatry. 1998;173:203-208.
9500.	McCabe C, Mishor Z, Filippini N, Cowen PJ, Taylor MJ, Harmer CJ. SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex. Molecular psychiatry. 2011;16:592-594.
9501.	McCabe C, PJ C, CJ H. Neural effects of 7-day anti-depressant treatment on reward. European neuropsychopharmacology. 2009;Conference:S374-S375.
9502.	McCall C, WV M. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Current psychiatry reports. 2012;14:494-502.
9503.	Objective Vs. Subjective Measurements of Sleep in Depressed Insomniacs: First Night Effect or Reverse First Night Effect?, Journal of clinical sleep medicine(2012).
9504.	McCall W, JN B, D'Agostino R, et al. Insomnia predicts suicidal ideation during a depression clinical trial. Sleep. 2010;Conference:A247.
9505.	McCamey K, Evans P. Low Back Pain. Primary Care - Clinics in Office Practice. 2007;34:71-82.
9506.	McCartan D, Bell R, JF G, et al. The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. Journal of psychopharmacology (Oxford, England). 2001;15:96-104.
9507.	Mccleane G. Antidepressants as Analgesics. CNS drugs. 2008;22:139-156.
9508.	McClendon J. Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety. Journal of clinical psychiatry. 2005;66:1494-1495; author reply 1495.
9509.	McCusker J, Cole M, Keller E, Bellavance F, Berard A, Jacoby R. Review: Heterocyclic antidepressants and rational psychological therapies reduce depression in older ambulatory patients. Evidence-based medicine. 1998;3:152.
9510.	Mcdowell D, EV N, AM S, et al. Desipramine Treatment of Cocaine-Dependent Patients With Depression: a Placebo-Controlled Trial. Drug and alcohol dependence. 2005;80:209-221.
9511.	McFarlane A, MV K, EL F, Malcolm V, Cherian F, Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American heart journal. 2001;142:617-623.
9512.	McGauran N, Wieseler B, Kreis J, Schuler Y, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials. 2010.
9513.	McGechan A, Wellington K. Ramelteon. CNS drugs. 2005;19:1057-1065.
9514.	McGeough E, Pollock A, LN S, et al. Interventions for post-stroke fatigue. Cochrane database of systematic reviews (Online). 2009.
9515.	McGown A, Whitbread J. Out of control! the most effective way to help the binge-eating patient. Journal of psychosocial nursing and mental health services. 1996;34:30-37.
9516.	McIntyre J, MaA M. Augmentation in treatment-resistant depression. Drugs of the future. 2006;31:1069-1081.
9517.	McIntyre J, MaA M. Initial findings on lamotrigine as augmentation strategy in treatment-resistant depression. Drug news & perspectives. 2006;19:427-430.
9518.	McKeage K. Aripiprazole: A review of its use in the treatment of manic episodes in adolescents with bipolar i disorder. CNS drugs. 2014;28:171-183.
9519.	McKendrick J, KH C, Lloyd A, D'Ausilio A, Dando S, Chinn C. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. Journal of psychopharmacology (Oxford, England). 2007;21:588-596.
9520.	McLean S. Do substance P and the NK1 receptor have a role in depression and anxiety? Current pharmaceutical design. 2005;11:1529-1547.
9521.	McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: A literature review. CNS spectrums. 2008;13:501-510.
9522.	McNeil C. Cancer fatigue: One drug fails but more are in the pipeline. Journal of the National Cancer Institute. 2001;93:892-893.
9523.	McNicol A, SJ I. Platelets and anti-platelet therapy. Journal of pharmacological sciences. 2003;93:381-396.
9524.	McRobbie H, Lee M, Juniper Z. Non-nicotine pharmacotherapies for smoking cessation. Respiratory medicine. 2005;99:1203-1212.
9525.	McSweeney K, Jeffreys A, Griffith J, Plakiotis C, Kharsas R, DW OC. Specialist mental health consultation for depression in Australian aged care residents with dementia: A cluster randomized trial. International journal of geriatric psychiatry. 2012;27:1163-1171.
9526.	McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs. 1990;39:136-153.
9527.	MD L, JD S, AM H, DK F. Indiplon in the management of insomnia. Drug design, development and therapy. 2009:131-142.
9528.	MD L, Malphurs J, Prieto S, SanJuan-Horvath M, MA S. 10 Assessment of psychiatric disorders among older adults with diabetes mellitus. Clinical geriatrics. 2006.
9529.	MD M. Using interpersonal therapy (IPT) with older adults today and tomorrow: A review of the literature and new developments. Current psychiatry reports. 2008;10:16-22.
9530.	MD M, Adamo D, Schiavone V, MG R, Fortuna G. Burning Mouth Syndrome Responsive to Duloxetine: a Case Report. Pain medicine (Malden, Mass.). 2011;12:466-469.
9531.	MD M, AE N. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: A systematic review of placebo-controlled studies. Expert review of neurotherapeutics. 2010;10:1285-1293.
9532.	MD M, LA P, SP C. Burning mouth syndrome. [Spanish]. Dermatologia Revista Mexicana. 2002;46:164-170.
9533.	MD M, RR W, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. American journal of psychiatry. 1990;147:876-881.
9534.	MD M, SL L, Manatunga A, et al. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: Symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology. 2012;37:1444-1454.
9535.	MD S. Maintaining good morale in old age. Western journal of medicine. 1997;167:276-284.
9536.	MD S, BJ A, DA S, et al. Reductions in HIV risk behaviors among depressed drug injectors. American journal of drug and alcohol abuse. 2005;31:417-432.
9537.	MD S, DA S, DS H, et al. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users.[Erratum appears in Arch Gen Psychiatry. 2005 Feb;62(2):224]. Archives of general psychiatry. 2004;61:152-159.
9538.	MD S, DA S, DS H, et al. Pharmacotherapy Plus Psychotherapy for Treatment of Depression in Active Injection Drug Users. Archives of general psychiatry. 2004;61:152-159.
9539.	MD S, DS H, DA S, et al. Adherence to treatment of depression in active injection drug users: the minerva study. Journal of substance abuse treatment. 2004;26:87-93.
9540.	MD S, JP R. Antidepressant and Anticonvulsant Medication for Chronic Pain. Physical medicine and rehabilitation clinics of North America. 2006;17:381-400.
9541.	MD S, Leach A. Looking beyond myocardial ischemia in chest pain treatment. Pain. 2011;152:707-708.
9542.	MD S, RT S, JL D. Tinnitus: Current understanding and contemporary management. Current opinion in otolaryngology & head and neck surgery. 2010;18:363-368.
9543.	MD S, WJ K, JE R, et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. Journal of the American Board of Family Practice / American Board of Family Practice. 2003;16:22-31.
9544.	MD S, WJ K, JE R, et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. Journal of the American Board of Family Practice. 2003;16:22-31.
9545.	MD VD, Burger H, Teede H, Bone K. Vitex agnus-castus extracts for female reproductive disorders: A systematic review of clinical trials. Planta medica. 2013;79:562-575.
9546.	MD W. Drug treatment of premature ejaculation: Pharmacodynamic and pharmacokinetic paradigms. Drug discovery today. Therapeutic strategies. 2005;2:37-40.
9547.	MD W. Premature ejaculation: Definition and drug treatment. Drugs. 2007;67:547-568.
9548.	MD W. Pharmacotherapy for Bipolar disorder. U.S. 2007;Pharmacist:26-32.
9549.	MD W, AH Z, Olivier B. Antidepressants and ejaculation: A double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. Journal of clinical psychopharmacology. 2003;23:467-470.
9550.	MD W, HHG B, DH S. Treatment of Hot Flushes With Mirtazapine: Four Case Reports. Maturitas. 2000;36:165-168.
9551.	MD W, Wasdell M, KD G, Greenfield B, Hechtman L, Gibbins C. Clinical correlates of oppositional defiant disorder and attention-deficit/hyperactivity disorder in adults. Postgraduate medicine. 2011;123:177-184.
9552.	MD Z, AV R, Griffiths J, Merali Z, Anisman H. Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. Journal of affective disorders. 2000;58:1-10.
9553.	ME C, Cuestas E. [Approximate entropy of the placebo effect in clinical trials of newer antidepressants]. [Spanish]. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina). 2010;67:141-149.
9554.	ME C-R, JR S, JG K, SP R. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. International journal of geriatric psychiatry. 2012;27:777-784.
9555.	ME DJ, NI G, JB R, AD A. Open-label zonisamide for refractory migraine. Clinical neuropharmacology. 2004;27:278-280.
9556.	ME DM, MC M. Obesity. [Portuguese]. Revista brasileira de medicina. 2009;66:100-108.
9557.	ME E. Depression in elderly physically ill inpatients: A 12-month prospective study. International journal of geriatric psychiatry. 1993;8:587-592.
9558.	ME F. Seeing the complexities: A comment on "combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis". Clinical Psychology: Science and Practice. 2005;12:87-91.
9559.	ME F, HB S. Combining pharmacotherapy and exposure plus ritual prevention for obsessive compulsive disorder: Research findings and clinical applications. Journal of cognitive psychotherapy. 2005;19:317-330.
9560.	ME F, MJ K, LA C, ME C, AA R, EB F. Cognitive-Behavioral Treatment of Pediatric Obsessive-Compulsive Disorder: an Open Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:412-419.
9561.	ME G, BL S. Use of Trazodone as an Adjunctive Agent in the Treatment of Canine Anxiety Disorders: 56 Cases (1995-2007). Javma-Journal of the American Veterinary Medical Association. 2008;233:1902-1907.
9562.	ME H, BT S, TL B, ML C. Duloxetine Hydrochloride: a New Dual-Acting Medication for the Treatment of Major Depressive Disorder. Clinical therapeutics. 2005;27:1126-1143.
9563.	ME H, Martinez-Fong D, Perez-Tapia M, Estrada-Garcia I, Estrada-Parra S, Pavon L. Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder. European neuropsychopharmacology. 2010;20:88-95.
9564.	ME H, PM F, CG J, et al. Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: A [11C]SB207145 PET study. Molecular psychiatry. 2014;19:427-432.
9565.	ME J, MCG VDH, JI UDH, et al. Augmentation strategies to improve treatment of major depression. Central nervous system agents in medicinal chemistry. 2006;6:135-152.
9566.	ME K, AR F, HS M, PE H. The Illness Density Index (IDI): A longitudinal measure of treatment efficacy. Clinical trials (London, England). 2012;9:596-604.
9567.	ME L, JM B, RD E, AD H, SW C, RN G. The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects. Biological psychiatry. 1999;45:238-240.
9568.	ME O, Suppes T. Methyltestosterone Add-on in Bipolar Depression: a Case Report. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2009;19:S166-S167.
9569.	ME P, Vaidya V, LT D, et al. Sertraline for the treatment of depression in Alzheimer disease: genetic influences.[Erratum appears in J Geriatr Psychiatry Neurol. 2012 Sep;25(3):188 Note: Dimitri, Avramopoulos [corrected to Avramopoulos, Dimitri]]. Journal of geriatric psychiatry and neurology. 2011;24:222-228.
9570.	ME P, Vaidya V, LT D, et al. Sertraline for the treatment of depression in Alzheimer's disease: Genetic influences. American journal of geriatric psychiatry. 2011;Conference:S67-S68.
9571.	ME T. Long-term treatments of recurrent depressive disorders. Journal of clinical psychiatry. 1992;53:32-44.
9572.	ME T. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. Journal of clinical psychiatry. 1998;59:502-508.
9573.	ME T. Neuroimaging profiles and the differential therapies of depression. Archives of general psychiatry. 2001;58:651-653.
9574.	ME T. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. American journal of managed care. 2001;7:S377-S385.
9575.	ME T. The Need for Clinically Relevant Research on Treatment-Resistant Depression. Journal of clinical psychiatry. 2001;62:221-224.
9576.	ME T. Studying new antidepressants: If there were a light at the end of the tunnel, could we see it? Journal of clinical psychiatry. 2002;63:24-28.
9577.	ME T. What role do atypical antipsychotic drugs have in treatment-resistant depression?. [Review] [84 refs]. Journal of clinical psychiatry. 2002;63:95-103.
9578.	ME T. Evaluating Antidepressant Therapies: Remission as the Optimal Outcome. Journal of clinical psychiatry. 2003;64:18-25.
9579.	ME T. Effectiveness of antidepressants: comparative remission rates. [Review] [40 refs]. Journal of clinical psychiatry. 2003;64 Suppl 2:3-7.
9580.	ME T. Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence. CNS spectrums. 2004;9:808-821.
9581.	ME T. The failure of evidence-based medicine to guide treatment of antidepressant nonresponders. Journal of clinical psychiatry. 2006;67:1833-1835.
9582.	ME T. Treatment of anxiety disorders with venlafaxine XR. Expert review of neurotherapeutics. 2006;6:269-282.
9583.	ME T. Pharmacotherapy of bipolar depression: An update. Current psychiatry reports. 2006;8:478-488.
9584.	ME T. Managing depressive and anxiety disorders with escitalopram. [Review] [78 refs]. Expert opinion on pharmacotherapy. 2006;7:429-440.
9585.	ME T. Bipolar depression: Diagnostic and treatment considerations. Development and psychopathology. 2006;18:1213-1230.
9586.	ME T. Introduction: New directions in the treatment of atypical depression. Journal of clinical psychiatry. 2007;68:4-7.
9587.	ME T. New Directions in the Treatment of Atypical Depression - Introduction. Journal of clinical psychiatry. 2007;68:4-7.
9588.	ME T. STEP-BD and bipolar depression: What have we learned? Current psychiatry reports. 2007;9:497-503.
9589.	ME T. Selecting appropriate treatments for maintenance therapy for bipolar disorder. Journal of clinical psychiatry. 2008;69:28-35.
9590.	ME T. Are SNRIs more effective than SSRIs? A review of the current state of the controversy. [Review]. Psychopharmacology bulletin. 2008;41:58-85.
9591.	ME T. Update on partial response in depression. [Review] [20 refs]. Journal of clinical psychiatry. 2009;70 Suppl 6:4-9.
9592.	ME T. Augmentation Strategies. CNS spectrums. 2009;14:7-10.
9593.	ME T. Does concomitant antidepressant therapy enhance response to electroconvulsive therapy? Current psychiatry reports. 2009;11:423-425.
9594.	ME T. Atypical depression: Useful concept, but it's time to revise the dsm-iv criteria. Neuropsychopharmacology. 2009;34:2633-2641.
9595.	ME T. No evidence for switching antidepressants in treatment-resistant depressed patients. Evidence-based medicine. 2010;15:120-121.
9596.	ME T. The small specific effects of antidepressants in clinical trials: What do they mean to psychiatrists? Current psychiatry reports. 2011;13:476-482.
9597.	ME T. Applying antidepressant study results to clinical practice. Journal of clinical psychiatry. 2012;73:e21.
9598.	ME T. The multifactorial presentation of depression in acute care. Journal of clinical psychiatry. 2013;74:3-8.
9599.	ME T. Antidepressant Combinations: Cutting Edge Psychopharmacology or Passing Fad? Current psychiatry reports. 2013;15.
9600.	ME T. Antidepressant combinations: Cutting edge psychopharmacology or passing fad? Topical collection on mood disorders. Current psychiatry reports. 2013.
9601.	ME T. Using biomarkers to predict treatment response in major depressive disorder: Evidence from past and present studies. Dialogues in clinical neuroscience. 2014;16:539-544.
9602.	ME T, AA N, MB K, Panagides J, Group RPS. Efficacy of mirtazapine for prevention of depressive relapse: A placebo-controlled double-blind trial of recently remitted high-risk patients. Journal of clinical psychiatry. 2001;62:782-788.
9603.	ME T, AH C, BR H, AH T, JG M, JA J. A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. Journal of clinical psychopharmacology. 2006;26:482-488.
9604.	ME T, AJ R, MH R, et al. Fluoxetine Not Found to Increase Suicidality Over Placebo During Treatment of Adults With Minor Depressive Disorder. Biological psychiatry. 2005;57:191S.
9605.	ME T, AJ R, MH R, et al. Fluoxetine Not Found to Increase Suicidality Over Placebo During Treatment of Adults With Minor Depressive Disorder. Biological psychiatry. 2005;57:191S.
9606.	ME T, BR H, Richard N, et al. Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors: a Meta-Analysis of Original Data From 7 Randomized Controlled Trials. Journal of clinical psychiatry. 2005;66:974-981.
9607.	ME T, BR H, Richard N, et al. Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors: a Meta-Analysis of Original Data From 7 Randomized Controlled Trials. Journal of clinical psychiatry. 2005;66:974-981.
9608.	ME T, Demyttenaere K, WR E, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: Analysis in patients with anxious depression. Depression and anxiety. 2012;29:574-586.
9609.	ME T, Denko T. Pharmacotherapy of Mood Disorders.4:53-+.
9610.	ME T, Entsuah R, RL R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. [Italian]. Italian Journal of Psychopathology. 2002;8:362-369.
9611.	ME T, ES F, RH H. Is depression-focused psychotherapy just an elaborate placebo? Economics of Neuroscience. 2001;3:52-61.
9612.	ME T, Fava M, DeBattista C, Arora S, RJ H. The Authors respond [2]. CNS spectrums. 2006;11:340-341.
9613.	ME T, Fava M, Debattista C, Arora S, RJ H. Modafinil Augmentation of Ssri Therapy in Patients With Major Depressive Disorder and Excessive Sleepiness and Fatigue: a 12-Week, Open-Label, Extension Study. CNS spectrums. 2006;11:93-102.
9614.	ME T, Fava M, Zimmerman M, Culpepper L. Review of the pharmacologic management of depression. Journal of clinical psychiatry. 2006;67:478-489.
9615.	Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: A pooled analysis, Current medical research and opinion(2015).
9616.	ME T, GS S. Bipolar depression: pharmacotherapy and related therapeutic strategies. [Review] [121 refs]. Biological psychiatry. 2000;48:558-572.
9617.	ME T, IM S, JD C. Comorbid Alcoholism and Depression: Treatment Issues. Journal of clinical psychiatry. 2001;62:32-41.
9618.	ME T, JM Z, CN G, UA S, TL S. Using what we have: Combining medications to achieve remission. Clinical Neuropsychiatry. 2011;8:4-27.
9619.	ME T, KG L, Reines E, SH K. The cardiovascular safety profile of escitalopram. European neuropsychopharmacology. 2013;23:1391-1400.
9620.	Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies, Primary care companion to the Journal of clinical psychiatry(2008).
9621.	ME T, Montgomery S, GI P, et al. Quetiapine Xr Monotherapy in Major Depressive Disorder: a Pooled Analysis to Assess the Influence of Baseline Severity on Efficacy. International clinical psychopharmacology. 2013;28:113-120.
9622.	ME T, Murck H, Post A. Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: A review. Primary care companion to the Journal of clinical psychiatry. 2010.
9623.	ME T, PT N. New goals in the treatment of depression: moving toward recovery. [Review] [38 refs]. Psychopharmacology bulletin. 2002;36 Suppl 2:24-35.
9624.	ME T, PT N, JJ M, MH T. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: A randomized, open-label study. Primary care companion to the Journal of clinical psychiatry. 2011;13:e1-e9.
9625.	ME T, PV T, Wiltse C, BA P, Mallinckrodt C, MJ D. Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine. Journal of clinical psychopharmacology. 2005;25:132-140.
9626.	ME T, RE R, Curry E, Runfola C, WH K. Management of bulimia nervosa. Women's Health. 2007;3:255-265.
9627.	ME T, SG K, JM G, Jiang Q, Guico-Pabia C, PT N. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. [Review] [34 refs]. CNS spectrums. 2009;14:144-154.
9628.	ME T, Trivedi M. Optimizing treatment outcomes for patients with depression and generalized anxiety disorder. [Review] [35 refs]. Psychopharmacology bulletin. 2002;36 Suppl 2:93-102.
9629.	MEA A, MA S, Marsh L, et al. Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: a clinical review. [Review]. Journal of Parkinsons Disease Print. 2012;2:135-151.
9630.	Meana M, KT B, VK B. When women hurt in mind and body: Managing depression and physical symptoms. Primary psychiatry. 2004;11:1-11.
9631.	MEC VE, Avorn J, AJ P, A DB. Reducing prescribing of highly anticholinergic antidepressants for elderly people: Randomised trial of group versus individual academic detailing. British medical journal. 2001;322:654-657.
9632.	Medawar C. The antidepressant web. International journal of risk & safety in medicine. 1997;10:75-126.
9633.	Meera N, O BT, Prakash M. Review of olanzapine in the management of bipolar disorders. Neuropsychiatric disease and treatment. 2007;3:579-587.
9634.	Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: Getting to remission, Journal of clinical psychiatry(2009).
9635.	Meesters Y, MJ R, WA N. Is it acceptable to use placebos in depression research?. [Dutch]. Tijdschrift voor psychiatrie. 2010;52:575-582.
9636.	Megumi S, Kazumi K, Tomoyuki K, Atsuko O, Shin-Ichi T, Nobuyuki T. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. International journal of neuroscience. 2002;112:1173-1181.
9637.	MEH H, Einarson A, Koren G, KL L, TR E. Antidepressant Use During Pregnancy and the Rates of Spontaneous Abortions: a Meta-Analysis. Annals of pharmacotherapy. 2005;39:803-809.
9638.	MEH H, Einarson A, Koren G, KL L, TR E. Antidepressant Use During Pregnancy and the Rates of Spontaneous Abortions: a Meta-Analysis. Annals of pharmacotherapy. 2005;39:803-809.
9639.	MEH H, Kasper S, Walter E, TR E. Cost-Effectiveness Analysis of Escitalopram: a New Ssri in the First-Line Treatment of Major Depressive Disorder in Austria. Current medical research and opinion. 2004;20:869-878.
9640.	MEH H, Kasper S, Walter E, TR E. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.[Erratum appears in Ann Pharmacother. 2004 Sep;38(9):1545]. Annals of pharmacotherapy. 2004;38:954-960.
9641.	MEH H, Kasper S, Walter E, TR E. Cost-Effectiveness Analysis of Escitalopram: a New Ssri in the First-Line Treatment of Major Depressive Disorder in Austria. Current medical research and opinion. 2004;20:869-878.
9642.	Mehler-Wex C, Kolch M. Depression in children and adolescents. [German]. Deutsches Arzteblatt. 2008;105:149-155.
9643.	Mehler-Wex C, Kolch M. Depression in Children and Adolescents. Deutsches Arzteblatt international. 2008;105:149-U149.
9644.	Mehta S, Lobo L, Salter K, Teasell R. Post stroke depression symptoms: Therapeutic interventions initiated more than six months post-stroke. Archives of physical medicine and rehabilitation. 2012;Conference:E35.
9645.	Mehta S, Pereira S, Janzen S, McIntyre A, McClure A, RW T. Effectiveness of psychological interventions in chronic stage of stroke: A systematic review. Topics in stroke rehabilitation. 2012;19:536-544.
9646.	Meier G, R VM, BT P. Cost-effectiveness of quetiapine extended release versus paroxetine and lithium in acute bipolar depression. Value in health. 2009;Conference:A359-A360.
9647.	Meijer A, Roseman M, VC D, et al. Effects of screening for psychological distress on patient outcomes in cancer: A systematic review. Journal of psychosomatic research. 2013;75:1-17.
9648.	Meijer A, Zuidersma M, P dJ. Depression as a non-causal variable risk marker in coronary heart disease. BMC medicine. 2013.
9649.	Meir S, Marilyn K, John L, Annette W. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacology bulletin. 1997;33:771-774.
9650.	Meir S, Susanne S, Donna S, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. New England journal of medicine. 1995;332:1529-1534.
9651.	Melander H, Salmonson T, Abadie E, B vZ-B. A regulatory Apologia - A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. European neuropsychopharmacology. 2008;18:623-627.
9652.	Melong J, Gardner D. Women with depression should be offered folic acid. Canadian Family Physician. 2011;57:993-995.
9653.	Meltzer H, Bastani B, Jayathilake K, Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology. 1997;17:1-11.
9654.	Meltzer-Brody S, Churchill E, JRT D. Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. Psychiatry research. 1999;88:63-70.
9655.	Menard G, Allain H, Beneton C, J-M NG. Use of MAOIs in the treatment of depression epidemiological survey on prescription of antidepressants. [French]. Psychologie medicale. 1992;24:1550-1554.
9656.	Mencacci C, Aguglia E, Biggio G, et al. C-QUALITY: Cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia. ClinicoEconomics and outcomes research. 2013;5:611-621.
9657.	Mencacci C, Riva M, Buffa G, et al. Depression and anxiety disorders. A retrospective and comparative evaluation of cases and treatments. [Italian]. Quaderni Italiani di Psichiatria. 2007;26:70-77.
9658.	Menchetti M, Bortolotti B, Rucci P, Scocco P, Bombi A, Berardi D. Depression in Primary care: Interpersonal Counseling vs Selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design. BMC psychiatry. 2010.
9659.	Menchetti M, Rucci P, Bortolotti B, et al. Moderators of remission with interpersonal counselling or drug treatment in primary care patients with depression: Randomised controlled trial. British journal of psychiatry. 2014;204:144-150.
9660.	Mendels J. Clinical experience with serotonin reuptake inhibiting antidepressants. Journal of clinical psychiatry. 1987;48:26-30.
9661.	Mendels J. Clinical Management of the Depressed Geriatric-Patient - Current Therapeutic Options. American journal of medicine. 1993;94:S13-S18.
9662.	Mendels J, Kiev A, LF F. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depression and anxiety. 1999;9:54-60.
9663.	Mendels J, Reimherr F, RN M, DL R, RJ F, SF A. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Journal of clinical psychiatry. 1995;56:30-36.
9664.	Mendis S, Rickards H, AE C. Causes and consequences of depression in multiple sclerosis. Progress in neurology and psychiatry. 2010;14:11-17.
9665.	Mendlewicz J. Efficacy of fluvoxamine in severe depression. Drugs. 1992;43:32-39.
9666.	Mendlewicz J. Efficacy of fluvoxamine in severe depression. [Review] [10 refs]. Drugs. 1992;43 Suppl 2:32-39.
9667.	Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. [Review] [17 refs]. International clinical psychopharmacology. 1995;10 Suppl 2:5-13.
9668.	Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. International clinical psychopharmacology. 1995;10:5-13.
9669.	Mendlewicz J. Predicting Response: Serotonin Reuptake Inhibition. International clinical psychopharmacology. 1999;14:S17-S20.
9670.	Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. Antidepressants and ABCB1 gene C3435T functional polymorphism: A naturalistic study. Neuropsychobiology. 2010;62:193-197.
9671.	A controlled trial of antidepressants in patients with Parkinson disease and depression, Neurology(2009).
9672.	Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: The impact on anxiety, disability, and cognition. Journal of neuropsychiatry and clinical neurosciences. 2004;16:315-319.
9673.	The Impact of Treatment of Depression on Quality of Life, Disability and Relapse in Patients With Parkinson's Disease, Movement disorders(2009).
9674.	Menza M, RD D, Marin H. Treatment of depression in parkinson's disease. Current psychiatry reports. 2006;8:234-240.
9675.	Meoni P, Hackett D, Lader M. Pooled Analysis of Venlafaxine Xr Efficacy on Somatic and Psychic Symptoms of Anxiety in Patients With Generalized Anxiety Disorder. Depression and anxiety. 2004;19:127-132.
9676.	Meoni P, Hackett D, Lader M. Pooled Analysis of Venlafaxine Xr Efficacy on Somatic and Psychic Symptoms of Anxiety in Patients With Generalized Anxiety Disorder. Depression and anxiety. 2004;19:127-132.
9677.	Mercer D. Medications in the treatment of borderline personality disorder 2006. Current psychiatry reports. 2007;9:53-62.
9678.	Mercer D, AB D, PS L. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of personality disorders. 2009;23:156-174.
9679.	Mercier C, Bret P, M-C B, Queuille E. Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing. [French]. Encephale. 2009;35:321-329.
9680.	Merens W, AJ WVdD, Spinhoven P. The effects of serotonin manipulations on emotional information processing and mood. Journal of affective disorders. 2007;103:43-62.
9681.	Mergl R, Henkel V, A-K A, et al. Are treatment preferences relevant for response to serotonergic antidepressants and cognitive-behavioural therapy in depressed primary care patients. European psychiatry.
9682.	Mergl R, Pogarell O, Juckel G, et al. Hand-motor dysfunction in depression: characteristics and pharmacological effects. Clinical EEG and neuroscience. 2007;38:82-88.
9683.	Merideth C, AJ C, She F, Eriksson H. Efficacy and Tolerability of Extended Release Quetiapine Fumarate Monotherapy in the Acute Treatment of Generalized Anxiety Disorder: a Randomized, Placebo Controlled and Active-Controlled Study. International clinical psychopharmacology. 2012;27:40-54.
9684.	Merims D, Freedman M. Cognitive and behavioural impairment in Parkinson's disease. International review of psychiatry. 2008;20:364-373.
9685.	Merkl A, Heuser I, Bajbouj M. Antidepressant electroconvulsive therapy: Mechanism of action, recent advances and limitations. Experimental neurology. 2009;219:20-26.
9686.	Merlo J, Gullberg B, C VB. Controlled withdrawal of selective serotonin reuptake inhibitors in elderly patients in nursing homes with no indication of depression - A commentary [4] (multiple letters). European journal of clinical pharmacology. 2005;61:321-326.
9687.	Merlo-Pich E, Gomeni R. Model-Based Approach and Signal Detection Theory to Evaluate the Performance of Recruitment Centers in Clinical Trials With Antidepressant Drugs. Clinical pharmacology and therapeutics. 2008;84:378-384.
9688.	Merlo-Pich E, RC A, Fava M, Gomeni R. A New population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clinical pharmacology and therapeutics. 2010;88:634-642.
9689.	Merskey H. The neuropsychopharmacology of neuropathic pain. Pain research & management. 2006;11:3A-4A.
9690.	Mertens C, Pintens H. Paroxetine in the treatment of depression: A double-blind multicenter study versus mianserin. Acta psychiatrica Scandinavica. 1988;77:683-688.
9691.	Mertens C, Pintens H. A double-blind, multicentre study of paroxetine and mianserin in depression. Acta psychiatrica Scandinavica. Supplementum. 1989;350:140.
9692.	Mertens C, Pintens H. A double-blind, multicentre study of paroxetine and mianserin in depression. Acta Psychiatrica Scandinavica, Supplement. 1989;80:140.
9693.	Messer T, Schnitker J, Friede M. Meta-analysis of placebo-controlled clinical trials with escitalopram and agomelatine. [German]. Psychopharmakotherapie. 2012;19:18-24.
9694.	Mestre T, Ferreira J, MM C, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane database of systematic reviews (Online). 2009.
9695.	Meszaros K, Jiresch M. Sertraline: A new antidepressant in the treatment of depression and obsessive-compulsive disorder. [German]. Neuropsychiatrie. 1996;10:177-182.
9696.	Metin O, Yazici K, Tot S, AE Y. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: An open trial. Human psychopharmacology. 2003;18:463-467.
9697.	Mewton L, Andrews G. Cognitive Behaviour Therapy Via the Internet for Depression: a Useful Strategy to Reduce Suicidal Ideation. Journal of affective disorders. 2015;170:78-84.
9698.	Meynen G, DF S. Why medication in involuntary treatment may be less effective: The placebo/nocebo effect. Medical hypotheses. 2011;77:993-995.
9699.	Meza E, HR K. Closing the gap between alcoholism research and practice: The case for pharmacotherapy. Psychiatric services (Washington, D.C.). 1996;47:917-920.
9700.	MF B, Bassetti R, Colombo A, et al. Intravenous augmentation in resistant Major Depressive Episode: Preliminary results in a naturalistic study. European neuropsychopharmacology. 2008;Conference:S309.
9701.	MF D, CH H, HH H, GH B, GG H. Pediatric indications for deep brain stimulation. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2012;28:1701-1714.
9702.	MF F, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. International journal of neuropsychopharmacology. 2012;15:189-207.
9703.	MF F, Lane R. Acute antidepressant response to fluoxetine and sertraline in psychiatric outpatients with psychomotor agitation. International journal of psychiatry in clinical practice. 2001;5:103-109.
9704.	MF F, RM L, Zhu R, Ying Z. Predictors of an Acute Antidepressant Response to Fluoxetine and Sertraline. International clinical psychopharmacology. 1999;14:259-275.
9705.	MF G, JG K, SP E, et al. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial. Journal of clinical psychiatry. 2013;74:872-879.
9706.	MF G, SP E, Duan N, AK B, MA O, J JM. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology. 2012;37:697-706.
9707.	MF J, AJ C, CM P. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. [Portuguese]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2004;26:189-201.
9708.	MF J, CS G, Berk M, PS B-D-A. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): Case series. Journal of psychopharmacology (Oxford, England). 2009;23:985-987.
9709.	MF J, EA Y, JC S. Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors. Future neurology. 2009;4:87-102.
9710.	MF K. Neuropsychiatric sequelae of stroke and traumatic brain injury: The role of psychostimulants. International journal of psychiatry in medicine. 1995;25:39-51.
9711.	MF P. [The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine]. [French]. L'Enc�phale. 1999;25 Spec No:55-61.
9712.	MF P. The concept of resistant depression and therapeutic strategies, particularly with venlafaxine. [French]. Encephale. 1999;25:55-57.
9713.	MF P. The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine. [French]. Encephale. 1999;25 Spec No:55-5761.
9714.	MF P, Gourion D, JP O. Daily treatment of patients with major depressive disorder: An exploratory study evaluating milnacipran and venlafaxine. European neuropsychopharmacology. 2009;Conference:S419.
9715.	MF P, NC B. Venlafaxine-associated tinnitus. American journal of health-system pharmacy. 2009;66:1606+1608.
9716.	MF T. Pharmacotherapy of Affective Disorders in Old Age. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1997;42:S10-S18.
9717.	MF W. Treatment of behavioral/psychological symptoms in Alzheimer's disease. Expert review of neurotherapeutics. 2001;1:70-80.
9718.	MF Z, AS D. Nonsteroidal selective androgen receptor modulator OstarineTM in cancer cachexia. Future oncology (London, England). 2009;5:1211-1220.
9719.	MFDS T, CVW B, FRDB C, SMDC T, MF J. Effectiveness of psychoeducation for depression: A systematic review. Australian and New Zealand journal of psychiatry. 2013;47:1019-1031.
9720.	MG A, CA F, Hollway J, LE A. Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders. Child and adolescent psychiatric clinics of North America. 2008;17:713-738.
9721.	MG A, LE A, SC A. Review of Serotonergic Agents and Perseverative Behavior in Patients With Developmental Disabilities. Mental retardation and developmental disabilities research reviews. 1999;5:279-289.
9722.	MG C, KM B, Preti A. Gabaergic Neuroactive Steroids: a New Frontier in Bipolar Disorders? Behavioral and brain functions. 2012;8.
9723.	MG C, LM E, McCusker J, Bellavance F, Mansour A. Feasibility and effectiveness of treatments for depression in elderly medical inpatients: a systematic review. International Psychogeriatrics. 2000;12:453-461.
9724.	MG C, Petretto D, Adamo S, et al. Counseling in primary care improves depression and quality of life. Clinical practice and epidemiology in mental health. 2012;8:152-157.
9725.	MG C, Zairo F, Mellino G, MC H. Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage. Clinical practice and epidemiology in mental health. 2007.
9726.	MG F, SE H, WJ B, DR J. Clinical Response Augments Nk Cell Activity Independent of Treatment Modality: a Randomized Double-Blind Placebo Controlled Antidepressant Trial. Psychological medicine. 2004;34:491-498.
9727.	MG H, Benfield P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. [Review] [122 refs]. Drugs & aging. 1995;6:64-84.
9728.	MG H, EW S, KB S, Passchier J, Kragh-Soerensen P, Group DUA. Are Gender Differences Important for the Clinical Effects of Antidepressants? [References]. American journal of psychiatry. 2003;160:1643-1650.
9729.	MG K, GN E, EJ B. Generalized anxiety disorder: Practical assessment and management. American family physician. 2009;79:785-791.
9730.	MG L, Clark A. Curvaceous model of recovery from depression. Lancet. 1997;349:447.
9731.	MG L, HM L. New antidepressants for old people? British medical journal. 1999;318:1640-1641.
9732.	MG O. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug safety. 2011;34:733-754.
9733.	MG R, Hara C, FL R. Duloxetine Treatment of Premenstrual Dysphoric Disorder: Case Reports. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:579-580.
9734.	MG R, Hara C, FL R. Duloxetine Treatment for Women With Premenstrual Dysphoric Disorder: a Single-Blind Trial. International journal of neuropsychopharmacology. 2009;12:1081-1088.
9735.	MG S, ID K. A 64-year-old man with low-risk prostate cancer: Review of prostate cancer treatment. JAMA - Journal of the American Medical Association. 2009;301:2141-2151.
9736.	MG S-d-S, VV D, Missio G, et al. Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). Experimental and therapeutic medicine. 2015;9:643-652.
9737.	MG U, EY M, NM M, OP V. Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action. Human psychopharmacology. 2006;21:109-115.
9738.	MG U, NM M, EIu M, OP V. [Dynamics of biochemical parameters in patients with anxious depression treated with serotonergic antidepressants with different mechanisms of action]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 2008;Korsakova.:38-43.
9739.	MG W, MB K. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. Journal of clinical psychiatry. 1996;57:158-166.
9740.	MH A, Izadi A, MR H, et al. Effect of etomidate versus thiopental on major depressive disorder in electroconvulsive therapy, a randomized double-blind controlled clinical trial. Journal of ECT. 2012;28:10-13.
9741.	MH B. Emerging treatment for Tourette's disorder. Current psychiatry reports. 2008;10:323-330.
9742.	MH B, Green C, SA K, et al. Long-term outcome in adults with obsessive-compulsive disorder. Depression and anxiety. 2013;30:716-722.
9743.	MH B, Issari Y, Jakubovski E. Meta-analysis: Response curve to SSRIs in OCD. Neuropsychopharmacology. 2013;Conference:S525-S526.
9744.	MH B, Mcguire J, Landeros-Weisenberger A, JF L, Pittenger C. Meta-Analysis of the Dose-Response Relationship of Ssri in Obsessive-Compulsive Disorder. Molecular psychiatry. 2010;15:850-855.
9745.	MH C, AQ D, CE W, RJ R, DL E. Comparison of Pramipexole, Fluoxetine, and Placebo in Patients With Major Depression. Depression and anxiety. 2000;11:58-65.
9746.	MH C, HH C, PW G, YK Y, PS C. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term treatment response to fluoxetine or venlafaxine in major depressive disorder. International journal of neuropsychopharmacology. 2010;Conference:202-203.
9747.	MH D, DQ L, Han Y. [Effect of venlafaxine on cognitive function and hippocampal brain-derived neurotrophic factor expression in rats with post-stroke depression]. [Chinese]. Zhejiang da xue xue bao. 2011;Yi xue ban:527-534.
9748.	MH DG, JPCM VC, MA M, LR T, JH B, CJC L. The effects of fall-risk-increasing drugs on postural control: A literature review. Drugs & aging. 2013;30:901-920.
9749.	MH G, Richter J, Sennewald R, Guserle R, Renner J, Martin W. Bioavailability Investigation of Two Different Oral Formulations of Citalopram, a So-Called 'second Generation' Antidepressant Drug. Arzneimittel-Forschung-Drug Research. 2005;55:730-737.
9750.	MH G, Richter J, Sennewald R, Guserle R, Renner J, Martin W. Bioavailability Investigation of Two Different Oral Formulations of Citalopram, a So-Called 'second Generation' Antidepressant Drug. Arzneimittel-Forschung-Drug Research. 2005;55:730-737.
9751.	MH L. Tolerability and safety: Essentials in antidepressant pharmacotherapy. Journal of clinical psychiatry. 1996;57:39-44.
9752.	MH M, RA L. Treatment of premenstrual complaints. [Norwegian]. Tidsskrift for den Norske laegeforening. 2004;124:1933-1934.
9753.	MH O, LM F, DW M. Weight changes on fluoxetine as a function of baseline weight in depressed outpatients. Psychopharmacology bulletin. 1990;26:327-330.
9754.	MH P. Optimizing Pharmacotherapy of Generalized Anxiety Disorder to Achieve Remission. Journal of clinical psychiatry. 2001;62:20-25.
9755.	MH P. Comorbidity, Neurobiology, and Pharmacotherapy of Social Anxiety Disorder. Journal of clinical psychiatry. 2001;62:24-29.
9756.	MH P, Allgulander C, Bandelow B, et al. WCA Recommendations for the Long-Term Treatment of Panic Disorder. CNS spectrums. 2003;8:17-30.
9757.	MH P, Endicott J, Liebowitz M, et al. Examining Quality of Life in Patients With Generalized Anxiety Disorder: Clinical Relevance and Response to Duloxetine Treatment. Journal of psychiatric research. 2008;42:1042-1049.
9758.	MH P, III WJJ, MW O, et al. Venlafaxine for panic disorder: Results from a double-blind, placebo- controlled study. Psychopharmacology bulletin. 1996;32:667-670.
9759.	MH P, Lepola U, Koponen H, et al. A Double-Blind Study of the Efficacy of Venlafaxine Extended-Release, Paroxetine, and Placebo in the Treatment of Panic Disorder. Depression and anxiety. 2007;24:1-14.
9760.	MH P, Meoni P, MW O, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: A pooled analysis of short- and long-term studies. Journal of clinical psychopharmacology. 2003;23:250-259.
9761.	MH P, MH R, CM C, Mardekian J, Wolkow R. Sertraline Treatment of Panic Disorder: Response in Patients at Risk for Poor Outcome. Journal of clinical psychiatry. 2000;61:922-927.
9762.	MH P, NM S, AK Z, et al. Olanzapine Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: a Placebo Controlled Study. Biological psychiatry. 2006;59:211-215.
9763.	MH P, PC M. Panic: Course, Complications and Treatment of Panic Disorder. Journal of psychopharmacology (Oxford, England). 2000;14:S25-S30.
9764.	MH P, PC M. Pharmacotherapeutic options in the treatment of comorbid depression and anxiety. CNS spectrums. 2000;5:23-30.
9765.	MH P, PP R-B, M VA, et al. The Selective Gaba Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder: Results of a Placebo-Controlled Study. Journal of clinical psychiatry. 2005;66:1401-1408.
9766.	MH P, SG K, ME S, Crits-Christoph P, Raskin J, JM R. Early Improvement During Duloxetine Treatment of Generalized Anxiety Disorder Predicts Response and Remission at Endpoint. Journal of psychiatric research. 2008;42:1176-1184.
9767.	MH P, Tiller J, Xie F, MH T. Tiagabine in Adult Patients With Generalized Anxiety Disorder - Results From 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies. Journal of clinical psychopharmacology. 2008;28:308-316.
9768.	MH P, Zaninelli R, Goddard A, et al. Paroxetine in the Treatment of Generalized Anxiety Disorder: Results of a Placebo-Controlled, Flexible-Dosage Trial. Journal of clinical psychiatry. 2001;62:350-357.
9769.	MH R. Translating the evidence on atypical depression into clinical practice. Journal of clinical psychiatry. 2007;68:31-36.
9770.	MH R, Bose A, HJ Z. Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes. Journal of clinical psychiatry. 2004;65:44-49.
9771.	MH R, Clary C, Fayyad R, Endicott J. Quality-of-Life Impairment in Depressive and Anxiety Disorders. American journal of psychiatry. 2005;162:1171-1178.
9772.	MH R, Clary C, Fayyad R, Endicott J. Quality-of-Life Impairment in Depressive and Anxiety Disorders. American journal of psychiatry. 2005;162:1171-1178.
9773.	MH R, GM G, CM C, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.[Erratum appears in Neuropsychopharmacology. 2007 May;32(5):1208], [Erratum appears in Neuropsychoph. Neuropsychopharmacology. 2006;31:2505-2513.
9774.	MH R, JP B. Randomized clinical stroke trials in 2006. Current vascular pharmacology. 2008;6:61-66.
9775.	MH R, LL J. Minor Depressive Disorder and Subsyndromal Depressive Symptoms: Functional Impairment and Response to Treatment. Journal of affective disorders. 1998;48:227-232.
9776.	MH R, LS S, DL D, JT D, CD P. Efficacy of controlled-release paroxetine in the treatment of late-life depression. Journal of clinical psychiatry. 2003;64:1065-1074.
9777.	MH R, RE M. Challenges in the development of clinical trials for major depressive disorder: Lessons learned from trials in minor depression. Dialogues in clinical neuroscience. 2002;4:402-407.
9778.	MH S. Insomnia. CONTINUUM Lifelong Learning in Neurology. 2007;13:85-100.
9779.	MH T, AA P, AJ C, et al. Efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with major depressive disorder treated with an antidepressant. International journal of neuropsychopharmacology. 2012;Conference:192-193.
9780.	MH T, AJ R, BN G, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32:2479-2489.
9781.	MH T, AJ R, J-Y P, TJ C. Which Depressed Patients Respond to Nefazodone and When? Journal of clinical psychiatry. 2001;62:158-163.
9782.	MH T, BA K. Using treatment algorithms for the effective management of treatment-resistant depression. [Review] [22 refs]. Journal of clinical psychiatry. 2001;62 Suppl 1:25-29.
9783.	MH T, BA K. Algorithm for the Treatment of Chronic Depression. Journal of clinical psychiatry. 2001;62:22-29.
9784.	Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: A pooled analysis of four randomized acute studies, International journal of neuropsychopharmacology(2013).
9785.	MH T, BT K, BD G. Clinical predictors in major depressive disorder. Primary psychiatry. 2007;14:47-53.
9786.	MH T, CA G, JO C. Antidepressant drugs and the emergence of suicidal tendencies. [Review] [163 refs]. Drug safety. 1993;8:186-212.
9787.	MH T, Desaiah D, MJ O, YL P, SK B, MJ D. Clinical Evidence for Serotonin and Norepinephrine Reuptake Inhibition of Duloxetine. International clinical psychopharmacology. 2008;23:161-169.
9788.	MH T, DW M, BD G, Mahadi S. Symptom Clusters as Predictors of Late Response to Antidepressant Treatment. Journal of clinical psychiatry. 2005;66:1064-+.
9789.	MH T, DW M, BD G, Mahadi S. Symptom Clusters as Predictors of Late Response to Antidepressant Treatment. Journal of clinical psychiatry. 2005;66:1064-+.
9790.	MH T, EJ C. The therapeutic potential of escitalopram in the treatment of panic disorder. Neuropsychiatric disease and treatment. 2007;3:835-838.
9791.	MH T, Fava M, LB M, DN O, RC S. Use of Treatment Algorithms for Depression. Journal of clinical psychiatry. 2006;67:1458-1465.
9792.	Medication Augmentation after the Failure of SSRIs for Depression, New England journal of medicine(2006).
9793.	MH T, GJ W, Mallick R, et al. Cost and Effectiveness of Venlafaxine Extended-Release and Selective Serotonin Reuptake Inhibitors in the Acute Phase of Outpatient Treatment for Major Depressive Disorder. Journal of clinical psychopharmacology. 2004;24:497-506.
9794.	Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features, Journal of clinical psychiatry(2008).
9795.	MH T, Orsel S, EN I, Akdemir A, EZ K, MH O. Moclobemide and sertraline in the treatment of melancholic and nonmelancholic major depression: A comparative study. Human psychopharmacology. 1998;13:21-27.
9796.	MH T, Richards C, PD H, et al. Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on level of executive function impairment. Biological psychiatry. 2013;Conference:49S.
9797.	MH T, Rush J. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994;11:33-43.
9798.	MH T, SM B. Clinical Significance of Monitoring Early Symptom Change to Predict Outcome. Journal of clinical psychiatry. 2001;62:27-33.
9799.	MH T, TA P, Perera P, KE D, ML C, CD P. Effectiveness of Low Doses of Paroxetine Controlled Release in the Treatment of Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:1356-1364.
9800.	MH T, TL G. Exercise in the treatment of depression. Current psychiatry reports. 2009;11:466-472.
9801.	MH T, TL G. Cognitive dysfunction in unipolar depression: Implications for treatment. Journal of affective disorders. 2014;152-154:19-27.
9802.	Exercise as an augmentation treatment for nonremitted major depressive disorder: A randomized, parallel dose comparison, Journal of clinical psychiatry(2011).
9803.	MH T, WJ K, Daly E, AH C, Frank E. Recent advances in the treatment of depression in the presence of physical symptoms. Journal of clinical psychiatry. 2006;67:310-321.
9804.	MH W. Antidepressants for the Treatment of Insomnia a Suitable Approach? Drugs. 2008;68:2411-2417.
9805.	MH W, Galanakis P, Schreiner R. Nefazodone in Primary Insomnia: an Open Pilot Study. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28:1071-1078.
9806.	MH W, Galanakis P, Schreiner R. Nefazodone in Primary Insomnia: an Open Pilot Study. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28:1071-1078.
9807.	MHN C, LH dM, JAS C. Pharmacotherapy treatment of depression in patients with neurodegenerative diseases: Where are we? Arquivos de neuro-psiquiatria. 2012;70:559-563.
9808.	MI R, JR S. Psychosocial assessment and intervention in cardiac rehabilitation. Physical medicine and rehabilitation clinics of North America. 1995;6:173-189.
9809.	MI S, MB S, SW A, Siziya S. Fluoxetine and moclobemide versus amitriptyline in major depression: A single blind randomized clinical trial in Zimbabwe. Central African journal of medicine. 1997;43:38-40.
9810.	MI W, Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. [Review] [116 refs][Erratum appears in Drugs 1995 Jul;50(1):156]. Drugs. 1995;49:411-439.
9811.	MI W, GL P, Benfield P. Fluvoxamine - an Updated Review of Its Pharmacology, and Therapeutic Use in Depressive-Illness. Drugs. 1993;46:895-924.
9812.	Miao Y, Ai Q, X-D C. Effect of blood-letting puncture at hand twelve Jing-acupoints on the behaviour, interleukin-1 beta and interleukin-6 in the plasma of depression rats. [Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research. 2007;11:7161-7164.
9813.	Micallef J, Fakra E, Blin O. Use of antidepressant drugs in schizophrenic patients with depression. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2006;32:263-269.
9814.	Micallef J, Fakra E, Blin O. [Use of antidepressant drugs in schizophrenic patients with depression]. [Review] [43 refs] [French]. Encephale. 2006;32:263-269.
9815.	Micallef J, Fakra E, Blin O. Use of Antidepressant Drugs in Schizophrenic Patients With Depression. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2006;32:263-269.
9816.	Michael B, A BJ, Steve H, et al. Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosomatic medicine. 2000;62:633-638.
9817.	Michael B, A BJ, Steve H, et al. Exercise treatment for major depression: Maintenance of therapeutic benefit. 2007:529-540.
9818.	Michael B, B LN, Bruce S, et al. Fluoxetine in depressed patients on dialysis. International journal of psychiatry in medicine. 1997;27:71-80.
9819.	Michael B, Maud G, Verena L, M GG, A HE, J HC. Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety. Neuropsychopharmacology. 2011;36:2689-2697.
9820.	Michael B, Puvan T, Hans-Peter V, Hans-Juergen M, Nick F. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression : AAA meta-analysis. European archives of psychiatry and clinical neuroscience. 2009;259:172-185.
9821.	Michael B, Rocco Z, Bruno M-O, Wolfgang M. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: A double-blind study. Journal of clinical psychopharmacology. 1999;19:164-171.
9822.	Michael BR, H KS, R SD, et al. Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: A retrospective analysis. Journal of affective disorders. 1997;45:161-166.
9823.	Michael D, Carolin O-R, Ion A. Escitalopram, problem-solving therapy, and poststroke depression. JAMA: Journal of the American Medical Association. 2008;300:1757.
9824.	Michael D, Dusan H-P, Doug A, Tania P. New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence?. [Review] [107 refs]. Australian and New Zealand journal of psychiatry. 2008;42:456-466.
9825.	Michael F. Treatment of mild depression in elderly patients. JAMA: Journal of the American Medical Association. 2000;284:2993.
9826.	Michael F, -H HvZH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry. 2001;34:S38-S41.
9827.	Michael M, Eric V, Roger D. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of affective disorders. 1996;41:201-210.
9828.	Michael M, Herman W, Eric V, et al. Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. Journal of clinical psychopharmacology. 1997;17:358-364.
9829.	Michael M, Isabelle L, Fran vH, Dirk C, Y MH. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. Journal of clinical psychopharmacology. 1999;19:177-182.
9830.	Michael M, Isabelle L, Laure D, et al. Changes in platelet alpha-2-adrenoceptors in fibromyalgia: Effects of treatment with antidepressants. Neuropsychobiology. 1999;40:129-133.
9831.	Michael M, Libbrecht I, F VH, et al. Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychological medicine. 1998;28:957-965.
9832.	A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode, International clinical psychopharmacology(2012).
9833.	Acute and long-term treatment of late-life major depressive disorder: Duloxetine versus placebo, The American Journal of Geriatric Psychiatry(2014).
9834.	Michael S. "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women": Erratum. Journal of sexual medicine. 2011;8:2954.
9835.	Michael T, A NC, L DR. Fluoxetine and dothiepin therapy in primary care and health resource utilization: Evidence from the United Kingdom. International journal of psychiatry in clinical practice. 1999;3:23-30.
9836.	Michel D, Luigi R, Renzo R, Alain M. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in neuro-psychopharmacology & biological psychiatry. 1996;20:57-71.
9837.	Michele M, G WA, Giulio P, Alan L-S, Alexander S. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. Journal of psychiatric research. 2014;51:21-29.
9838.	Michele M, V SD, Koen D, et al. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan Disability Scale: Pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. International clinical psychopharmacology. 2012;27:298-309.
9839.	Michelson D, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. American journal of psychiatry. 2000;157:239-243.
9840.	Michelson D, Fava M, Amsterdam J, et al. Interruption of Selective Serotonin Reuptake Inhibitor Treatment - Double-Blind, Placebo-Controlled Trial. British journal of psychiatry. 2000;176:363-368.
9841.	Michelson D, JD A, FM Q, et al. Changes in Weight During a 1-Year Trial of Fluoxetine. American journal of psychiatry. 1999;156:1170-1176.
9842.	Michelson D, Kociban K, Tamura R, MF M. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: A randomized, placebo controlled trial. Journal of psychiatric research. 2002;36:147-152.
9843.	Michelson D, Lydiard B, MH P, et al. Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo. American journal of psychiatry. 1998;155:1570-1577.
9844.	Michelson D, Pollack M, RB L, Tamura R, Tepner R, Tollefson G. Continuing Treatment of Panic Disorder After Acute Response: Randomised, Placebo-Controlled Trial With Fluoxetine. British journal of psychiatry. 1999;174:213-218.
9845.	Michl M, Schnopfhagen K, RM B. Pridopidine in the pharmacological treatment of Huntington's disease. Clinical investigation. 2013;3:691-699.
9846.	Mickael L, Michiel H, Clement F, Bengt J. A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Primary Care Psychiatry. 2004;9:153-161.
9847.	Mico U, Bruno A, Pandolfo G, et al. Duloxetine as Adjunctive Treatment to Clozapine in Patients With Schizophrenia: a Randomized, Placebo-Controlled Trial. International clinical psychopharmacology. 2011;26:303-310.
9848.	Migone P. Real efficacy of antidepressant drugs in psychiatric practice. [Italian]. Psicoterapia e Scienze Umane. 2005;39:312-322.
9849.	Miguel E, Diniz J, Joaquim M, et al. Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared with sustained fluoxetinetreatment. Neuropsychopharmacology. 2010;Conference:S281-S282.
9850.	Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and Immunological Basis of Action of Antidepressants in Chronic Pain - Clinical and Experimental Studies. Pharmacological Reports. 2013;65:1611-1621.
9851.	Mikael L, Elias E, Hans A, Tom F. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. Journal of clinical psychopharmacology. 1999;19:268-271.
9852.	Mikael L, Goran B, Hans A, Tom F. A randomized, double-blind, placebo-controlled trial of busiprone in combination with an SSRI in patients with treatment-refractory depression. Journal of clinical psychiatry. 1998;59:664-668.
9853.	Mikael L, Helena E, Finn B, Bjorn A, Elias E. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Neuropsychopharmacology. 2009;34:585-592.
9854.	Mikael L, Per H, E TM. Incidence of Sexual Side Effects in Refractory Depression During Treatment With Citalopram or Paroxetine. Journal of clinical psychiatry. 2005;66:100-106.
9855.	Mikami K, Matsumoto H. Childhood and adolescent depression. [Japanese]. Nihon rinsho [Japanese journal of clinical medicine]. 2007;Japanese j:1679-1683.
9856.	Mikami K, Matsumoto H. [Childhood and adolescent depression]. [Review] [19 refs] [Japanese]. Nippon Rinsho - Japanese Journal of Clinical Medicine. 2007;65:1679-1683.
9857.	Mikami K, RE J, DJ M, et al. Prevention of poststroke apathy using escitalopram or problem-solving therapy. American journal of geriatric psychiatry. 2013;21:855-862.
9858.	Increased Frequency of First-Episode Poststroke Depression After Discontinuation of Escitalopram, Stroke; a journal of cerebral circulation(2011).
9859.	Mikami K, RE J, DJ M, et al. Prevention of Post-Stroke Generalized Anxiety Disorder, Using Escitalopram or Problem-Solving Therapy. Journal of neuropsychiatry and clinical neurosciences. 2014;26:323-328.
9860.	Mikami K, RE J, HPJr A, et al. Effect of Antidepressants on the Course of Disability Following Stroke. American journal of geriatric psychiatry. 2011;19:1007-1015.
9861.	The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: A randomized, double-blind, placebo-controlled study, Journal of clinical psychiatry(2012).
9862.	Miklosova Z, Kucerova J, Amchova P, Sulcova A. The effect of paroxetine on intravenous self-administration of methamphetamine in an animal model of depression. European neuropsychopharmacology. 2013;Conference:S570.
9863.	Milana Z, B RKC, G PA. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: A meta-analysis. Human Psychopharmacology: Clinical and Experimental. 1995;10:S135-S145.
9864.	Milano W, M DR, Milano L, Riccio A, Capasso A. Pharmacotherapy in Anorexia Nervosa: An overview. Current Neurobiology. 2013;4:25-29.
9865.	Tibetan sound meditation for cognitive dysfunction: Results of a randomized controlled pilot trial, Psycho-oncology(2013).
9866.	Milev R, Abraham G, Zaheer J. Add-on quetiapine for bipolar depression: A 12-month open-label trial. Canadian Journal of Psychiatry. 2006;51:523-530.
9867.	Milin R, Walker S, Chow J. Major Depressive Disorder in Adolescence: A Brief Review of the Recent Treatment Literature. Canadian Journal of Psychiatry. 2003;48:600-606.
9868.	Miller A, Rabe-Jablonska J. The efficacy of antidepressants in the treatment of chronic noncancer pain - A review. [Polish]. Psychiatria polska. 2005;39:21-32.
9869.	Miller L, MA R. Venlafaxine extended release in pediatric anxiety and depression. Pediatric health. 2008;2:279-288.
9870.	Miller M, Pate V, SA S, Azrael D, White A, Sturmer T. Antidepressant class, age, and the risk of deliberate self-harm: A propensity score matched cohort study of SSRI and SNRI users in the USA. CNS drugs. 2014;28:79-88.
9871.	Miller M, SA S, Azrael D, Pate V, Sturmer T. Antidepressant Dose, Age, and the Risk of Deliberate Self-Harm. Jama Internal Medicine. 2014;174:899-909.
9872.	Miller M, Zisook S, Iglewicz A, JF K. Treatment strategies for intense, prolonged or complicated grieving. American journal of geriatric psychiatry. 2013;Conference:S37-S38.
9873.	Miller SM, Naylor GJ, Murtagh M, Winslow G. A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta neurologica Scandinavica. 1989;80:143-144.
9874.	Millet B. Use of ISRS (serotonin uptake inhibitor) and IRSNA (serotonin noradrenaline reuptake inhibitor) in anxiety-depression. [French]. Encephale. 2007;33:S699-S700.
9875.	Millet B. Contribution of the Isrs and Irsna in Anxiodepression. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2007;33:S699-S700.
9876.	Millet B. Role of Escitalopram in Severe Depressive Episodes. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2008;34:S111-S114.
9877.	Millet B. [The place of escitalopram in the severe depressive episodes]. [French]. Encephale. 2008;34 Suppl 3:S111-114.
9878.	Millet B. Escitalopram versus SNRIs (serotonin-noradrenaline reuptake inhibitors). [French]. Encephale. 2008;34:280-283.
9879.	Millet B. Escitalopram versus IRSNa. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2008;34:280-283.
9880.	Millet B. The role of escitalopram in severe depressive episodes. [French]. Encephale. 2008;34:S111-S114.
9881.	Millet B. [Escitalopram versus serotonin reuptake inhibitors]. [French]. Encephale. 2008;34:280-283.
9882.	Millet B, Touitou Y, MF P, et al. Obsessive-Compulsive Disorder: Evaluation of Clinical and Biological Circadian Parameters During Fluoxetine Treatment. Psychopharmacology. 1999;146:268-274.
9883.	Mimica N, Presecki P. Side effects of approved antidementives. Psychiatria Danubina. 2009;21:108-113.
9884.	Mimica N, Uzun S, Folneoovic-Smalc V, Markan-Sosic V, Ljubin T. Sertraline: A novel antidepressant with broad treatment spectrum. Periodicum Biologorum. 2001;103:301-308.
9885.	Minako H, Kunihiro I, Branko A, Norio O. What is a rational antidepressant treatment for major depression in patients with parkinson's disease? [References]. Psychiatry and clinical neurosciences. 2012;66:463.
9886.	Ming X, Gordon E, Kang N, GC W. Use of clonidine in children with autism spectrum disorders. Brain & development. 2008;30:454-460.
9887.	Miniati M, Rucci P, Benvenuti A, et al. Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse. Journal of psychiatric research. 2010;44:302-309.
9888.	Miniati M, Rucci P, Frank E, et al. Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version. Psychotherapy and psychosomatics. 2009;78:116-124.
9889.	Miniati M, Rucci P, Frank E, et al. Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version. Psychotherapy and psychosomatics. 2009;78:116-124.
9890.	Minichino A, FS B, WK C, et al. Smoking behaviour and mental health disorders-mutual influences and implications for therapy. International journal of environmental research and public health. 2013;10:4790-4811.
9891.	Minkel J, AD K. Optimizing the pharmacologic treatment of insomnia: Current status and future horizons. Sleep medicine clinics. 2013;8:333-350.
9892.	Improving outcome after stroke: Time to treat new targets, Stroke; a journal of cerebral circulation(2012).
9893.	Mintzer J, DF M. Anticholinergic effects of common pharmacological treatments in the elderly. International Journal of Geriatric Psychopharmacology. 2000;2:153-158.
9894.	Mintzes B, Jureidini J. Should paroxetine be used to treat depression during pregnancy? American journal of psychiatry. 2008;165:1487; author reply 1487-1488.
9895.	Minuzzi L, BN F, GB H, et al. Antidepressant effects on brain activation during the emotional conflict task in perimenopausal women: A functional MRI study. Menopause (New York, N.Y.). 2011;Conference:1371.
9896.	Miodownik C, Bergman J, PP L, Kreinin A, Lerner V. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: Retrospective case series. Clinical neuropharmacology. 2015;38:26-29.
9897.	Miozzo R, Tisminetzky M. Preventive antidepressant use in patients with hepatitis C treated with interferon-alfa: A systematic review. Current psychiatry reviews. 2013;9:331-341.
9898.	Miranda J, Siddique J, Belin T, et al. One-year outcomes of a randomized clinical trial treating depression in low-income minority women. Journal of consulting and clinical psychology. 2006;74:99-111.
9899.	Miro J, Vujic D, Henigsberg N, Aleksandrovsky Y, Faltus F, Szelenberger W. Central-east European study of fluoxetine (SSRI) and maprotiline (NRI) in major depressive episode. Psychiatria Danubina. 1998;10:287-292.
9900.	Mischoulon D. Update and Critique of Natural Remedies as Antidepressant Treatments. Obstetrics and gynecology clinics of North America. 2009;36:789-807.
9901.	Mischoulon D, KT E, Keshaviah A, et al. Depression and Eating Disorders: Treatment and Course. Journal of affective disorders. 2011;130:470-477.
9902.	Mischoulon D, Lamon-Fava S, Selhub J, et al. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS spectrums. 2012;17:76-86.
9903.	A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder, Journal of clinical psychiatry(2014).
9904.	Mischoulon D, LH P, LL C, et al. A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl-L-Methionine (Same) Versus Escitalopram in Major Depressive Disorder. Journal of clinical psychiatry. 2014;75:370-U133.
9905.	Mischoulon D, LH P, LL C, AR T, GI P, Fava M. Failed Studies Should Not Be Used to Malign Good Treatments Reply. Journal of clinical psychiatry. 2014;75:E1328-E1329.
9906.	Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: A controlled study. Bipolar disorders. 2003;5:464-467.
9907.	Mishra S, Jena M, Pal A. Evaluation of antidepressant activity of Eclipta alba using animal models. Asian Journal of Pharmaceutical and Clinical Research. 2013;6:118-120.
9908.	Misri S, Reebye P, Corral M, Milis L. The Use of Paroxetine and Cognitive-Behavioral Therapy in Postpartum Depression and Anxiety: a Randomized Controlled Trial. Journal of clinical psychiatry. 2004;65:1236-1241.
9909.	Mitch P. To the editor. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:364.
9910.	Mittal D, Chekuri L, LY L, JC F. Demographic, Economic, and Clinical Correlates of Depression Treatment Response in an Underserved Primary Care Population. Journal of clinical psychiatry. 2014;75:848-854.
9911.	Mittal D, JC F, JM P, JL W. Predictors of Persistence of Comorbid Generalized Anxiety Disorder Among Veterans With Major Depressive Disorder. Journal of clinical psychiatry. 2011;72:1445-1451.
9912.	Mittal M, Pasnoor M, RB M, et al. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. International journal of neuroscience. 2011;121:521-527.
9913.	Mitte K, Noack P, Steil R, Hautzinger M. A Meta-Analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder. Journal of clinical psychopharmacology. 2005;25:141-150.
9914.	Mitte K, Noack P, Steil R, Hautzinger M. A Meta-Analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder. Journal of clinical psychopharmacology. 2005;25:141-150.
9915.	Mittur A. Trazodone: Properties and utility in multiple disorders. Expert review of clinical pharmacology. 2011;4:181-196.
9916.	Miura S. Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes: Double-blind, Parallel Group Study with amitriptyline HCl. [Japanese]. Japanese Pharmacology and Therapeutics. 2000;28:S187-S210.
9917.	Miyata S, Hirano S, Kamei J. Diabetes Attenuates the Antidepressant-Like Effect Mediated by the Activation of 5-Ht1a Receptor in the Mouse Tail Suspension Test. Neuropsychopharmacology. 2004;29:461-469.
9918.	Miyata S, Hirano S, Kamei J. Diabetes Attenuates the Antidepressant-Like Effect Mediated by the Activation of 5-Ht1a Receptor in the Mouse Tail Suspension Test. Neuropsychopharmacology. 2004;29:461-469.
9919.	Mizukami K, Hatanaka K, Tanaka Y, Sato S, Asada T. Therapeutic Effects of the Selective Serotonin Noradrenaline Reuptake Inhibitor Milnacipran on Depressive Symptoms in Patients With Alzheimer's Disease. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:349-352.
9920.	Mizukami K, Tanaka Y, Asada T. Efficacy of Milnacipran on the Depressive State in Patients With Alzheimer's Disease. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:1342-1346.
9921.	MJ B. Pharmacological Treatment of Depression - Consulting With Dr Oscar. Canadian Family Physician. 1999;45:2663-2668.
9922.	MJ B, RL R, GJ E, PE S, TW C, Kroenke K. Impact of Pain on Depression Treatment Response in Primary Care. Psychosomatic medicine. 2004;66:17-22.
9923.	MJ C, Clark L, JP R, et al. Converging evidence for central 5-HT effects in acute tryptophan depletion. Molecular psychiatry. 2012;17:121-123.
9924.	MJ C, KE F, MM B, et al. Predictors of treatment response for depression and inadequate social support--the ENRICHD randomized clinical trial. Psychotherapy and psychosomatics. 2008;77:27-37.
9925.	MJ C, RP G, HB L. To prevent depression recurrence, interpersonal psychotherapy is a first-line treatment with long-term benefits. Current psychiatry. 2014;13:33-41.
9926.	MJ D, CG W, CH M, RK M, MA D, Bitter I. Duloxetine in the Acute and Long-Term Treatment of Major Depressive Disorder: a Placebo- and Paroxetine-Controlled Trial. European neuropsychopharmacology. 2004;14:457-470.
9927.	MJ D, Gilaberte I, DG P, et al. Duloxetine Vs Placebo in the Prevention of Relapse of Major Depressive Disorder. International journal of neuropsychopharmacology. 2004;7:S175.
9928.	MJ D, Gilaberte I, DG P, et al. Duloxetine Vs Placebo in the Prevention of Relapse of Major Depressive Disorder. International journal of neuropsychopharmacology. 2004;7:S175.
9929.	MJ D, Gilaberte I, DG P, et al. Duloxetine Vs. Placebo in the Prevention of Relapse of Major Depressive Disorder. European psychiatry. 2004;19:214S.
9930.	MJ D, Gilaberte I, DG P, et al. Duloxetine Vs. Placebo in the Prevention of Relapse of Major Depressive Disorder. European psychiatry. 2004;19:214S.
9931.	MJ D, JA G, Petkova E, et al. Cognitive Behavioral Therapy and Fluoxetine as Adjuncts to Group Behavioral Therapy for Binge Eating Disorder. Obesity research. 2005;13:1077-1088.
9932.	MJ D, JA G, Petkova E, et al. Cognitive Behavioral Therapy and Fluoxetine as Adjuncts to Group Behavioral Therapy for Binge Eating Disorder. Obesity research. 2005;13:1077-1088.
9933.	MJ D, JA G, Petkova E, Liu L, BT W. Cognitive Behavioral Therapy and Fluoxetine for Binge Eating Disorder: Two-Year Follow-up. Obesity (Silver Spring, Md.). 2007;15:1702-1709.
9934.	MJ D, MC B, TW H, Jayaseelan D, Moats N, Nava A. Treatment of myofascial pain. Pain management. 2013;3:67-79.
9935.	MJ D, VS A. Evaluating the tolerability of the newer antidepressants. Journal of nervous and mental disease. 1999;187:96-101.
9936.	MJ E, Chavez B. A review of the STAR*D trial. Journal of pharmacy practice. 2006;19:353-360.
9937.	MJ E, GM L. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy. 2006;26:1134-1147.
9938.	MJ F, Baruch P, YD L, Bakish D, Blanchard A. SSRIs in anxious-agitated depression: A post-hoc analysis of 279 patients. International clinical psychopharmacology. 1995;10:51-54.
9939.	MJ F, PJ L, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of clinical oncology. 2003;21:1937-1943.
9940.	MJ F, PJ L, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: A double-blinded trial of the Hoosier Oncology Group. Journal of clinical oncology. 2003;21:1937-1943.
9941.	MJ G. Antidepressants in bipolar depression: Much confusion, many questions, few answers. Australian and New Zealand journal of psychiatry. 2012;46:295-297.
9942.	MJ G, AJ D, Harich S, BA E, Cesura A, Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug discovery today. 2009;14:509-515.
9943.	MJ G, JF G. Do antidepressants reduce the burden imposed by depression on employers? CNS drugs. 2005;19:253-264.
9944.	MJ G, Olfson M. Major Depressive Disorder, Somatic Pain, and Health Care Costs in an Urban Primary Care Practice. Journal of clinical psychiatry. 2006;67:1232-1239.
9945.	MJ H, CH S, SJ C. A review of nighttime eating disorders. Sleep medicine reviews. 2009;13:23-34.
9946.	MJ J, ME S, Fava M, et al. Long-Term Treatment Outcomes of Depression With Associated Anxiety: Efficacy of Continuation Treatment With Fluoxetine. Journal of clinical psychiatry. 2004;65:373-378.
9947.	MJ JC, Moyer M, JP OR. Monoamine oxidase inhibitors: An important but underutilized treatment part II: Safety and tolerability. Psychopharm Review. 2012;47:81-88.
9948.	MJ K, HJ D, MI G, et al. Influence of Antidepressants on Glycaemic Control in Patients With Diabetes Mellitus. Pharmacoepidemiology and drug safety. 2008;17:577-586.
9949.	MJ K, ME H, BDB F, et al. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: A proton magnetic resonance spectroscopic imaging study. Biological psychiatry. 2003;54:534-539.
9950.	MJ L, JT W, MA R. The new antidepressants: Selective serotonin reuptake inhibitors. Pediatric clinics of North America. 1998;45:1137-1155.
9951.	MJ M, Gonzalez P, Muniz J, Bobes J. Sexual Dysfunction in Depressed Patients Undergoing Treatment With Antidepressants. International journal of psychiatry in clinical practice. 2000;4:311-317.
9952.	MJ M, Handem I, Saldana S, Jacobe H, Getachew Y, AJ R. Sertraline as a First-Line Treatment for Cholestatic Pruritus. Hepatology (Baltimore, Md.). 2007;45:666-674.
9953.	MJ M, Saarialho-Kere U, Mattila M. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. Journal of clinical psychiatry. 1988;49 Suppl:52-58.
9954.	MJ M, Tom-Revzon C, OG B, ML C. Changes and challenges: Managing ADHD in a fast-paced world. Journal of managed care pharmacy. 2007;13:S2-S13.
9955.	MJ M, Weston J, Singh J, AG M. Antidepressants for people with epilepsy and depression. [Review]. Cochrane database of systematic reviews (Online). 2014;12:CD010682.
9956.	MJ M, Weston J, Singh J, AG M. Antidepressants for People With Epilepsy and Depression. Cochrane database of systematic reviews (Online). 2014.
9957.	MJ M, Wetzel H, Benkert O. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: An evaluation using confirmatory factor analysis. International clinical psychopharmacology. 2002;17:249-261.
9958.	MJ N, ID H, DA L, CA ZJ, DS C. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: Ketamine and other compounds. Annual review of pharmacology and toxicology. 2014;54:119-139.
9959.	MJ O. The evidence for antidepressant use in bipolar depression. Journal of clinical psychiatry. 2006;67:18-21.
9960.	MJ O. Comorbid Alcohol and Substance Abuse Dependence in Depression: Impact on the Outcome of Antidepressant Treatment. Psychiatric clinics of North America. 2007;30:69-76.
9961.	MJ O. STEP-BD: Lessons learned, outcomes and directions. Biological psychiatry. 2010;Conference:186S.
9962.	MJ O, AE E, CL H, CS B. Milnacipran for the management of fibromyalgia syndrome. Journal of pain research. 2010;3:15-24.
9963.	MJ O, Krulewicz S, JS S, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33:3201-3212.
9964.	MJ P. Are SSRIs really more effective for anxious depression?. [Review] [46 refs]. Annals of clinical psychiatry. 2005;17:23-29.
9965.	MJ P, JL T, CS W, et al. Increase in PAS-induced neuroplasticity after a treatment courseof transcranial direct current stimulation for depression. Journal of affective disorders. 2014;167:140-147.
9966.	MJ P, RM B. Sleep in Mood Disorders. Sleep medicine clinics. 2008;3:231-249.
9967.	MJ R. Do antidepressants improve recovery from neurologic illness? American journal of geriatric psychiatry. 2011;19:985-988.
9968.	MJ R, Ahl J, AL M, BH M, Iyengar S. Management of painful symptoms with duloxetine: A review of the efficacy in pre-clinical and clinical studies. Current drug therapy. 2011;6:121-136.
9969.	MJ R, DL E, DG C, DR G, SD D, JM P. Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals. CNS spectrums. 2003;8:59-63.
9970.	MJ R, JM P. Psychopharmacology in Hiv-Infected Patients. Psychosomatic medicine. 2008;70:585-592.
9971.	MJ R, RB Q. Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatric clinics of North America. 2002;25:149-175.
9972.	MJ R, SE E, Iyengar S, Bymaster F, Clark M, Katon W. Depression and Pain. Frontiers in bioscience. 2009;14:5031-5051.
9973.	MJ R, TO M, Raskin J, Liu P, Shoemaker S, CJ N. Duloxetine versus placebo in the long-term treatment of patients with late-life major depression. American journal of geriatric psychiatry. 2011;Conference:S103-S104.
9974.	MJ R-L. Duloxetine: A new drug for an old problem. [Spanish]. Revista de la Sociedad Espanola del Dolor. 2006;13:1-3.
9975.	MJ RDLT, Roman M. Serotonin-reuptake inhibitor drugs for the tratment of depression. [Spanish]. Revista de la Sociedad Espanola del Dolor. 2006;13:10-20.
9976.	MJ S. New clinical trials target breast cancer. Cancer bulletin (Houston, Tex.). 1991;43:287-288.
9977.	MJ S. Update on sleep and psychiatric disorders. Chest. 2009;135:1370-1379.
9978.	MJ S, Ackenheil M. The role of substance P in depression: Therapeutic implications. Dialogues in clinical neuroscience. 2002;4:21-29.
9979.	MJ S, BJ L. Sleep and cancer: Recent developments. Current oncology reports. 2008;10:309-318.
9980.	MJ T. Strategies for managing antidepressant-induced sexual dysfunction: A review. Current psychiatry reports. 2006;8:431-436.
9981.	MJ T. Rapid onset of true antidepressant action. Current psychiatry reports. 2007;9:475-479.
9982.	MJ T, BR G, Norbury R, Selvaraj S, Near J, PJ C. Early increase in the neuronal marker N-acetyl-aspartate with antidepressant treatment of major depression. European neuropsychopharmacology. 2012;Conference:S265.
9983.	MJ T, Freemantle N, JR G, Bhagwagar Z. Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action - Systematic Review and Meta-Analysis. Archives of general psychiatry. 2006;63:1217-1223.
9984.	MJ T, Norbury R, Murphy S, Rudebeck S, Jezzard P, PJ C. Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. Journal of psychopharmacology (Oxford, England). 2010;24:1217-1221.
9985.	MJ T, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication. Cochrane database of systematic reviews (Online). 2013.
9986.	MJ T, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. [Review] [47 refs]. Journal of affective disorders. 2005;88:241-254.
9987.	MJ T, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biological psychiatry. 2010;68:536-543.
9988.	MJ T, SM C, GM G, JR G. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. [Review] [28 refs]. Journal of psychopharmacology (Oxford, England). 2004;18:251-256.
9989.	MJ VDM, Kenemans P. Postmenopausal hormone therapy: Impact on menopause-related symptoms, chronic disease and quality of life. Drugs. 2004;64:821-836.
9990.	MJAJM H. Inhibition of the enzyme monoamine oxidase (MAO); position of moclobemide (Aurorix). [Dutch]. TGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek. 1993;18:145-150.
9991.	MJC N, Brignone M, Marteau F, JA DB, Hoencamp E. Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical therapeutics. 2012;34:1364-1378.
9992.	MJJ C, Moyer M, JP OR. Monoamine oxidase inhibitors: An important but underutilized treatment. Psychopharm Review. 2012;47:73-79.
9993.	MJM D, LJ S, KL G. Terbinafine: A review of its use in onychomycosis in adults. American journal of clinical dermatology. 2003;4:39-65.
9994.	MJM H, Volz F, JG VM, et al. Using the analytic hierarchy process to elicit patient preferences: Prioritizing multiple outcome measures of antidepressant drug treatment. Patient. 2012;5:225-237.
9995.	MJr BC, C KS, E NM, S GJ. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2000;22:1319-1330.
9996.	MJr BC, G BS, E NM, et al. Fluoxetine and adult suicidality revisited: An updated meta-analysis using expanded data sources from placebo-controlled trials. Journal of clinical psychopharmacology. 2007;27:682-686.
9997.	MJr MG, B HS, E RH, Charlotte K, F SA. Effects of the Serotonin Transporter Gene Promoter Polymorphism on Mirtazapine and Paroxetine Efficacy and Adverse Events in Geriatric Major Depression. Archives of general psychiatry. 2004;61:1163-1169.
9998.	MJr MG, Charlotte K, E RH, F SA. Pharmacogenetics of Antidepressant Medication Intolerance. American journal of psychiatry. 2003;160:1830-1835.
9999.	MK A, Kurz A. Antidepressants for Demented Patients. Zeitschrift fur Gerontologie und Geriatrie. 2000;33:396-400.
10000.	MK A, RW L. Comparative Efficacy of Escitalopram in the Treatment of Major Depressive Disorder. Neuropsychiatric disease and treatment. 2011;7:39-49.
10001.	MK M, DC G, Baer L, Cioffi J, DB H. Dissociation, Childhood Trauma, and the Response to Fluoxetine in Bulimic Patients. International journal of eating disorders. 1994;15:219-226.
10002.	MK N, Nickel C, Lahmann C, et al. Changes in instrumental activities of daily living disability after treatment of depressive symptoms in elderly women with chronic musculoskeletal pain: A double-blind, placebo-controlled trial. Aging clinical and experimental research. 2005;17:293-296.
10003.	MK N, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study. Journal of clinical psychopharmacology. 2005;25:211-217.
10004.	MK O. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochimica et Biophysica Acta - General Subjects. 2010;1800:1136-1144.
10005.	MK O, LV R. Wishing upon a STAR*D: the promise of ideal depression care by primary care providers. Psychiatric services (Washington, D.C.). 2009;60:1460-1462.
10006.	MK R, MJ A, NC S, RR S, JM K, JJ A. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. British journal of clinical practice. 1991;45:255-258.
10007.	MK S, AJW VDD, MA R, et al. Tryptophan Depletion in Ssri-Recovered Depressed Outpatients. Psychopharmacology. 2001;155:123-127.
10008.	MK S, JC P, DH B, RA K, MP D. Medical management of pediatric mood disorders. Pediatric annals. 2007;36:552-563.
10009.	MK S, KD C. The Neural Effects of Psychotropic Medications in Children and Adolescents. Child and adolescent psychiatric clinics of North America. 2012;21:753-771.
10010.	MK S, RM P, GS L, Brandt D, Nolen W. Modification of the Clinical Global Impressions (Cgi) Scale for Use in Bipolar Illness (Bp): the Cgi-Bp. Psychiatry research. 1997;73:159-171.
10011.	MK S, Skritskaya N, Wang Y, et al. Suicide, depression, and complicated grief. Neuropsychopharmacology. 2011;Conference:S358-S359.
10012.	ML B. Bipolar depression. Clinical and therapeutic aspects. [French]. Annales medico-psychologiques. 2001;159:251-260.
10013.	ML B, Engedal K, Laks J, Selbaek G. A 12 months follow-up study of depression among nursing-home patients in Norway. Journal of affective disorders. 2010;120:141-148.
10014.	ML B, Selbaek G, Laks J, Engedal K. Factors associated with depression in Norwegian nursing homes. International journal of geriatric psychiatry. 2009;24:417-425.
10015.	ML B, TR TH, 3rd RCF, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA. 2004;291:1081-1091.
10016.	ML D. Child and Adolescent Depression: Psychotherapeutic, Ethical, and Related Nonpharmacologic Considerations for General Psychiatrists and Others Who Prescribe. Psychiatric clinics of North America. 2012;35:181-201.
10017.	ML F, CA ZJ. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects. Journal of clinical psychiatry. 2013;74:850-851.
10018.	Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?, Journal of clinical psychiatry(2014).
10019.	ML G, Martinez-Mota L, Estrada-Camarena E, Fernandez-Guasti A. Influence of the brain sexual differentiation process on despair and antidepressant-like effect of fluoxetine in the rat forced swim test. Neuroscience. 2014;261:11-22.
10020.	ML H, BY L, JB H, et al. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial. Australian and New Zealand journal of psychiatry. 2012;46:257-264.
10021.	ML H, BY L, JB H, et al. Combination of Citalopram Plus Paliperidone Is Better Than Citalopram Alone in the Treatment of Somatoform Disorder: Results of a 6-Week Randomized Study. International clinical psychopharmacology. 2012;27:151-158.
10022.	ML H, CS A, AO H. Management of Depression After Stroke - a Systematic Review of Pharmacological Therapies. Stroke; a journal of cerebral circulation. 2005;36:1092-1097.
10023.	ML H, CS A, AO H. Management of Depression After Stroke - a Systematic Review of Pharmacological Therapies. Stroke; a journal of cerebral circulation. 2005;36:1092-1097.
10024.	ML H, CS A, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane database of systematic reviews (Online). 2008.
10025.	ML H, CS A, House A, Xia J. Interventions for treating depression after stroke. Cochrane database of systematic reviews (Online). 2008.
10026.	ML H, HP vH, Terluin B, et al. Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial. BMC medicine. 2007;5:36.
10027.	ML H, Xu Y, JB H, et al. [Repetitive transcranial magnetic stimulation combined with antidepressant medication in treatment of first-episode patients with major depression]. [Chinese]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences. 2011;Yi Xue Ban:286-290.
10028.	ML H, Xu Y, JB H, et al. [Repetitive transcranial magnetic stimulation combined with antidepressant medication in treatment of first-episode patients with major depression]. [Chinese]. Zhejiang da xue xue bao. 2011;Yi xue ban:286-290.
10029.	Randomized, controlled trial of Interpersonal and Social Rhythm Therapy for young people with bipolar disorder, Bipolar disorders(2015).
10030.	ML L, Lonnroos E, JS B, Lavikainen P, Sulkava R, Hartikainen S. Use of Antidepressants Among Community-Dwelling Persons With Alzheimer's Disease: a Nationwide Register-Based Study. International Psychogeriatrics. 2015;27:669-672.
10031.	ML M, CS DV, ICK W. A Drug Utilisation Study of Antidepressants in Children and Adolescents Using the General Practice Research Database. Archives of disease in childhood. 2004;89:1098-1102.
10032.	ML M, CS DV, ICK W. A Drug Utilisation Study of Antidepressants in Children and Adolescents Using the General Practice Research Database. Archives of disease in childhood. 2004;89:1098-1102.
10033.	ML M, IA C, AJ R, AF L. Estrogen augmentation of antidepressants in perimenopausal depression: A pilot study. Journal of clinical psychiatry. 2005;66:774-780.
10034.	ML M, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127:e1312-e1321.
10035.	ML N, Spettigue W. How much do we really know about the effectiveness of olanzapine use in patients with anorexia nervosa? Neuropsychiatry. 2012;2:83-85.
10036.	ML P, Feeny N, Zoellner L, DL D. The Impact of Ptsd Treatment on the Cortisol Awakening Response. Depression and anxiety. 2014;31:862-869.
10037.	ML R. Treatment of depression using citalopram with less side-effects. Acta psychiatrica Scandinavica. 1988;77:239.
10038.	ML S, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. Current drug targets. 2013;14:1237-1248.
10039.	Elevated Stress-Hemoconcentration in Major Depression Is Normalized by Antidepressant Treatment: Secondary Analysis From a Randomized, Double-Blind Clinical Trial and Relevance to Cardiovascular Disease Risk, PloS one(2008).
10040.	ML W, Dong C, Esposito K, et al. Elevated stress-hemoconcentration in major depression is normalized by antidepressant treatment: secondary analysis from a randomized, double-blind clinical trial and relevance to cardiovascular disease risk. PLoS ONE [Electronic Resource]. 2008;3:e2350.
10041.	ML W, WS A, RA G. Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments. Behavior therapy. 1999;30:117-135.
10042.	ML Z. Role of atypical antipsychotics in rapid cycling bipolar disorder: A review of the literatures. Annals of clinical psychiatry. 2011;23:141-149.
10043.	ML Z, BL V, Whitney J, et al. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: A retrospective chart review. Journal of child and adolescent psychopharmacology. 2007;17:165-174.
10044.	MLJM vH, Rotter T, Ellermann T, SMAA E. The effectiveness of individual interpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: A systematic review. BMC psychiatry. 2013.
10045.	MLM H, HPJ VH, Terluin B, et al. Clinical Effectiveness of Usual Care With or Without Antidepressant Medication for Primary Care Patients With Minor or Mild-Major Depression: a Randomized Equivalence Trial. BMC medicine. 2007;5.
10046.	MLM VDL, PGH M, Egtm H, et al. Efficacy and Safety of Lamotrigine as Add-on Treatment to Lithium in Bipolar Depression: a Multicenter, Double-Blind, Placebo-Controlled Trial. Journal of clinical psychiatry. 2009;70:223-231.
10047.	MM B. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiatrica Scandinavica, Supplement. 1989;80:138-139.
10048.	MM B. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta psychiatrica Scandinavica. Supplementum. 1989;350:138-139.
10049.	MM B, DA G. Editorial: Antidepressants in the treatment of stroke. Expert review of neurotherapeutics. 2010;10:1237-1241.
10050.	MM B, Lesperance F, Rieckmann N, Clemow L, Skotzko C, KW D. Treating persistent depressive symptoms in post-ACS patients: The project COPES phase-I randomized controlled trial. Contemporary clinical trials. 2008;29:231-240.
10051.	MM B, Soufer R. Psychological Stress and Induced Ischemic Syndromes. Current cardiovascular risk reports. 2014;8:1-6.
10052.	MM C. Agomelatine: A novel antidepressant therapy. Psychopharm Review. 2012;47:89-95.
10053.	MM D. Effects of depressive disorders on coronary artery disease: A review. Harvard review of psychiatry. 1997;5:115-122.
10054.	MM F. Medication for Anorexia and Bulimia-Nervosa - a Review. Der Nervenarzt. 1993;64:21-35.
10055.	MM F, Kruger R, Rief W, Holland R, Dohne J. Fluvoxamine in Prevention of Relapse in Bulimia Nervosa: Effects on Eating-Specific Psychopathology. Journal of clinical psychopharmacology. 1996;16:9-18.
10056.	MM F, Leibl K, Rief W, Brunner E, Schmidtauberger S, RR E. Fluoxetine Versus Placebo - a Double-Blind-Study With Bulimic Inpatients Undergoing Intensive Psychotherapy. Pharmacopsychiatry. 1991;24:1-7.
10057.	MM G. Pharmaceutical approval update. P and T. 2009;34:157-160.
10058.	MM G, Abramowitz W. Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: A single-dose, randomized, crossover study. Clinical therapeutics. 2000;22:1525-1532.
10059.	MM G, ES F, RF H, LP R, ME T. Urinary free cortisol levels among depressed men and women: Differential relationships to age and symptom severity? Archives of women's mental health. 2007;10:73-78.
10060.	MM G, HL E, GJ E, et al. Psychopharmacological treatment for very young children: Contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:1532-1572.
10061.	MM G, RH D, Weise J, LL H. Serum sepsis, not sickness. American journal of the medical sciences. 2011;341:88-91.
10062.	MM H, AJ R, Fink M, et al. Speed of Response and Remission in Major Depressive Disorder With Acute Electroconvulsive Therapy (Ect): a Consortium for Research in Ect (Core) Report. Journal of clinical psychiatry. 2004;65:485-491.
10063.	MM H, AJ R, Fink M, et al. Speed of Response and Remission in Major Depressive Disorder With Acute Electroconvulsive Therapy (Ect): a Consortium for Research in Ect (Core) Report. Journal of clinical psychiatry. 2004;65:485-491.
10064.	Family history of depression and therapeutic outcome: Findings from STAR*D, Journal of clinical psychiatry(2009).
10065.	MM H, Carter R, Mihalopoulos C, et al. Assessing cost-effectiveness - Mental health: Introduction to the study and methods. Australian and New Zealand journal of psychiatry. 2004;38:569-578.
10066.	MM H, Tonge B, Littlefield L, Carter R, Vos T. Cost-Effectiveness of Cognitive Behavioural Therapy and Selective Serotonin Reuptake Inhibitors for Major Depression in Children and Adolescents. Australian and New Zealand journal of psychiatry. 2004;38:579-591.
10067.	MM H, Tonge B, Littlefield L, Carter R, Vos T. Cost-Effectiveness of Cognitive Behavioural Therapy and Selective Serotonin Reuptake Inhibitors for Major Depression in Children and Adolescents. Australian and New Zealand journal of psychiatry. 2004;38:579-591.
10068.	MM K, AL M, Prakash A, PJ G, JP H. Early Symptom Change Prediction of Remission in Depression Treatment. Psychopharmacology bulletin. 2009;42:94-107.
10069.	MM K, Bowden C, Stokes P, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? (multiple letters) [1]. Neuropsychopharmacology. 1997;17:110-115.
10070.	MM K, JL T, CL B, et al. Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression. Neuropsychopharmacology. 2004;29:566-579.
10071.	MM K, JP H, Brannan S, et al. A Video Method for the Evaluation of Antidepressant Clinical and Behavioural Actions. International journal of neuropsychopharmacology. 2006;9:327-336.
10072.	MM L, JS C, Robertson M. Complementary and alternative medicine usage for behavioral health indications. Primary Care - Clinics in Office Practice. 2010;37:213-236.
10073.	MM M. Neurocardiogenic syncope in children: Current concepts in diagnosis and management. Pediatric Drugs. 2003;5:327-334.
10074.	MM O, AV K, AIu E. [Cymbalta in the treatment of chronic pain syndromes]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 2009;Korsakova.:32-34.
10075.	MM P, Avellaneda V, Musselman D, G SJ, Illa L. Treatment of Depression in Individuals Living With Hiv/Aids. Psychosomatics. 2013;54:336-344.
10076.	MM R, Donati R, Fu C, Costafreda S, Liu P, Marangell L. The extent of the incorporation of the G protein, GSA, in lipid raft membrane fractions from erythrocyte membranes may provide a biomarker for major depressive disorder. Neuropsychopharmacology. 2013;Conference:S333-S334.
10077.	MM R, KE P, Martin A, MH B. Time-Lag Bias in Trials of Pediatric Antidepressants: a Systematic Review and Meta-Analysis. Journal of the American Academy of Child and Adolescent Psychiatry. 2011;50:63-72.
10078.	MM S, GM M. Antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Journal of clinical psychiatry. 2011;72:156-167.
10079.	MM S, GM M. Drs Sidor and MacQueen reply. Journal of clinical psychiatry. 2011;72:416.
10080.	MM S, GM M. An Update on Antidepressant Use in Bipolar Depression. Current psychiatry reports. 2012;14:696-704.
10081.	MM S, JL C. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug safety. 2002;25:511-523.
10082.	MM S, MB W, MD F, Pascual-Leone A. Exploration and modulation of brain network interactions with noninvasive brain stimulation in combination with neuroimaging. European journal of neuroscience. 2012;35:805-825.
10083.	MM S, Pascualy M, NL L, Flatness D, RC V. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology. 2001;26:433-439.
10084.	MM W. Social functioning and the treatment of depression. Journal of clinical psychiatry. 2000;61:33-38.
10085.	MM W. Teenaged, depressed, and treatment resistant: What predicts self-harm? American journal of psychiatry. 2009;166:385-387.
10086.	MM W. Treatment of Depression: Men and women are different? American journal of psychiatry. 2014;171:384-387.
10087.	MM W, CG W, Desaiah D, et al. Duloxetine in practice-based clinical settings: Assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study. Primary care companion to the Journal of clinical psychiatry. 2007;9:271-279.
10088.	MM W, CH M, JG W, Prakash A. Duloxetine for the Treatment of Major Depressive Disorder: Safety and Efficacy Associated With Rapid Dose Escalation (60-120 Mg Qd). International journal of neuropsychopharmacology. 2004;7:S174-S175.
10089.	MM W, CH M, JG W, Prakash A. Duloxetine for the Treatment of Major Depressive Disorder: Safety and Efficacy Associated With Rapid Dose Escalation (60-120 Mg Qd). International journal of neuropsychopharmacology. 2004;7:S174-S175.
10090.	MM W, JG W, JS G. Duloxetine's Role in the Treatment of Depression and Associated Painful Physical Symptoms. Journal of clinical psychiatry. 2004;65:1018-1019.
10091.	MM W, JG W, JS G. Duloxetine's Role in the Treatment of Depression and Associated Painful Physical Symptoms. Journal of clinical psychiatry. 2004;65:1018-1019.
10092.	Efficacy of Sertraline in Prevention of Depression Recurrence in Older Versus Younger Adults With Diabetes, Diabetes care(2007).
10093.	MM W, Wickramaratne P, DJ P, et al. Treatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children. American journal of psychiatry. 2015;172:450-459.
10094.	MN K, Wattis J, Curran S. Pharmacological management of behavioural and psychological disturbance in dementia. Human psychopharmacology. 2006;21:1-12.
10095.	MN L, Papelbaum M, AE N. Profile of Agomelatine and Its Potential in the Treatment of Generalized Anxiety Disorder. Neuropsychiatric disease and treatment. 2015;11:1149-1155.
10096.	MN L, Papelbaum M, Nardi A. A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Experimental and clinical psychopharmacology. 2012;20:504-509.
10097.	MN M, CL N, BE M, PG F, RA K, KE F. Variable Dosing of Sertraline for Premenstrual Exacerbation of Depression: a Pilot Study. Journal of women's health (2002). 2008;17:993-997.
10098.	MN P, DB H, Devineni B, JA C, MW N, PG J. A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:859-867.
10099.	Mnie-Filali O, Lambas-Senas L, Scarna H, Haddjeri N. Therapeutic potential of 5-HT7 receptors in mood disorders. Current drug targets. 2009;10:1109-1117.
10100.	MNS K. Comparison of Escitalopram a new SSRI with TCA, clomipramine in major depressive disorder: A double blind study. Pakistan Journal of Medical Sciences. 2004;20:238-241.
10101.	MO G, IL P. Pharmacotherapy for comorbid depression and alcohol dependence. Current psychiatry. 2013;12:25-32.
10102.	Moch S. Analysing antidepressants. SA Pharmaceutical Journal. 2009;76:19-25.
10103.	Moch S. Decisions about depression: Treatment options depend on diagnosis. SA Pharmaceutical Journal. 2010;77:22-33.
10104.	Modabbernia A, Akhondzadeh S. Saffron, Passionflower, Valerian and Sage for Mental Health. Psychiatric clinics of North America. 2013;36:85-91.
10105.	Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: A selective literature review. Hepatitis Monthly. 2013.
10106.	Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: A selective literature review. Hepatitis Monthly. 2013.
10107.	Modabbernia A, Sepanjnia K, Akhondzadeh S. Pioglitazone as an Adjunct to Citalopram for Moderate to Severe Major Depressive Disorder : Randomized Double Blind Placebo-Controlled Trial. International journal of neuropsychopharmacology. 2012;Conference:151.
10108.	Modirrousta M, BH P, BC D. Neuropsychiatric symptoms in primary progressive aphasia: Phenomenology, pathophysiology, and approach to assessment and treatment. Neurodegenerative disease management. 2013;3:133-146.
10109.	Moeller O, Evers S, Deckert J, et al. The Impact of Ziprasidone in Combination With Sertraline on Visually-Evoked Event-Related Potentials in Depressed Patients With Psychotic Features. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:1440-1443.
10110.	Moeller O, Hetzel G, Michael N, Rothermundt M, Arolt V, Erfurth A. Basal Prolactin Values Correlate With Response to Reboxetine Treatment in Major Depression, but Not With Response to Citalopram. Neuropsychobiology. 2005;51:67-71.
10111.	Moeller O, Hetzel G, Rothermundt M, et al. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. Journal of psychiatric research. 2003;37:261-262.
10112.	A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression, Psychological medicine(2008).
10113.	Mogg K, DS B, Brodrick P, BP B. Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology. 2004;176:466-470.
10114.	Mohamed S, RA R. Pharmacotherapy of Ptsd in the Us Department of Veterans Affairs: Diagnostic- and Symptom-Guided Drug Selection. Journal of clinical psychiatry. 2008;69:959-965.
10115.	Mohammad H, Saeed K, Leila J, et al. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. Journal of psychiatric research. 2014;58:109-114.
10116.	Mohammadi M, Akhondzadeh S. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy. Acta medica Iranica. 2011;49:487-498.
10117.	Mohatt J, SM B, JT W. Treatment of separation, generalized, and social anxiety disorders in youths. [Review]. American journal of psychiatry. 2014;171:741-748.
10118.	Mohr P. Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuro endocrinology letters. 2007;28:117-133.
10119.	Mohr P, Anders M, Masopust J. Vortioxetine in treatment of depressive disorder and potential improvement of cognitive functions. [Czech]. Psychiatrie (Stuttgart, Germany). 2014;18:206-211.
10120.	Mohr P, Bitter I, Svestka J, et al. Management of depression in the presence of pain symptoms.[Erratum appears in Psychiatr Danub. 2010 Sep;22(3):476]. Psychiatria Danubina. 2010;22:4-13.
10121.	Mohr P, Bitter I, Svestka J, et al. Management of depression in the presence of pain symptoms. Psychiatria Danubina. 2010;22:4-13.
10122.	Mohsenin V. Narcolepsy-Master of Disguise: Evidence-Based Recommendations for Management. Postgraduate medicine. 2009;121:99-104.
10123.	Moira R, Dineen WK, Craig D, et al. Long-term sertraline treatment of children and adolescents with major depressive disorder. Journal of child and adolescent psychopharmacology. 2006;16:103-116.
10124.	Mokhber N, Abdollahian E, Soltanifar A, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. 2014;47:131-140.
10125.	Mokhber N, MR A, Khajehdaluee M, Velayati A, Hopwood M. Randomized, Single-Blind, Trial of Sertraline and Buspirone for Treatment of Elderly Patients With Generalized Anxiety Disorder. Psychiatry and clinical neurosciences. 2010;64:128-133.
10126.	Mollenhauer B, Wenzel S, Trenkwalder C. Pharmacotherapy of dementia and other neuropsychiatric symptoms in Parkinson disease. [German]. Zeitschrift fur Psychiatrie, Psychologie und Psychotherapie. 2008;56:13-18.
10127.	Moller M, Andersen G, Gjedde A. Serotonin 5HT1A receptor availability and pathological crying after stroke. Acta neurologica Scandinavica. 2007;116:83-90.
10128.	Molyneaux E, LM H, HR M, AM K, Trevillion K. Antidepressant Treatment for Postnatal Depression. Cochrane database of systematic reviews (Online). 2014.
10129.	Molyneaux E, LM H, HR M, AM K, Trevillion K. Antidepressant treatment for postnatal depression. Advances in Psychiatric Treatment. 2014;20:368.
10130.	Monami M, Marchionni N. Psychological disorders and cardiovascular diseases. [Italian]. Giornale italiano di cardiologia. 2007;8:335-348.
10131.	Moncrieff J. Challenging conventional models of psychiatric drug therapy: An alternative patient-centered approach. Future neurology. 2010;5:213-225.
10132.	Moncrieff J, Cohen D. Do antidepressants cure or create abnormal brain states? PLoS medicine. 2006;3:961-965.
10133.	Moncrieff J, Cohen D, Porter S. The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room. Journal of psychoactive drugs. 2013;45:409-415.
10134.	Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine Effects of Citalopram Infusion in Anorexia Nervosa. Psychoneuroendocrinology. 2006;31:1139-1148.
10135.	Mondino M, Bennabi D, Poulet E, Galvao F, Brunelin J, Haffen E. Can transcranial direct current stimulation (tDCS) alleviate symptoms and improve cognition in psychiatric disorders? World journal of biological psychiatry. 2014;15:261-275.
10136.	Montanes-Rada F, MT DL-T, Sanchez-Romero S. Mirtazapine Versus Paroxetine in Panic Disorder: an Open Study. International journal of psychiatry in clinical practice. 2005;9:87-93.
10137.	Montanes-Rada F, MT DL-T, Sanchez-Romero S. Mirtazapine Versus Paroxetine in Panic Disorder: an Open Study. International journal of psychiatry in clinical practice. 2005;9:87-93.
10138.	Monteleone P, Brambilla F, Bortolotti F, Ferraro C, Maj M. Plasma Prolactin Response to D-Fenfluramine Is Blunted in Bulimic Patients With Frequent Binge Episodes. Psychological medicine. 1998;28:975-983.
10139.	Monteleone P, Brambilla F, Bortolotti F, Maj M. Serotonergic dysfunction across the eating disorders: Relationship to eating behaviour, purging behaviour, nutritional satus and general psychopathology. Psychological medicine. 2000;30:1099-1110.
10140.	Monteleone P, Catapano F, Dimartino S, Ferraro C, Maj M. Prolactin Response to D-Fenfluramine in Obsessive-Compulsive Patients, and Outcome of Fluvoxamine Treatment. British journal of psychiatry. 1997;170:554-557.
10141.	Montgomery D, Evans R, SA M. Pharmacological differences between brief and major depressions. European neuropsychopharmacology. 1993;3:214-215.
10142.	Montgomery DB, Roberts A, Green M, Bullock T, Baldwin D, Montgomery SA. Lack of efficacy of fluxotine in recurrent brief depression and suicidal attempts. European archives of psychiatry and clinical neuroscience. 1994;244:211-215.
10143.	Montgomery S. Serotonin, Sertraline and Depression. Journal of psychopharmacology (Oxford, England). 1995;9:179-184.
10144.	Montgomery S. Serotonin Noradrenaline Reuptake Inhibitors: Logical Evolution of Antidepressant Development. International journal of psychiatry in clinical practice. 2006;10:5-11.
10145.	Montgomery S. Treatment of depression and its associated comorbidities. International journal of psychiatry in clinical practice. 2007;11:13.
10146.	Montgomery S. Early treatment and long-term outcome in depressive disorders. International journal of psychiatry in clinical practice. 2009;Conference:12.
10147.	Montgomery S. Favoured treatments for treatment resistant depression. International journal of psychiatry in clinical practice. 2013;Conference:9.
10148.	Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and Safety of Pregabalin in Elderly People With Generalised Anxiety Disorder. British journal of psychiatry. 2008;193:389-394.
10149.	Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared to citalopram: a meta-analysis. [Review]. International journal of neuropsychopharmacology. 2011;14:261-268.
10150.	Montgomery S, Kalali A, RS M, WR E, Nyberg S, Eriksson H. Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder. European neuropsychopharmacology. 2010;Conference:S353.
10151.	Montgomery SA. The efficacy of fluoxetine as an antidepressant in the short and long term. International clinical psychopharmacology. 1989;4:113-119.
10152.	Montgomery SA. The advantages of paroxetine in different subgroups of depression. International clinical psychopharmacology. 1992;6 Suppl 4:91-100.
10153.	Montgomery SA. Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. [Review] [14 refs]. International clinical psychopharmacology. 1995;10 Suppl 1:23-27.
10154.	Montgomery SA. Rapid onset of action of venlafaxine. [Review] [16 refs]. International clinical psychopharmacology. 1995;10 Suppl 2:21-27.
10155.	Montgomery SA. Efficacy of nefazodone in the treatment of depression. Journal of psychopharmacology (Oxford, England). 1996;10:5-10.
10156.	Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. International clinical psychopharmacology. 2001;16:169-178.
10157.	Montgomery SA, -E RP, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study. International clinical psychopharmacology. 1998;13:63-73.
10158.	Montgomery SA, Djarv L. The antidepressant efficacy of citalopram. International clinical psychopharmacology. 1996;11:29-33.
10159.	Montgomery SA, Doogan DP, Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. [Review] [16 refs]. International clinical psychopharmacology. 1991;6 Suppl 2:37-46.
10160.	Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. European neuropsychopharmacology. 1995;5:5-13.
10161.	Montgomery SA, Huusom AKT, Bothmer J. A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder. Neuropsychobiology. 2004;50:57-64.
10162.	Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - A meta-analysis of nine placebo-controlled studies. International clinical psychopharmacology. 1994;9 Suppl 1:35-40.
10163.	Montgomery SA, Roberts A. SSRIs: Well tolerated treatment for depression. Human Psychopharmacology: Clinical and Experimental. 1994;9:S7-S10.
10164.	Montgomery SA, Roberts A, Patel AG. Placebo-controlled efficacy of antidepressants in continuation treatment. [Review] [22 refs]. International clinical psychopharmacology. 1994;9 Suppl 1:49-53.
10165.	Montorsi F, Salonia A. Medical therapy for premature ejaculation. Lancet. 2006;368:894-896.
10166.	Monz B, ME P, Hampel C, et al. Patient-Reported Impact of Urinary Incontinence - Results From Treatment Seeking Women in 14 European Countries. Maturitas. 2005;52:S24-S34.
10167.	Moon C, CM V. Treatment of major depression in general practice: A double-blind comparison of paroxetine and lofepramine. British journal of clinical practice. 1996;50:240-244.
10168.	Moon CAL, Jago W, Wood K, Doogan DP. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. Journal of psychopharmacology (Oxford, England). 1994;8:171-176.
10169.	Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease, Parkinsonism & related disorders(2014).
10170.	Mooney P, Oakley J, Ferriter M, Travers R. Sertraline as a treatment for PTSD: A systematic review and meta-analysis. Irish journal of psychological medicine. 2004;21:100-103.
10171.	Moore N, Verdoux H, Fantino B. Prospective, Multicentre, Randomized, Double-Blind Study of the Efficacy of Escitalopram Versus Citalopram in Outpatient Treatment of Major Depressive Disorder. International clinical psychopharmacology. 2005;20:131-137.
10172.	Moore N, Verdoux H, Fantino B. Prospective, Multicentre, Randomized, Double-Blind Study of the Efficacy of Escitalopram Versus Citalopram in Outpatient Treatment of Major Depressive Disorder (Vol 21, Pg 131, 2005). International clinical psychopharmacology. 2005;20:242.
10173.	Moore P, J CG, Bhatti T, et al. Rapid Tryptophan Depletion, Sleep Electroencephalogram, and Mood in Men With Remitted Depression on Serotonin Reuptake Inhibitors. Archives of general psychiatry. 1998;55:534-539.
10174.	Moore R, DeJoseph D, B BS. Managing patients on antipsychotics: Your domain, too. Journal of family practice. 2014;63:142-149.
10175.	Moradveisi L, Huibers M, Renner F, Arntz A. The influence of patients' preference/attitude towards psychotherapy and antidepressant medication on the treatment of major depressive disorder. Journal of behavior therapy and experimental psychiatry. 2014;45:170-177.
10176.	Moradveisi L, MJ H, Renner F, Arasteh M, Arntz A. Behavioural activation v. antidepressant medication for treating depression in Iran: randomised trial. British journal of psychiatry. 2013;202:204-211.
10177.	Moradveisi L, MJH H, Arntz A. The influence of patients' attributions of the immediate effects of treatment of depression on long-term effectiveness of behavioural activation and antidepressant medication. Behaviour research and therapy. 2015;69:83-92.
10178.	Moradveisi L, MJH H, Renner F, Arasteh M, Arntz A. The influence of comorbid personality disorder on the effects of behavioural activation vs. antidepressant medication for major depressive disorder: results from a randomized trial in Iran. Behaviour research and therapy. 2013;51:499-506.
10179.	Moradveisi L, MJH H, Renner F, Arasteh M, Arntz A. Authors' reply. British journal of psychiatry. 2013;202:466-467.
10180.	Moreno C, AM R, LL G. Pharmacotherapy of Child and Adolescent Depression. Child and adolescent psychiatric clinics of North America. 2006;15:977-998.
10181.	Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: Where are the bugs? Acta psychiatrica Scandinavica. 2007;115:184-195.
10182.	Moret C. Depression: Emerging research and treatment approaches: 16-17 January 2002, Paris, France. IDrugs : the investigational drugs journal. 2003;6:183-186.
10183.	Moretti R, Torre P, RM A, Cazzato G, Bava A. Rivastigmine in vascular dementia. Expert opinion on pharmacotherapy. 2004;5:1399-1410.
10184.	Moretti R, Torre P, Vilotti C, RM A, Pizzolato G. Rivastigmine and Parkinson dementia complex. Expert opinion on pharmacotherapy. 2007;8:817-829.
10185.	Morgan C. In this issue. Psychological medicine. 2009;39:177-178.
10186.	Morgan L, Gartlehner G. Comparative efficacy, effectiveness and harms of second-generation antidepressants in the pharmacologic treatment of adult depression. European psychiatry. 2011.
10187.	Morishita S, Arita S. Possible predictors of response to fluvoxamine for depression. Human psychopharmacology. 2003;18:197-200.
10188.	Morris MJ, Noam S, J SG, et al. fMRI response to negative words and SSRI treatment outcome in major depressive disorder: a preliminary study.[Erratum appears in Psychiatry Res. 2014 Jun 30;222(3):173-5]. Psychiatry Research - Neuroimaging. 2013;214:296-305.
10189.	Morris RK. "Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome": Reply. The British Journal of Psychiatry. 1998;173:353.
10190.	Morrison J, TL S. Adolescent angst or true intent? Suicidal behavior, risk, and neurobiological mechanisms in depressed children and teenagers taking antidepressants. [Review]. International journal of emergency mental health. 2014;16:247-250.
10191.	Morrison J, TL S. Adolescent angst or true intent? Suicidal behavior, risk, and neurobiological mechanisms in depressed children and teenagers taking antidepressants. [Review]. International journal of emergency mental health. 2014;16:247-250.
10192.	Mortberg E, DM C, Sundin O, AA W. Intensive Group Cognitive Treatment and Individual Cognitive Therapy Vs. Treatment as Usual in Social Phobia: a Randomized Controlled Trial. Acta psychiatrica Scandinavica. 2007;115:142-154.
10193.	Mortimore C, CVR B. A Naturalistic Prospective Study of the Use of Fluoxetine in General Psychiatric Outpatients. Human Psychopharmacology-Clinical and Experimental. 1996;11:365-372.
10194.	Mortimore C, IM A. D-Fenfluramine in Panic Disorder: a Dual Role for 5-Hydroxytryptamine. Psychopharmacology. 2000;149:251-258.
10195.	Moscovitch A, CA B, JM E, et al. A Placebo-Controlled Study of Sertraline in the Treatment of Outpatients With Seasonal Affective Disorder. Psychopharmacology. 2004;171:390-397.
10196.	Moscovitch A, CA B, JM E, et al. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology. 2004;171:390-397.
10197.	Moscrop A. An end to depression in primary care? British journal of general practice. 2012;62:e656-e658.
10198.	Moses T, AF L, Cook I, Abrams M. Does the Clinical Course of Depression Determine Improvement in Symptoms and Quality of Life? Journal of nervous and mental disease. 2006;194:241-248.
10199.	Moslinger-Gehmayr R, Zaninelli R, Contu A, et al. A double-blind study comparing the efficacy and tolerability of paroxetine and amitriptyline in the treatment of breast-cancer patients with depression. [German]. Zentralblatt fur Gynakologie. 2000;122:195-202.
10200.	Moslinger-Gehmayr R, Zaninelli R, Contu A, et al. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression]. [German][Erratum appears in Zentralbl Gynakol 2000;122(7):389]. Zentralblatt fur Gynakologie. 2000;122:195-202.
10201.	Mossner R, Mikova O, Koutsilieri E, et al. Consensus paper of the WFSBP task force on biological markers: Biological markers in depression. World journal of biological psychiatry. 2007;8:141-174.
10202.	Mostany R, EM V, Pazos A. A Role for Nuclear Beta-Catenin in Snri Antidepressant-Induced Hippocampal Cell Proliferation. Neuropharmacology. 2008;55:18-26.
10203.	Mota-Pereira J, Silverio J, Carvalho S, JC R, Fonte D, Ramos J. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. Journal of psychiatric research. 2011;45:1005-1011.
10204.	Mouchabac S. Severe Depression : Pharmacological Treatments. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2009;35:S319-S324.
10205.	Mouchet-Mages S, FJ B. Sadness as an integral part of depression. Dialogues in clinical neuroscience. 2008;10:321-327.
10206.	Moudgil R, Haddad H. Depression in heart failure. Current opinion in cardiology. 2013;28:249-258.
10207.	Mountifield R, JM A. Managing irritable bowel syndrome. Medicine today. 2010;11:32-40.
10208.	Mourilhe P, PE S. Risks and Benefits of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression. Drug safety. 1998;18:57-82.
10209.	Mowla A, Ghanizadeh A, Pani A. A comparison of effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder. Journal of clinical psychopharmacology. 2006;26:209-211.
10210.	Mowla A, Mosavinasab M, Haghshenas H, Borhani-Haghighi A. Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer's Dementia? - A Double-Blind, Placebo-Controlled Clinical Trial. Journal of clinical psychopharmacology. 2007;27:484-487.
10211.	MP A, MA M. A Combination of Antidepressants and Neuroleptics in the Treatment of Affective Disorders and Schizophrenia: Indications, Side Effects, and Complications. Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova. 2000;100:60-65.
10212.	MP B. Starting age in the administration of antidepressant agents. [French]. Encephale. 1994;20:287-290.
10213.	MP C. Duloxetine: In patients with fibromyalgia. Drugs. 2009;69:1217-1227.
10214.	MP C. Aripiprazole: In the treatment of irritability associated with autistic disorder in pediatric patients. Pediatric Drugs. 2011;13:197-204.
10215.	MP C, ME G, Jacobs J, MC L. Duloxetine HCl (Cymbalta) for the treatment of depression, neuropathic pain, fibromyalgia, and stress urinary incontinence. P and T. 2006;31:84-97.
10216.	MP D. Does trazodone have a role in palliating symptoms? Supportive care in cancer. 2007;15:221-224.
10217.	MP D, Khoshknabi D, GH Y. Management of fatigue in cancer patients. Current pain and headache reports. 2006;10:260-269.
10218.	MP D, RA K. Pharmacological interventions for bipolar youth: Developmental considerations. Development and psychopathology. 2006;18:1231-1246.
10219.	MP D, TJ H, Blanchard K, et al. A Double-Blind, Placebo-Controlled Study of Selegiline Transdermal System in Depressed Adolescents. Journal of child and adolescent psychopharmacology. 2014;24:311-317.
10220.	MP DAF, Lafer B, E BS, JA DP, MA B, MF J. Guidelines of the Brazilian Medical Association for the treatment of depression (complete version). [Portuguese]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2003;25:114-122.
10221.	MP F. Perinatal psychiatry: Risk factors, treatment data, and specific challenges for clinical researchers. Journal of clinical psychiatry. 2008;69:633-634.
10222.	MP F. An imperfect literature and evidence-based medicine. Journal of clinical psychiatry. 2009;70:412-413.
10223.	MP F. Complementary and alternative medicine for perinatal depression. Journal of affective disorders. 2009;112:1-10.
10224.	MP F. Depression in women: New findings. Journal of clinical psychiatry. 2013;74:1002.
10225.	MP F, Fava M, Lake J, MH T, KL W, Mischoulon D. Complementary and alternative medicine in major depressive disorder: The American psychiatric association task force report. Journal of clinical psychiatry. 2010;71:669-681.
10226.	MP F, Joffe H, LS C. Postpartum depression: Help patients find the right treatment. Current psychiatry. 2012;11:14-21.
10227.	MP F, McKinney A, Bradshaw M, Tran P, Hsu T, Fava M. The triple reuptake inhibitor antidepressant effects (triade) trial: Amitifadine for the treatment of major depressive disorder. Neuropsychopharmacology. 2013;Conference:S370-S371.
10228.	MP F, Mischoulon D, Tedeschini E, et al. Complementary and alternative medicine for major depressive disorder: A meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. Journal of clinical psychiatry. 2010;71:682-688.
10229.	MP F, MT B, Lafer B, et al. Revision of the guidelines of the Brazilian Medical Association for the treatment of depression (Complete version). [Portuguese, English]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2009;31:S7-S17.
10230.	MP G-P, MT B, PA S, et al. Effectiveness of Venlafaxine in the Treatment of Alcohol Dependence With Comorbid Depression. Actas espanolas de psiquiatria. 2005;33:41-45.
10231.	MP G-P, MT B, PA S, et al. Effectiveness of Venlafaxine in the Treatment of Alcohol Dependence With Comorbid Depression. Actas espanolas de psiquiatria. 2005;33:41-45.
10232.	MP K. Current Concepts in the Drug-Treatment of Paraphilias and Paraphilia-Related Disorders. CNS drugs. 1995;3:9-21.
10233.	MP K, Lobo E, Chappell J, Bergstrom R. Duloxetine Clinical Pharmacokinetics and Drug Interactions. Clinical pharmacokinetics. 2011;50:281-294.
10234.	MP L, RAC H, PJ W. Duloxetine for treating painful neuropathy or chronic pain; a Cochrane systematic review. Neuromuscular Disorders. 2010;Conference:S23.
10235.	MP L, RAC H, PJ W. Duloxetine for treating painful neuropathy or chronic pain; a Cochrane systematic review. Neuromuscular Disorders. 2010;Conference:S23.
10236.	MP R. Safety, efficacy, and patient acceptability of aripiprazole in the maintenance treatment of bipolar disorder. Clinical Medicine Insights: Therapeutics. 2012;4:131-144.
10237.	MP W, EEM M. Personalizing medicine: A review of adaptive treatment strategies. Pharmacoepidemiology and drug safety. 2014;23:580-585.
10238.	MP W, LM K. Open-Label Trial of Aripiprazole in the Treatment of Trichotillomania. Journal of clinical psychopharmacology. 2011;31:503-506.
10239.	MPT L, RAC H, PJ W. Duloxetine for Treating Painful Neuropathy or Chronic Pain. Cochrane database of systematic reviews (Online). 2009.
10240.	MPT L, RAC H, PJ W. Duloxetine for treating painful neuropathy or chronic pain: A cochrane systematic review. Journal of the Peripheral Nervous System. 2010;Conference:20-21.
10241.	MPT L, RAC H, PJ W. Duloxetine for Treating Painful Neuropathy, Chronic Pain or Fibromyalgia. Cochrane database of systematic reviews (Online). 2014.
10242.	MQ H, DD D, RG S, et al. Differential Prefrontal Gray Matter Correlates of Treatment Response to Fluoxetine or Cognitive-Behavioral Therapy in Obsessive-Compulsive Disorder. European neuropsychopharmacology. 2013;23:569-580.
10243.	Gray Matter Volumes in Obsessive-Compulsive Disorder Before and After Fluoxetine or Cognitive-Behavior Therapy: a Randomized Clinical Trial, Neuropsychopharmacology(2012).
10244.	MR B. Short-term antidepressant treatment improves fibromyalgia symptoms. [Spanish]. FMC Formacion Medica Continuada en Atencion Primaria. 2009;16:460.
10245.	MR C. Psychiatric issues in chronic pain. Current psychiatry reports. 2009;11:243-250.
10246.	MR C, EJ S, D'Amico A, PR C. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urologica e Nefrologica. 2003;55:219-238.
10247.	MR D, MJ S. So many options, so little difference in efficacy: What is the appropriate antidepressant? U.S. 2009;Pharmacist:26-39.
10248.	MR E, CM OC. Depression after myocardial infarction. Current heart failure reports. 2010;7:185-193.
10249.	MR F. Alzheimer's disease. CONTINUUM Lifelong Learning in Neurology. 2007;13:39-68.
10250.	MR K, Schafer A, Schottker K, et al. Therapy of Interferon-Induced Depression in Chronic Hepatitis C With Citalopram: a Randomised, Double-Blind, Placebo-Controlled Study. Gut. 2008;57:531-536.
10251.	MR L. Depression With Anxiety and Atypical Depression. Journal of clinical psychiatry. 1993;54:10-15.
10252.	MR L. Social Anxiety Disorder: Importance and Awareness of Treatment. Primary Care Psychiatry. 2004;9:97-104.
10253.	MR L. Social Anxiety Disorder: Importance and Awareness of Treatment. Primary Care Psychiatry. 2004;9:97-104.
10254.	MR L. Antidepressant Effects of Dopamine Agonists. Experimental and Clinical Findings. Der Nervenarzt. 2007;78:31-+.
10255.	MR L. [Antidepressant effects of dopamine agonists. Experimental and clinical findings]. [Review] [47 refs] [German]. Der Nervenarzt. 2007;78:31-38.
10256.	MR L. Depressive symptoms in Parkinson's disease. European journal of neurology. 2008;15:21-25.
10257.	MR L. Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: Depression. European journal of neurology. 2008;15:9-14.
10258.	MR L, AJ G, Munjack D. Venlafaxine Extended Release Vs Placebo, and Paroxetine in Social Anxiety Disorder. Archives of general psychiatry. 2005;62:190-198.
10259.	MR L, AJ G, Munjack D. Venlafaxine Extended Release Vs Placebo, and Paroxetine in Social Anxiety Disorder. Archives of general psychiatry. 2005;62:190-198.
10260.	MR L, AL M, SK P, Ganguly R, Tummala R, KA T. Efficacy, Safety, and Tolerability of Desvenlafaxine 50 Mg/Day and 100 Mg/Day in Outpatients With Major Depressive Disorder. Current medical research and opinion. 2008;24:1877-1890.
10261.	MR L, Asnis G, Mangano R, Tzanis E. A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine Extended Release Capsules in Adult Outpatients With Panic Disorder. Journal of clinical psychiatry. 2009;70:550-561.
10262.	MR L, JR F. Assessment and management of psychiatric issues during cancer treatment. Current pain and headache reports. 2008;12:262-269.
10263.	MR L, KA T. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: A systematic review of clinical trials. Primary care companion to the Journal of clinical psychiatry. 2010.
10264.	MR M, HA R, BH G. Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. Toronto, Ontario, Canada, September 20-23, 2008. Journal of the American College of Cardiology. 2009;53:514-522.
10265.	MR M, Hayward G, Harmer C. Selective processing of social threat cues following acute tryptophan depletion. Journal of psychopharmacology (Oxford, England). 2006;20:33-39.
10266.	MR M, JK S, JA F, DA R. Cost Effectiveness of Acute Imipramine Therapy Versus Two Imipramine Maintenance Treatment Regimens for Panic Disorder. PharmacoEconomics. 2000;18:383-391.
10267.	MR M, Lerman C, Niaura R, AE S, GE S. Smoking cessation treatment: Pharmacogenetics assessment. Current opinion in molecular therapeutics. 2005;7:202-208.
10268.	MR M, Rombold F, Quante A. Efficacy and safety of low-dose doxepin in depressed patients suffering from insomnia: A retrospective, naturalistic case series analysis. Primary care companion to the Journal of clinical psychiatry. 2014.
10269.	MR S. The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: A double-blind placebo-controlled and randomized study. BJU international. 2010;106:840-847.
10270.	MR S, BJ E. Topiramate for use in adult migraine prophylaxis. Journal of pharmacy technology. 2009;25:100-110.
10271.	MR S, Davis B. Efficacy of Sustained-Release Bupropion in Neuropathic Pain: an Open-Label Study. Clinical journal of pain. 2000;16:6-11.
10272.	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.[Erratum appears in Lancet Oncol. 2007 Jul 8;8(7):574], The Lancet. Oncology(2007).
10273.	MR T. Worldwide use of clomipramine. Journal of clinical psychiatry. 1990;51:51-54.
10274.	MR W. Fluvoxamine: a review of the controlled trials in depression. [Review] [42 refs]. Journal of clinical psychiatry. 1997;58 Suppl 5:15-23.
10275.	MR Y, Randhawa I. Antidepressants in chronic idiopathic urticaria. Allergy and asthma proceedings. 2011;32:419-424.
10276.	MS A, KS K. Selegiline orally disintegrating tablets (Zelapar): A new formulation of an old drug for parkinson's disease. P and T. 2007;32:653-660.
10277.	MS B, Hollander E, MM H, et al. Effect of Fluoxetine on Regional Cerebral Metabolism in Autistic Spectrum Disorders: a Pilot Study. International journal of neuropsychopharmacology. 2001;4:119-125.
10278.	MS B, Hollander E, Pallanti S, et al. Positron Emission Tomography Imaging of Risperidone Augmentation in Serotonin Reuptake Inhibitor-Refractory Patients. Neuropsychobiology. 2006;53:157-168.
10279.	MS B, McBride L, WO W, et al. Collaborative care for bipolar disorder: Part I. Intervention and implementation in a randomized effectiveness trial. Psychiatric services (Washington, D.C.). 2006;57:927-936.
10280.	MS B, Mitchner L. What Is a "Mood Stabilizer"? An Evidence-Based Response. American journal of psychiatry. 2004;161:3-18.
10281.	Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure, Journal of pharmacological sciences(2013).
10282.	MS C, EP B, Tuten M, EC S, HE J. The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. American journal of drug and alcohol abuse. 2010;36:46-51.
10283.	MS C, KL J, J AC. Treatment of childhood and adolescent depression. American family physician. 2012;86:442-448.
10284.	MS C, PO S. Antidepressants for the treatment of insomnia in patients with depression. American family physician. 2011.
10285.	MS D, KD W. Bipolar depression in children and adolescents. CNS spectrums. 2013;18:209-213.
10286.	MS D, KR S, Upton N. Latency to Paroxetine-Induced Anxiolysis in the Rat Is Reduced by Co-Administration of the 5-Ht1a Receptor Antagonist Way100635. British journal of pharmacology. 2000;130:1713-1719.
10287.	MS DL, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: A systematic appraisal of the evidence. Drug safety. 2003;26:55-64.
10288.	MS DL, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis. Psychological medicine. 1999;29:1273-1289.
10289.	MS G, AM S, Molloy M, et al. Low frequency daily left prefrontal rTMS improves mood in bipolar depression: A placebo-controlled case report. Human psychopharmacology. 1998;13:271-275.
10290.	MS G, MR T, MM R. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette Syndrome. Human psychopharmacology. 1993;8:327-334.
10291.	Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial, Archives of general psychiatry(2010).
10292.	MS H, JM U, Cariss M, Browne S, Jelley R, Katz M. Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: A study of treatment processes. Journal of psychosomatic research. 2002;53:811-817.
10293.	MS H, JM U, SJ B, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. Journal of psychosomatic obstetrics and gynaecology. 2002;23:193-199.
10294.	MS I, Dagerman K, PN T, Abbott S, Kavanagh S, LS S. National institute of mental health clinical antipsychotic trials of intervention effectiveness- Alzheimer's disease (CATIE-AD): Baseline characteristics. Current Alzheimer research. 2007;4:325-335.
10295.	MS K. A Reconsideration of the Nosological Status of Obsessive-Compulsive Disorder. Neurology Psychiatry and Brain Research. 1995;3:35-46.
10296.	MS K, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (New York, N.Y.). 1998;281:1640-1645.
10297.	MS M, KK Z. The impact of treatment on HPA axis activity in unipolar major depression. Journal of psychiatric research. 2010;44:183-192.
10298.	MS M, MA S, ML W, Licinio J. Modeling of the Temporal Patterns of Fluoxetine Prescriptions and Suicide Rates in the United States. PLoS medicine. 2006;3:816-824.
10299.	MS M, Matthews A, Phillipi C, et al. Depression drug treatment outcomes in pregnancy and the postpartum period: a systematic review and meta-analysis. [Review]. Obstetrics and gynecology. 2014;124:526-534.
10300.	MS N, DP D, MK K, et al. Fluoxetine Treatment of Dysthymia in the Elderly. Journal of clinical psychiatry. 1996;57:254-256.
10301.	MS N, JJ M, HA S. Serotonin, Cerebral Blood Flow, and Cerebral Metabolic Rate in Geriatric Major Depression and Normal Aging. Brain research reviews. 1999;30:250-263.
10302.	MS N, SP R, Prohovnik I, et al. Regional cerebral blood flow in mood disorders, V.: Effects of antidepressant medication in late-life depression. American journal of geriatric psychiatry. 2000;8:289-296.
10303.	MS R. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience. 2011;191:91-100.
10304.	MS T. Letter to the editor. European Journal of Oriental Medicine. 2011;6:52.
10305.	MS W, DL A, RR A, SN B, NF W. Treatment of narcolepsy and other hypersomnias of central origin: An American Academy of Sleep Medicine review. Sleep. 2007;30:1712-1727.
10306.	MST G, Fastbom J, Winblad B. Clinical Trials of Potential Antidepressants: to What Extent Are the Elderly Represented: a Review. International journal of geriatric psychiatry. 2005;20:201-217.
10307.	MST G, Fastbom J, Winblad B. Clinical Trials of Potential Antidepressants: to What Extent Are the Elderly Represented: a Review. International journal of geriatric psychiatry. 2005;20:201-217.
10308.	MT B. Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly. American journal of health-system pharmacy. 2007;64:S9-S17.
10309.	MT B, CM M. Gradual dose reduction and medication tapering: A clinical perspective. Consultant pharmacist. 2007;22:628-644.
10310.	MT B, F VDE, ZJ D. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: A meta-analysis of randomized, double-blind, and sham-controlled trials. Journal of clinical psychiatry. 2013;74:e122-e129.
10311.	MT B, McGirr A, M-M B, Turecki G. High frequency repetitive transcranial magnetic stimulation as an augmenting strategy in severe treatment-resistant major depression: A prospective 4-week naturalistic trial. Journal of affective disorders. 2011;130:312-317.
10312.	MT B, MG T. Using psychostimulants for treating residual symptoms in major depression. Journal of psychiatry & neuroscience. 2007;32:304.
10313.	MT B, MP F, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: An overview. Annals of medicine. 2008;40:149-159.
10314.	MT B, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. European neuropsychopharmacology. 2007;17:696-707.
10315.	MT C, CB N. The treatment of bipolar depression. Journal of clinical psychiatry. 2000;61:57-67.
10316.	MT H, Imming J, Cyr-Provost M, PH N, PA A, Unutzer J. Role of behavioral health professionals in a collaborative stepped care treatment model for depression in primary care: Project IMPACT. Families, Systems and Health. 2002;20:265-277.
10317.	MT H, Unutzer J, LQ T, et al. Impact of Comorbid Panic and Posttraumatic Stress Disorder on Outcomes of Collaborative Care for Late-Life Depression in Primary Care. American journal of geriatric psychiatry. 2005;13:48-58.
10318.	MT H, Unutzer J, LQ T, et al. Impact of Comorbid Panic and Posttraumatic Stress Disorder on Outcomes of Collaborative Care for Late-Life Depression in Primary Care. American journal of geriatric psychiatry. 2005;13:48-58.
10319.	MT I. Treating depression with SNRIs: who will benefit most?. [Review] [32 refs]. CNS spectrums. 2008;13:15-21.
10320.	MT I, MB T. Pindolol-paroxetine combination. American journal of psychiatry. 1997;154:1790-1791.
10321.	MT I, MB T, Bordet R, Thomas P, Dupuis B, Terao T. Selective serotonin reuptake inhibitors plus pindolol (multiple letters) [9]. Lancet. 1997;350:288-289.
10322.	MT J, PC C. A critical review of published economic modelling studies in depression. PharmacoEconomics. 2000;17:555-583.
10323.	MT L. The Comorbidity of Alcohol Dependence and Affective Disorders: Treatment Implications. Drug and alcohol dependence. 1998;52:201-209.
10324.	MT P. Beyond Depression: Citalopram for Obsessive-Compulsive Disorder. International clinical psychopharmacology. 1999;14:S19-S26.
10325.	MT S, TA W, MH K. Comorbidity of personality disorders and depression: Implications for treatment. Journal of consulting and clinical psychology. 1992;60:857-868.
10326.	MT T, DH Z. Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neuroscience and biobehavioral reviews. 2011;35:537-555.
10327.	MTC L, SH K. Desvenlafaxine in the Treatment of Major Depressive Disorder. Neuropsychiatric disease and treatment. 2009;5:127-136.
10328.	MTD T, Skovbjerg S, Arendt-Nielsen L, Bech P, Lunde M, Elberling J. Two of three patients with multiple chemical sensitivity had less symptoms and secondary hyperalgesia after transcranially applied pulsed electromagnetic fields. Scandinavian Journal of Pain. 2014;5:104-109.
10329.	Mucci M. Reboxetine: a review of antidepressant tolerability. [Review] [0 refs]. Journal of psychopharmacology (Oxford, England). 1997;11:S33-37.
10330.	Muck-Seler D, Jakovljevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. Journal of affective disorders. 1991;23:157-164.
10331.	Muck-Seler D, Sagud M, Mihaljevi-Peles A, Jakovljevi M, Pivac N. Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women. Journal of clinical psychopharmacology. 2011;31:387-390.
10332.	Muehlbacher M, MK N, Nickel C, et al. Mirtazapine Treatment of Social Phobia in Women - a Randomized, Double-Blind, Placebo-Controlled Study. Journal of clinical psychopharmacology. 2005;25:580-583.
10333.	Mufaddel A, OT O, Almugaddam F, Jafferany M. A review of body dysmorphic disorder and its presentation in different clinical settings. Primary care companion to the Journal of clinical psychiatry. 2013.
10334.	Mufson L, KP D, Wickramaratne P, Nomura Y, Olfson M, MM W. A Randomized Effectiveness Trial of Interpersonal Psychotherapy for Depressed Adolescents. Archives of general psychiatry. 2004;61:577-584.
10335.	Mufson L, KP D, Wickramaratne P, Nomura Y, Olfson M, MM W. A Randomized Effectiveness Trial of Interpersonal Psychotherapy for Depressed Adolescents. Archives of general psychiatry. 2004;61:577-584.
10336.	Mufson L, MM W, Moreau D, Garfinkel R. Efficacy of Interpersonal Psychotherapy for Depressed Adolescents. Archives of general psychiatry. 1999;56:573-579.
10337.	Mufson L, Sills R. Interpersonal psychotherapy for depressed adolescents (IPT-A): An overview. Nordic journal of psychiatry. 2006;60:431-437.
10338.	Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta psychiatrica Scandinavica. 1988;78:384-390.
10339.	Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Human psychopharmacology. 2014;29:55-63.
10340.	Mukai Y, RR T. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. [Review] [41 refs]. Clinical therapeutics. 2009;31:945-961.
10341.	Mula M, Schmitz B. Depression in epilepsy: Mechanisms and therapeutic approach. Therapeutic advances in neurological disorders. 2009;2:337-344.
10342.	Muldoon C. The safety and tolerability of citalopram. [Review] [17 refs][Erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153]. International clinical psychopharmacology. 1996;11 Suppl 1:35-40.
10343.	Mulholland C, Lynch G, DJ K, SJ C. A Randomised Controlled Trial of Sertraline for Depressive Symptoms in Stable, Chronic Schizophrenia. Schizophrenia research. 1998;29:153-154.
10344.	Muller A, JE M, Sondag C, M DZ. Psychiatric aspects of bariatric surgery topical collection on eating disorders. Current psychiatry reports. 2013.
10345.	Muller H, H-J M. Methodological problems in the estimation of the onset of the antidepressant effect. Journal of affective disorders. 1998;48:15-23.
10346.	COX-2 inhibitors as antidepressants and antipsychotics: Clinical evidence, Current opinion in investigational drugs (London, England : 2000)(2010).
10347.	Muller N. Cytokines in psychiatric disorders: Therapeutic approaches. International journal of neuropsychopharmacology. 2012;Conference:28-29.
10348.	Muller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina. 2013;25:292-298.
10349.	Muller N, A-M M, MJ S. Inflammatory biomarkers and depression. Neurotoxicity research. 2011;19:308-318.
10350.	Muller N, Bechter K. The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurology Psychiatry and Brain Research. 2013;19:87-101.
10351.	Muller N, MJ S. Antiinflammatory treatment approaches in major depression. European psychiatry.
10352.	Muller N, MJ S. COX-2 inhibition in schizophrenia and major depression. Current pharmaceutical design. 2008;14:1452-1465.
10353.	Muller N, MJ S. Anti-inflammatory treatment approaches in major depression. European psychiatry. 2011.
10354.	Muller N, Schennach R, Riedel M, H-J M. Duloxetine in the treatment of major psychiatric and neuropathic disorders. [Review] [101 refs]. Expert review of neurotherapeutics. 2008;8:527-536.
10355.	Muller-Spahn F. Psychotropic drugs. [German]. Therapeutische Umschau. Revue therapeutique. 1999;56:719-725.
10356.	Mullins N, Perroud N, Uher R, et al. Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: A genome-wide association and polygenic scoring study. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2014;165:428-437.
10357.	Mundo E, Bianchi L, Bellodi L. Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: a Single-Blind Study. Journal of clinical psychopharmacology. 1997;17:267-271.
10358.	Mundo E, Cattaneo E, Zanoni S, AC A. The use of atypical antipsychotics beyond psychoses: Efficacy of quetiapine in bipolar disorder. Neuropsychiatric disease and treatment. 2006;2:139-148.
10359.	Mundo E, Guglielmo E, Bellodi L. Effect of Adjuvant Pindolol on the Antiobsessional Response to Fluvoxamine: a Double-Blind, Placebo-Controlled Study. International clinical psychopharmacology. 1998;13:219-224.
10360.	Mundo E, Rouillon F, ML F, Stigler M. Fluvoxamine in Obsessive-Compulsive Disorder: Similar Efficacy but Superior Tolerability in Comparison With Clomipramine. Human Psychopharmacology-Clinical and Experimental. 2001;16:461-468.
10361.	Mundo E, SR B, Pirola R, Bellodi L, Smeraldi E. Long-Term Pharmacotherapy of Obsessive-Compulsive Disorder: a Double-Blind Controlled Study. Journal of clinical psychopharmacology. 1997;17:4-10.
10362.	Muneer A. Treatment of the depressive phase of bipolar affective disorder: A review. Journal of the Pakistan Medical Association. 2013;63:763-769.
10363.	Munizza C, Olivieri L, G DL, Dionisio P. A Comparative, Randomized, Double-Blind Study of Trazodone Prolonged-Release and Sertraline in the Treatment of Major Depressive Disorder. Current medical research and opinion. 2006;22:1703-1713.
10364.	Munno D, Sterpone S, Fania S, et al. Plasma Brain Derived Neurotrophic Factor Levels and Neuropsychological, Aspects of Depressed Patients Treated With Paroxetine. Panminerva medica. 2013;55:377-384.
10365.	Mura G, MF M, SB P, MG C. Exercise as an add-on strategy for the treatment of major depressive disorder: A systematic review. CNS spectrums. 2013;19:496-508.
10366.	Mura G, MF M, SB P, MG C. Exercise as an add-on strategy for the treatment of major depressive disorder: A systematic review. CNS spectrums. 2014;19:496-508.
10367.	Murad A, Selahattin K, Ertan T. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Human Psychopharmacology: Clinical and Experimental. 2003;18:191-195.
10368.	Murai N, Fushiki H, Honda S, et al. Relationship Between Serotonin Transporter Occupancies and Analgesic Effects of As1069562, the (+)-Isomer of Indeloxazine, and Duloxetine in Reserpine-Induced Myalgia Rats. Neuroscience. 2015;289:262-269.
10369.	Murali DP, M KZ, J DRM, E RN. Quality of life in geriatric depression: A comparison of remitters, partial responders, and nonresponders. The American Journal of Geriatric Psychiatry. 2001;9:423-428.
10370.	Murali DP, Rama KKR, Thomas O, et al. Does Antidepressant Therapy Improve Cognition in Elderly Depressed Patients? [References]. The Journals of Gerontology: Series A: Biological Sciences and Medical Sciences. 2003;58A:1137-1144.
10371.	Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: A preliminary review. CNS drugs. 2006;20:969-979.
10372.	Murasaki M, Kamijima K, Yamashita I, et al. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor for depression and depressive state-A double-blind study compared with imipramine hydrochloride. [Japanese]. Japanese Journal of Neuropsychopharmacology. 1997;19:505-527.
10373.	Murata Y, Kobayashi D, Imuta N, et al. Effects of the Serotonin 1a, 2a, 2c, 3a, and 3b and Serotonin Transporter Gene Polymorphisms on the Occurrence of Paroxetine Discontinuation Syndrome. Journal of clinical psychopharmacology. 2010;30:11-17.
10374.	Murawiec S, Jakima S. Bupropion - The effective antidepressant with favorable clinical profile of action on sexual functions. [Polish]. Seksuologia Polska. 2007;5:83-88.
10375.	Murck H. Atypical depression spectrum disorder - Neurobiology and treatment. Acta neuropsychiatrica. 2003;15:227-241.
10376.	Murck H, Fava M, Alpert J, et al. Hypericum Extract in Patients With Mdd and Reversed Vegetative Signs: Re-Analysis From Data of a Double-Blind, Randomized Trial of Hypericum Extract, Fluoxetine, and Placebo. International journal of neuropsychopharmacology. 2005;8:215-221.
10377.	Murck H, Schussler P, Steiger A. Renin-angiotensin-aldosterone system: The forgotten stress hormone system: Relationship to depression and sleep. Pharmacopsychiatry. 2012;45:83-95.
10378.	Murdoch D, Mctavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. [Review] [72 refs]. Drugs. 1992;44:604-624.
10379.	Murdoch D, SJ K. Escitalopram - a Review of Its Use in the Management of Major Depressive Disorder. Drugs. 2005;65:2379-2404.
10380.	Murdoch D, SJ K. Escitalopram - a Review of Its Use in the Management of Major Depressive Disorder. Drugs. 2005;65:2379-2404.
10381.	Murdoch D, SJ K. Spotlight on Escitalopram in the Management of Major Depressive Disorder. CNS drugs. 2006;20:167-170.
10382.	Murray A, R PE, R SR. Reflections of depression in acoustic measures of the patient's speech. Journal of affective disorders. 2001;66:59-69.
10383.	Murray G, EE M, AJ L, et al. Therapeutic Mechanism in Seasonal Affective Disorder: Do Fluoxetine and Light Operate Through Advancing Circadian Phase? Chronobiology international. 2005;22:937-943.
10384.	Murray G, EE M, AJ L, et al. O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep. Journal of affective disorders. 2006;90:227-231.
10385.	Murray V, M VA, Bartfai A, et al. Double-Blind Comparison of Sertraline and Placebo in Stroke Patients With Minor Depression and Less Severe Major Depression. Journal of clinical psychiatry. 2005;66:708-716.
10386.	Murthy P, Chand P. Treatment of Dual Diagnosis Disorders. Current opinion in psychiatry. 2012;25:194-200.
10387.	Musazzi L, Mallei A, Tardito D, et al. Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. Journal of psychiatric research. 2010;44:511-520.
10388.	Musetti L, C DG, Marazziti D, Dell'Osso L. Treatment of bipolar depression. CNS spectrums. 2013;18:177-187.
10389.	Mushtaq D, Ali A, MA M, Murtaza I, Andrade C. Association Between Serotonin Transporter Gene Promoter-Region Polymorphism and 4- and 12-Week Treatment Response to Sertraline in Posttraumatic Stress Disorder. Journal of affective disorders. 2012;136:955-962.
10390.	Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: A drug safety review. Expert opinion on drug safety. 2015;14:73-96.
10391.	Musil R, Zill P, Seemuller F, et al. Genetics of Emergent Suicidality During Antidepressive Treatment-Data From a Naturalistic Study on a Large Sample of Inpatients With a Major Depressive Episode. European neuropsychopharmacology. 2013;23:663-674.
10392.	Musselman D, EB R, Wang M, et al. The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology. 2013;38:1921-1928.
10393.	Musselman D, EB R, Wang M, et al. The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: Preliminary findings. Neuropsychopharmacology. 2013;38:1921-1928.
10394.	Musters C, McDonald E, Jones I. Management of postnatal depression. BMJ (Clinical research ed.). 2008;337:399-403.
10395.	Muthen B, HC B. Estimating drug effects in the presence of placebo response: Causal inference using growth mixture modeling. Statistics in medicine. 2009;28:3363-3385.
10396.	Mutlu O, I CK, Gumuslu E, F YA, Erden F, Ulak G. An atypical antidepressant tianeptine prevents unpredictable chronic mild stress-induced depressive effects in mice. European neuropsychopharmacology. 2011;Conference:S402.
10397.	Mutschler J, Rusch N, Schonfelder H, et al. Agomelatine for depression in schizophrenia: A case-series. Psychopharmacology bulletin. 2012;45:35-43.
10398.	Mutushiro N, Takeaki T, Kyoko N, Tamio T, Eiji Y. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry and clinical neurosciences. 2006;60:605-610.
10399.	Muzerengi S, Lewis H, Edwards M, et al. Non-motor symptoms in Parkinson's disease: An underdiagnosed problem. Aging health. 2006;2:967-982.
10400.	Muzik M, SM M, JE H, Flynn H. When Depression Complicates Childbearing: Guidelines for Screening and Treatment During Antenatal and Postpartum Obstetric Care. Obstetrics and gynecology clinics of North America. 2009;36:771-788.
10401.	MV L, MM R. Depression in epilepsy: etiology, phenomenology, and treatment. [Review] [398 refs]. Epilepsia. 1999;40 Suppl 1:S21-47.
10402.	MV L, MM R. Depression in Epilepsy: Etiology, Phenomenology, and Treatment. Epilepsia. 1999;40:S21-S47.
10403.	MW A, Majewski T, Wurthmann C, et al. Autonomic Neurocardiac Function in Patients With Major Depression and Effects of Antidepressive Treatment With Nefazodone. Journal of affective disorders. 2001;62:187-198.
10404.	MW E, BJ C, AJ L, et al. Personality and seasonal affective disorder: results from the CAN-SAD study. Journal of affective disorders. 2006;93:35-42.
10405.	MW G. Headaches: Psychiatric Aspects. Neurologic clinics. 2011;29:65-80.
10406.	MW G, Shults J, Amsterdam J, Ten-Have T. The analysis of binary longitudinal data with time-dependent covariates. Statistics in medicine. 2012;31:931-948.
10407.	MW J. Diagnosis and treatment of bipolar disorders in adults: A review of the evidence on pharmacologic treatments. American Health and Drug Benefits. 2014;7:489-498.
10408.	MW J, JH S. Antidepressant Agents for the Treatment of Chronic Pain and Depression. Pharmacotherapy. 2007;27:1571-1587.
10409.	MW K, Glazenborg A, Uyttenboogaart M, Mostert J, J DK. Pharmacologic treatment of depression in multiple sclerosis. [Review]. Cochrane database of systematic reviews (Online). 2011;2:CD007295.
10410.	MW K, PJ P, SG H, MJ G. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Therapeutic drug monitoring. 1989;11:165-170.
10411.	MW M, MR T, MA T, GS S, JL P. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacology bulletin. 1997;33:149-154.
10412.	MW O, CA P, Wernicke R, HE R, MS B, MH P. Posttraumatic stress disorder in patients with bipolar disorder: A review of prevalence, correlates, and treatment strategies. Bipolar disorders. 2004;6:470-479.
10413.	MW O, JAJ S, HE R. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clinical Psychology: Science and Practice. 2005;12:72-86.
10414.	MW OD, C-CD L, Harrison V. Stroke rehabilitation: Strategies to enhance motor recovery. Annual review of medicine. 2009;60:55-68.
10415.	MW OH, JE MC. Postpartum depression: Current status and future directions. Annual review of clinical psychology. 2013;9:379-407.
10416.	MW R, MW F. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719.
10417.	MW VDH, HJ K, PAM P. Bioequivalence Trial of Orally Disintegrating Mirtazapine Tablets and Conventional Oral Mirtazapine Tablets in Healthy Volunteers. Clinical drug investigation. 2001;21:437-442.
10418.	MW W, DJ S, LM H, KM A. Attitudes and adjustment to the parental role in mothers following treatment for postnatal depression. Journal of affective disorders. 2011;131:284-292.
10419.	MY A. Sleep-wake disturbances in fibromyalgia. Sleep and hypnosis. 2002;4:93-105.
10420.	Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: Results of an open-label, flexible-dose, 52-week extension study, International clinical psychopharmacology(2014).
10421.	MY A, PL J, Chen Y, Serenko M, AR M. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. International clinical psychopharmacology. 2014;29:36-44.
10422.	MY C, KH M, YJ J, SS K, WC K, EM J. Efficacy and Tolerability of Mirtazapine and Sertraline in Korean Veterans With Posttraumatic Stress Disorder: a Randomized Open Label Trial. Human Psychopharmacology-Clinical and Experimental. 2004;19:489-494.
10423.	MY C, KH M, YJ J, SS K, WC K, EM J. Efficacy and Tolerability of Mirtazapine and Sertraline in Korean Veterans With Posttraumatic Stress Disorder: a Randomized Open Label Trial. Human Psychopharmacology-Clinical and Experimental. 2004;19:489-494.
10424.	MY D, EE M, Waraich P, JE A, RW L. Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. BMC family practice. 2004.
10425.	Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: Primary outcomes from two trials conducted under the same protocol, Human Psychopharmacology: Clinical and Experimental(2012).
10426.	MYH M, FY J. Treating depression in HIV/AIDS. South African Journal of Psychiatry. 2007;13:86-88.
10427.	MYH M, FY J. Antidepressants versus interpersonal psychotherapy in treating depression in HIV-positive patients. South African Journal of Psychiatry. 2012;18:47-52.
10428.	MYH M, FY J. Treating depression in HIV-positive patients affects adherence. Southern African journal of HIV medicine. 2012;13:144-149.
10429.	Myhr G, Payne K. Cost-effectiveness of cognitive-behavioural therapy for mental disorders: Implications for public health care funding policy in Canada. Canadian Journal of Psychiatry. 2006;51:662-670.
10430.	Mynors-Wallis L. Problem-solving treatment in general psychiatric practice. Advances in Psychiatric Treatment. 2001;7:417-425.
10431.	Mynors-Wallis L. Does problem-solving treatment work through resolving problems? Psychological medicine. 2002;32:1315-1319.
10432.	Myriam K, Christiane R, Viviane DM, Paul L, Marc C, Julien M. Fluoxetine in Major Depression - Efficacy, Safety and Effects on Sleep Polygraphic Variables. International clinical psychopharmacology. 1990;5:253-260.
10433.	The placebo effect and homeopathy, Homeopathy(2010).
10434.	N BT, J CC. Antidepressant medications in preadolescent children with unipolar depression: A review of the evidence. Directions in Psychiatry. 2013;33:89-100.
10435.	N GB, Diane W, H TM, R WS, Maurizio F, John RA. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric services (Washington, D.C.). 2009;60:1439-1445.
10436.	N GB, Diane W, H TM, R WS, Maurizio F, John RA. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 2013:129-135.
10437.	N GC, E TM, M ZJ. Second generation antipsychotic medications in the treatment of affective disorders. 2013:9-31.
10438.	N GR, B NC, Paul M, D PC, M DE. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. Journal of clinical psychiatry. 2002;63:577-584.
10439.	N KD, F SA, P MJ, et al. Early- Versus Late-Onset Dysthymic Disorder: Comparison in Out-Patients With Superimposed Major Depressive Episodes. Journal of affective disorders. 1999;52:187-196.
10440.	N KM, G FG. Trajectory classes of depression in a randomized depression trial of heart failure patients: A reanalysis of the SADHART-CHF trial. American Journal of Geriatric Pharmacotherapy (AJGP). 2011;9:483-494.
10441.	N MM, N GB, N GR. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. Journal of clinical psychiatry. 1999;60:237-240.
10442.	N MR, D MR, H CW, et al. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder - a Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Journal of clinical psychopharmacology. 2008;28:156-165.
10443.	Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram, CNS drugs(2011).
10444.	N SK, C CJ, J BB, M DE. Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry research. 2004;125:81-86.
10445.	N WT. Efficacy, tolerability, and safety of duloxetine. CNS spectrums. 2005;10:10-11.
10446.	N-A R, Schroder P, LR O, Brodsgaard M, Unden M, Bech P. Modafinil augmentation in depressed patients with partial responce to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Sympton Checklist (SCL-92). Nordic journal of psychiatry. 2005;59:173-178.
10447.	N-D N, Osterweil D, Hoffman J. Charles bonnet syndrome: Treating nonpsychiatric hallucinations. Consultant pharmacist. 2013;28:184-188.
10448.	NA B, AA O, KS A. Anticraving-therapy of alcoholism in patients with comorbid arterial hypertension: Abilities of paroxetine. European neuropsychopharmacology. 2008;Conference:S528.
10449.	NA B, Seres-Mailo J, Hanstock C, et al. Proton Magnetic Resonance Spectroscopy Measurement of Brain Glutamate Levels in Premenstrual Dysphoric Disorder. Biological psychiatry. 2008;63:1178-1184.
10450.	NA C, Alexander B. Increased Rate of Trazodone Prescribing With Bupropion and Selective Serotonin-Reuptake Inhibitors Versus Tricyclic Antidepressants. Annals of pharmacotherapy. 2000;34:1007-1012.
10451.	NA C, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. Journal of clinical psychiatry. 2007;68:935-940.
10452.	NA D, Winokur A. Effects of psychiatric medications on sleep and sleep disorders. CNS and Neurological Disorders - Drug Targets. 2007;6:17-29.
10453.	NA F, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. International journal of neuropsychopharmacology. 2012;15:1173-1191.
10454.	NA F, Bullock T, DB M, SA M. Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder. International clinical psychopharmacology. 1992;7:43-47.
10455.	NA F, Reghunandanan S, HB S, et al. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults. Psychiatry research. 2015;227:114-125.
10456.	NA F, TM G. Evidence-based pharmacotherapy of obsessive-compulsive disorder. International journal of neuropsychopharmacology. 2005;8:107-129.
10457.	NA F, TM G, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. Journal of psychopharmacology (Oxford, England). 2006;20:97-103.
10458.	NA K, GD B, DL C, et al. Beyond the evidence: Is there a place for antidepressant combinations in the pharmacotherapy of depression? Medical journal of Australia. 2007;186:142-144.
10459.	NA K, Hope J, Culhane C. Management of Antidepressant-Induced Sexual Dysfunction. Australasian psychiatry. 2014;22:525-528.
10460.	NA K, Pastuszak A, SR S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors; A prospective controlled multicenter study. Journal of the American Medical Association. 1998;279:609-610.
10461.	NA Q, Mohammed A, Al-Bedah. Mood disorders and complementary and alternative medicine: A literature review. Neuropsychiatric disease and treatment. 2013;9:639-658.
10462.	NA Q, TA A-H. Making gynecological and psychiatric sense out of premenstrual pains, tension and dysphoria. Saudi medical journal. 2004;25:717-727.
10463.	Nabi H, Virtanen M, Singh-Manoux A, et al. Trait Anxiety Levels Before and After Antidepressant Treatment a 3-Wave Cohort Study. Journal of clinical psychopharmacology. 2013;33:371-377.
10464.	Naci H, Fleurence R. Using indirect evidence to determine the comparative effectiveness of prescription drugs: Do benefits outweigh risks? Health outcomes research in medicine. 2011;2:e241-e249.
10465.	Nadeau J, ML S, Ung D, et al. Treatment of comorbid anxiety and autism spectrum disorders. Neuropsychiatry. 2011;1:567-578.
10466.	Nader P, Rudolf U, Joanna H, et al. History of suicide attempts among patients with depression in the GENDEP project. Journal of affective disorders. 2010;123:131-137.
10467.	Nadia I, Adrienne vN, Alisabet C, Lee B, A NA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depression and anxiety. 2011;28:137-144.
10468.	Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: Efficacy, safety and patient preference. Neuropsychiatric disease and treatment. 2010;6:17-28.
10469.	NAFNB F. A review of central neuropathic pain states. Current opinion in anaesthesiology. 2008;21:586-589.
10470.	Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic Amine Depletion Causes Chronic Muscular Pain and Tactile Allodynia Accompanied by Depression: a Putative Animal Model of Fibromyalgia. Pain. 2009;146:26-33.
10471.	Nagao K, Kishi T, Moriwaki M, et al. Comparative Clinical Profile of Mirtazapine and Duloxetine in Practical Clinical Settings in Japan: a 4-Week Open-Label, Parallel-Group Study of Major Depressive Disorder. Neuropsychiatric disease and treatment. 2013;9:781-786.
10472.	Nagaoka S, Ohno M, Sekiguchi A. An Open-Label Clinical Trial of Milnacipran in Fibromyalgia Syndrome With Co-Morbid Depressive Symptoms. International journal of psychiatry in clinical practice. 2004;8:47-51.
10473.	Nagaoka S, Ohno M, Sekiguchi A. An Open-Label Clinical Trial of Milnacipran in Fibromyalgia Syndrome With Co-Morbid Depressive Symptoms. International journal of psychiatry in clinical practice. 2004;8:47-51.
10474.	Nagashima W, Kimura H, Ito M, et al. Effectiveness of Duloxetine for the Treatment of Chronic Nonorganic Orofacial Pain. Clinical neuropharmacology. 2012;35:273-277.
10475.	Nagata H, Nozaki M, Nakano H. Short-Term Combinational Therapy of Low-Dose Estrogen With Selective Serotonin Re-Uptake Inhibitor (Fluvoxamine) for Oophorectomized Women With Hot Flashes and Depressive Tendencies. Journal of obstetrics and gynaecology research. 2005;31:107-114.
10476.	Nagata H, Nozaki M, Nakano H. Short-Term Combinational Therapy of Low-Dose Estrogen With Selective Serotonin Re-Uptake Inhibitor (Fluvoxamine) for Oophorectomized Women With Hot Flashes and Depressive Tendencies. Journal of obstetrics and gynaecology research. 2005;31:107-114.
10477.	Nagata T, I VV, Yamada H, Kataoka K, Iketani T, Kiriike N. An Open Trial of Paroxetine for the "Offensive Subtype" of Taijin Kyofusho and Social Anxiety Disorder. Depression and anxiety. 2006;23:168-174.
10478.	Nagpal S, Riess J, Wakelee H. Treatment of leptomeningeal spread of NSCLC: A continuing challenge. Current treatment options in oncology. 2012;13:491-504.
10479.	Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Canadian Family Physician. 2011;57:659-663.
10480.	Nahas Z, FA K, Li X, Anderson B, MS G. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: A pilot study of acute safety and efficacy. Bipolar disorders. 2003;5:40-47.
10481.	Nahas Z, Jiang Y, YH Z, et al. Anti-Ceramidase Lcl385 Acutely Reduces Bcl-2 Expression in the Hippocampus but Is Not Associated With an Increase of Learned Helplessness in Rats. Behavioural brain research. 2009;197:41-44.
10482.	Nahas Z, Teneback C, J-H C, et al. Serial vagus nerve stimulation functional MRI in treatment-resistant depression. Neuropsychopharmacology. 2007;32:1649-1660.
10483.	Najafi B, Bharara M, TK T, DG A. Advances in balance assessment and balance training for diabetes. Diabetes management (London, England). 2012;2:293-308.
10484.	Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. [Review] [98 refs]. Clinical therapeutics. 2009;31:142-176.
10485.	Neuroinflammation and psychiatric illness, Journal of neuroinflammation(2013).
10486.	Nakagawa A, MF G, SP E, et al. Association of Suicide and Antidepressant Prescription Rates in Japan, 1999-2003. Journal of clinical psychiatry. 2007;68:908-916.
10487.	Nakagawa A, Watanabe N, IM O, et al. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: A systematic review and meta-analysis. CNS drugs. 2008;22:587-602.
10488.	Nakagawa A, Watanabe N, IM O, et al. Milnacipran versus other antidepressive agents for depression. Cochrane database of systematic reviews (Online). 2009.
10489.	Nakajima S, HU U, TS S, et al. Benefits of switching antidepressants following early nonresponse. European neuropsychopharmacology. 2009;Conference:S407.
10490.	Nakajima S, Suzuki T, Funaki K, et al. Benefits of switching antidepressants following early nonresponse. International journal of neuropsychopharmacology. 2010;Conference:79.
10491.	Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:259-264.
10492.	Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Potentials and Current Limitations of Brain Stimulation Therapies to Accelerate Antidepressant Response Reply. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:439-440.
10493.	Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E. Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. [Japanese]. Therapeutic Research. 2006;27:859-867.
10494.	Nakatani E, Nakagawa A, Nakao T, et al. A Randomized Controlled Trial of Japanese Patients With Obsessive-Compulsive Disorder - Effectiveness of Behavior Therapy and Fluvoxamine. Psychotherapy and psychosomatics. 2005;74:269-276.
10495.	Nakatani E, Nakagawa A, Nakao T, et al. A Randomized Controlled Trial of Japanese Patients With Obsessive-Compulsive Disorder - Effectiveness of Behavior Therapy and Fluvoxamine. Psychotherapy and psychosomatics. 2005;74:269-276.
10496.	Nakayama K. Menstruation-related syndrome: Clinical relations and treatment. Japan Medical Association Journal. 2005;48:417-421.
10497.	Namaka M, Leong C, Grossberndt A, et al. A treatment algorithm for neuropathic pain: An update. Consultant pharmacist. 2009;24:885-902.
10498.	NAMNT M. Dynamic optimization of chronic migraine treatment: Current and future options. Neurology. 2009;72:S14-S20.
10499.	Nancy F-S, Diana K, Robert SJ, et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE).[Erratum appears in Psychosom Med. 2007 Mar-Apr;69(2):216]. Psychosomatic medicine. 2006;68:87-93.
10500.	Nancy F-S, Diana K, Robert SJ, et al. "Design and Rationale for a Randomized, Controlled Trial of Interpersonal Psychotherapy and Citalopram for Depression in Coronary Artery Disease (CREATE)": Erratum. Psychosomatic medicine. 2007;69:216.
10501.	Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. American journal of psychiatry. 2012;169:141-151.
10502.	Nappi G, Perrotta A, Rossi P, Sandrini G. Chronic daily headache. Expert review of neurotherapeutics. 2008;8:361-384.
10503.	Nappi R, Salonia A, AM T, et al. Clinical biologic pathophysiologies of women's sexual dysfunction. Journal of sexual medicine. 2005;2:4-25.
10504.	Narasimhan M, JD R, AB J. Depression in the medically ill: Diagnostic and therapeutic implications. Current psychiatry reports. 2008;10:272-279.
10505.	Narasimhan M, MH K. Treating depression and achieving remission. Asian journal of psychiatry. 2010;3:163-168.
10506.	Nardini S. Smoking cessation: The role of bupropion among new pharmacologic agents. Monaldi Archives for Chest Disease - Pulmonary Series. 2001;56:467-472.
10507.	Narushima K, Paradiso S, DJ M, Jorge R, RG R. Effect of antidepressant therapy on executive function after stroke. British journal of psychiatry. 2007;190:260-265.
10508.	Narushima K, RG R. The Effect of Early versus Late Antidepressant Treatment on Physical Impairment Associated with Poststroke Depression: Is There a Time-Related Therapeutic Window? Journal of nervous and mental disease. 2003;191:645-652.
10509.	Natalie R, Robin L, V WB, Paul H. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. [Review]. General hospital psychiatry. 2014;36:466-473.
10510.	Naudet F, AS M, Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS ONE [Electronic Resource]. 2011;6:e20811.
10511.	Naudet F, Millet B, Charlier P, JM R, AS M, Falissard B. Which Placebo to Cure Depression? A Thought-Provoking Network Meta-Analysis. BMC medicine. 2013;11.
10512.	Naudet F, Millet B, Charlier P, JM R, AS M, Falissard B. Which placebo to cure depression? A thought-provoking network meta-analysis. BMC medicine. 2013;11:230.
10513.	Naudet F, Millet B, Charlier P, JM R, AS M, Falissard B. Placebo vs. Placebo to cure depression. Fundamental & clinical pharmacology. 2014;Conference:24.
10514.	Naukkarinen H, Raassina R, Penttinen J, et al. Deramciclane in the Treatment of Generalized Anxiety Disorder: a Placebo-Controlled, Double-Blind, Dose-Finding Study. European neuropsychopharmacology. 2005;15:617-623.
10515.	Navari R. Treatment of depressive symptoms in breast cancer patients undergoing adjuvant therapy. Supportive care in cancer. 2013;Conference:S126.
10516.	Navarro V, Gasto C, Guarch J. The drug-delivery system could be an important factor in improving antidepressant medication compliance in primary care. Therapeutic delivery. 2012;3:675-677.
10517.	Navarro-Odriozola V, Garcia-Pares G, Perez-Blanco J, et al. Treatment of Depression With Bupropion in Monotherapy. Actas espanolas de psiquiatria. 2011;39:2-7.
10518.	Navines R, Martin-Santos R, Gomez-Gil E, MJM DO, ML I, Gasto C. Effects of Citalopram Treatment on Hypothermic and Hormonal Responses to the 5-Ht1a Receptor Agonist Buspirone in Patients With Major Depression and Therapeutic Response. Psychoneuroendocrinology. 2007;32:411-416.
10519.	Nayan A, S RA, P PJ, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.[Erratum appears in J Clin Psychopharmacol. 2007 Feb;27(1):57]. Journal of clinical psychopharmacology. 2006;26:587-594.
10520.	Nayan A, S RA, P PJ, et al. Erratum re: Article by Dr Acharya "Duloxetine: Meta-analyses of Suicidal Behaviors and Ideation in Clinical Trials for Major Depressive Disorder". Journal of clinical psychopharmacology. 2007;27:57.
10521.	Nayereh K, Mehdi T-D, Shima J, Aghafateme H, Abolghassem D. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. Australian and New Zealand journal of psychiatry. 2013;47:271-275.
10522.	Nazeer A. Psychopharmacology of Autistic Spectrum Disorders in Children and Adolescents. Pediatric clinics of North America. 2011;58:85-97.
10523.	Nazila S, Mehdi F, Seyed-Hesammeddin A, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. Journal of affective disorders. 2014;155:216-222.
10524.	Nazir A, Ichinomiya T, Miyamura N, Sekiya Y, Kinosada Y. Identification of suicide-related events through network analysis of adverse event reports. Drug safety. 2014;37:609-616.
10525.	NB A, SE H, JG S, IB H. Early Intervention for Depressive Disorders in Young People: the Opportunity and the (Lack of) Evidence. Medical journal of Australia. 2007;187:S15-S17.
10526.	NB K, Kazi A, Smith T, et al. Cancer cachexia: Traditional therapies and novel molecular mechanism-based approaches to treatment. Current treatment options in oncology. 2010;11:107-117.
10527.	NB R, Norbury R, PJ C, CJ H. A single dose of mirtazapine modulates neural responses to emotional faces in healthy people. Psychopharmacology. 2010;212:625-634.
10528.	NC B, CW M, KA H, et al. Use of Nutritional Supplements to Increase the Efficacy of Fluoxetine in the Treatment of Anorexia Nervosa. International journal of eating disorders. 2004;35:10-15.
10529.	NC B, CW M, KA H, et al. Use of Nutritional Supplements to Increase the Efficacy of Fluoxetine in the Treatment of Anorexia Nervosa. International journal of eating disorders. 2004;35:10-15.
10530.	NC B, MJ F. Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (Ptsd): What Have We Learned? Current psychiatry reports. 2015;17.
10531.	NC B-M. Neurochemistry and pharmacological treatments: Where is the field of anorexia nervosa heading? Central nervous system agents in medicinal chemistry. 2007;7:35-43.
10532.	NC F, LA Z, MR M, PP R-B. What Would You Choose? Sertraline or Prolonged Exposure in Community and Ptsd Treatment Seeking Women. Depression and anxiety. 2009;26:724-731.
10533.	NCC V, Figee M, Denys D. Review of atypical antipsychotics in anxiety. European neuropsychopharmacology. 2011;21:429-449.
10534.	NCC V, HGM W, F VN, et al. Catechol-O-Methyltranferase Gene Expression Is Associated With Response to Citalopram in Obsessive-Compulsive Disorder. International journal of psychiatry in clinical practice. 2012;16:277-283.
10535.	ND D, AA S. Correction of Motor and Affective Symptoms of Parkinsonism by Selective Serotonine Reuptake Inhibition Antidepressant. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2008;108:29-35.
10536.	ND M, J-M LM, Banasch M, GB B. Neuroactive steroids in depressive disorders. Current psychiatry reviews. 2012;8:151-160.
10537.	ND R. Pharmacotherapy of adolescent major depression: Beyond TCAs. Psychopharmacology bulletin. 1990;26:75-79.
10538.	ND R. Child and adolescent depression: Short-term treatment effectiveness and long-term opportunities. International journal of methods in psychiatric research. 2003;12:44-53.
10539.	ND R. Medication treatment for depression in children and adolescents. CNS spectrums. 2003;8:283-287.
10540.	ND R. Treatment of Depression in. Children and Adolescents. Lancet. 2005;366:933-940.
10541.	ND R. Treating anxiety in youth: Does maintenance treatment maintain? Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53:269-270.
10542.	ND R, Varma D. Child and adolescent mood disorders - Experience with serotonin- based therapies. Biological psychiatry. 1998;44:336-340.
10543.	ND V, JM S. Adult attention deficit-hyperactivity disorder. New England journal of medicine. 2013;369:1935-1944.
10544.	NE H, KF S, RJ B. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacology bulletin. 1988;24:220-223.
10545.	NE H, Palesh O. Acupuncture in the treatment of cancer-related psychological symptoms. Integrative cancer therapies. 2014;13:371-385.
10546.	NE P, Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotoxicity research. 2007;11:1-32.
10547.	Nebe J. The treatment of bipolar depression. [German]. Krankenhauspsychiatrie. 2002;13:S38-S43.
10548.	Nedim H, Yavuz A, Cengiz D, Cem IM, Baki A. Escitalopram in treatment of post-stroke depression. [Turkish]. Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology. 2010;20:74-78.
10549.	Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Practice and Research: Clinical Gastroenterology. 2010;24:183-192.
10550.	Neil S, B FD, Ian H. Effects of fluoxetine and dothiepin on 24-hour activity in depressed patients. Neuropsychobiology. 1999;39:44-48.
10551.	Nelson C, TM O, Liu P, et al. Falls assessment in older patients treated with duloxetine. Journal of the American Geriatrics Society. 2012;Conference:S144.
10552.	Nelson JC, Zhang Q, Deberdt W, Marangell LB, Karamustafalioglu O, Lipkovich IA. Predictors of remission with placebo using an integrated study database from patients with major depressive disorder. Current medical research and opinion. 2012;28:325-334.
10553.	Nemets B, Bersudsky Y, RH B. Controlled Double-Blind Trial of Phenytoin Vs. Fluoxetine in Major Depressive Disorder. Journal of clinical psychiatry. 2005;66:586-590.
10554.	Nemets B, Levine J. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. International clinical psychopharmacology. 2013;28:127-133.
10555.	Nemets B, Mishory A, Levine J, RH B. Inositol addition does not improve depression in SSRI treatment failures. Journal of neural transmission. 1999;106:795-798.
10556.	Nemets B, Stahl Z, RH B. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American journal of psychiatry. 2002;159:477-479.
10557.	Neri S, Bertino G, Petralia A, et al. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Journal of clinical gastroenterology. 2010;44:e210-e217.
10558.	Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: Comparison between interferon-alpha-2a and interferon-alpha-2b. Clinical drug investigation. 2006;26:655-662.
10559.	Ness-Abramof R, CM A. Drug-Induced Weight Gain. Drugs of today (Barcelona, Spain : 1998). 2005;41:547-555.
10560.	Ness-Abramof R, CM A. Drug-Induced Weight Gain. Drugs of today (Barcelona, Spain : 1998). 2005;41:547-555.
10561.	Neu P, Schwertfeger N, Schlattmann P, Heuser I, RM B. Cerebrovascular Reactivity Following Administration of Mirtazapine in Healthy Probands - a Randomized, Placebo Controlled Double-Blind Clinical Study. Journal of psychiatric research. 2006;40:349-352.
10562.	Neuger J, Khoury A, BF K, Wahlund B, Aberg-Wistedt A, Stain-Malmgren R. Platelet serotonin functions in untreated major depression. Psychiatry research. 1999;85:189-198.
10563.	Neumeister A. Paroxetine in the Treatment of Depression With Associated Anxiety. Neuropsychiatrie. 2001;15:18-24.
10564.	Neumeister A, Stastny J. New antidepressants - An overview. [German]. MMW Fortschritte der Medizin. 2000;142:28-32.
10565.	Nevatte T, PMS OB, Backstrom T, et al. ISPMD consensus on the management of premenstrual disorders. Archives of women's mental health. 2013;16:279-291.
10566.	Newhouse A, Jiang W. Heart failure and depression. Heart failure clinics. 2014;10:295-304.
10567.	Newton J, Langlands A, Benbow A. Depressing misrepresentation? [1] (multiple letters). Lancet. 2004;363:1732-1733.
10568.	Neziroglu F, Henricksen J, JA Y-T. Psychotherapy of Obsessive-Compulsive Disorder and Spectrum: Established Facts and Advances, 1995-2005. Psychiatric clinics of North America. 2006;29:585-604.
10569.	NF G, ZJ C, Liang S, et al. Fluvoxamine in the Treatment of Depression: Results From a Chinese Population. Primary Care Psychiatry. 2004;9:89-94.
10570.	NF G, ZJ C, Liang S, et al. Fluvoxamine in the Treatment of Depression: Results From a Chinese Population. Primary Care Psychiatry. 2004;9:89-94.
10571.	Ng C, Sarris J, Singh A, et al. Pharmacogenetic Polymorphisms and Response to Escitalopram and Venlafaxine Over 8 Weeks in Major Depression. Human Psychopharmacology-Clinical and Experimental. 2013;28:516-522.
10572.	Ng F, Berk M, Dean O, AI B. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. International journal of neuropsychopharmacology. 2008;11:851-876.
10573.	Ng F, Dodd S, Berk M. Atypical antipsychotics for bipolar disorder: Overblown or blown over? Clinical Psychopharmacology and Neuroscience. 2007;5:53-64.
10574.	Ng F, Hallam K, Lucas N, Berk M. The role of lamotrigine in the management of bipolar disorder. Neuropsychiatric disease and treatment. 2007;3:463-474.
10575.	NG N, AV B. [A new quality of the therapy of anxiety and depression--escitalopram]. [Review] [29 refs] [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. 2005;Korsakova 79-84.
10576.	NG P, CS B. Citalopram in the treatment of depression. [Review] [60 refs]. Annals of pharmacotherapy. 2000;34:761-771.
10577.	NG W, BE C, SD H, Beckjord E. Measurement of depressive symptoms in women with breast cancer and women with clinical depression: A differential item functioning analysis. Journal of clinical psychology in medical settings. 2005;12:127-141.
10578.	Nguyen B, RR T. Psychostimulants in the treatment of depression in the older patient. Clinical geriatrics. 2005;13:39-45.
10579.	NH A, Teichner G. Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients. Behaviour research and therapy. 1998;36:849-861.
10580.	NH B, GK S, LA B, AS H, AL S. Suicidal ideation and behaviours after traumatic brain injury: A systematic review. Brain impairment. 2013;14:92-112.
10581.	NH G, Attia E. Psychopharmacology of Eating Disorders in Children and Adolescents. Pediatric clinics of North America. 2011;58:121-138.
10582.	NH K. Management of the depressive component of bipolar disorder. Depression and anxiety. 1997;4:190-198.
10583.	Nicholas M, Helene V, Bruno F. Prospective, Multicentre, Randomized, Double-Blind Study of the Efficacy of Escitalopram Versus Citalopram in Outpatient Treatment of Major Depressive Disorder (Vol 21, Pg 131, 2005). International clinical psychopharmacology. 2005;20:242.
10584.	Nicholas M, Helene V, Bruno F. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International clinical psychopharmacology. 2005;20:131-137.
10585.	Nicholson B. Treatment of painful polyneuropathies. Current pain and headache reports. 2005;9:178-183.
10586.	Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain practice. 2009;9:71-81.
10587.	Nickel M, Nickel C, Tritt K, et al. In-patient treatment of mothers with depressive disorders - Does joint admission of their children have a negative effect on the results of treatment? A randomised, prospective, controlled study. Psychotherapy and psychosomatics. 2005;74:366-370.
10588.	Nickerson B. Recent advances in the treatment of pain associated with fibromyalgia. U.S. 2009;Pharmacist:49-55.
10589.	Nicol FI. Treatment of major depression: is improvement enough?. [Review] [31 refs]. Journal of clinical psychiatry. 1999;60 Suppl 6:10-14.
10590.	Nicola C, Jean-Philipe B. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. [Review] [93 refs]. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 1998;43:722-730.
10591.	Nicolau J, Rivera R, Frances C, Chacartegui B, Masmiquel L. Treatment of Depression in Type 2 Diabetic Patients: Effects on Depressive Symptoms, Quality of Life and Metabolic Control. Diabetes research and clinical practice. 2013;101:148-152.
10592.	Nicole D, Lesley D, Brian P, Jonas H. Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain, behavior, and immunity. 2013;31:197-204.
10593.	Nicolini H, Bakish D, Duenas H, et al. Improvement of Psychic and Somatic Symptoms in Adult Patients With Generalized Anxiety Disorder: Examination From a Duloxetine, Venlafaxine Extended-Release and Placebo-Controlled Trial. Psychological medicine. 2009;39:267-276.
10594.	Niederhofer H. Venlafaxine has modest effects in autistic children. Therapy. 2004;1:87-90.
10595.	Niederhofer H, K vK. Bright light treatment as add-on therapy for depression in 28 adolescents: A randomized trial. Primary care companion to the Journal of clinical psychiatry. 2011.
10596.	Niedermaier N, Bohrer E, Schulte K, Schlattmann P, Heuser I. Prevention and Treatment of Poststroke Depression With Mirtazapine in Patients With Acute Stroke. Journal of clinical psychiatry. 2004;65:1619-1623.
10597.	Nielsen OA, Morsing I, Petersen JS, et al. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. Acta psychiatrica Scandinavica. 1991;84:233-241.
10598.	Niemegeers P, KE M, Morrens M, et al. Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression. Expert opinion on drug metabolism & toxicology. 2012;8:1189-1197.
10599.	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: A CO-MED report, International journal of neuropsychopharmacology(2012).
10600.	Nierenberg A, Kennedy S, RB L, MH R. Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder. CNS spectrums. 2009;14:1-+.
10601.	Nieuwenhuis S, BU F, E-J W. Erroneous analyses of interactions in neuroscience: A problem of significance. Nature neuroscience. 2011;14:1105-1107.
10602.	Niitsu T, Fabbri C, Serretti A. Predictors for manic switch at depressive episodes in bipolar disorder: The Systematic Treatment Enhancement Program for Bipolar Disorder. European neuropsychopharmacology. 2014;Conference:S431-S432.
10603.	Niitsu T, Fujisaki M, Shiina A, et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. Journal of clinical psychopharmacology. 2012;32:593-601.
10604.	Niitsu T, Iyo M, Hashimoto K. Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases. Current pharmaceutical design. 2012;18:875-883.
10605.	Nijhawan A, Nijhawan M. A study of efficacy and tolerability of fluvoxamine and imipramine in patients of major depressive disorder. Indian journal of psychiatry. 2010;Conference:S45.
10606.	Nikfar S, Abdollahi M, Hendoiee N, Rahimi R. Pregnancy outcomes folowing exposure to serotonin reuptake inhibitors: A meta-analysis. Value in health. 2012;Conference:A638.
10607.	Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis. DARU, Journal of Pharmaceutical Sciences. 2012.
10608.	Nikfarjam M, Parvin N, Assarzadegan N, Asghari S. The Effects of Lavandula Angustifolia Mill Infusion on Depression in Patients Using Citalopram: a Comparison Study. Iranian Red Crescent Medical Journal. 2013;15:734-739.
10609.	Nikolaj N, Eva B, Kerstin S, Peter S, Isabella H. Prevention and Treatment of Poststroke Depression With Mirtazapine in Patients With Acute Stroke. Journal of clinical psychiatry. 2004;65:1619-1623.
10610.	Nil R. Observational vs randomised controlled studies. International journal of psychiatry in clinical practice. 2012;Conference:2-3.
10611.	Nilsson M, MJ J, CM M, EB B, JH H. Safety of Subchronic Treatment With Fluoxetine for Major Depressive Disorder in Children and Adolescents. Journal of child and adolescent psychopharmacology. 2004;14:412-417.
10612.	Nimatoudis I, NP Z, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission Rates With Venlafaxine Extended Release in Greek Outpatients With Generalized Anxiety Disorder. A Double-Blind, Randomized, Placebo Controlled Study. International clinical psychopharmacology. 2004;19:331-336.
10613.	Nimatoudis I, NP Z, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission Rates With Venlafaxine Extended Release in Greek Outpatients With Generalized Anxiety Disorder. A Double-Blind, Randomized, Placebo Controlled Study. International clinical psychopharmacology. 2004;19:331-336.
10614.	Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression, Psychoneuroendocrinology(2014).
10615.	Nina S, Caroline N, Cornelius S, et al. The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: A randomized trial. Journal of psychiatric research. 2014;53:76-83.
10616.	Nisenbaum L, KF L, Dharia S, et al. Association between snps in SCL6A2 and comt and response to LY2216684 in patients with major depressive disorder. Neuropsychopharmacology. 2010;Conference:S345.
10617.	Nishawala M, RJ B, Koplewicz H. Beyond the black box: Prescribing SSRIs to adolescents. Primary psychiatry. 2006;13:51-56.
10618.	Nishikai M, Akiya K. Fluvoxamine therapy for fibromyalgia [6]. Journal of rheumatology. 2003;30:1124-1125.
10619.	Nishikawa H, Inoue T, Izumi T, Koyama T. Synergistic Effects of Tandospirone and Selective Serotonin Reuptake Inhibitors on the Contextual Conditioned Fear Stress Response in Rats. European neuropsychopharmacology. 2007;17:643-650.
10620.	Nishikawa H, Inoue T, Masui T, Izumi T, Nakagawa S, Koyama T. Pharmacokinetic Interaction Between Tandospirone and Fluvoxamine in the Rat Contextual Conditioned Fear Stress Model and Its Functional Consequence: Involvement of Cytochrome P450 3a4. Psychiatry and clinical neurosciences. 2008;62:591-596.
10621.	Nishimura T, Saito A, Yagyu T, Kinoshita T, Saito M. Psychotropic properties of fluvoxamine maleate: Pharmaco-EEG study and pharmacodynamics on healthy subjects. [Japanese]. Japanese Journal of Neuropsychopharmacology. 1996;18:319-329.
10622.	Nishiyori M, Uchida H, Nagai J, et al. Permanent Relief From Intermittent Cold Stress-Induced Fibromyalgia-Like Abnormal Pain by Repeated Intrathecal Administration of Antidepressants. Molecular pain. 2011;7.
10623.	Nitschke M. Depression and anxiety disorders: Escitalopram for the treatment of social phobia. [German]. Deutsche Apotheker-Zeitung. 2004;144:49-50.
10624.	Niwa T, Murayama N, Yamazaki H. Stereoselectivity of human cytochrome P450 in metabolic and inhibitory activities. Current drug metabolism. 2011;12:549-569.
10625.	NJ C, PL M. Duloxetine a Review of Its Use in the Treatment of Generalized Anxiety Disorder. CNS drugs. 2009;23:523-541.
10626.	NJ D, CG G. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008;71:677-684.
10627.	NJ D, SA H, ER H. Valproate Prophylaxis for Migraine Induced by Selective Serotonin Reuptake Inhibitors. Headache. 2000;40:248-251.
10628.	NJ K, DJ N, AR L-H. The role of central noradrenergic dysregulation in anxiety disorders: Evidence from clinical studies. Journal of psychopharmacology (Oxford, England). 2011;25:3-16.
10629.	NJ K, GA B. School Refusal in Children and Adolescents: a Review of the Past 10 Years. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:197-205.
10630.	NJ K, Jameson M, Loh R, Deckersbach T, Wilhelm S, DD D. Open-label escitalopram treatment for pathological skin picking. International clinical psychopharmacology. 2007;22:268-274.
10631.	NJ K, RL OS, Sprich-Buckminster S. Trichotillomania: Current issues in conceptualization and treatment. Psychotherapy and psychosomatics. 1998;67:202-213.
10632.	NJ K, RS N, Borrelli B, et al. Comorbidity, Smoking Behavior and Treatment Outcome. Psychotherapy and psychosomatics. 2000;69:244-250.
10633.	NJ L, Y-W L. Ion channels as potential targets for the treatment of depression. Current opinion in drug discovery & development. 2008;11:633-641.
10634.	NJ M, RMA H. Intravenous Antidepressants: a Review. Depression and anxiety. 2004;19:1-9.
10635.	NJ M, RMA H. Intravenous antidepressants: a review. [Review] [26 refs]. Depression and anxiety. 2004;19:1-9.
10636.	NJ P, ME C. The Role of Venlafaxine in the Treatment of Obsessive-Compulsive Disorder. Annals of pharmacotherapy. 2005;39:136-140.
10637.	NJ P, ME C. The Role of Venlafaxine in the Treatment of Obsessive-Compulsive Disorder. Annals of pharmacotherapy. 2005;39:136-140.
10638.	NJ T. SSRIs in IBS: Sensing a dash of disappointment. Clinical gastroenterology and hepatology. 2003;1:155-159.
10639.	NJ T, Camilleri M, DK C, et al. Effects of Desipramine and Escitalopram on Postprandial Symptoms Induced by the Nutrient Drink Test in Healthy Volunteers: a Randomized, Double-Blind, Placebo-Controlled Study. Digestion. 2005;72:97-103.
10640.	NJ T, Camilleri M, DK C, et al. Effects of Desipramine and Escitalopram on Postprandial Symptoms Induced by the Nutrient Drink Test in Healthy Volunteers: a Randomized, Double-Blind, Placebo-Controlled Study. Digestion. 2005;72:97-103.
10641.	NJ T, JE K, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome: a Double-Blind, Randomized, Placebo-Controlled Trial. Digestive diseases and sciences. 2008;53:108-115.
10642.	NJ W, Mulligan J, TJ P, et al. Severity of depression and response to antidepressants: GENPOD randomised controlled trial. British journal of psychiatry. 2012;200:130-136.
10643.	NJC S, DL N, DHK S, McConnell H, Hamilton-Craig I. The impact of methodology and confounding variables on the association between major depression and coronary heart disease: Review and recommendations. Current psychiatry reviews. 2013;9:342-352.
10644.	NK O, Karlidere T, Bozkurt A, et al. Mirtazapine Augmentation in Depressed Patients With Sexual Dysfunction Due to Selective Serotonin Reuptake Inhibitors. Human Psychopharmacology-Clinical and Experimental. 2008;23:321-326.
10645.	NK R. The emerging science of hot flash relief: Legitimizing the "obecalp" effect. Menopause (New York, N.Y.). 2005;12:4-7.
10646.	Early Neurological Outcome of Young Infants Exposed to Selective Serotonin Reuptake Inhibitors during Pregnancy: Results from the Observational SMOK Study, PloS one(2013).
10647.	Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms, Cancer(2011).
10648.	NL H, Stearns V, DA F, DF H, Riba M. Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression. American journal of psychiatry. 2008;165:1251-1255.
10649.	NL K, RJ S, WD L, JC C, IA B, AV J. Health Outcomes and Costs Among Employees With Fibromyalgia Treated With Pregabalin Vs. Standard of Care. Pain practice. 2011;11:540-551.
10650.	NL M, JH K, AC L, Portera L, Dauber S, JC M. Maintenance Desipramine for Dysthymia: a Placebo-Controlled Study. Journal of affective disorders. 2001;64:231-237.
10651.	NL R, HA K, KE W, Powers B, Wroolie T, AF S. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: A pilot study. TheScientificWorldJournal. 2010;10:321-328.
10652.	NL S, Li M. Drug-Drug Conditioning Between Citalopram and Haloperidol or Olanzapine in a Conditioned Avoidance Response Model: Implications for Polypharmacy in Schizophrenia. Behavioural pharmacology. 2012;23:658-668.
10653.	NL S, Walter G. Complementary medicine for psychiatric disorders in children and adolescents. Current opinion in psychiatry. 2008;21:350-355.
10654.	NM B, AJLM VB, DJ S. Evidence-based pharmacotherapy of panic disorder: An update. International journal of neuropsychopharmacology. 2012;15:403-415.
10655.	NM J, JR B. Risk of Qt/Qtc Prolongation Among Newer Non-Ssri Antidepressants. Annals of pharmacotherapy. 2014;48:1620-1628.
10656.	NM K, Peppercorn J. CYP2D6 testing in breast cancer: Ready for prime time? Oncology. 2009.
10657.	NM L, JW K, Fellows I, TL P, Golshan S, Zisook S. Subsyndromal depressive symptoms in schizophrenia: Effect of treatment response on functional outcomes. American journal of geriatric psychiatry. 2009;Conference:A128-A129.
10658.	NM M, Abali O. Venlafaxine in Children and Adolescents With Attention Deficit Hyperactivity Disorder. Psychiatry and clinical neurosciences. 2004;58:92-95.
10659.	NM M, Abali O. Venlafaxine in Children and Adolescents With Attention Deficit Hyperactivity Disorder. Psychiatry and clinical neurosciences. 2004;58:92-95.
10660.	NM M, OP V. Dynamics of anxious depression during treatment with antidepressants with different mechanisms of action. Neuroscience and behavioral physiology. 2014;44:180-186.
10661.	NM N, Idkaidek N, Beshtawi M, et al. Bioequivalence Evaluation of Two Brands of Fluoxetine 20 Mg Capsules (Flutin and Prozac) in Healthy Human Volunteers. Biopharmaceutics & drug disposition. 2005;26:243-247.
10662.	NM P. How treatments for pathological gambling can be informed by treatments for substance use disorders. Experimental and clinical psychopharmacology. 2002;10:184-192.
10663.	NM P. Disordered Gambling and Its Treatment. Cognitive and behavioral practice. 2009;16:457-467.
10664.	NM S. Treating complicated grief. JAMA - Journal of the American Medical Association. 2013;310:416-423.
10665.	NM S, AK Z, 3rd WJJ, et al. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depression and anxiety. 2006;23:373-376.
10666.	NM S, JJ W, AC D, et al. An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder. Journal of clinical psychiatry. 2004;65:1219-1222.
10667.	NM S, JJ W, AC D, et al. An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder. Journal of clinical psychiatry. 2004;65:1219-1222.
10668.	NM S, MW O, JA S, DC N, HE R, MH P. Changes in Anxiety Sensitivity With Pharmacotherapy for Panic Disorder. Journal of psychiatric research. 2004;38:491-495.
10669.	NM S, MW O, JA S, DC N, HE R, MH P. Changes in Anxiety Sensitivity With Pharmacotherapy for Panic Disorder. Journal of psychiatric research. 2004;38:491-495.
10670.	NM S, RE K, EA H, et al. Open-Label Support for Duloxetine for the Treatment of Panic Disorder. CNS neuroscience & therapeutics. 2009;15:19-23.
10671.	NMJ R. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Current opinion in investigational drugs (London, England : 2000). 2002;3:257-261.
10672.	NN H, RS M. What are the implications of the STAR*D trial for primary care? A review and synthesis. Primary care companion to the Journal of clinical psychiatry. 2008;10:91-96.
10673.	NN K, DF A, NP B, MV T, IL K. An experimental approach for the study of psychotropic drug effects under simulated clinical conditions. Current drug metabolism. 2008;9:352-360.
10674.	Nobile M, Bellotti B, Marino C, Molteni M, Battaglia M. An Open Trial of Paroxetine in the Treatment of Children and Adolescents Diagnosed With Dysthymia. Journal of child and adolescent psychopharmacology. 2000;10:103-109.
10675.	Noble S, Benfield P. Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS drugs. 1997;8:410-431.
10676.	Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker, European journal of clinical pharmacology(2009).
10677.	Noel MM, Lee NC, Earl MB, Graham FP, Allen KR, Emil FK. Variable dosing of sertraline for premenstrual exacerbation of depression: A pilot study. Journal of women's health. 2008;17:1-5.
10678.	Noel RW, A RE, Fatima G, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. The American Journal on Addictions. 2014;23:68-75.
10679.	Noel RW, Lisa S, Martina P, et al. Dysregulation of diurnal cortisol secretion affects abstinence induction during a lead-in period of a clinical trial for depressed cocaine-dependent patients. The American Journal on Addictions. 2014;23:1-6.
10680.	Noguera R, Altuna R, Alvarez E, JL A, Casais L, Udina C. Fluoxetine Vs Clomipramine in Depressed-Patients - a Controlled Multicenter Trial. Journal of affective disorders. 1991;22:119-124.
10681.	Nolen W, Wijkstra J, Burger H, et al. Imipramine, venlafaxine or venlafaxine plus quetiapine in psychotic depression, a randomized, double-blind study. European neuropsychopharmacology. 2008;Conference:S326.
10682.	Nolen WA, J VdPJ, Dijken WA, et al. Treatment strategy in depression: I. Non-tricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta psychiatrica Scandinavica. 1988;78:668-675.
10683.	Nollet M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S. Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology. 2011;61:336-346.
10684.	Noonan D, Cowley G. Prozac vs. placebos. Newsweek. 2002;140:48-49.
10685.	Noorafshan A, MA A, Asadi-Golshan R, Rashidian-Rashidabadi A, Karbalay-Doust S. Curcumin and Sertraline Prevent the Reduction of the Number of Neurons and Glial Cells and the Volume of Rats' Medial Prefrontal Cortex Induced by Stress. Acta neurobiologiae experimentalis. 2014;74:44-53.
10686.	Noorafshan A, MA A, Karbalay-Doust S. Stress Changes the Spatial Arrangement of Neurons and Glial Cells of Medial Prefrontal Cortex and Sertraline and Curcumin Prevent It. Psychiatry investigation. 2015;12:73-80.
10687.	Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: A randomized controlled trial, Journal of ECT(2013).
10688.	Nordstrom G, Danchenko N, Despiegel N, Marteau F. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Value in health. 2012;15:231-239.
10689.	Norman S, Craig NJ. Augmentation in depression and other issues. Primary psychiatry. 2008;15:22-23.
10690.	Norquist G, TG M, SM E. Cost-effectiveness of depression treatment for adolescents. American journal of psychiatry. 2008;165:549-552.
10691.	Norra C, Peddersen A, Juckel G, Waniek S. Mismatch negativity in depressed patients under selective noradrenergic and serotonergic antidepressants. European neuropsychopharmacology. 2011;Conference:S251-S252.
10692.	Norra C, Pedersen A, Juckel G, Waniek S. Mismatch negativity generation deficits and selective monoaminergic treatments in patients with major depression. Klinische Neurophysiologie.
10693.	Norra C, Waniek S. Mismatch negativity source activity: A follow-up study in patients with acute depressive episode under selective monoaminergic antidepressants. Clinical neurophysiology. 2011;Conference:S24.
10694.	Norton KRW, Sireling LI, Bhat AV, Rao B, Paykel ES. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. Journal of affective disorders. 1984;7:297-308.
10695.	Norwood R, Balkissoon R. Current perspectives on management of co-morbid depression in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005;2:185-193.
10696.	Nose M, Cipriani A, Biancosino B, Grassi L, Barbui C. Efficacy of Pharmacotherapy Against Core Traits of Borderline Personality Disorder: Meta-Analysis of Randomized Controlled Trials. International clinical psychopharmacology. 2006;21:345-353.
10697.	Nose M, Cipriani A, TA F, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane database of systematic reviews (Online). 2007.
10698.	Noterdaeme M. Medication for mutism. [German]. Padiatrische Praxis. 2008;72:207-208.
10699.	Nothdurfter C, Schmotz C, Sarubin N, et al. Effects of Escitalopram/Quetiapine Combination Therapy Versus Escitalopram Monotherapy on Hypothalamic-Pituitary-Adrenal-Axis Activity in Relation to Antidepressant Effectiveness. Journal of psychiatric research. 2014;52:15-20.
10700.	Novick D, Montgomery W, Moneta V, XM P, Brugnoli R, JM H. Antidepressant Medication Treatment Patterns in Asian Patients With Major Depressive Disorder. Patient preference and adherence. 2015;9:421-428.
10701.	Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study. Polish journal of pharmacology. 2003;55:1143-1147.
10702.	Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacological Reports. 2005;57:713-718.
10703.	Nowakowski S, CJ M, LF M, BL P. Sleep and menopause. Current neurology and neuroscience reports. 2009;9:165-172.
10704.	Nozawa K, Sekine A, Hozumi S, Shimizu T. Effect of Augmentation With Olanzapine in Outpatients With Depression in Partial Remission With Melancholic Features: Consecutive Case Series. Psychiatry and clinical neurosciences. 2011;65:199-202.
10705.	NP G, TJ K. Antidepressants and advertising: Psychopharmaceuticals in crisis. Yale journal of biology and medicine. 2012;85:153-158.
10706.	NP M, Doknic M, Pavlovic D, et al. Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy. Journal of endocrinological investigation. 2010;33:770-775.
10707.	NP Z, Harmoussi S, Vlaikidis N, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Venlafaxine Xr in Out-Patients With Tension-Type Headache. Cephalalgia. 2007;27:315-324.
10708.	NPLG V. Pharmacotherapy of agitation and psychotic symptoms in Alzheimer's disease. Expert review of neurotherapeutics. 2002;2:655-664.
10709.	NPV N, SK A, NMK NYK, TEG W. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatrica Scandinavica, Supplement. 1995;91:28-35.
10710.	NR B. Cognitive, Affective, and Psychiatric Features of Parkinson's Disease. Clinics in geriatric medicine. 2006;22:773-796.
10711.	NR F, Cremonini F, NJ T. Management of constipation in patients with cancer. American journal of cancer. 2006;5:319-330.
10712.	NR F, RJ D. Pretreatment anxiety predicts patterns of change in cognitive behavioral therapy and medications for depression. Journal of consulting and clinical psychology. 2013;81:774-782.
10713.	NR H, Gyulai L, Weintraub D, Streim J. Pharmacologic Management of Psychosis in the Elderly: A Critical Review. Journal of geriatric psychiatry and neurology. 2003;16:213-218.
10714.	NR S, JB J, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Obstetrics and gynecology. 2008;111:1175-1182.
10715.	NR Z, SC K, Viktrup L. Pharmacotherapy for Stress Urinary Incontinence - Present and Future Options. Drugs. 2004;64:1503-1516.
10716.	NR Z, SC K, Viktrup L. Pharmacotherapy for Stress Urinary Incontinence - Present and Future Options. Drugs. 2004;64:1503-1516.
10717.	NS B, Sigurdsson T, JM G, BS M, JE L. Chronic Antidepressant Treatment Impairs the Acquisition of Fear Extinction. Biological psychiatry. 2013;73:1078-1086.
10718.	NS G, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. [Review] [159 refs]. Drugs. 1998;55:85-120.
10719.	Varenicline augmentation in depressed smokers: An 8-week, open-label study, Journal of clinical psychiatry(2009).
10720.	NS P, LL C, AR T, LH P. Augmentation of Antidepressants With Atypical Antipsychotics: a Review of the Current Literature. Journal of psychiatric practice. 2008;14:34-44.
10721.	NS P, LL C, AR T, LH P. Nicotinic acetylcholine receptors and depression: A review of the preclinical and clinical literature. Psychopharmacology. 2010;212:1-12.
10722.	NS P, LL C, AR T, LH P. Pharmacologic approaches to treatment resistant depression: A re-examination for the modern era. Expert opinion on pharmacotherapy. 2010;11:709-722.
10723.	NS R, SM B, Zhao Y, TK L. A Meta-Analysis of Pain Response in the Treatment of Fibromyalgia. Pain practice. 2011;11:516-527.
10724.	NTKHEMLVCAINTKAHEMLVC I, Investigators S. Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients. Journal of psychiatric practice. 2013;19:5-14.
10725.	Nuijten M, Hadjadjeba L, Evans C, J VDB. Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France. PharmacoEconomics. 1998;14:433-445.
10726.	Numakawa T, Richards M, Nakajima S, et al. The role of brain-derived neurotrophic factor (BDNF) in comorbid depression: Possible linkage with steroid hormones, cytokines, and nutrition. Frontiers in Psychiatry. 2014.
10727.	Nuria C, Jose S-M, Ferran T, Manuel GJ, Marc V, Eduard V. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: A meta-analysis. International journal of neuropsychopharmacology. 2010;13:5-14.
10728.	Nussbaumer B, LC M, Reichenpfader U, et al. Comparative Efficacy and Risk of Harms of Immediate- Versus Extended-Release Second-Generation Antidepressants: a Systematic Review With Network Meta-Analysis. CNS drugs. 2014;28:699-712.
10729.	Nutt D. The Anxiety Factor in Depression. Journal of psychopharmacology (Oxford, England). 1995;9:185-189.
10730.	Nutt D. Management of Patients With Depression Associated With Anxiety Symptoms. Journal of clinical psychiatry. 1997;58:11-16.
10731.	Nutt D. Substance-P antagonists: A new treatment for depression? Lancet. 1998;352:1644-1646.
10732.	Nutt D. Treatment of Depression and Concomitant Anxiety. European neuropsychopharmacology. 2000;10:S433-S437.
10733.	Nutt D. Potential clinical benefits of Multimodals in depression. International journal of neuropsychopharmacology. 2012;Conference:253.
10734.	Nutt D, FN J. Potential Applications of Venlafaxine. Reviews in Contemporary Pharmacotherapy. 1998;9:321-331.
10735.	NV A, AS R, JP P, et al. Duloxetine: Meta-Analyses of Suicidal Behaviors and Thoughts in Clinical Trials for Major Depressive Disorder. Neuropsychopharmacology. 2005;30:S97.
10736.	NV F, IP C. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. Neuroscience and behavioral physiology. 2007;37:539-546.
10737.	Nyer M, Doorley J, Durham K, AS Y, MP F, Mischoulon D. What is the Role of Alternative Treatments in Late-life Depression? Psychiatric clinics of North America. 2013;36:577-596.
10738.	Nyer M, Kasckow J, Fellows D, et al. The relationship of marital status and clinical characteristics in middle-aged and older patients with schizophrenia and depressive symptoms. Annals of clinical psychiatry. 2010;22:172-179.
10739.	Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta psychiatrica Scandinavica. 1992;86:138-145.
10740.	O DP, GW S, Danhof M. The missing link between clinical endpoints and drug targets in depression. Trends in pharmacological sciences. 2010;31:144-152.
10741.	O GM, R OJ, FJ CDV, F MO, V AC, MA DLRN. Polypharmacy related to increased risk of hip fracture in elderly patients. Atencion Farmaceutica. 2014;16:117-123.
10742.	O'Brien J. Behavioral symptoms in vascular cognitive impairment and vascular dementia. International Psychogeriatrics. 2003;15:133-138.
10743.	O'Brien P, Oyebode F. Psychotropic medication and the heart. Advances in Psychiatric Treatment. 2003;9:414-423.
10744.	O'Callaghan D, SP G. Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension. Clinics in chest medicine. 2007;28:169-185.
10745.	O'Connor J, Chen L, Gommoll C, SR Z. Levomilnacipran inhibits both norepinephrine and serotonin reuptake across the clinical dose range. Neuropsychopharmacology. 2013;Conference:S563-S564.
10746.	O'connor M, Silver H. Adding Risperidone to Selective Serotonin Reuptake Inhibitor Improves Chronic Depression. Journal of clinical psychopharmacology. 1998;18:89-91.
10747.	O'Donovan C. Achieving and Sustaining Remission in Depression and Anxiety Disorders: Introduction. Canadian Journal of Psychiatry. 2004;49:5S-9S.
10748.	O'Hara R. The reciprocal relationship of neurocognitive and neuropsychiatric function in late life. American journal of geriatric psychiatry. 2012;20:1001-1005.
10749.	O'Keane V, McLoughlin D, TG D. D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. Journal of affective disorders. 1992;26:143-150.
10750.	O'Keane V, MS M. Depression during pregnancy. British medical journal. 2007;334:1003-1005.
10751.	O'Kearney R, KJ A, C VS. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane database of systematic reviews (Online). 2006.
10752.	O'Neil A, Sanderson K, Oldenburg B, CB T. Impact of depression treatment on mental and physical health-related quality of life of cardiac patients: A meta-analysis. Journal of cardiopulmonary rehabilitation and prevention. 2011;31:146-156.
10753.	OA A, Gitlin M, Altshuler L, MA F. Baseline Thyroid Indices and the Subsequent Response to Citalopram Treatment, a Pilot Study. Brain and Behavior. 2013;3:89-94.
10754.	OA L, EI S. Post-Stroke Depression. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2006:73-79.
10755.	Oakley F, NA K, Parks R, Bauer L, Sunderland T. Improvement in activities of daily living in elderly following treatment for post-bereavement depression. Acta psychiatrica Scandinavica. 2002;105:231-234.
10756.	Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of Selective Serotonin Reuptake Inhibitors on Objective and Subjective Sleep Quality. Neuropsychobiology. 2000;42:69-81.
10757.	Oberpichler-Schwenk H. Escitalopram in the treatment of generalized anxiety disorder. [German]. Psychopharmakotherapie. 2006;13:36-37.
10758.	Oberpichler-Schwenk H. Concurrent management of depression and anxiety with escitalopram. [German]. Psychopharmakotherapie. 2008;15:89-90.
10759.	Oberpichler-Schwenk H. Duloxetine: Because depression is also painful - Positive interim result after 5 years. [German]. Psychopharmakotherapie. 2010;17:1-2.
10760.	OC P, HS A. Lamotrigine as a Promising Approach to Borderline Personality: an Open Case Series Without Concurrent Dsm-Iv Major Mood Disorder. Journal of affective disorders. 1998;51:333-343.
10761.	Ocio S, I LF, JA FM, Cordero C. Use of psychopharmacotherapy in depressive patients in primary care: A comparative study of derivated patients to mental health services in 1991, 1996 and 1998. [Spanish]. Revista de Psiquiatria de la Facultad de Medicina de Barcelona. 2003;30:206-210.
10762.	OD W, Schroer M, DD R, et al. Onset of Response With Duloxetine Treatment in Patients With Osteoarthritis Knee Pain and Chronic Low Back Pain: a Post Hoc Analysis of Placebo-Controlled Trials. Clinical therapeutics. 2014;36:544-551.
10763.	Oelke M, Jpwr R, MC M. Safety and Tolerability of Duloxetine in Women With Stress Urinary Incontinence. Bjog-an International Journal of Obstetrics and Gynaecology. 2006;113:22-26.
10764.	Oender E, Tural U, Aker T. A Comparative Study of Fluoxetine, Moclobemide, and Tianeptine in the Treatment of Posttraumatic Stress Disorder Following an Earthquake. European psychiatry. 2006;21:174-179.
10765.	Oestergaard S, Moldrup C. Application of pharmacogenomics to clinical problems in depression. Personalized medicine. 2009;6:501-515.
10766.	Oestergaard S, Moldrup C. Anticipated Outcomes From Introduction of 5-Httlpr Genotyping for Depressed Patients: an Expert Delphi Analysis. Public health genomics. 2010;13:406-414.
10767.	Oestergaard S, Moldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: A meta-analysis. Journal of affective disorders. 2011;131:24-36.
10768.	OF A. Is it necessary to use antidepressant medication in treatment of depressive disorders in children and adolescents? Klinik Psikofarmakoloji Bulteni. 2013;Conference:S21.
10769.	Faster, better, stronger: Towards new antidepressant therapeutic strategies, European journal of pharmacology(2015).
10770.	Offenbaecher M, Ackenheil M. Current trends in neuropathic pain treatments with special reference to fibromyalgia. CNS spectrums. 2005;10:285-297.
10771.	Offidani E, Guidi J, Tomba E, GA F. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: A systematic review and meta-analysis. Psychotherapy and psychosomatics. 2013;82:355-362.
10772.	OG B, MS H. Management of the Adolescent with Substance Use Disorders and Comorbid Psychopathology. Child and adolescent psychiatric clinics of North America. 2010;19:609-623.
10773.	OG B, Seifritz E, TC W. Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects. World journal of biological psychiatry. 2012;13:556-568.
10774.	OG P, KM M, LJ P, et al. Impact of Paroxetine on Sleep Problems in 426 Cancer Patients Receiving Chemotherapy: a Trial From the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep medicine. 2012;13:1184-1190.
10775.	Oganesian A, AD S, Young-Sciame R, et al. Desvenlafaxine and Venlafaxine Exert Minimal in Vitro Inhibition of Human Cytochrome P450 and P-Glycoprotein Activities. Psychopharmacology bulletin. 2009;42:47-63.
10776.	Ohishi M, Kamijima K. A comparison of characteristics of depressed patients and efficacy of sertraline and amitriptyline between Japan and the West. Journal of affective disorders. 2002;70:165-173.
10777.	Ohrberg S, Christiansen PE, Severin B, et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta psychiatrica Scandinavica. 1992;86:437-444.
10778.	Ohrt T, Sjodin I, L-H T. Cognitive distortions in panic disorder and major depression: Specificity for depressed mood. Nordic journal of psychiatry. 1999;53:459-464.
10779.	Ojserkis R, Sysko R, JA G, MJ D. Does the overvaluation of shape and weight predict initial symptom severity or treatment outcome among patients with binge eating disorder? International journal of eating disorders. 2012;45:603-608.
10780.	Okan C, Funda G. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. Journal of affective disorders. 2005;88:75-78.
10781.	Okea R. Milnacipran (Savella) for fibromyalgia. American family physician. 2010;82:903-904.
10782.	Oktem M, Eroglu D, HB K, Taskintuna N, Kuscu E, HB Z. Black Cohosh and Fluoxetine in the Treatment of Postmenopausal Symptoms: a Prospective, Randomized Trial. Advances in therapy. 2007;24:448-461.
10783.	OL L. Mild cognitive impairment. CONTINUUM Lifelong Learning in Neurology. 2013;19:411-424.
10784.	Olaf M, Guenter H, Nikolaus M, Matthias R, Volker A, Andreas E. Basal Prolactin Values Correlate with Response to Reboxetine Treatment in Major Depression, but Not with Response to Citalopram. Neuropsychobiology. 2005;51:67-71.
10785.	Olaf S-H, Stefan R. Escitalopram, problem-solving therapy, and poststroke depression. JAMA: Journal of the American Medical Association. 2008;300:1757.
10786.	Olamazadeh S, Taghian F, Barakatain M, Rahnama N. Effects of aquatic exercises on selected physiological variables in panic disorder patients. Gazzetta Medica Italiana Archivio per le Scienze Mediche. 2014;173:185-195.
10787.	Olesen J, MG B, Freund T, et al. Consensus document on European brain research. Journal of neurology, neurosurgery, and psychiatry. 2006;77:i1-i49.
10788.	Olfson M, Gerhard T. Re-examining antidepressant risk of self-injury in children and adolescents. Pharmacoepidemiology and drug safety. 2015;24:215-217.
10789.	Olfson M, MJ G. Generalized Anxiety Disorder, Somatic Pain and Health Care Costs. General hospital psychiatry. 2007;29:310-316.
10790.	Olfson M, SC M, HA P, JM Z, JW T, DA Z. Antidepressant Prescribing Practices of Outpatient Psychiatrists. Archives of general psychiatry. 1998;55:310-316.
10791.	Olfson M, SC M, MM W, PS J. National Trends in the Use of Psychotropic Medications by Children. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:514-521.
10792.	Olgiati P, Bajo E, Bigelli M, Montgomery S, Serretti A, Disorders)-group CC-EAoP. Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(*)D) trial. European neuropsychopharmacology. 2013;23:1739-1746.
10793.	Olgiati P, Serretti A, Bigelli M, D DR, Bajo E. Is pharmacogenetic testing ready for antidepressant treatment? A cost-effectiveness simulation. European neuropsychopharmacology. 2011;Conference:S389.
10794.	Olivier D, DI L, Fraser R. Tobacco smoking within psychiatric inpatient settings: A biospsychosocial perspective. Australian and New Zealand journal of psychiatry. 2007;41:572-580.
10795.	Olli-Pekka M, Jesper S, Pekka R, Kirsten B. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. Journal of clinical psychiatry. 2000;61:95-100.
10796.	OM A, RE F, MA K, et al. alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics. Journal of geriatric psychiatry and neurology. 2003;16:235-239.
10797.	OM K, SH W, LS S, JL O, SB V. Telaprevir: A novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. 2011;31:951-974.
10798.	OM W, VI R, Chan T, et al. Antiglucocorticoid Treatment of Depression: Double-Blind Ketoconazole. Biological psychiatry. 1999;45:1070-1074.
10799.	OM W, Wolf J, Shelly W, et al. Serum BDNF levels before treatment predict SSRI response in depression. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:1623-1630.
10800.	Omer A, Hakan E, Sermin K, Haldun S, Cankat T. Effect of citalopram versus escitalopram on quality of life in the treatment of the acute phase of major depressive disorder: a comparative, open-label study. [Turkish]. Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology. 2011;21:210-218.
10801.	Omerovic M, Hampel H, SJ T, Buerger K. Pharmacological treatment of Alzheimer's dementia: State of the art and current dilemmas. World journal of biological psychiatry. 2008;9:69-75.
10802.	Omidian H, Fesharaki S, Park K. Oral controlled delivery mechanisms and technologies. Controlled Release in Oral Drug Delivery. 2011;Advances i:109-129.
10803.	Omranifard V, GM H, MR S, Maracy M, Ghasemi F, Aminoroaia M. Sertraline as an Add-on Treatment for Depressive Symptoms in Stable Schizophrenia: a Double-Blind Randomized Controlled Trial. Journal of research in medical sciences. 2012;17:S1-S7.
10804.	Omranifard V, Shirzadi E, Samandari S, Afshar H, MR M. Memantine add on to citalopram in elderly pa tients with depression: A double-blind placebo-controlled study. Journal of research in medical sciences. 2014;19:525-530.
10805.	Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone [pooled analysis, Pfizer trials], Journal of clinical psychiatry(2011).
10806.	Onate J. Use of psychiatric drugs in patients with hepatitis C review and recommendations. Psychopharm Review. 2010;45:17-23.
10807.	Ongur D, DC G. Obsessive-Compulsive Symptoms in Schizophrenia: Associated Clinical Features, Cognitive Function and Medication Status. Schizophrenia research. 2005;75:349-362.
10808.	Ongur D, DC G. Obsessive-Compulsive Symptoms in Schizophrenia: Associated Clinical Features, Cognitive Function and Medication Status. Schizophrenia research. 2005;75:349-362.
10809.	Ono S, Suzuki Y, Fukui N, et al. Therapeutic drug monitoring for fluvoxamine: A receiver operating characteristics curve analysis in major depression. International journal of neuropsychopharmacology. 2010;Conference:80-81.
10810.	Onur E, PD Y. Frontotemporal dementia and psychiatric symptoms. Dusunen Adam. 2011;24:228-238.
10811.	Oosting R, JSW C, Olivier B, Banerjee P. Switching from paroxetine to vilazodone significantly reduces sexual side effects in male rats. Neuropsychopharmacology. 2014;Conference:S128-S129.
10812.	OP A, AH F, Hirani V, et al. B Vitamins to Enhance Treatment Response to Antidepressants in Middle-Aged and Older Adults: Results From the B-Vitage Randomised, Double-Blind, Placebo-Controlled Trial. British journal of psychiatry. 2014;205:450-457.
10813.	OP A, Barclay L. Sex hormones and their impact on dementia and depression: A clinical perspective. Expert opinion on pharmacotherapy. 2001;2:527-535.
10814.	Opielak G, Madej-Czerwonka B, Piotrkowicz J, et al. Antidepressant drugs and cardiovascular system. Current Issues in Pharmacy and Medical Sciences. 2013;26:144-147.
10815.	Oppel L, G vG, Meterissian G, Haiek L, McCusker J, Bellavance F. St John's wort as treatment for depression (multiple letters) [2]. Canadian Family Physician. 2002;48:1290.
10816.	Oranje B, Wienberg M, BY G. A Single High Dose of Escitalopram Disrupts Sensory Gating and Habituation, but Not Sensorimotor Gating in Healthy Volunteers. Psychiatry research. 2011;186:431-436.
10817.	Ordacgi L, MV M, LF F. Management of obsessive-compulsive disorder with fluvoxamine extended release. Neuropsychiatric disease and treatment. 2009;5:301-308.
10818.	Orlando R, Martin S, Andrighetto L, Floreani M, Palatini P. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. British journal of clinical pharmacology. 2010;69:279-286.
10819.	Ormerod S, SE M, JJ C, RE F. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: A systematic review and meta-analysis. Drug safety. 2008;31:597-607.
10820.	Ornah D, Sara LL, Kajsa K. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting. Current medical research and opinion. 2014;30:1301-1307.
10821.	Orr K, Taylor D. Psychostimulants in the treatment of depression: A review of the evidence. CNS drugs. 2007;21:239-257.
10822.	Orriols L, Wilchesky M, Lagarde E, Suissa S. Prescription of Antidepressants and the Risk of Road Traffic Crash in the Elderly: a Case-Crossover Study. British journal of clinical pharmacology. 2013;76:810-815.
10823.	Orsolini L, Bellantuono C. Serotonin Reuptake Inhibitors and Breastfeeding: a Systematic Review. Human Psychopharmacology-Clinical and Experimental. 2015;30:4-20.
10824.	Ortiz LS, Diaz MA, Mejias VJA, Ruvinskis PE, Juno R, Ortega SHA. Usage of venlafaxine and fluoxetine in ambulatory depressed patients of a university medical school. [Spanish]. Psiquiatria. 2003;19:22-26.
10825.	OS P. Heart-focused anxiety as a mediating variable in the treatment of non-cardiac chest pain by cognitive-behavioural and psychopharmacological treatment by paroxetine. Journal of psychosomatic research. 2010;69:237-239.
10826.	OS P, WE W. Psychological Treatments in Functional Gastrointestinal Disorders: A Primer for the Gastroenterologist. Clinical gastroenterology and hepatology. 2013;11:208-216.
10827.	OS S, AB C, Dimartini A. Psychiatric care of patients undergoing organ transplantation. Transplantation. 2009;87:1753-1761.
10828.	Osatuke K, Reid M, WB S, JW K, Zisook S, Mohamed S. Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia. Psychotherapy research. 2011;21:41-53.
10829.	Osborn J, Raetz J, Kost A. Seasonal Affective Disorder, Grief Reaction, and Adjustment Disorder. Medical clinics of North America. 2014;98:1065-+.
10830.	Oscar B, Beatriz C, Benjamin C, et al. Clinical variables, molecular genotypes and personality as predictors of antidepressant response: A parallel study of a clinical trial of fluvoxamine vs. imipramine. [Spanish]. Salud mental (Mexico City, Mexico). 1998;21:32-39.
10831.	Osher Y, RH B. Omega-3 fatty acids in depression: A review of three studies. CNS neuroscience & therapeutics. 2009;15:128-133.
10832.	Oswald P, Souery D, Kasper S, et al. Current issues in bipolar disorder: A critical review. European neuropsychopharmacology. 2007;17:687-695.
10833.	Oswald P, Souery D, Mendlewicz J. Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression [1]. International journal of neuropsychopharmacology. 2003;6:85-87.
10834.	OT O, Mufaddel A, Almugaddam F, EF A. The psychiatric aspects of skin disorders. Expert review of dermatology. 2011;6:195-209.
10835.	Otsubo T, Akimoto Y, Yamada H, et al. A Comparative Study of the Efficacy and Safety Profiles Between Fluvoxamine and Nortriptyline in Japanese Patients with Major Depression. Pharmacopsychiatry. 2005;38:30-35.
10836.	Otsubo T, Akimoto Y, Yamada H, et al. A Comparative Study of the Efficacy and Safety Profiles Between Fluvoxamine and Nortriptyline in Japanese Patients With Major Depression. Pharmacopsychiatry. 2005;38:30-35.
10837.	Otsuka T, Togo T, Sugiyama N, et al. Perospirone Augmentation of Paroxetine in Treatment of Refractory Obsessive-Compulsive Disorder With Depression. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:564-566.
10838.	Otte C. Incomplete remission in depression: Role of psychiatric and somatic comorbidity. Dialogues in clinical neuroscience. 2008;10:453-460.
10839.	Otte C, Hinkelmann K, Moritz S, et al. Modulating the mineralocorticoid receptor as add-on therapy in antidepressant treatment with SSRI: A randomised controlled trial. European neuropsychopharmacology. 2009;Conference:S193-S194.
10840.	Otter M, Cohen D. Electroconvulsive therapy in depressed adolescent [3]. [Dutch]. Nederlands tijdschrift voor geneeskunde. 2007;151:2643-2644.
10841.	Otto B, Gerhard G, Hermann W, David H. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of psychiatric research. 1996;30:441-451.
10842.	Otto M, FW B, TS J, Brosen K, SH S. Escitalopram in Painful Polyneuropathy: a Randomized, Placebo-Controlled, Cross-Over Trial. Pain. 2008;139:275-283.
10843.	Outhred T, Das P, Dobson-Stone C, et al. The Impact of 5-Httlpr on Acute Serotonin Transporter Blockade by Escitalopram on Emotion Processing: Preliminary Findings From a Randomised, Crossover Fmri Study. Australian and New Zealand journal of psychiatry. 2014;48:1115-1125.
10844.	OV F, A SJ, ES H, RC F. Antidepressant efficacy of sertraline and imipramine for the treatment of major depression in elderly outpatients. S�o Paulo medical journal = Revista paulista de medicina. 2000;118:99-104.
10845.	OV T, JO S. Pharmacotherapy of adult attention deficit/hyperactivity disorder: Review of evidence-based practices and future directions. Expert opinion on pharmacotherapy. 2008;9:1299-1310.
10846.	OV T, LM L. Pharmacotherapy of Postpartum Depression: Current Practice and Future Directions. Expert opinion on pharmacotherapy. 2005;6:1999-2005.
10847.	Overlack M, Gastpar M, Davids E. Escitalopram (Cipralex). [German]. Internistische Praxis. 2006;46:899-902.
10848.	Overlack M, Gastpar M, Davids E. Cipralex. [German]. Chirurgische Praxis. 2006;66:541-544.
10849.	Overlack M, Gastpar M, Davids E. Escitalopram (Cipralex). [German]. Gynakologische Praxis. 2006;30:769-772.
10850.	Overlack M, Gastpar M, Davids E. Escitalopram (Cipralex). [German]. Padiatrische Praxis. 2006;69:171-174.
10851.	Overshott R, Byrne J, Burns A. Nonpharmacoloqical and pharmacological interventions for symptoms in Alzheimer's disease. Expert review of neurotherapeutics. 2004;4:809-821.
10852.	Owe-Larsson B, Sall L, Salamon E, Allgulander C. HIV infection and psychiatric illness. African Journal of Psychiatry (South Africa). 2009;12:115-128.
10853.	Oz M, DE L, GA P. Methylene blue and Alzheimer's disease. Biochemical pharmacology. 2009;78:927-932.
10854.	Ozcan L, EC P, Otunctemur A, Ozbek E. Duloxetine, Dual Serotonin and Norepinephrine Reuptake Inhibitor, Versus Paroxetine, Selective Serotonin Reuptake Inhibitor, in the Treatment for Premature Ejaculation. International urology and nephrology. 2015;47:283-287.
10855.	Ozdel K, Yilmaz A, Soykan A. What are the treatment outcomes in neurotic disorders with pharmacotherapy?. [Turkish]. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2009;19:S170-S172.
10856.	Ozdel O, Oguzhanoglu A, NK O, Karadag F, FC A, Aybek Z. A Follow-up Study of Male Sexual Disorders - the Neurophysiological Assessments, Anxiety-Depression Levels, and Response to Fluoxetine Treatment. Journal of clinical psychopharmacology. 2004;24:461-463.
10857.	Ozdel O, Oguzhanoglu A, NK O, Karadag F, FC A, Aybek Z. A Follow-up Study of Male Sexual Disorders - the Neurophysiological Assessments, Anxiety-Depression Levels, and Response to Fluoxetine Treatment. Journal of clinical psychopharmacology. 2004;24:461-463.
10858.	Ozen B, DI G, Turkmen C, Agan K, NT E. Speech-induced primary lingual dystonia: A rare focal dystonia. Neurological sciences. 2011;32:155-157.
10859.	Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: Etiologic and therapeutic concerns. Rheumatology international. 2006;26:598-603.
10860.	Ozgoli G, Shahveh M, Esmaielli S, Nassiri N. Essential oil of citrus sinensis for the treatment of premenstrual syndrome; a randomized double-blind placebo-controlled trial. [Arabic]. Journal of Reproduction and Infertility. 2011;12:123-129.
10861.	Ozilhan S, Melikoglu U, Tarhan N, Ozden T, AM S. Exploring Novelties in Psychopharmacology; Therapeutic Drug Monitoring. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2009;19:S37-S41.
10862.	Ozkan B, Wilkins K, Muralee S, RR T. Pharmacotherapy for inappropriate sexual behaviors in dementia: A systematic review of literature. American journal of Alzheimer's disease and other dementias. 2008;23:344-354.
10863.	Ozomaro U, Wahlestedt C, CB N. Personalized medicine in psychiatry: Problems and promises. BMC medicine. 2013.
10864.	Ozturk M, Ucar S, Sar F, Erdogan S, Topdag M, Iseri M. Possible protective effect of sertraline against cisplatin-induced ototoxicity: An experimental study. TheScientificWorldJournal. 2013.
10865.	Ozyildirim I, Kosecioglu S. Mirtazapine induced tardive akathisia: A case report. European psychiatry. 2009;Conference:S507.
10866.	P AE, C MD, Haim EM. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Current medical research and opinion. 2008;24:1115-1121.
10867.	P AO, Anna W, J HG. Preventing depression after stroke: Results from a randomized placebo-controlled trial. Journal of clinical psychiatry. 2006;67:1104-1109.
10868.	Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: A randomized, placebo-controlled trial, Journal of clinical psychiatry(2012).
10869.	P BJ, S BM, Robert G, A RM, Karl R. "Evidence for short-term psychodynamic psychotherapy for depression": Reply. Journal of clinical psychiatry. 2012;73:718-720.
10870.	P BR. To the editor. American journal of psychiatry. 2005;162:817-818.
10871.	P CM, Valentina G, Sonja E, John K, Mark R, Christian GJ. A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. Journal of affective disorders. 2003;77:135-141.
10872.	P DC, Koleva D, Mangia A, Motterlini N, Garattini L. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. Journal of medical economics. 2008;11:151-163.
10873.	P dJ. Cardiovascular disease and depression: Caring for the brokenhearted. Dialogues in cardiovascular medicine. 2012;17:87-103.
10874.	P DJ, FB H, Boffa D, et al. Prevention of Major Depression in Complex Medically Ill Patients: Preliminary Results From a Randomized, Controlled Trial. Psychosomatics. 2009;50:227-233.
10875.	P dJ, Honig A, JP vM, et al. Nonresponse to treatment for depression following myocardial infarction: Association with subsequent cardiac events. American journal of psychiatry. 2007;164:1371-1378.
10876.	P DJ, JP VM, Ormel J. Authors' reply [4]. British journal of psychiatry. 2007;191:456-457.
10877.	P DJ, K RP, E TS, W BS, H CM. Treatment of social anxiety with paroxetine: Mediation of changes in anxiety and depression symptoms. Comprehensive psychiatry. 2009;50:135-141.
10878.	P FJ. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Journal of clinical psychiatry. 1985;46:369-372.
10879.	P FJ, A GE, Andrew JJ, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. Journal of clinical psychiatry. 1991;52:329-335.
10880.	P FJ, B CJ. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. Journal of clinical psychiatry. 1985;46:20-25.
10881.	P FJ, Boyer WF. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Acta neurologica Scandinavica. 1989;80:125-129.
10882.	P FJ, F BW. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Journal of clinical psychiatry. 1992;53:44-47.
10883.	P FJ, F BW, H MC, Gordon H. An overview of fluoxetine in geriatric depression. The British Journal of Psychiatry. 1988;153:105-108.
10884.	P FJ, F BW, H MC, Gordon HG. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. International clinical psychopharmacology. 1989;4:239-244.
10885.	P FJ, F BW, H MC, Gordon HG. A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. International clinical psychopharmacology. 1989;4:127-134.
10886.	P FJ, Kerstin O. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Journal of clinical psychiatry. 1999;60:824-830.
10887.	P FJ, Richard EA, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. Journal of affective disorders. 1998;47:55-62.
10888.	P FM. Reproductive neuroscience: Biology, environment, and clinical implications in women's mental health. Journal of clinical psychiatry. 2008;69:971-972.
10889.	P FM. The tenets of perinatal psychiatry. Journal of clinical psychiatry. 2012;73:233-234.
10890.	P FM, M HA, Betty W, et al. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. Maturitas. 2013;75:170-174.
10891.	P FM, Rebecca H, H BB. Escitalopram for perimenopausal depression: an open-label pilot study.[Erratum appears in J Womens Health (Larchmt). 2006 Oct;15(8):988]. Journal of women's health (2002). 2006;15:857-861.
10892.	P G-JK, L MP. Escitalopram: a review of its use in the management of major depressive disorder in adults. [Review]. CNS drugs. 2010;24:769-796.
10893.	P GR, F BR, J ZM, Seymour F, D GM. A meta-analysis of fluoxetine outcome in the treatment of depression. Journal of nervous and mental disease. 1994;182:547-551.
10894.	P GR, Seymour F. Mood-mending medicines: Probing drug, psychotherapy, and placebo solutions. 1997:115-172.
10895.	Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: A candidate gene analysis, Journal of clinical psychiatry(2012).
10896.	P HJ, Wei Z, Virginie A, et al. Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder. Psychiatry research. 2012;200:63-65.
10897.	P HS, V NE, Malvin J, Laurie W. The effect of sertraline on methadone plasma levels in methadone- maintenance patients. American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2000;9:63-69.
10898.	P R-BP, Joan R, S CD, J KW. Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Journal of clinical psychiatry. 2003;64:383-389.
10899.	P R-BP, Philip P, D PC, A CJ. Paroxetine Response and Tolerability Among Ethnic Minority Patients With Mood or Anxiety Disorders: A Pooled Analysis. Journal of clinical psychiatry. 2005;66:1228-1233.
10900.	P R-BP, Wayne K, S CD, Joan R. A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Archives of general psychiatry. 2001;58:869-876.
10901.	P RL. Listening to Prozac and hearing noise: Commentary on Kirsch and Sapirstein's "Listening to Prozac but hearing placebo". Prevention & Treatment. 1998;1:No Pagination Specified.
10902.	P RS, A SH. Antidepressant medication for the treatment of late-life depression. 2004:192-202.
10903.	P RS, Erica S. Treatment of depression in patients with heart disease. [Review] [37 refs]. Journal of clinical psychiatry. 1999;60 Suppl 2:34-37.
10904.	P RS, Fouzia L-T, S KJ, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA: Journal of the American Medical Association. 1998;279:287-291.
10905.	P RS, S BP, L MM, et al. Transcranial direct stimulation and fluoxetine for the treatment of depression. European Psychiatry: the Journal of the Association of European Psychiatrists. 2008;23:74-76.
10906.	P SD, S GS, K CD. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. [Review]. International journal of geriatric psychiatry. 2010;25:1296-1305.
10907.	P SS, Vidhi S, Nilamadhab K. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. [Review]. International journal of neuropsychopharmacology. 2012;15:417-428.
10908.	Relationship between obesity and depression: Characteristics and treatment outcomes with antidepressant medication, Psychosomatic medicine(2013).
10909.	P VD. Escitalopram, a complete clinical development. [French]. Encephale. 2007;33:134-139.
10910.	P VD. Escitalopram, Full Clinical Development. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2007:S134-S139.
10911.	P VO, Ajlm VB, E DH, R VD. Cognitive Therapy and Exposure in Vivo Alone and in Combination With Fluvoxamine in Obsessive-Compulsive Disorder: a 5-Year Follow-up. Journal of clinical psychiatry. 2005;66:1415-1422.
10912.	P-H Z, W-S Z. Effects of depression on treatment progress of adhesiveness scapulohumeral periarthritis. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:4696-4697.
10913.	P-L W, H-S T, H-Y L, C-A T, GE T. Sarcosine therapy for obsessive compulsive disorder: A prospective, open-label study. Journal of clinical psychopharmacology. 2011;31:369-374.
10914.	P-M L, Brousse G, Schwan R. [Escitalopram for treatment of major depressive disorder in adults]. [Review] [28 refs] [French]. Encephale. 2005;31:490-501.
10915.	P-M L, J-M A, Despiegel N, Verpillat P. Efficacy of Escitalopram in Patients With Severe Depression: a Pooled Analysis. International journal of clinical practice. 2005;59:268-275.
10916.	P-M L, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: A 3-month double-blind study. Journal of clinical psychiatry. 2002;63:1020-1027.
10917.	P-Y C, S-C W, RE P, K-M L. Biological variations in depression and anxiety between east and west. CNS neuroscience & therapeutics. 2009;15:283-294.
10918.	PA A, Pahissa J. QT alterations in psychopharmacology: Proven candidates and suspects. Current drug safety. 2010;5:97-104.
10919.	PA C, TW E, Barton C, Ahmed D, PA F. Management of depression and anxiety in COPD. European Respiratory Monograph. 2013;59:144-163.
10920.	PA K, DS C, RS M. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Canadian Journal of Psychiatry. 2012;57:782-788.
10921.	PA K, DS C, RW L, RS M. Sleep architecture variation: A mediator of metabolic disturbance in individuals with major depressive disorder. Sleep medicine. 2013;14:943-949.
10922.	PA K, RS M, RW L. Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions. CNS drugs. 2014;28:601-609.
10923.	PA M, RW P. Emerging treatments for bipolar disorder: Safety and adverse effect profiles. Annals of pharmacotherapy. 2006;40:276-285.
10924.	PA N. Use of Serotonin Selective Reuptake Inhibitors in Geriatric Depression. Journal of clinical psychiatry. 1996;57:12-22.
10925.	PA N, CW H, TL M, et al. A Comparison of Various Methods of Measuring Antidepressant Medication Adherence Among Children and Adolescents With Major Depressive Disorder in a 12-Week Open Trial of Fluoxetine. Journal of child and adolescent psychopharmacology. 2010;20:431-439.
10926.	PA S. Treatment of depression in patients with congestive heart failure. Heart failure reviews. 2009;14:7-12.
10927.	PA S. Depression treatment and coronary artery disease outcomes: Time for reflection. Journal of psychosomatic research. 2013;74:4-5.
10928.	PA S, DA F, LA E, EGE M, CV D. Psychiatric Aspects of Heart and Lung Disease in Critical Care. Critical care clinics. 2008;24:921-947.
10929.	PA S, DJ W, PJ C. Brain 5-HT neurotransmission during paroxetine treatment. British journal of psychiatry. 1998;172:49-52.
10930.	PA S, Lesperance F, Frasure-Smith N, et al. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. American heart journal. 1999;137:1100-1106.
10931.	PA S, SG B. Teaching clinical psychopharmacology on an inpatient psychiatric research center. Journal of clinical pharmacology. 1994;34:215-221.
10932.	PA S-M, KC L, MT A, Golding M, SS G. Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients. Journal of affective disorders. 2004;79:51-61.
10933.	PA T. Drug therapy in women: "Off-label use"?. [German]. Psychopharmakotherapie. 2007;14:237-242.
10934.	PA V, SN G. Solving the Antidepressant Efficacy Question: Effect Sizes in Major Depressive Disorder. Clinical therapeutics. 2011;33:B49-B61.
10935.	PABP B. Treatment of depressive symptoms in Parkinson's disease. [Review]. European journal of neurology. 2011;18 Suppl 1:11-15.
10936.	Pacchiarotti I. Antipsychotics in the treatment of bipolar depression. European psychiatry. 2011.
10937.	Pacchiarotti I, DJ B, RJ B, et al. The International Society for Bipolar Disorders (Isbd) Task Force Report on Antidepressant Use in Bipolar Disorders. American journal of psychiatry. 2013;170:1249-1262.
10938.	Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: Towards a new definition. Acta psychiatrica Scandinavica. 2009;120:429-440.
10939.	Pacher P, Kecskemeti V. Trends in the Development of New Antidepressants. Is There a Light at the End of the Tunnel? Current medicinal chemistry. 2004;11:925-943.
10940.	Pacher P, Kecskemeti V. Trends in the Development of New Antidepressants. Is There a Light at the End of the Tunnel? Current medicinal chemistry. 2004;11:925-943.
10941.	Pacher P, Kohegyi E, Kecskemeti V, Furst S. Current Trends in the Development of New Antidepressants. Current medicinal chemistry. 2001;8:89-100.
10942.	Pacher P, Ungvari Z, Kecskemeti V, Furst S. Review of Cardiovascular Effects of Fluoxetine, a Selective Serotonine Reuptake Inhibitor, Compared to Tricyclic Antidepressants. Current medicinal chemistry. 1998;5:381-390.
10943.	Pacher P, Ungvari Z, PP N, Furst S, Kecskemeti V. Speculations on Difference Between Tricyclic and Selective Serotonin Reuptake Inhibitor Antidepressants on Their Cardiac Effects. Is There Any? Current medicinal chemistry. 1999;6:469-480.
10944.	Paclt I, Slav�cek J, Dohnalov� A, Kitzlerov� E, Pisvejcov� K. Electrocardiographic dose-dependent changes in prophylactic doses of dosulepine, lithium and citalopram. Physiological research. 2003;52:311-317.
10945.	Padberg F, H-J M, Bottlender R, Hampel H. Modern therapy for dementia. [German]. MMW Fortschritte der Medizin. 2005;147:71-77.
10946.	Padberg F, Zwanzger P, ME K, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: Relation between efficacy and stimulation intensity. Neuropsychopharmacology. 2002;27:638-645.
10947.	Padberg F, Zwanzger P, Thoma H, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: Comparative study of fast, slow and sham rTMS. Psychiatry research. 1999;88:163-171.
10948.	Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. American journal of psychiatry. 2007;164:1181-1188.
10949.	Padideh G, Esmail S, Mojdeh M, Mahammad-Zaman K, Majid S, Simin D-K. Comparing the Effects of 8-Week Treatment With Fluoxetine and Imipramine on Fasting Blood Glucose of Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2004;24:386-388.
10950.	PAFP F. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram]. [Review] [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2012;38:86-96.
10951.	Page K, Brownie S, Wohlmuth H. Natural management options for menopause. Integrative medicine. 2005;4:20-28.
10952.	PAGM DS. Herbal remedies. New England journal of medicine. 2002;347:2046-2056.
10953.	PAGM DS, DJ T. St. John's wort on the balance of benefit and risk. Important new information on efficacy and safety. [Dutch]. Pharmaceutisch weekblad. 2000;135:455-462.
10954.	PAGP G. Restoring circadian rhythms: a new way to successfully manage depression. [Review]. Journal of psychopharmacology (Oxford, England). 2010;24:15-19.
10955.	PAHP H. Fibromyalgia Syndrome. New Developments in Pharmacotherapy. Zeitschrift fur Rheumatologie. 2008;67:75-82.
10956.	PAHP H. Treatment of Patients With Comorbid Depression and Diabetes With Metformin and Milnacipran. Neuropsychiatric disease and treatment. 2010;6:9-15.
10957.	Pahwa R, KE L. Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study. Movement disorders. 2003;18:584-587.
10958.	Paile-Hyvarinen M, Wahlbeck K, JG E. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC family practice. 2003;4:7.
10959.	Paile-Hyvarinen M, Wahlbeck K, JG E. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial. BMC family practice. 2003;4:1-6.
10960.	Quality of Life and Metabolic Status in Mildly Depressed Patients With Type 2 Diabetes Treated With Paroxetine: a Double-Blind Randomised Placebo Controlled 6-Month Trial, BMC family practice(2007).
10961.	Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial, BMC family practice(2007).
10962.	PAJ R, Ilchef R, Cooper A. Psychiatric morbidity in psoriasis: A review. Australasian journal of dermatology. 2004;45:155-160.
10963.	Pakesch G, Dossenbach M. [Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners]. [German]. Wiener klinische Wochenschrift. 1991;103:176-182.
10964.	Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The Impact of Left Prefrontal Repetitive Transcranial Magnetic Stimulation on Depression in Parkinson's Disease: a Randomized, Double-Blind, Placebo-Controlled Study. Movement disorders. 2010;25:2311-2317.
10965.	Palaniyappan L, RH M-W. Antidepressants: Will New Mechanisms of Action Improve Poor Outcomes? British journal of hospital medicine. 2008;69:88-90.
10966.	Palatnik A, Frolov K, Fux M, Benjamin J. Double-Blind, Controlled, Crossover Trial of Inositol Versus Fluvoxamine for the Treatment of Panic Disorder. Journal of clinical psychopharmacology. 2001;21:335-339.
10967.	Palego L, Marazziti D, Biondi L, et al. Simultaneous Plasma Level Analysis of Clomipramine, N-Desmethylclomipramine, and Fluvoxamine by Reversed-Phase Liquid Chromatography. Therapeutic drug monitoring. 2000;22:190-194.
10968.	Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS spectrums. 2014;19:50-61.
10969.	Pallanti S, Quercioli L, Bruscoli M. Response Acceleration With Mirtazapine Augmentation of Citalopram in Obsessive-Compulsive Disorder Patients Without Comorbid Depression: a Pilot Study. Journal of clinical psychiatry. 2004;65:1394-1399.
10970.	Pallanti S, Quercioli L, Bruscoli M. Response Acceleration With Mirtazapine Augmentation of Citalopram in Obsessive-Compulsive Disorder Patients Without Comorbid Depression: a Pilot Study. Journal of clinical psychiatry. 2004;65:1394-1399.
10971.	Palma A, Pancheri P. Antidepressant drugs in the treatment of somatic pain Focus on venlafaxine. [Italian]. Italian Journal of Psychopathology. 2004;10:140-166.
10972.	Palmer E, Roche J, Fuller M. Influence of smoking status on time to discontinuation of duloxetine in patients with major depressive disorder (MDD). Journal of pharmacy practice. 2013;Conference:330.
10973.	PALP-M L. The Antidepressant Agomelatine Improves the Quality of Life of Depressed Patients: Implications for Remission. Journal of psychopharmacology (Oxford, England). 2010;24:21-26.
10974.	Palta P, LJ S, ER M, SL S. Depression and Oxidative Stress: Results From a Meta-Analysis of Observational Studies. Psychosomatic medicine. 2014;76:12-19.
10975.	Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. British journal of psychiatry. 2002;180:104-109.
10976.	Pan A, Sun Q, OI O, et al. Use of antidepressant medication and risk of type 2 diabetes: Results from three cohorts of US adults. Diabetologia. 2012;55:63-72.
10977.	Panay N, Hamoda H, Arya R, Savvas M. The 2013 British Menopause Society & Women's health concern recommendations on hormone replacement therapy. Menopause international. 2013;19:59-68.
10978.	Pancheri P, Brugnoli R, Cirignotta F, et al. Correlation between psychiatric and sleep disorders: Results of an Italian survey. [Italian]. Italian Journal of Psychopathology. 2007;13:1-24.
10979.	Pancheri P, Tarsitani L. A new approach to antipsychotic therapy: A D2-5HT1A partial agonist. [Italian]. Italian Journal of Psychopathology. 2005;11:96-119.
10980.	Pande AC, Sayler ME. Severity of depression and response to fluoxetine. International clinical psychopharmacology. 1993;8:243-245.
10981.	Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder, Journal of affective disorders(2013).
10982.	Pankiewicz O, Jagodzinska K, Rys P, et al. Clinical Efficacy and Safety of Duloxetine in Comparison With Placebo in Patients With Major Depressive Disorder in Poland. Value in health. 2009;12:A351.
10983.	Pankiewicz O, Jagodzinska K, Rys P, et al. Clinical efficacy and safety of duloxetine in comparison with placebo in patients with major depressive disorder in Poland. Value in health. 2009;Conference:A351.
10984.	Pao M, Bosk A. Anxiety in medically ill children/adolescents. Depression and anxiety. 2011;28:40-49.
10985.	Paola R, Livio M, Roberta R, Elisa R, Filippo B. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: Efficacy and psychosocial outcomes. Psychiatry research. 2002;112:145-152.
10986.	Paolo B, Cipriani A, Hotopf M, Barbui C. Side-Effect Profile of Fluoxetine in Comparison with Other SSRIs, Tricyclic and Newer Antidepressants: A Meta-Analysis of Clinical Trial Data. Pharmacopsychiatry. 2005;38:69-77.
10987.	Paolo G, Maurizio P, Marco I, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. [Review] [68 refs]. Human Psychopharmacology: Clinical and Experimental. 2009;24:177-190.
10988.	Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatric disease and treatment. 2008;4:145-154.
10989.	Paolucci S, Antonucci G, MG G, et al. Post-Stroke Depression, Antidepressant Treatment and Rehabilitation Results - a Case-Control Study. Cerebrovascular diseases (Basel, Switzerland). 2001;12:264-271.
10990.	Paolucci S, D DA. New Developments on Drug Treatment Rehabilitation. Clinical and experimental hypertension. 2006;28:345-348.
10991.	Papafragkakis H, MS R, Moehlen M, Dhillon S, Martin P. Depression and pegylated interferon-based hepatitis C treatment. International journal of interferon, cytokine and mediator research. 2012;4:25-35.
10992.	Papakostas G, Dragheim M, RZ N. Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response. European neuropsychopharmacology. 2014;Conference:S466.
10993.	Papakostas G, MB S, Baer L, RC S. An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Ziprasidone in Patients With Major Depressive Disorder Receiving Treatment With Escitalopram. Neuropsychopharmacology. 2014;Conference:S344-S345.
10994.	Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Journal of psychopharmacology (Oxford, England). 2008;22:843-848.
10995.	Papanikolaou K, Richardson C, Pehlivanidis A, Papadopoulou-Daifoti Z. Efficacy of Antidepressants in Child and Adolescent Depression: a Meta-Analytic Study. Journal of neural transmission. 2006;113:399-415.
10996.	Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I. An Open Pilot Study of Tiagabine in Alcohol Dependence: Tolerability and Clinical Effects. Journal of psychopharmacology (Oxford, England). 2010;24:1375-1380.
10997.	Parakh K, Sakhuja A, Bhat U, RC Z. Platelet function in patients with depression. Southern medical journal. 2008;101:612-617.
10998.	Paranthaman R, RC B. Treatment of psychiatric syndromes due to cerebrovascular disease. International review of psychiatry. 2006;18:453-470.
10999.	Parashar S, Vaccarino V. Depression and CHD risk: How should we intervene? Current treatment options in cardiovascular medicine. 2007;9:272-277.
11000.	Pardini M, Guida S, Primavera A, Krueger F, Cocito L, LE G. Amisulpride Vs. Fluoxetine Treatment of Chronic Fatigue Syndrome: a Pilot Study. European neuropsychopharmacology. 2011;21:282-286.
11001.	Parekar R, Jadhav K, Marathe P, Rege N. Effect of Saraswatarishta in animal models of behavior despair. Journal of Ayurveda and integrative medicine. 2014;5:141-147.
11002.	Parellada M, Moreno C, Moreno M, Espliego A, E dP, Arango C. Placebo effect in child and adolescent psychiatric trials. European neuropsychopharmacology. 2012;22:787-799.
11003.	Parikh C. Antidepressants in the elderly: Challenges for study design and their interpretation. British journal of clinical pharmacology. 2000;49:539-547.
11004.	Parinda K, A BJ, A BM, et al. Effects of exercise training on cognitive functioning among depressed older men and women. Journal of aging and physical activity. 2001;9:43-57.
11005.	Parissis J, Fountoulaki K, Paraskevaidis I, DT K. Sertraline for the Treatment of Depression in Coronary Artery Disease and Heart Failure. Expert opinion on pharmacotherapy. 2007;8:1529-1537.
11006.	Park M, CF R. Depression among older adults with diabetes mellitus. Clinics in geriatric medicine. 2015;31:117-137.
11007.	Parker G. Do the newer antidepressant have mood stabilizing properties [6]. Australian and New Zealand journal of psychiatry. 2002;36:427-428.
11008.	Parker G. Critique of the guidelines for the treatment of depression: Flaws in the construction. Australian and New Zealand journal of psychiatry. 2004;38:885-890.
11009.	Parker G. What is the place of psychological treatments in mood disorders? International journal of neuropsychopharmacology. 2007;10:137-145.
11010.	The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: A 12-week single-blind randomized study, Acta psychiatrica Scandinavica(2013).
11011.	Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? American journal of psychiatry. 2005;162:796-798.
11012.	Parker G, Parker I, Brotchie H, Stuart S. Interpersonal psychotherapy for depression? The need to define its ecological niche. Journal of affective disorders. 2006;95:1-11.
11013.	Parker G, Parker K. Which antidepressants flick the switch? Australian and New Zealand journal of psychiatry. 2003;37:464-468.
11014.	Parker G, Paterson A, Blanch B. Suggested early onset of true action of antidepressant drugs may be artefactual: A heuristic study. International clinical psychopharmacology. 2013;28:29-32.
11015.	Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of affective disorders. 2006;92:205-214.
11016.	Parker J, Buga S, JE S, PE S. Advancements in the management of urologic chronic pelvic pain: What is new and what do we know? Current urology reports. 2010;11:286-291.
11017.	Parmentier H, Garcia-Campayo J, Prieto R. Comprehensive Review of Generalized Anxiety Disorder in Primary Care in Europe. Current medical research and opinion. 2013;29:355-367.
11018.	Parsons A, Ingram J, Inglis J, et al. A Proof of Concept Randomised Placebo Controlled Factorial Trial to Examine the Efficacy of St John's Wort for Smoking Cessation and Chromium to Prevent Weight Gain on Smoking Cessation. Drug and alcohol dependence. 2009;102:116-122.
11019.	Partinen M. Challenging issues: Sleep-wake, augmentation and quality of life. Sleep medicine. 2007;8:S19-S24.
11020.	Partonen T, Lonnqvist J. Seasonal affective disorder. Lancet. 1998;352:1369-1374.
11021.	Partonen T, Lonnqvist J. Seasonal affective disorder: A guide to diagnosis and management. CNS drugs. 1998;9:203-212.
11022.	Partonen T, Sihvo S, JK L. Patients Excluded From an Antidepressant Efficacy Trial. Journal of clinical psychiatry. 1996;57:572-575.
11023.	Pascal A, Stephane R, Pierre-Michel L, Benoit R. Comparison of escitalopram and citalopram efficacy: A meta-analysis. International journal of psychiatry in clinical practice. 2003;7:259-268.
11024.	Pascal B, Christine D, Michelle K, et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. Journal of pharmacology and experimental therapeutics. 2012;342:429-440.
11025.	Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: A case series. Pharmacopsychiatry. 2010;43:33-35.
11026.	Paslakis G, Westphal S, Hamann B, Gilles M, Lederbogen F, Deuschle M. Unstimulated and glucose-stimulated ghrelin in depressed patients and controls. Journal of psychopharmacology (Oxford, England). 2014;28:582-586.
11027.	Pasquina P, Kirtley R, Ling G. Moderate-to-severe traumatic brain injury. Seminars in neurology. 2014;34:572-583.
11028.	Pasquina P, Kirtley R, Ling G. Moderate-to-severe traumatic brain injury. Seminars in neurology. 2014;34:572-583.
11029.	Pasquini M, Biondi M, Costantini A, et al. Detection and treatment of depressive and anxiety disorders among cancer patients: Feasibility and preliminary findings from a liaison service in an oncology division. Depression and anxiety. 2006;23:441-448.
11030.	Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. [Review]. Expert opinion on drug metabolism & toxicology. 2014;10:121-128.
11031.	Pastor A, DML J, Currie J. High-dose baclofen for treatment-resistant alcohol dependence. Journal of clinical psychopharmacology. 2012;32:266-268.
11032.	Patat A, Troy S, Burke J, et al. Absolute Bioavailability and Electroencephalographic Effects of Conventional and Extended-Release Formulations of Venlafaxine in Healthy Subjects. Journal of clinical pharmacology. 1998;38:256-267.
11033.	Patatanian E, NT W. Drug-induced yawning-A review. Annals of pharmacotherapy. 2011;45:1297-1301.
11034.	Patel L, Lindley C. Aprepitant - A novel NK1 -receptor antagonist. Expert opinion on pharmacotherapy. 2003;4:2279-2296.
11035.	Patel V, AJ F, Hetrick S, McGorry P. Mental health of young people: a global public-health challenge. Lancet. 2007;369:1302-1313.
11036.	Patel V, Chisholm D, Rabe-Hesketh S, Dias-Saxena F, Andrew G, Mann A. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: A randomised, controlled trial. Lancet. 2003;361:33-39.
11037.	Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): A cluster randomised controlled trial, Lancet(2010).
11038.	Pathak S, CJ K, GM R, et al. Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: Initial lessons from the treatment for adolescents with depression study. Current psychiatry reports. 2005;7:429-434.
11039.	Pathak S, ES J, RA K. Adjunctive Quetiapine for Treatment-Resistant Adolescent Major Depressive Disorder: a Case Series. Journal of child and adolescent psychopharmacology. 2005;15:696-702.
11040.	Pathak S, ES J, RA K. Adjunctive Quetiapine for Treatment-Resistant Adolescent Major Depressive Disorder: a Case Series. Journal of child and adolescent psychopharmacology. 2005;15:696-702.
11041.	Pathiyal A, TR H, JK J, Davtian D, Sverdlov L, Keyser M. Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in the Netherlands: A multivariate analysis. Clinical therapeutics. 1997;19:798-810.
11042.	Patin A, Hurlemann R. Modulating amygdala responses to emotion: Evidence from pharmacological fMRI. Neuropsychologia. 2011;49:706-717.
11043.	Paton C. Venlafaxine versus fluoxetine. Journal of clinical psychiatry. 1999;60:708.
11044.	Patrice B, Stuart M, Ulla L, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. International clinical psychopharmacology. 2008;23:243-253.
11045.	Patrick G, Combs G, Gavagan T. Initiating antidepressant therapy? Try these 2 drugs first. Journal of family practice. 2009;58:365-369.
11046.	Patrick L. Treatment of depression: Are we finally on the right track? [References]. Current medical research and opinion. 2013;29:835-838.
11047.	Patrick L, Christian G, Enric A. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. Journal of clinical psychiatry. 2007;68:1723-1732.
11048.	Patrick P, Martin H. Effects of pharmaco- and psychotherapeutic interventions in depression among children and adolescents. [German]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2006;34:243-255.
11049.	Patris M, J-M B, Bougerol T, et al. Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. International clinical psychopharmacology. 1996;11:129-136.
11050.	Patrizia B, Arianna dL, Alberto A, Sonia I, Alice DE, Paolo C. Plasma Catecholamine Levels after Fluoxetine Treatment in Depressive Patients. Neuropsychobiology. 2005;51:72-76.
11051.	Patroneva A, SM C, Fatato P, et al. An Assessment of Drug-Drug Interactions: the Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the Cyp2d6 Probe Desipramine in Healthy Subjects. Drug metabolism and disposition. 2008;36:2484-2491.
11052.	Patten S, Cipriani A, Brambilla P, Nose M, Barbui C. International Dosage Differences in Fluoxetine Clinical Trials. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:31-38.
11053.	Patten S, Cipriani A, Brambilla P, Nose M, Barbui C. International Dosage Differences in Fluoxetine Clinical Trials. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:31-38.
11054.	Achievement and maintenance of sustained response during the treatment for adolescents with depression study continuation and maintenance therapy, Archives of general psychiatry(2008).
11055.	Paul S, David HC. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. Journal of clinical psychiatry. 1985;46:53-58.
11056.	Paul W, S HA, Spilios A. Dopaminergic mechanism of antidepressant action in depressed patients. Journal of affective disorders. 2005;86:37-45.
11057.	Paulig M. Multiple sclerosis - Diagnosis and treatment of neuropsychological symptoms. [German]. Nervenheilkunde. 2005;24:908-912.
11058.	Cardiovascular effects of melatonin receptor agonists, Expert opinion on investigational drugs(2012).
11059.	Pavel M. False conclusions regarding Duloxetine's purported efficacy in pain among depressed patients - Reply. Psychiatria Danubina. 2010;22:551.
11060.	Pavlou M, Lingeswaran A, RA D, MA G, AM B. Simulator based rehabilitation in refractory dizziness. Journal of neurology. 2004;251:983-995.
11061.	Pavlovic Z. Withdrawal symptoms after missing a single dose of Venlafaxine Extended Release. International journal of neuropsychopharmacology. 2010;Conference:81-82.
11062.	Paykel ES. "Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression": Erratum. Acta psychiatrica Scandinavica. 1995;92:467.
11063.	Paz-Filho G, Licinio J, M-L W. Pathophysiological basis of cardiovascular disease and depression: A chicken-and-egg dilemma. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2010;32:181-191.
11064.	PB F, Benitez J, A DC, ZJ D, TL B, Kulkarni J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. American journal of psychiatry. 2006;163:88-94.
11065.	PB F, TJ O, AR L, Kulkarni J, GF E, ZJ D. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Research - Neuroimaging. 2006;148:33-45.
11066.	PB F, TL B, NAU M, et al. Motor cortical excitability and clinical response to rTMS in depression. Journal of affective disorders. 2004;82:71-76.
11067.	PB G, Scuteri A, SE B, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation. 2011;42:2672-2713.
11068.	PB M. Selective Serotonin Reuptake Inhibitors - Adverse-Effects, Toxicity and Interactions. Adverse drug reactions and toxicological reviews. 1994;13:121-144.
11069.	PB M. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Australian and New Zealand journal of psychiatry. 2004;38:280-305.
11070.	PB M, Brodaty H, DL C. Psychiatry. Medical journal of Australia. 2002;176:35.
11071.	PB M, CK L. Transcranial magnetic stimulation for depression. Australian and New Zealand journal of psychiatry. 2006;40:406-413.
11072.	PB M, CK L, Breakspear M. Recent progress in the pharmacotherapy of bipolar disorder. Future neurology. 2009;4:493-508.
11073.	PB M, Gould B. Bipolar disorder: What the GP needs to know. Medicine today. 2004;5:46-53.
11074.	PB M, GS M. Treatment of bipolar depression: Focus on pharmacologic therapies. Expert review of neurotherapeutics. 2005;5:69-78.
11075.	PB M, GS M. Emerging drugs for bipolar disorder. Expert opinion on emerging drugs. 2006;11:621-634.
11076.	PB M, GS M, BL R, Ball J. Summary of guideline for the treatment of bipolar disorder. Australasian psychiatry. 2003;11:39-53.
11077.	PB M, GS M, JR B. Major advances in bipolar disorder. Medical journal of Australia. 2004;181:207-210.
11078.	PB R, KL L, LT D, et al. Safety and Efficacy of Methylphenidate for Apathy in Alzheimer's Disease: a Randomized, Placebo-Controlled Trial. Journal of clinical psychiatry. 2013;74:810-816.
11079.	PB R, LT D, BK M, et al. Sertraline for the treatment of depression in Alzheimer disease. The American Journal of Geriatric Psychiatry. 2010;18:136-145.
11080.	PB R, MM M, CG L. Caregiver assessment of patients' depression in Alzheimer disease: longitudinal analysis in a drug treatment study. American journal of geriatric psychiatry. 2005;13:822-826.
11081.	PB R, RB M, YP M, Wamer A, RB R, Balish M. Repetitive transcranial magnetic stimulation treatment of comorbid posttraumatic stress disorder and major depression. Journal of neuropsychiatry and clinical neurosciences. 2002;14:270-276.
11082.	PC G. Why i think antidepressants cause more harm than good. The Lancet Psychiatry. 2014;1:104-106.
11083.	PC J. Affective Disorder and Epilepsy Comorbidity: Implications for Development of Treatments, Preventions and Diagnostic Approaches. Clinical EEG and neuroscience. 2004;35:53-68.
11084.	PC M, FR V, Machuca M. Drug interactions and possible serotonin syndrome in a patient with fibromyalgia. Vitae. 2014;21:60-61.
11085.	PC M, MH P. Panic: Course, complications and treatment of panic disorder. Journal of psychopharmacology (Oxford, England). 2000;14:S25-S30.
11086.	PC M, PR J, Deng X, MA K. A polymorphism of the GTP-cyclohydrolase i feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants. Pharmacogenomics journal. 2011;11:207-213.
11087.	PC R. Recent literature: Feature Editor: Paul C. Rousseau. Journal of palliative medicine. 2011;14:1275-1276.
11088.	PC S, MD B, CA A. Depression and associated anxiety in primary care: A double-blind comparison of paroxetine and amitriptyline. European neuropsychopharmacology. 1993;3:324-325.
11089.	PC W. Toward a final common pathway of depression: An editorial comment to Jarnum H, Eskildsen SF, Steffensen EG et al. 'Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in depressed patients' (1) Editorial comment. Acta psychiatrica Scandinavica. 2011;124:415-416.
11090.	PC W, Graf T, Germer M, JJ F, Howald H. Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine. Biological psychiatry. 1993;33:373-379.
11091.	PCJ TB, E VO, WW VDB, BE H, HR VB. Fluvoxamine for Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Randomised Controlled Trial [Isrctn88246634]. BMC gastroenterology. 2004;4.
11092.	PCJ TB, E VO, WW VDB, BE H, HR VB. Fluvoxamine for Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Randomised Controlled Trial [Isrctn88246634]. BMC gastroenterology. 2004;4.
11093.	PD H, Bakish D, Chudzik J, Ravindran A, YD L. Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. Journal of psychiatry & neuroscience. 1995;20:11-19.
11094.	PD K, CA ZJ. The acute treatment of bipolar depression: Historically relevant and recent controlled trials. Current psychosis & therapeutics reports. 2006;4:151-158.
11095.	PD R, AS K, GE B, AM F. Treatment of Generalised Anxiety Disorder With Venlafaxine Xr - a Randomised, Double-Blind Trial in Comparison With Buspirone and Placebo. Clinical drug investigation. 2000;19:163-165.
11096.	PD R, SK M, LM C, TJ C. Fluoxetine in Drug-Dependent Delinquents With Major Depression: an Open Trial. Journal of child and adolescent psychopharmacology. 1997;7:87-95.
11097.	PD R, SK M-G, RD D, Lohman M, Klein C, SK S. A Randomized Controlled Trial of Fluoxetine and Cognitive Behavioral Therapy in Adolescents With Major Depression, Behavior Problems, and Substance Use Disorders. Archives of pediatrics & adolescent medicine. 2007;161:1026-1034.
11098.	PD S. Complementary psychocutaneous therapies in dermatology. Dermatologic clinics. 2005;23:723-734.
11099.	PD S. Therapeutic management of psychodermatological disorders. Expert opinion on pharmacotherapy. 2008;9:973-985.
11100.	PD S. Update on psychodermatological disorders. Expert review of dermatology. 2010;5:95-107.
11101.	PD S. Psychodermatological disorders: recognition and treatment. [Review]. International journal of dermatology. 2011;50:1309-1322.
11102.	PD S, Ivey J, Helton M, AL B, Cerna A. Nutritional Issues in Long-Term Care. Journal of the American Medical Directors Association. 2008;9:476-485.
11103.	PD T. Cancer pain and anxiety. Current pain and headache reports. 2003;7:249-261.
11104.	PD T, MA R-A. [Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression]. [Dutch]. Nederlands tijdschrift voor geneeskunde. 2005;149:1314-1317.
11105.	PD W. Clinical Therapeutics: Editorial comment. Clinical therapeutics. 1999;21:279-280.
11106.	PE B, ME T-D, MA Z-S. Duloxetine prophylaxis in chronic tension type headache. Journal of headache and pain. 2010;Conference:S84.
11107.	PE B-H, AG W, Kragh-Sorensen P. Mortality in major affective disorder: relationship to subtype of depression. The Danish University Antidepressant Group. Acta psychiatrica Scandinavica. 1993;87:329-335.
11108.	PE C. Paroxetine and imipramine in the treatment of depressed patients in psychiatric specialist practice. Nordic Journal of Psychiatry, Supplement. 1992;46:33-39.
11109.	PE C, AJ L, ZJ D. Evidence for GABAergic inhibitory deficits in major depressive disorder. Neuroscience and biobehavioral reviews. 2011;35:818-825.
11110.	PE C, Behnke K, CH B, JK O, Bork-Rasmussen H, Nilsson J. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta psychiatrica Scandinavica. 1996;93:158-163.
11111.	PE H, Veitengruber J, CC W, et al. Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. General hospital psychiatry. 2010;32:426-432.
11112.	PE K. Bipolar Depression: a New, Role for Atypical Antipsychotics? Bipolar disorders. 2005;7:34-40.
11113.	PE K, RS M, RC S. Case Studies in Bipolar Depression: Best Practices for the Outpatient. CNS spectrums. 2007;12:4-+.
11114.	PE K, SA C, LL A, et al. Analyses of Treatment-Emergent Mania With Olanzapine/Fluoxetine Combination in the Treatment of Bipolar Depression. Journal of clinical psychiatry. 2005;66:611-616.
11115.	PE K, SL M. New Uses for Antidepressants: Social Phobia. Journal of clinical psychiatry. 1997;58:32-38.
11116.	PE KJ. Bipolar depression: A new role for atypical antipsychotics? Bipolar Disorders, Supplement. 2005;7:34-40.
11117.	PE KJ, EB N, SL M. Advances in the pharmacologic treatment of bipolar depression. Biological psychiatry. 2003;53:671-679.
11118.	PE KJ, JA W, SL M, LM A, SM S. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biological psychiatry. 2000;47:748-755.
11119.	PE KJ, MA F, ME T. Bipolar depression: Best practices for the hospitalized patient. CNS spectrums. 2007;12:1-11.
11120.	PE KJ, RS M, RC S. Bipolar depression: Best practices for the outpatient. CNS spectrums. 2007;12:1-15.
11121.	PE KJ, SL M. New approaches in managing bipolar depression. Journal of clinical psychiatry. 2003;64:13-18.
11122.	PE KJ, SL M. Redefining mood stabilization. Journal of affective disorders. 2003;73:163-169.
11123.	PE KJ, SL M, JM H. Bipolar disorder: An update on recent therapeutic trials. Psychopharm Review. 2011;46:25-30.
11124.	PE KJ, SM S, SL M. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Journal of clinical psychiatry. 2000;61:4-9.
11125.	PE M, LK G, EJ T, et al. Structure-Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors. Journal of medicinal chemistry. 2008;51:4038-4049.
11126.	PE S. The changing horizon in the treatment of depression: scientific/clinical publication overview. [Review] [21 refs]. Journal of clinical psychiatry. 1991;52 Suppl:35-43.
11127.	PE S, Holtz A. Fluoxetine Tenth Anniversary Update: the Progress Continues. Clinical therapeutics. 1997;19:1135-1250.
11128.	Pearce S, Ahmed N, GM V. Case study a case study of delayed serotonin syndrome: Lessons learned. Consultant pharmacist. 2009;24:64-68.
11129.	Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. The emerging gold standard? Drugs. 2002;62:1869-1885.
11130.	Pearlstein T. Psychotropic medications and other non-hormonal treatments for premenstrual disorders. [Review]. Menopause international. 2012;18:60-64.
11131.	Pearlstein T, Howard M, Salisbury A, Zlotnick C. Postpartum depression. American journal of obstetrics and gynecology. 2009;200:357-364.
11132.	Pearlstein T, KA Y. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert opinion on pharmacotherapy. 2002;3:979-991.
11133.	Pearlstein T, KA Y, Fayyad R, JA G. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of affective disorders. 2005;85:275-282.
11134.	Pearlstein T, MJ J, EB B, CM M. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. American journal of obstetrics and gynecology. 2003;188:887-895.
11135.	Pearlstein T, Steiner M. Premenstrual dysphoric disorder: Burden of illness and treatment update. Journal of psychiatry & neuroscience. 2008;33:291-301.
11136.	Pearlstein TB, Zlotnick C, Battle CL, et al. Patient choice of treatment for postpartum depression: A pilot study. Archives of women's mental health. 2006;9:303-308.
11137.	Pecenak J, Novotny V. Agomelatine as Monotherapy for Major Depression: an Outpatient, Open-Label Study. Neuropsychiatric disease and treatment. 2013;9:1595-1604.
11138.	Smoking cessation intervention for severe mental ill health trial (SCIMITAR): A pilot randomised control trial of the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation service, Health technology assessment(2015).
11139.	Pedrelli P, Iovieno N, Vitali M, Tedeschini E, KH B, GI P. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: A meta-analysis. Journal of clinical psychopharmacology. 2011;31:582-586.
11140.	Pei-Chen CJ, Po-Lun W, Hsien-Yuan L, Kuan-Pin S, Chon-Haw T. Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) treatment for Isaacs syndrome with depression. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:739-740.
11141.	Pei-Xian M, Yi-Lang T, Feng J, et al. Escitalopram in Major Depressive Disorder: a Multicenter, Randomized, Double-Blind, Flxed-Dose, Parallel Trial in a Chinese Population. Depression and anxiety. 2008;25:46-54.
11142.	Peikert G, Wagner G, Tauber R, Gruhn U, Sobanski T. Effectiveness of Cognitive Behavior Therapy in Inpatients With Severe Panic Disorder and Agoraphobia. Verhaltenstherapie. 2004;14:253-263.
11143.	Peikert G, Wagner G, Tauber R, Gruhn U, Sobanski T. Effectiveness of Cognitive Behavior Therapy in Inpatients With Severe Panic Disorder and Agoraphobia. Verhaltenstherapie. 2004;14:253-263.
11144.	Pelicier Y, Schaeffer P. A multi-centre, double-blind study to compare the efficacy and tolerability of paroxetine and clomipramine in elderly patients with reactive depression. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1993;19:257-261.
11145.	Pelissolo A. Efficacy and tolerability of escitalopram in anxiety disorders: A review. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2008;34:400-408.
11146.	Pelkonen M, Marttunen M. Child and adolescent suicide: Epidemiology, risk factors, and approaches to prevention. Pediatric Drugs. 2003;5:243-265.
11147.	Pelser D. New drug comment - Escitalopram [1]. Australian Prescriber. 2004;27:28-29.
11148.	Peng D, Yuan X, Zhu R. Memantine hydrochloride in the treatment of dementia subtypes. Journal of clinical neuroscience. 2013;20:1482-1485.
11149.	Peng L, Zhang X, DY K, XT L, Hong Q. Effectiveness and safety of Wuling capsule for post stroke depression: a systematic review. [Review]. Complementary therapies in medicine. 2014;22:549-566.
11150.	Penn E, DK T. The drugs don't work? antidepressants and the current and future pharmacological management of depression. Therapeutic Advances in Psychopharmacology. 2012;2:179-188.
11151.	Pennington K, Focking M, CA M, CM P, MJ D, DR C. A Proteomic Investigation of Similarities Between Conventional and Herbal Antidepressant Treatments. Journal of psychopharmacology (Oxford, England). 2009;23:520-530.
11152.	Penttila J, Kajander J, Aalto S, et al. Effects of Fluoxetine on Dopamine D-2 Receptors in the Human Brain: a Positron Emission Tomography Study With [C-11]Raclopride. International journal of neuropsychopharmacology. 2004;7:431-439.
11153.	Penttila J, Kajander J, Aalto S, et al. Effects of Fluoxetine on Dopamine D-2 Receptors in the Human Brain: a Positron Emission Tomography Study With [C-11]Raclopride. International journal of neuropsychopharmacology. 2004;7:431-439.
11154.	Per A, Lars G, Kristina T, Kirsten B, Martin H, Jesper S. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram. International journal of geriatric psychiatry. 2004;19:1123-1130.
11155.	Per B. A review of the antidepressant properties of serotonin reuptake inhibitors. Advances in Biological Psychiatry. 1988;17:58-69.
11156.	Per B. Selective serotonin reuptake inhibitors for the depressive spectrum disorders. Psychiatriki. 1991;2:193-199.
11157.	Per B. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. International journal of neuropsychopharmacology. 2001;4:337-345.
11158.	Per B, K KD, Vibeke P. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology. 2006;188:273-280.
11159.	Per B, L LS, F OK. Relapse prevention and residual symptoms: A closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. Journal of clinical psychiatry. 2010;71:121-129.
11160.	Per B, Per T, Philippe C, Friis AH, Gersel PA. Escitalopram dose-response revisited: An alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. International journal of neuropsychopharmacology. 2004;7:283-290.
11161.	Perahia D, Lu-Pritchett Y, Tamura R, Detke N, D'souza D, Tran P. Global Benefit-Risk Evaluation for the Treatment of Major Depressive Disorder With Duloxetine: Results From Six Pooled Placebo- and Ssri-Controlled Clinical Trials. European psychiatry. 2005;20:S136.
11162.	Perahia D, Lu-Pritchett Y, Tamura R, Detke N, D'souza D, Tran P. Global Benefit-Risk Evaluation for the Treatment of Major Depressive Disorder With Duloxetine: Results From Six Pooled Placebo- and Ssri-Controlled Clinical Trials. European psychiatry. 2005;20:S136.
11163.	Perahia DGS, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. European Psychiatry: the Journal of the Association of European Psychiatrists. 2006;21:367-378.
11164.	Peretti S, Judge R, Hindmarch I. Safety and selective: Tricyclic antidepressant vs. selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, Supplement. 2000;101:17-25.
11165.	Perez A, JJ A. A double-blind, randomized comparison of fluvoxamine with mainserin in depressive illness. Current medical research and opinion. 1990;12:234-241.
11166.	Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349:1594-1597.
11167.	Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson's disease. Expert opinion on drug safety. 2011;10:633-643.
11168.	Perez-Lloret S, Rascol O. Parkinson disease: Serotonin reuptake inhibitors for depression in PD. Nature reviews. Neurology. 2012;8:365-366.
11169.	Perez-Parada J. Depression and cardiovascular disease: The need for improved case definition. [Turkish]. Klinik Psikofarmakoloji Bulteni. 2011;21:7-10.
11170.	Peritogiannis V, Antoniou K, Mouka V, Mavreas V, TN H. Duloxetine-Induced Hypomania: Case Report and Brief Review of the Literature on Snris-Induced Mood Switching. Journal of psychopharmacology (Oxford, England). 2009;23:592-596.
11171.	Perovic B, Jovanovic M, Miljkovic B, Vezmar S. Getting the Balance Right: Established and Emerging Therapies for Major Depressive Disorders. Neuropsychiatric disease and treatment. 2010;6:343-364.
11172.	Perrot S, IJ R. More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: A meta-analysis examining six core symptoms. European Journal of Pain (United Kingdom). 2014;18:1067-1080.
11173.	Perrot S, Maheu E, R-M J, et al. Guidelines for the use of antidepressants in painful rheumatic conditions. European journal of pain (London, England). 2006;10:185-192.
11174.	Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011;12:365-377.
11175.	Perroud N, KJ A, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology. 2009;34:2517-2528.
11176.	Perroud N, KJ A, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology. 2009;34:2517-2528.
11177.	Perroud N, Uher R, Hauser J, et al. History of suicide attempts among patients with depression in the GENDEP project. Journal of affective disorders. 2010;123:131-137.
11178.	Perroud N, Uher R, Marusic A, et al. Suicidal Ideation During Treatment of Depression With Escitalopram and Nortriptyline in Genome-Based Therapeutic Drugs for Depression (Gendep): a Clinical Trial. BMC medicine. 2009;7.
11179.	Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): A clinical trial, BMC medicine(2009).
11180.	Perroud N, Uher R, MY N, et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics journal. 2012;12:68-77.
11181.	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project, Pharmacogenomics journal(2012).
11182.	Perry R, Cassagnol M. Desvenlafaxine: a New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Adults With Major Depressive Disorder. Clinical therapeutics. 2009;31:1374-1404.
11183.	Perugi G, Frare F, Toni C. Diagnosis and Treatment of Agoraphobia With Panic Disorder. CNS drugs. 2007;21:741-764.
11184.	Perugi G, Giannotti D, S DV, Frare F, Saettoni M, GB C. Fluvoxamine in the Treatment of Body Dysmorphic Disorder (Dysmorphophobia). International clinical psychopharmacology. 1996;11:247-254.
11185.	Perugi G, Romano A, Tusini G. Short-term and long-term treatment in depressive syndromes: Focus on antidepressants tolerability. [Italian]. Italian Journal of Psychopathology. 2007;13:378-386.
11186.	Pesce V, SN S, SP R. Depression, antidepressants and sexual functioning in men. Sexual and relationship therapy. 2002;17:281-287.
11187.	Peter H, Bandelow B, Krausz M. Impact of the central serotonergic system on alcoholism and pharmacotherapeutic consequences. [German]. Fortschritte der Neurologie-Psychiatrie. 1998;66:459-465.
11188.	Peter H, Tabrizian S, Hand I. Serum Cholesterol in Patients With Obsessive Compulsive Disorder During Treatment With Behavior Therapy and Ssri or Placebo. International journal of psychiatry in medicine. 2000;30:27-39.
11189.	Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Molecular psychiatry. 2004;9:879-889.
11190.	Petersein C, Sack U, Mergl R, et al. Impact of Lithium Alone and in Combination With Antidepressants on Cytokine Production in Vitro. Journal of neural transmission. 2015;122:109-122.
11191.	Petersen T, Harley R, GI P, HD M, Fava M, JE A. Continuation Cognitive-Behavioural Therapy Maintains Attributional Style Improvement in Depressed Patients Responding Acutely to Fluoxetine. Psychological medicine. 2004;34:555-561.
11192.	Petersen T, Harley R, Papakostas GI, Montoya HD, Fava M, Alpert JE. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychological medicine. 2004;34:555-561.
11193.	Petersen T, Hughes M, GI P, et al. Treatment-resistant depression and Axis II comorbidity. Psychotherapy and psychosomatics. 2002;71:269-274.
11194.	Petersen T, RH P, Ticknor C, et al. Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial. Psychopharmacology bulletin. 2008;41:34-45.
11195.	Peterson J, Sheldon C. Treating persistent adolescent aggression. Current treatment options in neurology. 2006;8:427-438.
11196.	Petersson S, Mathillas J, Wallin K, Olofsson B, Allard P, Gustafson Y. Risk Factors for Depressive Disorders in Very Old Age: a Population-Based Cohort Study With a 5-Year Follow-up. Social psychiatry and psychiatric epidemiology. 2014;49:831-839.
11197.	Petkova E, Tarpey T. Partitioning of Functional Data for Understanding Heterogeneity in Psychiatric Conditions. Statistics and its interface. 2009;2:413-424.
11198.	Petkova E, Tarpey T, Govindarajulu U. Predicting potential placebo effect in drug treated subjects. International journal of biostatistics. 2009;5:Article 23.
11199.	Petkova E, Tarpey T, Govindarajulu U. Predicting potential placebo effect in drug treated subjects. International journal of biostatistics. 2009.
11200.	Petkova E, Tarpey T, Huang L, Deng L. Interpreting meta-regression: Application to recent controversies in antidepressants' efficacy. Statistics in medicine. 2013;32:2875-2892.
11201.	Petra SS. Symptom dimensions of depression over the course of treatment: An application of the tripartite model. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008;69:1973.
11202.	Petrak F, Herpertz S. Treatment of depression in diabetes: An update. Current opinion in psychiatry. 2009;22:211-217.
11203.	Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controll, BMC psychiatry(2013).
11204.	Petrak F, Herpertz S, Albus C, et al. Nonadherence to treatment strongly predicts therapy outcome in patients with depression and diabetes: Results of the diabetes depression study (dad study). Psychosomatic medicine. 2014;Conference:A-134.
11205.	Petrakis I, JS J, O'Brien E, Keegan K, Ralevski E, Desai N. Effect of depression on outcomes in a clinical trail evaluating antidepressants +/-naltrexone for treatment of alcohol dependence and PTSD. Alcoholism, clinical and experimental research. 2013;Conference:19A.
11206.	Petrescu B, Vasile D, Vasiliu O, Tudor C, Mangalagiu A, Ungureanu D. SSRI dose escalation versus duloxetine in treatment of major depressive disorder not responding to initial SSRI. European neuropsychopharmacology. 2014;Conference:S455-S456.
11207.	Petrides G, KG T, CH K, MV R. Continuation and maintenance electroconvulsive therapy for mood disorders: Review of the literature. Neuropsychobiology. 2011;64:129-140.
11208.	Petrovic M, P DP, L VB. Pharmacotherapy of depression in old age. [Review] [60 refs]. Acta clinica Belgica. 2005;60:150-156.
11209.	Petrovic M, P DP, L VB. Pharmacotherapy of Depression in Old Age. Acta clinica Belgica. 2005;60:150-156.
11210.	Petrovic M, P DP, L VB. Pharmacotherapy of depression in old age. Acta clinica Belgica. 2005;60:150-156.
11211.	Petursson H. Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. Acta psychiatrica Scandinavica. Supplementum. 1995;386:36-39.
11212.	Peveler R, Kendrick T, Buxton M, et al. A Randomised Controlled Trial to Compare the Cost-Effectiveness of Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors and Lofepramine. Health technology assessment. 2005;9:III-+.
11213.	Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health technology assessment (Winchester, England). 2005;9:1-134, iii.
11214.	Peveler R, Kendrick T, Buxton M, et al. A Randomised Controlled Trial to Compare the Cost-Effectiveness of Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors and Lofepramine. Health technology assessment. 2005;9:III-+.
11215.	Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibators and lofepramine. Health technology assessment. 2005;9:iii-91.
11216.	Pezawas L, Angst J, Gamma A, Ajdacic V, Eich D, Rossler W. Recurrent brief depression - Past and future. Progress in neuro-psychopharmacology & biological psychiatry. 2003;27:75-83.
11217.	Pezawas L, Angst J, Kasper S. Recurrent brief depression revisited. International review of psychiatry. 2005;17:63-70.
11218.	Pezawas L, Stamenkovic M, Aschauer N, Moffat R, Kasper S. Successful treatment of recurrent brief depression with reboxetine -- a single case analysis. Pharmacopsychiatry. 2002;35:75-76.
11219.	Pezawas L, Stamenkovic M, Kasper S. Recurrent brief depressive episodes - Epidemiology, clinical diagnostics, and therapy. [German]. Der Nervenarzt. 2001;72:169-180.
11220.	Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: A comparison between paroxetine and amitriptyline. Breast cancer research and treatment. 2001;70:1-10.
11221.	PF A, JR C. Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of affective disorders. 2008;111:21-30.
11222.	PF B. From acute to maintenance: Strategies in the treatment of bipolar disorder. Advanced Studies in Medicine. 2004;4:S970-S973.
11223.	PF B. Second-generation antipsychotic medications in the treatment of mood disorders: Focus on aripiprazole. Drugs of today (Barcelona, Spain : 1998). 2005;41:5-11.
11224.	PF S, CL D. Recent Developments in Drug Therapy for Multiple Sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 1999;5:110-120.
11225.	Pfeiffer E, Baxter D, Candelora E, Haag S, Nadiminti L, Leaverton P. Finding and Treating Depression in Alzheimer's Patients: a Study of the Effects on Patients and Caregivers. Psychopharmacology bulletin. 1997;33:721-729.
11226.	Pfennig A, Sasse J, Bauer M. Mood-stabilizer, antidepressants and atypical antipsychotics in bipolar depression. [German]. Psychopharmakotherapie, Supplement. 2008;15:20-24.
11227.	PG C, AJ R, CF OB, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Movement disorders. 1997;12:397-401.
11228.	PG F, JC B, NS F, HR T. Depression in Parkinson's disease: Health risks, etiology, and treatment options. Neuropsychiatric disease and treatment. 2008;4:81-91.
11229.	PG H, FM V, DA G. Selective Serotonin Reuptake Inhibitors in Pediatric Psychopharmacology: a Review of the Evidence. Journal of pediatrics. 2006;148:158-165.
11230.	PG J, JP Or, SM S, et al. Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: a Comprehensive Summary of Safety Experience From Acute Exposure, Extended Exposure, and During Reintroduction Treatment. Journal of clinical psychiatry. 2008;69:222-232.
11231.	PG J, JT R. Quetiapine monotherapy for bipolar depression. Expert opinion on pharmacotherapy. 2011;12:1643-1651.
11232.	PG J, Rado J. Recent second-generation antipsychotics implications for treating elderly patients with schizophrenia. Psychopharm Review. 2012;47:57-64.
11233.	PG J, SM D. Treatment-resistant depression: An update on diagnosis and management. Psychopharm Review. 2009;44:41-48.
11234.	PG M, Garza I. Headache. Seminars in neurology. 2011;31:5-17.
11235.	PG V, HF H. Treatment of refractory ascites. Current treatment options in gastroenterology. 2006;9:530-537.
11236.	PH D, AJ W, EE M, et al. A Controlled Trial of the Litebook Light-Emitting Diode (Led) Light Therapy Device for Treatment of Seasonal Affective Disorder (Sad). BMC psychiatry. 2007;7.
11237.	PH F, JL T, Kotchern L, Masia-Warner C. Psychosocial and pharmacological treatment for pediatric anxiety disorders. Expert review of neurotherapeutics. 2006;6:1707-1719.
11238.	PH G. Amyotrophic lateral sclerosis: Pathophysiology, diagnosis and management. CNS drugs. 2011;25:1-15.
11239.	Ph L, MF P-L, Pringuey D, Galinowski A. New statistical proposals to evaluate the benefit/risk ratio of long-term treatment of depression. Application to a one-year double-blind study comparing medifoxamine with fluoxetine. Clinical drug investigation. 1998;15:285-295.
11240.	Ph Q, Thomas P. [Efficacy of atypical antipsychotics in depressive syndromes]. [Review] [51 refs] [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:583-589.
11241.	PH R, Benoit M, Clairet S, Michel E. Recurrent Depressive Syndrome and Cerebral Organic Disorder. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:S36-S38.
11242.	PH R, Benoit M, Clairet S, Michel E. Recurrent Depressive Syndrome and Cerebral Organic Disorder. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:S36-S38.
11243.	Ph R, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study. International clinical psychopharmacology. 1995;10 Suppl 1:29-35.
11244.	PH S. Qualitative Review of Snris in Anxiety. Journal of clinical psychiatry. 2004;65:19-28.
11245.	PH S. Qualitative Review of Snris in Anxiety. Journal of clinical psychiatry. 2004;65:19-28.
11246.	PH S, Cornelius J, George A, Nathan S, JM P, RF U. Efficacy of Phenelzine and Haloperidol in Borderline Personality-Disorder. Archives of general psychiatry. 1993;50:377-385.
11247.	PH S, E VS. Defining Anxious Depression: Going Beyond Comorbidity. Canadian Journal of Psychiatry. 2003;48:675-680.
11248.	PH T. Obsessions: the Impact and Treatment of Obsessive-Compulsive Disorder in Children and Adolescents. Journal of psychopharmacology (Oxford, England). 2000;14:S31-S37.
11249.	PH T, HU M. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases. European child & adolescent psychiatry. 1999;8:143-148.
11250.	Phanjoo AL, Sheila W, Hodgson A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta psychiatrica Scandinavica. 1991;83:476-479.
11251.	PhDA T, MAW R-A. Selective serotonin reuptake inhibitors (SSRI's) are not indicated for depressive children and adolescents. [Dutch]. Nederlands tijdschrift voor geneeskunde. 2005;149:1314-1317.
11252.	Phil L, Liang S, Xiufeng X, et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and clinical neurosciences. 2007;61:295-307.
11253.	Philip G, Emmanuelle W, Ole L, Cornelius K. Escitalopram prevents relapse in older patients with major depressive disorder. The American Journal of Geriatric Psychiatry. 2007;15:581-593.
11254.	Philipp M, JWG T, Baier D, Kohnen R. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups. European neuropsychopharmacology. 2000;10:305-314.
11255.	Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004;37:196-199.
11256.	Phillip C, Thomsen HY, Pedersen OL, Gram LF, Kragh-Sorensen P. Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology. 1985;86:383-385.
11257.	Phillips W, KM S, RA B. The current clinical management of Huntington's disease. Movement disorders. 2008;23:1491-1504.
11258.	PI H, PL M, MP C. Eszopiclone: A review of its use in the treatment of insomnia. Drugs. 2008;68:1415-1434.
11259.	24- and 36-week outcomes for the child/adolescent anxiety multimodal study (CAMS), Journal of the American Academy of Child and Adolescent Psychiatry(2014).
11260.	Picardi A, Biondi M. Integrated sequential treatment of Obsessive-Compulsive Disorder: A follow-up study of 13 cases. [Italian]. Rivista di psichiatria. 2004;39:323-339.
11261.	Picardi A, Pancheri P. Differential response to antidepressant drugs in outpatients affected by anxiety or depressive disorders and scoring high on the scales 1 and 3 of the MMPI-2. [Italian]. Rivista di psichiatria. 1997;32:241-250.
11262.	Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of Drug-Treatment in Obsessive-Compulsive Disorder - a Metaanalytic Review. British journal of psychiatry. 1995;166:424-443.
11263.	Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson's disease. Parkinsonism & related disorders. 2010;15:S81-S84.
11264.	Piek E, K VDM, WA N. Guideline recommendations for long-term treatment of depression with antidepressants in primary care--a critical review. [Review] [31 refs]. European journal of general practice. 2010;16:106-112.
11265.	Piero A, Locati E. An Open, Non-Randomised Comparison of Escitalopram and Duloxetine for the Treatment of Subjects With Generalized Anxiety Disorder. Human Psychopharmacology-Clinical and Experimental. 2011;26:63-71.
11266.	Pierre B. Reply to Smith letter. American journal of psychiatry. 2010;167:995-996.
11267.	Pierre B. Combined treatments for depression as for other medical disorders. American journal of psychiatry. 2012;169:95.
11268.	Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study, American journal of psychiatry(2010).
11269.	Pierre B, Gabriella G, E TJ, et al. Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European neuropsychopharmacology. 2009;19:457-465.
11270.	Pierre B, John RA. Reply to El-Mallakh et al. letter. American journal of psychiatry. 2010;167:996-997.
11271.	Pierre B, Nil R, Alain S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. Journal of clinical psychopharmacology. 1996;16:307-314.
11272.	Pierre LJ, Carlo A, Marc A, et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: An international, 6-week double blind study. Human Psychopharmacology: Clinical and Experimental. 2001;16:219-227.
11273.	Pies R. Adverse neuropsychiatric reactions to herbal and over-the-counter 'antidepressants'. Journal of clinical psychiatry. 2000;61:815-820.
11274.	Pies R. Antidepressants work, sort of-our system of care does not. Journal of clinical psychopharmacology. 2010;30:101-104.
11275.	Pies R. Are antidepressants effective in the acute and long-term treatment of depression? Sic et Non. Innovations in clinical neuroscience. 2012;9:31-40.
11276.	Pies R, Shaughnessey J, Sarango R. Putative fluoxetine-related suicidality. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1994;39:580-581.
11277.	Pigato G, Toffanin T, Ferri G, A DF, Giannunzio V, GI P. A Naturalistic Study Comparing Two Initial Duloxetine Dosing Strategies in a Clinical "Real World" Setting. Rivista di psichiatria. 2009;44:384-392.
11278.	Pilhatsch M, Bauer M. Modern antidepressant treatment. [German]. Psychiatrische Praxis, Supplement. 2007;34:S281-S286.
11279.	Pilhatsch M, Wolf R, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: A reanalysis of a randomised, double-blind study. European archives of psychiatry and clinical neuroscience. 2010;Conference:S47.
11280.	Pilkington K, Boshnakova A, Richardson J. St John's wort for depression: Time for a different perspective? Complementary therapies in medicine. 2006;14:268-281.
11281.	Pilkington K, Kirkwood G, Rampes H, Fisher P, Richardson J. Homeopathy for depression: A systematic review of the research evidence. Homeopathy. 2005;94:153-163.
11282.	Pilkington K, Rampes H, Richardson J. Complementary medicine for depression. Expert review of neurotherapeutics. 2006;6:1741-1751.
11283.	Pilton R. Battling depression, 'worts' and all. American druggist. 1999;216:48-49.
11284.	Pinessi L. Antidepressants in the treatment of chronic headaches: Therapy of psychiatric comorbidity or other mechanisms? Journal of headache and pain. 2004;5:S121-S122.
11285.	Pini S, Abelli M, GB C. The role of quetiapine in the treatment of bipolar disorder. Expert opinion on pharmacotherapy. 2006;7:929-940.
11286.	Pinkney V, Bamford S, DS B, MR M, Garner M. The effects of duloxetine on subjective, autonomic and neurocognitive response to 7.5% carbon dioxide challenge. European neuropsychopharmacology. 2014;Conference:S579.
11287.	Pinkney V, Bamford S, DS B, MR M, Garner M. The effects of duloxetine on subjective, autonomic and neurocognitive response to 7.5% carbon dioxide challenge. European neuropsychopharmacology. 2014;Conference:S72-S73.
11288.	Pinna G, AM R. Up-Regulation of Neurosteroid Biosynthesis as a Pharmacological Strategy to Improve Behavioural Deficits in a Putative Mouse Model of Post-Traumatic Stress Disorder. Journal of neuroendocrinology. 2012;24:102-116.
11289.	Pinquart M, PR D, JM L. Treatments for later-life depressive conditions: A meta-analytic comparison of pharmacotherapy and psychotherapy. American journal of psychiatry. 2006;163:1493-1501.
11290.	Pinson L, GE G. Number needed to treat: An underused measure of treatment effect. Psychiatric services (Washington, D.C.). 2003;54:145-146+154.
11291.	Pinto C, JK T, GK V, PS S, Narasimha V. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. Journal of the Indian Medical Association. 2007;105:364, 366, 368 passim.
11292.	Pirritano D, Plastino M, Fava A, et al. Pathological gambling in parkinson's disease: An update on medical management. Current Psychopharmacology. 2012;1:365-374.
11293.	Pitchot W, Scantamburlo G, Ansseau M. Antidepressants in bipolar disorder: Beware of risks!. [French]. Revue medicale de Liege. 2008;63:391-395.
11294.	Pitkin J. Alternative and complementary therapies for the menopause. Menopause international. 2012;18:20-27.
11295.	Pittenger C, Vladimir C, Banasr M, Bloch M, JH K, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS drugs. 2008;22:761-786.
11296.	Pivac N, Muck-Seler D. EPHAR '99 - Second European Congress of Pharmacology: 3-7 July 1999, Budapest, Hungary. IDrugs : the investigational drugs journal. 1999;2:845-847.
11297.	Pivac N, Muck-Seler D. Pharmacology - Fourth Croatian Congress. 15-18 September 2004, Split, Croatia. IDrugs : the investigational drugs journal. 2004;7:1000-1004.
11298.	Piver A, LN Y, RW L. Bipolar spectrum disorders: New perspectives. Canadian Family Physician. 2002;48:896-904.
11299.	Piwowarska J, Chimiak A, Matsumoto H, et al. Serum cortisol concentration in patients with major depression after treatment with fluoxetine. Psychiatry research. 2012;198:407-411.
11300.	Piwowarska J, Dryll K, Szelenberger W, Pachecka J. Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine. Acta poloniae pharmaceutica. 2008;65:159-164.
11301.	Pizzi C, AWS R, GM C, Fontana F, Mezzetti A, Manzoli L. Meta-Analysis of Selective Serotonin Reuptake Inhibitors in Patients With Depression and Coronary Heart Disease. American journal of cardiology. 2011;107:972-979.
11302.	Pizzi C, Mancini S, Angeloni L, Fontana F, GM C. Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European heart journal. 2009;Conference:520.
11303.	Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, GM C. Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease. Clinical pharmacology and therapeutics. 2009;86:527-532.
11304.	PJ A, KD W, Biederman J, et al. Multicenter Open-Label Sertraline Study in Adolescent Outpatients With Major Depression. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:566-572.
11305.	PJ A, MD B, Rabinovich H, Elia J. Antidepressant treatments in children and adolescents I. Affective disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 1993;32:1-6.
11306.	PJ B. Drug-induced hyperkinetic movement disorders. Hyperkinetic Movement Disorders. 2012;Current Cl:187-220.
11307.	PJ C. Advances in psychopharmacology: Mood disorders and dementia. British medical bulletin. 1996;52:539-555.
11308.	PJ C. New drugs, old problems. Revisiting: Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment. 2005;11:19-27.
11309.	PJ C. Commentary on STAR*D: A summary and UK perspective. Journal of psychopharmacology (Oxford, England). 2009;23:618-619.
11310.	PJ C, AD O, Gama J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. [Review] [72 refs]. Current medical research and opinion. 2005;21:345-356.
11311.	PJ C, AD O, Gama J. Efficacy, Safety and Tolerability of Duloxetine 60 Mg Once Daily in Major Depression. Current medical research and opinion. 2005;21:345-355.
11312.	PJ C, AD O, Gama J. Efficacy, Safety and Tolerability of Duloxetine 60 Mg Once Daily in Major Depression. Current medical research and opinion. 2005;21:345-355.
11313.	PJ C, DJ W, SF M. Effect of valine on 5-HT neurotransmission and mood. Advances in experimental medicine and biology. 1996;398:67-71.
11314.	PJ C, SE L, SM C. Exercise for the treatment of depression and anxiety. International journal of psychiatry in medicine. 2011;41:15-28.
11315.	PJ F. Is elevated noradrenaline an aetiological factor in a number of diseases? Autonomic & autacoid pharmacology. 2009;29:143-156.
11316.	PJ F. A neurochemical yin and yang: Does serotonin activate and norepinephrine deactivate the prefrontal cortex? Psychopharmacology. 2011;213:171-182.
11317.	PJ G. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. [Review] [83 refs]. Annals of clinical psychiatry. 2001;13:31-41.
11318.	PJ G. Bipolar depression: A review of randomised clinical trials. Expert opinion on pharmacotherapy. 2007;8:13-21.
11319.	PJ G, BJ G. Selective Serotonin Reuptake Inhibitors in Affective Disorders - I. Basic Pharmacology. Journal of psychopharmacology (Oxford, England). 1998;12:S5-S20.
11320.	PJ G, BJ G. Selective Serotonin Reuptake Inhibitors in Affective Disorders - Ii. Efficacy and Quality of Life. Journal of psychopharmacology (Oxford, England). 1998;12:S21-S54.
11321.	PJ G, CA B. Use of olanzapine in non-psychotic psychiatric disorders. Expert opinion on pharmacotherapy. 2001;2:667-680.
11322.	PJ G, Hernandez M. Treatment of depression in comorbid medical illness. [Review] [107 refs]. Expert opinion on pharmacotherapy. 2000;1:1367-1384.
11323.	PJ G, L EI. Bupropion and fluoxetine in depressive subtypes. Annals of clinical psychiatry. 1989;1:119-122.
11324.	PJ G, Liu P, MA W, MM W. Comparison of Safety Outcomes Among Caucasian, Hispanic, Black, and Asian Patients in Duloxetine Studies of Chronic Painful Conditions. Current medical research and opinion. 2013;29:549-560.
11325.	PJ G, RR F, ED P, Barouche F, Schlegel A. Double-blind treatment of major depression with fluoxetine: Use of pattern analysis and relation of HAM-D score to CGI change. Psychopharmacology bulletin. 1987;23:162-163.
11326.	PJ G, Sandoval R. Psychotropic Treatment of Chronic Fatigue Syndrome and Related Disorders. Journal of clinical psychiatry. 1993;54:13-20.
11327.	PJ H. Assessment and management of eating disorders: An update. Australian Prescriber. 2013;36:154-157.
11328.	PJ L, KE F, LS G, RE C. Flouxetine for depression in diabetes: A randomized double-blind placebo-controlled trial. Diabetes care. 2000;23:618-623.
11329.	PJ L, KE F, LS G, RE C. Fluoxetine for Depression in Diabetes - a Randomized Double-Blind Placebo-Controlled Trial. Diabetes care. 2000;23:618-623.
11330.	PJ L, LS G, KE F, RE C. The course of major depression in diabetes. General hospital psychiatry. 1997;19:138-143.
11331.	PJ L, RE C. Treatment of depression in diabetes: Impact on mood and medical outcome. Journal of psychosomatic research. 2002;53:917-924.
11332.	PJ L, SM P, RE C. Recent advances in understanding depression in adults with diabetes. Current diabetes reports. 2007;7:114-122.
11333.	PJ L, SM P, RE C. Recent advances in understanding depression in adults with diabetes. Current psychiatry reports. 2008;10:495-502.
11334.	PJ M. Further Strategies for Treating Fibromyalgia: The Role of Serotonin and Norepinephrine Reuptake Inhibitors. American journal of medicine. 2009;122:S44-S55.
11335.	PJ M, Arnold L, Wang F, et al. The effect of duloxetine on cognition in patients with fibromyalgia. Arthritis and rheumatism. 2010;Conference:113.
11336.	PJ M, AY K, MH T, et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. Journal of clinical psychiatry. 2008;69:1847-1855.
11337.	PJ M, Boom Y, Peen J, RA S, Van R, JJ D. Is there a dose-effect relationship between the number of psychotherapy sessions and improvement of social functioning? British journal of clinical psychology. 2011;50:268-282.
11338.	PJ M, Dekker J, Van R, Hendriksen M, Vink A, RA S. Does adding psychotherapy to pharmacotherapy improve social functioning in the treatment of outpatient depression? Depression and anxiety. 2007;24:553-562.
11339.	PJ M, DJ C, Christensen R, et al. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. Journal of rheumatology. 2011;38:1487-1495.
11340.	PJ M, Dundon K, Sarzi-Puttini P. Pharmacotherapy of Fibromyalgia. Best Practice & Research in Clinical Rheumatology. 2011;25:285-297.
11341.	PJ M, EH C. Pharmacotherapy of Fibromyalgia. Rheumatic Disease Clinics of North America. 2009;35:359-372.
11342.	PJ M, EV N, JW S, et al. Imipramine Treatment of Alcoholics With Primary Depression - a Placebo-Controlled Clinical Trial. Archives of general psychiatry. 1996;53:232-240.
11343.	PJ M, IJ R, DK K, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in arthritis and rheumatism. 2010;39:454-464.
11344.	PJ M, JW S, EN N, FM Q. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. Journal of clinical psychiatry. 1994;55:336-339.
11345.	PJ M, JW S, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. American journal of psychiatry. 2006;163:1531-1541; quiz 1666.
11346.	PJ M, Spaeth M, DJ C, et al. Estimation of Minimum Clinically Important Difference for Pain in Fibromyalgia. Arthritis care & research. 2011;63:821-826.
11347.	PJ P. Corticosteroid- and anabolic steroid-induced mental status disturbances. Journal of pharmacy practice. 2007;20:334-340.
11348.	PJ P, MJ G, DL D, AJ R, Kyhl J. A report of trazodone-associated laboratory abnormalities. Therapeutic drug monitoring. 1990;12:517-519.
11349.	PJ R, KH M, EP P, HR B, TT H, ML B. The wish to die and 5-year mortality in elderly primary care patients. American journal of geriatric psychiatry. 2010;18:341-350.
11350.	PJ S, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS drugs. 2011;25:737-763.
11351.	PJ W, PJ S. Pharmacological interventions for neuropathic pain following spinal cord injury: An update. Topics in spinal cord injury rehabilitation. 2007;13:58-71.
11352.	Pjrek E, Konstantinidis A, Assem-Hilger E, et al. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. Journal of psychiatric research. 2009;43:792-797.
11353.	Pjrek E, Winkler D, Kasper S. Pharmacotherapy of seasonal affective disorder. CNS spectrums. 2005;10:664-669.
11354.	Pjrek E, Winkler D, Stastny J, Praschak-Rieder N, Willeit M, Kasper S. Escitalopram in Seasonal Affective Disorder: Results of an Open Trial. Pharmacopsychiatry. 2007;40:20-24.
11355.	PK C-L, Nash R, Stang P, Swindle R. Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression. Archives of internal medicine. 2004;164:1197-1204.
11356.	PK C-L, Nash R, Stang P, Swindle R. Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression. Archives of internal medicine. 2004;164:1197-1204.
11357.	PK G, Nourse R, TE W. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: An open label study. Journal of clinical sleep medicine. 2009;5:28-33.
11358.	PK M, Kar N, GC K, Behera M. Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: Six month prospective study on outcome. Clinical practice and epidemiology in mental health. 2005.
11359.	PK M, Oyebode F. Prevention of postnatal depression. Journal of the Royal Society for the Promotion of Health. 2005;125:221-226.
11360.	PK S, DT C, RD E, JK W. Pharmacological treatment of Insomnia. Clinical Handbook of Insomnia. 2010;Current Cl:297-316.
11361.	PL B, PD K, RB S, Suarez E, Oo C. Clonazepam and sertraline: Absence of drug interaction in a multiple- dose study. Journal of clinical psychopharmacology. 2000;20:19-27.
11362.	PL D. Depression: The case for a monoamine deficiency. Journal of clinical psychiatry. 2000;61:7-11.
11363.	PL D. Serotonin Noradrenaline Reuptake Inhibitors: New Hope for the Treatment of Chronic Pain. International journal of psychiatry in clinical practice. 2006;10:16-21.
11364.	PL D, LH P, HL M, et al. Rapid Serotonin Depletion as a Provocative Challenge Test for Patients With Major Depression - Relevance to Antidepressant Action and the Neurobiology of Depression. Psychopharmacology bulletin. 1991;27:321-330.
11365.	PL D, Michaels T. Reboxetine: A review of efficacy and tolerability. Drugs of today (Barcelona, Spain : 1998). 1999;35:725-737.
11366.	PL D, SK B, CH M, et al. Sexual Functioning Assessed in 4 Double-Blind Placebo- and Paroxetine-Controlled Trials of Duloxetine for Major Depressive Disorder. Journal of clinical psychiatry. 2005;66:686-692.
11367.	PL F, DJ B. Sleep disturbances and depression: Risk relationships for subsequent depression and therapeutic implications. Dialogues in clinical neuroscience. 2008;10:473-481.
11368.	PL H. In children with attention-deficit hyperactivity disorder who have been taking methylphenidate for at least 1 year, is there any evidence of harmful effects? Evidence-Based Healthcare and Public Health. 2005;9:10-15.
11369.	PL H, CK S, EH U, PJ C. Escitalopram: an open-label study of bereavement-related depression and grief. Journal of affective disorders. 2009;113:142-149.
11370.	PL J, AR M, Chen Y, Chrones L, AH C. Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction. European neuropsychopharmacology. 2014;Conference:S464-S465.
11371.	PL K, Levy N, Vassalotti J, et al. Psychosocial factors in dialysis patients. Kidney international. 2001;59:1599-1613.
11372.	PL L. Presentation, diagnosis, and treatment of ADHD. Drug Benefit Trends. 2003;15:3-16.
11373.	PL M, LR W. Olanzapine: A review of its use in the management of bipolar I disorder. Drugs. 2004;64:2709-2726.
11374.	PL M, LR W. Spotlight on olanzapine in bipolar I disorder. CNS drugs. 2005;19:553-555.
11375.	PL M, Raj V, BK B, et al. Acute Hemodynamic Effects of a Selective Serotonin Reuptake Inhibitor in Postural Tachycardia Syndrome: a Randomized, Crossover Trial. Journal of psychopharmacology (Oxford, England). 2014;28:155-161.
11376.	Plakiotis C, DW OC. Bifrontal ECT: A systematic review and meta-analysis of efficacy and cognitive impact. Current psychiatry reviews. 2009;5:202-217.
11377.	Plattner A, Dantz B. Tricyclic antidepressants: An underutilized treatment? Part II. Psychopharm Review. 2011;46:17-23.
11378.	Treatment of major depression with bilateral theta burst stimulation: A randomized controlled pilot trial, Journal of affective disorders(2014).
11379.	Plouffe L, Stewart K, KS C, MS M, JL R. Diagnostic and Treatment Results From a Southeastern Academic Center Based Premenstrual-Syndrome Clinic - the 1st Year. American journal of obstetrics and gynecology. 1993;169:295-307.
11380.	PM A, Abrahams S, GD B, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. European journal of neurology. 2012;19:360-375.
11381.	PM B. Treatment of sleep dysfunction and psychiatric disorders. Current treatment options in neurology. 2006;8:367-375.
11382.	PM B, AR B. The growing knowledge of St. John's wort (Hypericum perforatum L) drug interactions and their clinical significance. Current therapeutic research, clinical and experimental. 2000;61:389-394.
11383.	PM B, LGW F, UMH K. Could Pramipexole Induce Acute Mania? A Case Report. Bipolar disorders. 2013;15:446-448.
11384.	PM B, Sattar M. Treatment of Sleep Dysfunction and Psychiatric Disorders. Current treatment options in neurology. 2009;11:349-357.
11385.	PM C, JY T, DW W, et al. Combined Effects of Venlafaxine, Nicotine Replacement, and Brief Counseling on Smoking Cessation. Experimental and clinical psychopharmacology. 2005;13:282-292.
11386.	PM D. Contemporary Management of Comorbid Anxiety and Depression in Geriatric Patients. Journal of clinical psychiatry. 2001;62:30-35.
11387.	PM D, KR K, Oxman T, et al. Does antidepressant therapy improve cognition in elderly depressed patients? Journals of gerontology. Series A, Biological sciences and medical sciences. 2003;58:M1137-1144.
11388.	PM D, KRR K, Oxman T, et al. Does Antidepressant Therapy Improve Cognition in Elderly Depressed Patients? Journals of gerontology. Series A, Biological sciences and medical sciences. 2003;58:1137-1144.
11389.	PM E, DAR S. Treating depression: The beyondblue guidelines for treating depression in primary care: "Not so much what you do but that you keep doing it". Medical journal of Australia. 2002;176:S77-S83.
11390.	PM E, IB H, DAR S. Evidence-based guidelines: Response to Professor Gordon Parker's critique. Australian and New Zealand journal of psychiatry. 2004;38:891-895.
11391.	PM F, ME H, CG J, VG F, HR S, GM K. Fluctuations in [C-11]Sb207145 Pet Binding Associated With Change in Threat-Related Amygdala Reactivity in Humans. Neuropsychopharmacology. 2015;40:1510-1518.
11392.	PM H, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert opinion on drug metabolism & toxicology. 2009;5:539-551.
11393.	PM H, SM D. Neurological complications of psychiatric drugs: Clinical features and management. Human psychopharmacology. 2008;23:15-26.
11394.	PM K. Bipolar disorder as cell membrane dysfunction. Progress toward integrative management. Alternative medicine review. 2004;9:107-135.
11395.	PM L, Brousse G, Schwan R. Escitalopram for Treatment of Major Depressive Disorder in Adults. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:490-501.
11396.	PM L, Brousse G, Schwan R. Escitalopram for Treatment of Major Depressive Disorder in Adults. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:490-501.
11397.	PM L, JL F. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. [Review] [56 refs]. International journal of clinical practice. 2007;61:702-710.
11398.	PM L, JM A, Despiegel N, Verpillat P. Efficacy of Escitalopram in Patients With Severe Depression: a Pooled Analysis. International journal of clinical practice. 2005;59:268-275.
11399.	PM L, Lancon C, Brignone M, et al. Evolution of antidepressant efficacy over time: Illustration with escitalopram. Value in health. 2012;Conference:A334.
11400.	PM L, Lancon C, Brignone M, et al. Relative Efficacy and Tolerability of Vortioxetine Versus Selected Antidepressants by Indirect Comparisons of Similar Clinical Studies. Current medical research and opinion. 2014;30:2589-2606.
11401.	PM L, Lancon C, Brignone M, Rive B, Salah S, Francois C. Relative efficacy and acceptability of vortioxetine versus marketed antidepressants. Value in health. 2013;Conference:A543.
11402.	PM M. New data on mindfulness-based stress reduction for hot flashes: How do alternative therapies compare with selective serotonin reuptake inhibitors? Menopause (New York, N.Y.). 2011;18:596-598.
11403.	PM M, BN G, DK S, Janakiramaiah N. Discontinuation of antidepressant drugs during electroconvulsive therapy: A controlled study. Journal of affective disorders. 2000;58:37-41.
11404.	PM P, Kokras N, Sanoudou D, Dalla C, Papadopoulou-Daifoti Z. Pharmacogenetic considerations for late life depression therapy. Expert opinion on drug metabolism & toxicology. 2013;9:989-999.
11405.	PM W, Kluge M, Maras A, et al. Fluoxetine Versus Trimipramine in the Treatment of Depression in Geriatric Patients. Pharmacopsychiatry. 2005;38:13-16.
11406.	PMJ H, CAL H, Timmerman L, et al. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. International clinical psychopharmacology. 1996;11:157-164.
11407.	PMJ V, M VB, TR E. Duloxetine and Venlafaxine-Xr in the Treatment of Major Depressive Disorder: a Meta-Analysis of Randomized Clinical Trials. Annals of pharmacotherapy. 2005;39:1798-1807.
11408.	PN D, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert review of neurotherapeutics. 2006;6:73-80.
11409.	PN D, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate Versus Fluvoxamine in the Treatment of Pathological Gambling - a Randomized, Blind-Rater Comparison Study. Clinical neuropharmacology. 2005;28:6-10.
11410.	PN D, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate Versus Fluvoxamine in the Treatment of Pathological Gambling - a Randomized, Blind-Rater Comparison Study. Clinical neuropharmacology. 2005;28:6-10.
11411.	PN D, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Pathological gambling: A review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Primary care companion to the Journal of clinical psychiatry. 2006;8:334-339.
11412.	PN D, Lowengrub K, Musin E, Gonopolski Y, Kotler M. Sustained-release bupropion in the treatment of SSRI nonresponder pathologic gamblers: Pilot study and review of the literature. Therapy. 2005;2:753-757.
11413.	PN D, OT D, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals - Preliminary report. Biological psychiatry. 2002;51:687-690.
11414.	PN D, Sasson Y, Hirschmann S, Iancu I, LJ G, Zohar J. Pindolol Augmentation in Treatment-Resistant Obsessive Compulsive Disorder: a Double-Blind Placebo Controlled Trial. European neuropsychopharmacology. 2000;10:165-169.
11415.	PO B, Hannifah H. 5-HT reuptake inhibitors in CFS. EOS Rivista di Immunologia ed Immunofarmacologia. 1995;15:66-69.
11416.	PO W. Managing depression in childhood and adolescence. London Journal of Primary Care. 2009:15-20.
11417.	Pochon S. 63rd Annual meeting of the American Academy of neurology: 617 April 2011; Honolulu, HI, USA. Pharmaceutical medicine. 2011;25:245-250.
11418.	Podea D, Georgescu R. An observational study to evaluate social and occupational functioning in depressed patients treated with escitalopram. European neuropsychopharmacology. 2013;Conference:S342.
11419.	Poelinger W, Haber H. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. International clinical psychopharmacology. 1989;4 Suppl 1:47-50.
11420.	Poewe W. Depression in Parkinson's Disease. Journal of neurology. 2007;254:49-55.
11421.	Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. Journal of Neurology, Supplement. 2001;248:12-21.
11422.	Pohl R, Balon R, Jayaraman A, RG D, Yeragani V. Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. Journal of psychosomatic research. 2003;55:247-251.
11423.	Poirier MF. The concept of resistant depression and therapeutic strategies, particularly with venlafaxine. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1999;25:55-57.
11424.	Poitras P, Gougeon A, Binn M, Bouin M. Extra digestive manifestations of irritable bowel syndrome: Intolerance to drugs? Digestive diseases and sciences. 2008;53:2168-2176.
11425.	Pol S, Bourliere M. Optimizing treatment outcomes in chronic hepatitis C: Management of non-response. Antiviral therapy. 2006;11:955-970.
11426.	Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: Serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology. 1991;24:53-81.
11427.	Poleszak E, Wosko S, Serefko A, et al. The Effects of Ifenprodil on the Activity of Antidepressant Drugs in the Forced Swim Test in Mice. Pharmacological Reports. 2014;66:1031-1036.
11428.	Poling J, Pruzinsky R, TR K, et al. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2007;16:187-194.
11429.	Politi P, Sciarini P, GS L, Micieli G. Depression and stroke: An up-to-date review. [Italian]. Epidemiologia e psichiatria sociale. 2006;15:284-294.
11430.	Polk B. Current aspects on geriatric patients in the hospital. The 3rd German-French Congress in Strasbourg, October 6-7, 2005. [German]. Krankenhauspharmazie. 2005;26:490-495.
11431.	Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder, Archives of general psychiatry(2008).
11432.	Pollack M, Mangano R, Entsuah R, Tzanis E, NM S. A Randomized Controlled Trial of Venlafaxine Er and Paroxetine in the Treatment of Outpatients With Panic Disorder. Psychopharmacology. 2007;194:233-242.
11433.	Poluzzi E, Piccinni C, Sangiorgi E, et al. Trend in Ssri-Snri Antidepressants Prescription Over a 6-Year Period and Predictors of Poor Adherence. European journal of clinical pharmacology. 2013;69:2095-2101.
11434.	Pompili M, Rihmer Z, Gonda X, Serafini G, Sher L, Girardi P. Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: The role of quetiapine XR in the treatment of unipolar and bipolar depression. Rivista di psichiatria. 2012;47:489-497.
11435.	Pompili M, RJ B, Tondo L, et al. Response to Intravenous Antidepressant Treatment by Suicidal Vs. Nonsuicidal Depressed Patients. Journal of affective disorders. 2010;122:154-158.
11436.	Pompili M, Serafini G, Innamorati M, et al. Antidepressants and suicide risk: A comprehensive overview. Pharmaceuticals (Basel, Switzerland). 2010;3:2861-2883.
11437.	Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. World journal of biological psychiatry. 2013;14:412-431.
11438.	Pompili M, Serafini G, Palermo M, et al. Hypothalamic pituitary adrenal axis and prolactin abnormalities in suicidal behavior. CNS and Neurological Disorders - Drug Targets. 2013;12:954-970.
11439.	Pompili M, Venturini P, Palermo M, et al. Mood disorders medications: Predictors of nonadherence - Review of the current literature. Expert review of neurotherapeutics. 2013;13:809-825.
11440.	Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk. Pharmacokinetic principles and recommendations. Clinical pharmacokinetics. 1994;27:270-289.
11441.	Pontarollo F, Cipriani A, Signoretti A, Girardi S, Barbui C. Efficacy and tolerability profile of escitalopram versus other antidepressants in the acute treatment of major depressive disorder: A systematic review and meta-analysis. [Italian]. Minerva psichiatrica. 2007;48:129-141.
11442.	Ponticaccia J, Salles N. Pain management in palliative care. [French]. Revue de geriatrie. 2006;31:A-33.
11443.	Popiel A, Zawadzki B, Praglowska E, Teichman Y. Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident. A randomized clinical trial - The "tRAKT" study. Journal of behavior therapy and experimental psychiatry. 2015;48:17-26.
11444.	Popoli M. Agomelatine Innovative Pharmacological Approach in Depression. CNS drugs. 2009;23:27-34.
11445.	Popp J, Arlt S. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease. Current opinion in psychiatry. 2011;24:556-561.
11446.	Popp J, Leuchi S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study.[Erratum appears in Pharmacogenomics. 2010 Oct;11(10):1504]. Pharmacogenomics. 2006;7:159-166.
11447.	Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. European neuropsychopharmacology. 2012;22:239-258.
11448.	Porro V, Fiorenzioni S, Menga C, A DC, Bertolino A. Single-blind comparison of the efficacy of fluvoxamine versus placebo in patients with depressive syndrome. Current therapeutic research, clinical and experimental. 1988;43:621-629.
11449.	Porter R. The hypothalamic-pituitary-adrenal axis: A target for intervention in early psychosis? Australian and New Zealand journal of psychiatry. 2006;40:722-724.
11450.	Porter R, Frampton C, PR J, RT M. Randomized controlled trials in psychiatry. Part 1: Methodology and critical evaluation. Australian and New Zealand journal of psychiatry. 2003;37:257-264.
11451.	Porter R, RT M, Menkes D. PHARMAC and availability of pharmaceuticals (multiple letters) [1]. New Zealand medical journal. 2002;115:274-275.
11452.	Porto R. Depressive Symptoms and Sexuality. Presse medicale. 2014;43:1111-1115.
11453.	Portzky G, K VH. Deliberate self-harm in adolescents. Current opinion in psychiatry. 2007;20:337-342.
11454.	The addition of low frequency and low intensity hatha yoga into standard antidepressants does not further down-regulate the hypothalamic-pituitary- adrenal-axis activity, Focus on Alternative and Complementary Therapies(2014).
11455.	Posner K, MA O, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. American journal of psychiatry. 2007;164:1035-1043.
11456.	Possel P, Hautzinger M. [Effects of pharmaco- and psychotherapeutic interventions in depression among children and adolescents]. [Review] [60 refs] [German]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2006;34:243-245.
11457.	Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline. The British Journal of Psychiatry. 2006;189:124-131.
11458.	Post RM, Altshuler LL, Leverich GS, et al. "Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline": Corrigendum. The British Journal of Psychiatry. 2006;189:569.
11459.	Posternak M, Novak S, Stern R, et al. A pilot effectiveness study: Placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. International journal of neuropsychopharmacology. 2008;11:15-25.
11460.	Potenza S, Pompili M, Ruberto A, Tatarelli R. Social phobia: Therapeutic approaches. [Italian]. Rivista di psichiatria. 2005;40:123-134.
11461.	Potthast R, Vervolgyi V, McGauran N, MF K, Wieseler B, Kaiser T. Impact of inclusion of industry trial results registries as an information source for systematic reviews. PloS one. 2014.
11462.	Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand S. Add-on Treatment of Quetiapine for Fibromyalgia a Pilot, Randomized, Double-Blind, Placebo-Controlled 12-Week Trial. Journal of clinical psychopharmacology. 2012;32:684-687.
11463.	Poulet E, Brunelin J, Boeuve C, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. European Psychiatry: the Journal of the Association of European Psychiatrists. 2004;19:382-383.
11464.	Pourcher E, Remillard S, Cohen H. Affect in Parkinson's disease: validation of the two-factor approach. Journal of the neurological sciences. 2010;289:27-31.
11465.	Power R, Muthen B, Henigsberg N, et al. Informative dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. European neuropsychopharmacology. 2012;Conference:S53-S54.
11466.	Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial. Biological psychiatry. 2006;59:1071-1077.
11467.	Pozzilli C, Sbardella E, L DG, Tomassini V. Treatment of multiple sclerosis-related fatigue: Pharmacological and non-pharmacological approaches. Neurological sciences. 2006;27:s297-s299.
11468.	PP F, IR M. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy. 2009;29:281-294.
11469.	PP K, Addepalli V. Enhancement of Nootropic Effect of Duloxetine and Bupropion by Caffeine in Mice. Indian journal of pharmacology. 2015;47:199-201.
11470.	PP S, CA L. Work-Related Outcomes Among Female Veterans and Service Members After Treatment of Posttraumatic Stress Disorder. Psychiatric services (Washington, D.C.). 2012;63:1072-1079.
11471.	PP Z, JT J. The Promise and Reality of Pharmacogenetics in Psychiatry. Clinics in laboratory medicine. 2010;30:931-974.
11472.	PR B. Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International journal of risk & safety in medicine. 2007;19:3-15.
11473.	PR B. Antidepressant-induced suicide, violence, and mania: Risks for military personnel. Ethical human psychology and psychiatry. 2010;12:111-121.
11474.	PR B. Antidepressant-induced suicide, violence and mania: Risks for military personnel. International journal of risk & safety in medicine. 2010;22:149-157.
11475.	PR B, FN Y, Zhao Y. Effects of pharmaceutical medications on male fertility. Journal of Reproduction and Infertility. 2012;13:3-11.
11476.	PR F. Selective Serotonin Reuptake Inhibitors - Pharmacological Profiles and Potential Therapeutic Distinctions. Annals of pharmacotherapy. 1994;28:1359-1369.
11477.	PR F. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. [Review] [140 refs]. Annals of pharmacotherapy. 1994;28:1359-1369.
11478.	PR H, Mazumdar S, Koru-Sengul T, et al. Estimating treatment effects from longitudinal clinical trial data with missing values: Comparative analyses using different methods. Psychiatry research. 2004;129:209-215.
11479.	PR J, JM M, RT M, et al. Genetic, developmental and personality correlates of self-mutilation in depressed patients. Australian and New Zealand journal of psychiatry. 2006;40:225-229.
11480.	PR J, PC M, JM M, et al. A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients. Psychological medicine. 2006;36:807-813.
11481.	PR J, RJ P, RT M, et al. Reversed Diurnal Variation in Depression: Associations With a Differential Antidepressant Response, Tryptophan: Large Neutral Amino Acid Ratio and Serotonin Transporter Polymorphisms. Psychological medicine. 2005;35:511-517.
11482.	PR J, RT M, JM M, SE L, CR C. Atypical Depression, Atypical Temperament and a Differential Antidepressant Response to Fluoxetine and Nortriptyline. Depression and anxiety. 2004;19:180-186.
11483.	PR J, RT M, SE L, et al. Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. International journal of neuropsychopharmacology. 2003;6:339-346.
11484.	PR J, SE L, JM M, et al. Bipolar Ii Disorder: Personality and Outcome in Two Clinical Samples. Australian and New Zealand journal of psychiatry. 2004;38:433-438.
11485.	PR M. Efficacy of antidepressants: Similar but different. International journal of neuropsychopharmacology. 2011;14:1433-1434.
11486.	PR M, Adinoff B, Lane E, et al. Fluvoxamine Treatment of Alcoholic Amnestic Disorder. European neuropsychopharmacology. 1995;5:27-33.
11487.	PR P, Madison J, Monnahan M, et al. Risperidone Monotherapy for Post-Traumatic Stress Disorder Related to Sexual Assault and Domestic Abuse in Women. International clinical psychopharmacology. 2006;21:275-280.
11488.	PR S, KL N, OR P, et al. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophrenia bulletin. 2012;38:569-578.
11489.	PR S, YE G, DA M. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010;11:1305-1330.
11490.	Prabhakar S. Comparison of Venalafaxine and HRT in management of postmenopausal depression and vasomotor symptoms. Human reproduction (Oxford, England). 2010;Conference:i286.
11491.	Pradeep J, Isaacs A, Shanbag D, Selvan S, Srinivasan K. Enhanced care by community health workers in improving treatment adherence to antidepressant medication in rural women with major depression. Indian journal of medical research. 2014;139:236-245.
11492.	Prakash A, Pons A, Shelton R, et al. Efficacy of Duloxetine Vs. Placebo in Mild, Moderate, and More Severely Ill Patients With Major Depressive Disorder. International journal of neuropsychopharmacology. 2006;9:S246.
11493.	Prakash A, RC R, CH M. The Impact of Analytic Method on Interpretation of Outcomes in Longitudinal Clinical Trials. International journal of clinical practice. 2008;62:1147-1158.
11494.	Prakash A, XH F. Paroxetine - a Review of Its Use in Social Anxiety Disorder. CNS drugs. 1999;12:151-169.
11495.	Prakash S, Mandal P, Sagar R. Paroxetine in the treatment of recurrent brief depressive disorder. Journal of pharmacology & pharmacotherapeutics. 2013;4:288-290.
11496.	Prasad S. A New Paradigm for Developing Drugs in Children: Atomoxetine as a Model. Archives of disease in childhood. 2005;90:I13-I16.
11497.	Prasad S. A New Paradigm for Developing Drugs in Children: Atomoxetine as a Model. Archives of disease in childhood. 2005;90:I13-I16.
11498.	Praschak-Rieder N, Hussey D, AA W, et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study. Biological psychiatry. 2004;56:587-591.
11499.	Praschak-Rieder N, Willeit M. Treatment of seasonal affective disorders. Dialogues in clinical neuroscience. 2003;5:389-398.
11500.	Prasko J, Horacek J, Zalesky R, et al. The Change of Regional Brain Metabolism ((18)Fdg Pet) in Panic Disorder During the Treatment With Cognitive Behavioral Therapy or Antidepressants. Neuro endocrinology letters. 2004;25:340-348.
11501.	Prasko J, Horacek J, Zalesky R, et al. The Change of Regional Brain Metabolism ((18)Fdg Pet) in Panic Disorder During the Treatment With Cognitive Behavioral Therapy or Antidepressants. Neuro endocrinology letters. 2004;25:340-348.
11502.	Prentice A. Medical management of chronic pelvic pain. Bailliere's Best Practice and Research in Clinical Obstetrics and Gynaecology. 2000;14:495-499.
11503.	Previti G, Pawlby S, Chowdhury S, Aguglia E, CM P. Neurodevelopmental outcome for offspring of women treated for antenatal depression: a systematic review. Archives of women's mental health. 2014;17:471-483.
11504.	Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the Treatment of Depression in Neurological Disorders: a Systematic Review and Meta-Analysis of Randomised Controlled Trials. Journal of neurology, neurosurgery, and psychiatry. 2011;82:914-923.
11505.	Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Australian and New Zealand journal of psychiatry. 2004;38:219-225.
11506.	Prieto E, Vazquez-Noguerol R, Franco M, Artal J, AL M, Gonzalez-Pinto A. Effectiveness of quetiapine XR vs. sertraline in acute bipolar depression as add-on therapy to previous mood stabilizer treatment: A pilot study. European psychiatry. 2012.
11507.	Pringle A, Parsons E, Cowen LG, McTavish SF, Cowen PJ, Harmer CJ. Using an experimental medicine model to understand the antidepressant potential of the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine. Journal of psychopharmacology (Oxford, England). 2012;26:1417-1423.
11508.	Pringsheim T, WJ D, Mackie G, et al. Canadian Headache Society Guideline for Migraine Prophylaxis. Canadian Journal of Neurological Sciences. 2012;39:S1-S2.
11509.	Pringsheim T, WJ D, MacKie G, et al. Systematic review: Medications for migraine prophylaxis - Section II. Canadian Journal of Neurological Sciences. 2012;39:S8-S28.
11510.	Pringuey D. Pharmacological guidelines in the treatment of phobic states. [French]. Psychologie medicale. 1993;25:1468-1474.
11511.	Pringuey D, Robert P, Giacomoni F, Talichet L, Darcourt G. Effectiveness of antidepressants and thymoregulator drugs on the long-term course of depressions. [French]. Encephale. 1995;21:61-70.
11512.	Prokselj T, Jerin A, Kogoj A. Memantine May Affect Pseudobulbar Affect in Patients With Alzheimer's Disease. Acta neuropsychiatrica. 2013;25:361-366.
11513.	Provinciali L, Coccia M. Post-stroke and vascular depression: A critical review. Neurological sciences. 2002;22:417-428.
11514.	Prudic J, RF H, WV M, et al. Pharmacological Strategies in the Prevention of Relapse After Electroconvulsive Therapy. Journal of ECT. 2013;29:3-12.
11515.	Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. Journal of neuropsychiatry and clinical neurosciences. 2005;17:20-28.
11516.	Prukkanone B, Kongsuk T. Cost-effectiveness of agomelatine in the treatment of major depressive episodes in Thailand. Value in health. 2011;Conference:A292.
11517.	Prukkanone B, Vos T, Bertram M, Burgess P. Cost-4ffectiveness analysis for pharmacological intervention and cognitive behavioral treatment (CBT) for major depression in Thailand. Value in health. 2010;Conference:A555.
11518.	Prukkanone B, Vos T, Bertram M, Lim S. Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand. Value in health. 2012;15:S3-8.
11519.	Pruter C, Norra C. Depressive disorders in epilepsy and their treatment. [German]. Nervenheilkunde. 2002;21:372-378.
11520.	Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer's disease. Expert opinion on drug metabolism & toxicology. 2010;6:345-354.
11521.	PS B, Fregni F, Bermpohl F, et al. Effect of Repetitive Tms and Fluoxetine on Cognitive Function in Patients With Parkinson's Disease and Concurrent Depression. Movement disorders. 2005;20:1178-1184.
11522.	PS B, Fregni F, Bermpohl F, et al. Effect of Repetitive Tms and Fluoxetine on Cognitive Function in Patients With Parkinson's Disease and Concurrent Depression. Movement disorders. 2005;20:1178-1184.
11523.	PS G, EA J, MacKinnon J, Charney P. Update in Women's Health. Journal of general internal medicine. 2009;24:765-770.
11524.	PS J. After TADS, can we measure up, catch up, and ante up? Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1456-1460.
11525.	PS M. Tolerability and adherence issues in antidepressant therapy. Clinical therapeutics. 2003;25:2289-2304.
11526.	PS M. Atypical antipsychotics in the treatment of affective symptoms: A review. Annals of clinical psychiatry. 2004;16:3-13.
11527.	PS M, DK B, RS D, Sharma A. Efficacy and safety of add on low-dose mirtazapine in depression. Indian journal of pharmacology. 2012;44:173-177.
11528.	PS M, FS F, AA P. Safety considerations in pharmacotherapy of bipolar disorder. CNS spectrums. 2004;9:16-26.
11529.	PS M, Narasimhan M, AA P. Paroxetine for somatic pain associated with physical illness: A review. Primary care companion to the Journal of clinical psychiatry. 2006;8:122-130.
11530.	PS N, AJ M, JS B, TF C. Determinants of Antidepressant Medication Prescribing in Elderly Residents of Aged Care Homes in Australia: a Retrospective Study. American journal of geriatric pharmacotherapy. 2009;7:210-219.
11531.	PS P, NL C. Psychopharmacologic Treatment of Obesity and Eating Disorders in Children and Adolescents. Child and adolescent psychiatric clinics of North America. 2012;21:831-859.
11532.	PS P, Santana C. Available pharmacological treatments for anorexia nervosa. Expert opinion on pharmacotherapy. 2004;5:2287-2292.
11533.	PT CJ, RM B, JH H, RR M. Personality self-reports are concurrently reliable and valid during acute depressive episodes. Journal of affective disorders. 2005;89:45-55.
11534.	PT K, P vO, E dH, et al. Predictors of course in obsessive-compulsive disorder: logistic regression versus Cox regression for recurrent events. Acta psychiatrica Scandinavica. 2007;116:201-210.
11535.	PT N. Use of venlafaxine in other psychiatric disorders. [Review] [29 refs]. Depression and anxiety. 2000;12 Suppl 1:90-94.
11536.	PT N. Recent perspectives on the diagnosis and treatment of generalized anxiety disorder. American journal of managed care. 2001;7:S367-S376.
11537.	PT N, BW D. Contemporary choices in the short-term pharmacologic management of depression and anxiety. Primary psychiatry. 2005;12:1-11.
11538.	PT N, HA H, SJ G, FC M. Adjunctive Modafinil at Initiation of Treatment With a Selective Serotonin Reuptake Inhibitor Enhances the Degree and Onset of Therapeutic Effects in Patients With Major Depressive Disorder and Fatigue. Journal of clinical psychiatry. 2004;65:414-420.
11539.	PT N, HA H, SJ G, FC M. Adjunctive Modafinil at Initiation of Treatment With a Selective Serotonin Reuptake Inhibitor Enhances the Degree and Onset of Therapeutic Effects in Patients With Major Depressive Disorder and Fatigue. Journal of clinical psychiatry. 2004;65:414-420.
11540.	PT N, RC S, WH B, CJ G-P. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine. Progress in neuro-psychopharmacology & biological psychiatry. 2014;48:86-91.
11541.	PT N, SL M, CP K, et al. Placebo-Controlled Study of Fluvoxamine in the Treatment of Patients With Compulsive Buying. Journal of clinical psychopharmacology. 2000;20:362-366.
11542.	PT T, Cummings J, Konechnik T, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International psychogeriatrics / IPA. 2013;25:707-719.
11543.	PT T, RL R. Skin disorders and sleep in adults: Where is the evidence? Sleep medicine reviews. 2010;14:351-358.
11544.	PTC L. Advances in bipolar affective disorder. Hong Kong Practitioner. 2006;28:208-214.
11545.	Puca F, PL S, Trabucchi M, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Journal of clinical psychiatry. 2002;63:396-402.
11546.	Deep brain stimulation of the subcallosal cingulate gyrus: Further evidence in treatment-resistant major depression, International journal of neuropsychopharmacology(2012).
11547.	Puntmann I, Schmacke N, Melander A, Lindberg G, Muhlbauer B. EVITA: A tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage. BMC clinical pharmacology. 2010.
11548.	Purandare N, NHP A, Burns A. Behavioural and psychological symptoms of dementia. Reviews in clinical gerontology. 2000;10:245-260.
11549.	Purgato M, Papola D, Gastaldon C, et al. Paroxetine Versus Other Anti-Depressive Agents for Depression. Cochrane database of systematic reviews (Online). 2014.
11550.	Purper-Ouakil D. Treatment of depression. [French]. ANAE - Approche Neuropsychologique des Apprentissages chez l'Enfant. 2002;14:343-346.
11551.	Purper-Ouakil D. [Use of psychotropic drugs in children]. [Review] [9 refs] [French]. Archives de pediatrie. 2008;15:1834-1836.
11552.	Purper-Ouakil D. Is antidepressant prescription possible in children?. [French]. Revue du praticien. 2009;59:8-9.
11553.	Purper-Ouakil D, Fourneret P, Wohl M, J-P R. Atomoxetine: A new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. [French]. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:337-348.
11554.	Purper-Ouakil D, Fourneret P, Wohl M, JP R. Atomoxetine: a New Treatment for Attention Deficit/Hyperactivity Disorder (Adhd) in Children and Adolescents. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2005;31:337-348.
11555.	Purushottam J, Prerna M, Priti S, Minakshi S, D GAk. Comparative study of efficacy of L-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian journal of psychiatry. 2013;6:29-34.
11556.	Putzhammer A, Schoeler A, Rohrmeier T, Sand P, Hajak G, Eichhammer P. Evidence of a Role for the 5-Httlpr Genotype in the Modulation of Motor Response to Antidepressant Treatment. Psychopharmacology. 2005;178:303-308.
11557.	Putzhammer A, Schoeler A, Rohrmeier T, Sand P, Hajak G, Eichhammer P. Evidence of a Role for the 5-Httlpr Genotype in the Modulation of Motor Response to Antidepressant Treatment. Psychopharmacology. 2005;178:303-308.
11558.	Puzantian T. Mirtazapine, an antidepressant. [Review] [21 refs]. American journal of health-system pharmacy. 1998;55:44-49.
11559.	Puzantian T, Kawase K. Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants? Pharmacotherapy. 1999;19:205-212.
11560.	PW D, KM W, PW J, PMS Ob. Efficacy of Selective Serotonin-Reuptake Inhibitors in Premenstrual Syndrome: a Systematic Review. Lancet. 2000;356:1131-1136.
11561.	PW L, AJohn R, SR W, et al. Strengthening clinical effectiveness trials: Equipoise-stratified randomization. Biological psychiatry. 2001;50:792-801.
11562.	PW L, Dawson R, AJ R. Flexible treatment strategies in chronic disease: Clinical and research implications. Biological psychiatry. 2000;48:605-614.
11563.	PW S, Valuck R, DI B, EP A. A pharmacoeconomic model for making value-based decisions about serotonin reuptake inhibitors. P and T. 2005;30:96-106.
11564.	PW W, TA K. Clinical use of carbamazepine for bipolar disorders. Expert opinion on pharmacotherapy. 2005;6:2887-2902.
11565.	PW W, TA K, OV B, Nowakowska C. New Anticonvulsant Medication Uses in Bipolar Disorder. CNS spectrums. 2003;8:930-947.
11566.	Q-H Z, Zhang Y, Q-S L, H-F L, Ye Y, Y-M Z. Protective effect against myocardial ischemia/reperfusion induced by diazoxide-postconditioning and its interaction with PI3K/Akt signaling pathway. [Chinese]. Chinese Pharmacological Bulletin. 2012;28:127-131.
11567.	Q-S T, Y-C S, X-J H, J-H H, Q-T H. Changes of brain monoamine neurotransmitters and the interventional effects of Chinese herb of Yinao Jieyu prescription in rat model of post-stroke depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:139-141.
11568.	Qaseem A, Snow V, TD D, MA F, DK O. Using Second-Generation Antidepressants to Treat Depressive Disorders: a Clinical Practice Guideline From the American College of Physicians. Annals of internal medicine. 2008;149:725-U710.
11569.	Qaseem A, Snow V, TD D, MA F, DK O. Using second-generation antidepressants to treat depressive disorders: A clinical practice guideline from the American College of Physicians. Annals of internal medicine. 2008;149:725-733.
11570.	QCM B-SD, A NN, Gerritsen vdHR, W DM. Changes in daily life experience associated with clinical improvement in depression. Journal of affective disorders. 1995;34:139-154.
11571.	Qian J, Simoni-Wastila L, GB R, et al. Associations of depression diagnosis and antidepressant treatment with mortality among young and disabled Medicare beneficiaries with COPD. General hospital psychiatry. 2013;35:612-618.
11572.	Qian J, Simoni-Wastila L, Langenberg P, et al. Effects of depression diagnosis and antidepressant treatment on mortality in medicare beneficiaries with chronic obstructive pulmonary disease. Journal of the American Geriatrics Society. 2013;61:754-761.
11573.	Qin B, YQ Z, XY Z, et al. Selective Serotonin Reuptake Inhibitors Versus Tricyclic Antidepressants in Young Patients: a Meta-Analysis of Efficacy and Acceptability. Clinical therapeutics. 2014;36:1087-1095.
11574.	Qin B, Zhang Y, Zhou X, et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. [Review]. Clinical therapeutics. 2014;36:1087-1095.e1084.
11575.	Qin F, X-A W, Tang Y, Huang Q, Z-J Z, J-H Y. Meta-analysis of randomized controlled trials to assess the effectiveness and safety of free and easy Wanderer plus, a polyherbal preparation for depressive disorders. Journal of psychiatric research. 2011;45:1518-1524.
11576.	Qin J, Saeeduddin A. An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder. Annals of general psychiatry. 2009;8.
11577.	Qiu C-L, Xiao B, Xie W-J. A Controlled Clinical Trial of Citalopram and Citalopram Combined with Psychotherapy in the Treatment of Postpartum Depression. [Chinese]. Chinese Mental Health Journal. 2005;19:847-848.
11578.	Qiu J, S-Y H, C-H Z, G-Q S, S-E W, Xiang T. The effect of Chaihu-Shugan-San and its components on the expression of ERK5 in the hippocampus of depressed rats. Journal of ethnopharmacology. 2014;152:320-326.
11579.	QP Z, Jung L, KC R. The management of sleep and circadian disturbance in patients with dementia. Current neurology and neuroscience reports. 2012;12:193-204.
11580.	QQ T, Mausbach B. Treatments for patients with dual diagnosis: A review. Alcoholism, clinical and experimental research. 2007;31:513-536.
11581.	QR R. Antidepressant "treatment". Menopause (New York, N.Y.). 2010;17:672-675.
11582.	QS W, SL D, HP M, YL C, XJ Q. Antidepressant-like effect of ethanol extract from Zuojin Pill, containing two herbal drugs of Rhizoma Coptidis and Fructus Evodiae, is explained by modulating the monoaminergic neurotransmitter system in mice. Journal of ethnopharmacology. 2013;148:603-609.
11583.	Qu W, Meng P. Relationship between blood glucose levels in patients with type 2 diabetes mellitus, depression and anxiety and the anti-depression/anxiety intervention. Chinese Journal of Clinical Rehabilitation. 2005;9:213-215.
11584.	Qu W, Y-Y Q. Improvement of sleep and anxiety in patients of major depression with fluoxetine combined with small dose of olanzapine. Chinese Journal of Clinical Rehabilitation. 2005;9:254-256.
11585.	Quante A. Acute Pharmacotherapy for Anxiety Symptoms in Patients With Depression. Fortschritte der Neurologie-Psychiatrie. 2015;83:142-148.
11586.	Quante A, Roepke S, Merkl A, Anghelescu I, CH L. Psychopharmacologic Treatment of Personality Disorders. Fortschritte der Neurologie-Psychiatrie. 2008;76:139-+.
11587.	Quante A, Ropke S, Merkl A, Anghelescu I, C-H L. Psychopharmacologic treatment of personality disorders. [German]. Fortschritte der Neurologie-Psychiatrie. 2008;76:139-148.
11588.	Quasim M, Kumar A. Recent advances in antidepressant drug therapy. International journal of psychiatry in clinical practice. 1999;3:17-22.
11589.	Quelhas R. Psychiatric care in parkinson's disease. Journal of psychiatric practice. 2013;19:118-141.
11590.	Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clinical endocrinology. 2012;76:21-25.
11591.	Quintin P, Thomas P. Efficacy of Atypical Antipsychotics in Depressive Syndroms. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2004;30:583-589.
11592.	Quirk M, Johnson E, WC M, Doherty J, Bertrand D. Mechanisms of antidepressant activity for TC-5214: A selective, centrally-acting neuronal nicotinic channel modulator. European neuropsychopharmacology. 2011;Conference:S253-S254.
11593.	QZ Z, YF X, WC W. Quality of Life in Outpatients With Depression in China. Journal of affective disorders. 2013;150:513-521.
11594.	The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial, JAMA Psychiatry(2013).
11595.	Differential improvement in depressive symptoms for tDCS alone and combined with pharmacotherapy: an exploratory analysis from The Sertraline Vs. Electrical Current Therapy For Treating Depression Clinical Study, International journal of neuropsychopharmacology(2014).
11596.	Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): Results from a factorial, randomized, controlled trial, Psychopharmacology(2014).
11597.	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis, Progress in neuro-psychopharmacology & biological psychiatry(2015).
11598.	R BE, M KL, N FS, et al. Lost human capital from early-onset chronic depression. American journal of psychiatry. 2000;157:940-947.
11599.	R BE, M RJ, Robert M, V CS, Yikang X, N GA. Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data: The Role of Nonrandom Selection and Skewed Data. Value in health. 2000;3:208-221.
11600.	R BS, Bianchi L, Cavallaro R, Gervasoni M, Siliprandi F, Bellodi L. Citalopram Concentrations and Response in Obsessive-Compulsive Disorder: Preliminary Results. CNS drugs. 2004;18:329-335.
11601.	R CJ. How to treat bipolar II depression and bipolar II mixed depression? - A reply to Benazzi. International journal of neuropsychopharmacology. 2004;7:107.
11602.	R CJ, A PK, M SI, E TM, B MH. Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients [1]. Journal of clinical psychopharmacology. 1999;19:183-184.
11603.	R CJ, Antoine D, G BO, et al. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addictive behaviors. 2011;36:843-848.
11604.	R CJ, B DA, B CD, Tammy C, Scott WD, Dennis D. Mirtazapine in comorbid major depression and alcohol dependence: An open-label trial. Journal of dual diagnosis. 2012;8:200-204.
11605.	R CJ, D LP, D SM, E TM. Citalopram treatment of fluoxetine-intolerant depressed patients. Journal of clinical psychiatry. 2003;64:562-567.
11606.	R CJ, G BO, B DA, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug and alcohol dependence. 2010;112:39-45.
11607.	R CJ, G BO, Boris B, et al. Fluoxetine in adolescents with major depression and an alcohol use disorder: An open-label trial. Addictive behaviors. 2001;26:735-739.
11608.	Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder, Addictive behaviors(2009).
11609.	R CJ, M SI, D CM, et al. Preliminary-Report - Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Alcoholics. Psychopharmacology bulletin. 1995;31:297-303.
11610.	R CJ, M SI, E TM, et al. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacology bulletin. 1998;34:117-121.
11611.	R CJ, M SI, F HR, et al. Fluoxetine versus placebo in depressed alcoholics: A 1-year follow-up study. Addictive behaviors. 2000;25:307-310.
11612.	R CJ, M SI, F HR, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addictive behaviors. 1999;24:111-114.
11613.	R CJ, M SI, G EJ, et al. Fluoxetine in Depressed Alcoholics - a Double-Blind, Placebo-Controlled Trial. Archives of general psychiatry. 1997;54:700-705.
11614.	R CJ, Omar E, Prashant G, Keming G. Clinical Highlights in Bipolar Depression: Focus on Atypical Antipsychotics. Journal of clinical psychiatry. 2005;66:26-33.
11615.	R CJ, Tammy C, Christopher M, Scott WD, B CD. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addictive behaviors. 2008;33:1500-1505.
11616.	R DC, H NM, A IC. The effects of mirtazapine for sleep in patients with major depressive disorder. Annals of clinical psychiatry. 2012;24:215-224.
11617.	R DC, Salviati M, Fiorentini S, Biondi M. Add-on Mirtazapine Enhances Effects on Cognition in Schizophrenic Patients Under Stabilized Treatment With Clozapine. Experimental and clinical psychopharmacology. 2007;15:563-568.
11618.	R DJ, John RA, Cathy H, David T, Polatin P, Weissenburger J. Fluoxetine versus trazodone in the treatment of outpatients with major depression. Journal of clinical psychiatry. 1988;49:422-426.
11619.	R DS, E DB, Wernicke JF, H PJ. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacology bulletin. 1990;26:173-180.
11620.	R EK, Terrence S, R WG, P MH. Worsening of depressive symptoms prior to randomization in clinical trials: A possible screen for placebo responders? [References]. Journal of psychiatric research. 2004;38:437-444.
11621.	R ET. Evidence based review of escitalopram in treating major depressive disorder in primary care.[Erratum appears in Int Clin Psychopharmacol. 2004 Nov;19(6):363]. International clinical psychopharmacology. 2004;19:305-310.
11622.	R ET. Errata: Evidence based review of escitalopram in treating major depressive disorder in primary care. International clinical psychopharmacology. 2004;19:363.
11623.	R ET, R AS, Julian C, J DJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 1999;21:296-308.
11624.	Venlafaxine extended-release for depression following spinal cord injury: A randomized clinical trial, JAMA Psychiatry(2015).
11625.	R FJ, M UJ, J KW. Sertraline in the treatment of major depression following mild traumatic brain injury. Journal of neuropsychiatry and clinical neurosciences. 2000;12:226-232.
11626.	R FJ, M UJ, J KW. Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2001;42:48-54.
11627.	R FN, J DR. Extreme response style and symptom return after depression treatment: The role of positive extreme responding. Journal of consulting and clinical psychology. 2014;82:500-509.
11628.	R FR, J GP, D PE, Faouzia B, Schlegel A. Pattern analysis of antidepressant response to fluoxetine. Journal of clinical psychiatry. 1986;47:560-562.
11629.	R FR, J GP, Eric P, Ann S. Fluoxetine response: Endpoint vs pattern analysis. International clinical psychopharmacology. 1986;1:320-323.
11630.	R HJ. Fluoxetine: Efficacy against placebo and by dose: An overview. The British Journal of Psychiatry. 1988;153:59-63.
11631.	R JM, Bruce LR, Alexander MW, et al. Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. Journal of psychiatric research. 1993;27:161-172.
11632.	R JP, E LS, M MJ, et al. Bipolar II disorder: Personality and outcome in two clinical samples. Australian and New Zealand journal of psychiatry. 2004;38:433-438.
11633.	R JP, J PR, T MR, et al. Reversed diurnal variation in depression: Associations with a differential antidepressant response, tryptophan: Large neutral amino acid ratio and serotonin transporter polymorphisms. Psychological medicine. 2005;35:511-517.
11634.	R JP, Mulder RT, Luty SE, McKenzie JM, Rae AM. A differential response to nortriptyline and fluoxetine in melancholic depression: The importance of age and gender. Acta psychiatrica Scandinavica. 2003;108:20-23.
11635.	R JP, T MR, E LS, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Australian and New Zealand journal of psychiatry. 2002;36:384-391.
11636.	R JP, T MR, E LS, M MJ, F SP, C CR. Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome. Comprehensive psychiatry. 2003;44:35-43.
11637.	R JP, T MR, E LS, et al. Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. International journal of neuropsychopharmacology. 2003;6:339-3460.
11638.	R JP, T MR, M MJ, E LS, Robert CC. Atypical Depression, Atypical Temperament and a Differential Antidepressant Response to Fluoxetine and Nortriptyline. Depression and anxiety. 2004;19:180-186.
11639.	R KEL, D LGM, Cornelis vH, Kurt A, Ellen D, Dirk DB. Investigation of early suicide-related symptoms in a non-suicidal depressed patient population after escitalopram administration: A pilot study. Internet Journal of Mental Health. 2010;6:1-19.
11640.	R KH, Timothy M, Jack C, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. Journal of clinical psychopharmacology. 2006;26:13-20.
11641.	R LF, Adam B, Wilfrid R, et al. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. Journal of substance abuse treatment. 2008;34:80-89.
11642.	Reanalyzing a randomized controlled trial of combination antidepressant treatment with mirtazapine: Confidence intervals suggest substantial uncertainty, Ethical Human Psychology and Psychiatry: An International Journal of Critical Inquiry(2011).
11643.	R LM, M MR, Jacques B, Gregory A. A Randomized Controlled Trial of Venlafaxine Extended Release in Generalized Social Anxiety Disorder. Journal of clinical psychiatry. 2005;66:238-247.
11644.	R LM, P YP, Richard E. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. Journal of clinical psychiatry. 2007;68:1663-1672.
11645.	R LR, D RC, I DC, D CH. Advances and controversies in medical treatment of depression. [Spanish]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 2003;31:194-197.
11646.	R LW, Howard T, F NJ, S HM, R TR, A TM. The effects of venlafaxine on social activity level in depressed outpatients. Journal of clinical psychiatry. 1999;60:157-163.
11647.	A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder, Current medical research and opinion(2013).
11648.	R MC. Behavioral activation for depression. 2009:138-143.
11649.	R MRB, L PG, Stuart N. Spotlight on sertraline in the management of major depressive disorder in elderly patients. [Review] [39 refs]. CNS drugs. 2002;16:789-794.
11650.	R NT, K JF, D BG. New pharmacological approaches to the management of depression: From theory to clinical practice. Australian and New Zealand journal of psychiatry. 1992;26:73-81.
11651.	R PA, Virginia S, Eugene M, Jan K, L HS, Lesley-Ann M. Child psychiatrists' self-reported treatment and monitoring of children and adolescents with major depressive disorder. Journal of psychiatric practice. 2012;18:253-261.
11652.	R PS, F FD, P KJ, E BS, E HS. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology. 1994;30:197-201.
11653.	R RM. Psychosis, dilemmas and therapeutic problems. [Spanish]. Atencion Farmaceutica. 2006;8:3-9.
11654.	R SJ, C PJ, P MM, L SK, E HJ. Clinical outcomes following a trial of sertraline in rheumatoid arthritis. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2002;43:36-41.
11655.	R SJ, E C-RM, M BA, et al. MRI signal hyperintensities and failure to remit following antidepressant treatment. Journal of affective disorders. 2011;135:315-320.
11656.	R SJ, E CM, G KJ, R RB, P DD, P RS. Antidepressant medication and executive dysfunction: A deleterious interaction in late-life depression. The American Journal of Geriatric Psychiatry. 2010;18:128-135.
11657.	R SJ, E RM, R RB, et al. Antidepressant treatment of melancholia in older adults. The American Journal of Geriatric Psychiatry. 2014;22:46-52.
11658.	R SJ, P RS, G KJ, Rama KKR, S AG, A SH. Response inhibition predicts poor antidepressant treatment response in very old depressed patients. The American Journal of Geriatric Psychiatry. 2007;15:553-563.
11659.	R SK, L WK, H HB, M PJ. Postpartum Depression Recurrence Versus Discontinuation Syndrome: Observations From a Randomized Controlled Trial. Journal of clinical psychiatry. 2004;65:1266-1268.
11660.	R SR. Psychopharmacology news and views. Journal of child and adolescent psychopharmacology. 2010;20:341-342.
11661.	R VDL, NJA VDW, T VV, FG Z. The Generalizability of Antidepressant Efficacy Trials to Routine Psychiatric Out-Patient Practice. Psychological medicine. 2011;41:1353-1363.
11662.	R VDL, NJA VDW, T VV, FG Z. Efficacy versus effectiveness: A direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychotherapy and psychosomatics. 2012;81:226-234.
11663.	R VJ, Anna CL, E TM, B JR. Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder. Journal of consulting and clinical psychology. 2014;82:1049-1059.
11664.	R VJ, Anna CL, E TM, B JR. Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder. Psychotherapy (Chicago, Ill.). 2015;52:268-277.
11665.	R WS, John RA, A NA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. American journal of psychiatry. 2009;166:59-607.
11666.	R WS, Maurizio F, H TM, et al. Acceptability of second-step treatments to depressed outpatients: A STAR*D report. American journal of psychiatry. 2007;164:753-760.
11667.	R-B L, S-Y L, S-L C, et al. Genotype variant associated with add-on memantine in bipolar II disorder. International journal of neuropsychopharmacology. 2014;17:189-197.
11668.	RA B, Lock T, DRL E, et al. Predictors of Response to Amine-Specific Antidepressants. Journal of affective disorders. 1995;35:97-106.
11669.	RA C. Navigating the Sequenced Treatment Alternatives to Relieve Depression (Star*D) Study: Practical Outcomes and Implications for Depression Treatment in Primary Care. Primary care. 2007;34:505-+.
11670.	RA C. Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study: Practical Outcomes and Implications for Depression Treatment in Primary Care. Primary Care - Clinics in Office Practice. 2007;34:505-519.
11671.	RA H, CG M, SB D, BI L, Gartlehner G, BN G. Controlling for Drug Dose in Systematic Review and Meta-Analysis: a Case Study of the Effect of Antidepressant Dose. Medical decision making. 2009;29:91-103.
11672.	RA H, Gartlehner G, KN L, BN G, TS C. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. [Review] [97 refs]. Annals of internal medicine. 2005;143:415-426.
11673.	RA H, RW M. Diabetic gastroparesis: A review of medical treatments. Practical gastroenterology. 2009;33:10-12+15-18+20.
11674.	RA H, TA Z. Sertraline for the Treatment of Depression in Parkinson's Disease. Movement disorders. 1997;12:756-759.
11675.	RA K, MP D, RL F. Depressive episodes in children and adolescents with bipolar disorders. Clinical neuroscience research. 2002;2:158-160.
11676.	RA K, TJ C, GJ E, JR R, CW H, AJ R. Multivariate Prediction of Response to Fluoxetine and Placebo in Children and Adolescents With Major Depressive Disorder. Psychopharmacology bulletin. 1997;33:539.
11677.	RA L. Gepirone Organon. Current opinion in investigational drugs (London, England : 2000). 2001;2:1120-1127.
11678.	RA L, Belisle S, WT C, et al. Should symptomatic menopausal women be offered hormone therapy? MedGenMed : Medscape general medicine. 2006.
11679.	RA L, CR B, JD B, et al. Does neuroimaging research examining the pathophysiology of posttraumatic stress disorder require medication-free patients? Journal of psychiatry & neuroscience. 2010;35:80-89.
11680.	RA L, RM W, JD W. The Response to Sertraline in Men With Chronic Pelvic Pain Syndrome. Sexually transmitted infections. 2005;81:147-149.
11681.	RA L, RM W, JD W. The Response to Sertraline in Men With Chronic Pelvic Pain Syndrome. Sexually transmitted infections. 2005;81:147-149.
11682.	RA L-P, LL VM, DJ G. Psychopharmacology in the elderly person with cardiovascular disease. Annals of long-term care. 2006;14:34-45.
11683.	RA M, Cai N, Skljarevski V, TR T. Duloxetine Use in Chronic Painful Conditions - Individual Patient Data Responder Analysis. European journal of pain (London, England). 2014;18:67-75.
11684.	RA M, Derry S, PJ W. Challenges in design and interpretation of chronic pain trials. British journal of anaesthesia. 2013;111:38-45.
11685.	RA M, GJ P, Turkoz I, et al. Risperidone for Treatment-Refractory Major Depressive Disorder - a Randomized Trial. Annals of internal medicine. 2007;147:593-602.
11686.	RA M, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia. 2013;68:400-412.
11687.	RA R, Davis S, Covell N, et al. Does Switching to a New Antipsychotic Improve Outcomes? Data From the Catie Trial. Schizophrenia research. 2009;107:22-29.
11688.	RA S, HL V, Koppelmans V, Kool S, JJ D. Managing the patient with co-morbid depression and an anxiety disorder. [Review] [76 refs]. Drugs. 2008;68:1621-1634.
11689.	RA S, KL B, AL K, Patel A, Peplinski C, AM S. On aerobic exercise and behavioral and neural plasticity. Brain Sciences. 2012;2:709-744.
11690.	RA S, LA S. Pharmacological alternatives for the treatment of obsessive compulsive disorder? Innovations in clinical neuroscience. 2011;8:10-14.
11691.	RA S, LA S. Agomelatine: A novel antidepressant. Innovations in clinical neuroscience. 2011;8:10-14.
11692.	RA S, TL S. A review of the neuropsychological effects of commonly used prescription medications. Archives of clinical neuropsychology. 1998;13:259-284.
11693.	Rabasseda X. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression. [Review] [120 refs]. Drugs of today (Barcelona, Spain : 1998). 2004;40:773-790.
11694.	Rabasseda X. A New Serotonin/Noradrenaline Reuptake Inhibitor for the Treatment of Depression. Drugs of today (Barcelona, Spain : 1998). 2004;40:773-790.
11695.	Rabasseda X. A New Serotonin/Noradrenaline Reuptake Inhibitor for the Treatment of Depression. Drugs of today (Barcelona, Spain : 1998). 2004;40:773-790.
11696.	Rabasseda X. A report from the 164th American Psychiatric Association (May 14-18, 2011 - Honolulu, Hawai'i, U.S.A.). Drugs of today (Barcelona, Spain : 1998). 2011;47:625-644.
11697.	Rabasseda X. A report from the 167th American psychiatric association annual meeting (May 3-7 - New York, U.S.A.). Drugs of today (Barcelona, Spain : 1998). 2014;50:527-542.
11698.	Rabe-Jablonska J. Therapeutic Effects and Tolerability of Fluvoxamine Treatment in Adolescents With Dysthymia. Journal of child and adolescent psychopharmacology. 2000;10:9-18.
11699.	Rabheru K. Special Issues in the Management of Depression in Older Patients. Canadian Journal of Psychiatry. 2004;49:41S-50S.
11700.	Rabinowitz I, Baruch Y, Barak Y. High-Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder. International clinical psychopharmacology. 2008;23:49-53.
11701.	Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues in clinical neuroscience. 2008;10:385-400.
11702.	Rachel M, D EJ, L GJ, San P-SMG, F KT, Tasha K. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep: Journal of Sleep and Sleep Disorders Research. 2008;31:489-495.
11703.	Rachid F, Bertschy G. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of depression: a critical appraisal of the last 10 years. Neurophysiologie Clinique. 2006;36:157-183.
11704.	Radhika B, R SJ. Lurasidone: A new treatment option for bipolar depression: A review. Innovations in clinical neuroscience. 2015;12:21-23.
11705.	The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment, Journal of psychiatric research(2015).
11706.	Raducanu I, Segarceanu A, Prada G, Ionescu C, Arsene A, Fulga I. Assessing Depressive Effect of Ketoprofen and Its Mechanism of Action Using the Forced Swimming Test in Mice. Farmacia. 2012;60:759-766.
11707.	Rafael S-P. Nicotine antidepressant effects as a predictor of response to desimipramine or fluoxetine in non-smoking major depressed patients. Salud mental (Mexico City, Mexico). 2002;25:16-20.
11708.	Rafanelli C, GA F, Sonino N. Sequential treatment of depression in primary care. International journal of clinical practice. 2007;61:1719-1729.
11709.	Raffaele R, Vecchio I, Malaguarnera M, Rampello L, Ruggieri M, Nicoletti F. Therapy of panic attacks in the elderly. Archives of gerontology and geriatrics. 2002;35:295-301.
11710.	Raffaella Z, Alessandro S, David R, et al. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological psychiatry. 2001;50:323-330.
11711.	Raffaella Z, David R, Alessandro S. "Problems with ensuring a double blind": Reply. Journal of clinical psychiatry. 2001;62:296.
11712.	Raffaella Z, Francesc A, Linda F, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? Journal of clinical psychopharmacology. 1997;17:446-450.
11713.	Raffaella Z, Linda F, Alessandro S, Jorge P, Enrico S. Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study. Journal of clinical psychiatry. 2000;61:26-29.
11714.	Raffaella Z, Linda F, Mariangela G, Adelio L, Enrico S, Jorge P. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. Journal of clinical psychopharmacology. 1998;18:441-446.
11715.	Rahimi R, Nikfar S, Abdollahi M. Pregnancy Outcomes Following Exposure to Serotonin Reuptake Inhibitors: a Meta-Analysis of Clinical Trials. Reproductive toxicology (Elmsford, N.Y.). 2006;22:571-575.
11716.	RAHRH H. Publication Bias and Outcome Reporting Bias Agomelatine as a Case Example. Journal of psychosocial nursing and mental health services. 2011;49:11-14.
11717.	RAHRH H. Dietary Supplement Drug Therapies for Depression. Journal of psychosocial nursing and mental health services. 2012;50:13-16.
11718.	Raimund B, Patrizia W, Uwe F. Efficacy of newer antidepressants. Journal of clinical psychiatry. 1994;55:499.
11719.	Rainer W, Dykierek P, Gattaz WF, et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry. 2001;34:60-65.
11720.	Raisi F, Habibi N, AA N, Akhondzadeh S. Combination of citalopram and nortriptyline in the treatment of severe major depression: A double-blind, placebo-controlled trial. Therapy. 2007;4:187-192.
11721.	Raj V, AA R, SB F, SY P, AM A, SE N. Psychogenic pseudosyncope: Diagnosis and management. Autonomic Neuroscience: Basic and Clinical. 2014;184:66-72.
11722.	Rajagopal S. The placebo effect. Psychiatric bulletin (London, England). 2006;30:185-188.
11723.	Rajagopalan M, Lecrubier Y. Comparison of venlafaxine and imipramine in depressive illness [2] (multiple letters). Acta psychiatrica Scandinavica. 1998;97:384-385.
11724.	Rajewski A, Rybakowski F. [Efficacy of buspirone and fluoxetine in short-term treatment of bulimia nervosa]. [Polish]. Psychiatria polska. 2006;40:75-82.
11725.	Rajinder J, M PJ, Vinod K, C KS, B KJ. Changes in energy during treatment of depression: An analysis of fluoxetine in double-blind, placebo-controlled trials. Journal of clinical psychopharmacology. 2000;20:666-672.
11726.	Rajiv M, Jieling C, Richard EA, F SA. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: A comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Journal of clinical psychiatry. 2003;64:321-330.
11727.	Mecamylamine for treatment of people with dual diagnoses of depression and alcohol dependence, Journal of dual diagnosis(2013).
11728.	Trajectories of depression severity in clinical trials of duloxetine: Insights into antidepressant and placebo responses, Archives of general psychiatry(2011).
11729.	RALRW L. The Importance of Early Symptom Relief in Antidepressant Treatment: Focus on Agomelatine. Journal of psychopharmacology (Oxford, England). 2010;24:27-30.
11730.	Rama KKR, Murali DP, M CC. Clinical and treatment response characteristics of late-life depression associated with vascular disease: A pooled analysis of two multicenter trials with sertraline. Progress in neuro-psychopharmacology & biological psychiatry. 2001;25:347-361.
11731.	Ramaekers JG, Ansseau M, Muntjewerff ND, Sweens JP, O'Hanlon JF. Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. International clinical psychopharmacology. 1997;12:159-169.
11732.	Ramakrishnan K, DC S. Treatment options for insomnia. American family physician. 2007;76:517-528.
11733.	Ramakrishnan V, Naveen KC, Shankar PR. A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes. Journal of affective disorders. 2013;150:644-648.
11734.	Ramamurthy G, Trejo E, SV F. Depression treatment in patients with coronary artery disease: A systematic review. Primary care companion to the Journal of clinical psychiatry. 2013.
11735.	Ramasubbu R. Therapy for prevention of post-stroke depression. Expert opinion on pharmacotherapy. 2011;12:2177-2187.
11736.	Ramasubbu R, Anderson S, Haffenden A, Chavda S, ZHT K. Double-blind optimization of subcallosal cingulate deep brain stimulation for treatment-resistant depression: A pilot study. Journal of psychiatry & neuroscience. 2013;38:325-332.
11737.	Ramasubbu R, Burgess A, Gaxiola I, et al. Amygdala responses as neuroimaging endpoint marker for antidepressant efficacy in patients with major depression and high risk alleles of serotonin transporter gene polymorphism. Biological psychiatry. 2014;Conference:239S-240S.
11738.	Ramasubbu R, Goodyear B, Gaxiola I, MacQueen G. Neural markers of early treatment response during antidepressant treatment in major depressive disorder. Biological psychiatry. 2010;Conference:145S.
11739.	Ramasubbu R, VH T, Samaan Z, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Annals of clinical psychiatry. 2012;24:91-109.
11740.	Ramezanzadeh F, A-A N, Abedinia N, AR F, MM N. Psychiatric intervention improved pregnancy rates in infertile couples. Malaysian Journal of Medical Sciences. 2011;18:16-24.
11741.	Ramos-Rios R, I ED, A AV, P ET. Depression and cerebrovascular disease. [Spanish]. Psiquiatria Biologica. 2008;15:80-89.
11742.	Rampello L, Alvano A, Chiechio S, et al. Evaluation of the Prophylactic Efficacy of Amitriptyline and Citalopram, Alone or in Combination, in Patients With Comorbidity of Depression, Migraine, and Tension-Type Headache. Neuropsychobiology. 2004;50:322-328.
11743.	Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M. An Evaluation of Efficacy and Safety of Reboxetine in Elderly Patients Affected by "Retarded" Post-Stroke Depression - a Random, Placebo-Controlled Study. Archives of gerontology and geriatrics. 2005;40:275-285.
11744.	Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M. An Evaluation of Efficacy and Safety of Reboxetine in Elderly Patients Affected by "Retarded" Post-Stroke Depression - a Random, Placebo-Controlled Study. Archives of gerontology and geriatrics. 2005;40:275-285.
11745.	Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New Possibilities of Treatment for Panic Attacks in Elderly Patients - Escitalopram Versus Citolopram. Journal of clinical psychopharmacology. 2006;26:67-70.
11746.	Rampello L, Battaglia G, Raffaele R, Vecchio I, Alvano A. Is it safe to use antidepressants after a stroke? Expert opinion on drug safety. 2005;4:885-897.
11747.	Rampello L, Chiechio S, Nicoletti G, et al. Prediction of the Response to Citalopram and Reboxetine in Post-Stroke Depressed Patients. Psychopharmacology. 2004;173:73-78.
11748.	Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clinical neuropharmacology. 2002;25:21-24.
11749.	Rampono J, Simmer K, KF I, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42:95-100.
11750.	RAMR M. The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder. Clinical drug investigation. 2011;31:5-17.
11751.	Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS ONE [Electronic Resource]. 2012;7:e42003.
11752.	Ranga K, Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. Journal of clinical psychiatry. 2002;63 Suppl 1:25-29.
11753.	Ranga K, Krishnan R. Broken heart: Depression in cardiovascular disease. Dialogues in clinical neuroscience. 2003;5:167-174.
11754.	Ranjan S, PS C, SK C, SC P, Gupta A. Atypical Antipsychotic-Induced Akathisia With Depression: Therapeutic Role of Mirtazapine. Annals of pharmacotherapy. 2006;40:771-774.
11755.	Ranjbar E, MS K, Mohammad-Shirazi M, et al. Effects of Zinc supplementation in patients with major depression: A randomized clinical trial. Iranian Journal of Psychiatry. 2013;8:73-79.
11756.	Ranjbar E, Shams J, Sabetkasaei M, et al. Effects of Zinc Supplementation on Efficacy of Antidepressant Therapy, Inflammatory Cytokines, and Brain-Derived Neurotrophic Factor in Patients With Major Depression. Nutritional neuroscience. 2014;17:65-71.
11757.	Ransom S, Moldenhauer J. Systematic Diagnosis and Individualized Therapy. Physician and sportsmedicine. 1998;26:35-+.
11758.	Rao N. The Clinical Pharmacokinetics of Escitalopram. Clinical pharmacokinetics. 2007;46:281-290.
11759.	Rao S, Zisook S. Anxious depression: Clinical features and treatment. Current psychiatry reports. 2009;11:429-436.
11760.	RAORT O. Folate Augmentation of Antidepressant Response. Drugs of today (Barcelona, Spain : 1998). 2013;49:791-798.
11761.	Rapkin A. A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003;28:39-53.
11762.	Rappaport N, JQ B, JB P, Jellinek M. Treating pediatric depression in primary care: Coping with the patients' blue mood and the FDA's black box. Journal of pediatrics. 2006;148:567-567.e564.
11763.	Rascol O. Rasagiline in the pharmacotherapy of Parkinson's disease - A review. Expert opinion on pharmacotherapy. 2005;6:2061-2075.
11764.	Raskin J, FJ W, YLL P, DJ G. Duloxetine for Patients With Diabetic Peripheral Neuropathic Pain: a 6-Month Open-Label Safety Study. Pain medicine (Malden, Mass.). 2006;7:373-385.
11765.	Raskin J, RE G, Hussain N, GW Z, LB M. Apathy in SSRI-treated patients with depression: Outcomes after switch to duloxetine or escitalopram. European neuropsychopharmacology. 2011;Conference:S387.
11766.	Raskin J, TR S, Wong K, et al. Duloxetine Versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain. Journal of palliative medicine. 2006;9:29-40.
11767.	Raskin J, Wiltse C, Dinkel J, Xu J, Katona C, Gandhi P. The Safety and Tolerability of Duloxetine Vs. Placebo in the Treatment of Elderly Patients With Major Depressive Disorder (Mdd). Journal of psychopharmacology (Oxford, England). 2005;19:A47.
11768.	Raskin J, YL P, FJ W, et al. A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine With Placebo in the Management of Diabetic Peripheral Neuropathic Pain. Pain medicine (Malden, Mass.). 2005;6:346-356.
11769.	Raskin J, YL P, FJ W, et al. A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine With Placebo in the Management of Diabetic Peripheral Neuropathic Pain. Pain medicine (Malden, Mass.). 2005;6:346-356.
11770.	Rasmussen A, Christensen J, PM C, et al. Platelet serotonin transporter in stroke patients. Acta neurologica Scandinavica. 2003;107:150-153.
11771.	Rasmussen K, DO C, JF C, et al. The Novel 5-Hydroxytryptamine(1a) Antagonist Ly426965: Effects on Nicotine Withdrawal and Interactions With Fluoxetine. Journal of pharmacology and experimental therapeutics. 2000;294:688-700.
11772.	RASR S. Pharmacological treatment of fibromyalgia syndrome: New developments. Drugs. 2010;70:1-14.
11773.	Ratti E, Bellew K, Bettica P, et al. Results from two double-blind, placebo-controlled studies of the novel nk1 receptor antagonist casopitant in patients with major depressive disorder. Neuropsychopharmacology. 2010;Conference:S323-S324.
11774.	Raucoules D, Levy C, JM A, Bruno M, Valli M. [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study]. [French]. L'Enc�phale. 1992;18:611-616.
11775.	Raul V-J, Adriana S, Pamela L, et al. Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: A prospective study. BMC psychiatry. 2014;14.
11776.	Ravera S, JG R, LTW DJ-vdB, JJ DG. Are Selective Serotonin Reuptake Inhibitors Safe for Drivers? What is the Evidence? Clinical therapeutics. 2012;34:1070-1083.
11777.	Ravindran AV, Charbonneau Y, Zaharia MD, Al-Zaid K, Wiens A, Anisman H. Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia. Journal of psychiatry & neuroscience. 1998;23:288-292.
11778.	Ravindran AV, Teehan MD, Bakish D, Yatham D. "The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression": Erratum. Human Psychopharmacology: Clinical and Experimental. 1997;12:86.
11779.	Ravindran AV, Teehan MD, Bakish D, et al. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Human Psychopharmacology: Clinical and Experimental. 1995;10:273-281.
11780.	Ravizza L. Amisulpride in Medium-Term Treatment of Dysthymia: a Six-Month, Double-Blind Safety Study Versus Amitriptyline. Journal of psychopharmacology (Oxford, England). 1999;13:248-254.
11781.	Ray B, Regan F, J CD, Christine T, Christel W. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. Journal of child and adolescent psychopharmacology. 2006;16:59-75.
11782.	Ray N, J TM, Sudhakar S, E MS, J HC, J CP. Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology. 2009;206:197-204.
11783.	Rayner L, Price A, Evans A, Valsraj K, Hotopf M, IJ H. Antidepressants for the Treatment of Depression in Palliative Care: Systematic Review and Meta-Analysis. Palliative medicine. 2011;25:36-51.
11784.	Rayner L, Price A, Hotopf M, IJ H. Expert opinion on detecting and treating depression in palliative care: A Delphi study. BMC palliative care. 2011.
11785.	Raza S, K JA, Renu S. Paroxetine in the treatment of adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1270.
11786.	Razay G, GK W. Galantamine in Alzheimer's disease. Expert review of neurotherapeutics. 2008;8:9-17.
11787.	RB D. 157th Annual Meeting of the American Psychiatric Association: Psychotherapy and psychopharmacology. Dissolving the mind-brain barrier. P and T. 2004;29:347-348+353.
11788.	RB H, JRT D. Selective Serotonin Reuptake Inhibitors in Post-Traumatic Stress Disorder. Journal of psychopharmacology (Oxford, England). 2000;14:70-76.
11789.	RB H, JRT D. Generalized anxiety disorder: An important clinical concern. Medical clinics of North America. 2001;85:691-710.
11790.	Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: Design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up, Contemporary clinical trials(2010).
11791.	Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo, JAMA Psychiatry(2013).
11792.	RB J, Minhajuddin A, PD B, et al. Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders. Behaviour research and therapy. 2012;50:280-286.
11793.	RB J, Schaffer M, Mcintire D, Witt-Browder A, Kraft D, RC R. Treatment of Atypical Depression With Cognitive Therapy or Phenelzine - a Double-Blind, Placebo-Controlled Trial. Archives of general psychiatry. 1999;56:431-437.
11794.	RB K, Richa S. Thyroid adverse effects of psychotropic drugs: A review. Clinical neuropharmacology. 2011;34:248-255.
11795.	RB L. Obsessive-Compulsive Disorder - a New Perspective in Diagnosis and Treatment. International clinical psychopharmacology. 1994;9:33-37.
11796.	RB L. Psychopharmacology in the treatment of irritable bowel syndrome. Primary psychiatry. 2007;14:40-50.
11797.	RB L, LK L, WA MJ, et al. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: Effects on depression. Psychopharmacology bulletin. 1989;25:68-70.
11798.	RB L, Pitrosky B, Hackett D, White C. Impact of Gastrointestinal Symptom Severity on Response to Venlafaxine Extended-Release in Patients With Generalized Anxiety Disorder. Journal of clinical psychiatry. 2004;65:838-844.
11799.	RB L, Pitrosky B, Hackett D, White C. Impact of Gastrointestinal Symptom Severity on Response to Venlafaxine Extended-Release in Patients With Generalized Anxiety Disorder. Journal of clinical psychiatry. 2004;65:838-844.
11800.	RB L, Rickels K, Herman B, DE F. Comparative Efficacy of Pregabalin and Benzodiazepines in Treating the Psychic and Somatic Symptoms of Generalized Anxiety Disorder. International journal of neuropsychopharmacology. 2010;13:229-241.
11801.	RB L, Steiner M, Burnham D, Gergel I. Efficacy Studies of Paroxetine in Panic Disorder. Psychopharmacology bulletin. 1998;34:175-182.
11802.	RB S. Advances in Pharmacotherapy - Depression in the Elderly - Issues and Advances in Treatment. Journal of clinical pharmacy and therapeutics. 1993;18:243-253.
11803.	RB T, JA N, JW WJ. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. [Review]. Journal of general internal medicine. 2011;26:643-650.
11804.	RB W. Anger and mental stress-induced myocardial ischemia:Mechanisms and clinical implications. American heart journal. 2014;169:4-5.
11805.	RBR M, GL P, Noble S. Sertraline: a review of its use in the management of major depressive disorder in elderly patients. [Review] [68 refs]. Drugs & aging. 2002;19:377-392.
11806.	RC A, Preskorn S. Clinical pharmacology in the development of new antidepressants: The challenges. Current opinion in pharmacology. 2014;14:6-10.
11807.	RC B. Commentary. Evidence-based medicine. 1998;3:124.
11808.	RC B. Research into depressive disorder in later life: Who is doing what? A literature search from 1998-2001. International Psychogeriatrics. 2002;14:335-346.
11809.	RC B. Potential uses of modafinil in psychiatric disorders. Journal of applied research. 2004;4:198-207.
11810.	RC B. Recent understandings in geriatric affective disorder. Current opinion in psychiatry. 2007;20:539-543.
11811.	RC B. Preventing late-life depression: A clinical update. International Psychogeriatrics. 2010;22:1216-1224.
11812.	RC C, BE F, JC L-A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Journal of pediatrics. 2003;142:402-408.
11813.	RC D. Treatment of generalized anxiety disorder. Psychiatry. 2007;6:183-187.
11814.	RC H, HR S, Bakker M, Munchau A, BR B. Repetitive transcranial magnetic stimulation to improve mood and motor function in Parkinson's disease. Journal of the neurological sciences. 2006;248:84-96.
11815.	RC J, Mudgal S. Advances in the management of psycho-Active substance dependence. Journal International Medical Sciences Academy. 2012;25:269-275.
11816.	RC N, CK H, Yeung W, Haller E, PR F. Pharmacologic treatment for postpartum depression: A systematic review. Pharmacotherapy. 2010;30:928-941.
11817.	RC S. The role of sertraline in the management of depression. [Review] [37 refs]. Clinical therapeutics. 1994;16:768-782; discussion 767.
11818.	RC S. Treatment Options for Refractory Depression. Journal of clinical psychiatry. 1999;60:57-63.
11819.	RC S. St John's wort for the treatment of depression. Lancet neurology. 2002;1:275.
11820.	RC S. The combination of olanzapine and fluoxetine in mood disorders. Expert opinion on pharmacotherapy. 2003;4:1175-1183.
11821.	RC S. The Dual-Action Hypothesis: Does Pharmacology Matter? Journal of clinical psychiatry. 2004;65:5-10.
11822.	RC S. The Dual-Action Hypothesis: Does Pharmacology Matter? Journal of clinical psychiatry. 2004;65:5-10.
11823.	RC S. Potential future therapies for irritable bowel syndrome: Will disease modifying therapy as opposed to symptomatic control become a reality? Gastroenterology clinics of North America. 2005;34:337-354.
11824.	RC S. Olanzapine/fluoxetine combination for bipolar depression. Expert review of neurotherapeutics. 2006;6:33-39.
11825.	RC S. The return of fixed combinations in psychiatry: Fluoxetine and olanzapine combination. Therapeutics and clinical risk management. 2006;2:187-192.
11826.	RC S. Augmentation strategies to increase antidepressant efficacy. Journal of clinical psychiatry. 2007;68:18-22.
11827.	RC S. Issues related to adherence in the treatment of depression. Primary psychiatry. 2007;14:42-46.
11828.	RC S. Long-term management of depression: Tips for adjusting the treatment plan as the patient's needs change. Journal of clinical psychiatry. 2009;70:32-37.
11829.	RC S. St John's wort (Hypericum perforatum) in major depression. Journal of clinical psychiatry. 2009;70:23-27.
11830.	RC S, AH M. Inflammation in depression: Is adiposity a cause? Dialogues in clinical neuroscience. 2011;13:41-54.
11831.	RC S, Davidson J, KA Y, et al. The undertreatment of dysthymia. Journal of clinical psychiatry. 1997;58:59-65.
11832.	RC S, GI P. Augmentation of Antidepressants With Atypical Antipsychotics for Treatment-Resistant Major Depressive Disorder. Acta psychiatrica Scandinavica. 2008;117:253-259.
11833.	RC S, Osuntokun O, AN H, SA C. Therapeutic Options for Treatment-Resistant Depression. CNS drugs. 2010;24:131-161.
11834.	Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. [Review] [43 refs], International journal of clinical practice(2007).
11835.	RC S, Reddy R. Adjunctive use of modafinil in bipolar patients: Just another stimulant or not? Current psychiatry reports. 2008;10:520-524.
11836.	RC S, SM S. Risperidone and Paroxetine Given Singly and in Combination for Bipolar Depression. Journal of clinical psychiatry. 2004;65:1715-1719.
11837.	RC Y. Evidence-based pharmacological treatment of geriatric bipolar disorder. Psychiatric clinics of North America. 2005;28:837-869.
11838.	RC Z. Treatment of depression in patients with coronary artery disease [4]. Journal of the American Medical Association. 2007;297:1878-1879.
11839.	RCL E, MA N, Battistella L, Fregni F. Why Do Some Promising Brain-Stimulation Devices Fail the Next Steps of Clinical Development? Expert review of medical devices. 2010;7:67-97.
11840.	RD B, JT H, JF K, Kloke J, Saleh A, SM H. A Review of the Effectiveness of Antidepressant Medications for Depressed Nursing Home Residents. Journal of the American Medical Directors Association. 2012;13:326-331.
11841.	RD C. Glucocorticoid receptor antagonists. Current topics in medicinal chemistry. 2008;8:813-838.
11842.	Neuropsychological Outcomes After Psychosocial Intervention for Depression in Parkinson's Disease, Journal of neuropsychiatry and clinical neurosciences(2014).
11843.	RD G. Suicide prevention is possible: A review of recent studies. Archives of suicide research. 1998;4:329-339.
11844.	RD G. Suicide and antidepressants: What is the evidence? Australian and New Zealand journal of psychiatry. 2006;40:381-385.
11845.	RD G, CH B, Hur K, JM D, JJ M. Suicide risk and efficacy of antidepressant drugs--reply. JAMA psychiatry (Chicago, Ill.). 2013;70:123-125.
11846.	RD G, CH B, Hur K, JM D, JJ M. Inappropriate data and measures lead to questionable conclusions--reply. JAMA Psychiatry. 2013;70:122-123.
11847.	RD G, JJ M. Strategies for quantifying the relationship between medications and suicidal behaviour: What has been learned? Drug safety. 2011;34:375-395.
11848.	RD G, Koren G. Motherisk update: Taking St. John's wort during pregnancy. Canadian Family Physician. 2003;49:29-30.
11849.	RD J. Insomnia in patients with depression: Some pathophysiological and treatment considerations. CNS drugs. 2009;23:309-329.
11850.	RD J, ME T. Integrating Psychotherapy and Pharmacotherapy to Improve Outcomes Among Patients With Mood Disorders. Psychiatric services (Washington, D.C.). 2003;54:1484-1490.
11851.	RD M, FR S, BA F, et al. An Open Trial of Paroxetine in Patients With Noncombat-Related, Chronic Posttraumatic Stress Disorder. Journal of clinical psychopharmacology. 1998;18:10-18.
11852.	RD M, KL B, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American journal of psychiatry. 2001;158:1982-1988.
11853.	RD M, Lewis-Fernandez R, Blanco C, et al. A Controlled Trial of Paroxetine for Chronic Ptsd, Dissociation, and Interpersonal Problems in Mostly Minority Adults. Depression and anxiety. 2007;24:77-84.
11854.	RD N, BG P, BH M, MA B, MD Z, 3rd RCF. Cognitive effects of paroxetine in older depressed patients. Journal of clinical psychiatry. 1999;60 Suppl 2:26-29.
11855.	RD N, MA B, PR H, et al. Dual-task performance in depressed geriatric patients. Psychiatry research. 2001;102:139-151.
11856.	RD T, LS L, SP B, Toor A, Maheshwari Y, NR R. Lansoprazole-associated microscopic colitis: A case series. American journal of gastroenterology. 2002;97:2908-2913.
11857.	RD T-S, Dienel A. Safety of Hypericum extract in mildly to moderately depressed outpatients: A review based on data from three randomized, placebo-controlled trials. Journal of affective disorders. 2004;82:303-307.
11858.	RD W, RC D, RM C, KE F, SP D. Depression Predicts Self-Reported Sleep Quality in Patients With Obstructive Sleep Apnea. Psychosomatic medicine. 2004;66:692-697.
11859.	RD W, RC D, RM C, KE F, SP D. Depression Predicts Self-Reported Sleep Quality in Patients With Obstructive Sleep Apnea. Psychosomatic medicine. 2004;66:692-697.
11860.	RE C. Managing functional bowel disorders from the top down: Lessons from a well-designed treatment trial. Gastroenterology. 2003;125:249-253.
11861.	RE D, RP B. Brain arachidonic acid uptake and turnover: Implications for signaling and bipolar disorder. Current opinion in clinical nutrition and metabolic care. 2010;13:130-138.
11862.	RE E, AI L, JV L, PA G. Effects of antidepressants and soybean association in depressive menopausal women. Acta poloniae pharmaceutica. 2014;71:323-327.
11863.	RE F, Blumenfield M, Orlowski B, WH F, Ovanessian S. A national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiology in review. 2006;14:164-169.
11864.	RE J. Neuropsychiatric consequences of traumatic brain injury: A review of recent findings. Current opinion in psychiatry. 2005;18:289-299.
11865.	RE J, RG R. Post-stroke depression. Geriatrics & aging. 2004;7:26-32.
11866.	RE J, RG R, JT OB. Top cited papers in international psychogeriatrics: 5. a controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. International Psychogeriatrics. 2009;21:855-857.
11867.	RE J, RG R, Tateno A, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: A preliminary study. Biological psychiatry. 2004;55:398-405.
11868.	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care, Oncotarget(2013).
11869.	RE M, Salzman C, EA Y, et al. Suicidality and risk of suicide - Definition, drug safety concerns, and a necessary target for drug development: A brief report. Journal of clinical psychiatry. 2010;71:1040-1046.
11870.	RE OC, APR M, KP E, GM G. Effects of Fluvoxamine Treatment on Cognitive-Functioning in the Alcoholic Korsakoff Syndrome. Psychopharmacology. 1994;116:85-88.
11871.	RE S, MS C, MS O, Haq I, MS S. Pseudobulbar Affect: Prevalence and Quality of Life Impact in Movement Disorders. Journal of neurology. 2010;257:1382-1387.
11872.	RE U, Arroyo E, JM A, et al. Clinical guidelines for the treatment of attention deficit hyperactivity disorder in children and adolescents. [Spanish]. Salud mental (Mexico City, Mexico). 2005;28:1-10.
11873.	Rechenberg K, Humphries D. Nutritional interventions in depression and perinatal depression. Yale journal of biology and medicine. 2013;86:127-137.
11874.	Rechlin T, Maria W, Claus D. Heart rate variability in depressed patients and differential effects of paroxetine and amitriptyline on cardiovascular autonomic functions. Pharmacopsychiatry. 1994;27:124-128.
11875.	Reddy J, Khanna S, Anand U, Banerjee A. Alprazolam-Induced Hypomania. Australian and New Zealand journal of psychiatry. 1996;30:550-552.
11876.	Reed C, Kalnik M, Rakin K, Athanasiou M, Judson R. Restoring value to stalled Phase II compounds: The case for developing a novel compound for depression using pharmacogenetics. Pharmacogenomics. 2005;6:95-100.
11877.	Reeves G, Anthony B. Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders: Implications of access, effectiveness, and contextual treatment. Pediatric Drugs. 2009;11:165-169.
11878.	Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study, Journal of clinical psychiatry(2008).
11879.	Regen F, Anghelescu I. How quickly do antidepressants work?. [German]. MMW Fortschritte der Medizin. 2006;148:82-86.
11880.	Regis B, Pierre T, Bernard D. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. American journal of psychiatry. 1998;155:1346-1351.
11881.	Reich M. Antidepressants in oncology: Specificity's and particularities. [French]. Psycho-Oncologie. 2010;4:51-64.
11882.	Reichenpfader U, Gartlehner G, LC M, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. [Review]. Drug safety. 2014;37:19-31.
11883.	Reichmann H, Schneider C, Lohle M. Non-motor features of Parkinson's disease: depression and dementia. Parkinsonism & related disorders. 2009;15:S87-S92.
11884.	Reichmann H, WMM S. Pramipexole in the management of Parkinson's disease. Aging health. 2008;4:225-235.
11885.	Reichmann H, Ziemssen T. Treatment strategies for nonmotor manifestations of Parkinson's disease. Expert opinion on pharmacotherapy. 2009;10:773-784.
11886.	Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ (Online). 2010;340:752-756.
11887.	Reiff J, Laux G, WE M, H-J M. Sertraline in the treatment of depressive disorders. [German]. Psychopharmakotherapie, Supplement. 1997;4:18-25.
11888.	Reiff J, Laux G, WE M, HJ M. Sertraline in the Treatment of Depressive Disorders. Psychopharmakotherapie. 1997;4:18-25.
11889.	Reiff J, WE M. Antidepressant-Induced Sexual Dysfunction. Psychopharmakotherapie. 1999;6:143-147.
11890.	Reiff J, Witt K, Deuschl G. Treatment of Depressive Disorders in Parkinson's Disease. Aktuelle Neurologie. 2005;32:77-85.
11891.	Reiff J, Witt K, Deuschl G. Treatment of Depressive Disorders in Parkinson's Disease. Aktuelle Neurologie. 2005;32:77-85.
11892.	Reiji Y, Masae M, Atsuko S, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2007;31:1034-1037.
11893.	Reiji Y, Ueda N, Nakamura J. Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine. International clinical psychopharmacology. 2000;15:233-235.
11894.	Reimherr FW, Chouinard G, K CC, et al. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of clinical psychiatry. 1990;51:18-27.
11895.	Reinares M, AR R, Franco C, et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. International journal of neuropsychopharmacology. 2013;16:485-496.
11896.	Reis M, Aberg-Wistedt A, Agren H, Hoglund P, A-C A, Bengtsson F. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: A pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Human psychopharmacology. 2004;19:283-291.
11897.	Reis M, AC A, LV K, Ekselius L. Hidden partial non-compliance with antidepressants and its effect on treatment response. European neuropsychopharmacology. 2009;Conference:S415.
11898.	Reis M, L VK, A-C A, Ekselius L. Hidden partial non-compliance with antidepressants and its effect on treatment response. Pharmacoepidemiology and Drug Safety (PDS). 2009;Conference:S169-S170.
11899.	Rej S, MA D, JF K. Treating Concurrent Chronic Low Back Pain and Depression With Low-Dose Venlafaxine: an Initial Identification of "Easy-to-Use" Clinical Predictors of Early Response. Pain medicine (Malden, Mass.). 2014;15:1154-1162.
11900.	REK S, LE Z, PS J. Interventions for adolescent depression in primary care. Pediatrics. 2006;118:669-682.
11901.	Rena C-K. Treatment of night eating syndrome with topiramate: Dawn of a new day. Journal of clinical psychopharmacology. 2012;32:143-145.
11902.	Rena C-K, Amihai R, Bernard L. Targeting remission by 8 weeks: When should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor? [References]. Comprehensive psychiatry. 2011;52:9-16.
11903.	Combined Treatment With Sertraline and Liothyronine in Major Depression - a Randomized, Double-Blind, Placebo-Controlled Trial, Archives of general psychiatry(2007).
11904.	Renaud J, Axelson D, Birmaher B. A Risk-Benefit Assessment of Pharmacotherapies for Clinical Depression in Children and Adolescents. Drug safety. 1999;20:59-75.
11905.	Renaud J, Birmaher B, SC W, Bridge J. Use of Selective Serotonin Reuptake Inhibitors for the Treatment of Childhood Panic Disorder: a Pilot Study. Journal of child and adolescent psychopharmacology. 1999;9:73-83.
11906.	Renaud J, DA B, Baugher M, Birmaher B, DJ K, Bridge J. Rapid Response to Psychosocial Treatment for Adolescent Depression: a Two-Year Follow-up. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:1184-1190.
11907.	Rene K, Jesper B-H, L HH, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: Placebo-controlled study of maintenance therapy. The British Journal of Psychiatry. 2002;181:29-35.
11908.	Rene K, Marc A. Unethical use of placebo controls: Reply. The British Journal of Psychiatry. 2002;181:533.
11909.	Renee R, Anita P, Martin K, Christine T. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care. International clinical psychopharmacology. 2004;19:125-134.
11910.	Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved. Frontiers in pharmacology. 2013.
11911.	Renoir T, Hasebe K, Gray L. Mind and body: How the health of the body impacts on neuropsychiatry. Frontiers in pharmacology. 2013.
11912.	Resler G, Lavie R, Campos J, et al. Effect of Folic Acid Combined With Fluoxetine in Patients With Major Depression on Plasma Homocysteine and Vitamin B-12, and Serotonin Levels in Lymphocytes. Neuroimmunomodulation. 2008;15:145-152.
11913.	Resnick B. Research Review: a New Option in Pain Management - Duloxetine Versus Placebo in Patients With Painful Diabetic Neuropathy. Geriatric nursing. 2005;26:355-356.
11914.	Rey-Sanchez F, JR G-C. Paroxetine in children with major depressive disorder: An open trial. Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36:1443-1447.
11915.	Reynaert C, Janne P, Vause M, Zdanowicz N, Lejeune D. Clinical trials of antidepressants: The hidden face: Where locus of control appears to play a key role in depression outcome. Psychopharmacology. 1995;119:449-454.
11916.	Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Do new antidepressants influence body weight? Comparing moclobemide to fluoxetine. European neuropsychopharmacology. 1993;3:354.
11917.	Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide versus fluoxetine for a major depressive episode. European neuropsychopharmacology. 1993;3:329-330.
11918.	Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology. 1995;118:183-187.
11919.	RF A. Neurobehavioural Basis for the Pharmacotherapy of Alcoholism: Current and Future Directions. Alcohol and Alcoholism. 1996;31:43-53.
11920.	RF H, HS A. The Long-Term Outcome of Dysthymia in Private Practice: Clinical Features, Temperament, and the Art of Management. Journal of clinical psychiatry. 1999;60:508-518.
11921.	RF H, Loo C. Adjunctive psychotropic medications during electroconvulsive therapy in the treatment of depression, mania, and schizophrenia. Journal of ECT. 2010;26:196-201.
11922.	RF K, CM A, Fujioka K. Obesity consults-comprehensive obesity management in 2013: Understanding the shifting paradigm. Obesity (Silver Spring, Md.). 2013;21:S3-S13.
11923.	RF M, RJ P. Atypical antipsychotics and anorexia nervosa: A review. European eating disorders review. 2010;18:10-21.
11924.	RG K, Mannuzza S, HS K, et al. Adolescent depression: Controlled desipramine treatment and atypical features. Depression and anxiety. 1998;7:15-31.
11925.	RG M, BH A. Managing menopause: Current therapeutic options for vasomotor symptoms. Advanced Studies in Medicine. 2004;4:484-492+494.
11926.	RG P, Gimbrett R, Roberts W, Steinert J. Reversible and Selective Inhibitors of Monoamine-Oxidase-a in Mental and Other Disorders. Acta Psychiatrica Scandinavica, Supplement. 1995;91:40-43.
11927.	RG R. Treatment issues in poststroke depression. Depression and anxiety. 1998;8:85-90.
11928.	RG R. Depression and anxiety in the context of physical illness. Depression and anxiety. 1998;7:147-148.
11929.	RG R, HP A. Selective serotonin-reuptake inhibitors and recovery after stroke. The Lancet Neurology. 2011;10:110-111.
11930.	RG R, Mikami K, Jang M, RE J. Prevention of anxiety disorder after stroke. Journal of neuropsychiatry and clinical neurosciences. 2011;Conference:18.
11931.	RG R, ML DC, Paradiso S. Poststroke Psychiatric-Problems - Diagnosis, Pathophysiology and Drug-Treatment Options. CNS drugs. 1995;3:436-447.
11932.	RG R, ML DC, Paradiso S. Post-stroke neuropsychiatric problems - Diagnosis, pathophysiology and treatment. [Portuguese]. Jornal brasileiro de psiquiatria. 1997;46:527-534.
11933.	RG R, RE J. Prevention of first-episode depression: Progress and potential. British journal of psychiatry. 2009;194:296-297.
11934.	RG R, Spalletta G. Poststroke depression: A review. Canadian Journal of Psychiatry. 2010;55:341-349.
11935.	RG S, Belotto C, Curi M, et al. Clinical Features Associated With Treatment Response in Obsessive-Compulsive Disorder. Comprehensive psychiatry. 2006;47:278-283.
11936.	RG S, CR M. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?. [Review] [115 refs]. American journal of cardiovascular drugs. 2003;3:149-162.
11937.	RG W, Hudak R, RJ G-W. Adverse reactions to aspartame: Double-blind challenge in patients from a vulnerable population. Biological psychiatry. 1993;34:13-17.
11938.	RH B. The future of depression psychopharmacology. CNS spectrums. 2008;13:682-687.
11939.	RH D, AB OC, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clinic proceedings. 2010;85:S3-S14.
11940.	RH D, Backonja M, MC R, et al. Advances in Neuropathic Pain - Diagnosis, Mechanisms, and Treatment Recommendations. Archives of neurology. 2003;60:1524-1534.
11941.	RH H. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. [Review] [15 refs]. Journal of psychosocial nursing and mental health services. 2008;46:21-24.
11942.	RH H. Understanding the Clinical Profile of a Drug on the Basis of Its Pharmacology Mirtazapine as an Example. Journal of psychosocial nursing and mental health services. 2008;46:19-23.
11943.	RH H. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatric disease and treatment. 2009;5:563-576.
11944.	RH H. Somatic Therapies for Seasonal Affective Disorder. Journal of psychosocial nursing and mental health services. 2009;47:17-20.
11945.	RH H. An overview of seasonal affective disorder and its treatment options. Physician and sportsmedicine. 2009;37:104-115.
11946.	RH H. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug safety. 2011;34:709-731.
11947.	RH H, LS S, SR B, CR S, Denko T. The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Annals of clinical psychiatry. 2011;23:48-62.
11948.	RH H, MG W, SG K, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Annals of clinical psychiatry. 2008;20:209-218.
11949.	RH H, Wisniewski S, GK B, Fava M, Trivedi M, AJ R. Thyroid disease, major depression, and treatment outcome in the COMED trial. Biological psychiatry. 2011;Conference:38S.
11950.	RH K, HS C, ML W, et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of psychopharmacology (Oxford, England). 2010;24:1755-1763.
11951.	RH L-J, Snowdon J. Depression in nursing homes: Ensuring adequate treatment. CNS drugs. 2007;21:627-640.
11952.	RH M-W. Commentary on STAR*D: A summary and UK perspective. Journal of psychopharmacology (Oxford, England). 2009;23:615-617.
11953.	RH M-W, DS B, PM H, Bazire S. The use of antidepressants in clinical practice: Focus on agomelatine. Human Psychopharmacology-Clinical and Experimental. 2010;25:95-102.
11954.	RH P. The role of pharmacologic treatment guidelines for bipolar disorder. Journal of clinical psychiatry. 2005;66:37-47.
11955.	RH P. Genetic predictors of antidepressant treatment response: Progress toward clinical pharmacogenetics. Primary psychiatry. 2007;14:54-59.
11956.	RH P. Treatment of Bipolar Disorder: the Evolving Role of Atypical Antipsychotics. American journal of managed care. 2007;13:S178-S188.
11957.	RH P. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biological psychiatry. 2013;74:7-14.
11958.	RH P, AA N, JE A, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. Journal of clinical psychopharmacology. 2002;22:474-480.
11959.	RH P, Alpert J, AA N, et al. Clinical and Sociodemographic Predictors of Response to Augmentation, or Dose Increase Among Depressed Outpatients Resistant to Fluoxetine 20 Mg/Day. Acta psychiatrica Scandinavica. 2003;108:432-438.
11960.	RH P, CMJr B, JDJr W, et al. Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes. Psychotherapy and psychosomatics. 2007;76:40-46.
11961.	RH P, DH A, Fijal B, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. Journal of clinical psychiatry. 2010;71:599-605.
11962.	RH P, DV I, Alpert J, AA N, JF R, Fava M. Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. Psychosomatics. 2004;45:224-229.
11963.	RH P, DV I, PF R. Biological predictors of treatment response in affective illness. Psychiatric clinics of North America. 2003;26:323-344.
11964.	RH P, Fijal B, Dharia S, AN H, JP H. Potential differences in pharmacogenomic associations with improvement in anxiety during duloxetine treatment of generalized anxiety disorder and major depressive disorder. Biological psychiatry. 2010;Conference:214S.
11965.	RH P, Fijal B, Dharia S, AN H, JP H. Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients. Biological psychiatry. 2010;67:1110-1113.
11966.	Pharmacogenetic Investigation of Response to Duloxetine Treatment in Generalized Anxiety Disorder, Pharmacogenomics journal(2013).
11967.	RH P, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology. 2008;33:2810-2819.
11968.	RH P, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology. 2008;33:2810-2819.
11969.	RH P, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Archives of general psychiatry. 2007;64:689-697.
11970.	RH P, Uher R, Ostacher M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Archives of general psychiatry. 2011;68:351-360.
11971.	RH S, JC V. Nefazodone in the treatment of patients with post-traumatic stress disorder. Expert review of neurotherapeutics. 2002;2:617-623.
11972.	RH W, AJ C, JC B, RM P, TA K. The use of antiepileptic drugs in bipolar disorders: A review based on evidence from controlled trials. CNS spectrums. 2006;11:788-799.
11973.	RH W, S VM, CL C, AJ G. Rapid onset of antidepressant activity with venlafaxine [2] (multiple letters). Journal of clinical psychiatry. 2002;63:534-536.
11974.	Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: A randomized controlled study), Journal of clinical psychiatry(2011).
11975.	RHB B, Fishman I, MM M, Bakshi R, Weinstock-Guttman B. Validity of Beck Depression Inventory-Fast Screen in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2003;9:393-396.
11976.	Rhee H, JH G, Heathcote P, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU international. 2015;115:3-13.
11977.	Rhodes-Kropf J, Cheng H, EH C, AT F. Managing the patient with dementia in long-term care. Clinics in geriatric medicine. 2011;27:135-152.
11978.	Rhondali W, Reich M, Filbet M. A brief review on the use of antidepressants in palliative care. European Journal of Hospital Pharmacy: Science and Practice. 2012;19:41-44.
11979.	RHS VDB, JP VM, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: Rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American heart journal. 2002;144:219-225.
11980.	RI B, AN F. Obesity, psychiatric status, and psychiatric medications. Psychiatric clinics of North America. 2005;28:39-54.
11981.	Riblet N, Larson R, BV W, Holtzheimer P. Reevaluating the role of antidepressants in cancer-related depression: A systematic review and meta-analysis. General hospital psychiatry. 2014;36:466-473.
11982.	Riblet N, Larson R, BV W, Holtzheimer P. Reevaluating the role of antidepressants in cancer-related depression: A systematic review and meta-analysis. General hospital psychiatry. 2014;36:466-473.
11983.	Ribolsi M, Magni V, IA R. Quetiapine fumarate for schizophrenia and bipolar disorder in young patients. Drugs of today (Barcelona, Spain : 1998). 2010;46:581-587.
11984.	Ricca V, Mannucci E, Dibernardo M, SM R, PL C, CM R. Sertraline Enhances the Effects of Cognitive-Behavioral Treatment on Weight Reduction of Obese Patients. Journal of endocrinological investigation. 1996;19:727-733.
11985.	Ricca V, Mannucci E, Paionni A, et al. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eating & Weight Disorders: EWD. 1999;4:10-14.
11986.	Rice T, Dobry Y, Wang E, Novakovic V, Sher L. Cognitive effects of quetiapine in a patient with dementia with Lewy bodies. Psychogeriatrics. 2013;13:52-57.
11987.	Richa S, J-C Y. Ocular adverse effects of common psychotropic agents: A review. CNS drugs. 2010;24:501-506.
11988.	Richard E, Albert D, Dianne K. Early onset of antidepressant action of venlafaxine: Pattern analysis in intent-to-treat patients. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 1998;20:517-526.
11989.	Richard E, M GJ. Global benefit-risk assessment of antidepressants: Venlafaxine XR and fluoxetine. Journal of psychiatric research. 2002;36:111-118.
11990.	Richard E, Michelle S, Jun Z. A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. Journal of psychiatric research. 2002;36:437-448.
11991.	Richard E, Rohini C. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacology bulletin. 1997;33:671-676.
11992.	Richard EA, Holly H, E TM. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Journal of clinical psychiatry. 2001;62:869-877.
11993.	Richard EA, L RR, Rohini C. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: A meta-analysis. Psychopharmacology bulletin. 1995;31:759-766.
11994.	Richard EA, M BM, S LG. Cumulative mean change procedure: Application to a comparative trial of venlafaxine, imipramine, and placebo in the treatment of major depression. Progress in neuro-psychopharmacology & biological psychiatry. 1994;18:695-706.
11995.	Richard H, Bradley G, Patricia T, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric services (Washington, D.C.). 2008;59:1121-1130.
11996.	Richard H, Bradley G, Patricia T, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. 2013:147-156.
11997.	The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. [Review], Expert review of neurotherapeutics(2013).
11998.	Richardson D, Goldmeier D. Recommendations for the management of retarded ejaculation: BASHH Special Interest Group for Sexual Dysfunction. International journal of STD & AIDS. 2006;17:7-13.
11999.	Richardson JS, Keegan DL, Bowen RC, et al. Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. International clinical psychopharmacology. 1994;9:35-40.
12000.	Richelson E. Multi-modality: A new approach for the treatment of major depressive disorder. International journal of neuropsychopharmacology. 2013;16:1433-1442.
12001.	Richings C, Feroz-Nainar C. Case series: Melatonin induced agitation in three patients with intellectual disability. British Journal of Developmental Disabilities. 2010;56:77-82.
12002.	Richou H, Ruimy P, Charbaut J, JP D, Brunner H, Patris M. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Human psychopharmacology. 1995;10:263-271.
12003.	Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatrica Scandinavica, Supplement. 1989;80:117-123.
12004.	Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta psychiatrica Scandinavica. Supplementum. 1989;350:117-123.
12005.	Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. Journal of clinical psychiatry. 1992;53:30-32.
12006.	Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. Journal of clinical psychiatry. 1992;53 Suppl:30-32.
12007.	Rickels K, Derivan A, Entsuah R, Miska S, Rudolph R. Rapid onset of antidepressant activity with venlafaxine treatment. Depression. 1995;3:146-153.
12008.	Rickels K, Etemad B, Khalid-Khan S, FW L, MA R, RJ G. Time to Relapse After 6 and 12 Months' Treatment of Generalized Anxiety Disorder With Venlafaxine Extended Release. Archives of general psychiatry. 2010;67:1274-1281.
12009.	Rickels K, Mangano R, Khan A. A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine Er in Adult Outpatients With Generalized Social Anxiety Disorder. Journal of clinical psychopharmacology. 2004;24:488-496.
12010.	Rickels K, Mangano R, Khan A. A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine Er in Adult Outpatients With Generalized Social Anxiety Disorder. Journal of clinical psychopharmacology. 2004;24:488-496.
12011.	Rickels K, MH P, DE F, et al. Pregabalin for Treatment of Generalized Anxiety Disorder - a 4-Week, Multicenter, Double-Blind, Placebo-Controlled Trial of Pregabalin and Alprazolam. Archives of general psychiatry. 2005;62:1022-1030.
12012.	Rickels K, MH P, DV S, JT H. Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder. American journal of psychiatry. 2000;157:968-974.
12013.	Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: A review of the paroxetine clinical trials database. Journal of clinical psychiatry. 2006;67:41-47.
12014.	Rickels K, SA M, KA T, et al. Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder Results of a Randomized Trial. Journal of clinical psychopharmacology. 2010;30:18-24.
12015.	Rickels K, WT S, Glaudin V, JB A, Weise C, GP S. Comparison of two dosage regimens of fluoxetine in major depression. Journal of clinical psychiatry. 1985;46:38-41.
12016.	Rico-Villademoros F, Saiz-Ruiz J. Fluvoxamine in the treatment of late-life depression: how much we know coming from randomized controlled trials: comment on article by Dr Rossini and colleagues. Journal of clinical psychopharmacology. 2007;27:98-99; author reply 99.
12017.	Riddle. The Pediatric Anxiety Rating Scale (PARS): Development and Psychometric Properties. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1061-1069.
12018.	Ridgway D, Khan A, Ridgway G, MA C, CG L. Subject numbers and placebo outcome variability in clinical trials of new CNS medications. Drug information journal. 2007;41:701-708.
12019.	Riedel M, H-J M, Obermeier M, et al. Clinical predictors of response and remission in inpatients with depressive syndromes. Journal of affective disorders. 2011;133:137-149.
12020.	Riedel M, Muller N, Stradding M, Spellmann I, Severus E, H-J M. Quetiapine in the treatment of schizophrenia and related disordes. Neuropsychiatric disease and treatment. 2007;3:219-235.
12021.	Riedel M, Muller N, WE M, H-J M. Nefazodone, a dual serotonergic anti-depressant. [German]. Psychopharmakotherapie. 2000;7:117-124.
12022.	Frontotemporal lobar degeneration: Current perspectives, Neuropsychiatric disease and treatment(2014).
12023.	Rief W, Nestoriuc Y, A VL-T, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. Drug safety. 2009;32:1041-1056.
12024.	Riem L. Alzheimer's disease: Everyday competence in focus. [German]. Nervenheilkunde. 2008;27:351-354.
12025.	Riem L. Prevention of recurrent episodes of depression and loss of quality of life. [German]. Nervenheilkunde. 2008;27:594-595.
12026.	Riemann D, Berger M, Voderholzer U. Sleep and depression - Results from psychobiological studies: An overview. Biological psychology. 2001;57:67-103.
12027.	Riemann D, Participants W. Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?. [Review] [115 refs]. Drugs. 2009;69 Suppl 2:43-64.
12028.	Riemekasten G, Sunderkotter C. Vasoactive therapies in systemic sclerosis. Rheumatology. 2006;45:iii49-iii51.
12029.	Riesenberg R, Rosenthal J, Moldauer L, Peterson C. Results of a Proof-of-Concept, Dose-Finding, Double-Blind, Placebo-Controlled Study of Rx-10100 (Serdaxina (R)) in Subjects With Major Depressive Disorder. Psychopharmacology. 2012;221:601-610.
12030.	Motor cortex stimulation does not improve dystonia secondary to a focal basal ganglia lesion, Neurology(2014).
12031.	Rifkin A. SSRI optimal dose remains at issue [2]. Journal of clinical psychiatry. 1997;58:87-88.
12032.	Rifkin A. Randomized controlled trials and psychotherapy research. American journal of psychiatry. 2007;164:7-8.
12033.	RIG H, CM VDF-C. Key concepts in screening for depression in people with diabetes. Journal of affective disorders. 2012;142:S72-S79.
12034.	Rigaud D, Brayer V, Biton-Jelic V, Pais V, Pennacchio H, JM B. Nasogastric Tube Feeding in Bulimia - Controlled Study With Follow-up at 3 Months. Presse medicale. 2007;36:1354-1363.
12035.	Riggin L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: a systematic review and meta-analysis. [Review][Erratum appears in J Obstet Gynaecol Can. 2013 Aug;35(8):691]. Journal d'obstetrique et gynecologie du Canada : JOGC [Journal of obstetrics and gynaecology Canada : JOGC]. 2013;35:362-369.
12036.	Riggs P, Levin F, AI G, Vocci F. Comorbid psychiatric and substance abuse disorders: Recent treatment research. Substance abuse. 2008;29:51-63.
12037.	Rihmer Z. Dysthymic disorder: Implications for diagnosis and treatment. Current opinion in psychiatry. 1999;12:69-75.
12038.	Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. Journal of affective disorders. 2006;94:3-13.
12039.	Rihmer Z, Dome P, Gonda X. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: Implications for practice and drug research. Journal of clinical psychopharmacology. 2013;33:449-452.
12040.	Rihmer Z, Gonda X. Pharmacological prevention of suicide in patients with major mood disorders. Neuroscience and biobehavioral reviews. 2013;37:2398-2403.
12041.	Rihmer Z, Gonda X, Dome P, Erdos P, Ormos M, Pani L. Novel Approaches to Drug-Placebo Difference Calculation: Evidence From Short-Term Antidepressant Drug-Trials. Human Psychopharmacology-Clinical and Experimental. 2011;26:307-312.
12042.	Rijavec N, VN G. Usher syndrome and psychiatric symptoms: A challenge in psychiatric management. Psychiatria Danubina. 2009;21:68-71.
12043.	Rincon F, ED L. Benefits and risks of pharmacological and surgical treatments for essential tremor: Disease mechanisms and current management. Expert opinion on drug safety. 2005;4:899-913.
12044.	Rita M, Paola T, M AR, Giuseppe C, Antonio B. Depression and Alzheimer's disease: Symptom or comorbidity? [References]. American journal of Alzheimer's disease and other dementias. 2002;17:338-344.
12045.	Ritzmann P. Vitex agnus castus. [German]. Pharma-Kritik. 2004;26:31-32.
12046.	Rivas D, JW A. Author Response. Journal of sexual medicine. 2008;5:990-994.
12047.	Rixon P. Bipolar explorations. Good Clinical Practice Journal. 2007;14:31-32.
12048.	RJ A, BM G, GS S, KE F, PJ L. Antidepressant pharmacotherapy in adults with type 2 diabetes: Rates and predictors of initial response. Diabetes care. 2010;33:485-489.
12049.	RJ A, PJ P. Review article: The management of side-effects during therapy for hepatitis C. Alimentary pharmacology & therapeutics. 2004;20:917-929.
12050.	RJ B. Diagnostics and Treatment of the Generalized Anxiety Syndrome (Gas). Fortschritte der Neurologie-Psychiatrie. 2005;73:694-701.
12051.	RJ B. Generalized anxiety disorder. Diagnosis and therapy. [German]. Internistische Praxis. 2010;50:655-664.
12052.	RJ B, GP R, SG S. Anxiety comorbidity in schizophrenia. Psychiatry research. 2013;210:1-7.
12053.	RJ B, HJ M. Treatment of Anxious-Depressive Disorders - Newer Therapeutic Approaches. Psychopharmakotherapie. 1998;5:46-53.
12054.	RJ B, HJ M. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry. 1999;32:119-126.
12055.	RJ B, Tondo L, IM S, et al. Ecological studies of antidepressant treatment and suicidal risks. Harvard review of psychiatry. 2007;15:133-145.
12056.	RJ B, Ventura D, CC C. A Double-Blind Comparison of Escitalopram and Venlafaxine Extended Release in the Treatment of Major Depressive Disorder. Journal of clinical psychiatry. 2004;65:1190-1196.
12057.	RJ D, Crits-Christoph P. Empirically supported individual and group psychological treatments for adult mental disorders. Journal of consulting and clinical psychology. 1998;66:37-52.
12058.	RJ D, SD H, JD A, et al. Cognitive Therapy Vs Medications in the Treatment of Moderate to Severe Depression. Archives of general psychiatry. 2005;62:409-416.
12059.	RJ D, ZD C, NR F, JC F, LA G, Lorenzo-Luaces L. The personalized advantage index: Translating research on prediction into individualized treatment recommendations. A demonstration. PloS one. 2014;9.
12060.	Randomised Clinical Trial: Escitalopram for the Prevention of Psychiatric Adverse Events During Treatment With Peginterferon-Alfa-2a and Ribavirin for Chronic Hepatitis C, Alimentary pharmacology & therapeutics(2011).
12061.	RJ E, KE L, Pahwa R. Levetiracetam is not effective for essential tremor. Clinical neuropharmacology. 2007;30:350-356.
12062.	RJ G. Nefazodone and Venlafaxine - 2 New Agents for the Treatment of Depression. Journal of family practice. 1995;41:591-594.
12063.	RJ G. Nefazodone and venlafaxine: Two new agents for the treatment of depression. Journal of family practice. 1995;41:591-594.
12064.	RJ G. Antidepressant Use in the Elderly - Current Status of Nefazodone, Venlafaxine and Moclobemide. Drugs & aging. 1997;11:119-131.
12065.	RJ H, DA H, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clinical interventions in aging. 2008;3:251-262.
12066.	RJ K, JP L, SE K, et al. Deep Brain Stimulation of the Basolateral Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder (Ptsd): Study Protocol for a Pilot Randomized Controlled Trial With Blinded, Staggered Onset of Stimulation. Trials. 2014;15.
12067.	RJ L. Ethics in reporting: Truth and the scientific literature. Photomedicine and laser surgery. 2004;22:v-vi.
12068.	RJ L. Chronic pain and comorbid depression. Current treatment options in neurology. 2005;7:403-412.
12069.	RJ L. Milnacipran, a serotonin and norepinephrine reuptake inhibitor: A novel treatment for fibromyalgia. International journal of clinical rheumatology. 2009;4:507-517.
12070.	RJ M, KL G. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. [Review] [122 refs]. Drugs. 1991;41:450-477.
12071.	RJ M, VSL W, JC C, et al. Development and Evaluation of the Daily Assessment of Symptoms-Anxiety (Das-a) Scale to Evaluate Onset of Symptom Relief in Patients With Generalized Anxiety Disorder. Journal of psychiatric research. 2008;42:1024-1036.
12072.	RJ O, Li L, M-J K, et al. Fda Approval of Paroxetine for Menopausal Hot Flushes Editorial Comment. Obstetrical & gynecological survey. 2014;69:590-591.
12073.	RJ P, RH M-W, AH Y. Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology. 1999;146:194-198.
12074.	RJ P, RT M. Inadequate availability of pharmacological treatment for affective disorders in New Zealand. New Zealand medical journal. 2002;115:78-81.
12075.	RJ P, RT M, PR J, SE L. Tryptophan and Tyrosine Availability and Response to Antidepressant Treatment in Major Depression. Journal of affective disorders. 2005;86:129-134.
12076.	RJ R, FM W, Gamba R, Mojtabai R, JB S. Behavioral Therapy and Serotonin Reuptake Inhibitor Pharmacotherapy in the Treatment of Obsessive-Compulsive Disorder: a Systematic Review and Meta-Analysis of Head-to-Head Randomized Controlled Trials. Depression and anxiety. 2014;31:641-652.
12077.	RJ S, DR D, SJ G, KL S, JP B. Current perspectives on the pharmacotherapy of depressive disorders in children and adolescents. Harvard review of psychiatry. 1995;2:313-326.
12078.	RJ S, MacPherson H, AH Y. Atypical antipsychotics and other therapeutic options for treatment of resistant major depressive disorder. Pharmaceuticals (Basel, Switzerland). 2010;3:3522-3542.
12079.	RJ S, WD C. Recent developments in the therapy of irritable bowel syndrome. Expert opinion on investigational drugs. 2008;17:117-130.
12080.	RJ U. Treatment of Parkinson's disease: Focus on quality of life issues. Parkinsonism & related disorders. 2012;18:S34-S36.
12081.	RJ V, AM L, MR S, AA G, RR A. Antidepressant Treatment and Risk of Suicide Attempt by Adolescents With Major Depressive Disorder - a Propensity-Adjusted Retrospective Cohort Study. CNS drugs. 2004;18:1119-1132.
12082.	RJ V, AM L, MR S, AA G, RR A. Antidepressant Treatment and Risk of Suicide Attempt by Adolescents With Major Depressive Disorder - a Propensity-Adjusted Retrospective Cohort Study. CNS drugs. 2004;18:1119-1132.
12083.	RJ V, RC VDM, MW H, JP T, AH Z, GMJ VK. Reduction by Paroxetine of Suicidal Behavior in Patients With Repeated Suicide Attempts but Not Major Depression. American journal of psychiatry. 1998;155:543-547.
12084.	RJ VH, W VDB, DJ V, AE G. Brain imaging studies in pathological gambling. Current psychiatry reports. 2010;12:418-425.
12085.	RJ VL, MacQueen G. Psychological factors in asthma. Allergy, asthma, and clinical immunology. 2008;4:12-28.
12086.	RJ W. Report from Great Britain. [German]. Pharmazeutische Industrie. 2005;67:1463-1466.
12087.	RJr PJ, L LJ. Recent advances in prepubertal mood disorders: Phenomenology and treatment. Current opinion in psychiatry. 2004;17:31-36.
12088.	RJT M, HF V, AM W, et al. Longitudinal interplay between paroxetine response, cortisol and fatty acid metabolism in major depressive disorder. European neuropsychopharmacology. 2014;Conference:S396-S397.
12089.	RJT M, HG R, AM W, et al. Longitudinal interplay between paroxetine and fatty acid metabolism in recovery from major depressive disorder. European neuropsychopharmacology. 2014;Conference:S56-S57.
12090.	RK B, MA B, BH M, et al. Persistence of neuropsychologic deficits in the remitted state of late-life depression. American journal of geriatric psychiatry. 2006;14:419-427.
12091.	RK G, H-J M. St. John's Wort: An option for the primary care treatment of depressive patients? European archives of psychiatry and clinical neuroscience. 2003;253:140-148.
12092.	RK M. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: Current status, future directions, and dietary recommendations. Prostaglandins, leukotrienes, and essential fatty acids. 2009;81:223-231.
12093.	RK M. Long-chain omega-3 fatty acid deficiency in mood disorders: Rationale for treatment and prevention. Current drug discovery technologies. 2013;10:233-244.
12094.	RK M, FE L. Elevated immune-inflammatory signaling in mood disorders: A new therapeutic target? Expert review of neurotherapeutics. 2012;12:1143-1161.
12095.	RK M, JAJ S, MW O. Empirically Supported Treatments for Panic Disorder. Psychiatric clinics of North America. 2009;32:593-610.
12096.	RK M, JR S. Role of long-chain omega-3 fatty acids in psychiatric practice. PharmaNutrition. 2013;1:41-49.
12097.	RK M, JR S, KD C, MP D. Interventions for Youth at High Risk for Bipolar Disorder and Schizophrenia. Child and adolescent psychiatric clinics of North America. 2012;21:739-751.
12098.	RK O, LT B, JN B. Use of risperidone as augmentation treatment for major depressive disorder. Annals of pharmacotherapy. 2011;45:95-100.
12099.	RK S, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of clinical psychopharmacology. 1994;14:322-329.
12100.	RK S, Puri A, Agarwal M. Depression and the heart. Indian heart journal. 2012;64:397-401.
12101.	RK S, SHP S, Overweg N, CL B. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. Journal of clinical psychiatry. 1992;53 Suppl:48-51.
12102.	RK Z, Cheng G, Tang J, Song J, WX P. Pharmacokinetics of Duloxetine Hydrochloride Enteric-Coated Tablets in Healthy Chinese Volunteers: a Randomized, Open-Label, Single- and Multiple-Dose Study. Clinical therapeutics. 2009;31:1022-1036.
12103.	RKR S, Saarijarvi S, Taiminen T, et al. Citalopram as an Adjuvant in Chronic Schizophrenia: a Double-Blind Placebo-Controlled Study. Acta psychiatrica Scandinavica. 1996;94:175-180.
12104.	RL B, SJ B, DS B. Perception, Assessment, Treatment, and Management of Pain in the Elderly. Clinics in geriatric medicine. 2005;21:465-+.
12105.	RL B, SJ B, DS B. Perception, Assessment, Treatment, and Management of Pain in the Elderly. Clinics in geriatric medicine. 2005;21:465-+.
12106.	RL B, SJ B, GA I, Gordon A. Management of chronic noncancer pain in depressed patients. Postgraduate medicine. 2011;123:143-154.
12107.	RL D. Issues in Polypharmacotherapy: Focus on Major Depression. Psychopharmacology bulletin. 1996;32:547-553.
12108.	RL D, Aalten P, Winogrodzka A, FRJ V, AFG L. Pharmacological treatment of apathy in neurodegenerative diseases: A systematic review. Dementia and geriatric cognitive disorders. 2009;28:13-22.
12109.	RL D, JM D, RJ O, TR H. Selective serotonin re-uptake inhibitor anti-depressant prescribing in primary care in the United Kingdom: A longitudinal analysis. Primary Care Psychiatry. 1998;4:141-148.
12110.	RL F. Open-Label Treatment of Comorbid Depression and Attentional Disorders With Co-Administration of Serotonin Reuptake Inhibitors and Psychostimulants in Children, Adolescents, and Adults: a Case Series. Journal of child and adolescent psychopharmacology. 1996;6:165-175.
12111.	RL F. Pharmacological Treatment of Major Depressive Disorder in Adolescents. TheScientificWorldJournal. 2005;5:420-426.
12112.	RL F. Pharmacological Treatment of Major Depressive Disorder in Adolescents. TheScientificWorldJournal. 2005;5:420-426.
12113.	RL F, Groark J, Chiles D, Ramaker S, LF Y, KA T. Safety and Tolerability of Desvenlafaxine in Children and Adolescents With Major Depressive Disorder. Journal of child and adolescent psychopharmacology. 2014;24:201-209.
12114.	Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study, Journal of the American Academy of Child and Adolescent Psychiatry(2010).
12115.	RL F, MD R, JL B. Pharmacological treatment of depression in children and adolescents. [Review] [203 refs]. Paediatric drugs. 1999;1:161-182.
12116.	RL F, NC F, RJ S, DelPorto-Bedoya D, Demeter C. Somatic treatment for depressive illnesses in children and adolescents. Child and adolescent psychiatric clinics of North America. 2002;11:555-578.
12117.	RL F, Nucci G, AA P, et al. Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents With Major Depressive Disorder or Obsessive-Compulsive Disorder. Neuropsychopharmacology. 2006;31:1274-1285.
12118.	RL M. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part II. Expert opinion on drug safety. 2010;9:917-935.
12119.	RL O, RL R, RW S. Cost-effectiveness inferences from bootstrap quadrant confidence levels: Three degrees of dominance. Journal of biopharmaceutical statistics. 2005;15:419-436.
12120.	RL O, RL R, RW S. Cost-Effectiveness Inferences From Bootstrap Quadrant Confidence Levels: Thee Degrees of Dominance. Journal of biopharmaceutical statistics. 2005;15:419-436.
12121.	RL O, SR P, Luh J, Tatum R. An Open Trial of Venlafaxine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Journal of child and adolescent psychopharmacology. 1996;6:241-250.
12122.	RL R. Achieving remission from depression with venlafaxine and venlafaxine extended release: A literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, Supplement. 2002;106:24-30.
12123.	RL R. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta psychiatrica Scandinavica. Supplementum. 2002;Supplement:24-30.
12124.	RL R, AT D, Khan A. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. Journal of clinical psychopharmacology. 1996;16:54S-61S.
12125.	RL R, ML J. In Search of Pharmacoeconomic Evaluations for Fibromyalgia Treatments: a Review. Expert opinion on pharmacotherapy. 2006;7:1027-1039.
12126.	RL R, PR J, RT M, EJ B, MA K. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics journal. 2002;2:191-196.
12127.	RL R, RT M, PR J, SE L, MA K. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human psychopharmacology. 2004;19:17-23.
12128.	RL S. Making information about clinical trials publicly available. BMJ (Online). 2009;339:250.
12129.	RM B. Consequences of insomnia and its therapies. Journal of clinical psychiatry. 2001;62:33-38.
12130.	RM B. Fibromyalgia syndrome review. Journal of musculoskeletal pain. 2004;12:35-49.
12131.	RM B. Letter to the editor. Journal of clinical psychiatry. 2008;69:1121-1122.
12132.	RM B, GK W. Pharmacological Management of Huntington's Disease: an Evidence-Based Review. Current pharmaceutical design. 2006;12:2701-2720.
12133.	RM B, GK W, HP K. Huntington's Disease: Present Treatments and Future Therapeutic Modalities. International clinical psychopharmacology. 2004;19:51-62.
12134.	RM B, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert opinion on pharmacotherapy. 2007;8:141-153.
12135.	RM B, LC Q, ZV S, CC M, SH K, PT CJ. Personality and differential treatment response in major depression: A randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Canadian Journal of Psychiatry. 2008;53:361-370.
12136.	RM B, ME T, MH T, et al. Long-Term Safety and Tolerability of Open-Label Aripiprazole Augmentation of Antidepressant Therapy in Major Depressive Disorder. Neuropsychiatric disease and treatment. 2011;7:303-312.
12137.	RM B, RD L, SH K, AJ L, RT J. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. Psychiatry research. 1999;86:211-216.
12138.	RM B, Russell J, JC C, AG B, Zlateva G, Sadosky A. Identification of Symptom and Functional Domains That Fibromyalgia Patients Would Like to See Improved: a Cluster Analysis. BMC musculoskeletal disorders. 2010;11.
12139.	RM C, JA B, KE F, et al. Depression and Late Mortality After Myocardial Infarction in the Enhancing Recovery in Coronary Heart Disease (Enrichd) Study. Psychosomatic medicine. 2004;66:466-474.
12140.	RM C, JA B, KE F, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosomatic medicine. 2004;66:466-474.
12141.	RM C, KE F. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biological psychiatry. 2003;54:241-247.
12142.	RM C, KE F. Depression following myocardial infarction. General hospital psychiatry. 2005;27:381-382.
12143.	RM C, KE F. Depression in Patients with Coronary Heart Disease. American journal of medicine. 2008;121:S20-S27.
12144.	RM C, KE F. Treatment-resistant depression and mortality after acute coronary syndrome. [Review] [60 refs]. American journal of psychiatry. 2009;166:410-417.
12145.	RM C, KE F. Is there a high-risk subtype of depression in patients with coronary heart disease? Current psychiatry reports. 2012;14:1-7.
12146.	RM C, KE F, Steinmeyer B, et al. History of depression and survival after acute myocardial infarction. Psychosomatic medicine. 2009;71:253-259.
12147.	RM C, RC S. Agomelatine for the treatment of major depressive disorder. Expert opinion on pharmacotherapy. 2011;12:2411-2419.
12148.	RM F. Safety of ephedra and related anorexic medications. Expert opinion on drug safety. 2008;7:749-759.
12149.	RM G. Treatment of adolescents with major depression: Contributions of a major trial. Journal of the American Medical Association. 2004;292:861-863.
12150.	RM G, CH K. Electroconvulsive therapy: A selected review. American journal of geriatric psychiatry. 2005;13:268-281.
12151.	RM H. Guidelines for the long-term treatment of depression. [Review] [25 refs]. Journal of clinical psychiatry. 1994;55 Suppl:61.
12152.	RM H. Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. [Review] [16 refs]. Acta psychiatrica Scandinavica. Supplementum. 2000;403:35-38.
12153.	RM H. The use of mirtazapine in difficult-to-treat patient populations. [Review] [22 refs]. Human psychopharmacology. 2002;17 Suppl 1:S33-36.
12154.	RM K. What Is the Role of Medications in Late Life Depression? Psychiatric clinics of North America. 2013;36:597-605.
12155.	RM K, Vink D, Westers P, WA N, TJ H. Early behavioural changes during antidepressant treatment in elderly patients. International journal of geriatric psychiatry. 2008;23:769-771.
12156.	RM K, WA N, TJ H. Efficacy of treatment in older depressed patients: A systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. Journal of affective disorders. 2012;141:103-115.
12157.	RM L. A Critical Review of Selective Serotonin Reuptake Inhibitor-Related Sexual Dysfunction; Incidence, Possible Aetiology and Implications for Management. Journal of psychopharmacology (Oxford, England). 1997;11:72-82.
12158.	RM N. Treatment of depressive symptoms in breast cancer patients undergoing adjuvant therapy. Journal of clinical oncology. 2013.
12159.	RM N, MC B, MN W. Treatment of Depressive Symptoms in Patients With Early Stage Breast Cancer Undergoing Adjuvant Therapy. Breast cancer research and treatment. 2008;112:197-201.
12160.	RM O, Rodriguez-Rodriguez E, AM L-S. Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders. British journal of nutrition. 2012;107:S261-S270.
12161.	RM P. Depression may be associated with hippocampal volume changes and HPA axis dysfunction: Is treatment to remission the answer? South African Psychiatry Review. 2004;7:5-9.
12162.	RM P. Adjunctive strategies in the treatment of refractory bipolar depression: Clinician options in the absence of a systematic database. Expert opinion on pharmacotherapy. 2005;6:531-546.
12163.	RM P. Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications. Journal of psychiatric research. 2007;41:979-990.
12164.	RM P. Promising avenues of therapeutics for bipolar illness. Dialogues in clinical neuroscience. 2008;10:193-201.
12165.	RM P. Why the discrepancy between antidepressant drug use and evidence base in bipolar disorder? Future neurology. 2014;9:285-288.
12166.	RM P, GS L, LL A, et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar disorders. 2003;5:310-319.
12167.	RM P, GS L, WA N, et al. A Re-Evaluation of the Role of Antidepressants in the Treatment of Bipolar Depression: Data From the Stanley Foundation Bipolar Network. Bipolar disorders. 2003;5:396-406.
12168.	RM P, GS L, WA N, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. [Review] [64 refs]. Bipolar disorders. 2003;5:396-406.
12169.	RM P, JR C. Bipolar depression: The role of atypical antipsychotics. Expert review of neurotherapeutics. 2004;4:S27-S33.
12170.	RM P, KD D, GS L, MA F. Drug-induced switching in bipolar disorder: Epidemiology and therapeutic implications. CNS drugs. 1997;8:352-365.
12171.	RM P, LL A, GS L, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.[Erratum appears in Br J Psychiatry. 2006 Dec;189:569]. British journal of psychiatry. 2006;189:124-131.
12172.	RM P, LL A, MA F, et al. New findings from the Bipolar Collaborative Network: clinical implications for therapeutics. [Review] [42 refs]. Current psychiatry reports. 2006;8:489-497.
12173.	RM P, TA K, PJ P, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy research. 1996;Supplement:153-180.
12174.	RM P, WA N, RW K, et al. The Stanley Foundation Bipolar Network I. Rationale and Methods. British journal of psychiatry. 2001;178:S169-S176.
12175.	RM P, WA N, RW K, et al. The Stanley Foundation Bipolar Network. I. Rationale and methods. The British journal of psychiatry. 2001;Supplement:s169-176.
12176.	RM R. Treatments for childhood anxiety disorders: Integrating physiological and psychosocial interventions. Expert review of neurotherapeutics. 2011;11:1095-1097.
12177.	RM R, LA F, TW M. Apathy and its treatment. Current treatment options in neurology. 2007;9:363-370.
12178.	RM R, Reich J, Dehring D. Tricyclic antidepressants in treatment of depression and chronic pain: Analysis of the supporting evidence. Anesthesia and analgesia. 1984;63:1025-1032.
12179.	RM S, JS K, BW J, et al. Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes. Neuropsychopharmacology. 2005;30:2082-2091.
12180.	RM T, AL B. Treatment of frontotemporal dementia. Current treatment options in neurology. 2014;16:1-14.
12181.	RM vdM, MC W, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. [Review]. Cochrane database of systematic reviews (Online). 2013;8:CD006102.
12182.	RM VDM, MC W, Smit F, Cuijpers P. Smoking Cessation Interventions for Smokers With Current or Past Depression. Cochrane database of systematic reviews (Online). 2013.
12183.	RMA H. Pharmacotherapy of Borderline Personality Disorder. Journal of clinical psychiatry. 1997;58:48-53.
12184.	RMA H. Suicide and antidepressant treatment. Archives of general psychiatry. 2000;57:325-326.
12185.	RMA H. Sertraline in the Treatment of Anxiety Disorders. Depression and anxiety. 2000;11:139-157.
12186.	RMA H. The use of mirtazapine in difficult-to-treat patient populations. Human psychopharmacology. 2002;17:S33-S36.
12187.	RMA H. The efficacy of atypical antipsychotics in bipolar disorders. Journal of clinical psychiatry. 2003;64:15-21.
12188.	RMA H. The epidemiology of depression and the evolution of treatment. Journal of clinical psychiatry. 2012;73:5-9.
12189.	RMA H, CB N, DL D, CB M, CL D. Guidelines for the long-term treatment of depression. Journal of clinical psychiatry. 1994;55:61-69.
12190.	RMA H, Judge R. Antidepressants in Long-Term Therapy: a Review of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors. Acta Psychiatrica Scandinavica, Supplement. 2000;101:35-38.
12191.	RMA H, LA V. Newer Antidepressants: Review of Efficacy and Safety of Escitalopram and Duloxetine. Journal of clinical psychiatry. 2004;65:46-52.
12192.	RMA H, Mallinckrodt C, TC L, MJ D. Time Course of Depression-Symptom Improvement During Treatment With Duloxetine. Depression and anxiety. 2005;21:170-177.
12193.	RMA H, PJ C, Cohen I, et al. Practice guideline for the treatment of patients with bipolar disorder. American journal of psychiatry. 1994;151:1-36.
12194.	RMA H, SA M, MB K, et al. Social functioning in depression: a review. [Review] [59 refs]. Journal of clinical psychiatry. 2000;61:268-275.
12195.	RMF B. Depression and anxiety in oncology: The psychiatrist's perspective. Journal of clinical psychiatry. 2001;62:58-63.
12196.	RN G, Nicholas L. Antidepressant Efficacy of Venlafaxine. Depression and anxiety. 2000;12:45-49.
12197.	RN H, Adams J, GM B, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of fluoxetine. Birth defects research. Part B, Developmental and reproductive toxicology. 2004;71:193-280.
12198.	RN M, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. Journal of clinical psychiatry. 1996;57:19-23.
12199.	RN T, DE F, Feng J. Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von mises test. Statistics in medicine. 2000;19:2169-2184.
12200.	RN T, Lu Y. Reassessment of global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. Journal of psychiatric research. 2003;37:175-177.
12201.	RN T, Lu Y, Entsuah R. Reassessment of global benefit-risk assessment of antidepressants: Venlafaxine XR and fluoxetine [2] (multiple letters). Journal of psychiatric research. 2003;37:175-177.
12202.	Rob K, Willem N, Thea H. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. The American Journal of Geriatric Psychiatry. 2007;15:725.
12203.	Robb A, McCracken J, Salpekar J, Auby P, Cohen D. Clinical trials in anxiety and affective disorders, lessons learned and new directions. European child & adolescent psychiatry. 2013;Conference:S163-S164.
12204.	Robbins A, MD W. Comments on "a double-blind, randomized fixed-dose study with paroxetine and citalopram" by Waldinger and associates [7] (multiple letters). Journal of clinical psychopharmacology. 2003;23:108-109.
12205.	Robert G, Dierdre R, Maryanne G, et al. Efficacy of open-label venlafaxine in subjects with major depressive disorder: Associations with neuroendocrine response to serotonergic and noradrenergic probes. Psychiatry research. 2004;128:203-206.
12206.	Robert G, Mareen S-H, Karoline S, et al. Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression. Journal of sleep research. 2011;20:544-551.
12207.	Robert K, Cristian B, Catia S, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of psychopharmacology (Oxford, England). 2011;25:867-874.
12208.	Robert K, Rudolf U, Bhanu G, et al. Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of affective disorders. 2010;127:337-342.
12209.	Robert P, David R, Mulin E, Derreumaux A, Mall P. Treating early behavioral and psychological symptoms of dementias. Neurobiology of aging. 2010;Conference:S26.
12210.	Robert S, MB H, HG U, JP L, VL D. Open-Label Trial of Escitalopram in the Treatment of Posttraumatic Stress Disorder. Journal of clinical psychiatry. 2006;67:1522-1526.
12211.	Roberto L, Giorgio DL, Manfredi T, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: Pilot observations on the effects of selective serotonin reuptake inhibitor therapy. Journal of clinical psychiatry. 2006;67:1760-1766.
12212.	Roberto L-F, Carlos B, H MC, M WM, G WJ, M PJ. Duloxetine in the treatment of major depressive disorder: Comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. Journal of clinical psychiatry. 2006;67:1379-1390.
12213.	Roberts C, Inamdar A, Koch A, et al. A Randomized, Controlled Study Comparing the Effects of Vestipitant or Vestipitant and Paroxetine Combination in Subjects With Tinnitus. Otology & neurotology. 2011;32:721-727.
12214.	Robinson S. Antidepressants for treatment of tinnitus. Tinnitus: Pathophysiology and Treatment. 2007;Progress i:263-271.
12215.	Robinson-papp J, DM S. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain medicine (Malden, Mass.). 2007;8:S43-S49.
12216.	Rocca P, Calvarese P, Faggiano F, et al. Citalopram versus sertraline in late-life nonmajor clinically significant depression: A 1-year follow-up clinical trial. Journal of clinical psychiatry. 2005;66:360-369.
12217.	Rocca P, Fonzo V, Ravizza L, et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. Journal of affective disorders. 2002;70:313-317.
12218.	Rocco Z, Michael B, Marc J, Bruno M-O. Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. Journal of clinical psychopharmacology. 2001;21:190-198.
12219.	Roch C, Barde M, Boulanger H, et al. Effectiveness of pramipexole for treatment-resistant depression: A case report. International journal of clinical pharmacy. 2013;Conference:942-943.
12220.	Rockhill C. In this issue. Journal of the American Academy of Child and Adolescent Psychiatry. 2011;50:733-734.
12221.	Rodda J, Walker Z, Carter J. Depression in older adults. BMJ (Online). 7825.
12222.	Roder C, Schaefer M, Leucht S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort. [German]. Fortschritte der Neurologie-Psychiatrie. 2004;72:330-343.
12223.	Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. [Review] [61 refs]. Supportive care in cancer. 2007;15:123-136.
12224.	Rodriguez B, DA B. Management of hepatitis C in HIV- infected patients. Current infectious disease reports. 2005;7:91-102.
12225.	Rodriguez-Antona C, Gurwitz D, J dL, et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: Considerations for cost-effectiveness studies. Pharmacogenomics. 2009;10:685-699.
12226.	Roessner V, KJ P, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European child & adolescent psychiatry. 2011;20:173-196.
12227.	Roger L. Placebo responses to antidepressants. German Journal of Psychiatry. 1999;2:1-11.
12228.	Roger M, Martin K. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar disorders. 2003;5:20-35.
12229.	Rogoz Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: Preclinical and clinical efficacy. Pharmacological Reports. 2013;65:1535-1544.
12230.	Rohde A. Use of antidepressants in premenstrual syndrome and in the climacteric. [German]. Gynakologische Praxis. 2004;28:436-437.
12231.	Rohricht F, Papadopoulos N, Priebe S. An exploratory randomized controlled trial for patients with chronic depression ofbody psychotherapy. Journal of affective disorders. 2013;151:85-91.
12232.	Roja R, Shekoufeh N, Mohammad A. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:118-127.
12233.	Treatment of postnatal depression in low-income mothers in primary-care clinics in Santiago, Chile: a randomised controlled trial, Lancet(2007).
12234.	Rojas-Fernandez C, Mikhail M. Contemporary concepts in the pharmacotherapy of depression in older people. Canadian Pharmacists Journal. 2012;145:128-135.e122.
12235.	Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients' choice arm, Psychotherapy and psychosomatics(2010).
12236.	Rollema H, HM F. Pharmacodynamic and pharmacokinetic profiles of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, a smoking cessation aid. Journal of pediatric biochemistry. 2010;1:175-184.
12237.	Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callieco R, Cosi V. Fatigue in Multiple Sclerosis: Multidimensional Assessment and Response to Symptomatic Treatment. Multiple sclerosis (Houndmills, Basingstoke, England). 2004;10:462-468.
12238.	Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callieco R, Cosi V. Fatigue in Multiple Sclerosis: Multidimensional Assessment and Response to Symptomatic Treatment. Multiple sclerosis (Houndmills, Basingstoke, England). 2004;10:462-468.
12239.	Romano S, Judge R, Dillon J, Shuler C, Sundell K. The Role of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder. Clinical therapeutics. 1999;21:615-633.
12240.	Romeo E, Pompili E, F dM, et al. Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World journal of biological psychiatry. 2000;1:101-104.
12241.	Cost-Effectiveness Analyses for Mirtazapine and Sertraline in Dementia: Randomised Controlled Trial, British journal of psychiatry(2013).
12242.	Romer B, Lewicka S, Kopf D, et al. Cortisol metabolism in depressed patients and healthy controls. Neuroendocrinology. 2009;90:301-306.
12243.	Romera I, Gilaberte I, Perez V, et al. Early antidepressant switch in MDD with pain symptoms: Functional improvement. International journal of psychiatry in clinical practice. 2011;Conference:36.
12244.	Romera I, Perez V, JM M, et al. Early Vs. Delayed Switch to Duloxetine in Patients With Major Depressive Disorder Not Exhibiting Early Improvement With Escitalopram: a Double-Blind Randomized Study. International journal of psychiatry in clinical practice. 2010;Conference:34.
12245.	Romera I, Perez V, Quail D, Berggren L, Lenox-Smith A, Gilaberte I. Individual Residual Symptoms and Functional Impairment in Patients With Depression. Psychiatry research. 2014;220:258-262.
12246.	Ronald B, Madhusoodanan S, Monika P. Efficacy of continuation treatment with Hypericum perforatum in depression. Journal of clinical psychiatry. 2002;63:455.
12247.	Ronald B, Vadim A, Subramoniam M, Monika P. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2000;22:411-419.
12248.	Rong H, H-Y D, Z-Y G, J-Y Z, X-J Z. Effects of beta-asarone on neuroplasticity-related factors in hippocampus of rat model of depression. [Chinese]. Chinese Journal of New Drugs. 2014;23:2185-2188 and 2194.
12249.	Ronsley R, Elbe D, DH S, EJ G. Do hospital and community ssri usage patterns in children and adolescents match the evidence? Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2010;19:218-226.
12250.	Ronson A. Psychiatric Disorders in Oncology: Recent Therapeutic Advances and New Conceptual Frameworks. Current opinion in oncology. 2004;16:318-323.
12251.	Ronson A. Psychiatric Disorders in Oncology: Recent Therapeutic Advances and New Conceptual Frameworks. Current opinion in oncology. 2004;16:318-323.
12252.	Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for Pediatric Functional Abdominal Pain: a Randomized, Placebo-Controlled Trial. Neurogastroenterology and motility. 2014;26:1642-1650.
12253.	Ropert A. Unexplained chest pain. [French]. Hepato-Gastro. 2002;9:357-366.
12254.	Ropert R. Fluoxetine versus clomipramine in major depressive disorders. International clinical psychopharmacology. 1989;4 Suppl 1:89-95.
12255.	Rore C, Brace V, Danielian P, Williams D. Smoking cessation in pregnancy. Expert opinion on drug safety. 2008;7:727-737.
12256.	Roschke J, Kogel P, Schlosser R, et al. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology. 1997;132:44-49.
12257.	Roschke J, Pia K, Michael G. Lorazepam and the sleep EEG's microstructure: A novel approach to quantitative pharmaco-EEG investigations. German Journal of Psychiatry. 2000;3:13-18.
12258.	Roseanne A, Kimberly Y, Darwynn C, John RA. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. Journal of clinical psychopharmacology. 1997;17:161-168.
12259.	Suicide attempts and nonsuicidal self-injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA study, Journal of the American Academy of Child and Adolescent Psychiatry(2011).
12260.	Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response, Journal of the American Academy of Child and Adolescent Psychiatry(2009).
12261.	Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice: A Nordic multicentre clinical study. International clinical psychopharmacology. 1994;9 Suppl 1:41-48.
12262.	Rosenberg C, Lauritzen L, Brix J, JB J, Kofod P, LB B. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice. Psychopharmacology bulletin. 2007;40:63-73.
12263.	Rosenberg O, LK D, PN D. Four-Year Follow-up Study of Pharmacological Treatment in Pathological Gamblers. Clinical neuropharmacology. 2013;36:42-45.
12264.	Rosenbluth M, Sinyor M. Off-label use of atypical antipsychotics in personality disorders. Expert opinion on pharmacotherapy. 2012;13:1575-1585.
12265.	Rosenheck R. The growth of psychopharmacology in the 1990s: Evidence-based practice or irrational exuberance. International journal of law and psychiatry. 2005;28:467-483.
12266.	Rosenthal J, Hemlock C, DJ H, et al. A Preliminary-Study of Serotonergic Antidepressants in Treatment of Dysthymia. Progress in neuro-psychopharmacology & biological psychiatry. 1992;16:933-941.
12267.	Rosmond R. Obesity and depression: Same disease, different names? Medical hypotheses. 2004;62:976-979.
12268.	Ross J, Gowers S. Body dysmorphic disorder. Advances in Psychiatric Treatment. 2011;17:142-149.
12269.	Ross S, Williams D. Bupropion: Risks and benefits. Expert opinion on drug safety. 2005;4:995-1003.
12270.	Rosser S, Erskine A, Crino R. Pre-Existing Antidepressants and the Outcome of Group Cognitive Behaviour Therapy for Social Phobia. Australian and New Zealand journal of psychiatry. 2004;38:233-239.
12271.	Rosser S, Erskine A, Crino R. Pre-Existing Antidepressants and the Outcome of Group Cognitive Behaviour Therapy for Social Phobia. Australian and New Zealand journal of psychiatry. 2004;38:233-239.
12272.	Rossi A, Barraco A, Donda P. Fluoxetine: A review on evidence based medicine. Annals of general hospital psychiatry. 2004.
12273.	Rossini D, Lucca A, Zanardi R, Magri L, Smeraldi E. Transcranial magnetic stimulation in treatment-resistant depressed patients: A double-blind, placebo-controlled trial. Psychiatry research. 2005;137:1-10.
12274.	Rossini D, Magri L, Lucca A, Giordani S, Smeraldi E, Zanardi R. Does rTMS Hasten the Response to Escitalopram, Sertraline, or Venlafaxine in Patients With Major Depressive Disorder? A Double-Blind, Randomized, Sham-Controlled Trial. Journal of clinical psychiatry. 2005;66:1569-1575.
12275.	Rosso G, Crespi C, Martini B, Maina G. Combining brief dynamic therapy with antidepressants in major depressive disorder. Clinical Neuropsychiatry. 2009;6:56-62.
12276.	Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. Journal of affective disorders. 2012;136:172-176.
12277.	Rota E, Broda R, Cangemi L, et al. Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment. Psychiatry research. 2005;133:281-284.
12278.	Rotberg B, Kronenberg S, Carmel M, et al. Additive Effects of 5-Httlpr (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703t Gene Polymorphisms on the Clinical Response to Citalopram Among Children and Adolescents With Depression and Anxiety Disorders. Journal of child and adolescent psychopharmacology. 2013;23:117-122.
12279.	Roth T. Narcolepsy: Treatment issues. Journal of clinical psychiatry. 2007;68:16-19.
12280.	Rothbart R, Amos T, Siegfried N, et al. Pharmacotherapy for Trichotillomania. Cochrane database of systematic reviews (Online). 2013.
12281.	Rottraut I, Jurgen S, Michaela Z, et al. "Add-on"-therapy with an individualized preparation consisting of free amino acids for patients with a major depression. European archives of psychiatry and clinical neuroscience. 2007;257:222-229.
12282.	Rouillon F. Early symptom relief for superior outcome of depression. European psychiatry.
12283.	Rouillon F. Anxiety With Depression: a Treatment Need. European neuropsychopharmacology. 1999;9:S87-S92.
12284.	Rouillon F. Depression Comorbid With Anxiety or Medical Illness: the Role of Paroxetine. International journal of psychiatry in clinical practice. 2001;5:3-10.
12285.	Rouillon F. Long Term Therapy of Generalized Anxiety Disorder. European psychiatry. 2004;19:96-101.
12286.	Rouillon F. Long Term Therapy of Generalized Anxiety Disorder. European psychiatry. 2004;19:96-101.
12287.	Rouillon F. Efficacy and Tolerance Profile of Agomelatine and Practical Use in Depressed Patients. International clinical psychopharmacology. 2006;21:S31-S35.
12288.	Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. International clinical psychopharmacology. 2006;21 Suppl 1:S31-35.
12289.	Rouillon F, Berdeaux G, JC B, et al. Prevention of Recurrent Depressive Episodes With Milnacipran: Consequences on Quality of Life. Journal of affective disorders. 2000;58:171-180.
12290.	Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. Journal of clinical psychiatry. 1998;59:32-41.
12291.	Rouillon F, Phillips R, Serrurier D, Ansart E, MJ G. Prophylactic efficacy of maprotiline on relapses of unipolar depression. [French]. Encephale. 1989;15:527-534.
12292.	Rouillon F, Phillips R, Serrurier D, Ansart E, MJ G. [Recurrence of unipolar depression and efficacy of maprotiline]. [Review] [26 refs] [French]. L'Enc�phale. 1989;15:527-534.
12293.	Rouillon F, Serrurier D, HD M, M-J G. Prophylactic efficacy of maprotiline on unipolar depression relapse. Journal of clinical psychiatry. 1991;52:423-431.
12294.	Rouillon F, Thalassinos M. Suicide, depression and antidepressants. [French]. Annales de Psychiatrie. 1993;8:158-165.
12295.	Roy-Byrne P. Treatment in nonresponsive patients with social anxiety: Back to the future with benzodiazepines. American journal of psychiatry. 2014;171:1-4.
12296.	Effects of Pain and Prescription Opioid Use on Outcomes in a Collaborative Care Intervention for Anxiety, Clinical journal of pain(2013).
12297.	Roya A, Mahdi H, Ahmad G, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depression and anxiety. 2011;28:297-302.
12298.	Rozanski A. Exercise as medical treatment for depression. Journal of the American College of Cardiology. 2012;60:1064-1066.
12299.	Rozanski A, JA B, KW D, PG S, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: The emerging field of behavioral cardiology. Journal of the American College of Cardiology. 2005;45:637-651.
12300.	RP B. Child psychopharmacology, effect sizes, and the big bang. American journal of psychiatry. 2005;162:817-819.
12301.	RP B. Child psychopharmacology, effect sizes, and the big bang. American journal of psychiatry. 2005;162:817-819.
12302.	RP G, ED G. Antidepressants, psychotherapy or their combination: Weighing options for depression treatments. Journal of contemporary psychotherapy. 2009;39:83-91.
12303.	Bipolar disorder: Recent clinical trials and emerging therapies for depressive episodes and maintenance treatment, Drug discovery today(2014).
12304.	RP H, JE S. Gonadal steroids, selective serotonin reuptake inhibitors, and mood disorders in women. Medical clinics of North America. 2003;87:1065-1076.
12305.	RP K, VD C, DL W, SD B, Owens R. Impact of the Selective Serotonin Reuptake Inhibitor Citalopram on Insulin Sensitivity, Leptin and Basal Cortisol Secretion in Depressed and Non-Depressed Euglycemic Women of Reproductive Age. Gynecological endocrinology. 2005;21:129-137.
12306.	RP N, MV K, JS F, et al. Heart Rate Variability Biofeedback as a Behavioral Neurocardiac Intervention to Enhance Vagal Heart Rate Control. American heart journal. 2005;149.
12307.	RP N, MV K, JS F, et al. Heart Rate Variability Biofeedback as a Behavioral Neurocardiac Intervention to Enhance Vagal Heart Rate Control. American heart journal. 2005;149.
12308.	RP R, Burman D, IF T, Rodin G, Zimmermann C. Phase Ii Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia. American Journal of Hospice & Palliative Medicine. 2010;27:106-110.
12309.	RR B, Feng Y, FE L, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. Journal of clinical pharmacology. 2004;44:1352-1359.
12310.	RR C, MHH E, SI L, M-C V. Fluoxetine in the treatment of premenstrual dysphoric disorder. Annals of pharmacotherapy. 2002;36:713-717.
12311.	RR D. Fluoxetine treatment and repeated partial sleep deprivation: Impact on suicidal ideation. Sleep. 2013;Conference:A314-A315.
12312.	RR dP, WC G, Page M. Major depressive disorder as a co-morbid diagnosis in schizophrenia versus the diagnosis of schizoaffective disorder - Depressed type. South African Psychiatry Review. 2005;8:134-139.
12313.	RR N, CH H. [Post-stroke depression treated with acupuncture and moxibustion: an evaluation of therapeutic effect and safety]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2013;33:490-494.
12314.	RR N, CH H, WB F. [Observation of therapeutic effect on post stroke depression treated by differentiation of spleen and stomach]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2011;31:325-328.
12315.	RR R, ME L. Antidepressant-induced suicidality: Implications for clinical practice. Southern medical journal. 2009;102:713-718.
12316.	RR R, ME L, RH H, RS B. Nocebo effects with antidepressant clinical drug trial placebos. General hospital psychiatry. 2007;29:275-277.
12317.	RR S. Psychopharmacology news and views. Journal of child and adolescent psychopharmacology. 2009;19:777-778.
12318.	RR S, Gabbay V, Minami H, Munoz-Silva D, Alonso C. When to use antidepressant medication in youths. Primary psychiatry. 2005;12:42-50.
12319.	RR T, Balderas M, KV C, et al. Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics. 2015;56:36-43.
12320.	RR T, Emslie G, Mayes T, Nakonezny P, Kennard B, Hughes C. Early Prediction of Acute Antidepressant Treatment Response and Remission in Pediatric Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48:71-78.
12321.	RR W, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. Journal of psychosomatic research. 2002;53:877-881.
12322.	RS B, Paris J. Evaluating treatments of borderline personality disorder. Clinical Practice. 2012;9:425-437.
12323.	RS C, Cremonini F, Thapa P, AR Z, NJ T. The Effect of Short-Term, Low-Dose Tricyclic and Tetracyclic Antidepressant Treatment on Satiation, Postnutrient Load Gastrointestinal Symptoms and Gastric Emptying: a Double-Blind, Randomized, Placebo-Controlled Trial. Neurogastroenterology and motility. 2008;20:220-227.
12324.	RS D, Avci A. Selective serotonin reuptake inhibitor discontinuation syndrome in children: Six case reports. Current therapeutic research, clinical and experimental. 2002;63:188-197.
12325.	RS D, Kerr-Correa F, RA M, et al. Efficacy of Hormone Therapy With and Without Methyltestosterone Augmentation of Venlafaxine in the Treatment of Postmenopausal Depression: a Double-Blind Controlled Pilot Study. Menopause-the Journal of the North American Menopause Society. 2006;13:202-211.
12326.	RS D, Kibar M, Avci A. Pharmacotherapy and regional cerebral blood flow in children with obsessive compulsive disorder. Yonsei medical journal. 2004;45:90-99.
12327.	RS E-M. Medication adherence and the use of long-acting antipsychotics in bipolar disorder. Journal of psychiatric practice. 2007;13:79-85.
12328.	RS E-M. Innovation in the Treatment of Bipolar Depression. Journal of clinical psychiatry. 2014;75:E1185.
12329.	RS E-M, AZ E, Loganathan M, Lohano K, YL G. Bipolar Disorder: an Update. Postgraduate medicine. 2010;122:24-31.
12330.	RS E-M, Briscoe B. Studies of long-term use of antidepressants: How should the data from them be interpreted? CNS drugs. 2012;26:97-109.
12331.	RS E-M, Karippot A. Chronic depression in bipolar disorder. American journal of psychiatry. 2006;163:1337-1341.
12332.	RS E-M, MR S, AS C, GJ M, Penagaluri P. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: A blinded, randomized study. International clinical psychopharmacology. 2009;24:145-149.
12333.	RS E-M, MR S, Chopra A, GJ M, Penagaluri P, Movva R. A blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects. Annals of clinical psychiatry. 2010;22:3-8.
12334.	RS E-M, R JR, Swann A, Surja A. Tardive dysphoria: Antidepressant-induced chronic depression. Irish journal of psychological medicine. 2011;28:38-41.
12335.	RS E-M, YL G, RJ R. Tardive Dysphoria: the Role of Long Term Antidepressant Use in-Inducing Chronic Depression. Medical hypotheses. 2011;76:769-773.
12336.	RS G, KA G, Bahce A, Goodman C, WJ K, ZM K. Antidepressant-induced sexual dysfunction. [Review] [76 refs]. Annals of pharmacotherapy. 2002;36:1577-1589.
12337.	RS M. Using measurement strategies to identify and monitor residual symptoms. Journal of clinical psychiatry. 2013;74:14-18.
12338.	RS M. Major Depressive Disorder and Cognitive Impairment. Journal of psychiatry & neuroscience. 2014;39:E36-E37.
12339.	RS M, DA M, Lin P, Jordan J. Treating bipolar disorder: Evidence-based guidelines for family medicine. Canadian Family Physician. 2004;50:388-394.
12340.	RS M, DA M, McCann S, Srinivasan J, Sagman D, SH K. Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar disorders. 2002;4:207-213.
12341.	RS M, DA M, MM P, et al. Mood and psychotic disorders and type 2 diabetes: A metabolic triad. Canadian Journal of Diabetes. 2005;29:122-132.
12342.	RS M, DJ M, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. [Review] [24 refs]. Expert opinion on pharmacotherapy. 2009;10:3061-3075.
12343.	RS M, DJ M, DE K, et al. Bipolar disorder and suicide: Research synthesis and clinical translation. Current psychiatry reports. 2008;10:66-72.
12344.	RS M, DS C, JK S, et al. Cognitive Deficits and Functional Outcomes in Major Depressive Disorder: Determinants, Substrates, and Treatment Interventions. Depression and anxiety. 2013;30:515-527.
12345.	RS M, DS C, RD K, RB M. A review of FDA-approved treatment options in bipolar depression. CNS spectrums. 2013;18:4-21.
12346.	RS M, DS C, RD K, RB M. A Review of Fda-Approved Treatment Options in Bipolar Depression. CNS spectrums. 2013;18:1-21.
12347.	RS M, JK S, HO W, Alsuwaidan M, JZ K. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert opinion on pharmacotherapy. 2007;8:1211-1219.
12348.	RS M, JK S, JZ K, SH K. The Effect of Antidepressants on Lipid Homeostasis: a Cardiac Safety Concern? Expert opinion on drug safety. 2006;5:523-537.
12349.	RS M, JK S, JZ K, SH K. The Effect of Antidepressants on Glucose Homeostasis and Insulin Sensitivity: Synthesis and Mechanisms. Expert opinion on drug safety. 2006;5:157-168.
12350.	RS M, JZ K. Duloxetine: Pharmacoeconomic Implications of an Antidepressant That Alleviates Painful Physical Symptoms. Expert opinion on pharmacotherapy. 2005;6:707-713.
12351.	RS M, JZ K. Duloxetine: Pharmacoeconomic Implications of an Antidepressant That Alleviates Painful Physical Symptoms. Expert opinion on pharmacotherapy. 2005;6:707-713.
12352.	RS M, JZ K, JK S, SH K. Residual anxiety symptoms in depressed primary care patients. Journal of psychiatric practice. 2007;13:125-128.
12353.	RS M, JZ K, LN Y. Comorbidity in bipolar disorder: A framework for rational treatment selection. Human psychopharmacology. 2004;19:369-386.
12354.	RS M, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disorders, Supplement. 2003;5:20-35.
12355.	RS M, KY P, CWY L, et al. The Association Between Conventional Antidepressants and the Metabolic Syndrome a Review of the Evidence and Clinical Implications. CNS drugs. 2010;24:741-753.
12356.	RS M, O'Donovan C. The human cost of not achieving full remission in depression. [Review] [99 refs]. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2004;49:10S-16S.
12357.	RS M, PA A. Evidence-based psychotherapeutic interventions for geriatric depression. Psychiatric clinics of North America. 2005;28:805-820.
12358.	RS M, Scivoletto S. Depression. [Portuguese]. Revista brasileira de medicina. 2003;60:457-465.
12359.	RS M, ZD P, HT N, et al. The hepatic safety profile of duloxetine: A review. Expert opinion on drug metabolism & toxicology. 2008;4:281-285.
12360.	RS N, JM P, BG P, DJ K. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. Journal of clinical psychiatry. 1990;51:367-372.
12361.	RS N, JM P, BG P, DJ K. The role of neuropharmacologic selectivity in antidepressant action: Fluvoxamine versus desipramine. Journal of clinical psychiatry. 1990;51:367-372.
12362.	RS R, EM P, RM H, et al. A Pilot Study to Evaluate Symptom-Oriented Selection of Antidepressants in Patients With Cancer. Journal of palliative medicine. 2014;17:167-175.
12363.	RS T. Lowering antidepressant dosages in the elderly. Clinical gerontologist. 1995;16:67-70.
12364.	RS T, JA A, CK I, Lafer B, AA N. Reply to Dr. Kauer-Sant'Anna and Dr. Yatham's letter "Comment on 'Antidepressant treatment-emergent affective switch in bipolar disorder: A prospective case-control study of outcome'" [3]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2007;29:87-88.
12365.	RSE K, AR M, CK O. Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine. European neuropsychopharmacology. 2013;Conference:S402-S403.
12366.	RSE K, SM M, RM R, P MD, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review. Journal of clinical psychiatry. 2014;75:864-876.
12367.	RSE K, SM M, RM R, PM D, Tiger S, Madhoo M. Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: a Systematic Review. Journal of clinical psychiatry. 2014;75:864-+.
12368.	RT J. Combined treatments for major depression. Expert opinion on investigational drugs. 2007;16:1379-1389.
12369.	RT J. Hormone treatment of depression. Dialogues in clinical neuroscience. 2011;13:127-138.
12370.	RT J, AM M, DK L. A large open-label study of venlafaxine in depressed outpatients by community-based physicians. Journal of clinical psychiatry. 1998;59:515-520.
12371.	RT J, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. Journal of clinical psychiatry. 1994;55:24-25.
12372.	RT J, Panda J, Srivastava A. Two Formulations of Venlafaxine Are Bioequivalent When Administered as Open Capsule Mixed With Applesauce to Healthy Subjects. Indian journal of pharmaceutical sciences. 2011;73:28-34.
12373.	RT L, DF K, SR S. Bright light augments antidepressant effects of medication and wake therapy. Depression and anxiety. 2002;16:1-3.
12374.	RT M, CMA F, SE L, PR J. Eighteen months of drug treatment for depression: Predicting relapse and recovery. Journal of affective disorders. 2009;114:263-270.
12375.	RT M, PR J, CM F. Personality disorders improve in patients treated for major depression. Acta psychiatrica Scandinavica. 2010;122:219-225.
12376.	RT M, PR J, CM F, SE L. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta psychiatrica Scandinavica. 2008;118:116-122.
12377.	RT M, WG W, PR J, SE L. Age may affect response to antidepressants with serotonergic and noradrenergic actions. Journal of affective disorders. 2003;76:143-149.
12378.	RT O. Olanzapine/Fluoxetine Combination for Bipolar Depression and Other Mood Disorders: a Review. Drugs of today (Barcelona, Spain : 1998). 2006;42:185-192.
12379.	RT O. Extended-release carbamazepine for acute bipolar mania: A review. Drugs of today (Barcelona, Spain : 1998). 2006;42:283-289.
12380.	RT O. Pregabalin: Its Efficacy, Safety and Tolerability Profile in Generalized Anxiety. Drugs of today (Barcelona, Spain : 1998). 2007;43:601-610.
12381.	RT O. Controlled-Release Fluvoxamine in Obsessive-Compulsive Disorder and Social Phobia. Drugs of today (Barcelona, Spain : 1998). 2008;44:887-893.
12382.	RT O. Agomelatine: a novel pharmacological approach to treating depression. [Review] [38 refs]. Drugs of today (Barcelona, Spain : 1998). 2009;45:599-608.
12383.	RT O. Vilazodone: A new treatment option for major depressive disorder. Drugs of today (Barcelona, Spain : 1998). 2011;47:531-537.
12384.	RT R, Gentil V, Gorenstein C. Clomipramine and Initial Worsening in Panic Disorder - Beyond the Jitteriness Syndrome. Journal of psychopharmacology (Oxford, England). 1993;7:265-269.
12385.	RT S. Sexual Dysfunction Associated With Antidepressant Therapy. Urologic clinics of North America. 2007;34:575-+.
12386.	RT S, Balon R. Antidepressant-induced sexual dysfunction in men. Pharmacology, biochemistry, and behavior. 2014;121:132-137.
12387.	RT S, Kavoussi R, AR H, et al. Evaluation of sexual functioning depressed outpatients: A double-blind comparison of sustained-release bupropion and sertraline treatment. Journal of clinical psychopharmacology. 2000;20:122-128.
12388.	RT S, Lee J, Stevenson R, DJ W, WC W, RA D. Tadalafil for treatment of erectile dysfunction in men on antidepressants. Journal of clinical psychopharmacology. 2007;27:62-66.
12389.	RT W, CS W, AW H, et al. Identifying depression severity risk factors in persons with traumatic spinal cord injury. Rehabilitation psychology. 2014;59:50-56.
12390.	RTP P, AP M, CB K. Folic acid: Neurochemistry, metabolism and relationship to depression. Human psychopharmacology. 2004;19:477-488.
12391.	RTW C, JM R, PL H. Clinical practice guidelines for depression in young people: Are the treatment recommendations outdated? Medical journal of Australia. 2002;177:448-451.
12392.	Rubio G, Ponce G, Rodriguez-Jimenez R, MA J-A, Hoenicka J, Palomo T. Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone? Alcohol and Alcoholism. 2005;40:227-233.
12393.	Rucci P, Frank E, Scocco P, et al. Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. Depression and anxiety. 2011;28:303-309.
12394.	Ruddell M, Spencer A, Hill K, House A. Fluoxetine vs placebo for depressive symptoms after stroke: Failed randomised controlled trial. International journal of geriatric psychiatry. 2007;22:963-965.
12395.	Rudolf H-S, Philip N, W BD, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Archives of general psychiatry. 2000;57:76-82.
12396.	Adverse reactions to antidepressants.[Erratum appears in Br J Psychiatry. 2010 May;196(5):417], The British Journal of Psychiatry(2009).
12397.	Rudolf U, E TK, Tracy D, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. American journal of psychiatry. 2014;171:1278-1286.
12398.	Genome-wide pharmacogenetics of antidepressant response in the GENDEP project, American journal of psychiatry(2010).
12399.	Body weight as a predictor of antidepressant efficacy in the GENDEP project, Journal of affective disorders(2009).
12400.	Rudolf U, Ole M, Joanna H, et al. Changes in body weight during pharmacological treatment of depression. International journal of neuropsychopharmacology. 2011;14:367-375.
12401.	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression.[Erratum appears in Br J Psychiatry. 2009 Jul;195(1):87], The British Journal of Psychiatry(2009).
12402.	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline, Journal of affective disorders(2011).
12403.	Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: A literature review of comparative studies with selective serotonin reuptake inhibitors. Acta psychiatrica Scandinavica. 2002;106:24-30.
12404.	Rufer M, Hand I, Alsleben H, et al. Long-Term Course and Outcome of Obsessive-Compulsive Patients After Cognitive-Behavioral Therapy in Combination With Either Fluvoxamine or Placebo - a 7-Year Follow-up of a Randomized Double-Blind Trial. European archives of psychiatry and clinical neuroscience. 2005;255:121-128.
12405.	Rufer M, Hand I, Alsleben H, et al. Long-Term Course and Outcome of Obsessive-Compulsive Patients After Cognitive-Behavioral Therapy in Combination With Either Fluvoxamine or Placebo - a 7-Year Follow-up of a Randomized Double-Blind Trial. European archives of psychiatry and clinical neuroscience. 2005;255:121-128.
12406.	Ruffolo G, Perugi G. Use of benzodiazepines in the treatment of Panic Disorders. [Italian]. Giornale Italiano di Psicopatologia. 2002;8:66-81.
12407.	Ruhe E, Booij J, H VW, et al. Increasing SSRIs dosage in depression is not significant. [Dutch]. Huisarts en wetenschap. 2009;52:289-296.
12408.	Ruhe HG, Booij J, C vWH, et al. [Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines]. [Dutch]. Tijdschrift voor psychiatrie. 2010;52:615-625.
12409.	Ruhrmann S, Bechdolf A, K-U K, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British journal of psychiatry. 2007;191:s88-s95.
12410.	Ruhrmann S, Kasper S, Hawellek B, H-J B, H-J M. Fluoxetine treatment and thyroid hormones in seasonal affective disorder (SAD). European neuropsychopharmacology. 1993;3:336-337.
12411.	Ruhrmann S, Klosterkotter J, Bodatsch M, et al. Pharmacological prevention and treatment in clinical at-risk states for psychosis. Current pharmaceutical design. 2012;18:550-557.
12412.	Ruiz-Chow A, Ramirez-Bermudez J, L A-dlS, Rios C. Amantadine: A treatment for major depressive disorder. European neuropsychopharmacology. 2010;Conference:S352.
12413.	Rummel C, Kissling W, Leucht S. Antidepressants as Add-on Treatment to Antipsychotics for People With Schizophrenia and Pronounced Negative Symptoms: a Systematic Review of Randomized Trials. Schizophrenia research. 2005;80:85-97.
12414.	Rummel C, Kissling W, Leucht S. Antidepressants for the Negative Symptoms of Schizophrenia. Cochrane database of systematic reviews (Online). 2006.
12415.	Rupprecht R, TC B, H-J M. New pharmacological treatment options in depression. [German]. Der Nervenarzt. 2004;75:273-279.
12416.	Rush A, LM W, SH K, et al. The international study to predict optimized treatment - In depression: Rational, design and initial findings. European psychiatry. 2012.
12417.	Russell I, Wang F, Ahl J, Choy E, Wohlreich M. Does baseline severity of symptoms in fibromyalgia impact the pain response? A pooled analysis of four placebo-controlled trials. Journal of pain. 2009;Conference:S40.
12418.	Heart rate variability is a trait marker of major depressive disorder: Evidence from the sertraline vs. electric current therapy to treat depression clinical study, International journal of neuropsychopharmacology(2013).
12419.	Comparison of blinding effectiveness between sham tDCS and placebo sertraline in a 6-week major depression randomized clinical trial, Clinical neurophysiology(2014).
12420.	Rutherford B, Sneed J, Devanand D, Eisenstadt R, Roose S. Antidepressant study design affects patient expectancy: A pilot study. Psychological medicine. 2010;40:781-788.
12421.	Rutherford B, Sneed J, Miyazaki M, et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. International journal of geriatric psychiatry. 2007;22:986-991.
12422.	Ruths S, Steiner H. Psychopharmacologic Treatment of Aggression in Children and Adolescents. Pediatric annals. 2004;33:318-327.
12423.	Ruthven L, JM P. Psychotherapy versus drugs in treating depression (multiple letters). Drug Benefit Trends. 2003;15:7-8+17.
12424.	Ruttley A, Reid S. Depression in physical illness. Clinical Medicine, Journal of the Royal College of Physicians of London. 2006;6:533-536.
12425.	RV G, Sanacora G. Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Statistics in medicine. 2006;25:1307-1322.
12426.	RV L. Sleep Disturbances and Depression: a Challenge for Antidepressants. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2008;108:75-78.
12427.	RV P, JM K, MA O, et al. Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [C-11]Dasb and Positron Emission Tomography. Biological psychiatry. 2006;59:821-828.
12428.	RW B, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine Augmentation of Clozapine Treatment in Patients With Schizophrenia. American journal of psychiatry. 1996;153:1625-1627.
12429.	RW D. Which Patients Are Treated With Fluoxetine. Psychopharmakotherapie. 1997;4:17-22.
12430.	RW E. A rational approach to the management of chronic migraine. Headache. 2013;53:168-176.
12431.	RW E, Rosen N. Migraine, psychiatric comorbidities, and treatment. Headache. 2008;48:952-958.
12432.	RW J. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. International journal of geriatric psychiatry. 2010;25:547-553.
12433.	RW L. Priorities in Treating Depression Only. International journal of psychiatry in clinical practice. 2004;8:25-29.
12434.	RW L. Generalized Anxiety Disorder: How to Treat, and for How Long? International journal of psychiatry in clinical practice. 2006;10:10-15.
12435.	RW L. Challenges in the Treatment of Anxiety Disorders: Beyond Guidelines. International journal of psychiatry in clinical practice. 2006;10:18-24.
12436.	RW L. Sleep Disturbances and Depression: a Challenge for Antidepressants. International clinical psychopharmacology. 2006;21:S25-S29.
12437.	RW L. High-quality remission: Potential benefits of the melatonergic approach for patients with major depressive disorder. International clinical psychopharmacology. 2007;22:S21-S25.
12438.	RW L. Onset, time course and trajectories of improvement with antidepressants. European neuropsychopharmacology. 2012;22:S492-S498.
12439.	RW L. Lithium: Still a Major Option in the Management of Bipolar Disorder. CNS neuroscience & therapeutics. 2012;18:219-226.
12440.	RW L, Annemans L. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert review of pharmacoeconomics & outcomes research. 2007;7:559-576.
12441.	RW L, Chan P, Wilkins-Ho M, LN Y. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and metaanalysis. Canadian Journal of Psychiatry. 2008;53:621-631.
12442.	RW L, DDC W, NL C, SH K. Combining antidepressants for treatment-resistant depression: a review. [Review] [52 refs]. Journal of clinical psychiatry. 2002;63:685-693.
12443.	RW L, DI O-M, MB P, Greenberg A. Role of vaptans in the management of hyponatremia. American journal of kidney diseases. 2013;62:364-376.
12444.	RW L, Endicott J, MA H, Fayyad R, Guico-Pabia C, Boucher M. Predictors of Functional Improvement in Employed Adults With Major Depressive Disorder Treated With Desvenlafaxine. International clinical psychopharmacology. 2014;29:239-251.
12445.	RW L, Gijsman H, WA N, Angst J. Are Antidepressants Safe in the Treatment of Bipolar Depression? A Critical Evaluation of Their Potential Risk to Induce Switch Into Mania or Cycle Acceleration. Acta psychiatrica Scandinavica. 2008;118:337-346.
12446.	RW L, Group DUA. Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5). Journal of affective disorders. 2013;148:286-290.
12447.	RW L, McLeod J, Woo C, EE M, LN Y, DJ B. A systematic review of treatment effects of antidepressants on work productivity outcomes. European neuropsychopharmacology. 2012;Conference:S235-S236.
12448.	RW L, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in Patients With Major Depression; Is the Total Score a Valid Measure of Illness Severity? Acta psychiatrica Scandinavica. 2005;111:144-149.
12449.	RW L, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in Patients With Major Depression; Is the Total Score a Valid Measure of Illness Severity? Acta psychiatrica Scandinavica. 2005;111:144-149.
12450.	RW L, SH K. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. [Review] [69 refs]. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2004;49:17S-26S.
12451.	RW L, SH K. Using metaanalysis to evaluate evidence: practical tips and traps. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005;50:167-174.
12452.	RW L, SK L, EM T, Grewal A, LN Y. An open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. Journal of clinical psychiatry. 2001;62:164-168.
12453.	RW L, SL L, Despiegel N. Escitalopram versus SNRIs as second-line treatment. International journal of psychiatry in clinical practice. 2009;Conference:35-36.
12454.	RW L, SV P, Ramasubbu R, LN Y, EE M, CV M. A comparison of work productivity outcome scales for depression clinical trials. European neuropsychopharmacology. 2012;Conference:S236-S237.
12455.	RW S. Controlled trials of therapy in fibromyalgia syndrome. Bailliere's clinical rheumatology. 1994;8:917-934.
12456.	RW VE, Berger T, Weisbrod M, Unverricht S, Hartmann M. Hiv Patients With Psychiatric Diseases: Treatment Strategies and Pharmacological Interactions. Der Nervenarzt. 2001;72:204-215.
12457.	RY G, Su L, LA L, CX W. [Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of post-stroke depression]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2009;29:785-790.
12458.	RY V, GE M, TS R, GI R. The Choice of Therapeutic Tactics in Treatment of Endogenous Depressions by Means of Statusmetric Expert System. Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova. 1997;97:32-34.
12459.	Rybakowski J. Neurobiological aspects of theory and practice of psychotherapy. Archives of Psychiatry and Psychotherapy. 2001;3:79-87.
12460.	Rybakowski J, AB B. [Escitalopram--second generation of serotonin transporter inhibitors?]. [Review] [37 refs] [Polish]. Psychiatria polska. 2004;38:227-239.
12461.	Rynn M, Khalid-Khan S, JF G-E, Etemad B, Rickels K. Early Response and 8-Week Treatment Outcome in Gad. Depression and anxiety. 2006;23:461-465.
12462.	RZ L, JP A. Pharmacotherapies for alcoholism: Promising agents and clinical issues. Alcoholism, clinical and experimental research. 1991;15:620-633.
12463.	RZ L, JP A. Advances in Development of Medications for Alcoholism Treatment. Psychopharmacology. 1998;139:20-33.
12464.	RZ L, JP A. Medications for alcohol, illicit drug, and tobacco dependence: An update of research findings. Journal of substance abuse treatment. 1999;16:105-112.
12465.	S AG, E GC, J HM, et al. BDNF Val66met polymorphism, white matter abnormalities and remission of geriatric depression. Journal of affective disorders. 2010;125:262-268.
12466.	S AG, F MC, M G-DF, et al. Serotonin transporter polymorphisms, microstructural White matter abnormalities and remission of geriatric depression. Journal of affective disorders. 2009;119:132-141.
12467.	S AG, F MC, M G-DF, et al. Microstructural white matter abnormalities and remission of geriatric depression. American journal of psychiatry. 2008;165:238-244.
12468.	S AG, J HM, Dora K, F MC, O LK, M GF. Functional connectivity in the cognitive control network and the default mode network in late-life depression. Journal of affective disorders. 2012;139:56-65.
12469.	S AG, M CC, M GG, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. The American Journal of Geriatric Psychiatry. 2008;16:21-30.
12470.	S BD, A CJ, T HAK, Ian H. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International clinical psychopharmacology. 2006;21:159-169.
12471.	S BD, A MS, Rico N, Malcolm L. Discontinuation symptoms in depression and anxiety disorders. [Review] [24 refs]. International journal of neuropsychopharmacology. 2007;10:73-84.
12472.	S BD, Claire P. Evidence-based pharmacotherapy of generalized anxiety disorder. International journal of neuropsychopharmacology. 2005;8:293-302.
12473.	A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD), European neuropsychopharmacology(2012).
12474.	S BD, J HC, T AR, P MB, al e. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Journal of clinical psychiatry. 1996;57:46-52.
12475.	S BD, J SD, T DO, Borwin B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. [Review] [46 refs]. Human Psychopharmacology: Clinical and Experimental. 2009;24:269-275.
12476.	S BD, Mary G, A MS. Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: Results from an exploratory randomized, double-blind, placebo-controlled treatment study. International clinical psychopharmacology. 2014;29:339-343.
12477.	S BM, Joseph W, V SB, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biological psychiatry. 1997;41:15-22.
12478.	S BZ, Zincir S, Izci F, Izci S, Sumbul M, Yanartas O. Effects of escitalopram and duloxetine on electrocardiography at therapeutic doses in patients with major depression. European neuropsychopharmacology. 2014;Conference:S458.
12479.	S CD. Antidepressant treatment reduces poststroke mortality. Journal of family practice. 2004;53:96-97.
12480.	S CL, Andrew B, Yin YGW. History of depression and smoking cessation: A rejoinder [1]. Nicotine & tobacco research. 2006;8:315-319.
12481.	S DG, J TA, M FC, Stephanie A, C SR. Do venlafaxine XR and paroxetine equally influence negative and positive affect? [References]. Journal of affective disorders. 2005;85:333-339.
12482.	S DM, Dekker J, Schoevers R, F DJ. Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis. Psychotherapy research. 2006;16:566-578.
12483.	S DM, Dekker J, Schoevers R, et al. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: A mega-analysis based on three randomized clinical trials. Depression and anxiety. 2008;25:565-574.
12484.	S DR, Frasca V, Inghilleri M, et al. Duloxetine for the Treatment of Overactive Bladder Syndrome in Multiple Sclerosis: a Pilot Study. Clinical neuropharmacology. 2012;35:231-234.
12485.	S DW, Cremers L, Hirsch D, Zulian C, Clumeck N, Kormoss N. Efficacy and Safety of Trazodone Versus Clorazepate in the Treatment of Hiv-Positive Subjects With Adjustment Disorders: a Pilot Study. Journal of international medical research. 1999;27:223-232.
12486.	S DW, S VB. Cancer-related fatigue. Acta clinica Belgica. 2010;65:378-385.
12487.	S DY-, Naganawa M, D GJ-, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. NeuroImage. 2014;86:164-171.
12488.	S E-MR, Gagandeep K, Steven L. Placebo group needed for interpretation of combination trial: Comment on Blier et al. and Rush. American journal of psychiatry. 2010;167:996.
12489.	S FE, E TM, R WS, et al. Cognitive therapy augmentation versus CT switch treatment: A STAR*D report. International journal of cognitive therapy. 2009;2:66-87.
12490.	S FJ. Exercise, pharmacotherapy, and depression. Psychosomatic medicine. 2008;70:263.
12491.	S GM, Bruce LR. Speed of Onset of Action of the Newer Antidepressants - Fluoxetine and Bupropion. International clinical psychopharmacology. 1991;6:209-217.
12492.	S GM, Bruce T, A MG. Outcome of adolescent depression: 6 months after treatment. Australian and New Zealand journal of psychiatry. 2011;45:232-239.
12493.	S HA, Tom J, J PM, G KG, H KN, J DR. Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. JAMA Psychiatry. 2013;70:1-10.
12494.	S KA, M HA, A CI, F LA. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clinical neurophysiology. 2009;120:1313-1319.
12495.	S KA, M HA, A CI, F LA. Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. Psychiatry Research - Neuroimaging. 2011;192:188-194.
12496.	S KM, D BW, Rosemary O, E WD. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Journal of clinical psychiatry. 1995;56:142-145.
12497.	Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder, The British Journal of Psychiatry(2014).
12498.	S LG, L AL, A FM, et al. Risk of Switch in Mood Polarity to Hypomania or Mania in Patients With Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers. American journal of psychiatry. 2006;163:232-239.
12499.	Is bigger better for depression trials? [References], Journal of psychiatric research(2008).
12500.	S LP, Fuschillo C, Giorgio D, et al. Serotonin (5-Ht)-Related Symptoms and Fluoxetine in Geriatric Depression. Archives of gerontology and geriatrics. 2001:213-225.
12501.	S lP, Giorgio D, Ciriello R, et al. Evaluation of the efficacy, tolerability, and therapeutic profile of fluoxetine versus mianserin in the treatment of depressive disorders in the elderly. Current therapeutic research, clinical and experimental. 1992;52:847-858.
12502.	S LP, Giorgio D, Ciriello R, et al. Double blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitive-behavioral parameters. New Trends in Experimental and Clinical Psychiatry. 1992;8:139-146.
12503.	S LSA. Defense functioning in depressed patients treated with medication and group psychotherapy. Dissertation Abstracts International: Section B: The Sciences and Engineering. 1999;59:5095.
12504.	S MB, J FA, J RA, et al. "A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The Study of Pharmacotherapy of Psychotic Depression (STOP-PD)": Correction. Archives of general psychiatry. 2011;68:626.
12505.	S MG, B MP. Dual Action Antidepressants: Mechanisms of action and clinical use. Primary psychiatry. 2003;10:62-66.
12506.	S MG, Felicity N, Michael B. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Australian and New Zealand journal of psychiatry. 2008;42:346-349.
12507.	S MH, Arturo SJ, K BS, et al. The functional neuroanatomy of the placebo effect. American journal of psychiatry. 2002;159:728-737.
12508.	S MH, Arturo SJ, K BS, et al. "Brain changes and placebo": Reply. American journal of psychiatry. 2003;160:390-391.
12509.	S MJ. "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial": Reply. JAMA: Journal of the American Medical Association. 2004;292:2578-2579.
12510.	S MJ. Commentary on 'Forum: Use of antidepressants in children and adolescents.' [References]. Current opinion in psychiatry. 2010;23:63-65.
12511.	S MJ, A KK, W JJ, Jim M, Greist JH. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. Journal of clinical psychiatry. 1990;51:200-202.
12512.	Clinical messages from the Treatment for Adolescents With Depression Study (TADS). [Review] [44 refs], American journal of psychiatry(2009).
12513.	S MJ, J KB, E KCM. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. Journal of child and adolescent psychopharmacology. 2006;16:91-102.
12514.	S ML, Curt BR, Antonios P, et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: Findings from DIADS. International journal of geriatric psychiatry. 2006;21:930-936.
12515.	S MP, K BD, Prem K, S DR. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: Pragmatic randomized open-label comparison. Human Psychopharmacology: Clinical and Experimental. 2007;22:477-482.
12516.	S NA, Ann W-M, Vivian M, et al. Serotonin and the prediction of response time to fluoxetine in patients with mild depression. Psychiatry research. 1999;88:89-93.
12517.	S NG, DJ H, Soldani F, FK G. Antidepressants in bipolar disorder: The case for caution. Bipolar disorders. 2003;5:421-433.
12518.	S NG, PA V, EA W. Antidepressants from a public health perspective: Re-examining effectiveness, suicide, and carcinogenicity. Acta psychiatrica Scandinavica. 2013;127:89-93.
12519.	S OD, MH T, EZ OK, et al. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study. Acta psychiatrica Belgica. 1995;95:139-151.
12520.	S OM, H FH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? [References]. Neurology. 2009;72:868-869.
12521.	Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: A multicenter trial comparing 2 switching techniques, Journal of clinical psychiatry(2008).
12522.	S PDG, Deborah Q, Durisala D, L MA, F SA. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: Effects on painful physical symptoms of depression. Journal of psychiatric research. 2009;43:512-518.
12523.	S PDG, Giuseppe M, E TM, et al. "Duloxetine in the prevention of depressive recurrences: A randomized, double-blind, placebo-controlled trial": Correction. Journal of clinical psychiatry. 2009;70:1729.
12524.	Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial.[Erratum appears in J Clin Psychiatry. 2009 Dec;70(12):1729], Journal of clinical psychiatry(2009).
12525.	S PDG, K KD, G RM, J WD, Joel R. Duloxetine in the treatment of major depressive disorder: An assessment of the relationship between outcomes and episode characteristics. International clinical psychopharmacology. 2006;21:285-295.
12526.	S PDG, L PY, Durisala D, Joel R. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?. [Review] [48 refs]. International clinical psychopharmacology. 2006;21:311-317.
12527.	S PDG, Lu PY, K KD, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of psychiatric research. 2008;42:22-34.
12528.	S RD. Vitamins, monoamines, and depression. Primary psychiatry. 2009;16:19-21.
12529.	S RR, RB P. Treatment of restless legs syndrome. Current treatment options in neurology. 2013;15:396-409.
12530.	S SG, Charles B, E TM. "Effectiveness of adjunctive antidepressant treatment for bipolar depression": Reply to commentaries. New England journal of medicine. 2007;357:615-616.
12531.	S SG, Elisse K, Carol H, et al. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biological psychiatry. 2009;66:259-266.
12532.	S SG, Elisse K, R HC, et al. Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. The American Journal of Geriatric Psychiatry. 2002;10:715-723.
12533.	S SG, FIII RC, R HP, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: A randomized, placebo-controlled study. Psychiatry Research - Neuroimaging. 2009;171:1-9.
12534.	S SG, G SL, G LH. Pharmacological treatment of acute bipolar depression. 2009:147-158.
12535.	S SG, I WC, Elisse K, et al. The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. The American Journal of Geriatric Psychiatry. 2011;19:53-63.
12536.	S SJ, B NC. Aripiprazole Augmentation of Antidepressants for the Treatment of Partially Responding and Nonresponding Patients With Major Depressive Disorder. Journal of clinical psychiatry. 2005;66:1216-1220.
12537.	S SJ, M AL, R KN, Dean L. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder: Corrigendum. Journal of psychiatric research. 2004;38:451.
12538.	S SJ, M AL, R KN, Dean L. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.[Erratum appears in J Psychiatr Res. 42004 Jul-Aug;38(4):51]. Journal of psychiatric research. 2004;38:249-257.
12539.	S SL, Craig NJ, M CC, et al. "An 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression": Reply. American journal of psychiatry. 2004;161:759-761.
12540.	S SL, W SG, H HS, Alexander B, B NC, S MB. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. The American Journal of Geriatric Psychiatry. 1997;5:97-106.
12541.	S TW, J BA. Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology. 2002;159:216-221.
12542.	S WJ. Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data. International clinical psychopharmacology. 1986;1:221-230.
12543.	S WJ. The role of serotonin in depression and suicide: Do serotonin reuptake inhibitors provide a key? Advances in Biological Psychiatry. 1988;17:70-83.
12544.	S WVJ, H GC, T GG, M GK. Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial. Journal of clinical psychopharmacology. 2012;32:341-345.
12545.	S YG, Saumya B, J LB, et al. Apathy in late-life depression: Common, persistent, and disabling. The American Journal of Geriatric Psychiatry. 2015;23:488-494.
12546.	A pilot controlled trial of a combination of dense cranial electroacupuncture stimulation and body acupuncture for post-stroke depression, BMC complementary and alternative medicine(2014).
12547.	S-D C, X-Y T, C-J L, Yang G. Role of fluoxertine hypochloride and clomipramine in ameliorating vascular depression and the side effects. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:24-25.
12548.	S-H W, Z-J Z, Y-J G, G-J T, B-A C. [Establishment of rat model of post-stroke depression and the effects of citalopram on behavior thereof]. [Chinese]. National Medical Journal of China. 2007;87:1355-1357.
12549.	S-H Z. Acupuncture in the treatment of female climacteric depression in 60 cases. [Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research. 2007;11:7817-7819.
12550.	S-J H, X-H Z, Y-Y W, et al. Effects of Kaixin Jieyu Decoction on behavior, monoamine neurotransmitter levels, and serotonin receptor subtype expression in the brain of a rat depression model. Chinese journal of integrative medicine. 2014;20:280-285.
12551.	S-J T, C-J H, Y-J L. Effects of bdnf polymorphisms on antidepressant action. Psychiatry investigation. 2010;7:236-242.
12552.	S-J T, C-J H, Y-J L. Recent molecular genetic studies and methodological issues in suicide research. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:809-817.
12553.	S-L A, Ikonen U, Pulkkinen M, et al. Paroxetine and imipramine: A 12-week, double-blind multicentre study in hospitalized depressed patients. Nordic Journal of Psychiatry, Supplement. 1992;46:27-31.
12554.	S-L A, Ikonen U, Pulkkinen P, et al. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta psychiatrica Scandinavica. 1994;89:382-389.
12555.	S-L C, S-Y L, Y-H C, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. European neuropsychopharmacology. 2014;24:1753-1759.
12556.	S-M H, Bhattaram A, Mehrotra N, Wang Y. Is this the dose for you?: The role of modeling. Clinical pharmacology and therapeutics. 2013;93:159-162.
12557.	S-M W, Han C, S-J L, AA P, PS M, C-U P. A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of psychiatric research. 2014;53:30-37.
12558.	S-Q X, Cao J, W-W H. Comparison of escitalopram with fluoxetine in old depressive patients. [Chinese]. Chinese Journal of New Drugs. 2010;19:207-209.
12559.	S-S H-T, H-R S, Dashti N, Rahimdel A. Comparing the efficacy of fluvoxamine and sertraline in treating major depressive disorder (MDD). [Persian]. Journal of Isfahan Medical School. 2013.
12560.	S-W L, H-H W, Kim H, et al. Genetic prediction of antidepressant drug response and nonresponse in Korean patients. PloS one. 2014.
12561.	S-Y H, C-H Z, M-Q C, G-J P, C-Y H. Anti-depressive effect of Baisong tablets on the chronic mild unpredicted stress depression in rats. [Chinese]. Journal of Central South University (Medical Sciences). 2006;31:676-681.
12562.	Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naive Patients with Bipolar II Disorder, PloS one(2013).
12563.	S-Y L, S-L C, Y-H C, et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: A 12-week double-blind, randomized controlled trial. Journal of clinical psychopharmacology. 2014;34:337-343.
12564.	S-Y L, S-L C, Y-H C, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. Journal of affective disorders. 2012;138:295-300.
12565.	S-Y M, Y-J S. Related factors of post-stroke depression and therapeutical effect of citalopram. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:3718-3719.
12566.	S-Y N, Li N, You H, S-X S, C-M L. Effect of integrated therapy of Chinese and western medicine on differentiation of symptoms and signs of patients with depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:7-9.
12567.	S-Y W, D-J H, G-X Z, et al. Influence of fluoxetine combined with psychotherapy in treatment of hypertensive patients with depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2003;7:2938-2940.
12568.	SA B, Heyl A. Communicating with women about menstrual cycle symptoms. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2008;53:837-846.
12569.	SA B, NA S. Treatment for hot flushes in women receiving tamoxifen. Medical journal of Australia. 2002;177:266.
12570.	SA C, RH P, PE KJ, et al. A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression. Journal of clinical psychiatry. 2006;67:798-806.
12571.	SA D. Fluoxetine--do the benefits outweigh the risks in adolescent major depression?. [Review] [9 refs]. Expert opinion on pharmacotherapy. 2005;6:147-150.
12572.	SA D. Fluoxetine - Do the Benefits Outweigh the Risks in Adolescent Major Depression? Expert opinion on pharmacotherapy. 2005;6:147-150.
12573.	SA D. After the failure of citalopram for depression, what next? Expert opinion on pharmacotherapy. 2006;7:1515-1518.
12574.	SA D. Adherence to oral endocrine treatments in women with breast cancer: Can it be improved? Breast cancer research and treatment. 2011;129:299-308.
12575.	SA D, DL R, Valenstein M, et al. A Tailored Smoking, Alcohol, and Depression Intervention for Head and Neck Cancer Patients. Cancer Epidemiology Biomarkers and Prevention. 2006;15:2203-2208.
12576.	SA D, TS B, NP B, AV J, HT R. Paliperidone ER - A novel antipsychotic. Internet Journal of Pharmacology. 2009.
12577.	SA H. Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications. Expert opinion on drug safety. 2011;10:913-934.
12578.	SA I, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. Journal of palliative medicine. 2010;13:903-908.
12579.	SA J, S-J W. How biased are indirect comparisons, particularly when comparisons are made over time in controlled trials? Drug information journal. 2008;42:625-633.
12580.	SA M. Development of new treatments for depression. Journal of clinical psychiatry. 1985;46:3-6.
12581.	SA M. New antidepressants and 5-HT uptake inhibitors. Acta Psychiatrica Scandinavica, Supplement. 1989;80:107-116.
12582.	SA M. New antidepressants and 5-HT uptake inhibitors. [Review] [59 refs]. Acta psychiatrica Scandinavica. Supplementum. 1989;350:107-116.
12583.	SA M. Clinical-Significance of 5-Ht Uptake Inhibitors. Human Psychopharmacology-Clinical and Experimental. 1991;6:S3-S7.
12584.	SA M. Suicide prevention and serotonergic drugs. International clinical psychopharmacology. 1993;8:83-85.
12585.	SA M. Long-term treatment with antidepressants. European neuropsychopharmacology. 1993;3:283-284.
12586.	SA M. Safety of mirtazapine: a review. [Review] [28 refs][Erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153]. International clinical psychopharmacology. 1995;10 Suppl 4:37-45.
12587.	SA M. Rapid onset of action of venlafaxine. International clinical psychopharmacology. 1995;10:21-27.
12588.	SA M. Efficacy in long-term treatment of depression. [Review] [28 refs]. Journal of clinical psychiatry. 1996;57 Suppl 2:24-30.
12589.	SA M. Clinical measures of rapid onset of action. European psychiatry. 1997;12:295s-300s.
12590.	SA M. Reboxetine: additional benefits to the depressed patient. [Review] [24 refs]. Journal of psychopharmacology (Oxford, England). 1997;11:S9-15.
12591.	SA M. Suicide and antidepressants. [Review] [27 refs]. Annals of the New York Academy of Sciences. 1997;836:329-338.
12592.	SA M. Chairman's overview. The place of reboxetine in antidepressant therapy. [Review] [34 refs]. Journal of clinical psychiatry. 1998;59 Suppl 1:26-29.
12593.	SA M. The place of reboxetine in antidepressant therapy. Journal of clinical psychiatry. 1998;59:26-29.
12594.	SA M. The efficacy and safety of reboxetine, a novel selective noradrenaline reuptake inhibitor, in the treatment of depression. Today's Therapeutic Trends. 1999;17:35-56.
12595.	SA M. New developments in the treatment of depression. [Review] [20 refs]. Journal of clinical psychiatry. 1999;60 Suppl 1:10-15.
12596.	SA M. New developments in the treatment of depression. Journal of clinical psychiatry. 1999;60:10-15.
12597.	SA M. Predicting response: noradrenaline reuptake inhibition. [Review] [29 refs]. International clinical psychopharmacology. 1999;14 Suppl 1:S21-26.
12598.	SA M. Social Phobia: Diagnosis, Severity and Implications for Treatment. European archives of psychiatry and clinical neuroscience. 1999;249:S1-S6.
12599.	SA M. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. [Review] [23 refs]. International clinical psychopharmacology. 2002;17 Suppl 4:S9-15; discussion S16-17.
12600.	SA M. Guidelines in major depressive disorder, and their limitations. International journal of psychiatry in clinical practice. 2006;10:3-9.
12601.	SA M. Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants. CNS spectrums. 2008;13:27-33.
12602.	SA M. The Under-Recognized Role of Dopamine in the Treatment of Major Depressive Disorder. International clinical psychopharmacology. 2008;23:63-69.
12603.	SA M, AC A, Katila H, Datto C, Szamosi J, Eriksson H. Efficacy of Extended Release Quetiapine Fumarate Monotherapy in Elderly Patients With Major Depressive Disorder: Secondary Analyses in Subgroups of Patients According to Baseline Anxiety, Sleep Disturbance, and Pain Levels. International clinical psychopharmacology. 2014;29:93-105.
12604.	SA M, AF S, JD G, et al. Pharmacotherapy of depression and mixed states in bipolar disorder. Journal of affective disorders. 2000;59:S39-S56.
12605.	SA M, AKT H, Bothmer J. A Randomised Study Comparing Escitalopram With Venlafaxine Xr in Primary Care Patients With Major Depressive Disorder. Neuropsychobiology. 2004;50:57-64.
12606.	SA M, B vZ-B. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004. European neuropsychopharmacology. 2007;17:70-77.
12607.	SA M, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D. Plasma-level response relationships with fluoxetine and zimelidine. Clinical neuropharmacology. 1990;13:S71-S75.
12608.	SA M, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D. Plasma-level response relationships with fluoxetine and zimelidine. Clinical neuropharmacology. 1990;13 Suppl 1:S71-75.
12609.	SA M, Djarv L. The antidepressant efficacy of citalopram. [Review] [9 refs]. International clinical psychopharmacology. 1996;11 Suppl 1:29-33.
12610.	SA M, DS B, Riley A. Antidepressant medications: A review of the evidence for drug-induced sexual dysfunction. Journal of affective disorders. 2002;69:119-140.
12611.	SA M, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry - Supplementum. 1988:69-76.
12612.	SA M, Entsuah R, Hackett D, NR K, RL R. Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression. Journal of clinical psychiatry. 2004;65:328-336.
12613.	SA M, Entsuah R, Hackett D, NR K, RL R, Group VS. Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression. Journal of clinical psychiatry. 2004;65:328-336.
12614.	SA M, Evans R. Relapse prevention with antidepressants. Nordic Journal of Psychiatry, Supplement. 1993;47:83-88.
12615.	SA M, Fava M, SK P, CJ G-P, KA T. Discontinuation Symptoms and Taper/Poststudy-Emergent Adverse Events With Desvenlafaxine Treatment for Major Depressive Disorder. International clinical psychopharmacology. 2009;24:296-305.
12616.	SA M, Hale A, GM G. Agomelatine the first melatonergic antidepressant: A sustained efficacy in severely depressed patients. European psychiatry.
12617.	SA M, Henry J, Mcdonald G, et al. Selective Serotonin Reuptake Inhibitors - Metaanalysis of Discontinuation Rates. International clinical psychopharmacology. 1994;9:47-53.
12618.	SA M, JC L, Svedsater H, Eriksson H. Efficacy of Once-Daily Extended Release Quetiapine Fumarate in Patients With Different Levels of Severity of Generalized Anxiety Disorder. International clinical psychopharmacology. 2014;29:252-262.
12619.	SA M, Judge R. Treatment of Depression With Associated Anxiety: Comparisons of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors. Acta psychiatrica Scandinavica. 2000;101:9-16.
12620.	SA M, Kasper S. Severe Depression and Antidepressants: Focus on a Pooled Analysis of Placebo-Controlled Studies on Agomelatine. International clinical psychopharmacology. 2007;22:283-291.
12621.	SA M, Kasper S, DJ S, KB H, OM L. Citalopram 20 Mg, 40 Mg and 60 Mg Are All Effective and Well Tolerated Compared With Placebo in Obsessive-Compulsive Disorder. International clinical psychopharmacology. 2001;16:75-86.
12622.	SA M, Lecrubier Y, DS B, et al. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. European neuropsychopharmacology. 2004;14:425-433.
12623.	SA M, Loft H, Sanchez C, EH R, Papp M. Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted From a Rat Model. Pharmacology & toxicology. 2001;88:282-286.
12624.	SA M, Manceaux A. Fluvoxamine in the treatment of obsessive compulsive disorder. [Review] [29 refs]. International clinical psychopharmacology. 1992;7 Suppl 1:5-9.
12625.	SA M, Mansuy L, AC R, DY L, Gommoll C. The Efficacy of Extended-Release Levomilnacipran in Moderate to Severe Major Depressive Disorder: Secondary and Post-Hoc Analyses From a Randomized, Double-Blind, Placebo-Controlled Study. International clinical psychopharmacology. 2014;29:26-35.
12626.	SA M, Mansuy L, Ruth A, Bose A, Li H, DY L. Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study. Journal of clinical psychiatry. 2013;74:363-369.
12627.	SA M, Nil R, Durr-Pal N, Loft H, JP B. A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder. Journal of clinical psychiatry. 2005;66:1270-1278.
12628.	SA M, RZ N, LH P, Haggstrom L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin -noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomela. Human psychopharmacology. 2014;29:470-782.
12629.	SA M, RZ N, LH P, Haggstrom L. A Randomised, Double-Blind Study in Adults With Major Depressive Disorder With an Inadequate Response to a Single Course of Selective Serotonin Reuptake Inhibitor or Serotonin-Noradrenaline Reuptake Inhibitor Treatment Switched to Vortioxetine or Agomelat. Human Psychopharmacology-Clinical and Experimental. 2014;29:470-482.
12630.	SA M, SH K, GD B, Lejoyeux M, Hindmarch I. Absence of Discontinuation Symptoms With Agomelatine and Occurrence of Discontinuation Symptoms With Paroxetine: a Randomized, Double-Blind, Placebo-Controlled Discontinuation Study. International clinical psychopharmacology. 2004;19:271-280.
12631.	SA S, AD W, L dlF, VG D-R. Role of Serotoninergic Pathways in Drug-Induced Valvular Heart Disease and Diagnostic Features by Echocardiography. Journal of the American Society of Echocardiography. 2009;22:883-889.
12632.	SA S, ML C, DN K, et al. Dysfunctional attitudes as a moderator of pharmacotherapy and psychotherapy for chronic depression. Journal of psychiatric research. 2013;47:113-121.
12633.	SA S, RM B, DJ A. Herbal and dietary supplements for treatment of anxiety disorders. American family physician. 2007;76:549-556.
12634.	SA S, TJ B. Seasonal affective disorders. American family physician. 1998;57:1340-1346.
12635.	SA W. Review: SSRIs lead to improvement in depression by the end of the first week: Commentary. Evidence-based medicine. 2007;12:72.
12636.	SA Y, Campbell N, Harper A. Depression in women of reproductive age: Considerations in selecting safe, effective therapy. Postgraduate medicine. 2002;112:45-50.
12637.	Saatcioglu O, Gumus S, Kamberyan K, Yanik M. Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: A case report. European neuropsychopharmacology. 2009;Conference:S524-S525.
12638.	Sabljic V, Rakun R, Ruzic K, Grahovac T. Duloxetine-Related Panic Attacks. Psychiatria Danubina. 2011;23:114-116.
12639.	Sachs G, Amering M, Berger P, Katschnig H. Gender related disabilities in panic disorder. Archives of women's mental health. 2002;4:121-127.
12640.	Sadosky A, Dukes E, Evans C. Reliability of a 1-Week Recall Period for the Medical Outcomes Study Sleep Scale (Mos-Ss) in Patients With Fibromyalgia. Health and quality of life outcomes. 2009;7.
12641.	SADS D. Pregabalin or morphine and gabapentin for neuropathic pain. Expert opinion on pharmacotherapy. 2005;6:2535-2539.
12642.	SADSL D. Pharmacokinetic Evaluation of Olanzapine Plus Fluoxetine for the Treatment of Bipolar Depression. Expert opinion on drug metabolism & toxicology. 2013;9:207-214.
12643.	Saeidnia S. Future position of crocus sativus as a valuable medicinal herb in phytotherapy. Pharmacognosy Journal. 2012;4:71.
12644.	Saeki Y, Watanabe T, Ueda M, et al. Genetic and Pharmacokinetic Factors Affecting the Initial Pharmacotherapeutic Effect of Paroxetine in Japanese Patients With Panic Disorder. European journal of clinical pharmacology. 2009;65:685-691.
12645.	Safa M, SF T, FG B, Talischi F. Clinical trial in the treatment of 80 Iranian patients with major depression disorder by the combination of omega 3 fatty acid and a selective serotonin reuptake inhibitor. Therapeutic Advances in Psychopharmacology. 2013;3:186-190.
12646.	Sageman S, RP B. 3-Acetyl-7-Oxo-Dehydroepiandrosterone for Healing Treatment-Resistant Posttraumatic Stress Disorder in Women: 5 Case Reports. Journal of clinical psychiatry. 2006;67:493-496.
12647.	Saghafi N, Mahmoodinya M, Ayati S, Behdani F, M TS, Rakhshandeh A. Comparison of effects of black cohosh and fluoxetine in treatment of menopausal symptoms. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility. 2013;15:1-7.
12648.	Saghafi R, Brown C, MA B, et al. Predicting 6-Week Treatment Response to Escitalopram Pharmacotherapy in Late-Life Major Depressive Disorder. International journal of geriatric psychiatry. 2007;22:1141-1146.
12649.	Sagman D, Mcintosh D, MS L, et al. Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine. International journal of clinical practice. 2011;65:73-81.
12650.	SAGSN G. Antidepressants in Bipolar Depression: the Clinical Debate. Australian and New Zealand Journal of Psychiatry Ri Ghaemi, Nassir/J-4934-2013. 2012;46:298-301.
12651.	Sagud M, Mihaljevic-Peles A, Begic D, et al. Antipsychotics as Antidepressants: What Is the Mechanism? Psychiatria Danubina. 2011;23:302-307.
12652.	Sagud M, Pivac N, Mustapic M, et al. The Effect of Lamotrigine on Platelet Serotonin Concentration in Patients With Bipolar Depression. Psychopharmacology. 2008;197:683-685.
12653.	Sahoo S, Mishra B. Management of treatment-resistant obsessive-compulsive disorder: An update on therapeutic strategies. Annals of Indian Academy of Neurology. 2007;10:145-153.
12654.	Vitamin C as an Adjuvant for Treating Major Depressive Disorder and Suicidal Behavior, a Randomized Placebo-Controlled Clinical Trial, Trials(2015).
12655.	Sajatovic M, Chen P. Geriatric Bipolar Disorder. Psychiatric clinics of North America. 2011;34:319-333.
12656.	Sajatovic M, Madhusoodanan S, MA F. Risperidone in the treatment of bipolar mania. Neuropsychiatric disease and treatment. 2006;2:127-138.
12657.	Sajatovic M, Sanders R, Alexeenko L, Madhusoodanan S. Primary prevention of psychiatric illness in special populations. Annals of clinical psychiatry. 2010;22:262-273.
12658.	Sakamoto A, Ogawa R, Suzuki H, Kimura M, Okubo Y, Fujiya T. Landiolol attenuates acute hemodynamic responses but does not reduce seizure duration during maintenance electroconvulsive therapy. Psychiatry and clinical neurosciences. 2004;58:630-635.
12659.	Sakinofsky I. Treating suicidality in depressive illness. Part 2: does treatment cure or cause suicidality?. [Review] [218 refs]. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2007;52:85S-101S.
12660.	Sakinofsky I. Treating suicidality in depressive illness. Part 2: does treatment cure or cause suicidality? Canadian journal of psychiatry. 2007;Revue cana:85S-101S.
12661.	Sakolsky D, Birmaher B. Pediatric Anxiety Disorders: Management in Primary Care. Current opinion in pediatrics. 2008;20:538-543.
12662.	Sala M, Coppa F, Cappucciati C, et al. Antidepressants: Their effects on cardiac channels, QT prolongation and Torsade de Pointes. Current opinion in investigational drugs (London, England : 2000). 2006;7:256-263.
12663.	Sala M, Lazzaretti M, G DV, et al. Electrophysiological changes of cardiac function during antidepressant treatment. Therapeutic advances in cardiovascular disease. 2009;3:29-43.
12664.	Salbach-Andrae H, Bohnekamp I, Pfeiffer E, Lehmkuhl U, AL M. Dialectical Behavior Therapy of Anorexia and Bulimia Nervosa Among Adolescents: A Case Series. Cognitive and behavioral practice. 2008;15:415-425.
12665.	Salehi B. Comparison of the effect on 8 weeks treatment with fluoxetine and imipramine on fasting blood sugar of major depressive patient. European psychiatry. 2009;Conference:S509.
12666.	Salehi B, FG S. Comparison of the effect of fluoxetine and imipramine on fasting blood sugar of patients with major depressive disorders, four and eight weeks after treatment. [Arabic]. Scientific Journal of Kurdistan University of Medical Sciences. 2009;14:45-51.
12667.	Salehi I, SM H, Haghighi M, et al. Electroconvulsive therapy and aerobic exercise training increased BDNF and ameliorated depressive symptoms in patients suffering from treatment-resistant major depressive disorder. Journal of psychiatric research. 2014;57:117-124.
12668.	Saletu B, Anderer P, GM S-Z. Eeg Topography and Tomography (Loreta) in Diagnosis and Pharmacotherapy of Depression. Clinical EEG & Neuroscience: Official Journal of the EEG & Clinical Neuroscience Society (ENCS). 2010;41:203-210.
12669.	Saletu B, Anderer P, GM S-Z, RD P-M. EEG topography and tomography in diagnosis and treatment of mental disorders: Evidence for a key-lock principle. Methods and findings in experimental and clinical pharmacology. 2002;24:97-106.
12670.	Saletu B, Anderer P, GM S-Z, RD P-M. EEG mapping and low-resolution brain electromagnetic tomography (LORETA) in diagnosis and therapy of psychiatric disorders: Evidence for a key-lock principle. Clinical EEG and neuroscience. 2005;36:108-115.
12671.	Saletu B, Grunberger J, Anderer P, Linzmayer L, Zyhlarz G. Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and - inhibiting fluvoxamine utilizing EEG mapping and psychometry. Journal of neural transmission. General section. 1996;103:191-216.
12672.	Salloway S, Correia S, Boyle P, et al. MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. Journal of the neurological sciences. 2002;203-204:227-233.
12673.	Salloway S, PA B, Correia S, et al. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. American journal of geriatric psychiatry. 2002;10:107-111.
12674.	Salmon J. Evaluation of an acupuncture service in oncology. Journal of radiotherapy in practice. 2013;12:39-55.
12675.	Salvador C-E, A SC, Ignacio L, Ricardo M-J. Quality of life in 833 outpatients with major depression treated with open-label venlafaxine extended release: An observational 24-week study. International journal of psychiatry in clinical practice. 2003;7:193-197.
12676.	Salvadore G, JA Q, Machado-Vieira R, ID H, HK M, CA ZJ. The neurobiology of the switch process in bipolar disorder: A review. Journal of clinical psychiatry. 2010;71:1488-1501.
12677.	Salvi R, Loborinas E, Sun W. Pharmacological Treatments for Tinnitus: New and Old. Drugs of the future. 2009;34:381-400.
12678.	Salvi V, Fagiolini A, HA S, Maina G, Frank E. The Use of Antidepressants in Bipolar Disorder. Journal of clinical psychiatry. 2008;69:1307-1318.
12679.	Salzman C. Monoamine oxidase inhibitors and atypical antidepressants. [Review] [64 refs]. Clinics in geriatric medicine. 1992;8:335-348.
12680.	Salzman C. Pharmacologic treatment of disturbed sleep in the elderly. Harvard review of psychiatry. 2008;16:271-278.
12681.	Salzman C, Jimerson D, Vasile R, Watsky E, Gerber J. Response of SSRI antidepressants correlates with reduction in plasma HVA: Pilot study. Biological psychiatry. 1993;34:569-571.
12682.	Salzman C, Wong E, BCody W. Drug and ECT treatment of depression in the elderly, 1996-2001: A literature review. Biological psychiatry. 2002;52:265-284.
12683.	Samain V. Psychostimulants: A therapeutic alternative in thymic and obsessive compulsive disorders (second part). [French]. Revue medicale de Bruxelles. 2004;25:29-39.
12684.	Samalin L, Guillaume S, Courtet P, Abbar M, Lancrenon S, P-M L. Methodological differences between pharmacological treatment guidelines for bipolar disorder: What to do for the clinicians? Comprehensive psychiatry. 2013;54:309-320.
12685.	Samborski W, Lezanska-Szpera M, JK R. Open Trial of Mirtazapine in Patients With Fibromyalgia. Pharmacopsychiatry. 2004;37:168-170.
12686.	Samborski W, Lezanska-Szpera M, K RJ. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry. 2004;37:168-170.
12687.	Sambunaris A, Bose A, Gommoll C, et al. A phase iii, double-blind, placebo-controlled flexible-dose study of levomilnacipran sr in patients with major depressive disorder. Neuropsychopharmacology. 2012;Conference:S322-S323.
12688.	Sambunaris G, JK H, Pinder R, Panagides J, SM S. Development of New Antidepressants. Journal of clinical psychiatry. 1997;58:40-53.
12689.	Samuel S, Ricardo N. Melhora cognitiva com tratamento antidepressivo na fase aguda do acidente vascular cerebral. [Portuguese]. Arquivos de neuro-psiquiatria. 2006;64:412-417.
12690.	Samuelian JC, David H. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. Journal of psychopharmacology (Oxford, England). 1998;12:273-278.
12691.	San L, Arranz B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European psychiatry. 2008;23:396-402.
12692.	San L, Arranz B. Agomelatine: A new antidepressant approach for high-quality remission. [Spanish]. Revista de Psiquiatria y Salud Mental. 2010;3:15-20.
12693.	San L, Arranz B, Perez V, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry research. 2012;200:693-701.
12694.	Do glutamatergic agents represent a new class of antidepressant drugs? Part 2, Journal of clinical psychiatry(2009).
12695.	Sanacora G, CA Z, JH K, HK M. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature reviews. Drug discovery. 2008;7:426-437.
12696.	Sanacora G, RM B, Cappiello A, et al. Addition of the Alpha 2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology. 2004;29:1166-1171.
12697.	Sanada K, Mimura M, Noda Y, et al. Comparison of effect of paroxetine and milnacipran for outpatients with pain disorder. European neuropsychopharmacology. 2010;Conference:S543.
12698.	Sanchez C, EH R, SA M. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?. [Review]. International clinical psychopharmacology. 2014;29:185-196.
12699.	Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data, Pharmacology & therapeutics(2015).
12700.	Sanchez C, KP B, Ebert B, EH R, Braestrup C. Escitalopram Versus Citalopram: the Surprising Role of the R-Enantiomer. Psychopharmacology. 2004;174:163-176.
12701.	Sanchez C, KP B, Ebert B, EH R, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. [Review] [89 refs]. Psychopharmacology. 2004;174:163-176.
12702.	Sanchez MJ, Gomez CA, Mendez CFX. Psychological treatment of obsessive-compulsive disorder in Europe: A meta-analytic study. [Spanish]. Psicologia Conductual Revista Internacional de Psicologia Clinica de la Salud. 2003;11:213-237.
12703.	Sanchez-Borrego R, Mendoza N, Beltran E, et al. Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients. Maturitas. 2013;75:294-300.
12704.	Sanchez-Meca J, AI R-A, Iniesta-Sepulveda M, Rosa-Alcazar T. Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: a meta-analysis. [Review]. Journal of anxiety disorders. 2014;28:31-44.
12705.	Sanders S, C DM, Purdy S, Spinks A, Tait L, McAvoy B. Evidence in practice - Number 7: Can postpartum depression be prevented? British journal of general practice. 2005;55:398-399.
12706.	Sandor P, Baker B, Irvine J, Dorian P, McKessok D, Mendlowitz S. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients. Depression and anxiety. 1998;7:69-72.
12707.	Sandrini G, Ruiz L, Patruno G, Bussone G, AP V, Nappi G. Antalgic and antidepressant activities of fluoxetine in daily chronic headache. Cephalalgia. 1991;11:280-281.
12708.	Sandy H, Ashutosh D. Acceleration of onset of action in schedule-induced polydipsia: Combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacology, biochemistry, and behavior. 2004;77:69-75.
12709.	Quetiapine extended release: Adjunctive treatment in major depressive disorder, CNS drugs(2011).
12710.	Sanford M, GM K. Quetiapine: A review of its use in the management of bipolar depression. CNS drugs. 2012;26:435-460.
12711.	Sani G, GD K, Romano S, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence. CNS drugs. 2012;26:663-690.
12712.	Sanjay D, Anne DM, Marcia J, et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. Journal of psychiatric research. 2010;44:356-363.
12713.	Sanjay D, D TG, E TM, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar disorders. 2007;9:618-627.
12714.	Efficacy and Safety of Curcumin in Major Depressive Disorder: a Randomized Controlled Trial, Phytotherapy research : PTR(2014).
12715.	Santen G, Danhof M, O DP. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. Journal of psychiatric research. 2008;42:1189-1197.
12716.	Santen G, Danhof M, O DP. Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy. Journal of psychiatric research. 2009;43:1049-1056.
12717.	Santen G, E VZ, Danhof M, O DP. From Trial and Error to Trial Simulation. Part 1: the Importance of Model-Based Drug Development for Antidepressant Drugs. Clinical pharmacology and therapeutics. 2009;86:248-254.
12718.	Santone G, Bellantuono C. Maintenance pharmacotherapy for unipolar depression: Focus on efficacy. [Italian]. Giornale Italiano di Psicopatologia / Italian Journal of Psychopathology. 2009;15:401-414.
12719.	Santoro D, Malusa M, Pallanti S. Chronic depression: A concept to be revised. Minerva psichiatrica. 2012;53:289-303.
12720.	Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A. Development of Potent Dopamine-Norepinephrine Uptake Inhibitors (Dnris) Based on a (2s,4r,5r)-2-Benzhydryl-5-((4-Methoxybenzyl) Amino)Tetrahydro-2h-Pyran-4-Ol Molecular Template. Bioorganic & medicinal chemistry. 2015;23:821-828.
12721.	SAPSH P. The Use of Biomarkers in Psychiatric Research: How Serotonin Transporter Occupancy Explains the Dose-Response Curves of Ssris. Journal of psychiatric practice. 2012;18:38-45.
12722.	Sara B, Nilay H, Valeria M, M PC. Symptomatic treatment of interaction-alpha-induced depression in hepatitis C: A systematic review. Journal of clinical psychopharmacology. 2012;32:531-543.
12723.	Sara G, Agnese M, Alessandro S. Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. [Review]. International journal of neuropsychopharmacology. 2014;17:1-8.
12724.	Saraga M, Stiefel F. Psychiatry and the scientific fallacy. Acta psychiatrica Scandinavica. 2011;124:70-72.
12725.	Sarah H, Maria-Antonia Q-S. Implication of circadian rhythms and melatonin in major depressive disorder: The evidence base for new antidepressant treatment. Current psychiatry reviews. 2014;10:223-234.
12726.	Sargam J. "Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: A randomized, placebo-controlled trial": Comment. Journal of the American Psychoanalytic Association. 2014;62:113-115.
12727.	Sarkar S, Grover S. A systematic review and meta-analysis of trials of treatment of depression from India. Indian journal of psychiatry. 2014;56:29-38.
12728.	Sarko J. Antidepressants, Old and New - a Review of Their Adverse Effects and Toxicity in Overdose. Emergency medicine clinics of North America. 2000;18:637-+.
12729.	Sarris J. Herbal medicines in the treatment of psychiatric disorders: A systematic review. Phytotherapy research : PTR. 2007;21:703-716.
12730.	Sarris J. St. John's Wort for the Treatment of Psychiatric Disorders. Psychiatric clinics of North America. 2013;36:65-72.
12731.	Sarris J, DJ K, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. Journal of psychiatric research. 2010;44:32-41.
12732.	St John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: Continuation data from a 26-week RCT, Pharmacopsychiatry(2012).
12733.	St Johns Wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: Continuation data from a 26-week RCT, Pharmacopsychiatry(2012).
12734.	Sarris J, Laporte E, Schweitzer I. Kava: A comprehensive review of efficacy, safety, and psychopharmacology. Australian and New Zealand journal of psychiatry. 2011;45:27-35.
12735.	Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. European neuropsychopharmacology. 2011;21:841-860.
12736.	Sarris J, Schoendorfer N, DJ K. Major depressive disorder and nutritional medicine: A review of monotherapies and adjuvant treatments. Nutrition reviews. 2009;67:125-131.
12737.	SARSI R. Lithium and the Other Mood Stabilizers Effective in Bipolar Disorder Target the Rat Brain Arachidonic Acid Cascade. ACS chemical neuroscience. 2014;5:459-467.
12738.	Sarzi-Puttini P, LM A, Arsenault P, et al. A randomized controlled study of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication. Annals of the rheumatic diseases. 2014.
12739.	Sasaki T, Hashimoto K, Okawada K, et al. Ifenprodil for the treatment of flashbacks in adolescent female posttraumatic stress disorder patients with a history of abuse. Psychotherapy and psychosomatics. 2013;82:344-345.
12740.	Sassarini J, MA L. Non-hormonal management of vasomotor symptoms. Climacteric. 2013;16:31-36.
12741.	Sasse J, Pilhatsch M, Weikert B, Bauer M. The noradrenergic and dopaminergic antidepressant bupropion: Mechanism of action and clinical profile. [German]. Psychopharmakotherapie. 2008;15:110-114.
12742.	SASSM S. Mechanism of Action of Agomelatine: a Novel Antidepressant Exploiting Synergy Between Monoaminergic and Melatonergic Properties. CNS spectrums. 2014;19:207-212.
12743.	Sasson Y, Iancu I, Fux M, Taub M, PN D, Zohar J. A Double-Blind Crossover Comparison of Clomipramine and Desipramine in the Treatment of Panic Disorder. European neuropsychopharmacology. 1999;9:191-196.
12744.	Sato H, Skelin I, Diksic M. Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study. Brain research. 2010;1345:28-44.
12745.	Sato Y, Yasui-Furukori N, Nakagami T, Saito M, Kaneko S. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:416-418.
12746.	Satra T, Ngamthipwatthana T. Cost-effectiveness of antidepressant after 24 months of treatment based on discrete event simulation modeling (DESM): Ag omelatine versus matrix comparator of escitalopram, sertraline and venlafaxine in a thai setting. Value in health. 2013;Conference:A547.
12747.	Satzger U. Consideration of the Utterances of Patients Regarding Pain During Therapy Concept. Nervenheilkunde. 2008;27:958-959.
12748.	Satzger U. Physically painful symptoms in depression: Consider statements of patients about pain in the therapy concept. [German]. Nervenheilkunde. 2008;27:958-959.
12749.	Savitz J, AC N, Bogers W, et al. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication. NeuroImage. 2010;49:2966-2976.
12750.	Minocycline and aspirin in the treatment of bipolar depression: A protocol for a proof-of-concept, randomised, doubleblind, placebo-controlled, 232 clinical trial, BMJ Open(2012).
12751.	Savli M, Lanzenberger R, Hausler D, et al. Serotonin transporter occupancy in single and multiple dosing of S-citalopram. International journal of neuropsychopharmacology. 2010;Conference:180-181.
12752.	Savovic J. Neither Hypericum perforatum nor fluoxetine are more effective than placebo in short-term treatment of mild to moderate depression. Focus on Alternative and Complementary Therapies. 2005;10:286-287.
12753.	Sawamura T, Shimizu K, Nibuya M, et al. Effect of Paroxetine on a Model of Posttraumatic Stress Disorder in Rats. Neuroscience letters. 2004;357:37-40.
12754.	Sawamura T, Shimizu K, Nibuya M, et al. Effect of Paroxetine on a Model of Posttraumatic Stress Disorder in Rats. Neuroscience letters. 2004;357:37-40.
12755.	Saxena S, Sumner J. Venlafaxine Extended-Release Treatment of Hoarding Disorder. International clinical psychopharmacology. 2014;29:266-273.
12756.	Saxena S, Sumner J, Barrios B. Venlafaxine treatment of compulsive hoarding. Neuropsychopharmacology. 2011;Conference:S226.
12757.	Sayakhot P, HJ T, Gibson-Helm M, Vincent A. Differences in Clinician Understanding and Management of Early Menopause After Breast Cancer. Climacteric. 2013;16:479-489.
12758.	Sayegh R, Schiff I, Wurtman J, Spiers P, Mcdermott J, Wurtman R. The Effect of a Carbohydrate-Rich Beverage on Mood, Appetite, and Cognitive Function in Women With Premenstrual-Syndrome. Obstetrics and gynecology. 1995;86:520-528.
12759.	Saygm ES, Cengiz A, Semra A, Asli S, Selcuk K. [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. [Turkish]. Turk psikiyatri dergisi [Turkish journal of psychiatry]. 2005;16:153-163.
12760.	Saylan M, MJ T, Postema R, et al. Cost-effectiveness analysis of aripiprazole augmentation treatment of patients with major depressive disorder compared to olanzapine and quetiapine augmentation in Turkey: A microsimulation approach. Value in Health Regional Issues. 2013;2:171-180.
12761.	Sayyah M, Boostani H, Pakseresht S, Malayeri A. A Preliminary Randomized Double-Blind Clinical Trial on the Efficacy of Celecoxib as an Adjunct in the Treatment of Obsessive-Compulsive Disorder. Psychiatry research. 2011;189:403-406.
12762.	Sayyah M, Feizy F, Boostani H. A preliminary randomized double-blind clinical trial on efficacy of estrogen after hysterectomy in postmenopausal women with major depression disorder. Minerva psichiatrica. 2010;51:73-77.
12763.	SB G-R. Migraine prophylaxis. Clinics in Family Practice. 2005;7:445-462.
12764.	SB M. Medications as adjunct therapy for weight loss: Approved and off-label agents in use. Journal of the American Dietetic Association. 2005;105:948-959.
12765.	SB M, Pierce J, CC M, PO S. Can counseling prevent or treat postpartum depression? Journal of family practice. 2009;58:152-154.
12766.	SB M, YC JR. Issues in the pharmacological treatment of obsessive-compulsive disorder. International journal of clinical practice. 2007;61:1188-1197.
12767.	SB P. A framework for describing the impact of antidepressant medications on population health status. Pharmacoepidemiology and drug safety. 2002;11:549-559.
12768.	SB P. Treatment of neuropsychiatric syndromes in multiple sclerosis. Expert review of neurotherapeutics. 2005;5:413-420.
12769.	SB P. Diagnosing depression in MS in the face of overlapping symptoms. International MS Journal. 2010;17:3-5.
12770.	SB P, Barbui C. Drug-induced depression: A systematic review to inform clinical practice. Psychotherapy and psychosomatics. 2004;73:207-215.
12771.	SB S. Citalopram in the maintenance treatment of major depressive Disorder [1]. Journal of clinical psychiatry. 2001;62:993.
12772.	SB S, AH F, VM L, JA P, JD M, Fava M. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:1415-1419.
12773.	SB S, Farabaugh A, MW J, et al. Fluoxetine treatment of depressed patients with comorbid anxiety disorders. Journal of psychopharmacology (Oxford, England). 2002;16:215-219.
12774.	SB S, MK S, AR K, et al. Efficacy of Fluvoxamine in the Treatment of Major Depression With Comorbid Anxiety Disorders. Journal of clinical psychiatry. 1999;60:580-583.
12775.	SB W, EA OC, Eder M, EP W. Screening for child and adolescent depression in primary care settings: A systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2009;123:e716-e735.
12776.	SC C. Listening to fluoxetine: a hot message from the FLAME trial of poststroke motor recovery. International journal of stroke. 2011;6:315-316.
12777.	SC G, DA P, LF J. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. Journal of clinical psychopharmacology. 1988;8:311-322.
12778.	SC G, Yadav R, Pavuluri R, BJ M, DJ S, SM D. Essential role of GluD1 in dendritic spine development and GluN2B to GluN2A NMDAR subunit switch in the cortex and hippocampus reveals ability of GluN2B inhibition in correcting hyperconnectivity. Neuropharmacology. 2015;93:274-284.
12779.	SC K, EB B, CM M. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. American journal of obstetrics and gynecology. 2002;187:551-555.
12780.	SC L, AL P, PJ R, Sanchez C. Multimodal Antidepressant Vortioxetine Increases Frontal Cortical Oscillations Unlike Escitalopram and Duloxetine - a Quantitative Eeg Study in Rats. British journal of pharmacology. 2014;171:4255-4272.
12781.	SC L, JE J, NA C, JP W, SE L. Zolpidem increases GABA in depressed volunteers maintained on SSRIs. Psychiatry Research - Neuroimaging. 2014;224:28-33.
12782.	SC M, AN S, IA S, Arce E, MB S, MP P. Escitalopram Attenuates Posterior Cingulate Activity During Self-Evaluation in Healthy Volunteers. Psychiatry Research-Neuroimaging. 2010;182:81-87.
12783.	SC M, Hassan M, Olfson M. Antidepressant Switching Among Adherent Patients Treated for Depression. Psychiatric services (Washington, D.C.). 2009;60:617-623.
12784.	SC S, Bacaltchuk J, SL B, JC A. Antidepressants in short-term treatment of binge eating disorder: Systematic review and meta-analysis. Eating behaviors. 2008;9:129-136.
12785.	The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations, Journal of clinical psychiatry(2012).
12786.	SC S, HA P. Asenapine: A Clinical Review of a Second-Generation Antipsychotic. Clinical therapeutics. 2012;34:1023-1040.
12787.	SC S, JA H. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents - Practitioner Review. Clinical drug investigation. 2006;26:247-255.
12788.	SC S, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics journal. 2013;13:1-11.
12789.	SC S, KL C, SA B, JA J. Olanzapine Safety and Efficacy in Patients With Borderline Personality Disorder and Comorbid Dysthymia. Biological psychiatry. 1999;46:1429-1435.
12790.	SC S, LA N, JW L, PA M, RW S, MM D. Historical review of carbamazepine for the treatment of bipolar disorder. Pharmacotherapy. 2007;27:68-88.
12791.	SC S, MC Z, Bateman A, et al. Olanzapine for the Treatment of Borderline Personality Disorder: Variable Dose 12-Week Randomised Double-Blind Placebo-Controlled Study. British journal of psychiatry. 2008;193:485-492.
12792.	SC S, Moen R, Miller M, Long B, Romine A, Nelson K. Borderline personality disorder: A review of treatment approaches. Minerva psichiatrica. 2009;50:309-318.
12793.	SC S, SR W, GK B, et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychological medicine. 2013;43:945-960.
12794.	SC S, SR W, JF L, MH T, AJ R. Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report. Journal of affective disorders. 2015;174:157-164.
12795.	SC W. Depression--augmentation or switch after initial SSRI treatment. New England journal of medicine. 2006;354:2611-2613.
12796.	Scaccabarozzi L, ML T, RA F, PML S, ACM T. Economic evaluation of desvenlafaxine in the acute management of inpatients with major depressive disorder from a Brazilian public hospital perspective. Value in health. 2011;Conference:A193.
12797.	Scaccabarozzi L, ML T, RA F, PML S, ACM T. Economic evaluation of desvenlafaxine in the acute management of associated major depressive disorder in medically ill inpatients from a brazilian public general hospital perspective. Value in health. 2011;Conference:A193.
12798.	Scahill L, Erenberg G, CM BJ, et al. Contemporary Assessment and Pharmacotherapy of Tourette Syndrome. NeuroRx. 2006;3:192-206.
12799.	Scahill L, Hamrin V, ME P. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. [Review] [17 refs]. Journal of child and adolescent psychiatric nursing. 2005;18:86-89.
12800.	Scahill L, MA R, RA K, et al. Fluoxetine Has No Marked Effect on Tic Symptoms in Patients With Tourette's Syndrome: a Double-Blind Placebo-Controlled Study. Journal of child and adolescent psychopharmacology. 1997;7:75-85.
12801.	Scapicchio PL. Beyond remission. Prevention of recurrences in long-term treatment of depression. First data from the PREVENT study. [Italian]. Giornale Italiano di Psicopatologia / Italian Journal of Psychopathology. 2008;14:80-87.
12802.	Scazufca M, MCB CM. Review of the efficacy of psychotherapy vs. pharmacotherapy for depression treatment in old age. [Portuguese]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2002;24:64-69.
12803.	Schacht A, Gorwood P, Boyce P, Schaffer A, Picard H. Depression symptom clusters and their predictive value for treatment outcomes: Results from an individual patient data meta-analysis of duloxetine trials. Journal of psychiatric research. 2014;53:54-61.
12804.	Schaefer M, Berg T, Sarkar S, Neumann K. In response. Annals of internal medicine. 2013;158:140.
12805.	Schaefer M, Berg T, Sarkar S, Neumann K. Re: Escitalopram for the prevention of peginterferon-alpha2a- associated depression. Annals of internal medicine. 2013;158:140.
12806.	Schaefer M, MA E, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: A review. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:731-746.
12807.	Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.[Summary for patients in Ann Intern Med. 2012 Jul 17;157(2):I-40; PMID: 22801693, Annals of internal medicine(2012).
12808.	Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the Prevention of Peginterferon-Alpha 2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease a Randomized Trial. Annals of internal medicine. 2012;157:94-+.
12809.	Schaefer M, Sarkar R, Weich V, et al. Escitalopram for the prevention of peginterferon alpha-2aand ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial. Neurology Psychiatry and Brain Research. 2012;Conference:82-83.
12810.	Schaefer M, Sarkar R, Weich V, et al. Escitalopram for the prevention of PEG-IFN-alpha and ribavirin associated depression in HCV-infected patients: Final results from the cippad-trial. Journal of hepatology. 2010;Conference:S125.
12811.	Schaefer M, Schwaiger M, AS G, et al. Prevention of Interferon-Alpha Associated Depression in Psychiatric Risk Patients With Chronic Hepatitis C. Journal of hepatology. 2005;42:793-798.
12812.	Schaefer M, Schwaiger M, AS G, et al. Prevention of Interferon-Alpha Associated Depression in Psychiatric Risk Patients With Chronic Hepatitis C. Journal of hepatology. 2005;42:793-798.
12813.	Schafer I, Fischer M, Reimer J, Karow A, Haasen C. Significance of psychiatric comorbidity for the outcome of maintenance treatment - A review of the literature. Mental Health and Substance Use: Dual Diagnosis. 2011;4:62-71.
12814.	Schafer M, Schwaiger M. Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects. [German]. Fortschritte der Neurologie-Psychiatrie. 2003;71:469-476.
12815.	Schaffer A, Mamdani M, Levitt A, Hermann N. Effect of antidepressant use on admissions to hospitals among elderly bipolar patients. International journal of geriatric psychiatry. 2006;21:275-280.
12816.	Schaffer A, McIntosh D, BI G, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Annals of clinical psychiatry. 2012;24:6-22.
12817.	Schaper J. Treatment of depression in Germany: Psychotherapy or placebo therapy?. [German]. TW Neurologie Psychiatrie. 1994;8:11.
12818.	Schara U, Lochmuller H. Therapeutic Strategies in Congenital Myasthenic Syndromes. Neurotherapeutics. 2008;5:542-547.
12819.	Scharf M. Eszopiclone for the treatment of insomnia. Expert opinion on pharmacotherapy. 2006;7:345-356.
12820.	Schatzberg A. Psychiatric and Medical Comorbidity: Treatment Considerations in Special Patient Populations. European neuropsychopharmacology. 2004;14:S398-S399.
12821.	Schatzberg A. Psychiatric and Medical Comorbidity: Treatment Considerations in Special Patient Populations. European neuropsychopharmacology. 2004;14:S398-S399.
12822.	Schatzberg A, DeBattista C, Etkin A, Williams L. ABCB1 genetic variants and neurocognitive function predict antidepressant outcomes. Neuropsychopharmacology. 2014;Conference:S521-S522.
12823.	Schechter C, Gagliano S, Traversa G, et al. The use of placebo controls [1]. New England journal of medicine. 1995;332:60-62.
12824.	Schechter D, Endicott J, Nee J. Quality of Life of 'normal' Controls: Association With Lifetime History of Mental Illness. Psychiatry research. 2007;152:45-54.
12825.	Scheggi S, Pelliccia T, Ferrari A, MG DM, Gambarana C. Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats. Neuroscience. 2015;291:189-202.
12826.	Schertz M, Steinberg T. Seizures Induced by the Combination Treatment of Methylphenidate and Sertraline. Journal of child and adolescent psychopharmacology. 2008;18:301-303.
12827.	Schifano F. Pharmacological Strategies for Preventing Suicidal-Behavior. CNS drugs. 1994;1:16-25.
12828.	Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?, Journal of clinical psychopharmacology(2013).
12829.	Schindler B. Fibromyalgia syndrome: Do antidepressants help in fibromyalgia?. [German]. Psychopharmakotherapie. 2009;16:137-138.
12830.	Schins A, Hamulyak K, Scharpe S, et al. Whole Blood Serotonin and Platelet Activation in Depressed Post-Myocardial Infarction Patients. Life sciences. 2004;76:637-650.
12831.	Schirman S, Kronenberg S, Apter A, et al. Effectiveness and Tolerability of Citalopram for the Treatment of Depression and Anxiety Disorders in Children and Adolescents: an Open-Label Study. Journal of neural transmission. 2010;117:139-145.
12832.	Schloredt K, CK V. Current perspectives on the diagnosis and treatment of adolescent depression in the primary care setting. Journal of clinical outcomes management. 2005;12:260-274.
12833.	Schlosser N, OT W, Wingenfeld K. Cognitive correlates of hypothalamic-pituitary-adrenal axis in major depression. Expert review of endocrinology & metabolism. 2011;6:109-126.
12834.	Schmauss M, Erfurth A. Augmentation strategies in the treatment of refractory depression - A review. [German]. Fortschritte der Neurologie-Psychiatrie. 1996;64:390-402.
12835.	Schmauss M, Messer T. Pharmacological treatment strategies in severe depression: Advantages for dual or selective antidepressants?. [German]. Psychopharmakotherapie, Supplement. 2005;12:11-17.
12836.	Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: Pharmacology and clinical uses. Wiener medizinische Wochenschrift (1946). 2007;157:315-319.
12837.	Schmidt U, Harrer G, Biller A, Schmidt S. A long-term, change-over study with the St John's wort extract LoHyp-57. An observational study of 95 patients with mild and moderate depression. [German]. Nervenheilkunde. 1999;18:106-109.
12838.	Schmidt U, Harrer G, Kuhn U, Biller A. Equivalence comparison of the St John's wort extract LoHyp-57 versus fluoxetine HCL. [German]. Zeitschrift fur Phytotherapie. 1999;20:89-90.
12839.	Schmidt U, Jiwany A, Treasure J. A controlled study of alexithymia in eating disorders. Comprehensive psychiatry. 1993;34:54-58.
12840.	Schmitt A, DF B. Effective Treatment With Olanzapine of a Depressive Syndrome With Psychotic Symptoms. Deutsche medizinische Wochenschrift (1946). 2000;125:1526-1529.
12841.	Schmitt A, H-P V, Wiedemann K, Fritze J, P-A L. Therapy effects on working ability by venlafaxine compared to serotonin reuptake inhibitors in the treatment of major depressive disorder of different severity. [German]. Gesundheitsokonomie und Qualitatsmanagement. 2008;13:269-275.
12842.	Schmitt L, Arbus C, Tonnoir B. Safety and Efficacy of Oral Escitalopram as Continuation Treatment of Intravenous Citalopram, in Patients With Major Depressive Disorder - the Navigade Switch Study. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2006;32:270-277.
12843.	Schmitt L, Tonnoir B, Arbus C. Safety and Efficacy of Oral Escitalopram as Continuation Treatment of Intravenous Citalopram in Patients With Major Depressive Disorder. Neuropsychobiology. 2006;54:201-207.
12844.	Schneider C, Korsen N. Complementary and alternative medical approaches to treating depression in a family practice setting. Clinics in Family Practice. 2002;4:873-893.
12845.	Schneider T, Popik P. An animal model of premenstrual dysphoric disorder sensitive to antidepressants. Current Protocols in Neuroscience. 2009:9.31.31-39.31.10.
12846.	Schneiderman N, PG S, DJ C, et al. Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. Psychosomatic medicine. 2004;66:475-483.
12847.	Schnyder U, Koller-Leiser A. A Double-Blind, Multicentre Study of Paroxetine and Maprotiline in Major Depression. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1996;41:239-244.
12848.	Schoenecker B, Heller KE. Stimulation of serotonin (5-HT) activity reduces spontaneous stereotypies in female but not in male bank voles (Clethrionomys glareolus): Stereotyping female voles as a new animal model for human anxiety and mood disorders? [References]. Applied animal behaviour science. 2003;80:161-170.
12849.	Schofield I. UK regulator calls for 'absolute clarity' in safety reporting. Good Clinical Practice Journal. 2008;15:9-10.
12850.	Schollmann C. Phytopharmaceutics are better tolerated than synthetic drugs in depression. [German]. Arztliche Praxis Neurologie Psychiatrie. 2001:28-29.
12851.	Scholtissen B, FRJ V, JJ A, Weber W, AFG L. Challenging the Serotonergic System in Parkinson Disease Patients: Effects on Cognition, Mood, and Motor Performance. Clinical neuropharmacology. 2006;29:276-285.
12852.	Schon S, Nowak D. Pharmacological strategies for smoking cessation. [German]. Suchtmedizin in Forschung und Praxis. 2002;4:189-199.
12853.	Schone W, Ludwig M. [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine]. [German]. Fortschritte der Neurologie-Psychiatrie. 1994;62 Suppl 1:16-18.
12854.	Schone W, Ludwig M. Paratoxetine in the treatment of geriatric depressed patients - A double-blind comparison with fluoxetine. [German]. Fortschritte der Neurologie-Psychiatrie. 1994;62:16-18.
12855.	Schonfeldt-Lecuona C, Cardenas-Morales L, RW F, Kammer T, Herwig U. Transcranial magnetic stimulation in depression - Lessons from the multicentre trials. Restorative neurology and neuroscience. 2010;28:569-576.
12856.	Attentional Bias Modification in Posttraumatic Stress Disorder: a Randomized Controlled Trial, Psychotherapy and psychosomatics(2013).
12857.	Schopf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry. 1989;22:183-187.
12858.	Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: A randomized, controlled study in mild-moderate depression. International clinical psychopharmacology. 2000;15:61-68.
12859.	Schrag A. Psychiatric aspects of Parkinson's disease: An Update. Journal of neurology. 2004;251:795-804.
12860.	Schramm E, D VC, Dykierek P, et al. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: Acute and long-term results. American journal of psychiatry. 2007;164:768-777.
12861.	Schramm E, Schneider D, Zobel I, et al. Efficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients. Journal of affective disorders. 2008;109:65-73.
12862.	Schreiber S, Bleich A, CG P. Venlafaxine and mirtazapine: Different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects - A possible opioid involvement in severe depression? Journal of molecular neuroscience. 2002;18:143-149.
12863.	Schrijvers D, Hulstijn W, BGC S. Psychomotor symptoms in depression: A diagnostic, pathophysiological and therapeutic tool. Journal of affective disorders. 2008;109:1-20.
12864.	Schrijvers D, YJ M, BG S. Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study. Clinical therapeutics. 2009;31:123-129.
12865.	Schrijvers D, YJ M, Mpbi P, Madani Y, Hulstijn W, BGC S. Psychomotor Changes in Major Depressive Disorder During Sertraline Treatment. Neuropsychobiology. 2009;59:34-42.
12866.	Schroeder E, Gao Y, RJ R, RS E-M. Recognition and management of bipolar depression. Journal of clinical outcomes management. 2011;18:515-525.
12867.	Schruers K, Griez E. The Effects of Tianeptine or Paroxetine on 35% Co2 Provoked Panic in Panic Disorder. Journal of psychopharmacology (Oxford, England). 2004;18:553-558.
12868.	Schruers K, Griez E. The Effects of Tianeptine or Paroxetine on 35% Co2 Provoked Panic in Panic Disorder. Journal of psychopharmacology (Oxford, England). 2004;18:553-558.
12869.	Schubert H. The ECNP Congress 2003 in Prague: The newest study results clearly show a low risk of relapse during long-term treatment with duloxetine. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2003;4:35-36.
12870.	Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. Journal of neuroendocrinology. 2007;19:213-226.
12871.	Schule C, Baghai T, Bidlingmaier M, Strasburger C, Laakmann G. Endocrinological effects of mirtazapine in healthy volunteers. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:1253-1261.
12872.	Schule C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology. 2002;163:95-101.
12873.	Schule C, Eser D, TC B, Nothdurfter C, JS K, Rupprecht R. Neuroactive steroids in affective disorders: Target for novel antidepressant or anxiolytic drugs? Neuroscience. 2011;191:55-77.
12874.	Schule C, TC B, Alajbegovic L, et al. The Influence of 4-Week Treatment With Sertraline on the Combined T3/Trh Test in Depressed Patients. European archives of psychiatry and clinical neuroscience. 2005;255:334-340.
12875.	Schule C, TC B, Eser D, et al. Mirtazapine Monotherapy Versus Combination Therapy With Mirtazapine and Aripiprazole in Depressed Patients Without Psychotic Features: a 4-Week Open-Label Parallel-Group Study. World journal of biological psychiatry. 2007;8:112-122.
12876.	Schule C, TC B, Eser D, Nothdurfter C, Rupprecht R. Lithium but Not Carbamazepine Augments Antidepressant Efficacy of Mirtazapine in Unipolar Depression: an Open-Label Study. World journal of biological psychiatry. 2009;10:390-399.
12877.	Schule C, TC B, Eser D, Rupprecht R. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert review of neurotherapeutics. 2009;9:1005-1019.
12878.	Schule C, TC B, Eser D, et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology. 2006;186:601-611.
12879.	Schulte-Altedorneburg M, Bereczki D. Post-Stroke Depression. Orvosi hetilap. 2014;155:1335-1343.
12880.	Schulte-Herbruggen O, Ropke S. Escitalopram, problem-solving therapy, and poststroke depression [1]. JAMA - Journal of the American Medical Association. 2008;300:1757.
12881.	Schultz P, Pralong W, Dick P. Antidepressant therapy. [French]. Medecine et hygiene. 1983;41:917-926.
12882.	Schulz P, J-P M. The clinical pharmacology of depressive states. Dialogues in clinical neuroscience. 2002;4:47-56.
12883.	Schulz V. Herbal medicinal products: Luxury or basic therapy in the general practice?. [German]. Arztezeitschrift fur Naturheilverfahren. 2002;43:206-216.
12884.	Schulz V. Clinical study with hypericum extracts in depressive patients. Results, comparison, conclusions, for anti-depressive pharmacotherapy. [German]. Zeitschrift fur Phytotherapie. 2002;23:11-15.
12885.	Schulz V. Clinical trials with hypericum extracts in patients with depression--results, comparisons, conclusions for therapy with antidepressant drugs. [Review] [35 refs]. Phytomedicine. 2002;9:468-474.
12886.	Schulz V. New therapeutic studies and meta-analyses: St John's wort extracts versus synthetics. [German]. Pharmazie in unserer Zeit. 2003;32:228-234.
12887.	Schulz V. St John's wort in the treatment of moderate to severe depression. [German]. Zeitschrift fur Phytotherapie. 2005;26:127-128.
12888.	Schulz V. A study on the efficacy of the Hypericum extract LI 160 in 135 depressive patients in the USA. [German]. Zeitschrift fur Phytotherapie. 2006;27:124-125.
12889.	Schulz V. Single dose of St John's wort versus citalopram in patients with moderate depression. [German]. Zeitschrift fur Phytotherapie. 2008;29:131-132.
12890.	Schulz V. Cochrane report 2008 on Saint John's wort in depression: Effective and more tolerable than synthetic antidepressants. [German]. Zeitschrift fur Phytotherapie. 2008;29:286-287.
12891.	Schulz V. Single dose of 900 mg of hypericum extract STW3-VI in double blind study with 388 moderately severe depressive patients is equivalent to 20 mg citalopram and significantly better than placebo. [German]. KIM - Komplementare und Integrative Medizin, Artztezeitschrift fur Naturheilverfahren. 2009;50:71-72.
12892.	Schurks M, H-C D, Goadsby P. Update on the prophylaxis of migraine. Current treatment options in neurology. 2008;10:20-29.
12893.	Schuurmans J, Comijs H, PMG E, et al. A Randomized, Controlled Trial of the Effectiveness of Cognitive - Behavioral Therapy and Sertraline Versus a Waitlist Control Group for Anxiety Disorders in Older Adults. American journal of geriatric psychiatry. 2006;14:255-263.
12894.	Schuurmans J, Comijs H, PMG E, IJC W, M VDH, R VD. Long-Term Effectiveness and Prediction of Treatment Outcome in Cognitive Behavioral Therapy and Sertraline for Late-Life Anxiety Disorders. International Psychogeriatrics. 2009;21:1148-1159.
12895.	Schwarz B. Tricyclic antidepressant agents versus selective serotonin reuptake inhibitors. [German]. Pharmazeutische Zeitung. 1994;139:50-51.
12896.	Schweitzer I, Morris P, Hopwood M, Maguire K, Norman T. Prolactin Response to D-Fenfluramine in Combat-Related Post-Traumatic Stress Disorder. International journal of neuropsychopharmacology. 2004;7:291-298.
12897.	Schweitzer I, Morris P, Hopwood M, Maguire K, Norman T. Prolactin Response to D-Fenfluramine in Combat-Related Post-Traumatic Stress Disorder. International journal of neuropsychopharmacology. 2004;7:291-298.
12898.	Schweizer E, Rickels K. Placebo response in generalized anxiety: Its effect on the outcome of clinical trials. Journal of clinical psychiatry. 1997;58:30-38.
12899.	Schweizer E, RJ T, Frazer A. Venlafaxine: A novel antidepressant compound. Expert opinion on investigational drugs. 1997;6:65-78.
12900.	Schweizer E, Rynn M, LA M, Demartinis N, Garcia-Espana F, Rickels K. The Antidepressant Effect of Sertraline Is Not Enhanced by Dose Titration: Results From an Outpatient Clinical Trial. International clinical psychopharmacology. 2001;16:137-143.
12901.	Schweizer E, Rynn M, Mandos LA, DeMartinis N, Garcia-Espana F, Rickels K. The antidepressant effect of sertaline is not enhanced by dose titration: Results from an outpatient clinical trial. International clinical psychopharmacology. 2001;16:137-143.
12902.	Schwenger E, Dumontet J, MHH E. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clinical pharmacokinetics. 2011;50:415-428.
12903.	Schwiersch M. Psychological support in pulmonary rehabilitation. [German]. Atemwegs- und Lungenkrankheiten. 2004;30:450-455.
12904.	Sch�le C, TC B, Michele F, et al. Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. Psychoneuroendocrinology. 2007;32:669-680.
12905.	SCM R, Tandon R, Grunhaus L, JF G. The DST as a predictor of outcome in depression: A meta-analysis. American journal of psychiatry. 1993;150:1618-1629.
12906.	Scoppetta M, G DG, Scoppetta C. Selective serotonine reuptake inhibitors prevents emotional lability in healthy subjects. European review for medical and pharmacological sciences. 2005;9:343-348.
12907.	Scoriels L, PB J, BJ S. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology. 2013;64:168-184.
12908.	Scott J, Colom F, Popova E, et al. Long-term mental health resource utilization and cost of care following group psychoeducation or unstructured group support for bipolar disorders: A cost-benefit analysis. Journal of clinical psychiatry. 2009;70:378-386.
12909.	Scott T. Tricks of the trade. Ethical human psychology and psychiatry. 2006;8:133-146.
12910.	Scuteri A, Modestino A, Fedullo F, AP A, Gianni W. Depression Treatment Selectively Modifies Arterial Stiffness in Older Participants. Journals of gerontology. Series A, Biological sciences and medical sciences. 2013;68:719-725.
12911.	Scuteri A, Modestino A, Fedullo F, AP A, Gianni W. Depression treatment selectively modifies arterial stiffness in older participants. The journals of gerontology. 2013;Series A, :719-725.
12912.	SD B. Psychological issues in end-of-life care. Journal of palliative medicine. 2006;9:751-772.
12913.	SD B, HM T, MA H, SM S, KM C, JRT D. Tolerability of fluoxetine in posttraumatic stress disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:363-367.
12914.	SD C, Suarez L, Sylvester C. Assessment and treatment of anxiety disorders in children and adolescents. [Review]. Current psychiatry reports. 2011;13:99-110.
12915.	SD G-W, CW L. Zinc in the central nervous system: From molecules to behavior. BioFactors (Oxford, England). 2012;38:186-193.
12916.	SD H. Improving clinical outcomes over the continuum of a patient's care. Drug Benefit Trends. 2003;15:32-40.
12917.	SD H, DA H, SJC D, et al. Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology. 2010;208:223-232.
12918.	SD H, RB J, AA N, ME T, Trivedi M, AJ R. Psychotherapy and medication in the treatment of adult and geriatric depression: Which monotherapy or combined treatment? Journal of clinical psychiatry. 2005;66:455-468.
12919.	SD H, RJ D, RC S, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of general psychiatry. 2005;62:417-422.
12920.	SD K, GN D, SS K, Saoji A, Palasodkar R. Oxidative damage and major depression: The potential antioxidant action of selective serotonin-re-uptake inhibitors. Redox report. 2003;8:365-370.
12921.	SD K, GNJ T, GEE B. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study. Clinical gastroenterology and hepatology. 2003;1:219-228.
12922.	SD M, Martin E, SS R, MA R, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Archives of general psychiatry. 2001;58:641-648.
12923.	SD O, Bech P, MH T, SR W, AJ R, Fava M. Brief, Unidimensional Melancholia Rating Scales Are Highly Sensitive to the Effect of Citalopram and May Have Biological Validity: Implications for the Research Domain Criteria (Rdoc). Journal of affective disorders. 2014;163:18-24.
12924.	SD O, BS M, AJ F, et al. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. Journal of affective disorders. 2014;160:68-73.
12925.	Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account, Journal of affective disorders(2014).
12926.	SD O, SOW J, Bech P. The heterogeneity of the depressive syndrome: When numbers get serious. Acta psychiatrica Scandinavica. 2011;124:495-496.
12927.	Sexual function in nondepressed women using escitalopram for vasomotor symptoms: A randomized controlled trial, Obstetrics and gynecology(2012).
12928.	SD S. Preventive Migraine Treatment. Neurologic clinics. 2009;27:429-443.
12929.	SD T. SSRIs and sexual dysfunction. Drug Benefit Trends. 2000;12:3BH+7BH-12BH+15BH.
12930.	SD T. Identification and treatment of antidepressant tachyphylaxis. Innovations in clinical neuroscience. 2014;11:24-28.
12931.	SD V, Arean P, Unutzer J. Advantages of Using Estimated Depression-Free Days for Evaluating Treatment Efficacy. Psychiatric services (Washington, D.C.). 2010;61:160-163.
12932.	SD W, MK M, JA G, et al. Comparison of Symptom Management Strategies for Pain, Erectile Dysfunction, and Depression in Patients Receiving Chronic Hemodialysis: a Cluster Randomized Effectiveness Trial. Clinical journal of the American Society of Nephrology. 2013;8:90-99.
12933.	SE A, CH A, Dean J, et al. International Society for Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation. Journal of sexual medicine. 2010;7:2947-2969.
12934.	SE B. Use of SSRIs in children. Journal of family practice. 1998;46:118.
12935.	SE B, AJ R. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. Journal of clinical psychiatry. 1998;59:279-288.
12936.	SE D, MA F. Duloxetine: a Dual Reuptake Inhibitor. Annals of pharmacotherapy. 2004;38:2078-2085.
12937.	SE D, MA F. Duloxetine: a dual reuptake inhibitor. [Review] [20 refs]. Annals of pharmacotherapy. 2004;38:2078-2085.
12938.	SE F, CO C. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Annals of pharmacotherapy. 2004;38:1482-1499.
12939.	Economic inequalities in the effectiveness of a primary care intervention for depression and suicidal ideation, Epidemiology (Cambridge, Mass.)(2013).
12940.	SE H. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. American Journal Geriatric Pharmacotherapy. 2009;7:34-59.
12941.	SE H, JE M, GR C, MB S, SN M. Newer generation antidepressants for depressive disorders in children and adolescents. [Review][Update of Cochrane Database Syst Rev. 2007;(3):CD004851; PMID: 17636776]. Cochrane database of systematic reviews (Online). 2012;11:CD004851.
12942.	SE H, JE M, GR C, MB S, SN M. Newer Generation Antidepressants for Depressive Disorders in Children and Adolescents. Cochrane database of systematic reviews (Online). 2012.
12943.	SE H, JE M, SN M. The Use of Ssris in Children and Adolescents. Current opinion in psychiatry. 2010;23:53-57.
12944.	SE H, Merry S, McKenzie J, Sindahl P, Proctor M. Selective Serotonin Reuptake Inhibitors (Ssris) for Depressive Disorders in Children and Adolescents. Cochrane database of systematic reviews (Online). 2007.
12945.	SE H, Thompson A, Yuen K, Finch S, AG P. Is There a Gap Between Recommended and 'real World' Practice in the Management of Depression in Young People? A Medical File Audit of Practice. BMC health services research. 2012;12.
12946.	SE K, RA K, EA Y, J-K Z. Dysregulation of Endogenous Opioid Emotion Regulation Circuitry in Major Depression in Women. Archives of general psychiatry. 2006;63:1199-1208.
12947.	SE L, EB C, Hill K. A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder. Journal of clinical psychopharmacology. 2007;27:677-681.
12948.	SE L, GE H-J. The impact of prescribed psychotropics on youth. Clinical practice and epidemiology in mental health. 2007.
12949.	SE L, PR J, RT M, JM M. Social adjustment in depression: The impact of depression severity, personality, and clinic versus community sampling. Journal of affective disorders. 2002;70:143-154.
12950.	SE M, AF C, DS C, RB M, RS M. The mechanism, efficacy, and tolerability profile of agomelatine. Expert opinion on pharmacotherapy. 2014;15:259-274.
12951.	SE M, Bech P, Bjerrum H, et al. Plasma ratio tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. Journal of affective disorders. 1990;18:59-66.
12952.	SE M-B. St. John's wort: Clinical status in psychiatry. CNS spectrums. 2001;6:835-840.
12953.	Cognitive effects of treatment of depression with repetitive transcranial magnetic stimulation, Cognitive and behavioral neurology(2014).
12954.	SE N, CB N. Ziprasidone in the treatment of mania in bipolar disorder. Neuropsychiatric disease and treatment. 2007;3:823-834.
12955.	SE N, JP C, DE W, TA S. Comorbid pain, depression, and anxiety: Multifaceted pathology allows for multifaceted treatment. Harvard review of psychiatry. 2009;17:407-420.
12956.	SE S, Brockman S, BD H. Psychiatric syndromes in Parkinson's disease. Current opinion in psychiatry. 2012;25:468-472.
12957.	SE S, Hezel D, AC S. Assessment and medication management of paediatric obsessive-compulsive disorder. Drugs. 2012;72:881-893.
12958.	SE S, JT K. Depression in children and adolescents. American family physician. 2000;62:2297-2308.
12959.	SE S, Lischinsky A. Diagnosis, phenomenology and treatment of poststroke depression. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2002;24:44-49.
12960.	SE S, MA J, NJ K. Severe Obsessive-Compulsive Disorder With and Without Comorbid Hair Pulling: Comparisons and Clinical Implications. Journal of clinical psychiatry. 2005;66:864-869.
12961.	SE S, MA J, NJ K. Severe Obsessive-Compulsive Disorder With and Without Comorbid Hair Pulling: Comparisons and Clinical Implications. Journal of clinical psychiatry. 2005;66:864-869.
12962.	SE S, Mizrahi R. Depression in Alzheimer's disease. [Review] [49 refs]. Expert review of neurotherapeutics. 2006;6:887-895.
12963.	SE S, Mizrahi R, BD P. Antidepressant therapy in post-stroke depression. [Review] [59 refs]. Expert opinion on pharmacotherapy. 2008;9:1291-1298.
12964.	SE S, Mizrahi R, BD P. Antidepressant Therapy in a Post-Stroke Depression. Expert opinion on pharmacotherapy. 2008;9:1291-1298.
12965.	SE W, JM W. Recent advances in the discovery of selective and non-selective 5-HT 1D receptor ligands. Current topics in medicinal chemistry. 2010;10:479-492.
12966.	SE W, JP B. Should treatment for depression be based more on patient preference? Patient preference and adherence. 2013;7:1047-1057.
12967.	Sebastian S, R PA, H SD, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: A propensity score-adjusted analysis of 9 years' data. Archives of general psychiatry. 2010;67:497-506.
12968.	Sechter D, Troy S, Paternetti S, Boyer P. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. European Psychiatry: the Journal of the Association of European Psychiatrists. 1999;14:41-48.
12969.	Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A. A Comparative Study of Milnacipran and Paroxetine in Outpatients With Major Depression. Journal of affective disorders. 2004;83:233-236.
12970.	Sedgwick P. Placebo run in periods. BMJ (Online). 7860.
12971.	Seedat S. Antidepressants and suicide in children and adolescents: A storm in a teacup? South African Journal of Psychiatry. 2004;10:52-53.
12972.	Seedat S. Controversies in the use of antidepressants in children and adolescents: A decade since the storm and where do we stand now? Journal of Child and Adolescent Mental Health. 2014;26:iii-v.
12973.	Seedat S, DJ S. Inositol Augmentation of Serotonin Reuptake Inhibitors in Treatment-Refractory Obsessive - Compulsive Disorder: an Open Trial. International clinical psychopharmacology. 1999;14:353-356.
12974.	Seedat S, DJ S, PD C. Post-traumatic stress disorder in women: Epidemiological and treatment issues. CNS drugs. 2005;19:411-427.
12975.	Seedat S, DJ S, RA E. Open Trial of Citalopram in Adults With Post-Traumatic Stress Disorder. International journal of neuropsychopharmacology. 2000;3:135-140.
12976.	Seedat S, E vRvO, JE M, Mohr N, DJ S. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. International clinical psychopharmacology. 2003;18:279-284.
12977.	Seedat S, Haskis A, DJ S. Benefits of Consumer Psychoeducation: a Pilot Program in South Africa. International journal of psychiatry in medicine. 2008;38:31-42.
12978.	Seelinger G, Mannel M. Antidepressants for juveniles: What about St. John's Wort?. [German]. Zeitschrift fur Phytotherapie. 2007;28:162-168.
12979.	Seelinger G, Mannel M. Drug treatment in juvenile depression - Is St. John's wort a safe and effective alternative? Child and adolescent mental health. 2007;12:143-149.
12980.	Seemuller F, Forsthoff A, Dittmann S, et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert opinion on drug safety. 2005;4:849-868.
12981.	Seemuller F, Riedel M, Obermeier M, et al. Outcomes of 1014 Naturalistically Treated Inpatients With Major Depressive Episode. European neuropsychopharmacology. 2010;20:346-355.
12982.	Seemuller F, Riedel M, Obermeier M, et al. The Controversial Link Between Antidepressants and Suicidality Risks in Adults: Data From a Naturalistic Study on a Large Sample of in-Patients With a Major Depressive Episode. International journal of neuropsychopharmacology. 2009;12:181-189.
12983.	Seetal D, Michael B, Katarina K, Michele M, Alexander S. Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder. Journal of affective disorders. 2013;150:344-349.
12984.	Seethalakshmi R, ES K. Depression in epilepsy: Phenomenology, diagnosis and management. Epileptic disorders. 2007;9:1-10.
12985.	Segrave R, PJ N. Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Human psychopharmacology. 2005;20:163-174.
12986.	Segrave R, RJ C, Illic S, KL P, PJ N. Pindolol Does Not Augment Central Serotonin Function Increases to Citalopram in Humans: an Auditory Evoked Potential Investigation. Pharmacology, biochemistry, and behavior. 2006;85:82-90.
12987.	Segui J, Lopez-Munoz F, Alamo C, Camarasa X, Garcia-Garcia P, Pardo A. Effects of Adjunctive Reboxetine in Patients With Duloxetine-Resistant Depression: a 12-Week Prospective Study. Journal of psychopharmacology (Oxford, England). 2010;24:1201-1207.
12988.	Seidel L, JT W. Selective Serotonin Reuptake Inhibitor Use in the Treatment of the Pediatric Non-Obsessive-Compulsive Disorder Anxiety Disorders. Journal of child and adolescent psychopharmacology. 2006;16:171-179.
12989.	Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane database of systematic reviews (Online). 2008.
12990.	Seif-Eddeine H, Y-T N. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. Expert review of neurotherapeutics. 2012;12:385-393.
12991.	Seiko M, Akiko N, Kunihiro I, et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on the equilibrium function in healthy subjects: A double-blind crossover trial. International journal of psychiatry in clinical practice. 2014;18:32-36.
12992.	Selcuk K, Mecit C. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophrenia research. 1998;33:103-112.
12993.	Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: Meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47:43-52.
12994.	Selvaraj S, Mouchlianitis E, Arnone D, Cowen P, Howes O, Roiser J. Cortical serotonin change and amygdala reactivity to aversive emotion processing in humans: An intravenous citalopram and combined 5-HT1A [11C]CUMI-101 PET and fMRI study. Neuropsychopharmacology. 2014;Conference:S223-S224.
12995.	Selvaraj V, Veeravalli S, Ramaswamy S, Balon R, VK Y. Depression, suicidality and antidepressants: A coincidence. Indian journal of psychiatry. 2010;52:17-20.
12996.	Sen S, Duman R, Sanacora G. Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications. Biological psychiatry. 2008;64:527-532.
12997.	Sen S, Sanacora G. Major depression: Emerging therapeutics. Mount Sinai Journal of Medicine. 2008;75:204-225.
12998.	Sennef C, Timmer CJ, Sitsen JMA. Mirtazapine in combination with amitriptyline: A drug-drug interaction study in healthy subjects. Human Psychopharmacology: Clinical and Experimental. 2003;18:91-101.
12999.	Sensky T. The utility of systematic reviews: The case of psychological debriefing after trauma. Psychotherapy and psychosomatics. 2003;72:171-175.
13000.	Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial, Neuropsychopharmacology(2012).
13001.	Sepede G, Martinotti G, Gambi F, RM S, M DG. Lamotrigine augmentation in premenstrual dysphoric disorder: A case report. Clinical neuropharmacology. 2013;36:31-33.
13002.	Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease. Movement disorders. 2011;26:S42-S80.
13003.	Septien-Velez L, Pitrosky B, SK P, JM G, KA T. A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in the Treatment of Major Depressive Disorder. International clinical psychopharmacology. 2007;22:338-347.
13004.	Serafini G, Pompili M. Antidepressants in unipolar and bipolar depression and increased suicidal risk: Is there scientific evidence? European psychiatry. 2011.
13005.	Serafini G, Pompili M, A DC, et al. Duloxetine Versus Venlafaxine in the Treatment of Unipolar and Bipolar Depression. Clinica terapeutica. 2010;161:321-327.
13006.	Serata D, GD K, Rapinesi C, et al. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Human psychopharmacology. 2015;30:70-84.
13007.	Seripa D, GH P, D'Onofrio G, et al. Cytochrome P450 (Cyp) gene polymorphisms and response to escitalopram treatment in elderly patients with late-onset depression. European geriatric medicine. 2013;Conference:S43.
13008.	Serra E. Duloxetine and Pregabalin: Safe and Effective for the Long-Term Treatment of Fibromyalgia? Nature clinical practice. Neurology. 2008;4:594-595.
13009.	Serrano-Blanco A, Pinto-Meza A, MT P, et al. Selective Serotonin Reuptake Inhibitors: Are There Differences in Effectiveness in Primary Care? Primary care & community psychiatry. 2006;11:113-120.
13010.	Serrano-Blanco A, Suarez D, Pinto-Meza A, MT P, JM H, Gava) DDeAPd. Fluoxetine and imipramine: Are there differences in cost-utility for depression in primary care? [References]. Journal of evaluation in clinical practice. 2009;15:195-203.
13011.	Serrano-Duenas M. [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease]. [Spanish]. Revista de neurologia. 2002;35:1010-1014.
13012.	Serretti A. Choosing the adequate SSRI: Efficacy and tolerability are enough? International journal of neuropsychopharmacology. 2010;Conference:250-251.
13013.	Serretti A, Artioli P, Zanardi R, et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology. 2004;174:504-511.
13014.	Serretti A, Artioli P, Zanardi R, Rossini D. Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2003;27:751-757.
13015.	Serretti A, Benedetti F, Zanardi R, Smeraldi E. The Influence of Serotonin Transporter Promoter Polymorphism (Sertpr) and Other Polymorphisms of the Serotonin Pathway on the Efficacy of Antidepressant Treatments. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:1074-1084.
13016.	Serretti A, Benedetti F, Zanardi R, Smeraldi E. The Influence of Serotonin Transporter Promoter Polymorphism (Sertpr) and Other Polymorphisms of the Serotonin Pathway on the Efficacy of Antidepressant Treatments. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:1074-1084.
13017.	Serretti A, Calati R, Goracci A, M DS, Castrogiovanni P, D DR. Antidepressants in Healthy Subjects: What Are the Psychotropic/Psychological Effects? European neuropsychopharmacology. 2010;20:433-453.
13018.	Serretti A, Chiesa A. Treatment-Emergent Sexual Dysfunction Related to Antidepressants a Meta-Analysis. Journal of clinical psychopharmacology. 2009;29:259-266.
13019.	Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, D DR. Novel Antidepressants and Panic Disorder: Evidence Beyond Current Guidelines. Neuropsychobiology. 2011;63:1-7.
13020.	Serretti A, Cusin C, Benedetti F, et al. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. American Journal of Medical Genetics - Neuropsychiatric Genetics. 2005;137 B:36-39.
13021.	Serretti A, Cusin C, Benedetti F, et al. Insomnia Improvement During Antidepressant Treatment and Clock Gene Polymorphism. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2005;137B:36-39.
13022.	Serretti A, Cusin C, Benedetti F, et al. Insomnia Improvement During Antidepressant Treatment and Clock Gene Polymorphism. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2005;137B:36-39.
13023.	Serretti A, Cusin C, JL R, Bondy B, Smeraldi E. Pooling Pharmacogenetic Studies on the Serotonin Transporter: a Mega-Analysis. Psychiatry research. 2006;145:61-65.
13024.	Serretti A, Kato M. The serotonin transporter gene and effectiveness of SSRIs. Expert review of neurotherapeutics. 2008;8:111-120.
13025.	Serretti A, Kato M, D DR, Kinoshita T. Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-Httlpr) Association With Selective Serotonin Reuptake Inhibitor Efficacy in Depressed Patients. Molecular psychiatry. 2007;12:247-257.
13026.	Serretti A, Mandelli L. Antidepressants and Body Weight: a Comprehensive Review and Meta-Analysis. Journal of clinical psychiatry. 2010;71:1259-1272.
13027.	Serretti A, MC J, Casadei G, Ravizza L, Smeraldi E, Akiskal H. Delineating psychopathologic clusters within dysthymia: A study of 512 out-patients without major depression. Journal of affective disorders. 1999;56:17-25.
13028.	Serretti A, Olgiati P. Biochemistry of depressive disorders. Role of serotonin, amino acid neurotransmitters, substance P and neurosteroids. Clinical Neuropsychiatry. 2008;5:225-239.
13029.	Serretti A, Olgiati P, Bajo E, Bigelli M, D DR. A Model to Incorporate Genetic Testing (5-Httlpr) in Pharmacological Treatment of Major Depressive Disorders. World journal of biological psychiatry. 2011;12:501-515.
13030.	Serretti A, Zanardi R, Galbusera E, et al. Genetics of the response to antidepressants in mood disorders. [Italian]. Giornale Italiano di Psicopatologia. 2001;7:244-258.
13031.	Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular psychiatry. 2001;6:586-592.
13032.	Serruya G, Grant P. Cognitive-behavioral therapy of delusions: Mental imagery within a goal-directed framework. Journal of clinical psychology. 2009;65:791-802.
13033.	Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Movement disorders. 2008;23:S521-S533.
13034.	Severino G, Squassina A, Costa M, et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013;14:655-674.
13035.	Severus E, MJ T, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders. 2014.
13036.	Seyam R. A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men. Therapeutic advances in urology. 2013;5:254-297.
13037.	Seyed-Hesameddin A, Fahimeh H, Amirhossein M, Mandana A, Shahin A. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. Journal of affective disorders. 2012;141:308-314.
13038.	SF A, Long Q, EB R, et al. Sequential Multiple-Assignment Randomized Trial Design of Neurobehavioral Treatment for Patients With Metastatic Malignant Melanoma Undergoing High-Dose Interferon-Alpha Therapy. Clinical trials (London, England). 2009;6:480-490.
13039.	SF G, JM R, LR M, Kopans B, RC K, DG J. Treatment for depression following the 1996 National Depression Screening Day. American journal of psychiatry. 2000;157:1867-1869.
13040.	SF G, SE B, Lawson K, KT B. Substance Abuse in Women. Psychiatric clinics of North America. 2010;33:339-355.
13041.	SF K. Living with bipolar disorder. Expert review of neurotherapeutics. 2004;4:S9-S15.
13042.	SF K, JH K, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert opinion on therapeutic targets. 2005;9:153-168.
13043.	SF N, Turner A, Dean O, Sureda A, SM N. Post-stroke Depression Therapy: Where are we now? Current neurovascular research. 2014;11:279-289.
13044.	SF P, JA N. Sex and the mature woman. Journal of women's health. 1998;7:849-859.
13045.	SG B, CB N. Emerging antidepressants to treat major depressive disorder. Asian journal of psychiatry. 2014;12:7-16.
13046.	Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: A meta-analysis of 11 double-blind, placebo-controlled clinical trials, Primary care companion to the Journal of clinical psychiatry(2011).
13047.	SG B, Desaiah D, Zhang Q, ME T, DGS P. Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: A review with expert commentary. Drugs in Context. 2013.
13048.	SG B, Ellingrod V, PJ P. Reassessment of nefazodone [3]. American journal of health-system pharmacy. 1996;53:2339-2343.
13049.	SG K. Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study. [Review] [20 refs]. Expert review of neurotherapeutics. 2008;8:737-742.
13050.	SG K, CJ G-P, RS F. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: A pooled analysis of seven randomized, placebo-controlled studies. Human psychopharmacology. 2014;29:492-501.
13051.	SG K, Clayton A, WH B, CJ G-P. Post Hoc Analysis of the Efficacy and Safety of Desvenlafaxine 50 Mg/Day in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. Menopause-the Journal of the North American Menopause Society. 2014;21:799-806.
13052.	SG K, Culpepper L. Biopsychosocial contributors to depression during the menopausal transition. Primary psychiatry. 2007;14:55-64.
13053.	SG K, Fava M, Jiang Q, KA T. Analysis of Depressive Symptoms in Patients With Major Depressive Disorder Treated With Desvenlafaxine or Placebo. Psychopharmacology bulletin. 2009;42:21-35.
13054.	SG K, JH K, Ahmed S, et al. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. International clinical psychopharmacology. 2008;23:357-363.
13055.	SG K, KC S. Antidepressant treatment of premenstrual syndrome and premenstrual dysphoric disorder. Primary psychiatry. 2004;11:53-57.
13056.	SG K, RS M, ME T, Boucher M. Desvenlafaxine for the Treatment of Major Depressive Disorder. Expert opinion on pharmacotherapy. 2014;15:1449-1463.
13057.	SG K, Toups M, AJ R, SR W, ME T, Luther J. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Journal of women's health. 2013;22:121-131.
13058.	SG R. Current Progress in the Pharmacological Therapy of Fibromyalgia. Expert opinion on investigational drugs. 2009;18:1479-1493.
13059.	SG R, RM B. Pharmacological therapies in fibromylagia. Best Practice and Research: Clinical Rheumatology. 2003;17:611-627.
13060.	SG R, RM B. Pharmacological therapies in fibromyalgia. Best Practice and Research: Clinical Rheumatology. 2003;17:611-627.
13061.	SG S, Clarke D. Melatonin and sleep disorders associated with intellectual disability: A clinical review. Journal of intellectual disability research. 2007;51:2-13.
13062.	SG S, Morgan C, Clarke D. Pharmacological management of inappropriate sexual behaviours: A review of its evidence, rationale and scope in relation to men with intellectual disabilities. Journal of intellectual disability research. 2008;52:1078-1090.
13063.	SH A, Behpournia H, Ghoreshi A, et al. The Effect of Mirtazapine Add on Therapy to Risperidone in the Treatment of Schizophrenia: a Double-Blind Randomized Placebo-Controlled Trial. Schizophrenia research. 2010;116:101-106.
13064.	SH A, Hosseinzadeh H. Bioactivity assessment and toxicity of crocin: A comprehensive review. Food and chemical toxicology. 2014;64:65-80.
13065.	SH A, Zaheeruddin. Early experience with fluoxetine. JPMA - Journal of the Pakistan Medical Association. 1991;41:275-277.
13066.	SH F, Chuang R, JM B. Serotonin and Parkinson's disease: On movement, mood, and madness. Movement disorders. 2009;24:1255-1266.
13067.	SH H, Espahbodi F, SM MG. Citalopram Versus Psychological Training for Depression and Anxiety Symptoms in Hemodialysis Patients. Iranian journal of kidney diseases. 2012;6:446-451.
13068.	SH H, SS W, MM Z, et al. Repetitive Transcranial Magnetic Stimulation-Induced Seizure of a Patient With Adolescent-Onset Depression: a Case Report and Literature Review. Journal of international medical research. 2011;39:2039-2044.
13069.	SH J, DI K, M-S C. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: Systematic review. BMC complementary and alternative medicine. 2014.
13070.	SH K. More complete and sustained remission:The key to success in depression. European psychiatry.
13071.	SH K. Current Treatment Options: Relief of Symptoms and Ultimate Recovery. International journal of psychiatry in clinical practice. 2006;10:22-26.
13072.	SH K. Agomelatine: An antidepressant with a novel mechanism of action. Future neurology. 2007;2:145-151.
13073.	SH K. Efficacy of agomelatine from treatment initiation to treatment completion. European neuropsychopharmacology. 2008;Conference:S293.
13074.	SH K. Agomelatine antidepressant: Advantages over sertraline and venlafaxine in "clinical effectiveness". European neuropsychopharmacology. 2009;Conference:S419-S420.
13075.	SH K. The earlier the improvement of symptoms, the better the outcome of depression. International journal of neuropsychopharmacology. 2010;Conference:248.
13076.	SH K. Improving the clinical effectiveness of antidepressant treatment. Journal of affective disorders. 2011;132:S1-S2.
13077.	SH K. A review of antidepressant therapy in primary care: Current practices and future directions. Primary care companion to the Journal of clinical psychiatry. 2013.
13078.	SH K, Avedisova A, Gimenez-Montesinos N, Belaidi C, C DB. A Placebo-Controlled Study of Three Agomelatine Dose Regimens (10 Mg, 25 Mg, 25-50 Mg) in Patients With Major Depressive Disorder. European neuropsychopharmacology. 2014;24:553-563.
13079.	SH K, BS E. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatric disease and treatment. 2007;3:423-428.
13080.	SH K, BS E, JH M, RM B. Antidepressants in Clinical Practice: Limitations of Assessment Methods and Drug Response. Human Psychopharmacology-Clinical and Experimental. 2001;16:105-114.
13081.	SH K, BS E, SE D, JR B, RM B. Antidepressant-Induced Sexual Dysfunction During Treatment With Moclobemide, Paroxetine, Sertraline, and Venlafaxine. Journal of clinical psychiatry. 2000;61:276-281.
13082.	SH K, DS G, Ralevski E, Davis C, JD DS, Lofchy J. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. Journal of clinical psychopharmacology. 1993;13:415-422.
13083.	SH K, Emsley R. Placebo-Controlled Trial of Agomelatine in the Treatment of Major Depressive Disorder. European neuropsychopharmacology. 2006;16:93-100.
13084.	SH K, Guilleminault C. Antidepressant Efficacy of Agomelatine 25-50 Mg Versus Venlafaxine 75-150 Mg: Two Randomized, Double Blind Studies. European neuropsychopharmacology. 2006;16:S319-S320.
13085.	SH K, KR E, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. American journal of psychiatry. 2001;158:899-905.
13086.	SH K, M-R L, K-C L, et al. Use of antidepressants in patients with breast cancer taking tamoxifen. Journal of breast cancer. 2010;13:325-336.
13087.	SH K, PE G. Advances in Diagnosis and Treatment of Anorexia-Nervosa and Bulimia-Nervosa. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1992;37:309-315.
13088.	SH K, Ralevski E, Davis C, Neitzert C. The Effects of Moclobemide on Sexual Desire and Function in Healthy Volunteers. European neuropsychopharmacology. 1996;6:177-181.
13089.	SH K, Rizvi S. Sexual Dysfunction, Depression, and the Impact of Antidepressants. Journal of clinical psychopharmacology. 2009;29:157-164.
13090.	SH K, RW L. Enhancing outcomes in the management of treatment resistant depression: A focus on atypical antipsychotics. Bipolar Disorders, Supplement. 2003;5:36-47.
13091.	SH K, RW L, NL C, et al. Medications and other biological treatments. Canadian Journal of Psychiatry. 2001;46:38S-58S.
13092.	SH K, SJ R. Emerging drugs for major depressive disorder. Expert opinion on emerging drugs. 2009;14:439-453.
13093.	SH K, SJ R, Fulton K, Ellis J, LC Q, Ravindran L. The Sex Effects Scale: Pilot Validation in a Healthy Population. Psychopharmacology bulletin. 2010;43:15-25.
13094.	SH K, SM M, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Journal of clinical psychiatry. 2002;63:181-186.
13095.	SH K, ZV S, NL C, RD L, Gemar M, RM B. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: An exploratory trial. Journal of clinical psychiatry. 2003;64:439-444.
13096.	SH L, BL L. Migraine treatment throughout the lifecycle. Expert review of neurotherapeutics. 2005;5:343-353.
13097.	SH L, JY C, PC L, et al. Validity and Reliability of the Chinese Version of the Sheehan Disability Scale (Sds-C). Asia-Pacific Psychiatry. 2015;7:215-222.
13098.	SH L, MS L, JH L, et al. MRP1 polymorphisms associated with citalopram response in patients with major depression. Journal of clinical psychopharmacology. 2010;30:116-125.
13099.	SH L, SC A, YJ L, TK C, KH Y, SY S. Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder. Journal of psychosomatic research. 2007;62:189-195.
13100.	SH M, SS Q, Huang Y, et al. Improvement in Quality of Life in Depressed Patients Following Verum Acupuncture or Electroacupuncture Plus Paroxetine a Randomized Controlled Study of 157 Cases. Neural Regeneration Research. 2012;7:2123-2129.
13101.	SH P. Introduction: Update on antidepressant therapy. Journal of clinical psychiatry. 1994;55:3-5.
13102.	SH P. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. [Review] [143 refs]. Clinical pharmacokinetics. 1997;32 Suppl 1:1-21.
13103.	SH P. Milnacipran: A Dual Norepinephrine and Serotonin Reuptake Pump Inhibitor. Journal of psychiatric practice. 2004;10:119-126.
13104.	SH P. Reboxetine: A Norepinephrine Selective Reuptake Pump Inhibitor. Journal of psychiatric practice. 2004;10:57-63.
13105.	SH P. Flat dose-response curves for efficacy: what do they mean to the clinician? Journal of psychiatric practice. 2008;14:232-236.
13106.	SH P. How and why study designs affect the nature and validity of study results: Appearance versus true knowledge. part i. Journal of psychiatric practice. 2009;15:306-310.
13107.	SH P. Understanding outliers on the usual dose-response curve: Venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. Journal of psychiatric practice. 2010;16:46-49.
13108.	SH P. Psychopharmacology what do the terms "drug-specific response/remission rate" and "placebo" really mean? Journal of psychiatric practice. 2011;17:420-424.
13109.	SH P. The use of bmarkers in pychiatric rsearch: How srotonin tansporter ocupancy eplains the de-response crves of SSRIs. Journal of psychiatric practice. 2012;18:38-45.
13110.	SH P. Psychopharmacology: Declining differences in response rates with antidepressants versus placebo: A modest proposal for another contributing cause. Journal of psychiatric practice. 2013;19:227-233.
13111.	SH P, AY K. Rational use of multiple medications in medicine and psychiatry: A dimensional perspective. Journal of psychiatric practice. 2013;19:54-61.
13112.	SH P, Flockhart D. 2010 guide to psychiatric drug interactions. Primary psychiatry. 2009;16:45-74.
13113.	SH P, GA F. Beyond Signs and Symptoms - the Case Against a Mixed Anxiety and Depression Category. Journal of clinical psychiatry. 1993;54:24-32.
13114.	SH P, Richelson E, JP F, LA C, SP R, MB K. Antidepressant drug selection: Criteria and options. Journal of clinical psychiatry. 1994;55:6-24.
13115.	Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial.[Erratum appears in BMC Psychiatry. 2009;9. doi: 10.1186/1471-244X-9-14 Note: Menkes, David B [added]; Thome, Johannes [added]], BMC psychiatry(2007).
13116.	SH R, Bedson E, Hughes D, et al. Folate Augmentation of Treatment-Evaluation for Depression (Folated): Protocol of a Randomised Controlled Trial. BMC psychiatry. 2007;7.
13117.	SH R, SH L, HJ L, et al. Association between norepinephrine transporter gene polymorphism and major depression. Neuropsychobiology. 2004;49:174-177.
13118.	SH S, LF G, Brosen K, Eshoj O, EF M. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42:135-144.
13119.	SH W, JF M, Y-F C, Moossazadeh F, SSC Y. Treatment of Premenstrual-Syndrome With Fluoxetine - a Double-Blind, Placebo-Controlled, Crossover Study. Obstetrics and gynecology. 1992;80:339-344.
13120.	SH W, JH T, GH W, XP W, Wang H. Comparison of the Addition of Siberian Ginseng (Acanthopanax Senticosus) Versus Fluoxetine to Lithium for the Treatment of Bipolar Disorder in Adolescents: a Randomized, Double-Blind Trial. Current therapeutic research, clinical and experimental. 2007;68:280-290.
13121.	SH W, ZJ Z, YJ G, GJ T, BA C. Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress. Behavioural brain research. 2008;189:9-16.
13122.	SH Z, Awang R, SA S, SW A-J. A cross-sectional observation of the factors associated with deliberate self-poisoning with acetaminophen: impact of gender differences and psychiatric intervention. Human psychopharmacology. 2010;25:500-508.
13123.	Sha Y. General situation of electro-acupuncture in treating depressive disorders: Comparing the effect with that of drug therapy. Chinese Journal of Clinical Rehabilitation. 2005;9:181-183.
13124.	Shah D, Agrawal S. Vasomotor symptoms: Viewpoint from the Indian subcontinent and management of a common menopausal problem. Seminars in reproductive medicine. 2010;28:388-395.
13125.	Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. American journal of medicine. 2012;125:381-393.
13126.	Shah H, Kadia S, Bawa R, Lippmann S. Management of depression induced by interferon hepatitis therapies. Primary care companion to the Journal of clinical psychiatry. 2013.
13127.	Shah M. Depression treatment update. Drug topics. 2011;155:42.
13128.	Shah S, Schoenbachler B, Streim J, Meeks S. Antidepressant Prescribing Patterns in the Nursing Home: Second-Generation Issues Revisited. Journal of the American Medical Directors Association. 2012;13:406.e413-406.e418.
13129.	Shahin A, Sara J, Firoozeh R, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depression and anxiety. 2009;26:607-611.
13130.	Shahsavand-Ananloo E, Berenji F, Sadeghniiat K, et al. Comparing Effects of Citalopram With Fluoxetine on Sleep Quality in Patients With Major Depressive Disorder. European review for medical and pharmacological sciences. 2013;17:1155-1161.
13131.	Shaila M, Pratibha R, Maria C, Lisa M. The Use of Paroxetine and Cognitive-Behavioral Therapy in Postpartum Depression and Anxiety: A Randomized Controlled Trial. Journal of clinical psychiatry. 2004;65:1236-1241.
13132.	Shailesh J, J CT, H TM, et al. A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:1204-1212.
13133.	Shalaby A, Kamal S. Effect of Escitalopram on GABA level and anti-oxidant markers in prefrontal cortex and nucleus accumbens of chronic mild stress-exposed albino rats. International journal of physiology, pathophysiology and pharmacology. 2009;1:154-161.
13134.	Shamsaei F, Rahimi A, MK Z. Efficacy of pharmacotherapy and cognitive therapy, alone and in combination in major depressive disorder. European psychiatry. 2009;Conference:S676.
13135.	Shamsaei F, Rahimi A, Zarabian MK, Sedehi M. Efficacy of pharmacotherapy and cognitive therapy, alone and in combination in major depressive disorder. Hong Kong Journal of Psychiatry. 2008;18:76-80.
13136.	Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break, Journal of the American Academy of Child and Adolescent Psychiatry(2011).
13137.	Shamsi A, Cichon D, Obey J, et al. Pharmacotherapy for late-life depression with psychotic features: A review of literature of randomized control trials. Current psychiatry reviews. 2010;6:219-222.
13138.	Shan-Shan Q, Yong H, Zhang-Jin Z, et al. A 6-Week Randomized Controlled Trial With 4-Week Follow-up of Acupuncture Combined With Paroxetine in Patients With Major Depressive, Disorder. Journal of psychiatric research. 2013;47:726-732.
13139.	Shanmugham B, Karp J, Drayer R, IIICF R, Alexopoulos G. Evidence-based pharmacologic interventions for geriatric depression. Psychiatric clinics of North America. 2005;28:821-835.
13140.	Shanti P, Sanjay K, Umesh A, et al. Escitalopram and mirtazapine for the treatment of depression in HIV patients: A randomzied controlled open label trial. ASEAN Journal of Psychiatry. 2013;14:31-39.
13141.	Shapira B, Nemets B, Trachtenberg A, RH B. Phenytoin as an Augmentation for Ssri Failures: a Small Controlled Study. Journal of affective disorders. 2006;96:123-126.
13142.	Sharan P, Saxena S. Treatment-resistant depression: clinical significance, concept and management. [Review] [152 refs]. National medical journal of India. 1998;11:69-79.
13143.	Shareh H, Gharraee B, MK A-V, Eftekhar M. Metacognitive Therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with Obsessive-Compulsive Disorder (OCD). Iranian Journal of Psychiatry and Behavioral Sciences. 2010;4:17-25.
13144.	Sharma A, JV B, Ribeiro L, et al. Suicidality scores during double-blind fluoxetine and desipramine treatment in Mexican Americans [9]. Journal of clinical psychopharmacology. 2007;27:99-102.
13145.	Sharma A, JV B, Ribeiro L, et al. Suicidality scores during double-blind fluoxetine and desipramine treatment in Mexican Americans. Journal of clinical psychopharmacology. 2007;27:99-101.
13146.	Sharma V. Pharmacotherapy of postpartum depression. Expert opinion on pharmacotherapy. 2002;3:1421-1431.
13147.	Sharma V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disorders, Supplement. 2003;5:48-52.
13148.	Sharma V, Khan M. Identification of Bipolar Disorder in Women With Postpartum Depression. Bipolar disorders. 2010;12:335-340.
13149.	Sharma V, Sommerdyk C. Are antidepressants effective in the treatment of postpartum depression? A systematic review. Primary care companion to the Journal of clinical psychiatry. 2013.
13150.	Shaw E, Kaczorowski J. Postpartum care - What's new? Current opinion in obstetrics & gynecology. 2007;19:561-567.
13151.	Shaw M, DW B. Internet addiction: Definition, assessment, epidemiology and clinical management. CNS drugs. 2008;22:353-365.
13152.	Sheehan D, GC D, DL F. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacology bulletin. 1992;28:139-144.
13153.	Sheehan D, GC D, DL F. The Effect of Paroxetine on Anxiety and Agitation Associated With Depression (Reprinted From Psychopharmacology Bulletin, Vol 28, Pg 139-143, 1992). Hospital formulary. 1993;28:31-35.
13154.	Shelton C, Entsuah R, SK P, PE V. Venlafaxine Xr Demonstrates Higher Rates of Sustained Remission Compared to Fluoxetine, Paroxetine or Placebo. International clinical psychopharmacology. 2005;20:233-238.
13155.	Sheng-Min W, Changsu H, Soo-Jung L, A PA, S MP, Chi-Un P. A review of current evidence for acetyl-l-carnitine in the treatment of depression. [Review]. Journal of psychiatric research. 2014;53:30-37.
13156.	Sher Y, Lolak S, JR M. The impact of depression in heart disease. Current psychiatry reports. 2010;12:255-264.
13157.	Sherafat-Kazemzadeh R, SZ Y, JA Y. Pharmacotherapy for childhood obesity: Present and future prospects. International journal of obesity. 2013;37:1-15.
13158.	Sherman S, Miller H, Nerurkar L, Schiff I. Research opportunities for reducing the burden of menopause-related symptoms. American journal of medicine. 2005;118:166S-171S.
13159.	Sherwood BE, Christina H, A KD, J CT. Escitalopram for severe asthma and major depressive disorder: A randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 2012;53:75-80.
13160.	Sherwood BE, Luis V, A KD, M LJD, J CT, John RA. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: A proof of concept study. Biological psychiatry. 2005;58:865-870.
13161.	Sherwood N, Hindmarch I. A comparison of five commonly prescribed antidepressants with particular reference to their behavioural toxicity. Human psychopharmacology. 1993;8:417-422.
13162.	Sherwood N, Hindmarch I. A Comparison of 5 Commonly Prescribed Antidepressants With Particular Reference to Their Behavioral Toxicity. Human Psychopharmacology-Clinical and Experimental. 1993;8:417-422.
13163.	Shi L-X, Li G, Yang Y. Sertraline combined with minocycline for the treatment of chronic prostatitis complicated with depression. [Chinese]. Chinese Mental Health Journal. 2006;20:476-478.
13164.	Shiber A, Reuveni H, Elhayany A, IZ B-Z. [Comparison between every-day and every-3-days fluoxetine in young, moderately depressed out-patients]. [Hebrew]. Harefuah. 1998;135:596-598,654.
13165.	Shiber A, Reuveni H, Elhayany A, IZ B-Z. Comparison between every-day and every-3-days fluoxetine in young, moderately depressed out-patients. [Hebrew]. Harefuah. 1998;135:596-598+654.
13166.	Shih-Jen T, A GY-T, Chen-Jee H, Ying-Jay L, W-Y YY, Tai-Jui C. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. Journal of affective disorders. 2009;113:183-187.
13167.	Shima J, Mehdi T-D, A KS, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Australian and New Zealand journal of psychiatry. 2008;42:192-198.
13168.	Shimoda K, Kimura M. Two Cases of Emotional Disorder After Middle Cerebral Artery Infarction Showing Distinct Responses to Antidepressant Treatment. Neuropsychiatric disease and treatment. 2014;10:965-970.
13169.	The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): Examination of feasibility and adherence during the pilot phase, Trials(2012).
13170.	The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase, Trials [Electronic Resource](2012).
13171.	Shimon T, M YM, Kenji M. Ethical issues of placebo-controlled studies in depression and a randomized withdrawal trial in Japan : Case study in the ethics of mental health research. Journal of nervous and mental disease. 2012;200:255-259.
13172.	Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial, Progress in neuro-psychopharmacology & biological psychiatry(2011).
13173.	Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. Associations between Baseline Plasma MHPG (3-methoxy-4-hydroxyphenylglycol) Levels and Clinical Responses with Respect to Milnacipran Versus Paroxetine Treatment. Journal of clinical psychopharmacology. 2004;24:11-17.
13174.	Shiozawa P, Cordeiro Q, Fregni F, AR B. Is sertraline plus transcranial direct current stimulation the future of effective depression treatment? Journal of Comparative Effectiveness Research. 2013;2:213-215.
13175.	Shirazi E, Alaghband-Rad J. An Open Trial of Citalopram in Children and Adolescents With Depression. Journal of child and adolescent psychopharmacology. 2005;15:233-239.
13176.	Shirazi E, Alaghband-Rad J. An Open Trial of Citalopram in Children and Adolescents With Depression. Journal of child and adolescent psychopharmacology. 2005;15:233-239.
13177.	Shlik J, Maron E, Toru I, Aluoja A, Vasar V. Citalopram Challenge in Social Anxiety Disorder. International journal of neuropsychopharmacology. 2004;7:177-182.
13178.	Shlik J, Maron E, Toru I, Aluoja A, Vasar V. Citalopram Challenge in Social Anxiety Disorder. International journal of neuropsychopharmacology. 2004;7:177-182.
13179.	Shoenfeld N, Rosenberg O, Kotler M, PN D. Tricotillomania: Pathopsychology theories and treatment possibilities. Israel Medical Association journal. 2012;14:125-129.
13180.	Shopsin B. Second generation antidepressants. Journal of clinical psychiatry. 1980;41:45-56.
13181.	Shoptaw S, Huber A, Peck J, et al. Randomized, Placebo-Controlled Trial of Sertraline and Contingency Management for the Treatment of Methamphetamine Dependence. Drug and alcohol dependence. 2006;85:12-18.
13182.	Shorter E, Tyrer P. Separation of anxiety and depressive disorders: Blind alley in psychopharmacology and classification of disease. British medical journal. 2003;327:158-160.
13183.	Shoshana B, Deborah H, Christopher N, Shelley W. Noteworthy Briefs From the Field. Primary psychiatry. 2005;12:14-16.
13184.	Shoval G, Nahshoni E, Gothelf D, et al. Effectiveness and Safety of Citalopram in Hospitalized Adolescents With Major Depression: a Preliminary, 8-Week, Fixed-Dose, Open-Label, Prospective Study. Clinical neuropharmacology. 2011;34:182-185.
13185.	Shrestha S. PET imaging of serotoninergic system in monkeys: Effects of maternal separation, and chronic fluoxetine treatment during development. International journal of neuropsychopharmacology. 2012;Conference:218.
13186.	Shrestha S, J-S L, Gladding R, et al. PET imaging of serotonin transporter in monkeys: Effects of maternal separation, and long-term fluoxetine treatment during adolescence. Journal of cerebral blood flow and metabolism. 2012;Conference:S32.
13187.	Shu L, Sulaiman AH, Huang YS, Soon LCF, Strijckmans CV, Kim YS. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50 mg or fluoxetine 20-40 mg in Asian out-patients with major depressive disorder. Asian journal of psychiatry. 2014;8:26-32.
13188.	Shufflebotham J, Hood S, Hendry J, et al. Acute Tryptophan Depletion Alters Gastrointestinal and Anxiety Symptoms in Irritable Bowel Syndrome. American journal of gastroenterology. 2006;101:2582-2587.
13189.	Shuken B, Takeshi I, Hiroshi H, Shigehiro M, Shin N, Tsukasa K. Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: An open study. Human Psychopharmacology: Clinical and Experimental. 2011;26:237-241.
13190.	Shults J, JD A. Response to Eppel letter. American journal of psychiatry. 2010;167:1408-1409.
13191.	A comparison of several approaches for choosing between working correlation structures in generalized estimating equation analysis of longitudinal binary data, Statistics in medicine(2009).
13192.	Shultz E, DA M. A Practical Approach to Prescribing Antidepressants. Cleveland Clinic journal of medicine. 2013;80:625-631.
13193.	Shuster J. Citalopram for post-stroke pathological crying. Psychosomatics. 1994;35:100.
13194.	SI B, Tourkodimitris S, Ruth A. Evaluation of Functional Health and Well-Being in Patients Receiving Levomilnacipran Er for the Treatment of Major Depressive Disorder. Journal of affective disorders. 2015;170:230-236.
13195.	SI F. Efficacy and Tolerability of Antidepressant Therapy in the Old-Old. Journal of clinical psychiatry. 1996;57:23-28.
13196.	SI F. Depression in the very old differences in presentation and approach to treatment: A case example. Geriatrics. 2003;58:48-52.
13197.	SI F, EM R, CM C, Batzar E. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. American journal of geriatric psychiatry. 1999;7:221-227.
13198.	SI F, JE M, Dysken M, KRR K, Burt T, Mcrae T. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Sertraline in the Treatment of the Behavioral Manifestations of Alzheimer's Disease in Outpatients Treated With Donepezil. International journal of geriatric psychiatry. 2004;19:9-18.
13199.	SI F, JE M, Dysken M, KRR K, Burt T, Mcrae T. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Sertraline in the Treatment of the Behavioral Manifestations of Alzheimer's Disease in Outpatients Treated With Donepezil. International journal of geriatric psychiatry. 2004;19:9-18.
13200.	SI H, Haider I. Comparative trial of selective serotonin reuptake inhibitors in depression. Pakistan Journal of Medical Sciences. 2001;17:237-239.
13201.	Siamouli M, Magiria S, Panagiotidis P, et al. Advances in the treatment of geriatric depression. Aging health. 2007;3:495-507.
13202.	Siddiqi K, Siddiqi N. Treatment of common mental disorders in primary care in low- and middle-income countries. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101:957-958.
13203.	Sidney K. Flibanserin: Initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. Journal of sexual medicine. 2010;7:3449-3459.
13204.	Sidney Z, H TM, Diane W, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study. Journal of affective disorders. 2009;117:63-73.
13205.	Sidney Z, Joanna P, J GK, Paul S, Hampton AJ, Igor G. Treatment of major depression of HIV-seropositive men. Journal of clinical psychiatry. 1998;59:217-224.
13206.	Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: An exploratory report form the combining medications to enhance depression outcomes study, Journal of clinical psychiatry(2011).
13207.	Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: A randomized controlled trial, Journal of clinical psychiatry(2010).
13208.	Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial, Journal of clinical psychiatry(2009).
13209.	Sie M. Mood stabilisers in the management of bipolar disorder. Progress in neurology and psychiatry. 2009;13:33-41.
13210.	Sie M. Mood stabilisers in the management of bipolar affective disorder. Progress in neurology and psychiatry. 2014;18:22-32.
13211.	Siegfried K. Recent developments in the treatment of Panic Disorder (PD) and Generalized Anxiety Disorder (GAD). European psychiatry.
13212.	Siegfried K. Treatment benefits of reboxetine. International journal of psychiatry in clinical practice. 1999;3:S3-S8.
13213.	Siegfried K. Unique mechanism of action for escitalopram: Does it hold the promise? [References]. International journal of psychiatry in clinical practice. 2004;8:15-18.
13214.	Siegfried K, A MS, Hans-Jurgen M, et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. The World Journal of Biological Psychiatry. 2010;11:36-44.
13215.	Siegfried K, Bjarke E, Klaus L, Brigitte T. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. International journal of neuropsychopharmacology. 2012;15:715-725.
13216.	Siegfried K, Christian S, Patrice V, Jules A. Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis. International clinical psychopharmacology. 2006;21:105-110.
13217.	Siegfried K, Goran H. The efficacy of agomelatine in previously-treated depressed patients. European neuropsychopharmacology. 2013;23:814-821.
13218.	Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline, Journal of clinical psychiatry(2010).
13219.	Siegfried K, Hans dS, Friis AH. Escitalopram in the Treatment of Depressed Elderly Patients. The American Journal of Geriatric Psychiatry. 2005;13:884-891.
13220.	Siegfried K, Markus D, Hermes K, H VA, Hans-Jurgen M. Plasma concentrations of fluvoxamine and maprotiline in major depression: Implications on therapeutic efficacy and side effects. European neuropsychopharmacology. 1993;3:13-21.
13221.	Siegfried K, Markus G, Hans-Juergen M, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: A reanalysis of data from controlled clinical trials in acute major depression. International clinical psychopharmacology. 2010;25:204-213.
13222.	Siegfried K, Michael LO, Hans dS. Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology. 2006;54:152-159.
13223.	Siegfried K, S BD, Larsson LS, Jean-Philippe B. Superiority of escitalopram to paroxetine in the treatment of depression. European neuropsychopharmacology. 2009;19:229-237.
13224.	D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial, Journal of psychiatric research(2011).
13225.	Sieron A, RT H, Sobis J, Cieslar G. [Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression]. [Polish]. Psychiatria polska. 2004;38:217-225.
13226.	Sierra M. Depersonalization disorder: Pharmacological approaches. Expert review of neurotherapeutics. 2008;8:19-26.
13227.	Sigyn Z, Jan S, Kajsa-Mia H. The Effects of Sertraline on Severe Tinnitus Suffering - a Randomized, Double-Blind, Placebo-Controlled Study. Journal of clinical psychopharmacology. 2006;26:32-39.
13228.	SIJ S, Hjgm VM, JF VV, KRJ S, HGM W. Paroxetine Augmentation in Patients With Generalised Social Anxiety Disorder, Non-Responsive to Mirtazapine or Placebo. Human Psychopharmacology-Clinical and Experimental. 2011;26:72-76.
13229.	Sikander A, SV R, KK P. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clinica Chimica Acta. 2009;403:47-55.
13230.	Silva N, Atlantis E, Ismail K. A review of the association between depression and insulin resistance: Pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes? Current psychiatry reports. 2012;14:8-14.
13231.	Silver B, Greenbaum A, McCarthy S. Improvement in sleep apnea associated with closure of a patent foramen ovale. Journal of clinical sleep medicine. 2007;3:295-296.
13232.	Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS drug reviews. 2001;7:283-304.
13233.	Silver H, Aharon N, Hausfater N, Jahjah N. The Effect of Augmentation With Moclobemide on Symptoms of Schizophrenia. International clinical psychopharmacology. 1999;14:193-195.
13234.	Silver H, Aharon N, Kaplan A. Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms. Schizophrenia bulletin. 2003;29:541-546.
13235.	Silver H, Shmugliakov N. Augmentation With Fluvoxamine but Not Maprotiline Improves Negative Symptoms in Treated Schizophrenia: Evidence for a Specific Serotonergic Effect From a Double-Blind Study. Journal of clinical psychopharmacology. 1998;18:208-211.
13236.	Silverstone PH, Richard E, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: Comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. International clinical psychopharmacology. 2002;17:273-280.
13237.	Silvio B, Giulio B, Filippo B, Giuseppe M, Sara V, Luigi R. An open-label, randomized, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly. Current therapeutic research, clinical and experimental. 1997;58:798-808.
13238.	Silvio B, Monica Z, Camilla R, Filippo B. Le traitement combine de la depression majeure chez des patients souffrant du trouble de la personnalite limite: Une comparaison avec la pharmacotherapie. [French]. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2006;51:453-460.
13239.	Silvio B, Monica Z, Camilla R, Filippo B. Combined therapy of major depression with concomitant borderline personality disorder: Comparison of interpersonal and cognitive psychotherapy. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2007;52:718-725.
13240.	SIM T, DA D. Treatment of functional GI disorders with psychotropic medicines: A review of evidence with a practical approach. Gastroenterology & hepatology. 2006;2:678-688.
13241.	Simeon D, DJ S, Gross S, Islam N, Schmeidler J, Hollander E. A Double-Blind Trial of Fluoxetine in Pathologic Skin Picking. Journal of clinical psychiatry. 1997;58:341-347.
13242.	Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine Therapy in Depersonalisation Disorder: Randomised Controlled Trial. British journal of psychiatry. 2004;185:31-36.
13243.	Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine Therapy in Depersonalisation Disorder: Randomised Controlled Trial. British journal of psychiatry. 2004;185:31-36.
13244.	Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. Journal of clinical psychopharmacology. 2005;25:267-270.
13245.	Simeon J, MK N, Milin R, Jovanovic R, Walker S. Open-Label Pilot Study of St. John's Wort in Adolescent Depression. Journal of child and adolescent psychopharmacology. 2005;15:293-301.
13246.	Simeon J, MK N, Milin R, Jovanovic R, Walker S. Open-Label Pilot Study of St. John's Wort in Adolescent Depression. Journal of child and adolescent psychopharmacology. 2005;15:293-301.
13247.	Simis S, Nitrini R. Cognitive Improvement After Treatment of Depressive Symptoms in the Acute Phase of Stroke. Arquivos de neuro-psiquiatria. 2006;64:412-417.
13248.	Simon G. Review: Paroxetine and placebo do not differ for treatment discontinuation in major depression: Commentary. Evidence-based medicine. 2008;13:110.
13249.	Simon N, Pollack M. Current status and future prospects for anxiolytic drug therapy. Primary Care Psychiatry. 1998;4:157-167.
13250.	Simone K, Jack D, J DI, Frans dJ, Barteld P. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harvard review of psychiatry. 2003;11:133-141.
13251.	Simonsen A, Scheel-Kruger J, Jensen M, et al. Serotoninergic Effects on Judgments and Social Learning of Trustworthiness. Psychopharmacology. 2014;231:2759-2769.
13252.	Simpson B. Hot flash pharmacotherapy in breast cancer survivors: A literature review. Canadian pharmaceutical journal. 2004;137:36-45.
13253.	Simpson K, Noble S. Fluoxetine - a Review of Its Use in Women's Health. CNS drugs. 2000;14:301-328.
13254.	Simuni T, KE L, Pahwa R, et al. Treatment of early Parkinson's disease: Part 2. European neurology. 2009;61:206-215.
13255.	Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Annals of neurology. 2008;64:S65-S80.
13256.	Sindhi A, Leroi I. Nonpharmacological therapies for cognitive enhancement in Parkinson's disease: Applying old interventions in a new setting? Neurodegenerative disease management. 2013;3:539-547.
13257.	Singer A, Schmidt M, Hauke W, Stade K. Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: A reanalysis of data from a controlled clinical trial. Phytomedicine. 2011;18:739-742.
13258.	Singer B, AP R, Tobias K. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. International journal of clinical practice. 2011;65:887-895.
13259.	Singh A, Bousman C, Ng C, Byron K, Berk M. Effects of child abuse and norepinephrine transporter polymorphisms on antidepressant symptom reduction and remission in depression. Australian and New Zealand journal of psychiatry. 2013;Conference:68.
13260.	Singh A, DK D, ME K. Mecamylamine: Targacept. IDrugs : the investigational drugs journal. 2006;9:205-217.
13261.	Singh A, Ng C, Byron K, Berk M, Osborne C. Child abuse and depression severity more than genotype predictive of antidepressant response. European neuropsychopharmacology. 2011;Conference:S362.
13262.	Singh A, Ng C, Byron K, Berk M, Osborne C, Dean B. Child abuse and depression severity not genotype predictive of response to antide-pressants. Australian and New Zealand journal of psychiatry. 2011;Conference:A52-A53.
13263.	Singh G, Sputova K, Hecht E. The use of mirtazapine as add-on therapy in the treatment of schizophrenia. Schizophrenia research. 2014;Conference:S278.
13264.	Singh J, Chen G, CM C. Antipsychotics in the treatment of bipolar disorder. Current Antipsychotics. 2012;Handbook o:187-212.
13265.	Singh M, TL S. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatric disease and treatment. 2012;8:123-130.
13266.	Singh V, DJ M, JR C. Anticonvulsants in bipolar disorder. Psychiatric clinics of North America. 2005;28:301-323.
13267.	Singletary T, DS N, Weiss M, Marman G. A Cost-Effective Approach to the Use of Selective Serotonin Reuptake Inhibitors in a Veterans Affairs Medical Center. American journal of managed care. 1997;3:125-129.
13268.	Sinyor M, AJ L, AH C, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. Journal of clinical psychiatry. 2010;71:270-279.
13269.	Sinyor M, Schaffer A, KA S, AJ L, KL L, NH G. Sponsorship, antidepressant dose, and outcome in major depressive disorder: Meta-analysis of randomized controlled trials. Journal of clinical psychiatry. 2012;73:e277-e287.
13270.	Sipowicz S, YL L, Tamura R, Perahia D, Detke M, Tran P. Global Benefit-Risk Evaluation for the Treatment of Major Depressive Disorder With Duloxetine: Results From Six Pooled Placebo- and Ssri- Controlled Clinical Trials. Journal of affective disorders. 2004;78:S135.
13271.	Sipowicz S, YL L, Tamura R, Perahia D, Detke M, Tran P. Global Benefit-Risk Evaluation for the Treatment of Major Depressive Disorder With Duloxetine: Results From Six Pooled Placebo- and Ssri- Controlled Clinical Trials. Journal of affective disorders. 2004;78:S135.
13272.	Sirisha G, NS U, Santhamma B. Study of antidepressant activity of chronic administration of tramadol and when it is co-administered with fluoxetine in low doses in Swiss albino mice using despair swim test. International Journal of Pharmaceutical Sciences and Research. 2015;6:2185-2190.
13273.	Sirkka-Liisa A, Urpu I, Markus P, et al. Paroxetine and imipramine: A 12-week, double-blind, multicentre study in hospitalized depressed patients. Nordic journal of psychiatry. 1992;46:27-31.
13274.	Sirkka-Liisa K. Treatment of depressive disorders in old age. Current opinion in psychiatry. 2001;14:387-393.
13275.	Sitra T-W, Damon D, John P, Susan B, MJr BC. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Psychological medicine. 2007;37:1585-1593.
13276.	Sitsen JMA, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. Journal of psychopharmacology (Oxford, England). 2000;14:172-176.
13277.	Sivalcumaran D, Dursun SM. Olanzapine plus venlafaxine in treatment-resistant depression. Journal of psychopharmacology (Oxford, England). 2005;19:434-435.
13278.	SJ B, AR D, TE O, et al. Evidence-based practices in geriatric mental health care. Psychiatric services (Washington, D.C.). 2002;53:1419-1431.
13279.	SJ B, AR D, TE O, et al. Evidence-based practices in geriatric mental health care: An overview of systematic reviews and meta-analyses. Psychiatric clinics of North America. 2003;26:971-990.
13280.	SJ B, Kutcher S. The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: Assessment of Its Evaluative Properties Over the Course of a 16-Week Pediatric Psychopharmacotherapy Trial. Journal of child and adolescent psychopharmacology. 2004;14:273-286.
13281.	SJ B, Kutcher S. The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: Assessment of Its Evaluative Properties Over the Course of a 16-Week Pediatric Psychopharmacotherapy Trial. Journal of child and adolescent psychopharmacology. 2004;14:273-286.
13282.	SJ C, CB K. Psychopharmacology of depression and anxiety. Current opinion in psychiatry. 1992;5:79-83.
13283.	SJ C, Mulholland C, Lynch G, Baynes D, DJ K. Sertraline in the Treatment of Depressive Symptoms in Stable, Chronic Schizophrenia: a Placebo Controlled Trial. Schizophrenia research. 2000;41:209.
13284.	SJ C, Sullo E. How can you prevent migraines during pregnancy? Journal of family practice. 2006;55:429-432.
13285.	SJ D. A double-blind parallel group study of dothiepin and mianserin in depressed psychiatric in/out-patients. Round Table Series - Royal Society of Medicine. 1990:55-63.
13286.	SJ D, BH M, AJ F, et al. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Comprehensive psychiatry. 2014;55:1069-1076.
13287.	SJ D, BH M, AJ F, et al. Differential Impact of Anxiety Symptoms and Anxiety Disorders on Treatment Outcome for Psychotic Depression in the Stop-Pd Study. Comprehensive psychiatry. 2014;55:1069-1076.
13288.	SJ D, Joffe H, JC L, et al. Effects of Escitalopram on Markers of Bone Turnover: a Randomized Clinical Trial. Journal of clinical endocrinology and metabolism. 2014;99:E1732-E1737.
13289.	SJ E. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: A systematic review and economic evaluation. Health technology assessment. 2013;17:1-34.
13290.	SJ E, Hamilton V, Nherera L, Trevor N. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. [Review]. Health technology assessment (Winchester, England). 2013;17:1-190.
13291.	SJ E, Wakefield V, Nherera L, Trevor N. Systematic review and mixed treatment comparison of lithium or an atypical anti-psychotic (AAP) used to augment a selective serotonin reuptake inhibitor (SSRI) in treatment resistant depression (TRD). Value in health. 2014;Conference:A455.
13292.	SJ F. Psychopharmacologic treatment of patients with HIV/AIDS. Current psychiatry reports. 2009;11:235-242.
13293.	SJ F, Freyberg Z. Treatment of depression in HIV positive individuals: A critical review. International review of psychiatry. 2008;20:61-71.
13294.	SJ F, JD G, WE C. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: Improvements in affective and somatic symptoms. General hospital psychiatry. 1997;19:89-97.
13295.	SJ G. Sadness in heart failure: What is a clinician to do? Journal of the American College of Cardiology. 2010;56:700-701.
13296.	SJ G, Anger-Friedfeld K, Beren S, Rudolph D, Boeck M, Aronne L. Psychiatric illness in patients presenting for obesity treatment. International journal of eating disorders. 1992;12:63-71.
13297.	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder, Journal of psychiatric research(2012).
13298.	SJ J, Manceur A, RD M, et al. Glucocorticoid receptor translocation is impaired in neural cells from patients with major depressive disorder. Biological psychiatry. 2012;Conference:13S-14S.
13299.	SJ L, Gawinski B, Pierce D, SJ R. Seasonal Affective Disorder. American family physician. 2006;74:1521-1524.
13300.	SJ L, Liu T. [Clinical observation on treatment of melancholia by acupuncture following principle of relieving depression and regulating mentality]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2007;27:155-157.
13301.	SJ M. Glycine transporter-I inhibitors: A new class of antidepressant? Biological psychiatry. 2013;74:710-711.
13302.	SJ M, DS C. Publication bias and the efficacy of antidepressants. American journal of psychiatry. 2009;166:140-145.
13303.	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial, International journal of neuropsychopharmacology(2010).
13304.	SJ M, Vythilingam M, JW M, et al. A Selective Neurokinin-1 Receptor Antagonist in Chronic Ptsd: a Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial. European neuropsychopharmacology. 2011;21:221-229.
13305.	SJ R, SH K. Management Strategies for Ssri-Induced Sexual Dysfunction. Journal of psychiatry & neuroscience. 2013;38:E27-E28.
13306.	SJ S, MF B, Schaefer K, Sarocco P, Barry N, AS P. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. Journal of mental health policy and economics. 2010;13:27-35+46+50.
13307.	SJ T. Medication-overuse headache. CONTINUUM Lifelong Learning in Neurology. 2012;18:807-822.
13308.	SJ T, Shin M, MG M, JR B. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35:433-449.
13309.	SJ V. Comparing Ssris - From Chemistry to Clinical Choice. Human Psychopharmacology-Clinical and Experimental. 1995;10:S199-S209.
13310.	SJ W. Clinical Implications of the Pharmacology of Serotonin Reuptake Inhibitors. International clinical psychopharmacology. 1992;7:13-19.
13311.	SJ W, JE B, Alford C, Weinstein A, DJ N. Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. Journal of psychopharmacology (Oxford, England). 2002;16:321-331.
13312.	SJ Y, CU P, DJ K, et al. Mirtazapine for Patients With Alcohol Dependence and Comorbid Depressive Disorders: a Multicentre, Open Label Study. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:1196-1201.
13313.	SJ Y, Stewart R, HJ K, et al. Response to Antidepressants in Major Depressive Disorder With Melancholic Features: the Crescend Study. Journal of affective disorders. 2013;144:42-50.
13314.	SJ Z, QC K, JG W, et al. Pilot and Pivotal Study to Evaluate the Bioequivalence of Two Paroxetine 40 Mg Tablet Formulations in Healthy Chinese Subjects. International journal of clinical pharmacology and therapeutics. 2012;50:514-523.
13315.	SJB M. Postpartum depression: An essential overview for the practitioner. Southern medical journal. 2011;104:128-132.
13316.	SJC D, BG P, Kirshner M, et al. Sertraline co-administration increases olanzapine clearance in people with psychotic depression-a population pharmacokinetic analysis. Biological psychiatry. 2014;Conference:124S-125S.
13317.	SJC D, SD H, SV A, et al. Depleting Serotonin Enhances Both Cardiovascular and Psychological Stress Reactivity in Recovered Patients With Anxiety Disorders. Journal of clinical psychopharmacology. 2006;26:414-418.
13318.	SJC D, SL D. Treatment: Special conditions: Psychological aspects relating to the treatment of hypertension. Journal of the American Society of Hypertension. 2015;9:150-153.
13319.	SJO L, Mdmd T, ER M, SS V, TA R, JM J-H. Quantitative Evaluation of Spect With Fp-Cit. Importance of the Reference Area. Revista espanola de medicina nuclear. 2010;29:246-250.
13320.	Sjosten N, S-L K. The effects of physical exercise on depressive symptoms among the aged: A systematic review. International journal of geriatric psychiatry. 2006;21:410-418.
13321.	SJP G, Vidas M, Gruden V. Stomatodynia - An indication for antidepressant therapy. [Croatian]. Socijalna Psihijatrija. 2004;32:90-93.
13322.	SK A, Margolin A, TR K. Cocaine abuse in methadone maintenance programs: Integrating pharmacotherapy with psychosocial interventions. Journal of psychoactive drugs. 1994;26:137-146.
13323.	SK B, AJ R, Vitiello B, MA S, BA B, CJ K. Antidepressant Prescribing Practices for the Treatment of Children and Adolescents. Journal of child and adolescent psychopharmacology. 2008;18:70-80.
13324.	SK B, CH M, EB B, MM W, JG W, AF S. Duloxetine 60 Mg Once-Daily in the Treatment of Painful Physical Symptoms in Patients With Major Depressive Disorder. Journal of psychiatric research. 2005;39:43-53.
13325.	SK B, CH M, MJ D, JG W, GD T. Onset of Action for Duloxetine 60 Mg Once Daily: Double-Blind, Placebo-Controlled Studies. Journal of psychiatric research. 2005;39:161-172.
13326.	SK B, CH M, MJ D, JG W, GD T. Onset of Action for Duloxetine 60 Mg Once Daily: Double-Blind, Placebo-Controlled Studies. Journal of psychiatric research. 2005;39:161-172.
13327.	SK B, SC B. Childhood and Adolescent Depression. American family physician. 2007;75:73-80.
13328.	SK B, SC B. Childhood and adolescent depression. American family physician. 2007;75:73-84.
13329.	SK B, Teasell R, Foley N, Speechley M. Heterocyclics and Selective Serotonin Reuptake Inhibitors in the Treatment and Prevention of Poststroke Depression. Journal of the American Geriatrics Society. 2005;53:1051-1057.
13330.	SK B, Teasell R, Foley N, Speechley M. Heterocyclics and Selective Serotonin Reuptake Inhibitors in the Treatment and Prevention of Poststroke Depression. Journal of the American Geriatrics Society. 2005;53:1051-1057.
13331.	SK G. Sertraline - a New Specific Serotonin Reuptake Blocker. DICP : the annals of pharmacotherapy. 1991;25:952-961.
13332.	SK K, Dhir A. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytotherapy research : PTR. 2010;24:317-324.
13333.	SK L, CH C, CH P. Venlafaxine for Acute Heroin Detoxification - a Double-Blind, Randomized, Control Trial. Journal of clinical psychopharmacology. 2008;28:189-194.
13334.	SK L, XM Z, ZM X. [Incidence rate and acupuncture-moxibustion treatment of post-stroke depression]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2006;26:472-474.
13335.	SK R. Management of poststroke depression in older people. Clinics in geriatric medicine. 1999;15:765-783.
13336.	SK R, ES V, KA B, MA G, JP H. Randomized Placebo-Controlled Trial of a Selective Serotonin Reuptake Inhibitor in the Treatment of Nondepressed Tinnitus Subjects. Psychosomatic medicine. 2005;67:981-988.
13337.	SK R, ES V, MB S. Antidepressant therapy in tinnitus. [Review] [55 refs]. Hearing research. 2007;226:221-231.
13338.	SK S. Moving forward in clinical trials for late-life disorders. American journal of geriatric psychiatry. 2008;16:1-4.
13339.	SK S, ML M. Premenstrual syndrome. Identification and management. Drugs. 1995;49:71-82.
13340.	Skapinakis P. Evidence-Based Medicine Quiz (EBMQ8). Archives of Hellenic Medicine. 2002;19:710-712.
13341.	Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: A systematic review and meta-analysis of randomized controlled trials, BMC neurology(2010).
13342.	Skarstein J. A 'trouble-blind' placebo controlled comparative study between two new antidepressant agents (Seroxat (paroxetine) and Tolvon (mianserin)). [Norwegian]. Tidsskrift for den Norske laegeforening. 1998;118:265-266.
13343.	Skausig O, Nielsen O, Morsing I, et al. Paroxetine and imipramine treatment of depressed patients in a controlled, multicentre study with plasma amino acid measurements. Nordic Journal of Psychiatry, Supplement. 1992;46:23-26.
13344.	Skerritt U, Evans R, SA M. Selective Serotonin Reuptake Inhibitors in Older Patients - a Tolerability Perspective. Drugs & aging. 1997;10:209-218.
13345.	SKH T, Hartung H, Sharp T, Temel Y. Serotonin-dependent depression in Parkinson's disease: A role for the subthalamic nucleus? Neuropharmacology. 2011;61:387-399.
13346.	Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain. Spine. 2010;35:E578-E585.
13347.	Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain. Diabetes/metabolism research and reviews. 2009;25:623-631.
13348.	Skljarevski V, Ossanna M, Liu-Seifert H, et al. A Double-Blind, Randomized Trial of Duloxetine Versus Placebo in the Management of Chronic Low Back Pain. European journal of neurology. 2009;16:1041-1048.
13349.	Skljarevski V, Zhang S, AS C, DJ W, Murray I, Backonja M. Maintenance of Effect of Duloxetine in Patients With Chronic Low Back Pain: a 41-Week Uncontrolled, Dose-Blinded Study. Pain medicine (Malden, Mass.). 2010;11:648-657.
13350.	Skolnick P, AS B. Triple reuptake inhibitors as antidepressants. Drug discovery today. Therapeutic strategies. 2006;3:489-494.
13351.	Skolnick P, AS B. Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS and Neurological Disorders - Drug Targets. 2007;6:141-149.
13352.	Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. [Review] [21 refs]. CNS drug reviews. 2006;12:123-134.
13353.	Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends in pharmacological sciences. 2009;30:563-569.
13354.	Skolnick P, Popik P, Trullas R. N-methyl-D-aspartate (NMDA) antagonists for the treatment of depression. Gene Therapy for Autoimmune and Inflammatory Diseases. 2010;Milestones:1-20.
13355.	SL A, Ikonen U, Pulkkinen P, et al. A 12-Week Double-Blind Multicenter Study of Paroxetine and Imipramine in Hospitalized Depressed-Patients. Acta psychiatrica Scandinavica. 1994;89:382-389.
13356.	SL B. Criteria for Use of Fluvoxamine Maleate in Adult Inpatients and Outpatients. American journal of hospital pharmacy. 1994;51:2282-2285.
13357.	SL B, Marinho V. Depression in the elderly. [Portuguese]. Revista brasileira de medicina. 2007;64:150-155.
13358.	SL B, MW Y. Atomoxetine. Formulary (Cleveland, Ohio). 2003;38:85-100.
13359.	SL C, DE A, Aberg K, et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychological medicine. 2012;42:1151-1162.
13360.	SL D, AN D. Mood Disorders and the Outcome of Suicidal Thoughts and Attempts. Critical care clinics. 2008;24:857-874.
13361.	SL D, AN D. Ziprasidone for maintenance treatment of bipolar i disorder in adults. Expert opinion on pharmacotherapy. 2011;12:817-824.
13362.	SL D, Maroteaux L. Implication of 5-HT(2B) receptors in the serotonin syndrome. Neuropharmacology. 2011;61:495-502.
13363.	SL D, Thomas M. Serotonergic Mechanisms and Current and Future Psychiatric Practice. Journal of clinical psychiatry. 1995;56:38-48.
13364.	SL D, Warren C. Agomelatine, a Melatonin Agonist With Antidepressant Properties. Expert opinion on investigational drugs. 2009;18:1533-1540.
13365.	SL H, AF S, SC J. On humility. Annals of neurology. 2009;65:A7-A8.
13366.	SL H, MA H, Diefenbach M, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. Journal of the National Cancer Institute. 2012;104:990-1004.
13367.	SL K, AD I. Seasonal affective disorder. [Review]. American family physician. 2012;86:1037-1041.
13368.	SL K, LB C. Treatment of pathological gambling. Current opinion in psychiatry. 2009;22:69-74.
13369.	SL L, KP Y, LY T, et al. L-5-Hydroxytryptophan Augments the Neuroendocrine Response to a Ssri. Psychoneuroendocrinology. 2006;31:473-484.
13370.	SL L, SL G, Ciechanowski P, Schwartz S, LoGerfo J. Antidepressant use in nonmajor depression: Secondary analysis of a program to encourage active, rewarding lives for seniors (PEARLS), a randomized controlled trial in older adults from 2000 to 2003. American Journal Geriatric Pharmacotherapy. 2008;6:12-20.
13371.	SL M, AI G, Martens B, PE KJ, HG P, JI H. Role of antiepileptic drugs in the management of eating disorders. CNS drugs. 2009;23:139-156.
13372.	Current pharmacotherapy options for bulimia nervosa and binge eating disorder, Expert opinion on pharmacotherapy(2012).
13373.	SL M, AI G, Mori N, AM OM. Pharmacological management of binge eating disorder: Current and emerging treatment options. Therapeutics and clinical risk management. 2012;8:219-241.
13374.	Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania, Journal of clinical psychiatry(2010).
13375.	SL M, CL B, MA C, PJ W, PE KJ, JR C. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. Journal of affective disorders. 2008;107:127-133.
13376.	SL M, Guerdjikova A, Kotwal R, et al. Atomoxetine in the Treatment of Binge-Eating Disorder: a Randomized Placebo-Controlled Trial. Journal of clinical psychiatry. 2007;68:390-398.
13377.	SL M, Guerdjikova A, Mori N, PE KJ. Therapeutic potential of new second generation antipsychotics for major depressive disorder. [Review]. Expert opinion on investigational drugs. 2010;19:1527-1544.
13378.	SL M, JI H, Malhotra S, JA W, EB N, PE KJ. Citalopram in the treatment of binge-eating disorder: A placebo-controlled trial. Journal of clinical psychiatry. 2003;64:807-813.
13379.	SL M, Kotwal R, Kaneria R, PE KJ. Antidepressants and suicidal behavior in bipolar disorder. Bipolar disorders. 2006;8:596-617.
13380.	SL M, Kotwal R, PE KJ, HS A. Comorbidity of bipolar and eating disorders: Distinct or related disorders with shared dysregulations? Journal of affective disorders. 2005;86:107-127.
13381.	SL M, PE K, KA P. Kleptomania, Compulsive Buying, and Binge-Eating Disorder. Journal of clinical psychiatry. 1995;56:14-27.
13382.	SL M, PE KJ. Refining the definition of mood stabilization. Jornal brasileiro de psiquiatria. 2005;54:82-83.
13383.	SL M, PE KJ. Obesity in bipolar disorder: An overview. Current psychiatry reports. 2012;14:650-658.
13384.	SL M, RA B. Emerging drug therapies in Huntington's disease. Expert opinion on emerging drugs. 2009;14:273-297.
13385.	SL M, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. Journal of clinical psychopharmacology. 2012;32:165-172.
13386.	SL N. Health-related quality of life among adults with diabetes. Current diabetes reports. 2005;5:124-130.
13387.	SL S. Recent Advances in the Understanding and Treatment of Anxiety Disorders. Primary Care - Clinics in Office Practice. 2007;34:475-504.
13388.	Sladky R, Spies M, Hoffmann A, et al. (S)-Citalopram Influences Amygdala Modulation in Healthy Subjects: a Randomized Placebo-Controlled Double-Blind Fmri Study Using Dynamic Causal Modeling. NeuroImage. 2015;108:243-250.
13389.	Slatkoff J, Greenfield B. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults. Expert opinion on investigational drugs. 2006;15:649-667.
13390.	Sleath B, Chewning B, BM DV, et al. Communication about depression during rheumatoid arthritis patient visits. Arthritis care and research. 2008;59:186-191.
13391.	SM A, Gershon S. Clinical application of time-dependent sensitization to antidepressant therapy. Progress in neuro-psychopharmacology & biological psychiatry. 1998;22:65-78.
13392.	SM C. Effects of Treating Depression and Low Perceived Social Support on Clinical Events after Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. Journal of the American Medical Association. 2003;289:3106-3116.
13393.	SM C, KL G. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. [Review] [161 refs]. Drugs. 2001;61:81-110.
13394.	SM E, IS K, Bhatia S, TD H. Obstructive sleep apnea and depression: A review. Innovations in clinical neuroscience. 2011;8:17-25.
13395.	Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial, Trials [Electronic Resource](2013).
13396.	SM G, MS K, Etkin A, et al. Brain Imaging Predictors and the International Study to Predict Optimized Treatment for Depression: Study Protocol for a Randomized Controlled Trial. Trials. 2013;14.
13397.	SM G, Rafeyan R, Watts J, TC N. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: Evidence from the bench and the bedside. Pharmacology & therapeutics. 2012;136:343-353.
13398.	SM H, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. [Review] [61 refs]. Drugs. 1995;49:280-294.
13399.	SM H, GL P. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. [Review] [104 refs]. Drugs & aging. 1993;3:278-299.
13400.	SM H, JJ P. Treatment of smokers with co-occurring disorders: Emphasis on integration in mental health and addiction treatment settings. Annual review of clinical psychology. 2009;5:409-431.
13401.	SM H, VI R, RF M, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Archives of general psychiatry. 1998;55:683-690.
13402.	SM K, Prins J, AM K, et al. The Many Different Faces of Major Depression: It Is Time for Personalized Medicine. European journal of pharmacology. 2015;753:88-104.
13403.	SM M. The status of pharmacotherapy for autism spectrum disorders. Expert opinion on pharmacotherapy. 2007;8:1579-1603.
13404.	SM M, Ahmadi M, Amini M, Vazirzadeh B. The effects of 40 and 80 mg hydro- alcoholic extract of crocus sativus in the treatment of mild to moderate depression. [Persian]. Journal of Mazandaran University of Medical Sciences. 2014;24:47-53.
13405.	SM M, GJ N, Murtagh M, Winslow G. A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta psychiatrica Scandinavica. Supplementum. 1989;350:143-144.
13406.	SM M, GJ N, Murtagh M, Winslow G. A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta Psychiatrica Scandinavica, Supplement. 1989;80:143-144.
13407.	SM M, JF G. Extended antidepressant maintenance and discontinuation syndromes. Depression and anxiety. 1998;8:43-53.
13408.	SM M, JS G, JL W, SA S. A review of treating depression in diabetes: Emerging findings. Psychosomatics. 2011;52:3.
13409.	SM M, MM H. Association of suicide in the elderly and SSRI antidepressants: Information from a population-based study. Aging health. 2006;2:917-918.
13410.	SM M, Queenan K, Faniran O, Ranginwala N, MM H. Sertraline in the treatment of depression in the elderly. Aging health. 2006;2:199-208.
13411.	SM R, AH P. Premature menopause in young breast cancer: Effects on quality of life and treatment interventions. Journal of Thoracic Disease. 2013;5:S55-S61.
13412.	SM S. Forced Titration as a Confound in an Ssri Comparator Study of Sertraline Versus Citalopram in the Treatment of Major Depressive Disorder - Reply. Biological psychiatry. 2001;50:67-68.
13413.	SM S. Selectivity of Ssris: Individualising Patient Care Through Rational Treatment Choices. International journal of psychiatry in clinical practice. 2004;8:3-10.
13414.	SM S. Selectivity of Ssris: Individualising Patient Care Through Rational Treatment Choices. International journal of psychiatry in clinical practice. 2004;8:3-10.
13415.	SM S. Antidepressant treatment of psychotic major depression: Potential role of the sigma receptor. CNS spectrums. 2005;10:319-323.
13416.	SM S. Approaching the challenge of bipolar depression: Results from STEP-BD. American journal of psychiatry. 2007;164:1301-1303.
13417.	SM S. Combining antidepressant therapies from the initiation of treatment: A paradigm shift for major depression. Journal of clinical psychiatry. 2009;70:1493-1494.
13418.	SM S, AA N, JM G. Evidence of early onset of antidepressant effect in randomized controlled trials. [Review] [35 refs]. Journal of clinical psychiatry. 2001;62 Suppl 4:17-40.
13419.	SM S, AA N, JM G. Evidence of Early Onset of Antidepressant Effect in Randomized Controlled Trials. Journal of clinical psychiatry. 2001;62:17-23.
13420.	SM S, Finnegan N, RM D. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. Journal of affective disorders. 2013;147:416-420.
13421.	SM S, GR E. Psychopharmacology of Depression in Children and Adolescents. Pediatric clinics of North America. 2011;58:155-171.
13422.	SM S, JJ N, EK D, et al. Treatment of chorea associated with Huntington's disease: Focus on tetrabenazine. Consultant pharmacist. 2009;24:524-537.
13423.	SM S, Lee-Zimmerman C, Cartwright S, DA M. Serotonergic Drugs for Depression and Beyond. Current drug targets. 2013;14:578-585.
13424.	SM S, MM G, Moret C, Briley M. Snris: the Pharmacology, Clinical Efficacy, and Tolerability in Comparison With Other Classes of Antidepressants. CNS spectrums. 2005;10:732-747.
13425.	SM S, MP DB, CM A, PE KJ. Atypical antipsychotics in the treatment of bipolar disorder. Expert opinion on pharmacotherapy. 2003;4:751-760.
13426.	SM S, Nielsen J, BE B, et al. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. Journal of cardiovascular pharmacology and therapeutics. 2010;15:373-379.
13427.	SM T, Lucki I, AA P, VD P, PM K, ST C. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. Journal of clinical pharmacology. 1995;35:410-419.
13428.	SM T, RG J, DC B, Himmelhoch J. Fluoxetine treatment of obsessive-compulsive disorder. Journal of clinical psychopharmacology. 1985;5:207-212.
13429.	SM T, Trinidad A, Roth A. Psychopharmacology in Cancer. Current psychiatry reports. 2014.
13430.	SM T, VD P, RJ F, ST C. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. Journal of clinical pharmacology. 1995;35:404-409.
13431.	SM T, VP P, DR H, GM P, ST C. Pharmacokinetics and Effect of Food on the Bioavailability of Orally Administered Venlafaxine. Journal of clinical pharmacology. 1997;37:954-961.
13432.	SM V, Vallabhaneni K, Sliwerska E, FJ M, EA Y, Burmeister M. Ssri Response in Depression May Be Influenced by Snps in Htr1b and Htr1a. Psychiatric genetics. 2009;19:281-291.
13433.	SM W, Han C, SJ L, AA P, PS M, CU P. Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry investigation. 2015;12:155-163.
13434.	SMA B. Drugs update. Emirates Medical Journal. 2006;24:159-165.
13435.	Smajkic A, Weine S, Djuric-Bijedic Z, Boskailo E, Lewis J, Pavkovic I. Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of traumatic stress. 2001;14:445-452.
13436.	SME V, FWNM W, J vT, JMA L. Efavirenz: A review. Expert opinion on pharmacotherapy. 2007;8:851-871.
13437.	Smeraldi E. Amisulpride in the treatment of dysthymia: Preliminary results in a comparative double-blind study with fluoxetine. [Italian]. Nuova Rivista di Neurologia. 1995;5:22-26.
13438.	Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C. Sustained Antidepressant Effect of Sleep Deprivation Combined With Pindolol in Bipolar Depression - a Placebo-Controlled Trial. Neuropsychopharmacology. 1999;20:380-385.
13439.	Smeraldi E, Delmonte D. Agomelatine in depression. Expert opinion on drug safety. 2013;12:873-880.
13440.	Smeraldi E, Haefele E, Crespi G, Casadei GL, Biondi F, Vigorelli E. Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study. European psychiatry. 1996;11:141s-143s.
13441.	Smeraldi E, Rizzo F, Crespi G. Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression. Primary Care Psychiatry. 1998;4:189-195.
13442.	Smeraldi E, Zanardi R, Benedetti F, D DB, Perez J, Catalano M. Polymorphism Within the Promoter of the Serotonin Transporter Gene and Antidepressant Efficacy of Fluvoxamine. Molecular psychiatry. 1998;3:508-511.
13443.	Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. [Review] [57 refs]. British journal of psychiatry. 2002;180:396-404.
13444.	Smith E. TORDIA: unique opportunity to explore half-life theory. American journal of psychiatry. 2009;166:936; author reply 936-937.
13445.	Weight gain during olanzapine treatment for psychotic depression: effects of dose and age, International clinical psychopharmacology(2008).
13446.	Weight gain during olanzapine treatment for psychotic depression: Effects of dose and age, International clinical psychopharmacology(2008).
13447.	Smith R, JJB A, JF T, Fort C, RD L. Increased Association Over Time Between Regional Frontal Lobe Bold Change Magnitude and Cardiac Vagal Control With Sertraline Treatment for Major Depression. Psychiatry Research-Neuroimaging. 2014;224:225-233.
13448.	Smith W, Sherrill A. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.[Erratum appears in Med Interface 1996 Oct;9(10):86]. Medical interface. 1996;9:88-92.
13449.	Smith Y, Wichmann T, SA F, MR D. Parkinson's disease therapeutics: New developments and challenges since the introduction of levodopa. Neuropsychopharmacology. 2012;37:213-246.
13450.	SN C, Kratochvil C, JS M. Pharmacotherapy for Anxiety Disorders in Children and Adolescents: an Evidence-Based Medicine Review. Pediatric annals. 2007;36:586-+.
13451.	SN C, PJ G, AK C, PJ G, VL B, JS M. Sertraline in Children and Adolescents With Social Anxiety Disorder: an Open Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:564-571.
13452.	SN F. Pharmacological treatment of major depressive disorder in children and adolescents: The paroxetine controversy. Canadian Journal of Clinical Pharmacology. 2004;11:e214-e217.
13453.	SN F, ER B, PE G, et al. Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group. Psychopharmacology bulletin. 1996;32:33-40.
13454.	SN F, Rose S. Is functional dyspepsia of particular concern in women? A review of gender differences in epidemiology, pathophysiologic mechanisms, clinical presentation, and management. American journal of gastroenterology. 2006;101:S644-S653.
13455.	SN G. New treatments for bipolar disorder: The role of atypical neuroleptic agents. Journal of clinical psychiatry. 2000;61:33-42.
13456.	SN G. Hippocrates and prozac: The controversy about antidepressants in bipolar disorder. Primary psychiatry. 2006;13:51-58.
13457.	SN G. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar disorders. 2008;10:957-968.
13458.	SN G, AA S, Filkowski M. Publication bias and the pharmaceutical industry: The case of lamotrigine. MedGenMed : Medscape general medicine. 2008.
13459.	SN G, AP W, MA F, RJ B. Long-term antidepressant treatment in bipolar disorder: Meta-analyses of benefits and risks. Acta psychiatrica Scandinavica. 2008;118:347-356.
13460.	SN G, FK G, JC F, et al. Antidepressants for bipolar depression [7] (multiple letters). American journal of psychiatry. 2005;162:1545-1548.
13461.	Antidepressant discontinuation in bipolar depression: A systematic treatment enhancement program for bipolar disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety, Journal of clinical psychiatry(2010).
13462.	SN G, SB T. Death by confounding: Bias and mortality. International journal of clinical practice. 2010;64:1009-1014.
13463.	SN G, Soldani F, DJ H. Evidence-based pharmacotherapy of bipolar disorder. International journal of neuropsychopharmacology. 2003;6:303-308.
13464.	SN H. Broken-hearted women: The complex relationship between depression and cardiovascular disease. Women's Health. 2009;5:709-725.
13465.	SN H, HR GS, Mohammadi A, GH Z-B, KH N, Malekzadeh M. Nortriptyline versus fluoxetine in the treatment of major depressive disorder: A six-month, double-blind clinical trial. Clinical Pharmacology: Advances and Applications. 2012.
13466.	SN L. Placebo effects and antidepressant medication: Implications for research and clinical care. Bulletin of the Menninger Clinic. 1996;60:94-101.
13467.	Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder, Biological psychiatry(2011).
13468.	Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder, Biological psychiatry(2011).
13469.	SN M, EG K, AV G, IV T. Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. 2005;Korsakova 22-29.
13470.	SN M, EG K, AV G, IV T. [Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 2005;Korsakova.:22-29.
13471.	SN M, EG K, AV G, IV T. Comparative Efficacy and Tolerability of Paroxetine and Amitriptiline in Long-Term Therapy Preventing Depressive Recurrences. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2005;105:22-29.
13472.	SN M, EG K, AV G, IV T. Comparative Efficacy and Tolerability of Paroxetine and Amitriptiline in Long-Term Therapy Preventing Depressive Recurrences. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2005;105:22-29.
13473.	SN M, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. International journal of clinical practice. 1997;51:209-213.
13474.	SN M, JL M. The Depression-Executive Dysfunction (Ded) Syndrome and Response to Antidepressants: a Meta-Analytic Review. International journal of geriatric psychiatry. 2010;25:933-944.
13475.	SN S, Miyazaki M, SP R. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: Randomized placebo-controlled clinical trial. Journal of clinical psychopharmacology. 2005;25:584-588.
13476.	SN V, BN F, CN S, Steiner M. Approach to Premenstrual Dysphoria for the Mental Health Practitioner. Psychiatric clinics of North America. 2010;33:257-272.
13477.	SN V, LE R, Steiner M. Understanding and Treating Premenstrual Dysphoric Disorder: An Update for the Women's Health Practitioner. Obstetrics and gynecology clinics of North America. 2009;36:907-924.
13478.	SN Y, DS M. Serotonin and affiliative behavior. Behavioral and brain sciences. 2005;28:367-368.
13479.	SN Y, DS M, M ahR. Possible role of more positive social behaviour in the clinical effect of antidepressant drugs. Journal of psychiatry & neuroscience. 2014;39:60-65.
13480.	Snekkevik H, HR E, Tangen T, Chalder T, SE R. Fatigue and Depression in Sick-Listed Chronic Low Back Pain Patients. Pain medicine (Malden, Mass.). 2014;15:1163-1170.
13481.	Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: A review of the literature. Journal of the American Geriatrics Society. 2003;51:1305-1317.
13482.	Snyderman D, Wynn D. Depression in Cancer Patients. Primary Care - Clinics in Office Practice. 2009;36:703-719.
13483.	Sobieraj D. Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha. Formulary (Cleveland, Ohio). 2012;47:414.
13484.	Sobis J, Hese R, Jarzab M, et al. Estimation of therapeutic efficacy of magnetic fields in patients with drugresistant depression. European neuropsychopharmacology. 2008;Conference:S379-S380.
13485.	Sobo S. Pursuing treatments that are not evidence based: How DSM IV clarifies, how it blinds psychiatrists to issues in need of investigation. Medical hypotheses. 2009;72:491-498.
13486.	Sobocki P, Ekman M, Ovanfors A, Khandker R, Jonsson B. The Cost-Utility of Maintenance Treatment With Venlafaxine in Patients With Recurrent Major Depressive Disorder. International journal of clinical practice. 2008;62:623-632.
13487.	Sobow T. SSRI and SNRI antidepressants in the treatment of old age depression: A systematic literature review and meta-analysis of randomized controlled trials. [Polish]. Postepy Psychiatrii i Neurologii. 2007;16:281-290.
13488.	Sockalingam S, SE A. Managing depression during hepatitis C treatment. Canadian Journal of Psychiatry. 2009;54:614-625.
13489.	Pharmacological treatment of comorbid PTSD and substance use disorder: Recent progress, Addictive behaviors(2014).
13490.	Sohita D. Duloxetine: a review of its use in the management of major depressive disorder in older adults. [Review]. Drugs & aging. 2013;30:59-79.
13491.	Sohita D, H YLP, P CM. Spotlight on bupropion in major depressive disorder. [Review] [38 refs]. CNS drugs. 2008;22:613-617.
13492.	Sokolowski M, Wasserman J, Wasserman D. Genome-wide association studies of suicidal behaviors: A review. European neuropsychopharmacology. 2014;24:1567-1577.
13493.	Solomon D, Adams J, Graves N. Economic Evaluation of St. John's Wort (Hypericum Perforatum) for the Treatment of Mild to Moderate Depression. Journal of affective disorders. 2013;148:228-234.
13494.	Solomon D, Ford E, Adams J, Graves N. Potential of St John's Wort for the treatment of depression: The economic perspective. Australian and New Zealand journal of psychiatry. 2011;45:123-130.
13495.	Solyom L, Solyom C, Ledwidge B. Fluoxetine Treatment of Obsessive-Compulsive Disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 1991;36:723-727.
13496.	Sommer C. Peripheral neuropathies: New recommendations for neuropathic pain pharmacotherapy. Nature reviews. Neurology. 2015;11:250-252.
13497.	Sommer C, Hauser W, Alten R, et al. [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. [Review] [German]. Schmerz (Berlin, Germany). 2012;26:297-310.
13498.	Sommer C, Hauser W, Berliner M, et al. Pharmacological treatment of fibromyalgia syndrome. [German]. Schmerz (Berlin, Germany). 2008;22:313-323.
13499.	Sommers-Flanagan J, DG C. Psychotherapy and (or) medications for depression in youth? an evidence-based review with recommendations for treatment. Journal of contemporary psychotherapy. 2009;39:111-120.
13500.	Sondergaard MP, Jarden JO, Martiny K, Andersen G, Bech P. Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression: A randomised, double-blind pilot study. Psychotherapy and psychosomatics. 2006;75:244-248.
13501.	Song C. Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders. Inflammation in Psychiatry. 2013;Modern Tre:75-89.
13502.	Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: The effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry. 2009;42:182-188.
13503.	Song F, Harvey I, Lilford R. Adjusted Indirect Comparison May Be Less Biased Than Direct Comparison for Evaluating New Pharmaceutical Interventions. Journal of clinical epidemiology. 2008;61:455-463.
13504.	Treatment of Traumatized Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - Study Protocol for a Randomized Clinical Trial, Trials(2013).
13505.	Sorensen J, KB S, Damsbo N, A LL, MEH H. A Danish Cost-Effectiveness Model of Escitalopram in Comparison With Citalopram and Venlafaxine as First-Line Treatments for Major Depressive Disorder in Primary Care. Nordic journal of psychiatry. 2007;61:100-108.
13506.	Souche A, Montaldi S, Uehlinger C, et al. Citalopram with addition of lithium-placebo (double blind) in the treatment of therapy-resistant depressive patients: Methodology and biological investigations. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 1991;17:213-219.
13507.	Souche A, Montaldi S, Uehlinger C, et al. [Treatment of resistant depression with the citalopram-lithium combination. Methodology of a double-blind multicenter study and preliminary results]. [French]. L'Enc�phale. 1991;17:213-219.
13508.	Souery D. How an internist should deal with psychotropic drugs? Acta clinica Belgica. 2004;59:279-284.
13509.	Souery D, Amsterdam J, C DM, et al. Treatment Resistant Depression: Methodological Overview and Operational Criteria. European neuropsychopharmacology. 1999;9:83-91.
13510.	Souery D, GI P, MH T. Treatment-Resistant Depression. Journal of clinical psychiatry. 2006;67:16-22.
13511.	Souery D, Mendlewicz J. Compliance and Therapeutic Issues in Resistant Depression. International clinical psychopharmacology. 1998;13:S13-S18.
13512.	Souery D, Serretti A, Calati R, et al. Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. World journal of biological psychiatry. 2011;12:364-375.
13513.	Souery D, Serretti A, Montgomery S, Kasper S, Zohar J, Mendlewicz J. Advances on the treatment of resistant depression. International journal of psychiatry in clinical practice. 2010;Conference:13.
13514.	Souetre E, Lozet H, Cimarosti I. Predicting factors for absenteeism in patients with major depressive disorders. European journal of epidemiology. 1997;13:87-93.
13515.	Soutullo C, Figueroa-Quintana A. When do you prescribe antidepressants to depressed children? Topical collection on mood disorders. Current psychiatry reports. 2013.
13516.	Soutullo C, Figueroa-Quintana A. When Do You Prescribe Antidepressants to Depressed Children? Current psychiatry reports. 2013;15.
13517.	Soutullo C, Figueroa-Quintana A. When do you prescribe antidepressants to depressed children?. [Review]. Current psychiatry reports. 2013;15:366.
13518.	Soyka M. Relapse Prevention in Alcoholism - Recent Advances and Future Possibilities. CNS drugs. 1997;7:313-327.
13519.	Soyka M. Neuropsychiatric adverse events of bupropion treatment: A brief update. International journal of psychiatry in clinical practice. 2004;8:251-254.
13520.	Soyka M, HB R, Preuss U, HJ M. Antidepressants in Alcoholism - New Findings on Indications, Interactions, and Efficiency. Psychopharmakotherapie. 1997;4:138-144.
13521.	Soyka M, Niederecker M, Meyendorf R. Successful Treatment of Electroconvulsive-Therapy. Der Nervenarzt. 1991;62:448-450.
13522.	SP P, Suominen K, ET I. Suicide in alcohol-dependent individuals: Epidemiology and management. CNS drugs. 2004;18:423-436.
13523.	SP R. Tolerability and patient compliance. Journal of clinical psychiatry. 1999;60:14-17.
13524.	SP R. Considerations for the use of antidepressants in patients with cardiovascular disease. American heart journal. 2000;140:S84-S88.
13525.	SP R. Considerations for the Use of Antidepressants in Patients With Cardiovascular Disease. American heart journal. 2000;140:584-588.
13526.	SP R. Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. [Review] [28 refs]. Journal of clinical psychiatry. 2001;62 Suppl 8:19-22; discussion 23.
13527.	SP R. Depression, Anxiety, and the Cardiovascular System: the Psychiatrist's Perspective. Journal of clinical psychiatry. 2001;62:19-23.
13528.	SP R. Treatment of depression in patients with heart disease. Biological psychiatry. 2003;54:262-268.
13529.	SP R, AF S. The efficacy of antidepressants in the treatment of late-life depression. Journal of clinical psychopharmacology. 2005;25:S1-S7.
13530.	SP R, AH G, Attia E, Woodring S. Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia. American journal of psychiatry. 1994;151:1735-1739.
13531.	SP R, AH G, Attia E, Woodring S, E-GV G, JT BJ. Cardiovascular effects of fluoxetine in depressed patients with heart disease. American journal of psychiatry. 1998;155:660-665.
13532.	SP R, AH G, SN S. Relationship between depression and other medical illnesses. Journal of the American Medical Association. 2001;286:1687-1690.
13533.	SP R, GW R, AS G. Medication management of pediatric eating disorders. International review of psychiatry. 2008;20:183-188.
13534.	SP R, HA S, KR K, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: A randomized, placebo-controlled trial. American journal of psychiatry. 2004;161:2050-2059.
13535.	SP R, HA S, KRR K, et al. Antidepressant Pharmacotherapy in the Treatment of Depression in the Very Old: a Randomized, Placebo-Controlled Trial. American journal of psychiatry. 2004;161:2050-2059.
13536.	SP R, JC N, Salzman C, SB H, Rodrigues H, Group MitNHS. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Current medical research and opinion. 2003;19:737-746.
13537.	SP R, Spatz E. Depression and heart disease. Depression and anxiety. 1998;7:158-165.
13538.	SP R, Spatz E. Treating depression in patients with ischaemic heart disease: which agents are best to use and to avoid?. [Review] [25 refs]. Drug safety. 1999;20:459-465.
13539.	SP S, KR R. Life after the women's health initiative: Evaluation of postmenopausal symptoms and use of alternative therapies after discontinuation of hormone therapy. Pharmacotherapy. 2006;26:1403-1409.
13540.	SP S, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. [Review][Erratum appears in Br J Psychiatry. 2011 Feb;198:159]. British journal of psychiatry. 2010;197:174-179.
13541.	SP T, HS N, Jayaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). Journal of mental health (Abingdon, England). 2010;19:168-175.
13542.	Spadone C. [Effects of escitalopram on anxiety symptoms in depression]. [French]. Encephale. 2002;28:461-465.
13543.	Spadone C. [Efficacy of escitalopram and severity of depression: new data]. [Review] [17 refs] [French]. Encephale. 2009;35:577-585.
13544.	Spadone C. Efficacy of escitalopram and severity of depression: New data. [French]. Encephale. 2009;36:577-585.
13545.	Spadone C. Efficacy of escitalopram and severity of depression: New data. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2009;35:577-585.
13546.	Spadone C. [Severe forms of depression: the efficacy of escitalopram]. [Review] [19 refs] [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2009;35:152-159.
13547.	Spaeth M. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119: 5-15, 2. Journal of musculoskeletal pain. 2006;14:55.
13548.	Spaeth M. Fibromyalgia syndrome review. Journal of musculoskeletal pain. 2007;15:55-62.
13549.	Spaeth M. Fibromyalgia syndrome review. Journal of musculoskeletal pain. 2009;17:195-201.
13550.	Spaeth M. Fibromyalgia literature review. Journal of musculoskeletal pain. 2009;17:416-422.
13551.	Spaeth M, Briley M. Fibromyalgia: a Complex Syndrome Requiring a Multidisciplinary Approach. Human Psychopharmacology-Clinical and Experimental. 2009;24:S3-S10.
13552.	Spalletta G. Depression in Alzheimer disease: What treatment? Journal of Alzheimer's disease. 2012;29:41-42.
13553.	Spalletta G, Caltagirone C, Padovani A, et al. Cognitive and Affective Changes in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: a 6-Month Observational Study. PloS one. 2014;9.
13554.	Spalletta G, Caramia M, Caltagirone C. Neurorehabilitation and treatment with venlafaxine of depression associated with stroke: Preliminary study. [Italian]. Nuova Rivista di Neurologia. 2002;12:133-137.
13555.	Spanemberg L, Massuda R, Lovato L, et al. Pharmacological treatment of bipolar depression: Qualitative systematic review of double-blind randomized clinical trials. Psychiatric quarterly. 2012;83:161-175.
13556.	Sparhawk R. Treatment of mood disorders: A surprising omission, and the role of lamotrigine as a prototypical bipolar antidepressant. Primary psychiatry. 2010;17:17-19.
13557.	Spathis A, Booth S. End of life care in chronic obstructive pulmonary disease: In search of a good death. International Journal of COPD. 2008;3:11-29.
13558.	Spedding M, Neau I, Harsing L. Brain plasticity and pathology in psychiatric disease: Sites of action for potential therapy. Current opinion in pharmacology. 2003;3:33-40.
13559.	Spedding S. Vitamin D and depression: A systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients. 2014;6:1501-1518.
13560.	Spence D. Bad Medicine: the Rise of Duloxetine. Bmj-British Medical Journal. 2014;348.
13561.	Sperling W, Demling J. New Tetracyclic Antidepressants. Drugs of today (Barcelona, Spain : 1998). 1997;33:95-102.
13562.	Spigset O. Are the new antidepressant agents just as effective as the tricyclic antidepressant agents?. [Norwegian]. Tidsskrift for den Norske laegeforening. 1994;114:2873-2874.
13563.	Spijker J, A VS, CLH B, JAC M, AJLM VB. Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: A systematic review. Canadian Journal of Psychiatry. 2013;58:386-392.
13564.	Spina E, Avenoso A, AM P, AP C, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. Therapeutic drug monitoring. 1993;15:247-250.
13565.	Spina E, Fava G, Makos X. Off-label use of second-generation antipsychotics. Clinical Neuropsychiatry. 2009;6:11-20.
13566.	Spina E, J DL. Clinically Relevant Interactions Between Newer Antidepressants and Second-Generation Antipsychotics. Expert opinion on drug metabolism & toxicology. 2014;10:721-746.
13567.	Spina E, P DD, Ruello C, et al. Adjunctive Fluoxetine in the Treatment of Negative Symptoms in Chronic-Schizophrenic Patients. International clinical psychopharmacology. 1994;9:281-285.
13568.	Spinhoven P, AJW VDD, E VD, YR VR. Heart-Focused Anxiety as a Mediating Variable in the Treatment of Noncardiac Chest Pain by Cognitive-Behavioral Therapy and Paroxetine. Journal of psychosomatic research. 2010;69:227-235.
13569.	Spirito A, Esposito-Smythers C, Wolff J, Uhl K. Cognitive-Behavioral Therapy for Adolescent Depression and Suicidality. Child and adolescent psychiatric clinics of North America. 2011;20:191-204.
13570.	Spirito A, KZ A, Iyengar S, et al. Sources of Site Differences in the Efficacy of a Multisite Clinical Trial: The Treatment of SSRI-Resistant Depression in Adolescents. Journal of consulting and clinical psychology. 2009;77:439-450.
13571.	SR A. Noncardiac Chest Pain-Treatment Approaches. Gastroenterology clinics of North America. 2008;37:859-878.
13572.	SR B, Bianchi L, Cavallaro R, Gervasoni M, Siliprandi F, Bellodi L. Citalopram Concentrations and Responsein Obsessive-Compulsive Disorder - Preliminary Results. CNS drugs. 2004;18:329-335.
13573.	SR B, Mundo E, Dell'osso B, AC A. The Use of Escitalopram Beyond Major Depression: Pharmacological Aspects, Efficacy and Tolerability in Anxiety Disorders. Expert opinion on drug metabolism & toxicology. 2007;3:741-753.
13574.	SR B, WJ K, CM C, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. Journal of clinical psychiatry. 2014;75:e441-e449.
13575.	SR C, BL O, Boulougouris V, NA F, JE G. Trichotillomania: Neurobiology and treatment. Neuroscience and biobehavioral reviews. 2009;33:831-842.
13576.	SR C, Menzies L, BJ S, NA F. Lifting the veil on trichotillomania. American journal of psychiatry. 2007;164:568-574.
13577.	SR C, TW R. Noradrenergic modulation of cognition: Therapeutic implications. Journal of psychopharmacology (Oxford, England). 2013;27:694-718.
13578.	SR D, Jane F. Drugs for the treatment of menopausal symptoms. Expert opinion on pharmacotherapy. 2010;11:1329-1341.
13579.	SR D, NM C, Richards T, Dunner D, IK L, PF R. Imaging brain metabolism: Evidence for altered brain bioenergetics in bipolar disorder. Bipolar disorders. 2014;Conference:25.
13580.	SR G, MW J. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. [Review] [240 refs]. Clinical pharmacy. 1992;11:930-957.
13581.	SR J. Estrogen replacement therapy and breast cancer survivors. Problems in General Surgery. 2000;17:79-86.
13582.	SR J. Premenstrual Syndrome, Premenstrual Dysphoric Disorder, and Beyond: a Clinical Primer for Practitioners. Obstetrics and gynecology. 2004;104:845-859.
13583.	SR J. Premenstrual Syndrome, Premenstrual Dysphoric Disorder, and Beyond: a Clinical Primer for Practitioners. Obstetrics and gynecology. 2004;104:845-859.
13584.	SR P, ML C, CW H, et al. The Texas children's medication algorithm project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:642-657.
13585.	SR P, YS R, SR G. Depression in patients with HIV infection. American journal of health-system pharmacy. 2000;57:376-389.
13586.	SR P-P, Moscovitch A, Srinivasan V, DW S, DP C, GM B. Bidirectional communication between sleep and circadian rhythms and its implications for depression: Lessons from agomelatine. Progress in neurobiology. 2009;88:264-271.
13587.	SR P-P, Srinivasan V, DP C, JM M. Could agomelatine be the ideal antidepressant? Expert review of neurotherapeutics. 2006;6:1595-1608.
13588.	SR P-P, Srinivasan V, Poeggeler B, Hardeland R, DP C. Drug Insight: The use of melatonergic agonists for the treatment of insomnia - Focus on ramelteon. Nature clinical practice. Neurology. 2007;3:221-228.
13589.	SR T, DB S, CM C. Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy. Journal of the American Medical Association. 2003;290:1624-1632.
13590.	SR T, MA F. Sertraline: A new serotonin reuptake inhibitor. Journal of pharmacy technology. 1992;8:238-241.
13591.	Can Phase Iii Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A Star*D Report, American journal of psychiatry(2009).
13592.	SR W, CC C, Kim E, et al. Global Benefit-Risk Analysis of Adjunctive Aripiprazole in the Treatment of Patients With Major Depressive Disorder. Pharmacoepidemiology and drug safety. 2009;18:965-972.
13593.	SR W, Stegman D, Trivedi M, et al. Methods of Testing Feasibility for Sequenced Treatment Alternatives to Relieve Depression (Star*D). Journal of psychiatric research. 2004;38:241-248.
13594.	SR W, Stegman D, Trivedi M, et al. Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). Journal of psychiatric research. 2004;38:241-248.
13595.	Srihari V, Martin A. Gained in translation: Evidence-based medicine meets pediatric psychopharmacology. Child and adolescent psychiatric clinics of North America. 2006;15:263-287.
13596.	Srinivasan K. "blues" ain't good for the heart. Indian journal of psychiatry. 2011;53:192-194.
13597.	Srinivasan V, Brzezinski A, SR P-P, DW S, DP C, GM B. Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics? Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:913-923.
13598.	Srinivasan V, D DB, SD S, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert opinion on investigational drugs. 2012;21:1503-1522.
13599.	Srinivasan V, SR P-P, Trakht I, et al. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiatry research. 2009;165:201-214.
13600.	Srisurapanont M. Response and discontinuation rates of newer antidepressants: A meta- analysis of randomized controlled trials in treating depression. Chotmaihet thangphaet [Journal of the Medical Association of Thailand]. 1998;81:387-392.
13601.	Srivastava R, Ahmed H, Dixit R, Dharamveer, Saraf S. Crocus sativus L.: A comprehensive review. Pharmacognosy Reviews. 2010;4:200-208.
13602.	Srivastava S, TA K. Clinical Relevance of Treatments for Acute Bipolar Disorder: Balancing Therapeutic and Adverse Effects. Clinical therapeutics. 2011;33:B40-B48.
13603.	SRL P, LAB C, CS L, MAB DS. Nefazodone in Out-Patient Treatment of Inhaled Cocaine Dependence: a Randomized Double-Blind Placebo-Controlled Trial. Addiction (Abingdon, England). 2005;100:489-494.
13604.	SRL P, LAB C, CS L, MAB DS. Nefazodone in Out-Patient Treatment of Inhaled Cocaine Dependence: a Randomized Double-Blind Placebo-Controlled Trial. Addiction (Abingdon, England). 2005;100:489-494.
13605.	Srour M, Lesperance P, Richer F, Chouinard S. Psychopharmacology of tic disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2008;17:150-159.
13606.	SS B, LA G, SP S, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. Journal of affective disorders. 2008;110:161-166.
13607.	SS B, LA G, SP S, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. Journal of affective disorders. 2008;110:161-166.
13608.	SS D, Zouhair K, Moutawakil B, Hmamouchi B, Benchikhi H. Primary Erythermalgia: Efficacy of Oxcarbazepine. Annales de dermatologie et de venereologie. 2009;136:337-340.
13609.	SS E. Group discussion. Statistics in medicine. 2006;25:3326-3347.
13610.	SS E, Akkaya C, Cangur S, Yuvanc U, Sarandol A, Kirli S. The effects of reboxetine and venlafaxine on ECG variables in depressed patients. [Turkish]. Klinik Psikofarmakoloji Bulteni. 2011;21:11-17.
13611.	SS E, Akkaya C, Sarandol A, Cangur S, Sarandol E, Kirli S. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:955-961.
13612.	SS E, Kirli S, Akkaya C, Cangur S, Sarandol A. Are There Differences Between Serotonergic, Noradrenergic and Dual Acting Antidepressants in the Treatment of Depressed Women? World journal of biological psychiatry. 2009;10:400-408.
13613.	SS G, Utkan T, Gacar N. Chronic Administration of Imipramine but Not Agomelatine and Moclobemide Affects the Nitrergic Relaxation of Rabbit Corpus Cavernosum Smooth Muscle. European journal of pharmacology. 2013;714:442-447.
13614.	SS G, WJ K, SA T, et al. A Double-Blind Placebo-Controlled Pilot Study of Controlled-Release Paroxetine on Depression and Quality of Life in Chronic Heart Failure. American heart journal. 2007;153:868-873.
13615.	SS H. Improving symptoms of pain, erectile dysfunction, and depression in patients on dialysis. Clinical journal of the American Society of Nephrology. 2013;8:5-7.
13616.	SS H, SR B. The pharmacological treatment and management of obesity. Postgraduate medicine. 2011;123:34-44.
13617.	A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. [Review], Kidney international(2012).
13618.	SS K. Role of fluoxetine in anorexia nervosa. Annals of pharmacotherapy. 2003;37:890-892.
13619.	SS L, RC Z. Depression in patients with heart disease: The case for more trials. Future cardiology. 2010;6:547-556.
13620.	SS L, RS M. Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert opinion on pharmacotherapy. 2010;11:2827-2837.
13621.	SS M, BE W, GS A. Neuroplasticity-based computerized cognitive remediation for geriatric depression. International journal of geriatric psychiatry. 2012;27:1239-1247.
13622.	SS M, BE W, Hu W, GS A. Computerized cognitive remediation for geriatric depression. Neuropsychopharmacology. 2013;Conference:S247-S248.
13623.	SS M, FM G, Kanellopoulos D, et al. Semantic organizational strategy predicts verbal memory and remission rate of geriatric depression. International journal of geriatric psychiatry. 2012;27:506-512.
13624.	SS P, DA Y-T, CM B, Lafer B, Fava M, PF R. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: Relationship to treatment response and clinical severity. Biological psychiatry. 1997;42:79-84.
13625.	SS P, PF R, CM B, BC L, Fava M, Yurgelun-Todd D. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Psychiatry research. 1998;84:61-74.
13626.	SS R, Singh M, Parkar M, Sugumaran R. Health maintenance for postmenopausal women. American family physician. 2008;78:583-594.
13627.	SS S, Abu-Arafeh I, AD H. Tension-Type headache in children: The cinderella of headache disorders! Canadian Journal of Neurological Sciences. 2009;36:687-695.
13628.	SS S, Guilleminault C. Emerging drugs for insomnia: New frontiers for old and novel targets. Expert opinion on emerging drugs. 2009;14:411-422.
13629.	SS S, MM R, Stein G, Bernadt M, CLE K. Outcome in refractory depression. Journal of affective disorders. 1999;54:287-294.
13630.	SS S, Yfantis A, Lamboussis E, et al. Escitalopram in Clinical Practice in Greece: Treatment Response and Tolerability in Depressed Patients. Expert opinion on pharmacotherapy. 2009;10:937-945.
13631.	ST G, RM N, NH W, AE K. Methylphenidate and Its Under-recognized, Underexplained, and Serious Drug Interactions: A Review of the Literature with Heightened Concerns. German Journal of Psychiatry. 2013;16:29-42.
13632.	Stacey H, Irina F, Natalia M, C MD. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation. 2005;14:695-703.
13633.	Stadler T, Bader M, Uckert S, Staehler M, Becker A, CG S. Adverse Effects of Drug Therapies on Male and Female Sexual Function. World journal of urology. 2006;24:623-629.
13634.	Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in Serotonergic Pathways Influence the Outcome of Antidepressant Therapy in Psychiatric Inpatients. Genetic testing and molecular biomarkers. 2014;18:20-31.
13635.	Staffan S, R MP. Escitalopram: Superior to Citalopram or a Chiral Chimera? [References]. Psychotherapy and psychosomatics. 2004;73:10-16.
13636.	Stafford L, Berk M, Reddy P, HJ J. Comorbid depression and health-related quality of life in patients with coronary artery disease. Journal of psychosomatic research. 2007;62:401-410.
13637.	Stahl S, Briley M. Understanding pain in depression. Human psychopharmacology. 2004;19:S9-S13.
13638.	Stahl S, Zivkov M, PE R, Panagides J, Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta psychiatrica Scandinavica. Supplementum. 1997;391:22-30.
13639.	Stahl S, Zivkov M, PE R, Panagides J, Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatrica Scandinavica, Supplement. 1997;96:22-30.
13640.	Stain-Malmgren R, A EK, Aberg-Wistedt A, Tham A. Serotonergic function in major depression and effect of sertraline and paroxetine treatment. International clinical psychopharmacology. 2001;16:93-101.
13641.	Stam R. PTSD and stress sensitisation: A tale of brain and body. Part 1: Human studies. Neuroscience and biobehavioral reviews. 2007;31:530-557.
13642.	Stamenkovic M, Blasbichler T, Riederer F, et al. Fluoxetine Treatment in Patients With Recurrent Brief Depression. International clinical psychopharmacology. 2001;16:221-226.
13643.	Stamenkovic M, Pezawas L, M DZ, HN A, Kasper S. Mirtazapine in Recurrent Brief Depression. International clinical psychopharmacology. 1998;13:39-40.
13644.	Stamenkovic M, Schindler S, Kasper S. Fluoxetine in the treatment of poststroke depression: A pilot study. [German]. Der Nervenarzt. 1996;67:62-67.
13645.	Stamenkovic M, Schindler S, Kasper S. Poststroke depression and fluoxetine [11]. American journal of psychiatry. 1996;153:446-447.
13646.	Stamenkovic M, Schindler S, Kasper S. Fluoxetin therapy in poststroke depression: A pilot study. [German]. Der Nervenarzt. 1996;67:62-67.
13647.	Stamenkovic M, Schindler S, Kasper S. Fluoxetin in the Treatment of Poststroke Depression: a Pilot Study. Der Nervenarzt. 1996;67:62-67.
13648.	Stamenkovic M, Schindler S, Kasper S. [Therapy of post-stroke depression with fluoxetine. A pilot project]. [German]. Der Nervenarzt. 1996;67:62-67.
13649.	Stamouli S, Lagari V, Liakouras A, Grigoriou P, Piperos P, Giailoglou D. Outcome of escitalopram treatment based on baseline severity of depression. European neuropsychopharmacology. 2009;Conference:S429.
13650.	Stan K, J CD, Regan F, et al. Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:422-430.
13651.	Stan K, John L, Connie M, Vratislav H. A randomized trail of a specific adherence enhancement program in setraline-treated adults with major depressive disorder in a primary care setting. Progress in neuro-psychopharmacology & biological psychiatry. 2002;26:591-596.
13652.	Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, Subchronic and Withdrawal Sleep Eeg Changes During Treatment With Paroxetine and Amitriptyline - a Double-Blind Randomized Trial in Major Depression. Sleep: Journal of Sleep Research & Sleep Medicine. 1995;18:470-477.
13653.	Star K, Iessa N, NB A, et al. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: A case series analysis. Journal of child and adolescent psychopharmacology. 2012;22:440-451.
13654.	Starcevic V. Treatment of panic disorder: Recent developments and current status. Expert review of neurotherapeutics. 2008;8:1219-1232.
13655.	Stasi C, Rosselli M, AL Z, Laffi G, Milani S. Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions. Hepatology research. 2014;44:9-16.
13656.	Stassen H, I-G A, Angst J, et al. Predicting response to psychopharmacological treatment: Survey of recent results. Pharmacopsychiatry. 2011;44:263-272.
13657.	Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: Cross-comparison between the time courses of improvement. Pharmacopsychiatry. 1999;32:56-60.
13658.	Stathopoulou G, MB P, AC B, JAJ S, MW O. Exercise interventions for mental health: A quantitative and qualitative review. Clinical Psychology: Science and Practice. 2006;13:179-193.
13659.	Staud R. Treatment of fibromyalgia and its symptoms. Expert opinion on pharmacotherapy. 2007;8:1629-1642.
13660.	Stearns V, Isaacs C, Rowland J, et al. A Pilot Trial Assessing the Efficacy of Paroxetine Hydrochloride (Paxil (R)) in Controlling Hot Flashes in Breast Cancer Survivors. Annals of oncology. 2000;11:17-22.
13661.	Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial. Journal of clinical oncology. 2005;23:6919-6930.
13662.	Steckler T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: Is the challenge still ahead? Behavioral Neurobiology of Anxiety and Its Treatment. 2010;Current To:415-428.
13663.	Stedman M, HM P, ES B, Kotz M, JR C, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcoholism, clinical and experimental research. 2010;34:1822-1831.
13664.	Steen A, JA DB. A Double-Blind Six Months Comparative Study of Milnacipran and Clomipramine in Major Depressive Disorder. International clinical psychopharmacology. 1997;12:269-281.
13665.	Stefan B, Martin T, Martin G, Roland vK. Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: An observational study in primary care. European Psychiatry: the Journal of the Association of European Psychiatrists. 2008;23:178-186.
13666.	Stefan W, Markus K, Thomas B. "Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: Meta-analysis": Authors' reply. Psychopharmacology. 2008;199:133-134.
13667.	Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. Journal of palliative medicine. 2008;11:1268-1271.
13668.	Stefano P, F AX, Liliana DO, et al. Treatment of depression with comorbid anxiety disorders: Differential efficacy of paroxetine versus moclobemide. International clinical psychopharmacology. 2003;18:15-21.
13669.	Steidtmann D, Manber R, BA A, et al. Patient treatment preference as a predictor of response and attrition in treatment for chronic depression. Depression and anxiety. 2012;29:896-905.
13670.	Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. Journal of psychiatric research. 2010;44:242-252.
13671.	Steimer W, Zopf K, S VA, et al. Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clinical chemistry. 2005;51:376-385.
13672.	Stein D, A GL. The effects of escitalopram on sleep problems in patients with major depressive disorder or GAD: A comparison with SSRIs and SNRIs. European neuropsychopharmacology. 2011;Conference:S365-S366.
13673.	Steinberg M, Hess K, Corcoran C, et al. Vascular Risk Factors and Neuropsychiatric Symptoms in Alzheimer's Disease: the Cache County Study. International journal of geriatric psychiatry. 2014;29:153-159.
13674.	Steinberg S. The treatment of late luteal phase dysphoric disorder. Life sciences. 1991;49:767-802.
13675.	Steinberg S, Annable L, SN Y, Liyanage N. A Placebo-Controlled Clinical Trial of L-Tryptophan in Premenstrual Dysphoria. Biological psychiatry. 1999;45:313-320.
13676.	Steiner M. Premenstrual dysphoric disorder: An update. General hospital psychiatry. 1996;18:244-250.
13677.	Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: Guidelines for management. Journal of psychiatry & neuroscience. 2000;25:459-468.
13678.	Steiner M. Recognition of premenstrual dysphoric disorder and its treatment. Lancet. 2000;356:1126-1127.
13679.	Steiner M, AL H, Bergeron R, Holland F, MD G, E VE. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. American journal of obstetrics and gynecology. 2005;193:352-360.
13680.	Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C. Gender Differences in Clinical Presentation and Response to Sertraline Treatment of Generalized Anxiety Disorder. Human Psychopharmacology-Clinical and Experimental. 2005;20:3-13.
13681.	Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C. Gender Differences in Clinical Presentation and Response to Sertraline Treatment of Generalized Anxiety Disorder. Human Psychopharmacology-Clinical and Experimental. 2005;20:3-13.
13682.	Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder:A randomized, double-blind, placebo-Controlled trial in Canadian women, Journal of clinical psychiatry(2008).
13683.	Steiner M, Born L. Diagnosis and Treatment of Premenstrual Dysphoric Disorder: an Update. International clinical psychopharmacology. 2000;15:S5-S17.
13684.	Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS drugs. 2000;13:287-304.
13685.	Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Archives of women's mental health. 2003;6:71-77.
13686.	Steiner M, DL S. Validation of a revised visual analog scale for premenstrual mood symptoms: Results from prospective and retrospective trials. Canadian Journal of Psychiatry. 2005;50:327-332.
13687.	Steiner M, Lamont J, Steinberg S, Stewart D, Reid R, Streiner D. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstetrics and gynecology. 1997;90:590-595.
13688.	Steiner M, Li T. Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: Clinical evidence and rationale. CNS drugs. 2013;27:583-589.
13689.	Steiner M, MacDougall M, Berger C, et al. Assessment of sexual drive and desire in women with premenstrual dysphoric disorder who have been treated with fluoxetine. International journal of psychiatry in clinical practice. 2005;9:120-123.
13690.	Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: Pathophysiology and treatment. Journal of clinical psychiatry. 2000;61:17-21.
13691.	Steiner M, Pearlstein T, LS C, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: The role of SSRIs. Journal of women's health. 2006;15:57-69.
13692.	Steiner M, SJ R, Babcock S, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. British journal of obstetrics and gynaecology. 2001;108:462-468.
13693.	Steinert T, Baier H, Froscher W, Jandl M. Epileptic Seizures During Treatment With Antidepressants and Neuroleptics. Fortschritte der Neurologie-Psychiatrie. 2011;79:138-143.
13694.	Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: A case-control study. International journal of epidemiology. 2003;32:961-966.
13695.	Stek ML, B vdWF, Uitdehaag BMJ, Beekman ATF, Hoogendijk WJG. ECT in the treatment of depressed elderly: Lessons from a terminated clinical trial. International journal of geriatric psychiatry. 2007;22:1052-1054.
13696.	Stella B, H FA, E AV, et al. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. International clinical psychopharmacology. 2011;26:206-212.
13697.	Treating PTSD in refugees and asylum seekers within the general health care system. A randomized controlled multicenter study, Behaviour research and therapy(2013).
13698.	Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: A randomized controlled trial, Journal of clinical psychiatry(2007).
13699.	Stephan B, Daniel K, Susan B, E TM. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. International clinical psychopharmacology. 2008;23:317-324.
13700.	Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: A double-blind randomized trial, Journal of clinical psychiatry(2011).
13701.	Stephan E, RR H. Urinary incontinence in older adults. Journal Medical Libanais. 2012;60:220-227.
13702.	Stephen M, Roderick M, C LJ. Limited antidepressant efficacy in depression in dementia, in the context of limited evidence .. Australian and New Zealand journal of psychiatry. 2012;46:595-597.
13703.	Stephen R, Kasper S, Hawellek B, et al. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychological medicine. 1998;28:923-933.
13704.	Stephenson DA, Harris B, Davies RH, et al. The impact of antidepressants on sleep and anxiety: A comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire. Human Psychopharmacology: Clinical and Experimental. 2000;15:529-534.
13705.	Stephenson T. The medicines for children agenda in the UK. British journal of clinical pharmacology. 2006;61:716-719.
13706.	Stevanovic D, Tadic I, Knez R. Are antidepressants effective in quality of life improvement among children and adolescents? A systematic review. [Review]. CNS spectrums. 2014;19:134-141.
13707.	Stevanovic D, Tadic I, Knez R. Are antidepressants effective in quality of life improvement among children and adolescents? A systematic review. CNS spectrums. 2014;19:134-141.
13708.	Steve H, A BJ, Michael B, et al. Exercise therapy for depression in middle-aged and older adults: Predictors of early dropout and treatment failure. Health psychology. 2002;21:553-563.
13709.	Steven CJ. Sertraline treatment of selective mutism: A single-case research trial. Dissertation Abstracts International: Section B: The Sciences and Engineering. 1997;58:3356.
13710.	Steven R, Michael D. Depression and cardiovascular disorders. 2012:541-556.
13711.	Stevens I, HJ G. Adverse event recording in new antidepressants. [German]. Nervenheilkunde. 1996;15:85-91.
13712.	Stevinson C. Potential value of Crocus sativus (saffron) extract for treating depression. Focus on Alternative and Complementary Therapies. 2005;10:193.
13713.	Stevinson C, Ernst E. Safety of hypericum in patients with depression: A comparison with conventional antidepressants. CNS drugs. 1999;11:125-132.
13714.	Stevinson C, Ernst E. A Pilot Study of Hypericum Perforatum for the Treatment of Premenstrual Syndrome. British journal of obstetrics and gynaecology. 2000;107:870-876.
13715.	Stewart A. Choosing an antidepressant: Effectiveness based pharmacoeconomics. Journal of affective disorders. 1998;48:125-133.
13716.	Stewart BD, Mark SW, A CM, Jill S. Which drug for which patient? Is there a fluoxetine responding versus a bupropion responding personality profile? [References]. Clinical practice and epidemiology in mental health. 2013;9.
13717.	Stewart T, Yusim A, Desan P. Depression as a risk factor for cardiovascular disease. Primary psychiatry. 2005;12:36-41.
13718.	Stiefelhagen P. Bipolar psychosis: What is the effect of adjunctive antidepressant treatment?. [German]. MMW Fortschritte der Medizin. 2007;149:21.
13719.	Stiles-Shields C, Smyth A, Glunz C, RR H, Boepple L, D lG. A review of the role of psychiatrists and pediatricians in Outpatient treatment of adolescents with anorexia and bulimia nervosa. Current psychiatry reviews. 2011;7:177-188.
13720.	Stilwell E, Entsuah R, Zhang J. Remission of Individual Symptoms of Depression in Patients Treated With Venlafaxine, Ssris or Placebo. Journal of psychopharmacology (Oxford, England). 2004;18:A13.
13721.	Stilwell E, Entsuah R, Zhang J. Remission of Individual Symptoms of Depression in Patients Treated With Venlafaxine, Ssris or Placebo. Journal of psychopharmacology (Oxford, England). 2004;18:A13.
13722.	Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. British journal of psychiatry. 2002;181:284-294.
13723.	Stoffers J, BA V, Rucker G, Timmer A, Huband N, Lieb K. Pharmacological Interventions for Borderline Personality Disorder. Cochrane database of systematic reviews (Online). 2010.
13724.	Stone M, Laughren T, ML J, et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ (Online). 2009;339:431-434.
13725.	Storch A, Schneider C, Ebersbach G, et al. Depression in Parkinson's Disease - Part 2: Therapy and Management. Fortschritte der Neurologie-Psychiatrie. 2010;78:456-467.
13726.	Stoudemire A, CD H, BJ L, Marquardt M, Dalton S. Lithium intolerance in a medical-psychiatric population. General hospital psychiatry. 1998;20:85-90.
13727.	Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: A randomized, double-blind controlled study, Acta neuropsychiatrica(2013).
13728.	Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: A randomized, double-blind controlled study, Acta neuropsychiatrica(2014).
13729.	Stratta P, Bolino F, Cupillari M, Casacchia M. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. International clinical psychopharmacology. 1991;6:193-196.
13730.	Stratta P, Cupillari M, Casacchia M. A double-blind study comparing fluoxetine with imipramine in the treatment of atypical depression. [Italian]. Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali. 1992;116:148-158.
13731.	Striepens N, KM K, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Frontiers in neuroendocrinology. 2011;32:426-450.
13732.	Strik JJMH, Honig A, Lousberg R, Cheriex EC, M VPH. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients.[Erratum appears in Int Clin Psychopharmacol 1999 Mar;14(2):138 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected]. International clinical psychopharmacology. 1998;13:263-267.
13733.	Strik JJMH, Honig A, Lousberg R, Cheriex EC, M VPH. "Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients": Erratum. International clinical psychopharmacology. 1999;14:138.
13734.	Strnad A, Lennkh C, M DZ. Treatment of Bulimia Nervosa With Antidepressants. Psychopharmakotherapie. 1998;5:19-25.
13735.	Strober M, Deantonio M, Schmidt-Lackner S, et al. The Pharmacotherapy of Depressive Illness in Adolescents: an Open-Label Comparison of Fluoxetine With Imipramine-Treated Historical Controls. Journal of clinical psychiatry. 1999;60:164-169.
13736.	Strohmaier J, Wust S, Henigsberg N, et al. Antidepressant treatment in females and males: Sexual dysfunction and the 5-HTTLPR. Archives of women's mental health. 2011;Conference:S121-S122.
13737.	Sexual Dysfunction During Treatment With Serotonergic and Noradrenergic Antidepressants: Clinical Description and the Role of the 5-Httlpr, World journal of biological psychiatry(2011).
13738.	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR, World journal of biological psychiatry(2011).
13739.	Stryjer R, Budnik D, Ebert T, et al. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs - an open-label study. Clinical neuropharmacology. 2014;37:79-81.
13740.	Stryjer R, Dambinsky Y, Timinsky I, et al. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: An open-label, prospective study. International clinical psychopharmacology. 2013;28:96-98.
13741.	Stryjer R, RD S, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. International clinical psychopharmacology. 2003;18:93-96.
13742.	Stryjer R, Rosenzcwaig S, Bar F, AM U, Weizman A, Spivak B. Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia: a Placebo-Controlled, Double-Blind, Crossover Study. Clinical neuropharmacology. 2010;33:219-222.
13743.	Stryjer R, Spivak B, RD S, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: A preliminary open-label study. Clinical neuropharmacology. 2009;32:82-84.
13744.	Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: A case study, Neuropsychiatric disease and treatment(2015).
13745.	Strzelecki D, Szyburska J, Rabe-Jablonska J. Two Grams of Sarcosine in Schizophrenia - Is It Too Much? A Potential Role of Glutamate-Serotonin Interaction. Neuropsychiatric disease and treatment. 2014;10:263-266.
13746.	Strzelecki D, Tabaszewska A, Barszce Z, Jodzefowicz O, Kropiwnicki P, Rabe-Jablonska J. A 10-Week Memantine Treatment in Bipolar Depression: a Case Report. Focus on Depressive Symptomatology, Cognitive Parameters and Quality of Life. Psychiatry investigation. 2013;10:421-424.
13747.	Stuart N, Paul B. Amisulpride - a Review of Its Clinical Potential in Dysthymia. CNS drugs. 1999;12:471-483.
13748.	Stuart S, Butler P, DJ N, ESJ R. A novel rodent model of affective stateinduced memory bias for psychiatry research and CNS drug safety. European neuropsychopharmacology. 2012;Conference:S35.
13749.	Stuart S, MW OH. The efficacy of psychotherapy for perinatal depression. Economics of Neuroscience. 2001;3:46-51.
13750.	Stubhaug B, SA L, Ursin H, HR E. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: Randomised placebo-controlled trial. British journal of psychiatry. 2008;192:217-223.
13751.	Stucke K, Kieser M. A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design. Statistics in medicine. 2012;31:3579-3596.
13752.	Studd J. Why are physicians reluctant to use estrogens for anything - Or do they prefer 'PROFOX'? Menopause international. 2009;15:52-54.
13753.	Studd J, Panay N. Are oestrogens useful for the treatment of depression in women? Best Practice and Research: Clinical Obstetrics and Gynaecology. 2009;23:63-71.
13754.	Stute P, Kiesel L. Premenstrual syndrome. [German]. Gynakologische Endokrinologie. 2008;6:241-248.
13755.	Su H, J-T W, Z-S L, HT L. Cognitive-exposure therapy for post-traumatic stress disorder. [Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research. 2007;11:7783-7786.
13756.	SU I, Prashker M. Pharmacoeconomic evaluation of antidepressants: A critical appraisal of methods. PharmacoEconomics. 2005;23:595-606.
13757.	Su N, Zhang L, Fei F, et al. The Brain-Derived Neurotrophic Factor Is Associated With Alcohol Dependence-Related Depression and Antidepressant Response. Brain research. 2011;1415:119-126.
13758.	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. [Review], Lancet(2011).
13759.	Subramaniam M, Soh P, JA V, Picco L, SA C. Quality of life in obsessive-compulsive disorder: Impact of the disorder and of treatment. CNS drugs. 2013;27:367-383.
13760.	Suddath R. The role neuroscience in informed consent for antidepressants in adolescents. Clinical Neuropsychiatry. 2006;3:245-255.
13761.	Sugarman P, Mitchell A, Frogley C, GL D, Picchioni M. Off-licence prescribing and regulation in psychiatry: Current challenges require a new model of governance. Therapeutic Advances in Psychopharmacology. 2013;3:233-243.
13762.	Sughondhabirom A, Chamchitchun S. Cost-effectiveness of antidepressant based on discrete event simulation modeling in treatment of major depressive episodes: A comparison of agomelatine versus escitalopram-venlafaxine. Value in health. 2012;Conference:A670.
13763.	Suliman S, Seedat S, Pingo J, Sutherland T, Zohar J, DJ S. Escitalopram in the Prevention of Posttraumatic Stress Disorder: a Pilot Randomized Controlled Trial. BMC psychiatry. 2015;15.
13764.	Sullivan G, MG C, Sherbourne C, et al. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders. General hospital psychiatry. 2007;29:379-387.
13765.	Sullivan M, Bentley S, M-Y F, Gardner G. A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. Pain medicine (Malden, Mass.). 2009;10:806-812.
13766.	Sulser F, Vetulani J, PL M. Mode of action of antidepressant drugs. Biochemical pharmacology. 1978;27:257-261.
13767.	Sultan A, Gaskell H, Derry S, RA M. Duloxetine for Painful Diabetic Neuropathy and Fibromyalgia Pain: Systematic Review of Randomised Trials. BMC neurology. 2008;8.
13768.	Sumiyoshi T. Antipsychotic treatments; focus on lurasidone. Frontiers in pharmacology. 2013.
13769.	Summers R, Dube N, Meyer H. Pharmacovigilance: A vital tool or a wasted effort? SA Pharmaceutical Journal. 2013;80:51-53.
13770.	Sun H, Zhao H, Zhang J, et al. [Effect of acupuncture at Baihui (GV 20) and Zusanli (ST 36) on the level of serum inflammatory cytokines in patients with depression]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2010;30:195-199.
13771.	Sun M, X-P Z, C-Y J, J-Z S, Xu S, Y-L W. clinical observation on treatment of post-craniocerebral traumatic mental disorder by integrative medicine. Chinese journal of integrative medicine. 2008;14:137-141.
13772.	Sun P, XM P, Sun S, et al. Direct Medical Costs and Medication Compliance Among Fibromyalgia Patients: Duloxetine Initiators Vs. Pregabalin Initiators. Pain practice. 2014;14:22-31.
13773.	Sun P, Zhao Y, ZX Z, Watson P. Medication Dosing Patterns Associated With Duloxetine and Pregabalin Among Patients With Fibromyalgia. Current medical research and opinion. 2011;27:1793-1801.
13774.	Sun Y, Bao Y, Wang S, Chu J, Li L. [Efficacy on post-stroke depression treated with acupuncture at the acupoints based on ziwuliuzhu and prozac]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2015;35:119-122.
13775.	Sunami E, Usuda K, Nishiyama Y, Otori T, Katsura K, Katayama Y. A Preliminary Study of Fluvoxamine Maleate on Depressive State and Serum Melatonin Levels in Patients After Cerebral Infarction. Internal medicine (Tokyo, Japan). 2012;51:1187-1193.
13776.	Sundblad C, MA H, Eriksson E. Clomipramine Administered During the Luteal-Phase Reduces the Symptoms of Premenstrual-Syndrome - a Placebo-Controlled Trial. Neuropsychopharmacology. 1993;9:133-145.
13777.	Sunderkotter C, Riemekasten G. Raynaud phenomenon in dermatology. Part 2: Therapy. [German]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2006;57:927-942.
13778.	Sundstrom I, Backstrom T, Wang M, Olsson T, Seippel L, Bixo M. Premenstrual syndrome, neuroactive steroids and the brain. Gynecological endocrinology. 1999;13:206-220.
13779.	Sundstrom I, Nyberg S, Bixo M, Hammarback S, Backstrom T. Treatment of Premenstrual Syndrome With Gonadotropin-Releasing Hormone Agonist in a Low Dose Regimen. Acta obstetricia et gynecologica Scandinavica. 1999;78:891-899.
13780.	Sung M, CH C, CG L, et al. What's in the pipeline? Drugs in development for autism spectrum disorder. Neuropsychiatric disease and treatment. 2014;10:371-381.
13781.	Suppes T, EB D. Evidence-based long-term treatment of bipolar II disorder. Journal of clinical psychiatry. 2002;63:29-33.
13782.	Suppes T, Kelly D, Hynan L, et al. Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder. Australian and New Zealand journal of psychiatry. 2007;41:397-402.
13783.	Suri A, Reddy S, Gonzales C, MP K, RA B, MH S. Duloxetine Pharmacokinetics in Cirrhotics Compared With Healthy Subjects. International journal of clinical pharmacology and therapeutics. 2005;43:78-84.
13784.	Suri A, Reddy S, Gonzales C, MP K, RA B, MH S. Duloxetine Pharmacokinetics in Cirrhotics Compared With Healthy Subjects. International journal of clinical pharmacology and therapeutics. 2005;43:78-84.
13785.	Suri R, Hellemann G, ZN S, LS C, Aquino A, LL A. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. Journal of clinical psychiatry. 2011;72:1002-1007.
13786.	Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials, Journal of psychopharmacology (Oxford, England)(2012).
13787.	Sussman N. Anxiolytic antidepressant augmentation. Journal of clinical psychiatry. 1998;59:42-50.
13788.	Sussman N. Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose. [Review] [40 refs]. Postgraduate medicine. 1999;106:31-36.
13789.	Sussman N. Insight into the sequenced treatment alternatives to relieve depression study. CNS spectrums. 2007;12:898-901.
13790.	Sussman N. In session with Russell T. Joffe, MD: The impact and psychological manifestations of thyroid dysfunction. Primary psychiatry. 2007;14:36-38.
13791.	Sussman N. Counterproductive FDA advisories. Primary psychiatry. 2007;14:15-16.
13792.	Sussman N. Diabetes and depression. Primary psychiatry. 2007;14:13-14.
13793.	Sussman N. Thyroid augmentation: Reassessing an overlooked strategy. Primary psychiatry. 2007;14:14-15.
13794.	Sussman N. Reducing the trial and error factor in antidepressant treatment. Primary psychiatry. 2010;17:16-18.
13795.	Sussman N, DL G, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. Journal of clinical psychiatry. 2001;62:256-260.
13796.	Sutej I, Wiethoff K, Neuhaus K, Bauer M. Pharmacotherapy and psychotherapy in unipolar depression: Is a combined therapy superior to monotherapy?. [German]. Zeitschrift fur Psychiatrie, Psychologie und Psychotherapie. 2006;54:163-172.
13797.	Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: A systematic review and meta-analysis. Drug design, development and therapy. 2014;8:827-838.
13798.	Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and Fluoxetine in the Treatment of Postmenopausal Symptoms: a Prospective, Randomized, 9-Month, Placebo-Controlled, Double-Blind Study. Menopause-the Journal of the North American Menopause Society. 2005;12:18-26.
13799.	Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and Fluoxetine in the Treatment of Postmenopausal Symptoms: a Prospective, Randomized, 9-Month, Placebo-Controlled, Double-Blind Study. Menopause-the Journal of the North American Menopause Society. 2005;12:18-26.
13800.	Suveg C, SG A, PC K. Separation anxiety disorder, panic disorder, and school refusal. Child and adolescent psychiatric clinics of North America. 2005;14:773-795.
13801.	Suzuki H, JM I, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterology and motility. 2009;21:688-696.
13802.	Suzuki T, Remington G, Uchida H, TK R, Graff-Guerrero A, DC M. Management of schizophrenia in late life with antipsychotic medications: A qualitative review. Drugs & aging. 2011;28:961-980.
13803.	Suzuki T, Uchida H, Nakajima S. Depression severity and effect of antidepressant medications [4]. JAMA - Journal of the American Medical Association. 2010;303:1597-1598.
13804.	Suzuki Y, Sawamura K, Someya T. The Effects of a 5-Hydroxytryptamine 1a Receptor Gene Polymorphism on the Clinical Response to Fluvoxamine in Depressed Patients. Pharmacogenomics journal. 2004;4:283-286.
13805.	Suzuki Y, Sawamura K, Someya T. The Effects of a 5-Hydroxytryptamine 1a Receptor Gene Polymorphism on the Clinical Response to Fluvoxamine in Depressed Patients. Pharmacogenomics journal. 2004;4:283-286.
13806.	SV A, DJ N. Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression? Journal of psychopharmacology (Oxford, England). 2013;27:869-877.
13807.	SV A, JA H, JR N, et al. Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. [Review] [29 refs]. Psychiatry research. 2003;120:179-190.
13808.	SV A, SD H, Adrover M, et al. Tryptophan Depletion Reverses the Therapeutic Effect of Selective Serotonin Reuptake Inhibitors in Social Anxiety Disorder. Biological psychiatry. 2004;56:503-509.
13809.	SV A, SD H, Adrover M, et al. Tryptophan Depletion Reverses the Therapeutic Effect of Selective Serotonin Reuptake Inhibitors in Social Anxiety Disorder. Biological psychiatry. 2004;56:503-509.
13810.	SV A, SJ W. Sleep disturbances in depression and the effects of antidepressants. International review of psychiatry. 2005;17:237-245.
13811.	SV P, T-JM K. Adjunct Mirtazapine for Negative Symptoms of Schizophrenia. Pharmacotherapy. 2011;31:1017-1030.
13812.	SV S, Calis K, Grothe D, et al. Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter. Journal of fluency disorders. 2005;30:319-335.
13813.	Svedater H, Thase M, Locklear J, Datto C. Efficacy of extended release Quetiapine Fumarate (Quetiapine XR) in patients with severe Major Depressive Disorder (MDD). International journal of psychiatry in clinical practice. 2009;Conference:43-44.
13814.	Sven L, Owe B, Hans A. Efficacy and Tolerability of Reboxetine Compared With Citalopram - a Double-Blind Study in Patients With Major Depressive Disorder. Journal of clinical psychopharmacology. 2006;26:121-127.
13815.	Svenningsson P, Stan T. Both lurasidone and fluoxetine exerts antidepressant-like effects on novelty-induced hypophagia and reduce nmda receptor subunits along with PSD-95 in mice hippocampus and frontal cortex. Neuropsychopharmacology. 2014;Conference:S605-S606.
13816.	Svensson J, B-A B, M-R T, Wiklund O, Johannsson G. A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth hormone & IGF research. 2000;10:118-126.
13817.	Svensson S, PR M. Escitalopram: Superior to Citalopram or a Chiral Chimera? Psychotherapy and psychosomatics. 2004;73:10-16.
13818.	Svestka J. New psychotropics: Mirtazapine, a noradrenergic and specific serotonergic antidepressant. [Czech]. Psychiatrie (Stuttgart, Germany). 1999;3:248-258.
13819.	Svestka J. New psychotropic drugs: Milnacipran - A fourth generation antidepressant of the first denomination. [Czech]. Psychiatrie (Stuttgart, Germany). 2000;4:46-56.
13820.	Svestka J. New antidepressants: Reboxetine - The first selective noradrenaline reuptake inhibitor. [Czech]. Psychiatrie (Stuttgart, Germany). 2001;5:41-49.
13821.	Svestka J. Bupropion - A dopaminergic and noradrenergic antidepressant. [Czech]. Psychiatrie (Stuttgart, Germany). 2001;5:196-209.
13822.	Svestka J. Aripiprazole, A New Generation Antipsychotic, and only Partial Agonist of Dopamine D2/D3 and Serotonin 5-HT1A Receptors. [Czech]. Psychiatrie (Stuttgart, Germany). 2003;7:279-289.
13823.	Svestka J. Olanzapine in treatment of affective disorders. [Czech]. Psychiatrie (Stuttgart, Germany). 2003;7:194-202.
13824.	Svestka J. Escitalopram - The selective stereoisomer of citalopram. [Czech]. Psychiatrie (Stuttgart, Germany). 2003;7:38-45.
13825.	Svestka J. Duloxetine: A dual specific inhibitor of serotonin and norepinephrine reuptake in the treatment of acute depressive disorder. [Czech]. Psychiatrie (Stuttgart, Germany). 2005;9:23-30.
13826.	Svestka J, Ceskova E, Kamenicka V, Buresova A, al e. Citalopram (Seropram) - Tablets and Infusions - in the treatment of major depression. [Czech]. Ceska a Slovenska Psychiatrie. 1993;89:331-339.
13827.	Svestka J, Mohr P. Agomelatine - An antidepressant with novel mechanism of action. [Czech]. Psychiatrie (Stuttgart, Germany). 2010;14:98-108.
13828.	SW A, DB C, SA C. Long-Term Weight Gain in Patients Treated With Open-Label Olanzapine in Combination With Fluoxetine for Major Depressive Disorder. Journal of clinical psychiatry. 2005;66:1468-1476.
13829.	SW B. A review of fluvoxamine and its uses in depression. International clinical psychopharmacology. 1991;6 Suppl 3:1-1721.
13830.	SW B. A review of fluvoxamine and its uses in depression. [Review] [60 refs]. International clinical psychopharmacology. 1991;6 Suppl 3:1-21.
13831.	SW B, SE T, PK R, CL R. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. Journal of anxiety disorders. 2008;22:310-318.
13832.	SW C, Hu M, Tomlinson B. The pharmacogenetics of beta-adrenergic receptor antagonists in the treatment of hypertension and heart failure. Expert opinion on drug metabolism & toxicology. 2012;8:767-790.
13833.	SW K. A pill for every ill: Is this best for our patients? Consultant pharmacist. 2005;20:237-242.
13834.	SW L. Psychiatric disorders in older women. International review of psychiatry. 2003;15:269-279.
13835.	SW T, Helmeste D. Paroxetine. Expert opinion on pharmacotherapy. 2008;9:787-794.
13836.	SW T, Helmeste D, Leonard B. Is Neurogenesis Relevant in Depression and in the Mechanism of Antidepressant Drug Action? A Critical Review. World journal of biological psychiatry. 2012;13:402-412.
13837.	SW W. Pharmacoeconomic studies of antidepressants: focus on venlafaxine. [Review] [80 refs]. Depression and anxiety. 2000;12 Suppl 1:102-109.
13838.	SW W, JA R. Cost effectiveness of antidepressant treatment reassessed. British journal of psychiatry. 1997;170:257-263.
13839.	Swanson L, Bertram H, Mooney A, et al. Insomnia symptom changes in adults with major depressive disorder treated with fluoxetine and repeated partial sleep deprivation. Sleep. 2012;Conference:A327.
13840.	Swanson L, Burgess H, Holli B, et al. A preliminary investigation of circadian measures and response to fluoxetine and repeated partial sleep deprivation for depression. Sleep. 2015;Conference:A341-A342.
13841.	Swanson L, Langenecker S, Kassel M, et al. Effects of partial sleep deprivation on cognitive performance in major depressive disorder. Sleep. 2011;Conference:A86.
13842.	Swanton A, Reginald P. Medical management of chronic pelvic pain: The evidence. Reviews in Gynaecological Practice. 2004;4:65-70.
13843.	Swardfager W, Herrmann N, RS M, et al. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neuroscience and biobehavioral reviews. 2013;37:911-929.
13844.	Swartz M, Barak Y, Mirecki I, Naor S, Weizman A. Treating Depression in Alzheimer's Disease: Integration of Differing Guidelines. International Psychogeriatrics. 2000;12:353-358.
13845.	Swenne I, Rosling A. No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders. Journal of child and adolescent psychopharmacology. 2011;21:221-227.
13846.	Swift R. Emerging approaches to managing alcohol dependence. American journal of health-system pharmacy. 2007;64:S12-S22.
13847.	SXW P, Agius M. Atypical anti-psychotics in adult bipolar disorder: Current evidence and updates in the nice guidelines. Psychiatria Danubina. 2014;26:322-329.
13848.	SY H, CH Z, MQ C, GJ P, CY H. [Anti-depressive effect of Baisong tablets on the chronic mild unpredicted stress depression in rats]. [Chinese]. Zhong Nan da Xue Xue Bao. 2006;Yi Xue Ban:676-681.
13849.	SY L, MK F, Imanbayev A, JJ G, AP S, HB L. Non-pharmacological prevention of major depression among community-dwelling older adults: A systematic review of the efficacy of psychotherapy interventions. Archives of gerontology and geriatrics. 2012;55:522-529.
13850.	SYH K. Benefits and burdens of placebos in psychiatric research. Psychopharmacology. 2003;171:13-18.
13851.	SZ N, Drury D. Appetite stimulants use in cystic fibrosis. Pediatric pulmonology. 2008;43:209-219.
13852.	SZ Y. Long-term pharmacotherapy in the management of obesity. Journal of the American Medical Association. 1996;276:1907-1915.
13853.	Szadoczky E, Furedi J. [Efficacy and acceptability of tianeptine and sertraline in the acute treatment phase of depression]. [French]. L'Encephale: Revue de psychiatrie clinique biologique et therapeutique. 2002;28:343-349.
13854.	Szalat A, Raz I. Gender-specific care of diabetes. Women's Health. 2007;3:735-764.
13855.	Szanto K, BH M, Houck P, MA D, 3rd RCF. Occurrence and course of suicidality during short-term treatment of late-life depression. Archives of general psychiatry. 2003;60:610-617.
13856.	Szanto K, BH M, PR H, et al. Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. Journal of affective disorders. 2007;98:153-161.
13857.	Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine.[Erratum appears in BMJ. 2005 Apr 2;330(7494):759 Note: Dosage error in article te. BMJ: British Medical Journal. 2005;330:503.
13858.	Szegedi A, Kohnen R, Dienel A, Kieser M. Acute Treatment of Moderate to Severe Depression With Hypericum Extract Ws 5570 (St John's Wort): Randomised Controlled Double Blind Non-Inferiority Trial Versus Paroxetine. British medical journal. 2005;330:503-506.
13859.	Szegedi A, Kohnen R, Dienel A, Kieser M. Acute Treatment of Moderate to Severe Depression With Hypericum Extract Ws 5570 (St John's Wort): Randomised Controlled Double Blind Non-Inferiority Trial Versus Paroxetine. British medical journal. 2005;330:503-506.
13860.	Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics journal. 2005;5:49-53.
13861.	Szegedi A, Schwertfeger N. Mirtazapine: A review of its clinical efficacy and tolerability. Expert opinion on pharmacotherapy. 2005;6:631-641.
13862.	Szegedi A, Wetzel H, Angersbach D, et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry. 1997;30:97-105.
13863.	Szegedi A, Wetzel H, Angersbach D, Philipp M, Benkert O. Response to treatment in minor and major depression: Results of a double-blind comparative study with paroxetine and maprotiline. Journal of affective disorders. 1997;45:167-178.
13864.	Szentagotai A, David D, Lupu V, Cosman D. RATIONAL EMOTIVE BEHAVIOR THERAPY VERSUS COGNITIVE THERAPY VERSUS PHARMACOTHERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: MECHANISMS OF CHANGE ANALYSIS. Psychotherapy (Chicago, Ill.). 2008;45:523-538.
13865.	Szewczyk B, Palucha-Poniewiera A, Poleszak E, Pilc A, Nowak G. Investigational NMDA receptor modulators for depression. Expert opinion on investigational drugs. 2012;21:91-102.
13866.	Szewczyk B, Poleszak E, Sowa-Kucna M, et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacological Reports. 2008;60:588-599.
13867.	Szygula-Jurkiewicz B, Pudlo R, Samborski K, Muzyk P. Depression in Chronic Heart Failure. Kardiochirurgia I Torakochirurgia Polska. 2012;9:502-506.
13868.	T AR, WJr WJ. Rational treatment choices for non-major depressions in primary care: an evidence-based review. [Review] [58 refs]. Journal of general internal medicine. 2002;17:293-301.
13869.	T BK, Bruce LR, H KC, et al. A comparison of the effects of imipramine and fluvoxamine on the thyroid axis. Biological psychiatry. 1994;36:778-779.
13870.	T BK, M CC. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Comprehensive psychiatry. 2003;44:360-369.
13871.	T DJR. "Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial." Reply. JAMA: Journal of the American Medical Association. 2002;288:448-449.
13872.	T DJR, Paolo M, Vincent H, Marc C, David H. Achieving remission with venlafaxine and fluxoetine in major depression: Its relationship to anxiety symptoms. Depression and anxiety. 2002;16:4-13.
13873.	T DO, Schmuel H, Leon G. Melatonin for the treatment of sleep disturbances in major depressive disorder. American journal of psychiatry. 1998;155:1119-1121.
13874.	T HA, S SB, G KS, M CC. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: Differences by sex and menopausal status. Journal of clinical psychiatry. 2007;68:951-958.
13875.	T IM, B TM. Pindolol-paroxetine combination. American journal of psychiatry. 1997;154:1790.
13876.	T LJ, A KT, A KT, et al. Clinical trials-Major depression. Psychopharmacology bulletin. 1996;32:629-635.
13877.	T LJ, A KT, A KT, et al. Bupropion and Venlafaxine Responders Differ in Pretreatment Regional Cerebral Metabolism in Unipolar Depression. Biological psychiatry. 2005;57:220-228.
13878.	T LJ, A KT, A MA, A FM, Dave L, M PR. Venlafaxine but not bupropion decreases cerebrospinal fluid 5- hydroxyindoleacetic acid in unipolar depression. Biological psychiatry. 1999;45:285-289.
13879.	T MR, R JP, A FCM, E LS, F SP. Six Months of Treatment for Depression: Outcome and Predictors of the Course of Illness. American journal of psychiatry. 2006;163:95-100.
13880.	T MR, R JP, Chris F. Relationships among measures of treatment outcome in depressed patients. Journal of affective disorders. 2003;76:127-135.
13881.	T MR, R JP, E LS. The relationship of personality disorders to treatment outcome in depressed outpatients. Journal of clinical psychiatry. 2003;64:259-264.
13882.	T SM, R ZI, F GT, G PM. Olanzapine plus fluoxetine for bipolar disorder: A systematic review and meta-analysis. Journal of affective disorders. 2013;146:310-318.
13883.	T SW, D LP, Vincent G, R PJ. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study. American journal of psychiatry. 1998;155:1339-1345.
13884.	T SW, Vincent G. A placebo-controlled trial of paroxetine in the treatment of major depression. Journal of clinical psychiatry. 1992;53:36-39.
13885.	T SW, Vincent G, John P, Edna G. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacology bulletin. 1990;26:191-196.
13886.	T TN-H, Irene S, J MP, et al. Examining the role of race and ethnicity in relapse rates of major depressive disorder. Comprehensive psychiatry. 2011;52:151-155.
13887.	T TT, V LV. A Double-Blind Parallel Study to Compare Fluoxetine With Doxepin in the Treatment of Major Depressive-Disorders. International clinical psychopharmacology. 1989;4 Suppl 1:51-56.
13888.	T VA, G WH, T WJ. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology. 1990;102:414-416.
13889.	T vZL, Hoshiar A, Kevin P. Antidepressant prevention of depression and cardiovascular sequelae post-acute coronary syndrome: The "AVERT" trial. 2006:213-218.
13890.	T WJ, Scott C. Deputy Editor's Comment. Journal of the American Academy of Child and Adolescent Psychiatry. 2010;49:186-188.
13891.	T-P S, C-C H, I-H W. Add-on rTMS for medication-resistant depression: A randomized, double-blind, sham-controlled trial in Chinese patients. Journal of clinical psychiatry. 2005;66:930-937.
13892.	T-T H, S-Q Z. Effect of fluoxetine on the depressive status and quality of life in patients with stroke. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:6-7.
13893.	T-T Y, F-H H, K-C W, et al. The effect of psychotherapy added to pharmacotherapy on cortisol responses in outpatients with major depressive disorder. Journal of nervous and mental disease. 2009;197:401-406.
13894.	T-Y C, N-S T. Aripiprazole: A dopamine modulator that mimics methylphenidate in producing faster antidepressant effects. Medical hypotheses. 2013;81:183-185.
13895.	A Randomized Controlled Trial of Sertraline for the Treatment of Depression in Persons With Traumatic Brain Injury, Archives of physical medicine and rehabilitation(2009).
13896.	TA B. Pharmacotherapy of depression: A historical analysis. Journal of neural transmission. 2001;108:707-716.
13897.	TA B. Academic psychiatry and the pharmaceutical industry. Psychiatria Danubina. 2006;18:230-233.
13898.	TA B, PK K. Current and emerging directions in the treatment of eating disorders. Substance abuse : research and treatment. 2012;6:33-61.
13899.	Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol, Trials(2011).
13900.	Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol, Trials [Electronic Resource](2011).
13901.	TA F, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing Missing Standard Deviations in Meta-Analyses Can Provide Accurate Results. Journal of clinical epidemiology. 2006;59:7-10.
13902.	TA F, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. International clinical psychopharmacology. 2005;20:49-52.
13903.	TA F, Cipriani A, Barbui C, JR G. Long-term treatment of depression with antidepressants: A systematic narrative review. Canadian Journal of Psychiatry. 2007;52:545-552.
13904.	TA F, DL S, LT Y. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. Journal of affective disorders. 2001;65:173-177.
13905.	TA F, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane database of systematic reviews (Online). 2007.
13906.	TA G, TA P, L'Heureux F, JL H, SE B, DL M. Double-Blind-Study of Adjuvant Buspirone for Fluoxetine-Treated Patients With Obsessive-Compulsive Disorder. American journal of psychiatry. 1993;150:819-821.
13907.	TA H, Laughren T, Racoosin J. Suicidality in Pediatric Patients Treated With Antidepressant Drugs. Archives of general psychiatry. 2006;63:332-339.
13908.	TA H, TP L, JA R. Suicide Rates in Short-Term Randomized Controlled Trials of Newer Antidepressants. Journal of clinical psychopharmacology. 2006;26:203-207.
13909.	TA K. Monotherapy Versus Combined Treatment With Second-Generation Antipsychotics in Bipolar Disorder. Journal of clinical psychiatry. 2008;69:9-15.
13910.	TA K, Citrome L, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Bipolar disorders.Conference.
13911.	TA K, Citrome L, PW W, JL C, Srivastava S. Treatments for bipolar disorder: Can number needed to treat/harm help inform clinical decisions? Acta psychiatrica Scandinavica. 2011;123:175-189.
13912.	TA K, JH G, JA G, JN R, TR T, KP N. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: A randomized trial. Journal of clinical psychiatry. 2006;67:400-406.
13913.	TA K, Miller S, Dell'Osso B, JR C, MA F, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. Journal of affective disorders. 2014;169:S24-S33.
13914.	TA K, PW W, Nowakowska C, WK M. New Medication Treatment Options for Bipolar Disorders. Acta psychiatrica Scandinavica. 2004;110:18-33.
13915.	TA K, PW W, Nowakowska C, WK M. New Medication Treatment Options for Bipolar Disorders. Acta psychiatrica Scandinavica. 2004;110:18-33.
13916.	TA K, WC D. Neuroimaging studies of bipolar depression: Functional neuropathology, treatment effects, and predictors of clinical response. Clinical neuroscience research. 2002;2:182-192.
13917.	TA M, JJ F. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism & related disorders. 2012;18:316-320.
13918.	5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders, Expert opinion on investigational drugs(2013).
13919.	TA P, L'Heureux F, CS R, SE B, JL H, DL M. A Double-Blind, Placebo Controlled-Study of Trazodone in Patients With Obsessive-Compulsive Disorder. Journal of clinical psychopharmacology. 1992;12:156-162.
13920.	TA P, L'Heureux F, JL H, Bihari K, SE B, DL M. A Double-Blind-Study of Adjuvant Buspirone Hydrochloride in Clomipramine-Treated Patients With Obsessive-Compulsive Disorder. Journal of clinical psychopharmacology. 1992;12:11-18.
13921.	TA P, MT P, Lheureux F, et al. A Controlled Comparison of Adjuvant Lithium-Carbonate or Thyroid-Hormone in Clomipramine-Treated Patients With Obsessive-Compulsive Disorder. Journal of clinical psychopharmacology. 1991;11:242-248.
13922.	TA P, MT P, SE B, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: Behavioral and biological results. Archives of general psychiatry. 1990;47:926-932.
13923.	Duloxetine Versus Escitalopram and Placebo: an 8-Month, Double-Blind Trial in Patients With Major Depressive Disorder, Current medical research and opinion(2007).
13924.	TA R, EC L, CE C, et al. Pharmacologic Efficacy in Neuropsychiatry: a Review of Placebo-Controlled Treatment Trials - a Report of the Anpa Committee on Research. Journal of neuropsychiatry and clinical neurosciences. 1999;11:176-189.
13925.	TA S, AB W, Maizels M, DB P. The Use of Antidepressants for Headache Prophylaxis. CNS neuroscience & therapeutics. 2011;17:462-469.
13926.	TA S, ED K, JR B. Panic disorder and migraine: Comorbidity, mechanisms, and clinical implications. Headache. 2013;53:23-45.
13927.	TA T, EI H. Transcranial direct current stimulation for the treatment of major depression. Psychopharm Review. 2013;48:89-96.
13928.	Impact of Two or Less Missing Treatment Sessions on Tdcs Clinical Efficacy: Results From a Factorial, Randomized, Controlled Trial in Major Depression, Neuromodulation(2014).
13929.	TA Z, Gold M, Chari G, RA H. Current issues in depression in Parkinson's disease. American journal of geriatric psychiatry. 1999;7:110-118.
13930.	TA Z, JD S, KG A, JS S, MS O, KL S. Update on treatment of essential tremor. Current treatment options in neurology. 2013;15:410-423.
13931.	TA Z, RA H. Depression in patients with Parkinson's disease: Epidemiology, pathophysiology and treatment options. CNS drugs. 2000;13:253-264.
13932.	Tabachnikov S, Vasylyeva A, Bugaytsov S, YU M. Psychopharmacotherapy depressive disorders of patients suffering from malignant neoplasms. European neuropsychopharmacology. 2008;Conference:S378-S379.
13933.	Tabas G, Beaves M, JP W, Friday P, Mardini H, Arnold G. Paroxetine to Treat Irritable Bowel Syndrome Not Responding to High-Fiber Diet: a Double-Blind, Placebo-Controlled Trial. American journal of gastroenterology. 2004;99:914-920.
13934.	Tabas G, Beaves M, JP W, Friday P, Mardini H, Arnold G. Paroxetine to Treat Irritable Bowel Syndrome Not Responding to High-Fiber Diet: a Double-Blind, Placebo-Controlled Trial. American journal of gastroenterology. 2004;99:914-920.
13935.	Tack J, Broekaert D, Fischler B, L VO, AM G, Janssens J. A Controlled Crossover Study of the Selective Serotonin Reuptake Inhibitor Citalopram in Irritable Bowel Syndrome. Gut. 2006;55:1095-1103.
13936.	Tadayon-Nejad R, Ajilore O, BJ M, et al. Pharmacological modulation of pulvinar-amygdala resting-state neurodynamics in major depression. Biological psychiatry. 2015;Conference:348S.
13937.	Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial, Trials(2010).
13938.	Tadic A, Lieb K. Pharmacological therapy for therapy-resistant depression: New developments. [German]. Der Nervenarzt. 2007;78:551-564.
13939.	Tadic A, Lieb K. Pharmacological Therapy for Therapy-Resistant Depression. New Developments. Der Nervenarzt. 2007;78:551-563.
13940.	Tadic A, MJ M, Rujescu D, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2007;Part B, Ne:the Official Publication of the International Soci.
13941.	Tadic A, MJ M, Rujescu D, et al. The Maoa T941g Polymorphism and Short-Term Treatment Response to Mirtazapine and Paroxetine in Major Depression. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2007;144B:325-331.
13942.	Tadic A, Wagner S, Gorbulev S, et al. Peripheral Blood and Neuropsychological Markers for the Onset of Action of Antidepressant Drugs in Patients With Major Depressive Disorder. BMC psychiatry. 2011;11.
13943.	Tadic A, Wagner S, KF S, et al. The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35:415-420.
13944.	TAFT F. Prenatal Depression and Selective Serotonin Reuptake Inhibitors. International journal of neuroscience. 2010;120:163-167.
13945.	Tajima O. Japanese experience with dual-action antidepressants. International clinical psychopharmacology. 2002;17:S37-S42.
13946.	Takahashi H, Yahata N, Koeda M, et al. Effects of Dopaminergic and Serotonergic Manipulation on Emotional Processing: a Pharmacological Fmri Study. NeuroImage. 2005;27:991-1001.
13947.	Takano A, Suzuki K, Kosaka J, et al. A Dose-Finding Study of Duloxetine Based on Serotonin Transporter Occupancy. Psychopharmacology. 2006;185:395-399.
13948.	Talaei A, M HM, SA ST, SA M. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial. Journal of affective disorders. 2015;174:51-56.
13949.	Talati A, PJ W, DJ P, et al. Remission of maternal depression and child symptoms among single mothers. A STAR*D-child report. Social psychiatry and psychiatric epidemiology. 2007;42:962-971.
13950.	Taleb M, Ph G, JH B, Rouillon F. The tolerability and efficacy of combined antidepressant therapy. [French]. Encephale. 1996;22:450-460.
13951.	Taler M, Bar M, Korob I, et al. Evidence for an Inhibitory Immunomodulatory Effect of Selected Antidepressants on Rat Splenocytes: Possible Relevance to Depression and Hyperactive Mmune Disorders. International immunopharmacology. 2008;8:526-533.
13952.	TAM K. Medscape psychopharmacology today - Talking points about antidepressants and suicide. MedGenMed : Medscape general medicine. 2004.
13953.	TAM K. Psychiatry guest editor's column - International consensus group on bipolar I depression treatment guidelines: Synopsis and discussion. MedGenMed : Medscape general medicine. 2004.
13954.	TAM K. Medscape psychopharmacology today - Psychopharmacology in the New York Times. MedGenMed : Medscape general medicine. 2004.
13955.	Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: A review. Advances in therapy. 2002;19:17-26.
13956.	Tamar W, Frits L, Barbara vZ. Use of selective serotonin reuptake inhibitors in childhood depression. Lancet. 2004;364:659-660.
13957.	Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundamental & clinical pharmacology. 2007;21:9-28.
13958.	Taneja C, GI P, YH J, RA B, RA F, Oster G. Cost-Effectiveness of Adjunctive Therapy With Atypical Antipsychotics for Acute Treatment of Major Depressive Disorder. Annals of pharmacotherapy. 2012;46:642-649.
13959.	Taner E, EY D, Cosar R. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial. Advances in therapy. 2006;23:974-987.
13960.	Taneri Z, Kohler R. Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder. International clinical psychopharmacology. 1989;4 Suppl 1:57-61.
13961.	Tang J-H, Wang G-H, Bai X-G. Combining Acanthopanax Senticosus and Lithium Carbonate in the Treatment of Adolescent Bipolar Depression. [Chinese]. Chinese Mental Health Journal. 2005;19:480-482.
13962.	Tang M, Jiang P, Li H, et al. Antidepressant-like effect of n-3 PUFAs in CUMS rats: Role of tPA/PAI-1 system. Physiology & behavior. 2015;139:210-215.
13963.	Tang Y, Liu Y, Qin L, Zhang R, Chen R. [Concentration increase in Hcy and anti-CCP antibody in the serum of depression rat model induced by chronic unpredictable mild stress]. [Chinese]. Zhong nan da xue xue bao. 2012;Yi xue ban:790-795.
13964.	Tansella M, Thornicroft G, Barbui C, Cipriani A, Saraceno B. Seven criteria for improving effectiveness trials in psychiatry. Psychological medicine. 2006;36:711-720.
13965.	Tanum L. Reboxetine: tolerability and safety profile in patients with major depression. [Review] [12 refs]. Acta psychiatrica Scandinavica. Supplementum. 2000;402:37-40.
13966.	Tanum L. Reboxetine: Tolerability and safety profile in patients with major depression. Acta Psychiatrica Scandinavica, Supplement. 2000;101:37-40.
13967.	Tao R, CS C, Hart J, et al. Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. American journal of psychiatry. 2012;169:381-388.
13968.	Tao R, GJ E, TL M, PA N, BD K. Symptom Improvement and Residual Symptoms During Acute Antidepressant Treatment in Pediatric Major Depressive Disorder. Journal of child and adolescent psychopharmacology. 2010;20:423-430.
13969.	Taragano FE, Bagnatti P, Allegri RF. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression". International psychogeriatrics / IPA. 2005;17:487-498.
13970.	Taraz M, M-R K, Dashti-Khavidaki S, et al. Sertraline Decreases Serum Level of Interleukin-6 (Il-6) in Hemodialysis Patients With Depression: Results of a Randomized Double-Blind, Placebo-Controlled Clinical Trial. International immunopharmacology. 2013;17:917-923.
13971.	Tarlaci S. Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders. Clinical neuropharmacology. 2009;32:254-258.
13972.	Tarolla E, Brugnoli R, Pancheri P. Duloxetine: Clinical efficacy, safety and tolerability in treatment of major depressive disorder. [Italian]. Italian Journal of Psychopathology. 2007;13:258-278.
13973.	TASTL S. Fibromyalgia: Disease synopsis, medication cost effectiveness and economic burden. PharmacoEconomics. 2014;32:457-466.
13974.	Tatiana U, Antonio C, Alessandro Z, Maurizio B. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. [Review] [93 refs]. European neuropsychopharmacology. 2008;18:62-73.
13975.	Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Pharmacotherapy in Depressed Children and Adolescents. World journal of biological psychiatry. 2011;12:11-15.
13976.	Taurines R, Gerlach M, Warnke A, Wewetzer C. Antidepressant Therapy in Childhood and Adolescence. Psychopharmakotherapie. 2010;17:165-174.
13977.	Tauscher-Wisniewski S, Nilsson M, Caldwell C, Plewes J, AJ A. Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. [Review] [21 refs]. Journal of child and adolescent psychopharmacology. 2007;17:713-718.
13978.	Taylor D. Perimenstrual symptoms and syndromes: Guidelines for symptom management and self care. Advanced Studies in Medicine. 2005;5:228-241.
13979.	Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. [Review] [99 refs]. Acta psychiatrica Scandinavica. 2008;118:434-442.
13980.	Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D. Pharmacological interventions for people with depression and chronic physical health problems: Systematic review and meta-analyses of safety and efficacy. British journal of psychiatry. 2011;198:179-188.
13981.	Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant Efficacy of Agomelatine: Meta-Analysis of Published and Unpublished Studies. Bmj-British Medical Journal. 2014;348.
13982.	Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis. Acta psychiatrica Scandinavica. 2014;130:452-469.
13983.	Taylor E. Managing bipolar disorders in children and adolescents. Nature reviews. Neurology. 2009;5:484-491.
13984.	Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - First upgrade. European Child and Adolescent Psychiatry, Supplement. 2004;13:I/7-I/30.
13985.	Taylor SR, Richard K, R HA, et al. Evaluation of sexual functioning in depressed outpatients: A double blind comparison of sustained-release bupropion and sertraline treatment. Journal of clinical psychopharmacology. 2000;20:122-128.
13986.	TB H-M, BT J, Kirsch I. Kirsch et al.'s (2008) calculations are correct: Reconsidering Fountoulakis & Mller's re-analysis of the Kirsch data. International journal of neuropsychopharmacology. 2012;15:1193-1198.
13987.	TB J. Antidepressants and alternative approaches to helping children and adolescents struggling with depression. Ethical human psychology and psychiatry. 2010;12:238-253.
13988.	TB N. A black-box warning for antidepressants in children? New England journal of medicine. 2004;351:1595-1598.
13989.	TB P. Hormonal and nonpharmacologic treatments for premenstrual syndrome and premenstrual dysphoric disorder. Primary psychiatry. 2004;11:48-52.
13990.	TB P, AB S. Long-Term Fluoxetine Treatment of Late Luteal-Phase Dysphoric Disorder. Journal of clinical psychiatry. 1994;55:332-335.
13991.	TB P, Halbreich U, ED B, et al. Psychosocial Functioning in Women With Premenstrual Dysphoric Disorder Before and After Treatment With Sertraline or Placebo. Journal of clinical psychiatry. 2000;61:101-109.
13992.	TB P, KM B, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial. Primary care companion to the Journal of clinical psychiatry. 2005;7:53-60.
13993.	TB S. The relationship between cytokines and pain/depression: A review and current status. Current pain and headache reports. 2007;11:98-103.
13994.	TBM R, CP Z, SC C, Kieling C. Mood disorders in childhood and adolescence. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2013;35:S22-S31.
13995.	TC B, Blier P, DS B, et al. Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. European archives of psychiatry and clinical neuroscience. 2012;262:13-22.
13996.	TC B, Blier P, DS B, et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: A report by the WPA section of pharmacopsychiatry. European archives of psychiatry and clinical neuroscience. 2011;261:S207-S245.
13997.	TC B, Eser D, H-J M. Effects of different antidepressant treatments on the core of depression. Dialogues in clinical neuroscience. 2008;10:309-320.
13998.	TC B, Eser D, Schule C, Born C, Rupprecht R. Selegiline transdermal system in the treatment of depressive disorders. Future neurology. 2007;2:601-611.
13999.	TC B, H-J M. Electroconvulsive therapy and its different indications. Dialogues in clinical neuroscience. 2008;10:105-117.
14000.	TC B, H-J M, Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Current pharmaceutical design. 2006;12:503-515.
14001.	TC B, H-P V, H-J M. Drug Treatment of Depression in the 2000s: an Overview of Achievements in the Last 10 Years and Future Possibilities. World journal of biological psychiatry. 2006;7:198-222.
14002.	TC D, ME T. Bipolar disorder pharmacotherapy. Future neurology. 2007;2:441-450.
14003.	TC P, RC S. Treatment resistant depression: Strategies for primary care topical collection on psychiatry in primary care. Current psychiatry reports. 2013.
14004.	TC P, RC S. Treatment Resistant Depression: Strategies for Primary Care. Current psychiatry reports. 2013;15.
14005.	TC R, BA M, Pretorius R, Malik K. Fatigue: an Overview. American family physician. 2008;78:1173-1180.
14006.	TC S, RR A. Depression and heart disease: Therapeutic implications. Cardiology. 2008;111:75-81.
14007.	TCO H, E VR, PLBJ L. Wishful pharmaceutical thinking. British journal of general practice. 2003;53:971.
14008.	TCTF A, Rays J, RMS T, et al. Effects of antidepressant treatment on cognitive performance in elderly subjects with heart failure and comorbid major depression: An exploratory study. Psychosomatics. 2007;48:22-30.
14009.	TD B. Depression and HIV/AIDS. Current psychiatry reports. 2008;10:280-285.
14010.	TD G, 3rd RCF, BH M, et al. Accelerating Antidepressant Response in Geriatric Depression: a Post Hoc Comparison of Combined Sleep Deprivation and Paroxetine Versus Monotherapy With Paroxetine, Nortriptyline, or Placebo. Journal of geriatric psychiatry and neurology. 1999;12:67-71.
14011.	TD GJ, MA K, RM P, PW G. Antithyroid antibody-linked symptoms in borderline personality disorder. Endocrine. 2003;21:153-158.
14012.	TD P, AJ D, KA K, et al. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult Nonhuman primates. PloS one. 2011.
14013.	TD P, Thirumangalakudi L, Glennon E, et al. Role of Hippocampal Neurogenesis in Mnemonic Segregation: Implications for Human Mood Disorders. World journal of biological psychiatry. 2013;14:602-610.
14014.	TD S, Hatch A, Largay K, et al. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: A pooled analysis. Journal of affective disorders. 2014;162:20-25.
14015.	TD W, BJ VZ, FJ L, et al. Antidepressants Use in Children and Adolescents and the Risk of Suicide. European neuropsychopharmacology. 2006;16:79-83.
14016.	TE O, JG H. Social support and treatment response in older depressed primary care patients. Journals of gerontology. Series B, Psychological sciences and social sciences. 2001;56:P35-P45.
14017.	TE O, JG H. Social support and treatment response in older depressed primary care patients. Journals of gerontology. Series B, Psychological sciences and social sciences. 2001;56:P35-45.
14018.	TE P, Connolly S. Psychopharmacologic Treatment for Pediatric Anxiety Disorders. Child and adolescent psychiatric clinics of North America. 2012;21:789-806.
14019.	TE S, Agren H, Monteleone P, et al. The hidden third: Improving outcome in treatment-resistant depression. Journal of psychopharmacology (Oxford, England). 2012;26:587-602.
14020.	TE S, MX C, Frick C, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008;33:368-377.
14021.	TE S, SM S, RK C. Pregabalin for the treatment of painful neuropathy. Expert review of neurotherapeutics. 2006;6:1629-1635.
14022.	TE W. Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder. Drugs. 2003;63:2395-2411.
14023.	TE W, Biederman J, JS M, et al. Absence of Cardiovascular Adverse Effects of Sertraline in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:573-577.
14024.	TE W, KE W, Keller J, et al. Mood and Neuropsychological Changes in Women With Midlife Depression Treated With Escitalopram. Journal of clinical psychopharmacology. 2006;26:361-366.
14025.	TE W, NR M, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert review of neurotherapeutics. 2011;11:1443-1465.
14026.	The Treatment for Adolescents with Depression Study (TADS): Outcomes over 1 year of naturalistic follow-up, American journal of psychiatry(2009).
14027.	Tecco J, Monreal J, Staner L. Citalopram May Reduce Sympathoadrenal Hyperactivity in Elderly Depressed Patients: an Open Multicenter Study in Belgium and Luxembourg. Psychiatria Danubina. 2011;23:S35-S42.
14028.	Tedeschini E, Fava M, GI P. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: A pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. Journal of clinical psychiatry. 2011;72:98-103.
14029.	Tedeschini E, Fava M, TM G, GI P. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-analysis. European neuropsychopharmacology. 2010;20:562-567.
14030.	Tedlow J, Fava M, Uebelacker L, AA N, JE A, Rosenbaum J. Outcome definitions and predictors in depression. Psychotherapy and psychosomatics. 1998;67:266-270.
14031.	Tendolkar I, G VW, Urner M, RJ V, Fernandez G. Short-Term Duloxetine Administration Affects Neural Correlates of Mood-Congruent Memory. Neuropsychopharmacology. 2011;36:2266-2275.
14032.	Tenor H, Hatzelmann A, Beume R, Lahu G, Zech K, TD B. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: Impact of human pharmacokinetics. Phosphodiesterases as Drug Targets. 2011;Handbook o:85-119.
14033.	Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury - Clinical experience in 111 patients. Progress in neuro-psychopharmacology & biological psychiatry. 2005;29:61-67.
14034.	Tenovuo O. Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury. Current opinion in neurology. 2006;19:528-533.
14035.	Teper E, JT OB. Vascular factors and depression. International journal of geriatric psychiatry. 2008;23:993-1000.
14036.	Teranishi M, Kurita M, Nishino S, et al. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: A blinded, randomized trial. Journal of clinical psychopharmacology. 2013;33:600-607.
14037.	Terao T. Comparison of manic switch onset during fluoxetine and trazodone treatment. Biological psychiatry. 1993;33:477-478.
14038.	Terao T. Female sexual dysfunction and antidepressant use. American journal of psychiatry. 2001;158:326-327.
14039.	Terhardt J, Lederbogen F, Feuerhack A, et al. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clinical neuropharmacology. 2013;36:198-202.
14040.	Teri G, George E, Kurt K. The Outcome of Physical Symptoms with Treatment of Depression. Journal of general internal medicine. 2004;19:813-818.
14041.	Terluin B, D VD, J VDK, Hulshof C, Romeijnders A. Treatment of nervous breakdown, a systematic review. [Dutch]. Huisarts en wetenschap. 2005;48:7-12.
14042.	Terman M, JS T. Light therapy for seasonal and nonseasonal depression: Efficacy, protocol, safety, and side effects. CNS spectrums. 2005;10:647-663.
14043.	Paroxetine controlled-release formulation in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled study in Japan and Korea, Psychiatry and clinical neurosciences(2011).
14044.	Tervonen T, G vV, Buskens E, HL H, Postmus D. A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis. Statistics in medicine. 2011;30:1419-1428.
14045.	Tessmer M. Agomelatine. [German]. Medizinische Monatsschrift fur Pharmazeuten. 2009;32:282-288.
14046.	Tetsu T, Yasushi S, Taku N, et al. Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment. Clinical neuropharmacology. 2015;38:6-10.
14047.	TG C, JS K, AJ R. Focus on venlafaxine: A new option for the treatment of depression. Hospital formulary. 1994;29:25-33.
14048.	TG D. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: A pilot study. Human psychopharmacology. 2000;15:461-469.
14049.	TG D. Efficacy and Safety of Weekly Treatment With Enteric-Coated Fluoxetine in Patients With Major Depressive Disorder. Journal of clinical psychiatry. 2001;62 Suppl 2:48-52.
14050.	TG OC, Creswell C. Cognitive-behavioural therapy for children and adolescents. Psychiatry. 2008;7:363-366.
14051.	TH C, KHO D, Ghazi-Noori S, Rickards H, CE C. Systematic review of antidepressant therapies in Parkinson's disease. [Review] [59 refs]. Parkinsonism & related disorders. 2003;10:59-65.
14052.	TH O. Medical therapy for obstructive sleep apnoea. Proceedings of Singapore Healthcare. 2011;20:279-290.
14053.	TH T, Jow V. Night eating syndrome presenting as anorexia in an athlete: Case report and review. Current sports medicine reports. 2009;8:182-185.
14054.	Thaisetthawatkul P, James P, Dyck B. Treatment of Diabetic and Nondiabetic Lumbosacral Radiculoplexus Neuropathy. Current treatment options in neurology. 2010;12:95-99.
14055.	Thakur M, DG B. Depression in Long-Term Care. Journal of the American Medical Directors Association. 2008;9:82-87.
14056.	Thaler K, Delivuk M, Chapman A, BN G, Kaminski A, Gartlehner G. Second-generation antidepressants for seasonal affective disorder. [Review]. Cochrane database of systematic reviews (Online). 2011;12:CD008591.
14057.	Thaler K, Delivuk M, Chapman A, BN G, Kaminski A, Gartlehner G. Second-Generation Antidepressants for Seasonal Affective Disorder. Cochrane database of systematic reviews (Online). 2011.
14058.	Thaler K, Gartlehner G, RA H, et al. The comparative efficacy of second-generation antidepressants for the accompanying symptoms of depression: A systematic review. European psychiatry. 2011.
14059.	Thapar A, Collishaw S, Potter R, AK T. Managing and preventing depression in adolescents. BMJ (Online). 2010;340:254-258.
14060.	Thase M. Modern depression therapy: Early detection is essential for a good prognosis. [German]. Nervenheilkunde. 1999;18:1-4.
14061.	THH P, FCF I, NY I. Recent development in the search for effective antidepressants using traditional Chinese medicine. Central nervous system agents in medicinal chemistry. 2008;8:64-71.
14062.	Thibaut F, FDL B, Gordon H, Cosyns P, JMW B. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of paraphilias. World journal of biological psychiatry. 2010;11:604-655.
14063.	Thomas F, Johanna S, Veronika S, et al. Different effects of mirtazapine and venlafaxine on brain activation: An open randomized controlled fMRI study. Journal of clinical psychiatry. 2011;72:448-457.
14064.	Thomas K, Monika S, D SS, et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry research. 1999;88:75-88.
14065.	Thomas L, BH M, FX S, et al. Response speed and rate of remission in primary and specialty care of elderly patients with depression. American journal of geriatric psychiatry. 2002;10:583-591.
14066.	Prevalence of treatment-resistant depression in primary care: Cross-sectional data, British journal of general practice(2013).
14067.	Thomas L, Mulligan J, Mason V, et al. Genetic and Clinical Predictors of Treatment Response in Depression: the Genpod Randomised Trial Protocol. Trials. 2008;9.
14068.	Thomas N, Annette S, Julia S, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. Journal of clinical psychopharmacology. 2003;23:155-168.
14069.	Thomas R. The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability. Journal of clinical psychopharmacology. 1994;14:392-395.
14070.	Thompson C. Bridging the gap between psychiatric practice and primary care. International clinical psychopharmacology. 1992;7 Suppl 2:31-36.
14071.	Thompson C. Management of depression in real-life settings: Knowledge gained from large-scale clinical trials. [Portuguese]. Jornal brasileiro de psiquiatria. 1994;43:76S-80S.
14072.	Thompson C. Management of Depression in Real-Life Settings - Knowledge Gained From Large-Scale Clinical-Trials. International clinical psychopharmacology. 1994;9 Suppl 3:21-25.
14073.	Thompson C. Discontinuation of antidepressant therapy: emerging complications and their relevance. Journal of clinical psychiatry. 1998;59:541-548.
14074.	Thompson C. Onset of action of antidepressants: results of different analyses. [Review] [22 refs]. Human psychopharmacology. 2002;17 Suppl 1:S27-32.
14075.	Thompson C. Onset of action of antidepressants: Results of different analyses. Human psychopharmacology. 2002;17:S27-S32.
14076.	Thompson S, Herrmann N, MJ R, KL L. Efficacy and safety of antidepressants for treatment of depression in alzheimer's disease: A metaanalysis. Canadian Journal of Psychiatry. 2007;52:248-255.
14077.	Thompson S, JA R. Risperdal ConstaTM: The first long-acting atypical antipsychotic agent. P and T. 2004;29:555-562.
14078.	Thompson S, KL L, Hermann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert opinion on drug safety. 2004;3:425-440.
14079.	Thornett A. Developing models for assessing the cost-effectiveness of antidepressants in primary care. Primary Care Psychiatry. 2001;7:69-74.
14080.	Thuile J, Even C, Rouillon F. Long-Term Outcome of Anxiety Disorders: a Review of Double-Blind Studies. Current opinion in psychiatry. 2009;22:84-89.
14081.	TI W, PM S, Forrester L, Turner S, White H, MA A. A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. European child & adolescent psychiatry. 2010;19:449-456.
14082.	Tianlun Y, Jun Z, Meifang C. The Effects and Clinical Implications of Drug Therapy on Anxiety and Depression of Patients win Essential Hypertension. [Chinese]. Chinese Mental Health Journal. 2004;18:810-812.
14083.	Tianmei S, MP K, MT L, et al. Pharmacokinetics and Tolerability of Duloxetine Following Oral Administration to Healthy Chinese Subjects. Clinical pharmacokinetics. 2007;46:767-775.
14084.	Tifh C, Dremencov E, FJ B, BHC W. Oxazepam and Temazepam Attenuate Paroxetine-Induced Elevation of Serotonin Levels in Guinea-Pig Hippocampus. International journal of neuropsychopharmacology. 2010;13:807-811.
14085.	Tifh C, P DB, Liao Y, et al. Augmentation With a 5-Ht1a but Not a 5-Ht1b Receptor Antagonist Critically Depends on the Dose of Citalopram. European journal of pharmacology. 2000;397:63-74.
14086.	Tignol J. Treatment of severe depression with paroxetine. European psychiatry. 1993;8:21S-23S.
14087.	Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. International clinical psychopharmacology. 1992;7:91-94.
14088.	Tiihonen J, O-P R, Kauhanen J, HPA H, Salaspuro M. Citalopram in the treatment of alcoholism: A double-blind placebo-controlled study. Pharmacopsychiatry. 1996;29:27-29.
14089.	Tiina T, Brita H, Eija K. Venlafaxine in neuropathic pain following treatment of breast cancer. European journal of pain (London, England). 2002;6:17-24.
14090.	Tillisch K, Chang L. Diagnosis and treatment of irritable bowel syndrome: State of the art. Current gastroenterology reports. 2005;7:249-256.
14091.	Tim O, Pritha D, L FK, et al. Impact of acute administration of escitalopram on the processing of emotional and neutral images: A randomized crossover fMRI study of healthy women. Journal of psychiatry & neuroscience. 2014;39:267-275.
14092.	Timimi S. Child psychiatry and its relationship with the pharmaceutical industry: Theoretical and practical issues. Advances in Psychiatric Treatment. 2008;14:3-9.
14093.	Timmerman L, P dB, Tan BK, et al. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. International clinical psychopharmacology. 1987;2:239-253.
14094.	Timo P, Jouko L. Moclobemide and fluoxetine in treatment of seasonal affective disorder. Journal of affective disorders. 1996;41:93-99.
14095.	Tiwari R, JS T, Sanjay G, KRC R. Pharmaceutical and clinical studies on compound ayurvedic formulation, Saraswata churna. International Research Journal of Pharmacy. 2011;2:77-84.
14096.	TJ A. Central and peripheral neuroendocrine peptides and signalling in appetite regulation: Considerations for obesity pharmacotherapy. Obesity reviews. 2008;9:108-120.
14097.	TJ A, Fudin J, Pandula A, Mirza M. Medication pain management in the elderly: Unique and underutilized analgesic treatment options. Clinical therapeutics. 2013;35:1669-1689.
14098.	TJ E, Kofoed L. An unusual indication for a single-subject clinical trial. Journal of nervous and mental disease. 1994;182:587-590.
14099.	TJ F, MA D, BG P, et al. Endogenous concentrations of DHEA and DHEA-S Decrease with remission of depression in older adults. Biological psychiatry. 2001;50:767-774.
14100.	Improvement in functional outcomes with adjunctive Aripiprazole versus placebo in major depressive disorder: A pooled post Hoc analysis of 3 short-term studies, Primary care companion to the Journal of clinical psychiatry(2012).
14101.	TJ H. Inpatient treatment of depression. Should we combine drugs and psychotherapy?. [German]. Der Nervenarzt. 2005;76:270-277.
14102.	TJ H, JC F, JM P, Lu L, Mittal D. Reduction of patient-reported antidepressant side effects, by type of collaborative care. Psychiatric services (Washington, D.C.). 2015;66:272-278.
14103.	TJ L, BM R, RL F. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harvard review of psychiatry. 2008;16:97-112.
14104.	TJ M. The pharmacoeconomics of venlafaxine in depression. American journal of managed care. 2001;7:S386-S392.
14105.	TJ R, Jahn H, Arlt J, et al. Adjunctive Use of Reboxetine in Schizophrenia. European psychiatry. 2004;19:366-369.
14106.	TJ R, Jahn H, Arlt J, et al. Adjunctive Use of Reboxetine in Schizophrenia. European psychiatry. 2004;19:366-369.
14107.	TJ R, SJ L, Berg-Weger M, GT G. Caregiver health: Health of caregivers of Alzheimer's and other dementia patients topical collection on geriatric disorders. Current psychiatry reports. 2013.
14108.	TJ S. Treatment of adult adhd and comorbid depression. CNS spectrums. 2008;13:14-16.
14109.	TJ S. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS drugs. 2009;23:9-20.
14110.	TJ S. New pharmacologic approaches in the management of osteoarthritis. Arthritis care and research. 2010;62:1174-1180.
14111.	TJ S. Sodium oxybate: A potential new pharmacological option for the treatment of fibromyalgia syndrome. Therapeutic advances in musculoskeletal disease. 2011;3:167-178.
14112.	TJ S. Symptom management in the older adult. 2015 Update. Clinics in geriatric medicine. 2015;31:155-175.
14113.	Supraphysiologic goses of levothyroxine as adjunctive therapy in bipolar depression: A randomized, double-blind, placebo-controlled study, Journal of clinical psychiatry(2014).
14114.	TJ S, Valadez-Meltzer A. Premenstrual Dysphoric Disorder in Adolescents: Case Reports of Treatment With Fluoxetine and Review of the Literature. Journal of adolescent health. 2005;37:518-525.
14115.	TJ T, Syvalahti E, Saarijarvi S, et al. Citalopram as an Adjuvant in Schizophrenia: Further Evidence for a Serotonergic Dimension in Schizophrenia. International clinical psychopharmacology. 1997;12:31-35.
14116.	TK A, CM M. Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI. Journal of sex & marital therapy. 2009;35:311-319.
14117.	TK B. Psychological treatments for hypochondriasis: A narrative review. Current psychiatry reviews. 2014;10:58-69.
14118.	TK B, WA N, Moleman P. Is there a place for benzodiazepines in the treatment of depression?. [Dutch]. Tijdschrift voor psychiatrie. 1992;34:465-482.
14119.	TK B, WW VDB, Moleman P, AG V, JA B. Imipramine dose in relation to therapeutic plasma level: Are clinical trials using imipramine as a positive control flawed? Psychopharmacology. 2005;181:595-599.
14120.	TK B, WW VDB, PG M, JA B, Moleman P. Efficacy and Tolerability of Tranylcypromine Versus Phenelzine: a Double-Blind Study in Antidepressant- Refractory Depressed Inpatients. Journal of clinical psychiatry. 2004;65:1505-1510.
14121.	TK B, WW VDB, PG M, JA B, Moleman P. Comparison of Two-Phase Treatment With Imipramine or Fluvoxamine, Both Followed by Lithium Addition, in Inpatients With Major Depressive Disorder. American journal of psychiatry. 2004;161:2060-2065.
14122.	TK B, WW vdB, PG M, JA B, Moleman P. [Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition]. [Dutch]. Tijdschrift voor psychiatrie. 2006;48:271-281.
14123.	TK B, WW VDB, PG M, Moleman P, JA B. Efficacy of Imipramine in Psychotic Versus Nonpsychotic Depression. Journal of clinical psychopharmacology. 2008;28:166-170.
14124.	TK B, WW VDB, Wijkstra J, et al. Treatment of unipolar psychotic depression: An open study of lithium addition in refractory psychotic depression. Journal of clinical psychopharmacology. 2009;29:513-515.
14125.	TK M, EB R, DS G, et al. High dose IL-2 in patients with malignant melanoma: Impact on depression, neurotoxicity, and treatment adherence. Biological psychiatry. 2011;Conference:179S.
14126.	TK M, Segarra A, EA S, WK G. SSRI adverse events: How to monitor and manage. International review of psychiatry. 2008;20:203-208.
14127.	TK R, BH M, FE L, Lokker C, IIICF R. Use of antidepressants in late-life depression. Drugs & aging. 2008;25:841-853.
14128.	TK R, DS R. The Treatment of Adolescent Depression in the Era of the Black Box Warning. Current opinion in pediatrics. 2005;17:466-472.
14129.	TK R, DS R. The treatment of adolescent depression in the era of the black box warning. [Review] [36 refs]. Current opinion in pediatrics. 2005;17:466-472.
14130.	TK R, KE W. Biologically based treatment approaches to the patient with resistant perinatal depression. Archives of women's mental health. 2013;16:343-351.
14131.	TK R, Miranda D, BH M, et al. The Mmse Is Not an Adequate Screening Cognitive Instrument in Studies of Late-Life Depression. Journal of psychiatric research. 2009;43:464-470.
14132.	TL DS, KL W. Pharmacotherapy of postpartum depression. Expert opinion on pharmacotherapy. 2009;10:2593-2607.
14133.	TL H, HS L, JW L. Lymphocyte Subsets and Viral Load in Male Aids Patients With Major Depression: Naturalistic Study. Psychiatry and clinical neurosciences. 2006;60:687-692.
14134.	TL H, KJ L, PF R. A Review of Treatment Options for Co-Occurring Methamphetamine Use Disorders and Depression. Journal of addictions nursing. 2015;26:14-23.
14135.	TL L, DE B. Reviews of fluvoxamine maleate and testosterone transdermal system. Hospital pharmacy. 1994;29:613+616-618.
14136.	TL L, PW L. Innovative Clinical Trial Designs. Statistics in biosciences. 2011;3:145-168.
14137.	TL M, RR T, JW R, et al. Do children and adolescents have differential responsive rates in placebo-controlled trials of fluoxetine? CNS spectrums. 2007;12:147-154.
14138.	TL P, JH G, JW J, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive-compulsive disorder. American journal of psychiatry. 1987;144:1543-1548.
14139.	TL R, EM M, WD D, HM P. Combination pharmacotherapy sertraline and naltrexone decreases suicidal ideation scores in co-morbid depressed alcoholics. Alcoholism, clinical and experimental research. 2012;Conference:245A.
14140.	TL S. Diaphoresis and pruritus with extended-release venlafaxine [3]. Annals of pharmacotherapy. 1999;33:1009.
14141.	TL S, DA S, LM R, RS G. The need for an iterative process for assessing economic outcomes associated with SSRIs. PharmacoEconomics. 2000;18:205-214.
14142.	TL S, Nihalani N. Tiagabine in anxiety disorders. Expert opinion on pharmacotherapy. 2006;7:1977-1987.
14143.	TL S, Rashid A. Augmentation and combination pharmacotherapy trends in major depressive disorder: Results of a brief survey of psychiatrists. P and T. 2007;32:28-31.
14144.	TL S, SM S. Optimizing antidepressant management of depression: Current status and future perspectives. Depression: From Psychopathology to Pharmacotherapy. 2010;Modern Tre:254-267.
14145.	TM B. Treatment of dysthymia. Journal of family practice. 1997;44:528-529.
14146.	TM dS, RP M, Alvarez C, et al. Depression in Parkinson's disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. Journal of affective disorders. 2008;111:351-359.
14147.	TM I, RK S, Mukherjee S, BS C, ST M. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. British journal of clinical pharmacology. 1983;15 Suppl 3:433S-438S.
14148.	TM M, WJ B. Clinical experience with escitalopram, a stereoisomer antidepressant. Today's Therapeutic Trends. 2003;21:117-126.
14149.	TM M-O, ME T, AL M, Ahl J, Prakash A, LB M. Duloxetine Versus Placebo in Patients With Major Depressive Disorder (Mdd): Assessment of Energy and Vitality in Mdd. European neuropsychopharmacology. 2009;Conference:S425-S426.
14150.	TM P, BG C, ED P, Mulcare L. Discontinuation of Maintenance Selective Serotonin Reuptake Inhibitor Monotherapy After 5 Years of Stable Response: a Naturalistic Study. Journal of clinical psychiatry. 2008;69:1811-1817.
14151.	TM S, LA S. Citalopram in the Treatment of Depressive Disorders: an Open Label, Multicenter Study in China. African Journal of Pharmacy and Pharmacology. 2008;2:59-65.
14152.	TMT N, GD E. Systematic Review: the Treatment of Noncardiac Chest Pain With Antidepressants. Alimentary pharmacology & therapeutics. 2012;35:493-500.
14153.	TN B, JS R, CH B, et al. Screening for neuropathic pain after spinal cord injury with the spinal cord injury pain instrument (SCIPI): a preliminary validation study. Spinal cord. 2014;52:407-412.
14154.	TN C. Apathy in neuropsychiatric disease: Diagnosis, pathophysiology, and treatment. Neurotoxicity research. 2011;19:266-278.
14155.	TN W. Duloxetine in the treatment of osteoarthritis knee pain. Current psychiatry reports. 2010;12:2-3.
14156.	TN W. Prophylactic citalopram treatment in hepatitis C patients on antiviral therapy: Will it limit drug-induced depression and enhance adherence? Current psychiatry reports. 2011;13:1-2.
14157.	TN W, AL M, Desaiah D, CH M, MJ R, DK K. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: A post hoc analysis of 2 trials. Primary care companion to the Journal of clinical psychiatry. 2008;10:270-275.
14158.	The Safety and Tolerability of Duloxetine in Depressed Elderly Patients With and Without Medical Comorbidity, International journal of clinical practice(2007).
14159.	TN W, DA F, Holder-Perkins V. Painful Physical Symptoms in Depression: a Clinical Challenge. Pain medicine (Malden, Mass.). 2007;8:S75-S82.
14160.	TN W, DGS P, BA P, WG L, CG W. Effects of the antidepressant duloxetine on body weight: Analyses of 10 clinical studies. Primary care companion to the Journal of clinical psychiatry. 2006;8:269-278.
14161.	TN W, LM A, Maletic V, DL G. Management of Painful Physical Symptoms Associated With Depression and Mood Disorders. CNS spectrums. 2005;10:1-13.
14162.	TN W, MJ S. Venlafaxine versus sertraline for major depressive disorder. Journal of clinical psychiatry. 2000;61:873-874.
14163.	TO S, Gaster B, MD S, RA D. Systematic Review of Antidepressants in the Treatment of Chronic Low Back Pain. Spine. 2003;28:2540-2545.
14164.	Todd Z, A SC, Gerhard H, Steve S, D LE. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug and alcohol dependence. 2011;118:500-503.
14165.	Todem D, Kim K, Lesaffre E. A sensitivity approach to modeling longitudinal bivariate ordered data subject to informative dropouts. Health services & outcomes research methodology. 2006;6:37-57.
14166.	Todem D, KM K, Lesaffre E. Latent-variable models for longitudinal data with bivariate ordinal outcomes. Statistics in medicine. 2007;26:1034-1054.
14167.	Tohen M, Brunner E, Osuntokun O, Landry J, Schroer R, Thase M. Longer-term efficacy and safety of olanzapine and fluoxetine combination versus fluoxetine monotherapy following successful combination therapy of treatment-resistant depression. Neuropsychopharmacology. 2012;Conference:S349-S350.
14168.	Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies, Journal of clinical psychiatry(2010).
14169.	Tohen M, CC A. Use of electroconvulsive therapy in bipolar depression. American journal of psychiatry. 2015;172:3-5.
14170.	Tohen M, DP M, Case M, et al. Randomised, Double-Blind, Placebo-Controlled Study of Olanzapine in Patients With Bipolar I Depression. British journal of psychiatry. 2012;201:376-382.
14171.	Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: A pooled analysis of controlled studies. Journal of affective disorders. 2013;149:196-201.
14172.	Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacology, biochemistry, and behavior. 2012;100:688-704.
14173.	Tollefson GD, Holman SL. How long to onset of antidepressant action: A m eta-analysis of patients treated with fluoxetine or placebo. International clinical psychopharmacology. 1994;9:245-250.
14174.	Tom B, Manfred U, Christopher B, et al. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. Journal of clinical psychopharmacology. 2013;33:38-44.
14175.	Tomba E. Nowhere patients. Psychotherapy and psychosomatics. 2012;81:69-72.
14176.	Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International clinical psychopharmacology. 1997;12:81-89.
14177.	Tomillero A, MA M. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. 2008;30:643-672.
14178.	Tomislav K, Ivan S, Mirko D. Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats.[Erratum appears in Synapse. 2011 Aug;65(8):832]. Synapse (New York, N.Y.). 2010;64:231-240.
14179.	Tomislav K, Ivan S, Mirko D. "Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats": Erratum. Synapse (New York, N.Y.). 2011;65:832.
14180.	Tomita T, Yasui-Furukori N, Kaneko S. Visual Hallucinations During Duloxetine Treatment in a Patient With Major Depressive Disorder. Clinical neuropharmacology. 2013;36:175-176.
14181.	Tomori S, Braho I, Elezi F. Efficacy of paroxetine compare to fluoxetine in the elderly patient with major depressive disorder. International journal of neuropsychopharmacology. 2012;Conference:156.
14182.	Tondlova H, Bastecky J. Citalopram and dosulepine in adjuvant treatment of oncological pain. [Czech]. Bolest. 2002;5:247-252.
14183.	Tonelli H, CE A, Bertolucci C, DD R. Compulsive buying: Systematic review of the therapeutic options. [Portuguese]. Revista de Psiquiatria do Rio Grande do Sul.
14184.	Tonge B, King N, Klimkeit E, Melvin G, Heyne D, Gordon M. The Self-Efficacy Questionnaire for Depression in Adolescents (SEQ-DA): Development and psychometric evaluation. European child & adolescent psychiatry. 2005;14:357-363.
14185.	Toni G, M BM, Zanetidou S, et al. Physical exercise for late life Major Depression: The SEEDS study. European Journal of Preventive Cardiology. 2014;Conference:S107.
14186.	Tonkin A, Jureidini J. Wishful thinking: Antidepressant drugs in childhood depression. British journal of psychiatry. 2005;187:304-305.
14187.	Topiwala A, Chouliaras L, KP E. Prescribing selective serotonin reuptake inhibitors in older age. Maturitas. 2014;77:118-123.
14188.	Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A. A Possible Antienuretic Effect of Reboxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder: Case Series. Neuropsychobiology. 2005;51:239-242.
14189.	Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A. A Possible Antienuretic Effect of Reboxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder: Case Series. Neuropsychobiology. 2005;51:239-242.
14190.	Toro J. Anorexia nervosa. Medicina clinica. 2001;117:334-335.
14191.	Torrens M, Fonseca F, Mateu G, Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: A systematic review and meta-analysis. Drug and alcohol dependence. 2005;78:1-22.
14192.	Torrens M, Martinez-Sanvisens D, Martinez-Riera R, Bulbena A, Szerman N, Ruiz P. Dual diagnosis: Focusing on depression and recommendations for treatment. Addictive disorders & their treatment. 2011;10:50-59.
14193.	Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta psychiatrica Scandinavica. 2008;118:4-18.
14194.	Torta R, Berra C, Caldera P. Depression as systemic disease: Continuum between psychological, somatic symptoms and therapeutic approach. [Italian]. Rivista di psichiatria. 2005;40:135-141.
14195.	Torta R, Ieraci V. Migraine and depression comorbidity: Antidepressant options. Neurological sciences. 2012;33:S117-S118.
14196.	Torta R, Leombruni P, Borio R, Castelli L. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Human Psychopharmacology-Clinical and Experimental. 2011;26:291-299.
14197.	Toru I, Shlik J, Maron E, Vasar V, DJ N. Tryptophan Depletion Does Not Modify Response to Cck-4 Challenge in Patients With Panic Disorder After Treatment With Citalopram. Psychopharmacology. 2006;186:107-112.
14198.	Toshiaki F. Antidepressant-benzodiazepine combination therapy. American journal of psychiatry. 1999;156:1840.
14199.	Tosun M. Selective serotonin reuptake inhibitors in the treatement of cannabis dependence. Klinik Psikofarmakoloji Bulteni. 2011;Conference:S84.
14200.	Toth I, ID N, DA S. Social Fear Conditioning: a Novel and Specific Animal Model to Study Social Anxiety Disorder. Neuropsychopharmacology. 2012;37:1433-1443.
14201.	Toulkidis V, Loblay R, Stewart G, et al. Chronic fatigue syndrome: Clinical practice guidelines - 2002. Medical journal of Australia. 2002;176:S17-S55.
14202.	Toups M, Xiao G, Xie Y, Carmody T, Kurian B, Trivedi M. Empirical development of depression subtypes using factor analysis of subject self-reports across symptom domains. Neuropsychopharmacology. 2012;Conference:S331.
14203.	Tourian K, Wang Y, YC I. A 10-Month, Open-Label Evaluation of Desvenlafaxine in Japanese Outpatients With Major Depressive Disorder. International clinical psychopharmacology. 2013;28:206-213.
14204.	Tourian K, Yang L, Maffei B, Vialet C, Pitrosky B. Evaluation of the efficacy and safety of desvenlafaxine sustained-release tablets in Asian outpatients with major depressive disorder. International journal of neuropsychopharmacology. 2010;Conference:83.
14205.	Tourian L, LeBoeuf A, J-J B, et al. Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2015;24:41-54.
14206.	Tousoulis D, AS A, Antoniades C, et al. Role of depression in heart failure - Choosing the right antidepressive treatment. International journal of cardiology. 2010;140:12-18.
14207.	Towler P, Molassiotis A, SG B. What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: An integrative overview of reviews. Supportive care in cancer. 2013;21:2913-2923.
14208.	Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: A preliminary study, Journal of clinical psychopharmacology(2008).
14209.	TP G, SS OM. Current pharmacological treatments for nicotine dependence. Trends in pharmacological sciences. 2004;25:42-48.
14210.	TP J, Leinisch E, HJ K. [A clinical challenge. Pragmatic treatment of migraine and concomitant depression]. [Review] [40 refs] [German]. Der Schmerz. 2008;22 Suppl 1:11-16.
14211.	TP L. What's next after 50 years of psychiatric drug development: An FDA perspective. Journal of clinical psychiatry. 2010;71:1196-1204.
14212.	TP U, RE P. A review of empirical evidence of somatic treatment options for the MI/DD population. Psychiatric quarterly. 2008;79:265-273.
14213.	TP W, JM B. Psychiatric adverse effects of corticosteroids. Mayo Clinic proceedings. 2006;81:1361-1367.
14214.	TR A, JF G, Harrow M. A review of medication side effects and treatment adherence in bipolar disorder. Primary psychiatry. 2004;11:48-54.
14215.	TR B. Off-Label Use of Venlafaxine in Psychiatric and Nonpsychiatric Conditions. Primary psychiatry. 2003;10:82-86.
14216.	TR dJ, JG V, Olivier B, MD W. Oxytocin involvement in SSRI-induced delayed ejaculation: A review of animal studies. Journal of sexual medicine. 2007;4:14-28.
14217.	TR E. Evidence Based Review of Escitalopram in Treating Major Depressive Disorder in Primary Care. International clinical psychopharmacology. 2004;19:305-310.
14218.	TR E, Addis A, Iskedjian M. Pharmacoeconomic Analysis of Venlafaxine in the Treatment of Major Depressive Disorder. PharmacoEconomics. 1997;12:286-296.
14219.	TR E, Addis A, Mittmann N, Iskedjian M. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. Canadian Journal of Clinical Pharmacology. 1998;5:205-216.
14220.	TR E, Arikian S, Sweeney S, Doyle J. A Model to Evaluate the Cost-Effectiveness of Oral Therapies in the Management of Patients With Major Depressive-Disorders. Clinical therapeutics. 1995;17:136-153.
14221.	TR E, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiology and drug safety. 2005;14:823-827.
14222.	TR F, CA VF, MW R. Caring for the older person with chronic obstructive pulmonary disease. JAMA - Journal of the American Medical Association. 2012;308:1254-1263.
14223.	TR H, Dossenbach M, Meneades L, WH C, Simhandl C. Antidepressant use in the psychiatrist setting in Austria: A comparison of citalopram, fluoxetine, and paroxetine. Journal of Serotonin Research. 1998;4:295-303.
14224.	TR H, Hammerquist R, Termaat J. Withdrawal Symptoms After Gabapentin Discontinuation. American journal of health-system pharmacy. 2010;67:910-912.
14225.	TR J, DJ S, Despiegel N, PB D, MEH H, DS B. Cost-Effectiveness Analysis of Escitalopram Compared With Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom. Annals of pharmacotherapy. 2006;40:1752-1758.
14226.	TR L, JQ M, Mendelson T, Robins C. Dialectical behavior therapy for depressed older adults: A randomized pilot study. American journal of geriatric psychiatry. 2003;11:33-45.
14227.	TR M, AM E. Depression in women across the life cycle. Journal of pharmacy practice. 2001;14:511-525.
14228.	TR N. Prospects for the Treatment of Depression. Australian and New Zealand journal of psychiatry. 2006;40:394-401.
14229.	TR N, GD B. Emerging treatments for major depression. Expert review of neurotherapeutics. 2007;7:203-213.
14230.	TR N, JS O. New Formulations of Existing Antidepressants - Advantages in the Management of Depression. CNS drugs. 2004;18:505-520.
14231.	TR N, JS O. New Formulations of Existing Antidepressants - Advantages in the Management of Depression. CNS drugs. 2004;18:505-520.
14232.	TR N, JS O. Continuation treatment of major depressive disorder: is there a case for duloxetine?. [Review] [58 refs]. Drug design, development and therapy. 2010;4:19-31.
14233.	TR N, RK G, GD B, Parker G, FK J. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. International clinical psychopharmacology. 1993;8:25-29.
14234.	TR P, KE T, Breen G, et al. ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. Journal of psychopharmacology (Oxford, England). 2013;27:609-615.
14235.	TR P, LC S, AL H, et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European neuropsychopharmacology. 2013;23:1105-1114.
14236.	TR P, LC S, AL H, et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European neuropsychopharmacology. 2013;23:1105-1114.
14237.	TR P, RG S, Hackinger S, et al. Dna Methylation in Interleukin-11 Predicts Clinical Response to Antidepressants in Gendep. Translational psychiatry. 2013;3.
14238.	TR P, RG S, Hackinger S, et al. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl Psychiatry Psychiatry. 2013;3:e300.
14239.	TR Z, MAFJ VdL, JA W, LM A, JI H. The lack of a placebo effect in a trial of fluoxetine in the treatment of fibromyalgia [1] (multiple letters). American journal of medicine. 2002;113:614.
14240.	TR Z, Taal E, Mafj VDL, JJ R. Validation of a Dutch Translation of the Fibromyalgia Impact Questionnaire. Rheumatology. 2007;46:131-134.
14241.	Traeger L, JA G, Fernandez-Robles C, JS T, WF P. Evidence-based treatment of anxiety in patients with cancer. Journal of clinical oncology. 2012;30:1197-1205.
14242.	Tramontina S, CP Z, Pheula G, LA R. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: An open clinical trial. Journal of child and adolescent psychopharmacology. 2007;17:129-134.
14243.	Trankner A, Sander C, Schonknecht P. A Critical Review of the Recent Literature and Selected Therapy Guidelines Since 2006 on the Use of Lamotrigine in Bipolar Disorder. Neuropsychiatric disease and treatment. 2013;9:101-111.
14244.	Tranter R, Bell D, Gutting P, Harmer C, Healy D, IM A. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. Journal of affective disorders. 2009;118:87-93.
14245.	Tranulis C, Skalli L, Nicole L, Stip E. Benefits and risks of antipsychotic polypharmacy: An evidence-based review of the literature. Drug safety. 2008;31:7-20.
14246.	Trappler B. Treatment of Obsessive-Compulsive Disorder Using Clomipramine in a Very Old Patient. Annals of pharmacotherapy. 1999;33:686-690.
14247.	Trento M, Kucich C, Tibaldi P, et al. A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care. Journal of endocrinological investigation. 2010;33:624-628.
14248.	Treuer T, CY L, Salazar G, et al. Use of Antidepressants in the Treatment of Depression in Asia: Guidelines, Clinical Evidence, and Experience Revisited. Asia-Pacific Psychiatry. 2013;5:219-230.
14249.	Trevor YL. What is the best treatment for bipolar depression? [References]. Journal of psychiatry & neuroscience. 2008;33:487-488.
14250.	Trevor YL, T JR, C RJ, M MG, Michael M, Irene P-S. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American journal of psychiatry. 2000;157:124-126.
14251.	Triebwasser J, LJ S. Pharmacotherapy of personality disorders. Journal of mental health (Abingdon, England). 2007;16:5-50.
14252.	Triezenberg D, Vachon D, Helmen J. How should you manage a depressed patient unresponsive to an SSRI? Journal of family practice. 2006;55:1081-1082+1087.
14253.	Triezenberg D, Vachon D, Helmen J. How Should You Manage a Depressed Patient Unresponsive to an Ssri? Journal of family practice. 2006;55:1081-+.
14254.	Triin E, Kaja M, Ija T, Eduard M, Raivo U, Veiko V. Thyroid autoimmunity and treatment response to escitalopram in major depression. Nordic journal of psychiatry. 2010;64:253-257.
14255.	Trisha S. Is there a role for antidepressants in the treatment of bipolar II depression? [References]. American journal of psychiatry. 2010;167:738-740.
14256.	Trivedi M, Kholi A, VK V, RK D. Comparative study of safety and efficacy of duloxetine versus escitalopram:A Randomised Control Trial. International Journal of Pharmaceutical and Phytopharmacological Research. 2012;2:216-221.
14257.	Trivedi M, PJ M, Fava M, et al. The establishing moderators and biosignatures of antidepressant response for clinical care (EMBARC) study: Rationale, design and progress. Neuropsychopharmacology. 2013;Conference:S393-S394.
14258.	Trivedi M, Toups M, Carmody T, et al. Non-steroidal anti-inflammatory drug use is associated with lower remission rate with escitalopram but not with other antidepressants. Neuropsychopharmacology. 2012;Conference:S356.
14259.	Trkanjec Z. Post stroke dementia and Post stroke depression. Periodicum Biologorum. 2012;114:377-385.
14260.	Trockel M, Burg M, Jaffe A, Barbour K, CB T. Smoking behavior postmyocardial infarction among ENRICHD trial participants: Cognitive behavior therapy intervention for depression and low perceived social support compared with care as usual. Psychosomatic medicine. 2008;70:875-882.
14261.	Troeung L, SJ E, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PloS one. 2013.
14262.	TS H. The use of tyramine sulphate excretion as a biological marker predicting treatment response in major depression. Biogenic Amines. 1993;9:403-430.
14263.	TS H, KL G. Long-Acting Risperidone: A Review of Its Use in Schizophrenia. CNS drugs. 2004;18:113-132.
14264.	TS J, M-M B, S HJ, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes & vascular disease research. 2006;3:108-119.
14265.	TS L, KT K, Laitila J, Martensson K, PJ N. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. European journal of clinical pharmacology. 1998;54:761-766.
14266.	TS W, YH C, IS S. Combined Treatment of Olanzapine and Mirtazapine in Anorexia Nervosa Associated With Major Depression. Progress in neuro-psychopharmacology & biological psychiatry. 2006;30:306-309.
14267.	Tsao D, JS W, Rashid N, et al. Serotonin-Induced Hypersensitivity Via Inhibition of Catechol O-Methyltransferase Activity. Molecular pain. 2012;8.
14268.	Tsaousides T, TA A, WA G. Diagnosis and treatment of depression following traumatic brain injury. Brain impairment. 2013;14:63-76.
14269.	TSS R, Andrade C. Exploring new frontiers in neuropsychopharmacology: SSRIs for stroke. Indian journal of psychiatry. 2011;53:283-286.
14270.	Tsutsui S. Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes: Double-blind, Parallel Group Study with trazodone HCl. [Japanese]. Japanese Pharmacology and Therapeutics. 2000;28:S161-S185.
14271.	Tsutsui S, Okuse S, Sasaki D, et al. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of depression and depressive state: A double blind, group comparison study of sertraline hydrochloride vs. trazodone hydrochloride. [Japanese]. Japanese Journal of Neuropsychopharmacology. 1997;19:549-568.
14272.	Tsuyoshi M, Rei W, Motohide F, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Progress in neuro-psychopharmacology & biological psychiatry. 2012;37:222-226.
14273.	TT L, Cortes-Ladino A, Weiss M, ML P. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. [Review] [29 refs]. General hospital psychiatry. 2008;30:372-377.
14274.	TT P, RN R, DJ H, et al. Early augmentation of sertraline with methylphenidate [2]. Journal of clinical psychiatry. 1999;60:123-124.
14275.	TT Y, LJ W, WH K, et al. Brain-Derived Neurotrophic Factor Val66met Polymorphism Association With Antidepressant Efficacy: a Systematic Review and Meta-Analysis. Asia-Pacific Psychiatry. 2014;6:241-251.
14276.	Tuccori M, Montagnani S, Testi A, et al. Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update. [Review] [79 refs]. Postgraduate medicine. 2010;122:49-65.
14277.	Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. [Review] [125 refs]. Clinical therapeutics. 2009;31 Pt 1:1426-1453.
14278.	Tucker I. Management of inappropriate sexual behaviors in dementia: A literature review. International Psychogeriatrics. 2010;22:683-692.
14279.	Tucker P, KL B, Burgin C, et al. Paroxetine Treatment of Depression With Posttraumatic Stress Disorder - Effects on Autonomic Reactivity and Cortisol Secretion. Journal of clinical psychopharmacology. 2004;24:131-140.
14280.	Tucker P, KL B, Burgin C, et al. Paroxetine Treatment of Depression With Posttraumatic Stress Disorder - Effects on Autonomic Reactivity and Cortisol Secretion. Journal of clinical psychopharmacology. 2004;24:131-140.
14281.	Tucker P, KL S, Marx B, Jones D, R MJ, Lensgraf J. Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. Journal of clinical psychopharmacology. 2000;20:367-372.
14282.	Tucker P, WD R, Masters B, et al. Neuroimmune and Cortisol Changes in Selective Serotonin Reuptake Inhibitor and Placebo Treatment of Chronic Posttraumatic Stress Disorder. Biological psychiatry. 2004;56:121-128.
14283.	Tucker P, WD R, Masters B, et al. Neuroimmune and Cortisol Changes in Selective Serotonin Reuptake Inhibitor and Placebo Treatment of Chronic Posttraumatic Stress Disorder. Biological psychiatry. 2004;56:121-128.
14284.	Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, CD P. Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. Journal of clinical psychiatry. 2001;62:860-868.
14285.	Tucker S, Ahl M, H-H C, et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Current Alzheimer research. 2006;3:221-227.
14286.	Tulner DM, Smith ORF, Schins A, et al. Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: Data from the MIND-IT. Neuropsychobiology. 2011;63:169-176.
14287.	Tuma I, Tvrda V, Libiger J. Zolpidem and perceptual disturbances. [Czech]. Psychiatrie (Stuttgart, Germany). 2002;6:169-172.
14288.	Tundo A, Cavalieri P. Antidepressant treatment in bipolar depression: A vexing clinical problem. [Italian]. Italian Journal of Psychopathology. 2007;13:243-254.
14289.	Tundo A, Cavalieri P, Navari S, Marchetti F. Treating Bipolar Depression - Antidepressants and Alternatives: a Critical Review of the Literature. Acta neuropsychiatrica. 2011;23:94-105.
14290.	Tung-Ping S, J SP, A DM, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997;16:346-356.
14291.	Turgay A. Atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder. Therapy. 2006;3:19-38.
14292.	Turner B, Williams S, Taichman D, TL F, RL K. Depression. Annals of internal medicine. 2010;152:ITC5-1-ITC5-16.
14293.	Turner P, Kantaria R, AH Y. A Systematic Review and Meta-Analysis of the Evidence Base for Add-on Treatment for Patients With Major Depressive Disorder Who Have Not Responded to Antidepressant Treatment: a European Perspective. Journal of psychopharmacology (Oxford, England). 2014;28:85-98.
14294.	Turner R. Quality of life: experience with sertraline. International clinical psychopharmacology. 1994;9 Suppl 3:27-31.
14295.	Turner-Stokes L, Hassan N, Pierce K, Clegg F. Managing depression in brain injury rehabilitation: The use of an integrated care pathway and preliminary report of response to sertraline. Clinical rehabilitation. 2002;16:261-268.
14296.	TW C. Treatment approaches to symptoms associated with frontotemporal degeneration. Current psychiatry reports. 2005;7:376-380.
14297.	TW C, BG P, NW M. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatric disease and treatment. 2007;3:627-636.
14298.	TW H, Marcangelo M. Psychiatric issues in solid organ transplantation. Harvard review of psychiatry. 2009;17:398-406.
14299.	TW M. Psychopharmacological issues in the treatment of TBI and PTSD. Clinical neuropsychologist. 2009;23:1338-1367.
14300.	TW M, Newton W. Are there differences by gender in response to pharmacotherapy for depression? Journal of family practice. 2000;49:1149.
14301.	Modulation of cortical activity by transcranial direct current stimulation in patients with affective disorder, PloS one(2014).
14302.	Tylee A. The patient's perspective on antidepressant therapy: Patient preferences from the DEPRES II Survey and the Patient Preference Study. Primary Care Psychiatry. 1999;5:S25-S27.
14303.	Tylee A, Beaumont G, MW B, Reynolds A. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry. 1997;3:51-58.
14304.	Tylee A, Gastpar M, JP L, Mendlewicz J. Identification of Depressed Patient Types in the Community and Their Treatment Needs: Findings From the Depres Ii (Depression Research in European Society Ii) Survey. International clinical psychopharmacology. 1999;14:153-165.
14305.	Tyrer P, AW B. Drug treatment for personality disorders. Advances in Psychiatric Treatment. 2004;10:389-398.
14306.	Tyrer P, CA M, Casey P, Seivewright N. Clinical efficacy of paroxetine in resistant depression. Journal of psychopharmacology (Oxford, England). 1987;1:251-257.
14307.	Tyszkowska M, Adamowski T. Risperidone in old age psychiatry. [Polish]. Psychogeriatria Polska. 2006;3:31-42.
14308.	TZ T, RJ D, SD H, Amsterdam J, Shelton R, Schalet B. Personality change during depression treatment: a placebo-controlled trial. Archives of general psychiatry. 2009;66:1322-1330.
14309.	Tzanakaki M, Guazzelli M, Nimatoudis I, NP Z, Smeraldi E, Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.[Erratum appears in Int Clin Psychopharmacol 2000 Mar;15(2):120]. International clinical psychopharmacology. 2000;15:29-34.
14310.	Tzavellas E, Karaiskos D, Spengos K, et al. Duloxetine versus sertraline in the treatment of post-stroke depression. European neuropsychopharmacology. 2010;Conference:S387.
14311.	U DO, Yurttas L, Ozkay Y, UI U, OD C, Ozturk Y. Synthesis of new 1-phenyl-2-(4-substituted-piperazin-1-yl)-propanol derivatives and evaluation of their antidepressant-like effects. Archives of pharmacal research. 2013;36:802-811.
14312.	U vB, Holsboer F, Gerken A, Benkert O. Mood elevating effect of fluoxetine in a diagnostically homogeneous inpatient population with major depressive disorder. International clinical psychopharmacology. 1989;4 Suppl 1:31-35.
14313.	UA S, SK C, DK J. The tolerance and antidepressive activity of fluvoxamine as a single dose compared to a twice daily dose. Current medical research and opinion. 1985;9:681-690.
14314.	UB K. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial. Danish Medical Journal. 2012;59:B4426.
14315.	The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder: - An experimental medicine blinded controlled trial, Danish Medical Journal(2012).
14316.	UB W, JR R, AS J. Assessing the efficacy of antidepressants: The transactional paradigm. Medical hypotheses. 2005;64:1229-1236.
14317.	UC A, AH M, HM C. Inflammatory aspects of depression. Inflammation and Allergy - Drug Targets. 2008;7:19-23.
14318.	Homeopathy for depression--DEP-HOM: study protocol for a randomized, partially double-blind, placebo controlled, four armed study, Trials [Electronic Resource](2011).
14319.	Homeopathy for Depression - Dep-Hom: Study Protocol for a Randomized, Partially Double-Blind, Placebo Controlled, Four Armed Study, Trials [Electronic Resource](2011).
14320.	Homeopathy for Depression - Dep-Hom: Study Protocol for a Randomized, Partially Double-Blind, Placebo Controlled, Four Armed Study, Trials(2011).
14321.	UC A, NMP P, AT C, et al. Homeopathic Individualized Q-Potencies Versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority Trial. Evidence-Based Complementary and Alternative Medicine. 2011:1-7.
14322.	Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. [Review] [57 refs]. Arthritis & Rheumatism-Arthritis Care & Research. 2008;59:1279-1298.
14323.	Uceyler N, Offenbacher M, Petzke F, Hauser W, Sommer C. New treatment options for fibromyalgia: Critical appraisal of duloxetine. Neuropsychiatric disease and treatment. 2008;4:525-529.
14324.	Uchida H, Takeuchi H, Nomura K, Suzuki T, Watanabe K, Kashima H. A Randomized Open-Label Trial of Paroxetine Versus Paroxetine Plus Sulpiride in the Treatment of Major Depressive Disorder. International clinical psychopharmacology. 2005;20:A16.
14325.	Uchida H, Takeuchi H, Nomura K, Suzuki T, Watanabe K, Kashima H. A Randomized Open-Label Trial of Paroxetine Versus Paroxetine Plus Sulpiride in the Treatment of Major Depressive Disorder. International clinical psychopharmacology. 2005;20:A16.
14326.	Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. [Review]. Australian and New Zealand journal of psychiatry. 2010;44:978-996.
14327.	Udina M, Hidalgo D, Navines R, et al. Prophylactic Antidepressant Treatment of Interferon-Induced Depression in Chronic Hepatitis C: a Systematic Review and Meta-Analysis. Journal of clinical psychiatry. 2014;75:E1113-+.
14328.	Udina M, Hidalgo D, Navines R, et al. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. [Review]. Journal of clinical psychiatry. 2014;75:e1113-1121.
14329.	Udo D, T BB, Iris B, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: Positive effects on symptom reduction, psychopathology and remission rates. Human Psychopharmacology: Clinical and Experimental. 2008;23:587-593.
14330.	Udupa K, Thirthalli J, TN S, KR K, TR R, BN G. Differential actions of antidepressant treatments on cardiac autonomic alterations in depression: A prospective comparison. Asian journal of psychiatry. 2011;4:100-106.
14331.	UE M, RC A, Gurland B, MC R. Management of persistent pain in the older patient: A clinical review. JAMA - Journal of the American Medical Association. 2014;312:825-836.
14332.	Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry. 2002;35:175-181.
14333.	Uehleke B, Schaper S, Dienel A, Schlaefke S, Stange R. Phase Ii Trial on the Effects of Silexan in Patients With Neurasthenia, Post-Traumatic Stress Disorder or Somatization Disorder. Phytomedicine. 2012;19:665-671.
14334.	Uehlinger C, Nil R, Amey M, Baumann P, Dufour H. Citalopram-lithium combination treatment of elderly depressed patients: A pilot study. International journal of geriatric psychiatry. 1995;10:281-287.
14335.	UF M, Moncrieff J. The antidepressant debate continues [1] (multiple letters). British journal of psychiatry. 2002;181:531.
14336.	UF M, OH R, H-P M, Bakke O, Loeb M. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)- I: Randomised double blind study. BMJ (Clinical research ed.). 1999;318:1180-1184.
14337.	UF M, OH R, H-P M, Bakke O, Loeb M, Smedsrud T. Predicting antidepressant response in general practice. Nordic journal of psychiatry. 1998;52:99.
14338.	UG A, Elovaara S, Harma P, et al. Clinical multicentre study of citalopram compared double-blindly with mianserin in depressed patients in Finland. Nordisk Psykiatrisk Tidsskrift. 1988;42:201-210.
14339.	UH P, Lenhard P, Metz M. Therapy of depression in the psychiatrist's office - A double-blind multicenter study. [German]. Nervenheilkunde. 1990;9:28-31.
14340.	Uher R. Inflammatory biomarkers predict differential outcome of depression treatment with escitalorpam and nortriptyline in the gendep project. Neuropsychopharmacology. 2013;Conference:S7.
14341.	Uher R, Carver S, RA P, et al. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological medicine. 2012;42:2027-2035.
14342.	Uher R, Carver S, RA P, et al. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological medicine. 2012;42:2027-2035.
14343.	Uher R, Huezo-Diaz P, Perroud N, et al. Genetic Predictors of Response to Antidepressants in the Gendep Project. Pharmacogenomics journal. 2009;9:225-233.
14344.	Uher R, KE T, Malki K, RH P. Biomarkers Predicting Treatment Outcome in Depression: What Is Clinically Significant? Pharmacogenomics. 2012;13:233-240.
14345.	Uher R, KE T, Rietschel M, et al. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. American journal of psychiatry. 2013;170:207-217.
14346.	Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. International journal of neuropsychopharmacology. 2011;14:367-375.
14347.	Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, Journal of clinical psychiatry(2011).
14348.	Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: A secondary analysis of data from the genome-based therapeutic drugs for depression (GENDEP) study, Journal of clinical psychiatry(2011).
14349.	Uher R, Muthen B, Souery D, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychological medicine. 2010;40:1367-1377.
14350.	Uher R, Muthen B, Souery D, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychological medicine. 2010;40:1367-1377.
14351.	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline, Journal of affective disorders(2011).
14352.	Genome-wide pharmacogenetics of antidepressant response in the GENDEP project, American journal of psychiatry(2010).
14353.	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms, Psychological medicine(2012).
14354.	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms, Psychological medicine(2012).
14355.	Self-report and clinician-rated measures of depression severity: can one replace the other?, Depression and anxiety(2012).
14356.	Uher R, Ripke S, Muller-Myhsok B, CM L, RH P. Association of a brain methylation site with clinical outcomes in depression does not replicate across populations. American journal of psychiatry. 2015;172:395-397.
14357.	Influence of levothyroxine in augmentation therapy for bipolar depression on central serotonergic function, Pharmacopsychiatry(2014).
14358.	Ulfvarson J, Adami J, Wredling R, Kjellman B, Reilly M, C VB. Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression. European journal of clinical pharmacology. 2003;59:735-740.
14359.	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients - a Randomized Placebo-Controlled Trial, PloS one(2011).
14360.	Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: A randomized trial, PloS one(2012).
14361.	Ulla K, Maj V, Ulrik G, et al. The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial. Psychiatry research. 2012;200:354-360.
14362.	Ulla L, Alan W, Friis AH. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.[Erratum appears in Int Clin Psychopharmacol. 2004 Jul;19(4):255]. International clinical psychopharmacology. 2004;19:149-155.
14363.	Ulla L, Mihaly A, Young Z, Carol A. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Journal of clinical psychiatry. 2003;64:654-662.
14364.	Ullrich H, Kranaster L, Sigges E, Andrich J, Sartorius A. Neuron specific enolase and serum remain unaffected by ultra high frequency left prefrontal transcranial magnetic stimulation in patients with depression: A preliminary study. Journal of neural transmission. 2013;120:1733-1736.
14365.	Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: A randomized, controlled trial including a patients' choice arm, International journal of neuropsychopharmacology(2010).
14366.	Ulrich S. Sudden recovery from depression under treatment with paroxetine. The European Journal of Psychiatry. 1996;10:184-187.
14367.	Ulrich S, Annemarie K-L. A double-blind, multicentre study of paraoxetine and maprotiline in major depression. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 1996;41:239-244.
14368.	UM A, Marteinsdottir I, L VK. Citalopram in Patients With Fibromyalgia - a Randomized, Double Blind, Placebo-Controlled Study. European journal of pain (London, England). 2000;4:27-35.
14369.	UM S, Gupta V, VP R, RS S, MK Y. A review on biological activities and conservation of endangered medicinal herb Nardostachys jatamansi. International Journal of Medicinal and Aromatic Plants. 2013;3:113-124.
14370.	Umberto A, Bogetto F. Combining pharmacological and psychotherapeutic interventions for obsessive-compulsive disorder patients. Clinical Neuropsychiatry. 2006;3:372-381.
14371.	Umene-Nakano W, Yoshimura R, Ikenouchi-Sugita A, et al. Serum Levels of Brain-Derived Neurotrophic Factor in Comorbidity of Depression and Alcohol Dependence. Human Psychopharmacology-Clinical and Experimental. 2009;24:409-413.
14372.	Umit T, Emin O. Fluoxetine once every third day in the treatment of major depressive disorder. European archives of psychiatry and clinical neuroscience. 2003;253:307-312.
14373.	Undurraga J, RJ B. Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37:851-864.
14374.	Unutzer J. Late-life depression. New England journal of medicine. 2007;357:2269-2276.
14375.	Unutzer J, Rubenstein L, WJ K, et al. Two-year effects of quality improvement programs on medication management for depression. Archives of general psychiatry. 2001;58:935-942.
14376.	UP M. Escitalopram. [German]. Pharma-Kritik. 2003;25:11-12.
14377.	UP M, Schmitt W, BD G, et al. Repetitive transcranial magnetic stimulation: A putative add-on treatment for major depression in elderly patients. Psychiatry research. 2004;126:123-133.
14378.	Serotonin synthesis and presence of tryptophan hydroxylase in lymphocytes of patients with depression treated with fluoxetine and folic acid. [Spanish], Archivos Venezolanos de Farmacologia y Terapeutica(2008).
14379.	Urquhart J. Pharmionics: Research on what patients do with prescription drugs. Pharmacoepidemiology and drug safety. 2004;13:587-590.
14380.	Ursini F, Pipicelli G, RD G. Efficacy and Safety of Duloxetine in Fibromyalgia. Clinica terapeutica. 2010;161:391-395.
14381.	Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia, Journal of clinical psychiatry(2014).
14382.	Usherwood T. Review: Differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression - Commentary. Annals of internal medicine. 2009;151:JCI-10.
14383.	Ushiroyama T, Ikeda A, Ueki M. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. Journal of medicine. 2004;35:151-162.
14384.	Uvnas-Moberg K, Bjorkstrand E, Hillegaart V, Ahlenius S. Oxytocin as a Possible Mediator of Ssri-Induced Antidepressant Effects. Psychopharmacology. 1999;142:95-101.
14385.	Uzbay T. Neuroplasticity: Anew approach to treatment of depression. Psychiatry Research Journal. 2011;2:75-139.
14386.	Uzun S, Kozumplik O, Mimica N, Folnegovic-Smalc V. Aripiprazole: An overview of a novel antipsychotic. Psychiatria Danubina. 2005;17:67-75.
14387.	Uzunova V, Sheline Y, JM D, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:3239-3244.
14388.	V AS, A HJ, R NJ, et al. Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. Journal of sleep research. 2009;18:342-348.
14389.	V BW, C SR. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues. Neuropsychiatric disease and treatment. 2009;5.
14390.	V BW, C SR. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. [Review] [148 refs]. Expert review of neurotherapeutics. 2010;10:651-670.
14391.	V BW, Helen C, H TM, et al. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. Journal of affective disorders. 2011;133:467-476.
14392.	V CDC, Dauvilliers Y. Current and future therapeutic approaches in narcolepsy. Future neurology. 2011;6:771-782.
14393.	V DC, John RA, F HAW, et al. Impairment and distress patterns distinguishing the melancholic depression subtype: An iSPOT-D report. Journal of affective disorders. 2015;174:493-502.
14394.	V FO, P AO, Jr SA, S HE, C FR. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: Results from a double-blind, randomized, controlled clinical trial. International psychogeriatrics / IPA. 2001;13:75-84.
14395.	V FP, Addeo L, Laezza R. Therapeutic efficacy of generic drugs versus branded antipsychotics and antidepressants: Comparative results. European neuropsychopharmacology. 2014;Conference:S740-S741.
14396.	V PR, Kozielska M, Johnson M, et al. Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clinical pharmacokinetics. 2011;50:429-450.
14397.	V PS, R LS, M OM. Advancing bipolar disorder: Key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2010;55:136-143.
14398.	V RA, Colin C, Raj B, N RL, L dST. Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. Asian journal of psychiatry. 2013;6:157-161.
14399.	V RA, D GJ, M LR, B CG. Treatment of dysthymia with sertraline: A double-blind, placebo-controlled trial in dysthymic patients without major depression. Journal of clinical psychiatry. 2000;61:821-827.
14400.	V RA, Hymie A, Zul M, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. American journal of psychiatry. 1999;156:1608-1617.
14401.	Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale, International clinical psychopharmacology(2011).
14402.	V SD, Kunitoshi K. An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. [Review]. International clinical psychopharmacology. 2009;24:43-60.
14403.	V SZ, Peter B, Trevor Y, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Archives of general psychiatry. 2010;67:1256-1264.
14404.	VA H, Herting B. Antidepressant therapy in idiopathic Parkinson's disease. [German]. Psychopharmakotherapie. 2005;12:26-29.
14405.	Vahabzadeh A, Buxton D, CJ M, KA S. Current state and future prospects of pharmacological interventions for autism. Neuropsychiatry. 2013;3:245-259.
14406.	Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, JRT D. Modafinil for Atypical Depression: Effects of Open-Label and Double-Blind Discontinuation Treatment. Journal of clinical psychopharmacology. 2006;26:373-378.
14407.	Valducci M, Valducci A, Paoletti C, CV C. A double blind, placebo controlled clinical trial of evaluate efficacy and safety of fluoxetine in the treatment of major depression. [Italian]. Giornale Italiano di Ricerche Cliniche e Terapeutiche. 1992;13:59-64.
14408.	Valenstein M. Keeping our eyes on STAR*D. American journal of psychiatry. 2006;163:1484-1486.
14409.	Valentim G, Florence K-C, Ricardo M, et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. Journal of psychopharmacology (Oxford, England). 2000;14:61-66.
14410.	Valerio C, Fossaluza V, JB D, et al. Impact of conventional treatments for OCD on comorbid psychiatric disorders after 1 year follow-up. Biological psychiatry. 2011;Conference:36S-37S.
14411.	Valerio C, JB D, Fossaluza V, et al. Does anti-obsessional pharmacotherapy treat so-called comorbid depressive and anxiety states? Journal of affective disorders. 2012;139:187-192.
14412.	The sertraline versus electrical current therapy for treating depression clinical study (SELECT-TDCS): Results of the crossover and follow-up phases, Depression and anxiety(2013).
14413.	VAMVE M. Valdoxane (Agomelatine) in Combined Therapy of Moderate and Severe Non-Psychotic Depressions. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2012;112:37-40.
14414.	Vanameringen M, Mancini C, Wilson C. Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors (Ssris) in Social Phobia. Journal of affective disorders. 1996;39:115-121.
14415.	Vandel P, Haffen E, Nezelof S, Broly F, JP K, Sechter D. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Human psychopharmacology. 2004;19:293-298.
14416.	Vandel P, Sechter D, Weiller E, et al. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Human Psychopharmacology: Clinical and Experimental. 2004;19:585-586.
14417.	Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacological research. 1995;31:347-353.
14418.	Vanhalle F, Appelboom J. Psychiatric diagnosis of a child suffering from neuronal ceroid lipofuscinoses. [French]. Neuropsychiatrie de l'enfance et de l'adolescence. 2001;49:141-146.
14419.	Vanhoudenhove B, Onghena P, Floris M, et al. An Open Study of Sertraline in Acute and Continuation Treatment of Depressed Out-Patients. Journal of international medical research. 1997;25:340-353.
14420.	Varia I, Logue E, O'connor C, et al. Randomized Trial of Sertraline in Patients With Unexplained Chest Pain of Noncardiac Origin. American heart journal. 2000;140:367-372.
14421.	Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. International clinical psychopharmacology. 2002;17:103-107.
14422.	Varia I, Venkataraman S, Hellegers C, Gersing K, PM D. Effect of Mirtazapine Orally Disintegrating Tablets on Health-Related Quality of Life in Elderly Depressed Patients With Comorbid Medical Disorders: a Pilot Study. Psychopharmacology bulletin. 2007;40:47-56.
14423.	Varkonyi T, Kempler P. Diabetic neuropathy: New strategies for treatment. Diabetes, obesity & metabolism. 2008;10:99-108.
14424.	Varley C, McClellan J. In Reply [4]. JAMA - Journal of the American Medical Association. 2010;303:730-731.
14425.	Varrassi G, Muller-Schwefe G, Pergolizzi J, et al. Pharmacological treatment of chronic pain the need for CHANGE. Current medical research and opinion. 2010;26:1231-1245.
14426.	Vartanian F. Neurobiological differences on populational level. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28:909-912.
14427.	Varteresian T, Lavretsky H. Natural products and supplements for geriatric depression and cognitive disorders: An evaluation of the research. Current psychiatry reports. 2014.
14428.	Vartiainen H, Leinonen E. Double-Blind-Study of Mirtazapine and Placebo in Hospitalized-Patients With Major Depression. European neuropsychopharmacology. 1994;4:145-150.
14429.	Vasile D, RA M, Vasiliu O, Vasile F. Pharmacologic treatment strategies in premenstrual dysphoric disorder. European neuropsychopharmacology. 2014;Conference:S481-S482.
14430.	Vasile D, RA M, Vasiliu O, Vasile F, DG O. Efficacy and tolerability of agomelatine switch in patients with sexual dysfunctions treated with serotonin selective reuptake inhibitors. European neuropsychopharmacology. 2014;Conference:S395.
14431.	Vasile D, Vasiliu O, AG M, GA S, RE B. Mirtazapine versus sertraline in the treatment of post-psychotic depression. European neuropsychopharmacology. 2013;Conference:S320.
14432.	Vasile D, Vasiliu O, ML V, et al. The efficacy of psychopharmacologic treatment in depressive disorder associated with Parkinson's disease dementia. European psychiatry.
14433.	Vasile D, Vasiliu O, ML V, Terpan M, DG O. Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus. European neuropsychopharmacology. 2011;Conference:S383-S384.
14434.	Vasile D, Vasiliu O, Tudor C, et al. Therapeutic efficacy of duloxetine versus selective serotonin reuptake inhibitors in irritable bowel syndrome. European psychiatry. 2011.
14435.	Highlights from the 5th joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), Drugs of the future(2012).
14436.	Vaswani M, FK L, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Progress in neuro-psychopharmacology & biological psychiatry. 2003;27:85-102.
14437.	Vasylyeva A, Tabachnikov S, Bugaytsov S. Psychopharmacotherapy anxiety disorders of patients suffering from different cancer localization. European neuropsychopharmacology. 2009;Conference:S616.
14438.	VATV T. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. [Review] [44 refs]. Croatian medical journal. 2010;51:61-73.
14439.	Vaughan B, Fegert J, CJ K. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert opinion on pharmacotherapy. 2009;10:669-676.
14440.	Vaughn MW. A rest-activity biomarker to predict response to SSRIs in major depressive disorder. Journal of psychiatric research. 2015;64:19-22.
14441.	Vaughn MW, B RP, James K, et al. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: Effects immediately after ECT and at 24 weeks. Journal of ECT. 2011;27:97-102.
14442.	Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs, Sleep medicine(2011).
14443.	Insomnia severity is an indicator of suicidal ideation during a depression clinical trial, Sleep medicine(2010).
14444.	Vavrusova L. Depressive diseases and multiple sclerosis. [Czech]. Ceska a Slovenska Psychiatrie. 2009;105:173-176.
14445.	Vazquez G, Tondo L, RJ B. Comparison of Antidepressant Responses in Patients With Bipolar Vs. Unipolar Depression: a Meta-Analytic Review. Pharmacopsychiatry. 2011;44:21-26.
14446.	Vazquez-Palacios G, Hernandez-Gonzalez M, MAG P, Bonilla-Jaime H. Nicotine and Fluoxetine Induce Arousing Effects on Sleep-Wake Cycle in Antidepressive Doses: a Possible Mechanism of Antidepressant-Like Effects of Nicotine. Pharmacology, biochemistry, and behavior. 2010;94:503-509.
14447.	VB M, BA M, Margetic B. Outpatient Treatment of Children and Adolescents With Antidepressants in Croatia. International journal of psychiatry in clinical practice. 2012;16:214-222.
14448.	VB M, Grgic N, Juretic Z, Zecevic I. Antidepressants and youth: Healing or harmful?. [Croatian]. Socijalna Psihijatrija. 2011;39:204-210.
14449.	VC A, PSA S, Guilleminault C. Sleep and rheumatologic disorders. Sleep medicine reviews. 2008;12:211-228.
14450.	VC D, Arthurs E, RC Z, BD T. A meta-analysis of selective serotonin reuptake inhibitors in acute coronary syndrome: Cause for concern. Journal of psychopharmacology (Oxford, England). 2011;25:1730-1731.
14451.	VCK W, CED L, Luo X, WSF W. Current alternative and complementary therapies used in menopause. Gynecological endocrinology. 2009;25:166-174.
14452.	VE F, LW A, RM C, AS J, DS S, WC R. The Editor's Roundtable: Major Depression in Patients With Coronary Heart Disease. American journal of cardiology. 2007;99:519-529.
14453.	Veale D. Behavioural activation for depression. Advances in Psychiatric Treatment. 2008;14:29-36.
14454.	Veale D, Anson M, Miles S, Pieta M, Costa A, Ellison N. Efficacy of Cognitive Behaviour Therapy Versus Anxiety Management for Body Dysmorphic Disorder: a Randomised Controlled Trial. Psychotherapy and psychosomatics. 2014;83:341-353.
14455.	Veazey C, SOE A, KF C, EC L, ME K. Prevalence and treatment of depression in Parkinson's disease. Journal of neuropsychiatry and clinical neurosciences. 2005;17:310-323.
14456.	Vecchio M, SC P, Tonelli M, DW J, GFM S. Depression and sexual dysfunction in chronic kidney disease: A narrative review of the evidence in areas of significant unmet need. Nephrology, dialysis, transplantation. 2012;27:3420-3428.
14457.	Vecerova-Prochazkova A. Are the neuropsychopharmacological agents in the treatment of pain effective?. [Czech]. Bolest. 2005;8:128-138.
14458.	Vellante F, Cornelio M, Acciavatti T, et al. Treatment of Resistant Insomnia and Major Depression. Clinica terapeutica. 2013;164:429-435.
14459.	Ventura D, EP A, GH S, M HE. Escitalopram Versus Sertraline in the Treatment of Major Depressive Disorder: a Randomized Clinical Trial. Current medical research and opinion. 2007;23:245-250.
14460.	Vera M, Perez-Pedrogo C, SE H, et al. Collaborative care for depressed patients with chronic medical conditions: a randomized trial in Puerto Rico. Psychiatric services (Washington, D.C.). 2010;61:144-150.
14461.	Verbeeck W, Tuinier S, GE B. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: A systematic review. Advances in therapy. 2009;26:170-184.
14462.	Verdeli H, Mufson L, Lee L, JA K. Review of evidence-based psychotherapies for pediatric mood and anxiety disorders. Current psychiatry reviews. 2006;2:395-421.
14463.	Vermeiden M, WW vdB, PG M, TK B. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. Journal of psychopharmacology (Oxford, England). 2010;24:497-502.
14464.	Veronica M, Magnus vA, Aniko B, et al. Double-Blind Comparison of Sertraline and Placebo in Stroke Patients With Minor Depression and Less Severe Major Depression. Journal of clinical psychiatry. 2005;66:708-716.
14465.	Verrusio W, Andreozzi P, Marigliano B, et al. Exercise training and music therapy in elderly with depressive syndrome: A pilot study. Complementary therapies in medicine. 2014;22:614-620.
14466.	Versiani M. The Selective Noradrenaline Re-Uptake Inhibitor Reboxetine Has an Early Onset of Antidepressant Action. International journal of psychiatry in clinical practice. 2000;4:293-297.
14467.	Versiani M, AE N, Figueira I. Dysthymia: Review - new findings - treatment guidelines. Psiquiatria Biologica. 1997;5:75-83.
14468.	Versiani M, Amin M, Chouinard G. Double-Blind, Placebo-Controlled Study With Reboxetine in Inpatients With Severe Major Depressive Disorder. Journal of clinical psychopharmacology. 2000;20:28-34.
14469.	Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Journal of clinical psychiatry. 2002;63:31-37.
14470.	Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. Journal of clinical psychiatry. 1999;60:400-406.
14471.	Versiani M, Moreno R, CJ R-vM, AJ S, Group CEAS. Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients. CNS drugs. 2005;19:137-146.
14472.	Versiani M, Moreno R, CJA R-VM, AJ S. Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients. CNS drugs. 2005;19:137-146.
14473.	Versiani M, Nardi AE, Figueira I. Pharmacotherapy of dysthymia: Review and new findings. European psychiatry. 1998;13:203-209.
14474.	Versiani M, Ontiveros A, Mazzotti G, et al. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): A double-blind comparison. International clinical psychopharmacology. 1999;14:321-327.
14475.	Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression, Expert review of neurotherapeutics(2013).
14476.	Vetter C. Treatment of depression: Are tricyclic antidepressant agents still current. [German]. TW Neurologie Psychiatrie. 1994;8:542.
14477.	Vetter C. Atypical neuroleptic agents: Quetiapine for all phases of bipolar disorder. [German]. Psychopharmakotherapie. 2009;16:141-142.
14478.	Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression. Journal of pharmacological sciences. 2009;110:98-104.
14479.	VG F. Ovarian-hormone fluctuations influence serotonergic signaling; human in vivo pet-imaging and rat autoradiography data. Biological psychiatry. 2014;Conference:298S.
14480.	VG M, Oulis P, AV K, GV M, CR S. Bilateral Ankle Oedema in a Patient Taking Escitalopram. World journal of biological psychiatry. 2009;10:939-941.
14481.	VG M, Oulis P, Florakis A, Valamoutopoulos T, Markatou M, GN P. The Safety of the Electroconvulsive Therapy-Escitalopram Combination. Journal of ECT. 2008;24:289-291.
14482.	VI S, Schredl M, JVD B. Nightmares: From anxiety symptom to sleep disorder. Sleep medicine reviews. 2006;10:19-31.
14483.	VI S, VA K, MA S, EA P, IA S, TV S. Poststroke Generalized Anxiety Disorder Correlations With Depression, Risk Factors, the Influence on the Restoration of Lost Functions, Pathogenesis, Treatment. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. 2010;110:4-7.
14484.	Viacheslav T, Jan-Henry S, Jari T, et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: A double-blind randomized placebo-controlled study with an open-label extension phase. Human Psychopharmacology: Clinical and Experimental. 2011;26:188-193.
14485.	Vickers A. The management of acute pain. Surgery. 2010;28:175-180.
14486.	Victor N, Gasto C, Torres X, Marcos T, Pintor L. Citalopram versus nortriptyline in late-life depression: A 12-week randomized single-blind study. Acta psychiatrica Scandinavica. 2001;103:435-440.
14487.	Victor P, Dolors P, Inmaculada G, Enric A, Afectius GdReT, Francesc A. Augmentation of fluoxetine's antidepressant action by pindolol: Analysis of clinical, pharmacokinetic, and methodologic factors. Journal of clinical psychopharmacology. 2001;21:36-45.
14488.	Victor P, Joaquim S, Dolors P, Enrique A, Francesc A. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Archives of general psychiatry. 1999;56:375-379.
14489.	Videnovic A. Treatment of huntington disease. Current treatment options in neurology. 2013;15:424-438.
14490.	Vieira dSMP. Open trials in psychiatry: Comments on article by Uchida et al. Journal of clinical psychopharmacology. 2007;27:318.
14491.	Vieta E. Atypical antipsychotics in the treatment of mood disorders. Current opinion in psychiatry. 2003;16:23-27.
14492.	Vieta E. Olanzapine in Bipolar Disorder. Expert opinion on pharmacotherapy. 2004;5:1613-1619.
14493.	Vieta E. Olanzapine in Bipolar Disorder. Expert opinion on pharmacotherapy. 2004;5:1613-1619.
14494.	Vieta E. Mood stabilization in the treatment of bipolar disorder: Focus on quetiapine. Human psychopharmacology. 2005;20:225-236.
14495.	Vieta E. The treatment of mixed states and the risk of switching to depression. European psychiatry. 2005;20:96-100.
14496.	Vieta E. Antidepressants in bipolar depression. Acta psychiatrica Scandinavica. 2008;118:335-336.
14497.	Vieta E. Are antidepressants useful in treating bipolar depression? International journal of psychiatry in clinical practice. 2009;Conference:15-16.
14498.	Vieta E. Advances in the treatment for depression: An update on antipsychotics. European neuropsychopharmacology. 2009;Conference:S715.
14499.	Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. Journal of affective disorders. 2009;119:22-27.
14500.	Vieta E, JR C, Hennen J, et al. Comparison of Rapid-Cycling and Non-Rapid-Cycling Bipolar I Manic Patients During Treatment With Olanzapine: Analysis of Pooled Data. Journal of clinical psychiatry. 2004;65:1420-1428.
14501.	Vieta E, Suppes T. Bipolar II disorder: Arguments for and against a distinct diagnostic entity. Bipolar disorders. 2008;10:163-178.
14502.	Vieta E, Valenti M. Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis. CNS drugs. 2013;27:515-529.
14503.	Vignau J, Costisella O, Canva V, Imbenotte M, Duhamel A, Lhermitte M. Impact of Interferon Alpha Immunotherapy on Tryptophan Metabolism in Patients With Chronic Hepatitis C Results of a Pilot Study on Ten Patients. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique. 2009;35:477-483.
14504.	Vigod S, CL D, Daskalakis Z, et al. Transcranial Direct Current Stimulation (Tdcs) for Treatment of Major Depression During Pregnancy: Study Protocol for a Pilot Randomized Controlled Trial. Trials. 2014;15.
14505.	Viktrup L, Koke S, KL B, JG O. Stress urinary incontinence in active elderly women. Southern medical journal. 2005;98:79-89.
14506.	Viktrup L, Yalcin I. Duloxetine treatment of stress urinary incontinence in women: Effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. European journal of obstetrics, gynecology, and reproductive biology. 2007;133:105-113.
14507.	Villarreal G, JM C, LA C, Toney G, AK S. Duloxetine in military posttraumatic stress disorder. Psychopharmacology bulletin. 2010;43:26-34.
14508.	Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: What needs to be known for practice. Climacteric. 2012;15:115-124.
14509.	Vinai P, KC A, Cardetti S, et al. Psychopathology and treatment of Night Eating Syndrome: A review. Eating and weight disorders. 2008;13:54-63.
14510.	Vinar O, DF K, WZ P, EM G. A survey of psychotropic medications not available in the United States. Neuropsychopharmacology. 1991;5:201-217.
14511.	Vincent A, Clauw D, TH O, MO W, LL T. Decreased Physical Activity Attributable to Higher Body Mass Index Influences Fibromyalgia Symptoms. Pm&R. 2014;6:802-807.
14512.	Vincent A, RP B, MO W, SJ M, PJ E, LN S. Beyond pain in fibromyalgia: Insights into the symptom of fatigue. Arthritis research & therapy. 2013.
14513.	Vincenzo M, Francesca B, Loredana DC. Chronic tension-type headache, mood depression and serotonin: Therapeutic effects of fluvoxamine and mianserine. Headache: The Journal of Head and Face Pain. 1994;34:44-49.
14514.	Vincenzo M, Nicole M, Alessandro A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. International clinical psychopharmacology. 1989;4 Suppl 1:81-88.
14515.	VIO A. Epidemiology, aetiology and management of major depression with comorbid alcohol use disorder-a review of the literature. Current psychiatry reviews. 2013;9:271-283.
14516.	Viswambharan V, JN M, GT G. Orexigenic agents in geriatric clinical practice. Aging health. 2013;9:49-65.
14517.	Vita A, L DP, Sacchetti E. Antipsychotics, Antidepressants, Anticonvulsants, and Placebo on the Symptom Dimensions of Borderline Personality Disorder a Meta-Analysis of Randomized Controlled and Open-Label Trials. Journal of clinical psychopharmacology. 2011;31:613-624.
14518.	Vitali M, Tedeschini E, Mistretta M, et al. Adjunctive Pregabalin in Partial Responders With Major Depressive Disorder and Residual Anxiety. Journal of clinical psychopharmacology. 2013;33:95-98.
14519.	Vitiello B. An update on publicly funded multisite trials in pediatric psychopharmacology. Child and adolescent psychiatric clinics of North America. 2006;15:1-12.
14520.	Research in child and adolescent psychopharmacology: Recent accomplishments and new challenges, Psychopharmacology(2007).
14521.	Vitiello B. Recent NIMH clinical trials and implications for practice. Journal of the American Academy of Child and Adolescent Psychiatry. 2008;47:1369-1374.
14522.	Vitiello B. Treating depression in adolescents. Psychopharm Review. 2011;46:57-63.
14523.	Vitiello B, Davis M, LL G, DS P. Blindness of Clinical Evaluators, Parents, and Children in a Placebo-Controlled Trial of Fluvoxamine. Journal of child and adolescent psychopharmacology. 2006;16:219-225.
14524.	Vitiello B, Grabb M. The Development of Targeted Neurobiological Therapies in Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry. 2013;52:775-779.
14525.	Vitiello B, Rohde P, Silva S, et al. Functioning and Quality of Life in the Treatment for Adolescents With Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1419-1426.
14526.	Vitiello B, SG S, Rohde P, et al. Suicidal events in the treatment for adolescents with depression study (TADS). Journal of clinical psychiatry. 2009;70:741-747.
14527.	Vitiello B, Swedo S. Antidepressant Medications in Children. New England journal of medicine. 2004;350:1489-1491.
14528.	Vito A, J MP. Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. Journal of affective disorders. 2002;71:113-120.
14529.	Vittorino A, Vincent C, S DR, K RJ, Marcio V. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. Journal of clinical psychopharmacology. 2002;22:393-399.
14530.	VJ CL, MC BA, MA FM, MS GU. [Critical evaluation of the use of antidepressives in childhood]. [Review] [63 refs] [Spanish]. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1997;25:105-117.
14531.	Vjmc L, MCB A, MAF M, MSG U. Critical Evaluation of Antidepressive Use in Adolescence. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1997;25:251-270.
14532.	Vjmc L, MCB A, MAF M, MSG U. Critical Review of Antidepressive Use in Childhood. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. 1997;25:105-117.
14533.	VK B. Plotting the Course to Remission: the Search for Better Outcomes in the Treatment of Depression. Journal of clinical psychiatry. 2004;65:20-25.
14534.	VK B. Plotting the Course to Remission: the Search for Better Outcomes in the Treatment of Depression. Journal of clinical psychiatry. 2004;65:20-25.
14535.	VK B, AS A, NV L. [Placebo to antidepressant effects ratio by electroencephalographic data]. [Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. 2004;Korsakova 42-48.
14536.	VK B, MM W, CH M, MJ D, JG W, DE S. Duloxetine for the Treatment of Major Depressive Disorder in Women Ages 40 to 55 Years. Psychosomatics. 2005;46:345-354.
14537.	VK Y, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: Effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological psychiatry. 2002;52:418-429.
14538.	VK Y, Pohl R, Mallavarapu M, Balon R. Approximate entropy of symptoms of mood: An effective technique to quantify regularity of mood. Bipolar disorders. 2003;5:279-286.
14539.	VK Y, Roose S, Mallavarapu M, RK R, Pesce V. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46:125-135.
14540.	VKK B, PG V, Selmi C, HM M, ME G. Recent advances in the treatment of systemic sclerosis. Clinical reviews in allergy & immunology. 2009;36:176-200.
14541.	VL E. Pharmacotherapy of Primary Obsessive-Compulsive Disorder: Review of the Literature. Pharmacotherapy. 1998;18:936-960.
14542.	VL E, PJ P. Venlafaxine: a heterocyclic antidepressant. [Review] [32 refs]. American journal of hospital pharmacy. 1994;51:3033-3046.
14543.	VL E, PJ P. Nefazodone: A new antidepressant. American journal of health-system pharmacy. 1995;52:2799-2812.
14544.	VL S, AH G, AI M, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy.[Erratum appears Circulation. 2003;108:939-944.
14545.	VL S, RF S, TB C, et al. Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving Ssri Treatment for Depression. American journal of psychiatry. 2005;162:1165-1170.
14546.	Vladimir N, Frantisek F. Tianeptine and fluoxetine in major depression: A 6-week randomised double-blind study. Human Psychopharmacology: Clinical and Experimental. 2002;17:299-303.
14547.	Vlassenko A, YI S, Fischer K, MA M. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. Journal of neuropsychiatry and clinical neurosciences. 2004;16:360-363.
14548.	VM P, Arias-Carrion O, Machado S, AE N, AC S. Bupropion in the Depression-Related Sexual Dysfunction: a Systematic Review. CNS and Neurological Disorders - Drug Targets. 2014;13:1079-1088.
14549.	VN P, Gupta R, CM H, TT T, RG N. The neuro-critical care management of the endovascular stroke patient. Current treatment options in neurology. 2013;15:113-124.
14550.	Vo D, DL D. Treatment-Resistant Bipolar Disorder: A Comparison of Rapid Cyclers and Nonrapid Cyclers. CNS spectrums. 2003;8:948-952.
14551.	VO D, H-J G, JWR N, CJH VD, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clinical cancer research. 2009;15:15-21.
14552.	Vocks S, Tuschen-Caffier B, Pietrowsky R, SJ R, Kersting A, Herpertz S. Meta-Analysis of the Effectiveness of Psychological and Pharmacological Treatments for Binge Eating Disorder. International journal of eating disorders. 2010;43:205-217.
14553.	Voderholzer U. Adjustment and combination of antidepressants - What can we learn from the Star-D report. [German]. Nervenheilkunde. 2009;28:293-297.
14554.	Vollm B, Richardson P, Mckie S, Elliott R, JFW D, IM A. Serotonergic Modulation of Neuronal Responses to Behavioural Inhibition and Reinforcing Stimuli: an Fmri Study in Healthy Volunteers. European journal of neuroscience. 2006;23:552-560.
14555.	Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Maenpaa J. Metabolism of Ophthalmic Timolol: New Aspects of an Old Drug. Basic & clinical pharmacology & toxicology. 2011;108:297-303.
14556.	Voss S, Gandhi P, Porkess S, Viktrup L. Duloxetine a new serotonin and noradrenaline reuptake inhibitor for the treatment of both major depressive disorder and female stress urinary incontinence: The implication of more than one indication for a new therapeutic agent. Primary Care Mental Health. 2005;3:83-92.
14557.	Vossen H, Monsieur D, J vO, Leue C. [Serotonin-noradrenalin reuptake inhibitors in the treatment of non-malignant pain syndromes; a systematic review]. [Review] [34 refs] [Dutch]. Tijdschrift voor psychiatrie. 2009;51:831-840.
14558.	VPY T, TK C, WM W, Pang R, BCY W. Treatment of Functional Dyspepsia With Sertraline: a Double-Blind Randomized Placebo-Controlled Pilot Study. World journal of gastroenterology. 2012;18:6127-6133.
14559.	VR B, AF T. Anxiety: A hidden element in dementia. Advances in Psychiatric Treatment. 2012;18:119-128.
14560.	VR S, Biesdorf C, DH R, Zangrossi H, FG G, EA A. Serotonin-1a Receptors in the Dorsal Periaqueductal Gray Matter Mediate the Panicolytic-Like Effect of Pindolol and Paroxetine Combination in the Elevated T-Maze. Neuroscience letters. 2011;495:63-66.
14561.	VR S, CM R, Zangrossi H, FG G, EA A. Pindolol Potentiates the Panicolytic Effect of Paroxetine in the Elevated T-Maze. Life sciences. 2010;87:445-450.
14562.	VR W. Testing theory or changing the world? Balancing the competing goals of psychotherapy research. Clinical Psychology: Science and Practice. 2006;13:342-345.
14563.	VR W, DA B. Cognitive behavioral therapy for depression in youth. [Review] [64 refs]. Child and adolescent psychiatric clinics of North America. 2006;15:939-957.
14564.	Vrabie M, Marinescu V. The risk of drug-drug interactions in the treatment of bipolar disorder. European neuropsychopharmacology. 2010;Conference:S416.
14565.	Vrabie M, Marinescu V. Unseen face of polypharmacy in Alzhemer's disease-a focus on drug-drug interactions. European neuropsychopharmacology. 2011;Conference:S159-S160.
14566.	VS R. Functional brain asymmetry as a determinative factor in the treatment of depression: Theoretical implications. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:1772-1777.
14567.	VS S, Krishnaraju V. Antidepressants as potential adjuvants in treating chronic pain and pain induced depression. International Journal of Pharma and Bio Sciences. 2013;4:P608-P615.
14568.	VS S, Main F. Compliance: The essence of depression therapy. [German]. Pharmazeutische Zeitung. 2009.
14569.	VSL W, RJ M, Feltner D. Psychometric Evaluation of a Visual Analog Scale for the Assessment of Anxiety. Health and quality of life outcomes. 2010;8.
14570.	VSP P, LC dS, AR B, AL T. Post stroke depression: Clinics, etiopathogenesis and therapeutics. Revista de Psiquiatria Clinica. 2015;42:18-24.
14571.	VT N. Switching antidepressant classes often works in treatment-resistant depression. Journal of family practice. 2002;51:512.
14572.	Vural M, Basar E. Impact of psychological factors on development and course of coronary heart desease: Should be negative psychological factors altered?. [Turkish]. Anadolu Kardiyoloji Dergisi. 2006;6:55-59.
14573.	VY G. Clinical Picture and Treatment of Somatogenic Affective Disorders. Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova. 1997;97:47-51.
14574.	W BD, Robert W, Wayne B, Patrick M, Janelle G. Acute treatment response in outpatients with panic disorder: High versus low depressive symptoms. Annals of clinical psychiatry. 1995;7:181-188.
14575.	W BS. A review of fluvoxamine and its uses in depression. International clinical psychopharmacology. 1991;6:1-21.
14576.	W DB, A DJ, Lauren M, J GS, B NC, O LS. The effects of sertraline on psychopathic traits. International clinical psychopharmacology. 2011;26:329-337.
14577.	W DB, E KM, C MT, M VC, Edward CW, S MH. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.[Erratum appears in J Psychiatr Res. 2014 Jul;54:141]. Journal of psychiatric research. 2012;46:375-381.
14578.	W DB, E KM, C MT, M VC, Edward CW, S MH. "Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder": Corrigendum. Journal of psychiatric research. 2014;54:141.
14579.	W DB, E TM, Chuan-Chuan W, et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: The importance of academic sites. Neuropsychopharmacology. 2012;37:2830-2836.
14580.	W DB, Peter H, Weihang B, T NP, B KM. Recovery and subsequent recurrence in patients with recurrent major depressive disorder. Journal of psychiatric research. 2012;46:708-715.
14581.	W DB, Thomas L, G KS, et al. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry research. 2010;177:177-183.
14582.	W DG, H GA, Sarah R, Lirio C, Fay S. Mood, major depression, and fluoxetine response in cigarette smokers. American journal of psychiatry. 1995;152:398-403.
14583.	W dHE, Jack D, F vEvdSJ, et al. Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: Design of a randomized placebo-controlled m. BMC psychiatry. 2013;13.
14584.	W FE. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS drugs. 2004;18:453-468.
14585.	W FE, Karl R, J SS, Marcia P. Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes [8]. Journal of clinical psychopharmacology. 2001;21:540-542.
14586.	W FE, Karl R, J SS, Marcia P, Sha X. Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder. American journal of psychiatry. 2004;161:343-351.
14587.	W HC, Graham E, Robert K, Warren W, Jeanne R, John RA. Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology. 2000;23:591-594.
14588.	W HS. Review of Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:953-955.
14589.	W JJ, H GJ, L PT, Rochelle R. Fluvoxamine-associated mania/hypomania in patients with obsessive-compulsive disorder. Journal of clinical psychopharmacology. 1991;11:391-392.
14590.	W LK, H PS, J G-PC, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder. Journal of clinical psychiatry. 2010;71:1482-1487.
14591.	W LR. Priorities in treating depression only. International journal of psychiatry in clinical practice. 2004;8:25-29.
14592.	W LR, F AH, G WA. Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials. International clinical psychopharmacology. 2008;23:181-187.
14593.	W LR, J LA, D LR, et al. The Can-SAD Study: A Randomized Controlled Trial of the Effectiveness of Light Therapy and Fluoxetine in Patients With Winter Seasonal Affective Disorder. American journal of psychiatry. 2006;163:805-812.
14594.	W LR, Larsson LS, Nicolas D. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis. International clinical psychopharmacology. 2010;25:199-203.
14595.	W LR, P GC, Max M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. American journal of psychiatry. 1995;152:1765-1770.
14596.	W LR, Susanne Q. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology. 2002;161:143-151.
14597.	Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder, The British Journal of Psychiatry(2013).
14598.	Depression treatment in patients with general medical conditions: Results from the CO-MED trial, Annals of family medicine(2012).
14599.	W OD. Treatment of Late-Life Depression Complicated by Alcohol Dependence. The American Journal of Geriatric Psychiatry. 2005;13:491-500.
14600.	W OD, E SJ, R KI, et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. The American Journal of Geriatric Psychiatry. 2000;8:141-149.
14601.	W OD, R THT, E SJ, et al. Probing the Safety of Medications in the Frail Elderly: Evidence From a Randomized Clinical Trial of Sertraline and Venlafaxine in Depressed Nursing Home Residents. Journal of clinical psychiatry. 2003;64:875-882.
14602.	W RF, D AJ, M QF, et al. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment. American journal of psychiatry. 1998;155:1247-1253.
14603.	W RJ, J EG, John RA, et al. The effects of extended evaluation on depressive symptoms in children and adolescents. Journal of affective disorders. 1996;41:149-156.
14604.	W SG, H HS, Alexander B, S MB, B NC. Clinical response predictors in a double-blind, placebo- controlled trial of fluoxetine for geriatric major depression. International Psychogeriatrics. 1995;7:41-53.
14605.	W SJ, A DD, J MP. Is duloxetine effective treatment for depression with atypical features? [References]. International clinical psychopharmacology. 2008;23:333-336.
14606.	Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? [References], Journal of psychiatric practice(2009).
14607.	Combination antidepressant therapy for major depressive disorder: Speed and probability of remission, Journal of psychiatric research(2014).
14608.	W SJ, M QF, J MP, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives of general psychiatry. 1998;55:334-343.
14609.	W SP, GE P. What is the place of st. John's Wort? U.S. 2012;Pharmacist:12-15.
14610.	W TS, E MK. Depression in children and youth. Journal of developmental and behavioral pediatrics. 2009;30:478.
14611.	W UR, M BC, C BJ. Efficacy and safety of morning versus evening fluoxetine administration. Journal of clinical psychiatry. 1991;52:134-136.
14612.	W vdB. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Current drug abuse reviews. 2012;5:3-31.
14613.	W vdBW, H MPG, E vO, Birkenhager TK, Pluijms E, Bruijn JA. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis. [Review] [34 refs]. Journal of psychopharmacology (Oxford, England). 2009;23:708-713.
14614.	W vdBW, K BT, H MPG, A BJ, Peter M. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology. 2004;175:481-486.
14615.	W VM, Reboussin D, Prudic J, et al. Poor health-related quality of life prior to ECT in depressed patients normalizes with sustained remission after ECT. Journal of affective disorders. 2013;147:107-111.
14616.	W WJ. Treatment of mild depression in elderly patients. JAMA: Journal of the American Medical Association. 2000;284:2994.
14617.	W-B F, Fan L, X-P Z, et al. Depressive neurosis treated by acupuncture for regulating the liver - A report of 176 cases. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2009;29:83-86.
14618.	W-D W, X-Y L, S-M N, et al. Effects of electro-acupuncture on personality traits in depression: A randomized controlled study. Chinese journal of integrative medicine. 2013;19:777-782.
14619.	W-F Y, K-F C, K-Y N, Y-M Y, ETC Z, BFL N. A systematic review on the efficacy, safety and types of Chinese herbal medicine for depression. Journal of psychiatric research. 2014;57:165-175.
14620.	W-H S, D-R Z, G-Q T, et al. A comparative study of cognitive-behavior therapy and paroxetine for minor depression. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2007;7:711-714.
14621.	W-H W, S-J H, C-Y C, C-J H, S-J T. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology. 2001;44:172-175.
14622.	W-H Y, Y-H Z, Li B, W-C F. Curative effect and safety of Tatinol in improving the negative emotions of patients with schizophrenia. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:26-28.
14623.	W-N Z, S-H C, L-Y G, K-L Z, Wang J. The neural correlates of reward-related processing in major depressive disorder: A meta-analysis of functional magnetic resonance imaging studies. Journal of affective disorders. 2013;151:531-539.
14624.	W-U W. Long-term therapy for depression. [German]. Gynakologische Praxis. 2002;26:769-770.
14625.	W-X S, S-Y H, C-Y H, C-H C, Wang Z. Effects of baisong tablets on the behavior and levels of norepinephrine and dopamine in the brain of stress rats. [Chinese]. Journal of Central South University (Medical Sciences). 2005;30:574-578.
14626.	W-Z H, Chen M, J-Z Z. Curative effect of fluoxetine for adjuvant treatment of migraine and its effect on serum lipid. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:5254-5255.
14627.	WA B, AE A. Cognitive-behavior therapy with eating disorders: The role of medications in treatment. Journal of cognitive psychotherapy. 2007;21:16-27.
14628.	WA B, Ancoli-Israel S. Breast Cancer and Fatigue. Sleep medicine clinics. 2008;3:61-71.
14629.	WA B, BE D, JF W. Placebo response in depression: a search for predictors. Psychiatry research. 1988;26:259-264.
14630.	WA B, DB S, RJ H, Szegedi A, Lines C, SA R. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: Results from a randomized clinical trial in patients with major depressive disorder. Human Psychopharmacology-Clinical and Experimental. 2014;29:568-577.
14631.	WA K, RB S. Focus on Mirtazapine: a New Antidepressant With Noradrenergic and Specific Serotonergic Activity. Formulary (Cleveland, Ohio). 1996;31:455-&.
14632.	WA M, SC S, MA V. Venlafaxine - a Structurally Unique and Novel Antidepressant. Annals of pharmacotherapy. 1995;29:387-395.
14633.	WA N. Are the monoamine oxidase inhibitors coming back?. [Dutch]. Nederlands tijdschrift voor geneeskunde. 1985;129:1571-1576.
14634.	WA N. Atypical antipsychotics in bipolar depression: A new major option? European neuropsychopharmacology. 2008;Conference:S193.
14635.	WA N. The continuum of unipolar depression - bipolar II depression - bipolar I depression: Different treatments indicated? World psychiatry. 2011;10:196-197.
14636.	WA N, JJ vdP, WA D, JS K. L-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. British journal of psychiatry. 1985;147:16-22.
14637.	WA N, JJ vdP, WA D, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta psychiatrica Scandinavica. 1988;78:676-683.
14638.	WA N, RW K, Hellemann G, et al. Tranylcypromine Vs. Lamotrigine in the Treatment of Refractory Bipolar Depression: a Failed but Clinically Useful Study. Acta psychiatrica Scandinavica. 2007;115:360-365.
14639.	WA N, WW VDB, TK B. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate [1]. American journal of psychiatry. 2007;164:524.
14640.	Wade A, Aitken C. Efficacy, tolerability and effect on sleep of morning and evening doses of paroxetine in depressed patients. British Journal of Clinical Research. 1993;4:105-111.
14641.	Wade A, H FA. The Onset of Effect for Escitalopram and Its Relevance for the Clinical Management of Depression. Current medical research and opinion. 2006;22:2101-2110.
14642.	Wade A, Michael LO, Bang HK. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International clinical psychopharmacology. 2002;17:95-102.
14643.	Wade A, Nemeroff C, AF S, Schlaepfer T, Haazen L, Buntinx E. Addition of a selective 5-HT2A/D4 antagonist accelerates the antidepressant effects of citalopram. European psychiatry.
14644.	Wade A, TE S, CD K. Treatment milestones predict symptom remission over 6-month treatment of patients with major depressive disorder (MDD). European neuropsychopharmacology. 2008;Conference:S293-S294.
14645.	Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: An 8-week, double-blind, randomized study on magnitude and timing of clinical response, Psychological medicine(2011).
14646.	Wade AG, Schlaepfer TE, Andersen HF, Kilts CD. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of psychiatric research. 2009;43:568-575.
14647.	WADS M, PR B, PL C, et al. Sedative antidepressants and insomnia. [Portuguese]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2011;33:91-95.
14648.	Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study, Journal of child and adolescent psychopharmacology(2012).
14649.	Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break, Journal of the American Academy of Child and Adolescent Psychiatry(2011).
14650.	Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent study (TORDIA), Journal of the American Academy of Child and Adolescent Psychiatry(2011).
14651.	Wager-Smith K, Markou A. Depression: A repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neuroscience and biobehavioral reviews. 2011;35:742-764.
14652.	Wagner G, Pietsch U, Peikert G, et al. Differential effect of serotonergic and noradrenergic antidepressants on brain activation during cognitive control task. European neuropsychopharmacology. 2009;Conference:S400.
14653.	Wahed M, DS R. Psychological stress and related mood disorders, and their therapeutic implications in IBD. Inflammatory Bowel Disease Monitor. 2013;13:143-153.
14654.	Waintrub L. Recognizing and Treating Depression in the Elderly. Presse medicale. 1998;27:2129-+.
14655.	Wakil L, Meltzer-Brody S, Girdler S. Premenstrual dysphoric disorder: How to alleviate her suffering. Current psychiatry. 2012;11:22-32.
14656.	Walach H, WB J. Placebo research: The evidence base for harnessing self-healing capacities. Journal of alternative and complementary medicine (New York, N.Y.). 2004;10:S-103-S-112.
14657.	Walczak J, Malysiak S, Rowinska M. Comparative analysis of the efficacy and safety of escitalopram with sertraline and venlafaxine in the treatment of major depressive disorder (MDD). Value in health. 2010;Conference:A107.
14658.	Walder B, Haase U, Rundshagen I. Sleep disturbances in critically ill patients. [German]. Der Anaesthesist. 2007;56:7-17.
14659.	Walderhaug E, Kasserman S, Aikins D, Vojvoda D, Nishimura C, Neumeister A. Effects of Duloxetine in Treatment-Refractory Men With Posttraumatic Stress Disorder. Pharmacopsychiatry. 2010;43:45-49.
14660.	Waldinger MD, Olivier B. Selective serotonin reuptake inhibitor-induced sexual dysfunction: Clinical and research considerations. International clinical psychopharmacology. 1998;13:S27-S33.
14661.	Waldschmitt C, Hiemke C, Eckermann G. Pharmacokinetic Interaction Potential of Duloxetine. Psychopharmakotherapie. 2009;16:14-18.
14662.	Waldschmitt C, Vogel F, Maurer C, Hiemke C. Measurement of Duloxetine in Blood Using High-Performance Liquid Chromatography With Spectrophotometric Detection and Column Switching. Therapeutic drug monitoring. 2007;29:767-772.
14663.	Walkup J. The child/adolescent anxiety multimodal trial. European child & adolescent psychiatry. 2013;Conference:S165.
14664.	Walkup J, Bernet W, Bukstein O, et al. Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48:961-973.
14665.	Wallenborn J, CE A. Comorbid depression in heart failure. Herz. 2013;38:587-596.
14666.	Wallnofer A, TW G, SA E, Dingemanse J. Moclobemide and Fluvoxamine Coadministration - a Prospective-Study in Healthy-Volunteers to Investigate the Potential Development of the Serotonin Syndrome. Human Psychopharmacology-Clinical and Experimental. 1995;10:25-31.
14667.	Walsh G. Editorial foreword. Therapeutics and clinical risk management. 2006;2:127-128.
14668.	Walsh K, Bennett G. Parkinson's disease and anxiety. Postgraduate medical journal. 2001;77:89-93.
14669.	Walter G, JM R, BJ T. Depression in young people [1] (multiple letters). Australian Prescriber. 1998;21:87-88.
14670.	Walter H, Berger M, Schnell K. Neuropsychotherapy: Conceptual, empirical and neuroethical issues. European archives of psychiatry and clinical neuroscience. 2009;259:S173-S182.
14671.	Walter H, Wolf R, F GW. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. European archives of psychiatry and clinical neuroscience. 1995;246:1-6.
14672.	Wang C, Zhang N, YL Z, Zhang J, Yang H, TC T. Comparison of the neurobiological effects of attribution retraininggroup therapywith those of selective serotonin reuptake inhibitors. Brazilian Journal of Medical and Biological Research. 2013.
14673.	Wang D, NS M, Duffin J, et al. Phenotyping Interindividual Variability in Obstructive Sleep Apnoea Response to Temazepam Using Ventilatory Chemoreflexes During Wakefulness. Journal of sleep research. 2011;20:526-532.
14674.	Wang G, Gislum M, Filippov G. Randomised, Double-Blind Study of Vortioxetine Versus Venlafaxine in Adults With Major Depressive Disorder (Mdd). International journal of neuropsychopharmacology. 2014;17:142.
14675.	Wang G, Mcintyre A, WR E, Raines S, Eriksson H. A Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine Xr) Monotherapy in Patients With Major Depressive Disorder. Psychopharmacology bulletin. 2012;45:5-30.
14676.	Wang G, Mcintyre A, WR E, SR R, Eriksson H. A Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended-Release Quetiapine Fumarate (Quetiapine Xr) Monotherapy in Patients With Major Depressive Disorder. Neuropsychiatric disease and treatment. 2014;10:201-216.
14677.	Efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of depression: study protocol for a randomized controlled trial, Trials [Electronic Resource](2013).
14678.	Wang R, DA S, Hoeppner B, AE E. Detecting treatment-covariate interactions using permutation methods. Statistics in medicine. 2015;34:2035-2047.
14679.	Wang S, Hu S, Zhang C, Qiu J, Li Y. Effect of Chaihu Shugan San and its components on expression of ERK1/2 mRNA in the hippocampus of rats with chronic mild unpredicted stress depression. Zhong Nan da Xue Xue Bao. 2011;Yi Xue Ban:93-100.
14680.	Wang S, Hu S, Zhang C, Qiu J, Li Y. Effect of chaihu shugan san and its components on expression of ERK1/2 mRNA in the hippocampus of rats with chronic mild unpredicted stress depression. Journal of Central South University (Medical Sciences). 2011;Yi Xue Ban:93-100.
14681.	Wang T, Qin F. [Effects of Chinese herbal medicine Xiaoyao Powder on monoamine neurotransmitters in hippocampus of rats with postpartum depression]. [Chinese]. Zhong xi yi jie he xue bao [Journal of Chinese integrative medicine]. 2010;8:1075-1079.
14682.	Wang X, Zhang B, Li J, X-L S. Double-blind, double-dummy, randomized controlled trials of Bupropion hydrochloride sustained-release tablets for depression. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2007;7:409-414.
14683.	Wang X, Zhang H, Shu L. Efficacy and safety of enteric-coated sustained release tablets paroxetine in the treatment of major depression in China. International journal of neuropsychopharmacology. 2010;Conference:84.
14684.	Wang Y, Fan R, Huang X. Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression. [Review]. Journal of ethnopharmacology. 2012;141:571-577.
14685.	Wang Y, LH Y, Xie J, JJ C, QP W. Comparative Efficacies of Fluoxetine and Paroxetine in Major Depression Across Varying Acute-Phase Treatment Periods: a Meta-Analysis. Asia-Pacific Psychiatry. 2014;6:353-362.
14686.	Wang Y, YP H, WC W, RZ P, AR Z. Clinical Studies on Treatment of Earthquake-Caused Posttraumatic Stress Disorder Using Electroacupuncture. Evidence-Based Complementary and Alternative Medicine. 2012.
14687.	Wang Y, YR F, XS C, et al. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients. Chinese medical journal. 2009;122:2956-2960.
14688.	Wang Z, DD Z, Hui S, YJ Z, SY H. Effect of tribulus terrestris saponins on behavior and neuroendocrine in chronic mild stress depression rats. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2013;33:228-232.
14689.	Wang Z, Hu S-y. Effect of Baisong Tablet on Behavior and CORT ACTH in Plasma of Chronic Stress Depression Rats. [Chinese]. Chinese Journal of Clinical Psychology. 2004;12:185-187.
14690.	Wang Z, SY H, DL L, WX S. [Effect of chronic stress on PKA and P-CREB expression in hippocampus of rats and the antagonism of antidepressors]. [Chinese]. Zhong Nan da Xue Xue Bao. 2006;Yi Xue Ban:767-771.
14691.	Warden D, AJ R, MH T, Fava M, SR W. The STAR*D project results: A comprehensive review of findings. Current psychiatry reports. 2007;9:449-459.
14692.	Warden D, AJ R, SR W, et al. What predicts attrition in second step medication treatments for depression?: a STAR*D Report. International journal of neuropsychopharmacology. 2009;12:459-473.
14693.	Warden D, MH T, SR W, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. American journal of psychiatry. 2007;164:1189-1197.
14694.	Warden D, PD R, S-J M, et al. Major Depression and Treatment Response in Adolescents With Adhd and Substance Use Disorder. Drug and alcohol dependence. 2012;120:214-219.
14695.	Waring D. Paradoxical drug response and the placebo effect: A discussion of Grunbaum's definitional scheme. Theoretical medicine and bioethics. 2003;24:5-17.
14696.	Warner J. Quality of evidence in meta-analysis. The British Journal of Psychiatry. 2001;179:79.
14697.	Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. [Review] [12 refs]. International clinical psychopharmacology. 1992;6 Suppl 4:59-64.
14698.	Wasielewski S. St John's wort for the treatment of severe depression?. [German]. Deutsche Apotheker-Zeitung. 2002;142:43-46.
14699.	Waslick B. Psychopharmacology interventions for pediatric anxiety disorders: A research update. Child and adolescent psychiatric clinics of North America. 2006;15:51-71.
14700.	Wasserman L, Shaw T, Vu M, Ko C, Bollegala D, Bhalerao S. An overview of traumatic brain injury and suicide. Brain injury. 2008;22:811-819.
14701.	Watanabe N, IM O, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. [Review]. Cochrane database of systematic reviews (Online). 2011;12:CD006528.
14702.	Watanabe N, IM O, Nakagawa A, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. [Review] [54 refs]. Journal of clinical psychiatry. 2008;69:1404-1415.
14703.	Watanabe N, IM O, Nakagawa A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. [Review] [CNS drugs. 2010;24:35-53.
14704.	Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial, Journal of clinical psychiatry(2011).
14705.	Watanabe T, Ueda M, Saeki Y, et al. High Plasma Concentrations of Paroxetine Impede Clinical Response in Patients With Panic Disorder. Therapeutic drug monitoring. 2007;29:40-44.
14706.	Watson K, KM S. Depression in patients with heart failure: clinical implications and management. [Review] [105 refs]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 2009;29:49-63.
14707.	Wayne J. St John's wort and depression. JAMA: Journal of the American Medical Association. 2002;288:446.
14708.	Wayne K, Joan R, Ellen F, et al. Predictors of nonresponse to treatment in primary care patients with dysthymia. General hospital psychiatry. 2002;24:20-27.
14709.	WB D. A review of co-morbid depression in pediatric ADHD: Etiology, phenomenology, and treatment. Journal of child and adolescent psychopharmacology. 2008;18:565-571.
14710.	WB F, Fan L, XP Z, et al. [Acupuncture for treatment of depressive neurosis: a multi-center randomized controlled study]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2008;28:3-6.
14711.	WB Y. Preventive treatment of migraine: Effect on weight. Current pain and headache reports. 2008;12:201-206.
14712.	WB Y, TD R. Preventive treatment of migraine: Effect on weight. Cephalalgia. 2005;25:1-11.
14713.	WC A-N, VG G, FG G, JFW D, CM D-B. Effect of Escitalopram on the Processing of Emotional Faces. Brazilian Journal of Medical and Biological Research. 2010;43:285-289.
14714.	WC D. Geriatric Depression - Brain Imaging Correlates and Pharmacological Considerations. Journal of clinical psychiatry. 1994;55:71-81.
14715.	WC L, GI K, GD P, et al. Pilot Pharmacologic Randomized Controlled Trial for Psychogenic Nonepileptic Seizures. Neurology. 2010;75:1166-1173.
14716.	WC L, GL B, JJ B, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: A randomized clinical trial. Jama Psychiatry. 2014;71:997-1005.
14717.	WC LJ, JJ B. Update on treatments of psychological nonepileptic seizures. Epilepsy & behavior. 2005;7:364-374.
14718.	WD H. How have the SSRI antidepressants affected suicide risk? Lancet. 2006;367:1959-1962.
14719.	WD H, Lucke J. How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Australian and New Zealand journal of psychiatry. 2006;40:941-950.
14720.	WD H, SH P. Mechanisms of Action and Clinical Characteristics of Three Atypical Antidepressants: Venlafaxine, Nefazodone, Bupropion. Journal of affective disorders. 1998;51:237-254.
14721.	WD T. Depression in the elderly. New England journal of medicine. 2014;371:1228-1236.
14722.	WE H. Paroxetine: A review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders. Expert opinion on investigational drugs. 1999;8:417-441.
14723.	WE M, RL OS, Osgood-Hynes D, Baer L. Trichotillomania: Clinical aspects and treatment strategies. Harvard review of psychiatry. 1994;1:336-344.
14724.	WE M, Singer A, Wonnemann M. The mechanism of action of St. John's wort. [German]. Praxis. 2000;89:2111-2121.
14725.	WE R. Alzheimer's Disease: Clinical Treatment Options. American journal of managed care. 2000;6:S1125-S1138.
14726.	WE S, Watzke S, Brieger P. Bipolar affective disorders part II: Genetics, cognition and therapy. [German]. Fortschritte der Neurologie-Psychiatrie. 2008;76:294-308.
14727.	Weber J, KA L-W, LJ S. Aripiprazole: In major depressive disorder. CNS drugs. 2008;22:807-813.
14728.	Weber J, PL M. Asenapine. CNS drugs. 2009;23:781-792.
14729.	Weber-Hamann B, Gilles M, Schilling C, et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. Journal of clinical psychopharmacology. 2008;28:581-584.
14730.	Weber-Hamann B, WF B, Kratzsch J, Gilles M, Heuser I, Deuschle M. Insulin-like Growth Factor-I (IGF-I) serum concentrations in depressed patients: Relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry. 2009;42:23-28.
14731.	Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B. A Randomized, Controlled Trial of Aerobic Exercise in Combination With Paroxetine in the Treatment of Panic Disorder. World journal of biological psychiatry. 2010;11:904-913.
14732.	Weerasundera R, DJ C. Extended-release quetiapine fumarate in the treatment of bipolar disorder. Neuropsychiatry. 2012;2:453-459.
14733.	Wegerer V, GH M, Bagli M, Rothenberger A, Ruther E, Huether G. Persistently Increased Density of Serotonin Transporters in the Frontal Cortex of Rats Treated With Fluoxetine During Early Juvenile Life. Journal of child and adolescent psychopharmacology. 1999;9:13-24.
14734.	Wehmeier PM, Kluge M, Maras A, et al. Fluoxetine Versus Trimipramine in the Treatment of Depression in Geriatric Patients. Pharmacopsychiatry. 2005;38:13-16.
14735.	Wei Q. Effect of new Morita therapy plus antipsychotic drugs in ameliorating post-schizophrenia depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:72-75.
14736.	Wei-Wei C, Jian-Min Y, Shu-Yan S, et al. Group psychotherapy in treatment of post stroke depression. [Chinese]. Chinese Mental Health Journal. 2009;23:100-104.
14737.	Wei-Xi S, Sui-Yu H, Zhe W. Effects of BAI-SONG Tablets on Expression of DAT mRNA in Hippocampus of Depression Model Rats. [Chinese]. Chinese Journal of Clinical Psychology. 2006;14:547-549.
14738.	Weijer C. Placebo trials and tribulations. CMAJ : Canadian Medical Association journal. 2002;166:603-604.
14739.	Weikop P, Kehr J, Scheel-Kruger J. The Role of Alpha(1)- and Alpha(2)-Adrenoreceptors on Venlafaxine-Induced Elevation of Extracellular Serotonin, Noradrenaline and Dopamine Levels in the Rat Prefrontal Cortex and Hippocampus. Journal of psychopharmacology (Oxford, England). 2004;18:395-403.
14740.	Weikop P, Kehr J, Scheel-Kruger J. The Role of Alpha(1)- and Alpha(2)-Adrenoreceptors on Venlafaxine-Induced Elevation of Extracellular Serotonin, Noradrenaline and Dopamine Levels in the Rat Prefrontal Cortex and Hippocampus. Journal of psychopharmacology (Oxford, England). 2004;18:395-403.
14741.	Weinberger T, Forrester A, Markov D, Chism K, EJS K. Women at a Dangerous Intersection: Diagnosis and Treatment of Depression and Related Disorders in Patients with Breast Cancer. Psychiatric clinics of North America. 2010;33:409-422.
14742.	Weiner R, SH L, MM H, et al. Electroconvulsive therapy device classification: Response to FDA advisory panel hearing and recommendations. Journal of clinical psychiatry. 2013;74:38-42.
14743.	Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology. 2008;196:511-512.
14744.	Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology. 2008;196:511-520.
14745.	Weinstock J, DM L, Modesto-Lowe V, NM P. Ludomania: Cross-cultural examinations of gambling and its treatment. [Portuguese, English]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2008;30:S3-S10.
14746.	Weintraub D, CL C, Horn S. Parkinson's disease - Part 3: Neuropsychiatric symptoms. American journal of managed care. 2008;14:S59-S69.
14747.	Weintraub D, JE S, CJ D, IR K, SD D, DW O. Effect of Increasing the Dose and Duration of Sertraline Trial in the Treatment of Depressed Nursing Home Residents. Journal of geriatric psychiatry and neurology. 2003;16:109-111.
14748.	Weintraub D, KH M, PJ M, et al. Antidepressant Studies in Parkinson's Disease: a Review and Meta-Analysis. Movement disorders. 2005;20:1161-1169.
14749.	Weintraub D, MB S. Psychiatric complications in Parkinson disease. American journal of geriatric psychiatry. 2005;13:844-851.
14750.	Weintraub D, PB R, LT D, et al. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. The American Journal of Geriatric Psychiatry. 2010;18:332-340.
14751.	Weintraub D, PJ M, JE D, IR K, MB S. Recognition and Treatment of Depression in Parkinson's Disease. Journal of geriatric psychiatry and neurology. 2003;16:178-183.
14752.	Weintraub D, Taraborelli D, KH M, JE D, IR K, MB S. Escitalopram for Major Depression in Parkinson's Disease: an Open-Label, Flexible-Dosage Study. Journal of neuropsychiatry and clinical neurosciences. 2006;18:377-383.
14753.	Weintrob A, JS M. Placebo use [2] (multiple letters). Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:624-625.
14754.	Weiss M, Hechtman L. A Randomized Double-Blind Trial of Paroxetine and/or Dextroamphetamine and Problem-Focused Therapy for Attention-Deficit/Hyperactivity Disorder in Adults. Journal of clinical psychiatry. 2006;67:611-619.
14755.	Weizman R, Weizman A. Use of atypical antipsychotics in mood disorders. Current opinion in investigational drugs (London, England : 2000). 2001;2:940-945.
14756.	Wells A, Fisher P, Myers S, Wheatley J, Patel T, CR B. Metacognitive therapy in recurrent and persistent depression: A multiple-baseline study of a new treatment. Cognitive therapy and research. 2009;33:291-300.
14757.	Wells A, Fisher P, Myers S, Wheatley J, Patel T, CR B. Metacognitive therapy in treatment-resistant depression: A platform trial. Behaviour research and therapy. 2012;50:367-373.
14758.	Wen-Jing Z, Xin-Bo Y, Bao-Liang Z. Combination of acupuncture and fluoxetine for depression: A randomized, double-blind, sham-controlled trial. Journal of alternative and complementary medicine (New York, N.Y.). 2009;15:837-844.
14759.	Wermuth L, Bech P. Depression in Parkinson's disease - A review [2]. Acta neurologica Scandinavica. 2006;114:360.
14760.	Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial. Nordic journal of psychiatry. 1998;52:163-169.
14761.	Werneke U, Northey S, Bhugra D. Antidepressants and Sexual Dysfunction. Acta psychiatrica Scandinavica. 2006;114:384-397.
14762.	Wernicke J, Lledo A, Raskin J, DK K, Wang F. An Evaluation of the Cardiovascular Safety Profile of Duloxetine - Findings From 42 Placebo-Controlled Studies. Drug safety. 2007;30:437-455.
14763.	Wernicke JF, C BJ, Earleen A. Fluoxetine at 20 mg per day: The recommended and therapeutic dose in the treatment of depression. International clinical psychopharmacology. 1989;4:63-67.
14764.	Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
14765.	Wesolowska A, Partyka A, Jastrzebska-Wiesek M, et al. Tail Suspension Test Does Not Detect Antidepressant-Like Properties of Atypical Antipsychotics. Behavioural pharmacology. 2011;22:7-13.
14766.	Wesolowska A, Partyka A, Jastrzebska-Wiesek M, et al. Atypical antipsychotics with clinical antidepressant activity do not produce anti immobility effect in the mouse tail suspension test. International journal of neuropsychopharmacology. 2010;Conference:69.
14767.	Wessely S, Hindmarch I. Taking the pain out of depression: Dual action antidepressants in the relief of pain in depression, fibromyalgia and other chronic pain syndromes. Human psychopharmacology. 2004;19:S1-S2.
14768.	Westlund TL, L PB. Does estrogen enhance the antidepressant effects of fluoxetine? [References]. Journal of affective disorders. 2003;77:87-92.
14769.	Westrin A, RW L. Seasonal affective disorder: A clinical update. Annals of clinical psychiatry. 2007;19:239-246.
14770.	Westrin A, RW L. Long-term and preventative treatment for seasonal affective disorder. CNS drugs. 2007;21:901-909.
14771.	Westwick F. Depression and selective serotonin reuptake inhibitors. British journal of hospital medicine. 1990;44:367.
14772.	Wetterling T. Prescription of drugs without registered indication. For which drugs and for which psychiatric indications are controlled studies available?. [German]. Fortschritte der Neurologie-Psychiatrie. 2004;72:245-254.
14773.	WF B. Potential Indications for the Selective Serotonin Reuptake Inhibitors. International clinical psychopharmacology. 1992;6:5-12.
14774.	WF B, CL B. The safety profile of paroxetine. [Review] [27 refs]. Journal of clinical psychiatry. 1992;53 Suppl:61-66.
14775.	WF B, JP F. An overview of fluoxetine, a new serotonin-specific antidepressant. [Review] [26 refs]. Mount Sinai Journal of Medicine. 1989;56:136-140.
14776.	WF B, JP F. Clinical significance of early non-response in depressed patients. Depression. 1994;2:32-35.
14777.	WF M. Exercise as an effective treatment option for major depression in older adults. Journal of family practice. 2000;49:109-110.
14778.	WF R, Hu F. Bootstrap methods for adaptive designs. Statistics in medicine. 1999;18:1757-1767.
14779.	WG K, AR S, JW F. Citalopram in the Treatment of Fibromyalgia. Journal of back and musculoskeletal rehabilitation. 2004;17:117-125.
14780.	WG K, AR S, JW F. Citalopram in the Treatment of Fibromyalgia. Journal of back and musculoskeletal rehabilitation. 2004;17:117-125.
14781.	WH C. Antidepressant selection and economic outcome: A review of methods and studies from clinical practice. British journal of psychiatry. 2001;179:s18-s22.
14782.	WH C, Judge R. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. Acta Psychiatrica Scandinavica, Supplement. 2000;101:62-66.
14783.	WH C, RL O, Englehart L, Lair T, DP B, Croghan T. The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization. Statistics in medicine. 1998;17:1943-1958.
14784.	WH F. Smoking cessation pharmacotherapy. Therapeutic advances in cardiovascular disease. 2009;3:287-308.
14785.	WH J, Marsalek P. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. [Review] [41 refs]. Clinical autonomic research. 2004;14:220-227.
14786.	WH K, Nagata T, TE W, et al. Double-Blind Placebo-Controlled Administration of Fluoxetine in Restricting- and Restricting-Purging-Type Anorexia Nervosa. Biological psychiatry. 2001;49:644-652.
14787.	WH K, TE W, LKG H, CM B. An Open Trial of Fluoxetine in Patients With Anorexia-Nervosa. Journal of clinical psychiatry. 1991;52:464-471.
14788.	WH S, JA B, SE K. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898.
14789.	WH S, JA B, SE K. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32-36.
14790.	Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol Augmentation of Serotonin Reuptake Inhibitors for the Treatment of Depressive Disorder: a Systematic Review. Journal of psychopharmacology (Oxford, England). 2010;24:513-520.
14791.	Whang W, KW D. Editorial: Is it time to treat depression in patients with cardiovascular disease? Circulation. 2009;120:99-100.
14792.	Wheatley D. Hypericum extract: Potential in the treatment of depression. CNS drugs. 1998;9:431-440.
14793.	Wheatley D. Side-effects are no problem with St John's wort in depression. Primary Care Psychiatry. 2002;8:31-33.
14794.	Wheatley D. Triple-blind, placebo-controlled trial of Gingko biloba in sexual dysfunction due to antidepressant drugs. Human psychopharmacology. 2004;19:545-548.
14795.	Wheaton P, JL M, Vink R. Impact of pharmacological treatments on cognitive and behavioral outcome in the postacute stages of adult traumatic brain injury: A meta-analysis. Journal of clinical psychopharmacology. 2011;31:745-757.
14796.	Whiskey E, Taylor D. Pramipexole in unipolar and bipolar depression. Psychiatric bulletin (London, England). 2004;28:438-440.
14797.	Whiskey E, Taylor D. A review of the adverse effects and safety of noradrenergic antidepressants. Journal of psychopharmacology (Oxford, England). 2013;27:732-739.
14798.	Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review. International clinical psychopharmacology. 2001;16:239-252.
14799.	Whitaker R. Anatomy of an epidemic: Psychiatric drugs and the astonishing rise of mental illness in America. Ethical human psychology and psychiatry. 2005;7:23-35.
14800.	Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: A systematic review. Psychological medicine. 2003;33:589-599.
14801.	Whiting D, PJ C. Drug information update: Agomelatine. Psychiatrist. 2013;37:356-358.
14802.	Whyte J, Peraud P. Premenstrual disorders: A primary care primer. Consultant. 2009.
14803.	Wiart L, Petit H, PA J, JM M, Barat M. Fluoxetine in Early Poststroke Depression - a Double-Blind Placebo-Controlled Study. Stroke; a journal of cerebral circulation. 2000;31:1829-1832.
14804.	Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Current pharmaceutical design. 2012;18:5802-5817.
14805.	Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. [Review]. Current pharmaceutical design. 2012;18:5802-5817.
14806.	Wick-Urban B. Dexloxiglumide as a sedative for the bowels. [German]. Pharmazeutische Zeitung. 2008;153:26-27.
14807.	Wieck A, Gregoire A. Drugs, hormones and ECT in childbearing women with psychiatric disorders. Psychiatry. 2006;5:25-28.
14808.	Wienberg M, BY G, KS J, Oranje B. A Single High Dose of Escitalopram Increases Mismatch Negativity Without Affecting Processing Negativity or P300 Amplitude in Healthy Volunteers. Journal of psychopharmacology (Oxford, England). 2010;24:1183-1192.
14809.	Wiese K, VL E. Do glutamatergic drugs have a role in treating depression? Current psychiatry. 2015;14:14-16 and 27.
14810.	Wiesegger G, Kienbacher C, Pellegrini E, et al. Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder (ADHD) and comorbid disorders. [German]. Neuropsychiatrie. 2007;21:187-206.
14811.	Wiesegger G, Tauscher J, Kasper S. Substance P-antagonism in treatment of major depressive disorder: An antidepressant strategy for the future?. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2003;4:21-23.
14812.	Wieseler B, Wolfram N, McGauran N, et al. Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data. PLoS medicine. 2013.
14813.	Wiethoff K, Bauer M, TC B, et al. Prevalence and Treatment Outcome in Anxious Versus Nonanxious Depression: Results From the German Algorithm Project. Journal of clinical psychiatry. 2010;71:1047-1054.
14814.	Wiggins J, Patel S. Management of chronic kidney disease in older adults. Aging health. 2010;6:41-51.
14815.	Wijeratne C, Hickie I, Brodaty H. The Characteristics of Fatigue in an Older Primary Care Sample. Journal of psychosomatic research. 2007;62:153-158.
14816.	Wijeratne C, Sachdev P. Treatment-resistant depression: Critique of current approaches. Australian and New Zealand journal of psychiatry. 2008;42:751-762.
14817.	Wijkstra J, Burger H, W vdBW, et al. Treatment of unipolar psychotic depression: A randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta psychiatrica Scandinavica. 2010;121:190-200.
14818.	Wijkstra J, CD S, WA N. Treatment of Unipolar Psychotic Depression: the Use of Evidence in Practice Guidelines. World journal of biological psychiatry. 2009;10:409-415.
14819.	Wijkstra J, Lijmer J, Burger H, Geddes J, WA N. Pharmacological Treatment for Psychotic Depression. Cochrane database of systematic reviews (Online). 2013.
14820.	Wijkstra J, Lijmer J, FJ B, JR G, WA N. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. British journal of psychiatry. 2006;188:410-415.
14821.	Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? Journal of clinical psychopharmacology. 1998;18:390-398.
14822.	Wild J. Antidepressant link to suicides confirmed. Nature. 2005;436:1073.
14823.	Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: The CoBalT randomised controlled trial, Health technology assessment(2014).
14824.	Wiles NJ, Fischer K, Cowen P, et al. Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): An example from the GENPOD trial. Psychological medicine. 2014;44:2855-2866.
14825.	Wilfried S, Monika L. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. Journal of clinical psychopharmacology. 1993;13:34S-39S.
14826.	Wilhelm S, FG B, Hegerl U, et al. Tolerability Aspects in Duloxetine-Treated Patients With Depression: Should One Use a Lower Starting Dose in Clinical Practice? Expert opinion on drug safety. 2012;11:699-711.
14827.	Wilhelmsen M, Amirian I, RJ R, Rosenberg J, Gogenur I. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. Journal of pineal research. 2011;51:270-277.
14828.	Wilkinson D, Holmes C, Woolford J, Stammers S, North J. Prophylactic therapy with lithium in elderly patients with Unipolar Major Depression. International journal of geriatric psychiatry. 2002;17:619-622.
14829.	Wilkinson P. Psychological treatments in the management of severe late-life depression: At least as important as ECT. International Psychogeriatrics. 2007;19:14-18.
14830.	Willemsen R, Vanderlinden J, Deconinck A, Roseeuw D. Hypnotherapeutic management of alopecia areata. Journal of the American Academy of Dermatology. 2006;55:233-237.
14831.	Willer B, JJ L. Management of concussion and pos-concussion syndrome. Current treatment options in neurology. 2006;8:415-426.
14832.	William B, Murray A, J FA, M RE, M CC, Evan B. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. American journal of psychiatry. 2000;157:729-736.
14833.	William B, Yesne A. Pharmacologic treatment options for cancer-related fatigue: Current state of clinical research. Clinical journal of oncology nursing. 2008;12:27-36.
14834.	William C. The search for improved antidepressant strategies: Is bigger better? [References]. American journal of psychiatry. 2011;168:664-666.
14835.	Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective Serotonin Reuptake Inhibitors (Ssris) for Autism Spectrum Disorders (Asd). Cochrane database of systematic reviews (Online). 2013.
14836.	Williams K, DM W, Silove N, Hazell P. Selective Serotonin Reuptake Inhibitors (Ssris) for Autism Spectrum Disorders (Asd). Cochrane database of systematic reviews (Online). 2010.
14837.	Williams K, Thomas E, Arnone D, et al. Impaired face emotion recognition in depression: The influence of pharmacological and psychological factors. European neuropsychopharmacology. 2014;Conference:S388.
14838.	Williams L. International study to predict optimized treatment for depression (iSPOT-D), a randomized clinical trial: Rationale and protocol. Neuropsychopharmacology. 2011;Conference:S3.
14839.	Williams L. Imaging emotion circuits as predictors of treatment outcomes in the iSPOT-D study of major depression. Biological psychiatry. 2013;Conference:139S.
14840.	Williams L, Korgaonkar M, SGA E. Amygdala activation to emotion stimuli as a predictor of treatment outcomes in major depressive disorder: The international study to predict optimized treatment in depression (ISPOT-d). Neuropsychopharmacology. 2013;Conference:S217-S218.
14841.	Williams L, Korgaonkar M, YJ S, et al. Imaging emotion circuits to predict treatment outcomes in major depressive disorder: The international study to predict optimized treatment in depression. Neuropsychopharmacology. 2012;Conference:S301-S302.
14842.	Williams L, McRae K, Rekshan W, Gross J. Effects of antidepressant medication on emotion regulation in major depressive disorder: An ispot-d report. Neuropsychopharmacology. 2013;Conference:S391.
14843.	Williams M. Editorial overview: From Vioxx to Luckenbach: Drug discovery at a crossroads. Current opinion in investigational drugs (London, England : 2000). 2005;6:17-20.
14844.	Williams N, AN S, Simpson K, Nahas Z. Relapse Rates With Long-Term Antidepressant Drug Therapy: a Meta-Analysis. Human Psychopharmacology-Clinical and Experimental. 2009;24:401-408.
14845.	Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. International clinical psychopharmacology. 1993;7:155-158.
14846.	Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: A systematic review. British journal of cancer. 2006;94:372-390.
14847.	Williamson E, Scahill L. Use of antidepressants in children: is it time for a comparative effectiveness trial? Journal of the American Academy of Child and Adolescent Psychiatry. 2010;49:184-188.
14848.	Willinger U, Lenzinger E, Hornik K, et al. Anxiety as a predictor or relapse in detoxified alcohol-dependent patients. Alcohol and Alcoholism. 2002;37:609-612.
14849.	Willinger U, Lenzinger E, Hornik K, et al. Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol and alcoholism (Oxford, Oxfordshire). 2002;37:609-612.
14850.	Willner N, Schiff E. A case of suicide attempt with Zolpidem - Will Zolpidem show up on standard urine toxicology screening? EXCLI Journal. 2014;13:454-456.
14851.	Willner P, AS H, Argyropoulosc S. Dopaminergic Mechanism of Antidepressant Action in Depressed Patients. Journal of affective disorders. 2005;86:37-45.
14852.	Wilson H, Mannix S, Oko-Osi H, DA R. The Impact of Medication on Health-Related Quality of Life in Patients With Generalized Anxiety Disorder. CNS drugs. 2015;29:29-40.
14853.	Wilson I, Duszynski K, Mant A. A 5-year follow-up of general practice patients experiencing depression. Family practice. 2003;20:685-689.
14854.	Wilson K. Vascular Disease, Depression and Cognitive Impairment. Encephale. 2008;34:S50-S54.
14855.	Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: A meta-analysis. International journal of geriatric psychiatry. 2004;19:754-762.
14856.	Wilson KCM, Mottram PG, Ashworth L, Abou-Saleh MT. Older community residents with depression: Long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. The British Journal of Psychiatry. 2003;182:492-497.
14857.	Wilson S, Argyropoulos S. Antidepressants and Sleep - a Qualitative Review of the Literature. Drugs. 2005;65:927-947.
14858.	Wilson S, Argyropoulos S. Antidepressants and Sleep - a Qualitative Review of the Literature. Drugs. 2005;65:927-947.
14859.	Wilson S, Buchbjerg J, AM H, Areberg J, DJ N. Effects of vortioxetine versus paroxetine on polysomnography in man: A pharmacokinetic/pharmacodynamic study. European neuropsychopharmacology. 2013;Conference:S195-S196.
14860.	Windischberger C, Lanzenberger R, Holik A, et al. Area-Specific Modulation of Neural Activation Comparing Escitalopram and Citalopram Revealed by Pharmaco-Fmri: a Randomized Cross-Over Study. NeuroImage. 2010;49:1161-1170.
14861.	Wingen M, KPC K, V VDV, Formisan E, JG R. Sustained Attention and Serotonin: a Pharmaco-Fmri Study. Human Psychopharmacology-Clinical and Experimental. 2008;23:221-230.
14862.	Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: A knowledge synthesis for better treatment for women and neonates. Addiction (Abingdon, England). 2008;103:1429-1440.
14863.	Winkler A, Dorsing B, Rief W, Shen Y, JA G. Treatment of internet addiction: A meta-analysis. Clinical psychology review. 2013;33:317-329.
14864.	Winkler D. Quetiapine - Novel developments. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2004;5:53-54.
14865.	Winkler D, Pjrek E, Kasper S. Gender-specific symptoms of depression and anger attacks. Journal of men's health & gender. 2006;3:19-24.
14866.	Winkler D, Pjrek E, Klein N, Kasper S. Escitalopram in Employed People - Results From an Observational Study in 2378 Patients. Psychopharmakotherapie. 2006;13:142-+.
14867.	Winkler D, Pjrek E, Moser U, Kasper S. Escitalopram in a Working Population: Results From an Observational Study of 2378 Outpatients in Austria. Human Psychopharmacology-Clinical and Experimental. 2007;22:245-251.
14868.	Winkler D, S KW. Escitalopram. [German]. Psychopharmakotherapie. 2002;9:128-132.
14869.	Winokur A, KA G, Rodner S, Rae-Red C, AT F, MP S. Depression, sleep physiology, and antidepressant drugs. Depression and anxiety. 2001;14:19-28.
14870.	Wise T, AJ C, Herane A, AH Y, Arnone D. Diagnostic and therapeutic utility of neuroimaging in depression: An overview. Neuropsychiatric disease and treatment. 2014;10:1509-1522.
14871.	Wisner K. Estradiol for postpartum depression: Translational challenges. Neuropsychopharmacology. 2014;Conference:S32.
14872.	Wittert G, Caterson I, Finer N. The clinical effectiveness of weight loss drugs. Obesity research & clinical practice. 2007;1:1-5.
14873.	WJ B. Escitalopram. [Review] [45 refs]. Expert opinion on investigational drugs. 2002;11:1477-1486.
14874.	WJ B, DA M-M. Exploring Treatment Alternatives: Weekly Dosing of Fluoxetine for the Continuation Phase of Major Depressive Disorder. Journal of clinical psychiatry. 2001;62 Suppl 2:38-42.
14875.	WJ G, CC NJ, Musil B, JT G. Managing seizures: Achieving control while minimizing risk. Journal of family practice. 2011;60:464-470.
14876.	WJ K. The Comorbidity of Diabetes Mellitus and Depression. American journal of medicine. 2008;121:S8-S15.
14877.	WJ K. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues in clinical neuroscience. 2011;13:7-24.
14878.	WJ K, EHB L, M VK. The authors reply. New England journal of medicine. 2011;364:1278-1279.
14879.	WJ N, GL X, AV B. Beta-blockers: Off-label use in psychiatric disorders. Psychopharm Review. 2013;48:73-80.
14880.	WJ R, Eikmans K, Heldens A, JA S. Specific Serotonergic Reuptake Inhibition Impairs Vigilance Performance Acutely and After Subchronic Treatment. Journal of psychopharmacology (Oxford, England). 2005;19:12-20.
14881.	WJ R, Eikmans K, Heldens A, JAJ S. Specific Serotonergic Reuptake Inhibition Impairs Vigilance Performance Acutely and After Subchronic Treatment. Journal of psychopharmacology (Oxford, England). 2005;19:12-20.
14882.	Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: A randomized, sham-controlled trial, Psychiatry research(2010).
14883.	WJG H. Emerging treatments for premature ejaculation: Focus on dapoxetine. Neuropsychiatric disease and treatment. 2009;5:37-46.
14884.	WJr WJ, James B, Tom O, et al. Treatment of Dysthymia and Minor Depression in Primary Care - a Randomized Controlled Trial in Older Adults. JAMA: Journal of the American Medical Association. 2000;284:1519-1526.
14885.	WK G. Obsessive-compulsive disorder: Diagnosis and treatment. Journal of clinical psychiatry. 1999;60:27-32.
14886.	WK G. Selecting Pharmacotherapy for Generalized Anxiety Disorder. Journal of clinical psychiatry. 2004;65:8-13.
14887.	WK G. Selecting Pharmacotherapy for Generalized Anxiety Disorder. Journal of clinical psychiatry. 2004;65:8-13.
14888.	WK G, Bose A, Wang Q. Treatment of Generalized Anxiety Disorder With Escitalopram: Pooled Results From Double-Blind, Placebo-Controlled Trials. Journal of affective disorders. 2005;87:161-167.
14889.	WK G, Bose A, Wang Q. Treatment of Generalized Anxiety Disorder With Escitalopram: Pooled Results From Double-Blind, Placebo-Controlled Trials. Journal of affective disorders. 2005;87:161-167.
14890.	WK G, CJ M, LC B, SC A, LH P. Biological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder. Journal of clinical psychiatry. 1993;54:16-26.
14891.	WK G, CJ M, LH P. Pharmacotherapy of obsessive compulsive disorder. Journal of clinical psychiatry. 1992;53:29-37.
14892.	WK G, DS C. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. Journal of clinical psychiatry. 1985;46:6-22.
14893.	WK G, EA S, GR G, TK M. Obsessive-Compulsive Disorder in Tourette Syndrome. Journal of child neurology. 2006;21:704-714.
14894.	WK G, LH P, PL D, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Archives of general psychiatry. 1990;47:577-585.
14895.	WK G, LH P, SA R, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of general psychiatry. 1989;46:1012-1016.
14896.	WK G, MJ K, Liebowitz M, KL W. Treatment of Obsessive-Compulsive Disorder With Fluvoxamine: a Multicentre, Double-Blind, Placebo-Controlled Trial. International clinical psychopharmacology. 1996;11:21-29.
14897.	WK G, TK M, EA S. Risk of Adverse Behavioral Effects With Pediatric Use of Antidepressants. Psychopharmacology. 2007;191:87-96.
14898.	WK G, TK M, Lazoritz M. Risk of suicidality during antidepressant treatment of children and adolescents. Primary psychiatry. 2006;13:43-50.
14899.	WK T, DJ K, Fagiolini A, JA S, Frank E. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: Analysis of acute-phase data from a randomized controlled trial. Journal of clinical psychiatry. 2006;67:783-788.
14900.	WK T, GS U, HFK C, KH S. Detecting Depression in Chinese Stroke Patients: a Pilot Study Comparing Four Screening Instruments. International journal of psychiatry in medicine. 2004;34:155-163.
14901.	WK T, GS U, HFK C, KH S. Detecting Depression in Chinese Stroke Patients: a Pilot Study Comparing Four Screening Instruments. International journal of psychiatry in medicine. 2004;34:155-163.
14902.	WM B, KU L, DI J, et al. Prescription pattern and side effect profiles of bupropion. European neuropsychopharmacology. 2009;Conference:S362.
14903.	Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: Randomized, double-blind, placebo-controlled clinical trial, JAMA Otolaryngology - Head and Neck Surgery(2013).
14904.	WM L, Denman D, DP M, SE P, WJ B. A Randomized, Placebo-Controlled Trial of Citalopram for the Prevention of Major Depression During Treatment for Head and Neck Cancer. Archives of otolaryngology--head & neck surgery. 2008;134:528-535.
14905.	WM L, Denman D, DP M, SE P, WJ B. A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Archives of otolaryngology--head & neck surgery. 2008;134:528-532.
14906.	WM L, Moran J, WJ B. A review of depression in the head and neck cancer patient. Clinical advances in hematology & oncology. 2009;7:397-403.
14907.	WM M, Easley K, EH B, et al. Combination rapid transcranial magnetic stimulation in treatment refractory depression. Neuropsychiatric disease and treatment. 2006;2:85-94.
14908.	WN B, Morrison A, AI W. Pharmaceuticals and worker productivity loss: A critical review of the literature. Journal of Occupational and Environmental Medicine. 2003;45:610-621.
14909.	WN R, EA R, Garawi F, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. American Journal on Addictions. 2014;23:68-75.
14910.	WN R, KM C, Aharonovich E, et al. Temperament Characteristics, as Assessed by the Tridimensional Personality Questionnaire, Moderate the Response to Sertraline in Depressed Opiate-Dependent Methadone Patients. Drug and alcohol dependence. 2006;81:283-292.
14911.	WN R, Sanfilippo L, Pavlicova M, et al. Dysregulation of diurnal cortisol secretion affects abstinence induction during a lead-in period of a clinical trial for depressed cocaine-dependent patients. American Journal on Addictions. 2014;23:1-6.
14912.	WO T. Recent and emerging anti-seizure drugs: 2013. Current treatment options in neurology. 2013;15:505-518.
14913.	Wojciechowski D, Papademetriou V. beta-blockers in the management of hypertension: Focus on nebivolol. Expert review of cardiovascular therapy. 2008;6:471-479.
14914.	Wolf I, Friede T, Hallier E, Straube S. Work-Related Outcomes in Randomised Placebo-Controlled Pain Trials: a Systematic Review and Meta-Analysis. Journal of occupational medicine and toxicology (London, England). 2014;9.
14915.	Wolfe F, MA C, DJ H. A Double-Blind Placebo-Controlled Trial of Fluoxetine in Fibromyalgia. Scandinavian journal of rheumatology. 1994;23:255-259.
14916.	Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995;28:56-60.
14917.	Wolff E, Gaudlitz K, B-L VL, Plag J, Heinz A, Strohle A. Exercise and physical activity in mental disorders. European archives of psychiatry and clinical neuroscience. 2011;261:S186-S191.
14918.	Amelioration of cognitive control in depression by transcranial direct current stimulation, Biological psychiatry(2013).
14919.	Wood A. Pharmacotherapy of bulimia nervosa--experience with fluoxetine. International clinical psychopharmacology. 1993;8:295-299.
14920.	Worcester S. Escitalopram cut depression in head and neck cancer patients. Oncology Report. 2013:16.
14921.	Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996;37:518-522.
14922.	WP M. Medical Therapies for Concussion. Clinics in sports medicine. 2011;30:115-124.
14923.	WR L, Hu M, Tennen H, JC C, CD P, AJ R. Daily Process Methodology for Measuring Earlier Antidepressant Response. Contemporary clinical trials. 2008;29:867-877.
14924.	WR L, Huang Y, JQ C, SX W. [Global improvement in agitated depression treated with the alliance therapy of acupuncture and seroxat and the observation of the quality of life]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2012;32:1063-1069.
14925.	WR P, TM B, JA M. Current pharmacological and nonpharmacological options for the management of insomnia. Clinical Medicine Insights: Therapeutics. 2013;5:151-162.
14926.	WR Y, Mitchell J, AJ R, et al. Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: Confirmatory analysis. Primary care companion to the Journal of clinical psychiatry. 2007;9:7-15.
14927.	Wright A, KE L, C vdB. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. Journal of pain research. 2011;4:1-10.
14928.	Wright A, VanDenBerg C. Duloxetine in the treatment of generalized anxiety disorder. International journal of general medicine. 2009;2:153-162.
14929.	WS B, RH D. Premenstrual syndrome and premenstrual dysphoric disorder. American family physician. 2011;84:918-924.
14930.	WS G, JK G, SR W, et al. Does the Duration of Index Episode Affect the Treatment Outcome of Major Depressive Disorder? A Star*D Report. Journal of clinical psychiatry. 2008;69:1246-1256.
14931.	WS L, CR H, MEJ L. Weight gain as an adverse effect of some commonly prescribed drugs: A systematic review. QJM : monthly journal of the Association of Physicians. 2007;100:395-404.
14932.	WS M, LB K. Multiple sclerosis - Related fatigue. Physical medicine and rehabilitation clinics of North America. 2005;16:483-502.
14933.	WS T, AJ B. Serotonergic involvement in the psychosocial dimension of personality. Journal of psychopharmacology (Oxford, England). 2001;15:195-198.
14934.	WS W, CE G, DJ M. Fibromyalgia and Bipolar Disorder: a Potential Problem? Bipolar disorders. 2010;12:514-520.
14935.	WT S, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. Journal of clinical psychiatry. 1992;53 Suppl:36-39.
14936.	WT S, PD L, Glaudin V, JR P, Network SR. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? [References]. Journal of affective disorders. 2002;70:251-259.
14937.	Wu F, EB L, IA L, Severus E. Who will benefit from antidepressants in the acute treatment of bipolar depression? A reanalysis of the STEP-BD study by Sachs et al. 2007, using Q-learning. International Journal of Bipolar Disorders. 2015.
14938.	Wu H, Li S, Wang X, et al. The control study of treating arrhythmia patients with depressive symptom by fluoxetine. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2003;7:1792-1793.
14939.	Wu J, AS Y, Schnyer R, Wang Y, Mischoulon D. Acupuncture for depression: A review of clinical applications. Canadian Journal of Psychiatry. 2012;57:397-405.
14940.	Wu K, Politis M, Piccini P. Impulse control disorders in parkinson's disease: A review. Current psychiatry reviews. 2012;8:235-246.
14941.	Wu Q, AF B, JG H, MD C. Selective serotonin reuptake inhibitor treatment and risk of fractures: Ameta-analysis of cohort and case-control studies. Osteoporosis international. 2012;23:365-375.
14942.	Wu R, DE K, Sajatovic M, Zhao J, JR C, Gao K. Communication of Potential Benefits and Harm to Patients and Payers in Psychiatry: A Review and Commentary. Clinical therapeutics. 2011;33:B62-B76.
14943.	Wu X, Liu F, Cai H, et al. Cognitive behaviour therapy combined fluoxetine treatment superior to cognitive behaviour therapy alone for school refusal. International Journal of Pharmacology. 2013;9:197-203.
14944.	Wu X, SL A, Moges H, L DT, CE T, JJ A. Pulsed light irradiation improves behavioral outcome in a rat model of chronic mild stress. Lasers in surgery and medicine. 2012;44:227-232.
14945.	Wulff K, Laigle L, Hajak G, Kasper S. Preliminary findings of the rest-activity cycles in patients with major depression following agomelatine and sertraline treatment. European neuropsychopharmacology. 2012;Conference:S264.
14946.	Wurtman J, Wurtman R, Berry E, et al. Dexfenfluramine, Fluoxetine, and Weight-Loss Among Female Carbohydrate Cravers. Neuropsychopharmacology. 1993;9:201-210.
14947.	Wurz A, MZ S. Does pharmacotherapy support or hinder psychotherapy? Questions, problems, mastery and expertise. Klinik Psikofarmakoloji Bulteni. 2009;19:S97-S101.
14948.	WV B. Asenapine, iloperidone and lurasidone: Critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert review of clinical pharmacology. 2013;6:61-91.
14949.	WV B, RA E, RC S. Olanzapine Monotherapy for Acute Depression in Patients With Bipolar I or Ii Disorder: Results of an 8-Week Open Label Trial. Human Psychopharmacology-Clinical and Experimental. 2010;25:30-36.
14950.	WV B, RA EJ, RC S. Acute bipolar depression: A review of the use of olanzapine/fluoxetine. Clinical Medicine Insights: Therapeutics. 2010;2:825-840.
14951.	WV B, RC S. Olanzapine and Fluoxetine Combination Therapy for Treatment-Resistant Depression: Review of Efficacy, Safety, and Study Design Issues. Neuropsychiatric disease and treatment. 2009;5:369-383.
14952.	WV B, RC S. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. [Review] [88 refs]. Expert opinion on pharmacotherapy. 2009;10:2145-2159.
14953.	WV B, RC S. Risperidone long-acting injectable (Risperdal Consta) for maintenance treatment in patients with bipolar disorder. Expert review of neurotherapeutics. 2010;10:1637-1658.
14954.	WV M. A psychiatric perspective on insomnia. Journal of clinical psychiatry. 2001;62:27-32.
14955.	WV M. What does star*D tell us about ECT? Journal of ECT. 2007;23:1-2.
14956.	Treatment of Insomnia in Depressed Insomniacs: Effects on Health-Related Quality of Life, Objective and Self-Reported Sleep, and Depression, Journal of clinical sleep medicine(2010).
14957.	WV M, RB DA, JN K, et al. Eszopiclone at bedtime improves the quality of life in depressed insomniacs receiving fluoxetine. Sleep. 2009;Conference:A348-A349.
14958.	WV M, RM B, PB R, et al. A Multi-Site Randomized Clinical Trial to Reduce Suicidal Ideation in Suicidal Adult Outpatients With Major Depressive Disorder: Development of a Methodology to Enhance Safety. Clinical trials (London, England). 2015;12:189-198.
14959.	WVR V, DA J, Fernandez A, et al. Treatment of Depression in Patients With Coronary Heart Disease. American journal of medicine. 2006;119:567-573.
14960.	WW D. Pharmacotherapy of adult ADHD. Journal of clinical psychology. 2005;61:589-606.
14961.	WW F, GM G. Effectiveness as an outcome measure for treatment trials in psychiatry. World psychiatry. 2009;8:23-27.
14962.	WW I, Bagot K, Thomas S, et al. Quality of life in patients suffering from insomnia. Innovations in clinical neuroscience. 2012.
14963.	WW I, Bokarius A, JK J, MC D, Bakhta Y. Disorders of orgasm in women: A literature review of etiology and current treatments. Journal of sexual medicine. 2010;7:3254-3268.
14964.	WW I, Christensen S, Sayer G, et al. Sexual Satisfaction and Quality of Life in Major Depressive Disorder Before and After Treatment With Citalopram in the Star*D Study. Journal of clinical psychiatry. 2013;74:256-261.
14965.	WW I, Elbau I, Ismail A, et al. Quality of life in borderline personality disorder. Harvard review of psychiatry. 2013;21:138-150.
14966.	WW I, MH R, JG G. Emerging Treatment Options in Treatment-Resistant Depression and Anxiety Disorders. CNS spectrums. 2004;9:25-32.
14967.	WW I, MH R, JG G. Emerging Treatment Options in Treatment-Resistant Depression and Anxiety Disorders. CNS spectrums. 2004;9:25-32.
14968.	WW I, MH R, JG G. The effectiveness of atypical antipsychotic medications in depressive disorders. Current psychiatry reports. 2004;6:422-424.
14969.	WW T. Cognitive processes in cognitive and pharmacological therapies. Cognitive therapy and research. 2009;33:570-584.
14970.	WW VDB, TK B, PGH M, JA B, Moleman P. A Double-Blind Randomized Study Comparing Imipramine With Fluvoxamine in Depressed Inpatients. Psychopharmacology. 2004;175:481-486.
14971.	WW VDB, TK B, PGH M, JA B, Moleman P. Imipramine Is Effective in Preventing Relapse in Electroconvulsive Therapy-Responsive Depressed Inpatients With Prior Pharmacotherapy Treatment Failure: a Randomized, Placebo-Controlled Trial. Journal of clinical psychiatry. 2006;67:263-268.
14972.	WW W. Preventive therapy in pediatric migraine. Journal of child neurology. 2001;16:71-78.
14973.	WX S, SY H, CY H, CH C, Wang Z. [Effects of baisong tablets on the behavior and levels of norepinephrine and dopamine in the brain of stress rats]. [Chinese]. Zhong Nan da Xue Xue Bao. 2005;Yi Xue Ban:574-578.
14974.	WY B, Jiao S, Lu J, et al. [Effect of electroacupuncture intervention on learning-memory ability and injured hippocampal neurons in depression rats]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2014;39:136-141.
14975.	WY L, SC L, Yang Y, ZY H, Davies H, MR F. Systematic Hypothesis for Post-Stroke Depression Caused Inflammation and Neurotransmission and Resultant on Possible Treatments. Neuro endocrinology letters. 2014;35:104-109.
14976.	WY W, Wang G, SG B, Desaiah D, QQ A. Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China. Chinese medical journal. 2011;124:3260-3268.
14977.	Wyrwich K, Harnam N, DA R, JC L, Svedsater H, Endicott J. Assessing Health-Related Quality of Life in Generalized Anxiety Disorder Using the Quality of Life Enjoyment and Satisfaction Questionnaire. International clinical psychopharmacology. 2009;24:289-295.
14978.	Wysokinski A, Kloszewska I. Vortioxetine - A new option in the treatment of depression and general anxiety disorder. [Polish]. Postepy Psychiatrii i Neurologii. 2013;22:187-192.
14979.	X-B Z, Z-X L, J-D L, G-M C. Effects of double syndrome differentiation therapy and fluoxetine in treating anxiety: Comparison of 6-month follow-up. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:6-7.
14980.	X-B Z, Z-X L, J-D L, Lu D, G-M C. Interventional efficacy of citalopram combined with shining and psychological morning exercise in the attack of depression in elderly people. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:24-25.
14981.	X-H H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2002;6:2296-2297.
14982.	X-H L, H-W Z, Y-D P. A comparative evaluation on the effect of citalopram and amitriptyline in treating senile depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:5762-5763.
14983.	X-H W, X-D G, Liu M. Effectiveness and safety of olanzapine combined with fluoxetine for refractory depression: A systematic review. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2010;10:1102-1109.
14984.	X-N H, F-D Y, H-W K, et al. Duloxetine hydrochloride enteric tablets in the treatment of major depressive disorder: a multicenter, randomized, double-blind, and positive drug parallel controlled clinical trial. [Chinese]. Chinese Journal of New Drugs. 2014;23:2767-2771 and 2780.
14985.	X-Q H, M-C L, Tao R. Treatment of internet addiction. Current psychiatry reports. 2010;12:462-470.
14986.	X-Q W, H-Y Z, Shu L, et al. Efficacy and safety of morinda officinalis oligose capsule in the treatment of mild or moderate depression. [Chinese]. Chinese Journal of New Drugs. 2009;18:802-805+843.
14987.	X-X D, Ye L. Meta-analysis of comparative studies for citalopram in the teatment of post-stroke depression. [Chinese]. Chinese Journal of New Drugs. 2009;18:810-814.
14988.	X-Y W, Hong H, Y-F L. Vilazodone: A new generation of antidepressants with multiple targets and new mechanisms. [Chinese]. Chinese Journal of Pharmacology and Toxicology. 2013;27:720-726.
14989.	X-Z H, AJ R, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of general psychiatry. 2007;64:783-792.
14990.	XC L, Gelwicks S, DE F, SL A. Initial Duloxetine Prescription Dose and Treatment Adherence and Persistence in Patients With Major Depressive Disorder. International clinical psychopharmacology. 2010;25:315-322.
14991.	XC L, PG T, SL A. Adherence and Persistence With Duloxetine and Hospital Utilization in Patients With Major Depressive Disorder. International clinical psychopharmacology. 2011;26:173-180.
14992.	XC L, ZL C, LY N, DE F, Ball T, Johnstone B. Dosing Patterns for Duloxetine and Predictors of High-Dose Prescriptions in Patients With Major Depressive Disorder: Analysis From a United States Third-Party Payer Perspective. Clinical therapeutics. 2011;33:1726-1738.
14993.	XF Z, YL H, DL L, CO H, QC K. Association Between the Tph1 A218c Polymorphism and Antidepressant Response: Evidence From an Updated Ethnicity, Antidepressant-Specific, and Ethnicity-Antidepressant Interaction Meta-Analysis. Psychiatric genetics. 2015;25:1-8.
14994.	XF Z, YL H, JY L, et al. Association Between the 5-Ht1a Receptor Gene Polymorphism (Rs6295) and Antidepressants: a Meta-Analysis. International clinical psychopharmacology. 2012;27:314-320.
14995.	XH Z, SJ H, YY W, et al. Effects of Kaixin Jieyu Decoction on Behavior and Glial Fibrillary Acidic Protein Expression in Cerebral Hippocampus of a Rat Vascular Depression Model. Chinese journal of integrative medicine. 2015;21:223-228.
14996.	Xia G, Gajwani P, DJ M, et al. Treatment-emergent mania in unipolar and bipolar depression: Focus on repetitive transcranial magnetic stimulation. International journal of neuropsychopharmacology. 2008;11:119-130.
14997.	Xia Q, Wang J, Zheng K. Rehabilitative therapy for the elderly chronic somatic disease complicated with depression. Chinese Journal of Clinical Rehabilitation. 2006;10:166-168.
14998.	Xia Y, HD W, Ding Y, Kang B, WG L. [Parkinson's disease combined with depression treated with electroacupuncture and medication and its effect on serum BDNF]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2012;32:1071-1074.
14999.	Xiao B, ZH L. [Efficacy on depression in breast cancer treated with acupuncture and auricular acupressure]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2014;34:956-960.
15000.	Xiao W, XB Z, HX H, Wang Z, XL G. [Acupuncture and drug for subcortical ischemic vascular disease complicated with depression: a randomized controlled trial]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2014;34:1051-1056.
15001.	Xiao-gang C, Li-wen T, Jing-ping Z, Le-hua L, Yuan-guang C. Randomized controlled clinical trials of remeron and fluoxetine in depressive patients. [Chinese]. Chinese Journal of Clinical Psychology. 2002;10:100-102,142.
15002.	Xie Q, Liu Y, CY L, et al. The Modulation of Venlafaxine on Cortical Activation of Language Area in Healthy Subjects With Fmri Study. Psychopharmacology. 2012;223:417-425.
15003.	Xin W, Yan H, Chun-Ling X, al e. A Clinical Trial of Paroxetine and Psychotherapy in Patients with Poststroke Depression and Anxiety. [Chinese]. Chinese Mental Health Journal. 2005;19:564-566.
15004.	Xin Z, Deying K, Lan Z, Le P. Shuganjieyu capsule for major depressive disorder (MDD) in adults: A systematic review. Aging & mental health. 2014;18:941-953.
15005.	Xin-Fa W, Huan W, Tao L. Effects of paroxetine combined with quetiapine in the treatment of double depression. [Chinese]. Chinese Mental Health Journal. 2011;25:196-199.
15006.	Xin-Jiang H, Jing-Hang X, Jun W, Yan-Yan Y. Can antidepressants prevent pegylated interferon-alpha/ribavirin-associated depression in patients with chronic hepatitis C: Meta-analysis of randomized, double-blind, placebo-controlled trials? [References]. PloS one. 2013;8.
15007.	Xing X, Li M, Lu W. Treatment of myocardiac injury caused by tricyclic antidepressant. Chinese Journal of Clinical Rehabilitation. 2003;7:858-859.
15008.	Xiong J, Y-H D, J-L L, et al. Acupuncture versus western medicine for depression neurosis: A systematic review. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2009;9:969-975.
15009.	Xiong J, YH D, JL L, et al. [Survey clinical evidence of acupuncture therapy for depressive neurosis]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2010;30:235-240.
15010.	Xiufang Z, Li Y, Zhou Z, Pan S. [Clinical observasion of acupuncture in patients with depression and its impact on serum 5-HT]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2015;35:123-126.
15011.	XJ C, XP B, Zhao Z, Wang L. [The effects of antidepressant treatment on efficacy of antihypertensive therapy in elderly hypertension]. [Chinese]. Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine. 2006;45:639-641.
15012.	XJ H, JH X, Wang J, YY Y. Can antidepressants prevent pegylated interferon-alpha/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS ONE [Electronic Resource]. 2013;8:e76799.
15013.	XJ W, LM W, ZL L, Huang A, YY L, JY H. Meta-Analysis on the Efficacy and Tolerability of the Augmentation of Antidepressants With Atypical Antipsychotics in Patients With Major Depressive Disorder. Brazilian Journal of Medical and Biological Research. 2014;47:605-616.
15014.	XK H, LS Z, LY R, QY L, Zhu Y. [Effect of electroacupuncture of "Hegu" (LI 4)-"Taichong" (LR 3) on colonic nitric oxide synthase and glutathione peroxidase activity and nitric oxide content in depression rats]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2008;33:183-185.
15015.	Xu B, WY Z, SJ Z. [Observation on effect of Wuling Capsule in treating poststroke depression]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2007;27:640-642.
15016.	Xu F. Caution in prescribing antidepressants for patients with cancer. American journal of health-system pharmacy. 2008;65:700.
15017.	Xu G, HW J, Fang J, et al. An Improved Dosage Regimen of Sertraline Hydrochloride in the Treatment for Premature Ejaculation: an 8-Week, Single-Blind, Randomized Controlled Study Followed by a 4-Week, Open-Label Extension Study. Journal of clinical pharmacy and therapeutics. 2014;39:84-90.
15018.	Xu J, Wang J-P, Liu J. Preventive Effects of Antidepressants on Post-stroke Depression. [Chinese]. Chinese Mental Health Journal. 2006;20:186-188.
15019.	Xue H. Paroxetine for Depression in Diabetes: A Randomized Controlled Trial. [Chinese]. Chinese Mental Health Journal. 2004;18:735-737.
15020.	Xue-Jun H, Mei-En G, Zi-Ying T. Comparison of mirtazapine and paroxetine in patients with first-episode climacteric depression. [Chinese]. Chinese Mental Health Journal. 2007;21:428-430.
15021.	XX G, Sun P, MQ Q, Wei S, Xue L, HY Z. Shu-Yu Capsule, a Traditional Chinese Medicine Formulation, Attenuates Premenstrual Syndrome Depression Induced by Chronic Stress Constraint. Molecular medicine reports. 2014;10:2942-2948.
15022.	XX Z, LL J, Chen C, et al. Danzhi Xiaoyao San ameliorates depressive-like behavior by shifting toward serotonin via the downregulation of hippocampal indoleamine 2,3-dioxygenase. Journal of ethnopharmacology. 2015;160:86-93.
15023.	XY Z, Qin B, C DG, et al. Efficacy and Tolerability of Antidepressants in the Treatment of Adolescents and Young Adults With Depression and Substance Use Disorders: a Systematic Review and Meta-Analysis. Addiction (Abingdon, England). 2015;110:38-48.
15024.	XZ J, YF L, YZ Z, HX C, Li J, NP W. [5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine]. [Chinese]. Yao Hsueh Hsueh Pao - Acta Pharmaceutica Sinica. 2008;43:467-473.
15025.	Y DA, J LE, Amanda DM, et al. Maintenance treatment for old-age depression preserves health-related quality of life: A randomized, controlled trial of paroxetine and interpersonal psychotherapy. Journal of the American Geriatrics Society. 2007;55:1325-1332.
15026.	Y KA, L CM, H PS. Double-blind crossover study of mirtazapine, amitriptyline and placebo in patients with major depressive disorder. Directions in Psychiatry. 2009;29:125-130.
15027.	Y YV, I BA, G YY, E GS, J BO, V AT. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy. 2007;29:2319-2332.
15028.	Y-B J. Systematic evaluation on the effect of paroxetine in treating post-stroke depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:3-5.
15029.	Y-B S, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta psychiatrica Scandinavica. 2011;123:247-265.
15030.	Y-B Y, X-B H, Shu L, et al. Duloxetine versus paroxetine in the treatment of major depressive disorder: a randomized double-blind multicentre controlled study. [Chinese]. Chinese Journal of New Drugs. 2011;20:334-338.
15031.	Y-C C, W-W L, Y-J C, W-C M, Y-J H. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators of inflammation. 2010.
15032.	Y-C L, P-P C. A Review of Ssris and Snris in Neuropathic Pain. Expert opinion on pharmacotherapy. 2010;11:2813-2825.
15033.	Y-C Y, P-H C, M-C H, C-Y L. Effective treatment of premenstrual violence in major depression: Augmentation with aripiprazole. Chang Gung medical journal. 2008;31:402-406.
15034.	Y-F Z, D-Q Y, X-L F, Su H, F-M P, F-F L. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. European neuropsychopharmacology. 2010;20:535-544.
15035.	Y-F Z, Wang F, X-L F, et al. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neuroscience letters. 2010;484:56-61.
15036.	Y-H L, C-H Z, S-E W, Qiu J, S-Y H, G-L X. [Effects of Chaihu Shugan San on behavior and plasma levels of corticotropin releasing hormone and adrenocorticotropic hormone of rats with chronic mild unpredicted stress depression]. [Chinese]. Zhong xi yi jie he xue bao [Journal of Chinese integrative medicine]. 2009;7:1073-1077.
15037.	Y-H W, L-T Y, Yang H, X-L L, K-G W. Hypoglycemic and anti-depressant effects of Zuogui Jiangtang Jieyu formulation in a model of unpredictable chronic mild stress in rats with diabetes mellitus. Experimental and therapeutic medicine. 2014;8:281-285.
15038.	Y-H W, Yang H, L-T Y, et al. Effects of Zuogui Jiangtang Jieyu Fang on blood glucose and lipids in diabetes mellitus rats with depression. [Chinese]. Chinese Traditional and Herbal Drugs. 2014;45:1602-1606.
15039.	Y-J P, Knapp M, McCrone P. Cost-effectiveness comparisons between antidepressant treatments in depression: Evidence from database analyses and prospective studies. Journal of affective disorders. 2012;139:113-125.
15040.	Y-L H, J-P Y, G-H W, Z-H C, Wang Q, Xiao L. Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum. World journal of gastroenterology. 2007;13:6060-6065.
15041.	Y-L L, M-Y Z, W-Y W, C-B L, Lu Z, Q-W L. A Randomized Double-Blind Clinical Trial on Analgesic Efficacy of Fluoxetine for Persistent Somatoform Pain Disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:1522-1525.
15042.	Y-L S, S-B C, Gao Y, Xiong J. Acupuncture versus western medicine for depression in China: A systematic review. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2008;8:340-345.
15043.	Y-M C, X-M H, Thompson R, Y-B Z. Clinical Features and Efficacy of Escitalopram Treatment for Geriatric Depression. Journal of international medical research. 2011;39:1946-1953.
15044.	Y-M H, Kang B, J-D L, X-B Z. Combined cognitive therapy with fluoxetine hydrochloride on patients with senile depressive neurosis in open wards: A randomized controlled study. Chinese Journal of Clinical Rehabilitation. 2003;7:4105-4107.
15045.	Y-M M, M-D Z. Augmentation with antidepressants in schizophrenia treatment: Benefit or risk. Neuropsychiatric disease and treatment. 2015;11:701-713.
15046.	Y-P H, Wehrly R, Gorrindo T, et al. Gender specific short stature in male adolescents with obsessive-compulsive disorder. Journal of Obsessive-Compulsive and Related Disorders. 2013;2:30-36.
15047.	Y-S D, Naganawa M, J-D G, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. NeuroImage. 2014;86:164-171.
15048.	Y-S W, Y-C C, R-B L. Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. Journal of clinical pharmacy and therapeutics. 2007;32:353-363.
15049.	Y-X F, H-Q M, Q-H L. Interventional effect of fluoxetine on patients with acute myocardial infarction accompanied by anxiety and depression. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:16-17.
15050.	Y-X H, Song L, Zhang X, W-W L, Pan C, Y-S H. [Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression]. [Chinese]. National Medical Journal of China. 2013;93:600-602.
15051.	Y-Y Y, S-L L, Xing Y, M-Z L, J-G L, F-P C. Effect of Shugan Hewei decoction on expression of 5-hydroxytryptamine in the medulla oblongata, spinal cord and gastric mucosa of depression rats. World Chinese Journal of Digestology. 2014:3251-3258.
15052.	YA B, LC H, BE E. Systemic drugs in patients with skin diseases. Giornale italiano di dermatologia e venereologia. 2011;146:397-424.
15053.	Yaariv K, Paul D, Brian B, et al. Autonomic correlates of antidepressant treatment using heart-rate variability analysis. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 1998;43:183-186.
15054.	Yadid G, Zangen A, Dmitrochenko A, DH O, Zohar J. Screening for New Antidepressants With Fast Onset and Long-Lasting Action. Drug development research. 2000;50:392-399.
15055.	Yael N, Ilan R, Yehuda B, Amir M, Ido L, Yoram B. Debunking the placebo effect in depression: The effect of patient and investigator expectation on escitalopram efficacy. International clinical psychopharmacology. 2014;29:106-110.
15056.	Yamada K, Inoue Y, Harada T, Ishigooka J, Kanba S. Evidence-based practice guidelines for treatment of premenstrual dysphoric disorder in Japan. International journal of neuropsychopharmacology. 2010;Conference:164.
15057.	Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressant-Like Activity of the Adenosine a(2a) Receptor Antagonist, Istradefylline (Kw-6002), in the Forced Swim Test and the Tail Suspension Test in Rodents. Pharmacology, biochemistry, and behavior. 2013;114:23-30.
15058.	Yan G, Tao J, Jian-Bing G, et al. Efficacy and safety of escitalopram in elderly patients with major depression: A randomized and control study. [Chinese]. Chinese Mental Health Journal. 2010;24:445-449.
15059.	Yan L, D AJ, J DR, Robert G, C SR, D HS. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. Journal of consulting and clinical psychology. 2007;75:267-276.
15060.	Yang H, SC Y, Liang W, Dai P, CH W, YL Z. Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials. Neural Regeneration Research. 2013;8:2962-2974.
15061.	Yang J, X-H Z, Y-P Z, et al. Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. [Chinese]. Chinese Journal of Cerebrovascular Diseases. 2011;8:235-238.
15062.	Yang X, Liang J, Sun L, et al. The anti-depressive mechanism of electroacupuncture (EA) on the ras-mek-erk signal pathway. Journal of alternative and complementary medicine (New York, N.Y.). 2013;Conference:A44.
15063.	Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153:1193-1198.
15064.	Yates S, Smith E, HA A, RH M-W. Future perspectives on the pharmacological management of depression. Clinical investigation. 2013;3:137-151.
15065.	YC C, YC S, YJ H, CH C, CB Y, CH P. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. Journal of affective disorders. 2007;103:257-261.
15066.	YC X, YH L. [Observation on therapeutic effect of acupuncture at Zhongwan (CV 12) and Si-guan points combined with reinforcing-reducing manipulation of respiration for treatment of depression]. [Chinese]. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2009;29:521-524.
15067.	YD L. Pharmacological therapy of dysthymia. Acta Psychiatrica Scandinavica, Supplement. 1994;89:42-48.
15068.	YD L. Pharmacological therapy of dysthymia. [Review] [41 refs]. Acta psychiatrica Scandinavica. Supplementum. 1994;383:42-48.
15069.	YD L. Suicidality with selective serotonin reuptake inhibitors: Valid claim? Journal of psychiatry & neuroscience. 2003;28:340-347.
15070.	YD L, Joffe R, McKenna K, et al. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. Journal of psychiatry & neuroscience. 1997;22:118-126.
15071.	Yechiel L, Ruth C, Avi A, Gal R-L. The SSRI's drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain research bulletin. 2002;58:345-350.
15072.	Yeciel L, Enrico T, I PG. Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. Journal of clinical psychiatry. 2011;72:509-514.
15073.	Yekta D, Nathan H, L SW, K RE, L LK. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: A meta-analysis. The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. 2010;55:91-99.
15074.	Yero T, JA R. Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington's disease-related chorea. P and T. 2008;33:690-694.
15075.	Yetimalar BY, Yaprak S, Belkiz GB. Pseudotumor cerebri in a patient being treated for bipolar disorder. General hospital psychiatry. 2010;32:e7-e8.
15076.	YH MM, R PV, Y JF, I JB. African women with depression: The effect of imipramine and fluoxetine on body mass index and leptin secretion. Journal of clinical psychopharmacology. 2003;23:549-552.
15077.	YH Y, JK L, WS C, et al. Duloxetine Improves Oxaliplatin-Induced Neuropathy in Patients With Colorectal Cancer: an Open-Label Pilot Study. Supportive care in cancer. 2012;20:1491-1497.
15078.	YI S, CF P, DM B, et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Archives of general psychiatry. 2010;67:277-285.
15079.	YI S, DM B, JM D, JM O, AZ S, MA M. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biological psychiatry. 2001;50:651-658.
15080.	YI S, KJ B, ME B, JG C. Platelet binding characteristics distinguish placebo responders from nonresponders in depression. Neuropsychopharmacology. 1995;12:315-322.
15081.	Yi Y, FM X, HW X. [Correlation between the liver meridian and the frontal lobe in depression by needling at taichong (LV3): a resting-state fMRI study]. Zhongguo Zhong xi yi jie he za zhi [Chinese journal of integrated traditional and Western medicine]. 2011;31:1044-1050.
15082.	Yildiz A, Mantar A, Simsek S, Onur E. A new strategy of continuation pharmacotherapy in the prevention of relapse following ECT: A controlled trial. European neuropsychopharmacology. 2008;Conference:S339-S340.
15083.	Yilmaz I, Sezer Z, Kayir H, TI U. Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. Epilepsy & behavior. 2007;11:1-5.
15084.	Yilmaz N, Demirdas A, Yilmaz M, et al. Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model. Journal of membrane biology. 2011;242:145-151.
15085.	Yilmaz Z, Ceschi A, Rauber-Luthy C, et al. Escitalopram Causes Fewer Seizures in Human Overdose Than Citalopram. Clinical toxicology. 2010;48:207-212.
15086.	Yiming W, Hongming Z, Fangxian C, Xingde L, Michael B. The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC psychiatry. 2014;14.
15087.	Yiming W, Zhengjun X, Xingde L, Michael B. Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bcl-xl mRNA in both hippocampus and myocardium. Human Psychopharmacology: Clinical and Experimental. 2011;26:95-101.
15088.	Ying Z, Thomas B, Yongchun M, Markus K. A systematic review of Chinese randomized clinical trials of SSRI treatment of depression. BMC psychiatry. 2014;14.
15089.	Yirmiya R, Pollak Y, Morag M, et al. Illness, Cytokines, and Depression. Annals of the New York Academy of Sciences. 2000;917:478-487.
15090.	YJ Q, YS Z, CC Z, Li Y, ZQ Z. [Effects of Rhodiola rosea on level of 5-hydroxytryptamine, cell proliferation and differentiation, and number of neuron in cerebral hippocampus of rats with depression induced by chronic mild stress]. [Chinese]. Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica. 2008;33:2842-2846.
15091.	YK W. Recent advances in the management of depression and psychopharmacology. Hong Kong Medical Journal. 2000;6:85-92.
15092.	YL H, JP Y, GH W, ZH C, Wang Q, Xiao L. Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum. World journal of gastroenterology. 2007;13:6060-6065.
15093.	YL Z, Yang H, SC Y, et al. Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials. Neural Regeneration Research. 2013;8:2962-2974.
15094.	YM C, KW K, JH J, et al. Multi-center, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression delaying effect in Alzheimer's disease: Anmri study for atrophy delaying effect. Alzheimer's & dementia. 2014;Conference:P302.
15095.	YM C, KW K, JH J, et al. Multi-center, randomized, placebocontrolled, double-blind clinicaltrial of escitalopram on the progressiondelaying effect in Alzheimer's disease: An MRI study for atrophy-delaying effect. Alzheimer's & dementia. 2014;Conference:P111.
15096.	YM D, CG L, CC X, S-F Z. Clinical drugs that interact with St. John's wort and implication in drug development. Current pharmaceutical design. 2008;14:1723-1742.
15097.	YN M, BF L, CB W, WX Z, Rao Y, SH H. Allelic Variation in 5-Httlpr and the Effects of Citalopram on the Emotional Neural Network. British journal of psychiatry. 2015;206:385-392.
15098.	Yonemoto N, Akechi T, Shimodera S, et al. Strategic use of new generation antidepressants for depression, SUN (-)D : Study design and rationale. Trials. 2011.
15099.	Yoram B, Marnina S, Daniel L, Ronit W. Age-related differences in the side effect profile of citalopram. Progress in neuro-psychopharmacology & biological psychiatry. 2003;27:545-548.
15100.	Yoshimi A, Togo T, Sugiyama N, et al. Treatment of refractory tardive dyskinesia with donepezil in an elderly patient with depression. Psychogeriatrics. 2008;8:196-198.
15101.	Yoshimura R, Hori H, Umene-Nakano W, et al. Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. Therapeutic Advances in Psychopharmacology. 2014;4:123-129.
15102.	Yoshimura R, Ikenouchi-Sugita A, Hori H, et al. [Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder]. [Japanese]. Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica. 2010;112:982-985.
15103.	Yoshimura R, Kishi T, Hori H, et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2012;39:355-357.
15104.	Yoshimura R, Kishi T, Hori H, et al. Comparison the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. International journal of neuropsychopharmacology. 2012;Conference:199.
15105.	Yoshimura R, Nakamura J. Plasma levels of IL-6, 5-HTT gene polymorphism, and SSRIs responses in patients with major depressive disorder. European neuropsychopharmacology. 2013;Conference:S398.
15106.	Yoshinaga N, Niitsu T, Hanaoka H, et al. Strategy for Treating Selective Serotonin Reuptake Inhibitor-Resistant Social Anxiety Disorder in the Clinical Setting: a Randomised Controlled Trial Protocol of Cognitive Behavioural Therapy in Combination With Conventional Treatment. Bmj Open. 2013;3.
15107.	You W, YJ S, YJ H, BH J, Tu Y. [Effect of electroacupuncture of "Baihui" (GV 20)-"Yintang" (EX-HN 3) on the expression of glucocorticoid and glucocorticoid receptor mRNA of the chronic stress model rats]. [Chinese]. Zhen ci yan jiu  [Acupuncture research]. 2010;35:261-266.
15108.	Young A, McElroy S, Chang W, Olaulsson B, Paulsson B, Brecher M. Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II). European neuropsychopharmacology. 2008;Conference:S371-S372.
15109.	YS N. Clinical features and rehabilitation of strokes in the less common vascular territories: Anterior and posterior cerebral artery strokes. Critical Reviews in Physical and Rehabilitation Medicine. 2007;19:295-329.
15110.	YS W, HR W, W-M B. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric disease and treatment. 2013;9:1521-1529.
15111.	YS W, WM B, JH J, et al. Tianeptine Combination for Partial or Non-Response to Selective Serotonin Re-Uptake Inhibitor Monotherapy. Psychiatry and clinical neurosciences. 2013;67:219-227.
15112.	Yu G, Ding G, Li X. Mirtazapine and Amitriptyline in the Maintenance Treatment of Depressed Patients: Comparison of Efficacy and Compliance. [Chinese]. Chinese Mental Health Journal. 2004;18:356-357.
15113.	Yu Q, CX Y, Hui Y, et al. [Comparison of the effect of fluoxetine combined with hormone replacement therapy (HRT) and single HRT in treating menopausal depression]. [Chinese]. Chung-Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics & Gynecology]. 2004;39:461-464.
15114.	Yu-Long C, Xia W. Effect of Mirtazapine in Patients with Anorexia Nervosa. [Chinese]. Chinese Mental Health Journal. 2005;19:640-642.
15115.	Yuan R, Peng Q, Liao Q, H-X L. Efficacy of hormone replacement plus antidepressant for anxiety and depression in patients with menopause syndrome. Chinese Journal of Clinical Rehabilitation. 2006;10:162-163.
15116.	Yue-Di S, Bai-Hua X, Na L, Li-Li W, Wei C. Effects of antidepressant on the expression of neuropeptide Y in brain of a rat model of depression induced by chronic stress. [Chinese]. Acta Psychologica Sinica. 2009;41:53-61.
15117.	Yuen G, Bhutani S, FM G, Seirup J, Woods E, Alexopoulos G. Apathy in late-life depression: Prevalence, persistence and associated disability. American journal of geriatric psychiatry. 2013;Conference:S64.
15118.	Yui K, Koshiba M, Nakamura S. Neurobiological basis and pharmacologic treatment of social impairment in autism spectrum disorders. Current Psychopharmacology. 2012;1:233-246.
15119.	Yulong C, Chunjin X, Min H. Efficacy of Paroxetine in the Treatment of Patients with Functional Low Fever. [Chinese]. Chinese Mental Health Journal. 2004;18:813-817.
15120.	Yuly B. Phenytoin: An anti-bipolar anticonvulsant? [References]. International journal of neuropsychopharmacology. 2006;9:479-484.
15121.	Yuqing S, Dongfeng Z, Jianhua F. Effects of Fluoxetine and Electroacupuncture on G-protein Level in Platelet Membrane from Patients with Major Depression. [Chinese]. Chinese Mental Health Journal. 2004;18:783-786.
15122.	YuQing S, DongFeng Z, JianHua F, Hechun L, Uriel H. Effects of electroacupuncture and fluoxetine on the density of GTP-binding-proteins in platelet membrane in patients with major depressive disorder. Journal of affective disorders. 2007;98:253-257.
15123.	Yutaro S, Naoki F, Kazushi S, et al. Concentration-Response. Relationship for Fluvoxamine Using Remission as an Endpoint - a Receiver Operating Characteristics Curve Analysis in Major Depression. Journal of clinical psychopharmacology. 2008;28:325-328.
15124.	Yves L, T DO, F AH, Emmanuelle W. Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder. European archives of psychiatry and clinical neuroscience. 2008;258:171-178.
15125.	YY C, BY N. Clinical Aspects and Management of Fibromyalgia Syndrome. Annals Academy of Medicine Singapore. 2009;38:967-973.
15126.	YY C, WY L, SN Y, YH C, JG L. The Benefit of Combined Acupuncture and Antidepressant Medication for Depression: a Systematic Review and Meta-Analysis. Journal of affective disorders. 2015;176:106-117.
15127.	Effect of Age, Weight, and Cyp2c19 Genotype on Escitalopram Exposure, Journal of clinical pharmacology(2010).
15128.	YY L, XY Z, Zhu D, et al. Is Pindolol Augmentation Effective in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors? A Systematic Review and Meta-Analysis. Human Psychopharmacology-Clinical and Experimental. 2015;30:132-142.
15129.	Yyldyz A, GS S. Administration of antidepressants: Single versus split dosing: A meta-analysis. Journal of affective disorders. 2001;66:199-206.
15130.	A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder, International clinical psychopharmacology(2008).
15131.	Z TT, J DR, D HS, Jay A, Richard S, Benjamin S. Personality change during depression treatment: A placebo-controlled trial. Archives of general psychiatry. 2009;66:1322-1330.
15132.	Z-H C, H-Y C, Qin L, G-L X. Meta-analysis on effectiveness and safety of escitalopram and citalopram in treatment of depression. [Chinese]. Journal of Jilin University Medicine Edition. 2013;39:1228-1232.
15133.	Z-H C, Xiao L, J-H C, et al. Effects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depression. World journal of gastroenterology. 2008;14:6993-6998.
15134.	Z-J W, Wang S, Shang L, Y-L L, Zhao Y. Comparison of pschological therapy plusdrug and single drug therapy for treatment of depressive patients with Parkinson's disease. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2004;8:1212-1213.
15135.	Z-L L, L-M W, Liu J, et al. Effect and safety of the treatment for comorbid anxiety and depression by use of short-term and low-dose olanzapine in combination with fluoxetine. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:6-8.
15136.	Z-W S, X-B L, Y-D L. Venlafaxine combined with low-dose risperidone for treatment-resistant depression. [Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research. 2007;11:10486-10488.
15137.	Z-Y Z, W-X W, H-Z G, Z-Q G, D-F Z. Anti-depressive effect of liquiritin on chronic stress depression in rats. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2006;10:69-72.
15138.	ZA A-S, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertility and sterility. 2014;101:905-915.
15139.	ZA H, KR S, CM S, et al. Simultaneous Blockade of 5-Ht1a/B Receptors and 5-Ht Transporters Results in Acute Increases in Extracellular 5-Ht in Both Rats and Guinea Pigs: in Vivo Characterization of the Novel 5-Ht1a/B Receptor Antagonist/5-Ht Transport Inhibitor Sb-649915-B. Psychopharmacology. 2007;192:121-133.
15140.	ZA H, Liu F, Marquis K, et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Current molecular pharmacology. 2009;2:215-236.
15141.	ZA S, BJ C. Tics and Tourette syndrome. Psychiatric clinics of North America. 2014;37:269-286.
15142.	Zafir A, Ara A, Banu N. In Vivo Antioxidant Status: a Putative Target of Antidepressant Action. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33:220-228.
15143.	Zajecka J. Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction. Journal of clinical psychiatry. 2001;62:35-43.
15144.	Zajecka J, DL D, AJ G, et al. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. Journal of clinical psychiatry. 2002;63:709-716.
15145.	Zajecka J, GW M, KM L. Antidepressant dosing and switching guidelines: Focus on nefazodone. Journal of clinical psychiatry. 2002;63:42-47.
15146.	Zajecka J, JD A, FM Q, et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. Journal of clinical psychiatry. 1999;60:389-394.
15147.	Zajecka J, KA T, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. [Review] [36 refs]. Journal of clinical psychiatry. 1997;58:291-297.
15148.	Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of clinical psychopharmacology. 2010;30:135-144.
15149.	Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson's disease. International Psychogeriatrics. 2011;23:325-327.
15150.	Zammit G. Comparative tolerability of newer agents for insomnia. Drug safety. 2009;32:735-748.
15151.	Zanardi R, Benedetti F, D DB, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of clinical psychopharmacology. 2000;20:105-107.
15152.	Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blinded controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American journal of psychiatry. 1996;153:1631-1633.
15153.	Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American journal of psychiatry. 1996;153:1631-1633.
15154.	Zanardi R, Magri L, Rossini D, et al. Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. European neuropsychopharmacology. 2007;17:651-657.
15155.	Zanardi R, Rossini D, Magri L, Malaguti A, Colombo C, Smeraldi E. Response to SSRIs and role of the hormonal therapy in post-menopausal depression. European neuropsychopharmacology. 2007;17:400-405.
15156.	Zaninelli R, Meister W. The Treatment of Depression With Paroxetine in Psychiatric Practice in Germany: the Possibilities and Current Limitations of Drug Monitoring. Pharmacopsychiatry. 1997;30:9-20.
15157.	New paradigms for treatment-resistant depression, Annals of the New York Academy of Sciences(2013).
15158.	Zareba G. New treatment options in the management of fibromyalgia: Role of pregabalin. Neuropsychiatric disease and treatment. 2008;4:1193-1201.
15159.	Zavoianu M, Cantemir A, Tudor C, Grigorescu G. Efficacy of duloxetine in perimenopausal women with depressive and vasomotor symptoms. European neuropsychopharmacology. 2011;Conference:S397.
15160.	Zdanowicz N, Jacques D, Reynaert C. Comparisons between psychotropic drugs: Must the risk of side effects dictate our practices? Acta clinica Belgica. 2008;63:235-241.
15161.	Zdanys K, RR T. A systematic review of off-label uses of memantine for psychiatric disorders. Progress in neuro-psychopharmacology & biological psychiatry. 2008;32:1362-1374.
15162.	ZE K, AN S, Halbreich U. Levetiracetam for treatment of premenstrual dysphoric disorder: A pilot, open-label study. Archives of women's mental health. 2008;11:207-211.
15163.	Zeller A. Medical therapy for smoking cessation. [German]. Therapeutische Umschau. Revue therapeutique. 2010;67:419-425.
15164.	Zeller K, Gastpar M. Hypericum extract STW3-VI in comparison to citalopram und placebo in patients with moderate depression. [German]. Psychopharmakotherapie. 2007;14:65-69.
15165.	Zemishlany Z, Weizman A. The Impact of Mental Illness on Sexual Dysfunction.29:89-106.
15166.	Zeng W, Ma H, Liang Q, Dong Y, Ye H, Zhang Y. [The influence of antidepressive therapy on short-term prognosis in elderly patients with unstable angina and depression]. [Chinese]. Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine. 2001;40:809-810.
15167.	Zerjav S, Tse G, MJW S. Review of duloxetine and venlafaxine in depression. Canadian Pharmacists Journal. 2009;142:144-152.
15168.	Zetin M, CT H. Relevance of Exclusion Criteria in Antidepressant Clinical Trials - a Replication Study. Journal of clinical psychopharmacology. 2007;27:295-301.
15169.	Zetin M, MA K. Obsessive-Compulsive Disorder. Hospital & community psychiatry. 1992;43:689-699.
15170.	ZG L, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: A systematic review and meta-analysis. BMC psychiatry. 2013.
15171.	ZG S, QZ H, CY X, LP C. [Effects of shuyu ningxln recipe on the praxiology and the expressions of hippocampal BDNF and trkB of model rats with chronic stress-induced depression]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2013;33:370-375.
15172.	ZH Y, LP Z, Long B. [Clinical observation on treatment of major depressive disorder by paroxetine combined with chaihu xiaoyao mixture]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2010;30:1257-1260.
15173.	Zhang C. The brain-resuscitation acupuncture method for treatment of post wind-stroke mental depression - A report of 45 cases. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2005;25:243-246.
15174.	Zhang G, Ruan J. Treatment of mental depression due to liver-qi stagnancy with herbal decoction and by magnetic therapy at the acupoints--a report of 45 cases. Journal of traditional Chinese medicine / Chung i tsa chih ying wen pan. 2004;24:20-21.
15175.	Zhang H, Cheng J, G-H W. Comparison of citalopram and venlafaxine for depressive disoder. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9:4-6.
15176.	Zhang J, Wu H, Zhu L, Zhang L, Wang Z, Wu Y. Influence of paroxetine combined with Chaihuxiaoyao mixture on life quality of patients with depression. [Chinese]. Pharmaceutical Care and Research. 2012;12:205-208.
15177.	Zhang J, X-H S, M-C Q, et al. [Effects of apolipoprotein E genetic polymorphism on susceptibility of depression and efficacy of antidepressants]. [Chinese]. Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae. 2012;34:595-600.
15178.	Zhang L, Chappell J, CR G, et al. Qt Effects of Duloxetine at Supratherapeutic Doses: a Placebo and Positive Controlled Study. Journal of cardiovascular pharmacology. 2007;49:146-153.
15179.	Zhang L, N-Y S, G-H D. Experimental study of searching for new antidepressant drugs by applying high throughput screening method. Chinese Journal of Clinical Rehabilitation. 2004;8:7577-7579.
15180.	Zhang L, Xia M, Wu L, Zhang B. Effects of Jiawei Wendan decoction on hippocampal p-CREB protein expression in a rat model of depression. Neural Regeneration Research. 2008;3:962-966.
15181.	Zhang M, D-R Z, W-H Y, Jiang J, Feng L, H-L W. A randomized controlled observation of fluoxertine hydrochloride in treating depression state in patients with non-organic chronic pain. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2003;7:3612-3613.
15182.	Zhang S, Xu Z, Gao Y, et al. Bidirectional Crosstalk between Stress-Induced Gastric Ulcer and Depression under Chronic Stress. PloS one. 2012.
15183.	Zhang W, J-H S, Gao Y, et al. System review on treating post-stroke depression with acupuncture. World Journal of Acupuncture - Moxibustion. 2014;24:52-59.
15184.	Zhang W, JRT D. Post-Traumatic Stress Disorder: an Evaluation of Existing Pharmacotherapies and New Strategies. Expert opinion on pharmacotherapy. 2007;8:1861-1870.
15185.	Zhang X, Yu T, Li X, et al. Neither Cytochrome P450 Family Genes nor Neuroendocrine Factors Could Independently Predict the Ssris Treatment in the Chinese Han Population. Pharmacopsychiatry. 2014;47:60-66.
15186.	Zhang Y, Kosters M, Becker T. Venlafaxine for the treatment of depression: A meta-analysis of chinese trials. European psychiatry.
15187.	Zhang Z, SS L, JJ H. Postweaning enriched environment and citalopram overcome memory deficits and anhedonia induced by maternal separation. European neuropsychopharmacology. 2010;Conference:S399-S400.
15188.	Dense cranial electroacupuncture stimulation for major depressive disorder-A single-blind, randomized, controlled study, PloS one(2012).
15189.	Zhao H, Wan X, J-X C. A mini review of traditional Chinese medicine for the treatment of depression in China. American journal of Chinese medicine. 2009;37:207-213.
15190.	Zhao L, M-Y Q, Xu J. Cognitive function features of patients with depression. [Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research. 2007;11:5935-5938.
15191.	Zhao X, RR S, Yun K, Peng T, Wang Z. The role of galanin system in modulating depression, anxiety, and addiction-like behaviors after chronic restraint stress. Neuroscience. 2013;246:82-93.
15192.	Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of Medication Adherence and Healthcare Costs Between Duloxetine and Pregabalin Initiators Among Patients With Fibromyalgia. Pain practice. 2011;11:204-216.
15193.	Zhao Z, Wang W, Guo H, Zhou D. Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behavioural brain research. 2008;194:108-113.
15194.	Zhen T, Ming L. Mirtazapine Compared with Paroxetine in Depressed Patients with Anxiety Symptoms. [Chinese]. Chinese Mental Health Journal. 2005;19:643-645.
15195.	Zheng H, GY M, XC F, DUHG. [Effects of paroxetine on protein kinase PKA, PKC and CaMKII activity in different brain regions in a rat depression model]. [Chinese]. Nan fang yi ke da xue xue bao [Journal of Southern Medical University]. 2008;28:1223-1225.
15196.	Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34:1189-1195.
15197.	Zheng K, Shi T, Liu X. The rehabilitation therapy of cerebral infarction with depressive symptom and its effect on platelet serotonin level. [Chinese]. Chinese Journal of Rehabilitation Medicine. 2006;21:1005-1007.
15198.	Zheng P, Y-D W, G-E Y, et al. Novel urinary biomarkers for diagnosing bipolar disorder. Metabolomics. 2013;9:800-808.
15199.	Zhi-Yu Z, Wei-Xing W, Hong-Zhu G. The Effect of Liquiritin on Body Weight and Behavior of Depressive Rats. [Chinese]. Chinese Mental Health Journal. 2006;20:787-790.
15200.	Zhiguo W, Jun C, Chengmei Y, et al. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: A report of OPERATION study. Journal of affective disorders. 2013;150:834-839.
15201.	Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, P-P R, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: A systematic review of the placebo-controlled monotherapy and add-on trials. International clinical psychopharmacology. 2011;26:183-192.
15202.	Zhou R, W-P X, Wang L, et al. The efficacy and safety of mirtazapine and fluoxetine for depression: A meta-analysis. [Chinese]. Chinese Journal of Evidence-Based Medicine. 2010;10:196-202.
15203.	Zhou X, KD M, Liu Y, et al. Systematic review of management for treatment-resistant depression in adolescents. BMC psychiatry. 2014.
15204.	Zhu H, MB B, SH B, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS ONE [Electronic Resource]. 2013;8:e68283.
15205.	Zhu J, Yan J, Ren J. Anxiety and Risk Factors of Graves' Disease. [Chinese]. Chinese Mental Health Journal. 2004;18:39-341.
15206.	Zhuang J, Wang X, Xu L, Wu T, Kang D. Antidepressants for polycystic ovary syndrome. [Review]. Cochrane database of systematic reviews (Online). 2013;5:CD008575.
15207.	Zhuang J, Wang X, Xu L, Wu T, Kang D. Antidepressants for polycystic ovary syndrome. The Cochrane database of systematic reviews. 2013;5:CD008575.
15208.	Zhuang J, XD W, LZ X, TX W, DY K. Antidepressants for Polycystic Ovary Syndrome. Cochrane database of systematic reviews (Online). 2013.
15209.	Zhuo Y-N, Zheng H. Therapeutic Effect of Mirtazapine Combined with Lithium Carbonate on Bipolar Depression. [Chinese]. Chinese Mental Health Journal. 2005;19:492-494.
15210.	Ziegler D, Fonseca V. From Guideline to Patient: a Review of Recent Recommendations for Pharmacotherapy of Painful Diabetic Neuropathy. Journal of diabetes and its complications. 2015;29:146-156.
15211.	Zieglmeier M, Goller C. Drugs and smoking cessation. [German]. Deutsche Apotheker-Zeitung. 2010;150:44-49.
15212.	Zielonka D, Mielcarek M, GB L. Update on Huntington's disease: Advances in care and emerging therapeutic options. Parkinsonism & related disorders. 2015;21:169-178.
15213.	Zigman D, Blier P. A framework to avoid irrational polypharmacy in psychiatry. Journal of psychopharmacology (Oxford, England). 2012;26:1507-1511.
15214.	Zilcha-Mano S, Dinger U, KS M, JP B. Does alliance predict symptoms throughout treatment, or is it the other way around? Journal of consulting and clinical psychology. 2015;82:931-935.
15215.	Changes in well-being and quality of life in a randomized trial comparing dynamic psychotherapy and pharmacotherapy for major depressive disorder, Journal of affective disorders(2014).
15216.	Zilcha-Mano S, KS M, Dinger U, JP B. To what extent is alliance affected by transference? An empirical exploration. Psychotherapy (Chicago, Ill.). 2014;51:424-433.
15217.	Zilcha-Mano S, SP R, JP B, BR R. Therapeutic alliance in antidepressant treatment: Cause or effect of symptomatic levels? Psychotherapy and psychosomatics. 2015;84:177-182.
15218.	Zilliox L, JW R. Treatment of Diabetic Sensory Polyneuropathy. Current treatment options in neurology. 2011;13:143-159.
15219.	Zimmerman M, Chelminski I, Posternak M. A Review of Studies of the Hamilton Depression Rating Scale in Healthy Controls - Implications for the Definition of Remission in Treatment Studies of Depression. Journal of nervous and mental disease. 2004;192:595-601.
15220.	Zimmerman M, Chelminski I, Posternak M. A Review of Studies of the Montgomery-Asberg Depression Rating Scale in Controls: Implications for the Definition of Remission in Treatment Studies of Depression. International clinical psychopharmacology. 2004;19:1-7.
15221.	Zimmerman M, Chelminski I, Posternak M. A Review of Studies of the Hamilton Depression Rating Scale in Healthy Controls - Implications for the Definition of Remission in Treatment Studies of Depression. Journal of nervous and mental disease. 2004;192:595-601.
15222.	Zimmerman M, Chelminski I, Posternak M. A Review of Studies of the Montgomery-Asberg Depression Rating Scale in Controls: Implications for the Definition of Remission in Treatment Studies of Depression. International clinical psychopharmacology. 2004;19:1-7.
15223.	Zimmerman M, MA P, Attiullah N, et al. Why Isn't Bupropion the Most Frequently Prescribed Antidepressant? Journal of clinical psychiatry. 2005;66:603-610.
15224.	Zimmerman M, MA P, Attiullah N, et al. Why Isn't Bupropion the Most Frequently Prescribed Antidepressant? Journal of clinical psychiatry. 2005;66:603-610.
15225.	Zimmerman M, MA P, CJ R. Impact of Study Design on the Results of Continuation Studies of Antidepressants. Journal of clinical psychopharmacology. 2007;27:177-181.
15226.	Zimmerman M, Thongy T. How Often Do Ssris and Other New-Generation Antidepressants Lose Their Effect During Continuation Treatment? Evidence Suggesting the Rate of True Tachyphylaxis During Continuation Treatment Is Low. Journal of clinical psychiatry. 2007;68:1271-1276.
15227.	Zimmermann U. Controlled long-term prophylaxis of unipolar depression with new antidepressant agents (SSRI). [German]. Psychiatrische Praxis. 1996;23:240-243.
15228.	Zimmermann U. [Controlled long-term prevention of unipolar depression with antidepressive agents of the second generation (SSRI)]. [Review] [29 refs] [German]. Psychiatrische Praxis. 1996;23:240-243.
15229.	Zimmermann U, Wolfersdorf M. Latest state of continuation therapy with antidepressants. [German]. TW Neurologie Psychiatrie. 1993;7:13-16+19.
15230.	Zimmermann-Viehoff F, Bergander B, Meissner K, HC D. [Integrative therapy of a patient with complex psychosomatic complaints]. [German]. Forschende Komplementarmedizin (2006). 2008;15:152-155.
15231.	Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Current opinion in psychiatry. 2010;23:103-111.
15232.	Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine Treatment of Major Depressive Episodes in the Course of Psychotic Disorders - a Case Report. Pharmacopsychiatry. 2006;39:109-111.
15233.	Ziolkowska E, Zarzycka M, Wisniewski T, Zyromska A. The side effects of hormonal therapy at the patients with prostate cancer. Wspolczesna Onkologia. 2012;16:491-497.
15234.	Zis AP, Goumeniouk AD, Clark CM, et al. ECT-induced prolactin release: Effect of sex, electrode placement and serotonin uptake inhibition. Human Psychopharmacology: Clinical and Experimental. 1991;6:155-160.
15235.	Zisook S. Treatment of Depressed Patients With Comorbid Anxiety Disorders. CNS spectrums. 2006;11:A8-+.
15236.	Zisook S, AJ R, BR H, DC C, CB R. Use of Bupropion in Combination With Serotonin Reuptake Inhibitors. Biological psychiatry. 2006;59:203-210.
15237.	Zisook S, Lesser I, JW S, et al. Effect of age at onset on the course of major depressive disorder. American journal of psychiatry. 2007;164:1539-1546.
15238.	Zisook S, Montross L, Kasckow J, et al. Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia. American journal of geriatric psychiatry. 2007;15:1005-1014.
15239.	Zisook S, Peterkin J, KJ G, Sledge P, JH A, Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. Journal of clinical psychiatry. 1998;59:217-224.
15240.	Zisook S, SR S, Pedrelli P, Sable J, SC D. Bupropion Sustained Release for Bereavement: Results of an Open Trial. Journal of clinical psychiatry. 2001;62:227-230.
15241.	Zitner D, Bischoff A, Koren G, et al. Using antidepressants during preganancy [1] (multiple letters). CMAJ : Canadian Medical Association journal. 2005;173:1205-1206.
15242.	Zitterl W, Meszaros K, Hornik K, et al. Efficacy of Fluoxetine in Austrian Patients With Obsessive-Compulsive Disorder. Wiener klinische Wochenschrift. 1999;111:439-442.
15243.	Zivin K, PN P, ASB B, et al. Safety of high-dosage citalopram. American journal of psychiatry. 2014;171:20-22.
15244.	Zivkov M, GD DJ. Org 3770 versus amitriptyline: A 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Human psychopharmacology. 1995;10:173-180.
15245.	Zivkov M, GD DJ. Mirtazapine - An antidepressant agent with new concept. [German]. TW Neurologie Psychiatrie. 1996;10:185-188.
15246.	Zivkovic N, Djokic G, Pavicevic D, Ilic V. Escitalopram in treatment of sleep disturbances in major depressive disorder. European psychiatry. 2009;Conference:S632.
15247.	Zivkovic N, Pavicevic D, Djokic G. Escitalopram in treatment of disability in major depressive patients. European psychiatry.
15248.	ZJ Y, CJ K, RA W, Mooreville M, EB W. From TADS and SOFTADS to TORDIA and beyond: what's new in the treatment of adolescent depression?. [Review] [47 refs]. Current psychiatry reports. 2010;12:88-95.
15249.	ZJ Z. Herbal medicine and acupuncture for unipolar and bipolar depression: Randomized controlled trials. Bipolar disorders. 2012;Conference:137.
15250.	Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.[Erratum appears in PLoS One. 2012 Feb 21;78(8). doi: 10.1371/annotation/b27d20b4-f41c-47af-b19f-a0278c993a2d], PLoS ONE [Electronic Resource](2012).
15251.	ZJ Z, QR T, Tong Y, et al. The Effectiveness of Carbamazepine in Unipolar Depression: a Double-Blind, Randomized, Placebo-Controlled Study. Journal of affective disorders. 2008;109:91-97.
15252.	ZL T, AM B, GQ Z, YJ L, JN Z. Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder. Neuro endocrinology letters. 2007;28:28-32.
15253.	ZM Y, Liu F, SD Z. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. [Review]. International journal of clinical practice. 2010;64:1310-1317.
15254.	ZN S, Casarella J, Landry J, CB N. Sertraline in the treatment of women with postpartum major depression. Depression. 1995;3:49-55.
15255.	Zohar J. Fluvoxamine in the Treatment of Severe Depression. Primary Care Psychiatry. 2004;9:115-119.
15256.	Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert review of neurotherapeutics. 2008;8:339-349.
15257.	Zohar J, Judge R, Ait, et al. Paroxetine Versus Clomipramine in the Treatment of Obsessive-Compulsive Disorder. British journal of psychiatry. 1996;169:468-474.
15258.	Zou C, Ding X, JH F, BR D. Clinical Efficacy and Safety of Fluoxetine in Generalized Anxiety Disorder in Chinese Patients. Neuropsychiatric disease and treatment. 2013;9:1661-1670.
15259.	Zou C, Ding X, JH F, Dong B. Clinical efficacy and safety of fuoxetine in generalized anxiety disorder in chinese patients. Neuropsychiatric disease and treatment. 2013;9:1661-1670.
15260.	Zourkova A. Effect of mirtazapine and paroxetine on residual symptoms of depressive disorders and their effect on P450 CYP 2D6 activity. Homeostasis in health and disease. 2001;41:242-248.
15261.	Zourkova A. Effect of mirtazapine and paroxetine on residual symptoms of depressive disorders and their effect on P450 CYP 2D6 activity. Homeostasis in health and disease. 2001;41:242-249.
15262.	Zourkova A. Clinical significance of CYP 2D6 during treatment with recent antidepressants. [Czech]. Ceska a Slovenska Psychiatrie. 2002;98:273-277.
15263.	Zourkova A, Jurica J, EM H, Pulkrabkova L. Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation. European neuropsychopharmacology. 2008;Conference:S328-S329.
15264.	Zourkov� A, Ceskov� E, Hadasov� E, Ravcukov� B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. Journal of sex & marital therapy. 2007;33:343-355.
15265.	ZS H, RL R, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics. 2009;50:317-324.
15266.	Zu S, Y-T X, Liu J, et al. A Comparison of Cognitive-Behavioral Therapy, Antidepressants, Their Combination and Standard Treatment for Chinese Patients With Moderate-Severe Major Depressive Disorders. Journal of affective disorders. 2014;152-154:262-267.
15267.	Zubin B, J CP, M GG, J HC. Normalization of Enhanced Fear Recognition by Acute SSRI Treatment in Subjects With a Previous History of Depression. American journal of psychiatry. 2004;161:166-168.
15268.	Zubin B, Richard W, Philip C. State and trait abnormalities in serotonin function in major depression. The British Journal of Psychiatry. 2002;180:24-28.
15269.	Zuidersma M, HJ C, JP vM, Ormel J, P dJ. Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: A randomized controlled trial. Journal of psychosomatic research. 2013;74:25-30.
15270.	Zullino D, Delacrausaz P, Baumann P. The place of SSRIs in the treatment of schizophrenia. [French]. Encephale. 2002;28:433-438.
15271.	Zundorf A. Duloxetine relieves peripheral neuropathic pain. [German]. Fortschritte der Neurologie-Psychiatrie. 2007;75:59.
15272.	Zundorf I, WE M. Antidepressants for children?. [German]. Pharmazie in unserer Zeit. 2004;33:270-271.
15273.	Zupancic M, Guilleminault C. Agomelatine: A preliminary review of a new antidepressant. CNS drugs. 2006;20:981-992.
15274.	Zupancic M, Lo H, Dhaenen H, et al. Agomelatine: A guide to its use in major depressive disorder. Drugs and Therapy Perspectives. 2010;26:6-9.
15275.	Zupancic M, ML G. Aripiprazole in the acute and maintenance phase of bipolar I disorder. Therapeutics and clinical risk management. 2012;8:1-6.
15276.	Zurowski B, Kordon A, Hohagen F. Depression and Comorbidity - New Treatment Indications for Antidepressiva. Psychopharmakotherapie. 2005;12:29-35.
15277.	Zurowski B, Kordon A, Hohagen F. Depression and comorbidity: New treatment indications for antidepressants. [German]. Psychopharmakotherapie, Supplement. 2005;12:29-35.
15278.	Zurowski B, Kordon A, Hohagen F. Depression and Comorbidity - New Treatment Indications for Antidepressiva. Psychopharmakotherapie. 2005;12:29-35.
15279.	Zuzana W, H WRW, M RM, Stephen S. Antidepressant treatment of chronic tension-type headache: A comparison between fluoxetine and desipramine. Headache: The Journal of Head and Face Pain. 1998;38:523-528.
15280.	ZV S, Kennedy S, Gemar M, Hood K, Pedersen R, Buis T. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Archives of general psychiatry. 2006;63:749-755.
15281.	ZX C, HQ W, WD J. [Selective serotonin reuptake inhibitor is more likely to induce sexual dysfunction than mirtazapine in treating depression]. [Chinese]. Zhonghua nan ke xue [National journal of andrology]. 2008;14:896-899.
15282.	ZY Y, WB Z, JL L. [Comparative study of Modified Xiaoyao Pill combining amitriptyline on therapeutic effect and compliance in treating patients with depression]. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2007;27:642-644.
15283.	ZY Z, YQ Z, HY H, et al. Effects of Low-Dose Olanzapine on Duloxetine-Related Nausea and Vomiting for the Treatment of Major Depressive Disorder. Journal of clinical psychopharmacology. 2014;34:495-498.
15284.	ZZ L, DK Q, Chen J, et al. Venlafaxine Inhibits the Upregulation of Plasma Tumor Necrosis Factor-Alpha (Tnf-Alpha) in the Chinese Patients With Major Depressive Disorder: a Prospective Longitudinal Study. Psychoneuroendocrinology. 2013;38:107-114.